|||||||||||||||||Exon|||||||Intron||Custom| ID|Nickname|Name(*)|Designation|Mode of inheritance(*)|Gene name(*)|Gene symbol(*)|Protein expression of altered gene|Gene synonyms|MGI Gene accession ID|Allele Name|Allele symbol|MGI Allele accession ID|Chromosome(*)|Ensemble Gene ID|Transcript ID|Transcript name|bp coding sequence position|bp cdna sequence position|bp change|Exon ID|Exon number|Amino acid position|Amino acid change|Genomic position|Intron number|Mutation type(*)|Strand type|Coding Sequence|Novelty|Transgene name|Transgene promoter|Transgene expression level|Congenic Gene name|Congenic Gene symbol|Congenic Protein expression of altered gene|Congenic Gene synonyms|Congenic MGI Gene accession ID|Congenic Allele Name|Congenic Allele symbol|Congenic MGI Allele accession ID|Congenic Gene Chromosome|Homozygous phenotype(*)|Heterozygous phenotype(*)|Current genetic background(*)|Female homozygous viable(*)|Female homozygous fertile(*)|Female heterozygotes/hemizygotes fertile|Male homozygous viable(*)|Male homozygous fertile(*)|Male heterozygotes/hemizygotes fertile|Evidence of compromised male fertility|Breeding performance|# generations backcrossed to background strain|# sib-mated generations|Mating scheme|Requires homozygous matings|Date created (dd/mm/yyyy)|Stock stored as|Frozen sperm straw count|Frozen embryo count|Does it Model a Human Condition?|Description of a Human Condition|Keywords|Is the strain available in any form to other researchers?| 1553.0||BALB/c-IL9 Tg(iFABPp-IL9)/AnuApb||Recessive|interleukin 9|Il9|Nil|Il-9, P40|MGI:96563|interleukin 9; targeted mutation 1, Andrew NJ McKenzie|Il9|MGI:2656470|13||||||||||||||||Yes|Interleukin 9|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences). |High||||||||||Restricted expression of IL9 transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|90.0|0.0|Unknown||T cell, inflamation, interleukin, anaphylaxis, mast cell, allergy|Yes| 6808.0|Dudley|SJL/Mrit-Gck/MritApb||Dominant|Glucokinase|Gck|Unknown|Gk, hexokinase 4, HK4, MODY2|MGI:1270854|Glucokinase;MRI32562|Gck||11|||||||||||||||||||||||||||||Growth retardationDramatic hyperglycemia|HyperglycemiaHyperinsulinemiaGlucose intolerant|SJL|Yes|No|Yes|Yes|No|Yes|No|Good||||No|01-Feb-2012|Cryopreserved sperm|60.0|0.0|Yes|Maturity onset diabetes of the young 2|Diabetes, Glucokinase, ENU|Yes| 7634.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|80.0|0.0|Unknown|||Yes| 3924.0|CC|BALB/c-Tg(Col1a2-cre/ESR1)7Cpd/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 7, Christopher P Denton|Col1a2 enhancer|fibroblast-specific expression, restricted to collagen||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|5||Backcross to balb/c|No|14-Oct-2008|Cryopreserved sperm|87.0|0.0|No||epidermis, inducible, fribroblast, collagen|Yes| 4774.0|5AT129|ENU5AT:129||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|60.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4774.0|5AT129|ENU5AT:129||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 10320.0||C57Bl/6-TFF3(CreGFP)GRP78/Apb||Semi-dominant|trefoil factor 3, intestinal|Tff3|||MGI:104638||||17|ENSMUSG00000024029 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Mar-2023|Cryopreserved sperm|54.0|0.0|Unknown|||Possibly| 10320.0||C57Bl/6-TFF3(CreGFP)GRP78/Apb||Semi-dominant|heat shock protein 5|Hspa5|| Grp78, Hsce70, mBiP, |MGI:95835||||2|ENSMUSG00000026864 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Mar-2023|Cryopreserved sperm|||Unknown|||Possibly| 6826.0|APP KO|B6.129-App/Apb||Recessive|amyloid beta (A4) precursor protein|App|Nil|Abeta, Adap, appican, betaAPP, Cvap, E030013M08Rik, protease nexin II|MGI:88059|amyloid beta (A4) precursor protein; targeted mutation 1, David R Borchelt|App|MGI:2136847|16|||||||||||||||||||||||||||||Abnormal active avoidance behavior: age-related impairment in conditioned avoidance tests, seen at 10 months of age, but not at 4 months of age.Abnormal spatial learning: impairment in watermaze test of spatial learning, both at 4 and 10 months of age.Decreased grip strength: significantly reduced grip strength.Abnormal locomotor activation: decreased locomotor activityHypoactivity.Gliosis: reactive gliosis was observed throughout the cortical layers of the neocortex and extensive astrogliosis was seen in the CA1 region of the hippocampus, however did not observe neuronal cell damage.Astrocytosis: reactive astrocytosis in many brain areas, but predominantly in the cortex and hippocampus at 14 weeks of age.Abnormal neuron morphology: the branching of dendrites of both cortical and hippocampal neurons was much less extensive, however did not show any loss of cells in the cortex or the hippocampus.Abnormal long term potentiation: impairment of ability of high frequency stimuli to induce LTP which correlated with extent of gliosis in stratum radiatum.Decreased body weight: body weight was 15-20% less at all ages compared with that of controls.||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|27-Feb-2012|Cryopreserved sperm|50.0|0.0|Yes|Alzheimer's disease (AD)|amyloid, tau, locomotion, neuron|Yes| 4579.0||SJL.129S7-Ifngr1/AnuApb||Recessive|interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10||||||||||||||||Yes|||||||||||||Abnormal immune system||SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Mar-2009|Cryopreserved sperm|60.0|0.0|Unknown||cytokine, interleukin, infection, immunoglobulin, macrophage|Yes| 7635.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 4779.0|wildtype control|129/Sv-Ifngr(WT)||Recessive|||Unknown||||||Unknown||||||||||||||||Yes|||||||||||||Control strain for conducting experiments with 129/Sv-Ifngr1 strain||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|100.0|0.0|No||infection, interleukin, splenocyte|Yes| 4919.0|CD9 -/-|FVB/N.B6(129)-CD9/AusbApb||Recessive|CD9 antigen|Cd9|Nil|Tspan29|MGI:88348|targeted mutation 1, Claude Boucheix|Cd9|MGI:2180795|6|||||||||||||||||||||||||||||Reduced female fertility: 40 - 50% of females fail to produce litters.Decreased litter size.Impaired fertilization: impaired sperm - egg fusion.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||No|20-Oct-2009|Cryopreserved sperm|135.0|0.0|Unknown||fertility, tetraspan, CD151|Yes| 7340.0|MommeD42|FVB/NJ-Brd1 Tg(Hba1-Gfp)1Ew/QimrApb||Dominant|bromodomain containing 1|Brd1|Unknown||MGI:1924161|bromodomain containing 1; modifiers of murine metastable epiallele D42|Brd1|MGI:5515395|15|ENSMUSG00000022387|ENSMUST00000109381|Brd1-001|||T to A||||Unknown to Unknown||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (~10.5 dpc)|Percentage of cells expressing the GFP transgene is decreased (enhancer of variegation).|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|27-May-2013|Cryopreserved sperm|50.0|0.0|Unknown||epigenetics, modifier, ENU|Yes| 2467.0||B6.CBA-Tg(hGMCSF-KBM)457/AnuApb||Dominant|||||||||Unknown||||||||||||||||No|human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|40.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 7644.0||B6/Mrit-135904|B6/Mrit-135904|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|33.0|0.0|Unknown||growth , ENU|Yes| 5200.0|ZIKO ; Zfp397 KO LacZ|STOCK Zfp397/Apb||Recessive|zinc finger protein 397|Zfp397|Nil||MGI:1916506|zinc finger protein 397; gene trap W131C06, German Gene Trap Consortium|Zfp397|MGI:4123642|18||||||||||||||||No|||||||||||||Normal|Normal|mixed|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|05-Aug-2010|Cryopreserved sperm|50.0|0.0|No||centromere, kinetochore, zinc finger, SCAN domain|No| 7595.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|8|||No|18-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7476.0|Rhea|FVB/N-MommeD34 Tg(Hba1-Gfp)1Ew||Semi-dominant|rearranged L-myc fusion sequence|Rlf|Reduced||MGI:1924705|rearranged L-myc fusion sequence; modifier of murine metastable epialleles, D34|Rlf|MGI:5515367|4||||||||||Unknown to Unknown||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Mutant mice show a reduction in survival past weaning. Survivors at weaning are smaller than controls.Postnatal lethality: * few animals survive to weaning * normal litter size at birthDecreased body size: at weaning||FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD34<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|13-Nov-2013|Cryopreserved sperm|30.0|0.0|Unknown||epigenetics, suppressor of variegation, ENU|Yes| 4860.0||C57BL/6-Tg(H2-K-huCD55,huCD59)/Apb||Dominant||||||||||||||||||||||||||human CD55/CD59 dual construct|H2-K|ubiquitous||||||||||Expression of membrane bound human CD55 and CD59 in all tissues on all cells.|Expression of membrane bound human CD55 and CD59 in all tissues on all cells.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|92.0|0.0|Unknown||complement, skeletal, muscle, ischemia, reperfusion|Yes| 7255.0|MLC:1IGF-1B_2B (Class 1Eb) ; SP1-IGF-1Eb|B6.FVB-Tg(Myl1-SP1/IGF1Ea)1Nros/MarpApb|FVB-Tg(Myl1-SP1/IGF1Ea)1Nros|Semi-dominant||||||||||||||||||||||||||mouse insulin-like growth factor-1|myosin light chain|skeletal muscle||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|15-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 68.0||Socks||Recessive|||Unknown||||||4||||||||||||||||Yes|||||||||||||Dilute coat, white belly spot and "socks", small eyes. Unique phenotype for chromosome location, 34 potential genes in this region.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|30.0|0.0|Unknown||melanocyte, migration, coat, ENU|Yes| 644.0|ATM-pKZ1|C57BL/6-Tg(pKZ1) Atm||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Unknown|C030026E19Rik|MGI:107202|ataxia telangiectasia mutated homolog (human); targeted mutation 1, Philip Leder|Atm|MGI:1926875|9||||||||||||||||Yes|β-galactosidase gene (lacZ) E. coli|chicken β-actin||||||||||||Irradiated Atm heterozygous knock-out mice did demonstrate fewer inversions after exposure to 15 mGy X-radiation than the Atm normal pKZ1 mice.|C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|25-Apr-2007||0.0|0.0|No||ATM, pKZ1, inversion, radiation, recombination|No| 6900.0|TGFbeta2|STOCK Tgfb2/MarpApb||Recessive|transforming growth factor, beta 2|Tgfb2|Nil|Tgfb-2, Tgf-beta2|MGI:98726|transforming growth factor, beta 2; targeted mutation 1, Thomas Doetschman|Tgfb2|MGI:1888389|1||||||||||||||||||||||||||||||TGFb2-null mice exhibit perinatal mortality and a wide range of developmental defects for a single gene disruption. These include cardiac, lung, craniofacial, limb, spinal column, eye, inner ear and urogenital defects (Sanford et al., 1997.Development 124, 2659-2670).TGFb2 heterozygotes exhibit a 30% increase in nephron number (Sims-Lucas et al., Pediatr Res. 2008 Jun;63(6):607-12). |Black Swiss/129/Ola mixed |No|Unknown|Yes|No|Unknown|Yes|No|Good|||Heterozygotes are crossed to Wildtypes|No|24-May-2012|Cryopreserved sperm|50.0|0.0|Yes|Peters Anomaly|signal transduction, kidney, heart|Yes| 7048.0|FST KO|STOCK Fst/MarpApb||Recessive|follistatin|Fst|Nil||MGI:95586|follistatin; targeted mutation 1, Martin M Matzuk|Fst|MGI:1857467|13|||||||||||||||||||||||||||||Lifespan and health is affected. FS knock-out mice are liveborn, but die within 6 hours of birth due to respiratory failure because of lung and chest muscle defects. These pups display growth retardation, defects of the hard palate and 13th rib, as well as whisker and tooth abnormalities and shiny taut skin.|Normal|C57BL/6 x 129 x FVB|No|No|Yes|No|No|Yes|No|Good|||Het x Het|No|13-Aug-2012|Cryopreserved sperm|50.0|0.0|No||activin, heparan sulphate proteoglycans, skeletal, muscle, teeth|Possibly| 1936.0||BALB/c-Tg(iFABPp-IL13)/AnuApb||Semi-dominant||||||||||||||||||||||||||interleukin 13|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP|High||||||||||Restricted expression of IL13 transgene to intestine - duodenum and proximal jejunum.||Balb/c ?|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Aug-2007|Cryopreserved sperm|150.0|0.0|Unknown||T cell, infection, intestine, interleukin, allergy, gastrointestinal disease, hyperresponsiveness|Yes| 7648.0||B6/Mrit-fech|B6/Mrit-fech|Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|47.0|0.0|Unknown||ENU|No| 4738.0||B6;Cg-H2 Cbl Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb|B6;Cg-H2 Cbl Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd|Recessive|Casitas B-lineage lymphoma|Cbl|Unknown|c-Cbl, cbl, Cbl-2|MGI:88279|targeted mutation 1, David D L Bowtell|Cbl|MGI:2180578|9||||||||||||||||Yes|transgene insertion 3, Christopher C Goodnow|For Tg(ILK3mHEL)3Ccg: Rat insulin promoter|||||||||||Defect in T cell function||B10.BR-H2 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5|hom x hom|No|20-Apr-2009|Cryopreserved sperm|105.0|0.0|Unknown||T cell, T cell receptor (TCR), signal transduction|Yes| 4738.0||B6;Cg-H2 Cbl Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb|B6;Cg-H2 Cbl Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd|Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis ||||||||||||Defect in T cell function||B10.BR-H2 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5|hom x hom|No|20-Apr-2009|Cryopreserved sperm|||Unknown||T cell, T cell receptor (TCR), signal transduction|Yes| 7376.0|ENU26:032:Birc6|C57BL/6NCrlAnu-Birc6/AnuApb|C57BL/6NCrlAnu-Birc6/AnuApb|Recessive|baculoviral IAP repeat-containing 6|Birc6|Unknown|A430032G04Rik, A430040A19Rik, apollon, Bruce, D630005A10Rik|MGI:1276108|baculoviral IAP repeat-containing 6; mutation 1, The Australian National University|Birc6|MGI:5563506|17|ENSMUSG00000024073|ENSMUST00000024879|Birc6-201|14218|14475|C to T|ENSMUSE00001248145|71|4740|Glutamine to STOP|||||AAGCAACGGTTAAATGGGCTATGCTAGAACAAATCAGAAATCCTTCACCGTGCTTTAAAGA||||||||||||||Probably embryonic lethal|Unknown|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Good||3|HET x HET|No|17-Jul-2013|Cryopreserved sperm|36.0|0.0|Unknown||embryo, lethal, ENU|Yes| 7649.0||B6/Mrit-pf|B6/Mrit-pf|Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|No| 7036.0|zeta-BALB/c 390 ; 14-3-3 zeta deficient (Line 390)|C.129-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST405390, Lexicon Genetics|Ywhaz||15|||||||||||||||||||||||||||||Infertile, reduced survival of KO pups at 21 days|None|BALB/c|Yes|No|Yes|Yes|No|Yes|Yes|Good|10||het x het|No|06-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown||14-3-3, signal transduction|Possibly| 7779.0|SGTA KO|B6(Cg)-Sgta<(tm1.1Drmcr)><(OzCre-Gt(ROSA)26Sor)>/J|DRMCR|Semi-dominant|Small Glutamine-Rich Tetratricopeptide Repeat (TPR)-Containing, Alpha|SGTA|Nil|alphaSGT, SGT, Vpu-Binding Protein|MGI:1098703 ||||10|MGI:5788685||B6(Cg)-Sgtatm1.1Drmcr/J||||||||||||||||||||||||||Homozygous SGTA knockout mice weigh less than their wildtype littermates. They appear to give birth to fewer young. |Normal/unknown.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||||No|06-Nov-2014|Cryopreserved sperm|67.0|0.0|No||SGTA, small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha, AR, Androgen receptor|Possibly| 7080.0|Momme D40|FVB/NJ-Uhrf1 Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|ubiquitin-like, containing PHD and RING finger domains, 1|Uhrf1|Unknown|ICBP90, Np95|MGI:1338889|ubiquitin-like, containing PHD and RING finger domains, 1; modifier of murine metastable epialleles, D40|Uhrf1|MGI:5515394|17||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Lethalhomozygous die E10.5|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD40<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|13-Sep-2012|Cryopreserved sperm|29.0|0.0|Unknown||ENU, variegation, modifier|Possibly| 1513.0|eNOSTg|B6.Cg-Tg(Edn1-NOS3)22Yky/Apb|B6.Cg-Tg(Edn1-NOS3)22Yky/Apb|Dominant||||||||||||||||||||||||||transgene insertion 22, Mitsuhiro Yokoyama|mouse Edn1|Active in vascular wall||||||||||Hypotension. Elevated cGMP, plasma nitrate and nitrite levels.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|7|||No|04-Jul-2007|Cryopreserved sperm|90.0|0.0|Unknown||eNOS, connexin, renal arterioles, hypotension|Yes| 7087.0|Bim Des RAG|B10.BR.(Cg)-H2 Bcl2l11/Wehi Rag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|BCL2-like 11 (apoptosis facilitator)|Bcl2l11|Nil|1500006F24Rik, Bim, Bod|MGI:1197519|BCL2-like 11 (apoptosis facilitator); targeted mutation 1.1, Andreas Strasser|Bcl2l11|MGI:2156498|2||||||||||||||||Yes|transgene insertion 10395, Bernd Arnold||||||||||||Similar phenotype as in C57BL/6 mice (Increased numbers of lymphoid and myeloid cells.)Bim-/- females are bad mothers and should not be used for breeding unless necessary. Bim -/-: blood - increased lymphocytes (B + T cells), granulocytes & monocytes. - decreased platelets - Increased serum Ig. Des-TCR onto Bim-deficient background can be generated but problems to generate RAG-/- mice. This strain is thus HETEROZYGOUS for RAG deficiency|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||Yes|20-Sep-2012|Cryopreserved sperm|50.0|0.0|No||T cell, RAG, Lymphoid, CD8, TCR|Yes| 7087.0|Bim Des RAG|B10.BR.(Cg)-H2 Bcl2l11/Wehi Rag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|recombination activating gene 1|Rag1|Normal|Rag-1|MGI:97848||||2|||||||||||||||||||||||||||||Similar phenotype as in C57BL/6 mice (Increased numbers of lymphoid and myeloid cells.)Bim-/- females are bad mothers and should not be used for breeding unless necessary. Bim -/-: blood - increased lymphocytes (B + T cells), granulocytes & monocytes. - decreased platelets - Increased serum Ig. Des-TCR onto Bim-deficient background can be generated but problems to generate RAG-/- mice. This strain is thus HETEROZYGOUS for RAG deficiency|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||Yes|20-Sep-2012|Cryopreserved sperm|||No||T cell, RAG, Lymphoid, CD8, TCR|Yes| 7093.0|F/F x Tlr2; gp130Y757F x Tlr2|STOCK Il6st Tlr2/MarpApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv x BALB/c|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|26-Sep-2012|Cryopreserved sperm|30.0|0.0|Yes|Gastric cancer|gastric, cancer, gp130, tlr|No| 7093.0|F/F x Tlr2; gp130Y757F x Tlr2|STOCK Il6st Tlr2/MarpApb||Dominant|toll-like receptor 2|Tlr2|Nil|Ly105|MGI:1346060|toll-like receptor 2; targeted mutation 1, Shizuo Akira|Tlr2|MGI:2178675|3||||||||||||||||No|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv x BALB/c|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|26-Sep-2012|Cryopreserved sperm|||Yes|Gastric cancer|gastric, cancer, gp130, tlr|No| 7099.0|Fst-oEX|B6;D2-Tg(KRT14-Fst)/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 1, |human keratin-14 (K14)|||||||||||unknown|only one copy required to demonstrate phenotype.Mice demonstrate larger ears, longer tails, reduced body weight, mild dermal and epidermal atrophy and delayed wound healing|B6D2F2|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Het mouse x wt mouse|No|01-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||activin, epidermis, follistatin|Possibly| 7104.0|MT-1/II KO|B6.129-Mt1 Mt2/SaApb||Recessive|metallothionein 1|Mt1|Nil|Mt-1, MT-I|MGI:97171|metallothionein 1; targeted mutation 1, Anna E Michalska|Mt1|MGI:2668454|8|||||||||||||||||||||||||||||Increased circulating alanine transaminase level: in acetaminophen-treated miceAbnormal ion homeostasis: * increased cadmium sensitivity * take up a hunched back posture, ruffed coat and display general lethargyAbnormal lipid homeostasis: acetaminophen-induced lipid peroxidation is increased compared to in similarly treated wild-type mice.Increased sensitivity to xenobiotic induced morbidity/mortality: mice are more sensitive to acetaminophen-induced lethality compared with similarly treated wild-type mice.Increased physiological sensitivity to xenobiotic: * mice exhibit increased susceptibility to acetaminophen-induced hepatotoxicity, alanine aminotransferase, hepatic necrosis, lipid peroxidation, and lethality compared with similarly treated wild-type mice * acetaminophen-induced injuries are not ameliorated by pretreatment with zinc unlike in similarly treated wild-type mice * hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress compared with similarly treated wild-type cells * however, acetaminophen metabolism is normalIncreased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.Abnormal hepatocyte morphology: hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress indicated by lactate dehydrogenase leakage compared with similarly treated wild-type cells.Hepatic necrosis: in acetaminophen-treated micetumorigenesis.Increased tumor incidence: 90% of mice with tumors by 13 weeks (earliest tumors by 9 weeks).Increased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|09-Oct-2012|Cryopreserved sperm|10.0|0.0|Unknown||Zinc, cadmium, diet|Yes| 7104.0|MT-1/II KO|B6.129-Mt1 Mt2/SaApb||Recessive|metallothionein 2|Mt2|Nil|Mt-2, MT-II|MGI:97172|metallothionein 2; targeted mutation 1, Anna E Michalska|Mt2|MGI:2668455|8|||||||||||||||||||||||||||||Increased circulating alanine transaminase level: in acetaminophen-treated miceAbnormal ion homeostasis: * increased cadmium sensitivity * take up a hunched back posture, ruffed coat and display general lethargyAbnormal lipid homeostasis: acetaminophen-induced lipid peroxidation is increased compared to in similarly treated wild-type mice.Increased sensitivity to xenobiotic induced morbidity/mortality: mice are more sensitive to acetaminophen-induced lethality compared with similarly treated wild-type mice.Increased physiological sensitivity to xenobiotic: * mice exhibit increased susceptibility to acetaminophen-induced hepatotoxicity, alanine aminotransferase, hepatic necrosis, lipid peroxidation, and lethality compared with similarly treated wild-type mice * acetaminophen-induced injuries are not ameliorated by pretreatment with zinc unlike in similarly treated wild-type mice * hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress compared with similarly treated wild-type cells * however, acetaminophen metabolism is normalIncreased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.Abnormal hepatocyte morphology: hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress indicated by lactate dehydrogenase leakage compared with similarly treated wild-type cells.Hepatic necrosis: in acetaminophen-treated micetumorigenesis.Increased tumor incidence: 90% of mice with tumors by 13 weeks (earliest tumors by 9 weeks).Increased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|09-Oct-2012|Cryopreserved sperm|||Unknown||Zinc, cadmium, diet|Yes| 7663.0||ENU17China14 ||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Reduced numbers of marginal zone B cells|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Apr-2014|Cryopreserved sperm|21.0|0.0|Unknown||ENU, B cell, lymphocyte|No| 7085.0|floxed CYP27B1 |B6.129-Cyp27b1/Apb||Dominant|cytochrome P450, family 27, subfamily b, polypeptide 1|Cyp27b1|Normal|1alpha(OH)ase, 25-hydroxyvitamin D3 1alpha-hydroxylase, 25(OH)D 1alpha-hydroxylase, Cp2b, Cyp1, Cyp27b, Cyp40, P450c1, P450VD1alpha, Pddr, Vdd1, Vddr, VddrI|MGI:1098274|cytochrome P450, family 27, subfamily b, polypeptide 1; targeted mutation 1.1, Rene St-Arnaud|Cyp27b1|MGI:2656261|10|||||||||||||||||||||||||||||Normal|Normal|C57BL6/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>4|||No|18-Sep-2012|Cryopreserved sperm|50.0|0.0|Yes|pseudovitamin D-deficiency rickets|Vitamin D3, rickets, cytochrome P450|Yes| 6766.0|Ert2/Stat3flox/gp130F |STOCK Stat3 Tg(Gpa33-cre/ERT2)/LudApb||Recessive|signal transducer and activator of transcription 3|Stat3|Normal|1110034C02Rik, Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 2, Shizuo Akira|Stat3|MGI:1926816|11|||||||||||||||||cre recombinase|glycoprotein A33 (transmembrane)|||||||||||Gastric polyps, maybe developing later and fewer than gp130 ff mice, and maybe additional phenotypes in other tissues.|Unknwon|Mixed|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, polyposis|Yes| 115.0|Ben|C57BL/6JSfdAnu-Tg(IghelMG6)6Ccg/AnuApb|C57BL/6JSfdAnu-Tg(IghelMG6)6Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 6, Christopher C Goodnow||High||||||||||B cells express immunoglobulin specific for Hen Egg Lysozyme.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16||No|06-Feb-2006|Cryopreserved sperm|17.0|0.0|No||Hen Egg Lysozyme, HEL, autoimmunity, tolerance, IgM, IgG, B cell|Yes| 7046.0|FST Flox|B6.129-Fst/MarpApb||Dominant|follistatin|Fst|||MGI:95586|follistatin; targeted mutation 2, Martin M Matzuk|Fst|MGI:3040645|13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J x 129S7|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Aug-2012|Cryopreserved sperm|70.0|0.0|No||activin, ovary, granulosa|Possibly| 7259.0|HSA-Cre-ER T2|B6.129S2-Tg(ACTA1-cre/ERT2)97.16Mtz/NrosMarpApb|B6.129S2-Tg(ACTA1-cre/ERT2)97.16Mtz/Nros|Semi-dominant||||||||||||||||||||||||||transgene insertion 97.16, Daniel Metzger|human skeletal alpha-actin (ACTA1)|||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|15-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown||Cre recombinase, tamoxifen, skeletal muscle|Possibly| 7432.0|Y20A|B6.129-Atp4b Tg(Atp4b*Y20A)/Ird/Apb||Dominant|ATPase, H+/K+ exchanging, beta polypeptide|Atp4b|Nil|H+,K+-ATPase, H+/K+-ATPase beta, H,K-ATPase-Beta|MGI:88114|ATPase, H+/K+ exchanging, beta polypeptide; targeted mutation 1, Ian R van Driel|Atp4b|MGI:2158258|8|||||||||||||||||Mutated form of H+/K+ ATPase β subunit|CMV|moderate to high||||||||||Gastric Parietal cells of these mice lacked a tubulovesicular compartment, and the H/K ATPase was resident exclusively on the apical plasma membrane. Despite the inability of the H/K ATPase to be endocytosed, the gastric acid secretory response to histamine or an antagonist was very similar to that of wild-type mice,|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>10|||No|10-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||gastric acid, gastric proton pump, stomach, endocytosis|Possibly| 36.0|Dopey ; ENU3strain:031|B6;NOD-Ddr2/AnuApb|B6;NOD-Ddr2/AnuApb|Recessive|discoidin domain receptor family, member 2|Ddr2||Ntrkr3|MGI:1345277|mutation 1, The Australian National University|Ddr2|MGI:5008734|1|ENSMUSG00000026674|ENSMUST00000170800|Ddr2-202||||||||171932145|6|||TCTCTTCTCTCCTCTTCCCATGGCCTGAGCAGCATGACTGAAGGGCTAGGCCAGTTGACT|Yes|||||||||||||Dwarf, short face||C57BL/6JSfdAnu x NOD/Lt.Cg-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||8||No|06-Feb-2006|Cryopreserved sperm|47.0|0.0|Unknown||Dawrf, ENU, craniofacial|Yes| 1947.0|C57BL/6-TLR-4 ; Teague|B6;129P2-Tlr4/AnuApb|B6;129P2-Tlr4|Recessive|toll-like receptor 4|Tlr4|Nil|lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; targeted mutation 1, Shizuo Akira|Tlr4|MGI:1860885|4||||||||||||||||Yes|||||||||||||Homozygotes for spontaneous or targeted mutations are hyporesponsive to bacterial lipopolysaccharide and more susceptible to infection by gram negative bacteria.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Sep-2007|Cryopreserved sperm|140.0|0.0|Unknown||infection, T cell, inflammation, eosinophil, hyperresponsiveness|Yes| 4704.0|NODβ2M-/- β2Mb homozygous 8.3TCRαβ|NOD.B6-B2m Tg(B2mb)1Rms Tg(TcraTcrbNY8.3)1Pesa/MarpApb||Recessive|beta-2 microglobulin|B2m|Unknown|beta 2 microglobulin, beta2-m, Ly-m11|MGI:88127|targeted mutation 1, Rudolf Jaenisch|B2m|MGI:1927183|2||||||||||||||||Yes|transgene insertion 1, Robyn M Slattery||||||||||||||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|50.0|0.0|Unknown||Autoimmunity, insulin, MHC II, beta cell|Yes| 4704.0|NODβ2M-/- β2Mb homozygous 8.3TCRαβ|NOD.B6-B2m Tg(B2mb)1Rms Tg(TcraTcrbNY8.3)1Pesa/MarpApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Pere Santamaria||||||||||||||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|||Unknown||Autoimmunity, insulin, MHC II, beta cell|Yes| 7047.0|βA Flox|B6.129S7-Inhba/MarpApb||Dominant|inhibin beta-A|Inhba||activin|MGI:96570|inhibin beta-A; targeted mutation 3, Martin M Matzuk|Inhba|MGI:3758877|13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6 x 129S7|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Aug-2012|Cryopreserved sperm|50.0|0.0|No||activin, ovary|Possibly| 4602.0||MRL/MpJ-Fas/MarpApb||Recessive|Fas (TNF receptor superfamily member 6)|Fas|Unknown|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||Yes|||||||||||||Premature death, decreased B cell number, decreased CD4 and CD8 -positive T cell number, decreased activated T cell number, increased double-negative T cell number, enlarged spleen and lymph nodes, abnormal leukocyte rolling - increased adhesion, development of anti-nuclear antibodies, glomerulonephritis. ||MRL/MpJ|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|13-Mar-2009|Cryopreserved sperm|115.0|0.0|Unknown||autoimmunity, T cell, B cell, leukocyte adhesion, glomerulonephritis|Yes| 7260.0|MLC-IGF/F08 (MLC=mIGF-1-8) |B6(Cg)-Tg(Myl1-Igf1)1Nros/MarpApb|B6(Cg)-Tg(Myl1-Igf1)1Nros|Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Naida Rosenthal|myosin light chain|||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|15-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown||Igf1, muscle|Possibly| 7280.0|B6 gamma -/-|C57Bl/6-Fcer1g/J|HOGA|Semi-dominant|FceR gamma chain|FceRIg|Nil||MGI:95496|Fc receptor, IgE, high affinity I, gamma polypeptide; targeted mutation 1, Jeffrey V Ravetch|Fcer1g|MGI:2162818|1||||||||||Unknown to Unknown|||||||||||||||||||normal|normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|12|||Yes|15-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|immune complex disease and allergy|Fc receptor, antibody, immune complex, inflammation, arthritis, thrombocytopenia, osteopetrosis, allergy|Possibly| 75.0|Theodor|ENU4AT:011||Recessive|Unknown||||||||Unknown||||||||||||||||Yes|||||||||||||Low IgG2a response to B. pertussis|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Aug-2004|Cryopreserved sperm|30.0|0.0|Unknown||ENU, Wellcome Trust, memory, immunization, T cell, B cell|Yes| 4601.0||NOD.B6-Socs3/WehiApb||Dominant|suppressor of cytokine signaling 3|Socs3|Normal|CIS3, Cish3, cytokine-inducible SH2 protein 3, E2a-Pbx1 target gene in fibroblasts 10, EF-10, SOCS-3, SSI-3, STAT-induced STAT inhibitor 3|MGI:1201791|targeted mutation 2, Warren S Alexander|Socs3|MGI:2663917|11||||||||||||||||Yes|||||||||||||Normal. When crossed with Cre expressing strain allows deletion of Socs3 in tissue specific manner.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|7||Socs3 x NOD|No|13-Mar-2009|Cryopreserved sperm|130.0|0.0|Unknown||cytokine signalling, G-CSF, STAT3, neutrophil|Yes| 6876.0|BRINP3 Targeted|C57BL/6-Fam5c/Marp||Recessive|family with sequence similarity 5, member C|Fam5c||DBC3, B830045N13Rik|MGI:2443035||||1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7345.0|PTEN lox P locus/MMTV CRE|B6.129P2-Pten Tg(MMTV-Cre)4Mam/Apb||Dominant|phosphatase and tensin homolog|Pten|||MGI:109583|phosphatase and tensin homolog; targeted mutation 2, Tak W Mak|Pten|MGI:2182005|19|||||||||||||||||transgene insertion 4, Lothar Hennighausen|mouse mammary tumor virus (MMTV) long terminal repeat|||||||||||Neoplastic proliferation of prostate and skin tissues|Susceptible to tumour development|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-May-2013|Cryopreserved sperm|45.0|0.0|Unknown||Cre recombinase, pten, prostate, hyperplasia|Yes| 7666.0|Depdc5-w|B6;C-Depdc5/AnuApb|B6.Cg;C-Depdc5/AnuApb|Recessive|DEP domain containing 5|Depdc5|Unknown||MGI:2141101|DEP domain containing 5; mutation 1, Walter and Eliza Hall Institute|Depdc5|MGI:5648439|5|ENSMUSG00000021431|ENSMUST00000091641|Snrnp48-201|794|828|A to G|ENSMUSE00000117800|7|265|Aspartic acid to Glycine|||||CTGGCAGGAAGAGCAGGGGAGAGCAGGAGACGCTGCTGAGAAGAATGAAGAAAGGCGGTCA||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||G3|Het x Het|No|28-Apr-2014|Cryopreserved sperm|72.0|0.0|Unknown||ENU|Possibly| 175.0|OVE550|FVB/N-Tg(Cryaa-Tgfbr2*)550/Apb||Dominant||||||||||||||||||||||||||truncated TGFβ receptor II, kinase deficient|αA-crystallin, Cryaa|||||||||||Nuclear cataract, characterised by rapid apoptosis and death of terminally differentiating lens fibres cells at E18.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Apr-2006|Cryopreserved sperm|50.0|0.0|Unknown||cataract, lens fibres, eye|Yes| 7084.0|MommeD33|FVB/NJ-MommeD33 Tg(Hba1-Gfp)1Ew||Semi-dominant|suppressor of variegation 3-9 1|Su-var39h|Unknown||MGI:1099440|suppressor of variegation 3-9 1; modifier of murine metastable epialleles, D33|Suv39h1|MGI:5515387|X||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||homo viable|Normal|FVB/NJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||MommeD33<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|14-Sep-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, epigenetics, modifier|Possibly| 5552.0|Dravid|C57BL/6-Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfp, Prf-1|MGI:97551|targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10|||||||||||||||||transgene insertion 1100, Michael J Bevan||High - 49 Copies||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Aug-2011|Cryopreserved sperm|45.0|0.0|Unknown||T cell receptor, CD8, ovalbumin, Natural Killer cell|No| 7344.0|PBCre|B6;DBA2-Tg(Pbsn-cre)4Prb/Apb||Dominant||||||||||||||||||||||||||transgene insertion 4, Pradip Roy-Burman|rat Pbsn|||||||||||| Cre recombinase is expressed postnatally in prostatic epithelium with the highest level of expression in the lateral lobe of the prostate gland. A very low level of transgene expression was detected in the seminal vesicles, testes, and ovaries.|(C57BL/6 x DBA/2)F1|No|Yes|Unknown|No|Yes|Unknown|No|Unknown||||No|28-May-2013|Cryopreserved sperm|54.0|0.0|Unknown||Cre recombinase, prostate, epithelium|Possibly| 6775.0|DBC3 Flpe ; BRINP3 Flpe|C57BL/6-Brinp3/Marp||Recessive|family with sequence similarity 5, member C|Fam5c|Normal|DBC3, Fam5c, Brinp3|MGI:2443035|bone morphogenetic protein/retinoic acid inducible neural specific 3; targeted mutation 1.1, Phillip I Bird|Brinp3|MGI:5604621|1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|11-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 4079.0||ENU6PH:058||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Hypo IgE response following allergic challenge.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||6||No|04-Dec-2008|Cryopreserved sperm|15.0|0.0|Unknown||allergic challenge, ENU, Immunoglobulin, IgE|No| 8574.0|MMTV-Neu/FVB/N|FVB-Tg(MMTVneu)/WehiVccc||Dominant||||||||||||||||||||||||||transgene insertion 202, William Muller|MMTV (mouse mammary tumor virus)|||||||||||These mice develop tumours at approximately 6 - 8 months. Mammary adenocarcinoma.Metastatic potential.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Sep-2018||0.0|87.0|Yes||Her2, breast cancer, signal transduction, c-erbB2, tyrosine kinase, adenocarcinoma|Yes| 4811.0|ENU8BAT:070:Banjora|C57BL6-Tg<(ILK3mHEL)3Ccg><(TcrHEL3A9)1Mmd>/AnuApb||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|45.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4811.0|ENU8BAT:070:Banjora|C57BL6-Tg<(ILK3mHEL)3Ccg><(TcrHEL3A9)1Mmd>/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4086.0||ENU8PH:025 , Cletus||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Alopecia (Hair loss).||C57BL/6 x C57BL/10 x Balb/b|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||3||No|04-Dec-2008|Cryopreserved sperm|60.0|0.0|Unknown||Alopecia, Hair loss, follicle, ENU|No| 7121.0|Id3Fva∆|FVB/N(Cg)-Id3/AusbApb||Recessive|inhibitor of DNA binding 3|Id3|Nil|bHLHb25, HLH462, Idb3|MGI:96398|inhibitor of DNA binding 3; targeted mutation 1, Cornelis Murre|Id3|MGI:3046425|4|||||||||||||||||||||||||||||Id3 nulls do not breed.Although ID3 deficiency (Id3(-/-) mice) had no noticeable impact on epididymal histology, the targeted mutation adversely affected sperm motility parameters. Moreover, principal component analysis of microarray data indicated that the gene expression signatures for tissues obtained from Id3(-/-) mice and their genotypic controls were distinct from each other in each epididymal region. The predominant effect of the Id3 null mutation was in the cauda region where the expression of many transcription factors, including Hoxb8 and Bclaf1, was markedly affected.Abnormal T cell differentiation: * the total number of thymocytes is unchanged however the percent and total number of CD4 single positive cells is significantly decreased and the percent and total number of CD8 single positive cells is slightly decreased * after 5 generations of backcrossing onto a C57BL/6J background slightly increased compared to wild-typeAbnormal double-positive T cell morphology: a small but consistent increase in CD5 expression is seen compared to wild-type littermates|None|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|6||Heterozygous pairs|No|31-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||transcription factor, DNA binding, helix-loop-helix|Yes| 8573.0|UBC-Cre/ERT2 Tg x FVB/N ; iCre|FVB/N.Cg-Tg(UBC-cre/ERT2)1Ejb/VcccApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Eric J Brown|human ubiquitin C (UBC) promoter||||||||||||Mice display tamoxifen-inducible Cre activity in all tissue types. |FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Sep-2018||0.0|30.0|Unknown||Cre recombinase, inducible, tamoxifen|Yes| 1750.0|Lck-Cre|B6.129-Tg(Lck-cre)157Jxm/WehiAnuApb||Dominant||||||||||||||||||||||||||targeted mutation I57, Jamey Marth; transgene insertion I57, Jamey Marth|mouse proximal Lck promoter|active in thymocytes and splenocytes||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10|sib x sib|No|02-Aug-2007|Cryopreserved sperm|82.0|0.0|Unknown||Cre recombinase, loxP, T cell, lymphocyte, expression|Yes| 5199.0|tghFS288(mFS WT)|129/C57BL6/FVB/N-Tg(hFST<288>)/Marp||Dominant||||||||||||||||||||||||||Human follistatin-288 splice variant|endogenous human promoter|unknown||||||||||Unknown|Hemizygous: normal Note: An abnormal phenotype is not observed until these mice are bred onto a mouse follistatin knockout background|129 x C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|04-Aug-2010|Cryopreserved sperm|50.0|0.0|No||FST315, FST288, angiogenesis, ovary|Possibly| 7206.0|classII-mOVA|C57BL/6-Tg(H2-Ab1-TFRC/OVA)3Cbn/Apb|C57BL/6-Tg(H2-Ab1-TFRC/OVA)3Cbn|Dominant||||||||||||||||||||||||||ovalbumin residues 139-385 fused to transferrin receptor membrane domain|MHC class II|moderate||||||||||NormalClass II mOVA mice express a membrane-bound form of ovalbumin (transferrin receptor membrane domain and OVA residues 139-385) under the control of the MHC class II promoter. OVA expression is directed to the membranes of cells that express MHC class II, such as B cells, macrophages and dendritic cells.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Nov-2012|Cryopreserved sperm|45.0|0.0|No||MHC, ovalbumin, B cell|Yes| 2744.0|SXR|B6.CBA-Tg(Sox3)1Pqt/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Paul Q Thomas|Sox3 promoter|2 copies; High with aberrant expression in gonads and CNS||||||||||Transgenic line only maintained as hemizygous. |High Sox3 expression with aberrant expression in gonads and CNS. Heterozygous females will develop phenotypically as males in approximately 80% of cases. These animals also have occasional dwarfism as well as a tendency to develop hydrocephalus due to CNS abnormalities. Sex-reversed XX tg/+ males are sterile|CBA x C57BL/6|No|No|Yes|No|No|Yes|No|Good|||Tg/+ Male mated to a wildtype female|No|10-Feb-2008|Cryopreserved sperm|120.0|0.0|Yes||Sex reversal, gonads, Sox3, Sry, Brain development|Yes| 7358.0|ENU25 26 TNPO3|C57BL/6NCrlAnu-Tnpo3/AnuApb|C57BL/6NCrlAnu-Tnpo3/AnuApb|Recessive|transportin 3|TNPO3|Unknown|5730544L10Rik, C430013M08Rik, D6Ertd313e |MGI:1196412|transport in 3; mutation 1, The Australian National University|Tnpo3|MGI:5563403|6|ENSMUSG00000012535|ENSMUST00000012679|Tnpo3-001|1508|1910|A to T|ENSMUSE00001238723|12|503|Leucine to STOP|||||CCGGAATCCCCAGTTCCTGGACCCTGTATTGGGCTATTTGATGAAAGGCCTGTGTGAAAAG||||||||||||||Homozygous mutation appears lethal|Heterozygous mice appear healthy and normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Good||Generation 4|HET x HET|No|20-Jun-2013|Cryopreserved sperm|36.0|0.0|Unknown||lethal, embryo, ENU|Possibly| 4997.0|ENU6AT:HELxTCR:line057:CBA:F2 ; Diablo|C57BL/6J: B10.BR/SgSnJ-Tg(ILK3mHEL)<3Ccg>Tg(TcrHEL3A9)<1Mmd>||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background.Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|75.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4997.0|ENU6AT:HELxTCR:line057:CBA:F2 ; Diablo|C57BL/6J: B10.BR/SgSnJ-Tg(ILK3mHEL)<3Ccg>Tg(TcrHEL3A9)<1Mmd>||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background.Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4516.0||ENU8C:011||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|60.0|0.0|Unknown||autoimmunity, Antinuclear antibodies (ANA), ENU, Wellcome Trust|Yes| 5297.0|CD39 KO|C57BL/6-Entpd1||Recessive|ectonucleoside triphosphate diphosphohydrolase 1|Entpd1|Nil|Cd39, ectoapyrase, NTPDase-1|MGI:102805|ectonucleoside triphosphate diphosphohydrolase 1; targeted mutation 1, Robert D Rosenberg|Entpd1|MGI:2182811|19||||||||||||||||No|||||||||||||Cardiac fibrosis.Abnormal blood flow velocity: terminal erythrocyte velocity is increased (17.1+/-5.2 compared to 3.3+/-3.3 mm per second in wild-type mice).Abnormal vascular endothelial cell physiology: ATPase and ADPase activities are substantially decreased compared to in wild-type mice.Decreased platelet cell number: platelet count is 20% lower than in wild-type mice (538+/-78x103 per mm3 compared to 740+/-81x103 per mm3 in wild-type mice).Decreased platelet aggregation: * in vitro, platelets fail to aggregate in response to ADP, collagen or low doses of thrombin. * however, treatment with a soluble potato ATPase restores aggregation response.Increased bleeding time: * bleed time is increased to greater than 20 minutes in 4 mice and greater than 7 minutes in 7 mice compared to 1.0+/-0.2 minutes in heterozygous mice. * treatment with ferric chloride revealed a delay in platelet plug formation with no thrombi formation after 20 minutes compared to 100% in wild-type mice.Abnormal neutrophil physiology: * polymorphonuclear (PMN) cells fail to convert etheno-AP into etheno-AMP as do wild-type PMNs. * following activation, the supernatant surrounding PMNs accumulate 1.6+/-0.09-fold more ATP than from wild-type PMNs. * unactivated PMN supernatant accumulates more ATP than wild-type.Fibrosis: mice exhibit increased fibrin deposits in the lungs, heart and spleen and in some mice the liver, kidney and brainPulmonary fibrosis: fibrin deposits are present in the lungs and worsen after thrombogenic challenge.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||vascular adenosine triphosphate diphosphohydrolase, platelet, coagulation|Possibly| 7246.0|MLC-hAP|C57BL/6-Tg(Myl1-AP)1Nros/MarpApb||Semi-dominant||||||||||||||||||||||||||human alkaline phosphatase|myosin light chain (MLC)|||||||||||Unknown|Normal.Expression of human alkaline phosphatase in skeletal muscle.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|12-Dec-2012|Cryopreserved sperm|70.0|0.0|Unknown|||Possibly| 4478.0||129-Nos2/AnuApb||Recessive|nitric oxide synthase 2, inducible|Nos2|Unknown|iNOS, Nos-2, NOS-II, Nos2a|MGI:97361|nitric oxide synthase 2, inducible; targeted mutation 1, John S Mudgett|Nos2|MGI:2158791|11||||||||||||||||No|||||||||||||||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|22-Feb-2009|Cryopreserved sperm|120.0|0.0|Unknown||infection, macrophage, interferon|Yes| 7254.0|FTL-BALB/C|BALB/c-Tg(fos-tau/LacZ)/Apb||Dominant||||||||||||||||||||||||||FOS-TAU-LACZ|C-FOS|Distribution and expression similar to engogenous c-fos||||||||||Normal|Normal|BALB/c|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Excellent|>30||FTL+ FEMALE X FTL+ MALE|No|09-Jan-2013|Cryopreserved sperm|40.0|0.0|No||c-fos, functionally activated neurons, BALB/c, marker mice, neuronal activation, LacZ, beta-galactosidase|Yes| 5298.0|CD39.Tg|C57BL/6-Tg(H2-K-ENTPD1)||Dominant||||||||||||||||||||||||||human ectonucleoside triphosphate diphosphohydrolase-1|H2-K||||||||||||Human CD39 (hCD39) is widely expressed in transgenic mice.hCD39 prolongs bleeding times and protects against induced thrombosis.AMP and adenosine levels are increased in hCD39 transgenic mice.hCD39 protects transgenic mouse cardiac grafts from Ab-mediated rejection.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||transplantation, ischemia-reperfusion injury (IRI), thrombosis, AMP and adenosine, rejection|Possibly| 2745.0|NSXR|B6.CBA-Tg(Sox3-EGFP)NrPqt/Apb||Dominant||||||||||||||||||||||||||transgene insertion Nr, Paul Q Thomas|Sox3 promoter|High level of expression at restricted regions in CNS||||||||||N/A as transgenic line is maintained at hemizygous state state|High level of expression at restricted regions in CNS. Hydrocephalus with at least 10% penetrance.|CBA x C57BL/6|No|No|Yes|No|No|Yes|No|Poor|||Tg/+ male to wt female|No|10-Feb-2008|Cryopreserved sperm|130.0|0.0|Unknown||Sry, Sox3, CNS development, Brain development|Yes| 5299.0|B6.TBM.Tg|C57BL/6-Tg(H2-K-THBD)||Dominant||||||||||||||||||||||||||human thrombomodulin|H2-K|Strong on peripheral blood lymphocytes|||||||||||hTBM transgenic mice were indistinguishable from WT littermates in appearance, size, level of activity and fertility.Transgenically expressed hTBM protects against pulmonary arterial thromboembolism.Transgenically expressed hTBM protects against venous thrombosis.Transgenically expressed hTBM reduces the inflammatory infiltrate after IVC ligation.Transgenically expressed hTBM reduces HMGB1 levels.Transgenically expressed hTBM prolongs cardiac graft survival and reduces infiltrating T cells.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||coagulation, rejection, thrombosis, xenotransplantation, T cell|Possibly| 8575.0|LGN-VenusC|B6.Cg-Gpsm2/FumaVcccApb||Dominant|G-protein signalling modulator 2 (AGS3-like, C. elegans)|Gpsm2||6230410J09Rik, LGN, Pins|MGI:1923373|G-protein signalling modulator 2 (AGS3-like, C. elegans); targeted mutation 1.1, Fumio Matsuzaki|Gpsm2|MGI:3850859|3|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Sep-2018||0.0|40.0|Unknown||Neuroepithelial progenitors, spindle orientation|Yes| 7362.0|Grhl3 flox|B6.129S1-Grhl3/MarpApb||Recessive|grainyhead-like 3 (Drosophila)|Grhl3|Normal||MGI:2655333|grainyhead-like 3 (Drosophila); targeted mutation 3.1, Stephen M Jane|Grhl3|MGI:5306651|4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||fl/fl x fl/fl|No|26-Jun-2013|Cryopreserved sperm|37.0|0.0|Unknown||squamous cell carcinoma (SCC), signalling, transcription factor|Possibly| 7082.0|Momme D31|FVB/NJ-Trim28 Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|tripartite motif-containing 28 |Trim28|Unknown|KAP-1, KRIP-1, Tif1b|MGI:109274|tripartite motif-containing 28; modifier of murine metastable epialleles, D31|Trim28|MGI:5515385|7||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Death at E6-E8|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD31<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|13-Sep-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, epigenetics, modifier|Possibly| 7257.0|MLC:2IGF-1B_3D (Class 2Eb) ; SP2-IGF-1Eb|B6.FVB-Tg(Myl1-SP2/IGF1Eb)1Nros/MarpApb|B6.FVB-Tg(Myl1-SP2/IGF1Eb)1Nros|Semi-dominant||||||||||||||||||||||||||mouse insulin-like growth factor-1|myosin light chain|skeletal muscle||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|15-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown||E-peptide, extracellular matrix|Possibly| 7258.0|MLC-Cre|B6.FVB-Tg(Myl1-cre)13Nros/MarpApb|B6.FVB-Tg(Myl1-cre)13Nros|Semi-dominant||||||||||||||||||||||||||Tg(Myl1-cre)13Nros|myosin light chain (MLC)|||||||||||Unknown|Normal.Expression of cre recombinase in skeletal muscle.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|15-Jan-2013|Cryopreserved sperm|54.0|0.0|Unknown||Cre recombinase, muscle|Possibly| 7310.0|K5rTA-Rae1-32|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)32Cbn/Apb||Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.Following doxycycline treatment, RaeT1e expression is weak in these mice.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 7310.0|K5rTA-Rae1-32|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)32Cbn/Apb||Dominant||||||||||||||||||||||||||retinoic acid early transcript 1E|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.Following doxycycline treatment, RaeT1e expression is weak in these mice.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|||Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 5008.0|Hbdd5.1|C57BL/6-Ptprc Hbb||Dominant|||||||||||||||||||||||||||||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|C57BL/6 mice express the a allele of Ptprc and the d allele of hemoglobin beta chain. Both alleles are homozygous.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-Feb-2010|Cryopreserved sperm|100.0|0.0|Unknown||erythroid, haemoglobin|Possibly| 5008.0|Hbdd5.1|C57BL/6-Ptprc Hbb||Dominant|||||||||||||||||||||||||||||hemoglobin beta chain complex|Hbb|||MGI:96020|hemoglobin beta chain complex; d|Hbb|MGI:1858119|7|C57BL/6 mice express the a allele of Ptprc and the d allele of hemoglobin beta chain. Both alleles are homozygous.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-Feb-2010|Cryopreserved sperm|||Unknown||erythroid, haemoglobin|Possibly| 7363.0|RhoGEF19 flox|B6.129S1-Arhgef19/Marp||Recessive|Rho guanine nucleotide exchange factor (GEF) 19|Arhgef19|Normal|6430573B13Rik, WGEF|MGI:1925912|Rho guanine nucleotide exchange factor (GEF) 19, targeted mutation 1 Stephen Jane|Arhgef19||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||fl/fl x fl/fl|No|27-Jun-2013|Cryopreserved sperm|47.0|0.0|Unknown||Rho, signal transduction|Possibly| 5152.0||ENU7B6:039 (ANA)||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6JStdAnu X CBA/CaJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|2|1||No|11-Jun-2010|Cryopreserved sperm|40.0|0.0|Unknown||Antinuclear antibodies, autoimmune disease, ENU, Wellcome Trust, NIH|Yes| 6916.0|FVBNJ-Momme D23|FVB/NJ-Smchd1 Tg(HBA1-Gfp)3Ew/Apb||Semi-dominant|SMC hinge domain containing 1|Smchd1||4931400A14Rik, mKIAA0650, MommeD1|MGI:1921605|SMC hinge domain containing 1; modifiers of murine metastable epiallele D1|Smchd1|MGI:5515369|17||||||||||Unknown to Unknown|||||||transgene insertion 3, Emma Whitelaw|Human α-Globin (-570 to +37) (4.1kb of enhancer)|36 copies||||||||||Lethal|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|25-Jun-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, DNA methylation, epigenetic|Possibly| 205.0|Nkx2-5 KO|C57BL/6-Nkx2-5/Apb||Dominant|NK2 transcription factor related, locus 5 (Drosophila)|Nkx2-5|Nil|Csx, Nkx-2.5, Nkx2.5, tinman|MGI:97350|targeted mutation 4, Richard P Harvey|Nkx2-5|MGI:3655239|17||||||||||||||||Yes|||||||||||||Arrested cardiac development, death E9.5-10|atrial septal abormalities, AV conduction defect|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|20-Apr-2006|Cryopreserved sperm|40.0|0.0|Unknown||heart, cardiac, embryonic lethal, homeobox, septal, valvular|Yes| 7289.0|TCRF5|B6(Cg)-Tg(Cd2-TcraF5,CD2-TcrbF5)1Kio/AnuApb|B6(Cg)-Tg(Cd2-TcraF5,CD2-TcrbF5)1KioAnu|Dominant||||||||||||||||||||||||||transgene insertion 1, Dimitris Kioussis|CD2 minigene|||||||||||This clone is CD8+ and recognises amino acids 366-374 of the nucleoprotein (NP 366-374) of influenza virus (A/NT/60/68), in the context of Class I MHC Db (Townsend et al., 1986). The usage of V beta 11 makes this TcR reactive to Class II IE molecules and an endogenous ligand recently identified as a product of the endogenous mammary tumour viruses (Mtv) 8, 9, and 11 (Dyson et al., 1991). The development of F5 transgenic T cells and their function in mice of the appropriate MHC (C57BL/10 H-2b, IE-) or in mice expressing Class II MHC IE (e.g., CBA/Ca H-2k and BALB/c H-2d) and the endogenous Mtv ligands. Positive selection of CD8+ T cells expressing the V beta 11 is seen in C57BL/10 transgenic mice (H-2b). Peripheral T cells from these mice are capable of killing target cells in an antigen-dependent manner after a period of in vitro culture with IL-2. In the presence of Class II MHC IE molecules and the endogenous Mtv ligand, most of the single-positive cells carrying the transgenic T-cell receptor are absent in the thymus. Unexpectedly, CD8+ peripheral T-cells in these (H-2k or H-2d) F5 mice are predominantly V beta 11 positive and also have the capacity to kill targets in an antigen-dependent manner. This is true even following backcrossing of the F5 TcR transgene to H-2d scid/scid mice, in which functional rearrangement of endogenous TcR alpha- and beta-chain genes is impaired.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Mar-2013|Cryopreserved sperm|27.0|0.0|No||T cell receptor, T cell, influenza, cytotoxic, CD8|Yes| 4724.0|Gpx1 -/-|B6.129-Gpx1/MarpApb||Recessive|glutathione peroxidase 1|Gpx1|Unknown|cellular GPx, CGPx, Gpx, GPx-1, GSHPx-1|MGI:104887|targeted mutation 1, Ismail Kola|Gpx1|MGI:2388705|9||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations show increased sensitivity to the oxidative stress agents paraquat and hydrogen peroxide and to ischemia/reperfusion and cold-induced brain injury. Mutants also show paradoxical bradykinin-induced vasoconstriction.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2009|Cryopreserved sperm|100.0|0.0|Unknown||oxidative stress, hydrogen peroxide (H2O2), neurodegeneration, NF-kappaB|Yes| 4735.0|Analiese|ENU5WT:035||Recessive|||Unknown|||Analiese|||Unknown||||||||||||||||Yes|||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6 x C57BL/10.Br|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||9||No|19-Apr-2009|Cryopreserved sperm|40.0|0.0|Unknown||autoimmunity, ENU, Wellcome Trust|Yes| 7305.0|RIP-mOVA|C57BL/6-Tg(Ins2-TFRC/OVA)Wehi/WehiApb||Dominant||||||||||||||||||||||||||transgene insertion, Walter and Eliza Hall Institute of Medical Research|rat insulin 2|||||||||||Normal. Mice express OVA in the pancreas beta cells and kidney proximal tubular cells. There is low level expression in the testes. No thymic expression detected but when crossed to OT-I TCR Tg mice, the OT-I T cells were deleted indicating low levels of OVA expression in the thymus.|Normal|C57BL/6|No|Unknown|Yes|No|Unknown|Yes|No|Good||>30|Tg x C57BL/6|No|05-Apr-2013|Cryopreserved sperm|50.0|0.0|No||pancreas, autoimmunity, ovalbumin|Yes| 6645.0|NOD.BID|NOD.B6-Bid/WehiStvApb||Dominant|BH3 interacting domain death agonist|Bid|Nil|2700049M22Rik|MGI:108093|BH3 interacting domain death agonist; targeted mutation 1.1, Andreas Strasser|Bid|MGI:4440571|6|||||||||||||||||||||||||||||Homozygous null mutants survive with little or no liver damage after injection with antibody against Fas, whereas wild-type mice normally die from hepatocellular apoptosis and hemorragic necrosisHomozygous null mice develop spontaneous type 1 diabetes at the same incidence as wild-type NOD mice.|Normal|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|10|Sister x Brother (hom x hom)|Yes|14-Nov-2011|Cryopreserved sperm|50.0|0.0|No||type 1 diabetes, beta cell apoptosis, NOD mouse, BH3-interacting , domain death agonist|Possibly| 7341.0|MommeD43|FVB/NJ-Setdb1 Tg(Hba1-Gfp)1Ew/QimrApb||Dominant|SET domain, bifurcated 1|Setdb1|Unknown|ESET, KMT1E, mKIAA0067|MGI:1934229|SET domain, bifurcated 1; modifiers of murine metastable epiallele D43|Setdb1||3|ENSMUSG00000015697|ENSMUST00000015841|Setdb1-005|||||||||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Normal|Percentage of cells expressing the GFP transgene is decreased (enhancer of variegation).|FVB/NJ|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||||No|27-May-2013|Cryopreserved sperm|45.0|0.0|Unknown||epigenetics, modifier, ENU|Yes| 4702.0|NOD.MRL(C3)-Fas/LtJ|NOD.Cg-Fas/Apb||Recessive|Fas (TNF receptor superfamily member 6)|Fas|Unknown|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||Yes|||||||||||||Mutations in this locus affect immune function and homozygotes show varying severity of lymphadenopathy, splenomegaly, lymphocytic infiltrations, elevated immunoglobulin levels, autoantibodies, impaired clonal deletion of T cells, and lupus-like disease.||NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|95.0|0.0|No||Autoimmunity, systemic lupus erythromatosis (SLE)|Yes| 4517.0|anda|ENU8C:014||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, Antinuclear antibodies (ANA), ENU, Wellcome Trust|Yes| 5154.0|RRFUR|BALB/c-FLii Gt(ROSA)26Sor/AnuApb||Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fliih|MGI:1342286|flightless I homolog (Drosophila); targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11|||||||||||||||||gene trap ROSA 26, Philippe Soriano; targeted mutation 1.1, Hugh D Campbell|SV40|Human FLII is not expressed until genetic exposure to Cre recombinase||||||||||Normal. Rescue of embryonic lethal phenotype of Flii strain.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|4||Hom x Hom|No|15-Jun-2010|Cryopreserved sperm|39.0|0.0|Unknown||ROSA, gelsolin, wound|Yes| 4116.0|Crimpy|ENU12WT:012a||Semi-dominant|||||||||Unknown||||||||||||||||Yes|||||||||||||First coat appears as wavy or crimped. Affected mice shed coat at 3-5 weeks. New coat growth is short, dense and dull. |||Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|05-Dec-2008|Cryopreserved sperm|30.0|0.0|Unknown||Coat, Fur, Wavy, Crimped, ENU|Yes| 7343.0|MommeD45|FVB/NJ-Klf1 Tg(Hba1-Gfp)1Ew/QimrApb||Dominant|Kruppel-like factor 1 (erythroid)|Klf1|Normal|Eklf, Nan|MGI:1342771|Kruppel-like factor 1 (erythroid); modifiers of murine metastable epiallele D45|Klf1|MGI:5752592|8|ENSMUSG00000054191|ENSMUST00000067060|Klf1-201|||A to G||||Unknown to Unknown||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||GFP transgene expression levels are increased (suppressor of variegation) in MommeD45.|GFP transgene expression levels are increased (suppressor of variegation) in MommeD45.|FVB/NJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|27-May-2013|Cryopreserved sperm|45.0|0.0|Unknown||epigenetics, modifier, ENU|Yes| 5084.0|Cas-L KO|C57BL/6-Nedd9/AnuApb||Recessive|neural precursor cell expressed, developmentally down-regulated gene 9|Nedd9|Nil|Cas-L, CasL, E230025G09Rik, HEF1|MGI:97302|neural precursor cell expressed, developmentally down-regulated gene 9; targeted mutation 1, Mineo Kurokawa|Nedd9|MGI:3700233|13||||||||||||||||No|||||||||||||Abnormal B cell number.Increased follicular B cell number: follicular zone B cells (FOB, B-2 cells) are concomitantly increased.Decreased lymphocyte cell number: there are reduced lymphocyte numbers in peripheral lymphoid organs in mutants.Decreased marginal zone B cell number: marginal zone B cell numbers are reduced in mutants, as shown by reduced CD1d cell numbers or IgMIgD cell numbers.Spleen hypoplasia: splenocyte number is ~50% of wild-type; both B and T cell numbers are reduced, with B cells more affected.Lymph node hypoplasia: total number of lymphocytes and numbers of T and B cells is significantly reduced compared to wild-type.Abnormal follicular B cell physiology: follicular zone B cells show aberrant migration and adhesion in response to chemotactic stimuli, compared to wild-type cells.Abnormal leukocyte migration: mutant splenocytes injected into wild-type hosts show abnormal homing with numbers of homing mutant cells found in spleen and lymph nodes decreased compared to wild-type cells.Abnormal T cell physiology: splenic T cells show attenuated responses to chemotactic (CXCL12 and CCL21) stimuli.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2010|Cryopreserved sperm|50.0|0.0|Unknown||Lymphocyte, migration, integrin, marginal zone (MZB), adhesion|Yes| 5533.0|B6NT|C57BL/6-Tg(Nup98-Top1)/MarpApb||Dominant||||||||||||||||||||||||||Nup98-top1 fusion|Topoisomerase I|||||||||||Normal.Normal blood counts at 6mo, no anemia, lymphopenia or thrombocytopenia in mice aged to 600 days|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sibling matings; transgenic male with wildtype female|No|07-Jul-2011|Cryopreserved sperm|60.0|0.0|No||Nup98, AML, nucleoprotein, leukaemogenic|Possibly| 4797.0|PLJ|PLJ||Dominant||||||||||||||||||||||||||||||||||||||Normal||PLJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Sep-2009|Cryopreserved sperm|110.0|0.0|Unknown||PLJ|Yes| 4926.0||B6;129-Gfpt2/Apb||Recessive|glutamine fructose-6-phosphate transaminase 2|Gfpt2|Unknown|GFAT2|MGI:1338883|glutamine fructose-6-phosphate transaminase 2; gene trap 352F9, Centre for Modeling Human Disease|Gfpt2|MGI:4965721|11||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Nov-2009|Cryopreserved sperm|90.0|0.0|Unknown||glucosamine, hexosamine|Yes| 4986.0|K14-Frem1|C57BL/6-Tg(KRT14-Frem1)||Dominant||||||||||||||||||||||||||Fras1 related extracellular matrix protein 1|keratin 14 (K14)|||||||||||Unknown||C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|27-Jan-2010|Cryopreserved sperm|63.0|0.0|Unknown|||Yes| 7353.0|Gnat2c.518A>G|BALB/c-Gnat2/MelbApb||Recessive|guanine nucleotide binding protein, alpha transducing 2|Gnat2|Normal|Gnat-2, Gt-2, Tcalpha |MGI:95779|Gnat2c.518A>G|||3|||||||||||||||||||||||||||||This mouse shows no evidence of cone photoreceptor function as measured by the electroretinogram. This lack of function probably results from a misfolding of the Gnat2 protein. There is also retinal remodelling, opsin mislocalisation by 3 months, increasing in severity by 12 months. At 12 months there is evidence of cone photoreceptor cell loss. At these late ages, there is also evidence of rod phototreceptor functional loss. |Unknown|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|approximately 4|unknown||No|17-Jun-2013|Cryopreserved sperm|50.0|0.0|Yes|Achromatopsia, ACHM4|retina, cone photoreptor, achromatopsia, eye, vision|No| 1988.0|Nkx2-5Cre x Nodal flox|129-Nkx2-5 Nodal/Apb||Recessive|Nodal|Nodal|Unknown||MGI:97359||||10||||||||||Unknown to Unknown||||||Yes|||||||||||||Deletion of Nodal in Nkx2-5 expressing cells.|||No|No|Yes|No|No|Yes|No|Unknown||||No|05-Sep-2007|Cryopreserved sperm|50.0|0.0|Unknown||heart, ventricle, mesoderm|Yes| 1988.0|Nkx2-5Cre x Nodal flox|129-Nkx2-5 Nodal/Apb||Recessive|NK2 transcription factor related, locus 5 (Drosophila)|Nkx2-5|Unknown|Csx, Csx, Nkx-2.5, Nkx2.5, tinman|MGI:97350|NK2 transcription factor related, locus 5 (Drosophila); targeted mutation 2, Richard P Harvey|Nkx2-5|MGI:2448972|17|||||||||||||||||||||||||||||Deletion of Nodal in Nkx2-5 expressing cells.|||No|No|Yes|No|No|Yes|No|Unknown||||No|05-Sep-2007|Cryopreserved sperm|||Unknown||heart, ventricle, mesoderm|Yes| 4526.0||B6.CBA-Tg(hGMCSF-CK1m)394/AnuApb||Dominant||||||||||||||||||||||||||human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2009|Cryopreserved sperm|30.0|0.0|Unknown||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 6774.0|DBC2 Flpe ; BRINP2 Flpe|C57BL/6-Brinp2/PibMarpApb||Recessive|bone morphogenic protein/retinoic acid inducible neural-specific 2|Brinp2|Normal|DBC2, Fam5b, 6430517E21Rik, mKIAA1747|MGI:2443333|bone morphogenic protein/retinoic acid inducible neural-specific 2; targeted mutation 1.2, Phillip I Bird|Brinp2|MGI:5604617|1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|11-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7374.0|CB28-KO|B6.129-Calb1/Apb||Dominant|calbindin 1|Calb1||Brain-2, Calb, Calb-1, calbindin, calbindin-D (28k), CalbindinD28K, CB|MGI:88248|calbindin 1; targeted mutation 1, Max-Planck-Institute for Neurobiology|Calb1|MGI:1857460|4|||||||||||||||||||||||||||||Ataxia• mutants do not display ataxia in standard environments; when challenged (with a runway test or rotarod test) coordination is severely disturbed compared to controls• mice display a shaky tremor which usually worsens during movement; controls do not show any tremors|Ataxia• 2-month old heterozygotes show significant deficits in initial trials in a thin horizontal rod test compared to controls but are significantly better than homozygotes; after first 2 sessions, no significant difference remains between mutant groups|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Jul-2013|Cryopreserved sperm|50.0|0.0|Unknown||ataxia, calcium|Yes| 7264.0||Ggn KO (-Neo)||Recessive|gametogenetin|Ggn|Unknown|GGN1, GGN2, GGN3|MGI:2181461||||7||||||||||||||||Yes|||||||||||||Embryonic Lethal|Appear normal, not studied extensively.|C57BL/6J x129Sv|No|No|Yes|No|No|Unknown|No|Unknown||||No|21-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown||Sperm, testis, embryonic lethal|Possibly| 7247.0|MLC:2IGF-1A_1C (Class 2Ea) ; SP2-IGF-1Ea|STOCK Tg(Myl1-Igf1)1Nros/MarpApb||Semi-dominant||||||||||||||||||||||||||mouse insulin-like growth factor-1|myosin light chain|||||||||||Transgenic IGF-1 propeptides are retained in skeletal muscle.E peptides bind to heparin agarose.IGF-1 E peptide moieties bind to extracellular matrix.|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|12-Dec-2012|Cryopreserved sperm|60.0|0.0|Unknown||insulin like growth factor, extracellular matrix, serum, circulation|Possibly| 7380.0|Batf3 KO|B6.129-Batf3/MelbAnuApb||Recessive|basic leucine zipper transcription factor, ATF-like 3|Batf3|Nil|9130211I03Rik|MGI:1925491|basic leucine zipper transcription factor, ATF-like 3; targeted mutation 1, Kenneth M Murphy|Batf3|MGI:3817232|Unknown|||||||||||||||||||||||||||||Mice that are homozygous for this allele are viable and fertile. Batf3 is highly expressed in CD11c+ CD8α+ conventional dendritic cells (cDCs), with low to absent expression in other immune cells.The deletion of Batf3 prevents development of splenic CD8α+ cDCs, which are important for cross-presentation during infections. Lymph nodes and thymi of Batf3-/- mice lack CD8α+ DCs, and DCs generated from Batf3-/- bone marrow (BM) and spleens are deficient in Toll-like receptor (TLR) 3-induced interleukin (IL)-12 production. These mice also lack CD103+CD11b- DCs in the lung, intestine, mesenteric lymph nodes (MLNs), dermis, and skin-draining lymph nodes. Exhibiting defects in CD8+T cell response priming, including lack of virus-specific responses, results in the inability to reject highly immunogenic syngeneic tumors.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Unknown|No|Unknown||||No|19-Jul-2013|Cryopreserved sperm|54.0|0.0|Unknown||CD8, T cell, infection, dendritic cell|Yes| 2399.0||MRL/MpJ||Dominant||||||||||||||||||||||||||||||||||||||The MRL/MpJ mice are large but docile to the point that males rarely fight. Mice submitted to APB for sperm cryopreservation bred as a control for MRL/MpJ-Faslpr, also exhibit autoimmune disorders but symptoms are manifested much later in life compared to those the MRL/MpJ-Fas mice. Starting at about three months of age, levels of circulating immune complexes rise greatly in the MRL-Fas mouse but not in the wildtype control, MRL/MpJ. Also beginning at 3 months Fas mice exhibit very severe proliferative glomerulonephritis, whereas in the MRL/MpJ controls usually only mild glomerular lesions are detected. The MRL/MpJ lymphoproliferation wildtype females die at 73 weeks of age and males at 93 weeks. This compares to a lifespan of 17 weeks in the female and 22 weeks for males in the mouse homozygous for Fas. Mice have increased healing ability.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Sib x Sib|Yes|20-Dec-2007|Cryopreserved sperm|70.0|0.0|No||Fas, lymphocyte, apoptosis, T cell|Yes| 4960.0|TNAP-Cre|129-Alpl/AnuApb||Recessive|alkaline phosphatase, liver/bone/kidney|Alpl|Nil|Akp-2, Akp2, TNSALP, TNAP|MGI:87983|targeted mutation 1, Andras Nagy|alpl|MGI:2177588|4||||||||||Unknown to Unknown||||||Yes|Cre recombinase||||||||||||Perinatal lethal|Normal|129|No|No|Yes|No|No|Yes|No|Unknown||||No|12-Jan-2010|Cryopreserved sperm|75.0|0.0|Unknown||alkaline phosphatase, primordial germ cell, Cre|Yes| 7050.0||B6.129P2-Lipe/MarpApb||Recessive|lipase, hormone sensitive|Lipe|Unknown|4933403G17Rik, HSL|MGI:96790|lipase, hormone sensitive; targeted mutation 1, Rudolf Zechner|Lipe|MGI:2388334|7|||||||||||||||||||||||||||||Abnormal lipid level: diglycerides accumulate in brown fat, white fat, testes, skeletal muscle, and cardiac muscle.Abnormal fatty acid level: shift from reduced short chain fatty acids to elevated long chain fatty acids is seen in the white fat.Abnormal triglyceride level:in white fat the fraction of triglycerides with shorter chain fatty acids is decreased and the fraction with longer chain fatty acids is increased.Decreased triglyceride level: decreased by about 70% in cardiac muscle compared to controls.Decreased liver triglyceride level:decreased by about 90% compared to controls.Increased triglyceride level: increased by about 30% in brown fat compared to controls.Abnormal metabolism: * decrease in the formation of free fatty acids in white and brown fat, skeletal and cardiac muscle, liver, and brain * reduced capacity for hydrolysis of diglycerides in all tissue examined * reduced capacity for hydrolysis of triglycerides only in white fat and testesAbnormal brown adipose tissue physiology: diglycerides accumulate in brown fatAbnormal white adipose tissue physiology: * diglycerides accumulate in white fat * the fraction of triglycerides with shorter chain fatty acids is decreased and the fraction with longer chain fatty acids is increased||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown||liver, fatty acid, triglycerides, adipose|Yes| 7395.0|B6-Lym1|B6.BALB/c-Nfkb2/WehiAnuApb||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100|Nfkb2|Unknown|NF kappaB2, p52|MGI:1099800|nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100; Lym1|Nfkb2|MGI:4412046|19|||||||||||||||||||||||||||||Increased circulating lymphocytes.A comprehensive histopathological analysis of these mice, however, revealed an absence of peripheral LN (inguinal, brachial, axillary, cervical) and Peyer’s patches. Mesenteric LN were present, but were reduced in size and cellularity.presence of inflammatory cell infiltrates in the lung and liver.The number of mature recirculating B cells was significantly reduced.Nfkb2 bone marrow was almost completely unresponsive to RANKL with osteoclast formation <0.5% of that seen with wt.Mild osteopetrosis, with significantly increased trabecular bone volume|The ability of Nfkb2 cells to form osteoclasts in response to RANKL stimulation was significantly reduced|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|12-Aug-2013|Cryopreserved sperm|4.0|0.0|Unknown||noncanonical, p52, signal transduction, lymph node, osteopetrosis, B cell|Yes| 9430.0||C57Bl/6J -Tg<(Ace2-ACE2)1Pqt>/Apb||Semi-dominant|angiotensin converting enzyme 2|Ace2 |||MGI:1917258|mAce2-hACE2|||X|||||||||||||||||transgene insertion 1, Paul Q Thomas|mAce2|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 4962.0|Ccr1 +/+|129-Ccr1||Recessive|chemokine (C-C motif) receptor 1|Ccr1|Nil|Cmkbr1, MIP-1 alphaR, Mip-1a-R|MGI:104618||||9||||||||||||||||No|||||||||||||Normal.Control for Ccr1 knockout mouse.||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jan-2010|Cryopreserved sperm|50.0|0.0|Unknown||chemokine, RANTES, neutrophil, inflammation|Yes| 5441.0|Men1 del/wt (Martin C)|B6.129T2-Men1/Apb|B6.129T2-Men1|Recessive|multiple endocrine neoplasia 1|Men1|Nil|menin|MGI:1316736|multiple endocrine neoplasia 1; targeted mutation 2.1, Graham F Kay|Men1|MGI:3810641|19||||||||||||||||No|||||||||||||Embryonic lethal|Tumours with age predominantly in pancreas, pituitary and parathyroids.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|14|1|heterozygote cross wildtype|No|17-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|Used to model human MEN1|menin, men1, Multiple Endocrine Neoplasia, Type I; MEN1, transcription factor, pancreas, Jun|Yes| 6913.0|ENU23:G1|ANU:ENU23:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|22-Jun-2012|Cryopreserved sperm|1398.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6911.0|ENU22:G1|ANU:ENU22:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|22-Jun-2012|Cryopreserved sperm|1096.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7409.0|Amigo2 KO ; TF3111|B6.129/SvEv-Amigo2/TacAnuApb||Recessive|adhesion molecule with Ig like domain 2|Amigo2|||MGI:2145995||||15|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Aug-2013|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 7435.0|CSTCR|C.B6-Thy1 Tg(TcraTcrbYA26)1/QimrAnuApb||Dominant|thymus cell antigen 1, theta|Thy1||CD90, T25, theta, Thy-1, Thy1.1, Thy 1.2, Thy-1.2, Thy1.2|MGI:98747|thymus cell antigen 1, theta; a variant|Thy1|MGI:3579311|9|||||||||||||||||tansgene insertion 1, Fidel Zavala||||||||||||The mice express a monoclonal TCR specific for SYVPSAEQI in context of H2Kd – these particular mice are backcrossed to Thy1.1||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||TCR, CD8, Plasmodium yoelii|Yes| 3339.0|cbfa2t3 -/-|C57BL/6-Cbfa2t3/Apb||Recessive|core-binding factor, runt domain, alpha subunit 2, translocated to, 3 (human)|cbfa2t3|Nil|ETO-2, MTGR2|MGI:1338013||||8||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||Hom x Hom|Yes|20-Jun-2008|Cryopreserved sperm|89.0|0.0|No||leukaemia / leukemia, translocation, breast, transcription|Yes| 4963.0|Sall-GFP|B6.129-Sall1/Apb||Dominant|sal-like 1 (Drosophila)|Sall1|Normal|Msal-3|MGI:1889585|sal-like 1 (Drosophila); targeted mutation 3, Ryuichi Nishinakamura|Sall1|MGI:3603818|8||||||||||||||||No|||||||||||||Embryonic lethal|Normal.GFP labelled Sall1 structures in embryonic kidney.|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|15-Jan-2010|Cryopreserved sperm|72.0|0.0|Unknown||Cap mesenchyme, Nephrogenesis|Yes| 4967.0|B6-HIPCre|B6.NOD-Tg(INS-cre)2Rms/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 2, Robyn M Slattery|human insulin promoter|beta islet cells||||||||||The human insulin promoter (INS) drives cre expression in beta islet cells. Resistance to development of diabetes and hyperglycemia||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Jan-2010|Cryopreserved sperm|100.0|0.0|Yes||Autoimmunity, insulin, Beta cell|Yes| 6915.0|ENU25:G2|ANU:ENU25:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|22-Jun-2012|Cryopreserved sperm|1438.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 6914.0|ENU25:G1|ANU:ENU25:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|22-Jun-2012|Cryopreserved sperm|497.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6912.0|ENU24:G1|ANU:ENU24:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|22-Jun-2012|Cryopreserved sperm|471.0|26.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6805.0|tenascin C KO|129/Sv-Tnc/MelbApb||Recessive|tenascin C|Tnc|Nil|C130033P17Rik, cytotactin, hexabrachion, Hxb, tenascin-C, TN, TN-C|MGI:101922|tenascin C; targeted mutation 1, Reinhard Fassler|Tnc|MGI:2148541|4|||||||||||||||||||||||||||||No abnormal phenotype.|No abnormal phenotype.|129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||matrix, fibronectin, RhoA|Yes| 4799.0|Dimit; ENU13NIH:039ab|C57BL/6JAnu-Ighd/AnuApb|C57BL/6JAnu-Ighd/AnuApb|Recessive|immunoglobulin heavy constant delta|Ighd|Unknown|IgD|MGI:96447|dimit|Ighd|MGI:4819235|12|ENSMUSG00000076616|ENSMUST00000103424|Igh-5-201|241|241|T to A|ENSMUSE00000663372|1|74|Isoleucine to Lysine|||||CAGAACTGAACCTCAACCACACTTGCACCATAAATAAACCCAAAAGGAAAGAAAAACCTTT|Yes|||||||||||||Shifted IgD expression measured by flow cytometry||C57BL/JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Sep-2009|Cryopreserved sperm|37.0|0.0|Unknown||IgD, immunoglobulin, B cell, ENU, NIH|Yes| 4588.0|Seshat ; ENU11B6:169b|C57BL/6JAnu-Cd4/AnuApb|C57BL/6JAnu-Cd4/AnuApb|Recessive|CD4 antigen|Cd4|Unknown|L3T4, Ly-4|MGI:88335|seshat|Cd4|MGI:4819228|6|ENSMUSG00000023274|ENSMUST00000024044|Cd4-001|374|543|T to C|ENSMUSE00000246632|4|125|Valine to Alanine|||||GAACAGGAAAGAGGAGGTGGAGTTGTGGGTGTTCAAAGTGACCTTCAGTCCGGGTACCAGC|Yes|||||||||||||Reduced T cell numbers in peripheral blood. Reduced CD4 expression.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Mar-2009|Cryopreserved sperm|97.0|0.0|Unknown||T cell, CD4, CD8, ENU, NIH, Wellcome Trust|Yes| 5158.0|4AT22 ; ANNA|ENU4AT:022||Recessive|Unknown||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Anti-nuclear antibodies, high.Both young and older mice.|Normal|C57BL/6 x B10BR X CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jun-2010|Cryopreserved sperm|15.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity, antinuclear antibody|No| 5158.0|4AT22 ; ANNA|ENU4AT:022||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Anti-nuclear antibodies, high.Both young and older mice.|Normal|C57BL/6 x B10BR X CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jun-2010|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity, antinuclear antibody|No| 6917.0|FVBNJ-Momme D35|FVB/NJ-Smarca5 Tg(HBA1-Gfp)3Ew/Apb||Semi-dominant|SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5|Smarca5|||MGI:1935129|SNF2 related chromatin remodeling ATPase 5; modifier of murine metastable epialleles, D35|Smarca5|MGI:5515388|8||||||||||Unknown to Unknown|||||||transgene insertion 3, Emma Whitelaw|Human alpha-globin promoter (-570 to +37) and 4.1kb of enhancer region|36 copies||||||||||Lethal|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|25-Jun-2012|Cryopreserved sperm|39.0|0.0|Unknown|||Possibly| 6918.0|FVBNJ-Momme D36|FVB/NJ-Smchd1 Tg(HBA1-Gfp)3Ew/Apb||Semi-dominant|SMC hinge domain containing 1|Smchd1||4931400A14Rik, mKIAA0650, MommeD1|MGI:1921605|SMC hinge domain containing 1; modifiers of murine metastable epiallele D36|Smchd1|MGI:5515389|17||||||||||Unknown to Unknown|||||||transgene insertion 3, Emma Whitelaw|Human alpha-globin promoter (-570 to +37) and 4.1kb of enhancer region|36 copies||||||||||Lethal|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|25-Jun-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, GFP, DNA methylation, epigenetic|Possibly| 7457.0|C2(129)|129X1-Cited2/VccriApb|129X1-Cited2|Recessive|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2|Cited2|Nil|ER154-like, Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1, Juan Pedro Martinez Barbera|Cited2|MGI:2176158|10||||||||||||||||No|||||||||||||Embryos die during gestation (~E15.5). Heart, left-right axis, neural tube, adrenal gland and placental defects.|None|129X1|No|No|Yes|No|No|Yes|No|Good|10|0|C2B6∆ +/- (heterozygous) mated with 129X1|No|22-Oct-2013|Cryopreserved sperm|50.0|0.0|Yes||Cited2, heart, placenta, left-right axis|Yes| 40.0|Flipper|B6;NODAnu-Chkb/AnuApb|B6;NODAnu-Chkb/AnuApb|Recessive|choline kinase beta|Chkb|Unknown|Chetk, Chkl, CK/EK-beta|MGI:1328313|flipper|Chkb|MGI:3847123|15|ENSMUSG00000022617|ENSMUST00000023289|Chkb-201|1|1|A to T|ENSMUSE00000322690|1|1|Methionine to Leucine|||||ATGGCGGCAGACGGGACAGGGGTAGTCGGAGG|No|||||||||||||Homozygotes develop shortened and lateral rotation (valgus?) of radius and ulna leading to short and splayed forelegs. Female homozygotes can breed. Male homozygotes die suddenly during mating with haemorrhages in seminiferous glands (this is currently being re-investigated). Some homozygotes also develop perineal hernias.Chkb Homozygous null mice display progressive muscular weakness and dystrophy in the hindlimbs but have normal nerve and neuromuscular junction morphology.||C57BL/6 x NOD|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|06-Feb-2006|Cryopreserved sperm|70.0|0.0|Unknown||limb, rostocaudal muscular dystrophy, kinase, phosphatidylcholine, ENU|Yes| 2444.0|Lightning ; ENU8B6:045|C57BL/6-Ptprc/AnuApb|C57BL/6-Ptprc/Apb|Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc|Unknown|B220, CD45, Cd45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; lightening|Ptprc|MGI:4441612|1|ENSMUSG00000026395|ENSMUST00000027645|Ptprc-201|1583|1681|T to C|ENSMUSE00000595907|14|528|Phenylalanine to Serine|||||TACAAAATACAACAAGACAAACTGTCAGTTTTATGTAGATAATCTCTACTATTCAACTGAC|No|||||||||||||Homozygous null mutants have defective T-cell maturation.Decreased CD4-positive T cell number: SP4 thymocytes are reduced compared to in wild-type mice.Abnormal T cell differentiation: * mice exhibit enhanced negative selection compared with wild-type mice. * positive selection of T cell is rescued and single positive thymic subsets compared to in Ptprc homozygotes.Decreased double-positive T cell number.Thymus hypoplasia.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jan-2008|Cryopreserved sperm|39.0|0.0|Unknown||T cell, Ly5, thymocyte, lymphocyte, B cell, ENU|Yes| 8355.0|Srsf3-UbcCreERT2-RFP|C57BL/6N-Srsf3 Tg(UBC-cre/ERT2)1Ejb Tg(RFP)/Apb||Recessive|serine/arginine-rich splicing factor 3|Srsf3||Sfrs3, X16|MGI:98285|serine/arginine-rich splicing factor 3; targeted mutation 1a, Mouse Biology Program, UCDavis|Srsf3|MGI:4462527|17|||||||||||||||||transgene insertion 1, Eric J Brown|human ubiquitin C |||||||||||Constitutive expression of RFP, tamoxifen inducible Srsf3 knockout, no phenotype until induced.|See above|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Nov-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8355.0|Srsf3-UbcCreERT2-RFP|C57BL/6N-Srsf3 Tg(UBC-cre/ERT2)1Ejb Tg(RFP)/Apb||Recessive||||||||||||||||||||||||||Red Fluorescence Protein||||||||||||Constitutive expression of RFP, tamoxifen inducible Srsf3 knockout, no phenotype until induced.|See above|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Nov-2017|Cryopreserved sperm|||Unknown|||Yes| 7038.0|zeta-C57BL/6 390|B6;129-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST405390, Lexicon Genetics|Ywhaz||15|||||||||||||||||||||||||||||Infertile, reduced survival of KO pups at 21 days|None|C57BL/6|Yes|No|Yes|Yes|No|Yes|Yes|Poor|N/A||het x het|No|06-Aug-2012|Cryopreserved sperm|80.0|0.0|Unknown||14-3-3, signal transduction|Possibly| 7267.0|Tuara|CBA-Stat1/AnuApb||Recessive|signal transducer and activator of transcription 1|Stat1|Unknown||MGI:103063||||1|||||||||||||||||||||||||||||Unknown||CBA|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5544.0|ENU18NIH:064a|C57BL/6JAnu-Dock2/AnuApb|C57BL/6JAnu-Dock2/AnuApb|Recessive|dedicator of cyto-kinesis 2|Dock2 |Unknown|CED-5, Hch, MBC |MGI:2149010|dedicator of cyto-kinesis 2; mutation 2, The Australian National University|Dock2|MGI:5563490|11|ENSMUSG00000020143|ENSMUST00000093193|Dock2-001|4311|4380|T to A|ENSMUSE00000376674|43|1437|Tyrosine to STOP|||||CAGATCATAAACTTTTACAAGTCTAATTATGTGCAAAAGTTCCACTACTCCAGGCCTGTGC||||||||||||||Reduced numbers of mature B cells in peripheral blood; reduced numbers of T cells in peripheral blood with increased expression of CD44 protein on CD4<+> and CD8<+> cells.|Unknown|C57BL6/JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Jul-2011|Cryopreserved sperm|36.0|0.0|No||cell migration, T cell, B cell, lymphocyte|Possibly| 4706.0|OT1xB6Ly5a|C57BL/6-Ptprc Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc|Unknown|B220, CD45, Cd45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1||||||||||Unknown to Unknown||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|25.0|0.0|Unknown||T cell, receptor, lymphocyte|Yes| 6919.0|FVBNJ-Momme D17|FVB/NJ-MommeD17 Tg(BA1-Gfp)3Ew/Apb||Semi-dominant|Setdb1|SET domain, bifurcated 1|||MGI:1934229|SET domain, bifurcated 1; modifier of murine metastable epialleles, D17|Setdb1|MGI:5515364|3||||||||||Unknown to Unknown|||||||transgene insertion 3, Emma Whitelaw|Human alpha-globin promoter (-570 to +37) and 4.1kb of enhancer region|36 copies||||||||||Lethal.Transgene expressed in red blood cells. Percentage of cells expressing GFP transgene is increased in Momme D17. |Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|25-Jun-2012|Cryopreserved sperm|19.0|0.0|Unknown||ENU, epigenetic, DNA methylation, GFP|Possibly| 5112.0|las vegas ; ENU7B6:142|C57BL/6JSfdAnu-Tnfaip3/AnuApb|C57BL/6JSfdAnu-Tnfaip3/AnuApb|Recessive|tumor necrosis factor, alpha-induced protein 3|Tnfaip3|Unknown|A20, Tnfip3, zinc finger protein A20|MGI:1196377|tumor necrosis factor, alpha-induced protein 3; las vegas|Tnfaip3|MGI:5563400|10|ENSMUSG00000019850|ENSMUST00000105527|Tnfaip3-002|974|1162|T to A|ENSMUSE00000098571|5|325|Isoleucine to Asparagine|||||AGGCTGGGACCACGGCACGACTCACCTGATCAACGCTGCAAAATTGGATGAAGCTAACTTA|Yes|||||||||||||Increased myeloid cells, lower % lymphocytes, increased % ofCD44 expressing activated/memory T cells||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-May-2010|Cryopreserved sperm|60.0|0.0|Unknown||T cell, TNF, CD8, ENU, NIH|Yes| 6920.0|FVBNJ-Momme D13|FVB/NJ-MommeD13 Tg(HBA1-Gfp)3Ew/Apb||Semi-dominant|SET domain, bifurcated 1|Setdb1|Unknown||MGI:1934229|SET domain, bifurcated 1; modifier of murine metastable epialleles, D13|Setdb1|MGI:5515361|3||||||||||Unknown to Unknown|||||||transgene insertion 3, Emma Whitelaw|Human alpha-globin promoter and enhancer region|36 copies||||||||||Lethal.Transgene expressed in red blood cells. Percentage of cells expressing GFP transgene is increased in Momme D13.|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|25-Jun-2012|Cryopreserved sperm|19.0|0.0|Unknown||ENU, DNA methylation, epigentic, GFP|Possibly| 4978.0|ENU11B6:108b|C57BL/6JAnu-Morc3/AnuApb||Recessive|microrchidia 3|Morc3|Unknown||MGI:2136841||||16|ENSMUSG00000039456|ENSMUST00000044068|Morc3-201||||||||93860848|10|||TAAACTTGCCAGTCGAAGACATACAGTAAGTACTGAGCACTGAATTTTGACATACCGTTA|Yes|||||||||||||High expression of Ly6c in peripheral blood.Maturation defect in NK cells.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|40.0|0.0|Unknown||B cell, T cell, immunity, NIH|Yes| 7626.0||C57BL/6NCrlAnu-Zfp831/Apb||Recessive|zinc finger protein 831|Zfp831|Unknown|ENSMUSG00000050600, OTTMUSG00000017459|MGI:3641861|mutation 1, The Australian National University|Zfp831||2|ENSMUSG00000050600|ENSMUST00000059452|Zfp831-001|2752|2752|T to C|ENSMUSE00000357407|1|918|Tyrosine to Histidine|||||CTCGGTCAGGTGGCTTCTTTCCTCCCAAGTACCTCCTCAGGTTACCTCAGGGAGAGAACCC||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Mar-2014|Cryopreserved sperm|22.0|0.0|Unknown||ENU|Yes| 7045.0|Activin BK transgenic ; Inhba BKBK|B6.129S7-Inhba/MarpApb||Dominant|inhibin beta-A|Inhba||activin|MGI:96570|inhibin beta-A; targeted mutation 2, Martin M Matzuk|Inhba|MGI:2386671|13|||||||||||||||||||||||||||||Mice are viable, but manifest poor overall health at 7 weeks of age|Normal|C57BL/6 x 129S|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown||Homozygous matings|No|06-Aug-2012|Cryopreserved sperm|40.0|0.0|No||activin, TGF-beta|Possibly| 5558.0|Caspase-1 KO|B6;129S2-Casp1/AnuApb||Recessive|caspase 1|Casp1|Nil|Caspase-1, ICE, Il1bc, interleukin 1 beta-converting enzyme|MGI:96544|caspase 1; targeted mutation 1, Tara Seshadri|Casp1|MGI:1927822|9|||||||||||||||||||||||||||||Cellular phenotype: * macrophages and thymocytes from mutant mice retain their capacity to undergo apoptosis upon ex vivo stimulation by several different signals. * in response to ATP, mutant peritoneal macrophages undergo normal apoptosis relative to wild-type. * in response to dexamethasone, aging or gamma irradiation, thymocytes from young homozygotes undergo normal apoptosis relative to wild-type. * in response to LPS and D-galactosamine, homozygotes undergo normal TNF-induced hepatocyte apoptosis and show normal kinetics of death from hepatic failure relative to wild-type mice.Abnormal apoptosis: * mutant peripheral blood neutrophils display retarded constitutive apoptosis relative to wild-type neutrophils * mutant peripheral blood neutrophils show no LPS-mediated inhibition of apoptosis but remain susceptible to Fas-mediated apoptosis.Abnormal cell migration: in homozygotes lacking bioactive IL-1beta, IL-18 fails to induce the expected migration of epidermal Langerhans cells to draining lymph nodes following skin sensitization; as a result, immunostimulatory dendritic cells fail to accumulate in regional lymph nodes resulting in impaired initiation of cutaneous immune responses.Hematopoietic system phenotype: * homozygotes exhibit normal numbers of leukocytes, erythrocytes, and platelets in peripheral blood * freshly isolated mutant thymuses, spleens and lymph nodes contain a normal % of various T cell subsets and B cells relative to wild-type.Immune system phenotype: * in homozygotes, the % of B lymphocytes and the various T lymphocyte subsets found in mutant thymuses, spleens and lymph nodes appear unaffected relative to wild-type. * the size and lymphocyte counts in these lymphoid organs appear normal; myeolopoiesis remains unaffected.Decreased circulating interleukin-1 alpha level: LPS-treated mice show a 5-fold decrease in IL-1alpha levels in vivo.Decreased circulating interleukin-1 beta level: in vivo, homozygous males injected with a high dose of LPS display undetectable levels of mature IL-1beta in their plasma; females are slightly less affected.Decreased circulating interleukin-6 level: after injection with a high dose of LPS, homozygotes display a moderate reduction in IL-6 levels relative to wild-type mice.Decreased circulating tumor necrosis factor level: after injection with a high dose of LPS, homozygotes display a moderate reduction in TNF levels relative to wild-type mice.Abnormal macrophage physiology: ex vivo, thioglycollate-elicited peritoneal macrophages stimulated with LPS and ATP are defective in IL-1beta processing and release.Abnormal neutrophil physiology: * in addition to delayed apoptosis, mutant neutrophils show absence of LPS-stimulated IL-1beta production relative to wild-type. * in response to LPS-mediated acute lung injury, homozygotes show significantly increased total and percent neutrophil counts at 24 and 48 h; however, these numbers decline to wild-type levels by 72 h suggesting a delay in inflammatory neutrophil apoptosis.Decreased T cell apoptosis: in vitro, thymocytes from young homozygotes are resistant to Fas-induced apoptosis as measured by cell viability.Decreased interleukin-1 alpha secretion: surprisingly, homozygous males are also defective in IL-1alpha production, with macrophages releasing only 20-25% of wild-type IL-1alpha levels after stimulation with LPS and ATP ex vivo.Decreased interleukin-1 beta secretion: * homozygotes are impaired in their capacity to produce mature IL-1beta. * ex vivo, mutant peritoneal macrophages stimulated with LPS and ATP release less that 1% of wild-type IL-1beta levels; however, no decrease in pro-IL-1beta synthesis or release is detected. * in culture, mutant cortical neurons exhibit inhibition of hypoxia-mediated generation of mature IL-1beta.Abnormal inflammatory response: in response to LPS-mediated acute lung injury, homozygotes exhibit a prolonged neutrophilic inflammatory response and evidence of caspase-1-independent IL-1beta production in the lung.Decreased susceptibility to endotoxin shock: * strikingly, homozygotes are significantly resistant to the lethal effects of endotoxic shock after a high dose of LPS. * whereas all LPS-treated wild-type mice die within 30 hours after injection, all homozygotes survive for >45 hours, with only 30% of mutants dying during the next 5 days.Reproductive system phenotype: * homozygotes are fertile and produce a normal litter size relative to wild-type. * in addition, post-lactation involution of mammary glands remains grossly normal in mutant post-partum females.Decreased susceptibility to ischemic brain injury: * following right carotid artery ligation, newborn homozygotes (P9-P10) are resistant to moderate, but not to severe cerebral hypoxic-ischemic insults relative to wild-type mice. * under mild lesioning conditions (right carotid ligation plus 40 min 10% O2), newborn homozygotes show attenuated hypoxia-ischemia induced CCL2 (chemokine (C-C motif) ligand 2; also, MCP-1) expression at 8 h post-hypoxia relative to wild-type; no genotype differences in CCL2 production are observed in animals undergoing longer periods of hypoxia-ischemia (severe insult)>Decreased neuron apoptosis: * cultured cerebrocortical neurons from homozygotes are highly resistant to oxygen/glucose deprivation (OGD)-induced neuronal cell death, showing only 50% of lactate dehydrogenase release relative to wild-type neurons. * also, mutant neurons are highly resistant to Ripk2-mediated cell death; transfecting caspase-1 into mutant neurons restores sensitivity to Ripk2-induced apoptosis. * notably, cultured neurons show inhibition of OGD-mediated processing of various members of the caspase pathway, cleavage of Bid, and hypoxia-associated loss of mitochondrial transmembrane potential; in vivo, these findings are confirmed in a cerebral ischemia model.|Decreased interleukin-1 beta secretion: * heterozygotes are slightly impaired in their capacity to produce mature IL-1beta: ex vivo, heterozygous peritoneal macrophages stimulated with LPS and ATP release 50% of wild-type IL-1beta levels * no decrease in pro-IL-1beta synthesis or release is detected|C57BL/6 x 129S2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown|2 since arrival at ANU||No|12-Aug-2011|Cryopreserved sperm|9.0|0.0|Unknown||caspase, ICE, inflammation, IL1, LPS|Possibly| 5559.0|Nos2 KO|B6;129S7-Nos2/AnuApb||Recessive|nitric oxide synthase 2, inducible|Nos2|Nil|iNOS, Nos-2, NOS-II, Nos2a|MGI:97361|nitric oxide synthase 2, inducible; targeted mutation 1, John S Mudgett|Nos2|MGI:2158791|11|||||||||||||||||||||||||||||Abnormal osteoclast morphology.Decreased osteoclast cell number: decreased by 25%Abnormal osteoclast differentiation: in vitro differentiation is markedly attenuated.Abnormal osteoclast physiology: resorption activity is considerably decreased.Increased bone mineral density: bone mineral density of the femur is elevated at both 4 and 9 weeks of age.Increased bone volume: total bone volume is increased.Increased compact bone mass: * increased cortical bone mass * trabecular bone thickness and connectivity unchanged from controls.Abnormal tooth hard tissue morphology: distance between cementoenamel junction and alveolar bone crest is greater than for controls from 6 weeks on (without any bacterial challenge).Abnormal response to infection: * do not respond to oral infection with Porphyromas gingivalis by bone loss * serum levels of specific IgG are comparable to controlsAbnormal involution of the mammary gland: * mammary gland regression after removal of pups is delayed * degree of regression at 72 hours is similar to controls * mammary gland development is normal at 10 days into lactation.Abnormal mammary gland physiology: increase in apoptosis levels of involuting mammary glands is delayed.Abnormal lactation: * elevated milk production * pups nourished by mutant mothers weigh more than pups nourished by control mothers.Increased circulating prolactin level: slightly elevated relative to controls.Abnormal cardiovascular system morphology.Abnormal uterine artery morphology: the large arteries of the uterus during pregnancy have thickened arterial walls and smaller lumina.Atherosclerotic lesions: found in about 35% of homozygotes.Abnormal heart ventricle morphology: total ventricle weights are greater than controls for males only.Abnormal cardiovascular system physiology.Abnormal blood circulation: islet blood flow under basal conditions is increased.Increased systemic arterial blood pressure.Increased mean systemic arterial blood pressure: * relative to controls * streptozotocin induced diabetes for 8 days results in a more modest increase in blood pressure than in similar controls.Increased systemic arterial systolic blood pressure: slightly increased at 3 months of age but not later.Increased infarction size: * area of infarction is greater than for controls in non-diabetic mice after ischemia-reperfusion * reperfusion injury is less in diabetic mice than in diabetic controls.Homeostasis/metabolism phenotype: * normal serum insulin. * obese mice on a high fat diet have normal insulin levels.Abnormal blood homeostasis.Increased circulating creatinine level: slightly elevated levels.Abnormal circulating estradiol level: the cyclic changes in estradiol level are abnormal in homozygous mutant females with the peak in estradiol concentration coming later than in 129/SvEv wild-type females.Increased circulating cholesterol level: levels 1.7 times normal at 9 months of age.Increased circulating triglyceride level: elevated plasma triglycerides.Abnormal circulating serum albumin level: slightly reduced at 3 months and tending to decline with age.Abnormal glucose homeostasis.Abnormal circulating glucose level: resistant to hyperglycemia induced by multiple low doses of streptozotocin.Improved glucose tolerance: * hyperglycemic in the first 30 minutes of a glucose tolerance test. * return to fasting glucose levels by 90 minutes when controls are still hyperglycemic.Increased insulin sensitivity.Abnormal hormone level.Decreased adiponectin level.Abnormal adrenocorticotropin level: plasma ACTH levels increase much more modestly after LPS treatment than for controls.Increased renin activity: plasma renin activity is increased.Decreased cerebral infarction size: * volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls. * volume of infarction is similar to controls 24 hours after cerebral artery occlusion.Decreased susceptibility to kidney reperfusion injury: * protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls * less tubular necrosis, tubular structure is almost normal * better survival rate at 24 hours after surgeriesAbnormal uterus morphology: the lining of the uterus during pregnancy shows a distinct lack of cellularity in homozygous female mutants compared to wild-type females.Abnormal uterine artery morphology: the large arteries of the uterus during pregnancy have thickened arterial walls and smaller lumina.Prolonged diestrus: diestrus length is increased in homozygous mutant females compared to 129/SvEv wild-type mice without an increase in total oestrus cycle length.Decreased litter size: by mid-gestation homozygous female mutants have significantly fewer viable embryos compared to wild-type females.Nervous system phenotype: chronic nerve constriction does not lead to breakdown of small myelinated fibers.Decreased cerebral infarction size: * volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls * volume of infarction is similar to controls 24 hours after cerebral artery occlusion.Neuron degeneration: * moderate breakdown of larger caliber myelinated fibers 5 days after chronic nerve constriction at a time when controls have far fewer surviving fibers * fiber numbers are declining at 14 days but at a slower rate than for controls * degenerating myelinated fibers persist longer after nerve crush injuryAbnormal peripheral nervous system regeneration: * no regenerative myelinated sprouts at 21 days when they have begun to appear in controls * regenerating fibers are smaller in caliber after nerve crush injury * similar to controls by 6 weeks after nerve crush injury * nerve fiber regeneration is delayed and new fibers are smaller in diameter after nerve transection.Increased eating behavior: consume 1.6 times as much food as controls on a high fat diet.Abnormal motor capabilities/coordination/movement: motor deficiencies improve between 24 and 96 hours after cerebral artery occlusion unlike controls.Abnormal sensory capabilities/reflexes/nociception.Allodynia: tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls.Abnormal response to tactile stimuli: tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls.Abnormal thermal nociception: * thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls * delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls.Pancreas inflammation: * low level of islet inflammation as compared to controls when treated with streptozotocin. * islet size is normal.Increased length of allograft survival: * lower rejection rate of CBA/CaJ cardiac grafts * lower levels of apoptosis by all measures usedDecreased susceptibility to kidney reperfusion injury: * protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls * less tubular necrosis, tubular structure is almost normal * better survival rate at 24 hours after surgeries.Increased body weight:body weight is greater than controls for males only.Increased growth rate: experience greater weight gain on a high fat diet.Abnormal digestion: do not respond to gastric luminal acid with as great an increase in gastric blood flow as do controlsvascular resistance is not diminished.Decreased digestive mucosecretion: * mucus accumulation rate about 25% of controls * firmly adherent layer of mucus is thinner than in controlsLiver fibrosis: * fibrotic changes in the livers of mice on a high fat diet particularly around degenerating hepatocytes and the central vein area * collagen fraction is higher than in controls when on a high fat diet.Allodynia: tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls.Abnormal response to tactile stimuli: tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls.Abnormal thermal nociception: * thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls * delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls.||C57BL/6 x 129S7|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown|2 since arrival at ANU||No|12-Aug-2011|Cryopreserved sperm|40.0|0.0|Unknown||infection, LPS, ischemia|Possibly| 5244.0|ENU18NIH 17a; ENU18NIH:017a|C57BL/6JAnu-Tnfsf13b/AnuApb|C57BL/6JAnu-Tnfsf13b/AnuApb|Recessive|tumor necrosis factor (ligand) superfamily, member 13b|Tnfsf13b|Unknown|BAFF, BLyS, D8Ertd387e, TALL-1, zTNF4|MGI:1344376|tumor necrosis factor (ligand) superfamily, member 13b; mutation 1, Australian National University|Tnfsf13b|MGI:5009047|8|ENSMUSG00000031497|ENSMUST00000033892|Tnfsf13b-201|81|81|T to A|ENSMUSE00000638270|1|27|Tyrosine to STOP|||||GAGAAAGGAGAAGATATGAAAGTGGGATATGATCCCATCACTCCGCAGAAGGAGGAGGGTG|Yes|||||||||||||T1 to T2 block in B cell development in spleen and increased % of immature B cells and decreased % of mature B cells in peripheral blood.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||1|Currently breeding at G4. Affected x affected, affected x unaffected, affected x B6|No|15-Oct-2010|Cryopreserved sperm|45.0|0.0|Unknown||B cell, immunoglobulin, spleen, peripheral, ENU|Possibly| 4849.0|ENU6AT:HELxTCR:line014:Infertility:G4|ENU6AT:14:infertility||Recessive|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Male infertility|Normal|C57BL/6 x CBA|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|5.0|0.0|Unknown||ENU, sperm, fertility|Yes| 10338.0|Igh2A10-GFP|C57BL/6JAnu-Itgal Tg(IgH2A10)1Anu/Anu||Recessive|Itgal|integrin alpha L||Cd11a, LFA-1|MGI:96606|Itgal:mutation 2, Australian National University|||7|ENSMUSG00000030830 ||||||||||||||||transgene insertion 30, Brina Schaefer||||||||||||Mice express the germline reverted heacy chain of the 2A10 monoclonal antibody specific for P. falciparum CSP. Mice have no overt abnormality.|Mice express the germline reverted heacy chain of the 2A10 monoclonal antibody specific for P. falciparum CSP. Mice have no overt abnormality.|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|31-May-2023|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 10338.0|Igh2A10-GFP|C57BL/6JAnu-Itgal Tg(IgH2A10)1Anu/Anu||Recessive|protein tyrosine phosphatase receptor type C|Ptprc ||B220, CD45, Ly-5|MGI:97810|Ptprc:a variant ; b variant|Ptprc:ab||1|||||||||||||||||Tg(IgH2A10)||||||||||||Mice express the germline reverted heacy chain of the 2A10 monoclonal antibody specific for P. falciparum CSP. Mice have no overt abnormality.|Mice express the germline reverted heacy chain of the 2A10 monoclonal antibody specific for P. falciparum CSP. Mice have no overt abnormality.|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|31-May-2023|Cryopreserved sperm|||Unknown|||Yes| 4975.0|Booreana ; Ped11.28 ; ENU11B6:028|B10;B6-Myb/AnuApb|B10;B6-Myb/AnuApb|Recessive|myeloblastosis oncogene|Myb|Unknown|c-myb|MGI:97249|myeloblastosis oncogene; booreana|Myb|MGI:4867909|10|ENSMUSG00000019982|ENSMUST00000020156|Myb-201|923|1189|A to G|ENSMUSE00000644654|8|308|Glutamic acid to Glycine|||||GGAGTTGCTCCTGATGTCAACAGAGAACGAGCTGAAGGGACAGCAGGCATTACCAACACAG|Yes|||||||||||||E14.5 embryo:15x increase in platelet numbers2x increase in stem cells in foetal liver.Increase in primitive RBCDecrease in definitive RBCIncrease in haemopoietic progenitor cellsPups are born and survive to adulthood. Adults display a 5x increase in platelet numbers|Normal|C57BL/6 x C57BL/10|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|30.0|0.0|Unknown||haemopoiesis, stem cell, platelet, differentiation, transcription factor, proliferation, ENU|Yes| 7268.0||SJL/J-Ank1/MriApb|SJL/J-Ank1|Dominant|ankyrin 1, erythroid|Ank1|Unknown|Ank-1, pale|MGI:88024|ankyrin 1, erythroid; MRI98545|Ank1||8|ENSMUSG00000031543|ENSMUST00000121802|Ank1-004|445|699|T to A|ENSMUSE00000995112|5|149|Tyrosine to Asparagine|||||CCCAGTCTCAGAAAGGCTTTACTCCCCTGTACATGGCTGCTCAGGAGAACCACTTGGAAGT||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility, splenomegaly and survival advantage to Plasmodium chabaudi |SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|05-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|Hereditary spherocytosis|Hereditary spherocytosis, Malaria resistance, microcytosis, ENU|Yes| 7627.0|ENU28:G3|ANU:ENU28:G3||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|31-Mar-2014|Cryopreserved sperm|44.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 5446.0|ENU12NIH:071b N2|C57BL/6JAnu-Hmbs/AnuApb|C57BL/6JAnu-Hmbs/AnuApb|Dominant|hydroxymethylbilane synthase|Hmbs||PBGD, porphobilinogen deaminase, Ups, Uros1|MGI:96112|hydroxymethylbilane synthase; mutation 1, The Australian National University|Hmbs|MGI:5563463|9|ENSMUSG00000032126|ENSMUST00000077353|Hmbs-201|719|905|A to G|ENSMUSE00000216802|11|240|Aspartic acid to Glycine|||||TATCTTGGACCTAGTGAGTGTGTTGCACGATCCTGAAACTCTGCTTCGCTGCATTGCTGAA|Unknown|||||||||||||Autoflourescence during FACs runs|Autoflourescence during FACs runs|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|1|5|Affected x B6|No|28-Feb-2011|Cryopreserved sperm|46.0|0.0|Unknown||ENU|Possibly| 7482.0|Cxcr KO|C57BL/6-Cxcr3/MarpAnuApb||Recessive|chemokine (C-X-C motif) receptor 3|Cxcr3||Cd183, Cmkar3, Cxcr3|MGI:1277207|chemokine (C-X-C motif) receptor 3; targeted mutation 1, Wayne W Hancock|Cxcr3|MGI:2180682|X|||||||||||||||||||||||||||||Females:Decreased susceptibility to viral infection induced morbidity/mortality: • most survive infection with lymphocytic choriomeningitis virus which is cleared in 1 month in survivors, controls do not survive.Impaired macrophage chemotaxis:• 45% decrease of monocyte/macrophage in ischemic calf and thigh muscle.Abnormal cellular extravasation: • reduced numbers of CD8+ cells in the brain 7 days after infection with lymphocytic choriomeningitis.• restricted to meninges and choroids plexus until late in infection unlike controls where white matter of the brain near ventricular surfaces will be penetrated by CD8+ cells.• 38% decrease in numbers of CD3+ T cells in ischemic calf and thigh muscles at 7 days but not at 21 days after ischemia.Abnormal interferon level:• increased levels of IFN-gamma in lung tissue and in bronchoalveolar lavage 1 day after treatment with bleomycin, effect dissipates after 3 days.Lung inflammation: • decreased total lymphocyte counts in bronchoalveolar lavage after bleomycin injury.• reduced numbers of CD8+ T cells after bleomycin injury.• reduced numbers of NK cells at day 7 after bleomycin injury, but also in the lungs of unchallenged mice.Decreased susceptibility to viral infection:• lack symptoms of infection at 7 days after infection with lymphocytic choriomeningitis virus.• less susceptibility to lymphocytic choriomeningitis virus.Increased length of allograft survival:• increased cardiac allograft survival.• grafts with fewer Cd4+ and Cd8+ T cells.Abnormal physiological neovascularization: • ischemic capillary density relative to nonischemic density 1.4 fold lower than in controls.• poor recovery of blood flow after schema.Abnormal interferon level: • increased levels of IFN-gamma in lung tissue and in bronchoalveolar lavage 1 day after treatment with bleomycin, effect dissipates after 3 days.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Nov-2013|Cryopreserved sperm|11.0|0.0|Unknown||allograft, macrophage, chemokine|Yes| 7066.0|Momme D30|FVB/NJ-MommeD30 Tg(Hba1-Gfp)1Ew||Semi-dominant|widely-interspaced zinc finger motifs|Wiz|||MGI:1332638|widely-interspaced zinc finger motifs; modifier of murine metastable epialleles, D30|Wiz|MGI:5515384|17||||||||||Unknown to Unknown|||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Unknown|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD30<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 6623.0|TG2.129T2|129-Tgm2/Apb||Recessive|transglutaminase 2, C polypeptide|Tgm2|Nil|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 1.1, Robert M Graham|Tgm2|MGI:3527996|2||||||||||||||||No|||||||||||||Abnormal cell adhesion: fewer homozygous fibroblasts (20% versus 79% of wild-type) adhered to poly-L-coated or fibronectin coated slidesAbnormal T cell physiology: 24 hours after induction of apoptosis by dexamethasone treatment, homozygotes had smaller thymuses due to decreased viability of thymocytes and increased clearance of dead cells compared to controls, however mutants are viable, normal in size and weight, have normal separation of digits and open eyelids and no difference in thymocyte numbers, indicating that developmental apoptosis was not impaired.||129T2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown||transgluatminase, Gh, G-protein, cross linking, T cell|Yes| 119.0|c-cbl KO|B6.129S1-Cbl/WlanAnuApb|B6.129S1-Cbl/WlanAnuApb|Recessive|Casitas B-lineage lymphoma|Cbl|Nil|c-Cbl, cbl, Cbl-2|MGI:88279|targeted mutation 1, David D L Bowtell|Cbl|MGI:2180578|9||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit increased thymic CD3 and CD4 expression and tyrosine-phosphorylation, lymphoid hyperplasia, and altered splenic hemopoiesis. Females show increased ductal density and branching in mammary fat pads.Abnormal spleen red pulp morphology- expandedenlarged spleen. Spleen is enlarged about 1.2- to 2-fold compared to wild type mice due to expansion of the red pulpspleen hyperplasia.Increase in the number of megakaryocytes, megakaryoblasts, and myelocytes but no increase in the number of lymphocytes is seen in the spleen.Abnormal adipocyte morphology- adipocyte volume is reduced by about 64% compared to wild type mice.Decreased adipose tissue amount- despite increased caloric intake, a 40-50% decrease in the size of the adipose tissue depots (including both white and brown fat) is seenthis phenotype is more pronounced in males than in females.Increased lean body mass- balances the decrease in adipose tissue resulting in no significant difference in total body weight.Polyphagia.Hyperactivity- about a 4-fold increase in ambulatory activity is seen, especially during the dark phase.Increased body temperature- rectal temperature is increased by 1 degree C independent of time of day or if the mice are fed or fasted overnight. However, circulating levels of triiodothyronine or thyroxine are similar to wild type in both the fed and fasted states.Decreased circulating leptin level- leptin levels are decreased by 66%; however adiponectin levels are similar to wild type.Abnormal gas homeostasis- increased oxygen consumption:whole body oxygen consumption corrected for the difference in lean mass is increased by 22% compared to wild type mice.Abnormal respiratory quotient- reduced respiratory quotientAbnormal glucose homeostasis- decreased circulating insulin level, after an overnight fast insulin levels are decreased relative to wild type but glucose levels are similar to wild type.Improved glucose tolerance- improved glucose tolerance despite decreased insulin levels throughout the test.Increased insulin sensitivity.Abnormal lipid homeostasis- decreased circulating free fatty acid level.Decreased triglyceride level- triglyceride levels in the liver are decreased but those in the quadriceps muscle are similar to wild type muscleAbnormal muscle physiology- glucose clearance in to glycogen is increased in the soleus and extensor digitorum longus muscles but not in the liver.Abnormal muscle cell glucose uptake- glucose uptake into skeletal muscle is increased about 2-fold; however glucose uptake into white and brown adipose tissue is not different from wild type. Basal and insulin-stimulated glucose uptake are increased in soleus muscle explants by 65% and 30%, respectively; however, glucose uptake is not increased in fat explants basal, but not insulin-stimulated, glucose uptake is increased by 30% in extensor digitorum longus muscle explantscellular.Abnormal mitochondrial morphology- a 2-fold increase in the average size of subsarcolemmal mitochondria is seen; however, no increase in mitochondrial area or cristae density is seen in the subsarcolemmal region.Spleen hyperplasia- increase in the number of megakaryocytes, megakaryoblasts, and myelocytes but no increase in the number of lymphocytes is seen in the spleen.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|11|||No|06-Feb-2006|Cryopreserved sperm|145.0|0.0|No||Cbl, tyrosine kinase, TKB, Zap-70, adipose|Yes| 2039.0|STAT1 KO|B6;129-Stat1/Apb|B6;129-Stat1/Apb|Recessive|signal transducer and activator of transcription 1|Stat1|Nil||MGI:103063|targeted mutation 1, Robert D Schreiber|Stat1|MGI:1861949|1||||||||||Unknown to Unknown||||||Yes|||||||||||||Increased sensitivity to microbial pathogens and viruses due to impaired responsiveness to interferons.Increased Bone mass.Increased osteoclast cell number.|No phenotype reported.|C57BL/6 x 129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozygous x homozygous|Yes|21-Sep-2007|Cryopreserved sperm|115.0|0.0|No||signal transduction, cytokine, JAK, kinase, phosphorylation|Yes| 7062.0|Momme D11|FVB/NJ-MommeD11 Tg(Hba1-Gfp)1Ew||Semi-dominant|Kruppel-like transcription factor 1 (erythroid)|Klf1|Unknown||MGI:1342771|Kruppel-like transcription factor 1 (erythroid); modifier of murine metastable epialleles, D11|Klf1|MGI:5752591|8||||||||||Unknown to Unknown|||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (~E14.5 dpc)|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD11<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 5161.0|ENU14 NIH 17b|ENU14NIH:017b||Recessive|Unknown|Unknown|Unknown||||||Unknown|||||||||||||||||||||||||||||Shaky gait, and uncoordinated|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Unknown|Yes|Yes|Poor||1||No|28-Jun-2010|Cryopreserved sperm|20.0|0.0|Unknown||Uncoordinated, Shaky, Neurological, gait|Possibly| 7064.0|Momme D21|FVB/NJ-MommeD21 Tg(Hba1-Gfp)1Ew||Semi-dominant|modifier of murine metastable epialleles, D21|MommeD21|||||||16|||||||||||||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Unknown|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD21<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 5474.0|Rosa 26; MF-05|C57BL/6-Gt(ROSA)26Sor/Apb||Recessive||||||||||||||||||||||||||gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Philippe Soriano||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Apr-2011|Cryopreserved sperm|50.0|0.0|Unknown||Cre recombinase, expression, genetrap|Yes| 4996.0|4AT22|ENU4AT:22||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Anti-nuclear antibodies, high.Both young and older mice.|Normal|C57BL/6 x B10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|40.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity, antinuclear antibody|No| 4996.0|4AT22|ENU4AT:22||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Anti-nuclear antibodies, high.Both young and older mice.|Normal|C57BL/6 x B10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity, antinuclear antibody|No| 4898.0|129/Sv|129/Sv Wildtype||Dominant||||||||||||||||||||||||||||||||||||||Normal.||129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Oct-2009|Cryopreserved sperm|60.0|0.0|Unknown||129, control|Yes| 6924.0|ENU20:B6:28:b|ANU:ENU20:028:b||Recessive|Unknown|unknown|||||||Unknown||||||||||||||||||||||||||||||We are currently looking for a prostate phenotype.|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Jun-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU|No| 6615.0|PIPP Floxed|C57BL/6J-Inpp5j/Marp||Dominant|inositol polyphosphate 5-phosphatase J|Inpp5j|Unknown|Pib5pa, Pipp|MGI:2158663||||11||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6887.0|APN178|C57Bl/6N-Gpx3/MarpApb||Recessive|glutathione peroxidase 3|Gpx3 |Unknown|EGPx, extracellular GPx, GPx, plasma GPx |MGI:105102|glutathione peroxidase 3; targeted mutation 1a, Wellcome Trust Sanger Institute |Gpx3 |MGI:4841147|11|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|03-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7271.0|APN182|C57BL/6N Tnfsf13/Marp||Recessive|tumor necrosis factor (ligand) superfamily, member 13|Tnfsf13 |Unknown|2310026N09Rik, APRIL, TALL2, TRDL1|MGI:1916833|tumor necrosis factor (ligand) superfamily, member 13; targeted mutation 1, Wellcome Trust Sanger Institute/Monash Animal Research Platform|Tnfsf13/Marp |MGI:4419527|11|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|06-Feb-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5376.0|HinsA Triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(Ins2-INS1)/Apb||Dominant||||||||||||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 7629.0||B6/Mrit-131297|B6/Mrit-131297|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a growth delay for a week.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 6925.0|APN151|C57BL/6N-A Ptafr/MarpApb||Recessive|platelet-activating factor receptor|Ptafr|Unknown|PAFR, PAF receptor|MGI:106066|platelet-activating factor receptor; targeted mutation 1a, Wellcome Trust Sanger Institute |Ptafr |MGI:4460278|4|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Jun-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 7299.0|RBC16|C;B6-Cpox/MarpApb||Dominant|coproporphyrinogen oxidase|Cpox|Unknown|Cpo|MGI:104841||||16|||||||||||||||||||||||||||||Embryonic lethal at E10.5|Low mean cell volume and mean cell hemoglobin and anemia|BALB/C|No|No|Yes|No|No|Yes|No|Good|||Heterozygous intercrosses|No|26-Mar-2013|Cryopreserved sperm|59.0|0.0|Unknown||Heme biosynthesis, Iron, Hereditary coproporphyria , Erythropoiesis|Possibly| 7633.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 10547.0|NOD.8.3/Tet-IGRP#11|NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/NOD-Tg(Tet)-IGRP)Tg(Iea-tTA)||Recessive|glucose-6-phosphatase, catalytic,subunit 2  |G6pc2||G6pc-rs, IGRP|MGI:1277193||||2|ENSMUSG00000005232 ||||||||||||||||IGRP/tet-transactivator|CMV tetracycline-response element/MHC class II IEa|||||||||||Normal|Normal|NOD/Lt|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Mar-2026|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7630.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7631.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|53.0|0.0|Unknown|||Yes| 2774.0|BALB/c.hK14-FLII 36|BALB/c-Tg(hK14-FLII)36/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|Human Flightless|Human Keratin 14|||||||||||Not bred to Homozygous state|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het FLII transgenic x WT BALB/c|No|16-Feb-2008|Cryopreserved sperm|150.0|0.0|Unknown||human, skin, enhancer element|Yes| 6651.0|RBC13|C;B6-Hbb-b1/WehiMarpApb||Dominant|Hbb-b1 hemoglobin, beta adult major chain|Hbb-b1|Reduced|beta maj, beta major globin, beta1, beta-s|MGI:96021|hemoglobin, beta adult major chain; red blood cell mutant 13|Hbb-b1|MGI:5460881|7|||||||||||||||||||||||||||||Lethal at E18.5 or just after (not present at birth). Embryos are normal until E16.5 where they manifest progressive pallor and reduced fetal liver cellularity.|Microcytic, hypochromic anemia with severe reticulocytosis. Compensatory erythropoiesis with splenic extramedullary hematopoiesis due to red cell destruction. |C57BL/6 and BALB/c|No|No|Yes|No|No|Yes|No|Excellent|||Heterozygote intercross and background strain wild type to heterozygote|No|28-Nov-2011|Cryopreserved sperm|50.0|0.0|Yes|Beta-thalassemia|Beta-thalassemia, Hbb-b1/beta major globin, ENU-mutagenesis|Possibly| 7669.0|ENU31:G1|ANU:ENU31:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-May-2014|Cryopreserved sperm|3828.0|110.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5339.0||C57BL/6-Tg(CAG-ATP7A)22Jmer/Apb||Dominant||||||||||||||||||||||||||human ATPase, Cu++ transporting, alpha polypeptide|chicken beta-actin|||||||||||The overall phenotype of transgenic mice was normal, and the transgene was transmissible to progeny, but the transgenic mice showed interesting changes in Cu concentration in various organs that were generally consistent with a role for ATP7A in efflux.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|9|||No|11-Dec-2010|Cryopreserved sperm|40.0|0.0|Unknown||copper, Menkes protein, lactation, mammary gland, transport, cuproenzymes|Yes| 7636.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|61.0|0.0|Unknown|||Yes| 7637.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 7639.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype for a week.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7641.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype for a week.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5447.0|Minnie ; ENU12NIH 71b CBA|ENU12NIH:071b CBA||Recessive|Unknown|Unknown|Unknown||||||Unknown|||||||||||||||||||||||||||||Small Mice|Normal|C57BL/6JAnu x CBA/CaJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|N/A|2|Sib x sib|No|28-Feb-2011|Cryopreserved sperm|40.0|0.0|Unknown||runted, dwarf, small, ENU|Possibly| 7638.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype for a week.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|20.0|0.0|Unknown|||Yes| 7640.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype for a week.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 6927.0|ENU18:::B6:G1|ANU:ENU18:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Jul-2012|Cryopreserved sperm|3067.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7373.0|ATARI:kk:Cbl-bKO|C57BL/6JSfdAnu-Aire Cblb H2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy) |Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|08-Jul-2013|Cryopreserved sperm|20.0|0.0|No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell, selection|Yes| 7373.0|ATARI:kk:Cbl-bKO|C57BL/6JSfdAnu-Aire Cblb H2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive|Casitas B-lineage lymphoma b|Cblb||Cbl-b|MGI:2146430|Casitas B-lineage lymphoma b; targeted mutation 1, Josef M Penninger|Cblb|MGI:2180570|16|||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|08-Jul-2013|Cryopreserved sperm|||No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell, selection|Yes| 6929.0|ENU20:G1|ANU:ENU20:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Jul-2012|Cryopreserved sperm|392.0|40.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6928.0|ENU19:G1|ANU:ENU19:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Jul-2012|Cryopreserved sperm|471.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 32.0|B-thy|C57BL/6JSfdAnu-Trp53/AnuApb|C57BL/6JSfdAnu-Trp53/AnuApb|Semi-dominant|transformation related protein 53|Trp53|Nil|p53|MGI:98834|bthy|Trp53|MGI:3611889|11|ENSMUSG00000059552|ENSMUST00000108658|Trp53-201|412|540|T to C|ENSMUSE00000111826|5|138|Cysteine to Arginine|||||ATAAGCTATTCTGCCAGCTGGCGAAGACGTGCCCTGTGCAGTTGTGGGTCAGCGCCACACC|No||||||||||||||primitive hematopoietic or T cell leukemia,Sudden death,hemorrhage,Thymic lymphomaFibrosarcomaMultinodal lymphomaOsteosarcomaHaemangiosarcomaBrain tumourTeratocarcinoma|C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||8||No|06-Feb-2006|Cryopreserved sperm|27.0|0.0|Yes||p53, apoptosis, tumour, cell cycle, ENU|Yes| 141.0|Pebbles ; DD6|C57BL/6JSfdAnu-Tg(IghelD4)Ccg/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 4, Christopher C Goodnow||low level||||||||||Mice express IgD immunoglobulin reactive to Hen Egg lysozyme||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|20.0|0.0|No||immunoglobulin, hen egg lysozyme, HEL, IgD|Yes| 5452.0|PD|B6;129/Sv-Eif2ak2/MarpApb||Recessive|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|Nil|dsRNA-activated kinase, eIF-2 alpha, eIF-2 alpha, IFN- type I-induced and dsRNA-activated kinase, IFN-induced and double-stranded RNA-activated kinase, Pkr, Prkr, Tik|MGI:1353449|eukaryotic translation initiation factor 2-alpha kinase 2; targeted mutation 1, Charles Weissmann|Eif2ak2|MGI:2182566|17||||||||||||||||No|||||||||||||Normal|Normal|129/Sv x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|02-Mar-2011|Cryopreserved sperm|50.0|0.0|No||Protein kinase, innate immunity, double stranded RNA, cell signalling, eif2alpha|Yes| 7647.0||B6/Mrit-amp|B6/Mrit-amp|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 7650.0||B6/Mrit-da|B6/Mrit-da|Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|No| 5437.0|Gq KO|B6.129-Gnaq/Apb||Semi-dominant|guanine nucleotide binding protein, alpha q polypeptide|Gnaq|Nil|Dsk1, Dsk10, G alpha q, Galphaq, Gq, GqI|MGI:95776||||19|||||||||||||||||||||||||||||Small agouti mouse, gold stomach, black eyes and extremeties.||C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|6|||No|16-Feb-2011|Cryopreserved sperm|50.0|0.0|No||Platelet|Yes| 7579.0|Spi6 KO x OT-I|C57BL/6J-SerpinB9 Tg(TcraTcrb)1100Mjb/MarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9|Nil|PI-9, Spi6|MGI:106603||||13|||||||||||||||||transgene insertion 1100, Michael J Bevan|MGI:3054907|||||||||||Increased apoptosis:• apoptosis is increased in LCMV- and LM-specific CTLs in mutantsAbnormal CD8-positive, alpha-beta cytotoxic T cell morphology:• upon infection with LCMV Armstrong or a strain of Listeria monocytogenes (LM), numbers of LCMV-specific CTLs are reduced 5-fold and LM-specific CTLs are reduced 9-fold compared to control B6 mice.• frequency of CTLs devoid of Gzmb granules is 3 times greater than in controls; number of Gzmb granules per CTL is 2-fold lower than in controls.Abnormal cytotoxic T cell physiology:• apoptosis is increased in LCMV- and LM-specific CTLs in mutants.Defective cytotoxic T cell cytolysis:• deficit in CTL activity is observed in ex vivo activity assay over course of LCMV infection; on day 10, activity is decrease 6-fold compared to controls.Abnormal enzyme/ coenzyme level:• caspase 3 in cytoplasm is increased.Abnormal enzyme/coenzyme activity:• GranzymeB activity is significantly increased in cytoplasm of mutants compared to controls.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Spi6 KO mice mated with OT-I mice|No|28-Jan-2014|Cryopreserved sperm|50.0|0.0|Unknown||T cell, CD8, dendritic cell, MHC I, cross-priming|Yes| 7273.0|ENU20 017b ; ENU20:017b|C57BL/6NCrlAnu-Dock2/AnuApb|C57BL/6NCrlAnu-Dock2/AnuApb|Recessive|dedicator of cyto-kinesis 2|Dock2|Unknown|CED-5, Hch, MBC |MGI:2149010|dedicator of cyto-kinesis 2; mutation 3, The Australian National University|Dock2|MGI:5563488|11|ENSMUSG00000020143|ENSMUST00000093193|Dock2-001|3921|3990|T to A|ENSMUSE00000351317|39|1307|Tyrosine to STOP|||||AGCCTGTGCAAGGAACTGGCGGAACAATATGAGATGGAGATCTTTGACTACGAGCTACTCA||||||||||||||Decreased CD4<+> T cells. Increased CD44 expression in CD4 and CD8 T cells.|Normal|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|0|G6|Het x Het|No|12-Feb-2013|Cryopreserved sperm|25.0|0.0|Unknown||ENU, T cell|Yes| 1550.0||BALB/c-Tg(iFABPp-TGFb1) ||Recessive||||||||||||||||||||||||||transforming growth factor, beta 1|at intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences).|high||||||||||Restricted expression of TGF beta transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||TGF beta, TGFb, allergy|Yes| 7068.0|Momme D32|FVB/NJ-Dnmt1 Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|DNA methyltransferase (cytosine-5) 1|Dnmt1|Unknown|Cxxc9, Dnmt1o, MommeD2, MTase|MGI:94912|DNA methyltransferase 1; modifier of murine metastable epialleles, D32|Dnmt1|MGI:5515386|9||||||||||Unknown to Unknown|||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Unknown|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD32<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|29-Aug-2012|Cryopreserved sperm|39.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 4739.0|Wink|C.129-Tg(hGM-CSFRb) Csf2rb Csf2rb2/Apb||Dominant|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb|Unknown|AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15||||||||||||||||Yes|human beta common chain receptor for GM-CSF/IL-3/IL-5|pgk|very low||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|0|Purchased BALB/c mated with transgenic mouse from colony to maintain colony|No|20-Apr-2009|Cryopreserved sperm|120.0|0.0|Unknown||growth factor, interleukin, signal transduction, receptor|Yes| 4739.0|Wink|C.129-Tg(hGM-CSFRb) Csf2rb Csf2rb2/Apb||Dominant|colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)|Csf2rb2|Unknown|AIC2A, BetaIl3, Bil3, Il3r, Il3rb2|MGI:1339760|targeted mutation 1, C Glenn Begley|Csf2rb2|MGI:3652583|15|||||||||||||||||||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|0|Purchased BALB/c mated with transgenic mouse from colony to maintain colony|No|20-Apr-2009|Cryopreserved sperm|||Unknown||growth factor, interleukin, signal transduction, receptor|Yes| 221.0|Chisel KO|C57BL/6-Smpx/Apb||Recessive|small muscle protein, X-linked|Smpx|Unknown|chisel, Csl|MGI:1913356|targeted mutation 1, Richard P Harvey|Smpx|MGI:2387819|X||||||||||||||||Yes|||||||||||||Mice homozygous for a null mutation do not exhibit defects in heart or skeletal muscle morphology or development|No reported phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Apr-2006|Cryopreserved sperm|45.0|0.0|Unknown||myocyte, insulin, heart|Yes| 1937.0||BALB/c.B6-IL13 Ccl11/AnuApb||Recessive|interleukin 13|Il13|Unknown|Il-13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11||||||||||||||||Yes|||||||||||||||BALB/c |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Aug-2007|Cryopreserved sperm|150.0|0.0|Unknown||Eosinophils, IL4, IL5, T cell, infection, stat6|Yes| 1937.0||BALB/c.B6-IL13 Ccl11/AnuApb||Recessive|small chemokine (C-C motif) ligand 11|Ccl11|Nil|eotaxin, Scya11|MGI:103576|chemokine (C-C motif) ligand 11; targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11|||||||||||||||||||||||||||||||BALB/c |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Aug-2007|Cryopreserved sperm|||Unknown||Eosinophils, IL4, IL5, T cell, infection, stat6|Yes| 5136.0|A9|C57BL/6-Tg(TcrbB3)8Cbn/CbnApb||Dominant||||||||||||||||||||||||||transgene insertion TcrbB3, Francis R Carbone|Tcrb|More than 10 copies||||||||||The majority of CD8 T cells express the trangenic Vb5.2 T cell receptor.|As for homozygous.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||br|No|26-May-2010|Cryopreserved sperm|45.0|0.0|No||TCR tansgenic, cytotoxic T lymphocytes, T cell repertoire|Yes| 639.0|Vav-rtTA|B6.129-Tg(Vav-rtTA)/Apb||Dominant||||||||||||||||||||||||||reverse tetracycline transactivator|vav|haemopoietic specific expression||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|9|0||No|25-Apr-2007|Cryopreserved sperm|40.0|0.0|No||vav, rtTA, haemopoeisis, tetracycline|Yes| 29.0|Babe|C57BL/6JSfdAnu-Agtpbp1/AnuApb|C57BL/6JSfdAnu-Agtpbp1/AnuApb|Recessive|ATP/GTP binding protein 1|Agtpbp1|Unknown|Nna1|MGI:2159437|ATP/GTP binding protein 1; babe|Agtpbp1|MGI:3847121|13|ENSMUSG00000021557|ENSMUST00000022040|Agtpbp1-201|2413|2543|C to T|ENSMUSE00000118960|19|804|Arginine to STOP|||||ACATTTGTTACTACAAAAATCACTTCTCACGAAGCTCAGTTGCCGCAGGCGGACAGAAGGG|No|||||||||||||Lethal dilute ataxia, weakness of the hindlimbs and mild uncoordination (ataxia) which is usually detectable at weaning.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||8||No|06-Feb-2006|Cryopreserved sperm|37.0|0.0|Unknown||Ataxia, Purkinje cell, degeneration, retinal, ENU|Yes| 133.0|Homer|B10.Cg-H2 Tg(Dct-mHELKK)1Rc Tg(TcrHEL3A9)1Mmd/AnuApb|B10.Cg-H2 Tg(Dct-mHELKK)1Rc Tg(TcrHEL3A9)1Mmd/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 1, Richard J Cornall|dopachrome tautomerase (Dct) ; Trp2, Tyrp2 |Melanocyte specific|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17|Mice develop a spontaneous autoimmune disease with striking similarity to human vitiligo vulgaris and Vogt-Koyanagi-Harada syndrome. ||C57BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5||No|06-Feb-2006|Cryopreserved sperm|60.0|0.0|Yes|human vitiligo vulgaris and Vogt-Koyanagi-Harada syndrome|CD4, T cell, vitiligo, melanocyte, autoimmunity|Yes| 133.0|Homer|B10.Cg-H2 Tg(Dct-mHELKK)1Rc Tg(TcrHEL3A9)1Mmd/AnuApb|B10.Cg-H2 Tg(Dct-mHELKK)1Rc Tg(TcrHEL3A9)1Mmd/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice develop a spontaneous autoimmune disease with striking similarity to human vitiligo vulgaris and Vogt-Koyanagi-Harada syndrome. ||C57BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5||No|06-Feb-2006|Cryopreserved sperm|||Yes|human vitiligo vulgaris and Vogt-Koyanagi-Harada syndrome|CD4, T cell, vitiligo, melanocyte, autoimmunity|Yes| 1532.0||BALB/c-IL9/AnuApb||Recessive|interleukin 9|Il9|Nil|Il-9, P40|MGI:96563|targeted mutation 1, Andrew NJ McKenzie|IL9|MGI:2656470|13||||||||||||||||Yes|||||||||||||Homozygous null mice are viable and show no overt phenotype, however when challenged, aspects of the inflammatory response are shown to be impaired.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|05-Jul-2007|Cryopreserved sperm|160.0|0.0|Unknown||inflammation, T cell, mast cell, asthma, anaphylaxis|Yes| 7616.0|EphA2 Knockout , EphA2 Reporter|B6.129-Epha2/QimrApb||Recessive|Eph Receptor A2|EphA2||Eck, Myk2, Sek2, Sek-2|MGI:95278|Eph receptor A2; gene trap CN3, Yoichiro Iwakura|Epha2|MGI:2448472|4|||||||||||||||||||||||||||||Abnormal tail morphology:• abnormal blood vessel formation in the tailsAbnormal caudal vertebrae morphology:• ectopic tail vertebra formationShort tail:• varying degrees of short tails, first seen around E12.5-13.5Kinked tail:• 40% exhibit varying degrees of kinky tails, first seen around E12.5-13.5Abnormal axial mesoderm:• aberrant axial mesoderm formationAbnormal neural tube morphology/development:• the wall of the neural tube in tails is thickened and multi-layeredSplit notochord:• notochord is abnormally bifurcated at the caudal end between E11.5 and E12.5 and the bifurcated notochords are abnormally intertwined• notochordal cells are spread broadly into the tail budAbnormal neural tube morphology/development:• the wall of the neural tube in tails is thickened and multi-layeredAbnormal vascular development:• abnormal blood vessel formation in tails, with the number of blood vessels changed and larger vessel caliberskeletonabnormal caudal vertebrae morphology ( J:69393 )• ectopic tail vertebra formationAbnormal sclerotome morphology• ectopic slerotomes form at the caudal tail where the bifurcated notochords form|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10||Homozygous x Homozygous|No|07-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown||kink tail, notochord|No| 6933.0|ENU19 WT:001:b:B6:G3|ANU:ENU19WT:001:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|58.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6934.0|ENU19 WT:002:b:B6:G3|ANU:ENU19WT:002:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6935.0|ENU19 WT:005:b:B6:G3|ANU:ENU19WT:005:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6937.0|ENU19 WT:008:b:B6:G3|ANU:ENU19WT:008:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7670.0|ENU31:G2|ANU:ENU31:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-May-2014|Cryopreserved sperm|4383.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7628.0|EphA1 Knockout|B6.129-Epha1/QimrApb||Recessive|Eph receptor A1|Epha1||5730453L17Rik, Eph, Esk|MGI:107381|Eph receptor A1; targeted mutation 1, Shannon L Duffy|Epha1|MGI:3822370|6|||||||||||||||||||||||||||||A Homozygous (PLAP/PLAP) mouse will result in the normal phenotype displaying PLAP activity however EphA1 expression will be lost.Endometrium inflammation: • mice exhibit endometrium inflammation secondary to hydrometrocolpos.Vaginal inflammation:• mice exhibit inflammation of the vaginal mucosa secondary to hydrometrocolpos.Dilated uterine horn: • mice exhibit dilated, attenuated uterine horns secondary to hydrometrocolpos.Enlarged uterus:• mice exhibit an enlarged uterus due to an accumulation of clear uterine fluid (hydrometrocolpos).Increased uterus weight.Vagina atresia:• 18% of mice exhibit a failure of vaginal opening.• despite normal estrogen receptor expression, beta-estradiol treatment fails to induce precocious vaginal opening in P12 mice unlike in wild-type mice and vaginal opening can not be induced by likewise treating affected adult mice.Hydrometrocolpos: • mice exhibit inflammation of the vaginal mucosa and endometrium with dilated, attenuated uterine horns secondary to hydrometrocolpos.Female infertility: • female mice affected by hydrometrocolpos are sterile.Kinked tail:• up to 80% of mice exhibit a kinky tail due to incorrectly positioned caudal vertebrae.Distended abdomen: • in some mice due to an enlarged uterusAbnormal response/metabolism to endogenous compounds:• treatment with beta-estradiol fails to induce apoptosis in the lower genital tract and precocious vaginal opening unlike in wild-type mice.Skeleton phenotype: • despite a kinky tail, mice exhibit normal skeletal morphology.|Normal PLAP activity with EphA1 expression.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||No|04-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||receptor tyrosine kinase, epithelium, hydrometrocolpos|No| 5202.0|Tmem26 conditional knockout|C57BL/6-Tmem26/UqbrApb||Recessive|Transmembrane protein 26|Tmem26|Nil||MGI:2143537||||10||||||||||||||||Yes|||||||||||||Normal,ubiquitous deletion of floxed region also produces normal animals.|normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2 crosses from founder mouse (derived from a C57 cell line) to C57 mice|approx. 7||No|06-Aug-2010|Cryopreserved sperm|47.0|0.0|Unknown|||Yes| 6936.0|ENU19 WT:007:b:B6:G3|ANU:ENU19WT:007:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 148.0|NODScid|NOD;Cg-H2 Prkdc/AnuApb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Nil|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16||||||||||||||||Yes|||||||||||||SCID mutation prevents TCR and BCR rearrangements. This prevents maturation of B and T cells at very early stages of development. These mice, therefore lack, T and B cells in periphery. Please refer to MGI allele page for further information using the link above.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||19||No|06-Feb-2006|Cryopreserved sperm|165.0|0.0|Yes||SCID, severe combined immunodeficiency, transplant, T cell, B cell|Yes| 1946.0||BALB/c.B6-Gata1 Il5/AnuApb||Recessive|GATA binding protein 1|Gata1|Unknown|Gata-1, Gf-1|MGI:95661|GATA binding protein 1; targeted mutation 6, Stuart Orkin|Gata1|MGI:3037864|X||||||||||||||||Yes|||||||||||||No eosinophils||BALB/c |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Sep-2007|Cryopreserved sperm|135.0|0.0|Unknown||infection, eosinophil, nematode|Yes| 1946.0||BALB/c.B6-Gata1 Il5/AnuApb||Recessive|interleukin 5|Il5|Unknown|IL-5|MGI:96557|targeted mutation 1, Manfred A Kopf|Il5|MGI:1861948|11|||||||||||||||||||||||||||||No eosinophils||BALB/c |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Sep-2007|Cryopreserved sperm|||Unknown||infection, eosinophil, nematode|Yes| 2442.0|Koy|C57BL/6JSfdAnu-Coro1a/Apb|C57BL/6JSfdAnu-Coro1a/Apb|Recessive|coronin, actin binding protein 1A|Coro1a|Reduced|Clabp, coronin 1, Lmb3, p57|MGI:1345961|coronin, actin binding protein 1A; koyaanisqatsi|Coro1a|MGI:3818509|7|ENSMUSG00000030707|ENSMUST00000106364|Coro1a-002|76|329|G to A|ENSMUSE00000202191|2|26|Glutamic acid to Lysine|||||GACAGCCAGCCAAGGCTGACCAGTGCTATGAGGATGTGCGCGTCTCACAAACCACTTGGGA|Yes|||||||||||||Mice have few peripheral blood CD4 or CD8 T cells. T cells are also reduced in spleen and LN. There is reduced transwell migration of thymocytes and naive mature T cells to SDF (CXCL12) or to ELC (CCL21). Elevated phalloidin staining (elevated F actin). Decreased CD4-positive T cell number: CD4+ T cell numbers in the periphery are significantly decreased about 5-fold.Decreased CD8-positive T cell number: CD8+ T cell numbers in the periphery are significantly decreased about 5-fold.Decreased thymocyte number: the percentage of mature (CD69loCD62Lhi) single-positive thymocytes is decreased in these mice.Abnormal T cell physiology:* in vitro transwell assays demonstrate migration defects in thymic CD4+ T cells' response to sphingosine 1-phosphate, CCL21, and CXCL12.* similar defects are observed in the migratory response of CD4+CD8+ T cells to CXCL12 and of splenic CD4+ T cells to CCL21.|Slight T cell deficit.|C57BL/6JStdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5||No|14-Jan-2008|Cryopreserved sperm|185.0|0.0|Yes|Severe Combined Immunodeficiency|T cell, CD8, SCID, CD4, migration, Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Positive, Nk Cell-Positive, egress|Yes| 6938.0|ENU19 WT:012:a:B6:G3|ANU:ENU19WT:012:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|18.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6940.0|ENU19 WT:014:a:B6:G3|ANU:ENU19WT:014:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6939.0|ENU19 WT:012:b:B6:G3|ANU:ENU19WT:012:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6941.0|ENU19 WT:018:a:B6:G3|ANU:ENU19WT:018:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6943.0|ENU19 WT:019:a:B6:G3|ANU:ENU19WT:019:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|36.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7701.0|B3K506 Tcra/b|C57BL/6-Tg(CD2-Tcra, -Tcrb)506/AnuApb||Recessive||||||||||||||||||||||||||T cell receptor alpha, T cell receptor beta|Human CD2|||||||||||Transgenic mice express the rearranged B3K506 Va4.1 and Vβ8.1 chains using the human CD2 promoter.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Jun-2014|Cryopreserved sperm|11.0|0.0|Unknown||T cell, receptor, MHC|Yes| 7699.0|YAe62 Tcrb|C57BL/6-Tg(CD2-Tcrb)62/AnuApb||Recessive||||||||||||||||||||||||||T cell receptor beta|Human CD2|||||||||||YAe62 β mice are biased toward creating TCRs reactive to IAb-3K and the related ligand IAb-P-1K.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Jun-2014|Cryopreserved sperm|11.0|0.0|Unknown||T cell, receptor, MHC|Yes| 7700.0|B3K506 Tcrb|C57BL/6-Tg(CD2-Tcrb)506/AnuApb||Recessive||||||||||||||||||||||||||T cell receptor beta|Human CD2|||||||||||TCRβ Tg mice express the rearranged B3K506 Vβ8.1 chain using the human CD2 promoter.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Jun-2014|Cryopreserved sperm|12.0|0.0|Unknown||T cell, receptor, MHC|Yes| 4117.0|Patchy|ENU12NIH:037a||Semi-dominant|||||||||Unknown||||||||||||||||Yes|||||||||||||White patch on underbelly. One mouse in G2 seen with white patch as well as curly tail.|White patch on underbelly. One mouse in G2 seen with white patch as well as curly tail.||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Dec-2008|Cryopreserved sperm|20.0|0.0|Unknown||Coat, White patch, Spot, ENU|Yes| 31.0|Blobby|C57BL/6JSfdAnu-Alms1/AnuApb|C57BL/6JSfdAnu-Alms1/AnuApb|Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|blobby|Alms1|MGI:3611799|6|ENSMUSG00000063810|ENSMUST00000072018|Alms1-001|6392|6507|T to A|ENSMUSE00000552223|10|2130|Leucine to STOP|||||TCTTCTTTCTGAAGGTCAGGATTATGAGTTAGAAGAGGTTCAGCATATACCTCAGTCATAC|No|||||||||||||Late onset obesity (apparent at 3-6 months). Homozygous null mice display obesity starting after puberty, hypogonadism, hyperinsulinemia, male-specific hyperglycemia, retinal dysfunction, and late-onset hearing loss.||C57BL/6JStdAnu|Yes|No|Yes|Yes|No|Yes|Yes|Poor||10||No|06-Feb-2006|Cryopreserved sperm|109.0|0.0|Yes||ENU, spermatogenesis, kidney, hyperinsulinemia|Yes| 2368.0|thiana|ENU5AT:149 ||Recessive|||Unknown|||thiana|||Unknown||||||||||||||||Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. ||C57BL/6 x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|43.0|0.0|Unknown||B cell, Th1, antibody, ENU, Wellcome Trust|Yes| 2371.0||ENU7B6:021||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|25.0|0.0|No||B cell, antibody, immunization, ENU, Wellcome Trust|Yes| 2778.0|BALB/c.hK14-FLII 5|BALB/c-Tg(hK14-FLII)5/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|Human Flightless|Human Keratin 14|||||||||||Not bred to Homozygous state|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het FLII transgenic x WT BALB/c|No|16-Feb-2008|Cryopreserved sperm|130.0|0.0|Unknown||human, keratin, enhancer, skin|Yes| 4747.0|Gelsolin KO ; Gen|STOCK Gsn/AnuApb||Recessive|gelsolin|Gsn|Nil||MGI:95851|targeted mutation 1, David J Kwiatkowski|Gsn|MGI:2179509|2||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions in this gene display abnormalities in the immune system, platelet and platelet function, bone density, nervous and circulatory system. In addition, there are background related effects on viability and mammary gland development. Have defects in cell motility, as might be expected for a protein involved in cytoskeletal actin filament regulation.||Unknown|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|27-Apr-2009|Cryopreserved sperm|170.0|0.0|Unknown||actin filament, cytoskeleton, wound healing, cell migration, cell adhesion|Yes| 2463.0||B6.CBA-Tg(hGMCSF-2CK1)1236/AnuApb||Dominant|||||||||Unknown||||||||||||||||No|human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|20.0|0.0|Unknown||T cell, Lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 6942.0|ENU19 WT:018:b:B6:G3|ANU:ENU19WT:018:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 3323.0|Metallic|ENU10B6:031 ||Recessive||||||||||||||||||||||||||||||||||||||Silver / grey coat. Mice appear otherwise healthy and are able to breed.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||1||No|15-Jun-2008|Cryopreserved sperm|45.0|0.0|Unknown||Coat colour, Fur, ENU, Hair, pigmentation|Yes| 2380.0|Jaffa|ENU8B6:085||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Coat colour defect.Dluted coat colour.Irregular coat pigmentation.Affected mice are born with a brown-coloured coat. Mice appear healthy otherwise. ||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|90.0|0.0|Unknown||Coat, melanocyte, hair, ENU, pigmentation|Yes| 2466.0||B6.CBA-Tg(hGMCSF-2KB)63/AnuApb||Dominant||||||||||||||||||||||||||human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|30.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 2468.0||B6.CBA-Tg(hGMCSF-KBM)498/AnuApb||Dominant||||||||||||||||||||||||||human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|30.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 4531.0|TNAP-Cre|C.B6-Alpl/AnuApb||Recessive|alkaline phosphatase, liver/bone/kidney|Alpl|Nil|Akp-2, Akp2, TNSALP, TNAP|MGI:87983|targeted mutation 1, Andras Nagy|Alpl|MGI:2177588|4||||||||||||||||Yes|Cre recombinase|TNAP|||||||||||Embryonic Lethal||Balb/c x C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|8|||No|27-Feb-2009|Cryopreserved sperm|120.0|0.0|Unknown||alkaline phosphatase, primordial germ cell|Yes| 5174.0|Nehmet ; Maat ; ENU15China:011a|C57BL/6JAnu-Cd4/AnuApb|C57BL/6JAnu-Cd4/AnuApb|Recessive|CD4 antigen|Cd4|Unknown|L3T4, Ly-4|MGI:88335|Maat|Cd4|MGI:4819382|6|ENSMUSG00000023274|ENSMUST00000024044|Cd4-001||||||||124816702|8|||GAGGACTGGGACCCTCACGACTACTCTCCTTGTCCCTGGGCAGCGCCAGGCAGCACGAAT|Yes|||||||||||||Low CD4 expression and CD4<+> T cell numbers.High CD8<+> T cell numbers||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|08-Jul-2010|Cryopreserved sperm|57.0|0.0|Unknown||T cell, CD4, CD8, selection, ENU, China|Yes| 61.0|PieBaldSeizures|ENU3strain:PieBaldSeizures||Recessive|||Unknown||||||16||||||||||||||||Yes|||||||||||||Mostly white coat with small black flecks and mottles (ie piebald). Eyes are black. Mice also show very subtle shaking/trembling but are otherwise healthy. Defect in melanisation. Seizures were seen in C57BL/6 background.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7||No|06-Feb-2006|Cryopreserved sperm|50.0|0.0|Unknown||melanisation, piebald, ENU|Yes| 6944.0|ENU19 WT:019:b:B6:G3|ANU:ENU19WT:019:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|90.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6945.0|ENU19 WT:021:b:B6:G3|ANU:ENU19WT:021:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|9.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7671.0|ENU26:008:IL7R:B6:G5|C57BL/6NCrlAnu-Il7r/AnuApb||Recessive|interleukin 7 receptor|Il7r|Unknown|CD127, IL-7Ralpha, IL-7 receptor alpha chain|MGI:96562||||15|ENSMUSG00000003882|ENSMUST00000003981|Il7r-201|166|300|T to G|ENSMUSE00000269798|2|56|Threonine to Proline|||||TGGAAGTGGATGGAAGTCAACATTTATTGACTTGTGCTTTTAATGACTCAGACATCAACAC||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-May-2014|Cryopreserved sperm|55.0|0.0|Unknown||ENU, B cell, lymphocyte|Yes| 4499.0|This and That|ENU4AT:017 ||Semi-dominant|||||||||Unknown||||||||||||||||Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Feb-2009|Cryopreserved sperm|44.0|0.0|Unknown||Immunization, B cell, IgG2c, ENU, Wellcome Trust|Yes| 85.0||Trembles||Recessive|||Unknown||||||4||||||||||||||||Yes|||||||||||||Non-progressive mild-moderate ataxia evident at weaning. Some affecteds have shaggy fur. Full histology as been requested by APN. Video available. Phenotype unique to this chromosome location||C57BL/6 x NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|110.0|0.0|Unknown||Ataxia, Shaking, ENU, Weakness|Yes| 6875.0|BRINP2 Targetted, DBC2 Targetted|B6.Cg-Brinp2/PibMarpApb||Recessive|bone morphogenic protein/retinoic acid inducible neural-specific 2|Brinp2||6430517E21Rik, Fam5b, mKIAA1747|MGI:2443333|bone morphogenic protein/retinoic acid inducible neural-specific 2; targeted mutation 1, Phillip I Bird|Brinp2|MGI:5604614|1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown||Membrane attack complex|Yes| 640.0|Gz alpha knockout|C.B6-Gnaz/AnuApb|C.B6-Gnaz/AnuApb|Dominant|guanine nucleotide binding protein, alpha z subunit|Gnaz|Nil|Gz|MGI:95780|targeted mutation 1, I A Hendry|Gnaz|MGI:3575007|10||||||||||||||||No|||||||||||||Hypertolerant to morphine, show anxiety.In previously unexposed female homozygotes reduced analgesia at low morphine doses is seen, a similar but not significant effect was seen in males.With repeated morphine doses mutants develop tolerance faster than wild type mice.Morphine treated homozygotes are able to tolerate higher morphine doses compared to wild type mice (LD50 of 800 mg/kg compared to 700 mg/kg for wild type)however no significant difference in the serum levels of morphine or its metabolites is seenreproductive systemLitters from homozygous parents on the C57BL/6 background had increased mortality that was not seen in litters from heterozygous or mixed strain parentstouch/vibrissae.|Decreased sensitivity to xenobiotic induced morbidity/mortality: morphine treated homozygotes are able to tolerate higher morphine doses compared to wild-type mice (LD50 of 750 mg/kg compared to 700 mg/kg for wild-type).Abnormal chemically-elicited antinociception: with repeated morphine doses heterozygotes develop tolerance faster than wild-type mice but not as quickly as homozygous mutants.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|20|||No|25-Apr-2007|Cryopreserved sperm|60.0|0.0|Unknown||morphine, receptor, G protein, tolerance, feeding behaviour|Yes| 2367.0|Mr Hankey ; ENU8CAT:005|B6;CB-Prkdc/AnuApb|B6;CB-Prkdc/AnuApb|Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|hankey|Prkdc|MGI:4820716|16|ENSMUSG00000022672|ENSMUST00000023352|Prkdc-201|1634|1657|T to A|ENSMUSE00000282431|16|545|Leucine to STOP|||||AGGCTGTGACCAGATGGAGGATTTTATTTTAGGAGATGAAACATTTCTCTTTGTGAACTCC|Yes|||||||||||||Diarrhoea.Lymphopenia||C57BL/6JAnu x CBA/CaJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|51.0|0.0|Unknown||gut, diarrhoea, intestine, ENU|No| 2464.0||B6.CBA-Tg(hGMCSF-2CK1)79/AnuApb||Dominant|||||||||Unknown||||||||||||||||No|human GM-CSF|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|40.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 1511.0||C57BL/6-Tcra Tg(TcrLCMV)327Sdz/AnuApb||Recessive|T-cell receptor alpha chain|Tcra|Unknown|Tcr alpha, Tcralpha|MGI:98553|targeted mutation 1, Peter Mombaerts|Tcra|MGI:1857255|14||||||||||||||||Yes|transgene insertion 327, Birgit Ledermann||High||||||||||T cell express T cell receptor specific for LCMV P14 protein.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||T cell, receptor, lymphocytic choriomeningitis virus (LCMV)|Yes| 46.0|Kenobi ; ENU5strain:045; ENU5WT:054 |C57BL/6JSfdAnu-Cd79a/AnuApb|C57BL/6JSfdAnu-Cd79a/AnuApb|Recessive|CD79A antigen (immunoglobulin-associated alpha)|Cd79a|Nil|Cd79a, Ig alpha, Ig-alpha, Iga, Ly54, mb-1|MGI:101774|CD79A antigen (immunoglobulin-associated alpha); mutation 1, The Australian National University|Cd79a|MGI:5006856|7|ENSMUSG00000003379|ENSMUST00000003469|Cd79a-001|186|327|G to A|ENSMUSE00000199568|2|62|Tryptophan to STOP|||||AATGGCAGGAACCCTAATATCACATGGTGGTTCAGCCTTCAGTCTAACATCACATGGCCCC|Yes|||||||||||||Immune deficiency. Hypogammaglobulinemia. Absolutely no B cells or pre-B cells.||C57BL/6 x C57BL/10.Br|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Unknown||||No|28-Apr-2004|Cryopreserved sperm|65.0|0.0|Unknown||B-cell antigen receptor, B cell, hypogammaglobulinemia, ENU, Wellcome Trust|Yes| 5002.0|aFO8 aa262|FVB/N-Tg(Prm1-Pebp1)8Mkob/MarpApb||Dominant||||||||||||||||||||||||||phosphatidylethanolamine binding protein 1|Protamine 1|low level expression||||||||||||FVB/N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|0|||No|22-Feb-2010|Cryopreserved sperm|60.0|0.0|Unknown||fertility, sperm|No| 4574.0|FATT-129Sv/EvTac|129Sv-Lepr/Apb||Semi-dominant|Leptin Receptor|LepR|Unknown|Leprb, LEPROT, leptin receptor gene-related protein, Modb1, OB-RGRP, obese-like, obl, Obr|MGI:104993|FATT|||4||||||||||||||||No|||||||||||||The homozygote mutant has juvenile obesity, florid diabetes. The adult is hypogonadal and does not breed, and had an increased body length (10-20%).|There is a slight change in adipose tissue distribution and liver weight but no other significant changes.|129Sv/EvTac|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|08-Mar-2009|Cryopreserved sperm|144.0|0.0|Yes||Obesity, diabetes, leptin, receptor|Yes| 4730.0||NOD.B6.Cg-H2 Tg(TLK2mHEL)2Ccg/AnuApb|NODB6.Cg-H2 Tg(TLK2mHEL)2Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher C Goodnow|rat thyroglobulin|expression limited to thyroid||||||||||Express low levels of membrane bound HEL in thyroid. Low serum levels of HEL detected.||NOD.Cg-H2 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|17-Apr-2009|Cryopreserved sperm|95.0|0.0|Unknown||autoimmunity, B cell, tolerance, Hen egg lysozyme (HEL), T cell|Yes| 6947.0|ENU19 WT:023:a:B6:G3|ANU:ENU19WT:023:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|59.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4434.0||ENU7B6:011||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||3||No|17-Feb-2009|Cryopreserved sperm|30.0|0.0|Unknown||autoimmunity, antinuclear antibodies (ANA), ENU, Wellcome Trust|Yes| 4577.0||NOD.129S7-H2 Ifngr1/AnuApb||Recessive|interferon gamma receptor 1|Ifngr1|Nil|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10||||||||||||||||Yes||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17|Abnormal immune system||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Mar-2009|Cryopreserved sperm|120.0|0.0|Unknown||cytokine, interleukin, infection, immunoglobulin, macrophage|Yes| 4578.0||PLJ.129S7-Ifngr1/AnuApb||Recessive|interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10||||||||||||||||Yes|||||||||||||Abnormal immune system||PLJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Mar-2009|Cryopreserved sperm|60.0|0.0|Unknown||cytokine, interleukin, infection, immunoglobulin, macrophage|Yes| 5010.0|Zedd|FVB/n-Luciferase Tg1 (ASD069)||Dominant||||||||||||||||||||||||||||||||||||||||10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|150.0|0.0|Unknown|||Possibly| 5519.0|17China 43b|C57BL/6JAnu-Ptprc/Apb||Dominant|protein tyrosine phosphatase, receptor type, C|Ptprc |Reduced|B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|mutation 1, The Australian National University|Prtprc||1||||||||||||||||No|||||||||||||Blood lymphopenia|Reduced expression of CD45|C57BL/JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||3|Sib x sib|No|07-Jun-2011|Cryopreserved sperm|50.0|0.0|Unknown||T cell|Possibly| 4918.0|CD9 -/-|B6.129-CD9/AusbApb||Recessive|CD9 antigen|Cd9|Nil|Tspan29|MGI:88348|targeted mutation 1, Claude Boucheix|Cd9|MGI:2180795|6|||||||||||||||||||||||||||||Reduced female fertility: 40 - 50% of females fail to produce litters.Decreased litter size.Impaired fertilization: impaired sperm - egg fusion.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|20-Oct-2009|Cryopreserved sperm|90.0|0.0|Unknown||fertility, tetraspan, CD151|Yes| 5251.0|FHWMKA|B6.129-Fxn Tg(FXN)CSars/Apb||Recessive|Frataxin|Fxn||Frda|MGI:1096879|frataxin; targeted mutation 1, Michel Koenig|Fxn|MGI:2177162|19||||||||||||||||No|Human FRATAXIN gene|FXN endogenous promoter|||||||||||Homozygous FXN transgene: Normal.Homozygous Fxn knockout: embryonic lethal, but completely complemented by presence of FXN transgene.|Hemizygous FXN transgene: Normal.Heterozygous Fxn knockout: Normal.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16|Hemizygous FXN transgene and Homozygous Fxn knockout X Hemizygous FXN transgene and Homozygous Fxn knockout|Yes|20-Oct-2010|Cryopreserved sperm|45.0|0.0|Yes|Friedreich ataxia|Friedreich ataxia, neurodegenerative disease, iron-sulfur clusters|Yes| 6948.0|ENU19 WT:025:b:B6:G3|ANU:ENU19WT:025:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6810.0|L12SLR1R|SJL.B6-L12SLR1R/MriApb||Recessive|||||||||||||||||||||||||||||Unknown||||||||9|This allele confers normo-susceptibility to Plasmodium chabaudi compared to wildtype SJL.||SJL|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||Yes|01-Feb-2012|Cryopreserved sperm|70.0|0.0|Unknown||Malaria, Red blood cells, Innate immune response|Yes| 6950.0|ENU19 WT:029:a:B6:G3|ANU:ENU19WT:029:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4520.0||ENU8C:051||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|150.0|0.0|Unknown||autoimmunity, Antinuclear antibodies (ANA), ENU, Wellcome Trust|Yes| 2780.0|C57BL/6.Flii 2.1A|B6.C-Flii/3AnuApb|B6.C-Flii/3AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethal|No obvious altered phenotype|C57BL/6|No|No|Yes|No|No|Yes|No|Good|10|11|Het male x WT female|No|16-Feb-2008|Cryopreserved sperm|105.0|0.0|Unknown||gelsolin, embryonic lethal, wound repair, egg cylinder, gastrulation|Yes| 4714.0|Rolex/129|129-Hccs/MarpApb||X-linked|holocytochrome c synthetase|Hccs|Unknown||MGI:106911|targeted mutation 1, Timothy C Cox|Hccs|MGI:3826866|X||||||||||||||||Yes|||||||||||||NormalHomozygous female or hemizygous males for a conditional allele activated in the heart exhibit fetal lethality associated with abnormal fetal cardiomyocyte morphology and physiology.||129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|150.0|0.0|Unknown||cardiac, midgestation, mitochondria|Yes| 4698.0||NOD.Cg-Tg(H2-Ea-Atp4b)1Wehi/WehiApb||Dominant||||||||||||||||||||||||||ATPase, H+/K+ exchanging, beta polypeptide (Atp4b)|1.8-kb fragment encoding nucleotides -1,903 through -39 of the 5' flanking sequence of the MHC Class II gene, H2-Ea (k allele)|||||||||||||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|155.0|0.0|Unknown||Tolerance, Autoimmunity, Autoantigen|Yes| 6809.0||SJL/Mrit-MRI47495||Dominant|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Macrocytic anaemia|Macrocytic anaemia|SJL|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Feb-2012|Cryopreserved sperm|70.0|0.0|Unknown||red blood cells, ENU|Yes| 7063.0|Momme D25|FVB/NJ-MommeD25 Tg(Hba1-Gfp)1Ew||Semi-dominant|modifier of murine metastable epialleles, D25|MommeD25|Unknown||||||3|||||||||||||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Unknown|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD25<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|39.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 4776.0|TOMtg|FVB-Tg(tetO-MYC)1Lach/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Lewis A Chodosh|bacterial tetracycline-resistance operon|||||||||||Normal||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-Sep-2009|Cryopreserved sperm|95.0|0.0|No||Mammary Gland, tetracycline, tumourigenesis, Myc, transcription factor|Yes| 5181.0|Mif -/- Fas|MRL/MpJ.Cg-Fas Mif/MarpApb||Recessive|Fas (TNF receptor superfamily member 6)|Fas|Unknown|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||Yes|||||||||||||MIF<–/–>MRL/lpr mice had significantly less proteinuria than MIF<+/+>MRL/lpr mice.Ab production in the MRL mice was largely unaffected by MIF deficiency.No difference in the percentage of CD4<+> or CD8<+> T cells, B cells (CD3<->B220<+>), CD3<+>CD4<->CD8<->B220<+> double-negative T cells (DNTCs), or CD11b<+>CD11c<+> dendritic cells between MIF<+/+> and MIF<–/–>MRL mice.MIF<–/–>MRL mice were protected from crescentic glomeruli formation as compared to MRL mice.MIF deficiency reduces renal macrophage recruitment and MCP-1 expression.||MRL/MpJ|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jul-2010|Cryopreserved sperm|70.0|0.0|Unknown||autoimmunity, T cell, B cell, leukocyte adhesion, glomerulonephritis, macrophage|Yes| 5181.0|Mif -/- Fas|MRL/MpJ.Cg-Fas Mif/MarpApb||Recessive|macrophage migration inhibitory factor|Mif|Nil|Glif|MGI:96982|macrophage migration inhibitory factor; targeted mutation 1, John R David|Mif|MGI:2176337|10||||||||||||||||No|||||||||||||MIF<–/–>MRL/lpr mice had significantly less proteinuria than MIF<+/+>MRL/lpr mice.Ab production in the MRL mice was largely unaffected by MIF deficiency.No difference in the percentage of CD4<+> or CD8<+> T cells, B cells (CD3<->B220<+>), CD3<+>CD4<->CD8<->B220<+> double-negative T cells (DNTCs), or CD11b<+>CD11c<+> dendritic cells between MIF<+/+> and MIF<–/–>MRL mice.MIF<–/–>MRL mice were protected from crescentic glomeruli formation as compared to MRL mice.MIF deficiency reduces renal macrophage recruitment and MCP-1 expression.||MRL/MpJ|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jul-2010|Cryopreserved sperm|||Unknown||autoimmunity, T cell, B cell, leukocyte adhesion, glomerulonephritis, macrophage|Yes| 6949.0|ENU19 WT:026:a:B6:G3|ANU:ENU19WT:026:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 657.0|transgenic line MBP-c-myc |B6.129-Tg(Mbp-MYC*)/Apb||Dominant|||||||||Unknown||||||||||||||||Yes|exons 2 and 3 of the human c-myc gene|1.3Kb of the mouse myelin basic protein (Mbp)|very low||||||||||Mice exhibit a transient shivering phenotype over the period corresponding to the peak of central nervous system myelination (4 to 8 weeks postnatally). Thereafter, shivering decreases abruptly and mice go on to live a normal life-span and breed normally.|As for heterozygous, but more pronounced. Death between 4 and 8 weeks has been observed but is rare. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Excellent|38||transgenic males mated to normal C57BL/6 females between about 7 to 15 weeks of age|No|26-Apr-2007|Cryopreserved sperm|110.0|0.0|Yes||myelination, congenital hypomyelination, leukodystrophy, oligodendrocyte loss, myelin, CNS, shivering|Yes| 5113.0|Joey-SCO|C57BL/6JAnu-Etv5/AnuMarpApb|C57BL/6JAnu-Etv5/AnuMarpApb|Recessive|ets variant gene 5|Etv5|Unknown|ERM|MGI:1096867|ets variant gene 5; sco|Etv5|MGI:5563470|16|ENSMUSG00000013089|ENSMUST00000079601|Etv5-202|1234|1414|A to T|ENSMUSE00000560895|12|412|Lysine to STOP|||||AAGAGGTTGCTCGCCGTTGGGGTATCCAGAAGAATCGGCCAGCCATGAACTATGACAAGCT|No|||||||||||||Sertoli cells only.Male infertility.Progressive loss of germ cells following the first wave of spermatogenesis.Germ cells appeared to be preferentially lost in a basal to apical direction from the seminiferous epithelium as detected in 7 week old testis.Reduced testis size, compared to WT, at 8 weeks of age.Etv5 mRNA levels 95% reduced compared to WT males.Etv5 mRNA is unstable.Reduced expression of Etv5 target genes Cxcr4 and Ccl9.Increased incidence of embryonic and perinatal lethality.Reduced body weight.Renal asymmetry.Polydactyly.||C57BL/6JAnu|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|10-May-2010|Cryopreserved sperm|50.0|0.0|Unknown||infertility, sperm, arrest, ENU, sertoli|Yes| 4712.0|T3RWT|B6.129-Tlr3||Dominant|toll-like receptor 3|Tlr3|Unknown||MGI:2156367||||8||||||||||||||||Yes|||||||||||||Wild-type strain used as control for Tlr3 knockout, APB ID#630||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|100.0|0.0|Unknown||Lymphocyte, viral infection, hypersensitivity, T cell, stimulation , proliferation|Yes| 4721.0|TGM2 floxed|C57BL/6-Tgm2/Apb||Recessive|transglutaminase 2, C polypeptide|Tgm2|Normal|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 1, Robert M Graham|Tgm2|MGI:3525256|2||||||||||||||||Yes|||||||||||||Normal - no phenotypic analysis * mice were only used to generate the null allele||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|59.0|0.0|Unknown||Transgluatminase, Gh, G-protein, cross-linking|Yes| 5456.0|ENU14Ch 036b; ENU14China:036b|C57BL/6JAnu-Cd22/AnuApb|C57BL/6JAnu-Cd22/AnuApb|Recessive|CD22 antigen|Cd22|Reduced|Lyb-8, Lyb8|MGI:88322|CD22 antigen; mutation 1, Australian National University|Cd22|MGI:5009050|7|ENSMUSG00000030577|ENSMUST00000019248|Cd22-201|1536|2116|T to A|ENSMUSE00000359124|7|511|Cysteine to STOP|||||GTCAGCTGTGCTGCCTGCAACCACAAGTGTTCGTGGGCCCTCCCTGTCATCCTGAATGTCC|Yes|||||||||||||Block in B cell maturation and reduced number of B cells in peripheral blood.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Mar-2011|Cryopreserved sperm|47.0|0.0|Unknown||B cell, lymphocyte, immunoglobulin, ENU|Possibly| 108.0|Alison2 ; AL3|C57BL/6JSfdAnu-Tg(AlsHEL)3Ccg/AnuApb|C57BL/6JSfdAnu-Tg(AlsHEL)3Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|liver specific albumin|high||||||||||High ubiquitous expression of soluble Hen Egg Lysozyme (sHEL). Females express approximately 2-fold more sHEL than males of this strain.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5|Hom xHom|No|06-Feb-2006|Cryopreserved sperm|125.0|0.0|Yes||Hen Egg Lysozyme (HEL), B cell, T cell, tolerance, autoimmunity|Yes| 4803.0|Mal ; ENU8BAT:012|B6(Cg);CBA-Rabl2a/AnuApb||Recessive|RAB, member of RAS oncogene family-like 2A|Rabl2a|||MGI:1915958|RAB, member of RAS oncogene family-like 2; mot|Rabl2|MGI:5469381|15|ENSMUSG00000022621|ENSMUST00000023294|Rabl2a-201|218|311|A to G|ENSMUSE00000128937|5|73|Aspartic acid to Glycine|||||CACAGTAGACGGCAAGACGATCCTTGTGGACTTCTGGGATACAGCAGGCCAGGAGCGGTTC|Yes|||||||||||||Male InfertilityDecreased testis weightOligozoospermiaShort sperm flagellumAsthenozoospermia:• low total motility and minimal progressive motility• however, ultrastructure is normal||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|115.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|No| 2767.0|BALB/c.Flii<-/-> FLII ; FICR|BALB/c-Flii Tg(FLII)1Hdc/AnuApb|BALB/c-Flii Tg(FLII)1Hdc|Recessive|flightless I homolog (Drosophila)|Flii|Unknown|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|transgene insertion 1, Hugh D Campbell|human flightless promoter|||||||||||Embryonic lethal phenotype of FLii knockout is rescued by human FLII transgene. Ubiquitous expression of human Flightless gene.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||FLii<-/-> FLII x FLii<-/-> FLII|No|15-Feb-2008|Cryopreserved sperm|120.0|0.0|Unknown||human flightless, wound repair, cellular proliferation, cell migration, gelsolin|Yes| 4705.0|NOD-HIPCre|NOD-Tg(INS-cre)2Rms/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 2, Robyn M Slattery|human insulin promoter|beta islet cells||||||||||The human insulin promoter (INS) drives cre expression in beta islet cells. Resistance to development of diabetes and hyperglycemia||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|135.0|0.0|Yes||Autoimmunity, insulin, Beta cell|Yes| 7703.0|ENU29:G3|ANU:ENU29:G3||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|17-Jun-2014|Cryopreserved sperm|138.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 109.0|Andrew2 ; ML4|C57BL/6JSfdAnu-Tg(ML4sHEL)4Ccg/AnuApb|C57BL/6JSfdAnu-Tg(ML4sHEL)4Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 4, Christopher C Goodnow ; soluble HEL (hen egg lysozyme)|zinc inducible mouse metallothionein I|High||||||||||Mice homozygous for the TgN(ML5sHEL)5Ccg transgene express a soluble form of hen egg lysozyme.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||10|sib x sib|No|06-Feb-2006|Cryopreserved sperm|140.0|0.0|No||hen egg lysozyme (HEL), autoimmunity, B cell, T cell, tolerance|Yes| 4737.0||ENU8C:060||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|1|||No|19-Apr-2009|Cryopreserved sperm|70.0|0.0|Unknown||Autoimmunity, ANA, ENU, Wellcome Trust|Yes| 5459.0|ENU16Ch:017a, Lyn|C57BL/6JAnu-Lyn/AnuApb|C57BL/6JAnu-Lyn/AnuApb|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog |Lyn|Unknown|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; mutation 1, Australian Phenomics Facility|Lyn|MGI:5501039|4|ENSMUSG00000042228|ENSMUST00000041377|Lyn-001|1228|1483|A to G|ENSMUSE00000605548|12|410|Threonine to Alanine|||||GGGAAGGTGCGAAGTTCCCTATCAAGTGGACAGCTCCAGAGGCCATCAACTTCGGCTGCTT|No|||||||||||||Very low B cells numbers but High IgM<+>IgD<-> cells.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Mar-2011|Cryopreserved sperm|45.0|0.0|Unknown||B cell, Lymphocyte, ENU, immunoglobulin, kinase, signal transduction|Possibly| 7704.0|H2A.Lap1:NM1|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|H2A histone family, member B2|H2afb2|Nil|EG624153, H2A.Bbd4, H2afb2-ps|MGI:3644980||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|18-Jun-2014|Cryopreserved sperm|48.0|0.0|Unknown||H2A.Lap1, histone, NM1|Possibly| 7704.0|H2A.Lap1:NM1|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|H2A histone family, member B3|H2afb3||EG624957, H2A.Bbd3, H2afb3-ps|MGI:3644875||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|18-Jun-2014|Cryopreserved sperm|||Unknown||H2A.Lap1, histone, NM1|Possibly| 7704.0|H2A.Lap1:NM1|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|predicted pseudogene 14920|Gm14920||ENSMUSG00000067441, H2A.Bbd1|MGI:3642445||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|18-Jun-2014|Cryopreserved sperm|||Unknown||H2A.Lap1, histone, NM1|Possibly| 7673.0|Solox Low x AR 2-/-|B6;CBA-Ifnar2 Tg(sIfnar2)Pjh/MarpApb||Recessive|interferon (alpha and beta) receptor 2|Ifnar2|Nil|Ifnar-2 |MGI:1098243 |interferon (alpha and beta) receptor 2; targeted mutation 1, Paul J Hertzog|Ifnar2|MGI:2680693|16||||||||||Unknown to Unknown|||||||interferon (alpha and beta) soluble receptor 2 low expression ||Low||||||||||Unknown|Unknown|C57BL/6 (tbc)|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|07-May-2014|Cryopreserved sperm|50.0|0.0|Unknown||septic shock, proinflammatory cytokines, agonist|No| 3340.0|C57BL/6 Tg(IL5)C2|B6.CBACa-Tg(CD2-Il5)5C2Ldt/Apb [cc]|B6.CBACa-Tg(CD2-Il5)5C2Ldt/Apb [cc]|Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blot analysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|C57BL/6|No|No|Yes|No|No|Yes|No|Excellent|20||Tg male wild type female|No|20-Jun-2008|Cryopreserved sperm|75.0|0.0|Yes||eosinophil, immune surveillance, esistance to helminthic parasites, asthma, allergy|Yes| 4736.0|Anasette|ENU5AT:140 ||Recessive|||Unknown|||Anasette|||Unknown||||||||||||||||Yes|||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6 x C57BL/10.Br|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10||No|19-Apr-2009|Cryopreserved sperm|120.0|0.0|Unknown||Autoimmunity, ANA, ENU, Wellcome Trust|Yes| 18.0|Androida|ENU5:028 ||Recessive|||Unknown|||Androida|||Unknown||||||||||||||||Yes|||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6 x C57BL/10.Br|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10||No|19-Aug-2006|Cryopreserved sperm|40.0|0.0|Unknown||ANA, autoimmunity, ENU, Wellcome Trust|Yes| 2781.0|C57BL/6.Flii 1.4A|B6.C-Flii/2AnuApb|B6.C-Flii/2AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||No|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop.embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|10|11||No|16-Feb-2008|Cryopreserved sperm|105.0|0.0|No||embryonic lethal, gelsolin, wound, cell migration, gastrulation|Yes| 4468.0|HB9-GFP|129-Tg(Mnx1-GFP)1Slp/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Samuel L Pfaff|Mnx1|||||||||||Enhanced Green Fluorescent protein highlights motoneurons in the spinal cord.||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||sib x sib|Yes|22-Feb-2009|Cryopreserved sperm|135.0|0.0|Unknown||GFP, neuron, transcription|Yes| 9.0|Anaconda|ENU4:006 ||Recessive|||Unknown|||Anaconda|||Unknown||||||||||||||||Unknown|||||||||||||Screened phenotype = positive for anti-nuclear antibodies||C57BL/6 x C57BL/10.Br|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10||No|20-Apr-2004|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, ENU, Wellcome Trust, ANA|Yes| 16.0|Anaya|ENU5:134 ||Recessive|||Nil|||Anaya|||Unknown||||||||||||||||Yes|||||||||||||Phenotypic screen= positive for anti-nuclear antibodies||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|2|||No|20-Apr-2004|Cryopreserved sperm|30.0|0.0|Yes||ANA, autoimmunity, ENU, Wellcome Trust|Yes| 5458.0|ENU16China:051a ; Berty|C57BL/6JAnu-Prkdc/AnuApb|C57BL/6JAnu-Prkdc/AnuApb|Recessive|protein kinase, DNA activated, catalytic polypeptide |Prkdc|Reduced|DNA-PK, DNA-PKcs, DNAPDcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|rotein kinase, DNA activated, catalytic polypeptide; berty|Prkdc|MGI:5009121|16|ENSMUSG00000022672|ENSMUST00000023352|Prkdc-201|10326|10349|T to A|ENSMUSE00000129337|73|3442|Tyrosine to STOP|||||CAGAAGACAAGTGCAGAAATGGAAGCATATCCAGCACTTGTGGTGGAAAAAATGCTGAGAG|Yes|||||||||||||No B or T cells.||C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|Yes|Poor||||No|07-Mar-2011|Cryopreserved sperm|48.0|0.0|Unknown||B cell, T cell, lymphocyte, ENU, severe combined immunodeficiency (SCID)|Possibly| 7517.0|HA-TetO|C57BL/6-Tg(tetO-CYP19A1)2/MarpApb||Dominant||||||||||||||||||||||||||Human Aromatase ; human cytochrome P450, family 19, subfamily a, polypeptide 1|TetO|||||||||||Normal; no phenotype|Normal; no phenotype|C57BL/6J|No|Yes|Unknown|No|Yes|Unknown|No|Unknown||||No|29-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9269.0||C57BL/6J-Sfd/AnuApb ||Semi-dominant|mucin 2|Muc2|||MGI:1339364|mucin 2; winnie|Muc2wnn|MGI:3614806|7|ENSMUSG00000025515 |||||||||Unknown to Unknown|||||||This is a missense mutation type||||||||||||spontaneous watery diarrhoea, and high incidence of rectal bleeding and prolapse, suggestive of ulcerative colitis.|Observable phenotype seems to present as normal, same as wildtype|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Sep-2021|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 5222.0|C57.Lyn-/-uMT-/-|B6.129-Lyn Ighm/Apb|B6.129-Lyn Ighm/Apb|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||Mice are B cell deficient, and do not develop autoimmune disease characteristics of lyn -/- mice.|Not Studied|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Sep-2010|Cryopreserved sperm|50.0|0.0|No||src kinase family, B cell, lymphocyte, signal transduction|Yes| 5222.0|C57.Lyn-/-uMT-/-|B6.129-Lyn Ighm/Apb|B6.129-Lyn Ighm/Apb|Recessive|immunoglobulin heavy constant mu|Ighm||BCR, Ig mu, Igh-M, Igh6, IgM, muH, muMT|MGI:96448|immunoglobulin heavy chain 6 (heavy chain of IgM); targeted mutation 1, University of Cologne|Ighm|MGI:1857187|12||||||||||||||||No|||||||||||||Mice are B cell deficient, and do not develop autoimmune disease characteristics of lyn -/- mice.|Not Studied|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Sep-2010|Cryopreserved sperm|||No||src kinase family, B cell, lymphocyte, signal transduction|Yes| 238.0|MLR39|FVB/N-Tg(Cryaa-cre)39Mlr/Apb||Dominant||||||||||||||||||||||||||transgene insertion 39, Mike Robinson|aA-crystallin with tyrosinase cassette|||||||||||Nil. Mice express Cre in lens fibres with very little ectopic expression elsewhere||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Apr-2006|Cryopreserved sperm|70.0|0.0|Unknown||crystallin, lens, eye, epithelial, Pax6|Yes| 6951.0|ENU19 WT:030:a:B6:G3|ANU:ENU19WT:030:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|27.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 17.0|Andrea|ENU4strain:AT007||Recessive|Unknown||||||||Unknown||||||||||||||||Yes|||||||||||||Homogeneous anti-nuclear antibodies. |||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Apr-2004|Cryopreserved sperm|10.0|0.0|Yes||ENU, Wellcome Trust, anti-nuclear anitbodies, autoimmunity, T cell, B cell|Yes| 5347.0|B6.hCD4|C57BL/6-Tg(Cd4-CD4)2362Litt/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells|||||||||||CD4 T cells express both the mouse and human CD4 without any adverse effects on phenotype.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|24|||No|15-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||T cell, lymphocyte|Yes| 4716.0||129-Shh/AnuApb||Recessive|sonic hedgehog|Shh|Unknown|Hhg1, Hx, Hxl3, M100081|MGI:98297|targeted mutation 1, Chin Chiang|Shh|MGI:1857796|5||||||||||||||||Yes|||||||||||||Perinatal Lethality, most die just before birth. abnormal dorsal-ventral axis patterning: indistinct midline at E8.5. Notochord degeneration: rostral-to-caudal loss of notochord tissue. Decreased brain size: abnormal forebrain morphology, ventral forebrain structures are lost. Abnormal diencephalon morphology: most of the diencephalon as an identifiable structure is absent. Abnormal telencephalon morphology: the bilateral lobes of the telencephalon are fused to form a single midline structure. Abnormal long bone morphology: absence or fusion of the paired distal limb bones. Abnormal humerus morphology: have a bony extension of the humerus in the forelimb. Absent fibula:the fibula is absent in the hindlimb. Absent tibia: the tibia is absent in the hindlimb. Abnormal axial skeleton morphology: most sclerotomal derivatives are absent. Abnormal craniofacial bone morphology: craniofacial bones are severely affected and almost entirely absent. Decreased rib number: most of the ribs are absent, with only 5-6 rib cartilages remaining. Absent vertebrae: most sclerotomal derivatives including the entire vertebral column are absent, with only 5-6 rib cartilages remaining. Absent cartilage: cartilage is absent at the elbow joint. Abnormal optic vesicle formation: optic vesicles are fused at the midline at E9.5, the optic stalks are deficient or absent, and there is no invagination to form the double-layered optic cups||129SvEv|No|No|Yes|No|No|Yes|No|Unknown|||Het x 129SvEv|No|08-Apr-2009|Cryopreserved sperm|105.0|0.0|Yes||embryonic lethal, limb, craniofacial, neural tube, notochord|Yes| 4717.0|SmoTgR|C57BL/6-Tg(CMV-RFP/Smo)/MarpApb||Dominant||||||||||||||||||||||||||red fluorescent protein tagged to Smoothened|cytomegalovirus (CMV)|||||||||||Animals express red fluorescent protein, are viable and healthy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|15|2|Mate positive RFP mice with wild type C57BL/6|No|08-Apr-2009|Cryopreserved sperm|90.0|0.0|Unknown||Smoothen, red fluorescent protein (RFP)|Yes| 4922.0|Kylie|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)|Csf2rb1|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, C Glenn Begley|Csf2rb|MGI:2181245|15||||||||||||||||Yes|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)||High||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|105.0|0.0|No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 4922.0|Kylie|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 4922.0|Kylie|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc||DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 5346.0|SS-01 ; Vegfd 2.2.36 (SS-01)|B6;129S1/Sv-Figf/Apb||X-linked|c-fos induced growth factor|Figf|Nil|VEGF-D, Vegfd|MGI:108037|c-fos induced growth factor; targeted mutation 1, Marc G Achen|Figf|MGI:3576785|X|||||||||||||||||||||||||||||No abnormal phenotype detected: homozygous females are morphologically normal, can suckle, and have grossly normal lymphatic system morphology and function.Mice have reduced numbers of lymphatic vessels in lungs.|Normal|129S1/Sv x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|0|||No|15-Dec-2010|Cryopreserved sperm|100.0|0.0|Unknown||growth factor, Vegf, lymphatics|Yes| 7.0|Alberta|C57BL/6JSfdAnu-Lepr/AnuApb|C57BL/6JSfdAnu-Lepr/AnuApb|Recessive|leptin receptor|LepR|Unknown|LEPROT, leptin receptor gene-related protein, OB-RGRP, obese-like, obl, Obr|MGI:104993|alberta|Lepr|MGI:3847119|4|ENSMUSG00000057722|ENSMUST00000037552|Lepr-001||||||||101768248|10|||ACCAACGTGTGTCCTTCCTGACTCCGTAGGTACGTCAGACTATATTATGTATTTTCCTTA|Yes|||||||||||||Homozygotes develop severe obesity evident by 4-8weeks. 50% develop diabetes by 6 weeks of age.Homozygotes don't breed||C57BL/6JSfdAnu|Yes|No|Yes|Yes|No|Yes|Yes|Good||9||No|06-Feb-2006|Cryopreserved sperm|57.0|0.0|Yes||obesity, leptin, diet, ENU|Yes| 3946.0|MommeD5|FVB/NJ-Hdac1/Apb|FVB/NJ-Hdac1/Apb|Semi-dominant|histone deacetylase 1|Hdac1|Unknown|HD1, RPD3|MGI:108086|modifier of murine metastable epialleles, D5|Hdac1||4||||||||||||||||Yes|Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Lethality/prenatal-perinatalEmbryonic lethality during organogenesis* homozygotes die at or before E14.5EmbryogenesisEmbryonic growth arrest * around E8-9Embryonic growth retardation * developmentally delayed at E10.5Growth/sizeEmbryonic growth retardation* developmentally delayed at E10.5|Percentage of cells expressing the Line3 GFP transgene is decreased (enhancer of variegation).|FVB/NJ|No|No|Yes|No|No|Yes|No|Poor|||MommeD5<+/->;Tg(α-Globin-GFP)3EWh x Tg(α-Globin-GFP)3EWh|No|17-Oct-2008|Cryopreserved sperm|95.0|0.0|No||epigenetics, histone modification|Yes| 9334.0||B6.B10-H2 Rag1Tg<(ILK3mHEL)3Ccg>/Apb ||Semi-dominant|recombination activating 1|Rag1 |||MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||transgene insertion 3, Christopher C Goodnow ||||||||||||Rag1 KO mice lack mature T and B cells. Hen egg lysozyme expressed on the pancreatic islet beta cells.|same|B10BR N10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Feb-2022|Cryopreserved sperm|26.0|0.0|Unknown|||Possibly| 9334.0||B6.B10-H2 Rag1Tg<(ILK3mHEL)3Ccg>/Apb ||Semi-dominant|histocompatibility-2, MHC|H2 |||MGI:95894|histocompatibility-2, MHC; k2 variant|H2k2|MGI:4936842|17|||||||||||||||||||||||||||||Rag1 KO mice lack mature T and B cells. Hen egg lysozyme expressed on the pancreatic islet beta cells.|same|B10BR N10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Feb-2022|Cryopreserved sperm|||Unknown|||Possibly| 6952.0|ENU19 WT:031:a:B6:G3|ANU:ENU19WT:031:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6814.0|NOD-SBmut10|NOD/Lt-Tn(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)10TCB/Apb||Recessive||||||||||||||||||||||||||TgTn(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)2TCB||||||||||||unknown|unknown|NOD/Lt|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Excellent||||No|08-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown|||No| 3947.0|mommeD6|FVB/NJ-MommeD6/Apb||Semi-dominant|||Unknown|||modifiers of murine metastable epiallele D6|MommeD6|MGI:3586553|14||||||||||||||||Yes|Green fluorescent protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (~9.5 dpc)|GFP transgene (Line3) expression levels are increased.|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD6<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|17-Oct-2008|Cryopreserved sperm|75.0|0.0|Unknown||epigenetics, embryonic lethal|Yes| 5348.0|NOD.hCD4|NOD-Tg(Cd4-CD4)2362Litt/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells|||||||||||CD4 T cells express both the mouse and human CD4 without any adverse effects on phenotype.|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|24|||No|15-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||T cell, lymphocyte|Yes| 4131.0|Line3c|C57BL/6-Tg(HBA1-GFP)3Ew/Apb||Dominant|||Unknown||||||Unknown||||||||||||||||No|Green Fluorescent Protein (GFP)|α-Globin (-570 to +37) (4.1kb of enhancer)|||||||||||Fluorescence in erythrocytes can be observed by FACS or fluorescent microscopy. The allele is subject to variegation.|Fluorescence in erythrocytes can be observed by FACS or fluorescent microscopy. The allele is subject to variegation|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||Hom x Hom|No|07-Dec-2008|Cryopreserved sperm|125.0|0.0|No||Metastable epiallele, Transgene silencing, Green fluorescent protein|Yes| 4699.0|NOD.Cg-Tg(RIP-Socs1)24Wehi NODPfp|NOD.Cg-Tg(Ins2-Socs1)24Wehi Prf1/WehiApb||Dominant|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfn, Pfp, Prf-1|MGI:97551|perforin 1 (pore forming protein); targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10||||||||||||||||No|suppressor of cytokine signaling 1 (Socs1)|Rat insulin promoter from RIP7 vector|||||||||||90–95% of Pancreatic β cells did not up-regulate class I MHC in response to 100 U/ml IFN-, whereas all other islets cells were responsive, as measured by flow cytometry. SOCS-1 overexpression in Pancreatic β cells prevents progression to diabetes in CD8+ TCR transgenic NOD8.3 mice||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|150.0|0.0|Yes||Tolerance, Autoimmunity, Autoantigen, insulin|Yes| 5316.0|RKO 44|B6;129S1-Ryk/Apb||Recessive|receptor-like tyrosine kinase|Ryk||ERK-3, Vik|MGI:101766|receptor-like tyrosine kinase; targeted mutation 1, Steven A Stacker|Ryk|MGI:2667542|9|||||||||||||||||||||||||||||Neonatal lethality: most mice died within 1 day of birth, though some survived up to 8 days, and 2 to adulthood.Abnormal gait: mice surviving to adulthood dragged their hindlimbs.Short mandible.Abnormal maxilla morphology: in conjunction with shortened nasal bone, resulting in flattened midface.Abnormal neurocranium morphology: slightly smaller and rounder than that of wild-type or heterozygous mutant mice.Short nasal bone: shortened nasal bone, resulting in flattened midface.Cleft secondary palate: * cleft secondary palate observed in 88% of mice * consequence of abnormally high positioning and enlargement of the tongue.Increased tongue size: enlargement observed around E14, resulting in the disruption of the development of the palatal shelf.Short snout.Microcephaly: exhibited by mice that survived to adulthood.Cachexia.Postnatal growth retardation: growth was severely impaired in mice surviving past the first day of life.Cyanosis: mice were largely unable to suckle, became dehydrated, cyanotic, and exhibited gasping respirations.Short ulna: reduced in length.Abnormal hindlimb morphology: hindlimbs were splayed laterally.Short fibula.Short limbs: 18% to 25% reduction in the length of the long bones.Microphthalmia: bilateral microphthalmia was observed in mice that survived to adulthood.||C57BL/6 X 129S1/Sv|No|No|Yes|No|No|Yes|No|Unknown|0|||No|11-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||craniofacial, Eph receptor, TGF, receptor protein tyrosine kinases (RTKs)|Yes| 3948.0|mommeD10|FVB/NJ-Baz1b/Apb|FVB/NJ-Baz1b|Semi-dominant|bromodomain adjacent to zinc finger domain, 1B|Baz1b|Unknown|Wbscr9, WSTF|MGI:1353499|modifier of murine metastable epialleles, D10|Baz1b|MGI:3821601|5||||||||||||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Most homozygotes die perinatally. One-fifth will survive to weaning and are occasionally fertile. Surviving homozygotes are mostly male and are small in size. Homozygotes display craniofacial abnormalities.Decreased body size: at weaning.Decreased fetal size: noticable in utero at E18.5.Short mandible: mandibular hypoplasia, particularly posteriorly.Micrognathia: mandibular hypoplasia.Small parietal bone: shortened 12% relative to controls.Short nasal bone: * shortened 12% relative to controls. * flattened.Abnormal palatine bone morphology: reduced in width.Malocclusion.Short snout: upward curvature of the nasal tip.Broad head: widened bulbous forehead.|Heterozygotes display subtle craniofacial abnormalities. Percentage of cells expressing the GFP transgene (Line3) is decreased (enhancer of variegation).Decreased litter size.Small parietal bone: shortened 12% relative to controls.Short nasal bone: * shortened 12% relative to controls. * flattened.Abnormal palatine bone morphology: reduced in width.|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD10<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|17-Oct-2008|Cryopreserved sperm|100.0|0.0|Yes|Williams-Beuren Syndrome; WBS|chromatin, epigenetics, Williams-Beuren Syndrome; WBS|Yes| 5330.0|RKO C57BL/6|C57BL/6-Ryk/Apb||Recessive|receptor-like tyrosine kinase|Ryk|Nil|ERK-3, Vik|MGI:101766|receptor-like tyrosine kinase; targeted mutation 1, Steven A Stacker|Ryk|MGI:2667542|9||||||||||||||||Yes|||||||||||||Homozygotes die on the day of birth. Approx. 90% of E18.5 embryos have heart defects, the probable cause of neonatal death. They also have a cleft palate, craniofacial defects, shortened limbs and body axis, inner ear defects and abnormal corpus callosum (brain).Abnormal gait: mice surviving to adulthood dragged their hindlimbs.Short mandible.Abnormal maxilla morphology: in conjunction with shortened nasal bone, resulting in flattened midface.Abnormal neurocranium morphology: slightly smaller and rounder than that of wild-type or heterozygous mutant mice.Short nasal bone: shortened nasal bone, resulting in flattened midface.Cleft secondary palate: * cleft secondary palate observed in 88% of mice * consequence of abnormally high positioning and enlargement of the tongue.Increased tongue size: enlargement observed around E14, resulting in the disruption of the development of the palatal shelf.Short snout.Microcephaly: exhibited by mice that survived to adulthood.Cachexia.Postnatal growth retardation: growth was severely impaired in mice surviving past the first day of life.Cyanosis: mice were largely unable to suckle, became dehydrated, cyanotic, and exhibited gasping respirations.Short ulna: reduced in length.Abnormal hindlimb morphology: hindlimbs were splayed laterally.Short fibula.Short limbs: 18% to 25% reduction in the length of the long bones.Microphthalmia: bilateral microphthalmia was observed in mice that survived to adulthood.|Apparently normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|19-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||craniofacial, Eph receptor, TGF, receptor protein tyrosine kinases (RTKs), Wnt signalling, axon guidance|Yes| 7676.0|CD4-cre.Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3 Tg(Cd4-Cre)1Cwi/JhmiAnu||Recessive|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296|early growth response 2; targeted mutation 3, Patrick Charnay|Egr2|MGI:2183227|10|||||||||||||||||transgene insertion 1, Christopher B Wilson|CD4|||||||||||Egr2 f/f.Egr3-/-.CD4-cre+ mice develop autoimmune disease at around three months of age or older. Egr2 f/f.CD4-cre+ mice develop milder autoimmune disease and at a slower rate. Egr3-/- exhibit some neurological defects.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|09-May-2014|Cryopreserved sperm|21.0|0.0|Unknown|||Yes| 7676.0|CD4-cre.Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3 Tg(Cd4-Cre)1Cwi/JhmiAnu||Recessive|early growth response 3|Egr3|Nil|Pilot|MGI:1306780|early growth response 3; targeted mutation 1, Jeffrey Milbrandt|Egr3|MGI:2180063|14|||||||||||||||||||||||||||||Egr2 f/f.Egr3-/-.CD4-cre+ mice develop autoimmune disease at around three months of age or older. Egr2 f/f.CD4-cre+ mice develop milder autoimmune disease and at a slower rate. Egr3-/- exhibit some neurological defects.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|09-May-2014|Cryopreserved sperm|||Unknown|||Yes| 6953.0|ENU19 WT:034:a:B6:G3|ANU:ENU19WT:034:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|56.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 9387.0||C57Bl/6J-Prox1/Apb||Dominant|prospero homeobox 1|Prox1|Normal||MGI:97772| -11kb enhancer|||1|||||||||||||||||LacZ|Hsp68|||||||||||Presence of the transgene drives LacZ expression, chiefly in lymphatic vessels and valves.|Presence of the transgene drives LacZ expression, chiefly in lymphatic vessels and valves.|C57Bl/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|19-May-2022|Cryopreserved sperm|40.0|0.0|No|||No| 6954.0|ENU19 WT:035:a:B6:G3|ANU:ENU19WT:035:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 86.0|T-wimp|C57BL/6JSfdAnu-Lcp2/AnuApb|C57BL/6JSfdAnu-Lcp2/AnuApb|Recessive|lymphocyte cytosolic protein 2|Lcp2|Reduced|SLP-76, SLP76, twm|MGI:1321402|t-wimp|Lcp2|MGI:3614800|11|ENSMUSG00000002699|ENSMUST00000052413|Lcp2-001||||||||33978410|12|||TGCAGCCCTCAGCCCCATTGGGGAGGTAAGTGTCTGTCATACTGTACCAAGTCCAGAATT|No|||||||||||||Few naïve CD4⁺ and CD8⁺ T cells, autoimmunity, 5 fold decrease in DP Tcells and significantly fewer CD4⁺ and CD8⁺ SP cells, partial block in T cell deveolpment at the Pre TCR checkpoint, very low expression of CD5 on DP thymocytes, defect in TCR signalling, mutation intrinsic to thymocytes, reduced expression of Slp76, Defects in positive selection and reduced negative thymocyte selection, hypergammaglobulinemia and hyper-IgE||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-Feb-2006|Cryopreserved sperm|142.0|0.0|Unknown||T cell, CD8, hypergammaglobulinaemia, autoimmunity, ENU|Yes| 4743.0||B6.129-Rc3h1 Icos/AnuApb|B6.129-Rc3h1 Icos/AnuApb|Semi-dominant|Ring finger and CCCH-type zinc finger domains 1|Rc3h1|Unknown|Roquin|MGI:2685397|sanroque|Rc3h1|MGI:3581675|1||||||||||Unknown to Unknown||||||Yes|||||||||||||||C57BL/JAnu|Yes|No|Yes|Yes|No|Yes|No|Unknown||1|Rc3h1 x ICOS -/-|No|27-Apr-2009|Cryopreserved sperm|90.0|0.0|Unknown||Systemic lupus erythematosus (SLE), autoimmunity, T cell, ubiquitin ligase, signal transduction, germinal centre|Yes| 4743.0||B6.129-Rc3h1 Icos/AnuApb|B6.129-Rc3h1 Icos/AnuApb|Semi-dominant|inducible T-cell co-stimulator|Icos|Unknown||MGI:1858745|targeted mutation 1, Richard A Flavell|Icos|MGI:2683635|1|||||||||||||||||||||||||||||||C57BL/JAnu|Yes|No|Yes|Yes|No|Yes|No|Unknown||1|Rc3h1 x ICOS -/-|No|27-Apr-2009|Cryopreserved sperm|||Unknown||Systemic lupus erythematosus (SLE), autoimmunity, T cell, ubiquitin ligase, signal transduction, germinal centre|Yes| 122.0|CD28 -/-|B6.129S2-Cd28/ThwAnuApb|B6.129S2-Cd28/ThwAnuApb|Recessive|CD28 antigen|CD28|Nil||MGI:88327|targeted mutation 1, Tak Mak|Cd28|MGI:1857150|1||||||||||||||||Yes|||||||||||||Homozygous mutation of this gene results in impairment of some T cell responses and decreased basal immunoglobulin levels. Mutant animals have reduced T helper cell activity and impaired T cell response to lectins, but cytotoxic T cells can still be induced||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|295.0|0.0|No||T cell, immunoglobulin, costimulation, lymphocyte, lectin|Yes| 6955.0|ENU19 WT:040:b:B6:G3|ANU:ENU19WT:040:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6956.0|ENU20:005:a:B6:G3|ANU:ENU20:005:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6958.0|ENU20:007:a:B6:G3|ANU:ENU20:007:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6879.0|RBC14|FVB/NJ-Hbb-b1/MarpApb||Dominant|hemoglobin, beta adult major chain|Hbb-b1|Reduced|beta maj, beta major globin, beta1, beta-s|MGI:96021|hemoglobin, beta adult major chain; modifier of murine metastable epialleles, D7|Hbb-b1|MGI:3821597|7|||||||||||||||||||||||||||||Lethal at E18.5 or just after (not present at birth). Embryos are normal until E16.5 where they manifest progressive pallor and reduced fetal liver cellularity.|Microcytic, hypochromic anemia with severe reticulocytosis. Compensatory erythropoiesis with splenic extramedullary hematopoiesis due to red cell destruction. |FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||Heterozygote intercrosses |No|26-Apr-2012|Cryopreserved sperm|50.0|0.0|Yes|Beta-thalassemia|Beta-thalassemia, Hbb-b1/beta major globin, ENU-mutagenesis, PolyA-tail|Possibly| 7707.0|Adra1aflx|B6(Cg)-Adra1a/MArpVccrApb||Recessive|adrenergic receptor, alpha 1a|Adra1a||Adra1c|MGI:104773|Adrenergic receptor, alpha 1a; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Adra1a|MGI:6502595|14||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Jun-2014|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 10524.0|hTreml2KI - T2KI|C57BL/6J-Treml4||Dominant|triggering receptor expressed on myeloid cells-like 4|Treml4 |||MGI:1923239|Trem4, endonuclease-mediated mutation 1, Monash Genome Modification Platform|Treml4||17|ENSMUSG00000051682 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Sep-2025|Cryopreserved sperm|50.0|0.0|Unknown|||No| 9261.0||C57BL/6NCrlAnu-Heatr3/Apb||Semi-dominant|HEAT repeat containing 3 |Heatr3|||MGI:2444491|HEAT repeat containing 3; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Heatr3||8||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-Aug-2021|Cryopreserved sperm|59.0|0.0|Unknown|||Possibly| 652.0|Activin Beta C+ FL1|C57BL/6-Tg(ACTIVIN-β{C})1Grb/Apb||Dominant|||||||||Unknown||||||||||||||||No|human activin beta C|CMV|low (2 copies)||||||||||Essentially normal at gross level. male fertility decreases from 10 weeks (decreased sperm production, decreased liter size)|Essentially normal at gross level. male fertility decreases from 16 weeks (decreased sperm production, decreased liter size), evidence of liver disease and prostate hyperplasia|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||3|Het x WT or Het x Het|No|25-Apr-2007|Cryopreserved sperm|70.0|0.0|Unknown||activin, inhibin, prostate, testis, liver|No| 7709.0|37L1MCM|B6.Cg-Gpr37L1 Tg(Myh6-cre/Esr1*)1Jmk/JVccrApb||Recessive|G protein-coupled receptor 37-like 1|Gpr37l1||CAG-18, D0Kist8|MGI:1928503|G protein-coupled receptor 37-like 1; targeted mutation 1d, Wellcome Trust Sanger Institute|Gpr37l1|MGI:6150820|1||||||||||Unknown to Unknown|||||||transgene insertion 1, Jeffery D Molkentin|mouse cardiac-specific alpha-myosin heavy chain|heart||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Jun-2014|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 4784.0|WT-127|WT Control for hGM-CSF transgenic mutants||Dominant|||||||||Unknown||||||||||||||||No|human GM-CSF|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|70.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 5135.0||ENU14NIH:089:G3b||Recessive|Unknown|Unknown|Unknown||||||Unknown|||||||||||||||||||||||||||||Skin continues to grow over the lifetime of the mouse|Normal|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|Unknown||||No|26-May-2010|Cryopreserved sperm|9.0|0.0|Unknown||Coat, skin, dermis, proliferation, ENU|No| 5227.0|129Sv/Ly5.1|129/Sv-Ptprc/Apb||Dominant|||||||||||||||||||||||||||||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|N/A (homogenous wild type line)|N/A (homogenous wild type line)|129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||More than 10|Sibling mating|No|05-Oct-2010|Cryopreserved sperm|45.0|0.0|No||transplantation, complementation, Ptprc|Yes| 4788.0||129/SvJ||Dominant||||||||||||||||||||||||||||||||||||||Normal.||129/SvJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Sep-2009|Cryopreserved sperm|73.0|0.0|Unknown||129|Yes| 168.0|Elf3 knockout|B6.129S4-Elf3/Apb|B6.129S4-Elf3/Apb|Recessive|E74-like factor 3|Elf3|Nil|ESE-1, ESX, jen|MGI:1101781|targeted mutation 1, Paul J Hertzog|Elf3|MGI:2662485|1||||||||||||||||Yes|Neomycin resistance gene||||||||||||embryonic lethality during organogenesis: only about 71% of expected numbers of homozygotes are still alive at E11.5postnatal lethality: by weaning, only about 27% of expected numbers are still alive.decreased body size: smaller than controls during suckling period although normal in size from E11.5 to birth. After 6 weeks of age, weight gain is normal and mice attain normal sizecachexia: 2-3 days before death, mice begin to display a wasted phenotype, appear malnourished, lethargic, watery diarrhoealethargy: beginning 2-3 days before deathabnormal intestinal epithelium morphology: intestinal endothelium fails to transform from pseudostratified to columnar by E17.5. Formation of villi is delayed and those present are misshapen. Connective tissue under the lamina propria of the villi is disorganized.abnormal enterocyte morphology: absorptive enterocytes are morphologically abnormal. Tightly packed with apical cytoplasmic snouts. Microvilli are short. Increased numbers of mitochondria and ribosomes.abnormal intestinal goblet cells: reduced numbers of goblet cells producing sialomucin.diarrhoea: watery diarrhea in mice that die starting 2-3 days before death. |No over phenotype|C57BL/6|No|No|Yes|No|No|Yes|No|Good|10||Het x Het OR Het male x WT female OR Het female x WT male|No|15-Apr-2006|Cryopreserved sperm|60.0|0.0|Unknown||ETS transcription factor, intestine, TGF, epithelium, differentiation|Yes| 5398.0|HK1-Shh|B6;CBA-Tg(KRT1-Shh)/Apb||Dominant||||||||||||||||||||||||||rat sonic hedgehog|human keratin 1 |increased||||||||||Unknown|skin anomalies, fore- and hindlimp abnormalities|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||het x wt|No|27-Jan-2011|Cryopreserved sperm|60.0|0.0|No||Sonic Hedgehog, skin, limb, embryonic development, overexpression|Possibly| 4800.0|Rain ; ENU11B6:226b|C57BL/6JAnu-Ptprc/AnuApb|C57BL/6JAnu-Ptprc/AnuApb|Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc|Unknown|B220, CD45, Ly-5, Lyt-4, T200 |MGI:97810|rain|Ptprc|MGI:4819248|1|ENSMUSG00000026395|ENSMUST00000027645|Ptprc-201||||||||140007727|11|||TGTTATAAATGTGCAGACAGATTTGGGGAGTAAGTATATCGTTTATGTTTATAAAATAAA|Yes|||||||||||||Shifted CD45 expression measured by flow cytometry||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Sep-2009|Cryopreserved sperm|75.0|0.0|Unknown||cd45, signal transduction, T cell, ENU, NIH|Yes| 237.0|MLR10|FVB/N-Tg(Cryaa-cre)10Mlr/Apb||Dominant||||||||||||||||||||||||||transgene insertion 10, Mike Robinson|modified alpha A crystallin promoter with an inserted copy of Pax6 consensus binding site|||||||||||Nil. Mice express Cre in lens, vibrissae. Weak expression in maxillary arch at E12.5. ||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Apr-2006|Cryopreserved sperm|70.0|0.0|Unknown||crystallin, lens, eye, epithelial, Pax6|Yes| 246.0|B6.B2m-/-|B6.129S2-B2m/AnuApb|B6.129S2-B2m/AnuApb|Recessive|beta-2 microglobulin|B2m|Nil|beta 2 microglobulin, beta2-m, Ly-m11|MGI:88127|targeted mutation 1, Rudolf Jaenisch|B2m|MGI:1927183|2||||||||||||||||No|||||||||||||Homozygotes lacking B2m appear normal, but have no detectable MHC class I antigen on their cells and are deficient in CD4- CD8+ T cells which mediate cytotoxic T cell function. Mutant mice are also subject to systemic iron loading.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Apr-2006|Cryopreserved sperm|110.0|0.0|Yes||MHC, antigen presentation, cytotoxic, T cell, lymphocyte|Yes| 8478.0|ASD777:TNFRSF13b:C76R|C57BL/6NCrlAnu-Tnfrsf13b/AnuApb||Recessive|tumor necrosis factor receptor superfamily, member 13b|Tnfrsf13b|Unknown|1200009E08Rik, Taci|MGI:1889411|Tnfrsf13b; endonuclease-mediated mutation 1, Australian National University|Tnfrsf13b||11||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Apr-2018|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 9464.0|TgmiR-146a KO|C57BL/6J-miR146a/Apb||Semi-dominant|microRNA 146|miR146a|||MGI:2676831||||11|||||||||||||||||||||||||||||T-cells: miR-146a-/- mice have been reported to have an increased incidence of T-cell derived lymphomas and exhibit enlarged spleens starting at 6 months of age. Seizure occurrence: Based on routine health monitoring of TgmiR-146a strain, 6 mice with a miR-146a-/- genotype over 11-months of age were observed to have seizure occurrence.Weight loss: 14 out of 120 TgmiR-146a mice that were over 12-month of age exhibited weight loss ranging from 5-15%. Overall, the TgmiR-146a strain over 12-month of age had 11.7% chance of weight loss.Skin irritation and inflammation: 7 out of 90 miR-146a-/- mice that were over 12-months of age were observed with skin irritation and inflammation. Overall, miR-146a-/- mice had a 7.8% chance of skin irritation and inflammation.Hind limb weakness: 10 out of 105 miR-146a-/- mice that were over 6-month of age were observed with hind limb weakness and decreased tail mobility. In total, miR-146a-/- mice had a 9.5% chance of hind limb weakness which potentially leads to hind limb paralysis.|Seizure occurrence: Based on routine health monitoring of TgmiR-146a strain, 2 out of 131 mice with a miR-146a-/+ genotype were observed to have seizure occurrence.Skin irritation and inflammation: 7 out of 90 miR-146a-/+ mice that were over 12-month of age were observed with skin irritation and inflammation. Overall, TgmiR-146a strain with -/+ genotypes had 7.8% chance of skin irritation and inflammation.Hind limb weakness: 10 out of 105 miR-146a-/+ mice that were over 6-month of age were observed with hind limb weakness and decreased tail mobility. In total, TgmiR-146a strain with miR-146a-/+ genotypes had 9.5% chance of hind limb weakness which potentially leads to hind limb paralysis.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Dec-2022|Cryopreserved sperm|39.0|100.0|Unknown|||Possibly| 5203.0|ENU15 NIH 17|ENU15NIH:017||Dominant|Unknown|Unknown|Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Kinked tail. Mice have variable types of kinks, some with a small kink at the end of the tail, and others with either a pronounced or slight zigzag. |C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||3|affected x B6|No|09-Aug-2010|Cryopreserved sperm|50.0|0.0|Unknown||kink tail, ENU|No| 5205.0|theoden ; ENU4AT:050 |B6JAnu(Cg)-Fas/AnuApb|B6JAnu(Cg)-Fas/AnuApb|Recessive|Fas (TNF receptor superfamily member 6)|Fas|Nil|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|theoden|Fas|MGI:4455060|19|ENSMUSG00000024778|ENSMUST00000025691|Fas-201|416|422|G to A|ENSMUSE00000144910|4|139|Cysteine to Tyrosine|||||CTACTGCGATTCTCCTGGCTGTGAACACTGTGTTCGCTGCGCCTCGTGTGAACATGGAACC|Yes|||||||||||||Antinuclear autoantibodies, lymphadenopathy.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|13-Aug-2010|Cryopreserved sperm|104.0|0.0|Unknown||B cell, T cell, lymphadenopathy, ENU, Wellcome Trust|Yes| 7706.0|Adra1aConR|B6(Cg)-Adra1a/MarpVccrApb||Recessive|adrenergic receptor, alpha 1a|Adra1a|Nil|Adra1c|MGI:104773|adrenergic receptor, alpha 1a; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Adra1a|MGI:4451809|14|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Jun-2014|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 9395.0|Met-K|B10.BR;B6.SJL-Tg(sMt1-H2-KGM)/Apb||Dominant|Major histocompatibility-2, MHC; b variant|H-2Kb|||MGI:3579319||||17|||||||||||||||||Major histocompatibility-2, MHC; b variant|sheep metallothionein promoter|||||||||||These transgenic mice have a normal phenotype but express a transgenic H-2Kb MHC I molecule in hepatocytes under the control of the sheep metallothionein promoter. These transgenic mice were originally generated in (C57BL/6 x SJL) ES cells and bred onto a B10.BR for more than 10 generations. Tg mice express the allogenic H-2Kb molecule mostly in hepatocytes as well as in some bone marrow derived cells in lymph nodes and spleen (low expression).|Same as homozygous mice |B10.BR|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Jun-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6957.0|ENU20:006:a:B6:G3|ANU:ENU20:006:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|39.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7281.0|Sppl2a KO2|C57BL/6N-A Sppl2a/2MarpAnu||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2a|MGI:4887673|2|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Feb-2013|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 4550.0||B6.129-Rnf2/WehiApb||Recessive|ring finger protein 2|Rnf2|Nil|dinG, Ring1B|MGI:1101759|targeted mutation 1, Haruhiko Koseki|Rnf2|MGI:2447529|1||||||||||||||||Yes|||||||||||||Abnormal sternum ossification* additional ossification at the cranial end of the sternumThoracic vertebral transformation * spinous process of thoracic vertebra 2 found on thoracic vertebra 1 in 40% of mice (T1 becomes T2)Cervical vertebral transformation * ectopic ribs are associated with cervical vertebra 7 in about 60% of mice (C7 becomes T1)||C57BL/6|No|No|Yes|No|No|Yes|No|Good|10||Het x WT|No|02-Mar-2009|Cryopreserved sperm|60.0|0.0|Unknown||Polycomb group proteins, polycomb repressive complex 1, skeletal|Yes| 240.0|MLR37|FVB/N-Tg(Cryaa-cre)37Mlr/Apb||Dominant||||||||||||||||||||||||||transgene insertion 37, Mike Robinson|modified alpha A crystallin promoter with an inserted copy of Pax6 consensus binding site|||||||||||Mice express Cre in lens fibres and retina and ciliary body with weak ectopic expression in skin and CNS.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Apr-2006|Cryopreserved sperm|40.0|0.0|Unknown||crystallin, lens, eye, epithelial, Pax6|Yes| 249.0||Balb/c-Cd40/Apb||Recessive|CD40 antigen|Cd40|Unknown|Bp50, Cd40, p50, Tnfrsf5|MGI:88336|targeted mutation 1, Hitoshi Kikutani|Cd40|MGI:1857457|2||||||||||||||||Yes|||||||||||||Absence of germinal center formation in response to TI-I antigen stimulation. Defective IgM and IgG response to TI antigen and TD antigen stimulation. Decreased IgG2b||Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Apr-2006|Cryopreserved sperm|105.0|0.0|Unknown||B cell, germinal centre, T cell dependent, immunoglobulin class switch|Yes| 9284.0|Six2TGC|CD1-Tg(Six2-EGFP/cre)1Amc/Apb||Semi-dominant|sine oculis-related homeobox 2|Six2|||MGI:102778 ||||17|||||||||||||||||Six2-EGFP/Cre BAC transgene|Six2|||||||||||Viable homozygous Six2TGC mice are not produced by intercross of heterozygous animals. Homozygous Six2TGC mice are assumed to die during development via an unknown mechanism.|Hemizygous Six2-TGCtg mice are viable and fertile. A slight reduction in kidney size during development, and ~20-30% reduction in nephrons in adults has been identified after detailed phenotypic analysis.|CD1|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-Oct-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7708.0|Adra1ackO|B6.Cg-Adra1a Tg(Myh6-cre/Esr1*)1Jmk/JVccrApb||Recessive|adrenergic receptor, alpha 1a|Adra1a||Adra1c|MGI:104773||||14|||||||||||||||||transgene insertion 1, Jeffery D Molkentin|mouse cardiac-specific alpha-myosin heavy chain|heart||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Jun-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 30.0|B-blast|C57BL/6JSfdAnu-Trp53/AnuApb|C57BL/6JSfdAnu-Trp53/AnuApb|Semi-dominant|transformation related protein 53|Trp53|Unknown|p53|MGI:98834|b-blast|Trp53|MGI:3611496|11|ENSMUSG00000059552|ENSMUST00000108658|Trp53-201||1111|T to A|||195|Isoleucine to Asparagine||||||No|||||||||||||Homozygotes develop B cell leukaemia/lymphoma or primitive haemopoietic leukaemia at 4-6 mths. |Heterozygotes develop solid tumours osteosarcoma, lymphoma, haemangiosarcoma, fibrosarcoma, thymic lymphoma, multinodal lymphoma, brain tumour and teratocarcinoma at 8-15mths.|C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||13||No|06-Feb-2006|Cryopreserved sperm|110.0|0.0|Yes||p53, apoptosis, tumour, cell cycle, ENU|Yes| 4186.0|CD151 KO|FVB.B6(C)-CD151/Apb|FVB.B6(C)-CD151/Apb|Recessive|CD151 antigen|Cd151|Nil|PETA-3, SFA-1, Tspan24|MGI:1096360|targeted mutation 1, Leonie K Ashman|Cd151|MGI:3050539|7||||||||||||||||Yes|||||||||||||Mice have kidney defects and eventually develop kidney failure due to problems with glomerular basement membrane formation and maintenance. Mutation is lethal in all cases, at from 4 months to 6 months of age. ||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||No|19-Dec-2008|Cryopreserved sperm|150.0|0.0|Unknown||tetraspanin, proteinuria, kidney, integrin, Alport syndrome|Yes| 7031.0|APN 235|C57BL/6N-Cdcp1/Marp||Recessive|CUB domain containing protein 1|Cdcp1 |Unknown|9030022E12Rik, E030027H19Rik |MGI:2442010 |CUB domain containing protein 1; targeted mutation 1, Wellcome Trust Sanger Institute |Cdcp1|MGI:4419722|9||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N |Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|30-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Possibly| 10317.0|Foxn1-Cre|B6;D2-Tg(Foxn1-cre)8Ghr/Apb||Semi-dominant|forkhead box N1|Foxn1||D11Bhm185e, Hfh11, whn|MGI:102949||||11|||||||||||||||||Cre|Foxn1|||||||||||Mice express Cre under the control of a Foxn1 promoter|Mice express Cre under the control of a Foxn1 promoter|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Mar-2023||0.0|0.0|Unknown|||Possibly| 7711.0|H2A.Lap1:NM10|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|H2A histone family, member B2|H2afb2|Nil|EG624153, H2A.Bbd4, H2afb2-ps (lap1c)|MGI:3644980||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|30-Jun-2014|Cryopreserved sperm|103.0|0.0|Unknown||H2A.Lap1, histone, NM10|Possibly| 7711.0|H2A.Lap1:NM10|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|H2A histone family, member B3|H2afb3|Nil|EG624957, H2A.Bbd3, H2afb3-ps (Lap1a)|MGI:3644875||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|30-Jun-2014|Cryopreserved sperm|||Unknown||H2A.Lap1, histone, NM10|Possibly| 7711.0|H2A.Lap1:NM10|FVB/NJArc-H2afb2 H2afb3 Gm14920/AnuApb||X-linked|predicted pseudogene 14920|Gm14920||ENSMUSG00000067441, H2A.Bbd1|MGI:3642445||||X|||||||||||||||||||||||||||||Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|Normal. Small percentage dies when reaches the age of 7-9 months. Under investigation|FVB/NJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||het to wt; homo to wt; homo to homo|No|30-Jun-2014|Cryopreserved sperm|||Unknown||H2A.Lap1, histone, NM10|Possibly| 9419.0|Plag1–/–|129- Plag1/Apb||Dominant|pleiomorphic adenoma gene 1|Plag1|||MGI:1891916|pleiomorphic adenoma gene 1; targeted mutation 1, Wim J M Van de Ven|Plag1|MGI:3580633|4||||||||||Unknown to Unknown||||||||||||||||||| No anatomical differences are obvious at birth, except that the weight of Plag1–/– mice is significantly lower in comparison to control litter mates. This early growth retardation is maintained throughout adult life with proportionally smaller organs except for the disproportionally small seminal vesicles and ventral prostate; however, plasma testosterone levels in males were not affected. Furthermore, fertility of both male and female Plag1–/– is reduced.|Normal|129S1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||||No|17-Aug-2022|Cryopreserved sperm|80.0|0.0|Unknown|||Yes| 8862.0|foz - Foz:BALB/c:R83/17|BALB/c-Alms1/AnuTchApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Mice are hyperphagic leading to obesity . Males are sterile. High fat feeding accelerates obesity development. Compared to foz/foz mice on NOD.B10 background, BALB/c foz/foz mice do not develop diabetes and liver disease is less severe.|normal|BALB/c|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|20-Feb-2020||0.0|347.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 4813.0|Binda|ENU8BAT:075||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|30.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4813.0|Binda|ENU8BAT:075||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4816.0|Warroo|ENU8BAT:084||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|35.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4816.0|Warroo|ENU8BAT:084||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4817.0|Apari|ENU8BAT:091||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|55.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4817.0|Apari|ENU8BAT:091||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 7375.0|ENU19:B6:Mlkl|C57BL6NCrlAnu-Mlkl/Anu||Recessive|mixed lineage kinase domain-like|Mlkl||9130019I15Rik|MGI:1921818||Mlkl||8|ENSMUSG00000012519|ENSMUST00000120432|Mlkl-002|949|1305|T to A|ENSMUSE00000214984|7|317|Arginine to STOP|||||ACAGGCTACACCATTCGGAAACACTCCACAGAAACATCAGCAGCTCCAGTTTCCTCGTAGC||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Jul-2013|Cryopreserved sperm|30.0|0.0|Unknown||ENU|Yes| 7713.0|Zdhhc2|C57BL/6N-Zdhhc2/MarpApb||Dominant|zinc finger, DHHC domain containing 2|Zdhhc2|Nil|5730415P04Rik, 6430583A19Rik|MGI:1923452|zinc finger, DHHC domain containing 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Zdhhc2|MGI:4362764|8|||||||||||||||||||||||||||||wildtype|wildtype|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2|4||No|01-Jul-2014|Cryopreserved sperm|50.0|0.0|Unknown||palmitoylation|Possibly| 10526.0||B6.129P2(Cg)-Cx3cr1 Drosha/AnuApb||Dominant|C-X3-C motif chemokine receptor 1|Cx3cr1|||MGI:1333815|C-X3-C motif chemokine receptor 1; targeted mutation 2.1, Dan R Littman|Cx3cr1|MGI:5450813|9|ENSMUSG00000052336 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|13-Oct-2025||0.0|0.0|Unknown|||Possibly| 10526.0||B6.129P2(Cg)-Cx3cr1 Drosha/AnuApb||Dominant|drosha, ribonuclease type III|Drosha|||MGI:1261425|drosha, ribonuclease type III; targeted mutation 1, Dan R Littman|Drosha|MGI:3801076|15|ENSMUSG00000022191 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|13-Oct-2025||||Unknown|||Possibly| 10316.0|Mr1-K43A|C57BL/6J-Mr1<(tm1K43A)JvUom>/Apb||Semi-dominant|major histocompatibility complex, class I-related|Mr1||H2ls, MR1|MGI:1195463||Mr1||1|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Mar-2023|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6821.0|A/J gp130Y757F|A/J(Cg)-IL6st/LudApb||Dominant|interleukin 6 signal transducer|Il6st|Normal|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|A/J|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|4|||No|15-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, JAK-STAT, cytokine, interferon, kinase, phosphorylation|Yes| 4824.0|Lluka|ENU8CAT:029||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|35.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|No| 4824.0|Lluka|ENU8CAT:029||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|No| 6959.0|ENU20:008:a:B6:G3|ANU:ENU20:008:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4836.0|Hopscotch|ENU8B6:027:B6||Recessive|Unknown||Unknown||||||13|||||||||||||||||||||||||||||Generalised ataxia usually noted between weaning and 75 days old.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|35.0|0.0|Unknown||ataxia, ENU|Possibly| 5395.0|KRN|C57BL/6SfdAnu-Tg(TcraR28,TcrbR28)KRNDimAnuApb||Recessive||||||||||||||||||||||||||transgene insertion KRN, Diane Mathis |natural TCR alpha and -beta promoter/enhancer elements.|||||||||||A single founder (KRN) in which TCRalpha and TCRbeta transgenes were cointegrated was identified. These constructs together express a T cell receptor that recognizes the 41-61 peptide of bovine pancreas ribonuclease (RNase) in the context of A. These mice develop spontaneous rheumatoid arthritis (RA) joint disease highly reminiscent of man. The trigger for the murine disorder is chance recognition of a NOD-derived major histocompatibility complex (MHC) class II molecule by the transgenic TCR.||C57BL/6SfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|23.0|0.0|Yes|Rheumatoid Arthritis; RA|rheumatoid arthritis, autoimmunity, TCR, T cell, CD4, B cell|Yes| 4835.0|TNAP-Cre|BALB/c-Alpl/AnuApb||Recessive|alkaline phosphatase, liver/bone/kidney|Alpl|Nil|Akp-2, Akp2, TNSALP, TNAP|MGI:87983|targeted mutation 1, Andras Nagy|Alpl|MGI:2177588|4||||||||||||||||Yes|Cre recombinase|TNAP|||||||||||Embryonic Lethal||Balb/c|No|No|Yes|No|No|Yes|No|Unknown|8|||No|24-Sep-2009|Cryopreserved sperm|40.0|0.0|Unknown||alkaline phosphatase, primordial germ cell|Yes| 5108.0|Plt20|B6.C-Bcl2l1/WehiAnuApb||Recessive|BCL2-like 1|Bcl2l1|Reduced|Bcl(X)L, bcl-x, Bcl-XL, Bcl-Xs, BclX|MGI:88139|BCL2-like 1; platelet 20|Bcl2l1|MGI:3847887|2|ENSMUSG00000007659|ENSMUST00000109820|Bcl2l1-201|44|437|A to G|ENSMUSE00001233620|2|15|Tyrosine to Cysteine|||||CCGGGAGCTGGTGGTCGACTTTCTCTCCTACAAGCTTTCCCAGAAAGGATACAGCTGGAGT|No|||||||||||||Decreased platelet cell number: * platelet counts are 25% of normal * splenectomy only partially restored platelet cell countExtramedullary hematopoiesis: there is a slight increase in splenic erythropoiesis.Increased megakaryocyte cell number: megakaryocyte numbers are significantly elevated compared to controls.Abnormal platelet physiology: platelet half-life is reduced to under 12 hours compared to 57 hours for controls.|Decreased platelet cell number: platelet counts are significantly lower than controls (598x10<3>/microliter vs 1100x10<3>/microliter).Increased megakaryocyte cell number: megakaryocyte numbers are marginally elevated compared to controls.Abnormal platelet physiology: platelet half-life is reduced by 50% compared to controls (57 hours to 24 hours).|BALB/c x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-May-2010|Cryopreserved sperm|40.0|0.0|Unknown||Bcl2, ENU, platelet, thrombocytopenia, Bak|Yes| 7717.0|KstC57|B6.129P2-Frem2/MarpApb||Dominant|Fras1 related extracellular matrix protein 2|Frem2|Unknown|6030440P17Rik, 8430406N05Rik, b2b1562Clo, my, ne|MGI:2444465|Fras1 related extracellular matrix protein 2; gene trap KST252, BayGenomics|Frem2|MGI:3578640|3|||||||||||||||||||||||||||||Embryonic lethal |wildtype|C57BL/6|No|No|Yes|No|No|Yes|No|Good|13|3||No|02-Jul-2014|Cryopreserved sperm|50.0|0.0|Yes|Fraser Syndrome an autosomal recessive congenic disorder affecting development|Fraser Syndrome|Possibly| 4856.0|T-Bird|STOCK Dsg4/AnuApb|STOCK Dsg4/AnuApb|Recessive|desmoglein 4|Dsg4|Unknown|CDHF13, lah|MGI:2661061|T-Bird|Dsg4|MGI:5007752|18|ENSMUSG00000001804|ENSMUST00000019426|Dsg4-001|643|777|A to C|ENSMUSE00000445469|6|215|Threonine to Proline|||||GTGCACCCATGTTCATGGTGAACAGGTACACTGGAGAAGTCCGCACGATGTCCAATTTCCT|Unknown|||||||||||||Greasy Coat. Affected mice develop a dull, sparse and greasy coat at about ~40 days of age. ||C57BL/6 x C57BL/10 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2|||No|24-Sep-2009|Cryopreserved sperm|7.0|0.0|Unknown||Coat, greasy, hair, ENU|Yes| 2376.0|Piaf|ENU7B6:022||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Ataxia||C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|60.0|0.0|Unknown||ataxia, ENU|Yes| 4993.0|Ring Finger TCR InsHel 129>B10.BR|STOCK H2 Cbl Tg(TcrHEL3A9)Mmd/AnuApb||Recessive|Casitas B-lineage lymphoma|Cbl|Unknown|c-Cbl, cbl, Cbl-2|MGI:88279|targeted mutation 2, Wallace Y Langdon|Cbl|MGI:3610727|9||||||||||||||||Yes|transgene insertion 1, Mark M Davis||||||||||||Mutants are embryonic lethal|Unknown|B10.BR-H2 x C57BL/6 x 129|No|No|Yes|No|No|Yes|No|Good||||No|28-Jan-2010|Cryopreserved sperm|30.0|0.0|No||cbl, thymocyte, T cell, ring finger, ubiquitin ligase|Yes| 6960.0|ENU20:009:b:B6:G3|ANU:ENU20:009:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|18.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6961.0|ENU20:010:b:B6:G3|ANU:ENU20:010:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6962.0|ENU20:011:a:B6:G3|ANU:ENU20:011:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6963.0|ENU20:013:b:B6:G3|ANU:ENU20:013:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|48.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6964.0|ENU20:015:a:B6:G3|ANU:ENU20:015:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|59.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6965.0|ENU20:017:b:B6:G3|ANU:ENU20:017:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|36.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6968.0|ENU20:022:a:B6:G3|ANU:ENU20:022:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6970.0|ENU20:025:a:B6:G3|ANU:ENU20:025:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|47.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5001.0|aF11 aa278|FVB/N-Tg(Prm1-Pebp1)11Mkob/MarpApb||Dominant||||||||||||||||||||||||||phosphatidylethanolamine binding protein 1|Protamine 1|low level expression||||||||||||FVB/N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|0|0||No|22-Feb-2010|Cryopreserved sperm|60.0|0.0|Unknown||fertility, sperm|No| 4839.0|Kenny ; ENU9CAT:040|STOCK Muc2/AnuApb|STOCK Muc2/AnuApb|Recessive|mucin 2|Muc2|Unknown||MGI:1339364|kenny|Muc2|MGI:4820425|7|ENSMUSG00000025515|ENSMUST00000026590|Muc2-202|4187|4192|C to A|ENSMUSE00000519387|31|1396|Serine to STOP|||||AATGGAATACTGTACTCCTTCAACTATCTCACCTACAACTTCAACAACAACCTTGTCTACC|No|||||||||||||Diarrhoea.Multiple plaques on GIT and lymphomegaly.Other mutants homozygote for a point mutation have soft feces at weaning and develop diarrhea associated with malapsorption syndrome. Homozygous null mutants pass blood in their feces at 6 months, and 65% of null mutants have intestinal tumors at 1 year.||C57BL/6 x CB10.BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|69.0|0.0|Unknown||malabsorption, colon, goblet cells, diarrhoea, ENU|Yes| 4880.0|B6.Rag1/Gal KO|C57BL/6-Rag1 Ggta1/Apb||Recessive|recombination activating gene 1|Rag1|Nil|Rag-1|MGI:97848|targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.All blood/tissue samples lack Gal expression.Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|70.0|0.0|Unknown||T cell, B cell, eosinophil, inflammation, interferon, Xenotransplantation, antibody, transferase, galactose|Yes| 4880.0|B6.Rag1/Gal KO|C57BL/6-Rag1 Ggta1/Apb||Recessive|glycoprotein galactosyltransferase alpha 1, 3|Ggta1|Nil|alpha Gal, alpha3GalT, Gal, GALT, Ggta, Ggta-1, glycoprotein alpha galactosyl transferase 1|MGI:95704||||2|||||||||||||||||||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.All blood/tissue samples lack Gal expression.Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|||Unknown||T cell, B cell, eosinophil, inflammation, interferon, Xenotransplantation, antibody, transferase, galactose|Yes| 6966.0|ENU20:019:b:B6:G3|ANU:ENU20:019:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|80.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6967.0|ENU20:021:b:B6:G3|ANU:ENU20:021:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|63.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6969.0|ENU20:023:b:B6:G3|ANU:ENU20:023:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4892.0||Infertility Project||Recessive|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6 x CBA|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-Sep-2009|Cryopreserved sperm|395.0|0.0|Unknown||ENU, sperm, lactation, milk|Possibly| 7719.0|gp130Y757F x Aim2|B6.129/Sv-Aim2 Il6st/MarpApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric tumours and splenomegaly.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|23-Jul-2014|Cryopreserved sperm|50.0|0.0|Yes|Gastric cancer|gastric, cancer, gp130|No| 7719.0|gp130Y757F x Aim2|B6.129/Sv-Aim2 Il6st/MarpApb||Dominant|absent in melanoma 2|Aim2|Nil||MGI:2686159|absent in melanoma 2; targeted mutation 1.1, Vishva M Dixit|Aim2|MGI:5428935|1||||||||||||||||No|||||||||||||Mice develop gastric tumours and splenomegaly.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|23-Jul-2014|Cryopreserved sperm|||Yes|Gastric cancer|gastric, cancer, gp130|No| 4903.0||BALB/c-IL13/MelbApb||Recessive|interleukin 13|Il13|Nil|Il-13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11|||||||||||||||||||||||||||||Decreased T-helper 2 cell number.Abnormal T-helper 2 cell differentiaion.Increase immunoglobulin levels.Increase susceptibility to parasitic infection.Impaired eosinophil response to parasitic infection||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|09-Oct-2009|Cryopreserved sperm|150.0|0.0|Unknown||interleukin, IL10, IL5, Th2, T cell, parasite|Yes| 4894.0|Ifngr1<441F>|C57BL/6-Ifngr1/Apb||Recessive|interferon gamma receptor 1|Ifngr1|Normal|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|interferon gamma receptor 1; targeted mutation 1.1, Robyn Starr|Ifngr1|MGI:4361521|10||||||||||Unknown to Unknown||||||Yes|||||||||||||Homozygous Ifngr1<441F> mice were born in the expected Mendelian ratios and showed no signs of illness or obvious pathological abnormalities to at least 6 mo of age (data not shown). Similarly, the cellularity of lymphoid organs and activation state of lymphocytes was comparable to that of wt mice. the IFNGR1 Y441F mutation had significant effects on IFN-γ sensitivity and tumor resistance in vivo. We have shown improved anti-metastatic activity of GalCer in Ifngr1441F mice, and further that these mice have a subtle but significantly increased innate resistance to tumor formation.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|100.0|0.0|Unknown||signal transduction, tumour, SOCS, STAT1, cytokine receptor, Jak|Yes| 5013.0|ASD078|B6.Cg-H2||Dominant||||||||||||||||||||||||||||||||||||||||7|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|139.0|0.0|Unknown|||Possibly| 7720.0|killer -/-|B6.129S6-Tnfrsf10b/Anu||Recessive|tumor necrosis factor receptor superfamily, member 10b|Tnfrsf10b|Nil|DR5, KILLER, Killer/Dr5, Ly98, TRAILR2, TRAIL-R2, Trail Receptor, TRICK2A, TRICK2B, TRICKB|MGI:1341090|tumor necrosis factor receptor superfamily, member 10b; targeted mutation 1, Astar Winoto|Tnfrsf10b|MGI:3522001|14|||||||||||||||||||||||||||||decreased susceptibility to viral infection induced morbidity/mortality ( J:94681 )• after encephalomyocarditis virus infection, homozygotes had a slightly enhanced survival rate than controls but not when a 10-fold higher viral dose was usedimmune systemincreased NK cell number ( J:94681 )• observed a slight increase in CD69+ natural killer cells in MCMV-infected homozygotes indicating that NK cells were slightly more activated, however lytic activity of NK cells was normalincreased circulating interleukin-12b level ( J:94681 )• 10-fold increase in serum levels of the IL-12 p40 subunit 24 hours after MCMV infection compared to controlsabnormal interferon level ( J:94681 )• elevated levels of interferon-alpha and interferon-beta in spleen of MCMV-infected homozygotes compared to wild-typeincreased circulating interferon-gamma level ( J:94681 )• serum levels of interferon-gamma at 36 hours postinfection with MCMV were greatly elevated compared to wild-typeincreased interleukin-12 secretion ( J:94681 )• spleen derived dendritic cells of MCMV-infected mutants produced 8-fold more IL-12 than infected wild-type• bone marrow derived dendritic cells stimulated with E.coli LPS had higher levels of IL-12 than controls• peritoneal macrophages stimulated with E.coli or Salmonella LPS, lipoteichoic acid, or poly (I:C) had higher levels of IL-12 than controlsincreased tumor necrosis factor secretion ( J:94681 )• peritoneal macrophages stimulated with E.coli or Salmonella LPS had higher levels of TNF-alpha than controlsabnormal innate immunity ( J:94681 )• enhanced innate immune responses to encephalomyocarditis virus and murine cytomegalovirus (MCMV) infection but not to Salmonella typhimurium or Listeria monocytogenes infectiondecreased susceptibility to viral infection ( J:94681 )• 3 days after murine cytomegalovirus infection, viral titers in the spleen, but not the liver or lung, were decreased by 40-fold compared to wild-type, indicating enhanced clearance of MCMVdecreased susceptibility to viral infection induced morbidity/mortality ( J:94681 )• after encephalomyocarditis virus infection, homozygotes had a slightly enhanced survival rate than controls but not when a 10-fold higher viral dose was used||C57BL/6|Yes|Yes|Yes|Yes|Yes|Unknown|No|Unknown||||No|23-Jul-2014|Cryopreserved sperm|54.0|0.0|Unknown||infection, receptor, Toll like|Yes| 1355.0|MSH2C delta|B6.129-Msh2/Apb||Recessive|mutS homolog 2 (E. coli)|Msh2|Unknown||MGI:101816|targeted mutation 1, H te Riele|Msh2|MGI:1858055|17||||||||||||||||Yes|||||||||||||T cell derived lymphoma: 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age.Msh2-deficient cells have lost mismatch binding and have acquired microsatellite instability, a mutator phenotype, and tolerance to methylating agents. Moreover, in these cells, homologous recombination has lost dependence on complete identity between interacting DNA sequences, suggesting that Msh2 is involved in safeguarding the genome from promiscuous recombination.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jun-2007|Cryopreserved sperm|50.0|0.0|Unknown||Lymphoma, genome stability, mismatch repair|Yes| 3685.0|Storm ; ENU9B6:023a|C57BL/6JAnu-Ptprc/AnuApb|C57BL/6JAnu-Ptprc/AnuApb|Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc|Unknown|B220, CD45, Cd45, Ly-5, Lyt-4, T200|MGI:97810|storm|Ptprc|MGI:4819159|1|ENSMUSG00000026395|ENSMUST00000027645|Ptprc-201|1393|1491|T to C|ENSMUSE00000595908|13|465|Cysteine to Arginine|||||AGATTCAAAGAAATGGGACTGCTGAGAAGTGCAATTTTCACACAAAAGCAGATCGTCCGGA|Yes|||||||||||||Low B and T cell numbers||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4|affected x littermate or affected by B6|No|26-Aug-2008|Cryopreserved sperm|110.0|0.0|Unknown||T cell, B cell, signal transduction, receptor, ENU, NIH, Wellcome Trust, Phosphorylation|Yes| 5471.0|APN 78|C57BL/6N-Zdhhc2/Marp||Recessive|zinc finger, DHHC domain containing 2|Zdhhc2|||MGI:1923452|zinc finger, DHHC domain containing 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Zdhhc2|MGI:4362764|8||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 4904.0|IL2 KO TCR Arjuna|C57BL/6-IL2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive|interleukin 2|IL2|Nil|Il-2|MGI:96548|targeted mutation 1, Ivan Horak|Il2|MGI:1857191|3|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Increased T cell numbers and prolonged T cell response to antigen.Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background. Phenotype Screen: Urine glucose|Normal|C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|120.0|0.0|Yes|Type I Diabetes|CD4, HEL, T cell, autoimmunity, T cell receptor|Yes| 4904.0|IL2 KO TCR Arjuna|C57BL/6-IL2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Increased T cell numbers and prolonged T cell response to antigen.Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background. Phenotype Screen: Urine glucose|Normal|C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|||Yes|Type I Diabetes|CD4, HEL, T cell, autoimmunity, T cell receptor|Yes| 6971.0|ENU20:026:b:B6:G3|ANU:ENU20:026:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 69.0|Sweaty|C57BL/6JStdAnu-Scd2/AnuApb|C57BL/6JStdAnu-Scd2/AnuApb|Recessive|stearoyl-Coenzyme A desaturase 2|Scd2|Unknown|Scd-2|MGI:98240|stearoyl-Coenzyme A desaturase 2; sweaty|Scd2|MGI:4888575|19|ENSMUSG00000025203|ENSMUST00000026221|Scd2-201|330|1042|C to T|ENSMUSE00000148829|3|109|Serine to Serine|||||CTCTTCGCGTATTTGTACTATGTAATCAGCGCCCTGGGCATCACAGCCGGGGCTCATCGCC|Unknown|||||||||||||Sweaty/oily thin coat; hyperplasia of sebacious glands, periocular inflammation, homozygote females breed poorly, males OK||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||G15|Het x Het|No|06-Feb-2006|Cryopreserved sperm|25.0|0.0|Unknown||Sweat, oily, coat, ENU|Yes| 7655.0||SJL/ASAM/Apb||Dominant|Unknown|Unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a slight growth retardation phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|09-Apr-2014|Cryopreserved sperm|53.0|0.0|Unknown||ENU|Yes| 4908.0|DeltaEF1|C57BL/6-Zeb1/AnuApb||Recessive|zinc finger E-box binding homeobox 1|Zeb1|Normal|[delta]EF1, 3110032K11Rik, AREB6, MEB1, Nil2, Tcf18, Tcf8, ZEB, Zfhep, Zfhx1a, Zfx1a|MGI:1344313|targeted mutation 1, Yujiro Higashi|Zeb1|MGI:1857515|18|||||||||||||||||||||||||||||Postnatal lethality.Decreased T cell number and abnormal T cell differentiation.Abnormal thymus development.Abnormal corneal morphology.||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|150.0|0.0|Unknown||Corneal Dystrophy, Posterior Polymorphous, 3; PPCD3, T cell, differentiation, thymus, spleen, lymph node|Possibly| 4910.0|MommeR1|FVB-Foxo3/Apb||Recessive|forkhead box O3|Foxo3|Unknown|Fkhr2, FKHRL1, Foxo3a|MGI:1890081|modifier of murine metastable epialleles, R1|Foxo3||10||||||||||||||||Yes|Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Percentage of cells expressing the Line3 GFP transgene is decreased (enhancer of variegation).||FVB/NJ|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Poor|||MommeD5<+/->;Tg(α-Globin-GFP)3EWh x Tg(α-Globin-GFP)3EWh|No|09-Oct-2009|Cryopreserved sperm|120.0|0.0|No||epigenetics, histone modification|Yes| 89.0||Wavy||Recessive|||Unknown||||||3||||||||||||||||Yes|||||||||||||Rough coat with slightly wavy hair most visible at weaning, adults have only subtle coat changes, normal vibrissae; no overt hematological abnormality based on complete blood counts.Phenotype unique to this chromosome location, approx 65 genes in this region.||C57BL/6 x NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|75.0|0.0|Unknown||coat, hair, follicle, ENU|Yes| 7721.0|Trail -/-|B6.129-Tnfsf10/AnuApb||Recessive|tumor necrosis factor (ligand) superfamily, member 10|Tnfsf10||A330042I21Rik, APO-2L, Trail|MGI:107414|tumor necrosis factor (ligand) superfamily, member 10; targeted mutation 1, Lisa M Sedger|Tnfsf10|MGI:2388390|3|||||||||||||||||||||||||||||Tumorigenesis:Normal • Background Sensitivity: unlike mice on a BALB/c congenic background, mice on a C57BL/6 congenic background show no difference from controls in the rate of A20 lymphoma tumor progression.Immune system phenotype:Normal• despite the potential contribution of genetic epistatic factors to autoimmune disease, no signs of lymphoproliferative disease are detected. • all lymphoid tissues and cell numbers of myeloid, lymphoid, and immature erythroid cell subpopulations are similar to controls.Skeleton phenotype:Normal:• despite the fact that this protein binds to osteoprotegrin, bone biology is normal and mice are not osteopetrotic (J:79085)||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Jul-2014|Cryopreserved sperm|49.0|0.0|Unknown||Trail, Toll, infection, lymphoid|Yes| 7656.0|ENU25:007:Wdfy3:B6|C57BL/6NCrlAnu-Wdfy3/AnuApb|C57BL/6NCrlAnu-Wdfy3/AnuApb|Recessive|WD repeat and FYVE domain containing 3|Wdfy3|Unknown|2610509D04Rik, Bchs, Bwf1, D5Ertd66e, Ggtb3, mKIAA0993|MGI:1096875|WD repeat and FYVE domain containing 3; mutation 1, The Australian National University|Wdfy3|MGI:5648436|5|ENSMUSG00000043940|ENSMUST00000053177|Wdfy3-001|1501|2046|A to T|ENSMUSE00000326146|11|501|Arginine to Tryptophan|||||GGCACGACTACATATTTAAAGATGTCTTCAGGGAGGTGGGCCTGCTGGAGGTCATGGTAAA||||||||||||||Unknown||C7BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|09-Apr-2014|Cryopreserved sperm|16.0|0.0|Unknown||ENU|Yes| 7722.0|Id4GFPB6|C57BL/6-Id4||Dominant|inhibitor of DNA binding 4|Id4||bHLHb27, Id4, Idb4|MGI:99414||||13|||||||||||||||||||||||||||||GFP at Id4 locus|GFP at Id4 locus|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4||Pairs|No|24-Jul-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7723.0|SoloxMed AR2|B6;CBA-Ifnar2 Tg(sIfnar2)2Pjh/MarpApb||Recessive|interferon (alpha and beta) receptor 2|Ifnar2|Increased|Ifnar-2 |MGI:1098243 |interferon (alpha and beta) receptor 2; targeted mutation 1, Paul J Hertzog|Ifnar2|MGI:2680693|16|||||||||||||||||interferon (alpha and beta) soluble receptor 2 |mouse Ifnar2|medium expression ||||||||||Normal. Increased expression of soluble IFNAR2 receptor.|Normal. |CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Jul-2014|Cryopreserved sperm|50.0|0.0|Unknown||septic shock, proinflammatory cytokine, agonist|Possibly| 2372.0||ENU8B6:061||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th2 polarized IgG1 antibody response to chicken gammaglobulin (CGG). ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|10.0|0.0|Unknown||B cell, antibody, immunization, ENU, Wellcome Trust|Yes| 6972.0|ENU20:027:a:B6:G3|ANU:ENU20:027:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|27.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 285.0||Balb/c.B6-IL13/Apb||Recessive|interleukin 13|Il13|Unknown|Il13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11||||||||||||||||No|||||||||||||abnormal T helper 2 physiology: homozygotes display impaired pulmonary granuloma formation in response to schistosome egg immunizationeosinophil infiltration is impaired in response to schistosome egg immunizationincreased susceptibility to parasitic infection:the expulsion of parasitic worms from the gut is delayedA neomycin cassette was inserted into exon 3.||Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-May-2006|Cryopreserved sperm|125.0|0.0|Unknown||IL4, IL5, T cell, infection|Yes| 4562.0|Krüppel-like Factor 3 (KLF3/BKLF) Knockout |FVB/NJ.129-Klf3/Apb||Recessive|Kruppel-like factor 3 (basic)|Klf3|Nil|BKLF, Bklf, Tef-2|MGI:1342773|targeted mutation 1, Merlin Crossley|Klf3|MGI:3799368|5||||||||||||||||Yes|||||||||||||Postnatal lethality, only 17% survive to weaning. Decreased adipose tissue, mice appear leaner, abnormal fat pads. Similar in size to wildtype at birth but significantly smaller than littermate controls from 3 to 12 weeks of age.|||Yes|No|Yes|Yes|No|Yes|Yes|Unknown||||No|05-Mar-2009|Cryopreserved sperm|100.0|0.0|Unknown||Kruppel-like Factor 3, Basic Kruppel-like Factor, KLF, Obesity, adipose|Yes| 6973.0|ENU20:027:b:B6:G3|ANU:ENU20:027:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4915.0|IL-13 -/- IL-4Ra -/-|BALB/c-IL13 IL4ra/AnuApb||Recessive|interleukin 13|Il13|Nil|Il-13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11|||||||||||||||||||||||||||||Unknown||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|16-Oct-2009|Cryopreserved sperm|100.0|0.0|Unknown||interleukin, IL10, IL5, Th2, T cell, parasite|Yes| 4915.0|IL-13 -/- IL-4Ra -/-|BALB/c-IL13 IL4ra/AnuApb||Recessive|interleukin 4 receptor, alpha|Il4ra|Unknown|D124, IL-4 receptor alpha chain, Il4r|MGI:105367|targeted mutation 1, Leonard Shultz|Il4ra|MGI:1861951|7|||||||||||||||||||||||||||||Unknown||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|16-Oct-2009|Cryopreserved sperm|||Unknown||interleukin, IL10, IL5, Th2, T cell, parasite|Yes| 6646.0|HOM.NOD.FADD51|NOD-Tg(RIP2-dnFADD)51Wehi/WehiStvApb||Dominant||||||||||||||||||||||||||human dominant negative FADD|rat insulin promoter 2 (RIP)|||||||||||NOD.FADD.51 homozygous mice have reduced incidence of diabetes compared to NOD/Lt mice. They are healthy and breed well.|Mice have a slightly reduced incidence of diabetes when compared to NOD/Lt mice|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10+|20+|Sister x Brother (hom x hom)|No|15-Nov-2011|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes|Pancreatic Beta cell, Type 1 diabetes, apoptosis, fas, cytikines|No| 273.0||BALB/c-H2-DMa||Recessive|histocompatibility 2, class II, locus DMa|H2-DMa|Unknown|H-2Ma, H2-Ma|MGI:95921||||17||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit impaired antigen presenting cell function, poor IgG responses to T-dependent antigens, reduced numbers of mature CD4+ T cells, and increased susceptibility to Leishmania major infection.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-May-2006|Cryopreserved sperm|125.0|0.0|Unknown||T cell, CD4, antigen presentation, IgG, infection|Yes| 4906.0|Stiliom; ENU4AT:032|B6;NODAnu-Tomm40/AnuApb||Semi-dominant|translocase of outer mitochondrial membrane 40 homolog (yeast)|Tomm40|Unknown|Tom40|MGI:1858259|Stiliom|Stil||7|ENSMUSG00000002984|ENSMUST00000093552|Tomm40-202|977|1048|C to T|ENSMUSE00000582554|10|326|Alanine to Valine|||||CTCTGTGAACAGTAACTGGATCGTGGGCGCCACGCTGGAGAAGAAGCTTCCGCCCTTGCCC|Yes|||||||||||||Lethal lung haemorrhage at 4 – 6 weeks, blood vessel fragility may be caused by suspected transdifferentiation of smooth muscle cells into skeletal muscle (a physiological process in the oesophagus) occurring throughout the body.TOM complex is absent in Blue-native PAGE analysis|Blue-native PAGE shows reduced levels of TOM complex in mitochondria in HETs; Monomeric Tomm40 is detected, but the mutant version of the protein migrates faster on SDS-PAGE than the wild-type protein (data from Diana Stojanovski and Mike Ryan at Latrobe.|C57BL/6JSfdAnu x NODk|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|30.0|0.0|Unknown||lung, haemorrhage, smooth muscle, mitochondrial myopathy, skeletal muscle, differentiation, blood vessel, transdifferentiation, JDRF|Yes| 6647.0|APN 89|C57BL/6N-ATP13a2/Marp||Recessive|ATPase type 13A2 |Atp13a2 |Unknown|1110012E06Rik |MGI:1922022 |ATPase type 13A2; targeted mutation 1e, Wellcome Trust Sanger Institute |Atp13a2|MGI:4433545|4||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Nov-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 10336.0|Lats1 fl:Lats2 fl:K5-creERT2 |STOCK Lats1 Lats2 Tg(KRT5-cre/ERT2)2Ipc||Recessive|large tumor suppressor|Lats1|||MGI:1333883|large tumor suppressor; targeted mutation 1.1, James F Martin|Lats1|MGI:5568586|10|ENSMUSG00000040021 ||||||||||||||||transgene insertion 2, I Pierre Chambon|transgene insertion 2, I Pierre Chambon|||||||||||Normal|Normal||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-May-2023|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 10336.0|Lats1 fl:Lats2 fl:K5-creERT2 |STOCK Lats1 Lats2 Tg(KRT5-cre/ERT2)2Ipc||Recessive|large tumor suppressor 2|Lats2|||MGI:1354386|large tumor suppressor 2; targeted mutation 1.1, James F Martin|Lats2|MGI:5568589|14|ENSMUSG00000021959 ||||||||||||||||||||||||||||Normal|Normal||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-May-2023|Cryopreserved sperm|||Unknown|||Possibly| 4549.0||B6.129-Ring1/WehiApb||Recessive|ring finger protein 1|Ring1|Nil||MGI:1101770|targeted mutation 1, Miguel Vidal|Ring1|MGI:1926913|17||||||||||||||||Yes|||||||||||||Increased rib number* 42% had 8 vertebrosternal ribs instead of 7Abnormal vertebrae morphology * 100% exhibited vertebrae abnormalities with abnormal C1 and C2Abnormal cervical atlas morphology Anormal cervical axis morphology Vertebral transformation * anterior transformations||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||No|02-Mar-2009|Cryopreserved sperm|100.0|0.0|No||Polycomb group proteins, polycomb repressive complex 1, skeletal, anterior|Yes| 6974.0|ENU20:028:a:B6:G3|ANU:ENU20:028:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 287.0|Tune|BALB/c-Il4/AnuApb||Recessive|interleukin 4|Il4|Unknown|IgG1, Il-4|MGI:96556|targeted mutation 2, Nancy Noben-Trauth|Il4|MGI:1857195|11||||||||||||||||No|||||||||||||abnormal dendritic cell differentiation:numbers of MHCII/CD86-positive dendritic cells found in inflamed lungs are reduced by two-thirdsdecreased IgE level:reduced serum concentrations of IgE, however lymphocyte composition and function comparable to wild-type controlsdecreased IgG1 level:reduced serum concentrations of IgG1, however lymphocyte composition and function comparable to wild-type controlsabnormal dendritic cell antigen presentation:memory CD4 T cells activated by mutant DCs from inflamed lungs secrete low levels of Th2 cytokinesincreased interferon-gamma secretion:T cells from mice sensitized and challenged with OVA produce more IFN-gamma than controlsdecreased interleukin-13 secretion:lymphocytes from mice sensitized and challenged with OVA produce less IL-13 than controlsdecreased interleukin-5 secretion:lymphocytes from mice sensitized and challenged with OVA produce less IL-5 than controlsdecreased susceptibility to autoimmune disorder:mice fail to develop blood eosinophilia after being sensitized and challenged with OVA peptideairway hyperresponsiveness still occurs in these mice though less mucosal cells are found in the inflamed airwayhematopoietic systemabnormal dendritic cell differentiation:numbers of MHCII/CD86-positive dendritic cells found in inflamed lungs are reduced by two-thirds||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-May-2006|Cryopreserved sperm|100.0|0.0|Unknown||infection, inflammation, immunoglobulin, lymphocyte|Yes| 5567.0|ENU14Ch:048b|C57BL/6JAnu-Prkdc/AnuApb|C57BL/6JAnu-Prkdc/AnuApb|Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNA-PK, DNA-PKcs, DNAPDcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; mutation 1, The Australian National University|Prkdc|MGI:5563438|16|ENSMUSG00000022672|ENSMUST00000023352|prkdc-201||||||||15714375|34|||GTTTCTCTCATGTTATATCACCATCTCAGGTAACTATGATCAGTTTGTTTTAACATATCT||||||||||||||Decreased % of T and B cells|Decreased % of T and B cells|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|4-6|5|Sib x sib|No|24-Aug-2011|Cryopreserved sperm|46.0|0.0|Unknown||ENU, T cell, B cell, lymphocyte|Possibly| 2777.0|C57BL/6.hK14-FLII 18|C57BL/6-Tg(hK14-FLII)18 ||Dominant|||||||||Unknown||||||||||||||||Yes|Human Flightless|Human Keratin 14|||||||||||Not bred to Homozygous state|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het FLII transgenic x WT C57BL/6|No|16-Feb-2008|Cryopreserved sperm|95.0|0.0|Unknown||human, skin, enhancer, keratin|Yes| 10335.0|R26-YAP5SA:K5-creERT|STOCK Gt(ROSA)26Sor(CAGGS-Yap5SA,LacZ)Mao Tg(KRT5-cre/ERT2)2Ipc/Anu||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3, Junhao Mao|Gt(ROSA)26Sor|MGI:6763056|6|ENSMUSG00000086429 |||||||||Unknown to Unknown|||||||transgene insertion 2, I Pierre Chambon|K5-Cre |||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-May-2023|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 5529.0|Joey-SCO CBA|CBA.B6-Etv5/MarpApb|CBA.B6-Etv5/MarpApb|Recessive|ets variant gene 5|Etv5|Unknown|ERM|MGI:1096867|ets variant gene 5; sco|Etv5|MGI:5563470|16|ENSMUSG00000013089|ENSMUST00000079601|Etv5-202|1234|1414|A to T|ENSMUSE00000560895|12|412|Lysine to STOP|||||AAGAGGTTGCTCGCCGTTGGGGTATCCAGAAGAATCGGCCAGCCATGAACTATGACAAGCT|No|||||||||||||Sertoli cells only.Male infertility.Progressive loss of germ cells following the first wave of spermatogenesis.Germ cells appeared to be preferentially lost in a basal to apical direction from the seminiferous epithelium as detected in 7 week old testis.Reduced testis size, compared to WT, at 8 weeks of age.Etv5 mRNA levels 95% reduced compared to WT males.Etv5 mRNA is unstable.Reduced expression of Etv5 target genes Cxcr4 and Ccl9.Increased incidence of embryonic and perinatal lethality.Reduced body weight.Renal asymmetry.Polydactyly.||CBA|Yes|Yes|Yes|Yes|No|Yes|No|Unknown|7|||No|04-Jul-2011|Cryopreserved sperm|50.0|0.0|Unknown||infertility, sperm, arrest, ENU, sertoli|Yes| 4895.0||C57BL/6-Lyn/Apb||Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Normal|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; multilineage defect 4 |Lyn|MGI:3832561|4|||||||||||||||||||||||||||||Peritneal inflammation.Increased T cell number: there is a bout a doubling in the number of T cells found in the peritoneum.Slight increase of macrophages in peripheral lymph tissues.Abnormal B cell morphology.Abnormal myelopoiesis.Glomerulonephritis||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|100.0|0.0|Unknown||signal transduction, kinase, receptor, B cell, autoimmunity, proinflammatory, signalling, myeloid, splenomegaly, autoantibody|Yes| 7724.0|Nasp KO|C57BL/6N-Nasp/MarpApb||Recessive|nuclear autoantigenic sperm protein (histone-binding)|Nasp||5033430J04Rik, D4Ertd767e, Epcs32, Nasp-T|MGI:1355328|nuclear autoantigenic sperm protein (histone-binding); targeted mutation 1a, Wellcome Trust Sanger Institute|Nasp|MGI:5006782|4|||||||||||||||||||||||||||||Unknown||C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Aug-2014|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 4471.0|cc10-rtTA|BALB/c-Tg(Scgb1a1-rtTA)/AnuApb||Dominant||||||||||||||||||||||||||reverse tetracycline response element (rtTA)|secretoglobin, family 1A, member 1 gene (Scgb1a1) or cc10|||||||||||Mice express reverse tetracycline response element under control of the promoter from the rat secretoglobin, family 1A, member 1 gene, which directs expression in Clara cells of the pulmonary epithelium. ||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|40.0|0.0|Unknown||inducible, tetracycline, inflammation, asthma|Yes| 7680.0|ENU7PMH:130:RagKO ; Krusty:Rag1 KO|B6.Cg-Ndfip1 Rag1/AnuApb||Recessive|Nedd4 family interacting protein 1|Ndfip1||0610010M22Rik|MGI:1929601|krusty|Ndfip1||18|ENSMUSG00000024425|ENSMUST00000025293|Ndfip1-201||||||||38612084|5|||TCTCTAATTAAGTGGATCCTTATTGTCAGGGTAAGTTGCATAGCAGAGAACAGATTGTGA||||||||||||||Autoimmune disease||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-May-2014|Cryopreserved sperm|30.0|0.0|Unknown||T cell, autoimmunity, CD4, ENU|Yes| 7680.0|ENU7PMH:130:RagKO ; Krusty:Rag1 KO|B6.Cg-Ndfip1 Rag1/AnuApb||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||||||||||||||Autoimmune disease||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-May-2014|Cryopreserved sperm|||Unknown||T cell, autoimmunity, CD4, ENU|Yes| 4470.0|eotaxin -/-|C57BL/6-Ccl11/AnuApb||Recessive|small chemokine (C-C motif) ligand 11|Ccl11|Nil|eotaxin, Scya11|MGI:103576|targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11||||||||||||||||Yes|||||||||||||Abnormal immune system physiology * mutant mice have markedly fewer eosinophils in the jejunum than do wild-type controls||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|150.0|0.0|Unknown||chemokine, asthma, eosinophil|Yes| 7725.0|Solox Low AR|B6;CBA-Ifnar2 Tg(sIfnar2)1Pjh/MarpApb||Recessive|interferon (alpha and beta) receptor 2|Ifnar2|Increased|Ifnar-2 |MGI:1098243 |interferon (alpha and beta) receptor 2; targeted mutation 1, Paul J Hertzog|Ifnar2|MGI:2680693|16|||||||||||||||||interferon (alpha and beta) soluble receptor 2 |mouse Ifnar2|Low expression ||||||||||Normal. Increased expression of soluble IFNAR2 receptor.|Normal. |CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Aug-2014|Cryopreserved sperm|50.0|0.0|Unknown||septic shock, proinflammatory cytokine, agonist|Possibly| 5211.0|Gpc1 knockout|B6;CD-1-Gpc1/Apb||Dominant|glypican 1|gpc1|Nil||MGI:1194891|glypican 1; targeted mutation 1.1, Arthur Lander|Gpc1|MGI:3774029|1|||||||||||||||||||||||||||||Lifespan, fertility and health are normal. Occasional malocclusions. Brain may be slightly smaller than normal.|Unknown|C57BL/6 x CD-1|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Aug-2010|Cryopreserved sperm|45.0|0.0|Unknown||growth plate, angiogenesis, heparan sulfate proteoglycans, fibroblast growth factor (FGF) signaling, glypican family|Possibly| 4476.0||C.B6-TLR2 TLR4/AnuApb||Recessive|toll-like receptor 2|Tlr2|Unknown|Ly105|MGI:1346060|toll-like receptor 2; targeted mutation 1, Shizuo Akira|Tlr2|MGI:2178675|3||||||||||||||||Yes|||||||||||||Homozygous null mice demonstrate abnormal responses to bacterial and viral infections.||Balb/c X C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|110.0|0.0|Unknown||Infection, lipopolysaccharide (LPS), MyD88, signal transduction|Yes| 4476.0||C.B6-TLR2 TLR4/AnuApb||Recessive|toll-like receptor 4|Tlr4|Unknown|lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; targeted mutation 1, Shizuo Akira |Tlr4|MGI:1860885|4|||||||||||||||||||||||||||||Homozygous null mice demonstrate abnormal responses to bacterial and viral infections.||Balb/c X C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|||Unknown||Infection, lipopolysaccharide (LPS), MyD88, signal transduction|Yes| 4453.0|Johnson|BALB/c-Tlr2/AnuApb||Recessive|toll-like receptor 2|Tlr2|Nil|Ly105|MGI:1346060|toll-like receptor 2; targeted mutation 1, Shizuo Akira|Tlr2|MGI:2178675|3||||||||||||||||Yes|||||||||||||Homozygous null mice demonstrate abnormal responses to bacterial and viral infections.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Feb-2009|Cryopreserved sperm|120.0|0.0|Unknown||infection, bacterial, viral infection, macrophage|Yes| 2432.0|B7h knockout (ICOS ligand)|B6;129P2-Icosl/AnuApb|B6;129P2-Icosl/AnuApb|Recessive|icos ligand|Icosl|Nil|B7-H2, B7h, B7RP-1, GL50, GL50-B, ICOS-L, LICOS|MGI:1354701|targeted mutation 1, Kong-Peng Lam|Icosl|MGI:2673557|10||||||||||||||||No|||||||||||||Mice homozygous for disruptions in this gene exhibit defects in the humoral immune response associated with an impaired interactions between T and B cells. impaired germinal center formation. impaired interaction between T and B cellswhile normal repsonses are mounted against both type I and type II Tcell-independent antigens, the response to T-cell-dependent antigen was attenuated||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Het x Het ; Hom x Hom|No|13-Jan-2008|Cryopreserved sperm|80.0|0.0|No||B cell, T cell, lymphocyte, Germinal centre, costimulation|Yes| 4465.0||C57BL/6-IL5 Eotaxin/AnuApb||Recessive|interleukin 5|Il5|Unknown|Il-5|MGI:96557|targeted mutation 1, Manfred A Kopf|Il5|MGI:1861948|11||||||||||||||||Yes|||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|22-Feb-2009|Cryopreserved sperm|160.0|0.0|Unknown||eosinophil, chemokine, asthma, B cell, infection|Yes| 4465.0||C57BL/6-IL5 Eotaxin/AnuApb||Recessive|chemokine (C-C motif) ligand 11|Ccl11|Unknown|eotaxin, Scya11|MGI:103576|targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|22-Feb-2009|Cryopreserved sperm|||Unknown||eosinophil, chemokine, asthma, B cell, infection|Yes| 6587.0|MLR34|FVB/N-Tg(Cryaa-cre)34Mlr/Apb||Dominant||||||||||||||||||||||||||transgene insertion 34, Mike Robinson|modified alpha A crystallin promoter with an inserted copy of Pax6 consensus binding site|||||||||||Nil. Mice express Cre in lens fibres, and retina and various embryonic structures|Normal|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|unkown||inbred|No|23-Sep-2011|Cryopreserved sperm|40.0|0.0|Unknown||crystallin, lens, eye, epithelial, Pax6|Yes| 343.0|B7C kk|B10.Cg-Tg(SERPINC1-CD86)/Apb||Dominant||||||||||||||||||||||||||murine CD86|human anti-thrombin III (SERPINC1) + regulatory intronic sequences of MHC class II|low on 15% of hepatocytes||||||||||Express CD86 on 15% of hepatocytes. Expression elsewhere has not been reported.|Express CD86 on 15% of hepatocytes. Expression elsewhere has not been reported.|C57BL/10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|15|B7Ckk X B7Ckk|No|22-Sep-2006|Cryopreserved sperm|30.0|0.0|No||costimulation, hepatocytes, T cells, liver, T cell activation, Hepatitis C (HCV), hepatocellular carcinoma|Yes| 6864.0|ENU16Ch:085a reln|C57BL/6JAnu-Reln/AnuApb|C57BL/6JAnu-Reln/AnuApb|Recessive|reelin|Reln|Unknown||MGI:103022|reelin; mutation 1, The Australian National University|Reln|MGI:5563426|5|ENSMUSG00000042453|ENSMUST00000161356|Reln-001||||||||21408594|59|||ATCCAGCTCCCAGACCACGTCTCGTCAAGGTGGGTTGTCTACAGAGGTAAGCCTAGTGGG||||||||||||||Pups are uncoordinated and runted|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Unknown|Yes|No|Good||G6|het x het|No|23-Mar-2012|Cryopreserved sperm|36.0|0.0|Unknown||runted, uncoordinated, small, ENU|Yes| 4992.0|c-cbl KO|STOCK H2 Cbl/AnuApb ||Recessive|Casitas B-lineage lymphoma|Cbl|Nil|c-Cbl, cbl, Cbl-2|MGI:88279|targeted mutation 1, David D L Bowtell|Cbl|MGI:2180578|9||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit increased thymic CD3 and CD4 expression and tyrosine-phosphorylation, lymphoid hyperplasia, and altered splenic hemopoiesis. Females show increased ductal density and branching in mammary fat pads.Abnormal spleen red pulp morphology- expandedenlarged spleen. Spleen is enlarged about 1.2- to 2-fold compared to wild type mice due to expansion of the red pulpspleen hyperplasia.Increase in the number of megakaryocytes, megakaryoblasts, and myelocytes but no increase in the number of lymphocytes is seen in the spleen.Abnormal adipocyte morphology- adipocyte volume is reduced by about 64% compared to wild type mice.Decreased adipose tissue amount- despite increased caloric intake, a 40-50% decrease in the size of the adipose tissue depots (including both white and brown fat) is seenthis phenotype is more pronounced in males than in females.Increased lean body mass- balances the decrease in adipose tissue resulting in no significant difference in total body weight.Polyphagia.Hyperactivity- about a 4-fold increase in ambulatory activity is seen, especially during the dark phase.Increased body temperature- rectal temperature is increased by 1 degree C independent of time of day or if the mice are fed or fasted overnight. However, circulating levels of triiodothyronine or thyroxine are similar to wild type in both the fed and fasted states.Decreased circulating leptin level- leptin levels are decreased by 66%; however adiponectin levels are similar to wild type.Abnormal gas homeostasis- increased oxygen consumption:whole body oxygen consumption corrected for the difference in lean mass is increased by 22% compared to wild type mice.Abnormal respiratory quotient- reduced respiratory quotientAbnormal glucose homeostasis- decreased circulating insulin level, after an overnight fast insulin levels are decreased relative to wild type but glucose levels are similar to wild type.Improved glucose tolerance- improved glucose tolerance despite decreased insulin levels throughout the test.Increased insulin sensitivity.Abnormal lipid homeostasis- decreased circulating free fatty acid level.Decreased triglyceride level- triglyceride levels in the liver are decreased but those in the quadriceps muscle are similar to wild type muscleAbnormal muscle physiology- glucose clearance in to glycogen is increased in the soleus and extensor digitorum longus muscles but not in the liver.Abnormal muscle cell glucose uptake- glucose uptake into skeletal muscle is increased about 2-fold; however glucose uptake into white and brown adipose tissue is not different from wild type. Basal and insulin-stimulated glucose uptake are increased in soleus muscle explants by 65% and 30%, respectively; however, glucose uptake is not increased in fat explants basal, but not insulin-stimulated, glucose uptake is increased by 30% in extensor digitorum longus muscle explantscellular.Abnormal mitochondrial morphology- a 2-fold increase in the average size of subsarcolemmal mitochondria is seen; however, no increase in mitochondrial area or cristae density is seen in the subsarcolemmal region.Spleen hyperplasia- increase in the number of megakaryocytes, megakaryoblasts, and myelocytes but no increase in the number of lymphocytes is seen in the spleen.||129/1SV x C57BL/6 x C57BL/10.BR-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|28-Jan-2010|Cryopreserved sperm|45.0|0.0|No||Cbl, tyrosine kinase, TKB, Zap-70, adipose|Yes| 1556.0|P47phox-/-|NOD/Lt-Ncf1/AnuApb||Recessive|neutrophil cytosolic factor 1|Ncf1|Unknown|NADPH oxidase subunit (47kDa), Ncf-1, NOXO2, p47phox, p47phox|MGI:97283||||5||||||||||||||||Yes|||||||||||||Abnormal neutrophil physiology. Granulomatous inflammation. Crystal in lungs and bile ducts. Skin abscess||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||neutrophil, granulocytes|Yes| 5354.0|rbp4 KO|B6;129/Sv-Rbp4/Apb||Recessive|retinol binding protein, plasma|Rbp4|Nil|Rbp-4, retinol binding protein 4, cellular|MGI:97879|retinol binding protein 4, plasma; targeted mutation 1, Max E Gottesman|Rbp4 |MGI:2445721|19||||||||||||||||No|||||||||||||Mutant mice fed a vitA-enriched diet are healthy and fertile. They exhibit impaired retinal function during the first few months of life but acquire normal vision on a vitA sufficient diet.Pups bred from dams maintained on vitA deficient diet for extended periods develop severe developmental deformities and die in utero.|Unknown but probably same as normal.|Mixed 129/Sv-C57BL/6 genetic background|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown|1|Inbred|No|20-Dec-2010|Cryopreserved sperm|70.0|0.0|Unknown||retinol, vitamin A, knockout, retinol binding protein, plasma|Yes| 641.0|c-Cbl (G304E)|STOCK Cbl/Apb|STOCK Cbl/Apb|Recessive|Casitas B-lineage lymphoma|Cbl|Normal|4732447J05Rik, c-Cbl, cbl, Cbl-2|MGI:88279|targeted mutation 1, Wallace Langdon|Cbl|MGI:2451336|9||||||||||||||||Yes|||||||||||||Mice have a physically normal outward appearance and are generally healthy. Up to ~40% homozygous females have blockages in the uterine horns and fallopian tubes, while ~25% of homozygous males appear infertile. All homozygous mice show slight splenomegaly (~50% larger than wildtype control).|Appear normal and healthy|129S1/SvJ x C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|||Hom x Het|No|25-Apr-2007|Cryopreserved sperm|100.0|0.0|Unknown||Cbl, tyrosine kinase binding domain, TKB, Zap-70|Yes| 1524.0||C.Cg-Myd88 Tg(CD2-IL5)5C2Ldt/Apb|C.Cg-Myd88 Tg(CD2-IL5)5C2Ldt/Apb|Recessive|myeloid differentiation primary response gene 88|Myd88|Nil||MGI:108005|targeted mutation 1, Shizuo Akira|Myd88|MGI:2385681|9||||||||||||||||Yes|transgene insertion 5C2, Lindsay A Dent |The dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Provide a source of Myd88 deficient eosinophils||BALB/c|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|80.0|0.0|Unknown||eosinophils, infection, virus clearance, TLR, interferon|Yes| 4528.0||B6.CBA-Tg(hGMCSF-CK1m)397/AnuApb||Dominant||||||||||||||||||||||||||human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2009|Cryopreserved sperm|40.0|0.0|Unknown||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 4969.0|Beta Tg|C.129/Sv-Tg(hGM-CSFRb) Csf2rb Csf2rb2/Apb||Dominant|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb|Unknown|AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15||||||||||||||||Yes|human beta common chain receptor for GM-CSF/IL-3/IL-5|human ubiquitin C promoter|low||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|0|Purchased BALB/c mated with transgenic mouse from colony to maintain colony|No|15-Jan-2010|Cryopreserved sperm|100.0|0.0|Unknown||growth factor, interleukin, signal transduction, receptor|Yes| 4969.0|Beta Tg|C.129/Sv-Tg(hGM-CSFRb) Csf2rb Csf2rb2/Apb||Dominant|colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)|Csf2rb2|Unknown|AIC2A, BetaIl3, Bil3, Il3r, Il3rb2|MGI:1339760|targeted mutation 1, C Glenn Begley|Csf2rb2|MGI:3652583|15|||||||||||||||||||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|0|Purchased BALB/c mated with transgenic mouse from colony to maintain colony|No|15-Jan-2010|Cryopreserved sperm|||Unknown||growth factor, interleukin, signal transduction, receptor|Yes| 6975.0|ENU20:028:b:B6:G3|ANU:ENU20:028:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|45.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6979.0|ENU20:034:a:B6:G3|ANU:ENU20:034:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|28.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7726.0|ShhTg|C57BL/6-Tg(CAG)LSL(eGFP/mShh)Dnw||Dominant||||||||||||||||||||||||||sonic hedgehog|chicken beta-actin|||||||||||Unknown|Normal in the absence of Cre recombinase.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|25-Aug-2014|Cryopreserved sperm|36.0|0.0|Unknown||signal transduction|Yes| 4527.0||B6.CBA-Tg(hGMCSF-CK1m)418/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2009|Cryopreserved sperm|50.0|0.0|Unknown||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 4965.0||FVB/N.129-Gt(ROSA)26Sor/AusbApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|MGI:1890203|6|||||||||||||||||||||||||||||Normal|Expresses Beta-galactosidase in cells where Cre recombinase is expressed|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Jan-2010|Cryopreserved sperm|90.0|0.0|Unknown||Cre recombinase, LacZ, ROSA26|Yes| 5171.0|Thin Coat|ENU16WT:006a||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Mice have "thin coats" at weaning. This develops into a "fluffy" coat as they get older||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||1|Random sib x sib intercross|No|01-Jul-2010|Cryopreserved sperm|36.0|0.0|Unknown||hair, coat, keratin, ENU, Wellcome Trust|Possibly| 6976.0|ENU20:029:a:B6:G3|ANU:ENU20:029:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|70.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4777.0|CCR +/+|B6.129-Ccr(WT)||Dominant||||||||||||||||||||||||||||||||||||||Normal.Control for experiments with Ccr5 knockouts. A control strain in which the CCR gene cluster is derived from the 129/Ola strain was developed by crossing wild-type F1 progeny of 129/Ola × C57BL/6J matings (40). A BglII restriction fragment length polymorphism was found that distinguishes the CCR5 allele in 129/Ola and C57BL/6J; a probe made from a 1.5-kb XbaI fragment located about 1.8 kb upstream of the CCR5 coding exon detects a 3.3-kb BglII fragment in 129/Ola and a 3.6-kb BglII fragment in C57BL/6J genomic DNA.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Sep-2009|Cryopreserved sperm|150.0|0.0|No||chemokine, Ccr2, Ccr5, Ccr1, control|Yes| 65.0||Rockstar||Recessive|||Unknown||||||2||||||||||||||||Yes|||||||||||||Microphthalmia or no eyes, weepy eyes; clumpy fur, chocolate coat and some hair loss in older mice|||Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|35.0|0.0|Unknown||eye, microphthalmia, ENU|Yes| 7727.0|ENU32:G1|ANU:ENU32:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|26-Aug-2014|Cryopreserved sperm|2197.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4532.0|Cat-1-eGFP|C57BL/6-Tg(Tie2-Slc7a1/eGFP)/Apb||X-linked||||||||||||||||||||||||||solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 fused to eGFP (Atrc-1, Atrc1, Cat1, mCAT-1, Rec-1, Rev-1)|endothelial-specific receptor tyrosine kinase (Tek, Tie2)|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|27-Feb-2009|Cryopreserved sperm|95.0|0.0|Yes||endothelial arginine transport, nitric oxide (NOS), hypertension|Yes| 7728.0|ENU32:G2|ANU:ENU32:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|26-Aug-2014|Cryopreserved sperm|3631.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7537.0|Smarta|C57BL/6-Tg(TcrLCMV)Aox/WehiAnuApb|C57BL/6-Tg(TcrLCMV)Aox/WehiAnuApb|Dominant||||||||||||||||||||||||||transgene insertion, Annette Oxenius|Tcr|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Dec-2013|Cryopreserved sperm|36.0|0.0|Unknown||TCR, MHC, CD4, lymphocytic choriomeningitis virus|Yes| 5009.0|Yastrzemski|B6.129-Ryr pTar 4E6 tg1||Dominant||||||||||||||||||||||||||||||||||||||||12|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|145.0|0.0|Unknown|||Possibly| 10339.0||C57BL/6J-mACE2-hACE2/Apb||Semi-dominant|hACE2 transgene||||||||Unknown|||||||||||||||||hACE2|mACE2|||||||||||hACE2 is expressed from a transgene under control of the mACE2 promoter - providing authentic gene expression. This hACE2 expression allows for SARS-CoV-2 infection of mouse lungs and nasal turbinates, with ensuing histopathology and inflammatory responses comparable to human disease. Please see the attached publication for more information and discussion. Homozygotes are viable and fertile (normal litter sizes etc.).|Same as homozygous|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Jun-2023||0.0|0.0|Unknown|||Possibly| 4985.0|FATSO ; ENU6AT:055|C57BL/6JSfdAnu-Ints10/AnuApb||Recessive|integrator complex subunit 10|Ints10|Unknown||MGI:1918135||||8|ENSMUSG00000031864|ENSMUST00000070713|Ints10-006|859|865|C to T|ENSMUSE00000214077|8|287|Arginine to Tryptophan|||||GGAGACGAAGCTGCAGTGACCTGCTGCACCGGATGAAGGAGCTCTGCAGATACATGAACAG|Yes|||||||||||||Obesity.|Normal|C57BL/6JSfdAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|45.0|0.0|Unknown||Obese, glucose|Yes| 9463.0||FVB/N-Ywhaz/Apb||Semi-dominant|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz||14-3-3zeta|MGI:109484|14-3-3ζGt(OST062)Lex |||15||||||||||Unknown to Unknown|||||||||||||||||||Viable to adulthood, but exhibit multi-organ dysfunction.|Normal|FVB/n|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Dec-2022|Cryopreserved sperm|100.0|0.0|Unknown|||Possibly| 10334.0||C57Bl/6-STOCK Gt(ROSA)26Sor(CAGGS-Yap5SA,LacZ)Mao Tg(KRT5-cre/ERT2)2Ipc/AnuApb||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3, Junhao Mao|Gt(ROSA)26Sor|MGI:6763056|6|ENSMUSG00000086429 |||||||||Unknown to Unknown|||||||transgene insertion 2, I Pierre Chambon|K5-Cre |||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-May-2023||0.0|0.0|Unknown|||Possibly| 5006.0|O'Driscoll ; C57BL/6-IL-13 tg|C57BL/6-Tg(IL13)||Dominant||||||||||||||||||||||||||||||||||||||||10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|100.0|0.0|Unknown|||Possibly| 5014.0|Anne|FVB/n-LAC 1 Tg1 (USA) (ASD068)||Dominant||||||||||||||||||||||||||||||||||||||||10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|140.0|0.0|Unknown|||Possibly| 233.0|TNAP-Cre|B6.129-Alpl/Apb||Recessive|alkaline phosphatase, liver/bone/kidney|Alpl|Nil|Akp-2, Akp2, TNSALP, TNAP|MGI:87983|targeted mutation 1, Andras Nagy|alpl|MGI:2177588|4||||||||||||||||Yes|||||||||||||Perinatal lethal|Normal|C57BL/6 x 129|No|No|Yes|No|No|Yes|No|Unknown|10|||No|25-Apr-2006|Cryopreserved sperm|150.0|0.0|Unknown||alkaline phosphatase, primordial germ cell, Cre|Yes| 6977.0|ENU20:030:a:B6:G3|ANU:ENU20:030:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|28.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4870.0|Bc.HTF1.Tg|BALB/c-Tg(H2-K-huFUT1)1/Apb||Dominant||||||||||||||||||||||||||human fucosyltransferase 1|H2-K|All blood/tissue samples express human fucosyltransferase 1||||||||||Attempts to breed homozygous animals failed. Unknown if homozygous transgene expression is embryonic lethal.|Normal.All blood/tissue samples express human fucosyltransferase.|BALB/c|No|No|Yes|No|No|Yes|No|Unknown|15|||No|28-Sep-2009|Cryopreserved sperm|80.0|0.0|Unknown||glycosylation, xenotransplantation, transplantation, transferase, lectins, H transferase, antibody|Yes| 5068.0||ENU8C:032||Recessive|Unknown||Unknown||||||Unknown||||||||||||||||Unknown|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Mar-2010|Cryopreserved sperm|53.0|0.0|Unknown||Autoimmune disease, autoimmunity, ANA, ENU|Yes| 6978.0|ENU20:033:a:B6:G3|ANU:ENU20:033:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4942.0|osterix-cre|B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Andrew P McMahon| tetracycline-regulated transactivator (tTA) cassette upstream of a tetracycline-responsive element (tetO)||||||||||||Hemizygous mice are viable and fertile. The Sp7 promoter limits EGFP-Cre fusion protein expression to the osteoblast lineage during embryonic/early postnatal development. Expression can be stopped by tetracycline/doxycycline addition. Fusion protein activity is largely absent from chondrocytes.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|88.0|38.0|Unknown||Cre recombinase, GFP, tTA|Yes| 7731.0|MPEG1 targeted KO clone 1B|C57BL/6J-Mpeg1/Pib||Dominant|macrophage expressed gene 1|Mpeg1||Mpg-1, MPS1|MGI:1333743|macrophage expressed gene 1; targeted mutation 1, Phillip I Bird|Mpeg1|MGI:7545676|19||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Sep-2014|Cryopreserved sperm|100.0|0.0|Unknown|||Yes| 6980.0|ENU20:034:b:B6:G3|ANU:ENU20:034:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6982.0|ENU20:038:a:B6:G3|ANU:ENU20:038:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6822.0|MTf knockout|B6.129X1-Mfi2/Apb|B6.129X1-Mfi2|Recessive|antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5|Mfi2|Nil|CD228, melanotransferrin, MTf|MGI:1353421|antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5; targeted mutation 1, Des R Richardson|Mfi2|MGI:3691276|16|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||20+||No|24-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown||melanoma, melanotransferrin, iron|Yes| 5080.0|APPyen|B6.D2-Tg(Thy1-APPswyen)1Jgo||Dominant||||||||||||||||||||||||||human Amyloid Precusor Protein|murine Thy1.2|3 fold higher levels of APP in neurons of transgenic mice compared to WT||||||||||Not fully characterised|Not fully characterised|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||||No|25-Mar-2010|Cryopreserved sperm|100.0|0.0|Yes|Alzhiemer’s disease|amyloid, Alzhiemer’s disease, overexpression, APP, plaque|Possibly| 6987.0|ENU20:046:b:B6:G3|ANU:ENU20:046:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|49.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6988.0|ENU20:047:a:B6:G3|ANU:ENU20:047:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|45.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6990.0|ENU20:053:a:B6:G3|ANU:ENU20:053:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6992.0|ENU20:055:a:B6:G3|ANU:ENU20:055:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6981.0|ENU20:036:a:B6:G3|ANU:ENU20:036:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6983.0|ENU20:039:b:B6:G3|ANU:ENU20:039:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6985.0|ENU20:043:a:B6:G3|ANU:ENU20:043:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|36.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6986.0|ENU20:045:b:B6:G3|ANU:ENU20:045:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|48.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6989.0|ENU20:051:b:B6:G3|ANU:ENU20:051:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6995.0|ENU21:001:a:B6:G3|ANU:ENU21:001:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7026.0|MommeD14|FVB/NJ-MommeD14 Tg(Hba1-Gfp)1Ew||Semi-dominant|DNA methyltransferase 3B|Dnmt3b|||MGI:1261819|DNA methyltransferase 3B; modifier of murine metastable epialleles, D14|Dnmt3b|MGI:5515362|2||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Some homozygous viable at 3 weeks.Transgene expressed in red blood cells. Percentage of cells expressing GFP transgene is increased in Momme D14. |Transgene expressed in red blood cells. Percentage of cells expressing GFP transgene is increased in Momme D14. |FVBNJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||MommeD14<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|23-Jul-2012|Cryopreserved sperm|39.0|0.0|Unknown||DNA methylation, epigenetics|Possibly| 5063.0|Montu|C.C3H-Rps7/AnuApb||Semi-dominant|ribosomal protein S7|Rps7|Unknown|S7|MGI:1333818|Montu|Rps7|MGI:3043039|12||||||||||||||||Yes|||||||||||||Unkown. Assumed lethal.|Phenotype may include variable ventral spotting, tail kinks and small size compared to littermates.|BALB/c x C3H/HeH|No|No|Yes|No|No|Yes|No|Good||||No|02-May-2007|Cryopreserved sperm|38.0|0.0|Unknown||organogenesis, ENU, Diamond-Blackfan anemia|Yes| 6993.0|ENU20:058:b:B6:G3|ANU:ENU20:058:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5233.0|Cid|C57BL/6-Tigd3||Recessive|tigger transposable element derived 3|Tigd3|||MGI:2681860||||19||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|08-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||chromosomal, epigenetics|Possibly| 6994.0|ENU20:059:a:B6:G3|ANU:ENU20:059:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 2378.0|ENU8F:030 , Hipster|B6Apb;CB-Adamts20/Apb|B6Apb;CB-Adamts20/Apb|Recessive|a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 20|Adamts20|Normal|ADAMTS-20, bt|MGI:2660628|a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 20; hipster|Adamts20|MGI:3847117|15|ENSMUSG00000022449|ENSMUST00000035342|Adamts20-001|3664|3833|G to A|ENSMUSE00000646542|26|1221|Glycine to Arginine|||||GGTCACCATGTTCAGCCTCCTGTGGACATGGGAAAACCACCCGACGTGTTTTATGCGTGAA|No|||||||||||||Coat abnormality. Belted, White spotting.Affected mice develop a white stripe transverse across abdomen or a large white spot in the same location.||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Dec-2007|Cryopreserved sperm|150.0|0.0|Unknown||Migration, pigment, melanocyte, stripe, white belly patch, ENU|Yes| 5073.0|Syrup|FVB/N-MommeD7||Semi-dominant|modifier of murine metastable epialleles, D7|MommeD7|Unknown||MGI:3821590|modifier of murine metastable epialleles, D7|MommeD7|MGI:3821597|7||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Mice homozygous for a mutation at this locus display semidominant lethality and are never seen at weaning.Postnatal lethality: * semidominant homozygous lethal * never seen at weaning * death occurs within a few days of birthPallor: about 1/4 of mice are pale in color at E17.5Decreased erythrocyte cell number: at E17.5|Percentage of cells expressing the GFP transgene (Line3) is increased (suppressor of variegation). Reticulocytosis: a 3 fold increase in the number of circulating reticulocytes.Enlarged spleen: severe|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD7<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|25-Mar-2010|Cryopreserved sperm|30.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 5076.0|Nutmeg|FVB/N-MommeD16||Semi-dominant|||Unknown||||||Unknown||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Unknown|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD16<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|25-Mar-2010|Cryopreserved sperm|30.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 5077.0|Charlie|FVB/N-MommeR2||Semi-dominant|||Unknown||||||Unknown||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Unknown|Percentage of cells expressing the GFP transgene (Line3) is decreased (enhancer of variegation). |FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeR2<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|25-Mar-2010|Cryopreserved sperm|40.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 5074.0|Rocky|FVB/N-MommeD8||Semi-dominant|modifier of murine metastable epialleles, D8|MommeD8|Unknown||MGI:3821592|modifier of murine metastable epialleles, D8|MommeD8|MGI:3821599|4||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Mutant mice show a reduction in survival past weaning. Survivors at weaning are smaller than controls.Postnatal lethality: * few animals survive to weaning * normal litter size at birthDecreased body size: at weaning||FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD8<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|25-Mar-2010|Cryopreserved sperm|40.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 6930.0|ENU21:G1|ANU:ENU21:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Jul-2012|Cryopreserved sperm|744.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7060.0|Momme D12|FVB/NJ-MommeD12 Tg(Hba1-Gfp)1Ew||Semi-dominant|eukaryotic translation initiation factor 3, subunit H|Eif3h|||MGI:1915385|eukaryotic translation initiation factor 3, subunit H; modifier of murine metastable epialleles, D12|Eif3h|MGI:5514383|15||||||||||Unknown to Unknown|||||||Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (before E9.5 dpc)|Unknown|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD12<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|27.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 5075.0|Sarah|FVB/N-MommeD9||Semi-dominant|modifier of murine metastable epialleles, D9|MommeD9|Unknown||MGI:3821594|modifier of murine metastable epialleles, D9|MommeD9|MGI:3821600|7||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein (GFP)|human alpha-globin promoter and enhancer region|||||||||||Homozygotes usually die as embryos. Abnormal sex ratios are seen among heterozygotes.Embryonic growth arrest: * semidominant homozygous lethality * developmental arrest before E9.5 * reduced litter size at birth|Abnormal sex determination: there is a paternal affect on sex ratio|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD9<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|25-Mar-2010|Cryopreserved sperm|37.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 6996.0|ENU21:004:b:B6:G3|ANU:ENU21:004:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|27.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6997.0|ENU21:007:a:B6:G3|ANU:ENU21:007:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6998.0|ENU21:007:b:B6:G3|ANU:ENU21:007:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|18.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4720.0|TGFbRIII KO|129S1(B6)-Tgfbr3/Apb|129S1(B6)-Tgfbr3/Apb|Recessive|transforming growth factor, beta receptor III|Tgfbr3|Nil|betaglycan, TBRIII|MGI:104637|targeted mutation 1, Kaye Stenvers|Tgfbr3|MGI:2664514|5||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions in this gene usually die as embryos. The very few individuals that survive are poorly fertile with abnormalities of the spleen, liver, heart, and skeletal system. Embryonic lethal E16.5-E18.5 of heart and liver defects||129S1/Sv|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|60.0|0.0|Unknown||Heart, Liver, embryonic lethal|Yes| 6999.0|ENU21:009:a:B6:G3|ANU:ENU21:009:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4998.0|Wanchi ; ENU8B6:053|C57BL/6JAnu-Cdk4/AnuApb|C57BL/6JAnu-Cdk4/AnuApb|Recessive|cyclin-dependent kinase 4|Cdk4||Crk3, p34/cdk4|MGI:88357|Wanchi|Cdk4|MGI:5009264|10|ENSMUSG00000006728|ENSMUST00000006911|Cdk4-001|910|1152|T to A|ENSMUSE00000796826|8|304|STOP to Arginine|||||ACCTGCACAAGGAGGAAAGCGACGCAGAGTGA|Yes|||||||||||||Diabetic as measured by glucose - diastix test.Diabetes independent of el/TCR transgenes.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|54.0|0.0|Unknown||T cell, glucose, ENU, Wellcome Trust, JDRF|Yes| 7542.0|ENU22::PAN2:B6|C57BL/6NCrlAnu-Pan2/AnuApb|C57BL/6NCrlAnu-Pan2/AnuApb|Recessive|PAN2 polyA specific ribonuclease subunit homolog (S. cerevisiae)|Pan2|Unknown|1200014O24Rik, Usp52|MGI:1918984|PAN2 polyA specific ribonuclease subunit homolog (S. cerevisiae); mutation 1, The Australian National University|Pan2|MGI:5563441|10|ENSMUSG00000005682|ENSMUST00000005825|Pan2-201|1408|1662|C to T|ENSMUSE00000271028|9|470|Glutamine to STOP|||||AGTCAGACCATGAATTTGACAACTTCAGCCAAGTCACGGAGTCACCGACAGGGCGAGAAGA||||||||||||||Embryonic Lethal||C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||G5||No|13-Dec-2013|Cryopreserved sperm|36.0|0.0|Unknown||ENU, embryonic lethal|Yes| 7543.0|ENU28:008:Ndst3|C57BL/6NCrlAnu-Ndst3/AnuApb|C57BL/6NCrlAnu-Ndst3/Apb|Recessive|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3|Ndst3||4921531K01Rik, 4930511P15Rik|MGI:1932544|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3; mutation 1, The Australian National University|Ndst3|MGI:5571271|3|ENSMUSG00000027977|ENSMUST00000154668|Ndst3-001|2351|2620|T to C|ENSMUSE00001216254|12|784|Glutamine to Arginine|||||TACCCCTGCGACAGTGATGGATGAAGTCCAGAAGTTTCTAGGAGTCTCACCTCATTATAAT||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G3||No|13-Dec-2013|Cryopreserved sperm|66.0|0.0|Unknown||ENU|Yes| 6825.0|MT-1/II KO|B6.129-Mt1 Mt2/Apb||Recessive|metallothionein 1|Mt1|Reduced|Mt-1, MT-I|MGI:97171|metallothionein 1; targeted mutation 1, Anna E Michalska|Mt1|MGI:2668454|8|||||||||||||||||||||||||||||Increased circulating alanine transaminase level: in acetaminophen-treated miceAbnormal ion homeostasis: * increased cadmium sensitivity * take up a hunched back posture, ruffed coat and display general lethargyAbnormal lipid homeostasis: acetaminophen-induced lipid peroxidation is increased compared to in similarly treated wild-type mice.Increased sensitivity to xenobiotic induced morbidity/mortality: mice are more sensitive to acetaminophen-induced lethality compared with similarly treated wild-type mice.Increased physiological sensitivity to xenobiotic: * mice exhibit increased susceptibility to acetaminophen-induced hepatotoxicity, alanine aminotransferase, hepatic necrosis, lipid peroxidation, and lethality compared with similarly treated wild-type mice * acetaminophen-induced injuries are not ameliorated by pretreatment with zinc unlike in similarly treated wild-type mice * hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress compared with similarly treated wild-type cells * however, acetaminophen metabolism is normalIncreased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.Abnormal hepatocyte morphology: hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress indicated by lactate dehydrogenase leakage compared with similarly treated wild-type cells.Hepatic necrosis: in acetaminophen-treated micetumorigenesis.Increased tumor incidence: 90% of mice with tumors by 13 weeks (earliest tumors by 9 weeks).Increased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|27-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown||Zinc, cadmium, diet|Yes| 6825.0|MT-1/II KO|B6.129-Mt1 Mt2/Apb||Recessive|metallothionein 2|Mt2|Nil|Mt-2, MT-II|MGI:97172|metallothionein 2; targeted mutation 1, Anna E Michalska|Mt2|MGI:2668455|8||||||||||Unknown to Unknown|||||||||||||||||||Increased circulating alanine transaminase level: in acetaminophen-treated miceAbnormal ion homeostasis: * increased cadmium sensitivity * take up a hunched back posture, ruffed coat and display general lethargyAbnormal lipid homeostasis: acetaminophen-induced lipid peroxidation is increased compared to in similarly treated wild-type mice.Increased sensitivity to xenobiotic induced morbidity/mortality: mice are more sensitive to acetaminophen-induced lethality compared with similarly treated wild-type mice.Increased physiological sensitivity to xenobiotic: * mice exhibit increased susceptibility to acetaminophen-induced hepatotoxicity, alanine aminotransferase, hepatic necrosis, lipid peroxidation, and lethality compared with similarly treated wild-type mice * acetaminophen-induced injuries are not ameliorated by pretreatment with zinc unlike in similarly treated wild-type mice * hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress compared with similarly treated wild-type cells * however, acetaminophen metabolism is normalIncreased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.Abnormal hepatocyte morphology: hepatocytes are more sensitive to acetaminophen and NAPQI-induced oxidative stress indicated by lactate dehydrogenase leakage compared with similarly treated wild-type cells.Hepatic necrosis: in acetaminophen-treated micetumorigenesis.Increased tumor incidence: 90% of mice with tumors by 13 weeks (earliest tumors by 9 weeks).Increased incidence of chemically-induced tumors: increased sensitivity to DMBA/TPA treatment; 100% of treated mice have tumors by 19 weeks, and only 10% of wild-type mice have tumors at 20 weeks, and the average tumor size of treated mice is 2X larger.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|27-Feb-2012|Cryopreserved sperm|||Unknown||Zinc, cadmium, diet|Yes| 7000.0|ENU21:011:a:B6:G3|ANU:ENU21:011:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|29.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7001.0|ENU21:013:b:B6:G3|ANU:ENU21:013:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7002.0|ENU21:015:b:B6:G3|ANU:ENU21:015:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7003.0|ENU21:017:a:B6:G3|ANU:ENU21:017:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|38.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7004.0|ENU21:017:b:B6:G3|ANU:ENU21:017:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|9.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7007.0|ENU21:022:b:B6:G3|ANU:ENU21:022:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7011.0|ENU21:029:a:B6:G3|ANU:ENU21:029:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7005.0|ENU21:020:a:B6:G3|ANU:ENU21:020:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 88.0|Vibes|C57BL/6JSfdAnu-Kcnv1/AnuApb|C57BL/6JSfdAnu-Kcnv1/AnuApb|Recessive|potassium channel, subfamily V, member 1|Kcnv1|Nil||MGI:1914748|vibes|Kcnv1|MGI:3614803|15|ENSMUSG00000022342|ENSMUST00000022967|Kcnv1-201||2612|T to C|ENSMUSE00000258359|3||Unknown to Unknown||||||No|||||||||||||Tetanic ataxia at weaning, shaking. Video available. Please contact APB Curator for the video. It is too large to post here.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|117.0|0.0|Unknown||Ataxia, Shaking, Weakness, ENU|Yes| 3942.0||B6-Tg(Cyp19a1-cre)5912Gle/Apb||Dominant||||||||||||||||||||||||||transgene insertion 5912, Gustavo Leone|cytochrome P450, family 19, subfamily a, polypeptide 1|Limited to Placenta||||||||||||FVB x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|1|9|Backcross to C57BL/6 (CYP19-Cre/+ X +/+)|No|17-Oct-2008|Cryopreserved sperm|69.0|0.0|No||Trophoblast giant cells, placenta, Tpbpa, GFP|Yes| 4917.0|eed3354|B6.C-Eed<17Rn5-3354SB>/WehiApb||Recessive|embryonic ectoderm development|Eed|Unknown|l(7)5Rn, l7Rn5|MGI:95286|lethal, Chr 7, Rinchik 5, 3354SB|Eed<17Rn5-3354SB>|MGI:1856856|7|||||||||||||||||||||||||||||Gastrulation defects.The amnion and chorion are formed.The head process and notochord are absent and somites fail to organise.Unlike eed deletion mutants, Eed<3354SB> embryos develop characteristic folds in the anterior embryonic ectoderm.|||No|No|Yes|No|No|Yes|No|Unknown||||No|16-Oct-2009|Cryopreserved sperm|100.0|0.0|Unknown||embryonic, anterior, axial, gastrulation|Yes| 7009.0|ENU21:026:b:B6:G3|ANU:ENU21:026:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5356.0|NOD.303|NOD-Tg(HLA DR3-DQ2)303/Apb||Dominant||||||||||||||||||||||||||human leukocyte antigen class II||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.Evaluation of HLA DR3-DQ2 haplotype-transgenic mice indicates regulated HLA gene expression, T cell selection and functional antigen presentation mediated by the DR and DQ genes encoded within the YAC transgene.Histological examination of tissues in transgenic mice including pancreatic B-islets did not reveal any evidence of spontaneous pathology.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|22|7||No|20-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity|Yes| 4511.0|fluoro ; ENU8B6:058|C57BL/10JAnu-Prdx1/AnuApb||Recessive|peroxiredoxin 1|Prdx1|Unknown|macrophage 23kDa stress protein, macrophase stress protein 22kDa, MSP23, OSF-3, osteoblast specific factor 3, PAG, Paga, Prx I, PrxI, Tdpx2, TDX2, thioredoxin dependent peroxide reductase 2, Trx dependent peroxide reductase 2|MGI:99523|fluoro|Prdx1|MGI:4819263|4|ENSMUSG00000005161|ENSMUST00000005292|Prdx2-001|236|301|C to G|ENSMUSE00000499125|3|79|Serine to Cysteine|||||CTGCGAGGTGCTGGGAGTGTCTGTGGACTCTCAGTTCACCCACCTGGCGTGGATCAATACC|Yes|||||||||||||Autofluorescence, multiple wavelengths, in flow cytometry of all lymphocyte subsets and erythrocytes.||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|107.0|0.0|Unknown||lymphocyte, erythrocyte, red blood cell, ENU, Wellcome Trust|Yes| 7008.0|ENU21:024:b:B6:G3|ANU:ENU21:024:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7010.0|ENU21:027:a:B6:G3|ANU:ENU21:027:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7013.0|ENU21:032:b:B6:G3|ANU:ENU21:032:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6829.0|APN 142|C57Bl/6NTac-Gpr18/Marp||Recessive|G protein-coupled receptor 18|Gpr18|Unknown||MGI:107859 |G protein-coupled receptor 18; targeted mutation 1, Velocigene|Gpr18 |MGI:3812675|14|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7012.0|ENU21:031:a:B6:G3|ANU:ENU21:031:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 2435.0|Louise2 ; TLK-2|C57BL/6JSfdAnu-Tg(TLK2mHEL)2Ccg/AnuApb|C57BL/6JSfdAnu-Tg(TLK2mHEL)2Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher C Goodnow|rat thyroglobulin|expression limited to thyroid||||||||||Express low levels of membrane bound HEL in thyroid. Low serum levels of HEL detected.||C57BL/6JStdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5|sib x sib|No|13-Jan-2008|Cryopreserved sperm|130.0|0.0|Unknown||autoimmunity, B cell, tolerance, Hen egg lysozyme (HEL), T cell|Yes| 7288.0|ENU12B6:020:G3|ANU:ENU12B6:020:G3||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6JSfdAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|14-Mar-2013|Cryopreserved sperm|27.0|0.0|Unknown|||Possibly| 5329.0||129T2/SvK-Ryk/Apb||Recessive|Receptor-like tyrosine kinase|Ryk|Nil|ERK-3, Vik|MGI:101766|receptor-like tyrosine kinase; targeted mutation 1, Steven A Stacker|Ryk|MGI:2667542|9||||||||||||||||Yes|||||||||||||Homozygotes die on the day of birth. Approx. 90% of E18.5 embryos have heart defects, the probable cause of neonatal death. They also have a cleft palate, craniofacial defects, shortened limbs and body axis, inner ear defects and abnormal corpus callosum (brain).Abnormal gait: mice surviving to adulthood dragged their hindlimbs.Short mandible.Abnormal maxilla morphology: in conjunction with shortened nasal bone, resulting in flattened midface.Abnormal neurocranium morphology: slightly smaller and rounder than that of wild-type or heterozygous mutant mice.Short nasal bone: shortened nasal bone, resulting in flattened midface.Cleft secondary palate: * cleft secondary palate observed in 88% of mice * consequence of abnormally high positioning and enlargement of the tongue.Increased tongue size: enlargement observed around E14, resulting in the disruption of the development of the palatal shelf.Short snout.Microcephaly: exhibited by mice that survived to adulthood.Cachexia.Postnatal growth retardation: growth was severely impaired in mice surviving past the first day of life.Cyanosis: mice were largely unable to suckle, became dehydrated, cyanotic, and exhibited gasping respirations.Short ulna: reduced in length.Abnormal hindlimb morphology: hindlimbs were splayed laterally.Short fibula.Short limbs: 18% to 25% reduction in the length of the long bones.Microphthalmia: bilateral microphthalmia was observed in mice that survived to adulthood.||129T2/Sv/K|No|No|Yes|No|No|Yes|No|Unknown||||No|19-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||craniofacial, Eph receptor, TGF, receptor protein tyrosine kinases (RTKs), Wnt signalling, axon guidance|Yes| 7546.0|APN 354|C57BL/6N-A Wars/MarpApb||Recessive|tryptophanyl-tRNA synthetase 1|Wars1 |||MGI:104630 |tryptophanyl-tRNA synthetase1; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH12|Wars1|MGI:4435065|12||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Dec-2013|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9189.0||B6.129S7-FoxP3(KO)-Rag1/Apb||Dominant|FoxP3ko||||||||Unknown|||||||||||||||||||||||||||||normal|normal|rag1|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-May-2021||0.0|76.0|Unknown|||Possibly| 9189.0||B6.129S7-FoxP3(KO)-Rag1/Apb||Dominant|Rag1(tm1Mom)||||||||Unknown|||||||||||||||||||||||||||||normal|normal|rag1|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-May-2021||||Unknown|||Possibly| 7014.0|ENU21:034:a:B6:G3|ANU:ENU21:034:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 219.0||C57BL/6-Gt(ROSA)26Sor/WehiAnuApb||Dominant||||||||||||||||||||||||||gene trap ROSA 26, Philippe Soriano|unknown endogenous|||||||||||Viable and fertile. Mice carrying this mutation are considered to be reporter strains, with successful Cre excision indicated by beta-gal expression in Cre-expressing tissues. There is no phenotype and mice appear normal.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Apr-2006|Cryopreserved sperm|43.0|0.0|Unknown||Lac Z, genetrap, beta-galactosidase, reporter|Yes| 5408.0|Gp130Y757f / Stat3+/- / Stat1-/-|STOCK Il6st Stat3 Stat1/LudApb||Recessive|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Unknown|Unknown|C57BL/6 x 129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, kinase, acute peritoneal inflammation, neutrophil|Yes| 5408.0|Gp130Y757f / Stat3+/- / Stat1-/-|STOCK Il6st Stat3 Stat1/LudApb||Recessive|signal transducer and activator of transcription 3|Stat3|Unknown|Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11||||||||||||||||Yes|||||||||||||Unknown|Unknown|C57BL/6 x 129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Feb-2011|Cryopreserved sperm|||Unknown||signal transduction, kinase, acute peritoneal inflammation, neutrophil|Yes| 5408.0|Gp130Y757f / Stat3+/- / Stat1-/-|STOCK Il6st Stat3 Stat1/LudApb||Recessive|signal transducer and activator of transcription 1|Stat1|||MGI:103063|signal transducer and activator of transcription 1; targeted mutation 1, Robert D Schreiber|Stat1|MGI:1861949|1||||||||||||||||No|||||||||||||Unknown|Unknown|C57BL/6 x 129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Feb-2011|Cryopreserved sperm|||Unknown||signal transduction, kinase, acute peritoneal inflammation, neutrophil|Yes| 8479.0|ENU22::ANAPC1|C57BL/6NCrlAnu-Ighm/AnuApb||Recessive|immunoglobulin heavy constant mu|Ighm|Unknown|BCR, Igh6, Igh-M, IgM, Ig mu, muH, muMT|MGI:96448|Ighm; endonuclease-mediated mutation 1, Australian National University|Ighm||12||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-May-2018|Cryopreserved sperm|66.0|0.0|Unknown||immunoglobulin|Yes| 8480.0|KRN TCR transgenic/B10.Br|B10.BR-Tg(TcraR28,TcrbR28)KRNDim/Apb||Dominant||||||||||||||||||||||||||transgene insertion KRN, Diane Mathis||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-May-2018|Cryopreserved sperm|40.0|0.0|Unknown||TCR, Rheumatoid arthritis|Yes| 8584.0|ASD538:Mrd:MrTless|B6(Cg)-Zap70 Zap70/AnuApb|B6(Cg)-Zap70 Zap70/AnuApb|Recessive|Zap70, zeta-chain (TCR) associated protein kinase|Zap70|Reduced|Zap-70, Srk, TZK|MGI:99613|Mr T-Less|Zap70|MGI:3614790|1|ENSMUSG00000026117|ENSMUST00000027291|Zap70-201|1510|1601|T to C|ENSMUSE00000230099|11|504|Tryptophan to Arginine|||||CCCGGTCTGCAGGGAAGTGGCCTCTGAAGTGGTACGCGCCAGAGTGCATCAACTTTCGGAA|No|||||||||||||Identified by severe reduction in T cell numbers in blood.B cells are normalBoth CD4⁺ and CD8⁺ T cell populations were almost completely absent in peripheral blood. Therefore, no αβ T cells but have increase in γδ T cellsNormal numbers of DN and DP T cells. Implies that have block at DP stage and mice unable to perform positive thymocyte selection.Intrinsic to T cells not microenvirnment.Cells unable to pass thymic selection steps.Cells unable to up-regulate TCRReduced signalling through TCR.Zap70 protein expression of mrt/mrt thymocytes was 25% of wildtype thymocytes.Kinase domain affected by mutation, kinase assays not performedHeterozygous mice, mrt/+ have normal levels of CD4⁺ and CD8⁺ thymocytes but Zap70 protein expression is 2 fold lower.Unlike cells devoid of ZAP-70, mrtless thymocytes showed partial induction of CD5 and CD69, and were sensitive to TCR stimulation with a dose-response shifted approximately 10-fold. However, essentially no T cells were able to compensate for the mrtless mutation and mature beyond the CD4⁺ CD8⁺ stage.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Oct-2018|Cryopreserved sperm|69.0|0.0|Unknown||T cell, zap70, B cell, TCR, lymphocyte , ENU|Yes| 8584.0|ASD538:Mrd:MrTless|B6(Cg)-Zap70 Zap70/AnuApb|B6(Cg)-Zap70 Zap70/AnuApb|Recessive|Zap70, zeta-chain (TCR) associated protein kinase|Zap70|Unknown|Zap-70, Srk, TZK|MGI:99613|Murdoch|Zap70|MGI:3614796|1|ENSMUSG00000026117|ENSMUST00000027291|Zap70-201|1099|1190|A to T|ENSMUSE00000448670|9|366|Isoleucine to Phenylalanine|||||GCATGCGCAAGAAGCAGATTGACGTGGCCATCAAGGTGCTGAAGCAGGGCACAGAGAAGGC||||||||||||||Identified by severe reduction in T cell numbers in blood.B cells are normalBoth CD4⁺ and CD8⁺ T cell populations were almost completely absent in peripheral blood. Therefore, no αβ T cells but have increase in γδ T cellsNormal numbers of DN and DP T cells. Implies that have block at DP stage and mice unable to perform positive thymocyte selection.Intrinsic to T cells not microenvirnment.Cells unable to pass thymic selection steps.Cells unable to up-regulate TCRReduced signalling through TCR.Zap70 protein expression of mrt/mrt thymocytes was 25% of wildtype thymocytes.Kinase domain affected by mutation, kinase assays not performedHeterozygous mice, mrt/+ have normal levels of CD4⁺ and CD8⁺ thymocytes but Zap70 protein expression is 2 fold lower.Unlike cells devoid of ZAP-70, mrtless thymocytes showed partial induction of CD5 and CD69, and were sensitive to TCR stimulation with a dose-response shifted approximately 10-fold. However, essentially no T cells were able to compensate for the mrtless mutation and mature beyond the CD4⁺ CD8⁺ stage.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Oct-2018|Cryopreserved sperm|||Unknown||T cell, zap70, B cell, TCR, lymphocyte , ENU|Yes| 7378.0|Yellow|SJL-ASAM||Dominant|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Yellow coat colour on a white coat colour background without other associated abnormalities.|Yellow coat colour on a white coat colour background without other associated abnormalities.|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Jul-2013|Cryopreserved sperm|47.0|0.0|Unknown||Dermatology, Coat colour, yellow, ENU|Yes| 4925.0||B6;129-Gfpt2/Apb||Recessive|glutamine fructose-6-phosphate transaminase 2|Gfpt2|Unknown|GFAT2|MGI:1338883|glutamine fructose-6-phosphate transaminase 2; gene trap 352F9, Centre for Modeling Human Disease|Gfpt2|MGI:4965721|11||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Nov-2009|Cryopreserved sperm|99.0|0.0|Unknown||glucosamine, hexosamine|Yes| 4841.0|ENU12NIH:030a|C57BL/6JAnu-Kcnq1/AnuApb|C57BL/6JAnu-Kcnq1/AnuApb|Recessive|potassium voltage-gated channel, subfamily Q, member 1|Kcnq1|Unknown||MGI:108083|mutation 1, The Australian National University|Kcnq1|MGI:5490247|7|ENSMUSG00000009545|ENSMUST00000009689|Kcnq1-201|1303|1408|A to T|ENSMUSE00000426955|10|435|Lysine to STOP|||||ATAAGGATAATGGGATGAGTCCTGGAGAGAAGATGTTCAATGTTCCTCACATCACTTATGA|Yes|||||||||||||Continuous tremors and circling in both directions.Abnormal motor capabilities/coordination/movement:• under high stress, mice occasionally fall and circle around the cage in very fast movements unlike wild-type miceOpisthotonus: • some miceTremors: • constantlyJerky movement: • under mild stressHead tossing: • oftenCircling: • under high stress|None|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||7||No|24-Sep-2009|Cryopreserved sperm|34.0|0.0|Unknown||tremors, circling, ENU|Yes| 1819.0|Col 2a1-cre transgenic|C57BL/6-Tg(Col2a1-cre)1Asz||Dominant||||||||||||||||||||||||||transgene insertion 1, Attila Aszodi|Cartilage specific Col2a1 gene promoter|||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10+|||No|06-Aug-2007|Cryopreserved sperm|30.0|0.0|Unknown||Collagen, Cartilage, Cre recombinase|Yes| 3402.0|Tssc6 genetrap|B6.129-Tspan32/Wehi||Recessive|tetraspanin 32|Tspan32|Nil|Art-1, D7Wsu37e, Phemx, Tspan32, Tssc6|MGI:1350360|gene trap 1, Jacqueline M Tarrant|Tspan32|MGI:2183564|7||||||||||||||||Yes|||||||||||||Increased T cell proliferation: in vitro proliferative responses of T cells were increased upon concanavalin A, anti-CD3 antibody or anti-CD28 antibody stimulation.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jul-2008||0.0|0.0|Unknown||T cell, IL2, IL-2, proliferation, receptor|Yes| 7016.0|ENU21:035:b:B6:G3|ANU:ENU21:035:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8489.0|NOD.Nkrp1b.Art2b|NOD-Klrb1b Art2b/BaxApb||Recessive|ADP-ribosyltransferase 2b|Art2b||ART2.2, Rt6, Rt-6, Rt6-2|MGI:107545|ADP-ribosyltransferase 2b; targeted mutation 1, Friedrich Koch-Nolte|Art2b|MGI:2388827|7||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell|Yes| 1836.0||B6.CBA-Tg(CAG-cre/Esr1)5Amc||Recessive||||||||||||||||||||||||||transgene insertion 5, Andrew P McMahon|chicken beta actin promoter/enhancer coupled with the cytomegalovirus (CMV) immediate-early enhancer|tamoxifen inducible||||||||||Embryonic lethal|Normal|C57BL/6 x CBA|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Aug-2007||0.0|0.0|Unknown||inducible, tamoxifen, estrogen receptor, temporal, Cre recombinase|Yes| 2329.0|Shewag|C57BL/6-Gzma Gzmb Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan|H-2Kb promoter|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2007|Cryopreserved sperm|106.0|0.0|No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 2329.0|Shewag|C57BL/6-Gzma Gzmb Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme B|Gzmb|Unknown|CCP-1/C11, CCP1, Ctla-1, Ctla1|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2007|Cryopreserved sperm|||No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 2329.0|Shewag|C57BL/6-Gzma Gzmb Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfp, Prf-1|MGI:97551|targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2007|Cryopreserved sperm|||No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 3598.0|B6.129-Tg(FoxP3-GFP)|B6.129-Foxp3/AnuApb||Dominant|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|targeted mutation 2, Alexander Y Rudensky|Foxp3|MGI:3574964|X||||||||||||||||No|||||||||||||Normal. Cells expressing FoxP3 fluoresce green, predominantly T cells||129 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Aug-2008|Cryopreserved sperm|176.0|0.0|Unknown||T cell, IL-2, GFP, transcription factor|Yes| 8484.0|IL-4 -/-|B6(Cg).129-Il4/AnuApb||Recessive|interleukin 4|Il4|Unknown|Il-4|MGI:96556|interleukin 4; targeted mutation 1, Manfred Kopf|Il4|MGI:2176268|11|||||||||||||||||||||||||||||Decreased IgE level: unlike in wild-type mice, IgE levels are undetectable prior to and following immunization.Decreased IgG1 level:* IgG1 levels are reduced 20-fold compared to in wild-type mice and following immunization IgG1 levels are 12-fold lower than in immunized wild-type mice.* following immunization with DNP-ovalbumin, IgG1 antibodies are 10-fold lower than in wild-type mice.Increased IgG level:* following infection with N. brasiliensis, IgG2 and IgG3 levels are slightly higher than in wild-type mice.* following immunization with DNP-ovalbumin, IgG2 and IgG3 levels are 100- to 500-fold higher than in wild-type mice.Decreased interleukin-10 secretion: stimulated CD4+ T cells in vitro fail to produce IL-10.Decreased interleukin-3 secretion: in stimulated CD4+ T cells, the production of IL-3 is reduced more than 70% of wild-type value.Decreased interleukin-4 secretion: stimulated CD4+ T cells in vitro fail to produce IL-4.Decreased interleukin-5 secretion: stimulated CD4+ T cells in vitro fail to produce IL-5.Abnormal response to infection: * following infection with N. brasiliensis, CD4+ T cells produce reduced levels of Th2 cytokines, increased levels of interferon-gamma, and reduced blood eosinophilia levels compared to infected wild-type mice.* however, CD8+ T cells do produce IL-5 following infection with N. brasiliensis.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5|||No|18-May-2018|Cryopreserved sperm|48.0|0.0|Unknown||T cell, infection, asthma, hyperresponsiveness, eosinophil, IFN, IL2|Yes| 5355.0|B6.303|C57BL/6-Tg(HLA DR3-DQ2)303/Apb||Dominant||||||||||||||||||||||||||human leukocyte antigen class II||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.Evaluation of HLA DR3-DQ2 haplotype-transgenic mice indicates regulated HLA gene expression, T cell selection and functional antigen presentation mediated by the DR and DQ genes encoded within the YAC transgene.Histological examination of tissues in transgenic mice including pancreatic B-islets did not reveal any evidence of spontaneous pathology.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|1|4||No|20-Dec-2010|Cryopreserved sperm|40.0|0.0|Unknown||MHC, B cell, selection, autoimmunity|Yes| 7745.0|ENU23:017:Pyhin1:G6:G3|C57BL/6NCrlAnu-Pyhin1/AnuApb||Recessive|pyrin and HIN domain family, member 1|Pyhin1|Unknown|Ifi209, Ifix|MGI:2138243|Pyhin1; mutation 1, the Australian National University|Pyhin1||1||||||||||Unknown to Unknown|||||||||||||||||||Embryonic Lethal|Unknown|C57BL/6NCrlAnu x 129|No|No|Yes|No|No|Yes|No|Good||||No|23-Sep-2014|Cryopreserved sperm|11.0|0.0|Unknown||ENU|Possibly| 8485.0|Gpr37l1 KO B6|B6(Cg).129S1-Gpr37l1/Apb||Recessive|G protein-coupled receptor 37-like 1|Gpr37l1||CAG-18, D0Kist8|MGI:1928503||||1|||||||||||||||||||||||||||||Reported elevated blood pressure|unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|23-May-2018|Cryopreserved sperm|39.0|0.0|Unknown|||Yes| 5258.0|DMP1.gp130fl/fl|C57BL/6-Il6st Tg(Dmp1-cre)1Jqfe||Recessive|interleukin 6 signal transducer|Il6st|Normal|CD130, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Werner Mueller|Il6st|MGI:1931239|13||||||||||||||||Yes|transgene insertion 1, Jian Q Feng|dentin matrix protein 1 (Dmp1)|Cre expression restricted to dontoblasts and osteocytes||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Oct-2010|Cryopreserved sperm|20.0|0.0|Unknown||osteocytes, signal transduction, dentin, Odontoblasts|Possibly| 7017.0|ENU21:036:a:B6:G3|ANU:ENU21:036:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|38.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 2762.0|BALB/c.Flii 1.4A|BALB/c-Flii/2AnuApb|BALB/c-Flii/2AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop. embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type|BALB/c|No|No|Yes|No|No|Yes|No|Poor|10|11|Het male x WT female|No|14-Feb-2008|Cryopreserved sperm|150.0|0.0|Unknown||gelsolin, embryonic lethal, wound repair, gastrulation, cell migration|Yes| 5438.0|Rap1b KO|B6.129-Rap1b/Apb||Semi-dominant|RAS related protein 1b|Rap1b|||MGI:894315||||10|||||||||||||||||||||||||||||Perinatal lethality: about 55% of homozygous embryos die perinatally.Embryonic lethality during organogenesis: * in heterozygous crosses only 4.4% of pups at weaning are homozygous. * 40% of homozygous embryos begin to die around E13.5.Hemorrhage: 40% of homozygous embryos had abdominal, cranial, and hepatic bleeding.Decreased body size: surviving homozygotes are smaller than their littermates.Decreased platelet aggregation: platelet aggregation in response to collagen, convulxin (snake venom), an F2RL3 activating peptide, or a calcium ionophore (A23187) is reducedhowever, similar to wild-type, P2RY1 and P2RY12 antagonists can block aggregation.Decreased litter size: crosses between surviving homozygotes produce 45% smaller litters at weaning; however more homozygous pups survive compared to heterozygous crosses.Increased bleeding time.Thrombosis: homozygotes begin to form thrombi in a platelet-dependent carotid artery thrombosis model however vessel occlusion is not seen.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|7|||No|16-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||platelet, aggregation, thrombosis|Yes| 7548.0|APN 388|C57BL/6N-A Gprc6a/MarpApb||Recessive| G protein-coupled receptor, family C, group 6, member A|Gprc6a |||MGI:2429498 |G protein-coupled receptor, family C, group 6, member A; targeted mutation 1a, Wellcome Trust Sanger Institute|Gprc6atm1a(EUCOMM)Wtsi|MGI:4461735|10|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Dec-2013|Cryopreserved sperm|46.0|0.0|Unknown|||Possibly| 6837.0|Gpc1 knockout|B6;CD-1-Gpc1/Apb||Dominant|glypican 1|Gpc1|Nil||MGI:1194891|glypican 1; targeted mutation 1.1, Arthur Lander|Gpc1|MGI:3774029|1|||||||||||||||||||||||||||||Lifespan, fertility and health are normal. Occasional malocclusions. Brain may be slightly smaller than normal.|Unknown|C57BL/6 x CD-1|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown||growth plate, angiogenesis, heparan sulfate proteoglycans, fibroblast growth factor (FGF) signaling, glypican family|Possibly| 7018.0|ENU21:037:b:B6:G3|ANU:ENU21:037:b:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5263.0|RARgamma|C57BL/6-Rarg/StvApb||Recessive|retinoic acid receptor, gamma|Rarg|Nil|MGC:11555, MGC:18523, RAR gamma 2, RARgamma2|MGI:97858|retinoic acid receptor, gamma; targeted mutation 1, Pierre Chambon|Rarg|MGI:1931079|15||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit stunted growth, homeotic transformations of the rostral axial skeleton and tracheal cartilage, Harderian gland agenesis, high postnatal mortality, and male sterility.||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|21-Oct-2010|Cryopreserved sperm|63.0|0.0|Unknown||bone marrow, progenitor, Myeloproliferative syndromes, Harderian gland agenesis, skeleton|Yes| 8488.0|NOD.Nkrp1b|NOD-Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8494.0|NOD.BDC2.5|NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/BaxApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Christophe Benoist||||||||||||These transgenic mice carry both rearranged TCR alpha and beta genes from the cytotoxic CD4+ T cell clone BDC-2.5. On the NOD background, mice carrying the transgenes have a reduced incidence of diabetes relative to NOD/ShiLtJ controls (12% incidence at age 30 weeks).||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown||Insulitis|Yes| 10337.0|K5-creERt :R26-YAP5SA|C57Bl/6-K5(creERt)-R26(YAP5SA)Anu/Apb||Semi-dominant|yes-associated protein 1|Yap|||MGI:103262||||9|||||||||||||||||K5 |K5 Cre |||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-May-2023|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 5379.0|TS1|C.Cg-Tg(Tcra/Tcrb)1Vbo||Dominant||||||||||||||||||||||||||transgene insertion 1, Harald von Boehmer||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Hom x Hom|Yes|06-Jan-2011|Cryopreserved sperm|90.0|0.0|No||TCR transgenic, CD4, influenza|Possibly| 6840.0|Captain Morgan, ENU4AT:038 |C57BL/6JAnu-Dock8/TacAnuApb|C57BL/6JAnu-Dock8/TacAnuApb|Recessive|dedicator of cytokinesis 8|Dock8|Nil||MGI:1921396|dedicator of cytokinesis 8; captain morgan|Dock8|MGI:3835422|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201||||||||25202202|20|||GCAGCCCATGGTCATTGCTGGCCAAACAGGTAGAGGCCTGTGGGTAGGGAGGAGGCATGG|Yes|||||||||||||Defective antibody response to immunization: failure to sustain antibody formation, undergo affinity maturation or to mount heightened recall (memory) response upon booster immunization. DOCK8-mutant B cells were unable to form marginal zone B cells or to persist in germinal centers and undergo affinity maturation. Dock8 mutations disrupted accumulation of the integrin ligand ICAM-1 in the B cell immunological synapse but did not alter other aspects of B cell antigen receptor signaling.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|3||No|08-Mar-2012|Cryopreserved sperm|92.0|0.0|Unknown||gammaglobulin, immunization, antibody, ENU, Wellcome Trust, memory, B cell, GTP|Yes| 7740.0|SB12|STOCK Gt(ROSA)26Sor TgTn(sb-T2/Onc3)12775Njen/Nci||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Nancy A Jenkins|Gt(ROSA)26Sor|MGI:3839796|6|||||||||||||||||transgenic transposon concatemer 12775, Nancy A Jenkins|CAG promoter |||||||||||Normal|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Poor||||No|15-Sep-2014|Cryopreserved sperm|60.0|0.0|Unknown|||Yes| 6839.0|APN 222|C57Bl/6N-mir-196a-1/MarpApb||Recessive|microRNA 196a-1|Mir196a-1|Unknown|Mirn196, Mirn196a-1, mmu-mir-196a-1|MGI:2676860||||11|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|08-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8492.0|BALB.cCrslc|BALB/cCrSlcBax||Dominant||||||||||||||||||||||||||||||||||||||Subline of BALB/c||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 10333.0|B10.BR CI/PB|B10.BR CI/PB||Recessive|NA|||||NA|||Unknown||||||||||||||||||||||||||||| B10.BR mouse line originally imported from ARC (Perth) in 1998. It has been used to backcross all Tg mouse lines under the B10.BR background at Centenary Institute (P. Bertolino group). Mice have a normal phenotype.|Normal|B10.BR|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-May-2023|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 8493.0|BALB.Gasa1|BALB/c-Gasa1/BaxApb||Recessive|||||||||||||||||||||||||||||gastritis type A susceptibility locus 1|Gasa1|||MGI:1346075|gastritis type A susceptibility locus 1; C57BL/6|Gasa1|MGI:2155785|4|This allele confers resistance to autoimmune gastritis compared to BALB/cCrSlc. ||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|49.0|0.0|Unknown||Gastritis|Yes| 5365.0|NOD.hCD4.IAE.427-3 ; triple 427|NOD-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5365.0|NOD.hCD4.IAE.427-3 ; triple 427|NOD-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 7097.0|DMP-cre|C57BL/6-Tg(Dmp1-cre)1Jqfe/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Jian Q Feng|dentin matrix protein 1 (Dmp1)|Cre expression restricted to dontoblasts and osteocytes||||||||||Normal.Cre expression in odontoblasts and osteocytes|Normal.Cre expression in odontoblasts and osteocytes|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown||Cre recombinase|Possibly| 8487.0|C57BL/6.Myd88-/-|B6.129P2-Myd88/BaxApb||Recessive|myeloid differentiation primary response gene 88|Myd88|Nil||MGI:108005|myeloid differentiation primary response gene 88; targeted mutation 1, Shizuo Akira|Myd88|MGI:2385681|9|||||||||||||||||||||||||||||Increased apoptosis:*5 days after lung injury, mutants show significantly increased numbers of apoptotic lung epithelial and inflammatory cells.Increased physiological sensitivity to xenobiotic:*Knockout mice are more susceptible to bleomycin-induced lung injury.Increased dendritic cell number:*Increased numbers of dendritic cells in brains of mice infected with Plasmodium.Abnormal dendritic cell differentiation:*Dendritic cell maturation fails to occur in vivo upon exposure to TLR9 agonists.Abnormal immune system physiology:*Response to LPS and CpG is completely abrogated. Abnormal dendritic cell physiology: *Cytokine secretion elicited by zymosan or LPS is impaired. *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40, IL-6 and interferon-gamma relative to wild-type mice. Abnormal macrophage physiology: *TNF production is impaired in thioglycollate-elicited macrophages treated with intact zymosan. *Cytokine production by macrophages cultured with P. carinii cysts is reduced compared to wild-type. Abnormal NK cell physiology: *NK cells fail to make IFN-gamma in response to injections of TLR9 agonists. Abnormal T cell physiology: *Induction of the antigen-specific CD8+ T-cell response by immunizing with soluble ovalbumin and TLR9 agonists, but not TLR2 and TLR6 agonists, was severely impaired. Abnormal cytokine secretion: *LPS-induced cytokine production by BMDCs is almost abolished compared to controls and Myd88-sufficient mutants. Abnormal chemokine secretion: *Hyaluronan fragment-induced expression of chemokines by peritoneal macrophages is completely abolished in double knockout mice. Decreased interferon-alpha secretion: *CpG-A or RNA polyuridylic acid induced production of interferon-alpha was abolished in plasmacytoid dendritic cells. Decreased interferon-gamma secretion: *Less up regulation of INF-gamma in Plasmodium infection. *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less interferon-gamma. Decreased interleukin-12 secretion: *After stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals. Decreased interleukin-12b secretion: *Less upregulation of IL-12b in Plasmodium infection. *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice. Decreased interleukin-6 secretion: *Following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, IL-6 secretion is reduced. *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-6 relative to wild-type mice. Decreased tumor necrosis factor secretion: *Less upregulation of TNF-alpha in Plasmodium infection. *Following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced. *After stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals. Decreased inflammatory response: *In a model of induced pneumococcal meningitis-associated labyrinthitis, homozygotes exhibit a significantly lower granulocytic infiltration of the labyrinth and increased bacterial density in the cochlea at 24 hrs post-infection relative to wild-type control mice. Abnormal response to infection: *Following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a decreased immune response in terms of TNF and IL-6 secretion and response to CpG. Decreased susceptibility to parasitic infection: *Resistant to cerebral malaria but eventually die of extremely high parasitemia. Increased susceptibility to viral infection: *Increased susceptibility to encephalomyocarditis virus (EMCV) infection compared to wildtype.Abnormal susceptibility to hearing loss:*In a model of induced pneumococcal meningitis-associated labyrinthitis, homozygotes exhibit significantly less hearing impairment at 24 hrs post-infection in response to click, 1- or 10-kHz stimuli relative to wild-type control mice.Abnormal neuron differentiation:*Improved differentiation of progenitor cells into neurons.*Survival of newly formed neurons is reduced.Abnormal nervous system physiology:*After cold induced cortical injury, recruitment of neutrophiles to lesion site is reduced by 85% in comparison to controls.*Cold induced cortical lesion volume is reduced by 25% compared to controls.*Fewer cortical cells have damaged DNA compared to controls after cold induced cortical injury.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|49.0|0.0|Unknown||MyD88, IL-1, IL-18, NF-kappaB, c-Jun N-terminal kinase (JNK)|Yes| 1543.0|C57BL/6.gZA-/- OT-1 ; Pathans|C57BL/6-Gzma Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan ||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|50.0|0.0|Unknown||T cell, Natural Killer cell, cytotoxicity, receptor, ovalbumin|Yes| 10342.0|Tcf3 A513X (46)|C57BL/6NCrlAnu-Tcf3Anu/46Anu||Dominant|transcription factor 3|Tcf3|||MGI:98510|Tcf3; endonuclease mutation 4, Australian National University|Tcf3||10||||||||||Unknown to Unknown|||||||||||||||||||Most likely embryonic lethal (so far not enough offspring tested to be certain)|Mild reduction of B cells.|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Jun-2023|Cryopreserved sperm|43.0|0.0|Unknown|||Possibly| 8496.0|NOD.Il10-/-|NOD.Cg-Il10/BaxApb||Recessive|interleukin 10|Il10||cytokine synthesis inhibitory factor, IL-10|MGI:96537|interleukin 10; targeted mutation 1, University of Cologne|Il10|MGI:1857199|1|||||||||||||||||||||||||||||This mutant develops type 1 diabetes at the same rate as the NOD/Lt parental strain. The Il10 tm1Cgn mutation also renders this NOD/Lt stock susceptible to colitis (although not as severe as other strains of Il10 deficient mice) when maintained under standard housing conditions.Large intestinal inflammation: • mutants develop severe inflammation in the colon leading to inflammatory bowel disease Abnormal regulatory T cell physiology: • CD25-positive CD4 T cells from these mice fail to protect against the wasting disease induced by transferring nave CD4 T cells into immunodeficient hosts|Unknown|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown||il10, colitis, T cell|Possibly| 7741.0|ENU23:B6:016:TACO1|C57BL/6NCrlAnu-Taco1/AnuApb||Recessive|translational activator of mitochondrially encoded cytochrome c oxidase I|Taco1 |Unknown| 2310066I18Rik, Ccdc44 |MGI:1917457 |Taco1; mutation 1, the Australian National University|Taco1||11|ENSMUSG00000001983|ENSMUST00000002048|Taco1-001|491|678|T to A|ENSMUSE00000108220|3|164|Isoleucine to Asparagine|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7|Het x Het|No|22-Sep-2014|Cryopreserved sperm|20.0|0.0|Yes|Leigh syndrome with cardiomyopathy|Mitochondrion, Translation, Molecular|Yes| 7098.0|APN193|Neo1/Marp||Recessive|neogenin|Neo1 |Unknown|2610028H22Rik, D930014N22Rik, Igdcc2 |MGI:1097159 |neogenin; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Neo1tm1a(EUCOMM)Hmgu|MGI:4435562|9|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|01-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 10332.0||C57Bl/6-Osx(Cre> p53 pRb R26-Adar1p150/AnuApb||Dominant|Osx-Cre p53fl/fl pRbfl/fl R26-Adar1p150|||||Osx-Cre p53fl/fl pRbfl/fl R26-Adar1p150|||Unknown|||||||||||||||||Osx-Cre|Sp7|||||||||||Homozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|Heterozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-May-2023|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 7742.0|ENU19:B6:MRPS34|C57BL/6JAnu-Mrps34/AnuApb||Recessive|mitochondrial ribosomal protein S34|Mrps34|Unknown|0610007F04Rik, 5330430D13Rik, Tce2 |MGI:1930188 |Mrps34; mutation 1, the Australian National University|Mrps34||17|ENSMUSG00000038880|ENSMUST00000043907|Mrps34-001|203|252|T to C|ENSMUSE00000747863|1|68|Leucine to Proline|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5|mut x mut|No|23-Sep-2014|Cryopreserved sperm|22.0|0.0|Unknown||mitochondrion, ribonucleoprotein complex, Molecular function|Yes| 251.0||129-Ccr1/Apb|129-Ccr1/Apb|Recessive|chemokine (C-C motif) receptor 1|Ccr1|Nil|Cmkbr1, MIP-1 alphaR, Mip-1a-R|MGI:104618|targeted mutation 1, Craig Gerard|Ccr1|MGI:1931849|9||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit altered trafficking and proliferation of myeloid progenitor cells, and impairments in granulomatous inflammation of the lung and neutrophil associated host defense.||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Apr-2006|Cryopreserved sperm|50.0|0.0|Unknown||chemokine, RANTES, neutrophil, inflammation|Yes| 7743.0|ENU23:005:MRPL44|C57BL/6NCrlAnu-Mrpl44/AnuApb||Recessive|mitochondrial ribosomal protein L44|Mrpl44 |Unknown|1810030E18Rik, 5730593H20Rik|MGI:1916413 |Mrpl44; mutation 1, the Australian National University|Mrpl44||1|ENSMUSG00000026248|ENSMUST00000027464|Mrpl44-001|868|983|C to T|ENSMUSE00000356749|4|290|Leucine to Phenylalanine|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7|het x het|No|23-Sep-2014|Cryopreserved sperm|21.0|0.0|Unknown||mitochondrial translational elongation, RNA processing, ribonucleoprotein complex, bidentate ribonuclease III , endonuclease activity|Yes| 7905.0|SGTA KO|C57BL/6-Sgta/DrmcrApb|DRMCR|Recessive|Small Glutamine-Rich Tetratricopeptide Repeat (TPR)-Containing, Alpha|Sgta|Nil|5330427H01Rik, D10Ertd190e, MGC:6336, Sgt|MGI:1098703|small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha; targeted mutation 1.1, Dame Roma Mitchell Cancer Research|Sgta|MGI:5788683|10||||||||||||||||Yes|||||||||||||Increased heart weight.Abnormal intestine morphology: • increased intestine weightAbnormal testis development: • increased testis descent (AGD)Decreased body size: • small body size observed in both males and females beginning at P19• feed intake, adiposity, lean and skeletal mass, when corrected for body weight, are similar to controlsDecreased body weight.Decreased body length.Decreased circulating insulin-like growth factor I level: • decreased serum IGF-1 levelsLethality, incomplete penetrance: • heterozygote x heterozygote matings produced fewer female homozygotes than expected (18.80% versus 25%)Neonatal lethality, incomplete penetrance: • high neonatal death rate (30.77%) day 2 to 21Increased brain weight.Large penis: • increased penis length and weightDecreased litter size: • litter size trends smaller for homozygote x homozygote matingsReduced fertility.|Small stomach: • reduced stomach weightAbnormal male preputial gland morphology:• increased preputial gland weightDecreased circulating insulin-like growth factor I level: • decreased serum IGF-1 levels in femalesLarge penis: • increased penis weight|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-Jun-2015|Cryopreserved sperm|50.0|0.0|Unknown||SGTA, AR, small glutamine-rich tetratricopeptide repeat-containing protein alpha, SGT|Possibly| 8499.0||A2(T172A) KI||Recessive|AMPK Alpha 2|a2|||||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|05-Jun-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6582.0|B6129-P2-GSK|B6.129P2-Gsk3b/MarpApb||Semi-dominant|glycogen synthase kinase 3 beta|Gsk3b|Nil|7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3|MGI:1861437||||16|||||||||||||||||||||||||||||Complete preweaning lethality. No homozygotes are found at weaning.|No abnormal phenotype detected. Heterozygotes are viable and fertile with no gross abnormalities.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||wildtype x heterozygote|No|13-Sep-2011|Cryopreserved sperm|50.0|0.0|No|||No| 2773.0|BALB/c.Flii<-/-> FLII ; FITR|BALB/c-Flii Tg(FLII)2Hdc/AnuApb|BALB/c-Flii Tg(FLII)2Hdc|Recessive|flightless I homolog (Drosophila)|Flii|Unknown|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|Human Flightless gene|Human Flightless|||||||||||Embryonic lethal phenotype of FLii knockout is rescued by human FLII transgene. ||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|1||Flii<-/-> FLII x Flii<-/-> FLII|No|16-Feb-2008|Cryopreserved sperm|150.0|0.0|No||human flightless, wound repair, cellular proliferation, cell migration, gelsolin|Yes| 7744.0|ENU26:048:Ptcd1|C57BL/6NCrlAnu-Ptcd1/AnuApb||Recessive|pentatricopeptide repeat domain 1|Ptcd1 |Unknown|1110069M14Rik |MGI:1919049 |Ptcd1; mutation 1, the Australian National University|Ptcd1||5|ENSMUSG00000029624|ENSMUST00000031628|Ptcd1-001||||||||145151282|8|||GCCGAGTACCCTCCCACCTTTGACCGGGTATGTGCACCAAGTTTACTGTCAGTGCTGATG||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||6|mut x mut|No|23-Sep-2014|Cryopreserved sperm|20.0|0.0|Unknown||tRNA processing, mitochondrion, molecular function|Yes| 4697.0|NOD260/260|NOD.Cg-Socs1/WehiApb||Recessive|suppressor of cytokine signaling 1|Socs1|Unknown|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|targeted mutation 1, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:1934607|16||||||||||||||||No|||||||||||||postnatal lethality (J:51281) mice die prior to weaning digestive/alimentary system pancreas inflammation (J:51281) monocytic infiltration postnatal growth retardation (J:51281) hematopoietic system decreased B cell number (J:51281) progressive loss of maturing B lymphocytes in the marrow, spleen, and peripheral blood small thymus (J:51281) thymus hypoplasia (J:51281) fatty liver||NOD|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|110.0|0.0|Unknown||Cytokine signalling, Phosphorylation, Signal transduction, IL-6 receptor, Growth retardation|Yes| 1509.0|H2-Bf|B6;129-Cfb/Apb|B6;129-Cfb/Apb|Recessive|complement factor B|Cfb|Nil|alternative-complement pathway C3/C5 convertase, B, Bf, Bf, Factor B, FB, H2-Bf, properdin|MGI:105975|targeted mutation 1, Harvey R Colten|Cfb|MGI:1861129|17||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations lack the alternative complement pathway, and have reduced overall complement activity.Abnormal complement cascade:total hemolytic complement activation was reduced 50% in mutant sera.Impaired complement alternative pathway:* serum from mutant mice showed no evidence of C3 deposition on zymosan.* serum from mutant mice did not support in vitro cleavage of C3 by cobra venom factor.* alternative pathway-dependent hemolytic activity was undetectable in mutant serum.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|04-Jul-2007|Cryopreserved sperm|146.0|49.0|Unknown||complement, C3, alternative pathway|Yes| 120.0|Cblb KO|B6.129P2-Cblb/AnuApb|B6.129P2-Cblb/AnuApb|Recessive|Casitas B-lineage lymphoma b|Cblb|Nil|Cbl-b|MGI:2146430|targeted mutation 1, Josef M Penninger|Cblb|MGI:2180570|16||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit elevated IL2 production by T cells, develop spontaneous autoimmunity, and are highly susceptible to experimental autoimmune encephalomyelitis.||B6/129 intercross, bred with wild type B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|1|2||No|06-Feb-2006|Cryopreserved sperm|63.0|0.0|No||IL-2, T cell, encephalomyelitis, autoimmune, signal transduction|Yes| 1528.0|B6.TNF-/-|C57BL/6-Tnf/AnuApb||Recessive|tumor necrosis factor|Tnf|Nil|DIF, TNF alpha, TNF-alpha, Tnfa, TNFalpha, Tnfsf1a, tumor necrosis factor-alpha|MGI:104798|targeted mutation 1, Johnathon D Sedgwick|Tnf|MGI:1860953|17||||||||||||||||No|||||||||||||Tnf–/– mice developed normally apart from absence of Peyer’s patches and abnormal microarchitectural lymphoid structure in secondary lymphoid tissues. Although the T and B cell number was not affected, T and B cell regions in lymphoid follicles were disorganized and primary B cell follicles and germinal centers were absent.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|225.0|0.0|Unknown||B cell, T cell, peyer's patches, infection, germinal centre|Yes| 83.0|Tipsy|NOD;B6JSfdAnu-Arhgap10/AnuApb|NOD;B6JSfdAnu-Arhgap10/AnuApb|Recessive|Rho GTPase activating protein 10|Arhgap10|Unknown|PSGAP-m, PSGAP-s|MGI:1925764|Rho GTPase activating protein 10; mutation 1, The Australian National University|Arhgap10|MGI:5563425|8|ENSMUSG00000037148|ENSMUST00000076316|Arhgap10-202|2094|2218|C to A|ENSMUSE00000249793|21|698|Serine to Serine|||||AATATGCAGTCTCCAACCACACCAAGCTCCAACCCAGCTGGAACACCTCCTTCACCCAGAA|Yes|||||||||||||Weak and ataxic hindlimbs evident after 100 days of age, splayed hindlimbs. Those animals displaying weaker phenotype can be detected with rotor-rod technique. Full histology requested by APN. Video available. Severely affected cannot breed. Phenotype unique to this chromosomal location. There is a QTL associated with engailed.||C57BL/6 x NODk|Yes|No|Yes|Yes|No|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|175.0|0.0|Unknown||Ataxia, Hindlimb, Weakness, ENU|Yes| 3943.0|TPBcreC2B6Δ|B6.CD1-Tg(Tpbpa-Cre-GFP)5 Cited2/Apb||Dominant|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2|Cited2|Unknown|Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1, Sally L Dunwoodie|Cited2|MGI:3696061|10||||||||||||||||Yes|Cre recombinase|5.4 kb of the trophoblast specific protein alpha (Tpbpa) promoter|||||||||||Not examined|Normal|C57BL/6 x CD1|No|No|Yes|No|No|Yes|No|Good|||This allele is kept with another one ie the TPB/+;+/+ X +/+;C2B6/+|No|17-Oct-2008|Cryopreserved sperm|57.0|0.0|Unknown||Trophoblast giant cells, placenta, GFP, transcription factor, embryonic lethal|Yes| 7746.0|ENU33:G1|ANU:ENU33:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Oct-2014|Cryopreserved sperm|1509.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8561.0|Cav1|BALB/c-Cav1/OnjcriApb||Recessive|caveolin 1, caveolae protein|Cav1|Unknown|Cav-1, caveolin-1|MGI:102709||||6|||||||||||||||||||||||||||||Null mutant females do not breed well and pups may be unable to feed due abnormal mammary gland development during pregnancy and abnormal lactation in the mother and/or low levels of fat tissue.|Normal|BALB/c|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Sep-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 4744.0|ICOS KO|C57BL/6-Icos/AnuApb||Recessive|inducible T-cell co-stimulator|Icos|Nil||MGI:1858745|Name: targeted mutation 1, Richard A Flavell|Icos|MGI:2683635|1||||||||||||||||No|||||||||||||Immune system phenotype: T lymphocyte development normal in the thymus.Abnormal interferon level: Ifn-gamma levels were normal to slightly increasedAbnormal interleukin level: Il-2 production defective, Il-4 production very low, Il-10 levels normal, Il-13 levels reduced.Small lymph nodes: lymph nodes were small in immunized miceabout 1/2 as many cells/node as in wild-type miceAbnormal immunoglobulin level: decreased IgE level, decreased IgG1 level.Abnormal T-helper 2 physiology: defect indicated by low Il-4 levels and low IgG1 and IgE levels, Th2 differentiation normal but function disruptedIncreased susceptibility to experimental autoimmune encephalomyelitis.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Apr-2009|Cryopreserved sperm|38.0|0.0|Unknown||CD28, T cell, germinal centre, IgG, humoral immunity|Yes| 10556.0|mPfCSPrev-mCherry FoxN1cre|B6;D2-Gt(ROSA)26Sor-Tg(FoxN1-Cre)8Ghr||Recessive|Gt(ROSA)26Sor|||||Gt(ROSA)26Sor:tm1(LPfCSPrev-mCherry)Anu|Gt(ROSA)26Sor:tm1(LPfCSPrev-mCherry)Anu||Unknown|||||||||||||||||transgene insertion 30, Brian Schaefer||||||||||||Normal|Normal||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jun-2026|Cryopreserved sperm|31.0|0.0|Unknown|||No| 10556.0|mPfCSPrev-mCherry FoxN1cre|B6;D2-Gt(ROSA)26Sor-Tg(FoxN1-Cre)8Ghr||Recessive||||||||||||||||||||||||||transgene insertion 8, Georg A Hollander||||||||||||Normal|Normal||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jun-2026|Cryopreserved sperm|||Unknown|||No| 5574.0|Shmu|C.C3H-Shamu/AnuApb||Semi-dominant|shamu|Shmu|||MGI:3047697|shamu|Shmu|MGI:3047738|9|||||||||||||||||||||||||||||Embryonic lethal, possibly at or before gastrulation|White ventral spotting, a head spot, a mild distal tail kink, and white feet|C3H/HeH|No|No|Yes|No|No|Yes|No|Good|19|0|Heterozygous carrier aniamals are paired with C3H/HeH animals|No|01-Sep-2011|Cryopreserved sperm|50.0|0.0|Unknown||ENU, neural crest|Yes| 5448.0|Idd14 R11|NOD.B6-Idd14 R11||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|NOD/Lt|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||Yes|01-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown|||No| 8505.0|NOD.Nkrplb.CD45.2|NOD.Nkrplb.CD45.2||Recessive|CD45.2||||||||Unknown||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8511.0|NOD.CD45.2|NOD.CD45.2||Recessive|CD45.2||||||||Unknown|||||||||||||||||||||||||||||Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 7747.0|ENU33:G2|ANU:ENU33:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Oct-2014|Cryopreserved sperm|1995.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8508.0|NOD.Nkrplb.Slam1A|NOD.Nkrplb.Slam1A||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8508.0|NOD.Nkrplb.Slam1A|NOD.Nkrplb.Slam1A||Recessive|||||||||||||||||||||||||||||slam1a||||||||Unknown|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 4834.0|6CAT:040|ENU6CAT:040||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|45.0|0.0|Yes|Type I Diabetes|ENU, JDRF, autoimmunity, T cell, B cell, glucose|No| 4834.0|6CAT:040|ENU6CAT:040||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, autoimmunity, T cell, B cell, glucose|No| 7560.0||SJL/Mrit-MRI28562|SJL/Mrit-MRI28562|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight decrease growth phenotype|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Jan-2014|Cryopreserved sperm|60.0|0.0|Unknown||growth, ENU|Yes| 7561.0||B6/Mrit-106370|B6/Mrit-106370|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display an harmonious and transient growth increase|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|07-Jan-2014|Cryopreserved sperm|30.0|0.0|Unknown||growth , ENU|Yes| 8506.0|NOD.Nkrplb.CD45.2.A8Ca|NOD.Nkrplb.CD45.2.A8Ca||Recessive|CD45.2||||||||Unknown||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 4188.0|(SOCS1/RIP)|B6.Cg-Socs1 Socs1 Tg(Ins2-cre)25Mgn/Apb||Recessive|suppressor of cytokine signaling 1|Socs1|Nil|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|suppressor of cytokine signaling 1|Socs1|MGI:1934607|16||||||||||||||||Yes|transgene insertion 25, Mark A Magnuson |rat insulin promoter 2|||||||||||Mice with SOCS1 targeted mutation in beta cells develop normally.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||12|Heterozygous For Cre transgene (T/+) and for SOCS1c with SOCS1 KO (fl/-)|No|19-Dec-2008|Cryopreserved sperm|50.0|0.0|Unknown||cytokine signalling, beta cells, phosphorylation, Glucose|Yes| 4188.0|(SOCS1/RIP)|B6.Cg-Socs1 Socs1 Tg(Ins2-cre)25Mgn/Apb||Recessive|suppressor of cytokine signaling 1|Socs1|Unknown|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|targeted mutation 3, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:2656917|16||||||||||||||||No|||||||||||||Mice with SOCS1 targeted mutation in beta cells develop normally.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||12|Heterozygous For Cre transgene (T/+) and for SOCS1c with SOCS1 KO (fl/-)|No|19-Dec-2008|Cryopreserved sperm|||Unknown||cytokine signalling, beta cells, phosphorylation, Glucose|Yes| 7381.0|Dicer|B6.129-Dicer1/WehiAnuApb||Recessive|dicer 1, ribonuclease type III|Dicer1|||MGI:2177178|dicer 1, ribonuclease type III; targeted mutation 1, Brian D Harfe|Dicer1|MGI:3589208|12|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jul-2013|Cryopreserved sperm|59.0|0.0|Unknown||microRNA, Cre|Yes| 8507.0|NOD.Nkrplb.CD45.2.CD-1|NOD.Nkrplb.CD45.2.CD-1||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 6845.0|Dhfr|SJL/Mrit-Dhfr/MritApb||Dominant|Dihydrofolate reductase|Dhfr|Unknown|8430436I03Rik|MGI:94890|Dhfr;MRI32666R|Dhfr||13||||||||||||||||||||||||||||||Normal red blood cells parameters.Normal susceptibility to P. chabaudi infection.|SJL|No|No|Yes|No|No|Yes|No|Good||||No|12-Mar-2012|Cryopreserved sperm|50.0|0.0|Yes|Maturity onset diabetes of the young 2|Dihydrofolate reductase, ENU|Yes| 8509.0|NOD.Nkrplb.Slam1B|NOD.Nkrplb.Slam1B||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8509.0|NOD.Nkrplb.Slam1B|NOD.Nkrplb.Slam1B||Recessive|||||||||||||||||||||||||||||slam1b||||||||Unknown|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8562.0|MMP-12|BALB/c-Mmp12/OnjcriApb||Recessive|matrix metallopeptidase 12|Mmp12|Unknown|macrophage elastase, Mmel, MMP12|MGI:97005||||9|||||||||||||||||||||||||||||The MMP-12 null mice look normal and are viable and fertile. They are less susceptible to stress/smoke-induced inflammation and emphysema. They have smaller litter sizes (~60% or wild type) due to placental abnormalities. MMP12 null macrophages lack degrading activity and are unable to invade through the basement membrane.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Sep-2018|Cryopreserved sperm|40.0|0.0|Unknown||Macrophage|Yes| 6946.0|ENU19 WT:022:a|ENU19 WT:022:a||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|05-Jul-2012|Cryopreserved sperm|58.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 6844.0|Dudley 2|SJL/Mrit-Gck/MritApb||Dominant|Glucokinase|Gck|Unknown|Gk, hexokinase 4, HK4, MODY2|MGI:1270854|Glucokinase;MRI30862|Gck||11||||||||||||||||||||||||||||||HyperglycemiaHyperinsulinemiaGlucose intolerant|SJL|No|No|Yes|No|No|Yes|No|Good||||No|12-Mar-2012|Cryopreserved sperm|60.0|0.0|Yes|Maturity onset diabetes of the young 2|Diabetes, Glucokinase, ENU|Yes| 8510.0|NOD.H2b.Nkrplb.CD-1|NOD.H2b.Nkrplb.CD-1||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Difficult breeders. Have had to restart the breeding, multiple times due to the difficulty in getting them homozygous. Seems homozygous mice do not breed. Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.Knockout lacking the CD1 antigen complex gene||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8510.0|NOD.H2b.Nkrplb.CD-1|NOD.H2b.Nkrplb.CD-1||Recessive|||||||||||||||||||||||||||||H2b||||||||Unknown|Difficult breeders. Have had to restart the breeding, multiple times due to the difficulty in getting them homozygous. Seems homozygous mice do not breed. Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.Knockout lacking the CD1 antigen complex gene||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 6812.0|B/c.CD39.Tg.1079-4|C.Cg-Tg(H2-K-ENTPI)/SvhmApb||Dominant||||||||||||||||||||||||||Human ectonucleoside triphosphate diphosphohydrolase 1|H2-K|moderate/high||||||||||Unknown|Normal|BALB/c|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|18|||No|08-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown||Cd39|Possibly| 8563.0|MMP-9|BALB/c-Mmp9/OnjcriApb||Recessive|matrix metallopeptidase 9|Mmp9|Unknown|B/MMP9, Clg4b, gelatinase B, Gelatinase B, Gel B, MMP-9|MGI:97011||||2|||||||||||||||||||||||||||||MMP-9 null mice have a very mild bone phenotype (lengthening of the growth plates) that tends to normalize with age. |Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Sep-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5040.0|APN21|129/Ola-Rab10/MAS||Recessive|RAB10, member RAS oncogene family|Rab10|Unknown||MGI:105066|RAB10, member RAS oncogene family; gene trap XC820, BayGenomics|Rab10|MGI:4125038|12|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6 x 129/OlaHsd|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|22-Feb-2010|Cryopreserved sperm|80.0|0.0|Unknown||ES cell|Yes| 7751.0|DBC3 knockout|C57BL/6-Brinp3/MarpApb||Recessive|bone morphogenetic protein/retinoic acid inducible neural specific 3|Brinp3|Nil|B830045N13Rik, Fam5c|MGI:2443035||||1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||From hetrozygous breeding|No|02-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7752.0|DBC1 knockout|C57BL/6-Brinp1/MarpApb||Recessive|bone morphogenic protein/retinoic acid inducible neural specific 1|Brinp1|Nil|Dbc1, Dbccr1, Fam5a|MGI:1928478||||4|||||||||||||||||||||||||||||Behavioural phenotypes|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10||From hetrozygous breeding|No|02-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9173.0|ASD1118:Kif13a G318R:F0|C57Bl/6NCrlAnu-Kif13a/Apb||Semi-dominant|kinesin family member 13A|Kif13a|||MGI:1098264|Kif13a:endonuclease-mediated mutation 1, Australian National University|Kif13a||13|||||||||||||||||||||||||||||Mouse #14|unknown|C57Bl/6NCrl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Apr-2021|Cryopreserved sperm|12.0|0.0|Unknown|||Possibly| 8512.0|NOD.Nkrplb.CD-1|NOD.Nkrplb.CD-1||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Difficult breeders. Have had to restart the breeding, multiple times due to the difficulty in getting them homozygous. Seems homozygous mice do not breed. Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.Knockout lacking the CD1 antigen complex gene||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Jun-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 7069.0|Momme D19|FVB/NJ-Smarcc1 Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1|Smarcc1|Unknown|BAF155, SRG3|MGI:1203524|SWI/SNF related BAF chromatin remodeling complex subunit C1; modifier of murine metastable epialleles, D19|Smarcc1|MGI:5515368|9||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Lethal|HET LOSS|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD19<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|29-Aug-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 8565.0|ASD948:PKR 1bp ins:EIF2AK2|C57BL/6NCrlAnu-Eif2ak2/AnuApb||Recessive|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|Unknown|2310047A08Rik, 4732414G15Rik, dsRNA-activated kinase, eIF-2 alpha, eIF-2 alpha, IFN-induced and double-stranded RNA-activated kinase, IFN- type I-induced and dsRNA-activated kinase, Pkr, Prkr, Tik|MGI:1353449|Eif2ak2, endonuclease-mediated mutation 1, Australian National University |Eif2ak2||17||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Sep-2018|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 6823.0|MTf Tg #1|B6.129-Tg(UBC-Mfi2)43Drrn/Apb||Dominant||||||||||||||||||||||||||murin melanotransferrin|human unbiquitin c|ubiquitous||||||||||Normal.Mild but significant decrease of erythrocyte number in both male and female MTf Tg mice compared to the wildtype counterparts||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Feb-2012|Cryopreserved sperm|30.0|0.0|Unknown||melanoma, melanotransferrin, iron, erythrocyte|Yes| 8513.0|ENU41:G2|ANU:ENU41:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|12-Jun-2018|Cryopreserved sperm|145.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7070.0|Momme D4|FVB/NJ-Smarca5 Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5|Smarca5|Unknown|4933427E24Rik, D030040M08Rik, D330027N15Rik, MommeD4, Snf2h|MGI:1935129|SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5; modifiers of murine metastable epiallele D4|Smarca5|MGI:3586551|8|ENSMUSG00000031715|ENSMUST00000043359|Smarca5-001|1558|1959|T to A|ENSMUSE00001218842|12|520|Tryptophan to Arginine|||||TATTAGACATTTTGGAAGATTATTGCATGTGGAGAAATTATGAGTACTGCAGGTTGGATGG||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality E17|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD4<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|29-Aug-2012|Cryopreserved sperm|49.0|0.0|Unknown||ENU, epigenetics|Possibly| 8515.0|ENU43:G2|ANU:ENU43:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|12-Jun-2018|Cryopreserved sperm|8459.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7564.0|ENU25:048:P2ry10:B6|C57BL/6NCrlAnu-P2ry10/AnuApb|C57BL/6NCrlAnu-P2ry10/AnuApb|X-linked|purinergic receptor P2Y, G-protein coupled 10|P2ry10|Unknown|5830408N17Rik, P2Y10|MGI:1926076|purinergic receptor P2Y, G-protein coupled 10; mutation 1, The Australian National University|P2ry10|MGI:5648450|X|ENSMUSG00000050921|ENSMUST00000053375|P2ry10-001|123|497|T to A|ENSMUSE00000710686|3|41|Serine to Arginine|||||ATATTCATCCCGGGTCTCCTGGCTAACAGTGCAGCCCTGTGGGTTCTGTGCCGCTTCATCA||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|14-Jan-2014|Cryopreserved sperm|60.0|0.0|Unknown||ENU, missense, mutation, MMP|Possibly| 8514.0|ENU42:G2|ANU:ENU42:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|12-Jun-2018|Cryopreserved sperm|3469.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8567.0|PKR 8bp del:EIF2AK2|C57BL/6NCrlAnu-Eif2ak2/AnuApb||Recessive|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|Unknown|2310047A08Rik, 4732414G15Rik, dsRNA-activated kinase, eIF-2 alpha, eIF-2 alpha, IFN-induced and double-stranded RNA-activated kinase, IFN- type I-induced and dsRNA-activated kinase, Pkr, Prkr, Tik|MGI:1353449|Eif2ak2, endonuclease-mediated mutation 3, Australian National University |Eif2ak2||17||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8516.0|MR1-tom|C57BL/6-Mr1||Recessive|major histocompatibility complex, class I-related|Mr1|Nil|H2ls, MR1|MGI:1195463||||1|||||||||||||||||||||||||||||Essentially normal but lacks a T cell known as a MAIT cell. |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2018|Cryopreserved sperm|50.0|0.0|Unknown||T cell, MAIT|Yes| 8568.0|ASD801:TgPKR|B6(Cg)-Tg(Vav1-EIF2AK2)#Wsmay/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion, W May|vav1||||||||||||peripheral blood counts from TgPKR mice decrease with age in association with dysplastic marrow changes. TgPKR mice have reduced colony-forming capacity and the colonies also are more sensitive to hematopoietic stresses. Furthermore, TgPKR mice have fewer hematopoietic stem/progenitor cells (HSPCs), and the percentage of quiescent (G0) HSPCs is increased. Importantly, treatment of TgPKR bone marrow (BM) with a PKR inhibitor specifically rescues sensitivity to growth factor deprivation. In contrast, marrow from PKR knockout (PKRKO) mice has increased potential for colony formation and HSPCs are more actively proliferating and resistant to stress. Significantly, TgPKR HSPCs have increased expression of p21 and IFN regulatory factor, whereas cells from PKRKO mice display mechanisms indicative of proliferation such as reduced eukaryotic initiation factor 2α phosphorylation, increased extracellular signal-regulated protein kinases 1 and 2 phosphorylation, and increased CDK2 expression.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2018||0.0|0.0|Unknown||Bone Marrow, Haemopoiesis|Yes| 8569.0|Cd47 KO|B6.129-Cd47/AnuApb||Recessive|CD47 antigen (Rh-related antigen, integrin-associated signal transducer)|Cd47||9130415E20Rik, B430305P08Rik, IAP, integrin-associated protein, Itgp|MGI:96617||||16|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8518.0|Rab32.3|C57BL/6-Rab32||Recessive|RAB32, member RAS oncogene family|Rab32|Nil|2810011A17Rik|MGI:1915094||||10|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2018||0.0|0.0|Unknown|||Yes| 8519.0|Ankrd13A.4|C57BL/6-Ankrd13a||Recessive|ankyrin repeat domain 13a|Ankrd13a|Nil|1100001D10Rik|MGI:1915670||||5|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8522.0|MARCH 1|B6.129-March1||Recessive|membrane-associated ring finger (C3HC4) 1|March1|Nil|2900024D24Rik|MGI:1920175|membrane-associated ring finger (C3HC4) 1; targeted mutation 1.1, Satoshi Ishido|March1|MGI:3706321|8|||||||||||||||||||||||||||||MARCH1 K.O. mice have enriched surface expression in professional antigen presenting cells (i.e. dendritic cells and B cells) compared to WT miceMARCH1 K.O. mice show reduced numbers of CD4+ T cells (i.e. regulatory T cells) in the thymus compared to WT mice.|The same as homozygous K.O. but to a lesser extent|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2018|Cryopreserved sperm|50.0|0.0|Unknown||T cell, B cell, E3 ubiquitin ligase, MHC, dendritic cells|Yes| 5334.0|NODβ2M-/- flβ2Ma 8.3TCRαβ|NOD-B2m Tg(B2m)1Rms Tg(TcraTcrbNY8.3)1Pesa/MarpApb||Recessive|beta-2 microglobulin|B2m|Unknown|beta 2 microglobulin, beta2-m, Ly-m11|MGI:88127|targeted mutation 1, Rudolf Jaenisch|B2m|MGI:1927183|2||||||||||||||||Yes|transgene insertion 1, Robyn M Slattery|B2m|||||||||||Unknown|TCR transgenic mouse with accelerated diabetes.|NOD|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|01-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||Autoimmunity, insulin, MHC I, beta cell|Possibly| 5334.0|NODβ2M-/- flβ2Ma 8.3TCRαβ|NOD-B2m Tg(B2m)1Rms Tg(TcraTcrbNY8.3)1Pesa/MarpApb||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 1, Pere Santamaria|TCR|||||||||||Unknown|TCR transgenic mouse with accelerated diabetes.|NOD|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|01-Dec-2010|Cryopreserved sperm|||Unknown||Autoimmunity, insulin, MHC I, beta cell|Possibly| 7112.0|ENU22:Stxbp2|C57BL/6NCrlAnu-Stxbp2/AnuApb|C57BL/6NCrlAnu-Stxbp2/AnuApb|Recessive|syntaxin binding protein 2|Stxbp2|Unknown|C79054, Munc-18-2, Munc18b, Munc-18b, muSec1, Sxtp2 |MGI:107370|syntaxin binding protein 2; mutation 1, The Australian National University|Stxbp2|MGI:5563406|8|ENSMUSG00000004626|ENSMUST00000160708|Stxbp2-001||||||||3636354|11|||ACGATCTCTACCCTCTCCTACCATTACCTCAGGCCAACATCAAAGACCTGTCCCACATCC||||||||||||||Reduced fusion of cytolytic granules with cell membrane|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|none|3|het x het|No|24-Oct-2012|Cryopreserved sperm|32.0|0.0|Yes|HLH or hemophagocytic lymphohistiocytosis type 5|ENU|Yes| 8595.0|mm1286del|C57Bl/6J-Grhl/Apb||Dominant|grainyhead like transcription factor 2|Grhl2|||MGI:2182543||||15|||||||||||||||||||||||||||||Normal|Heterozygous adults which completely lack Grhl2 (Grhl2+/-) present with no phenotypes. As the mm1286del line has only an enhancer element deleted, there is no possibility of heterozygosity leading to phenotypes; we have already observed that heterozygous adults present with no phenotype. We predict that nullizygous(-/-) embryos will have slight alterations to craniofacial morphology|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Nov-2018|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 7383.0|ENU28:G2|ANU:ENU28:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|26-Jul-2013|Cryopreserved sperm|1808.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 8523.0|primurus BALB/c|C.B6J-Dock8/AnuApb||Recessive|dedicator of cytokinesis 8|Dock8|Unknown||MGI:1921396|primurus|Dock8|MGI:3835421|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201|5479|5601|T to C|ENSMUSE00000145941|42|1827|Serine to Proline|||||AACCCGCAATCACGAAGCTCCCGGAGATCTCACATAGACTAGAGGGATTTTATGGCCAGTG|Yes|||||||||||||Defective antibody response to immunization: failure to sustain antibody formation, undergo affinity maturation or to mount heightened recall (memory) response upon booster immunization. DOCK8-mutant B cells were unable to form marginal zone B cells or to persist in germinal centers and undergo affinity maturation. Dock8 mutations disrupted accumulation of the integrin ligand ICAM-1 in the B cell immunological synapse but did not alter other aspects of B cell antigen receptor signaling.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|9|5||No|15-Jun-2018|Cryopreserved sperm|84.0|0.0|Unknown||memory, antibody, immunization, ENU, Wellcome Trust, B cell, GTP|Yes| 7566.0|ENU24:042:Usp15:B6|C57BL/6NCrlAnu-Usp15/AnuApb|C57BL/6NCrlAnu-Usp15/AnuApb|Recessive|Ubiquitin specific peptidase 15|Usp15|Unknown|4921514G19Rik, E430033I05Rik, Gcap18, mKIAA0529|MGI:101857|Ubiquitin specific peptidase 15; mutation 1, The Australian National University|Usp15|MGI:5648448|10|ENSMUSG00000020124|ENSMUST00000020334|Usp15-201|2855|2875|G to A|ENSMUSE00000403753|22|952|Serine to Leucine|||||CCCTCTTGACCGAGAAACTAAAGGTGCTTCAGCTGCCACAGGTATCCCCCTGGAAAGTGAC||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Jan-2014|Cryopreserved sperm|48.0|0.0|Unknown||ENU, missense, mutation, MMP|Possibly| 5296.0|B6.EPCR.Tg ; CBA/B6-Tg(HUEPCR)|CBA;B6-Tg(H2-K-EPCR)||Recessive||||||||||||||||||||||||||human protein C receptor, endothelial|H2-K|Strong, endothelial cells and neutrophils||||||||||Unknown||C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||transplantation, thrombin, inflammation, receptor|Possibly| 3592.0|Fasl-gld|B6.C3-Fasl/AnuApb|B6.C3-Fasl|Recessive|Fas ligand (TNF superfamily, member 6)|Fasl|Unknown|APT1LG1, CD178, CD95L, Fas-L, Tnfsf6|MGI:99255|generalized lymphoproliferative disease|Fasl|MGI:1856384|1||||||||||||||||Yes|||||||||||||Increased peripheral blood lymphocyte number. Increased T cell number. Increased neutrophil number. Abnormal T cell differentiation. Decreased B cell numbers. Anemia. Premature death - animals die around 60 weeks. Splenomegaly, lymphoadenopathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Aug-2008|Cryopreserved sperm|144.0|0.0|Unknown||T cell, lymphocyte, splenomegaly , lymphoadenopathy, autoimmunity, antinuclear antibodies|Yes| 3316.0|FATT-C57|C57BL/6-Lepr/Apb||Recessive|Leptin Receptor|LepR|Unknown|Leprb, LEPROT, leptin receptor gene-related protein, Modb1, OB-RGRP, obese-like, obl, Obr|MGI:104993|FATT|Lepr||4||||||||||||||||Yes|||||||||||||The homozygote mutant has juvenile obesity, florid diabetes. The adult is hypogonadal and does not breed, and had an increased body length (10-20%).|There is a slight change in adipose tissue distribution and liver weight but no other significant changes. |129Sv/EvTac x C57BL/6|Yes|No|Yes|Yes|No|Yes|Yes|Good|4||Heterozygous FATT-C57/BL6 mice crossed with C57/BL6 working towards a C57/BL6 background. Homozygous mutants are not fertile/do not breed. |No|09-Jun-2008|Cryopreserved sperm|130.0|0.0|Yes||Obesity, Diabetes, leptin, receptor|Yes| 5449.0|Idd14 R12|NOD.B6-Idd14 R12||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|NOD/Lt|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||Yes|01-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown|||No| 8525.0|CMV-cre|B6.Cg-Tg(CMV-cre)1Cgn/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, University of Cologne|human cytomegalovirus (CMV) promoter||||||||||||Cre recombinase under the control of a human cytomegalovirus (CMV) promoter, active in most cells and tissues.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jun-2018|Cryopreserved sperm|36.0|0.0|Unknown||CMV, Cre recombinase, ubiquitous, deleter|Yes| 4473.0|George|C(Cg)-Gstp1/Gstp2/AnuApb||Recessive|glutathione S-transferase, pi 1|Gstp1|Nil|Gst p-1, GstpiB|MGI:95865|targeted mutation 1, C Roland Wolf|Gstp1/Gstp2|MGI:3046099|19||||||||||||||||Yes|||||||||||||Mutant mice with null mutations in both Gstp1 and Gstp2 exhibit an increased susceptibility to DMBA and TPA induced skin papillomas. Male mutant mice exhibit an increased body weight with age. Studying allergic airway disease compared with allergic WT mice, eosinophilia, goblet cell hyperplasia, airway remodeling, lung resistance, and IL-5 were enhanced in allergic Gstp-null mice.||BALB/c x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|6|||No|22-Feb-2009|Cryopreserved sperm|135.0|0.0|Unknown||asthma, eosinophil, signal transduction, IL-5, phosphorylation, papilloma|Yes| 4473.0|George|C(Cg)-Gstp1/Gstp2/AnuApb||Recessive|glutathione S-transferase, pi 2|Gstp2|Nil|Gst p-2, Gst-3, Gst3, GSTpiA|MGI:95864|glutathione S-transferase, pi 2; targeted mutation 1, C Roland Wolf|Gstp1/Gstp2|MGI:3046101|19|||||||||||||||||||||||||||||Mutant mice with null mutations in both Gstp1 and Gstp2 exhibit an increased susceptibility to DMBA and TPA induced skin papillomas. Male mutant mice exhibit an increased body weight with age. Studying allergic airway disease compared with allergic WT mice, eosinophilia, goblet cell hyperplasia, airway remodeling, lung resistance, and IL-5 were enhanced in allergic Gstp-null mice.||BALB/c x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|6|||No|22-Feb-2009|Cryopreserved sperm|||Unknown||asthma, eosinophil, signal transduction, IL-5, phosphorylation, papilloma|Yes| 7296.0||SJL/Mrit||Dominant|unknown|unknown|||||||Unknown|||||||||||||||||||||||||||||Prenatal mortality (E15) with severe anaemia and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with decrease osmotic fragility.|SJL/J|No|No|Yes|No|No|Yes|No|Good|6|||No|22-Mar-2013|Cryopreserved sperm|50.0|0.0|Yes|thalassaemia|red blood cells, microcytosis, anaemia, thalassaemia, ENU|Yes| 7928.0|S6 Mx1-Cre|B6(Cg).129-Rps6 Tg(Mx1-Cre)1Cgn/JAnu||Recessive|ribosomal protein S6|Rps6|Normal|S6R|MGI:98159|ribosomal protein S6; targeted mutation 1, George Thomas|Rps6|MGI:2387471|4|||||||||||||||||transgene insertion 1, University of Cologne|Mx1|||||||||||Abnormal cell morphology:• mice induced with interferon gamma exhibited similar responses to starvation as controls, although it was noted that 40S ribosomes were absent and 60S ribosomes were increased in number in mutant liver recovering from starvationAbnormal cell cycle• xpression of cell cycle markers such as cyclin E and cyclin A were not seen in mutant hepatocytes suggesting a block in cell cycle progressionDecreased liver regeneration:• after partial hepatectomy, mutant liver failed to regenerate after 10 days; histopathology revealed no evidence of regenerative or pathological processes in mutant liver; expression of cell cycle markers such as cyclin E and cyclin A were not seen in mutants suggesting a block in cell cycle progression||C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|55.0|0.0|Unknown||Liver|Yes| 6856.0|AID KO|B6.CBA-Aicda/OlaAnu|B6.CBA-Aicda/OlaAnu|Dominant|activation-induced cytidine deaminase|Aicda|Nil|Aid|MGI:1342279|activation-induced cytidine deaminase; targeted mutation 1, Tasuku Honjo|Aicda|MGI:2156156|6|||||||||||||||||||||||||||||Increased susceptibility to bacterial infection induced morbidity/mortality: following administration of 15 ug cholera toxin.Abnormal class switch recombination: * absent class switching in B cells * class switching recombination (CSR)-induced Smu internal deletion is impaired * B cells cultured with LPS and IL-4 fail to switch immunoglobulin expression to IgG1 * similar defects in IgG3 switching are also observed.Abnormal somatic hypermutation frequency: * mice exhibit an increase in somatic hypermutation rates compared to in wild-type mice * the somatic mutation rates of the upstream region of the S-mu switch is severely reduced.Increased germinal center B cell number: * in Peyer's patches and spleen. * in the lamina propria and Peyer's patches.Decreased IgA level: serum and faecal.Decreased IgG level: faecal.Decreased IgG1 level: levels are less than one tenth of those in controls.Decreased IgG2a level: levels are less than one tenth of those in controls.Decreased IgG2b level.Decreased IgG3 level.Increased IgM level: * 2-3 fold elevation in IgM level. * faecal.|Abnormal class switch recombination: * absent class switching in B cells * class switching recombination (CSR)-induced Smu internal deletion is impaired * B cells cultured with LPS and IL-4 fail to switch immunoglobulin expression to IgG1 * similar defects in IgG3 switching are also observed.Abnormal somatic hypermutation frequency: * mice exhibit an increase in somatic hypermutation rates compared to in wild-type mice * the somatic mutation rates of the upstream region of the S-mu switch is severely reduced.Increased germinal center B cell number: * in Peyer's patches and spleen * in the lamina propria and Peyer's patches|C57BL/6JOla|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|15-Mar-2012|Cryopreserved sperm|30.0|0.0|Unknown||immunoglobulin, class switch, germinal centre, B cell|Possibly| 7297.0||SJL/Mrit||Dominant|unknown|unknown|||||||Unknown|||||||||||||||||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with decrease osmotic fragility.|SJL/J|No|No|Yes|No|No|Yes|No|Good|4|||No|22-Mar-2013|Cryopreserved sperm|50.0|0.0|Yes|thalassaemia|red blood cells, microcytosis, anaemia, thalassaemia, ENU|Yes| 5543.0|ENU14Yaa:032b|B6.SB-Lyn/AnuApb|B6.SB-Lyn/AnuApb|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn||Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; mutation 2, The Australian National University|Lyn|MGI:5563397|4|ENSMUSG00000042228|ENSMUST00000041377|Lyn-001||||||||3683632|9|||CTACATCATCACCGAGTTCATGGCTAAGGGTGAGTGGCATCACGAGTCTGTACCCCTAAA||||||||||||||Increased % immature B cells, and reduced % mature B cells (Almost no Mature B cells)||C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|27-Jul-2011|Cryopreserved sperm|45.0|0.0|Unknown||ENU, B cell, signal transduction|Possibly| 5522.0|Idd14 R10|NOD.B6-Idd14/R10Apb||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 14|Idd14|||MGI:99416||||13|Unknown|Unknown|NOD/Lt|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||Yes|10-Jun-2011|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7570.0|Grey macro|B6/Mrit-MRI114908|B6/Mrit-MRI114908|Recessive|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Grey coat color in a C57BL/6 mice associated with macrocytosis. The females are infertile.|The heterozygous are normal.|C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good||||No|20-Jan-2014|Cryopreserved sperm|70.0|0.0|Unknown||Macrocytosis, coat-color, ENU|Yes| 7298.0|Il7Tg:Thy1.1|B6.Cg-Thy1 Tg(H2-Ea-Il7)10Rhdr/ScrAusbAnu||Recessive|thymus cell antigen 1, theta|Thy1||CD90, T25, theta, Thy-1, Thy1.1, Thy 1.2, Thy-1.2, Thy1.2|MGI:98747|thymus cell antigen 1, theta; a variant|Thy1|MGI:3579311|9|||||||||||||||||transgene insertion 10, Rhodri Ceredig|H2-Ea promoter|||||||||||No B cells||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-Mar-2013|Cryopreserved sperm|44.0|0.0|Unknown||ENU, B cell, ATPase|Yes| 8587.0|F2rl1 fl|C57BL/6N-F2rl1/MarpApb||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1||Gpcr11, Par2, PAR-2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1c, Wellcome Trust Sanger Institute|F2rl1|MGI:6151132|12|||||||||||||||||||||||||||||Normal||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Oct-2018|Cryopreserved sperm|30.0|0.0|Unknown||T cell, periodontitis, thymic and splenic hypoplasia|Yes| 8588.0|MDX:PAR2|B6.B10-Dmd F2rl1/Apb||Recessive|dystrophin, muscular dystrophy|Dmd||Dp427, Dp71, Duchenne muscular dystrophy, dys, mdx, pke, X-linked muscular dystrophy|MGI:94909|mdx & F2rl1|dystrophin, muscular dystrophy; X linked muscular dystrophy|Dmd|X|||||||||||||||||||||||||||||Dystrophic (mdx)PAR2 deficiency|Normal|C57BL/6 ; C57BL/10|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Oct-2018|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8588.0|MDX:PAR2|B6.B10-Dmd F2rl1/Apb||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1||Gpcr11, Par2, PAR-2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1, Shaun R Coughlin|F2rl1|MGI:2179844|13|||||||||||||||||||||||||||||Dystrophic (mdx)PAR2 deficiency|Normal|C57BL/6 ; C57BL/10|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Oct-2018|Cryopreserved sperm|||Unknown|||Yes| 8532.0|ENU41:G3|ANU:ENU41:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|10-Jul-2018||0.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 9377.0|SEPS1 global knockout (GKO)|C57Bl/6-Selenos/Apb||Semi-dominant|selenoprotein S|Selenos||1500011E07Rik, C78786, H4, H-4, H47, H-47, Seps1, Vimp|MGI:95994||||7|||||||||||||||||||||||||||||Young Seps1 GKO knockout mice present with a reduction in muscle strength and exercise capacity, and there is a blood vessel phenotype characterised by increased vascular reactivity. The mice are otherwise healthy.|Young Seps1 GKO heterozygous mice present with a reduction in muscle strength and exercise capacity, and there is a blood vessel phenotype characterised by increased vascular reactivity. The mice are otherwise healthy, fertility and breeding performance are not compromised in the heterozygous male and female mice.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Apr-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8533.0|ENU42:G3|ANU:ENU42:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|10-Jul-2018|Cryopreserved sperm|286.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8534.0|ENU43:G3|ANU:ENU43:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|10-Jul-2018|Cryopreserved sperm|452.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7573.0|37L1lacZ|C57BL/6N-A Gpr37L1/Apb||Dominant|G protein-coupled receptor 37-like 1|Gpr37l1|Unknown|CAG-18, D0Kist8|MGI:1928503|G protein-coupled receptor 37-like 1; targeted mutation 1b, Wellcome Trust Sanger Institute|Gpr37L1||1||||||||||Unknown to Unknown|||||||||||||||||||Unknown. Reporter mouse with gene deletion.|Unknown. Reporter mouse with gene deletion.|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|Pure background||het x het|No|20-Jan-2014|Cryopreserved sperm|70.0|0.0|No|||Possibly| 4198.0|NOD-Tg(IE-Igrp)69Wehi/J|NOD-Tg(H2-Ea-G6pc2)69Tkay/Apb ||Dominant|||Unknown||||||Unknown||||||||||||||||No|transgene insertion 69, Thomas Kay|1.8-kb fragment encoding nucleotides -1,903 through -39 of the 5' flanking sequence of the MHC Class II gene, H2-Ea (k allele)|Low||||||||||Insulitis: * mice develop insulitis with similar incidence and severity as non-transgenic controlsDecreased T cell proliferation: * G6pc2206-214-specific CD8+ T cells transferred from Tg(TcraTcrbNY8.3)1Pesa NOD mice proliferate extensively in peripheral and other lymph nodesAbnormal CD8-positive T cell morphology:* T cells specific for IGRP206-214 (G6pc2206-214) are not detected in peripheral blood* a complete absence of G6pc2206-214-specific CD8+ T cells is observed in expanded, cultured islet-infiltrating T cells compared to 40% of cultured T cells from control littermatesAbnormal CD4-positive T cell physiology:* no spontaneous CD4+ T cell response by cultured splenocytes exposed to G6pc24-22 peptide is detected in contrast to wild-type NOD miceAbnormal immune tolerance:* expanded T cells from pancreatic islets demonstrate tolerance to MHC class I and II-restricted G6pc2 peptidesIncreased susceptibility to autoimmune diabetes:* mice develop Type I diabetes at rate similar to wild-type NOD controlsIncreased anti-insulin autoantibody level:* insulin autoantibodies are elevated in 12-week old transgenic animals, similar to control wild-type NOD mice.Decreased T cell proliferation:* G6pc2206-214-specific CD8+ T cells transferred from Tg(TcraTcrbNY8.3)1Pesa NOD mice proliferate extensively in peripheral and other lymph nodes.Abnormal CD8-positive T cell morphology:* T cells specific for IGRP206-214 (G6pc2206-214) are not detected in peripheral blood.* a complete absence of G6pc2206-214-specific CD8+ T cells is observed in expanded, cultured islet-infiltrating T cells compared to 40% of cultured T cells from control littermates.Insulitis:* mice develop insulitis with similar incidence and severity as non-transgenic controls.|Type 1 Diabetes with same incidence as NOD/Lt control or littermate control mice. Mice do not develop T cell responses to the beta cell autoantigen G6pc2.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Dec-2008|Cryopreserved sperm|130.0|0.0|Yes||Tolerance, Autoimmunity, Autoantigen|Yes| 2434.0|Laxman:Hamlet|C57BL/6-Tg(H2-sHELdimer)/Apb Tg(IghelMD4)4Ccg/AnuApb||Recessive||||||||||||||||||||||||||soluble Hen Egg Lysozyme dimeric molecule|H-2K promoter|High|||||||||||High serum expression of dimeric soluble HEL.B cells express immunoglobulin that has a high affinity for hen egg lysozyme antigen (HEL).|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jan-2008|Cryopreserved sperm|75.0|0.0|No||Hen Egg Lysozyme HEL, dimeric, immunoglobulin, B cell, lymphocyte|Yes| 2434.0|Laxman:Hamlet|C57BL/6-Tg(H2-sHELdimer)/Apb Tg(IghelMD4)4Ccg/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 4, Christopher C Goodnow|||||||||||||High serum expression of dimeric soluble HEL.B cells express immunoglobulin that has a high affinity for hen egg lysozyme antigen (HEL).|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jan-2008|Cryopreserved sperm|||No||Hen Egg Lysozyme HEL, dimeric, immunoglobulin, B cell, lymphocyte|Yes| 7574.0|37L1KO|C57BL/6-Gpr37L1/NsmitApb||Recessive|G protein-coupled receptor 37-like 1|Gpr37l1|Reduced|CAG-18, D0Kist8|MGI:1928503|G protein-coupled receptor 37-like 1; targeted mutation 1d, Wellcome Trust Sanger Institute|Gpr37L1||1||||||||||Unknown to Unknown|||||||||||||||||||deletion of GPR37L1 causes a female-specific increase in systolic, diastolic, and mean arterial pressures.When challenged with short-term AngII infusion, only male GPR37L1 KO/KO mice developed exacerbated left ventricular hypertrophy and evidence of heart failure, while the female GPR37L1 KO/KO mice were protected from cardiac fibrosis.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|6||het x het|No|20-Jan-2014|Cryopreserved sperm|54.0|0.0|No|||Possibly| 4781.0|T-Bird|B10.B6JAnu-Dsg4/AnuApb|B10.B6JAnu-Dsg4/AnuApb|Recessive|desmoglein 4|Dsg4|Unknown|CDHF13, lah|MGI:2661061|desmoglein 4; t-bird|Dsg4|MGI:5007752|18|ENSMUSG00000001804|ENSMUST00000019426|Dsg4-001|643|777|A to C|ENSMUSE00000445469|6|215|Threonine to Proline|||||GTGCACCCATGTTCATGGTGAACAGGTACACTGGAGAAGTCCGCACGATGTCCAATTTCCT|Unknown|||||||||||||Greasy Coat. Affected mice develop a dull, sparse and greasy coat at about ~40 days of age. ||C57BL/6 x C57BL10|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5|||No|06-Sep-2009|Cryopreserved sperm|114.0|0.0|Unknown||Coat, greasy, hair, ENU|Yes| 93.0|Xander|C57BL/6JSfdAnu-Nfkb2/AnuApb|C57BL/6JSfdAnu-Nfkb2/AnuApb|Recessive|nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100|NFkb2|Nil|lyt, NF-kappaB2, p49, p49/p100, p50B, p52|MGI:1099800|xander|Nfkb2|MGI:2667230|19|ENSMUSG00000025225|ENSMUST00000073116|Nfkb2-201||||||||46381842|6|||TCATGGTCAAAGAGGACAAAGCCTCCTCCTTGTCCTCTCCAGATTTAATAATCTGGGTGT|No|||||||||||||Normal Thy1.2⁺ cellsReduced B220⁺ cellsDecrease numbers of peripheral B cells, normal numbers of BM B cellsNormal T cell numbersDecreased mature B2 cells in spleenSeven fold decrease in B1 cells in peritoneal cavitySmall peripheral lymph nodesDisturbed splenic microarchitectureLack of follicular dendritic cell clusters in spleen.Intrinsic to B cells||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|20.0|0.0|Unknown||B cell, follicular dendritic cell, spleen, lymphocyte|Yes| 4474.0|SPC-rtTA|C.FVB/N-Tg(SFTPC-rtTA)5Jaw/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 5, Jeffrey A Whitsett|human SFTPC (SPC) (surfactant protein-C)|respiratory epithelial cells|||||||||||The human SFTPC promoter is active in respiratory epithelial cells.|BALB/c x FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|22-Feb-2009|Cryopreserved sperm|165.0|0.0|Unknown||epithelium, asthma, eosinophil, IgE, lung|No| 4521.0|blonde ; ENU8C:032|B6;CBA-Erp44/AnuApb|B6;CBA-Erp44/AnuApb|Recessive|endoplasmic reticulum protein 44|Erp44||1110001E24Rik, Txndc4|MGI:1923549|endoplasmic reticulum protein 44; mutation 1, The Australian National University|Erp44|MGI:5563471|4|ENSMUSG00000028343|ENSMUST00000030028|Erp44-001||||||||48231077|5|||TTTATATGTTGCAAAATAATTGGATGCTTTATTTTACAGCGCAGTAAGAGAAATATCATT|Yes|||||||||||||Light coat colour, small stature, scaly tail.Positive for anti-nuclear antibodies?||C57BL/6JSfdAnu x CBA/H|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|160.0|0.0|Unknown||Coat colour, dwarf, ENU, Wellcome Trust, ANAphylaxis|Yes| 8589.0|F2rl1tm1c:K14-cre|B6.129-F2rl1 Krt14/Apb||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1||Gpcr11, Par2, PAR-2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1c, Wellcome Trust Sanger Institute|F2rl1|MGI:6151132|13|||||||||||||||||||||||||||||These mice were subjected to a model of periodontitis involving placement of a ligature around a tooth, combined with P. gingivalis infection ("Lig + Inf"). The intervention caused a significant 44% decrease in alveolar bone volume (assessed by microcomputed tomography) in wildtype (K14-Cre:F2rl1wt/wt ), but not littermate keratinocyte-specific PAR2 -null (K14-Cre:F2rl1fl/fl ) mice. Keratinocyte-specific ablation of PAR2 prevented the significant Lig + Inf-induced increase (2.8-fold) in the number of osteoclasts in alveolar bone and the significant up-regulation (2.4-4-fold) of the inflammatory markers IL-6, IL-1β, interferon-γ, myeloperoxidase, and CD11b in gingival tissue.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Oct-2018|Cryopreserved sperm|20.0|0.0|Unknown||Periodontal disease, infection|Yes| 8589.0|F2rl1tm1c:K14-cre|B6.129-F2rl1 Krt14/Apb||Recessive|keratin 14|Krt14||Cytokeratin 14, epidermolysis bullosa simplex, Dowling-Meara, Koebner, K14, Krt-1.14, Krt1-14|MGI:96688|keratin 14; targeted mutation 1.1, Walter Birchmeier|Krt14|MGI:2148597|11|||||||||||||||||||||||||||||These mice were subjected to a model of periodontitis involving placement of a ligature around a tooth, combined with P. gingivalis infection ("Lig + Inf"). The intervention caused a significant 44% decrease in alveolar bone volume (assessed by microcomputed tomography) in wildtype (K14-Cre:F2rl1wt/wt ), but not littermate keratinocyte-specific PAR2 -null (K14-Cre:F2rl1fl/fl ) mice. Keratinocyte-specific ablation of PAR2 prevented the significant Lig + Inf-induced increase (2.8-fold) in the number of osteoclasts in alveolar bone and the significant up-regulation (2.4-4-fold) of the inflammatory markers IL-6, IL-1β, interferon-γ, myeloperoxidase, and CD11b in gingival tissue.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Oct-2018|Cryopreserved sperm|||Unknown||Periodontal disease, infection|Yes| 7575.0|37L1null|B6;129S1/SvImJ-Gpr37l1/Apb||Dominant|G protein-coupled receptor 37-like 1|Gpr37l1|Nil|CAG-18, D0Kist8|MGI:1928503||||1|||||||||||||||||||||||||||||Elevated blood pressure|Unknown. Potentially elevated blood pressure.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|unknown|unknown|hom x hom|No|20-Jan-2014|Cryopreserved sperm|50.0|0.0|No||Heart, myocardium|Possibly| 7350.0|ST2 knockout|C.Cg-Il1rl1/Apb||Recessive|interleukin 1 receptor-like 1|Il1rl1|Nil|DER4, Fit-1, Ly84, St2, ST2, ST2L, St2-rs1, T1, T1 gene, T1/ST2|MGI:98427|interleukin 1 receptor-like 1; targeted mutation 1, Andrew NJ McKenzie|Il1rl1|MGI:2386675|1|||||||||||||||||||||||||||||Mice lack ST2 and ST2L proteins (these arise from splice variants of transcripts) that are respectively the soluble decoy receptot and membrane bound high affinity receptor for interleukin-33 (IL33). This results in resistance to chronic inflammatory conditions and some defects in Th2-dependent immunity, although the mice in an unchallenged condition can be considered as almost same as WT.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|many, >10 years||KO x KO with backcrossing on BALB/c every 2 generations or so.|No|06-Jun-2013|Cryopreserved sperm|45.0|0.0|No||Inflammation, Th2 cell, Bone, Mast cells|Yes| 7576.0|37L1cTg|C57BL/6-Tg(αMHC-Gpr37L1)/Apb||Dominant||||||||||||||||||||||||||G protein-coupled receptor 37-like 1|alpha-myosin heavy chain|||||||||||Unknown.|Unknown. |C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Pure background||hom x hom|No|20-Jan-2014|Cryopreserved sperm|65.0|0.0|No||Heart, myocardium|Possibly| 5208.0|Line:TF23|FVB/NJ-Tg(Prm1-Fgfr1*)4-9/MarpApb||Dominant||||||||||||||||||||||||||mutant fibroblast growth factor receptor 1|Prm1|restricted to sperm|||||||||||Mating of transgenic mice showed a significant reduction in pups per litter compared with wild-type littermates. Further analysis demonstrated that this subfertility was driven by a combination of reduced daily sperm output and a severely compromised ability of those sperm that were produced to undergo capacitation prior to fertilization. An analysis of key signal transduction proteins indicated that FGFR-1 is functional on wild-type sperm and probably signals via the phosphatidylinositol 3-kinase pathway. FGFR-1 activation also resulted in the downstream suppression of mitogen activated protein kinase signaling. These data demonstrate the FGFR-1 is required for quantitatively and qualitatively normal spermatogenesis and has a key role in the regulation of the global tyrosine phosphorylation events associated with sperm capacitation.|FVB/NJ|Yes|Yes|Yes|Yes|No|Yes|Yes|Unknown||||No|23-Aug-2010|Cryopreserved sperm|30.0|0.0|Unknown||signal transduction, Capacitation, Spermatogenesis, FGFR-1, Sperm|Yes| 5207.0|Line:TF14|FVB/NJ-Tg(Prm1-Fgfr1*)4-9/MarpApb||Dominant||||||||||||||||||||||||||mutant fibroblast growth factor receptor 1|Prm1|restricted to sperm|||||||||||Mating of transgenic mice showed a significant reduction in pups per litter compared with wild-type littermates. Further analysis demonstrated that this subfertility was driven by a combination of reduced daily sperm output and a severely compromised ability of those sperm that were produced to undergo capacitation prior to fertilization. An analysis of key signal transduction proteins indicated that FGFR-1 is functional on wild-type sperm and probably signals via the phosphatidylinositol 3-kinase pathway. FGFR-1 activation also resulted in the downstream suppression of mitogen activated protein kinase signaling. These data demonstrate the FGFR-1 is required for quantitatively and qualitatively normal spermatogenesis and has a key role in the regulation of the global tyrosine phosphorylation events associated with sperm capacitation.|FVB/NJ|Yes|Yes|Yes|Yes|No|Yes|Yes|Unknown||||No|23-Aug-2010|Cryopreserved sperm|30.0|0.0|Unknown||signal transduction, Capacitation, Spermatogenesis, FGFR-1, Sperm|Yes| 7577.0|AKBbm1|STOCK H2-K Tg(Alb-H2-K)/Apb||Dominant|histocompatibility 2, K region|H2-K|Unknown||MGI:3040519|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17|||||||||||||||||mouse H2-K (MHC class I)|Mouse albumin promoter|similar to wild type H2-K expression||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|21-Jan-2014|Cryopreserved sperm|50.0|0.0|No||tolerance, liver, CD8 T cells, MHC class I, autoimmunity|Possibly| 7753.0|Y20A; (kls/kls)|BALB/c-Atp4b/Apb||Recessive|ATPase, H+/K+ exchanging, beta polypeptide|Atp4b|Nil|H+,K+-ATPase, H+/K+-ATPase beta, H,K-ATPase-Beta|MGI:88114|ATPase, H+/K+ exchanging, beta polypeptide; targeted mutation 1, Ian R van Driel|Atp4b|MGI:2158258|8||||||||||||||||||||||||||||| The stomachs of H+,K+-ATPase beta subunit-deficient mice were achlorhydric. Histological and immunocytochemical analyses with antibodies to the H+,K+-ATPase alpha subunit revealed that parietal cell development during ontogeny was retarded in H+,K+-ATPase beta subunit-deficient mice. In 15-day-old mice, cells with secretory canaliculi were observed in wild-type but not in H+,K+-ATPase beta subunit-deficient mice. Parietal cells of H+,K+-ATPase beta subunit-deficient mice 17 days and older contained an abnormal canaliculus that was dilated and contained fewer and shorter microvilli than normal. In older parietal cells, the abnormal canaliculus was massive (25 mu m in diameter) and contained few microvilli. We did not observe typical tubulovesicular membranes in any parietal cell from H+,K+-ATPase beta subunit-deficient mice. Histopathologic alterations were only observed in the stomach.|normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>10|||No|03-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown||gastric acid, gastric proton pump, stomach, endocytosis|Possibly| 4762.0|Fxy Mid|B6.A/J-Mid1/MarpApb ||Semi-dominant|midline 1|Mid1|Nil||MGI:1100537|midline 1; targeted mutation 1, Alan Ashworth|Mid1|MGI:5562687|X||||||||||||||||Yes|||||||||||||Viable. Reduced / delayed fertility. Litter size may be slightly reduced. No other phenpotype described as yet.Abnormal axon morphology:• axon length and branch number are increased in cultured cortical neurons• callosal axons grow further into the contralateral hemisphere at P4• at P14, axon distribution in the corpus callosum is disturbed with a greater number of axon terminals, with a wider distribution in both the S1 and S2 regions• broader distribution of the contralateral axon projection pattern in the corpus callosumEmbryogenesis phenotype:• no obvious midline defects, unlike in Opitz Syndrome patients|Breeder pairs often only litter down after 3 months together, if they litter down at all. Around 1 in 3 produce litters.|A/J ; C57BL6/J|Yes|Yes|Yes|No|No|Yes|Yes|Poor||||No|01-May-2009|Cryopreserved sperm|88.0|0.0|Yes||Reporter, X-linked, craniofacial, cleft lip|Yes| 6859.0|18YAA024a|ENU18Yaa:024a||Recessive|accelerated autoimmunity and lymphoproliferation transposition|Yaa|Unknown|Tp(X;Y)1Ekw|MGI:99140|||MGI:1856277|Y||||||||||||||||Yes|||||||||||||Low B cell numbers||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Mar-2012|Cryopreserved sperm|49.0|0.0|Unknown||Monocytes, T cell, lymphoma, autoantibody, ENU, B cell|Yes| 6859.0|18YAA024a|ENU18Yaa:024a||Recessive|Unknown|Unknown|Unknown||||||Unknown||||||||||||||||Yes|||||||||||||Low B cell numbers||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Mar-2012|Cryopreserved sperm|||Unknown||Monocytes, T cell, lymphoma, autoantibody, ENU, B cell|Yes| 4529.0|B6.129-163C KI Tg1|B6.129-Ryr1/AnuApb||Recessive|ryanodine receptor 1, skeletal muscle|Ryr1|Normal|calcium release channel isoform 1, Ryr, skrr|MGI:99659|ryanodine receptor 1, skeletal muscle; targeted mutation 2, Paul D Allen|Ryr1||7||||||||||||||||Yes|||||||||||||Embryonic Lethal E17-18.|Fulminant malignant hyperthermia episodes inR163C heterozygous mice after exposure to 1.25–1.75% halothaneor an ambient temperature of 42°C characterized by increasedrectal temperature, respiratory rate, and inspiratoryeffort, with significant blood biochemical changes indicatingmetabolic acidosis, ending in death and hyperacute rigor mortis;(3) intraperitoneal pretreatment with dantrolene provided100% protection from the halothane-triggered fulminant malignanthyperthermia episode; (4) significantly increased sensitivity(decreased effective concentration causing 50% of the maximalresponse) of R163C heterozygous and homozygousmyotubes to caffeine, 4-chloro-m-cresol, and K-induced depolarization;(5) R163C heterozygous and homozygous myotubeshave a significantly increased resting intracellular Ca2 concentrationcompared with wild type; (6) R163C heterozygous sarcoplasmicreticulum membranes have a twofold higher affinity(Kd =35.4 nM) for [3H]ryanodine binding compared with wild type (Kd= 80.1 nM) and a diminished inhibitory regulation byMg2.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|4|||No|27-Feb-2009|Cryopreserved sperm|50.0|0.0|Yes||hyperthermia, muscle, sarcoplasmic reticulum, myotubules, MALIGNANT hyperthermia|Yes| 8537.0|Tle2|C57BL/6NCrlAnu-Tle2/AnuApb||Recessive|transducin-like enhancer of split 2|Tle2|Unknown|Grg2|MGI:104635||||10|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jul-2018|Cryopreserved sperm|58.0|0.0|Unknown||CRISPR|Yes| 5528.0|LylKI ; Scl Lyl1 knockin|B6;129S1/Sv-Tal1/MarpApb||Dominant|T-cell acute lymphocytic leukemia 1|Tal1|Reduced|bHLHa17, Scl, SCL/tal-1|MGI:98480|T-cell acute lymphocytic leukemia 1; targeted mutation 2, Walter and Eliza Hall, Institute of Medical Research|Tal1|MGI:1858004|4||||||||||||||||Yes|||||||||||||Embryonic lethal.Complete embryonic lethality during organogenesis: homozygotes die by about E9.5 due to absolute anemia.Absent vitelline blood vessels: at E9.5, mutant yolk sacs lack large branching vitelline vessels.Disorganized yolk sac vascular plexus: by E8, mutant yolk sacs exhibit a disorganized network of fine vascular channels.Abnormal embryonic hematopoiesis: homozygotes exhibit failure of yolk sac hematopoiesis, with no erythrocytes found in embryonic vessels.Absent blood islands: at E8.5, mutant yolk sacs display bloodless channels; PECAM-1 staining is restricted to the endothelium.Embryonic growth arrest: at E9.5, preterminal homozygotes are severely growth-retarded.Abnormal blood vessel morphology: * at E8.5, homozygotes display reduced cerebral vasculature with dilated intraembryonic vessels. * at E9.0, incomplete somitic vessels appear to undergo apoptosis resulting in loss of vascular architecture by E9.5.Dilated dorsal aorta: at E8.5, homozygotes exhibit dilated dorsal aortae.Abnormal vein morphology: at E8.5, homozygotes display dilated cardinal and perineural veins.Abnormal heart development.Delayed heart looping: at E8.5, the mutant heart is still a straight tube as a result of delayed cardiac looping.Distended pericardium: at E8.5, homozygotes exhibit dilated pericardial sacs.Pericardial edema: at E8.5, homozygotes display significant pericardial edema.Anemia: at E8.5-E9, homozygotes exhibit absolute anemia leading to hypoxia.Hypoxia: by E9.0, homozygotes display widespread intraembryonic hypoxic cell death.Increased neuron apoptosis: at E8.5, homozygotes display an increased number of apoptotic cells in the neural tube, probably secondary to hypoxia.|Normal|C57BL/6J|No|No|Yes|No|No|Yes|No|Good|||Maintain on C57BL/6 background|No|24-Jun-2011|Cryopreserved sperm|50.0|0.0|No||TAL-1, Lyl-1, hematopoiesis, bHLH, stem cells|Yes| 7770.0|SB 9|STOCK Gt(ROSA)26Sor TgTn(sb-T2/Onc3)12740Njen/NciApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Nancy A Jenkins|Gt(ROSA)26Sor|MGI:3839796|6|||||||||||||||||transgenic transposon concatemer 12740, Nancy A Jenkins||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|13-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown||sleeping beauty|Possibly| 5494.0|APN 106|C57BL/6N-Socs4/Marp||Recessive|suppressor of cytokine signaling 4 |Socs4|Unknown|Socs7|MGI:1914546 |suppressor of cytokine signaling 4; targeted mutation 1a, Wellcome Trust Sanger Institute|Socs4|MGI:4434370|14||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 5495.0|APN 43|Egfl6/Marp||Recessive|EGF-like-domain, multiple 6 |Egfl6 |Unknown|Maeg |MGI:1858599 |EGF-like-domain, multiple 6; gene trap CMHD-GT_485H8-5S, Centre for Modeling Human Disease|Egfl6|MGI:3923078|X||||||||||||||||No|||||||||||||Not bred to homozygosity - unknown.|Normal|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Possibly| 7771.0|Ptcd3|C57BL/6NCrlAnu-Ptcd3/AnuApb||Recessive|pentatricopeptide repeat domain 3|Ptcd3|Unknown|2610034F17Rik, 2810422B04Rik |MGI:1917206 |Ptcd3; mutation 1, the Australian National University|Ptcd3||6|ENSMUSG00000063884|ENSMUST00000082094|Ptcd3-201|289|311|A to T|ENSMUSE00000432359|5|97|Isoleucine to Lysine|||||CTTATGTATTTCACGATGATCCTTACCTCATACCAACCTCTGCTCTGGAGTCTCGTTCATT||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5|Het x Het|No|13-Oct-2014|Cryopreserved sperm|22.0|0.0|Unknown||Mitochondion, Translation, RNA binding, ENU|Yes| 6860.0|RNAi-17|C57Bl/6J-HDAC6/Apb||X-linked|histone deacetylase 6|Hdac6|Unknown|mHDA2, Sfc6|MGI:1333752||||X|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|21-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8540.0|MARCH 8 KO|C57BL/6-March8/Apb||Recessive|membrane-associated ring finger (C3HC4) 8|March8||1300017E09Rik, Mir|MGI:1919029||||6|||||||||||||||||||||||||||||Absence of MARCH 8Increase MHCII at surface of cortical thyme epithet cells and autoimmune regulator medullary thyme epithelial cells|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Jul-2018|Cryopreserved sperm|50.0|0.0|Unknown||MHC II, T cell|Yes| 1491.0|Inos-/-|B6;129-Nos2/Apb|B6;129-Nos2|Recessive|nitric oxide synthase 2, inducible, macrophage|Nos2|Nil|iNOS, Nos-2, NOS-II, Nos2, Nos2a|MGI:97361|targeted mutation 1, John S Mudgett|Nos2|MGI:2158791|11||||||||||||||||No|||||||||||||Abnormal artery morphology:* the large arteries of the uterus during pregnancy have thickened arterial walls and smaller lumina.Abnormal circulating estradiol level:* the cyclic changes in estradiol level are abnormal in homozygous mutant females with the peak in estradiol concentration coming later than in 129/SvEv wild-type females.Abnormal uterus morphology:* the lining of the uterus during pregnancy shows a distinct lack of cellularity in homozygous female mutants compared to wild-type females.Abnormal oestrous cycle:* diestrus length is increased in homozygous mutant females compared to 129/SvEv wild-type mice without an increase in total oestrus cycle lengthDecreased litter size:* by mid-gestation homozygous female mutants have significantly fewer viable embryos compared to wild-type females.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|03-Jul-2007|Cryopreserved sperm|235.0|0.0|Unknown||viral infection, uterus, interferon, influenza, estradiol|Yes| 6831.0|APN 138|C57Bl/6N-Inpp4a/MarpApb||Recessive|inositol polyphosphate-4-phosphatase, type I |Inpp4a|Unknown|107kDa |MGI:1931123|inositol polyphosphate-4-phosphatase, type I; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Inpp4a |MGI:4434756|1|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6871.0|APN206|C57Bl/6NTac-Gpr183/MarpApb||Recessive|G protein-coupled receptor 183|Gpr183|Unknown|Ebi2|MGI:2442034|G protein-coupled receptor 183; targeted mutation 1, Velocigene |Gpr183|MGI:3808449|14|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7074.0|APN 196|C57BL/6N-Scmh1Mu||Dominant|sex comb on midleg homolog 1|Scmh1 ||Scml3 |MGI:1352762 |sex comb on midleg homolog 1; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Scmh1tm1a(EUCOMM)Hmgu|MGI:4456695|4|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|04-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5.0|Buffy|C57BL/6JSfdAnu-Jak3/AnuApb|C57BL/6JSfdAnu-Jak3/AnuApb|Recessive|Janus kinase 3|Jak3|Normal||MGI:99928|buffy|Jak3|MGI:3611885|8|ENSMUSG00000031805|ENSMUST00000051995|Jak3-001|1193|1490|T to C|ENSMUSE00000329342|9|398|Leucine to Proline|||||CGCTGGCTCCCTCCCAGGCACCTACATTCTCCGCCGCAGCCCGCAGGACTATGACAGCTTT|No|||||||||||||Pan-Lymphopenia with hyperactivated CD4⁺ cellsObstructed B cell maturationReduced B cell numbers in peripheryB220⁺CD19⁺cells, IgM⁺IgD⁺ cells or CD21⁺IgD⁺ cells were reduced in the spleen by factor of 3.Peritoneal cavity: reduced IgM⁺IgD⁻ cells and only partially reduced IgM⁺IgD⁺ cell numbersReduced numbers of thymocytes at all stages of T cell maturation.Thymi are smaller than aged-matched controls.50% of CD4⁺ cells compared to controls4 fold lower levels of CD8⁺ cells compared to controlsMutation intrinsic to B and T cells, exaggerated under competitive reconstitution with wild-type cells, SCID mouse. Develop diarrhoea||C57BL/6JSfdAnu|Yes|Yes|Unknown|Yes|Yes|Yes|No|Good||||No|28-Nov-2005|Cryopreserved sperm|25.0|0.0|Unknown||T cell, B cell, IL-2, Thymus, ENU|Yes| 34.0|Captain Morgan, ENU4AT:038 |C57BL/6JSfdAnu-Dock8/AnuApb|C57BL/6JSfdAnu-Dock8/AnuApb|Recessive|dedicator of cytokinesis 8|Dock8|Nil||MGI:1921396|dedicator of cytokinesis 8; captain morgan|Dock8|MGI:3835422|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201||||||||25202202|20|||GCAGCCCATGGTCATTGCTGGCCAAACAGGTAGAGGCCTGTGGGTAGGGAGGAGGCATGG|Yes|||||||||||||Defective antibody response to immunization: failure to sustain antibody formation, undergo affinity maturation or to mount heightened recall (memory) response upon booster immunization. DOCK8-mutant B cells were unable to form marginal zone B cells or to persist in germinal centers and undergo affinity maturation. Dock8 mutations disrupted accumulation of the integrin ligand ICAM-1 in the B cell immunological synapse but did not alter other aspects of B cell antigen receptor signaling.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Apr-2004|Cryopreserved sperm|26.0|0.0|Unknown||gammaglobulin, immunization, antibody, ENU, Wellcome Trust, memory, B cell, GTP|Yes| 1485.0|B6.OT-1|C57BL/6-Tg(TcraTcrb)1100Mjb/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1100, Michael J Bevan|H-2K promoter|||||||||||Transgenic mice on a C57BL/6 background are somewhat immunodeficient, and may be used to study the role of peptides in positive selection and the response of CD8+ T cells to antigen.Carry OVA-specific, H-2K-restricted T cell receptor|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Jul-2007|Cryopreserved sperm|150.0|0.0|No||T cell, receptor, ovalbumin, CD8|Yes| 6869.0||Porthos:kk||Dominant||||||||||||||||||||||||||Genomic IgG anti-HEL H + L||low copy|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant |H2|MGI:3579322|17|||C57BL/6 x B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Apr-2012|Cryopreserved sperm|68.0|0.0|No||Hen Egg Lysozyme, autoimmunity, T cell, B cell|Yes| 6861.0|APN 144|C57Bl/6NTac-Gpr18/MarpApb||Recessive|G protein-coupled receptor 18 |Gpr18|Unknown||MGI:107859|G protein-coupled receptor 18; targeted mutation 1, Velocigene |Gpr18 |MGI:3812675|14|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6830.0|APN 128|C57Bl/6N-Pxmp4/MarpApb||Recessive|peroxisomal membrane protein 4|Pxmp4 |Unknown|3010018P03Rik |MGI:1891701 |peroxisomal membrane protein 4; targeted mutation 1, Wellcome Trust Sanger Institute |Pxmp4 |MGI:4419659|2|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8541.0|MHCII KR |B6.129-H2-Ab1/SishApb||Recessive|histocompatibility 2, class II antigen A, beta 1|H2-Ab1||Abeta, A beta, H-2Ab, H2-Ab, Ia2, Ia-2, IAb, I-A, I-Abeta, Rmcs1|MGI:103070|histocompatibility 2, class II antigen A, beta 1; targeted mutation 1.1, Satoshi Ishido|H2-Ab1|MGI:4436864|17|||||||||||||||||||||||||||||MHCII cytoplasmic lysine residue replaced by arginine residue.MHCII unable to be modified by ubiquitinationIncreased MHCII surface levels on haematopoietic antigen presenting cells including dendritic cells. Higher levels of antigen presentation by thyme dendritic cells. Impaired abiliity of dendritic cells to differentiate immature thymocytes into T regulatory cells. Reduced frequency & number of regulatory T cells.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Jul-2018|Cryopreserved sperm|50.0|0.0|Unknown||E3 ubiquitin ligase, MHCII|Yes| 8318.0|CIB1 Knockout|B6.129S6-Cib1/Apb||Recessive|calcium and integrin binding 1 (calmyrin)|Cib1|Nil|Kip|MGI:1344418|calcium and integrin binding 1 (calmyrin); targeted mutation 1, Leslie V Parise|Cib1|MGI:3690129|7|||||||||||||||||||||||||||||Female, normalDecreased testis weight:• weight of testis at 3-4 months of age is about 47.5% that of controlsAbnormal spermatogenesis: • spermatogonia, spematocytes, and round spermatids are present in the testis; however, seminiferous tubules lack advanced spermatids, have multinucleated spermatids near the tubule lumen and no sperm are found in the epididymis• increase in spermatid apoptosis in the testisAzoospermia: • sperm production is undetectable in the epididymisAbnormal spermiogenesis.• disruption of the haploid phase of germ cell differentiationarrest of spermatogenesis.• spermatogenic cells complete both mitotic and meiotic divisions, however postmeiotic spermatids do not develop normally and sperm are not producedMale infertility: • males are sterile due to disruption of the haploid phase of spermatogenesis|Both female and male are normal|C57BL/6|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|03-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||Sperm|Yes| 51.0|LeukSkywalker, ENU3strain:004 |B6JSfdAnu;NODAnu-Eed/AnuApb|B6SfdAnu;NODAnu-Eed/AnuApb|Recessive|embryonic ectoderm development|Eed|Nil|l(7)5Rn, l7Rn5|MGI:95286|LeukSkywalker|Eed|MGI:3611895|7|ENSMUSG00000030619|ENSMUST00000107234|Eed-001||||||||97120003|4|||GTTTTTATAGCCCTGGTTTAAGAAATTTGATAAGTACATCAGAACTTTGAAAACGAATTC|No|||||||||||||Dwarf, dilute coat, possible leukemia ||C57BL/6JSfdAnu x NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7||No|06-Feb-2006|Cryopreserved sperm|121.0|0.0|Unknown||leukaemia, dwarfism, ENU|Yes| 5069.0|Elektra|C57BL/6J-Slfn2/BltrAnuApb|C57BL/6J-Slfn2/BltrAnuApb|Recessive|schlafen 2|Slfn2|Unknown|Shlf2|MGI:1313258|schlafen 2; mutation 1, Bruce Beutler|Slfn2|MGI:3850348|11||||||||||||||||Yes|||||||||||||CD8 deficiency, decreased CD8 response, hematopoietic system, immune system, mouse cytomegalovirus (MCMV) susceptibility, NKT cell deficiency.Elektra mice died six to eight days after infection with 2x10 5 PFU of MCMV, whereas nearly all wild type mice survived.Elektra homozygotes were also highly susceptible to infection with Listeria monocytogenes, exhibiting increased bacterial loads in the liver 2 days post-infection relative to those of wild type mice. Elektra mice displayed normal cellularity of the spleen, thymus, lymph nodes, and peripheral blood. B cells from elektra mice proliferated normally in response to BCR stimulation or CpG treatment. However, antibody production in response to MCMV infection was delayed. Elektra mice lacked NKT (CD3+NK1.1+) cells in the thymus and spleen, and had reduced numbers in the liver. When elektra NKT cells were stimulated with α-galactosylceramide tetramer, they produced greatly reduced levels of IFN-γ and IL-4 compared to wild type cells. Elektra mice displayed a 50% reduction in Foxp3+ regulatory T cells.Elektra CD8+ T cells failed to proliferate upon stimulation with CD3ε and CD28 antibodies, with PMA and ionomycin, or with IL-12 in vitro.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Mar-2010|Cryopreserved sperm|49.0|0.0|Unknown||CD8, MCMV, interferon, T cell, infection, NKT, ENU|Yes| 8590.0|mm1286del|C57BL/6-Grh2/Apb||Recessive|grainyhead like transcription factor 2|Grhl2|Unknown|0610015A08Rik, BOM, clft3, grainyheadlike, Tcfcp2l3|MGI:2182543||||15|||||||||||||||||||||||||||||We predict that nullizygous (-/-) embryos will have slight alterations to craniofacial morphology.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Oct-2018||0.0|0.0|Unknown|||Yes| 7075.0|ENU24:006:5730590G19RIK|C57BL/6NCrlAnu-Ticrr/AnuApb|C57BL/6NCrlAnu-Ticrr/AnuApb|Recessive|TOPBP1-interacting checkpoint and replication regulator|Ticrr||5730590G19Rik|MGI:1924261|TOPBP1-interacting checkpoint and replication regulator; mutation 1, The Australian National University|Ticrr|MGI:5563404|7|ENSMUSG00000046591|ENSMUST00000035977|Ticrr-201|1748|1892|A to C|ENSMUSE00000592184|7|583|Asparagine to Threonine|||||TACCATGTCCCGCTCCTTGAAGATGTTGAATGTGGCAAGGCTAAATGTAAAGGCTCAGAAA||||||||||||||Homozygous mice are mostly hairless, with only a light patch of hair around the face and tail. |Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|05-Sep-2012|Cryopreserved sperm|6.0|0.0|Unknown||ENU, coat, hair|Yes| 7088.0|SOCS-1 KO Des Rag|B10.BR.Cg-H2 SOCS1/Wehi Tag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|suppressor of cytokine signaling 1|Socs1|Nil|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|targeted mutation 1, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:1934607|16||||||||||||||||No|transgene insertion 10395, Bernd Arnold|||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Postnatal lethality:* homozygotes become ill and die before reaching 3 weeks of age.* mice die from inflammatory disease before weaning.Decreased body weight:* homozygotes become smaller within 10 days after birthPostnatal growth retardation.Pancreas inflammation: monocytic infiltration.Decreased hematocrit.Decreased lymphocyte cell number.Decreased B cell number:* progressive loss of maturing B lymphocytes in the marrow, spleen, and peripheral blood.Decreased pre-B cell number:* pre-B cells are depleted significantly in the marrow.Decreased eosinophil cell number:* moderate reduction in eosinophil numbersAbnormal mature B cell morphology:* number of mature B cells expressing surface Ig in the bone marrow is reduced.Abnormal follicular B cell morphology:* lymphoid follicles of the spleen are either completely absent or are composed of immature cells.Increased spleen red pulp amount:* most spleens show expanded areas of red pulp with nucleated erythroid cells as the main cell population.Thymus cortex hypoplasia:* the cortex becomes progressively depleted of lymphoid cellsSmall thymus.Abnormal Peyer's patch morphology:* Peyer's patches are present but contain few lymphocytes.Abnormal lymph node B cell domain:* lymph nodes show absence of lymphoid follicle formation.Increased inflammatory response:* mice die from massive generalized inflammation that affects multiple organs.Heart inflammation: monocytic, and less frequently, granulocytic infiltration.Pancreas inflammation: monocytic infiltration.Liver inflammation: livers exhibit both focal and generalized infiltration, predominantly by immature and mature monocytic and granulocytic cells, and less frequently, megakaryocytes and eosinophils.Hepatic steatosis: parenchymal cells contain an accumulation of lipid-containing vacuoles.Liver degeneration: fatty degeneration either involves local areas not related to portal vessels or is generalized to the entire liver.Abnormal respiratory alveoli morphology: increase in cellularity of alveolar walls in the lung, often associated with macrophage cuffing around major vessels.||B10.BR|No|No|Yes|No|No|Yes|No|Unknown||||No|20-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown||Cytokine signalling, phosphorylation, signal transduction, IL-6 receptor, growth retardation|Yes| 7088.0|SOCS-1 KO Des Rag|B10.BR.Cg-H2 SOCS1/Wehi Tag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|Recombination activating gene 1|Rag1||Rag-1|MGI:97848||||2|||||||||||||||||||||||||||||Postnatal lethality:* homozygotes become ill and die before reaching 3 weeks of age.* mice die from inflammatory disease before weaning.Decreased body weight:* homozygotes become smaller within 10 days after birthPostnatal growth retardation.Pancreas inflammation: monocytic infiltration.Decreased hematocrit.Decreased lymphocyte cell number.Decreased B cell number:* progressive loss of maturing B lymphocytes in the marrow, spleen, and peripheral blood.Decreased pre-B cell number:* pre-B cells are depleted significantly in the marrow.Decreased eosinophil cell number:* moderate reduction in eosinophil numbersAbnormal mature B cell morphology:* number of mature B cells expressing surface Ig in the bone marrow is reduced.Abnormal follicular B cell morphology:* lymphoid follicles of the spleen are either completely absent or are composed of immature cells.Increased spleen red pulp amount:* most spleens show expanded areas of red pulp with nucleated erythroid cells as the main cell population.Thymus cortex hypoplasia:* the cortex becomes progressively depleted of lymphoid cellsSmall thymus.Abnormal Peyer's patch morphology:* Peyer's patches are present but contain few lymphocytes.Abnormal lymph node B cell domain:* lymph nodes show absence of lymphoid follicle formation.Increased inflammatory response:* mice die from massive generalized inflammation that affects multiple organs.Heart inflammation: monocytic, and less frequently, granulocytic infiltration.Pancreas inflammation: monocytic infiltration.Liver inflammation: livers exhibit both focal and generalized infiltration, predominantly by immature and mature monocytic and granulocytic cells, and less frequently, megakaryocytes and eosinophils.Hepatic steatosis: parenchymal cells contain an accumulation of lipid-containing vacuoles.Liver degeneration: fatty degeneration either involves local areas not related to portal vessels or is generalized to the entire liver.Abnormal respiratory alveoli morphology: increase in cellularity of alveolar walls in the lung, often associated with macrophage cuffing around major vessels.||B10.BR|No|No|Yes|No|No|Yes|No|Unknown||||No|20-Sep-2012|Cryopreserved sperm|||Unknown||Cytokine signalling, phosphorylation, signal transduction, IL-6 receptor, growth retardation|Yes| 6862.0||ENU18NIH21a||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||few mature B cells|unknown|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Mar-2012|Cryopreserved sperm|40.0|0.0|Unknown||ENU, B cell|No| 7089.0|178.3|B10.BR.Cg-Tg(H2-K)178.3/Apb||Dominant||||||||||||||||||||||||||transgene insertion|H-2Kb|||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|20-Sep-2012|Cryopreserved sperm|50.0|0.0|No||MHC class II|Yes| 110.0|Arjuna ; ILK3|C57BL/6JSfdAnu-Tg(ILK3mHEL)3Ccg/AnuApb|C57BL/6JSfdAnu-Tg(ILK3mHEL)3Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||6|sib x sib|No|06-Feb-2006|Cryopreserved sperm|150.0|0.0|No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell|Yes| 7772.0|Hic1-lacz|B6.129S4-Hic1/AusbApb||Dominant|hypermethylated in cancer 1|Hic1|Nil|HIC-1|MGI:1338010|hypermethylated in cancer 1; targeted mutation 1, Stephen B Baylin|Hic1|MGI:2386879|11|||||||||||||||||||||||||||||Homozygotes die perinatally and exhibit varying combinations of gross developmental defects throughout the second half of development, including acrania, exenchephaly, cleft palate, limb abnormalities and omphalocele. |Develop many different spontaneous malignant tumours, including the predominance of epithelial tumours in males and lymphomas and sarcomas in females.|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|14-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown||zinc-finger transcription factor, epithelial, lymphoma, sarcoma, epigenetic|Yes| 7090.0|AKbDes|B10.BR(Cg)-Tg(Alb-H2-K) Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Dominant||||||||||||||||||||||||||mouse H2-Kb (MHC class I)|Mouse albumin promoter|similar to wild type H2-K expression||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|20-Sep-2012|Cryopreserved sperm|40.0|0.0|Unknown||CD8 , T cells, MHC Class I, Liver, hepatocyte|Yes| 7090.0|AKbDes|B10.BR(Cg)-Tg(Alb-H2-K) Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Dominant||||||||||||||||||||||||||transgene insertion 10395, Bernd Arnold||||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|20-Sep-2012|Cryopreserved sperm|||Unknown||CD8 , T cells, MHC Class I, Liver, hepatocyte|Yes| 10353.0|Adidias|C57BL/6NCrlAnu-Nfkb2/Anu||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B cells 2|Nfkb2 |||MGI:1099800 |nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100; endonuclease-mediated mutation 1, Matthew C Cook|Nfkb2Macc|MGI:6835770|19|||||||||||||||||||||||||||||thymic medullary hypoplasia|thymic medullary hypoplasia|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|18-Aug-2023|Cryopreserved sperm|33.0|0.0|Unknown|||Possibly| 7019.0||ENU22:Bcl2:022:b:B6||Recessive||||||||||||||||||||||||||||||||||||||The strain has a possible low lymphocyte phenotype.|||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Jul-2012|Cryopreserved sperm|10.0|0.0|Unknown||ENU|No| 6863.0|ENU18NIH57a vav1|C57BL/6JAnu-Vav1/AnuApb|C57BL/6JAnu-Vav1/AnuApb|Recessive|vav1 oncogene|Vav1|Unknown||MGI:98923|vav1 oncogene; mutation 1, The Australian National University|Vav1|MGI:5563399|17|ENSMUSG00000034116|ENSMUST00000169220|Vav1-004|607|705|T to C|ENSMUSE00000139022|8|203|Phenylalanine to Serine|||||AGCAGCACTTCATGAAGCCTCTGCAGCGATTCCTTAAGCCTCAAGACATGGAGACCATCTT||||||||||||||Increased Klrg1<+> CD8<+> T cells following immunisation|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||G5|homozygous x homozygous|No|23-Mar-2012|Cryopreserved sperm|46.0|0.0|Unknown||lymphocyte, T cell, KLRG1, CD8, immunisation, ENU|Yes| 67.0|Listerin, Senseless|STOCK Ltn1/AnuApb|STOCK Ltn1/AnuApb|Recessive|listerin E3 ubiquitin protein ligase 1|Ltn1|Normal|Listerin, Rnf160, Zfp294|MGI:1926163|listerin E3 ubiquitin protein ligase 1; lister|Ltn1|MGI:3838105|16|ENSMUSG00000052299|ENSMUST00000039449|Rnf160-201||||||||87415397|11|||GGAGTTCTCTTCTTCAGGTCATTGAAAAGGTATTTTAGCCCCCTCTCCCCTTTCCCTTTC|Yes|||||||||||||Late onset spastic paralysis & appear to have sensory defects, progresses to seizures and death||C57BL/6JSfdAnu x NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|127.0|0.0|Unknown||paralysis, seizures, ataxia, ENU|Yes| 7077.0|APN173|C57Bl/6N-A-Map3k5/Marp||Recessive|mitogen-activated protein kinase kinase kinase 5|Map3k5|Unknown|7420452D20Rik, ASK, ASK1, Mekk5|MGI:1346876|mitogen-activated protein kinase kinase kinase 5; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Map3k5|MGI:4434801|10||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|05-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 3934.0|RRFU|BALB/c-Gt(ROSA)26Sor/AnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1.1, Hugh D Campbell|Gt(ROSA)26Sor|MGI:4939371|6|||||||||||||||||||||||||||||Normal.impaired wound healing|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|4||Hom x Hom|No|16-Oct-2008|Cryopreserved sperm|80.0|0.0|Unknown||ROSA, flightless, wound healing|Yes| 201.0|TGFbRIII KO|B6;129S1-Tgfbr3/Apb|B6;129S1-Tgfbr3/Apb|Recessive|transforming growth factor, beta receptor III|Tgfbr3|Nil|betaglycan, TBRIII|MGI:104637|targeted mutation 1, Kaye Stenvers|Tgfbr3|MGI:2664514|5||||||||||||||||No|||||||||||||Mice homozygous for disruptions in this gene usually die as embryos. The very few individuals that survive are poorly fertile with abnormalities of the spleen, liver, heart, and skeletal system.Embryonic lethal E16.5-E18.5 of heart and liver defects||C57BL/6 x 129|No|No|Yes|No|No|Yes|Yes|Unknown||||No|18-Apr-2006|Cryopreserved sperm|210.0|0.0|Unknown||heart, liver, embryonic lethal, growth factor|Yes| 91.0|Winnie|C57BL/6JSfdAnu-Muc2/AnuApb|C57BL/6JSfdAnu-Muc2/AnuApb|Recessive|mucin 2|Muc2|Nil||MGI:1339364|Winnie|Muc2|MGI:3614806|7|ENSMUSG00000025515|ENSMUST00000026590|Muc2-202|2963|2968|G to A|ENSMUSE00000467940|25|988|Cysteine to Tyrosine|||||GCTGGACCCCTCTTACAAGGGCACTGTATGTGGTCTGTGTGGGAACTTTGATGACCAGACC|Yes|||||||||||||Diarrhoea, soft feces at weaning, some develop rectal prolapse. GIT does not appear inflamed, goblet cell hyperplasia and developmental or functional deficiency - malabsorption syndrome||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|34.0|0.0|Unknown||diarrhoea, malabsorption, goblet cell, ENU|Yes| 8597.0|Grhl2+/-;Noggin+/-|B6(Cg).129-Grhl2 Nog/Apb||Recessive|grainyhead like transcription factor 2|Grhl2|Nil|061001|MGI:2182543|grainyhead like transcription factor 2; targeted mutation 1.1, Stephen M Jane|Grhl2|MGI:4836381|15|||||||||||||||||||||||||||||Embryos resulting from intercrosses, and which are genetically null for both Grhl2 and Noggin will be expected to have neural tube, skeletal and/or craniofacial defects.|Grhl2+/-;Noggin+/- adult mice appear to have no discernible phenotype|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|02-Nov-2018|Cryopreserved sperm|40.0|26.0|Unknown|||Yes| 8597.0|Grhl2+/-;Noggin+/-|B6(Cg).129-Grhl2 Nog/Apb||Recessive|noggin|Nog|||MGI:104327|noggin; targeted mutation 1, Andrew P McMahon|Nog|MGI:1862000|11|||||||||||||||||||||||||||||Embryos resulting from intercrosses, and which are genetically null for both Grhl2 and Noggin will be expected to have neural tube, skeletal and/or craniofacial defects.|Grhl2+/-;Noggin+/- adult mice appear to have no discernible phenotype|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|02-Nov-2018|Cryopreserved sperm|||Unknown|||Yes| 5520.0|p47phox knockout|B6.129S2-Ncf1/MarpApb||Recessive|neutrophil cytosolic factor 1|Ncf1|Nil|NADPH oxidase subunit (47kDa), Ncf-1, NOXO2, p47, p47phox|MGI:97283|neutrophil cytosolic factor 1; targeted mutation 1, Steven M Holland|Ncf1|MGI:1934143|5||||||||||||||||No|||||||||||||Animals are immunocompromised and hence highly susceptible to bacterial infection.|Animals are immunocompromised and hence highly susceptible to bacterial infection.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Jun-2011|Cryopreserved sperm|50.0|0.0|Yes|Chronic granulomatous disease (CGD)|bacterial infection, Chronic granulomatous disease (CGD), nicotinamide dinucleotide phosphate (NADPH) oxidase, granuloma|Yes| 107.0|Albert ; KLK4|C57BL/6JSfdAnu-Tg(KLK4mHEL)6Ccg/AnuApb|C57BL/6JSfdAnu-Tg(KLK4mHEL)6Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 6, Christopher C Goodnow|H2-K|Ubiquitous||||||||||Express membrane bound HEL under control of H2-K promoter. Transmembrane domain cloned from H2-K molecule.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||21|hom x hom|No|06-Feb-2006|Cryopreserved sperm|122.0|0.0|Unknown||Hen egg lysozyme (HEL), membrane bound, H2, autoimmunity|Yes| 7572.0|37L1flx|C57BL/6N-A Gpr37L1/Apb||Dominant|G protein-coupled receptor 37-like 1|Gpr37l1|Unknown|CAG-18, D0Kist8|MGI:1928503|G protein-coupled receptor 37-like 1; targeted mutation 1c, Wellcome Trust Sanger Institute|Gpr37l1||1|||||||||||||||||||||||||||||Unknown. Predicted wild type expression.|Unknown. Predicted wild type expression.|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|Pure background||het x het|No|20-Jan-2014|Cryopreserved sperm|50.0|0.0|No|||Possibly| 7092.0|Mekk2: ENU7PMH 130 B10:B6 (no ndfip1) |C57Bl/6N-Map3k2/Anu||Recessive|mitogen-activated protein kinase kinase kinase 2|Map3k2|Unknown|9630061B06Rik, Mekk2, MEK kinase 2|MGI:1346873||||18|||||||||||||||||||||||||||||Unknown |Unknown|C57BL/6SfdAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|unknown|unknown|het x het|No|21-Sep-2012|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Possibly| 10356.0|Irf4K123R14 |C57BL/6NCrlAnu-Irf4/Anu||Recessive|interferon regulatory factor 4|Irf4 |||MGI:1096873 |Irf4:endonuclease-mediated mutation 3, Australian National University|Irf4||13|ENSMUSG00000021356 |ENSMUST00000021784|||||||||||||||||||||||||||Reduced GC responses, other phenotypes unknown|Reduced GC responses, other phenotypes unknown||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Sep-2023|Cryopreserved sperm|44.0|0.0|Unknown|||Possibly| 161.0|D3∆|B6.129P2-Dll3/Apb|B6.129P2-Dll3/Apb|Recessive|delta-like 3|Dll3|Nil||MGI:1096877|Dll3 targetted mutation 1, Rosa Beddington|Dll3|MGI:2178443|7||||||||||||||||No|||||||||||||Homozygous mutants have shortened tail and trunk, with disorganised vertebrae and costal defects resulting from defective segmentation in the embryo and delayed and irregular somite formation.|None|C57BL/6|No|No|No|No|No|Yes|No|Good|10|11|+/Dll3 x C57BL/6. This was found to produce larger litters than +/Dll3 sib-matings|No|09-Mar-2006|Cryopreserved sperm|140.0|0.0|Yes||Dll3, somitogenesis, spondylocostal dysostosis, abnormal vertbral segmentation|Yes| 346.0|NODlprT° (2004)|NOD.Cg-Tnfrsf1a Fas/Apb|NOD.Cg-Tnfrsf1a Fas/Apb|Recessive|Fas (TNF receptor superfamily member)|Fas|Reduced|APO-1, APT1, CD95, Fas, TNFR6, Tnfrsf6|MGI:95484|lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||Yes|||||||||||||NODlprT°(2004) homozygotes have lymphadenopathy similar to the NOD.MRL(C3)-Fas/LtJ parental strain (see http://jaxmice.jax.org/strain/004519.html for complete details of duplicate stran called NOD.MRL(c3)-Fas/DoiJ). This strain also has autoimmune characteristics similar to that seen on the MRL background (e.g. immune complex glomerulonephritis). Thee mice do not develop islet infiltrates. Older mice (>20weeks) develop larger livers. (This is possibly a consequence of liver infiltrates blocking vessels)|Similar to NOD/LtJ but there is a possible reduced incidence of diabetes though not formerly tested.|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|8|sib x sib or random within a generation|No|25-Sep-2006|Cryopreserved sperm|40.0|0.0|Unknown||autoimmunity, lymphadenopathy, glomerulonephritis, lymph node architechture|Yes| 346.0|NODlprT° (2004)|NOD.Cg-Tnfrsf1a Fas/Apb|NOD.Cg-Tnfrsf1a Fas/Apb|Recessive|Tumor necrosis family receptor superfamily, member 1a|Tnfrsf1a|Unknown|CD120a, p55, p55-R, TNF receptor alpha chain, TNF-R-I, TNF-R1, TNF-R55, TNFAR, Tnfr-2, Tnfr1, TNFR60, TNFRp55|MGI:1314884|targeted mutation 1, Horst Bluethmann|Tnfrsf1a|MGI:1861040|Unknown|||||||||||||||||||||||||||||NODlprT°(2004) homozygotes have lymphadenopathy similar to the NOD.MRL(C3)-Fas/LtJ parental strain (see http://jaxmice.jax.org/strain/004519.html for complete details of duplicate stran called NOD.MRL(c3)-Fas/DoiJ). This strain also has autoimmune characteristics similar to that seen on the MRL background (e.g. immune complex glomerulonephritis). Thee mice do not develop islet infiltrates. Older mice (>20weeks) develop larger livers. (This is possibly a consequence of liver infiltrates blocking vessels)|Similar to NOD/LtJ but there is a possible reduced incidence of diabetes though not formerly tested.|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|8|sib x sib or random within a generation|No|25-Sep-2006|Cryopreserved sperm|||Unknown||autoimmunity, lymphadenopathy, glomerulonephritis, lymph node architechture|Yes| 629.0|Elf5 KO|B6;129S4-Elf5/Apb|B6;129S4-Elf5/Apb|Semi-dominant|E74-like factor 5|Elf5|Nil|ESE-5|MGI:1335079|targeted mutation 1, Melanie A Pritchard|Elf5|MGI:3573855|2||||||||||||||||No|||||||||||||Homozygous embryos die between E3.5 and E7.5|Background Sensitivity: all heterozygous females resulting from backcrosses to 129T2/SvEms failed to lactate even after multiple pregnancies.Initial development of the mammary gland is normal however development stalls during the proliferation phase resulting in retarded alveolar genesis.About 84% of heterozygous females fail to support any pups and about 6% were able to support a reduced number of pups.No overt phenotype, mammary gland defect in females upon pregnancy resulting in a failure to nurse offspring.|129Sv|No|No|Yes|Yes|No|Yes|No|Good|10||Het x Het or Het male x WT female|No|25-Apr-2007|Cryopreserved sperm|70.0|0.0|Unknown||Mammary gland defect, embryonic lethal, prolactin receptor, pregnancy|No| 694.0|Galn KO|129-Gal/Apb|129-Gal/Apb|Recessive|Galanin|Gal|Nil|Galn|MGI:95637|targeted mutation 1, David Wynick|Gal|MGI:2183172|19||||||||||||||||Yes|||||||||||||abnormal branching of the mammary ductal tree -reduced ductal branching in the mammary glands of 8 week old virgin femalesreduced numbers of lactotrophsdecreased insulin secretion abnormal lactation - females unable to lactate resulting in death of all pups within 48 hours of birth unless fostered outinability to lactate is absolute for first pregnancies but pup survival improves to 20% after later pregnanciesabnormal pituitary secretion - prolactin levels in the hypophysis of randomly cycling females reduced about 40%, plasma levels of prolactin are generally normallevels of both prolactin message and peptide reduced in the pituitary 7 days postpartum, serum prolactin also reduced in serum 7 days postpartumestradiol-17beta induces increased prolactin mRNA but not proteinabnormal circulating insulin level - 2-deoxy-glucose has less effect on the initial drop in plasma insulin levels but a causes a greater increase in subsequent insulin levelsabnormal adenophysis morphologyreduced numbers of lactotrophshippocampal neuron degeneration - kainic acid injection induces significantly increased CA1 (62.9%) and CA2 (44.8%) apoptosis, staurosporine and glutamate both cause increased cell death of hippocampal neurons in culturedecreased sensory neuron number, abnormal dorsal root ganglia morphology - dorsal root ganglia of L4 and L5 are reduced 13% relative to controlssmall peptidergic neurons preferentially lostshort period of apoptosis occurs around 3-4 days of ageabnormal nervous system regeneration - nerve regeneration reduced by 30-40%sciatic nerve regeneration after injury incomplete until some time between 4 and 5 weeks whereas complete recovery only takes 2 weeks in controlsabnormal object recognition memory - increased exploration of objects placed in a familiar settingfailure to discriminate familiar objects in a changed location.||Sv129|Yes|No|Yes|Yes|Yes|Yes|No|Poor||||No|01-May-2007|Cryopreserved sperm|100.0|0.0|Unknown||lactation, prolactin, hormone, mammary gland|Yes| 8548.0|Foz:Tlr9 KO|C57BL/6-Alms1 Tlr9/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Foz mice are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.Tlr9 KO mice have:Abnormal immune system physiology:*Response to LPS and CpG is completely abrogated. Impaired NK cell cytolysis: *No NK cell activation is observed following infection with L. infantum. Decreased interferon-alpha secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interferon-beta secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interleukin-12b secretion: *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice. *Unlike in wild-type mice, IL-12p40 production from dendritic cells following infection with Leishmania infantum is indetectable. Decreased tumor necrosis factor secretion: *Following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced. Decreased susceptibility to experimental autoimmune encephalomyelitis: *Myelin oligodendrocyte glycoprotein injection results in delayed onset of disease, 17.9 days after injection rather than 15.9 days as in controls. *Fewer infiltrating foci in the spinal cord. Abnormal response to infection: *Following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a partially decreased immune response in terms of TNF secretion and response to CpG. Decreased susceptibility to parasitic infection: *Resistant to cerebral malaria. *Reduced accumulation of hemozoin. *Less upregulation of TNF-alpha in Plasmodium infection.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018|Cryopreserved sperm|72.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 8548.0|Foz:Tlr9 KO|C57BL/6-Alms1 Tlr9/AnuApb||Recessive|toll-like receptor 9|Tlr9|Nil||MGI:1932389|toll-like receptor 9; targeted mutation 1, Shizuo Akira|Tlr9|MGI:2660562|9|||||||||||||||||||||||||||||Foz mice are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.Tlr9 KO mice have:Abnormal immune system physiology:*Response to LPS and CpG is completely abrogated. Impaired NK cell cytolysis: *No NK cell activation is observed following infection with L. infantum. Decreased interferon-alpha secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interferon-beta secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interleukin-12b secretion: *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice. *Unlike in wild-type mice, IL-12p40 production from dendritic cells following infection with Leishmania infantum is indetectable. Decreased tumor necrosis factor secretion: *Following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced. Decreased susceptibility to experimental autoimmune encephalomyelitis: *Myelin oligodendrocyte glycoprotein injection results in delayed onset of disease, 17.9 days after injection rather than 15.9 days as in controls. *Fewer infiltrating foci in the spinal cord. Abnormal response to infection: *Following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a partially decreased immune response in terms of TNF secretion and response to CpG. Decreased susceptibility to parasitic infection: *Resistant to cerebral malaria. *Reduced accumulation of hemozoin. *Less upregulation of TNF-alpha in Plasmodium infection.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018|Cryopreserved sperm|||Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 319.0|B6.Prf -/-|C57BL/6-Prf1/AnuApb|C57BL/6-Prf1/Anu|Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfn, Pfp, Prf-1|MGI:97551|targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||Homozygous null mice exhibit increased susceptibility to viral infection and defective cytotoxic T cell cytolysis and NK cell cytolysis.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|19|||No|04-May-2006|Cryopreserved sperm|100.0|0.0|Unknown||cytotoxic T cell, CD8, Natural Killer cell, cytolysis, infection|Yes| 8545.0|Foz:Tlr4 |C57BL/6-Alms1 Tlr4/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Foz mice are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.Tlr4 KO mice are hyporesponsive to bacterial lipopolysaccharide and more susceptible to infection by gram negative bacteria.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018||0.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia, LPS, macrophage|Yes| 8545.0|Foz:Tlr4 |C57BL/6-Alms1 Tlr4/AnuApb||Recessive|toll-like receptor 4|Tlr4|Nil|lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; targeted mutation 1, Shizuo Akira|Tlr4|MGI:1860885|4|||||||||||||||||||||||||||||Foz mice are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.Tlr4 KO mice are hyporesponsive to bacterial lipopolysaccharide and more susceptible to infection by gram negative bacteria.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018||||Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia, LPS, macrophage|Yes| 1634.0|Itsn1Total KO +/- 129Sv|129/Sv-Itsn1/Apb|129/Sv-Itsn1/Apb|Recessive|intersectin 1 (SH3 domain protein 1A)|Itsn1|Nil|Eh domain, SH3 domain regulator of endocytosis 1, EHSH1, Ese1, Intersectin-L, Sh3p17|MGI:1338069|intersectin 1 (SH3 domain protein 1A); targeted mutation 1.1, Melanie A Pritchard|Itsn1|MGI:3812034|16||||||||||||||||Yes|||||||||||||Some homozygotes are runty after birth compared to the wildtype and die before weaning age. Otherwise they can catch up with the wildtype. |No overt phenotype|129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Het x Het|No|17-Jul-2007|Cryopreserved sperm|45.0|0.0|Yes|Alzheimer’s disease; Down syndrome|Alzheimer's disease, Down Syndrome, endocytosis, endosome, neuron|Yes| 8600.0|B6-Cpa3Cre;ELKSfl/fl|B6-Elks Tg(Cpa3-cre)3Glli/Apb||Recessive|ELKS||||||||Unknown|||||||||||||||||transgene insertion 3, Stephen J Galli|Carboxypeptidase A3 (Cpa3)|||||||||||It is anticipated that B6-Cpa3Cre;ELKSfl/fl mice will have a defect in mast cell degranulation. Mice should otherwise resemble wildtype mice|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Nov-2018|Cryopreserved sperm|50.0|0.0|Unknown||Mast cell|Yes| 1521.0||C.129S1(B6)-Gata1/AnuApb|C.129S1(B6)-Gata1/AnuApb|X-linked|GATA binding protein 1|Gata1|Nil|Gata-1, Gf-1|MGI:95661|targeted mutation 6, Stuart Orkin|Gata1|MGI:3037864|X||||||||||||||||Yes|||||||||||||No eosinophils||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|130.0|0.0|Unknown||eosinophil, promoter, inflammation, allergic|Yes| 8547.0|Foz:Ppara|C57BL/6-Alms1 Ppara/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Foz are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018|Cryopreserved sperm|60.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 8547.0|Foz:Ppara|C57BL/6-Alms1 Ppara/AnuApb||Recessive|peroxisome proliferator activated receptor alpha|Ppara|Unknown|4933429D07Rik, Nr1c1, Ppar, PPARalpha, PPAR-alpha|MGI:104740||||15|||||||||||||||||||||||||||||Foz are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|06-Aug-2018|Cryopreserved sperm|||Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 858.0|B10.HTG|B10.HTG-H2/HarAnuApb|B10.HTG-H2/HarAnuApb|Dominant|histocompatibility-2, MHC|H2|Normal|H-2, MHC-II|MGI:95894||||17||||||||||||||||No|||||||||||||||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|24-May-2007|Cryopreserved sperm|100.0|0.0|Unknown||Major Histocompability, haplotype, MHC, T cell|Yes| 845.0|SW{HEL}-HL|C57BL/6-Igh Tg(IgkHyHEL10)1Rbr/AnuApb|C57BL/6-Igh Tg(IgkHyHEL10)1Rbr/AnuApb|Dominant|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Robert Brink|Igh|MGI:3800383|12||||||||||||||||Yes|transgene insertion 1, Robert Brink||||||||||||B cells express Immunoglobulin specific for hen egg lysozyme and are capable of undergoing class switch.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-May-2007|Cryopreserved sperm|68.0|0.0|Unknown||Immunoglobulin, Hen Egg lysozyme (HEL), self-tolerance, autoimmunity, B cell|Yes| 8601.0|ENU44:G2|ANU:ENU44:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|07-Nov-2018|Cryopreserved sperm|1188.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7270.0||SJL/Mrit-MRI96570|SJL/Mrit-MRI96570|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Perinatal lethality with jaundice|Heterozygous mice display a microcytic anaemia with increase osmotic fragility.|SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|05-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|Hereditary spherocytosis|Hereditary spherocytosis, microcytosis, ENU|Yes| 5445.0|Servalan ; ENU11B6:025b|C57BL/6JAnu-Ebf1/AnuApb|C57BL/6JAnu-Ebf1/AnuApb|Dominant|early B-cell factor 1 |Ebf1|Reduced|O/E-1, Olf-1, Olf1 |MGI:95275|early B-cell factor 1; Servalan|Ebf1|MGI:5007783|11|ENSMUSG00000057098|ENSMUST00000081265|Ebf1-001|||||||||||||Yes|||||||||||||Low B cell numbers in the peripheral blood.|FACs phenotype - Low B cells|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|N/A|5|Sib x sib|No|28-Feb-2011|Cryopreserved sperm|28.0|0.0|Unknown||B cell, NIH, ENU|Yes| 2010.0|Stat3 heterozygous knockout|B6;129P2-Stat3/Apb|B6;129P2-Stat3|Recessive|Signal transducer and activator of transcription 3|Stat3|Nil|Aprf|MGI:103038|targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11||||||||||||||||Yes|||||||||||||Embryonic lethal (E7.5)|Viable, fertile - no apparent abnormalities.|129Sv x C57BL/6|No|No|Yes|No|No|Yes|No|Good|||heterozygous x heterozygous|No|17-Sep-2007|Cryopreserved sperm|115.0|0.0|No||STAT, cytokine, transcription, interleukin|Yes| 8602.0|ENU44:G3|ANU:ENU44:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|07-Nov-2018|Cryopreserved sperm|157.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5487.0|A33:Lgp130YFKQ.B6 (Line 6). |B6(Cg)-Tg(Gpa33-Il6*)6Ern/Lud||Dominant||||||||||||||||||||||||||transgene insertion 6 Matthias Ernst|glycoprotein A33 (transmembrane)|||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|12|||No|19-Apr-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, dimerization|Yes| 7283.0|Spi6 x Granzyme B double knockout|B6.129-Gzmb Serpin9/MarpApb|B6.129-Gzmb Serpin9|Dominant|granzyme B|Gzmb||CCP1, CCP-1/C11, Ctla1, Ctla-1, GZB|MGI:109267|granzyme B; targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||||||||||||||Immunocompromised|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-Mar-2013|Cryopreserved sperm|40.0|0.0|Unknown||T cell, CD8, dendritic cell, MHC I, cross-priming|Possibly| 7283.0|Spi6 x Granzyme B double knockout|B6.129-Gzmb Serpin9/MarpApb|B6.129-Gzmb Serpin9|Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9||ovalbumin, PI-9, Spi6|MGI:106603|serine (or cysteine) peptidase inhibitor, clade B, member 9; targeted mutation 1.1, Phil Bird|Serpinb9|MGI:5140012|13||||||||||Unknown to Unknown|||||||||||||||||||Immunocompromised|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-Mar-2013|Cryopreserved sperm|||Unknown||T cell, CD8, dendritic cell, MHC I, cross-priming|Possibly| 8603.0||FVB/N-Tg(Nos1-EGFP)DP185Gsat/Apb||Dominant||||||||||||||||||||||||||transgene insertion DP185, GENSAT Project at Rockefeller University|Nos1|||||||||||Normal. EGFP expression under control of Nos1 promoter region in modified BAC construct. NOTE: some aberrant expression in the enteric nervous system at different developmental ages. Haven't checked other parts of the nervous system.|Normal. EGFP expression under control of Nos1 promoter region in modified BAC construct. NOTE: some aberrant expression in the enteric nervous system at different developmental ages. Haven't checked other parts of the nervous system.|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Nov-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8543.0|CREB-lox|B6.129-Creb1/GscApb||Recessive|cAMP responsive element binding protein 1|Creb1||2310001E10Rik, 3526402H21Rik, Creb, Creb-1|MGI:88494|cAMP responsive element binding protein 1; targeted mutation 3, Gunther Schutz|Creb1|MGI:2181395|1|||||||||||||||||||||||||||||Normal phenotype until crossed with a Cre-transgenic mouse|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Aug-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5106.0|Tesk2 KO|C57BL/6-Tesk2/MarpApb||Recessive|testis-specific kinase 2|Tesk2|Unknown||MGI:2385204||||4||||||||||||||||Yes|||||||||||||No apparent phenotype. (No significant differences in weights of i) whole body, testis, reproductive tract, spleen, liver, pancreas, kidney, heart, lungs)|No apparent phenotype. (No significant differences in weights of i) whole body, testis, reproductive tract, spleen, liver, pancreas, kidney, heart, lungs)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Apr-2010|Cryopreserved sperm|63.0|0.0|Unknown||testis, kinase, spermatid|Possibly| 8551.0|Ddit3 tm1c|C57BL/6N-Ddit3||Recessive|DNA-damage inducible transcript 3|Ddit3||C/EBP homoologous protein 10, chop, CHOP10, CHOP-10, gadd153|MGI:109247|DNA-damage inducible transcript 3; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Ddit3|MGI:5520283|10||||||||||Unknown to Unknown|||||||||||||||||||Normal||C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|16-Aug-2018|Cryopreserved sperm|23.0|0.0|Unknown|||Yes| 6866.0|Perlecan ; Hspg2 3-/3- exon 3 null|B6.129P2-Hspg2/Apb||Dominant|perlecan (heparan sulfate proteoglycan 2)|Hspg2|Unknown|Pcn, per, Plc|MGI:96257|perlecan (heparan sulfate proteoglycan 2); targeted mutation 1, Raija Soininen|Hspg2|MGI:2449915|4|||||||||||||||||||||||||||||Normal with small eyes|Normal with small eyes|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|03-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown||Heparan sulfate, proteoglycan, perlecan|Possibly| 4877.0|B6.B-cell deficient/Gal KO|C57BL/6-Igh-6 Ggta/Apb||Recessive|immunoglobulin heavy chain 6 (heavy chain of IgM)|Igh-6|Nil|BCR, Ig mu, Igh-M, Igh6, IgM, muH, muMT|MGI:96448|targeted mutation 1, University of Cologne|Igh-6|MGI:1857187|12||||||||||||||||No|||||||||||||Mice lack mature B cells.All blood / tissue samples lack Gal expression.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|88.0|0.0|Unknown||Immunoglobulin, B cell, IgM, lymphocyte, Xenotransplantation, antibody, transferase, galactose|Yes| 4877.0|B6.B-cell deficient/Gal KO|C57BL/6-Igh-6 Ggta/Apb||Recessive|glycoprotein galactosyltransferase alpha 1, 3|Ggta1|Nil|alpha Gal, alpha3GalT, Gal, GALT, Ggta, Ggta-1, glycoprotein alpha galactosyl transferase 1|MGI:95704||||2|||||||||||||||||||||||||||||Mice lack mature B cells.All blood / tissue samples lack Gal expression.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|||Unknown||Immunoglobulin, B cell, IgM, lymphocyte, Xenotransplantation, antibody, transferase, galactose|Yes| 4882.0||C.B6-Socs1 Tg(Lck-cre)I57Jxm/Apb||Recessive|suppressor of cytokine signaling 1|socs1|Nil|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|targeted mutation 3, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:2656917|16||||||||||||||||Yes|transgene insertion I57, Jamey Marth|lymphocyte protein tyrosine kinase (Lck)|||||||||||Enhanced differentiation of thymocytes toward CD8+ T cells. Thymus hyperplasia.Enlarged lymph nodes||BALB/c|Yes|No|Yes|Yes|No|Yes|No|Poor|10|2||No|28-Sep-2009|Cryopreserved sperm|20.0|0.0|Unknown||cytokine signalling, T cell, thymus, hyperplasia|Yes| 4875.0|B6.Gal KO|C57BL/6-Ggta1/Apb||Recessive|glycoprotein galactosyltransferase alpha 1, 3|Ggta1||alpha Gal, alpha3GalT, Gal, GALT, Ggta, Ggta-1, glycoprotein alpha galactosyl transferase 1|MGI:95704||||2|||||||||||||||||||||||||||||Matings between mice heterozygous for the inactivated GalT gene produced genotype ratios that deviated significantly from the predicted Mendelian 1:2:1 (wild type:heterozygote:homozygote) ratio. Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|87.0|0.0|Unknown||Xenotransplantation, Transplantation, antibody, transferase, galactose|Yes| 8598.0|Beta-common chain KO BALB/c (BALB/c.Csf2rb-/-Csf2rb2-/-)|C.129-Csf2rb Csfrb2/CgbApb||Recessive|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb||AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage); targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15|||||||||||||||||||||||||||||In the steady-state, mice appear normal. Mice may develop pulmonary alveolar proteinosis (PAP) around 6-8 months of age. This is a build-up of fluid in the lungs that would otherwise be removed by alveolar macrophages that are absent in homozygous KO mice. This generally demonstrates no phenotype in mice but can result in breathing difficulty, thus mice will require additional monitoring if housed until this age.mice exhibit eosinopenia, increased surfactant accumulation in lung tissue, infection resistance and attenuated tissue repair after injury.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Nov-2018|Cryopreserved sperm|50.0|0.0|Unknown||IL3, beta common chain, signal transduction, GM-CSF|Yes| 8598.0|Beta-common chain KO BALB/c (BALB/c.Csf2rb-/-Csf2rb2-/-)|C.129-Csf2rb Csfrb2/CgbApb||Recessive|colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)|Csf2rb2|Nil|AIC2A, BetaIl3, Bil3, Il3r, Il3rb2|MGI:1339760|colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage); targeted mutation 1, C Glenn Begley|Csf2rb2|MGI:3652583|15|||||||||||||||||||||||||||||In the steady-state, mice appear normal. Mice may develop pulmonary alveolar proteinosis (PAP) around 6-8 months of age. This is a build-up of fluid in the lungs that would otherwise be removed by alveolar macrophages that are absent in homozygous KO mice. This generally demonstrates no phenotype in mice but can result in breathing difficulty, thus mice will require additional monitoring if housed until this age.mice exhibit eosinopenia, increased surfactant accumulation in lung tissue, infection resistance and attenuated tissue repair after injury.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Nov-2018|Cryopreserved sperm|||Unknown||IL3, beta common chain, signal transduction, GM-CSF|Yes| 2369.0|Tilcara ; ENU6WT:121|C57BL/6JSfdAnu-Prkcb/AnuApb|C57BL/6JSfdAnu-Prkcb/AnuApb|Semi-dominant|protein kinase C, beta 1|Prkcb1|Unknown|PKC-Beta, Pkcb, Prkcb2|MGI:97596|tilcara|Prkcb|MGI:4819152|7|ENSMUSG00000052889|ENSMUST00000064989|Prkcb-001|1654|1874|T to C|ENSMUSE00000439236|15|552|Serine to Proline|||||AAGGGGAGGATGAGGATGAACTCTTCCAGTCAATCATGGAACACAATGTGGCGTATCCCAA|Yes|||||||||||||Defective T-cell independent type 2 antibody response to NP-Ficoll.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|56.0|0.0|Unknown||B cell, protein kinase, signal transduction, ENU, Wellcome Trust|Yes| 4113.0|Helpless, ENU9B6:035|C57BL/6JAnu-Zbtb7b/AnuApb|C57BL/6JAnu-Zbtb7b/AnuApb|Recessive|zinc finger and BTB domain containing 7B|Zbtb7b|Unknown|c-Krox, Th-POK, Thpok, Zfp67|MGI:102755|zinc finger and BTB domain containing 7B; helpless|Zbtb7b|MGI:3838356|3|ENSMUSG00000028042|ENSMUST00000029677|Zbtb7b-001|305|480|T to G|ENSMUSE00000175423|2|101|Leucine to Arginine|||||CTTTGTAGGGCCAGAGGCCCTAGGTGCCCTGCTCGAGTTTGCTTACACAGCCACACTGACC|No|||||||||||||Defective antibody response to immunization: failure to mount a normal primary T cell dependent antibody response. Very few CD4 T cells in peripheral blood or in thymus.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>8||Affected Male x C57BL/6JAnu|No|05-Dec-2008|Cryopreserved sperm|51.0|0.0|Unknown||B cell, T cell, CD4, antibody, ENU, Wellcome Trust|Yes| 7580.0|Spi6 x Pfp KO|C57BL/6J-SerpinB9 Prf1/MarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9|Nil|PI-9, Spi6|MGI:106603||||13|||||||||||||||||||||||||||||Immunocompromised|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Jan-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7580.0|Spi6 x Pfp KO|C57BL/6J-SerpinB9 Prf1/MarpApb||Dominant|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfn, Pfp, Prf-1|MGI:97551|perforin 1 (pore forming protein); targeted mutation 1, Sandoz Pharmaceuticals|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||Immunocompromised|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Jan-2014|Cryopreserved sperm|||Unknown|||Possibly| 7581.0||B6/Mrit-135080|B6/Mrit-135080|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display an harmonious and transient growth decrease|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|03-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||growth , ENU|Yes| 158.0|Mr T-Less|C57BL/6SfdAnu-Zap70/AnuApb|C57BL/6SfdAnu-Zap70/AnuApb|Recessive|Zap70, zeta-chain (TCR) associated protein kinase|Zap70|Reduced|Zap-70, Srk, TZK|MGI:99613|Mr T-Less|Zap70|MGI:3614790|1|ENSMUSG00000026117|ENSMUST00000027291|Zap70-201|1510|1601|T to C|ENSMUSE00000230099|11|504|Tryptophan to Arginine|||||CCCGGTCTGCAGGGAAGTGGCCTCTGAAGTGGTACGCGCCAGAGTGCATCAACTTTCGGAA|No|||||||||||||Identified by severe reduction in T cell numbers in blood.B cells are normalBoth CD4⁺ and CD8⁺ T cell populations were almost completely absent in peripheral blood. Therefore, no αβ T cells but have increase in γδ T cellsNormal numbers of DN and DP T cells. Implies that have block at DP stage and mice unable to perform positive thymocyte selection.Intrinsic to T cells not microenvirnment.Cells unable to pass thymic selection steps.Cells unable to up-regulate TCRReduced signalling through TCR.Zap70 protein expression of mrt/mrt thymocytes was 25% of wildtype thymocytes.Kinase domain affected by mutation, kinase assays not performedHeterozygous mice, mrt/+ have normal levels of CD4⁺ and CD8⁺ thymocytes but Zap70 protein expression is 2 fold lower.Unlike cells devoid of ZAP-70, mrtless thymocytes showed partial induction of CD5 and CD69, and were sensitive to TCR stimulation with a dose-response shifted approximately 10-fold. However, essentially no T cells were able to compensate for the mrtless mutation and mature beyond the CD4⁺ CD8⁺ stage.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Mar-2006|Cryopreserved sperm|36.0|0.0|Unknown||T cell, zap70, B cell, TCR, lymphocyte , ENU|Yes| 4589.0|Collins ; ENU12NIH:065b|C57BL/6JAnu-Rag1/AnuApb||Recessive|recombination activating gene 1|Rag1|Unknown|Rag-1|MGI:97848|collins|Rag1|MGI:4819232|2|ENSMUSG00000061311|ENSMUST00000078494|Rag1-001|985|1079|C to T|ENSMUSE00000471535|2|328|Arginine to STOP|||||AAGTCATGGGCAGCTATTGTCCCTCTTGCCGATATCCGTGCTTCCCTACTGACCTGGAGAG|No|||||||||||||No B or T cells||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Mar-2009|Cryopreserved sperm|67.0|0.0|Unknown||T cell, B cell, maturation, ENU, NIH|Yes| 3689.0|Rose ; ENU11B6:058b|C57BL/6JAnu-Tap1/AnuApb|C57BL/6JAnu-Tap1/AnuApb|Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Unknown|Abcb2, Ham-1, Ham1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483|Rose|Tap1|MGI:3797750|17|ENSMUSG00000037321|ENSMUST00000041633|Tap1-201|1928|2074|A to T|ENSMUSE00000296635|10|643|Aspartic acid to Valine|||||GATCCGGAAGCCACTCCTGCTTATCTTGGATGATGCCACCAGTGCCCTGGATGCTGGCAAC|No|||||||||||||Very low CD8<+> T cell numbers.Mice homozygous for targeted mutations that inactivate the gene are deficient in antigen presentation, surface class I antigens, and CD4-8+ T cells.||C57BL/6jAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4|affected x B6|No|26-Aug-2008|Cryopreserved sperm|100.0|0.0|Unknown||T cell, CD8, presentation, ENU, NIH|Yes| 4980.0|Vila ; ENU12NIH:028|C57BL/6JAnu-Btk/AnuApb|C57BL/6JAnu-Btk/AnuApb|Recessive|Bruton agammaglobulinemia tyrosine kinase|Btk|Unknown|Bruton's tyrosine kinase, X-linked immune deficiency, xid|MGI:88216|vila|Btk|MGI:4820731|X|ENSMUSG00000031264|ENSMUST00000113214|Btk-201|586|722|C to T|ENSMUSE00000277322|7|196|Glutamine to STOP|||||AGCCTCTTCCCCCTACCCCAGAGGAAGATCAGATCTTGAAAAAACCGCTTCCCCCGGAGCC|Unknown|||||||||||||Low peripheral blood B cell numbers. Decreased CD45 expression.Lower IgD expression.Higher IgG expression.Hyper IgE.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|57.0|0.0|Unknown||B cell, immunoglobulin, IgE, IgD, NIH|Yes| 10360.0|Tcf3 KO|C57BL/6NCrlAnu-Tcf3/9Anu||Dominant|transcription factor 3|Tcf3||A1, ALF2, bHLHb21, E12, E2A, E47, Pan1, Pan2, Tcfe2a |MGI:98510|Tcf3: endonuclease-mediated mutation 3, Australian National University|Tcf3||10|ENSMUSG00000020167|ENSMUST00000105342|||||||||||||||||||||||||||embryonic lethal |Mild reduction of B cells.|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|20-Sep-2023|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 7370.0|ENU25:011:Zmym2:B6:G5|C57BL/6NCrlAnu-Zmym2/AnuApb|C57BL/6NCrlAnu-Zmym2/AnuApb|Recessive|zinc finger, MYM-type 2|Zmym2|Unknown|FIM, MGC:51607, MYM, RAMP, SCLL, Zfp198|MGI:1923257|zinc finger, MYM-type 2, mutation 1, The Australian National University|Zmym2|MGI:5648435|14|ENSMUSG00000021945|ENSMUST00000022511|Zmym2-201|3774|3847|T to A|ENSMUSE00000122336|22|1258|Cysteine to STOP|||||AATCCTTTAACAATGGAAAATAAAGCATGTCTTCGCTATCAGGTGTCTTCCTTATGTGGAA||||||||||||||No homozygous animals born. Presume embryonic lethal|Normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||5||No|05-Jul-2013|Cryopreserved sperm|46.0|0.0|Unknown||ENU, embryonic lethal|Yes| 8608.0|ENU43:005:Relb|C57BL/6NCrlAnu-Relb/AnuApb||Recessive|avian reticuloendotheliosis viral (v-rel) oncogene related B|Relb|Unknown|shep|MGI:103289||||7|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Nov-2018||0.0|0.0|Unknown|||Yes| 8606.0|NODHepse|NOD-Hpse/AnuApb||Recessive|heparanase|Hpse|Nil|Hpa|MGI:1343124|heparanase; targeted mutation 1, Jin-Ping Li|Hpse|MGI:3844469|5||||||||||||||||||||||||||||||Normal.|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Nov-2018|Cryopreserved sperm|60.0|0.0|Yes|Type 1 Diabetes|Heparan sulphate, MMP2, T1D|Yes| 4751.0|B-down|C57BL/6-Bach2/AnuApb|C57BL/6-Bach2/AnuApb|Recessive|BTB and CNC homology 2|Bach2|Unknown||MGI:894679|BTB and CNC homology 2; mutation 1, Christopher C Goodnow|Bach2|MGI:5056539|4|ENSMUSG00000040270|ENSMUST00000108180|Bach2-001|46|454|T to C|ENSMUSE00000361532|4|16|Serine to Proline|||||AGCCTGGCTCCCCCATGTATGTATATGAGTCCACAGTCCACTGTGCCAACATCCTCCTGGG|No|||||||||||||Mild myeloid expansion (or low lymphoctes), low numbers B220+ cells, elevated CD44 staining on B and T cells in the blood. Reduced marginal zone B cells (CD21bright CD23intermediate-low) in spleen. |Slightly reduced blood B cells.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7||No|29-Apr-2009|Cryopreserved sperm|39.0|0.0|Unknown||T cell, ENU, B cell, Cd44, marginal zone|Yes| 4979.0|Avon ; ENU11B6:178a|C57BL/6JAnu-Xrcc6/AnuApb|C57BL/6JAnu-Xrcc6/AnuApb|Recessive|X-ray repair complementing defective repair in Chinese hamster cells 6|Xrcc6||G22p1, Ku p70, Ku70|MGI:95606|avon|Xrcc6|MGI:4458398|15|ENSMUSG00000022471|ENSMUST00000069530|Xrcc6-201|1400|1494|T to C|ENSMUSE00000127289|10|467|Leucine to Proline|||||AGACAAGATGAAGGCCATTGTTCAAAAGCTCCGCTTCACATACAGGAGCGACAGTTTTGAG|Yes|||||||||||||Very low B and T cell numbers in peripheral blood and spleen.Phenotype similar to Rag1 KO.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|75.0|0.0|Unknown||B cell, T cell, immunocompromise, differentiation, NIH|Yes| 4780.0|Tg5C2 ; Young|C.CBA-Tg(CD2-IL5)5C2Ldt/AnuApb|C.CBA-Tg(CD2-IL5)5C2Ldt/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blotanalysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|BALB/c|No|No|Yes|No|No|Yes|No|Excellent|20||Transgenic male with wild type female|No|06-Sep-2009|Cryopreserved sperm|50.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 8607.0|DMP1Cre.Socs3|B6-Socs3 Tg(Dmp1-cre)1Jqfe/StVApb||Recessive|suppressor of cytokine signaling 3|Socs3|Unknown|CIS3, Cish3, cytokine-inducible SH2 protein 3, E2a-Pbx1 target gene in fibroblasts 10, EF-10, SOCS-3, SSI-3, STAT-induced STAT inhibitor 3|MGI:1201791|suppressor of cytokine signaling 3; targeted mutation 2, Warren S Alexander|Socs3|MGI:2663917|11|||||||||||||||||transgene insertion 1, Jian Q Feng|Dmp1|odontoblast-specific expression||||||||||We have assessed the bone phenotype of the osteocyte-specific SOCS3 null mouse, and have found that they have significant sex-specific changes in bone mass.|Normal|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Nov-2018|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 159.0|Murdoch|STOCK H2 Zap70/AnuApb|STOCK H2 Zap70/AnuApb|Recessive|Zap70, zeta-chain (TCR) associated protein kinase|Zap70|Nil|Zap-70, Srk, TZK|MGI:99613|Murdoch|Zap70|MGI:3614796|1|ENSMUSG00000026117|ENSMUST00000027291|Zap70-201|1099|1190|A to T|ENSMUSE00000448670|9|366|Isoleucine to Phenylalanine|||||GCATGCGCAAGAAGCAGATTGACGTGGCCATCAAGGTGCTGAAGCAGGGCACAGAGAAGGC|No||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17|Reduced naïve CD4⁺ and CD8⁺ T cells which are hyperactivated, reduced CD4⁺ cells, defect in TCR signal transduction, impaired but not severe response to anti-TCR stimulation, T cell intrinsic defect, Elevated serum levels of IgG2b||B10.BR x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||10|hom x hom|No|07-Mar-2006|Cryopreserved sperm|165.0|0.0|Unknown||T cell, zap70, B cell, TCR, signalling, ENU|Yes| 7667.0|ENU23:032:Lrig1:B6:G2|C57BL/6NCrlAnu-Lrig1/AnuApb|C57BL/6NCrlAnu-Lrig1/AnuApb|Recessive|leucine-rich repeats and immunoglobulin-like domains 1|Lrig1|Unknown|Img, LIG-1|MGI:107935|leucine-rich repeats and immunoglobulin-like domains 1; mutation 1, The Australian National University|Lrig1|MGI:5563390|6|ENSMUSG00000030029|ENSMUST00000101126|Lrig1-002|1763|2215|G to T|ENSMUSE00000194515|13|588|Threonine to Lysine|||||GTGTATCATCACAAACCACTTTGGCTCCACATACTCCCACAAAGCCAGGCTCACTGTGAAT||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|29-Apr-2014|Cryopreserved sperm|10.0|0.0|Unknown||ENU, immunoglobulin, lymphocyte|Yes| 8609.0|ENU43:030:Jak3|C57BL/6NCrlAnu-Jak3/AnuApb||Recessive|Janus kinase 3|Jak3|Unknown||MGI:99928||||8|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Nov-2018||0.0|0.0|Unknown|||Yes| 1541.0|Kapil Dev|C57BL/6-Gzma Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||High - 49 Copies||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|30.0|0.0|Unknown||T cell receptor, CD8, ovalbumin, Natural Killer cell|No| 1541.0|Kapil Dev|C57BL/6-Gzma Prf1 Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfp, Prf-1|MGI:97551|targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|||Unknown||T cell receptor, CD8, ovalbumin, Natural Killer cell|No| 7338.0|SerpinB5 cKO x FLPe|C57BL/6J-SerpinB5/MarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 5|Serpinb5|Nil|1110036M19Rik, Maspin, ovalbumin, Spi7|MGI:109579|targeted mutation 1.2, Phil Bird|Serpinb5|MGI:5484765|1||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-May-2013|Cryopreserved sperm|45.0|0.0|Unknown||serpin|No| 7662.0|ENU23 32 (PPM1E) Asb3|C57BL/6NCrlAnu-Asb3/AnuApb|C57BL/6NCrlAnu-Asb3/AnuApb|Recessive|ankyrin repeat and SOCS box-containing 3|Asb3|Unknown|2400011J03Rik|MGI:1929749|ankyrin repeat and SOCS box-containing 3; mutation 1, The Australian National University|Asb3|MGI:5563516|11|ENSMUSG00000020305|ENSMUST00000020551|Asb3-001|632|820|G to A|ENSMUSE00001205336|6|211|Aspartic acid to Asparagine|||||TGGTGCAAATGTCAATTGCCAAGCCTTGGATAAAGCTACTCCTTTGTTTATTGCTGCACAA||||||||||||||Reduced CD44 protein expression on B cells.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Apr-2014|Cryopreserved sperm|39.0|0.0|Unknown||ENU, B cell, lymphocyte|Possibly| 5549.0|Tg5C2 ; Eales|C.CBA-Tg(CD2-IL5)5C2Ldt/AnuApb|C.CBA-Tg(CD2-IL5)5C2Ldt/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blotanalysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|BALB/c|No|No|Yes|No|No|Yes|No|Excellent|20||Transgenic male with wild type female|No|08-Aug-2011|Cryopreserved sperm|50.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 8610.0|ENU43:054:Lck|C57BL/6NCrlAnu-Lck/Anu||Recessive|ymphocyte protein tyrosine kinase|Lck|Unknown|Hck-3, p56|MGI:96756||||4|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Nov-2018||0.0|0.0|Unknown|||Yes| 7239.0|TCRF5|C57BL/10-Tg(Cd2-TcraF5,CD2-TcrbF5)1Kio/CbnApb|C57BL/10-Tg(Cd2-TcraF5,CD2-TcrbF5)1Kio/CbnApb|Dominant||||||||||||||||||||||||||transgene insertion 1, Dimitris Kioussis|CD2 minigene|||||||||||This clone is CD8+ and recognises amino acids 366-374 of the nucleoprotein (NP 366-374) of influenza virus (A/NT/60/68), in the context of Class I MHC Db (Townsend et al., 1986). The usage of V beta 11 makes this TcR reactive to Class II IE molecules and an endogenous ligand recently identified as a product of the endogenous mammary tumour viruses (Mtv) 8, 9, and 11 (Dyson et al., 1991). The development of F5 transgenic T cells and their function in mice of the appropriate MHC (C57BL/10 H-2b, IE-) or in mice expressing Class II MHC IE (e.g., CBA/Ca H-2k and BALB/c H-2d) and the endogenous Mtv ligands. Positive selection of CD8+ T cells expressing the V beta 11 is seen in C57BL/10 transgenic mice (H-2b). Peripheral T cells from these mice are capable of killing target cells in an antigen-dependent manner after a period of in vitro culture with IL-2. In the presence of Class II MHC IE molecules and the endogenous Mtv ligand, most of the single-positive cells carrying the transgenic T-cell receptor are absent in the thymus. Unexpectedly, CD8+ peripheral T-cells in these (H-2k or H-2d) F5 mice are predominantly V beta 11 positive and also have the capacity to kill targets in an antigen-dependent manner. This is true even following backcrossing of the F5 TcR transgene to H-2d scid/scid mice, in which functional rearrangement of endogenous TcR alpha- and beta-chain genes is impaired.||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Nov-2012|Cryopreserved sperm|20.0|0.0|No||T cell receptor, T cell, influenza, cytotoxic, CD8|Yes| 5483.0||C57BL/6-Tg(UBC-GFP)30Scha/JAdelApb||Recessive||||||||||||||||||||||||||transgene insertion 30, Brian Schaefer|Human ubiquitin C|Higher than normal||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Homozygous x homozygous|No|15-Apr-2011|Cryopreserved sperm|50.0|0.0|No||GFP|Possibly| 5465.0|MLR37|FVB/N-Tg(Cryaa-cre)37Mlr/MelbApb||Dominant||||||||||||||||||||||||||transgene insertion 39, Mike Robinson|alpha A crystallin promoter|||||||||||Unknown|MLR37 transgenic line made from the CPV2/Cre construct, showed little or no LacZ activity in the lens epithelium.The staining patterns of these transgenic lines were characterized by positive staining in the embryonic lens. Although all transgenic embryos stained with x-gal in the eye, extraocular staining patterns were unique to each transgenic line and varied widely, probably due to different transgene integration sites.|FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||lens, epithelium, Pax6, alphaA-crystallin, Cre recombinase|Yes| 8611.0|ENU43:139:Pax5|C57BL/6NCrlAnu-Pax5/AnuApb|C57BL/6NCrlAnu-Pax5/AnuApb|Recessive|paired box gene 5|Pax5|Unknown|EBB-1, Pax-5|MGI:97489|paired box gene 5; mutation 4, The Australian National University|Pax5||4||||||||||Unknown to Unknown||||||Yes|||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Nov-2018|Cryopreserved sperm|22.0|0.0|Unknown||B cell, lymphocyte, ENU|Possibly| 2360.0|TCRF5|C57BL/10-Tg(Cd2-TcraF5,CD2-TcrbF5)1Kio/AnuApb|C57BL/10-Tg(Cd2-TcraF5,CD2-TcrbF5)1Kio/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 1, Dimitris Kioussis|CD2 minigene|||||||||||This clone is CD8+ and recognises amino acids 366-374 of the nucleoprotein (NP 366-374) of influenza virus (A/NT/60/68), in the context of Class I MHC Db (Townsend et al., 1986). The usage of V beta 11 makes this TcR reactive to Class II IE molecules and an endogenous ligand recently identified as a product of the endogenous mammary tumour viruses (Mtv) 8, 9, and 11 (Dyson et al., 1991). The development of F5 transgenic T cells and their function in mice of the appropriate MHC (C57BL/10 H-2b, IE-) or in mice expressing Class II MHC IE (e.g., CBA/Ca H-2k and BALB/c H-2d) and the endogenous Mtv ligands. Positive selection of CD8+ T cells expressing the V beta 11 is seen in C57BL/10 transgenic mice (H-2b). Peripheral T cells from these mice are capable of killing target cells in an antigen-dependent manner after a period of in vitro culture with IL-2. In the presence of Class II MHC IE molecules and the endogenous Mtv ligand, most of the single-positive cells carrying the transgenic T-cell receptor are absent in the thymus. Unexpectedly, CD8+ peripheral T-cells in these (H-2k or H-2d) F5 mice are predominantly V beta 11 positive and also have the capacity to kill targets in an antigen-dependent manner. This is true even following backcrossing of the F5 TcR transgene to H-2d scid/scid mice, in which functional rearrangement of endogenous TcR alpha- and beta-chain genes is impaired.||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Dec-2007|Cryopreserved sperm|20.0|0.0|No||T cell receptor, T cell, influenza, cytotoxic, CD8|Yes| 7587.0|Adar3 LacZ|C57BL/6N-Adarb2/MarpStvApb||Dominant|adenosine deaminase, RNA-specific, B2|Adarb2|Reduced|Adar3, RED2|MGI:2151118|adenosine deaminase, RNA-specific, B2; targeted mutation 1a, Mouse Biology Program, UCDavis|Adarb2|MGI:4944293|13|||||||||||||||||||||||||||||none apparent|none apparent|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||ki/+ to KI/+ or WT female|No|14-Feb-2014|Cryopreserved sperm|50.0|0.0|No||Adar3 LacZ|Yes| 1525.0|Chilcott|C57BL/6-Myd88/AnuApb||Recessive|myeloid differentiation primary response gene 88|Myd88|Nil||MGI:108005|targeted mutation 1, Shizuo Akira|Myd88|MGI:2385681|9||||||||||||||||Yes|||||||||||||Increased apoptosis:* 5 days after lung injury, mutants show significantly increased numbers of apoptotic lung epithelial and inflammatory cells.Increased physiological sensitivity to xenobiotics:* knockout mice are more susceptible to bleomycin-induced lung injury.Abnormal dendritic cell differentiation:* dendritic cell maturation fails to occur in vivo upon exposure to TLR9 agonists.Increased dendritic cell number:* increased numbers of dendritic cells in brains of mice infected with Plasmodium.Abnormal immune system physiology:* response to LPS and CpG is completely abrogatedAbnormal dendritic cell physiology:* cytokine secretion elicited by zymosan or LPS is impaired.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40, IL-6 and interferon-gamma relative to wild-type mice.Abnormal macrophage physiology:* TNF production is impaired in thioglycollate-elicited macrophages treated with intact zymosan.* cytokine production by macrophages cultured with P. carinii cysts is reduced compared to wild-type.Abnormal NK cell physiology:* NK cells fail to make IFN-gamma in response to injections of TLR9 agonists.Abnormal T cell physiology:* induction of the antigen-specific CD8+ T-cell response by immunizing with soluble ovalbumin and TLR9 agonists, but not TLR2 and TLR6 agonists, was severely impaired.Abnormal cytokine secretion:* LPS-induced cytokine production by BMDCs is almost abolished compared to controls and Myd88-sufficient mutantsAbnormal chemokine secretion:* hyaluronan fragment-induced expression of chemokines by peritoneal macrophages is completely abolished in double knockout mice.Decreased interferon-alpha secretion:* CpG-A or RNA polyuridylic acid induced production of interferon-alpha was abolished in plasmacytoid dendritic cells.Decreased interferon-gamma secretion:* less up regulation of INF-gamma in Plasmodium infection.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less interferon-gamma.Decreased interleukin-12 secretion:* after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals.Decreased interleukin-12b secretion:* less upregulation of IL-12b in Plasmodium infection>* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice.Decreased interleukin-6 secretion:* following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, IL-6 secretion is reduced.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-6 relative to wild-type mice.Decreased tumor necrosis factor secretion:* less upregulation of TNF-alpha in Plasmodium infection.* following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced.* after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals.Decreased inflammatory response:* in a model of induced pneumococcal meningitis-associated labyrinthitis, homozygotes exhibit a significantly lower granulocytic infiltration of the labyrinth and increased bacterial density in the cochlea at 24 hrs post-infection relative to wild-type control mice.Abnormal response to infection:* following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a decreased immune response in terms of TNF and IL-6 secretion and response to CpG.Decreased susceptibility to parasitic infection:* resistant to cerebral malaria but eventually die of extremely high parasitemia.Increased susceptibility to viral infection:* increased susceptibility to encephalomyocarditis virus (EMCV) infection compared to wildtype.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|81.0|0.0|Unknown||T cell, Natural Killer, IL-18, IL-1 receptor, interferon, eosinophil, dendritic cell, cytokine, infection|Yes| 5126.0|B6-ANU.A2G-Mx1 (Mx1+/+)|B6.A2G-Mx1/AnuApb||Dominant|myxovirus (influenza virus) resistance 1|Mx1|Normal|Mx, Mx-1, myxovirus (influenza) resistance 1 polypeptide|MGI:97243|myxovirus (influenza virus) resistance 1; myxovirus resistance|Mx1|MGI:3715151|16|||||||||||||||||||||||||||||Normal, i.e. highly influenza resistant.|Normal.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-May-2010|Cryopreserved sperm|99.0|0.0|Unknown||Infection, resistance, Interferon|Possibly| 7659.0|ENU26:041:(Bach2)|C57BL/6NCrlAnu-Bach2/AnuApb|C57BL/6NCrlAnu-Bach2/AnuApb|Recessive|BTB and CNC homology 2|Bach2||E030004N02Rik|MGI:894679|BTB and CNC homology 2; mutation 2, Christopher C Goodnow|Bach2|MGI:5563501|4|ENSMUSG00000040270|ENSMUST00000108180|Bach2-001|239|793|A to G|ENSMUSE00000361532|4|81|Glutamic acid to Glycine|||||GAAAGATGACTTGGTGGTCAGCTTGCCTGAGGAGGTCACGGCCAGGGGCTTTGGGCCACTG||||||||||||||Increased numbers of immature B cells, decreased numbers of mature B cells and increased expression of IgM on B cells. Increased CD44 protein expression on B, CD4<+> and CD8<+> T cells.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||B cell, lymphocyte|No| 7660.0|ENU27:039:PRC1|C57BL/6NCrlAnu-Prc1/AnuApb|C57BL/6NCrlAnu-Prc1/AnuApb|Recessive|protein regulator of cytokinesis 1|Prc1||D7Ertd348e, MGC:6745|MGI:1858961|protein regulator of cytokinesis 1; mutation 1, The Australian National University|Prc1|MGI:5563437|7|ENSMUSG00000038943|ENSMUST00000163812|Prc1-002||||||||80307696|8|||GAGAGCTGGAAACTTTTCCTAGAGTTTGAGGTAATATCCCTGTTTTAGCTGTGTTGCTCT||||||||||||||Embryonic lethal|normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|11-Apr-2014|Cryopreserved sperm|29.0|0.0|Unknown||embryonic lethal, ENU|No| 5115.0|ENU14Yaa:016a|B6.Cg-Btk Yaa/AnuApb|B6.Cg-Btk Yaa/AnuApb|Recessive|Bruton agammaglobulinemia tyrosine kinase|Btk|Unknown|Bruton's tyrosine kinase, X-linked immune deficiency, xid|MGI:88216|Bruton agammaglobulinemia tyrosine kinase; mutation 1, The Australian National University|Btk|MGI:5563504|X|ENSMUSG00000031264|ENSMUST00000033617|Btk-001||||||||131089223|11|||GTGTCTGTGTTTGCTAAATCTACTGGGTACGTGTTATGGTTCCAGTGATATGGGGTTAAA|Yes|||||||||||||Low B cell numbers in peripheral blood.While mice carry Yaa allele the phenotype does not appear to be dependent upon Yaa.||C57BL/6JAnu x B6.SB-Yaa|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-May-2010|Cryopreserved sperm|50.0|0.0|Unknown||Monocytes, T cell, lymphoma, autoantibody, ENU, B cell|Yes| 5115.0|ENU14Yaa:016a|B6.Cg-Btk Yaa/AnuApb|B6.Cg-Btk Yaa/AnuApb|Recessive|accelerated autoimmunity and lymphoproliferation transposition|Yaa||Tp(X;Y)1Ekw|MGI:99140|accelerated autoimmunity and lymphoproliferation transposition; accelerated autoimmunity and lymphoproliferation|Yaa|MGI:1856277|Y|||||||||||||||||||||||||||||Low B cell numbers in peripheral blood.While mice carry Yaa allele the phenotype does not appear to be dependent upon Yaa.||C57BL/6JAnu x B6.SB-Yaa|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-May-2010|Cryopreserved sperm|||Unknown||Monocytes, T cell, lymphoma, autoantibody, ENU, B cell|Yes| 7318.0|Nessy|B6(Cg)-Ncaph2/AnuApb|B6(Cg)-Ncaph2/AnuApb|Recessive|non-SMC condensin II complex, subunit H2|Ncaph2|Unknown|Kleisin beta|MGI:1289164|nessy|Ncaph2|MGI:3710093|15|ENSMUSG00000008690|ENSMUST00000074552|Ncaph2-001|44|144|T to A|ENSMUSE00000504356|1|15|Isoleucine to Asparagine|||||GGTGCGCTTTGCTCACCTCTTGCAGCCCATCCGGGATCTCACTAAGAACTGGGAGGTGGAC|Yes|||||||||||||The nessy mouse has a defect in T lymphocyte development that decreases circulating T cell numbers, increases their expression of the activation/memory marker CD44, and dramatically decreases the numbers of CD4(+)CD8(+) thymocytes and their immediate DN4 precursors. Thymic T cell differentiation defect at DN-DP transition, low peripheral T cell numbers, remaining cells all CD44high, Two fold more gd T cells, Defect resembles mice with exaggerated TCR signalling due to defects in c-cbl and slap proteins and defects in cbl plus cbl-b. No defect in B cells. Homozygotes grow at normal rate, size and are fertile. Intrinsic to T cells.Despite the ubiquitous expression and role of condensins, kleisin beta(nes/nes) mice were viable, fertile, and showed no defects even in the parallel pathway of B cell lymphocyte differentiation. ||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|6|||No|17-Apr-2013|Cryopreserved sperm|77.0|0.0|Unknown||T cell, lymphocyte, condensin, differentiation, ENU|Yes| 6902.0|Cornell|B6.129-Rel/AnuApb||Recessive|reticuloendotheliosis oncogene|Rel|Unknown|c-Rel|MGI:97897|targeted mutation 1, Steve Gerondakis|Rel|MGI:2179622|11||||||||||||||||No|||||||||||||In mice with an inactivated c-rel gene, whereas development of cells from all hemopoietic lineages appeared normal, humoral immunity was impaired and mature B and T cells were found to be unresponsive to most mitogenic stimuli. Phorbol ester and calcium ionophore costimulation, in contrast to certain membrane receptor-mediated signals, overcame the T cell-proliferative defect, demonstrating that T cell proliferation occurs by Rel-dependent and -independent mechanisms.This colony gets dermatitis.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-May-2012|Cryopreserved sperm|77.0|0.0|Unknown||Lymphocyte, IL-2, humoral immunity|Yes| 7588.0|Recql4 LacZ|C57BL/6N-Recql4/MarpStvApb||Dominant|RecQ protein-like 4|Recql4||RECQ4|MGI:1931028|RecQ protein-like 4; targeted mutation 3, Wellcome Trust Sanger Institute|Recql4|MGI:5050948|15|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Good|generated on a C57bl6 background||ki/+ to ki/+|No|14-Feb-2014|Cryopreserved sperm|20.0|0.0|Yes|Rothmund-Thomson syndrome|Recql4, Recql4-LacZ|Yes| 6867.0|SM02-Pro|SuprMam02-(B6.Balb/C-SM1)-Pro/AnuApb||Recessive|||||||||||||||||||||||||||||SuprMam|SuprMam|||||||7|Mice are more susceptible to mammary tumours.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|||No|03-Apr-2012|Cryopreserved sperm|69.0|0.0|Unknown||mammary, tumour, DMBT1, p53, modifier|Possibly| 6827.0|Dockland ; ENU16NIH19a|C57BL/6JAnu-Dock2/AnuApb|C57BL/6JAnu-Dock2/AnuApb|Recessive|dedicator of cyto-kinesis 2|Dock2|Unknown|CED-5, Hch, MBC|MGI:2149010|dedicator of cyto-kinesis 2; mutation 1, The Australian National University|Dock2|MGI:5563487|11|ENSMUSG00000020143|ENSMUST00000093193|Dock2-001|2323|2392|G to T|ENSMUSE00000249670|23|775|Glutamic acid to STOP|||||AGTTTGAAGAATCCATGAGACGGCTCTTCGAATCCATCAACAACCTGATGAAAAGTCAGTA||||||||||||||Low numbers of T cells, low numbers of activated B cells and T cells|Unknown|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Yes|Yes|No|Good||G7||No|29-Feb-2012|Cryopreserved sperm|46.0|0.0|Unknown||T cell, B cell, lymphocyte, ENU|Possibly| 6853.0|BRINP1 Flpe ; DBC Flpe|C57BL/6-Fam5a/Marp||Recessive|bone morphogenic protein/retinoic acid inducible neural specific 1|Brinp1|Unknown|Dbc1, Dbccr1, Fam5a|MGI:1928478||||4|||||||||||||||||||||||||||||Unknown. |Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|14-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8615.0|H2-T15|C57BL/6-H2-T15/MarpApb||Recessive|histocompatibility 2, T region locus 15|H2-T15||H-2T15|MGI:95947||||17|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Nov-2018|Cryopreserved sperm|20.0|0.0|Unknown|||Yes| 6868.0|SM02-Dist|SuprMam02-(B6.BALB/c-SM1)-Dist/AnuApb||Recessive|||||||||||||||||||||||||||||SuprMam|SuprMam||||SuprMam-BALB/c|SuprMam-BALB||7|Mice are more susceptible to mammary tumours.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|||No|03-Apr-2012|Cryopreserved sperm|82.0|0.0|Unknown||mammary, tumour, DMBT1, p53, modifier|Possibly| 10365.0|Irf5|C57BL/6NCrl-Irf5/Anu||Recessive|interferon regulatory factor 5|Irf5|Unknown|mirf5 |MGI:1350924 |Irf5; endonuclease-mediated mutation 1, Australian National University|Irf5||6|ENSMUSG00000029771 |ENSMUST00000163511.7||||G to T||||Unknown to Unknown|||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Sep-2023|Cryopreserved sperm|11.0|0.0|Unknown|||Possibly| 5460.0|ENU16NIH:003b|C57BL/6JAnu-Klrg1/AnuApb|C57BL/6JAnu-Klrg1/AnuApb|Recessive|killer cell lectin-like receptor subfamily G, member 1|Klrg1|Unknown|2F1-Ag|MGI:1355294|killer cell lectin-like receptor subfamily G, member 1; mutation 1, The Australian National University|Klrg1|MGI:5563460|6|ENSMUSG00000030114|ENSMUST00000032207|Klrg-1||||||||122232913||||GGGATTTGGTAGAGATGGCTGACAGCTCTATCTATTCAACACTAGAGCTGCCGGAGGCAC|Yes|||||||||||||No KLRG1 expression on NK cells||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Mar-2011|Cryopreserved sperm|46.0|0.0|Unknown||Natural Killer cell, ENU|Yes| 8619.0|NODScid|NOD-Prkdc/AnuApb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Nil|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16||||||||||||||||Yes|||||||||||||SCID mutation prevents TCR and BCR rearrangements. This prevents maturation of B and T cells at very early stages of development. These mice, therefore lack, T and B cells in periphery. Please refer to MGI allele page for further information using the link above.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||19||No|14-Dec-2018|Cryopreserved sperm|44.0|0.0|Yes||SCID, severe combined immunodeficiency, transplant, T cell, B cell|Yes| 10369.0|CRISP4 KO/BL6/J|C57BL/6J-Crisp4/MarpApb||Dominant|cysteine-rich secretory protein 4|CRISP4|||MGI:1925331 ||Crisp4||1|ENSMUSG00000025774|||||||||Unknown to Unknown|||||||||||||||||||Sub-fertile: issues binding sperm to zona pellucida and regulation of acrosome reaction. No in vitro fertilisation possible|Normal|C57Bl/6J|Yes|Yes|Yes|Unknown|Unknown|Unknown|Yes|Unknown||||No|12-Oct-2023|Cryopreserved sperm|40.0|0.0|Unknown|||No| 8621.0|K5-creERt R26-YAP5SA|STOCK Gt(ROSA)26Sor<(CAGGS-Yap5SA,LacZ)Mao> Tg(KRT5-cre/ERT2)2Ipc||Recessive||||||||||||||||||||||||||||||||||||||Overexpression of activated YAP (NLS-YAP-5SA) with Keratin-5 (K5-CreERt) is sufficient to induce rapid formation of both SCC and spSCC in mice. spSCC tumours arise at sites of epithelial scratch wounding, where tumour-initiating epithelial cells undergo EMT to generate spSCC. Expression of the EMT transcription factor ZEB1 arises upon wounding and is a defining characteristic of spSCC in mice and humans. Thus, the wound healing response synergises with YAP to drive metaplastic transformation of SCC to spSCC.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Dec-2018|Cryopreserved sperm|58.0|52.0|Unknown||Hippo, epithelium, Squamous cell carcinoma (SCC) |Yes| 6314.0|OT-II|C57BL/6-Tg(TcraTcrb)425Cbn/Wehi||Dominant||||||||||||||||||||||||||transgene insertion 425, Frank Carbone||||||||||||Abnormal cytokine level:*CD4 T cells cultured with OVA peptide-loaded spleen cells from B7 (CD80/86) deficient mice then restimulated with anti-CD3 produce lower amounts of IL-4, Il-17a, and interferon gamma (Ifng) than wild-type T cells.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Sep-2011|Cryopreserved sperm|21.0|0.0|Unknown||MHC II, TCR|Yes| 6872.0|A1f|C57BL/6-Acaca/AusbApb|C57BL/6-Acaca/Ausb|Dominant|acetyl-Coenzyme A carboxylase alpha|Acaca|Normal|A530025K05Rik, Acac, Acc1, acetyl-CoA carboxylase, LOC327983|MGI:108451|acetyl-Coenzyme A carboxylase alpha; targeted mutation 1, David E James|Acaca|MGI:5618483|11||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Apr-2012|Cryopreserved sperm|50.0|0.0|No||ACC1|Yes| 7290.0|GzmB KO x OT-1|B6.129-Gzmb Tg(TcraTcrb)1100Mjb/PibMarpApb|B6.129-Gzmb Tg(TcraTcrb)1100Mjb/Pib|Recessive|granzyme B|Gzmb||CCP1, CCP-1/C11, Ctla1, Ctla-1, GZB|MGI:109267|granzyme B; targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||transgene insertion 1100, Michael J Bevan|H-2Kb promoter|||||||||||Immunocompromised|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Mar-2013|Cryopreserved sperm|50.0|0.0|Unknown||T cell, natural killer, apoptosis, cytotoxic|Possibly| 6880.0|Krüppel-like Factor 3 (KLF3) Cherry Knock-in|Klf3-mCherry-loxP-neo-loxP||Recessive|Kruppel-like factor 3 (basic)|Klf3|Nil|BKLF, Bklf, Tef-2|MGI:1342773||||5||||||||||||||||Yes|||||||||||||No visible phenotype. Cells express "Cherry" fluorescence.|Same as homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|01-May-2012|Cryopreserved sperm|50.0|0.0|Unknown||Kruppel-like Factor 3, Basic Kruppel-like Factor, KLF, Obesity, adipose|Possibly| 6881.0|ENU15Ch:020a:mTOR|C57BL/6JAnu-Mtor/AnuApb|C57BL/6JAnu-Mtor/AnuApb|Recessive|mechanistic target of rapamycin (serine/threonine kinase)|Mtor|Unknown|2610315D21Rik, FKBP-rapamycin-associated protein FRAP, flat, Frap1, RAFT1, RAPT1 |MGI:1928394|mechanistic target of rapamycin (serine/threonine kinase); mutation 1, The Australian National University|Mtor|MGI:5484589|4|ENSMUSG00000028991|ENSMUST00000103221|mtor-001|614|705|T to G|ENSMUSE00000524008|5|205|Isoleucine to Serine|||||TGTGGCTGTGTGGGACCCCAAGCAGGCCATCCGGGAAGGCGCTGTAGCGGCCCTTCGTGCC||||||||||||||Low numbers of NK cells, few KLRG1 expressing NK cells, low CD44 protein expression on CD4<+> T cells in the blood|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||G5N1||No|02-May-2012|Cryopreserved sperm|45.0|0.0|Unknown||lymphocyte, T cell, NK cell, ENU|No| 7596.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|8|||No|18-Feb-2014|Cryopreserved sperm|72.0|0.0|Unknown||growth retardation, ENU|Yes| 7302.0||SJL/Mrit||Dominant|Unknown||||||||Unknown|||||||||||||||||||||||||||||Severe macrocytosis|Macrocytosis|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|03-Apr-2013|Cryopreserved sperm|47.0|0.0|No||haematology, macrocytosis, ENU|Yes| 6878.0|EL20 ; Embryonic Lethal 20|B6.129-Inpp5d/MarpApb|B6.129-Inpp5d/Marp|Recessive|inositol polyphosphate-5-phosphatase D|Inpp5d|Reduced|SHIP, SHIP1, SHIP-1, Src homology 2 domain-containing inositol-5-phosphatase, s-SHIP|MGI:107357|inositol polyphosphate-5-phosphatase D; early lethal|Inpp5d|MGI:5050823|1|||||||||||||||||||||||||||||From birth homozygous mutants exhibit runting and by 5-6 weeks of age, will develop myeloid leukemia characterised by anemia, leukopenia, thrombocytopenia and splenomegaly. Mice will die by 7 weeks of age due to myeloid infiltration of the lungs.|Normal|C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Excellent|10|10+|Heterozygous x Heterozygous|No|26-Apr-2012|Cryopreserved sperm|50.0|0.0|Yes|Leukemia|Ship1, sShip, myeloid, leukemia, ENU mutation|Yes| 6583.0|RalGDS|BALB/c-Ralgds/Apb|3574574|Semi-dominant|ral guanine nucleotide dissociation stimulator|Ralgds|Nil|Gnds, mKIAA1308, RalGDS, Rgds|MGI:107485||||2|||||||||||||||||||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||homozygous cross to heterozygous mouse|No|19-Sep-2011|Cryopreserved sperm|50.0|0.0|No|||No| 7021.0|SphK1 Tg|C57BL/6-Tg(CAG-Sphk1)/MarpApb||Dominant||||||||||||||||||||||||||Sphingosine kinase 1a|chicken beta-actin promoter, CAG|Moderate - High||||||||||Normal|Normal|C57BL/6|No|Yes|Yes|No|Yes|Yes|No|Excellent|more than 9 times||WT (-/-) x Het (+/-)|No|19-Jul-2012|Cryopreserved sperm|40.0|0.0|No||Ceramide, Insulin resistance|Possibly| 7597.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|8|||No|18-Feb-2014|Cryopreserved sperm|103.0|0.0|Unknown||growth retardation, ENU|Yes| 4869.0|B6.HTF1.Tg|C57BL/6-Tg(H2-K-huFUT1)1/Apb||Dominant||||||||||||||||||||||||||human fucosyltransferase 1|H2-K|All blood/tissue samples express human fucosyltransferase 1||||||||||Attempts to breed homozygous animals failed. Unknown if homozygous transgene expression is embryonic lethal.|All blood/tissue samples express human fucosyltransferase.Develop colitis from 6 weeks of age, skin disease from around 12 weeks of age, highly susceptible to infections such as MHV.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|90.0|0.0|Unknown||glycosylation, xenotransplantation, transplantation, transferase, lectins, H transferase, antibody|Yes| 5526.0|Klf8-LoxP|B6;129-Klf8||X-linked|Kruppel-like factor 8|Klf8||BKLF3, ZNF74|MGI:2442430||||X||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6-129SV/J|Yes|Unknown|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Jun-2011|Cryopreserved sperm|50.0|0.0|No|||Possibly| 6882.0|CKB|STOCK-Tg(Crp-H2-K)/Apb||Dominant||||||||||||||||||||||||||mouse H2-K (MHC class I)|C-reactive protein promoter|low in the absence of inflammation, induced upon inflammation||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|02-May-2012|Cryopreserved sperm|50.0|0.0|No||tolerance, liver, CD8 T cells, MHC class I, autoimmunity|Yes| 5541.0|ENU18Ch:065a|C57BL/6JAnu-Fcer2a/AnuApb|C57BL/6JAnu-Fcer2a/AnuApb|Dominant|Fc receptor, IgE, low affinity II, alpha polypeptide|Fcer2a |Reduced|CD23, FC epsilon RII, Fce2, low-affinity IgE receptor, Ly-42 |MGI:95497|Fc receptor, IgE, low affinity II, alpha polypeptide; mutation 1, The Australian National University|Fcer2a|MGI:5563468|8|ENSMUSG00000005540|ENSMUST00000005678|fcer2a-201|54|226|C to A|ENSMUSE00000484893|3|18|Cysteine to STOP|||||TACTGGGAACCTCCTAGAAAGCGTTGCTGCTGTGCAAGACGTGGGACACAGCTCATGTTGG||||||||||||||Reduced CD23 protein expression on B cells in peripheral blood. |Reduced CD23 protein expression on B cells in peripheral blood. |C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|6|4|Sib x sib|No|18-Jul-2011|Cryopreserved sperm|62.0|0.0|Unknown||B cell, lymphocyte, ENU|Yes| 5580.0|APN 170|C57BL/6N-Tnfsf12/Marp||Dominant|tumor necrosis factor (ligand) superfamily, member 12|Tnfsf12|Unknown|APO3L, DR3L, Tweak |MGI:1196259|tumor necrosis factor (ligand) superfamily, member 12; targeted mutation 1, Velocigene|Tnfsf12|MGI:4415424|11|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|08-Sep-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7301.0|CPEB|SJL-CPEB1/Apb||Dominant|cytoplasmic polyadenylation element binding protein 1|Cpeb1|Unknown||MGI:108442||||7|ENSMUSG00000025586|ENSMUST00000098331|Cpeb1-001||||||||||||||||||||||||||The homozygous females displays an infertility phenotype associated with a dysmorphology of the internal reproductive organs (uterus and ovaries)|The phenotype is normal|SJL/J|Yes|No|Yes|Yes|Yes|Yes|No|Poor||||No|03-Apr-2013|Cryopreserved sperm|50.0|0.0|No||Fertility, ovaries, ENU|Yes| 6586.0|MMP13KO BALB/c|C.FVB(Cg)-Mmp13/Apb||Recessive|matrix metallopeptidase 13|MMP13|Nil|Clg, collagenase-1, Collagenase-3, interstitial collagenase, MMP-13, Mmp1|MGI:1340026|matrix metallopeptidase 13; targeted mutation 1.1, Zena Werb|Mmp13|MGI:3521938|9|||||||||||||||||||||||||||||Increased width of hypertrophic chondrocyte zone: * the hypertrophic zone is expanded in the tibia and metatarsals, at E17 and 1 week after birth, respectively, however by 12 weeks of age the size of the hypertrophic zone is similar to wild-type. * chondrocytes proliferate and differentiate normally but accumulate in the most terminally differentiated hypertrophic state. * establishment of the primary ossification centers is normal.Abnormal cancellous bone morphology: * the amount of trabecular bone is increased in the tibia and metatarsals by 3 weeks or 1 week of age, respectively, however by 1 year of age the amount of trabecular bone was similar to wild-type. * the organization of the trabecular bone is also irregular.OA was surgically induced in the knees of MMP-13-knockout mice. No difference between wildtype and KO mice for aggrecan loss or cartilage erosion at 4 weeks. here was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks. Cartilaginous osteophytes were larger in knockout mice at 4 weeks, but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints. Authors conclude Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10||Het x Het|No|22-Sep-2011|Cryopreserved sperm|80.0|0.0|Yes|spondyloepimetaphyseal dysplasia|extracellular matrix, collagenase, chondrocyte, osteoblast, growth plate|Possibly| 3935.0|RRF|BALB/c-Gt(ROSA)26Sor/AnuApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Hugh D Campbell|Gt(ROSA)26Sor|MGI:4939369|6|||||||||||||||||||||||||||||Normal|Normal.No analysis performed|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|4||Hom x Hom|No|16-Oct-2008|Cryopreserved sperm|80.0|0.0|Unknown||ROSA, flightless, wound healing|Yes| 8631.0|TLR9 ApoE double knock out mice|C57BL/6-Apoe Tlr9||Recessive|apolipoprotein E|Apoe|Nil||MGI:88057|apolipoprotein E; targeted mutation 1, University of North Carolina|Apoe|MGI:1857129|7|||||||||||||||||||||||||||||Genetic deletion of the innate immune receptor TLR9 exacerbated atherosclerosis in ApoE−/− mice fed a high-fat diet. CD4+ T cells were identified as potential mediators of this effect.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2018|Cryopreserved sperm|40.0|0.0|Unknown||Atherosclerosis, Plaque, low-density-lipoprotein cholesterol|Yes| 8631.0|TLR9 ApoE double knock out mice|C57BL/6-Apoe Tlr9||Recessive|toll-like receptor 9|Tlr9|Nil||MGI:1932389|toll-like receptor 9; targeted mutation 1, Shizuo Akira|Tlr9|MGI:2660562|9|||||||||||||||||||||||||||||Genetic deletion of the innate immune receptor TLR9 exacerbated atherosclerosis in ApoE−/− mice fed a high-fat diet. CD4+ T cells were identified as potential mediators of this effect.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2018|Cryopreserved sperm|||Unknown||Atherosclerosis, Plaque, low-density-lipoprotein cholesterol|Yes| 1228.0|T-Bird|C57BL/6JAnu-Dsg4/AnuApb|C57BL/6JAnu-Dsg4/AnuApb|Recessive|desmoglein 4|Dsg4|Unknown|CDHF13, lah|MGI:2661061|T-Bird|Dsg4|MGI:5007752|18|ENSMUSG00000001804|ENSMUST00000019426|Dsg4-001|643|777|A to C|ENSMUSE00000445469|6|215|Threonine to Proline|||||GTGCACCCATGTTCATGGTGAACAGGTACACTGGAGAAGTCCGCACGATGTCCAATTTCCT|No|||||||||||||Greasy Coat. Affected mice develop a dull, sparse and greasy coat at about ~40 days of age. ||C57BL/6 x C57BL10|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5|||No|15-Jun-2007|Cryopreserved sperm|27.0|0.0|Unknown||Coat, greasy, hair, ENU|Yes| 1549.0||BALB/c-Tg(iFABPp-IL9)/AnuApb||Recessive||||||||||||||||||||||||||interleukin 9|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences). |High||||||||||Restricted expression of IL9 transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|103.0|0.0|Unknown||intestine, interleukin, mast cell, anaphylaxis, mastocytosis, allergy|Yes| 5183.0|Ggn knockout clone 16|B6.129-Ggn/16MarpApb||Recessive|gametogenetin|Ggn|Unknown|GGN1, GGN2, GGN3|MGI:2181461|gametogenetin; targeted mutation 1, Duangporn Jamsai|Ggn|MGI:5503309|7||||||||||||||||Yes|||||||||||||Embryonic Lethal|Appear normal.Abnormal double-strand DNA break repair:• increased unrepaired double-strand breaks in pachytene spermatocytes|C57BL/6J x129Sv|No|No|Yes|No|No|Unknown|No|Unknown||||No|23-Jul-2010|Cryopreserved sperm|50.0|0.0|Unknown||Sperm, testis, embryonic lethal, DNA repair|Possibly| 8632.0|Dmp1Cre.Efnb2|B6.Cg-Efnb2 Tg(Dmp1-cre)1Jqfe||Recessive|ephrin B2|Efnb2||ELF-2, Epl5, Eplg5, Htk-L, Lerk5, LERK-5, NLERK-1|MGI:105097|ephrin B2; targeted mutation 2, David J Anderson|Efnb2|MGI:2176538|8|||||||||||||||||transgene insertion 1, Jian Q Feng|Dmp1|odontoblast-specific||||||||||Normal bone shape and cortical width with a low bone material strength due to hypermineralization|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2018|Cryopreserved sperm|48.0|0.0|Unknown||homeostasis, osteoblasts, EphB4|Yes| 6838.0|APN 228|C57Bl/6N-mir-196a-2/MarpApb||Recessive|microRNA 196a-2 |Mir196a-2 |Unknown|mir 196a-2, Mirn196a-2, mmu-mir-196a-2|MGI:3618739||||15|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|07-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6886.0|APN174|C57Bl/6N-Map3k5/MarpApb||Recessive|mitogen-activated protein kinase kinase kinase 5|Map3k5|Unknown|7420452D20Rik, ASK, ASK1, Mekk5|MGI:1346876|mitogen-activated protein kinase kinase kinase 5; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Map3k5|MGI:4434801|10|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|03-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 4964.0|Ptch1|B6.129-Ptch1/Apb||Recessive|patched homolog 1|Ptch1|Normal|Patched 1, Ptc, Ptc1|MGI:105373|patched homolog 1; targeted mutation 1, Brandon J Wainwright|Ptch1|MGI:2675356|13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|12|||No|15-Jan-2010|Cryopreserved sperm|93.0|0.0|Unknown||BCC, neuroblastoma, hedgehog signalling, stem cell|Possibly| 7592.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays an harmonious growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|5|||No|18-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7593.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|8|||No|18-Feb-2014|Cryopreserved sperm|83.0|0.0|Unknown||growth retardation, ENU|Yes| 7391.0|B6.pIgR-/-|C57BL/6-Pigr/Apb||Recessive|polymeric immunoglobulin receptor|Pigr|Nil||MGI:103080|polymeric immunoglobulin receptor; targeted mutation 1, Richard A Strugnell|Pigr|MGI:2651659|1|||||||||||||||||||||||||||||These mice are unable to secrete IgA and IgM into the secretions. This results in 50-100 fold increased levels of IgA in blood, and very low to undetectable levels of IgA in faecal samples.|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||Yes|06-Aug-2013|Cryopreserved sperm|50.0|0.0|No||polymeric immunoglobulin receptor, IgA, SIgA, mucosal immunology|No| 6885.0|ARNEZ 2 MTf Tg #2|B6.129-Tg(UBC-Mfi2)43Drrn/Apb||Dominant||||||||||||||||||||||||||murin melanotransferrin|human unbiquitin c|ubiquitous||||||||||Normal.Mild but significant decrease of erythrocyte number in both male and female MTf Tg mice compared to the wildtype counterparts|Normal.Mild but significant decrease of erythrocyte number in both male and female MTf Tg mice compared to the wildtype counterparts|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|03-May-2012|Cryopreserved sperm|50.0|0.0|Unknown||melanoma, melanotransferrin, iron, erythrocyte, p97, ARNEZ , ARNEZ 2, MTf Tg|Yes| 6888.0|APN157|C57Bl/6N-Tgm5/MarpApb||Recessive|transglutaminase 5|Tgm5|Unknown|2310007C07Rik, TGx |MGI:1921426 |transglutaminase 5; targeted mutation 2a, Wellcome Trust Sanger Institute|Tgm5 |MGI:4451573|2|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|03-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6892.0|Gp130/IL10) (ME-263)|B6-Il6st Il10/LudApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|5133400A03Rik, CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst |Il6st|MGI:2388478|13|||||||||||||||||||||||||||||Homozygous mice do not breed when mated together.gp130 mice develop gastric polyps.|Unknown|C57BL/6|Yes|No|Unknown|Yes|No|Unknown|No|Unknown||||No|10-May-2012|Cryopreserved sperm|49.0|0.0|Unknown||il10, il6st, signal transduction, infection|Possibly| 6892.0|Gp130/IL10) (ME-263)|B6-Il6st Il10/LudApb||Dominant|interleukin 10|Il10||cytokine synthesis inhibitory factor, IL-10|MGI:96537|interleukin 10; targeted mutation 1, University of Cologne|Il10|MGI:1857199|1|||||||||||||||||||||||||||||Homozygous mice do not breed when mated together.gp130 mice develop gastric polyps.|Unknown|C57BL/6|Yes|No|Unknown|Yes|No|Unknown|No|Unknown||||No|10-May-2012|Cryopreserved sperm|||Unknown||il10, il6st, signal transduction, infection|Possibly| 6889.0|APN218|C57Bl/6N-mir-196b/MarpApb||Recessive|microRNA 196b|Mir196b |Unknown|mir 196b, Mirn196b, mmu-mir-196b |MGI:3618741 ||Mir196b ||6|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|03-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7111.0|APN278 (ARL SPF)|C57BL/6N-Dsg2Mu||Recessive|desmoglein 2|Dsg2 ||D18Ertd293e |MGI:1196466 |desmoglein 2; targeted mutation 1a, Wellcome Trust Sanger Institute |Dsg2tm1a(EUCOMM)Wtsi|MGI:4432319|18|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|24-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10361.0|ENU:Ninj1|C57BL/6JAnu-Ninji/Anu||Dominant|ninjurin 1|Ninj1|||MGI:1196617 |Ninji: mutation 1, Australian National University|Ninji||13|ENSMUSG00000037966||||||||||||||||||||||||||||Normal|Normal|C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Sep-2023|Cryopreserved sperm|56.0|0.0|Unknown|||Possibly| 8641.0|Chloe|C57BL/6-Acan/AfosSyd||Recessive|aggrecan|Acan||Agc1, b2b183Clo, Cspg1|MGI:99602|aggrecan; targeted mutation 1, Amanda J Fosang|Acan|MGI:3577026|7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Jan-2019||0.0|0.0|Unknown||Skeletal, metalloproteinases|Yes| 7308.0|mRI61689|B6.BKS-Lepr Ank1/Apb|B6.BKS-Lepr Ank1|Dominant|ankyrin 1, erythroid|Ank1|Unknown|Ank-1, pale|MGI:88024||||8|ENSMUSG00000031543|ENSMUST00000121802|Ank1-004||||||||23106021|17|||CTTCCCTGGCTTAAAGTTGGTGCACATCTGTTTCTTTTTAGAGTGGACTCACTCCCCTCC||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility, splenomegaly and survival advantage to Plasmodium chabaudi|B6.BKS-Lepr|No|No|Yes|No|No|Yes|No|Good||||No|09-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes|Hereditary spherocytosis|Hereditary spherocytosis, microcytosis, ENU|Yes| 7308.0|mRI61689|B6.BKS-Lepr Ank1/Apb|B6.BKS-Lepr Ank1|Dominant|leptin receptor|Lepr|||MGI:104993|leptin receptor; diabetes|Lepr|MGI:1856009|4|||||||||||||||||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility, splenomegaly and survival advantage to Plasmodium chabaudi|B6.BKS-Lepr|No|No|Yes|No|No|Yes|No|Good||||No|09-Apr-2013|Cryopreserved sperm|||Yes|Hereditary spherocytosis|Hereditary spherocytosis, microcytosis, ENU|Yes| 7598.0|Stk35KO or Clik1KO|B6.129-Stk35/MarpApb||Semi-dominant|serine/threonine kinase 35 |Stk35|Nil|1700054C12Rik, CLIK1, CLP-36 interacting kinase|MGI:1914583||||2|||||||||||||||||||||||||||||Male and female subfertility/infertility and abnormal eye development|Variable from subfertility to normal.|SV129/C57Bl6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||||No|19-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5535.0|Crash|STOCK Celsr1/MarpApb||Recessive|cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila)|Celsr1|Reduced|crash, Crsh, Scy|MGI:1100883|cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila); crash|Celsr1|MGI:2668337|15|ENSMUSG00000016028|ENSMUST00000016172|Celsr1-201|3119|3126|A to G|ENSMUSE00001038472|1|1040|Aspartic acid to Glycine|||||TTCAGTGGTAGCAAGAATAAGGGCCAACGACCCGGACGAAGGTCCGAATGCTCAGATCATG||||||||||||||Homozygous mice aren't viable. They have neural tube defects and planar cell polarity defects.|Heterozygous mice display a curly tail.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||+/- x +/+|No|07-Jul-2011|Cryopreserved sperm|40.0|0.0|No||planar cell polarity, neural tube, ENU|No| 6788.0|APN 253|C57BL/6N-Kat5 /Marp||Recessive|K(lysine) acetyltransferase 5 |Kat5 |Unknown|Htatip, mHTATIP/CPLA2, PLIP, Tip60 |MGI:1932051 | gene trap IST12384G7, Texas A&M Institute for Genomic Medicine |Gt(IST12384G7)Tigm|MGI:4076960|19||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell, Gene Trap|Yes| 7687.0|ENU26:017:Mef2c|C57BL/6NCrlAnu-Mef2c/AnuApb||Recessive|myocyte enhancer factor 2C|Mef2c|Unknown|5430401D19Rik, 9930028G15Rik|MGI:99458|myocyte enhancer factor 2C; mutation 1, The Australian National University|Mef2c|MGI:5571303|13|ENSMUSG00000005583|ENSMUST00000163888|Mef2c-202|374|952|A to T|ENSMUSE00000680752|5|125|Aspartic acid to Valine|||||CAAGTACAGGAAAATTAACGAAGATATTGATCTAATGATCAGCAGGCAAAGATTGTGTGCT||||||||||||||Embryonic Lethal|Appear normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||G5|Het x Het|No|22-May-2014|Cryopreserved sperm|45.0|0.0|Unknown||ENU, embryonic lethal|Yes| 5037.0|ENU11B6:221d ; ambrosius|C57BL/6JAnu-Atp11c/AnuApb|C57BL/6JAnu-Atp11c/AnuApb|X-linked|ATPase, class VI, type 11C|Atp11c||Ig|MGI:1859661|ambrosius|Atp11c|MGI:4456247|X|ENSMUSG00000062949|ENSMUST00000154051|Atp11c-001||||||||57491646|27|||TTTCTCATTCTTCTGGGGAGGAATTATTTGGTAAGCAGCTGTACCTGTGTGAGCAATATT|Yes|||||||||||||No B cells.Defective ATP11C resulted in a lower rate of phosphatidylserine translocation in pro-B cells and much lower pre-B cell and B cell numbers despite expression of pre-rearranged immunoglobulin transgenes or enforced expression of the prosurvival protein Bcl-2 to prevent apoptosis and abolished pre-B cell population expansion in response to a transgene encoding interleukin 7. ||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-Feb-2010|Cryopreserved sperm|93.0|0.0|Unknown||ENU, B cell, NIH, Wellcome Trust|Yes| 6890.0|ENU23:G2|ANU:ENU23:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|04-May-2012|Cryopreserved sperm|1312.0|0.0|Unknown||ENU, mutagenesis, random, screen|Yes| 2379.0|Dorian, ENU6AT:HELxTCR:035|B6JSfdAnu;CBA-Bcl2/AnuApb|B6JSfdAnu;CBA-Bcl2/AnuApb|Recessive|B-cell leukemia/lymphoma 2|Bcl2|Unknown|Bcl-2|MGI:88138|B-cell leukemia/lymphoma 2; dorian|Bcl2|MGI:3844731|1|ENSMUSG00000057329|ENSMUST00000080103|Bcl2-201|70|1244|T to C|ENSMUSE00000466735|2|24|Serine to Proline|||||TCGTGATGAAGTACATACATTATAAGCTGTCACAGAGGGGCTACGAGTGGGATGCTGGAGA|No|||||||||||||Coat colour change.Diluted coat colour.Irregular coat pigmentation.Affected mice undergo dramatic greying/whitening of their coat from about 4 - 5 weeks of age. Both black and agouti mice are affected. "Salt 'n' Pepper". Mice do not appear to "age" at a greater rate.||C57BL/6JStdAnu x CBA/CaJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Dec-2007|Cryopreserved sperm|100.0|0.0|Unknown||Coat, grey, salt and pepper, ageing, ENU, hair, Bcl2|Yes| 8643.0|Dap10/Dap12 double knock out (Dap10/12 DKO)|B6.129-Hcst/Tyrobp/Ttk||Recessive|hematopoietic cell signal transducer|Hcst|Nil|DAP10, KAP10|MGI:1344360|hematopoietic cell signal transducer; targeted mutation 1, Toshiyuki Takai|Hcst/Tyrobp|MGI:3840566|7|||||||||||||||||||||||||||||Normal; Mice lack Ly49H on cell surface |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown||NK cell|Yes| 8643.0|Dap10/Dap12 double knock out (Dap10/12 DKO)|B6.129-Hcst/Tyrobp/Ttk||Recessive|TYRO protein tyrosine kinase binding protein|Tyrobp|Nil|DAP12, KARAP, killer cell activating receptor associated protein|MGI:1277211|TYRO protein tyrosine kinase binding protein; targeted mutation 1, Toshiyuki Takai|Hcst/Tyrobp|MGI:3840567|7|||||||||||||||||||||||||||||Normal; Mice lack Ly49H on cell surface |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Jan-2019|Cryopreserved sperm|||Unknown||NK cell|Yes| 7079.0|Momme D26|FVB/NJ-Rlf Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|rearranged L-myc fusion sequence|Rlf|Unknown|9230110M18Rik, MommeD8|MGI:1924705|modifier of murine metastable epialleles, D26|||4|||||||||||||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Normal|Normal|FVB/NJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||MommeD26<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|13-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation|Possibly| 7602.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|Normal|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2|||No|24-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 6770.0|Hck/Stat6|STOCK Hck Stat6/LudApb||Recessive|hemopoietic cell kinase|Hck|Reduced|Bmk, Hck-1|MGI:96052|hemopoietic cell kinase; targeted mutation 1, Matthias Ernst|Hck|MGI:3663799|2|||||||||||||||||||||||||||||When maintained on a C57BL/6 background Hck mutant mice develop an age dependant inflammation that is restricted to the lung|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2011|Cryopreserved sperm|60.0|0.0|Unknown||signal transduction|Yes| 6770.0|Hck/Stat6|STOCK Hck Stat6/LudApb||Recessive|signal transducer and activator of transcription 6|Stat6|Nil||MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10|||||||||||||||||||||||||||||When maintained on a C57BL/6 background Hck mutant mice develop an age dependant inflammation that is restricted to the lung|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2011|Cryopreserved sperm|||Unknown||signal transduction|Yes| 5380.0|TSW ; TS1(SW)|BALB/c-Tg(Tcra/Tcrb) Rag2/Apb||Dominant|recombination activating gene 2|Rag2|Nil|Rag-2|MGI:97849||||2|||||||||||||||||T cell receptor alpha, T cell receptor beta||||||||||||Mice lack mature T and B cells|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Hom x Hom|Yes|06-Jan-2011|Cryopreserved sperm|50.0|0.0|No||TCR transgenic, CD4, influenza|Possibly| 7042.0|Loco|ENU20 Bcl2:016:a:B6||Recessive|caspase recruitment domain family, member 11|Card11|Unknown||MGI:1916978|loco|||5|||||||||||||||||transgene insertion 1, Jerry M Adams|mouse Vav promoter|||||||||||No Treg cells|Decreased circulating Treg cells.|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor|G6|3|best to maintain clony with Het breeders, hom's produced small litters size|No|06-Aug-2012|Cryopreserved sperm|65.0|0.0|Unknown||T cell|Possibly| 6893.0|tet(o)kras (ME-78)|FVB/N-Tg(tetO-Kras2)12Hev/LudApb||Dominant||||||||||||||||||||||||||transgene insertion 12, Harold E Varmus|tetracycline-responsive promoter element (tTA)|||||||||||This strain allows for the inducible and tissue-specific activation of Kras when crossed into a rtTA or rTA expressing line.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-May-2012|Cryopreserved sperm|40.0|0.0|Unknown||inducible|Possibly| 6894.0|GSTA3-/-|BALB/c-Gsta3/AnuApb||Recessive|glutathione S-transferase, alpha 3|GstA3|Nil|Gst2-3|MGI:95856||||1|||||||||||||||||||||||||||||Altered metabolism of aflatoxinB1|Unknown|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|N4||homozygote matings|No|11-May-2012|Cryopreserved sperm|46.0|0.0|Yes|This mouse is a model of normal human sensitivity to aflatoxinB1 carcinogenesis.||Yes| 7307.0|RIP-OVAlo|C57BL/6-Tg(Ins2-OVA)307Wehi/WehiApb|C57BL/6-Tg(Ins2-OVA)307Wehi/WehiApb|Dominant||||||||||||||||||||||||||transgene insertion 307, Walter and Eliza Hall Institute of Medical Research|rat insulin 2|low (relative to RIP-OVAhi mice)||||||||||Normal. Mice express OVA in the pancreas beta cells. |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||>30|brother-sister or Tg x C57BL/6|No|09-Apr-2013|Cryopreserved sperm|50.0|0.0|No||pancreas, autoimmunity, ovalbumin|Yes| 7081.0|Momme D20|FVB/NJ-D14Abb1e Tg(Hba1-Gfp)1Ew/QimrApb||Semi-dominant|transcription activation suppressor, DNA segment, Chr 14, Abbott 1 expressed|D14Abb1e|Unknown|4933409E02Rik, Tasor|MGI:1921694|DNA segment, Chr 14, Abbott 1 expressed; modifier of murine metastable epialleles, D20|D14Abb1e|MGI:5659903|14||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Death at E6-E8|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD20<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|13-Sep-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, epigenetics, modifier|Possibly| 8646.0|EGFL6 global KO|B6.129X1-Egfl6||Recessive|EGF-like-domain, multiple 6|Egfl6||Maeg|MGI:1858599|EGF-like-domain, multiple 6; gene trap 485H8, Centre for Modeling Human Disease|Egfl6|MGI:4954036|X|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5325.0|Acc2 floxed|C57BL/6-Acacb/Apb||Dominant|acetyl-Coenzyme A carboxylase beta|Acacb|Normal|Acc2, Accb|MGI:2140940||||5||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygous pairs|No|18-Nov-2010|Cryopreserved sperm|50.0|0.0|No||fatty acid, adipose, liver, glycogen|Yes| 5221.0|GRQ|B6.129-Fxn Tg(FXN-EGFP)CSars/Apb|SARS|Recessive|frataxin|Fxn||Frda|MGI:1096879|frataxin; targeted mutation 1, Michel Koenig|Fxn|MGI:2177162|19||||||||||||||||No|Human FRATAXIN gene|FXN endogenous promoter|||||||||||Homozygous FXN-EGFP transgene: Normal.Homozygous Fxn knockout: embryonic lethal, but completely complemented by presence of FXN-EGFP transgene.|Hemizygous FXN-EGFP transgene: Normal.Heterozygous Fxn knockout: Normal.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16|Hemizygous FXN-EGFP transgene X Homozygous FXN knockout|Yes|23-Sep-2010|Cryopreserved sperm|45.0|0.0|Yes|Friedreich ataxia|Friedreich ataxia, neurodegenerative disease, GAA repeat expansion, iron-sulfur clusters|Yes| 7311.0|K5rTA-Rae1-33|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)33Cbn/Apb|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)33Cbn|Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.Following doxycycline treatment, RaeT1e expression is patchy in these mice.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 7311.0|K5rTA-Rae1-33|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)33Cbn/Apb|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)33Cbn|Dominant||||||||||||||||||||||||||retinoic acid early transcript 1E|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.Following doxycycline treatment, RaeT1e expression is patchy in these mice.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|||Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 4896.0|Lym1|BALB/c-Nfkb2/Apb||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100|Nfkb2|Unknown|NF kappaB2, p52|MGI:1099800|nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100; Lym1|Nfkb2|MGI:4412046|19|||||||||||||||||||||||||||||Increased circulating lymphocytes.A comprehensive histopathological analysis of these mice, however, revealed an absence of peripheral LN (inguinal, brachial, axillary, cervical) and Peyer’s patches. Mesenteric LN were present, but were reduced in size and cellularity.presence of inflammatory cell infiltrates in the lung and liver.The number of mature recirculating B cells was significantly reduced.Nfkb2 bone marrow was almost completely unresponsive to RANKL with osteoclast formation <0.5% of that seen with wt.Mild osteopetrosis, with significantly increased trabecular bone volume|The ability of Nfkb2 cells to form osteoclasts in response to RANKL stimulation was significantly reduced|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|93.0|0.0|Unknown||noncanonical, p52, signal transduction, lymph node, osteopetrosis, B cell|Yes| 4941.0|Linie 5706|Swiss-Tg(tPA-LacZ)5706/MarpApb||Dominant||||||||||||||||||||||||||Beta-galactosidase|9.5kb of human t-PA gene promoter|||||||||||Normal.Expression of LacZ in brain. Very high expression in hippocampus, dentate gyrus and cortex.||Swiss white|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Tg Het x WT Swiss white|No|04-Dec-2009|Cryopreserved sperm|60.0|0.0|No||tissue type plasminogen activator, brain, hippocampus, medial habenula, dentate gyrus|Yes| 4871.0|B6.HTF2.Tg|C57BL/6-Tg(H2-K-huFUT1)2/Apb||Dominant||||||||||||||||||||||||||human fucosyltransferase 1|H2-K|All blood/tissue samples express human fucosyltransferase 1||||||||||Attempts to breed homozygous animals failed. Unknown if homozygous transgene expression is embryonic lethal.|All blood/tissue samples express human fucosyltransferase.Mice develop colitis.HFUT1 mice were profoundly lymphopenic, with aberrant T-cell markers and thymic medullary hypoplasia. Reconstitution with wild type bone marrow restored thymic morphology and prevented colitis in hFUT1 mice.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|88.0|0.0|Unknown||glycosylation, xenotransplantation, transplantation, transferase, lectins, H transferase, antibody, T cell|Yes| 5554.0|N1A-dko|Nox1-ApoE double knockout mouse||Recessive|NADPH oxidase 1|Nox1|Unknown|GP91 phox homolog, Nox-1|MGI:2450016||||X|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|11-Aug-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5554.0|N1A-dko|Nox1-ApoE double knockout mouse||Recessive|apolipoprotein E|Apoe|||MGI:88057||||7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|11-Aug-2011|Cryopreserved sperm|||Unknown|||Possibly| 8648.0|ENU45:G2|ANU:ENU45:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|31-Jan-2019|Cryopreserved sperm|1957.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4758.0|NOD H-2Kb|NOD-Tg(H2K)1Rms/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Robyn M Slattery|MHC Class II|||||||||||Normal NOD phenotype.|Normal NOD phenotype.|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Apr-2009|Cryopreserved sperm|150.0|0.0|Unknown||Major Histocompability, autoimmunity, diabetes, T cell|Yes| 4943.0|osteocalcin-cre|C57BL/6-Tg(BGLAP-cre)1Clem/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Thomas L Clemens|human osteocalcin (BGLAP) promoter|Osteoblasts|||||||||||Normal.Cre recombinase expression restricted to osteoblasts.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|68.0|0.0|Unknown||osteoblast, osteocalcin, Cre recombinase, IGF, mineralization|Yes| 4944.0|Mck-cre|C57BL/6-Tg(Ckmm-cre)5Khn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 5, C Ronald Kahn|muscle creatine kinase promoter|heart and skeletal muscle|||||||||||Expression of Cre recombinase in heart and skeletal muscle.|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|10|||No|04-Dec-2009|Cryopreserved sperm|95.0|0.0|Unknown||skeletal muscle, muscle, Cre recombinase|Yes| 4947.0|amylin KO|B6.129-Iapp/Apb||Recessive|islet amyloid polypeptide|Iapp|Nil|amylin|MGI:96382|islet amyloid polypeptide; targeted mutation 1, Samuel Gebre-Medhin|Iapp|MGI:2656235|6||||||||||||||||Yes|||||||||||||Homeostasis/metabolism phenotype: normal basal circulating insulin and glucose levels.Increased circulating insulin level: males, but not females, show an increased plasma insulin response to a glucose tolerance test.Improved glucose tolerance:* following glucose administration, males exhibit rapid glucose clearance associated with an increased insulin response.* following glucose administration, females exhibit rapid glucose clearance but show no increase in insulin response relative to wild-type.Increased body weight: from 18 weeks of age, males show a 20% increase in body mass.On 129 background animals show increased osteoclast number and greater bone resorption and corresponding decrease in trabecular thickness.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|66.0|0.0|Unknown||osteoclast, resorption, insulin, amylin|Yes| 5201.0|GOSSIP|C57BL/6J-Zfp397||Recessive|zinc finger protein 397|Zfp397|Nil||MGI:1916506||||18||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|05-Aug-2010|Cryopreserved sperm|50.0|0.0|No||centromere, kinetochore, zinc finger, SCAN domain|No| 5406.0|GM.G CSF.C57 (L-01) ;GM(-/-) G(-/-). C57|C57BL/6-Csf2 Csf3/LudApb||Recessive|colony stimulating factor 2 (granulocyte-macrophage)|Csf2|Nil|Csfgm, Gm-CSf, MGI-IGM|MGI:1339752|colony stimulating factor 2 (granulocyte-macrophage); targeted mutation 1, Ashley R Dunn|Csf2|MGI:1930997|11||||||||||||||||No|||||||||||||The phenotype of mice lacking both G-CSF and GM-CSF was additive to the features of the constituent genotypes, with three novel additional features: a greater degree of neutropenia among newborn mice than in those lacking G-CSF alone, an increased neonatal mortality rate, and a dominant influence of the lack of G-CSF on splenic hematopoiesis resulting in significantly reduced numbers of splenic progenitors. In contrast to newborn animals, adult mice lacking both G-CSF and GM-CSF exhibited similar neutrophil levels as G-CSF-deficient animals.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||granulocyte, lung, progenitor, neutropenia|Yes| 5406.0|GM.G CSF.C57 (L-01) ;GM(-/-) G(-/-). C57|C57BL/6-Csf2 Csf3/LudApb||Recessive|colony stimulating factor 3 (granulocyte)|Csf3|Nil|Csfg, G-CSF, MGI-IG|MGI:1339751|colony stimulating factor 3 (granulocyte); targeted mutation 1, Ashley R Dunn|Csf3|MGI:1857155|11||||||||||||||||No|||||||||||||The phenotype of mice lacking both G-CSF and GM-CSF was additive to the features of the constituent genotypes, with three novel additional features: a greater degree of neutropenia among newborn mice than in those lacking G-CSF alone, an increased neonatal mortality rate, and a dominant influence of the lack of G-CSF on splenic hematopoiesis resulting in significantly reduced numbers of splenic progenitors. In contrast to newborn animals, adult mice lacking both G-CSF and GM-CSF exhibited similar neutrophil levels as G-CSF-deficient animals.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Feb-2011|Cryopreserved sperm|||Unknown||granulocyte, lung, progenitor, neutropenia|Yes| 4879.0|Bc.Rag1.KO|C.B6-Rag1/ArcStvApb||Recessive|recombination activating gene 1|Rag1|Nil|Rag-1|MGI:97848|targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.||BALB/c x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|6|||No|28-Sep-2009|Cryopreserved sperm|90.0|0.0|Unknown||T cell, B cell, eosinophil, inflammation, interferon|Yes| 4946.0|CMV-cre|C57BL/6-Tg(CMV-cre)1Cgn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, University of Cologne|human cytomegalovirus (CMV) promoter||||||||||||Cre recombinase under the control of a human cytomegalovirus (CMV) promoter, active in most cells and tissues.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|89.0|0.0|Unknown||CMV, Cre recombinase, ubiquitous, deleter|Yes| 4948.0|a-actin-cre|C57BL/6-Tg(ACTA1-cre)1Jdz/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Jeffrey D Zajac|human actin, alpha 1, skeletal muscle promoter||||||||||||Cre expression in heart and skeletal muscle.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|99.0|0.0|Unknown||Cre recombinase, skeletal muscle, muscle, heart|Yes| 8649.0|ENU45:G3|ANU:ENU45:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|31-Jan-2019|Cryopreserved sperm|110.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5331.0|Pdx1-GFP|C57BL/6-Pdx1/MarpApb||Recessive|Pancreatic and duodedenal homeobox gene 1|Pdx1|Reduced|IDX-1, IPF-1, Ipf1, Mody4, pdx-1, STF-1|MGI:102851|pancreatic and duodenal homeobox 1; targeted mutation 1, Edouard G Stanley|Pdx1|MGI:3688420|5||||||||||||||||Yes|||||||||||||Pdx1 null mice lack a pancreas|Reduce glucose responsiveness|C57BL/6|No|No|Yes|No|No|Yes|No|Excellent|more than 15 back-crossed to B6||Pdx1-GFP males mated with C57BL/6 hets |No|24-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||Pancreas, endoderm, embryo|Yes| 5278.0|Lyn -/-|B6.129P2-Lyn/LudApb|B6.129P2-Lyn/LudApb|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||Peritoneal inflammation: there is about a doubling in the number of T cells found in the peritoneum.Increased T cell number: there is about a doubling in the number of T cells found in the peritoneum.Abnormal B cell morphology: B cells express lower levels of CD21 and higher levels of CD23 on the cell surface compared to controls.Decreased transitional stage B cell number: profound reduction in transitional stage-2 B cells.Decreased follicular B cell number: about a five-fold reduction in follicular B cells.Decreased marginal zone B cell number: profound reduction in marginal zone B cells.Abnormal B cell activation: * significant expression of MHCII complexes by circulating B cells suggest these B cells are in an activated state. * B cells have enhanced calcium flux upon activation.Abnormal myelopoiesis: * myelopoiesis is greatly enhanced in these mice. * there is a significant increase in the number of colonies generated by bone marrow cells or splenocytes in response to in vitro culturing with GM-CSF, M-CSF, or IL-3.Spleen hypoplasia: spleen cellularity is reduced by more than half due to B cell lymphopenia.Increased anti-nuclear antigen antibody level: auto-antibodies of the IgA, IgG IgM classes develop as the mice age.Increased anti-double stranded DNA antibody level: mice develop anti-DS DNA IgG antibodies as they age with high levels detectable in all mice by 20 weeks of age.Glomerulonephritis: * all mice have immunoglobulin complex deposition in the kidney by 8 weeks of age. * 83% of mice also have C3 complement deposition in the kidney. * severe glomerulonephritis occurs in these mice by one year of age.Increased basophil cell number: in cervical and inguinal lymph nodes and spleen.Increased mast cell number: in the peritoneum.Increased neutrophil cell number: mice exhibit decreased platelet numbers that becomes more pronounced with age (at 6 to 8 weeks in peripheral blood, 1089+/-242 per ul compared to 609+/-207 per ul in wild-type mice; at 52 to 58 weeks in peripheral blood, 2540+/-1050 per ul compared to 1264+/-434 per ul in wild-type mice).Decreased platelet cell number.Extramedullary hematopoiesis: * red and white pulp are often replaced with of red and white pulp with myelomonocytic cells that are often centers of extramedullary hematopoiesis. * myelomonocytic cells often accumulate in other organs and on the surface of the ears, tails and legs.Decreased spleen red pulp amount: red and white pulp are often replaced with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Enlarged spleen: * mice develop age-dependent splenomegaly * 20% of mice greater than 1 year of age exhibit severe splenomegaly with partial to complete replacement of red and white pulp with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Decreased spleen white pulp amount: red and white pulp are often replaced with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Abnormal circulating complement protein level: increased circulating immune complexes reactive to complement component 1 q.Abnormal level of surface class II molecules: basophils show high MHC II expression.Increased IgA level.Increased IgE level.Increased IgG2b level.Increased IgM level.Increased anti-nuclear antigen antibody level: of IgE isotype.Increased anti-double stranded DNA antibody level: of IgE isotype.Young mice are apparently healthy, but they start to show signs of autoimmune disease at >12 wks of age. The disease resembles the human condition systemic lupus erythematosus (SLE). The mice develop serum anti-nuclear antibodies and acquire crescentic glomerulonephritis due to immune complex deposition in kidney, leading to renal dysfunction. They show hematologic disorders such as lymphopenia and thrombocytopenia, and they develop lymphadenopathy and splenomegaly. They develop inflammatory lesions in multiple organs including skin, lung and kidney, and occasionally we observe neurologic disorders such as seizures and hind limb paralysis. Similar to SLE patients, the mice also have hyperactive B lymphocytes.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20||Hom x Hom|No|28-Oct-2010|Cryopreserved sperm|38.0|0.0|Yes|Systemic Lupus Erythematosus; SLE|B cell, immunoglobulin, spleen, kinase, signal transduction, src family, autoimmunity, lymphocyte|Yes| 5147.0|Cx40.354 ; Tie2Cx40.354|B6;CBA-Tg(Tie2-Gja5)/AnuApb||Dominant|gap junction protein, alpha 5|Gja5|Increased|connexin 40, Cx40, Gja-5|MGI:95716||||Unknown|||||||||||||||||overexpression of Cx40|Tie2 endothelial specific|||||||||||Unknown|unknown|N2 B6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2|||No|03-Jun-2010|Cryopreserved sperm|60.0|0.0|Yes|hypertension|connexins, hypertension, gap junctions|Possibly| 7355.0|MommeR1|FVB-Foxo3/QimrAnuApb||Recessive|forkhead box O3|Foxo3|Unknown|Fkhr2, FKHRL1, Foxo3a|MGI:1890081|modifier of murine metastable epialleles, R1|Foxo3|MGI:4949204|10||||||||||Unknown to Unknown||||||Yes|Green Fluorescent Protein|human alpha-globin promoter and enhancer region|||||||||||Percentage of cells expressing the Line3 GFP transgene is decreased (enhancer of variegation).||FVB/NJ|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Poor|||MommeD5<+/->;Tg(α-Globin-GFP)3EWh x Tg(α-Globin-GFP)3EWh|No|19-Jun-2013|Cryopreserved sperm|20.0|0.0|No||epigenetics, histone modification|Yes| 5312.0|Ship.C57BL/6|B6.129-Inpp5d/AcbdLudApb||Recessive|inositol polyphosphate-5-phosphatase D|Inpp5d|Nil|s-SHIP, SHIP, SHIP-1, SHIP1, Src homology 2 domain-containing inositol-5-phosphatase|MGI:107357|inositol polyphosphate-5-phosphatase D; targeted mutation 1, Dan Dumont|Inpp5d|MGI:1861956|1||||||||||||||||No|||||||||||||Young mice are apparently healthy, but they start to show signs of inflammatory lung disease at >12 wks of age.|Normal to 12 months of age.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|7|||No|09-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||phosphorylation, phosphatase, signal transduction, myeloid hyperplasia, apoptosis, PI3'K, inflammatory lung disease|Yes| 5532.0|PbT-I-27 ; C57BL/6-Tg(TCRaB4-46TcrbB4-46)27Cbn|C57BL/6-Tg(H2-K-Tcra,-Tcrb)27Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 27, Francis Carbone|H-2Kb|||||||||||Majority of CD8 T cells express the transgenic T cell recepter Va8Vb10 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||4|brother-sister or Tg positive to C57BL/6|No|07-Jul-2011|Cryopreserved sperm|50.0|0.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD8 TCR transgenic|Yes| 7356.0|CD28 :Ly5a|B6.129S2-Cd28 Ptprc/AnuApb|B6.129S2-Cd28 Ptprc/Anu|Recessive|CD28 antigen|CD28|Nil||MGI:88327|targeted mutation 1, Tak Mak|Cd28|MGI:1857150|1||||||||||||||||Yes|||||||||||||Homozygous mutation of this gene results in impairment of some T cell responses and decreased basal immunoglobulin levels. Mutant animals have reduced T helper cell activity and impaired T cell response to lectins, but cytotoxic T cells can still be induced||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Jun-2013|Cryopreserved sperm|50.0|0.0|No||T cell, immunoglobulin, costimulation, lymphocyte, lectin|Yes| 7356.0|CD28 :Ly5a|B6.129S2-Cd28 Ptprc/AnuApb|B6.129S2-Cd28 Ptprc/Anu|Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||Homozygous mutation of this gene results in impairment of some T cell responses and decreased basal immunoglobulin levels. Mutant animals have reduced T helper cell activity and impaired T cell response to lectins, but cytotoxic T cells can still be induced||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Jun-2013|Cryopreserved sperm|||No||T cell, immunoglobulin, costimulation, lymphocyte, lectin|Yes| 5439.0| Men1fl/fl ; Miles|B6;129T2-Men1/Apb|B6;129T2-Men1|Recessive|multiple endocrine neoplasia type 1|Men1|Nil|menin|MGI:1316736|multiple endocrine neoplasia 1; targeted mutation 1, Graham F Kay|Men1|MGI:2384620|19||||||||||||||||No|||||||||||||Normal.However tissue specific deletion of Men1 using RIP-Cre transgenic mice (C57BL/6-Tg(Ins2-cre)25Mgn/J) results in tumour formation in pancreatic islets and pituitary.|Normal|mixed C57BL/6 and 129T2/SvEms|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|N/A|8|homozygous cross|No|17-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|With tissue specific deletion can be used to model human MEN1|menin, men1, pancreas, islet, transcription factor, Multiple Endocrine Neoplasia, Type I; MEN1, Jun|Yes| 5440.0|Men1 del/wt (Marcel S)|129T2-Men1/Apb|129T2-Men1|Recessive|multiple endocrine neoplasia 1|Men1|Nil|menin|MGI:1316736|multiple endocrine neoplasia 1; targeted mutation 1.1, Graham F Kay|Men1|MGI:2384622|19||||||||||||||||No|||||||||||||Embryonic lethal.|Tumours with age predominantly in pancreas, pituitary and parathyroids.|129T2/SvEms|No|No|Yes|No|No|Yes|No|Good|N/A|6|heterozygote cross wildtype|No|17-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|Used to model human MEN1|menin, men1, transcription factor, pancreas, Jun, Multiple Endocrine Neoplasia, Type I; MEN1|Yes| 5534.0|Chuzhoi|B6;C-Ptk7/Apb||Recessive|protein tyrosine kinase 7|Ptk7|Reduced|hz, mPTK7/CCK4|MGI:1918711|PTK7 protein tyrosine kinase 7; chuzhoi|Ptk7|MGI:3640803|17|||||||||||||||||||||||||||||Homozygouse mice do not survive past birth. They suffer from impaired neural tube, heart and lung development, rib defects, polydactyly, failed eyelid closure and altered cell polarity.|normal|C57BL/6|No|No|Yes|No|No|Yes|Yes|Good|||+/- x +/+|No|07-Jul-2011|Cryopreserved sperm|40.0|0.0|Unknown||planar cell polarity, neural tube, ENU|No| 4757.0|NOD floxed IEα|NOD-Tg(H2-Ea)/MarpApb||Dominant||||||||||||||||||||||||||MHC class II H2-Ea|MHC Class II|||||||||||Mice maintained in hemizygous state|Normal NOD phenotype|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Apr-2009|Cryopreserved sperm|94.0|0.0|Unknown||Major Histocompability, I-E alpha-chain (E alpha)|Yes| 4973.0|DSCR1 P77 Tg|B6.CBA-Tg(RCAN1)77Mapr/MarpApb||Dominant||||||||||||||||||||||||||human regulator of cacineurin 1|RCAN1|low||||||||||Transgenics are indistinguishable from wild type animals|Normal|C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygous Tg x Homozygous Tg|No|22-Jan-2010|Cryopreserved sperm|100.0|0.0|Yes|Down syndrome|Down Syndrome, vesicle trafficking|Yes| 5476.0|Gin ; Col2a1Cre|C57BL/6-Tg(Col2a1-cre)1Asz/MrchApb||Dominant|||||||||X|||||||||||||||||transgene insertion 1, Attila Aszodi|mouse type II collagen gene|7 copies||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|16 generation|1||Yes|07-Apr-2011|Cryopreserved sperm|45.0|0.0|Unknown||Surgical model for Arthritis, chondrocyte, cartilage|Possibly| 5508.0|Fh2|FVB/N-Tg(ACTA1-Fhl1)12Hrd/Apb||Dominant||||||||||||||||||||||||||human four and a half LIM domains 1|Human Skeletal Actin Promoter|||||||||||Unknown|Increased whole-body strength and fatigue resistance|FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|N.A.|N.A.|heterozygote males crossed with FVB/N females|No|20-May-2011|Cryopreserved sperm|100.0|0.0|No||FHL1, Transgenic Mouse, Muscle hypertrophy, Mouse skeletal muscle|Yes| 4571.0||STOCK Asic2/Apb||Recessive|acid-sensing (proton-gated) ion channel 2|Asic2|Nil|ASIC2, BNaC1a, BNC1, Mdeg|MGI:1100867|acid-sensing (proton-gated) ion channel 2; targeted mutation 1, Michael J Welsh|Asic2|MGI:2180111|11||||||||||||||||Yes|||||||||||||Normal appearance, growth, size, temperature, fertility and life span, and show no obvious behavioural abnormalities.Abnormal nervous system electrophysiology:• low threshold, rapid adapting mechanoreceptors exhibit reduced sensitivity compared with wild-type mechanoreceptors• low threshold, rapid adapting mechanoreceptor stimulus response function exhibits reduced discharge frequency and flattens unlike in wild-type mechanoreceptors• low threshold, rapid adapting mechanoreceptors exhibit reduced sensitivity between 5 and 20 um displacement unlike wild-type mechanoreceptor• the stimulus-response of slowly adapting mechanoreceptor exhibits decreased sensitivity compared to wild-type mechanoreceptors• however, sensory neurons exhibit normal response to current injectionAbnormal hearing electrophysiology:• pH changes fail to generate firing of action potentials in spiral ganglion unlike similarly treated wild-type cells• proton-induced current flows in spiral ganglion compared with wild-type cells• following exposure to 110 dB white-band noise, mice exhibit a decrease in their susceptibilities to noise-induced temporary threshold shifts compared with wild-type mice• however, auditory brainstem response is normalDecreased vasoconstriction-• mice exhibit decreased pressure-induced constriction of the middle cerebral artery in the presence of calcium unlike similarly treated wild-type mice• mice develop myogenic tone with increases in intraluminal pressure but generate less tone at every pressure step compared with similarly treated wild-type mice|||Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Sibling Het x Het|No|07-Mar-2009|Cryopreserved sperm|135.0|0.0|Unknown||touch sensation, sodium channel, visceral afferents, mechanosensation, vasoconstriction|Yes| 8654.0|Prx1-Cre Dynll1|B6-Dynll1 Tg(Prx1-cre)/Jhh||Recessive|dynein light chain LC8-type 1|Dynll1||8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|dynein light chain LC8-type 1; targeted mutation 1.1, Jorg Heierhorst|Dynll1|MGI:5463937|5|||||||||||||||||Cre|Prx1|||||||||||Homozygous deleters (Prx1-Cre +/T Dynll1 fl/fl) have very short legs and lack of hair in areas where the Cre is active|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5511.0|CTR1 Tg|C57BL/6-Tg(CMV/CAG-SLC31A1)Jmer/Apb||Dominant||||||||||||||||||||||||||human Solute carrier family 31, member 1|Composite CMV chicken beta actin promoter (CAG)|Higher than endogenous||||||||||The hCTR1 transgenic mice display no overt phenotype resulting from the over-expression of the human CTR1 protein, however, in many tissues, copper levels are elevated compared to the non-transgenic mice consistent with enhanced copper uptake capacity of the cells expressing high levels of CTR1. |Same as homozygous. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|10|brother x sister mating|No|24-May-2011|Cryopreserved sperm|50.0|0.0|No||copper transport|Yes| 5513.0|prkfl/fl|C57BL/6-Prkar1a/Apb||Dominant|protein kinase, cAMP dependent regulatory, type I, alpha|Prkar1a|Normal|RIalpha, Tse-1, Tse1|MGI:104878||||11||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|More than 10|||No|25-May-2011|Cryopreserved sperm|50.0|0.0|Unknown|||No| 5488.0|B6NRG|C57BL/6-Tg(Vav1-Nup98/Rap1gds1)1Apla/Apb||Dominant||||||||||||||||||||||||||Nup98-Rap1GDS1|Vav1|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||T/+ male X +/+ female, maintain on c56Bl/6 background|No|20-Apr-2011|Cryopreserved sperm|50.0|0.0|Yes|Leukemia||Yes| 8655.0|129.8|129X1/Sv-Rec8/Cjo||Recessive|REC8 meiotic recombination protein|Rec8|Nil|mrec, Rec8L1|MGI:1929645|REC8 meiotic recombination protein; targeted mutation 1, Michael J McKay|Rec8|MGI:3583574|14|||||||||||||||||||||||||||||Prenatal lethality, incomplete penetrance:• only 12% of pups from heterozygous matings are homozygous and at E13.5 only 16% of embryos are homozygousAbnormal seminiferous tubule morphology: • more apoptotic cells are seen in the tubules compared to wild-type miceAbnormal female reproductive system morphology: • the genital tract is involutedAbnormal ovary morphology:• dense fibrovascular stoma is seenAbsent ovarian follicles. Abnormal gametogenesis.Absent oocytes:• complete absence of oocytesAzoospermia:• no mature sperm or spermatids are seen and testes are almost depleted of primary spemtocytes by 19 days of ageAbnormal female meiosis:• homozygous meiocytes fail to complete meiotic prophase I and abnormal synaptonemal complexes form between sister chromatids rather than between homologous chromososmes• leptotene chromosomes are seen at E16.5-E18.5 but normal pachytene nuclei are never seenArrest of male meiosis:• homozygous meiocytes fail to complete meiotic prophase I and abnormal synaptonemal complexes form between sister chromatids rather than between homologous chromososmes• zygotene but not pachytene nuclei are seenFemale infertility.Male infertility.Postnatal growth retardation. Decreased fetal size: • reduced size at E15.5||129S1/Sv|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown||Meiotic cohesin, chromatid|Yes| 5344.0|NfiB KO|C57BL/6-Nfib/Apb||Dominant|nuclear factor I/B|NFib|Normal||MGI:103188|nuclear factor I/B; targeted mutation 1, Richard M Gronostajski|Nfib|MGI:3530139|4||||||||||||||||No|||||||||||||Lung maturation and cortical development defects. Do not survive past birth due to lung defect. Abnormal cerebellar, corpus callosum, glia and hippocampal development.Abnormal lung morphology: * E17.5 lungs lacked saccules * observed minor surface indentations in E15.5 lungs and deep clefts or ruffles at E18.5 * higher levels of proliferation in E18.5 lung as detected by a fourfold increase in PCNA transcripts and a substantial increase in the total DNA in the lung but no differences in lung size.Abnormal lung development: E17.5 lungs were severely defective in maturation and resembled the less-mature E15.5 wildtype lungs however morphology at E15.5 was normal indicating that lung development is arrested between E15.5 and E16.5.Abnormal hippocampus development: a reduction in the entire hippocampal primordium at E15.5 and displayed more severe disruptions in the formation of the hippocampus, with the entire CA3 region absent or severely reduced, than on a mixed Black Swiss/129P2 background.Absent cerebellar foliation: cerebellum appears unfoliated at E18.5.Abnormal brain ventricle morphology: enlarged ventricles.Abnormal corpus callosum morphology: * exhibit agenesis of the corpus callosum * complete absence of GFAP labeling in the indusium griseum and the glial wedge and a reduction in the midline zipper glia, indicating a loss or reduction of glial populations in these areas.Absent dentate gyrus: at E17.5 the dentate gyrus was absentAbnormal hippocampal fimbria: greatly reduced fimbria in E17.5 hippocampus.Abnormal cerebellar granule cell morphology: at E18, axon formation by cerebrellar granule neurons (GCNs) is altered.Abnormal pons morphology: the basilar pons was virtually absent in the hindbrain, with only a small cap of cells remaining at E16.5 to E18.5 and the rest of the hindbrain appeared normal.Abnormal glial cell morphology: complete absence of GFAP labeling in the indusium griseum and the glial wedge and a reduction in the midline zipper glia, indicating a loss or reduction of glial populations in the midline.|Abnormal corpus callosum development and abnormal glial morphology.Postnatal lethality: only about 55% survive to 14 days after birth.Abnormal lung morphology: E17.5 lungs had smaller saccules.Abnormal lung development: E17.5 lungs had a developmental delay in maturation.Abnormal corpus callosum morphology: * displayed a less severe callosal phenotype with the formation of Probst bundles at the midline than heterozygotes on the mixed Black Swiss background * reduction in all three midline glial populations of the corpus callosum.Abnormal glial cell morphology: reduction in all three midline glial populations of the corpus callosum.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|14-Dec-2010|Cryopreserved sperm|50.0|0.0|Yes|Agenesis of the corpus callosum|respiratory system, lung, cerebellar, corpus callosum, transcription|Possibly| 5539.0|Looptail|A.C3H-Vangl2/MarpApb||Semi-dominant|vang-like 2 (van gogh, Drosophila)|Vangl2|Reduced| loop-tail, Lpp1, Ltap, mKIAA1215, ska, ska17, strabismus|MGI:2135272|vang-like 2 (van gogh, Drosophila); loop tail|Vangl2|MGI:1857642|1|||||||||||||||||||||||||||||Embryonic lethal - craniorachischisis|Heterozygous mice have a curly tail, abnormal head movement - rocking or wobbling, impaired balance, spina bifida in 5% of mice.|C3H|No|No|Yes|No|No|Yes|Yes|Good|||wildtype x heterzygote|No|18-Jul-2011|Cryopreserved sperm|50.0|0.0|No||planar cell polarity, neural tube, hearing, shake, ENU|No| 5182.0|Ggn Knockout clone 42|B6.129-Ggn/42MarpApb||Recessive|gametogenetin|Ggn||GGN1, GGN2, GGN3|MGI:2181461|gametogenetin; targeted mutation 1, Duangporn Jamsai|Ggn|MGI:5503309|7||||||||||||||||Yes|||||||||||||Embryonic lethal|Appear normal.Abnormal double-strand DNA break repair:• increased unrepaired double-strand breaks in pachytene spermatocytes|C57BL/6J x 129Sv|No|No|Yes|No|No|Unknown|No|Unknown||||No|22-Jul-2010|Cryopreserved sperm|50.0|0.0|Unknown||sperm, testis, embryonic lethal|Possibly| 5240.0|MIP-GFP|C57BL/6-Tg(Ins2-EGFP)1Hara/Arc||Dominant||||||||||||||||||||||||||transgene insertion 1, Manami Hara|mouse insulin 1 gene|high||||||||||Normal C57BL/6 phenotype. GFP expression in pancreatic islet beta cells. |Normal C57BL/6 phenotype. GFP expression in pancreatic islet beta cells. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||No|13-Oct-2010|Cryopreserved sperm|57.0|0.0|No||diabetes, pancreas, beta-cell, GFP, insulin|No| 8666.0|NOD.NfKb|NOD-Tg(TK-Nfkb*-EGFP/Luc)/Het||Dominant||||||||||||||||||||||||||eGFP-Luciferase|NfKappab enhancer- HSV-Thymidine Kinase promoter|||||||||||Normal|Normal|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7315.0|RNAi-9|C57BL/6J-HDAC1 219F||Dominant|histone deacetylase 1|Hdac1|Unknown|HD1, MommeD5, RPD3|MGI:108086||||4|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|11-Apr-2013|Cryopreserved sperm|50.0|0.0|Unknown||RNAi|Possibly| 5453.0|HH8-Ly5.1|C57BL/6-H2 Ptpcr Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II|||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20||intercross|No|03-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|No| 5453.0|HH8-Ly5.1|C57BL/6-H2 Ptpcr Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20||intercross|No|03-Mar-2011|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|No| 5453.0|HH8-Ly5.1|C57BL/6-H2 Ptpcr Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant||||||||||||||||||||||||||T cell receptor alpha, T cell receptor beta||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20||intercross|No|03-Mar-2011|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|No| 5479.0|Stat 3/MMTV neu|B6.Cg-Stat3 Tg(MMTVneu)202Mul/LudApb||Recessive|Signal transducer and activator of transcription 3|Stat3||Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11|||||||||||||||||transgene insertion 202, William Muller|MMTV|||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Apr-2011|Cryopreserved sperm|100.0|0.0|Unknown||signal transduction, kinase|Yes| 342.0|ATM 7271 T⇒G|B6.129-ATM ||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Normal|C030026E19Rik|MGI:107202|targeted mutation 1, Georgia Chenevix-Trench|ATM||9||||||||||Unknown to Unknown||||||No|||||||||||||Infertile. Increased sensitivity to ionizing radiation. Immune deficiencies. Increased susceptability to lymphoid tumours|Normal|C57BL/6|Yes|No|Yes|Yes|No|Yes|Yes|Good|14|4|sib x sib|No|22-Sep-2006|Cryopreserved sperm|90.0|0.0|Yes||ATM, cancer, Radiation, Breast|No| 5464.0|Kuche ; ENU18embryo:001|B6JAnu;B10SnJ-Casp8/AnuApb|B6JAnu;B10SnJ-Casp8/AnuApb|Recessive|caspase 8|Casp8|Unknown|Caspase-8, FLICE, MACH, Mch5|MGI:1261423|caspase 8; mutation 1, The Australian National University|Casp8|MGI:5563498|1|ENSMUSG00000026029|ENSMUST00000027189|Casp8-201|950|1343|T to A|ENSMUSE00000155085|8|317|Leucine to Glutamine|||||GAACAAAGACTGCTTCATCTGCTGTATCCTATCCCACGGTGACAAGGGTGTCGTCTATGGA|Yes|||||||||||||Reduced fetal liver size and haematopoetic failure at E14.5|not known|C57BL/6JAnu x C57BL/10Anu|No|No|Yes|No|No|Yes|No|Good||||No|11-Mar-2011|Cryopreserved sperm|10.0|0.0|Unknown||embryonic lethal|No| 5319.0|F/F x Mal ; gp130Y757F x Mal|B6;129-Il6st Tirap/MarpApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozogous x homozygous|No|12-Nov-2010|Cryopreserved sperm|50.0|0.0|Yes|Gastric cancer|gastric, cancer, gp130, TLR4|No| 5319.0|F/F x Mal ; gp130Y757F x Mal|B6;129-Il6st Tirap/MarpApb||Dominant|toll-interleukin 1 receptor (TIR) domain-containing adaptor protein|Tirap|Unknown|Mal, Mal, MyD88-adapter-like, wyatt|MGI:2152213|toll-interleukin 1 receptor (TIR) domain-containing adaptor protein; targeted mutation 1.1, Paul J Hertzog|Tirap|MGI:4939795|9||||||||||||||||Unknown|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6 x 129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozogous x homozygous|No|12-Nov-2010|Cryopreserved sperm|||Yes|Gastric cancer|gastric, cancer, gp130, TLR4|No| 4863.0||FVB/N-CD151/Apb||Recessive|CD151 antigen|Cd151|Normal|PETA-3, SFA-1, Tspan24|MGI:1096360||||7||||||||||||||||Yes|||||||||||||Normal|Normal|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|135.0|0.0|Unknown||tetraspanin, integrin, wound repair, cell migration, angiogenesis|Yes| 4861.0||C57BL/6-Tg(ICAM2-huCD55,huCD59)/Apb||Dominant||||||||||||||||||||||||||human CD55/CD59 dual construct|ICAM2|endothelial cells and neutrophils||||||||||Expression of membrane bound human CD55 and CD59 on endothelial cells and neutrophils.|Expression of membrane bound human CD55 and CD59 on endothelial cells and neutrophils.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|86.0|0.0|Unknown||complement, heart, endothelial, ischemia, reperfusion, xenotransplantation|Yes| 4872.0|Bc.HTF2.Tg|BALB/c-Tg(H2-K-huFUT1)2/Apb||Dominant||||||||||||||||||||||||||human fucosyltransferase 1|H2-K|All blood/tissue samples express human fucosyltransferase 1||||||||||Attempts to breed homozygous animals failed. Unknown if homozygous transgene expression is embryonic lethal.|Normal.All blood/tissue samples express human fucosyltransferase.|BALB/c|No|No|Yes|No|No|Yes|No|Unknown|15|||No|28-Sep-2009|Cryopreserved sperm|82.0|0.0|Unknown||glycosylation, xenotransplantation, transplantation, transferase, lectins, H transferase, antibody|Yes| 4873.0|B6.TFPI.Tg|C57BL/6-Tg(H2-K-huTFPI)/Apb||Dominant||||||||||||||||||||||||||human Tissue Factor Pathway Inhibitor|H2-K|All blood/tissue samples express human human Tissue Factor Pathway Inhibitor||||||||||Not attempted|Normal.All blood/tissue samples express human Tissue Factor Pathway Inhibitor.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|63.0|0.0|Unknown||glycosylation, xenotransplantation, transplantation, transferase, lectins, antibody|Yes| 6895.0|Germaine|STOCK Gstp1/Gstp2/Anu||Recessive|glutathione S-transferase, pi 1|Gstp1|Nil|Gst p-1, GstpiB|MGI:95865|glutathione S-transferase, pi 1; targeted mutation 1, C Roland Wolf|Gstp1/Gstp2|MGI:3046099|19|||||||||||||||||||||||||||||Altered drug metabolism |unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|N3||homozygote matings|No|11-May-2012|Cryopreserved sperm|50.0|0.0|Yes|This mouse is a model of normal human sensitivity to carcinogens||Possibly| 6895.0|Germaine|STOCK Gstp1/Gstp2/Anu||Recessive|glutathione S-transferase, pi 2|Gstp2|Nil|Gst3, Gst-3, Gst p-2, GSTpiA|MGI:95864|glutathione S-transferase, pi 2; targeted mutation 1, C Roland Wolf|Gstp1/Gstp2|MGI:3046101|19|||||||||||||||||||||||||||||Altered drug metabolism |unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|N3||homozygote matings|No|11-May-2012|Cryopreserved sperm|||Yes|This mouse is a model of normal human sensitivity to carcinogens||Possibly| 5232.0|Ben|C57BL/6-Tigd2||Recessive|tigger transposable element derived 2|Tigd2|Nil||MGI:1915390||||6||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|08-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||chromosomal, Epigenetics|Possibly| 5231.0|K14gBlo|C57BL/6-Tg(K14-HSVgB)35Cbn/WehiApb||Dominant||||||||||||||||||||||||||Herpes Simplex Virus-1 glycoprotein B - transgene insertion 35, Frank Carbone|human keratin-14 (K14)|low||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||at least 12|transgenic x C57BL/6|No|06-Oct-2010|Cryopreserved sperm|50.0|0.0|No||Herpes Simplex Virus (HSV-1), tolerance, T cell, CTL, cytotoxic, autoimmunity|Yes| 8660.0|SHMR|B6.Cg-Msh2 Rag1 Samhd1/Cjo||Recessive|mutS homolog 2|Msh2|||MGI:101816||||17|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8660.0|SHMR|B6.Cg-Msh2 Rag1 Samhd1/Cjo||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, David Baltimore|Rag1|MGI:2448994|2|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 8660.0|SHMR|B6.Cg-Msh2 Rag1 Samhd1/Cjo||Recessive|SAM domain and HD domain, 1|Samhd1||E330031J07Rik|MGI:1927468||||2|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 7603.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|Normal|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2|||No|24-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 4883.0|Fas10|NOD-Tg(RIP7-dnhFAS)10Het/Apb||Dominant||||||||||||||||||||||||||human Fas (Fas5)|rat insulin promoter (RIP7)|High, restricted to pancreatic beta cells||||||||||Unknown|Mice do not develop diabetes and have a delayed onset of insulitis.|NOD/Lt|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|15||NOD/Lt x Fas-10 transgenic positive|No|28-Sep-2009|Cryopreserved sperm|80.0|0.0|Unknown||Cytotoxic, T cell, Pancreatic beta cell, non obese diabetic, diabetes|Yes| 4900.0||B6.129-CdKn2a/Apb||Recessive|cyclin-dependent kinase inhibitor 2A|Cdkn2a|Nil|Arf, ARF-INK4a, INK4a-ARF, Ink4a/Arf, MTS1, p16, p16INK4a, p19, p19ARF, Pctr1|MGI:104738|targeted mutation 1, Charles J Sherr|Cdkn2a|MGI:1926877|4|||||||||||||||||||||||||||||fibrohistocytomalymphomacarcinomafibrosarcomaincreased incidence of ionizing radiation-induced tumorsincreased incidence of chemically-induced tumorsMEFs (embryonic fibroblasts showed increased proliferative capacity and less responsive to contact inhibition.Abnormal lens morphology: at around P14, the lens undergoes degenerative changes characterized by vacuolization and lens material degradation; an attempt at lens repair beyond P14 is manifested by the accumulation of lens epithelial cells lining a regenerated posterior capsuleattachment of the retrolental tissue to the posterior lens and extrusion of lens material into the retrolental tissue.primary vitreous hyperplasia.MicrophthalmiaRetinal detachment||C57BL/6 x 129|Yes|No|Yes|Yes|No|Yes|No|Good||||No|09-Oct-2009|Cryopreserved sperm|90.0|0.0|Unknown||tumour, lymphoma, tumour supressor, kinase, cyclin, oncogene, p53, Rb|Yes| 7601.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|Normal|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2|||No|24-Feb-2014|Cryopreserved sperm|82.0|0.0|Unknown||ENU|Yes| 4770.0|B6.Asciz|C57BL/6-Atmin/JhhApb||Dominant|ATM interactor|Atmin|Normal|Asciz, MGC:79206, mKIAA0431|MGI:2682328|ATM interactor; targeted mutation 1.2, Jorg Heierhorst|Atmin|MGI:5463937|8||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-May-2009|Cryopreserved sperm|90.0|0.0|Unknown||Base excision repair, embryonic lethal, zinc finger, ATM kinase|Yes| 5238.0|IL-6 knockout ; C57.IL-6 -/-|C57BL/6-IL6/LudApb||Recessive|interleukin 6|Il6|Nil|Il-6|MGI:96559|interleukin 6; targeted mutation 1, Manfred Kopf|Il6|MGI:1857197|5||||||||||||||||No|||||||||||||Decreased pro-B cell number: the percentage of CD19+ B cell progenitors in the bone marrow is decreased from 58% to 35%.Decreased interferon-gamma secretion: after restimulation of spleen cells with keyhole limpet hemocyanin one week following immunization of mutant mice, reduced interferon gamma production is observed.Increased interleukin-4 secretion: after restimulation of spleen cells with keyhole limpet hemocyanin one week following immunization of mutant mice, enhanced Il-4 secretion is observed.Abnormal interleukin-6 secretion: intraperitoneal administration of LPS does not induce production of Il6 in the livers of mutants compared to wild-type where expression is increase.Increased body temperature: injection of Il1beta results in body temperature elevation by about 0.5C.Abnormal glucose homeostasis: inhibition of hepatic glucose production by ICV infusion of insulin is attenuatedinhibition of hepatic glucose production assessed by a euglycemic hyperinsulinemic clamp is also attenuated.Impaired glucose tolerance: impaired glucose tolerance on a high fat diet.Abnormal emotion/affect behavior.Behavioral despair: increased latency to "give up" in a forced swim test.Increased anxiety-related response: * less time spent in the illuminated areas of a light-dark box. * significantly decreased time spent in the open arms of an elevated maze. * significantly decreased number of entries into the open arms of an elevated maze.Increased fear-related response: * lower latency to escape adverse stimuli. * fewer failures to escape adverse stimuliHyperactivity: * increased locomotor activity in open field testsabnormal sleep pattern. * injection of Il1beta results in reduced dark phase wakefulness. * injection of Il1beta results in increased non REM sleep. * increased time in non-REM sleep after sleep deprivation persists longer than for controls but increase in time is equivalent.Decreased body weight: lower body weight at 4 months of age is due largely to lower fat mass.Obese: obesity develops by 8 months of age.Increased susceptibility to induced colitis: severe erosion of the intestinal epithelium from exposure to 3.5% dextran sodium sulfate.Decreased T cell number: T cells are reduced in the periphery by 20-40%.Abnormal T cell differentiation: thymocytes are consistently reduced by 20-40%.Abnormal microglial cell morphology: modest increase in microglial density after haloperidol treatment relative to the increase seen in controls.Abnormal acute phase protein level: 100-fold reduction in SAA production by the liver in response to turpentine injection or listeria infection.Defective cytotoxic T cell cytolysis: cytolytic activity of CD8 T cells to vaccinia virus infected cells is reduced 3-10 fold.Increased susceptibility to bacterial infection: 10 to 100 fold increase in bacterial titers in the liver and spleen of mice infected with Listeria.Increased susceptibility to viral infection: viral titers are 10-1000 fold higher in the ovaries and lungs of vaccinia virus infected mice.Abnormal capillary morphology: fewer capillaries in the heartabnormal heart morphology.Abnormal heart development: * loss of cell-cell interaction between myocytes and fibroblasts. * increased number of fibroblasts and decreased numbers of myocytes.Decreased heart weight: heart weight/body weight and heart weight/tibia length ratios both significantly reduced.Abnormal heart ventricle morphology.Abnormal interventricular septum morphology: modestly increased interstitial collagen.Dilated heart left ventricle.Thin ventricular wall: * both anterior and posterior walls of the left ventricle are thin. * increased interstitial collagen in the free walls of both left and right ventricles.Abnormal cardiovascular system physiology: * increased cell proliferation and apoptosis in 5 day old hearts. * proliferation at 5 days primarily by non myocytes. * apoptosis at 5 days primarily of myocytes.Decreased cardiac muscle contractility: * both fractional shortening and ejection fraction are decreased in adults and at 5 and 15 days of age. * cardiac dysfunction beginning at 15 days of age. * cardiac dilation is more or less normal at 5 days of age.Abnormal learning/memory/conditioning.Abnormal object recognition memory: * increased exploration in novel object recognition tests. * reduced exploration in initial phase of novel object recognition tests.Abnormal long term object recognition memory: reduced object recognition when retested.Greater object recognition memory.Abnormal spatial learning: * longer escape latencies in a Morris water maze. * shorter time spent in the target quadrant of a Morris water maze. * slower to relocate platform after it is moved.Abnormal brain interneuron morphology: parvalbumin positive interneurons in the hippocampus suffer less loss in numbers with age.Abnormal CNS glial cell morphology:Abnormal microglial cell morphology: modest increase in microglial density after haloperidol treatment relative to the increase seen in controls.Abnormal astrocyte morphology: density fails to increase in response to neurotoxin (6-OHDA) lesioning.Aabnormal neuron morphology:Abnormal axon morphology: * axon terminal tree is 25% larger in the substantia nigra pars compacta than for controls. * resistant to the effects of haloperidol treatment on terminal trees. * neurotoxin lesion results in reduced terminal tree density.Abnormal nervous system physiology:Abnormal neuron physiology: age induced increase in oxygen consumption in synaptosomes is attenuated.Decreased cardiac muscle contractility: * both fractional shortening and ejection fraction are decreased in adults and at 5 and 15 days of age. * cardiac dysfunction beginning at 15 days of age. * cardiac dilation is more or less normal at 5 days of age.Abnormal muscle progenitor cell migration: migration of primary myoblasts is reduced relative to controls.Abnormal skeletal muscle fiber morphology: * cross-sectional area of myofibers does not increase after overload of the plantaris muscle by incapacitation of the gastrocnemius, measured 14 and 42 days after overload. * no change in myonuclear numbers.Abnormal skeletal muscle satellite cell proliferation: proliferation is defective.Retinal outer nuclear layer degeneration: * higher level of apoptosis after retinal separation from the retinal pigment epithelium. * higher rate of photoreceptor cell death after 1 month.Abnormal bone healing: * callus formed after bone fracture is denser after 2 weeks than is true in controls. * tissue mineral density is less at 4 and 6 weeks after injury than for controls. * greater collagen content at 2 weeks after fracture but not at 4 or 6 weeks.Decreased bone mineral density: * mineral density of cortical bone reduced * reduced crystallinity relative to controls * reduced mineral/matrix ratio in cortical bone at both 2 and 4 weeks.Decreased incidence of chemically-induced tumors: reduced incidence of hepatocellular cancer in males treated with diethyl nitrosamine relative to incidence in control males.Hepatic necrosis: less necrosis resulting from diethyl nitrosamine treatment.Liver degeneration: * less hepatic injury in males from treatment with diethyl nitrosamine. * less apoptosis due to diethyl nitrosamine treatmentless compensatory proliferation as a result of diethyl nitrosamine treatment.Abnormal pulmonary gas exchange: elevated respiratory exchange rate in young mice.Abnormal homeostasis.Increased circulating glucose level: * elevated basal glucose levels at 8 months but not in younger mice. * glucose levels do not differ from controls in young mice after 1 hour of exercise.Abnormal oxygen consumption: oxygen consumption is not maintained at as high a level after 12 minutes of running as in controls.Abnormal acute phase protein level: 100-fold reduction in SAA production by the liver in response to turpentine injection or listeria infection.Abnormal exercise endurance: reduced treadmill endurance.Abnormal bone healing: * callus formed after bone fracture is denser after 2 weeks than is true in controls. * tissue mineral density is less at 4 and 6 weeks after injury than for controls. * greater collagen content at 2 weeks after fracture but not at 4 or 6 weeks.Abnormal involution of the mammary gland: develops more slowly.Increased susceptibility to induced colitis: severe erosion of the intestinal epithelium from exposure to 3.5% dextran sodium sulfate.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||IL11, stat, signal transduction, receptor, phosphorylation, B cell, germinal centre|Possibly| 5235.0|PbT-I-25 ; C57BL/6-Tg(TCRaB4-46TcrbB4-46)25Cbn|C57BL/6-Tg(H2-K-Tcra,-Tcrb)25Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 25, Francis Carbone|H-2Kb|||||||||||Majority of CD8 T cells express the transgenic T cell recepter Va8Vb10 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Excellent||4|brother-sister|No|11-Oct-2010|Cryopreserved sperm|50.0|0.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD8 TCR transgenic|Yes| 5505.0|Sleeping Beauty|B6.Cg-Gt(ROSA)26Sor TgTn(sb-T2/Onc2)6070Njen/Apb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Nancy A Jenkins|Gt(ROSA)26Sor|MGI:3839796|6||||||||||||||||Yes|transgenic transposon concatemer 6070, Nancy A Jenkins|CMV enhancer/chicken beta-actin promoter|||||||||||normal|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||tumour|Possibly| 5320.0|Robo 1 KO|B6,129-Robo1/Apb||Dominant|roundabout homolog 1 (Drosophila)|Robo1|Nil|DUTT1|MGI:1274781|roundabout homolog 1 (Drosophila); targeted mutation 1.1, Linda J Richards|Robo1|MGI:3641236|16||||||||||||||||No|||||||||||||Malformation in the corpus callosum (axons tracing a dorso-ventral path instead of medio-lateral). Disruption of the hippocampal commissure. Fornix malformation. Some disruption of midline zipper glia.|Normal callosal projections.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||Het x Wt|No|16-Nov-2010|Cryopreserved sperm|50.0|0.0|Yes|Agenesis of the corpus callosum.|axon, interneuron migration, corticothalamic, thalamocortical, Slit|Possibly| 5569.0|HYf|B6;129-Hif1a/AusbApb||Recessive|hypoxia inducible factor 1, alpha subunit|Hif1a|Normal|bHLHe78, HIF-1alpha, HIF1alpha, MOP1|MGI:106918|hypoxia inducible factor 1, alpha subunit; targeted mutation 3, Randall S Johnson|Hif1a|MGI:2386679|12|||||||||||||||||||||||||||||Normal|Normal|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|29-Aug-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5353.0|Crbp1|B6;129-Rbp1/Apb||Recessive|retinol binding protein 1, cellular|Rbp1|Nil|Crbp, CRBPI, Rbp-1|MGI:97876|retinol binding protein 1, cellular; targeted mutation 1, Pierre Chambon|Rbp1|MGI:2181412|9||||||||||||||||Yes|||||||||||||Mutantmice fed a vitA-enriched diet are healthy and fertile.They do not present any of the congenital abnormalitiesrelated to retinoic acid (RA) deficiency, indicating thatCRBPI is not indispensable for RA synthesis. However,CRBPI deficiency results in an ~50% reduction ofretinyl ester (RE) accumulation in hepatic stellate cells.This reduction is due to a decreased synthesis and a6-fold faster turnover, which are not related to changesin the levels of RE metabolizing enzymes, but probablyreflect an impaired delivery of ROL to lecithin:retinolacyltransferase. CRBPI-null mice fed a vitA-deficientdiet for 5 months fully exhaust their RE stores. Thus,CRBPI is indispensable for efficient RE synthesis andstorage, and its absence results in a waste of ROL thatis asymptomatic in vitA-sufficient animals, but leadsto a severe syndrome of vitA deficiency in animals feda vitA-deficient diet.|Unknown but probably same as normal.|Mixed 129/Sv-C57BL/6 genetic background|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown|0|Cross to C57BL/6|Yes|20-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||retinol, vitamin A, knockout, retinol binding protein|Possibly| 4949.0|GreenSox|B6;CBA-Tg(Sox3-IRES-GFP)/Apb||Dominant||||||||||||||||||||||||||SRY-box containing gene 3 - green fluorescent protein fusion||||||||||||Normal|Normal|C57BL/6 x CBA|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Tg/+ male to wt female|No|04-Dec-2009|Cryopreserved sperm|90.0|0.0|Unknown||Sox3, SRY-box, growth retardation, hormone|Possibly| 5000.0|TRAP-cre|B6.CBA-Tg(Acp5-cre)3Rda/Apb||Dominant||||||||||||||||||||||||||transgene insertion 3, Rachel A Davey|promoters 1B and 1C from exon 1 of Acp5|||||||||||Transgenic mice express Cre recombinase in osteoclasts.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Feb-2010|Cryopreserved sperm|64.0|0.0|Unknown||osteoclast, Cre recombinase, tartrate-resistant acid phosphatase, chondrocytes|Yes| 5130.0|CBf|B6.129-Cbl/AusbApb||Recessive|Casitas B-lineage lymphoma|Cbl||c-Cbl, Cbl-2|MGI:88279|Casitas B-lineage lymphoma; targeted mutation 2.1, David E James|Cbl|MGI:6822331|9||||||||||Unknown to Unknown|||||||||||||||||||Mice appear normal||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|21-May-2010|Cryopreserved sperm|53.0|0.0|Unknown||Cre recombinase, transcription factor, signal transduction, phosphorylation, insulin|Yes| 5444.0|NODGrzB|NOD.B6-Gzmb/LtJApb||Dominant|granzyme B|Gzmb|Nil|CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB|MGI:109267|granzyme B; targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14||||||||||||||||No|||||||||||||Gzm B−/− mice develop normally and have normal hematopoiesis and lymphopoiesis.Mice develop diabetes at the same rate as wild type NOD mice|Mice develop diabetes similar to NOD mice|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|8|Sister X Brother|Yes|23-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||Cytotoxic T lymphocytes, Granzymes, Type 1 Diabetes, Apoptosis, Pancreatic beta cell|Possibly| 4876.0|Bc.Gal KO|BALB/c-Ggta1/Apb||Recessive|glycoprotein galactosyltransferase alpha 1, 3|Ggta1||alpha Gal, alpha3GalT, Gal, GALT, Ggta, Ggta-1, glycoprotein alpha galactosyl transferase 1|MGI:95704||||2|||||||||||||||||||||||||||||Matings between mice heterozygous for the inactivated GalT gene produced genotype ratios that deviated significantly from the predicted Mendelian 1:2:1 (wild type:heterozygote:homozygote) ratio. Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|11|||No|28-Sep-2009|Cryopreserved sperm|85.0|0.0|Unknown||Xenotransplantation, Transplantation, antibody, transferase, galactose|Yes| 5504.0|Ctsk-cre|B6.CBA-Tg(Ctsk-cre)8Rda/Apb|B6.CBA-Tg(Ctsk-cre)8Rda|Dominant||||||||||||||||||||||||||transgene insertion 8, Rachel A Davey|5kb of Ctsk promoter (nucleotides -3359 - +1660)|||||||||||Transgenic mice express Cre recombinase in osteoclasts.|Transgenic mice express Cre recombinase in osteoclasts.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|15||maintained in heterozygous state by backcrossing to C57BL/6|No|11-May-2011|Cryopreserved sperm|50.0|0.0|No||osteoclast, Cre recombinase, cathepsin K, Cre/loxP|No| 5404.0|G-/-|C57BL/6-Csf3/LudApb||Recessive|colony stimulating factor 3 (granulocyte)|Csf3|Nil|Csfg, G-CSF, MGI-IG|MGI:1339751|colony stimulating factor 3 (granulocyte); targeted mutation 1, Ashley R Dunn|Csf3|MGI:1857155|11||||||||||||||||Yes|||||||||||||Decreased leukocyte cell number: * homozygotes are viable, fertile, and developmentally normal with no overt signs of disease or significant changes in hemoglobin or platelet levels. * however, homozygotes exhibit leukopenia as a result of significant selective neutropenia. * some homozygotes exhibit reduced circulating lymphocyte levels; however, these changes are inconsistent.Decreased neutrophil cell number: * homozygotes exhibit a severe chronic neutropenia, with blood neutrophil levels reduced to ~30% of wild-type levels * however, no significant changes in circulating eosinophil numbers are observed.Decreased monocyte cell number: homozygotes display significantly reduced monocyte levels relative to wild-type miceImpaired myelopoiesis: * homozygotes show a 50% decrease in granulopoietic precursor cells in the bone marrow, with reduced levels of granulocyte, macrophage, and blast progenitor cells. * G-CSF administration reverses the granulopoietic defect: one day of G-CSF administration increases circulating neutrophil levels to normal, and after 4 days of G-CSF administration, mutant bone marrows are morphologically indistinguishable from wild-type marrows.Abnormal neutrophil physiology: homozygotes exhibit impaired neutrophil mobilization in response to a single dose of G-CSF, with only 21% of wild-type circulating neutrophil levels at 3 hrs post-treatment.Increased susceptibility to bacterial infection: homozygotes display a significantly impaired ability to control infection with Listeria monocytogenes, as shown by a 50% mortality rate at day 5 post-inoculation as well as diminished neutrophil and delayed monocyte increases in blood and reduced infection-driven granulopoiesis.|Decreased neutrophil cell number: heterozygotes exhibit a chronic neutropenia, with blood neutrophil levels reduced to ~67% of wild-type levels, suggesting a gene-dosage effect.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||granulocyte, haemopoiesis, neutrophil, stem cell, progenitor|Yes| 5081.0|Slc2a6 (Glut6) conditional KO|C57BL/6-Slc2a6||Recessive|solute carrier family 2 (facilitated glucose transporter), member 6|Slc2a6|Normal|Glut6, Glut9|MGI:2443286||||2||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|25-Mar-2010|Cryopreserved sperm|60.0|0.0|Unknown||transporter, glucose, channel|Possibly| 5417.0|A33:Lgp130YFKO ; line 6 backcross (ME-248)|CB;129-Tg(Gpa33-Il6st*)6Ern/Lud||Dominant|||||||||||||||||||||||||||glycoprotein A33 (transmembrane)|||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||stat, epithelium, colon|Yes| 5313.0|Bombay ; Rosa26/col2a1Cre|C57BL/6-Tg(Col2a1-cre)1Asz Gt(ROSA)26Sor/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Attila Aszodi|Col2a1|7 copies||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|09-Nov-2010|Cryopreserved sperm|70.0|0.0|No||Arthritis |Yes| 5313.0|Bombay ; Rosa26/col2a1Cre|C57BL/6-Tg(Col2a1-cre)1Asz Gt(ROSA)26Sor/Apb||Dominant||||||||||||||||||||||||||gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Philippe Soriano||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|09-Nov-2010|Cryopreserved sperm|||No||Arthritis |Yes| 5500.0|H2az|C.129P2-H2afz/Apb||Recessive|H2A histone family, member Z|H2afz|Nil|H2A.Z|MGI:1888388|H2A histone family, member Z; targeted mutation 1, Ian Lyons|H2afz|MGI:2387764|3||||||||||||||||Yes|||||||||||||Embryonic Lethality: Homozygous lethal with embryos dying from 3.5-6.5 d.p.c.Abnormal inner cell mass: cells derived from the inner cell mass of cultured blastocysts fail to persist whereas trophectoderm does persist|Heterozygotes appear normal and are fertile.|BALB/c|No|No|Yes|No|No|Yes|No|Good|Unknown but over 10|Unknown|Heterozygous intercross or Heterozygote x WT|No|09-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||Histone variant, epigenetics, embryo, transcription, chromatin|Yes| 5053.0|NOD.B6 R7 N12|NOD.B6(D1Mit48-D1Mit495)N12||Recessive||||||||||||||||||||||||||||||||||||||The incidence of diabetes in female mice is 80% after 43-weeks, which is significantly higher than the incidence of diabetes in female NOD/Lt mice in host facility (50-60% at 43-weeks of age). The incidence of diabetes in male mice is 58% after 43 weeks of age, which is significantly higher than the incidence of diabetes in male NOD/Lt mice in host facility (5-10% at 43-weeks of age).|The incidence of diabetes has not been tested in heterozygotes of this mouse strain.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|12|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 10382.0|ASD688:Tigger; Ddit3|C57BL/6NCrlAnu-Ddit3/Anu||Semi-dominant|DNA-damage inducible transcript 3|Ddit3||CHOP-10, gadd153|MGI:109247|Ddit3:endonuclease-mediated mutation 1, Australian National University|Ddit3||10|ENSMUSG00000025408||||||||||||||||||||||||||||Normal|Normal||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Nov-2023|Cryopreserved sperm|21.0|0.0|Unknown|||Possibly| 5242.0|FF:IFNAR2KO ; gp130Y757F x IFNAR2|B6;129/Sv-Il6st Ifnar2/Apb||Dominant|interleukin 6 signal transducer|Il6st|Normal|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Gastric tumoursSplenomegalyLymphadenopathy|unknown|C57BL/6 x 129/Sv |Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|14-Oct-2010|Cryopreserved sperm|40.0|0.0|Yes|gastric cancer|signal transduction, phosphorylation, Src, STAT, SHP|Possibly| 5242.0|FF:IFNAR2KO ; gp130Y757F x IFNAR2|B6;129/Sv-Il6st Ifnar2/Apb||Dominant|interferon (alpha and beta) receptor 2|Ifnar2|Nil|Ifnar-2|MGI:1098243|interferon (alpha and beta) receptor 2; targeted mutation 1, Paul J Hertzog|Ifnar2|MGI:2680693|16||||||||||||||||Yes|||||||||||||Gastric tumoursSplenomegalyLymphadenopathy|unknown|C57BL/6 x 129/Sv |Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|14-Oct-2010|Cryopreserved sperm|||Yes|gastric cancer|signal transduction, phosphorylation, Src, STAT, SHP|Possibly| 5095.0|Lzt-I.1|C57BL/6-Tg(TcraP3A4TcrbP3A4)37Cbn/JWehiApb||Dominant||||||||||||||||||||||||||transgene insertion P3A4 Tcrb, Francis R Carbone|Tcrb|||||||||||Preferential CD8 T cell development resulting in a decreased CD4/CD8 ratio. 80% of peripheral CD8 T cells express the transgenic TCR.|As for homozygous mice|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||9|brother x sister mating|Yes|19-Apr-2010|Cryopreserved sperm|100.0|0.0|No||TCR tansgenic, beta-galactosidase|Possibly| 5095.0|Lzt-I.1|C57BL/6-Tg(TcraP3A4TcrbP3A4)37Cbn/JWehiApb||Dominant||||||||||||||||||||||||||transgene insertion P3A4 Tcra, Francis R Carbone|H-2Kb|||||||||||Preferential CD8 T cell development resulting in a decreased CD4/CD8 ratio. 80% of peripheral CD8 T cells express the transgenic TCR.|As for homozygous mice|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||9|brother x sister mating|Yes|19-Apr-2010|Cryopreserved sperm|||No||TCR tansgenic, beta-galactosidase|Possibly| 7279.0|B6 RIIa Tg y-/-|B6;SJL-Tg(FCGR2A)11Mkz Fcer1g/J|HOGA|Semi-dominant|Fc receptor, IgE, high affinity I, gamma polypeptide|Fcer1g|Nil|FcR-gamma, FcRgamma, Ly-50|MGI:95496|Fc receptor, IgE, high affinity I, gamma polypeptide; targeted mutation 1, Jeffrey V Ravetch|Fcer1g|MGI:1857165|1|||||||||||||||||transgene insertion 11, Steven E McKenzie||||||||||||normal|normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|12|||Yes|15-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|immune complex disease and allergy|Fc receptor, antibody, immune complex, inflammation, arthritis, thrombocytopenia, osteopetrosis, allergy|Possibly| 10532.0|Irf4 A341V|C57BL/6J-Irf4/Anu||Dominant|interferon regulatory factor 4|Irf4||Spip|MGI:1096873|Irf4:endonuclease-mediated mutation 2, Monash Genome Modification Platform|Irf4||13|ENSMUSG00000021356|||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Nov-2025|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 5096.0|Lzt-I.2|B6-Tg(TcrLzT-I)39Cbn/WehiApb||Dominant||||||||||||||||||||||||||Tcrb|Cbeta2|yes||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||brother x sister mating|Yes|19-Apr-2010|Cryopreserved sperm|50.0|0.0|No||TCR tansgenic, beta-galactosidase|Possibly| 5096.0|Lzt-I.2|B6-Tg(TcrLzT-I)39Cbn/WehiApb||Dominant||||||||||||||||||||||||||Tcra|H-2|yes||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||brother x sister mating|Yes|19-Apr-2010|Cryopreserved sperm|||No||TCR tansgenic, beta-galactosidase|Possibly| 5249.0|FGFPC|C57BL/6-Tg(FXN/EGFP)CSars/Apb|C57BL/6-Tg(FXN/EGFP)CSars/Apb|Recessive||||||||||||||||||||||||||Human FRATAXIN gene|FXN endogenous promoter|Normal||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|21|Hemizygous FXN-EGFP transgene X Hemizygous FXN-EGFP transgene|No|20-Oct-2010|Cryopreserved sperm|50.0|0.0|Yes|Friedreich ataxia|Friedreich ataxia, neurodegenerative disease, GAA repeat expansion, iron-sulfur clusters|Yes| 3313.0|K369I tau ; K3|C57BL/6-Tg(Thy1-MAPT*K369I)K3Gotz/Apb||Recessive||||||||||||||||||||||||||transgene insertion K3, Jurgen Gotz|murine Thy1|High|||||||||||Transgene expression high in brain including Substantia nigra. Parkinsonism and amyotrophy (incl hind limbs clasping); memory impairment; Pick’s pathology; age of onset 4 weeks|C57BL/6|No|No|Yes|No|No|Yes|No|Good|10||T6 x C57BL/6|No|09-Jun-2008|Cryopreserved sperm|10.0|0.0|Yes||Parkinsonism, Pick’s disease, axonal transport, memory impairment, amyotrophy, tau, microtubule-associated protein tau|No| 5252.0|BMP4/LacZneo|STOCK BMP4/MarpApb||Semi-dominant|bone morphogenetic protein 4|Bmp4|Nil|Bmp-4, Bmp2b, Bmp2b-1, Bmp2b1|MGI:88180|bone morphogenetic protein 4; targeted mutation 2, Brigid L Hogan|Bmp4|MGI:2158495|14||||||||||||||||No|beta-galactosidase|endogenous Bmp4|||||||||||Prenatal lethality.Embryonic lethality during organogenesis: die at E8.5|Kidney anomalies|129/SvEv x Black Swiss|No|No|Yes|No|No|Yes|No|Good|||heterozygotes x wild-types within the colony|No|20-Oct-2010|Cryopreserved sperm|60.0|0.0|Yes|CAKUT- congenital anomalies of the kidney and urinary tract|CAKUT, kidney, ureter, hydronephrosis, duplicated ureter|Possibly| 3311.0|Δtau ; delta Tau74|C57BL/6-Tg(Thy1.2-hTau)||Recessive||||||||||||||||||||||||||truncated human tau 40 (projection domain) aa 1-255|murine Thy1.2||||||||||||No obvious altered phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||T6 x C57BL/6|No|09-Jun-2008|Cryopreserved sperm|20.0|0.0|Unknown||phosphorylation, tau, mitochondria, transport, membrane localization|Possibly| 5361.0|HH8-1|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|40.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5361.0|HH8-1|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5361.0|HH8-1|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303 Tg(TcraHH8,TcrbHH8)/Apb||Dominant||||||||||||||||||||||||||T cell receptor alpha, T cell receptor beta||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.TCR Tg T cells proliferated following systemic administration of Α-gliadin{57–73} Q65E or chymotrypsin-digested gliadin in vivo and secreted Th1-type cytokines implicated in Celiac disease in vitro. But ingestion of gluten or Α-gliadin{57–73} Q65E did not trigger intestinal pathology in TCR Tg mice, either spontaneously or induced by immunization strategies that have produced autoimmune disease in other TCR Tg models.Findings indicate that gluten ingestion in humanized mice expressing functional HLA-DQ2 and possessing a substantial population of CD4+ T cells specific for gluten is not sufficient to cause celiac-like enteropathy.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 10527.0||IL17rb||Semi-dominant|IL17rb|Dclk1||1700113D08Rik, 2810480F11Rik, Click-I, CPG16, Dcamkl1, Dcl, DCLK, mKIAA0369|MGI:1330861|IL17rb; targeted mutation 1a, Wellcome Trust Sanger Institute|IL17rb|MGI:5543459|3|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Oct-2025|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5364.0|B6.hCD4.IAE.427-3 ; triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5364.0|B6.hCD4.IAE.427-3 ; triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 8668.0|CRISP2 flox|B6(Cg)-Crisp2/Marp||Recessive|cysteine-rich secretory protein 2|Crisp2||CRISP-2, GAPDL5, Tpx1, Tpx-1|MGI:98815|cysteine-rich secretory protein 2; targeted mutation 1c, Mouse Biology Program, UC Davis|Crisp2|MGI:6369005|17||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Mar-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7276.0|B6.RIIa Tg|B6.Fcgr 2a Tg|HOGA|Semi-dominant|Fcgamma r2a|FcgR2a|Normal||||||Unknown|||||||||||||||||human FcyR2a|human FcyR2a|normal||||||||||normal|not known|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|12|||Yes|15-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|immune complex disease|Fc receptor, antibody, immune complex, inflammation, arthritis, thrombocytopenia|Possibly| 5133.0|Delta 359 ; Tie2DeltaCx40.359|B6;CBA-Tg(Tie2-Gja5)/AnuApb||Dominant|gap junction protein, alpha 5|Gja5|Increased|connexin 40, Cx40, Gja-5|MGI:95716||||Unknown|||||||||||||||||dominant negative of Cx40|Tie2 endothelial specific|||||||||||Unknown|Mild Hypertension|N3 B6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|3|||No|25-May-2010|Cryopreserved sperm|50.0|0.0|Yes|hypertension|connexins, hypertension, gap junctions|Possibly| 5271.0|Vegfb knockout|B6.129T2-Vegfb/QimrApb|Gfk|Recessive|vascular endothelial growth factor B|Vegfb|Nil|VEGF-B, Vrf|MGI:106199 |vascular endothelial growth factor B; targeted mutation 1, Graham F Kay|Vegfb|MGI:2178819|19||||||||||||||||No|||||||||||||Corneal vascularization: corneal injection of a plasmid encoding short hairpin RNA targeting secreted Flt1 (pshRNA-sflt1) induces corneal vascularization within 3 days of injection in wild-type and mutant mice.Small heart.Decreased heart weight: heart weight is reduced in juveniles but not in early postnatal mice, indicating impaired growth of hearts in the first few weeks after birth.Abnormal cardiovascular system physiology: abnormal reactive hyperemic response to coronary occlusion, with a lower overall flow-debt repayment during the initial 60 sec of reperfusion, although peak hyperemic flow was normal.Increased time of peak ischemic contracture: peak contracture during ischemia is greater, diastolic pressure is elevated during reperfusion and recovered only minimally, and the recovery of contractile function is slightly depressed throughout reperfusion, with the rate-pressure product lower at 30 min compared with controls.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|20||sib-mated homozygous mice|No|25-Oct-2010|Cryopreserved sperm|45.0|0.0|No||blood vessel, heart, angiogenesis, ischmia, myocardia|Yes| 5405.0| GM CSF (L.02) ; GM(-/-).C57|C57BL/6-Csf2/LudApb||Recessive|colony stimulating factor 2 (granulocyte-macrophage)|Csf2|Nil|Csfgm, Gm-CSf, MGI-IGM|MGI:1339752|colony stimulating factor 2 (granulocyte-macrophage); targeted mutation 1, Ashley R Dunn|Csf2|MGI:1930997|11||||||||||||||||No|||||||||||||Perinatal lethality: despite normal numbers of implantation sites in early pregnancy, homozygotes exhibit fetal loss during the second half of gestation and in the perinatal period.Postnatal lethality: during the first 3 weeks of life, the survival rate of pups is affected by parental genotype, with 91.1% survival of pups born to homozygous females vs 98.0% survival of pups born to heterozygous females.Prenatal lethality: * despite normal numbers of implantation sites in early pregnancy, homozygotes exhibit fetal loss during the second half of gestation and in the perinatal period. * on day 17 of pregnancy, the mean number of resorbing and malformed embryos is twice as high in pregnant female homozygotes (21%) vs female heterozygotes (11%).Abnormal placenta development: * mutant placentas show a ~28% reduction in the ratio of labyrinthine to spongiotrophoblast areas. * structural changes in placental architecture are associated with diminished nutrient transfer and appear to contribute to embryonic growth retardation.Abnormal glycogen cell morphology: the proportion of vacuolated trophoblast glycogen cells in the mutant spongiotrophoblast zone is reduced by 20%.Abnormal spongiotrophoblast layer morphology: on day 15 of pregnancy, mutant placentas exhibit a 22% increase in the area occupied by the spongiotrophoblast relative to wild-type placentas.Placental labyrinth hypoplasia: on day 15 of pregnancy, mutant placentas exhibit a 13% reduction in the area occupied by the labyrinth relative to wild-type placentas.Abnormal alveolar macrophage morphology: by 24 weeks, mutant intraalveolar macrophages exhibit phagosomes with "onion-like" structures resembling type-C lamellar bodies.Abnormal spleen size: on day 7 postinfection, P. chabaudi AS-infected homozygotes exhibit impaired development of malarial splenomegaly relative to wild-type mice.Lymphoid hyperplasia: by 11 weeks, mutant lungs display moderate to extensive lymphoid hyperplasia around central and peripheral vessels.Abnormal leukocyte physiology: * during the periovulatory period, homozygotes exhibit a normal size and composition of ovarian leukocyte populations in the stroma and follicle theca. * however, the number of macrophages/dendritic cells expressing MHC class II (Ia) is significantly reduced in mutant ovaries at ovulation. * after parturition, the number of ovarian macrophages and neutrophils is significantly decreased, with significantly reduced CD11b+ (Mac-1) staining in the stromal region.Abnormal MHC II cell surface expression on macrophages: at ovulation, mutant ovarian macrophages and/or dendritic cells exhibit reduced MHC class II (Ia) expression, suggesting impaired macrophage activation within the ovarian stroma and theca.Impaired macrophage recruitment: during the postpartum period, mutant ovaries exhibit reduced recruitment of macrophages and neutrophils in the stromal region.Lung inflammation: * starting at ~3 weeks, all homozygotes exhibit a nonfatal lung pathology, with local accumulation of surfactant protein within alveoli and a high incidence of bacterial and fungal infection resembling human alveolar proteinosis. * by 12-16 weeks, mutant lungs display extensive peribronchovascular infiltration with lymphocytes, primarily B cells and ~20% T cells (mostly CD4+).Increased susceptibility to bacterial infection: * one 4-week-old homozygote has been shown to die of purulent acute Pasteurella pneumotropica lobar pneumonia. * Gram-positive coccobacilli are detected in 7-week-old pneumonic consolidated areas. * virgin homozygotes exhibit an increased incidence of subclinical bacterial colonization of the uterus, with Pasteurella pneumotropica recovered from 50% of mutant uteri; clearance of bacterial organisms from the reproductive tract occurs normally after mating.Increased susceptibility to fungal infection: at 16 weeks, 3 of 15 mutant lungs contain foci of infection with Grocott-positive fungal particles.Increased susceptibility to parasitic infection: homozygotes are more susceptible to infection with P. chabaudi AS, as shown by higher peak parasitemia, recurrent recrudescent parasitemia, and significantly increased mortality relative to wild-type mice.Abnormal lung morphology.Abnormal respiratory alveoli morphology: * at 6-12 weeks, mutant alveoli contain large foamy macrophages, neutrophils, and eosinophilic alveolar debris. * surfactant-producing type-II alveolar cells are readily identifiable by their cytoplasmic type-C lamellar bodies.Abnormal alveolar macrophage morphology: by 24 weeks, mutant intraalveolar macrophages exhibit phagosomes with "onion-like" structures resembling type-C lamellar bodies.Emphysema: a number of older homozygotes display lungs with enlarged alveolar spaces, suggestive of emphysematous processes with peristent peribronchovascular lymphoid hyperplasia.Absent mature ovarian follicles: homozygotes exhibit impaired ovarian follicle maturation.Decreased ovary weight: * on day 4 of natural pregnancy, homozygotes show a significant reduction in ovarian weight relative to wild-type mice * in contrast, the number of corpora lutea remains normal.Abnormal uterus morphology: * homozygotes exhibit normal uterine development with no discernible differences in the process of decidualization and normal size and distribution of uterine granulocyte and macrophage populations during the estrous cycle, early pregnancy, and midgestation. * however, recently mated or parous mice are occasionally found to have chronic uterine abscesses, as a result of Pasteurella pneumotropica infection.Abnormal ovulation: * immature homozygotes primed with gonadotropins and naturally cycling adult homozygotes exhibit normal ovulation rates relative to wild-type counterparts. * however, in vitro, 70% of wild-type ovaries perfused with LH ovulate one or more oocytes vs 93% of homozygous mutant ovaries; the mean number of oocytes ovulated per mutant ovary is 2.8-fold higher but addition of rmGM-CSF has no effect on the ovulation rate in mutant ovaries. * in vitro, LH-perfused mutant ovaries show a 57% increase in nitrate/nitrite secretion relative to media-perfused and LH-perfused wild-type ovaries; however, addition of rmGM-CSF to mutant ovaries does not increase NO liberation.Prolonged diestrus: a significantly longer diestrus stage is observed.Prolonged metestrus: a significantly longer metestrus-2 stage is observed.Prolonged estrous cycle: in homozygotes, the mean duration of estrous cycle is extended by 1.5 days, with a significantly longer metestrus-2 and/or diestrus stage relative to wild-type mice.Impaired luteinization: * homozygotes display impaired luteinization and steroidogenic function of the corpus luteum during early pregnancy, as a result of altered recruitment and activation of ovarian myeloid leukocytes. * notably, homozygotes exhibit no differences in the time frame of corpus luteum demise, as the length of pseudopregnancy is comparable to that observed in wild-type mice.Abnormal fertility/fecundity.Decreased litter size: * the mean litter sizes of homozygous mutant breeding pairs are 25% smaller at weaning compared with heterozygous pairs, due to fetal death late in gestation and early in postnatal life. * reduced litter size appears to reflect a selective loss of male pups, with approximately one male less per litter weaned from homozygous mutant females than from heterozygous females.Reduced fertility: homozygotes display a moderate decrease in fertility, manifested as a 25% reduction in litter size at weaning.Decreased body size: * at weaning, surviving homozygous mutant pups are significantly smaller than wild-type pups. * in males, reduced body size persists into adulthood.Postnatal growth retardation: homozygotes exhibit slow growth kinetics after birth.Decreased fetal size: * on day 17 of pregnancy, the number of very small fetuses (< 500 mg) is 9-times as high in pregnant female homozygotes (23%) vs female heterozygotes (2.5%). * the mean fetal weight and the mean fetal:placental ratio in surviving conceptuses are reduced by 7% and 6%, respectively.Fetal growth retardation: homozygotes exhibit slow growth kinetics in utero.Decreased circulating progesterone level: * on day 4 of natural pregnancy, adult homozygotes exhibit significantly reduced plasma progesterone levels (116.5 ± 6 nM) relative to wild-type mice (141.6 ± 10.3 nM) * however, no major alterations in steroid secretion are noted at ovulation.Maternal effect: * litter sizes in homozygous deficient mothers are less severely affected in pregnancies sired by wild-type males, with resorption rates, fetal weights, and fetal:placental ratios being more comparable to normal values. * conversely, fetal weights and fetal:placental ratios are not reduced in homozygous deficient embryos gestating in replete mothers.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|Surfactant Metabolism Dysfunction, Pulmonary, 1; SMDP1|macrophage, lung, B cell, surfactant, progenitor|Yes| 5482.0|TGF (-/-) L-05|STOCK Tgfa/LudApb||Recessive|transforming growth factor alpha|Tgfa|||MGI:98724|transforming growth factor alpha; targeted mutation 1, Ashley R Dunn|Tgfa|MGI:1856577|6||||||||||||||||No|||||||||||||Increased incidence of corneal inflammation.Eyelids open at birth.Increased incidence of corneal inflammation.Waved hair: attenuated slightly with age.Increased curvature of hairs.Abnormal hair follicle orientation.Curly vibrissae: attenuated slightly with age.|Normal|Un|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Apr-2011|Cryopreserved sperm|50.0|0.0|Unknown||cornea, coat, fur|Yes| 5573.0|Par2 KO|129X1/Sv-PAR2/Apb||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1|Nil|Gpcr11, PAR-2, Par2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1, Mary Stevens|F2rl1|MGI:2389587|13|||||||||||||||||||||||||||||Normal|Normal|129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Sep-2011|Cryopreserved sperm|50.0|0.0|Unknown||protease, infection, eosinophil, inflammation|Yes| 4455.0||B6.129-Rel/WehiAnuApb||Recessive|reticuloendotheliosis oncogene|Rel|Unknown|c-Rel|MGI:97897|targeted mutation 1, Steve Gerondakis|Rel|MGI:2179622|11||||||||||||||||No|||||||||||||In mice with an inactivated c-rel gene, whereas development of cells from all hemopoietic lineages appeared normal, humoral immunity was impaired and mature B and T cells were found to be unresponsive to most mitogenic stimuli. Phorbol ester and calcium ionophore costimulation, in contrast to certain membrane receptor-mediated signals, overcame the T cell-proliferative defect, demonstrating that T cell proliferation occurs by Rel-dependent and -independent mechanisms.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Feb-2009|Cryopreserved sperm|120.0|0.0|Unknown||Lymphocyte, IL-2, humoral immunity|Yes| 5218.0|ATM null 129/SvJ|129/SvJ-Atm/AnuApb||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Nil||MGI:107202|ataxia telangiectasia mutated homolog (human); targeted mutation 1, Frederick W Alt|Atm|MGI:1933748|9|||||||||||||||||||||||||||||Smaller than littermate controls (about 20% reduction in size). ATM null male and females are infertile; 1% develop B or T cell lymphomas by >9 mths.|Normal|129/SvJ|Yes|No|Yes|Yes|No|Yes|Yes|Poor|||ATM het to ATM het crossings required|No|14-Sep-2010|Cryopreserved sperm|90.0|0.0|Yes|ataxia-telangiectasia (A-T)|human hepatocellular carcinoma (HCC), p53, kinase, Ataxia Telangiectasia Mutated (ATM), DNA repair, Purkinje cells, T cell (CD4+CD8+)|Possibly| 8678.0|Slc17a9 mutant|C57BL/6-Slc17a9/Marp||Recessive|solute carrier family 17, member 9|Slc17a9||1700019H03Rik, MGC:28538, Vnut|MGI:1919107||||2|||||||||||||||||||||||||||||No visual phenotype.Otherwise unknown.|Unknown|C57BL/6JArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8670.0|Bmi1|B6J;129-Bmi1/JAnu||Dominant|Bmi1 polycomb ring finger oncogen|Bmi1||Bmi1, Bmi-1, Pcgf4|MGI:88174|Bmi1 polycomb ring finger oncogene; targeted mutation 1, Mario R Capecchi|Bmi1|MGI:3805814|2||||||||||||||||||||||||||||||These targeted mutant mice carry tamoxifen-inducible Cre under the transcriptional control of the mouse Bmi1 (Bmi1 polycomb ring finger oncogene) promoter. When crossed with a strain containing a loxP-flanked sequence of interest, the offspring are useful for generating tamoxifen-induced, Cre-mediated targeted deletions, and when crossed with a floxed reporter strain, lineage tracing of Bmi1-expressing cells is possible. |C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Mar-2019|Cryopreserved sperm|11.0|0.0|Unknown||Cre, Crypt|Yes| 5094.0|gBT-I.1xA/J|A.B6-Tg(TcraHsv2.3,TcrbHsv2.3)L118-1Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion L118-1, Francis R Carbone|2 kb fragment of the H-2Kb and a 700 bp fragment including the Igh enhancer|||||||||||Normal|Normal|A/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|7|brother x sister mating|Yes|19-Apr-2010|Cryopreserved sperm|50.0|0.0|No||TCR tansgenic, Herpes Simplex Virus (HSV-1), glycoprotein B, cytotoxic T lymphocyte|Possibly| 5132.0|gBT-I.3beta|C57BL/6-Tg(TcrbHsv2.3)L118-3Cbn/CbnApb||Dominant||||||||||||||||||||||||||transgene insertion L118-3, Frank Carbone|Tcrb|||||||||||The majority of CD8 T cells express the transgenic Vb8.1 T cell receptor. The development of CD8 T cells is enhanced and CD4 T cells is diminished.In other respects the mouse has a similar phenotype to C57BL/6 mice.|As for homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||24|brother x sister mating|Yes|24-May-2010|Cryopreserved sperm|46.0|0.0|No||TCR tansgenic, Herpes Simplex Virus (HSV-1), glycoprotein B, cytotoxic T lymphocyte|Yes| 5138.0|Vb4-10|C57BL/6-Tg(Tcrb4BH-98)10Cbn/JWehiApb||Dominant||||||||||||||||||||||||||transgene insertion 4BH-98 TCRbeta, Francis R Carbone|Tcrb|||||||||||Greater than 95% of CD8+ T cells and 75% of CD4 T cell in the lymph node express the transgenic TCRbeta.|As for homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||brother-sister|No|27-May-2010|Cryopreserved sperm|50.0|0.0|No||TCR beta transgenic, murine gamma herpesvirus|Possibly| 5384.0|Stx16|C57BL/6-Stx16||Dominant|Syntaxin 16|Stx16|Unknown|SYN16|MGI:1923396||||2||||||||||||||||No|||||||||||||Unknown|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygous pairs|No|11-Jan-2011|Cryopreserved sperm|50.0|0.0|No||SNAREs, GLUT4 recycling, Trafficking, Trans Golgi Network|Possibly| 5421.0|Pax-6|C57BL/6-Pax6/Apb||Dominant|paired box gene 6|Pax6|Unknown|AEY11, Dey, Dickie's small eye, Gsfaey11, Pax-6|MGI:97490|paired box gene 6; small eye, Neuherberg|Pax6|MGI:1856158|2||||||||||||||||No|||||||||||||No remnants of eye formation, and a much shorter snout. Abnormal craniofacial morphology.|Smaller eye than wild type mice. Abnormal craniofacial morphology.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|07-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||Lens, eye, retina|Possibly| 5185.0|MMP13KO RAG1KO FVBn|FVB/N(Cg)-Mmp13 Rag1/Apb||Recessive|matrix metallopeptidase 13|MMP13|Nil|Clg, collagenase-1, Collagenase-3, interstitial collagenase, MMP-13, Mmp1|MGI:1340026|matrix metallopeptidase 13; targeted mutation 1.1, Zena Werb|Mmp13||9||||||||||Unknown to Unknown|||||||||||||||||||Increased width of hypertrophic chondrocyte zone: * the hypertrophic zone is expanded in the tibia and metatarsals, at E17 and 1 week after birth, respectively, however by 12 weeks of age the size of the hypertrophic zone is similar to wild-type. * chondrocytes proliferate and differentiate normally but accumulate in the most terminally differentiated hypertrophic state. * establishment of the primary ossification centers is normal.Abnormal cancellous bone morphology: * the amount of trabecular bone is increased in the tibia and metatarsals by 3 weeks or 1 week of age, respectively, however by 1 year of age the amount of trabecular bone was similar to wild-type. * the organization of the trabecular bone is also irregular.OA was surgically induced in the knees of MMP-13-knockout mice. No difference between wildtype and KO mice for aggrecan loss or cartilage erosion at 4 weeks. here was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks. Cartilaginous osteophytes were larger in knockout mice at 4 weeks, but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints. Authors conclude Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||No|28-Jul-2010|Cryopreserved sperm|50.0|0.0|Yes|spondyloepimetaphyseal dysplasia|extracellular matrix, collagenase, chondrocyte, osteoblast, growth plate|Possibly| 5185.0|MMP13KO RAG1KO FVBn|FVB/N(Cg)-Mmp13 Rag1/Apb||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848||Rag1||2||||||||||Unknown to Unknown||||||No|||||||||||||Increased width of hypertrophic chondrocyte zone: * the hypertrophic zone is expanded in the tibia and metatarsals, at E17 and 1 week after birth, respectively, however by 12 weeks of age the size of the hypertrophic zone is similar to wild-type. * chondrocytes proliferate and differentiate normally but accumulate in the most terminally differentiated hypertrophic state. * establishment of the primary ossification centers is normal.Abnormal cancellous bone morphology: * the amount of trabecular bone is increased in the tibia and metatarsals by 3 weeks or 1 week of age, respectively, however by 1 year of age the amount of trabecular bone was similar to wild-type. * the organization of the trabecular bone is also irregular.OA was surgically induced in the knees of MMP-13-knockout mice. No difference between wildtype and KO mice for aggrecan loss or cartilage erosion at 4 weeks. here was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks. Cartilaginous osteophytes were larger in knockout mice at 4 weeks, but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints. Authors conclude Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||No|28-Jul-2010|Cryopreserved sperm|||Yes|spondyloepimetaphyseal dysplasia|extracellular matrix, collagenase, chondrocyte, osteoblast, growth plate|Possibly| 7317.0|ENU22:49rik|C57BL/6NCrlAnu-Atp6v0a4/AnuApb|C57BL/6NCrlAnu-Atp6v0a4/AnuApb|Recessive|ATPase, H+ transporting, lysosomal V0 subunit A4|Atp6v0a4||Atp6n1b, V-ATPase alpha 4|MGI:2153480|ATPase, H+ transporting, lysosomal V0 subunit A4; mutation 1, The Australian National University|Atp6v0a4|MGI:5563513|6|ENSMUSG00000038600|ENSMUST00000114908|Atp6v0a4-002|166|464|G to A|ENSMUSE00001242165|4|56|Arginine to STOP|||||GCTTCCAGAGGAAGTTTGTGAATGAAGTCCGAAGGTGTGAGTCACTGGAGAGAATCCTGCG||||||||||||||Premature death|Unknown|C57BL/6NCrlAnu|Yes|No|Yes|Yes|No|Yes|No|Unknown||G4||No|12-Apr-2013|Cryopreserved sperm|26.0|0.0|Unknown||ENU, premature death|Yes| 5424.0|PRrtTAKI|129.Cg-Pgr/Apb||Dominant|progesterone receptor|Pgr||NR3C3, PR, PR-A, PR-B|MGI:97567|progesterone receptor; targeted mutation 3, John P Lydon|Pgr|MGI:3768562|9||||||||||||||||Yes|||||||||||||Abnormal female reproductive system morphology: authors state that the phenotype is identical to that of Pgr homozygotes.Female infertility: authors state that the phenotype is identical to that of Pgr homozygotes.|Unknown|crossed within line|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4 @ Host institution|All genotypes are viable and fertile, any combination can be used. We often cross Male Het with Female Hom|No|09-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||Progesterone Receptor, mammary gland, corpus luteum, ovarian follicle, uterus|Possibly| 5507.0|Blimp-Gfp|C57BL/6JWehi-Prdm1/AnuApb||Dominant|PR domain containing 1, with ZNF domain|Prdm1|Normal|Blimp-1, Blimp1, PRDI-BF1|MGI:99655|PR domain containing 1, with ZNF domain; targeted mutation 1, Stephen L Nutt|Prdm1|MGI:3510704|10||||||||||||||||Yes|||||||||||||Prenatal lethality: homozygotes die in late gestation||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|16-May-2011|Cryopreserved sperm|38.0|0.0|No||B cell, plasma cell|Yes| 7685.0|Notch4null|B6(Cg)-Notch4/Apb||Recessive|notch 4|Notch4|Nil|Int3, Int-3, N4|MGI:107471|notch 4; targeted mutation 1, Velocigene|Notch4|MGI:4842905|17|||||||||||||||||||||||||||||Mild delay in retinal angiogenesis|Normal|C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|7 generations|||No|22-May-2014|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 5473.0|Gpc3 knockout|B6;Cg-Gpc3/Apb||Dominant|glypican 3|Gpc3|Nil|OCI-5|MGI:104903|glypican 3; targeted mutation 1, Jorge Filmus|Gpc3|MGI:2159356|X||||||||||||||||No|||||||||||||Phenotype is highly strain dependent. For example, as the proportion of C57BL/6 background increases, phenotypic effects typical of Simpson-Golabi-Behmel syndrome begin to manifest and become more severe with increasing proportion of C57BL/6 background. For females, affected tissues include, craniofacial, skeletal, renal, urinary, respiratory and reproductive systems. Animals are also larger. Postnatal lethality: phenotype is stated to be similar to that of Gpc3tm1Fil male hemizygotes; however, no data are presented in.Mandible hypoplasia.Abnormal perineum morphology: mutant females with an imperforate vagina display swelling of the perineum.Abnormal perineum morphology: mutant females with an imperforate vagina display swelling of the perineum.Dilated uterus: mutant females with an imperforate vagina have a dilated, fluid-filled uterus.Vagina atresia: mutant females exhibit an imperforate vagina at a higher frequency (30%) than wild-type females (4%).Lung inflammation.Increased susceptibility to bacterial infection.Abnormal kidney development.Abnormal ureteric bud morphology.Abnormal ureteric bud branching morphogenesis.Kidney cysts.Increased body weight.|Because Gpc3 is on the X chromosome, affected males are hemizygous and show many of the phenotypic characteristics of homozygous females.Females:Abnormal kidney development: * from N4 on, some heterozygous females display dysplastic kidneys (also noted in a large proportion of mice from earlier backcrosses) * the degree of renal dysplasia varies from mouse to mouse.Abnormal ureteric bud morphology.Abnormal ureteric bud branching morphogenesis.Kidney cysts: from N4 on, some heterozygous females display cystic kidneys (also noted in a large proportion of mice from earlier backcrosses).Increased body weight: heterozygotes display an intermediate size between hemizygous mutant males and wild-type controls at all time points.|C57BL/6 x CD-1|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|unknown||Complex. Maintain on 50:50 C57BL/6 x CD-1 (or Swiss) until required to study phenotypic effects. Then, cross to C57BL/6 to "develop" phenotype.|No|01-Apr-2011|Cryopreserved sperm|45.0|0.0|Yes|Simpson-Golabi-Behmel syndrome|glypican, heparan sulfate proteoglycans, Simpson-Golabi-Behmel syndrome, Gpc 3|Possibly| 5425.0|Tpcn1∆|129S5/SvEvBrd-Tpcn1/Apb||Dominant|two pore channel 1|Tpcn1|Unknown||MGI:2182472|two pore channel 1; gene trap OST359423, Lexicon Genetics|Tpcn1|MGI:3529820|5||||||||||||||||No|||||||||||||Unknown|Unknown|129S5/SvEvBrd|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||4 @ Garvan|We keep Homozygous|No|09-Feb-2011|Cryopreserved sperm|35.0|0.0|Unknown||channel, Pore|Possibly| 5428.0|TnI.1; cTnIwt.1|C57BL/6-Tg(Myh6-TNNI3*wt)1Chs/Apb||Dominant||||||||||||||||||||||||||transgene insertion wild type 1, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|50% of endogenous (hemizygous)||||||||||Unknown|Indistinguishable from non-transgenic wild type C57BL/6 mice |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||17, of which 13 have been maintaned as homozygous|Homozygous transgenic x homozygous transgenic sibs|No|10-Feb-2011|Cryopreserved sperm|45.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 3325.0|TGM2 KO|B6.129-Tgm2/Apb||Recessive|transglutaminase 2, C polypeptide|Tgm2|Nil|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 1.1, Robert M Graham|Tgm2|MGI:3527996|2||||||||||||||||No|||||||||||||Abnormal cell adhesion: fewer homozygous fibroblasts (20% versus 79% of wild-type) adhered to poly-L-coated or fibronectin coated slidesAbnormal T cell physiology: 24 hours after induction of apoptosis by dexamethasone treatment, homozygotes had smaller thymuses due to decreased viability of thymocytes and increased clearance of dead cells compared to controls, however mutants are viable, normal in size and weight, have normal separation of digits and open eyelids and no difference in thymocyte numbers, indicating that developmental apoptosis was not impaired.||129S1/SvImJ * C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Jun-2008|Cryopreserved sperm|50.0|0.0|Unknown||transgluatminase, Gh, G-protein, cross linking, T cell|Yes| 7319.0|Raptorfl/fl|B6.129-Rptor/Adel||Dominant|regulatory associated protein of MTOR, complex 1|Rptor||4932417H02Rik, mKIAA1303, Rap, raptor|MGI:1921620|regulatory associated protein of MTOR, complex 1; targeted mutation 1, Markus A Ruegg|Rptor|MGI:3829770|11|||||||||||||||||||||||||||||Normal|Unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|||homozygote x homozygote|No|18-Apr-2013|Cryopreserved sperm|75.0|0.0|Unknown||Muscle, mTor|Possibly| 7320.0|Rictorfl/fl|B6.129-Rictor/Adel||Dominant|RPTOR independent companion of MTOR, complex 2|Rictor||921505C17Rik, 6030405M08Rik, D530039E11Rik|MGI:1926007|RPTOR independent companion of MTOR, complex 2; targeted mutation 1, Markus Ruegg|Rictor|MGI:3829768|15|||||||||||||||||||||||||||||Normal|Unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|||homozygote x homozygote|No|18-Apr-2013|Cryopreserved sperm|75.0|0.0|Unknown||mTOR, muscle|Possibly| 5294.0|CZ-SOD ; B6.huSOD1.Tg (TD)|C57BL/6-Tg(H2-K-SOD1)Apb||Dominant||||||||||||||||||||||||||human superoxide dismutase 1, soluble|H2-K|||||||||||These mice contain human CuZn superoxide dismutase (SOD1) with a hemagglutinin epitope tag expressed from the mouse H-2Kb (MHC Class I) promoter. The antioxidant enzyme is expressed in most nucleated cells, which should therefore be protected from (superoxide anion) oxidative injury. This has been demonstrated using pancreatic islets isolated from the transgenic mice.The mice show no overt phenotype. Phenotype does not differ from a wildtype of the same genetic background.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|10|||No|29-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||transplantation, rejection, oxidative stress, islet, reactive oxygen species (ROS) , hypoxia/reoxygenation|Possibly| 5295.0|EC-SOD ; B6.huSOD3.Tg (TE)|C57BL/6-Tg(H2-K-SOD3)/StvApb||Dominant||||||||||||||||||||||||||human superoxide dismutase 1, extracellular|H2-K|||||||||||These mice contain human extracellular superoxide dismutase (SOD3) modified to include a glycosyl phosphatidylinositol (GPI) membrane linkage signal & tagged with a FLAG epitope tag. SOD3 is expressed from the mouse H-2Kb (MHC Class I) promoter. The antioxidant enzyme is expressed in most nucleated cells, which should therefore be protected from (extracellular superoxide anion) oxidative injury. This has been demonstrated using pancreatic islets isolated from the transgenic mice.The mice show no overt phenotype. Phenotype does not differ from a wildtype of the same genetic background.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|10|||No|29-Oct-2010|Cryopreserved sperm|70.0|0.0|Unknown||transplantation, rejection, oxidative stress, islet, reactive oxygen species (ROS) , hypoxia/reoxygenation|Possibly| 5509.0|New York MPS IIIA|Stock Sgsh/Apb||Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Reduced|sulphamidase|MGI:1350341|N-sulfoglucosamine sulfohydrolase (sulfamidase); mucopolysaccharidosis IIIA|Sgsh|MGI:2151181|11||||||||||||||||Yes|||||||||||||Newborn MPS IIIA pups do not appear different to their unaffected coutnerparts. Significant changes in open-field activity are observed from 3 weeks in MPS IIIA mice. Abnormalities in tests of gait, grip strength and in the assessment of the negative geotaxis response are observable from ∼15 weeks of age (Hemsley & Hopwood, 2005). Memory and learning deficits in the Morris Water Maze are observed from 20 weeks of age (Gliddon & Hopwood, 2004). Behavioural changes were often detected in male MPS-IIIA mice before they appeared in females.Premature death: most died between 7 and 10 months of age with a small number living to 14 months.Circling:observed in some mice over 1 year of age.Abnormal heart morphology: endomysium and perivascular space is often expanded by abnormal fibroblasts and macrophages.Abnormal myocardium layer morphology: myocardiocytes ultimately undergo degenerative changes and are replaced by fibroblasts with foamy cytoplasm.Abnormal heart valve morphology: valvular cusps and arterial perivascular spaces are also invaded by fibroblasts.Abnormal cell content/ morphology: Vacuolated or vesiculated cells with enlarged cytoplasm in: * fibroblasts * cerebral and cerebellar neurons as well as other cells in and around the brain, dense inclusions * dorsal root ganglion * cells of the eye * kidney * cardiac tissuesAbnormal lysosome morphology: * "zebra body" type storage material identifiable by EM in the brain and skeletal muscle * lysosomal storage is particularly prominent in the liver and spleenAbnormal neurocranium morphology: thickened calvariumEnlarged spleen.Enlarged liver.Abnormal kidney morphology.Hydronephrosis: unilateral or bilateral hydronephrosis frequently seenAbnormal renal tubule morphology: microvesiculated cytoplasm in the distal convoluted tubules, podocytes, and epithelial cells lining the collecting tubules.Distended urinary bladder: * at death the bladder is grossly distended and contains 1-2 ml of turbid urine * heparan sulfate accumulation in the urineAbnormal neurocranium morphology: thickened calvariumAbnormal vertebrae morphology: vertebrae become deformed.Corneal opacity: corneal opacity develops around 7 months of age.Abnormal hair texture.Disheveled coat: appeared normal at birth but developed a scruffy, ill appearance around 6-7 months of age.|Normal|Mixed genetic background including predominantly 129SvJ and CD1, with some C57BL/6 and SJL strain contributions|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|20-May-2011|Cryopreserved sperm|50.0|0.0|Yes|Progressive neurodegenerative lysosomal storage disorder||Possibly| 5250.0|CAM|C57BL/6-Tg(PRPH1-EGFP)CSars/Apb||Recessive||||||||||||||||||||||||||Human Peripherin gene|PRPH1 endogenous promoter|Normal||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|16|Hemizygous PRPH1-EGFP transgene X Hemizygous PRPH1-EGFP transgene|No|20-Oct-2010|Cryopreserved sperm|44.0|0.0|Unknown|Friedreich ataxia|Peripherin, Neurodegenerative disease, Neuroregeneration|Yes| 8676.0|ASD1030:Bmi1:fl|STOCK Bmi1/JAnu||Recessive|Bmi1 polycomb ring finger oncogene|Bmi1|Unknown|Bmi1, Bmi-1, Pcgf4 |MGI:88174 |Bmi1 polycomb ring finger oncogene; targeted mutation 1.1, Sean J Morrison|Bmi1|MGI:5638198|2|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Mar-2019|Cryopreserved sperm|10.0|0.0|Unknown||Bmi-1, fate-mapping, forebrain, prospective identification, stem cell|Yes| 5253.0|Hoxb7/GFP|B6;CBA-Tg(Hoxb7-EGFP)33Cos/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 33, Franklin Costantini|Hoxb7|High level expression||||||||||GFP is too strong in homozygote state and embryos don't survive|Normal.GFP expression controlled by the activity of the HoxB7 promoter.GFP expressed in ureteric epithelium of the kidney, snout of pup and in regions of the brain.|(C57BL/6 x CBA)F2|No|Unknown|Yes|No|Unknown|Yes|No|Good||||No|20-Oct-2010|Cryopreserved sperm|90.0|0.0|No||GFP, expression pattern, kidney, ureteric bud, nephron|Yes| 7328.0|ENU25:009:BTK|C57BL/6NCrlAnu-Btk/AnuApb|C57BL/6NCrlAnu-Btk/AnuApb|Recessive|Bruton agammaglobulinemia tyrosine kinase|Btk|Unknown|Bruton's tyrosine kinase, X-linked immune deficiency, xid|MGI:88216|Bruton agammaglobulinemia tyrosine kinase; mutation 2, The Australian National University|Btk|MGI:5563503|X|ENSMUSG00000031264|ENSMUST00000033617|Btk-001|454|614|A to G|ENSMUSE00001191399|6|152|Tyrosine to Histidine|||||ACCATCCTTGCTTCTGGATTGATGGACAGTATCTCTGCTGCTCTCAGACAGCCAAGAATGC|Unknown|||||||||||||Mild BTK phenotype. Normal % peripheral B cells, increased numbers of immature B cells. Increased IgM expression on mature B cells.|Hemizygous phenotype same as homozygous females|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Unknown|Yes|No|Excellent||G3||No|01-May-2013|Cryopreserved sperm|37.0|0.0|Unknown||B cell, immunoglobulin, IgM, IgD, ENU|Yes| 7346.0|EphA1 conditional full knockout (EA1C KO)|B6.129-Epha1/QimrApb||Recessive|Eph receptor A1|Epha1|Normal|5730453L17Rik, Eph, Esk|MGI:107381|targeted mutation 2, Shannon L Duffy|Epha1||6||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|3|Hom x Hom|No|04-Jun-2013|Cryopreserved sperm|45.0|0.0|Unknown||Receptor Tyrosine Kinase, ephrin, epithelium, uterus, tail, embryonic|Yes| 2370.0|ENU6WTNIH:033|C57BL/6JSfdAnu-Stat1/AnuApb|C57BL/6JSfdAnu-Stat1/AnuApb|Recessive|signal transducer and activator of transcription 1|Stat1|||MGI:103063|signal transducer and activator of transcription 1; mutation 1, The Australian National University|Stat1|MGI:5563415|1|ENSMUSG00000026104|ENSMUST00000070968|Stat1-201|1633|1983|T to A|ENSMUSE00000630006|19|545|Tryptophan to Arginine|||||CTAATGCTGGCCCTGATGGTCTTATTCCATGGACAAGGTTTTGTAAGGAAAATATTAATGA|Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. Spontaneous formation of B cell lymphomas has also been observed in this pedigree, but it is not yet known if the two traits are linked.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||8||No|14-Dec-2007|Cryopreserved sperm|79.0|0.0|Unknown||B cell, immunization, Th1, ENU, Wellcome Trust, NH|Yes| 8677.0|Chloe - Acan tm1Afos|C57BL/6-Acan/AfosSyd||Recessive|aggrecan|Acan||Agc1, b2b183Clo, Cspg1|MGI:99602|aggrecan; targeted mutation 1, Amanda J Fosang|Acan|MGI:3577026|7|||||||||||||||||||||||||||||No abnormal phenotype detected:• mutants develop normally with no skeletal abnormalities but do not accumulate aggregan in cartilage even though Agc1 is not cleaved by matrix metalloproteases|knock In|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Mar-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 5332.0|ENU16NIH:024a|C57BL/6JAnu-Lepr/AnuApb|C57BL/6JAnu-Lepr/AnuApb|Recessive|leptin receptor|Lepr||Leprb, LEPROT, leptin receptor gene-related protein, Modb1, obese-like, obl, Obr, OB-RGRP|MGI:104993|leptin receptor; mutation 1, The Australian National University|Lepr|MGI:5563456|4|ENSMUSG00000057722|ENSMUST00000036552|Lepr-001|2148|2703|T to A|ENSMUSE00000278589|14|716|Asparagine to Lysine|||||GCGCACACTGTTACAGTTCTGGCTGTCAATTCCCTCGGCGCTTCCCTTGTGAATTTTAACC||||||||||||||Noted as obese from 6 weeks of age. Continue to gain weight throughout their life. Heaviest mouse so far is a female at 49.4g|Normal|C57BL/6JAnu|Yes|No|Yes|Yes|No|Yes|Yes|Poor||4|Het x Het|No|25-Nov-2010|Cryopreserved sperm|19.0|0.0|Yes|Obesity|Obesity, ENU|Possibly| 7322.0|Pdx1-cre|B6(Cg)-Tg(Ipf1-cre)1Tuv/AusbAnuApb||Dominant||||||||||||||||||||||||||transgene insertion 6, David A Tuveson|Ipf1|Islet cells of pancreas||||||||||Normal.Islet cells express Cre recombinase|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Apr-2013|Cryopreserved sperm|66.0|0.0|Unknown||Cre recombinase, islet, pancreas|Possibly| 7321.0|R26eYFP|B6.129-Gt(ROSA)26Sor/Adel||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Frank Costantini|Gt(ROSA)26Sor|MGI:2449038|Unknown|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|19-Apr-2013|Cryopreserved sperm|74.0|0.0|Unknown||eYFP, Cre recombinase|Possibly| 5461.0|ENU18NIH:030b|C57BL/6JAnu-Atp11c/AnuApb|C57BL/6JAnu-Atp11c/AnuApb|X-linked|ATPase, class VI, type 11C|Atp11c|Reduced|Ig|MGI:1859661|ATPase, class VI, type 11C; mutation 2, The Australian National University|Atp11c|MGI:5006936|X|ENSMUSG00000062949|ENSMUST00000101527|Atp11c-202||||||||57493948|26|||CAGTCTTAGTATTCACCGTAACTCTGAAGGTTAGATTTTTATTCATTCAAATATATTTTG|Yes|||||||||||||Near complete block at pro-B cell stage; normal marginal zone B cell development from fetal liver but not from bone marrow.Defective ATP11C resulted in a lower rate of phosphatidylserine translocation in pro-B cells and much lower pre-B cell and B cell numbers despite expression of pre-rearranged immunoglobulin transgenes or enforced expression of the prosurvival protein Bcl-2 to prevent apoptosis and abolished pre-B cell population expansion in response to a transgene encoding interleukin 7. The only other abnormalities we noted were anemia, hyperbilirubinemia and hepatocellular carcinoma.||C57BL/6JAnu|Yes|No|Unknown|Yes|Unknown|Yes|Yes|Poor||||No|07-Mar-2011|Cryopreserved sperm|45.0|0.0|Unknown||ENU, B cell, lymphocyte|Possibly| 4881.0|Bc.Rag1/Gal KO|C.B6-Rag1 Ggta1/Apb||Recessive|recombination activating gene 1|Rag1|Nil|Rag-1|MGI:97848|targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.All blood/tissue samples lack Gal expression.Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.Mice are deficient in mature B and T cells.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|83.0|0.0|Unknown||T cell, B cell, eosinophil, inflammation, interferon, Xenotransplantation, antibody, transferase, galactose|Yes| 4881.0|Bc.Rag1/Gal KO|C.B6-Rag1 Ggta1/Apb||Recessive|glycoprotein galactosyltransferase alpha 1, 3|Ggta1|Nil|alpha Gal, alpha3GalT, Gal, GALT, Ggta, Ggta-1, glycoprotein alpha galactosyl transferase 1|MGI:95704||||2|||||||||||||||||||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.All blood/tissue samples lack Gal expression.Cortical cataracts developed in all GalT-/- mice at 4-6 weeks of age.Mice are deficient in mature B and T cells.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|||Unknown||T cell, B cell, eosinophil, inflammation, interferon, Xenotransplantation, antibody, transferase, galactose|Yes| 5572.0|Zic5N|B6.CBA-Zic5/AnuApb|B6.CBA-Zic5/Anu|Semi-dominant|zinc finger protein of the cerebellum 5|Zic5|Nil|odd-paired related, Opr|MGI:1929518|zinc finger protein of the cerebellum 5; targeted mutation 1, Shinichi Aizawa|Zic5|MGI:3574814|14|||||||||||||||||||||||||||||Complete neonatal lethality: most mutants were live-born but died within 24 hours.Absent mandible: 2 out of 68 embryos exhibited agnathiaMicrognathia: one fifth of embryos exhibited mild micrognathiaMicrocephaly:most mutants were microcephalic.Abnormal optic vesicle formation:preoptic area was somewhat reduced medially in E12.5 and E18.5 embryos.Microphthalmia: found in some mutants.Anophthalmia:found in some mutants.Abnormal forebrain development: subtle defects in the ventromedial region of the forebrain at E12.5.Abnormal hippocampus development: development of hippocampus was somewhat poor at E18.5.Abnormal telencephalon development: * subtle defects in the dorsomedial region of the telencephalon at E12.5 * rostrally, development of the septum was poor at E12.5 and E18.5 and the fornix that normally becomes remarkable in septum at E15 was hardly visibleAbnormal folding of telencephalic vesicles: invagination of the telencephalic roof was less pronounced at E12.5.Exencephaly: observed in 9% of mutant embryos.Dilated lateral ventricles: the septum, striatum, and pallidum were underdeveloped, causing expansion of lateral ventricles at E18.5.Dilated third ventricle: at E18.5, the thalamus, hypothalamus, and preoptic area were reduced in the medial region, resulting in the expansion of the third ventricle.Abnormal choroid plexus morphology: choroid plexus was distorted at E12.5.Abnormal globus pallidus morphology: swelling of the pallidum was poor mediocaudally at E12.5 and was underdeveloped at E18.5.Abnormal striatum morphology: swelling of the striatum was poor mediocaudally at E12.5 and was underdeveloped at E18.5.Abnormal hypothalamus morphology: hypothalamus was reduced medially in E12.5 and E18.5 embryos.Abnormal thalamus morphology: swelling of the thalamus was poor ventrally at E15 and at E18.5 the thalamus was reduced in the medial region.Abnormal cerebral cortex morphology: * reduced medial pallium at E12.5. * the cortex was thinner at E18.5Abnormal axon morphology: the fornix that normally becomes remarkable in septum at E15 was hardly visible.Abnormal cranial ganglia morphology: mild reduction in facial ganglia.Abnormal glossopharyngeal ganglion morphology: mild reduction in glossopharyngeal ganglia.Abnormal trigeminal ganglion morphology: mild reduction in trigeminal ganglia.|Low prevalence of ventral spots and hydrocephaly on some genetic backgrounds.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|10|0|Heterozygous carrier aniamals are paired with C57BL/6 animals|No|31-Aug-2011|Cryopreserved sperm|70.0|0.0|Unknown||Cerebellum, Forebrain, Zic|Possibly| 7323.0|ENU19:B6:Trim7|C57BL/6-Trim7/AnuApb|C57BL/6-Trim7/AnuApb|Recessive|tripartite motif-containing 7|Trim7|||MGI:2137353|mutation 1, The Australian National University|Trim7||11|ENSMUSG00000040350|ENSMUST00000109213|Trim7-001|124|370|A to G|ENSMUSE00000679460|2|44|Asparagine to Aspartic acid|||||TGCTGTCCCGGGAAGTGACACAGAAACAGAATGAGAACCTGGCCCAGCTGGAGGGTGAGAT||||||||||||||Unknown||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Apr-2013|Cryopreserved sperm|20.0|0.0|Unknown||ENU|Yes| 5581.0|LMN|B6;129S1(Cg)-Lmna/Dfat||Dominant|lamin A|Lmna|Nil|Dhe, lamin A/C|MGI:96794|lamin A; targeted mutation 1, Colin L Stewart|Lmna|MGI:2177930|3|||||||||||||||||||||||||||||Lethal by 6-8weeks.Postnatal growth retardation.Muscle weakness.Small seminiferous tubules.Small testis.Azoospermia: spermatids and spermatozoa are largely absentArrest of male meiosis: * increased frequency of leptotene and zygotene spermatocytes and decreased frequency of pachytene and diplotene spermatocytes resulting from arrest and apoptosis of spermatocytes during the pachytene stage * unpaired chromosomes and/or improperly paired sex chromosomes and failure to progress through prophase I are seen * however, oogenesis in females is normal.|Viable, fertile.Abnormal nucleus morphology: in many MEFs, nuclei appear elongated but distribution of nuclear envelope proteins is normal except for increased levels of cytoplasmic emerin.|Mixed background, B6;129S1|No|Unknown|Yes|No|Unknown|Yes|No|Unknown||||No|09-Sep-2011|Cryopreserved sperm|50.0|0.0|Unknown||muscular dystrophy, membrane, interphase, spermatogenesis|Yes| 7324.0|PW1-LacZ|C57BL/6-Tg(Peg3-LacZ)/MarpApb||Semi-dominant||||||||||||||||||||||||||LacZ|paternally expressed gene 3 (PW1/Peg3) |||||||||||Unknown|Normal.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|23-Apr-2013|Cryopreserved sperm|60.0|0.0|Unknown||LacZ|Possibly| 7550.0|ENU25:009:TNIK:B6|C57BL/6NCrlAnu-Tnik/AnuApb|C57BL/6NCrlAnu-Tnik/AnuApb|Recessive|TRAF2 and NCK interacting kinase|Tnik||1500031A17Rik, 4831440I19Rik, C530008O15Rik, C630040K21Rik|MGI:1916264|TRAF2 and NCK interacting kinase; mutation 1, The Australian National University|Tnik|MGI:5571275|3|ENSMUSG00000027692|ENSMUST00000160307|Tnik-007|317|397|A to G|ENSMUSE00000593159|5|106|Glutamic acid to Glycine|||||CATGGATGACCAACTCTGGTTGGTTATGGAGTTCTGTGGTGCTGGCTCTGTCACTGACCTG||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2013|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Yes| 7349.0|Bmp2 - BAC clone RP23-85011 ; 5' Bac|B6.DBA-Tg(Bmp2)/VccriApb||Dominant||||||||||||||||||||||||||Bac Bmp2||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jun-2013|Cryopreserved sperm|54.0|0.0|Unknown||Lac Z|Possibly| 7411.0|ENU26:040:Dock8:B6|C57BL/6NCrlAnu-Dock8/AnuApb|C57BL/6NCrlAnu-Dock8/AnuApb|Recessive|dedicator of cytokinesis 8|Dock8|Unknown|1200017A24Rik, 5830472H07Rik, A130095G14Rik|MGI:1921396|dedicator of cytokinesis 8; mutation 2, The Australian National University|Dock8|MGI:5563483|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201|4888|5010|A to T|ENSMUSE00000145935|38|1630|Arginine to STOP|||||ACCCTGAGATGCTTATGGACCTCATGTACAGAATTGCCAAGAGCTACCAGGCATCGCCTGA||||||||||||||Peripheral blood shows reduced T cells, activated CD8<+> T cells (high CD44) and low IgM expression on mature B cells. No Margnal Zone B cells in spleen.Parameters measured by flow cytometry using antibodies against following antigens: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|23-Aug-2013|Cryopreserved sperm|41.0|0.0|Unknown||T cell, B cell, antibody, ENU|Yes| 10528.0|CX3CR1GFP knock-in/knock-out; CD45.1|B6.Cg-Ptprc Cx3cr1/LittJ||Dominant|protein tyrosine phosphatase, receptor type c|Ptprc||B220, CD45, Ly-5|MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc |MGI:4819849|1|ENSMUSG00000026395 ||||||||||||||||||||||||||||Mice that are homozygous for the CX3CR1-GFP targeted mutation are viable, fertile, normal in size. While they are CX3CR1-deficient, they do not display any gross physical or behavioral abnormalities. RT-PCR analysis of lymphoid tissue from homozygotes detects mutant gene product (mRNA) and no wild type gene product (mRNA). Flow cytometric analysis of peripheral blood cells identified a subset of green fluorescent cells not observed in wild type mice. Enhanced Green Fluorescent Protein (EGFP), but not the endogenous gene, is expressed in monocytes, dendritic cells, NK cells, and brain microglia, mimicking endogenous gene expression. The same subset of peripheral blood cells isolated from heterozygote mice express detectable levels of EGFP. These mice also express the CD45.1 (Ly5.1 or Ptprca) allele, which is atypical for the C57BL/6 congenic background, and this marker may be used to track donor cell populations in transplantation studies with C57BL/6 (CD45.2, Ly5.2 or Ptprcb) mice. These CX3CR1-GFP mice may be useful in studies of leukocyte migration and trafficking, as well as for transplantation studies.|To generate the Cx3cr1 mutant allele, a targeting vector containing an Enhanced Green Fluorescent Protein (EGFP, Clontech) cDNA sequence, loxP-flanked neomycin resistance gene, herpes simplex virus thymidine kinase gene, and SV40 polyadenylation site sequence was used to disrupt the first 390 bp of exon 2. The construct was electroporated into 129P2/OlaHsd derived E14.1 embryonic stem (ES) cells which were transiently transfected with a Cre recombinase vector to remove the selection cassette. ES cells that had successfully undergone Cre-mediated recombination (removing the loxP-flanked neo cassette and leaving a single loxP site downstream of EGFP) were injected into recipient blastocysts. The resulting chimeric animals were backcrossed to C57BL/6 for ten generations before being made homozygous. During the backcross, mice were likely bred to a B6.CD45.1 congenic strain and thus also harbor the CD45.1 (Ly5.1 or Ptprca) allele rather than the CD45.2 (Ly5.2 or Ptprcb) allele normally present in C57BL/6 mice. Upon arrival at The Jackson Laboratory Repository, mice were bred with C57BL/6J inbred mice to establish the colony.A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, 2 of the 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating (one on chromosome 11 and one on chromosome 13). Breeding mutant mice together at The Jackson Laboratory Repository for several generations may have fixed these 2 markers as C57BL/6N allele-type.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|16-Oct-2025||0.0|0.0|Unknown|||No| 10528.0|CX3CR1GFP knock-in/knock-out; CD45.1|B6.Cg-Ptprc Cx3cr1/LittJ||Dominant|C-X3-C motif chemokine receptor 1|Cx3cr1|||MGI:1333815|C-X3-C motif chemokine receptor 1; targeted mutation 1, Dan R Littman|Cx3cr1|MGI:2670351|9|ENSMUSG00000052336||||||||||||||||||||||||||||Mice that are homozygous for the CX3CR1-GFP targeted mutation are viable, fertile, normal in size. While they are CX3CR1-deficient, they do not display any gross physical or behavioral abnormalities. RT-PCR analysis of lymphoid tissue from homozygotes detects mutant gene product (mRNA) and no wild type gene product (mRNA). Flow cytometric analysis of peripheral blood cells identified a subset of green fluorescent cells not observed in wild type mice. Enhanced Green Fluorescent Protein (EGFP), but not the endogenous gene, is expressed in monocytes, dendritic cells, NK cells, and brain microglia, mimicking endogenous gene expression. The same subset of peripheral blood cells isolated from heterozygote mice express detectable levels of EGFP. These mice also express the CD45.1 (Ly5.1 or Ptprca) allele, which is atypical for the C57BL/6 congenic background, and this marker may be used to track donor cell populations in transplantation studies with C57BL/6 (CD45.2, Ly5.2 or Ptprcb) mice. These CX3CR1-GFP mice may be useful in studies of leukocyte migration and trafficking, as well as for transplantation studies.|To generate the Cx3cr1 mutant allele, a targeting vector containing an Enhanced Green Fluorescent Protein (EGFP, Clontech) cDNA sequence, loxP-flanked neomycin resistance gene, herpes simplex virus thymidine kinase gene, and SV40 polyadenylation site sequence was used to disrupt the first 390 bp of exon 2. The construct was electroporated into 129P2/OlaHsd derived E14.1 embryonic stem (ES) cells which were transiently transfected with a Cre recombinase vector to remove the selection cassette. ES cells that had successfully undergone Cre-mediated recombination (removing the loxP-flanked neo cassette and leaving a single loxP site downstream of EGFP) were injected into recipient blastocysts. The resulting chimeric animals were backcrossed to C57BL/6 for ten generations before being made homozygous. During the backcross, mice were likely bred to a B6.CD45.1 congenic strain and thus also harbor the CD45.1 (Ly5.1 or Ptprca) allele rather than the CD45.2 (Ly5.2 or Ptprcb) allele normally present in C57BL/6 mice. Upon arrival at The Jackson Laboratory Repository, mice were bred with C57BL/6J inbred mice to establish the colony.A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, 2 of the 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating (one on chromosome 11 and one on chromosome 13). Breeding mutant mice together at The Jackson Laboratory Repository for several generations may have fixed these 2 markers as C57BL/6N allele-type.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|16-Oct-2025||||Unknown|||No| 6897.0|APN188|C57Bl/6NTac-Notch4/Marp||Recessive|Notch gene homolog 4 (Drosophila|Notch4|Unknown|Int3, Int-3, N4|MGI:107471 |Notch gene homolog 4 (Drosophila); targeted mutation 1, Velocigene |Notch4 |MGI:4842905 |17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|17-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 630.0|T3RKO|B6;129S1-Tlr3/Apb|B6;129S1-Tlr3/Apb|Recessive|toll-like receptor 3|Tlr3|Normal||MGI:2156367|targeted mutation 1, Richard A Flavell|Tlr3|MGI:2653138|8||||||||||||||||No|||||||||||||Lymph node enlargement.Normal lymphocyte development.Normal expression of CD3, B220, CD4, and CD8 in thymocytes and splenocytesAbnormal B cell physiology.Impaired expression of CD69, CD80, and CD86 in response to poly(I:C), but not LPSImpaired expression of CD69 in response to viral genomic dsRNA from Type I Lang mammalian reovirusAbnormal macrophage physiology.Impaired ability to produce IL6, IL12 and TNF-alpha in response to poly(I:C), a synthetic dsRNA analogueproduction of IL6, IL12, and TNF-alpha in response to LPS, PGN, LTA, zymosan, mannan, or CpG DNA was comparable to wild type controlsDecreased inflammatory response.Resistant to poly(I:C)-induced shock compared to wild type mice produced less IL12 after poly(I:C) i.p. injection.Upregulation of costimulatory molecules, CD40 and CD86, by peritoneal macrophages in response to dsRNA was preserved on C57BL/6 background.Impaired ability to produce type I interferon and TNF-alpha in response to dsRNA, but not in response to LPS.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Excellent|||Hom x Hom|Yes|25-Apr-2007|Cryopreserved sperm|100.0|0.0|No||B cell, lymphocyte, Macrophage, inflammatory response, LPS|Yes| 8682.0|Nlrp9b KO ; Rice|C57BL/6NCrlAnu-Nlrp9b/AnuApb||Recessive|NLR family, pyrin domain containing 9B|Nlrp9b|Unknown|Nalp9b, Nalp-delta|MGI:2675377|Nlrp9b, endonuclease-mediated mutation 1, Australian National University|Nlrp9b||7||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Apr-2019|Cryopreserved sperm|21.0|20.0|Unknown|||Yes| 10529.0|Ai9(RCL-tdT) x Csf1rflox|B6.Cg-Gt(ROSA)26SorJ Csf1r/J||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 9, Hongkui Zeng|Gt(ROSA)26Sor|MGI:3809523|6|ENSMUSG00000086429 ||||||||||||||||||||||||||||This mouse line is a double mutant mouse line generated by crossing two mouse lines purchased from Jax labs : Ai9 (RRID:IMSR_JAX:007909) and CSF1R flox (RRID:IMSR_JAX:021212). The sperm was obtained from mice homozygous for CSF1Rfl (fl/fl, confirmed by PCR) and either homozygous or heterozygous for Ai9. Double homozygous mice are healthy and have a normal phenotype.Ai9 is a Cre reporter tool strain designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. This strain is congenic on the C57BL/6J genetic background.The Ai9 allele is very similar in design to the Ai14 allele (Stock No. 007914) - differing only in the presence (Ai9) or absence (Ai14) of an att site-flanked neo selection cassette at the 3' end of the targeted allele.Importantly, both Ai9 and Ai14 may exhibit low levels of tdTomato expression prior to exposure to Cre recombinase - but the tdTomato expression levels after Cre recombination are greater than those baseline levels. As such, it is recommended that researchers include Cre-negative controls to establish the baseline tdTomato levels in their experiments. See Detailed Description for additional details.Csf1rfl/fl floxed mutant mice possess loxP sites flanking exon 5 of the colony stimulating factor 1 receptor (Csf1r) gene. Csf1r encodes Cd115 which acts as the receptor for colony stimulating factor 1, a cytokine which controls the production, differentiation, and function of macrophages. Expressed in macrophages, expression is also seen in oocytes, osteoclasts, trophoblasts, CNS microglia, and some myoblasts. Mice that are homozygous for this allele are viable and fertile. When these mutant mice are bred to mice that express Cre recombinase, resulting offspring will have exon 5 and the neo cassette deleted in cre-expressing tissues.|Mice that are heterozygous for both mutant genes are normal and healthy.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Oct-2025||0.0|0.0|Unknown|||Possibly| 10529.0|Ai9(RCL-tdT) x Csf1rflox|B6.Cg-Gt(ROSA)26SorJ Csf1r/J||Dominant|colony stimulating factor 1 receptor|Csf1r||CD115|MGI:1339758|colony stimulating factor 1 receptor; targeted mutation 1.2, Jeffrey W Pollard|Csf1r|MGI:5780867|18|ENSMUSG00000024621||||||||||||||||||||||||||||This mouse line is a double mutant mouse line generated by crossing two mouse lines purchased from Jax labs : Ai9 (RRID:IMSR_JAX:007909) and CSF1R flox (RRID:IMSR_JAX:021212). The sperm was obtained from mice homozygous for CSF1Rfl (fl/fl, confirmed by PCR) and either homozygous or heterozygous for Ai9. Double homozygous mice are healthy and have a normal phenotype.Ai9 is a Cre reporter tool strain designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. This strain is congenic on the C57BL/6J genetic background.The Ai9 allele is very similar in design to the Ai14 allele (Stock No. 007914) - differing only in the presence (Ai9) or absence (Ai14) of an att site-flanked neo selection cassette at the 3' end of the targeted allele.Importantly, both Ai9 and Ai14 may exhibit low levels of tdTomato expression prior to exposure to Cre recombinase - but the tdTomato expression levels after Cre recombination are greater than those baseline levels. As such, it is recommended that researchers include Cre-negative controls to establish the baseline tdTomato levels in their experiments. See Detailed Description for additional details.Csf1rfl/fl floxed mutant mice possess loxP sites flanking exon 5 of the colony stimulating factor 1 receptor (Csf1r) gene. Csf1r encodes Cd115 which acts as the receptor for colony stimulating factor 1, a cytokine which controls the production, differentiation, and function of macrophages. Expressed in macrophages, expression is also seen in oocytes, osteoclasts, trophoblasts, CNS microglia, and some myoblasts. Mice that are homozygous for this allele are viable and fertile. When these mutant mice are bred to mice that express Cre recombinase, resulting offspring will have exon 5 and the neo cassette deleted in cre-expressing tissues.|Mice that are heterozygous for both mutant genes are normal and healthy.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Oct-2025||||Unknown|||Possibly| 5052.0|NOD.B6 R3 N12|NOD.B6(D1Mit48-D1Mit92)N12||Recessive||||||||||||||||||||||||||||||||||||||The incidence of diabetes in female mice is 78% after 43-weeks, which is higher than the incidence of diabetes in female NOD/Lt mice in our facility (50-60% at 43-weeks of age). The incidence of diabetes in male mice is 27% after 43 weeks of age, which is significantly higher than the incidence of diabetes in male NOD/Lt mice in host facility (5-10% at 43-weeks of age).|The incidence of diabetes has not been tested in heterozygotes of this mouse strain.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|13|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 6898.0|APN212|C57Bl/6N-Crisp2/MarpApb||Recessive|cysteine-rich secretory protein 2|Crisp2|Unknown|CRISP-2, GAPDL5, Tpx1, Tpx-1 |MGI:98815 |cysteine-rich secretory protein 2; targeted mutation 1a, Mouse Biology Program, UCDavis|Crisp2 |MGI:4888856|17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|17-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 860.0|B10.A(5R)|B10.A-H2(R5)/AnuApb|B10.A-H2(R5)/AnuApb|Recessive|histocompatibility-2, MHC|H2|Normal|H-2|MGI:95894|i5 variant|H2|MGI:3628763|17||||||||||||||||No|||||||||||||||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|24-May-2007|Cryopreserved sperm|100.0|0.0|Unknown||histocompatibility, H2, MHC, T cell, lymphocyte|Yes| 10384.0|Itk T503S |C57BL6/NCrl-ItkAnu/Apb||Semi-dominant|IL2 inducible T cell kinase|Itk|||MGI:96621|Itk |||11|ENSMUSG00000020395||||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Nov-2023|Cryopreserved sperm|31.0|0.0|Unknown|||No| 7325.0||SJL-Tfrc/Apb||Dominant|transferrin receptor|Tfrc||2610028K12Rik, CD71, E430033M20Rik, Mtvr1, Mtvr-1, p90, TfR1, Trfr|MGI:98822||Tfrc||16|ENSMUSG00000022797|ENSMUST00000023486|Tfrc-001|218|358|T to G|ENSMUSE00000130494|3|73|Leucine to Arginine|||||TGGAAGACTCTGCTTTGCAGCTATTGCACTAGTCATTTTCTTCTTGATTGGATTCATGAGT||||||||||||||Severe microcytosis associated with erythrocytosis and normochromia. The homozygous are not viable.|Microcytosis associated with erythrocytosis and normochromia|SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|23-Apr-2013|Cryopreserved sperm|50.0|0.0|Unknown||microcytosis, ENU, transferrin|Yes| 7115.0||ENU11B6053b||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Increased susceptibility to infection with ECTV|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|29-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||ENU, viral infection|Possibly| 7116.0||ENU11B6070b||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Increased susceptibility to infection with Ectromelia virus||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|29-Oct-2012|Cryopreserved sperm|46.0|0.0|Unknown||ENU, viral infection|Possibly| 7117.0||ENU11B6074c||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Increased susceptibility to infection with Ectromelia virus|Unknown|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|29-Oct-2012|Cryopreserved sperm|30.0|0.0|Unknown||ENU, viral infection|Possibly| 7107.0|Nude|B6-Foxn1/AnuApb||Recessive|forkhead box N1|Foxn1|Unknown|D11Bhm185e, Hfh11, whn|MGI:102949|nude|Foxn1|MGI:1856108|11||||||||||||||||Yes|||||||||||||Postnatal lethality:some mice die within 1 week of birth55% mortality within 2 weeksPremature death:100% mortality by 25 weeksDecreased body size and weight.Postnatal growth retardation.Abnormal T cell differentiation.Athymia.Abnormal cell-mediated immunity.Abnormal liver morphology:liver lobes were atrophied and covered with red scarsvariable degrees of severity, typically increasing with age at time of death.Small ovaryCoiled sperm flagellum: many sperm had coiled tailsAbnormal estrous cycle: many females exhibited continuous dioestrus and metaoestrus phasesFemale infertility: severely reduced fertilityReduced male fertility.Asthenozoospermia.Nude: sparse hair growth around 5 weeks of agein some mice, cephalo-caudal migration of an irregular band of short sparse hairThin skin:reduction in skin thickness at 3 weeks of age, corresponding to the catagen stage of normal skinAbsent vibrissae: absent at birthShort and wavy vibrissae: older mice show repeated growth and loss of short and wavy vibrissae.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Oct-2012|Cryopreserved sperm|18.0|0.0|Unknown||hair loss, T cell, thymus, body size / mass, growth retardation, alopecia, keratin|Yes| 7327.0|B6.SJL|B6.SJL-Ptprc Pep3/BoyJAnuApb||Recessive|||||||||||||||||||||||||||||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|Unknown|Normal||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Apr-2013|Cryopreserved sperm|10.0|0.0|Unknown|||No| 7327.0|B6.SJL|B6.SJL-Ptprc Pep3/BoyJAnuApb||Recessive|||||||||||||||||||||||||||||peptidase C|Pepc||Dip-1, Pep3, Pep-3|MGI:97541|peptidase C; b variant|Pepc|MGI:4819861|1|Normal||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Apr-2013|Cryopreserved sperm|||Unknown|||No| 7533.0|ENU24:014:Trps1|C57BL/6NCrlAnu-Trps1/AnuApb|C57BL/6NCrlAnu-Trps1/AnuApb|Recessive|trichorhinophalangeal syndrome I (human)|Trps1||D15Ertd586e|MGI:1927616|trichorhinophalangeal syndrome I (human); mutation 1, The Australian National University|Trps1|MGI:5563401|15|ENSMUSG00000038679|ENSMUST00000165201|Trps1-001|3436|3526|A to T|ENSMUSE00000478584|6|1146|Threonine to Serine|||||ATCCTTGCCAAAACTATGTGCCTTATCCCACCTTCAATCTGCCTCCTCATTTCTCAGCTGT||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G2N1||No|06-Dec-2013|Cryopreserved sperm|17.0|0.0|Unknown||ENU|Yes| 10351.0||C57Bl/6-TFF2(CreERT2)-Rosa26-delta(D3muc)/Apb||Semi-dominant|trefoil factor 2 (spasmolytic protein 1)|Tff2 |||MGI:1306805 |TFF2|||17|ENSMUSG00000024028 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Jul-2023|Cryopreserved sperm|33.0|0.0|Unknown|||Possibly| 7551.0|ENU25:010:RAP1GAP2:B6|C57BL/6NCrlAnu-Rap1gap2/AnuApb|C57BL/6NCrlAnu-Rap1gap2/AnuApb|Recessive|RAP1 GTPase activating protein 2|Rap1gap2|Unknown|Garnl4, LOC380710, mKIAA1039|MGI:3028623|RAP1 GTPase activating protein 2; mutation 1, The Australian National University|Rap1gap2|MGI:5563432|11|ENSMUSG00000038807|ENSMUST00000102521|Rap1gap2-001|830|1071|T to A|ENSMUSE00000578461|12|277|Aspartic acid to Valine|||||TTTCAAGGAGTTTTTGGATCTCCTGGGAGACACCATCACACTGCAGGATTTCAAAGGTTTC||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||G4||No|19-Dec-2013|Cryopreserved sperm|46.0|0.0|Unknown||ENU|Yes| 7114.0||ENU10B6043a||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Increased susceptibility to infection with Ectromelia.|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|29-Oct-2012|Cryopreserved sperm|47.0|0.0|Unknown||ENU, viral infection|Possibly| 7110.0|ROS-iePLA|ROS-iePLA||Dominant||||||||||||||||||||||||||ROS-iePLA||||||||||||Mouse express GFP|Mouse express GFP|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|19-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||green fluorescent protein|Yes| 7120.0|ANU:ENU22:Nr4a1:B6|C57BL/6NCrlAnu-Nr4a1/AnuApb||Recessive|nuclear receptor subfamily 4, group A, member 1|Nr4a1||Gfrp, GFRP1, Hbr1, Hbr-1, Hmr, N10, NGFI-B, NP10, Nur77, TIS1, TR3|MGI:1352454|nuclear receptor subfamily 4, group A, member 1; mutation 1, The Australian National University|Nr4a1|MGI:5570322|15|ENSMUSG00000023034 |ENSMUST00000023779|Nr4a1-201|815|943|T to C|ENSMUSE00000132956|2|272|Valine to Alanine|||||TTCAGGTGGCAGCGAGGGCCGCTGTGCAGTCTGTGGTGACAATGCTTCGTGTCAGCACTAT||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G3||No|30-Oct-2012|Cryopreserved sperm|26.0|0.0|Unknown||ENU|Yes| 5515.0|ENU15NIH36a|ENU15NIH:036a||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||High % of NKT cells.|Higher % of NKT cells then WT mice.|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||5|Sib x sib|No|26-May-2011|Cryopreserved sperm|70.0|0.0|Unknown||ENU|No| 10373.0||ENU43:040::B6||Semi-dominant|Unknown||||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-Nov-2023|Cryopreserved sperm|153.0|0.0|Unknown|||No| 7123.0|ENU26:G2|ANU:ENU26:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6Crl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|01-Nov-2012|Cryopreserved sperm|1539.0|78.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7330.0|ENU12NIH2b|ENU12NIH2b||Recessive|unknown|unknown|||||||Unknown|||||||||||||||||||||||||||||Increased IgE in plamsa|unknown|C57BL/6JAnu|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||G13||No|03-May-2013|Cryopreserved sperm|30.0|0.0|Unknown||IgE, Allergy, B cell, T cell, ENU|Possibly| 7329.0|ENU19 WT:029:a:B6:F3|C57BL/6JAnu-Gucd1/Anu||Recessive|guanylyl cyclase domain containing 1|Gucd1|Unknown|1110038D17Rik|MGI:1916028|mutation 1, The Australian National University|Gucd1||10|ENSMUSG00000033416|||536|721|G to C|ENSMUSE00000226356|5|179|Arginine to Proline|||||TACTCCCAGTGGCCACCGCTGCTTCTGCCGCACCCCCGACTACCAAGGCCACTTCATCGTC|Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-May-2013|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 867.0|B6.Fas-/-|B6;129P2-Fas/Apb|B6;129P2-Fas/Apb|Recessive|Fas (TNF receptor superfamily member)|Fas|Nil|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|targeted mutation 1, Osaka University Medical School|Fas|MGI:1861923|19||||||||||||||||No|||||||||||||Premature death: 50% dead at about 5 months of ageAbnormal hepatocyte morphology: hepatocyte nuclear areas are variable and larger.Liver hyperplasia: * significantly heavier at 12 weeks of age and becomes 50-60% heavier by 16 weeks of age.* number of hepatocytes per each liver lobe is increasedimmune system.Increased leukocyte cell number: 20x higher than in controls, attributable to increased lymphocyte numbers.Increased lymphocyte cell number:* lymphocytosis; progressively accumulate abnromal T cells Thy1<+> B220<+> CD4<-> CD8<->.Increased B cell number: increase in the number of normal B cells.Abnormal T cell clonal deletion:* peripheral clonal deletion of mature T cells against a bacterial superantigen is impaired.Abnormal lymph organ size.Enlarged spleen: spleen becomes progressively larger.Enlarged lymph nodes: lymph nodes become progressively larger.Lymphoid hyperplasia.Increased IgG level: 10-100x higher serum levels of IgG1, IgG2a, IgG2b, and IgG3 at 16 weeks of age.Increased IgG1 level.Increased IgG2a level.Increased IgG2b level.Increased IgG3 level.Increased autoantibody level:* 50-500x higher levels of dsDNA and ssDNA autoantibodies at 16 weeks of age.Increased anti-double stranded DNA antibody level.Increased anti-single stranded DNA antibody level.Increased susceptibility to parasitic infection:* decreased survival after infection with Trypanosoma cruzi even though were able to clear parasites from blood and affected organs.Hypersensitivity:* occasional infiltration of lymphocytes into tissues such as the lungs and liver.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-May-2007|Cryopreserved sperm|139.0|0.0|Yes|Autoimmune Lymphoproliferative Syndrome; ALPS|autoimmunity, hepatocyte, lymphocyte, T cell, B cell|Yes| 7122.0|ENU26:G1|ANU:ENU26:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|01-Nov-2012|Cryopreserved sperm|467.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7178.0|C57BLKaLwRij|C57BL/KaLwRij/AnuApb||Recessive||||||||||||||||||||||||||||||||||||||May have reduced litter size.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Nov-2012|Cryopreserved sperm|66.0|273.0|Yes|Multiple Myeloma|Multiple Myeloma, Samsn1, Tnfrsf22, Tnfrsf23|Yes| 7693.0|Tpbpa-Cre|C57BL/6-Tg(Tpbpa-cre-EGFP)5Jcc||Dominant||||||||||||||||||||||||||transgene insertion 5, James C Cross|trophoblast specific protein alpha|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|26-May-2014|Cryopreserved sperm|50.0|0.0|Unknown||Cre recombinase, trophoblast|Possibly| 7594.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|8|||No|18-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7694.0|ENU30:G3|ANU:ENU30:G3||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|27-May-2014|Cryopreserved sperm|242.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7332.0|bm1|B6.C-H2-K/ByApb||Dominant|histocompatibility 2, K region|H2-K|||MGI:3040519|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17||||||||||||||||||||||||||||17|Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Unknown|Unknown|No|Excellent|||bm1 x bm1|Yes|09-May-2013|Cryopreserved sperm|50.0|0.0|Unknown||H-2Kbm1, cross-presentation, antigen presentation|Possibly| 1545.0|C57BL/6.gZB-/- OT-1|C57BL/6-Gzmb Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme B|Gzmb|Unknown|CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|20.0|0.0|Unknown||Fas, Natural Killer Cell, cytotoxic T cell|Yes| 2328.0|C57BL6.gZAB-/-OT-1 ; Shastri|B6.129S2-Gzmb Gzma Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2007|Cryopreserved sperm|50.0|0.0|No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|No| 2328.0|C57BL6.gZAB-/-OT-1 ; Shastri|B6.129S2-Gzmb Gzma Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme B|Gzmb|Nil|CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2007|Cryopreserved sperm|||No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|No| 7204.0|AR2.3-tg|B6(Cg)-Tg(Col1a1*2.3-Ar)/Apb||Dominant||||||||||||||||||||||||||AR2.3-tg|2.3kb fragment of the rat type 1 alpha 1 collagen gene|||||||||||Low bone turnover phenotype with compromised bone quality and strength.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>10|||No|07-Nov-2012|Cryopreserved sperm|50.0|0.0|No||receptor, osteogenesis, osteoblast, androgen|Possibly| 7205.0|AR3.6-tg|B6(Cg)-Tg(Col1a1*3.6-Ar)/Apb||Dominant||||||||||||||||||||||||||AR3.6-tg|3.6kb fragment of the type 1 alpha 1 collagen gene|||||||||||Low bone turnover phenotype with compromised bone quality and strength.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>10|||No|07-Nov-2012|Cryopreserved sperm|50.0|0.0|No||receptor, androgen, osteoblast|Possibly| 7571.0|37L1ConR|C57BL/6N-A Gpr37L1/Apb||Dominant|G protein-coupled receptor 37-like 1|Gpr37l1|Unknown|CAG-18, D0Kist8|MGI:1928503|G protein-coupled receptor 37-like 1; targeted mutation 1a, Wellcome Trust Sanger Institute|Gpr37l1|MGI:4441736|1|||||||||||||||||||||||||||||Unknown. Predicted loss of expression mutant.|Unknown. Predicted loss of expression mutant.|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|Pure background||het x het|No|20-Jan-2014|Cryopreserved sperm|47.0|0.0|No|||Possibly| 7571.0|37L1ConR|C57BL/6N-A Gpr37L1/Apb||Dominant|nonagouti|a|||MGI:87853|nonagouti; targeted mutation 1, Allan Bradley|A|MGI:3842513|2|||||||||||||||||||||||||||||Unknown. Predicted loss of expression mutant.|Unknown. Predicted loss of expression mutant.|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|Pure background||het x het|No|20-Jan-2014|Cryopreserved sperm|||No|||Possibly| 7072.0|ABCA1ABCG1 Betacell KO|Ins2Cre ABCA1fl/flABCG1fl/fl||Recessive|ABCA1|ABCA1|||||||9|||||||||||||||||Ins2Cre|Rat insulin promoter|||||||||||Pancreatic beta islet cells do not express ABCA1 and ABCG1. Impaired glucose tolerance|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|03-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown||ABCA1, ABCG1, B cell, diabetes, cholesterol|Possibly| 7072.0|ABCA1ABCG1 Betacell KO|Ins2Cre ABCA1fl/flABCG1fl/fl||Recessive|ABCG1|ABCG1|||||||17|||||||||||||||||||||||||||||Pancreatic beta islet cells do not express ABCA1 and ABCG1. Impaired glucose tolerance|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|03-Sep-2012|Cryopreserved sperm|||Unknown||ABCA1, ABCG1, B cell, diabetes, cholesterol|Possibly| 7203.0|Vdr flox|B6-Vdr/Apb||Dominant|vitamin D (1,25-dihydroxyvitamin D3) receptor|Vdr|Normal|Nr1i1|MGI:103076|vitamin D (1,25-dihydroxyvitamin D3) receptor; targeted mutation 1, Pierre Chambon|Vdr|MGI:3663379|15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>10|||No|07-Nov-2012|Cryopreserved sperm|46.0|0.0|No||rickets, hyperparathyroidism, calcium, 1,25(OH)(2) vitamin D|Possibly| 7211.0||SJL-Ank1/MriApb|SJL-Ank1|Dominant|ankyrin 1, erythroid|Ank1|Reduced|Ank-1, pale|MGI:88024|ankyrin 1, erythroid; MRI23420|Ank1|MGI:5438699|8|ENSMUSG00000031543|ENSMUST00000121802|Ank1-004||||||||||||||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility, splenomegaly and survival advantage to Plasmodium chabaudi |SJL|No|No|Yes|No|No|Yes|No|Good||||No|14-Nov-2012|Cryopreserved sperm|50.0|0.0|Yes|Hereditary spherocytosis|Hereditary spherocytosis, Malaria resistance, microcytosis, ENU|Yes| 7027.0|CAG-H2B-GFP|C57BL/6N-Tg(CAG-H2/GFP)/MarpApb||Recessive||||||||||||||||||||||||||histocompatibility-2|chicken beta actin (CAG)|||||||||||Expresses H2B-GFP from CAG promoter|Expresses H2B-GFP from CAG promoter|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|24-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7212.0|APN329|C57Bl/6NSrsf3/Marp||Recessive|serine/arginine-rich splicing factor 3|Srsf3|Unknown|Sfrs3, X16|MGI:98285|serine/arginine-rich splicing factor 3; targeted mutation 1a, Mouse Biology Program, UCDavis|Srsf3tm1a(KOMP)Mbp|MGI:4462527|17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Nov-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7101.0|Cd8b KO|B6.129S-Cd8b/NIHAnuApb||Recessive|CD8 antigen, beta chain 1|Cd8b1|Nil|Ly-3, Ly-C, Lyt-3|MGI:88347|CD8 antigen, beta chain 1; targeted mutation 1, Dan R Littman|Cd8b1|MGI:3654103|6|||||||||||||||||||||||||||||Abnormal enzyme/coenzyme activity: thymocytes display 6-fold less CD8-associated Lck activity vs wild-type.Decreased thymocyte number: mice have 5-fold fewer CD8-lineage thymocytes compared to wild-type; there is a lack of mature CD8-lineage T cells.Decreased CD8-positive T cell number: * there is a lack of mature CD8-lineage T cells * number of mature single positive CD8+ thymocytes is reduced 5-fold vs wild-type * numbers in peripheral lymph nodes are reduced 5-fold also.Abnormal T cell subpopulation ratio: CD8 to CD4 ratio is 6.6 fold lower than in wild-type.Abnormal cytotoxic T cell physiology: splenocytes from mutants show a normal cytotoxic T lymphocyte response comparable to heterozygous mice to allogeneic stimuli even though mutants have only 20% of normal numbers of CD8+ T cells.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Oct-2012|Cryopreserved sperm|52.0|0.0|Unknown||T cell, MHC, TCR, CD8, selection|Possibly| 7094.0|RNAi-14|C57Bl/6J-HDAC3/MarpApb||X-linked|histone deacetylase 3|Hdac3|Unknown||MGI:1343091||||X|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|27-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6931.0|APN 256|C57BL/6N-Sema3d/Marp||Recessive| sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D|Sema3d ||4631426B19Rik |MGI:1860118 |sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D; targeted mutation 1a, Wellcome Trust Sanger Institute |Sema3dtm1a(KOMP)Wtsi|MGI:4820051|5|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7025.0|APN239|C57BL/6N-A Adarb2/Marp||Recessive|adenosine deaminase, RNA-specific, B2|Adarb2 |Unknown|Adar3, RED2 |MGI:2151118 |adenosine deaminase, RNA-specific, B2; targeted mutation 1a, Mouse Biology Program, UCDavis |Adarb2 |MGI:4944293|13|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|20-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 7037.0|zeta-SV129 390|129Sv-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST405390, Lexicon Genetics|Ywhaz||15|||||||||||||||||||||||||||||Infertile, reduced survival of KO pups at 21 days|None|129Sv/B6|Yes|No|Yes|Yes|No|Yes|Yes|Good|N/A||het x het|No|06-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown||14-3-3, signal transduction|Possibly| 7695.0|Dynll-loxP|C57BL/6-Dynll1/Stv||Dominant|dynein light chain LC8-type 1|Dynll1|Normal|8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|dynein light chain LC8-type 1; targeted mutation 1.1, Jorg Heierhorst|Dynll1|MGI:5463937|5||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|03-Jun-2014|Cryopreserved sperm|99.0|0.0|Unknown||Dynll-1, ASCIZ|Possibly| 4722.0|Joey-RSA|C57BL/6-Rbm5/MarpApb|C57BL/6-Rbm5/MarpApb|Recessive|RNA binding motif protein 5|Rbm5|Unknown||MGI:1933204|RNA binding motif protein 5; sda|Rbm5|MGI:5563424|9|ENSMUSG00000032580|ENSMUST00000035199|Rbm5-201|788|940|G to C|ENSMUSE00000251397|10|263|Arginine to Proline|||||CTATGCTTCCTTAGCTGTCAATAACATTCGCCTCATAAAAGACAAACAGACACAACAGAAC|Yes|||||||||||||Round spermatid arrest.Spermatid differentiation arrest, germ cell sloughing and apoptosis, which ultimately led to azoospermia (no sperm in the ejaculate) and male sterility.||C57BL/6|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|09-Apr-2009|Cryopreserved sperm|70.0|0.0|Unknown||infertility, sperm, arrest, ENU|Yes| 4808.0|River|ENU8BAT:038||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Male infertility. Mutant found in HEL:TCR ENU library.HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|30.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|Possibly| 4808.0|River|ENU8BAT:038||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Male infertility. Mutant found in HEL:TCR ENU library.HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|||Yes|Male Infertility|ENU, fertility, sperm|Possibly| 7024.0|APN97|C57BL/6N-A Ubr5/Marp||Recessive|ubiquitin protein ligase E3 component n-recognin 5|Ubr5 |Unknown|4432411E13Rik, Edd, Edd1, mKIAA0896 |MGI:1918040 |ubiquitin protein ligase E3 component n-recognin 5; targeted mutation 1a, Wellcome Trust Sanger Institute |Ubr5 |MGI:4455996|15|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 7029.0|APN257|C57BL/6N-Ift140/Marp||Recessive|intraflagellar transport 140 homolog (Chlamydomonas)|Ift140 |Unknown|mKIAA0590, Tce5, Wdtc2 |MGI:2146906 |intraflagellar transport 140 homolog (Chlamydomonas); targeted mutation 1a, Wellcome Trust Sanger Institute |Ift140tm1a(KOMP)Wtsi|MGI:4363217|17||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N |Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Possibly| 7059.0|B6.BlGpA|C57BL/6-Tg(ICAM2-FUT1, NAGAT)/StV||Dominant||||||||||||||||||||||||||human H transferase and human A transferase|human ICAM2||||||||||||Expression of human blood group A on endothelial cells and red blood cells|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|24-Aug-2012|Cryopreserved sperm|100.0|0.0|Unknown||blood group|Possibly| 5175.0||ENU15China:001b||Recessive|Unknown|Unknown|Unknown||||||Unknown|||||||||||||||||||||||||||||Increased Germinal Centre B cells in unimmunised mice|Unknown|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Jul-2010|Cryopreserved sperm|10.0|0.0|Unknown||B cell, germinal centre, ENU|Possibly| 1504.0|B6.IL-18-/-|B6.129P2-Il18/AnuApb|B6.129P2-Il18/AnuApb|Recessive|interleukin 18|Il18|Nil|Igif, Il-18|MGI:107936|targeted mutation 1, Shizuo Akira|Il18|MGI:2136769|9||||||||||||||||No|||||||||||||In Propionibacterium acnes (P. acnes)-primed IL-18-deficient mice, LPS-induced IFNgamma production was markedly reduced, despite normal IL-12 induction. Natural killer cell activity was significantly impaired. Th1 cell response after injection of P. acnes or Mycobacterium bovis (bacillus Calmette-Guerin [BCG]) was significantly reduced.||C57BL/6 x 129P2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|04-Jul-2007|Cryopreserved sperm|110.0|0.0|Unknown||T cell, interferon, Natural Killer, IL-12, IL12|Yes| 4457.0|Singh|C57BL/6-Gzmb Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|granzyme B|Gzmb|Unknown|CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Feb-2009|Cryopreserved sperm|20.0|0.0|Unknown||T cell, Natural Killer, cytotoxicity, receptor, ovalbumin|Yes| 7078.0|APN245|C57Bl/6NTac-Gpbar1/Marp||Recessive|G protein-coupled bile acid receptor 1|Gpbar1|Unknown|BG37, GPR131, M-BAR, TGR5 |MGI:2653863|G protein-coupled bile acid receptor 1; targeted mutation 1, Velocigene|Gpbar1|MGI:4399435|1||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7108.0|APN197|C57BL/6N(Ag)-Scmh1Mu||Recessive|sex comb on midleg homolog 1|Scmh1 ||Scml3 |MGI:1352762 |sex comb on midleg homolog 1; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Scmh1tm1a(EUCOMM)Hmgu|MGI:4456695|4|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|17-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 3384.0|Histamine receptor type 1 -/-|B6.129P2-Hrh1|B6.129P2-Hrh1|Recessive|histamine receptor H1|Hrh1|Nil|Bphs|MGI:107619|targeted mutation 1, Takeshi Watanabe|Hrh1|MGI:2182945|6||||||||||||||||Yes|||||||||||||Homozygous null mutants show decrease in exploratory behavior, diurnal activity, aggression, anxiety, serotonin release, respiratory reaction to temperature and leptin response. Natural variants affect B. pertussis induced vasoactive amine sensitization. Increased responses to papain sensitisation.Increased brown adipose tissue amount:* the amount of brown adipose tissue at 48 weeks of age is increased relative to in wild-type mice.* insulin levels during a 4 week feeding schedule are lower than in mice fed ad libitum.* however, the levels of brown adipose tissue at 12 weeks of age is normal.Increased white adipose tissue amount: at 28 weeks of age, white adipose tissue is increased by 23%, 48% and 40% in the epididymmal, mesenteric and retroperitoneal fat pads, respectively, compared to wild-type mice.Decreased adipose tissue amount: unlike in wild-type mice, intraperitoneal administration of the histamine agonist methyl(2[2-pyridyl]ethyl)amine dyhydrochloride (1 ug/g for 7 days) results in decreased in adiposity.Increased fat cell size:* adipocytes in the epididymal white adipose tissue are larger than in wild-type mice at 48 weeks of age.* however, adipocyte size at 12 weeks of age is normal.Decreased circulating insulin level:* at 48 weeks of age, serum insulin levels are increased relative to in wild-type mice.* however, at 12 weeks of age serum insulin levels are normal.Increased circulating leptin level:* at 48 weeks of age, leptin levels are increased by 66% compared to in wild-type mice.* however, at 12 weeks of age leptin levels are normalIncreased circulating free fatty acid level:* at 48 weeks of age, free fatty acid levels are increased relative to in wild-type mice.* however, at 12 weeks of age free fatty acid levels are normal.Increased triglyceride level: mice exhibit 45% and 20% more triglycerides in the liver and skeletal muscle, respectively, compared to wild-type mice.Abnormal response/metabolism to endogenous compounds: following intracerebroventricular administration of 0.5 ug leptin or intraperitoneal injection of 50 ug of leptin, mice exhibit a smaller decrease in food consumption and body mass relative to wild-type.Decreased body weight:* during 4 week on a feeding schedule, mice fail to gain weight as do wild-type mice despite equivalent food consumption.* unlike in wild-type mice, intraperitoneal administration of the histamine agonist methyl(2[2-pyridyl]ethyl)amine dyhydrochloride (1 ug/g for 7 days) results in decreased body mass.* however, intracerebroventricular administration of methyl(2[2-pyridyl]ethyl)amine dyhydrochloride has no effect on mice.Increased body weight: after 28 weeks of age mice exhibit increased body mass relative to wild-type mice.Increased IgG level: following ovalbumin challenge, IgG1, IgG2a and IgG2b levels are increased relative to similarly treated wild-type mice.Increased IgM level: following ovalbumin challenge, IgM levels are increased relative to similarly treated wild-type mice.Decreased interferon-gamma secretion: antigen stimulation of splenocytes results in the production of less interferon-gamma compared to in similarly treated wild-type mice.Decreased interleukin-13 secretion: antigen stimulation of splenocytes results in the production of less IL-13 compared to in similarly treated wild-type mice.Decreased interleukin-5 secretion: antigen stimulation of splenocytes results in the production of less IL-5 compared to in similarly treated wild-type mice.Decreased inflammatory response:* following challenge with ovalbumin, mice fail to develop lung inflammation as do wild-type mice with fewer eosinophils and lymphocytes detected in the bronchoalveolar lavage.* however, mice exhibit normal B cell immune responses and inhalation of IL-4 or IL-13 induces lung inflammation.Abnormal behavior:* during passive avoidance testing, mice display more frequent urination and defecation and decreased movement compared to wild-type mice.* however, passive avoidance behavior is normal.Abnormal circadian rhythm:* mice exhibit increased locomotor activity during early portions of the light phase and decreased ambulation during the dark phase of a 12 hours light 12 hour dark cycle relative to similarly treated wild-type mice.* the ratio of ambulation during the light phase to total ambulation during 24 hours is increased compared to in wild-type mice.* however, total ambulation during a 24 hours period is normal.Decreased exploration in new environment: despite normal motor coordination, mice exhibit decreased ambulation and time of rearing for the first 30 minutes when placed in a new environment.Decreased vertical activity: mice rear less when placed in a new environment compared to wild-type mice.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Jul-2008|Cryopreserved sperm|150.0|0.0|Unknown||behaviour, aggression, leptin, respiration, serotonin|Yes| 5239.0|Lyn knockout Viable Motheaten mice ; C57.Lyn-/- Me v/+|C57BL/6-Lyn Ptpn6/Apb||Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||B6-Lyn<-/-> Ptpn6 mice develop exaggerated autoimmune disease compared with Lyn<-/-> miceAbnormal mature B cell morphology: mature B cells have about 4-fold lower surface IgM levels.|Double heterozygotes develop autoimmunity with earlier onset than single heterozygote mice|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|20 for Lyn<-/->||B6-Lyn<-/-> Ptpn6 x B6-Lyn<-/-> Ptpn6|No|12-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||B cell, signal transduction, src kinase, phosphorylation, phosphatase, autoimmunity, inflammation|Yes| 5239.0|Lyn knockout Viable Motheaten mice ; C57.Lyn-/- Me v/+|C57BL/6-Lyn Ptpn6/Apb||Recessive|protein tyrosine phosphatase, non-receptor type 6|Ptpn6||hcp, Hcph, Ptp1C, SHP-1, Spin|MGI:96055|protein tyrosine phosphatase, non-receptor type 6; viable motheaten|Ptpn6|MGI:1856074|6||||||||||||||||No|||||||||||||B6-Lyn<-/-> Ptpn6 mice develop exaggerated autoimmune disease compared with Lyn<-/-> miceAbnormal mature B cell morphology: mature B cells have about 4-fold lower surface IgM levels.|Double heterozygotes develop autoimmunity with earlier onset than single heterozygote mice|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|20 for Lyn<-/->||B6-Lyn<-/-> Ptpn6 x B6-Lyn<-/-> Ptpn6|No|12-Oct-2010|Cryopreserved sperm|||Unknown||B cell, signal transduction, src kinase, phosphorylation, phosphatase, autoimmunity, inflammation|Yes| 4853.0|Taily ; ENU8CAT:006|CBA;B6JSfdAnu-Katnb1/AnuApb||Recessive|katanin p80 (WD40-containing) subunit B 1|Katnb1|Unknown|KAT|MGI:1921437|katanin p80 (WD40-containing) subunit B 1; taily|Katnb1|MGI:5428740|8|ENSMUSG00000031787|ENSMUST00000034239|Katnb1-201|700|972|G to T|ENSMUSE00000212968|9|234|Valine to Phenylalanine|||||TGAGCTGCATTGAAGGGGAGCCCGGGCCCGTCAGGAGTGTCCTCTTCAACCCCGACGGCTG|Yes|||||||||||||Male infertility. Reproductive system phenotype: • number of Sertoli cells, spermatogonia and spermatocytes are similar to controls.Small testis: • testes from 8-12 week old homozygous mice are 18.7% smaller than controls.Oligozoospermia: • epididymes from mutant males contain significantly lower sperm counts.Abnormal sperm flagellum morphology: • flimsy or absent outer dense fibers.Abnormal sperm axoneme morphology:• missing central microtubules and hemi-axenomes are present.Globozoospermia: • abnormally shaped spermatid heads.• all sperm in the cauda epididymis have abnormally shaped heads.Abnormal spermatid morphology:• ~30% fewer spermatids (round and elongating) compared to controls.Abnormal manchette morphology:• mutant spermatids exhibit constricted perinuclear rings, nuclear distortion and abnormally long microtubules extending in to the distal cytoplasm.• although the manchettes eventually resolved, the removal of manchettes was delayed at step 13.Abnormal male meiosis: • abnormal male meiotic cells appear at metaphase-anaphase; many cells are stalled in late anaphase in mutant males.• reduction in spermatid number is due to a decrease in the number of cells exiting meiosis.• apoptotic cells are present in the stage XII and stage I tubules where final events of meiosis occur.• telophase cells with prominent midbody microtubules are seen in testes from mutant male mice• binucleated haploid spermatids frequently appear.Abnormal meiotic spindle morphology:• metaphase spindles are more densely populated with microtubules and project from the poles at a wider angle than controls pole to pole measurements in metaphase spindles are longer than controls.Increased Sertoli cell phagocytosis: • 36-fold increase in the number of spermatozoa being phagocytosed by Sertoli cells in stages IX-X1 tubules.Asthenozoospermia:• all sperm in the cauda epididymis display compromised motility, with very few capable of forward (progressive) motility.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|175.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|Yes| 4912.0|Wombi ; ENU9CAT:006|B6;CBA(Cg)-Pou1f1/Apb||Recessive|POU domain, class 1, transcription factor 1|Pou1f1|Unknown|GHF-1, Hmp1, Pit-1, Pit1, Pit1-rs1, Snell dwarf|MGI:97588|wombi|Pou1f1||16|ENSMUSG00000004842|ENSMUST00000116588|Pou1f1-202|470|585|T to A|ENSMUSE00000131906|4|156|Leucine to Glutamine|||||ATACACCCAGACAAACGTGGGCGAAGCGCTGGCTGCTGTCCACGGCTCAGAATTCAGTCAA|No|||||||||||||Male infertility. Dwarf, affected mice are smaller than littermates.Mutant found in HEL:TCR ENU library. HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA|Yes|Yes|Yes|Yes|No|Yes|No|Poor|||Het x Het|No|16-Oct-2009|Cryopreserved sperm|210.0|0.0|Yes|Male Infertility|ENU, fertility, sperm, Dwarf|Yes| 5243.0|MMP13KO FVBn|FVB/N-Mmp13/Apb||Recessive|matrix metallopeptidase 13|MMP13|Nil|Clg, collagenase-1, Collagenase-3, interstitial collagenase, MMP-13, Mmp1|MGI:1340026|matrix metallopeptidase 13; targeted mutation 1.1, Zena Werb|Mmp13|MGI:3521938|9||||||||||Unknown to Unknown|||||||||||||||||||Increased width of hypertrophic chondrocyte zone: * the hypertrophic zone is expanded in the tibia and metatarsals, at E17 and 1 week after birth, respectively, however by 12 weeks of age the size of the hypertrophic zone is similar to wild-type. * chondrocytes proliferate and differentiate normally but accumulate in the most terminally differentiated hypertrophic state. * establishment of the primary ossification centers is normal.Abnormal cancellous bone morphology: * the amount of trabecular bone is increased in the tibia and metatarsals by 3 weeks or 1 week of age, respectively, however by 1 year of age the amount of trabecular bone was similar to wild-type. * the organization of the trabecular bone is also irregular.OA was surgically induced in the knees of MMP-13-knockout mice. No difference between wildtype and KO mice for aggrecan loss or cartilage erosion at 4 weeks. here was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks. Cartilaginous osteophytes were larger in knockout mice at 4 weeks, but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints. Authors conclude Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|||No|14-Oct-2010|Cryopreserved sperm|90.0|0.0|Yes|spondyloepimetaphyseal dysplasia|extracellular matrix, collagenase, chondrocyte, osteoblast, growth plate|Possibly| 7071.0|APN209|C57Bl/6N(Ag)-Rabl2/Marp||Recessive|RAB, member of RAS oncogene family-like 2|Rabl2|Unknown|1110031N17Rik, Rabl2a|MGI:1915958 |RAB, member of RAS oncogene family-like 2; targeted mutation 1, Wellcome Trust Sanger Institute |Rabl2/Marp |MGI:4431454|15|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|30-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5254.0|CNTFKO|C57BL/6-Cntf/StvApb||Recessive|ciliary neurotrophic factor|Cntf|Nil||MGI:88439|ciliary neurotrophic factor; targeted mutation 1, Max Planck Institute for Neurobiology|Cntf|MGI:1857773|19||||||||||||||||No|||||||||||||Abnormal microglial cell morphology: atrophic and degenerative changes in spinal motor neurons are accompanied by an increase in the numbers of activated microglial cells.Abnormal motor neuron morphology: at 8 weeks of age, lumbar motor neuron cell bodies are smaller and the nuclei are swollen, resulting in an increase in the ratio between nuclear and cytoplasmic areas of about 40%, however by 14 weeks of age, both cell area and nuclear area are smaller.Decreased motor neuron number: 22% reduction in facial motor neurons at 28 weeks of age but not at 4 weeks of age.Motor neuron degeneration: * with increasing age, spinal motor neurons exhibit progressive atrophy and finally degeneration. * trophy becomes apparent by 8 weeks of age and the first signs of degeneration are seen at 22 weeks of age.Muscle weakness: small but significant reduction in muscle strength at 28 weeks of age, as indicated by forelimb grip strength.Decreased grip strength: small but significant reduction in forelimb grip strength at 28 weeks of age.Abnormal microglial cell morphology: atrophic and degenerative changes in spinal motor neurons are accompanied by an increase in the numbers of activated microglial cells.This knockout results in progressive atrophy and loss of motor neurons in adult mice, functionally this means a small reduction in muscle strength.||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|21-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||Schwann cell, motor neuron, muscle, atrophy, growth factor|No| 4911.0|Per-gAB|C57BL/6-Gzma Gzmb Prf1/AnuApb||Recessive|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|||||||||||||Increased sensitivity to induced morbidity/mortality: West Nile Virus-infected triple homozygotes display prolonged mean survival time (MST) but significantly increased mortality (50%) relative to either wild-type (29%) or Prf1 (18%) mice.Immune system phenotype: triple homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type mice.Increased susceptibility to parasitic infection: decreased clearance and survival after infection with Trypanosoma cruziIncreased susceptibility to viral infection: triple homozygotes display increased susceptibility to West Nile flavivirus (WNV) infection relative to wild-type. Triple mutants show a higher level of infectious virus in brain relative to wild-type or Prf1 mice at the same time point||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2009|Cryopreserved sperm|50.0|0.0|No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 4911.0|Per-gAB|C57BL/6-Gzma Gzmb Prf1/AnuApb||Recessive|granzyme B|Gzmb|Unknown|CCP-1/C11, CCP1, Ctla-1, Ctla1|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||||||||||||||Increased sensitivity to induced morbidity/mortality: West Nile Virus-infected triple homozygotes display prolonged mean survival time (MST) but significantly increased mortality (50%) relative to either wild-type (29%) or Prf1 (18%) mice.Immune system phenotype: triple homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type mice.Increased susceptibility to parasitic infection: decreased clearance and survival after infection with Trypanosoma cruziIncreased susceptibility to viral infection: triple homozygotes display increased susceptibility to West Nile flavivirus (WNV) infection relative to wild-type. Triple mutants show a higher level of infectious virus in brain relative to wild-type or Prf1 mice at the same time point||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2009|Cryopreserved sperm|||No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 4911.0|Per-gAB|C57BL/6-Gzma Gzmb Prf1/AnuApb||Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfp, Prf-1|MGI:97551|targeted mutation 1, Sandoz Pharmaceutical|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||Increased sensitivity to induced morbidity/mortality: West Nile Virus-infected triple homozygotes display prolonged mean survival time (MST) but significantly increased mortality (50%) relative to either wild-type (29%) or Prf1 (18%) mice.Immune system phenotype: triple homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type mice.Increased susceptibility to parasitic infection: decreased clearance and survival after infection with Trypanosoma cruziIncreased susceptibility to viral infection: triple homozygotes display increased susceptibility to West Nile flavivirus (WNV) infection relative to wild-type. Triple mutants show a higher level of infectious virus in brain relative to wild-type or Prf1 mice at the same time point||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2009|Cryopreserved sperm|||No||T cell, Natural Killer Cell, cytotoxicity, receptor, ovalbumin|Yes| 8703.0|ASD752:Ssbp4|C57BL/6NCrlAnu-Ssbp4/Anu||Recessive|single stranded DNA binding protein 4|Ssbp4||1210002E11Rik|MGI:1924150||||8|||||||||||||||||||||||||||||Unknown|unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|16-Apr-2019|Cryopreserved sperm|92.0|0.0|Unknown|||Yes| 8702.0|PDCD2LKO|C57BL/6-Pdcd2l/MkobMarp||Recessive|programmed cell death 2-like|Pdcd2l||6030457N17Rik|MGI:1915329||||7|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6J|No|No|Yes|No|No|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7335.0||SJL/Mrit||Dominant|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility and splenomegaly|SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|14-May-2013|Cryopreserved sperm|70.0|0.0|Yes|hereditary spherocytosis|haematology, red blood cells, hereditary spherocytosis, ENU|Yes| 5269.0|Lyn IL-6 double knockout ; C57.Lyn-/- IL-6-/-|C57BL/6-Lyn IL6/Apb||Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||As compared to Lyn mice genetic deletion of IL-6 on a Lyn-deficient background does not alter B cell development, plasma cell accumulation, or dendritic cell hypermaturation, suggesting that these characteristics are intrinsic to the loss of Lyn. However, hyperactivation of B and T cell compartments, extramedullary hematopoiesis, expansion of the myeloid lineage and autoimmune disease are all ameliorated in Lyn<-/-> IL-6<-/-> mice. Importantly, our studies show that although Lyn<-/-> B cells may be autoreactive, it is the IL-6-dependent inflammatory environment they engender that dictates their disease-causing potential.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|20|||No|25-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||B cell, autoimmune disease, dendritic cell, signal transduction|Yes| 5269.0|Lyn IL-6 double knockout ; C57.Lyn-/- IL-6-/-|C57BL/6-Lyn IL6/Apb||Recessive|interleukin 6|Il6|Nil|Il-6|MGI:96559|interleukin 6; targeted mutation 1, Manfred Kopf|Il6|MGI:1857197|5||||||||||||||||No|||||||||||||As compared to Lyn mice genetic deletion of IL-6 on a Lyn-deficient background does not alter B cell development, plasma cell accumulation, or dendritic cell hypermaturation, suggesting that these characteristics are intrinsic to the loss of Lyn. However, hyperactivation of B and T cell compartments, extramedullary hematopoiesis, expansion of the myeloid lineage and autoimmune disease are all ameliorated in Lyn<-/-> IL-6<-/-> mice. Importantly, our studies show that although Lyn<-/-> B cells may be autoreactive, it is the IL-6-dependent inflammatory environment they engender that dictates their disease-causing potential.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|20|||No|25-Oct-2010|Cryopreserved sperm|||Unknown||B cell, autoimmune disease, dendritic cell, signal transduction|Yes| 5236.0|Viable Motheaten mice ; C57.Me v/+|C57BL/6J-Ptpn6/LudApb||Recessive|protein tyrosine phosphatase, non-receptor type 6|Ptpn6|Unknown|hcp, Hcph, Ptp1C, SHP-1, Spin|MGI:96055|protein tyrosine phosphatase, non-receptor type 6; viable motheaten|Ptpn6|MGI:1856074|6||||||||||||||||Yes|||||||||||||Decreased B cell number: lambda1 and lambda2, 3 B cells are reduced 14- and 4-fold, respectively, in the spleen and 5.9- and 2.2-fold, respectively, in the bone marrow compared to B cell numbers in wild-type mice.Decreased mature B cell number: a result of a rapid expansion of the plasma cell population.Increased plasma cell number: due to a factor in serum of mutant mice that increases cell maturation by three orders of magnitude.Abnormal immunoglobulin level: uncontrolled levelsAbnormal inflammatory response: * resembles rheumatoid arthritis. * immunosuppressant drugs inhibit arthritic symptoms, but non-steroid anti-inflammatory drugs do notRheumatoid arthritis.Chronic inflammation: * reactions in the paws consist mainly of polymorphonuclear and mononuclear cell infiltration in the subcutaneous tissue extending to the periosteum and joint * paws become deformed causing progressive problems walkingInterstitial pneumonia: pneumonitis progression is slower than in Ptpn6 homozygotes but still causes death.Premature death: * mice die at about 9 weeks instead of at 3 weeks as in Ptpn6 homozygotes * death is due to a progressive and fatal autoimmune syndromeAbsent skin pigmentation: at 3-4 days of age mice have focal depigmentation of the skin.Focal hair loss: patchy absence of hair follows focal skin depigmentation giving the coat an uneven or motheaten appearance.Spontaneous skin ulceration: necrotic lesions can develop on paws, tail and ears.Abnormal skin condition.Interstitial pneumonia: pneumonitis progression is slower than in Ptpn6 homozygotes but still causes death.Decreased body size.Homozygous Motheaten viable mice develop early onset systemic autoimmune and inflammatory disease. The lungs of the mice become consolidated with neutrophils and activated chitinase-laden macrophages. The mice do not thrive, are runted and their skin, paws and ears shows signs of inflammatory disease, which is observable at weaning. The mice are usually euthanized before 8 wks of age.|Heterozygous mice develop low level antinuclear antibodies at about 12 months of age.|C57BL/6J|Yes|No|Yes|Yes|No|Yes|No|Unknown|||Het x Het|No|11-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||src kinase, B cell, autoimmunity, neutrophil, inflammation, pigmentation|Possibly| 5292.0|SHIP(Flox47).C57|B6.Cg-Inpp5d/LudApb||Semi-dominant|inositol polyphosphate-5-phosphatase D|Inpp5d|Normal|s-SHIP, SHIP, SHIP-1, SHIP1, Src homology 2 domain-containing inositol-5-phosphatase|MGI:107357|inositol polyphosphate-5-phosphatase D; targeted mutation 1, Jeffrey V Ravetch|Inpp5d|MGI:3715982|1||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|7|||No|29-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||phosphatase, phosphorylation, signal transduction, PI3'K, myeloid cells, apoptosis, recceptor, inflammatory lung disease, hyperplasia|Yes| 5381.0|MF-04 ; EGFP|C57BL/6-Tg(CAG-EGFP)131Osb/LudApb||Dominant||||||||||||||||||||||||||transgene insertion 131, Research Institute for Microbial Diseases, Osaka University|ytomegalovirus immediate early + chicken beta-actin gene + rabbit hemoglobin beta gene|Ubiquitous||||||||||Ubiquitous expression of EGFP.|Ubiquitous expression of EGFP but weaker signal than homozygote.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jan-2011|Cryopreserved sperm|50.0|0.0|Unknown||GFP|Yes| 5337.0|C57.p110d KD/KD ; C57.p110d D910A|C57BL/6-Pik3cd/Apb||Recessive|phosphatidylinositol 3-kinase catalytic delta polypeptide|Pik3cd|Unknown|p110delta|MGI:1098211|phosphatidylinositol 3-kinase catalytic delta polypeptide; targeted mutation 1, Bart Vanhaesebroeck|Pik3cd|MGI:2385595|4||||||||||||||||Yes|||||||||||||Mice have a number of immune system disorders including impaired T and B cell function||C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Unknown|||Female Het x Male Hom|No|09-Dec-2010|Cryopreserved sperm|47.0|0.0|Unknown||T cell, B cell, signal transduction, PI3'K, receptor|Yes| 5510.0|gp130/stat3/MMTVneu|STOCK Il6st Stat3 Tg(MMTVneu)202Mul/LudApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|transgene insertion 202, William Muller|MMTV|||||||||||Unknown|Unknown|C57BL/6, 129, FVB/N mix|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|23-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, kinase, proliferation|Yes| 5510.0|gp130/stat3/MMTVneu|STOCK Il6st Stat3 Tg(MMTVneu)202Mul/LudApb||Dominant|signal transducer and activator of transcription 3|Stat3|Unknown|Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6, 129, FVB/N mix|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|23-May-2011|Cryopreserved sperm|||Unknown||signal transduction, kinase, proliferation|Yes| 5407.0|Stat 3 B6|B6.129P2-Stat3/LudApb||Recessive|Signal transducer and activator of transcription 3|Stat3|Nil|Aprf|MGI:103038|targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11||||||||||||||||Yes|||||||||||||Embryonic lethality before somite formation: * homozygotes develop into the egg cylinder stage until E6.0 but start undergoing rapid degeneration at E6.5 * all homozygotes are completely resorbed by E7.5.Failure to gastrulate: homozygotes die at ~E7.0, the day at which gastrulation initiates.Absent mesoderm: homozygotes show absence of mesoderm formation between E6.5 and E7.5.Decreased embryo size: at E6.0, homozygoys mutant embryos are smaller than wild-type embryos.Abnormal inner cell mass proliferation: in culture, E3.5 mutant blastocysts exhibit a reduced ICM outgrowth relative to wild-type blastocysts.||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|02-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||embryonic lethal, signal transduction, phosphorylation, cytokine, IL6|Yes| 5415.0|APC(580s).C57|C57BL/6-Apc/LudApb||Dominant|adenomatosis polyposis coli|Apc|Reduced|CC1, Min|MGI:88039|adenomatosis polyposis coli; targeted mutation 1, Tetsuo Noda|Apc|MGI:1857966|18||||||||||||||||Yes|||||||||||||Exposure to liver specific carcinogen diethynitrosamine results in higher tumour incidence than het mice including hepatocellular carcinoma.Colorectal adenomas observed when exon 14 was deleted by colorectal infection of an adenovirus exressing Cre recombinase.|Low incidence of hepatocellular carcinoma.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Feb-2011|Cryopreserved sperm|50.0|0.0|Unknown||Familial adenomatous polyposis coli (FAP), colorectal adenomas|Yes| 6765.0|A33:Lgp130YFKQ|CBA;129-Tg(Gpa33-Il6*)6Ern/LudApb||Dominant||||||||||||||||||||||||||transgene insertion 6 Matthias Ernst|glycoprotein A33 (transmembrane)|||||||||||Unknown|Unknwon|CBA/129|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|16-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, dimerization|Yes| 5463.0|ENU16NIH:003b coat phenotype|C57BL/6JAnu-Rab27a/AnuApb|C57BL/6JAnu-Rab27a/AnuApb|Recessive|RAB27A, member RAS oncogene family|Rab27a|Unknown|2210402C08Rik, 2410003M20Rik, 4933437C11Rik |MGI:1861441 |RAB27A, member RAS oncogene family; mutation 1, The Australian National University|Rab27a|MGI:5563433|9|ENSMUSG00000032202|ENSMUST00000034722|Rab27a-201|217|386|T to A|ENSMUSE00000217627|3|72|Tryptophan to Arginine|||||GCCGAGGCCAGAGAATCCACCTGCAGTTATGGGACACGGCGGGGCAGGAGAGGTTTCGTAG|No|||||||||||||Silver coat color|Normal|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|n/a|5|sib x sib|No|09-Mar-2011|Cryopreserved sperm|17.0|0.0|Unknown||Coat, fur, melanocyte, melanin|Yes| 5436.0|Funky|C.Cg-Ndufs4/DrthApb|C.Cg-Ndufs4/Drth|Recessive|NADH dehydrogenase (ubiquinone) Fe-S protein 4|Ndufs4|Reduced|C1-18k|MGI:1343135|funky|Ndufs4|MGI:4942335|13||||||||||||||||Yes|||||||||||||Homozygous mice initially present with fur loss around postnatal day 14, which regrows in the next hair cycle. They show reduced growth and several behavioural abnormalities that appear from postnatal week five, such as tilting of the head, walking in circles and twisting of the body when suspended by the tail. Due to progressively wobbly gait and general deterioration in physical condition, all homozygous mice have to be euthanased around postnatal week eight in compliance with ethical guidelines.|Animals show reduced growth and several behavioural abnormalities that appear from postnatal week five to six, such as a ruffled appearance, tilting of the head, walking in circles and twisting of the body when suspended by the tail. Due to progressively wobbly gait and general deterioration in physical condition, all homozygous mice have to be euthanased around postnatal week nine in compliance with ethical guidelines.|BALB/c|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|11||het X het|No|15-Feb-2011|Cryopreserved sperm|80.0|0.0|Yes|Mitochondrial Disease; Leigh Syndrome|Mitochondria, Oxidative Phosphorylation, Complex I|Possibly| 6903.0|ERT2/Pten/Gp130F; A33(CreERT2)/Pten loxP/Gp130y757F (ME-276)|STOCK Gpa33 Il6st Pten/LudApb||Dominant|glycoprotein A33 (transmembrane)|Gpa33||A33 antigen|MGI:1891703|glycoprotein A33 (transmembrane) targeted mutation 1, Matthias Ernst|Gpa33||1|||||||||||||||||||||||||||||Unknown|Unknown|Mixed 129 and C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|28-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6903.0|ERT2/Pten/Gp130F; A33(CreERT2)/Pten loxP/Gp130y757F (ME-276)|STOCK Gpa33 Il6st Pten/LudApb||Dominant|interleukin 6 signal transducer|Il6st||5133400A03Rik, CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13|||||||||||||||||||||||||||||Unknown|Unknown|Mixed 129 and C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|28-May-2012|Cryopreserved sperm|||Unknown|||Possibly| 6903.0|ERT2/Pten/Gp130F; A33(CreERT2)/Pten loxP/Gp130y757F (ME-276)|STOCK Gpa33 Il6st Pten/LudApb||Dominant|phosphatase and tensin homolog|Pten||2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, TEP1|MGI:109583|phosphatase and tensin homolog; targeted mutation 2, Tak W Mak|Pten|MGI:2182005|19|||||||||||||||||||||||||||||Unknown|Unknown|Mixed 129 and C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|28-May-2012|Cryopreserved sperm|||Unknown|||Possibly| 7054.0|Flp/E2acre|B6.Cg-Tg(ACTFLPe)9205Dym Tg((EIIa-cre)C5379Lmgd/LudApb||Dominant||||||||||||||||||||||||||transgene insertion 9205, Susan Dymecki|human ACTB promoter|spinal cord, heart, gonad, adrenal) as early as embryonic day 10.5||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Aug-2012|Cryopreserved sperm|41.0|0.0|Unknown||Flp, Cre recombinase|Possibly| 7054.0|Flp/E2acre|B6.Cg-Tg(ACTFLPe)9205Dym Tg((EIIa-cre)C5379Lmgd/LudApb||Dominant||||||||||||||||||||||||||transgene insertion C5379, Laboratory of Mammalian Genes and Development, Heiner Westphal|adenovirus EIIa promoter|Expression in nearly all tissues||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Aug-2012|Cryopreserved sperm|||Unknown||Flp, Cre recombinase|Possibly| 5481.0|APC (min) .C57 X C57 |C57BL/6-Apc/LudApb||Dominant|adenomatosis polyposis coli|Apc|Unknown|CC1, Min|MGI:88039|adenomatosis polyposis coli; multiple intestinal neoplasia|Apc|MGI:1856318|18||||||||||||||||Yes|||||||||||||Unknown|Increased colonic adenoma incidence: tubular adenomas in the colon.Increased intestinal adenoma incidence: tubular adenomas in the intestine.|Unknown|No|No|Yes|No|No|Yes|No|Unknown||||No|12-Apr-2011|Cryopreserved sperm|48.0|0.0|Yes|Adenomatous Polyposis of the Colon; APC; OMIM ID: 175100|adenoma, carcinoma, colon, mammary gland|Yes| 5576.0|∆SRI |B6.129T2-Atm/QimrApb||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Reduced|C030026E19RIK|MGI:107202|ataxia telangiectasia mutated homolog (human); targeted mutation 1, Martin F Lavin|Atm|MGI:2181756|9|||||||||||||||||||||||||||||Premature death: 50% mortality by 40 weeks of age Decreased body size: smaller size persists through adulthood Postnatal growth retardation: 20% growth reduction in males and 18% reduction in females from birth to 45 days of age. Increased tumor incidence: mice dying after 40 weeks of age usually have tumors that are not thymic lymphomas Thymic lymphoma: found in all mice dying before 40 weeks, diverse cell types involved, spongy tumors with a high proportion of cells undergoing apoptosis Abnormal immune system cell morphology: occasional increase in thymocyte size. Abnormal T lymphocyte development: lymph node T cells are primarily at early stages of development. Increased double-negative T cell count: occurs at random Abnormal effector T cell morphology/development: randomly observed increases in single positive T cells. Decreased thymocyte number: 10% reduction in thymocytes, 30-50% reduction in thymocytes expressing alpha and beta T cell receptors or CD3. Abnormal immune system organ morphology: enlarged spleen: usually found in mice dying after 40 weeks of age. small spleen: in mice under 40 weeks of age small thymus small lymph nodes Abnormal chromosome morphology: 3 fold increase in radiation induced chromosomal aberrations. Increased cellular sensitivity to ionizing radiation: increased sensitivity of thymocytes and splenocytes to ionizing radiation. Seminiferous tubule degeneration: tubules disrupted Abnormal testis development: poorly developed Abnormal gametogenesis: abnormal oogenesis: disrupted, lack of maturing follicles and oocytes. Abnormal spermatogenesis: disrupted spermatogenesis, degenerating spermatocytes, loss of spermatids Nervous system phenotype: no gross neuronal degeneration at time points between 2 and 16 months of age. Abnormal Purkinje cell morphology: survival of Purkinje cells in culture less than 60% of controls at 4 days and about 40% at 10 day, survival of cultured cells improves if cultured with cerebellar astroglial cells, develop simpler dendritic arboritization with reduced secondary branching, nitroxide free radicals improve survival and arborization Seminiferous tubule degeneration: tubules disrupted|Increased tumor incidence: average age at onset 18.6 months, varying tumor types including dermatoid cysts adenoma: 13% of total leukemia: 5% of total lymphoma:24% of total ovary tumor: 8% of total sarcoma: 32% of total, half of sarcomas are in Mammary glands|C57BL/6J x 129T2/Sv|Yes|No|Yes|Yes|Yes|Yes|Yes|Good|35|35|Hetrezygotes x Heterozygotes|Yes|05-Sep-2011|Cryopreserved sperm|50.0|0.0|Yes|A-T is characterized by immunodeficiency, neurological abnormalities and a |ataxia telangiectasia , T cell , spermatogenesis, thymocyte, lymphoma |Possibly| 7337.0|Il7tg|B6.Cg-Tg(H2-Ea-Il7)10Rhdr/ScrAusbAnuApb||Recessive||||||||||||||||||||||||||transgene insertion 10, Rhodri Ceredig|H2-Ea promoter|||||||||||Normal||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-May-2013|Cryopreserved sperm|9.0|0.0|Unknown||il7, B cell|Yes| 8704.0|TcrP14|B6.SJL-Ptprc Tg(TcrLCMV)327Sdz/AnuApb||Dominant|protein tyrosine phosphatase, receptor type, C|Ptprc|Normal|B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||transgene insertion 327, Birgit Ledermann||10 copies|||||||||||MIce express a T-cell receptor (Tcra-V2, Tcra-J TA31 / Tcrb-V8.1, Tcrb-D, Tcrb-J 2.4) specific for LCMV (lymphocytic choriomeningitis virus), H2-Db.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Apr-2019|Cryopreserved sperm|60.0|0.0|Unknown||T cell|Yes| 5246.0|BALB.Lyn knockout|BALB/c-Lyn/Apb||Semi-dominant|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||Young mice are apparently healthy, but they start to show signs of autoimmune disease at >16 wks of age. The disease resembles the human condition systemic lupus erythematosus (SLE). The mice develop serum anti-nuclear antibodies and acquire crescentic glomerulonephritis due to immune complex deposition in kidney, leading to renal dysfunction. They show hematologic disorders such as lymphopenia and thrombocytopenia, and they develop lymphadenopathy and splenomegaly. They develop inflammatory lesions in multiple organs including skin, lung and kidney, and occasionally we observe neurologic disorders such as seizures and hind limb paralysis. Similar to SLE patients, the mice also have hyperactive B lymphocytes.|Heterozygous mice are autoimmune-prone, but the disease is of later onset and less severe.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5|||No|18-Oct-2010|Cryopreserved sperm|50.0|0.0|Yes|Systemic Lupus Erythematosus; SLE|B cell, src family, immunoglobulin, spleen, signal transduction, autoimmunity, lymphocyte|Yes| 7783.0|403sv, MHC-403sv|129(Cg)-Myh6/Apb |MGI:2182704|Dominant|myosin, heavy polypeptide 6, cardiac muscle, alpha;|Myh6|Unknown|A830009F23Rik, alpha cardiac MHC, alpha-MHC, alpha myosin, cardiomyopathy, hypertrophic 1, Myhca, Myhc-a|MGI:97255|myosin, heavy polypeptide 6, cardiac muscle, alpha; targeted mutation 1, Jonathan G Seidman|Myh6|MGI:2182704|14|||||||||||||||||||||||||||||Lethal|Hypertrophy of myocytes with large hyperchromatic nuclei by 30 weeks of age, myocardial fiber disarray becoming marked by 30 weeks of age, moderate diffuse interstitial fibrosis by 30 weeks of age, starting as early as 15 weeks|129/SvEv|No|No|Yes|No|No|Yes|No|Good||24|Myh6/MYH6+ x MYH6/MYH6 |No|12-Nov-2014|Cryopreserved sperm|40.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Myosin heavy chain gene|Yes| 5123.0|IGF-1Ea ; sglt-2 IGF-1Ea|FVB-Tg(Slc5a2-rIGF1-Ea)UqbrApb||Dominant||||||||||||||||||||||||||rat Insulin-like growth factor-1 Ea isoform|mouse solute carrier family 5 (sodium/glucose cotransporter), member 2 (Slc5a2) ; Sglt2|high||||||||||No obvious developmental phenotype in kidneys. Adults show increase damage in kidneys after ischeamia reperfusion injury|Less severe than homozygous (damage model)|FVB|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-May-2010|Cryopreserved sperm|80.0|0.0|Unknown||kidney, nephron, renal|No| 6901.0|B6.3-PAPKO; C57BL/6-3-PAP knockout|C57BL/6-Mtmr12/Stv||Dominant|myotubularin related protein 12|Mtmr12|Nil|C730015A02Rik, mKIAA1682, Pip3ap|MGI:2443034||||15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||15||No|24-May-2012|Cryopreserved sperm|50.0|0.0|No|||Possibly| 7217.0|Sppl2a KO1|C57BL/6N-A Sppl2a/1MarpAnu||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2a|MGI:4887673|2|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Nov-2012|Cryopreserved sperm|29.0|0.0|Unknown|||Possibly| 5377.0|hPI Triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(TcraINS1,TcrbINS1)/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5377.0|hPI Triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(TcraINS1,TcrbINS1)/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5377.0|hPI Triple 427|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(TcraINS1,TcrbINS1)/Apb||Dominant||||||||||||||||||||||||||T cell receptor alpha, T cell receptor beta||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5390.0|Ndufs6gt/+|C.129P2-Ndufs6/MrchApb|C.129P2-Ndufs6/Mrch|Recessive|NADH dehydrogenase (ubiquinone) Fe-S protein 6|Ndufs6|Reduced|IP13|MGI:107932|NADH dehydrogenase (ubiquinone) Fe-S protein 6; gene trap AR0138, Wellcome Trust Sanger Institute|Ndufs6|MGI:4346527|13||||||||||||||||Yes|||||||||||||The homozygous mice seem unable to survive pass weaning. Further investigation is in progress.|Normal|BALB/c|No|No|Yes|No|No|Yes|No|Good|11|1|heterogygote X heterozygote|No|18-Jan-2011|Cryopreserved sperm|97.0|0.0|Yes|Mutations in human gene, NDUFS6, encoding one of the 45 subunits of Complex I, are one cause of Complex I deficiency. NDUFS6-/- patients suffer from seizures, hypotonia and abnormal eye movements and die in the first month of life. Currently, no effective treatment is available. |Mitochondria, Cardiac , Complex I, Oxidative phosphorylation, ES cell|Possibly| 7234.0|RIP-YMII|C57BL/6-Tg(Ins2-EYFP-MII)Wehi/WehiApb||Dominant||||||||||||||||||||||||||Ins2-EYFP-MII|Ins2|low||||||||||Normal. Mice express MHCI and MHCII resticted peptides from ovalbumin, influenza A virus and herpes simplex virus. The expression is directed to the pancreas under the rat insulin promoter. Expression of these peptides has no obvious effects on the life-span, well-being or breeding potential of the mice.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||brother-sister or Tg x C57BL/6|No|28-Nov-2012|Cryopreserved sperm|45.0|0.0|No||YFP|Yes| 7235.0|classI-mOVA|C57BL/6-Tg(H2-K1-TFRC/OVA)5Cbn/Apb||Dominant||||||||||||||||||||||||||ovalbumin residues 139-385 fused to transferrin receptor membrane domain|MHC class I|moderate||||||||||NormalClass I mOVA mice express a membrane-bound form of ovalbumin (transferrin receptor membrane domain and OVA residues 139-385) under the control of the MHC class I promoter. OVA expression is directed to the membranes of all cells except red blood cells.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Nov-2012|Cryopreserved sperm|50.0|0.0|No||MHC, ovalbumin, autoimmunity|Yes| 7282.0|Cathepsin-S Knockout|B6NCrl;129-Ctss/AnuApb||Recessive|cathepsin S|Ctss|Nil|Cat S|MGI:107341|cathepsin S; targeted mutation 1, Harold A Chapman|Ctss|MGI:2182133|3||||||||||||||||Yes|||||||||||||Defective CD4 T cell response and humoral responses, but no overt immunodeficiency. Homozygous null mice are resistant to the development of experimental autoimmune myasthenia gravis and showed reduced T and B cell responses to acetylcholine receptor.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2013|Cryopreserved sperm|20.0|0.0|Unknown||T cell, MHC class II, cysteine proteinase, Humoral resposne, arthritis, germinal centre|Yes| 7227.0|APN281|C57Bl/6N-A Oas2/Marp||Recessive|2'-5' oligoadenylate synthetase 2|Oas2|Unknown|2'-5' oligoadenylate synthetase-like 11, Oasl11|MGI:2180852|2'-5' oligoadenylate synthetase 2; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Oas2/Marp|MGI:4434541|5|||||||||||||||||||||||||||||Unknown|Normal|C57Bl6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|22-Nov-2012|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 7231.0|Sftpc+/+ 129|129/Sv-Sftpc/MarpApb||Recessive|surfactant associated protein C|Sftpc|Nil|pro-SpC, Sftp2, Sftp-2, SP-C|MGI:109517||||14|||||||||||||||||||||||||||||Normal.Wildtype strain developed from Het x het mating of knockout mice.Used as control for experiments.|Normal|129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>20|||No|27-Nov-2012|Cryopreserved sperm|50.0|0.0|Yes|Interstitial Pneumonitis, Desquamative, Familial; DIP|lung, alveolar, surfactant, respiratory, WT control|Possibly| 7233.0|APN318|C57Bl/6N-A Sppl2a||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2atm1a(EUCOMM)Hmgu|MGI:4887673|2|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|28-Nov-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7232.0|PbT-I-9 ; C57BL/6-Tg(TCRaB4-46TcrbB4-46)9Cbn|C57BL/6-Tg(H2-K-Tcra,-Tcrb)9Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 9, Francis Carbone|H-2Kb|||||||||||Majority of CD8 T cells express the transgenic T cell recepter Va8Vb10 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||7|brother-sister or Tg positive to C57BL/6|No|28-Nov-2012|Cryopreserved sperm|50.0|0.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD8 TCR transgenic|Yes| 7238.0|K5rTA-TSLP 1714|C57BL/6-Tg(K5-rTA)17Cbn Tg(TetO-TSLP)14Cbn/Apb||Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving TSLP expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Tg/+ +/+ x +/+ Tg/+|No|28-Nov-2012|Cryopreserved sperm|70.0|0.0|Yes||thymic stromal lymphopoietin, dermatitis, doxycyline inducible|Possibly| 7238.0|K5rTA-TSLP 1714|C57BL/6-Tg(K5-rTA)17Cbn Tg(TetO-TSLP)14Cbn/Apb||Dominant||||||||||||||||||||||||||thymic stromal lymphopoietin|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving TSLP expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Tg/+ +/+ x +/+ Tg/+|No|28-Nov-2012|Cryopreserved sperm|||Yes||thymic stromal lymphopoietin, dermatitis, doxycyline inducible|Possibly| 4842.0|Topsy-Turvy|ENU8C:063||Recessive|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Ataxia, tremors, jerky movements, falls over while walking, throws head back to look at ceiling.Affected mice shake constantly, roll onto their sides frequently while walking. These mice also seem to have difficulty righting themselves as they are often seen on their backs underneath the feeder. It seems likely that this is a spontaneous mutant as it was first seen in G10. Video available.|Normal|C57BL/6 x CBA|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|38.0|0.0|Unknown||ataxia, ENU, tremors, balance, jerky movement|Yes| 7384.0|B6.MHCII-GFP|B6.129S4-H2-Ab1/Apb||Dominant|histocompatibility 2, class II antigen A, beta 1|H2-Ab1||Abeta, A beta, H-2Ab, H2-Ab, Ia2, Ia-2, IAb, I-A, I-Abeta, Rmcs1|MGI:103070|histocompatibility 2, class II antigen A, beta 1; targeted mutation 1, Hidde Ploegh|H2-Ab1|MGI:2387946|17|||||||||||||||||||||||||||||Express MHCII GFP fusion protein.|Express MHCII GFP fusion protein.Mice are immunologically indistinguishable from wild-type controls|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Jul-2013|Cryopreserved sperm|41.0|48.0|Unknown||major histocompatibility complex, MHCII, antigen presentation, GFP|Yes| 7243.0|CTR flox|B6.129-Calcr/Apb||Dominant|calcitonin receptor|Calcr||Clr|MGI:101950|calcitonin receptor; targeted mutation 1, Rachel A Davey|Calcr|MGI:4352932|6|||||||||||||||||||||||||||||Normal.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>20|||No|06-Dec-2012|Cryopreserved sperm|60.0|0.0|Unknown||hypercalcemia|Possibly| 4972.0|DSCR1 P71 Tg|B6.CBA-Tg(RCAN1)71Mapr/MarpApb||Dominant||||||||||||||||||||||||||human regulator of cacineurin 1|RCAN1|low||||||||||Transgenics are indistinguishable from wild type animals|Normal|C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygous Tg x Homozygous Tg|No|22-Jan-2010|Cryopreserved sperm|155.0|0.0|Yes|Down syndrome|Down Syndrome, vesicle trafficking|Yes| 7445.0|ENU29:G1|ANU:ENU29:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|24-Sep-2013|Cryopreserved sperm|1222.0|38.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7554.0|ENU25:022:CASC5:B6|C57BL/6NCrlAnu-Casc5/AnuApb|C57BL/6NCrlAnu-Casc5/AnuApb|Recessive|cancer susceptibility candidate 5|Casc5|Unknown|2310043D08Rik, 5730505K17Rik|MGI:1923714|cancer susceptibility candidate 5; mutation 1, The Australian National University|Casc5|MGI:5563500|2|ENSMUSG00000027326|ENSMUST00000028802|Casc5-004|2645|2661|T to A|ENSMUSE00000642270|7|882|Isoleucine to Lysine|||||TCTACCAGCAAAAGGCAGCCAGCTAACAATATTAGAGGAAGGGTCTAATAGCGGGCTTGGA||||||||||||||Possible embryonic lethal.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Dec-2013|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 8711.0|GLIPR1L1|C57BL/6J-Glipr1l1/MarpApb||Recessive|GLI pathogenesis-related 1 like 1|Glipr1l1|Nil|1700011E04Rik|MGI:1916536||||10|||||||||||||||||||||||||||||Subfertile|Normal|C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7556.0|ENU26:042:SOAT1:B6|C57BL/6NCrlAnu-Soat1/AnuApb|C57BL/6NCrlAnu-Soat1/AnuApb|Recessive|sterol O-acyltransferase 1|Soat1|Unknown|8430426K15Rik, Acact, ACAT-1, hid|MGI:104665|sterol O-acyltransferase 1; mutation 1, The Australian National University|Soat1|MGI:5563410|1|ENSMUSG00000026600|ENSMUST00000051396|Soat1-201|1241|1452|A to C|ENSMUSE00000160863|13|414|Valine to Glycine|||||CAACTACTACAGGACCTGGAACGTGGTGGTGCACGACTGGCTCTACTACTATGTTTACAAA||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|19-Dec-2013|Cryopreserved sperm|59.0|0.0|Unknown||ENU|Yes| 7385.0|B6.bst2loxp|C57BL/6-Bst2/Apb||Dominant|bone marrow stromal cell antigen 2|Bst2||2310015I10Rik, Bst-2, C87040, GREG|MGI:1916800||||8|||||||||||||||||||||||||||||Express Bst2 flanked by loxp sites.|One allele will express Bst2 flanked by loxp sites.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Jul-2013|Cryopreserved sperm|44.0|0.0|Unknown||Bst2, immunology, antigen presentation|Yes| 7464.0|ENU30:G1|ANU:ENU30:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|29-Oct-2013|Cryopreserved sperm|1361.0|40.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8709.0|FANCM KO|FVB-Fancm/StVApb||Recessive|Fanconi anemia, complementation group M|Fancm|Nil|C730036B14Rik, D12Ertd364e|MGI:2442306||||11|||||||||||||||||||||||||||||Reduced fertility: smaller testis and epidydmis. Reduced sperm count and sperm motility.May have decreased lifespan.May have increased cancer susceptibility.|May have increased cancer susceptibility.|FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7368.0|ENU25:018:Nup35:B6|C57BL/6NCrlAnu-Nup35/Anu||Recessive|nucleoporin 35|Nup35|Unknown|2310006I24Rik, 5330402E05Rik|MGI:1916732|nucleoporin; mutation 1, The Australian National University|Nup35|MGI:6154324|2|ENSMUSG00000026999|ENSMUST00000028382|Nup35-001|576|653|T to A|ENSMUSE00001214171|6|192|Phenylalanine to Leucine|||||GCATCTGCTTCTTATATATTATTACAGTTTGCACAATATGGGAATATCTTAAAGCATGTGA||||||||||||||Mega colon|Probably normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2013|Cryopreserved sperm|43.0|0.0|Unknown||ENU, Colon|Yes| 7607.0|ENU19:Mcm5|C57BL/6JAnu-Mcm5/AnuApb|C57BL/6JAnu-Mcm5/AnuApb|Recessive|minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae)|Mcm5|Unknown|Cdc46, mCD46, Mcmd5|MGI:103197|minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae); mutation 1, The Australian National University|Mcm5|MGI:5563450|8|ENSMUSG00000005410|ENSMUST00000164309|Mcm5-202||||||||77648844|15|||GGATGCTGCTTTGTCTGGCAATCTGTCGGGTGAGTAAGCGCTGGACTGTGGTCTTGGACG||||||||||||||Embryonic Lethal.No pups carrying homozygous genotype are born||C57BL/6JAnu|No|No|Yes|No|No|Yes|No|Unknown||G3|Het x Het|No|27-Feb-2014|Cryopreserved sperm|40.0|0.0|Unknown||ENU, embryonic lethal|Yes| 7342.0|MommeD44|FVB/NJ-Nrf1 Tg(Hba1-Gfp)1Ew/QimrApb||Dominant|nuclear respiratory factor 1|Nrf1|Normal|D6Ertd415e|MGI:1332235|nuclear respiratory factor 1; modifiers of murine metastable epiallele D44|Nrf1||6|ENSMUSG00000058440|ENSMUST00000115212|Nrf1-001|||||||||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (~9.5dpc)|Percentage of cells expressing the GFP transgene is decreased (enhancer of variegation).|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|27-May-2013|Cryopreserved sperm|44.0|0.0|Unknown||epigenetics, modifier, ENU|Yes| 4525.0|ENU11B6:020b ; Servalan|C57BL/6JAnu-Ebf1/2AnuApb|C57BL/6JAnu-Ebf1/2AnuApb|Dominant|early B-cell factor 1|Ebf1|Unknown|O/E-1, Olf-1, Olf1|MGI:95275|early B-cell factor 1; Servalan|Ebf1|MGI:5007783|11|ENSMUSG00000057098|ENSMUST00000081265|Ebf1-001|||||||||||||No|||||||||||||Low B cell numbers in peripheral blood.|Low B cell numbers in peripheral blood.|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2009|Cryopreserved sperm|27.0|0.0|Unknown||B cell, ENU, NIH|Yes| 7388.0|fur|ENU24:006 unknown||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Wispy fur, looks to lack development of adult hair.||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-Jul-2013|Cryopreserved sperm|50.0|0.0|Unknown||Coat, hair, fur, ENU|Yes| 7784.0|403, MHC-403|B6.129-Myh6/Apb||Dominant|myosin, heavy polypeptide 6, cardiac muscle, alpha|Myh6|Unknown|A830009F23Rik, alpha cardiac MHC, alpha-MHC, alpha myosin, cardiomyopathy, hypertrophic 1, Myhca, Myhc-a|MGI:97255|myosin, heavy polypeptide 6, cardiac muscle, alpha; targeted mutation 1, Jonathan G Seidman|Myh6|MGI:2182704|14|||||||||||||||||||||||||||||Lethal|Hypertrophy of myocytes with large hyperchromatic nuclei by 30 weeks of age, myocardial fiber disarray becoming marked by 30 weeks of age, moderate diffuse interstitial fibrosis by 30 weeks of age, starting as early as 15 weeks|C57BL/6|No|No|Yes|No|No|Yes|No|Good|9|15|Myh6tm1Jse/MYH6+ x MYH6/MYH6 |No|12-Nov-2014|Cryopreserved sperm|68.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Myosin heavy chain gene|Yes| 4977.0|ENU11B6:024b ; Servalan|C57BL/6JAnu-Ebf1/3AnuApb|C57BL/6JAnu-Ebf1/3AnuApb|Recessive|early B-cell factor 1|Ebf1|Unknown|O/E-1, Olf-1, Olf1|MGI:95275|early B-cell factor 1; Servalan|Ebf1|MGI:5007783|11|ENSMUSG00000057098|ENSMUST00000081265|Ebf1-001|||||||||||||No|||||||||||||Small decrease in peripheral blood B cell numbers.Slight decrease in spleen B cell numbers|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|18.0|0.0|Unknown||B cell, immunity, NIH|Yes| 7608.0|BALB/b|BALB/c-H2/AnuApb||Recessive|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|Balb/c is usually H2. The H2 complex contains 3 major classes of highly polymorphic gene sets: class I (H2-K, H2-D, Q, H2-T18 genes), class II (H2-I genes), and class III (H2-S genes). These genes are involved in many processes, including graft rejection, immune response, antigen presentation and complement component.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||haplotype, presentation, antigen presentation, T cell|Yes| 7604.0|Crisp1 KO|B6.129-Crisp1/Marp||Recessive|Cysteine-rich secretory protien 1 C|Crisp1||Aeg1, CRISP-1|MGI:102553|cysteine-rich secretory protein 1; gene trap CMHD-GT_255A4-3, Centre for Modeling Human Disease|Crisp1|MGI:3879688|17||||||||||||||||Yes|||||||||||||Unknown|Normal|C57BL/6J|No|Unknown|Yes|No|Unknown|Unknown|No|Good|6|||No|27-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||Genetrap, Sperm, fertilization, ES cell|Possibly| 5335.0|NOD.scid β2M-/- |NOD-B2m Prkdc/MarpApb||Recessive|beta-2 microglobulin|B2m|Unknown|beta 2 microglobulin, beta2-m, Ly-m11|MGI:88127|targeted mutation 1, Rudolf Jaenisch|B2m|MGI:1927183|2||||||||||||||||Yes|||||||||||||Severe combined immuno deficiency; no B or T cells.|Normal|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||Autoimmunity, insulin, MHC I, beta cell|Possibly| 5335.0|NOD.scid β2M-/- |NOD-B2m Prkdc/MarpApb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||Severe combined immuno deficiency; no B or T cells.|Normal|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Dec-2010|Cryopreserved sperm|||Unknown||Autoimmunity, insulin, MHC I, beta cell|Possibly| 5336.0|Krüppel-like Factor 3 (KLF3/BKLF) Knockout |129/SvJ-Klf3/Apb||Recessive|Kruppel-like factor 3 (basic)|Klf3|Nil|BKLF, Bklf, Tef-2|MGI:1342773|targeted mutation 1, Merlin Crossley|Klf3|MGI:3799368|5||||||||||||||||Yes|||||||||||||Postnatal lethality, only 17% survive to weaning. Decreased adipose tissue, mice appear leaner, abnormal fat pads. Similar in size to wildtype at birth but significantly smaller than littermate controls from 3 to 12 weeks of age.||129/SvJ|Yes|No|Yes|Yes|No|Yes|Yes|Unknown|10|||No|02-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||Kruppel-like Factor 3, Basic Kruppel-like Factor, KLF, Obesity, adipose|Yes| 5575.0|Setx; Setx on C57/BL6Jx129Sv background|B6;129-Setx/QimrApb|15|Recessive|senataxin|Setx|Nil|AOA2; Als4; Sen1; SCAR1; AW060766; mKIAA0625; A130090N03; A930037J23Rik.|MGI:2443480 ||||2|||||||||||||||||||||||||||||Black or bown coat, Normal size, normal body, weight, normal life span. Male sterility|Normal|C57BL/6J x 129Sv|Yes|No|Yes|Yes|No|Yes|Yes|Good||30|Hetrezygotes x Heterozygotes|No|01-Sep-2011|Cryopreserved sperm|50.0|0.0|Yes|ataxia oculomotor Apraxia type 2 (AOA2)|DNA damage, AOA2, Senataxin, Transcription regulation, sterility|No| 7285.0|ENU27:G2|ANU:ENU27:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|12-Mar-2013|Cryopreserved sperm|1600.0|21.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7390.0|ENU24:G3|ANU:ENU24:G3||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|02-Aug-2013|Cryopreserved sperm|30.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 5338.0|B6.tx|C57BL/6-Atp7b/Apb||Recessive|ATPase, Cu++ transporting, beta polypeptide|Atp7b|Normal|Atp7a, Wilson protein, WND|MGI:103297|ATPase, Cu++ transporting, beta polypeptide; toxic milk|Atp7b|MGI:1856220|8||||||||||||||||Yes|||||||||||||Postnatal lethality: * mice die at about 14 days of age. * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Reduced female fertility: older female mice exhibit decreased fertility compared to wild-type mice.Abnormal mineral level: mice exhibit an increase in zinc the brain, liver and muscle.Abnormal copper level: mice exhibit an increase copper accumulation in the kidney, spleen, brain, muscle, serum and red blood cells.Decreased circulating copper level.Decreased liver copper level: in postnatal mice.Increased liver copper level: in adult mice.Tremors: * mice exhibit tremors. * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Ataxia: * mice exhibit difficulty walking, listing from side to side, overbalancing, falling over and exerting great effort in righting themselves. * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Decreased body weight: * mice reach their maximal weight at day 9 (70% of wild-type) and exhibit weight loss until their death. * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Postnatal growth retardation: * apparent within a day or two after birth * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Abnormal muscle physiology: * mice exhibit hyperextension of hindlimbs and hyperflexion of wrists. * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Diluted coat colour: * mice exhibit pale coat color * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age).Hypopigmentation: * pigment contained within melanocytes is lighter than normalseverity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Curly vibrissae: * mice exhibit curly whiskers * severity of defects depends on genetic background (less severe on a mixes C57BL/6 background) and maternal age (decreasing severity with increasing maternal age). * however, fostering with wild-type dams reverses many defects depending on the age of onset of fostering.Maternal effect: pups suckled by homozygous mothers are deficient in copper concentration in their stomach contents and liver, and supplementing the drinking water of the homozygous mother with copper does not increase the copper content of the milk but rather increases the copper accumulation in the mammary gland.Endocrine/exocrine gland phenotype: * mammary glands are structurally normal by histology.Defects are less severe on C57BL/6 background compared to DL background.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2010|Cryopreserved sperm|88.0|168.0|Yes|Wilson's Disease||Yes| 5343.0|F/F:STAT1KO ; gp130Y757F x STAT1|B6;129-IL6st Stat1/MarpApb||Dominant|signal transducer and activator of transcription 1|Stat1|Nil||MGI:103063|signal transducer and activator of transcription 1; targeted mutation 1, Robert D Schreiber|Stat1|MGI:1861949|1||||||||||||||||No|||||||||||||Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|C57BL/6 x 129S1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|13-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, JAK-STAT, cytokine, interferon, kinase, phosphorylation|Yes| 5343.0|F/F:STAT1KO ; gp130Y757F x STAT1|B6;129-IL6st Stat1/MarpApb||Dominant|interleukin 6 signal transducer|Il6st|Normal|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|Gastric tumors; splenomegaly; thrombocytosis; lymphadenopathy; multi-organ inflammation.|C57BL/6 x 129S1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|13-Dec-2010|Cryopreserved sperm|||Unknown||signal transduction, JAK-STAT, cytokine, interferon, kinase, phosphorylation|Yes| 7382.0|ENU28:G1|ANU:ENU28:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|26-Jul-2013|Cryopreserved sperm|522.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8713.0|Kynu null|C57BL/6N-Kynu/DunwApb||Recessive|kynureninase|Kynu|Nil|4432411A05Rik, L-kynurenine hydrolase|MGI:1918039|kynureninase; endonuclease-mediated mutation 1, Sally L Dunwoodi|Kynu|MGI:6285803|2|||||||||||||||||||||||||||||Normal|Normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-May-2019|Cryopreserved sperm|50.0|0.0|Unknown||NAD, Haao, Niacin|Yes| 7386.0|B6.IAbloxp|C57BL/6-H2-Ab1/Apb||Dominant|histocompatibility 2, class II antigen A, beta 1|H2-Ab1|Normal|Abeta, A beta, H-2Ab, H2-Ab, Ia2, Ia-2, IAb, I-A, I-Abeta, Rmcs1|MGI:103070|histocompatibility 2, class II antigen A, beta 1; targeted mutation 1, Pandelakis A Koni|H2-Ab1|MGI:2384629|17|||||||||||||||||||||||||||||Express IAb flanked by loxp sites.|One allele will express IAb flanked by loxp sites.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Jul-2013|Cryopreserved sperm|42.0|0.0|Unknown||MHCII, immunology, antigen presentation, major histocompatibility complex|Yes| 7248.0|IGF1 Exon5 total KO|B6.Cg-Igf1/MarpApb||Semi-dominant|insulin-like growth factor 1|Igf1|Nil|C730016P09Rik, Igf-1, Igf-I|MGI:96432||||10|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-Dec-2012|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 5345.0|SS-11 ; Vegfd 2.2.36|C57BL/6-Figf/Apb||X-linked|c-fos induced growth factor|Figf|Nil|VEGF-D, Vegfd|MGI:108037|c-fos induced growth factor; targeted mutation 1, Marc G Achen|Figf|MGI:3576785|X|||||||||||||||||||||||||||||No abnormal phenotype detected: homozygous females are morphologically normal, can suckle, and have grossly normal lymphatic system morphology and function.Mice have reduced numbers of lymphatic vessels in lungs.|Normal|129S1/Sv x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|0|||No|15-Dec-2010|Cryopreserved sperm|100.0|0.0|Unknown||growth factor, Vegf, lymphatics|Yes| 7284.0|ENU27:G1|ANU:ENU27:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|12-Mar-2013|Cryopreserved sperm|473.0|34.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7252.0|Nod il21R knock out|NOD(Cg)-Il21r/AusbApb||Dominant|interleukin 21 receptor|Il21r|Nil|NILR|MGI:1890475|interleukin 21 receptor; targeted mutation 1, Warren J Leonard|Il21r|MGI:2446509|7|||||||||||||||||||||||||||||Healthy and viable.Defect in IgG1 responses.NOD mice develop spontaneous diabetes type 1 but NOD mice carrying the IL21r mutation do not develop diabetes.|Healthy and viable|NOD|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown|10|||No|14-Dec-2012|Cryopreserved sperm|50.0|0.0|Unknown||Immunoglobulin, autoimmunity, B cell, T cell, CCR9|No| 7253.0|IL21ROT2tgThy|B6(Cg)-Thy1 Il21r Tg(Tg(TcraTcrb)425Cbn/AusbApb||Recessive|interleukin 21 receptor|Il21r|Nil|NILR|MGI:1890475|interleukin 21 receptor; targeted mutation 1, Warren J Leonard|Il21r|MGI:2446509|7|||||||||||||||||transgene insertion 425, Frank Carbone|||thymus cell antigen 1, theta|Thy1||CD90, T25, theta, Thy-1, Thy1.1, Thy 1.2, Thy-1.2, Thy1.2|MGI:98747|thymus cell antigen 1, theta; a variant|Thy1|MGI:3579311|9|Normal development and breeding|Normal development and breeding|C57BL6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Dec-2012|Cryopreserved sperm|60.0|0.0|Unknown|||No| 7251.0|ENU22:4930473A06Rik|C57BL/6NCrlAnu-Ccdc171/AnuApb||Dominant|coiled-coil domain containing 171|Ccdc171|Unknown|4930418J05Rik, 4930473A06Rik, A330015D16Rik|MGI:1922152|coiled-coil domain containing 171; mutation 1, The Australian National University|Ccdc171|MGI:5570360|4|ENSMUSG00000052407|ENSMUST00000053414|Ccdc171-001|2586|2913|T to A|ENSMUSE00001208951|18|862|Cysteine to STOP|||||CCAAAACATCAGAGGGAACAGTTACGCTGTTTACAGGCACTCGCGTGGCTCACCAGTTCTG||||||||||||||Reduced peripheral B cells, high IgM and low IgD expression|Reduced peripheral B cells, increased population of IgM very high immature B cells|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Yes|Yes|No|Good||3||No|14-Dec-2012|Cryopreserved sperm|32.0|0.0|Unknown||B cell, B lymphocyte, IgM, B cell development, ENU|No| 6891.0|ENU24:G2|ANU:ENU24:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|04-May-2012|Cryopreserved sperm|1647.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 5357.0|B6.427|C57BL/6-Tg(HLA DR4-DQ8)427/Apb||Dominant||||||||||||||||||||||||||human leukocyte antigen class II||||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||31||No|20-Dec-2010|Cryopreserved sperm|45.0|0.0|Unknown||autoimmunity, B cell, HLA, MHC, selection|Yes| 5385.0|WOMBAT ; Ndufs6gt/+|B6;129P2-Ndufs6/MrchApb|B6;129P2-Ndufs6/MrchApb|Recessive|NADH dehydrogenase (ubiquinone) Fe-S protein 6|Ndufs6|Reduced|IP13|MGI:107932|NADH dehydrogenase (ubiquinone) Fe-S protein 6; gene trap AR0138, Wellcome Trust Sanger Institute|Ndufs6|MGI:4346527|13||||||||||||||||Yes|||||||||||||Ndufs6gt/gt mice are fertile. For the first 4 months of life, Ndufs6gt/gt mice have no overt phenotype, with normal weight gain and survival. After 4 months of age, Ndufs6gt/gt mice develop cardiac hypertrophy, which can lead to sudden weight loss, lethargy and death. Ndufs6gt/gt males are more severely affected than females. |Normal|129P2/OlaHsd x C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||11|heterogygote X heterozygote|No|14-Jan-2011|Cryopreserved sperm|40.0|0.0|Yes|Mutations in human gene, NDUFS6, encoding one of the 45 subunits of Complex I, are one cause of Complex I deficiency. NDUFS6-/- patients suffer from seizures, hypotonia and abnormal eye movements and die in the first month of life. Currently, no effective treatment is available. |Mitochondria, Cardiac , Complex I, Oxidative phosphorylation, ES cell|Possibly| 7061.0|Momme D38|FVB/NJ-MommeD38 Tg(Hba1-Gfp)1Ew||Semi-dominant|eukaryotic translation initiation factor 3, subunit H|Eif3h|Unknown||MGI:1915385|eukaryotic translation initiation factor 3, subunit H; modifier of murine metastable epialleles, D38|Eif3h|MGI:5514384|15||||||||||Unknown to Unknown|||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Homozygous lethality (before E9.5 dpc)|Percentage of cells expressing the GFP transgene is decreased (enhancer of variegation).|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD38<+/->;Tg(Hba1-Gfp)1Ew x Tg(Hba1-Gfp)1Ew|No|24-Aug-2012|Cryopreserved sperm|47.0|0.0|Unknown||ENU, epigenetics, suppressor of variegation, modifier|Possibly| 7389.0|ENU19:G2|ANU:ENU19:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 5430.0|Idd14 R13|NOD.B6-Idd14/R13Apb||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 14|Idd14|||MGI:99416||||13|Unknown|Unknown|NOD/Lt|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||Yes|14-Feb-2011|Cryopreserved sperm|80.0|0.0|Unknown|||No| 6639.0|ENU16Ch:069b|C57BL/6JAnu-Mpz/AnuApb||Recessive|myelin protein zero|Mpz|Unknown|Mpp, P0|MGI:103177|myelin protein zero; enu16|Mpz|MGI:5490251|1|ENSMUSG00000056569|ENSMUST00000070758|Mpz-001|362|530|A to G|ENSMUSE00000476648|5|121|Aspartic acid to Glycine|||||CATTGTCATACACAACCTAGACTACAGTGACAACGGCACTTTCACATGTGATGTCAAAAAC||||||||||||||Circling Behaviour.Tremors and hypermetric gait. Worsens with age||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|02-Nov-2011|Cryopreserved sperm|18.0|0.0|Yes|Charcot-Marie-Tooth disease type 1 (CMT1B)|circling, tremours, myelin, Alzheimer's disease|Yes| 7614.0|ENU24:029:Agtr2|C57BL/6NCrlAnu-Agtr2/AnuApb|C57BL/6NCrlAnu-Agtr2/AnuApb|Recessive|angiotensin II receptor, type 2|Agtr2|Unknown|AT2 receptor|MGI:87966|angiotensin II receptor, type 2; mutation 1, The Australian National University|Agtr2|MGI:5648447|X|ENSMUSG00000068122|ENSMUST00000089188|Agtr2-001|353|599|A to T|ENSMUSE00000556750|3|118|Lysine to STOP|||||TGATTGGCTTTTTGGACCTGTGATGTGCAAAGTGTTTGGTTCTTTTCTGACTCTGAACATG||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Yes|Yes|No|Excellent||G4||No|04-Mar-2014|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Yes| 5358.0|NOD.427|NOD-Tg(HLA DR4-DQ8)427/Apb||Dominant||||||||||||||||||||||||||human leukocyte antigen class II||||||||||||HLA DR4 and DQ3 expression was evident on B cell but not T cells, dendritic cells and a proportion of macrophages.DR4-DQ3 mice develop protective immunity following infectious challenge with S. typhimurium.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|19|7||No|20-Dec-2010|Cryopreserved sperm|45.0|0.0|Unknown||autoimmunity, B cell, HLA, MHC, selection|Yes| 4135.0||NOD.B6-Prkdc B2m Tg(B2m)1Rms/MarpApb||Semi-dominant|beta-2 microglobulin|B2m|Unknown|beta 2 microglobulin, beta2-m, Ly-m11|MGI:88127|targeted mutation 1, Rudolf Jaenisch|B2m|MGI:1927183|2||||||||||||||||Yes|||||||||||||NOD phenotype|NOD phenotype|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|||No|07-Dec-2008|Cryopreserved sperm|100.0|0.0|Yes||microglobulin, autoimmune disease|Yes| 4135.0||NOD.B6-Prkdc B2m Tg(B2m)1Rms/MarpApb||Semi-dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||NOD phenotype|NOD phenotype|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|||No|07-Dec-2008|Cryopreserved sperm|||Yes||microglobulin, autoimmune disease|Yes| 5422.0|203.1 ; cTnI-G203S.1|C57BL/6-Tg(Myh6-TNNI3*G203S)1Chs/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|48% of endogenous||||||||||Unknown|Mice develop cardiac phenotype - hypertrophic cardiomyopathy by age 50 weeks. No differences were observed in LV systolic function at any age.|C57BL/6|No|Unknown|Yes|No|Unknown|Yes|No|Excellent|||Transgenic x non-transgenic sibs|No|07-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 5359.0|B6.hCD4.IAE.303-4 ; triple 303|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|39.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5359.0|B6.hCD4.IAE.303-4 ; triple 303|C57BL/6-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 7916.0|Eu myc|B6.SJL-Tg(IghMyc)22Bri/WehiAnu||Dominant||||||||||||||||||||||||||transgene insertion 22, Ralph L Brinster|Igh (E mu) enhancer and Myc promoter||||||||||||Mice invariably develop lymphomas, 90% succumbing in the first 5 mo of life. to almost invariably develop lymphomas, 90% succumbing in the first 5 mo of life. The tumors typically presented as rapidly progressive lymphadenopathy with thymic involvement and were highly malignant by transplantation assay. Morphologically, they were lymphoblastic lymphomas, usually accompanied by lymphoid leukemia and granulocytosis, and were distinct from the tumors that arose much later in 37% of nontransgenic mice of the same (C57BL/6 x SJL)F2 genetic background.Premature death: mice die at 6 to 15 weeks of age with 94% of mice dying by 4 months of age.Increased tumor incidence: mice occasionally develop thyoma without involvement of peripheral lymphoid organsLeukemia: mice develop multicentric lymphosarcoma associated with leukemia.Lymphoma:* 13 of 15 mice develop lymphomas* mice develop multicentric lymphosarcoma associated with leukemia.B cell derived lymphoma: lymphomas develop from single B-lymphoid clones at different stages of differentiation.Sarcoma: mice develop multicentric lymphosarcoma associated with leukemia.Abnormal lymphopoiesis: mice exhibit an increased in the number of lymphoblasts in lymph tissues and the blood compared to wild-type mice.Enlarged spleen: two-fold.Enlarged thymus.Enlarged lymph nodes.|C57BL/6 x SJL|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|18-Jun-2015|Cryopreserved sperm|88.0|0.0|Unknown||B cell, lymphoma, c-myc, B cell|Yes| 7615.0|EphA3 Knockout|B6;129S1-Epha3/QimrApb||Recessive|Eph Receptor A3|EphA3|Nil|Cek4, End3, Hek, Hek4, Mek4, Tyro4|MGI:99612|Eph receptor A3; targeted mutation 1, Arthur Brown|Epha3|MGI:2681606|16|||||||||||||||||||||||||||||Partial perinatal lethality:• about 70-75% of homozygotes die within 48 hours of birth from pulmonary edema secondary to cardiac failure• mice surviving perinatal period develop normally with no cardiac or other abnormalities and normal grip strength, motor column organization and spinal nerve projections.Liver vascular congestion:• venous congestionPulmonary vascular congestion:• venous congestionVenoocclusion:• venous congestion is seen in the lungs, liver, and other organsabnormal cardiac epithelial to mesenchymal transition.• atrioventricular canal explants exhibit a reduced number of mesenchymal cells that invade a collagen gel compared to wild-type, indicating reduced epithelial-mesenchymal transition (EMT).Abnormal heart development.Abnormal atrioventricular cushion morphology:• mutants exhibit delayed fusion of endocardial cushions; 75% of atrioventricular endocardial cushions are not yet fused at E11.5• 78% of E12.5 embryos exhibit rounded atrioventricular endocardial cushion cells with few or no processes instead of the flatted cells with multiple processes seen in wild-type• atrioventricular endocardial cushions exhibit increased apoptosis, however show no difference in proliferation• stress fibers in endocardial cushions are reduced in size and disorganised.Decreased atrioventricular cushion size:• hypoplastic endocardial cushions; endocardial cushions are 28.8% smaller than wild-type at E12.5 due to a reduction in cells within the cushion.Ostium primum atrial septal defect:• P0 mutants that become cyanotic have an atrial septal defect; the infolding representing the septum secundum is occasionally seen and the septum primum is either totally absent or is only a thin remnant.Dilated heart atrium:• enlarged atria that are engorged with blood and dilatedAbnormal atrioventricular septum morphology.• atrioventricular septum is thinnerAbnormal cardiovascular system physiology.Pulmonary alveolar hemorrhage:• neonatal lungs exhibit alveoli filled with blood, indicating exceedingly high cardiac filling pressures leading to capillary disruption.Atrioventricular valve regurgitation:• atrioventricular orifices are enlarged and their valvular leaflets inadequate to close the right and left atrioventricular canals.Decreased heart rate:• significant bradycardia at P0; average heart rate is 297 bpm compared to 396 bpm for wild-type.Atrioventricular block.Prolonged PR interval:• first-degree atrioventricular block as evidenced by prolonged PR interval• however, mutants show no evidence of arrhythmia or of second- or third-degree AV conduction blockCongestive heart failure:• cardiac failure in 70-75% of mutantsCyanosis:• mutants quickly become cyanotic after birthPulmonary edema:• seen in 70% of mutantsPulmonary alveolar haemorrhage:• neonatal lungs exhibit alveoli filled with blood, indicating exceedingly high cardiac filling pressures leading to capillary disruption.Abnormal lung morphology:• neonatal lungs are poorly inflatedPulmonary vascular congestion:• venous congestionLethargy:• mutants quickly become lethargic after birthLiver vascular congestion:• venous congestion|Normal|Mixed|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown||Homozygous x Homozygous|No|06-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown||Tyrosine kinase, axon, atrial septa, atrioventricular endocardial cushions, hypoplastic, migration|No| 5360.0|NOD.hCD4.IAE.303-4 ; NOD triple 303|NOD-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.On the NOD background mice immunised with gliadin and co-injected with pertusis toxin remained healthy.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|50.0|0.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 5360.0|NOD.hCD4.IAE.303-4 ; NOD triple 303|NOD-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR3-DQ2)303/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Expression of HLA DR and DQ evident on B cells, dendritic cells and a proportion of macrophages.These mice Tg for hCD4.DR3-DQ2.MHCII<Δ/Δ> express functional HLA-DR3 and DQ2 molecules that mediate thymic selection generating Ag-specific CD4<+> T cell immunity. Although about one in five Europeans homozygous for HLA-DQ2 develops celiac disease, homozygous and heterozygous hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice do not spontaneously develop hypersensitivity to gluten. However, standard immunization protocols do produce HLA-DQ2-restricted CD4+ T cells in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice that preferentially recognize the deamidated α-gliadin 17-mer immunodominant in human celiac disease. Nevertheless, we have found that preexisting DQ2-restricted CD4<+> T cell immunity to deamidated α-gliadin 17-mer in hCD4.DR3-DQ2.MHCII<Δ/Δ> Tg mice is not sufficient for gluten ingestion to cause measurable intestinal pathology.On the NOD background mice immunised with gliadin and co-injected with pertusis toxin remained healthy.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Dec-2010|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 7397.0|ENU23:037:DRD2:B6|C57BL/6NCrl-Drd2/AnuApb||Recessive|dopamine receptor D2|Drd2||D2R, D2 receptor, Drd-2|MGI:94924|dopamine receptor D2, mutation 1 Australian National University|||9|ENSMUSG00000032259|ENSMUST00000075764|Drd2-201|143|237|T to C|ENSMUSE00000462498|2|48|Isoleucine to Threonine|||||CATGCTGCTCACCCTCCTCATCTTTATCATCGTCTTTGGCAATGTGCTGGTGTGCATGGCT||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Aug-2013|Cryopreserved sperm|37.0|0.0|Unknown||ENU, receptor|Yes| 63.0|Polly|B6JSfdAnu;NODAnu-Nphp3/AnuApb|B6JSfdAnu;NODAnu-Nphp3/AnuApb|Recessive|nephronophthisis 3 (adolescent)|Nphp3|Nil|nephrocystin 3, pcy|MGI:1921275|polly|Nphp3|MGI:3847130|9|ENSMUSG00000032558|ENSMUST00000116516|Nphp3-202|1319|1496|T to A|ENSMUSE00000220789|8|441|Valine to Glutamic acid|||||AGAGGGAGTGTGTAAGATTTACGTGGGTGTGGAAAAGATTATTAAACAGGACATCCTTGGC|No|||||||||||||Juvenile polycystic kidney disease, brain defects: exencephaly. Homozygous mutant mice display slowly progressing kidney cysts, enlarged kidneys, increased blood urea nitrogen, kidney inflammation and associated fibrosis, and premature death.||C57BL/6JSfdAnu x NOD|Yes|No|Yes|Yes|No|Yes|Yes|Good|6|||No|06-Feb-2006|Cryopreserved sperm|102.0|0.0|Unknown||kidney, exencephaly, polycystic, juvenile, ENU|Yes| 7402.0|Mb1-creERT2|B6.129-Cd79a/RethAnu||Dominant|CD79A antigen (immunoglobulin-associated alpha)|Cd79a|Unknown|Cd79a, Iga, Igalpha, Ig alpha, Ig-alpha, Ly54, Ly-54, mb-1|MGI:101774|CD79A antigen (immunoglobulin-associated alpha); targeted mutation 3, Michael Reth|Cd79a|MGI:5568505|7||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Aug-2013|Cryopreserved sperm|44.0|0.0|Unknown||B cell, Cre recombinase, inducible|Yes| 7403.0|Cre-ERT2|B6.129-Gt(ROSA)26Sor/AusbAnu||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor |Unknown|Gt(ROSA)26Sor, R26, Rosa26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Tyler Jacks |Gt(ROSA)26Sor|MGI:3699244|6|||||||||||||||||||||||||||||Non tamoxifen treated animals are viable, fertile and are slightly smaller than wild-type controls|No apparent phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Aug-2013|Cryopreserved sperm|74.0|0.0|Yes||Cre recombinase, R26-CreERT2|Yes| 7396.0|FoxP3-cre|B6.129X-Foxp3/StvAnuApb||Dominant|forkhead box P3|Foxp3||JM2, scurfin|MGI:1891436|forkhead box P3; targeted mutation 4, Alexander Y Rudensky|Foxp3|MGI:3790499|X|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Unknown|No|Unknown||||No|14-Aug-2013|Cryopreserved sperm|80.0|0.0|Unknown||T cell, Cre recombinase, Foxp3|Yes| 8719.0||TRAIL-R-flox||Recessive|Tnfrsf10b|||||TRAIL-R-flox||||||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-May-2019||0.0|0.0|Unknown|||Yes| 7404.0|TOMGREtg ; mT/mG|B6.129(Cg)-Gt(ROSA)26Sor/JAusbAnu||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Normal|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 4, Liqun Luo|Gt(ROSA)26Sor|MGI:3716464|6|||||||||||||||||||||||||||||Normal|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Aug-2013|Cryopreserved sperm|46.0|0.0|Unknown||Cre/loxP, Mutagenesis, tomato|Yes| 5216.0|Lyn -/-|B6;129P2-Lyn/LudApb|B6;129P2-Lyn|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||Peritoneal inflammation: there is about a doubling in the number of T cells found in the peritoneum.Increased T cell number: there is about a doubling in the number of T cells found in the peritoneum.Abnormal B cell morphology: B cells express lower levels of CD21 and higher levels of CD23 on the cell surface compared to controls.Decreased transitional stage B cell number: profound reduction in transitional stage-2 B cells.Decreased follicular B cell number: about a five-fold reduction in follicular B cells.Decreased marginal zone B cell number: profound reduction in marginal zone B cells.Abnormal B cell activation: * significant expression of MHCII complexes by circulating B cells suggest these B cells are in an activated state. * B cells have enhanced calcium flux upon activation.Abnormal myelopoiesis: * myelopoiesis is greatly enhanced in these mice. * there is a significant increase in the number of colonies generated by bone marrow cells or splenocytes in response to in vitro culturing with GM-CSF, M-CSF, or IL-3.Spleen hypoplasia: spleen cellularity is reduced by more than half due to B cell lymphopenia.Increased anti-nuclear antigen antibody level: auto-antibodies of the IgA, IgG IgM classes develop as the mice age.Increased anti-double stranded DNA antibody level: mice develop anti-DS DNA IgG antibodies as they age with high levels detectable in all mice by 20 weeks of age.Glomerulonephritis: * all mice have immunoglobulin complex deposition in the kidney by 8 weeks of age. * 83% of mice also have C3 complement deposition in the kidney. * severe glomerulonephritis occurs in these mice by one year of age.Increased basophil cell number: in cervical and inguinal lymph nodes and spleen.Increased mast cell number: in the peritoneum.Increased neutrophil cell number: mice exhibit decreased platelet numbers that becomes more pronounced with age (at 6 to 8 weeks in peripheral blood, 1089+/-242 per ul compared to 609+/-207 per ul in wild-type mice; at 52 to 58 weeks in peripheral blood, 2540+/-1050 per ul compared to 1264+/-434 per ul in wild-type mice).Decreased platelet cell number.Extramedullary hematopoiesis: * red and white pulp are often replaced with of red and white pulp with myelomonocytic cells that are often centers of extramedullary hematopoiesis. * myelomonocytic cells often accumulate in other organs and on the surface of the ears, tails and legs.Decreased spleen red pulp amount: red and white pulp are often replaced with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Enlarged spleen: * mice develop age-dependent splenomegaly * 20% of mice greater than 1 year of age exhibit severe splenomegaly with partial to complete replacement of red and white pulp with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Decreased spleen white pulp amount: red and white pulp are often replaced with myelomonocytic cells that are often centers of extramedullary hematopoiesis.Abnormal circulating complement protein level: increased circulating immune complexes reactive to complement component 1 q.Abnormal level of surface class II molecules: basophils show high MHC II expression.Increased IgA level.Increased IgE level.Increased IgG2b level.Increased IgM level.Increased anti-nuclear antigen antibody level: of IgE isotype.Increased anti-double stranded DNA antibody level: of IgE isotype.Young mice are apparently healthy, but they start to show signs of autoimmune disease at >12 wks of age. The disease resembles the human condition systemic lupus erythematosus (SLE). The mice develop serum anti-nuclear antibodies and acquire crescentic glomerulonephritis due to immune complex deposition in kidney, leading to renal dysfunction. They show hematologic disorders such as lymphopenia and thrombocytopenia, and they develop lymphadenopathy and splenomegaly. They develop inflammatory lesions in multiple organs including skin, lung and kidney, and occasionally we observe neurologic disorders such as seizures and hind limb paralysis. Similar to SLE patients, the mice also have hyperactive B lymphocytes.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Hom x Hom|No|13-Sep-2010|Cryopreserved sperm|50.0|0.0|Yes|Systemic Lupus Erythematosus; SLE|B cell, immunoglobulin, spleen, kinase, signal transduction, src family, autoimmunity, lymphocyte|Yes| 7412.0|ENU27:007:ETS1|C57BL/6NCrlAnu-Ets1/AnuApb|C57BL/6NCrlAnu-Ets1/AnuApb|Recessive|E26 avian leukemia oncogene 1, 5' domain|Ets1|Unknown|Ets-1, MGC:18571, p42Ets-1, p51Ets-1, Tpl1|MGI:95455|E26 avian leukemia oncogene 1, 5' domain; mutation 1, The Australian National University|Ets1|MGI:5563474|9|ENSMUSG00000032035|ENSMUST00000034534|Ets1-001|1001|1363|C to T|ENSMUSE00000537123|7|334|Proline to Leucine|||||TGCCCTGGCTGGCTACACAGGAAGTGGGCCGATCCAGCTGTGGCAGTTTCTTCTGGAATTA||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, C4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Aug-2013|Cryopreserved sperm|29.0|0.0|Unknown||T cell, CD8, CD4, plasma cell|Yes| 7414.0|ENU23:005:ATG16L2:B6|C57BL/6NCrlAnu-Dclre1c/AnuApb|C57BL/6NCrlAnu-Dclre1c/AnuApb|Recessive|DNA cross-link repair 1C, PSO2 homolog (S. cerevisiae)|Dclre1c||9930121L06Rik, Art, Artemis|MGI:2441769||||2|ENSMUSG00000026648|ENSMUST00000061852|Dclre1c-001|284|371|T to A|ENSMUSE00001293954|4|95|Leucine to STOP|||||TGAAATTGAAACTCCTACGCAGATATCTTTAGTTGATGAGGCTTCGGGTGAGAAGGAAGAG||||||||||||||Lymphopenia||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|23-Aug-2013|Cryopreserved sperm|31.0|0.0|Unknown||T cell|Yes| 7413.0|ENU27:031:RAG1|C57BL/6NCrlAnu-Rag1/AnuApb|C57BL/6NCrlAnu-Rag1/AnuApb|Recessive|recombination activating gene 1|Rag1|Unknown|Rag-1|MGI:97848|recombination activating gene 1; mutation 1, The Australian National University|Rag1|MGI:5563427|2|ENSMUSG00000061311|ENSMUST00000078494|Rag1-001|2408|2502|A to C|ENSMUSE00000471535|2|803|Glutamic acid to Glycine|||||GCTTCACTGTGACATTGGCAATGCAGCTGAATTCTATAAGATTTTCCAGCTGGAGATAGGG||||||||||||||Lymphopenia||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|23-Aug-2013|Cryopreserved sperm|19.0|0.0|Unknown||T cell, B cell|Yes| 7418.0|ENU22::NFATc2|C57BL/6NCrlAnu-Nfatc2/AnuApb|C57BL/6NCrlAnu-Nfatc2/AnuApb|Recessive|nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2|Nfatc2|Unknown|NFAT1, NFAT1-D, NFATp|MGI:102463|nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2|Nfatc2|MGI:5563447|2|ENSMUSG00000027544|ENSMUST00000109184|Nfatc2-001|2283|2457|A to T|ENSMUSE00001264777|9|761|Proline to Arginine|||||GCCCTCTACCAGAGAAGCAAGAGCCTGAGTCCCGGCCTGCTGGGCTACCAGCAGCCGTCCC||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Aug-2013|Cryopreserved sperm|16.0|0.0|Unknown|||Yes| 7417.0|ENU27:043:ZFP644|C57BL/6NCrlAnu-Zfp644/AnuApb|C57BL/6NCrlAnu-Zfp644/AnuApb|Recessive|zinc finger protein 644|Zfp644|Unknown|1110068L01Rik, BM-005, D5Ertd689e, mKIAA1221, Zep-2|MGI:1277212|zinc finger protein 644; mutation 1, The Australian National University|Zfp644|MGI:5563394|5|ENSMUSG00000049606|ENSMUST00000112698|Zfp644-201||||||||106638637|2|||GCAAATCTACATTTTTGTTTTCCATTTTCTAGACTAAAGGTGTTAAATGATCTTGCCAAC||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Aug-2013|Cryopreserved sperm|16.0|0.0|Unknown|||Yes| 7416.0|ENU26:029:WDR89:B6|C57BL/6NCrlAnu-Wdr89/AnuApb|C57BL/6NCrlAnu-Wdr89/AnuApb|Recessive|WD repeat domain 89|Wdr89|Unknown|2600001A11Rik|MGI:1919588|WD repeat domain 89; mutation 1, The Australian National University|Wdr89|MGI:5563398|12|ENSMUSG00000045690|ENSMUST00000062370|Wdr89-201|428|524|A to T|ENSMUSE00000368540|2|143|Leucine to STOP|||||TGCAGAGAAAGTTGACGAGGATGCATTGTTGGTATTTTGGGATGCAAGGTTCACATCTCAG||||||||||||||Normal blood lymphocyte populations phenotype as measured by flow cytometry screen.Parameters tested-Expression of following proteins: B220, CD3, C4, CD44, KLRG1, NK1.1, IgM, IgD.||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||G3||No|23-Aug-2013|Cryopreserved sperm|15.0|0.0|Unknown|||Yes| 7618.0|SVS7 -/-|C57BL/6-Pate4||Semi-dominant|Prostate and Testes Expressed 4 (PATE4)|Pate4|Nil|9530004K16Rik, Pate-B, Svs7, SVS VII|MGI:1930790||||9|||||||||||||||||||||||||||||Display osteopenia - reduced bone volume in the femur and tibia at 3 months as assessed by microcomputed tomography.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7427.0||SJL/J-Ank1/Apb|SJL/J-Ank1|Dominant|ankyrin 1, erythroid|Ank1|Unknown|Ank-1, pale|MGI:88024|ankyrin 1, erythroid; ASAM142817|Ank1||8|ENSMUSG00000031543|ENSMUST00000121802|Ank1-004|2992|3246|C to T|ENSMUSE00001296345|27|998|Glutamine to STOP|||||CTCGCATCACCTGCCGCCTCGTTAAGCCGCAGAAGCTGAACACGCCACCCCCACTGGCTGA||||||||||||||Pre and Perinatal mortality with Jaundice, enlarge spleen and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with increase osmotic fragility and splenomegaly. |SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|27-Aug-2013|Cryopreserved sperm|50.0|0.0|Yes|Hereditary spherocytosis|Hereditary spherocytosis, Malaria resistance, microcytosis, ENU|Yes| 7419.0|ENU27:G3|ANU:ENU27:G3||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|2|||No|26-Aug-2013|Cryopreserved sperm|150.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7423.0||SJL/ASAM||Dominant|CXADR-like membrane protein|Clmp|Reduced||MGI:1918816||||9||||||||||Unknown to Unknown|||||||||||||||||||Unknown|The mice displays an harmonious growth retardation phenotype without other gross abrnomalities. The mice are viable and fertile.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|3|||No|27-Aug-2013|Cryopreserved sperm|40.0|0.0|Unknown||growth retardation, ENU|Yes| 7425.0||B6/Mrit-MRI95318|B6/Mrit-MRI95318|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display an harmonious and transient growth retardation|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|27-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7426.0||B6/Mrit-MRI109059|B6/Mrit-MRI109059|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a growth retardation phenotype|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|27-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7422.0||SJL/J-Tfrc/Apb||Dominant|transferrin receptor|Tfrc|Reduced|2610028K12Rik, CD71, E430033M20Rik, Mtvr1, Mtvr-1, p90, TfR1, Trfr|MGI:98822||Tfrc/Apb||9|ENSMUSG00000022797|ENSMUST00000023486|Tfrc-001|676|816|A to G|ENSMUSE00000130499|6|226|Lysine to Glutamic acid|||||AGTCTCCCGAGGGTTATGTGGCATTCAGTAAACCTACAGAAGTTTCTGGTAAACTGGTCCA||||||||||||||Prenatal mortality (E15) with severe anaemia and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with decrease osmotic fragility.|SJL/J|No|No|Yes|No|No|Yes|No|Good|5|||No|27-Aug-2013|Cryopreserved sperm|60.0|0.0|Yes|thalassaemia|red blood cells, microcytosis, anaemia, thalassaemia, ENU|Yes| 7421.0||SJL/Mrit-TfrcApb||Dominant|transferrin receptor|Tfrc|Reduced|2610028K12Rik, CD71, E430033M20Rik, Mtvr1, Mtvr-1, p90, TfR1, Trfr|MGI:98822||||16|||||||||||||||||||||||||||||Prenatal mortality (E15) with severe anaemia and fragmented red blood cells|Heterozygous mice display a microcytic anaemia with decrease osmotic fragility.|SJL/J|No|No|Yes|No|No|Yes|No|Good|4|||No|27-Aug-2013|Cryopreserved sperm|50.0|0.0|Yes|thalassaemia|red blood cells, microcytosis, anaemia, thalassaemia, ENU|Yes| 7429.0|GHSR-eGFP|Swiss-Tg(Ghsr-EGFP)KZ65Gsat/Apb||Dominant||||||||||||||||||||||||||transgene insertion KZ65, GENSAT Project at Rockefeller University|GHSR|||||||||||Normal|Normal|Swiss|No|No|Yes|No|No|Yes|No|Good||||No|02-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||GHSR, GFP|Possibly| 7428.0|Spi6 conditional KO clone 8F|C57BL/6J-SerpinB98F/PibMarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9||ovalbumin, PI-9, Spi6|MGI:106603||||13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|02-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8720.0|Tlr9 KO|B6.129-Tlr9/AnuApb||Recessive|toll-like receptor 9|Tlr9|Nil||MGI:1932389|toll-like receptor 9; targeted mutation 1, Shizuo Akira|Tlr9|MGI:2660562|9|||||||||||||||||||||||||||||Tlr9 KO mice have:Abnormal immune system physiology:*Response to LPS and CpG is completely abrogated. Impaired NK cell cytolysis: *No NK cell activation is observed following infection with L. infantum. Decreased interferon-alpha secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interferon-beta secretion: *Following infection with Leishmania baziliensis. *However, secretion could be restored by treatment with GU-rich ssRNA, a TLR7 ligand. Decreased interleukin-12b secretion: *Following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice. *Unlike in wild-type mice, IL-12p40 production from dendritic cells following infection with Leishmania infantum is indetectable. Decreased tumor necrosis factor secretion: *Following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced. Decreased susceptibility to experimental autoimmune encephalomyelitis: *Myelin oligodendrocyte glycoprotein injection results in delayed onset of disease, 17.9 days after injection rather than 15.9 days as in controls. *Fewer infiltrating foci in the spinal cord. Abnormal response to infection: *Following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a partially decreased immune response in terms of TNF secretion and response to CpG. Decreased susceptibility to parasitic infection: *Resistant to cerebral malaria. *Reduced accumulation of hemozoin. *Less upregulation of TNF-alpha in Plasmodium infection.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|>10||heterozygote mating|No|30-May-2019|Cryopreserved sperm|72.0|0.0|Yes|||Yes| 5058.0|Cauli ; ENU12B6:C3H:003|B6;C3H-Ift140/AnuApb|B6;C3H-Ift140/AnuApb|Recessive|intraflagellar transport 140 homolog (Chlamydomonas)|Ift140||mKIAA0590, Tce5, Wdtc2 |MGI:2146906 |cauli|Ift140|MGI:4458412|17|ENSMUSG00000024169|ENSMUST00000024983|Ift140-001|2564|3109|T to A|ENSMUSE00000551541|19|855|Isoleucine to Lysine|||||ACTGGAAGCCAGAGTGGCCATGCTGGCCATACAGCTGGGCATGCTGGAGGAGGCAGAACAA|Yes|||||||||||||Phenotype found in 13.5 dpc embryo. Phenotype is exencephaly, hind limb polydactyly, forelimbs have a mixture of polydactyly and oligodactyly and midfacial cleft.|Normal|C57BL/6 x C3H|No|No|Yes|No|No|Yes|No|Good||||No|02-May-2007|Cryopreserved sperm|60.0|0.0|Unknown||polydactyly, exencephaly, cleft, embryonic lethal, ENU|No| 7433.0|OG2tg|B6;CBA-Tg(Pou5F1-EGFP)2Mnn/Apb||Recessive||||||||||||||||||||||||||transgene insertion 2, Jeff Mann|promoter and distal enhancer of the POU domain, class 5, transcription factor 1, (Pou5fl)|||||||||||Viable, fertile, normal|Viable, fertile, normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown|||No| 5423.0|203.2 ; cTnI-G203S.2|C57BL/6-Tg(Myh6-TNNI3*G203S)2Chs/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|48% of endogenous||||||||||Unknown|Mice develop cardiac phenotype - hypertrophic cardiomyopathy. Onset age dependent upon the amount of transgene protein expressed.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|||Transgenic x non-transgenic sibs|No|08-Feb-2011|Cryopreserved sperm|45.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 7434.0|Mink|B6.129S6-Kcne1/Apb||Dominant|potassium voltage-gated channel, Isk-related subfamily, member 1|Kcne1|Nil|Isk, MinK, nmf190|MGI:96673|potassium voltage-gated channel, Isk-related subfamily, member 1; targeted mutation 1, Dan M Roden|Kcne1|MGI:3040614|16|||||||||||||||||||||||||||||Lethal|Normal,fertile, viable|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|16-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||congenital long-QT syndrome, cardiac myocytes|No| 7437.0||C3;SJL/Mrit-MRI16436|C3;SJL/Mrit-MRI16436|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight growth retardation phenotype|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 6622.0|APN 118|C57BL/6N-Slc13a4/Marp||Recessive|solute carrier family 13 (sodium/sulfate symporters), member 4 |Slc13a4 |Unknown|9630060C05Rik, SUT-1, SUT1 |MGI:2442367 | solute carrier family 13 (sodium/sulfate symporters), member 4; targeted mutation 1a, Wellcome Trust Sanger Institute |Slc13a4tm1a(EUCOMM)Wtsi|MGI:4441655|6||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6613.0|APN 114|CPT1c||Recessive|carnitine palmitoyltransferase 1c |Cpt1c ||9630004I06Rik, CPT I-C |MGI:2446526 ||||7|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Excellent||||No|11-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7431.0|APN 371|C57BL/6N-A Katna1MarpApb||Recessive|katanin p60 (ATPase-containing) subunit A1|Katna1 |||MGI:1344353 |katanin p60 (ATPase-containing) subunit A1; targeted mutation 1a, Wellcome Trust Sanger Institute |Katna1tm1a(KOMP)Wtsi|MGI:4458514|10|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Sep-2013|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 7619.0|R26 MUT-Hoxa1 ki|C57BL/6-Gt(ROSA)26Sor||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3237, TaconicArtemis|Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|18-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7436.0||C3;SJL/Mrit-MRI16932|C3;SJL/Mrit-MRI16932|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight growth retardation phenotype|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2013|Cryopreserved sperm|60.0|0.0|Unknown||growth retardation, ENU|Yes| 7438.0||C3;SJL/Mrit-MRI12512|C3;SJL/Mrit-MRI12512|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight growth retardation phenotype|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7439.0||C3;SJL/Mrit-MRI9417|C3;SJL/Mrit-MRI9417|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight growth retardation phenotype|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2013|Cryopreserved sperm|60.0|0.0|Unknown||growth retardation, ENU|Yes| 7440.0||C3;SJL/Mrit-MRI9434|C3;SJL/Mrit-MRI9434|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight growth retardation phenotype|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth retardation, ENU|Yes| 7442.0|ENU22:SCIN:B6|C57BL/6NCrlANu-Scin/Apb||Recessive|Scinderin|SCIN|Unknown|adseverin|MGI:1306794|scinderin; mutation 1, The Australian National University|Scin|MGI:5570658|12|ENSMUSG00000002565|ENSMUST00000002640|Scin-001|1375|1495|G to T|ENSMUSE00000106304|10|459|Glutamine to Lysine|||||AACTGACCATGTCCGCGTTTCTGACTGTCCAGTTGGACCGGTCCCTTGGAGGGCAGGCTGT|Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|20-Sep-2013|Cryopreserved sperm|66.0|0.0|Unknown||ENU, random, mutagenesis, screen|Possibly| 7620.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|Normal|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|5|||No|20-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU|Yes| 4798.0|ENU:G1 library|WEHI:ENU:G1||Dominant||||||||||||||||||||||||||||||||||||||Random induced point mutations.Library. Sperm and DNA stored||C57BL/6 x C3H x BALB/c ?|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|06-Sep-2009|Cryopreserved sperm|89736.0|0.0|Unknown||ENU, G1, next generation sequencing|Yes| 7326.0||SJL-Tfrc/Apb||Dominant|transferrin receptor|Tfrc||2610028K12Rik, CD71, E430033M20Rik, Mtvr1, Mtvr-1, p90, TfR1, Trfr|MGI:98822||Tfrc||16|ENSMUSG00000022797|ENSMUST00000023486|Tfrc-001|905|1045|A to T|ENSMUSE00001238795|8|302|Histidine to Leucine|||||TGTTGAGGCAGACCTTGCACTCTTTGGACATGCTCATCTAGGAACTGGTGATCCATACACA||||||||||||||Homozygous mice are not viable.|Microcytosis associated with erythrocytosis and normochromia|SJL/J|No|No|Yes|No|No|Yes|No|Good||||No|23-Apr-2013|Cryopreserved sperm|45.0|0.0|Unknown||microcytosis, ENU, transferrin|Yes| 7379.0|hairloss|C57BL/6-Frem2/Apb||Dominant|Fras1 related extracellular matrix protein 2|Frem2||6030440P17Rik, 8430406N05Rik, b2b1562Clo, my, ne|MGI:2444465||Frem2||3|ENSMUSG00000037016|ENSMUST00000091137|Frem2-201|3652|3923|A to T|ENSMUSE00000517528|1|1218|Isoleucine to Phenylalanine|||||ACATTCCCAGGGATGATCTAACGTTTACTATTACCCGGTTTCCAACTCACGGTCATGTCAT||||||||||||||The homozygous mice displays a patchy fur loss at 6 weeks old over the body without specific localisation and without specific phenotypic abnormalities.|The heterozygous mice displays a patchy fur loss at 6 weeks old over the body without specific localisation and without specific phenotypic abnormalities.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Jul-2013|Cryopreserved sperm|45.0|0.0|Unknown||Dermatology, Coat, patchy fur, ENU|Yes| 7452.0|Ghsr KO|C57BL/6-Ghsr/MarpApb||Dominant|Growth hormone secretagogue receptor|Ghsr|Nil|C530020I22Rik|MGI:2441906||||3|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||Yes|08-Oct-2013|Cryopreserved sperm|37.0|0.0|Unknown||growth hormone, homeostasis|No| 6807.0|Larry|SJL/Mrit-Krt25/MriApb||Dominant|keratin 25|Krt25||4631426H08Rik, mIRSa1|MGI:1918060||Krt25||11|||||||||||||||||||||||||||||Curly coat and curly whiskers |Curly coat and curly whiskers |SJL|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Feb-2012|Cryopreserved sperm|70.0|0.0|Unknown||Coat, wavy, curly, ENU|Yes| 7446.0|ENU29:G2|ANU:ENU29:G2||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|24-Sep-2013|Cryopreserved sperm|2355.0|40.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7443.0||C3;SJL/Mrit-MRI9414|C3;SJL/Mrit-MRI9414|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight increase growth phenotype|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|23-Sep-2013|Cryopreserved sperm|70.0|0.0|Unknown||growth, ENU|Yes| 7444.0||C3;SJL/Mrit-MRI24650|C3;SJL/Mrit-MRI24650|Dominant|unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Heterozygous mice display a slight increase growth phenotype|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|23-Sep-2013|Cryopreserved sperm|50.0|0.0|Unknown||growth, ENU|Yes| 7449.0|IL-10R flox|STOCK Il10ra/WehiAnuApb||Dominant|interleukin 10 receptor, alpha|Il10ra|Normal|CDw210, Il10r, mIL-10R|MGI:96538|interleukin 10 receptor, alpha; targeted mutation 1.1, Robert S Jack|Il10ra|MGI:4437317|9|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Oct-2013|Cryopreserved sperm|57.0|0.0|Unknown||colitis, LPS, T cell, macrophage|Yes| 7456.0|myo|C57BL/6-Gulo/MriApb|C57BL/6-Gulo|Recessive|Gulonolactone (L-) oxidase|Gulo|Unknown|L-gulono-gamma-lactone oxidase, MGC:29968, MGC:37793, MGC:37880, sfx|MGI:1353434||||14|ENSMUSG00000034450|ENSMUST00000059970|Gulo-201||||||||65990379|10|||ACAGCTGCTACATGAACATCATTATGTACAGGTGAAAGCTCTCTGCAGGGTGTGGGGTGT||||||||||||||Homozygous mice displays an impaired growth and mobility at 7 weeks old, especially on the extremities. This impaired growth is reversed with high protein diet content |Heterozygous mice are normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Oct-2013|Cryopreserved sperm|50.0|0.0|Yes||myopathy, growth, ENU|Yes| 6648.0|APN 141|C57BL/6N-1110008L16Rik/Marp||Recessive|protein only RNase P catalytic subunit|Prorp|Unknown||MGI:1913382 |RIKEN cDNA 1110008L16 gene; gene trap IST12983B7, Texas A&M Institute for Genomic Medicine |Gt(IST12983B7)Tigm|MGI:4105973|12||||||||||Unknown to Unknown||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Nov-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 7453.0|Ampd3|C57BL/6N-Ampd3/AnuApb||Recessive|adenosine monophosphate deaminase 3|Ampd3|||MGI:1096344|adenosine monophosphate deaminase 3; targeted mutation 2a, Wellcome Trust Sanger Institute|Ampd3|MGI:4362154|7|||||||||||||||||||||||||||||Unknown|||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Oct-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 5521.0|F/F x Tlr2; gp130Y757F x Tlr2|B6;129(Cg)-Il6st Tlr2/MarpApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|10-Jun-2011|Cryopreserved sperm|50.0|0.0|Yes|Gastric cancer|gastric, cancer, gp130, tlr|No| 5521.0|F/F x Tlr2; gp130Y757F x Tlr2|B6;129(Cg)-Il6st Tlr2/MarpApb||Dominant|toll-like receptor 2|Tlr2|Nil|Ly105|MGI:1346060|toll-like receptor 2; targeted mutation 1, Shizuo Akira|Tlr2|MGI:2178675|3||||||||||||||||No|||||||||||||Mice develop gastric and inflammation and tumours, as well as splenomegaly and lymphadenopathy.|If the mice are heterozygous for the gp130 knock-in mutation (F+) then the mice appear normal. |C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|10-Jun-2011|Cryopreserved sperm|||Yes|Gastric cancer|gastric, cancer, gp130, tlr|No| 7924.0|Rsp19 D:R26 M2-rtTa|C57BL/6-Col1a1 Gt(ROSA)26Sor/AnuApb||Recessive|collagen, type I, alpha 1|Col1a1||Col1a-1, Cola1, Cola-1, Mov-13|MGI:88467|collagen, type I, alpha 1; targeted mutation 2, Stefan Karlsson|Col1a1|MGI:5304755|11|||||||||||||||||||||||||||||Normal without doxycycline treatment.Premature death:• most mice die within 2 months following doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatment.Thrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased neutrophil cell number:• seven weeks after doxycycline treatment.Thrombocytopenia:• seven weeks after doxycycline treatment.Decreased lymphocyte cell number:• two and seven weeks after doxycycline treatment.Reticulocytopenia:• two weeks after doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment|Normal without doxycycline treatment.mortality/agingN • unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatmentAbnormal bone marrow cell morphology/development:• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment.Decreased bone marrow cell number:• by 10 days after doxycycline treatment• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment.Decreased megakaryocyte cell number:• seven weeks after doxycycline treatment.Abnormal proerythroblast morphology:• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatmentThrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased lymphocyte cell number:• two and seven weeks after doxycycline treatmentReticulocytopenia:• two weeks after doxycycline treatmentAbnormal bone marrow cell physiology:• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment• less pronounced than in homozygous mice|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Females Rps19 Het/R26 M2-rtTA Hom x Male Rps19 Het/R26 M2-rtTA Hom|No|19-Jun-2015|Cryopreserved sperm|107.0|0.0|Yes|Diamond-Blackfan anemia|Macrocytosis, Thrombocytosis, Thrombocytopaenia|Yes| 7924.0|Rsp19 D:R26 M2-rtTa|C57BL/6-Col1a1 Gt(ROSA)26Sor/AnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Rudolf Jaenisch|Gt(ROSA)26Sor|MGI:3702294|6|||||||||||||||||||||||||||||Normal without doxycycline treatment.Premature death:• most mice die within 2 months following doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatment.Thrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased neutrophil cell number:• seven weeks after doxycycline treatment.Thrombocytopenia:• seven weeks after doxycycline treatment.Decreased lymphocyte cell number:• two and seven weeks after doxycycline treatment.Reticulocytopenia:• two weeks after doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment|Normal without doxycycline treatment.mortality/agingN • unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatmentAbnormal bone marrow cell morphology/development:• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment.Decreased bone marrow cell number:• by 10 days after doxycycline treatment• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment.Decreased megakaryocyte cell number:• seven weeks after doxycycline treatment.Abnormal proerythroblast morphology:• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatmentThrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased lymphocyte cell number:• two and seven weeks after doxycycline treatmentReticulocytopenia:• two weeks after doxycycline treatmentAbnormal bone marrow cell physiology:• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment• less pronounced than in homozygous mice|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Females Rps19 Het/R26 M2-rtTA Hom x Male Rps19 Het/R26 M2-rtTA Hom|No|19-Jun-2015|Cryopreserved sperm|||Yes|Diamond-Blackfan anemia|Macrocytosis, Thrombocytosis, Thrombocytopaenia|Yes| 7463.0|gp130Y757F/gp130Y757F x ApoE-/- x Stat3-/+|B6.Cg-Apoe Il6st Stat3/MarpApb||Recessive|interleukin 6 signal transducer|Il6st|Normal|5133400A03Rik, CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13|||||||||||||||||||||||||||||Homozygous Stat3 mice are not viable. They are embryonic lethal.Mild gastric tumourigenesis and emphysema|Normal|C57L/6|No|No|Unknown|No|No|Unknown|No|Unknown||||No|25-Oct-2013|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, tumourigenesis|Yes| 7463.0|gp130Y757F/gp130Y757F x ApoE-/- x Stat3-/+|B6.Cg-Apoe Il6st Stat3/MarpApb||Recessive|signal transducer and activator of transcription 3|Stat3|Nil|1110034C02Rik, Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11|||||||||||||||||||||||||||||Homozygous Stat3 mice are not viable. They are embryonic lethal.Mild gastric tumourigenesis and emphysema|Normal|C57L/6|No|No|Unknown|No|No|Unknown|No|Unknown||||No|25-Oct-2013|Cryopreserved sperm|||Unknown||signal transduction, tumourigenesis|Yes| 7463.0|gp130Y757F/gp130Y757F x ApoE-/- x Stat3-/+|B6.Cg-Apoe Il6st Stat3/MarpApb||Recessive|apolipoprotein E|Apoe|Nil||MGI:88057|apolipoprotein E; targeted mutation 1, University of North Carolina|Apoe|MGI:1857129|7|||||||||||||||||||||||||||||Homozygous Stat3 mice are not viable. They are embryonic lethal.Mild gastric tumourigenesis and emphysema|Normal|C57L/6|No|No|Unknown|No|No|Unknown|No|Unknown||||No|25-Oct-2013|Cryopreserved sperm|||Unknown||signal transduction, tumourigenesis|Yes| 7510.0|APN 394|C57BL/6N-A Abca12MarpApb||Recessive| ATP-binding cassette, sub-family A (ABC1), member 12|Abca12 |||MGI:2676312 |ATP-binding cassette, sub-family A (ABC1), member 12; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbHmutation|Abca12tm1a(EUCOMM)Hmgu|MGI:4941545|1|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7465.0|ENU30:G2|ANU:ENU30:G2||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|29-Oct-2013|Cryopreserved sperm|2569.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7466.0|ENU22:MED28:G1|C57BL/6NCrlAnu-Med28/AnuApb||Recessive|mediator of RNA polymerase II transcription, subunit 28 homolog (yeast)|Med28||1500003D12Rik, Eg1, magicin|MGI:1914249|mediator complex subunit 28; mutation 1, The Australian National University|Med28|MGI:5570703|5|ENSMUSG00000015804|ENSMUST00000156481|Med28-001|275|380|A to G|ENSMUSE00001257470|3|92|Glutamic acid to Glycine|||||GAAGTTTTTGGACATTGCAAGACAGACAGAATGTTTTTTCCTACAAAAAAGGTTGCAGTTA|Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||1||No|29-Oct-2013|Cryopreserved sperm|16.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7455.0|APN376A|C57Bl/6NTac-Mlxipl/MarpApb||Recessive|MLX interacting protein-like|Mlxipl|Unknown|bHLHd14, ChREBP, Wbscr14, WS-bHLH |MGI:1927999|MLX interacting protein-like; targeted mutation 1, Velocigene |Mlxipltm1(KOMP)Vlcg |MGI:5051293|5|||||||||||||||||||||||||||||Unknown|Normal|C57Bl6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|10-Oct-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7468.0|Des lpr|B10.BR.(Cg)-H2 Fas Rag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|Fas (TNF receptor superfamily member 6)|Fas|Nil|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|Fas (TNF receptor superfamily member 6); lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||Yes|transgene insertion 10395, Bernd Arnold|||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Normal |Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||Yes|29-Oct-2013|Cryopreserved sperm|50.0|0.0|No||T cell, Fas, CD8, TCR|Yes| 7468.0|Des lpr|B10.BR.(Cg)-H2 Fas Rag1 Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|recombination activating gene 1|Rag1|Normal|Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||||||||||||||Normal |Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||Yes|29-Oct-2013|Cryopreserved sperm|||No||T cell, Fas, CD8, TCR|Yes| 7469.0|ENU12B6:020:G4|ANU:ENU12B6:020:G4||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6JSfdAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|31-Oct-2013|Cryopreserved sperm|11.0|0.0|Unknown||ENU|Possibly| 7473.0|MNABko:Cre_neg|C57BL/6-Rc3h2/AnuApb|C57BL/6-Rc3h2/Anu|Recessive|ring finger and CCCH-type zinc finger domains 2|Rc3h2|||MGI:2442789|ring finger and CCCH-type zinc finger domains 2; targeted mutation 1.1, Carola Vinuesa|Rc3h2|MGI:5508926|2|||||||||||||||||||||||||||||Normal||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Nov-2013|Cryopreserved sperm|29.0|0.0|Unknown||Roquin, T Cell, ICOS, interferon, RING|Yes| 7472.0|Maspin KO|C57BL/6J-SerpinB5/PibMarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 5|Serpinb5||1110036M19Rik, Maspin, ovalbumin, Spi7|MGI:109579|serine (or cysteine) peptidase inhibitor, clade B, member 5; targeted mutation 1.1, Phillip I Bird|Serpinb5|MGI:5484764|1|ENSMUSG00000067006 |||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7477.0|Gaia Momme D27|FVB/N-Pbrm1 Tg(HBA1-Gfp)1Ew/Apb||Semi-dominant|polybromo 1|Pbrm1|Unknown|2310032M22Rik, 2610016F04Rik, BAF180, Pb1|MGI:1923998|polybromo 1; modifier of murine metastable epialleles, D27|Pbrm1|MGI:5515370|14||||||||||Unknown to Unknown||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Mutant homozygous mice die before birth. Postnatal lethality: * Hetrozygous animals survive to weaning * normal litter size at birth||FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD27<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|13-Nov-2013|Cryopreserved sperm|49.0|0.0|Unknown||epigenetics, suppressor of variegation, ENU|Yes| 6762.0|SBmut9|NOD/Lt-Tn(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)9TCB/Apb|TCB|Semi-dominant||||||||||||||||||||||||||pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo||||||||||||Unknown|Unknown|NOD/Lt|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||sleeping beauty|No| 6762.0|SBmut9|NOD/Lt-Tn(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)9TCB/Apb|TCB|Semi-dominant||||||||||||||||||||||||||pRP-1345|proximal protamine 1 (Prm-1) promoter|||||||||||Unknown|Unknown|NOD/Lt|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Dec-2011|Cryopreserved sperm|||Unknown||sleeping beauty|No| 7471.0|square head|C57BL/6-Pfas/Apb||Dominant|phosphoribosylformylglycinamidine synthase (FGAR amidotransferase)|Pfas|Unknown|4432409B16Rik, Sofa|MGI:2684864||||11|ENSMUSG00000020899|ENSMUST00000021282|Pfas-001|2099|2192|T to C|ENSMUSE00001246828|18|700|Lysine to Proline|||||TGTTGCCCAACAGCAGTGTGTCGGACCCCTGCAGACTCCTCTGGCTGATGTGGCTGTTGTA||||||||||||||Unknown|Heterozygous mice displays a short snout, domed cranium and a decreased body weight.|C57BL/6|No|No|Yes|No|No|Yes|No|Poor||||No|07-Nov-2013|Cryopreserved sperm|40.0|0.0|Unknown||craniofacial, snout face, ENU|Yes| 7474.0|MNABko:Cre_pos|C57BL/6-Rc3h2/AnuApb|C57BL/6-Rc3h2/Anu|Recessive|ring finger and CCCH-type zinc finger domains 2|Rc3h2|||MGI:2442789|ring finger and CCCH-type zinc finger domains 2; targeted mutation 1.2, Carola Vinuesa|Rc3h2|MGI:5508928|2|||||||||||||||||||||||||||||Immune system phenotype:• homozygotes are viable and do not over express ICOS• effector and memory CD4+ cells, T follicular helper cells all normal• germinal centers all normalIncreased macrophage cytokine production:• increased portion of macrophage producing TNF||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Nov-2013|Cryopreserved sperm|47.0|0.0|Unknown||Roquin, T Cell, ICOS, interferon, RING|Yes| 7478.0|Line 3C|C57BL/6J-Tg(HBA1-Gfp)1Ew/Apb||Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region.|||||||||||Normal|Normal|C57BL/6J |Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Nov-2013|Cryopreserved sperm|30.0|0.0|Unknown||epigenetics, suppressor of variegation|Yes| 5548.0|Smg1|B6;129P2-Smg1/QimrApb||Semi-dominant|SMG1|SMG1|Reduced|mKIAA0421; 2610207I05Rik; 5430435M13Rik; C130002K18Rik |MGI:1919742 |SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans); gene trap AG0297, Wellcome Trust Sanger Institute|Smg1|MGI:3876748|7|||||||||||||||||||||||||||||Knockout is early embryonic lethal.|Heterozygous mice have increased cancer susceptibility.|C57BL/6J x 129P2/Sv|No|No|Yes|No|No|Yes|No|Good||34|Hetrezygotes x Heterozygotes|No|08-Aug-2011|Cryopreserved sperm|50.0|0.0|Yes|model of spontaneous cancer development associated with aging.|nonsense mediated decay, DNA damage, cancer |Possibly| 7483.0|Vav1KO/B6|B6.129S2-Vav1/AnuApb||Recessive|vav 1 oncogene|Vav1|Nil||MGI:98923|vav 1 oncogene; targeted mutation 1, Victor L J Tybulewicz|Vav1|MGI:2387838|17|||||||||||||||||||||||||||||Abnormal negative T cell selection:• deletion of CD4+ cells expressing Vbeta3, 5, and 11 is less than in wild-type mice suggesting impaired negative selection.Abnormal T cell number:• large decrease of single "+" cellsIncreased double-negative T cell number.Increased DN2 thymocyte number.Increased DN3 thymocyte number.Decreased double-positive T cell number.Abnormal immune system physiology.Abnormal CD8-positive T cell physiology:• reduced ability of CD8+ cells to form conjugates with antigen presenting cells.Abnormal interleukin-2 secretion.||C57BL/6|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|14-Nov-2013|Cryopreserved sperm|29.0|0.0|Unknown||T cell, GTP, selection, thymocyte, Rho|Yes| 7484.0|Clock Mel|CBA;B6-Clock/Apb||Semi-dominant|circadian locomotor output cycles kaput|Clock||5330400M04Rik, bHLHe8, KAT13D, mKIAA0334|MGI:99698|circadian locomotor output cycles kaput; Clock|Clock|MGI:1861634|5|||||||||||||||||||||||||||||The mutant animals displays an altered period of rhythmicity of wheel running activity in constant darkness (approx 27 hours), followed by arrythmicity after an extended period.|The heterozygote displays a slightly longer period of behavioural rhythmicity in constant darkness (approx 24.5 hours).|CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|4|0|Maintain mutant and wild type as separate lines.|No|14-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown||circadian, clock|No| 7485.0|WinSlpi|B6.129P2-Muc2 Slpi/Apb|UTAS|Recessive|mucin 2|Muc2|Unknown||MGI:1339364|mucin 2; winnie|Muc2|MGI:3614806|7|||||||||||||||||||||||||||||No explicit phenotype, normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown||endoplasmic reticulum , stress, mucin, colitis|No| 7485.0|WinSlpi|B6.129P2-Muc2 Slpi/Apb|UTAS|Recessive|secretory leukocyte peptidase inhibitor|Slpi|Nil||MGI:109297|secretory leukocyte peptidase inhibitor; targeted mutation 1, Toshihiro Nukiwa|Slpi|MGI:2652666|2|||||||||||||||||||||||||||||No explicit phenotype, normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Nov-2013|Cryopreserved sperm|||Unknown||endoplasmic reticulum , stress, mucin, colitis|No| 7475.0|Momme D28|FVB/NJ-Rlf Tg(Hba1-Gfp)1Ew/Apb||Recessive|rearranged L-myc fusion sequence|Rlf|Reduced||MGI:1924705|rearranged L-myc fusion sequence; modifier of murine metastable epialleles, D28|Rlf|MGI:5515366|4||||||||||Unknown to Unknown||||||Yes|transgene insertion 1, Emma Whitelaw|human alpha-globin promoter and enhancer region|11 copies||||||||||Homozygous die|Normal|FVB/NJ|No|No|Yes|No|No|Yes|No|Good||||No|12-Nov-2013|Cryopreserved sperm|20.0|0.0|Unknown||ENU|Yes| 8725.0|ACAD10KO|C57BL/6-Acad10/Apb||Recessive|Acyl-CoA Dehydrogenase Family Member 10|Acad10||2410021P16Rik|MGI:1919235||||5|||||||||||||||||||||||||||||Normal as far as initial experiments have shown|Normal as far as initial experiments have shown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 4524.0||C57BL/6-Socs1 Tg(Lck-cre)157Jxm/Apb||Recessive|suppressor of cytokine signaling 1|socs1|Nil|Cish1, Cish7, JAB, JAK-binding protein, JAK2-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|targeted mutation 3, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:2656917|16||||||||||Unknown to Unknown||||||Yes|transgene insertion I57, Jamey Marth|lymphocyte protein tyrosine kinase (Lck)|||||||||||Enhanced differentiation of thymocytes toward CD8+ T cells. Thymus hyperplasia.Enlarged lymph nodes||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|27-Feb-2009|Cryopreserved sperm|95.0|0.0|Unknown||cytokine signalling, T cell, thymus, hyperplasia|Yes| 5116.0|ENU11B6-C3H:005 ; bfb|B6;C3H-Fras1/AnuApb|B6;C3H-Fras1/AnuApb|Recessive|Fraser syndrome 1 homolog (human)|Fras1|Unknown|bl, E130113P14Rik, mKIAA1500|MGI:2385368|Fraser syndrome 1 homolog (human); blood filled blisters|Fras1|MGI:5463442|5|ENSMUSG00000034687|ENSMUST00000036019|Fras1-201|10762|11620|T to C|ENSMUSE00000318929|69|3588|Serine to Proline|||||AGCTCTTGTGGAGTGCTCAGACATTTGATTCTCCTCATCAACTCTGGCGAGCCACGAGCTC|Yes|||||||||||||Embryonic lethal.Cleft secondary palate:• at E18.5Eyelids open at birth:• at E18.5Bleb• blood filled blisters on the head and feet at E13.5.Preaxial polydactyly:• at E18.5Absent kidney:• at E18.5Cleft secondary palate:• at E18.5||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|11-May-2010|Cryopreserved sperm|50.0|0.0|Unknown||ENU, blebs, adhesion, Fraser syndrome|Yes| 5469.0|ENU12B6-C3/H:C3H:022|B6;C3H-Lig1/AnuApb||Recessive|ligase I, DNA, ATP-dependent|Lig1|Unknown|LigI, mLigI|MGI:101789|ligase I, DNA, ATP-dependent; mutation 1, The Australian National University|Lig1|MGI:5510743|7|ENSMUSG00000056394|ENSMUST00000148471|Lig-001|1798|2054|A to T|ENSMUSE00000537286|19|600|Isoleucine to Phenylalanine|||||TACATGTTCTGGAAGGTGGAGAAGTGAAGATCTTCAGCAGGAACCAGGAAGACAACACAGG|Yes|||||||||||||Embryonic lethality. Embryos at E13.5 exhibit a pale, orange liver with failure of definitive erythropoiesis|Normal|C57BL/6J X C3H|No|No|Yes|No|No|Yes|Yes|Good||3|het x het|No|24-Mar-2011|Cryopreserved sperm|45.0|0.0|Unknown||embryonic, erythropoiesis, ENU, anaemia|Yes| 3338.0|Cbfa2t3|C57BL/6-Cbfa2t3/Apb||Semi-dominant|core-binding factor, runt domain, alpha subunit 2, translocated to, 3 (human)|Cbfa2t3|Normal|ETO-2, Eto2, MTGR2|MGI:1338013||||8||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4|||No|20-Jun-2008|Cryopreserved sperm|57.0|25.0|No||leukaemia / leukemia, translocation, breast, transcription|Yes| 5467.0|D6|B6.129/Sv-Ccbp2/Apb||Recessive|chemokine binding protein 2|Ccbp2|Nil|CCR10, CCR9, Cmkbr9, D6|MGI:1891697|chemokine binding protein 2; targeted mutation 1, Gerard J Graham|Ccbp2|MGI:3623613|9||||||||||||||||Yes|||||||||||||Increased inflammatory response: * subcutaneous injection of complete Freund's adjuvant (CFA) produces a granuloma-like lesion in homozygotes by 3 days post injection and 18 of 28 mutants develop grade 2 or higher lesions by 7 days post injection versus 2 of 28 wild-type mice * at the site of CFA injection increased necrosis, angiogenesis and leukocyte infiltration are seen * 3 days after CFA injection increase lymph node cellularity is seen in homozygotes compared to wild-type mice; however 7 days after injection wild-type contralateral lymph nodes display hyperplasia which is not seen in homozygotes.Dermatitis: * 24 hours after a single exposure of dorsal skin to 12-O-tetradecanoylphorbol-13-acetate (TPA) beta-chemokine levels remain elevated suggesting a defect in post-inflammatory clearance. * after 3 daily applications of TPA homozygotes develop a psoriasis-like skin lesion that is characterized by skin thickening, basal and suprabasal epidermal hyperproliferation, severe epidermal acanthosis, parakeratosis, hyperkeratosis, extensive growth of convoluted blood vessels, and a dense inflammatory cell infiltrate that includes high numbers of T cells * this TPA-induced inflammatory skin lesion persists for 6 to 10 days. * injection of TNF neutralizing antibodies, depletion of CD4+ and CD8+ T cells, or blockage of mast cell degranulation can prevent development of the TPA-induced psoriaform lesion.||129/Sv x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||dermatitis|Yes| 5315.0|BALB.SHIP-1 knockout|C.129P2(B6)-Inpp5d/JAcbdLudApb|C.129P2(B6)-Inpp5d/JAcbdLudApb|Recessive|inositol polyphosphate-5-phosphatase D|Inpp5d|Nil|s-SHIP, SHIP, SHIP-1, SHIP1, Src homology 2 domain-containing inositol-5-phosphatase|MGI:107357|inositol polyphosphate-5-phosphatase D; targeted mutation 1, Dan Dumont|Inpp5d|MGI:1861956|1||||||||||||||||No|||||||||||||Young mice are apparently healthy, and do not develop inflammatory lung disease, unlike mixed genetic background or C57BL/6 background SHIP-1<-/-> mice. |No obvious disease is apparent in SHIP-1<+/-> mice, even at 12 months of age.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|7|||No|10-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||phosphorylation, phosphatase, PI3'K, inflammatory lung disease, myeloid hyperplasia, signal transduction|Yes| 6813.0|B6.hCD55.Tg.EA|CBA.B6-Tg(H2-K-CD55)/SvhmApb||Dominant||||||||||||||||||||||||||human CD55 Antigen|murine class 1 H2-K|moderate to high||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|14|||No|08-Feb-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 125.0|Ceres ; MM4|C57BL/6SfdAnu-Tg(IghelM)Ccg/AnuApb|C57BL/6SfdAnu-Tg(IghelM)Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 4, Christopher C Goodnow|Controlled by normal promoter|low, transgene H and L chains are cointergrated and driven under their normal elements||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|37.0|0.0|No||IgM, Hen Egg Lysozyme, B cell, receptor, Immunoglobulin|Yes| 5248.0|Lyn STAT6 double knockout ; BALB.Lyn-/-STAT6-/-|C.Cg-Lyn Stat6/Apb||Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Nil|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Ashley R Dunn|Lyn|MGI:2157129|4||||||||||||||||No|||||||||||||Mice develop exaggerated autoimmune disease compared with Lyn<-/-> mice.At a time-point where Lyn(-/-) mice showed only mild autoimmune disease, Lyn(-/-)STAT6(-/-) mice had maximal titres of IgG and IgA auto-Abs, impaired renal function, myeloid expansion and a highly activated T cell compartment. Remarkably, low level IgE auto-Abs but not IgG1 auto-Abs were a feature of some aged Lyn(-/-) STAT6(-/-) mice. Furthermore, aged Lyn(-/-)STAT6(-/-) mice showed dramatically increased levels of serum IgE but minimal IgG1, suggesting that class-switching to IgE can occur in the absence of an IgG1 intermediate.|Not defined|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||B cell, src family, kinase, signal transduction, autoimmunity, lymphocyte|Yes| 5248.0|Lyn STAT6 double knockout ; BALB.Lyn-/-STAT6-/-|C.Cg-Lyn Stat6/Apb||Recessive|signal transducer and activator of transcription 6|Stat6|Nil||MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10||||||||||||||||No|||||||||||||Mice develop exaggerated autoimmune disease compared with Lyn<-/-> mice.At a time-point where Lyn(-/-) mice showed only mild autoimmune disease, Lyn(-/-)STAT6(-/-) mice had maximal titres of IgG and IgA auto-Abs, impaired renal function, myeloid expansion and a highly activated T cell compartment. Remarkably, low level IgE auto-Abs but not IgG1 auto-Abs were a feature of some aged Lyn(-/-) STAT6(-/-) mice. Furthermore, aged Lyn(-/-)STAT6(-/-) mice showed dramatically increased levels of serum IgE but minimal IgG1, suggesting that class-switching to IgE can occur in the absence of an IgG1 intermediate.|Not defined|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Oct-2010|Cryopreserved sperm|||Unknown||B cell, src family, kinase, signal transduction, autoimmunity, lymphocyte|Yes| 6857.0|ENU15NIH85a ; enid|C57BL/6JAnu-Sppl2a/AnuApb|C57BL/6JAnu-Sppl2a/AnuApb|Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802 |signal peptide peptidase like 2A; mutation 1, The Australian National University|Sppl2a|MGI:5432126|2|ENSMUSG00000027366|ENSMUST00000028844|2010106G01Rik-001||||||||126746052|7|||ATTCATAGGATGCCATGTGGACAGTGCACGTACGTATCTGTTAGCCTATGATGCAATTAG||||||||||||||Decreased number of B cells.Very low expression of IgD on the IgM subset of mature B cells.25-fold less serum IgM.6-fold less serum IgG1.Almost no specific antibody was made after immunization with formalin-inactivated and heat-killed Bordetella pertussis and alum-precipitated chicken gamma globulin (CGG) coupled to p-azobenzenearsonate (ABA) hapten or after immunization with the T-independent antigen 4-hydroxy-3-nitrophenylacetyl-Ficoll (NP-Ficoll.Normal numbers of pro-B, pre-B, and immature B cells, and normal cell surface IgM and normal onset of IgD expression among the IgM T1 subset.Mature IgD<+>IgM recirculating B cells were selectively decreased in the bone marrow and had very low surface IgD. In the spleen, the T1 subset of recent bone marrow emigrants (CD93<+>IgMCD23<−>) was present in normal numbers and expressed levels of surface IgM comparable with controls.Subsequent maturational stages of T2, T3, and mature CD93<−>IgM B cells were 20-fold reduced, whereas the mature marginal zone B cell subset was decreased 200-fold. Immunofluorescent staining of spleen sections showed that the residual B cells in SPPL2A-deficient mice nevertheless localized normally in primary follicles.Sppl2a<−/−> mice had fewer CD11c<+> DCs as the result of only 12% of normal numbers in the CD4<+> and the CD4<−>CD8<−> double-negative (DN) DC subsets, whereas CD8<+> and plasmacytoid DCs were present at normal and increased numbers, respectively. Less CD11c and CD8 was present on the B220<−>CD8<+> DCs in Sppl2a<−/−> animals.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||G7||No|15-Mar-2012|Cryopreserved sperm|67.0|0.0|Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|No| 78.0|Thunder|C57BL/6JSfdAnu-Hnrnpll/AnuApb|C57BL/6JSfdAnu-Hnrnpll/AnuApb|Recessive|heterogeneous nuclear ribonucleoprotein L-like|Hnrpll|Nil||MGI:1919942|heterogeneous nuclear ribonucleoprotein L-like; thunder|Hnrpll|MGI:3707008|17|ENSMUSG00000024095|ENSMUST00000061331|Hnrpll-201|407|683|T to A|ENSMUSE00000138333|2|136|Valine to Aspartic acid|||||TGTCCATGTTCGAGGGCTCTGTGAATCTGTTGTGGAAGCTGACCTTGTGGAGGCACTGGAG|Yes|||||||||||||Low T cell numbers which are hyperactivated. By flow cytometric staining of blood, initially detected a strain with CD4 T cells decreased to 25% of wild-type. Further analysis revealed entirely normal thymic development and single positive cells, but a marked reduction in the number of peripheral T cells especially naïve CD4 and CD8 cells, and poor survival of thunder T cells upon adoptive transfer. During this analysis, it was found that thunder thymocytes stain with the RA3-6B2 antibody that selectively recognizes the CD45RABC B220 isoform normally restricted to B cells. Staining with antibodies to CD45RA, B or C showed a 50-fold increase in staining on all thymocytes and peripheral T cells, as well as macrophages and dendritic cells, so that the staining intensity matched that on B cells. Amplification of cDNA with primers spanning CD45 exons 4-6 showed a dramatic increase in the inclusion of these exons in thymocyte CD45 mRNA, establishing that the thunder mutation interferes with the normal CD45 exon 4-6 silencing process.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|48.0|0.0|Unknown||T cell, B cell, lymphocyte, CD45, ENU, NIH|Yes| 74.0|theoden ; ENU4AT:050 |STOCK H2 Fas/AnuApb|STOCK H2 Fas/AnuApb|Recessive|Fas (TNF receptor superfamily member 6)|Fas|Nil|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|theoden|Fas|MGI:4455060|19|ENSMUSG00000024778|ENSMUST00000025691|Fas-201|416|422|G to A|ENSMUSE00000144910|4|139|Cysteine to Tyrosine|||||CTACTGCGATTCTCCTGGCTGTGAACACTGTGTTCGCTGCGCCTCGTGTGAACATGGAACC|Yes||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17|Antinuclear autoantibodies, lymphadenopathy.||C57BL/6JStdAnu x C57BL/10.Cg-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Apr-2004|Cryopreserved sperm|44.0|0.0|Unknown||B cell, T cell, lymphadenopathy, ENU, Wellcome Trust|Yes| 10399.0| Dicer floxed:GtROSA |B6(Cg)-Dicer Gt(ROSA)26Sor/Anu||Dominant|dicer 1, ribonuclease type III|Dicer1|||MGI:2177178 |dicer 1, ribonuclease type III; targeted mutation 1, Brian D Harfe|Dicer |MGI:3589208|12|ENSMUSG00000041415|ENSMUST00000041987|||||||||||||||gene trap ROSA 26, Philippe Soriano||||||||||||Prone to seizures, handle gently and with hood light off.|Normal|C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Dec-2023|Cryopreserved sperm|33.0|0.0|Unknown|||Possibly| 10393.0|gBT-1|C57BL/6-Tg(TcraHsv2.3,TcrbHsv2.3)L118-1Cbn/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion L118-1, Frank Carbone||||||||||||Normal|Normal|Congenic B6 - B6Ncrl.SJL CD45.1|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Dec-2023||0.0|0.0|Unknown|||Possibly| 2455.0|anubis|CBA/CaJAnu-Cd83/AnuApb|CBA/CaJAnu-Cd83/AnuApb|Recessive|CD83 antigen|Cd83|Unknown||MGI:1328316|anubis|Cd83|MGI:3819968|13|ENSMUSG00000015396|ENSMUST00000015540|Cd83-201||||||||43895078|4|||TTCTACCTGACACTCATCATTTTCACCTGCGTAAGTGTCTGGTCAAAGCACCTGTTGCTG|Yes|||||||||||||Fewer CD4 T cells in peripheral blood or in thymus. Decreased cell surface expression of MHC II and CD86 on dendritic cells and B cells. Antinuclear autoantibodies (homogeneous nuclear) although this was incompletely penetrant on B6 background and absent on CBAxB6 background and may or may not be linked to CD4 cell deficiency. ||CBA/CaJAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jan-2008|Cryopreserved sperm|35.0|0.0|Unknown||T cell, CD4, B cell, MHC II, ENU, Wellcome Trust|Yes| 4523.0|batface|BALB/c-Ctnnb1/HAnuApb||Recessive|catenin (cadherin associated protein), beta 1|Ctnnb1|Unknown|beta catenin, beta-catenin, Catnb|MGI:88276|catenin (cadherin associated protein), beta 1; batface|Ctnnb1|MGI:2656734|9|ENSMUSG00000006932|ENSMUST00000007130|Ctnnb1-001|1958|2245|C to A|ENSMUSE00001277189|12|653|Threonine to Lysine|||||ACTCCACTCCAGGAATGAAGGCGTGGCAACATACGCAGCTGCTGTCCTATTCCGAATGTCT|Yes|||||||||||||Homozygous null embryos show anterior-posterior axis formation anomalies, but develop to E 7. Multiple conditional mutations have shown defects in distinct stem cell types that result in proliferation defects, such as intestinal polyps, brain and spinalcord size anomalies, etc.|Craniofacial defects|BALB/c|No|No|Yes|No|No|Yes|No|Good|10||Het male x wt Balb/c female|No|27-Feb-2009|Cryopreserved sperm|90.0|0.0|Unknown||embryonic lethal, ENU, craniofacial, forebrain, exencephaly|Yes| 3686.0|Thoth ; ENU9B6:064a|C57BL/6JSfdAnu-Cd4/AnuApb|C57BL/6JSfdAnu-Cd4/AnuApb|Recessive|CD4 antigen|Cd4|Unknown|L3T4, Ly-4|MGI:88335|CD4 antigen; thoth|Cd4|MGI:4819162|6|ENSMUSG00000023274|ENSMUST00000024044|Cd4-001||||||||124823158|3|||CAGGGCACCTCAACTTCTTTTGTATGGCTTCGATTTGCAGGAGGTTCGCCTTCGCAGTTT|Yes|||||||||||||No CD4<+> T cells in thymus or periphery||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4|affected x affected or affected x B6|No|26-Aug-2008|Cryopreserved sperm|55.0|0.0|Unknown||T cell, CD4, ENU, NIH, Wellcome Trust|Yes| 28.0|Armadillo|STOCK H2 Dsg4/AnuApb|STOCK H2 Dsg4/AnuApb|Recessive|desmoglein 4|Dsg4|Unknown|CDHF13, lah|MGI:2661061|armadillo|Dsg4|MGI:3846150|18||||||||||||||||No||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17|Hairless and wrinkly. The Armadillo mice have a very short hair coat all over the body. The short hair is most pronounced on the extremities, eg. Ears, tail, muzzle and limbs up to the hock and elbow, and ventrally. The hair dorsally looks more normal, but it appears to lack guard hairs. This appearance is possibly due to breakage of all hair follicles causing an overall shorter appearance to the coat. The skin also appears slightly hyperaemic (reddened), but this could just be due to less hair coverage. The affected mice appear to have no whiskers and are also smaller than normal littermates. On histology, the most obvious feature is generalised epidermal hyperplasia. The affected mice also have an "onion bulb" appearance to the base of the hair follicle. Above this is an area of bright orange/pink staining which suggests premature cornification of the hair shaft and adjacent inner root sheath. Some mice had a mild neutrophilic infiltrate into the dermis and some mice had focal pink swellings of the hair fibres. The hair follicle produced is abnormal and prone to breakage resulting in short hair. ||C57BL/6JSfdAnu x B10.BR-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||6|Affected male by unaffected female|No|06-Feb-2006|Cryopreserved sperm|87.0|0.0|Unknown||Hair, Coat, Epidermis, follicle, ENU|Yes| 90.0|Willow|C57BL/6JSfdAnu-Jak3/AnuApb|C57BL/6JSfdAnu-Jak3/AnuApb|Recessive|Janus kinase 3|Jak3|Nil||MGI:99928|willow|Jak3|MGI:3611885|8|ENSMUSG00000031805|ENSMUST00000051995|Jak3-001|2474|2771|G to T|ENSMUSE00000213233|18|825|Glycine to Valine|||||GAGACACCTTAAGTACATCTCTTTGCTGGGCAAGGGCAACTTTGGCAGCGTGGAGCTGTGC|No|||||||||||||Lymphopenia due to reduction of both Thy1.2⁺ and B220⁺ cellsReduced numbers of CD8⁺ cellsB cell block in transition from pro-pre B cells; Develop autoimmune inflammatory bowel disease associated with diarrhoea and prolapse. Homozygotes have reduced life span.? SCID phenotype.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|80.0|0.0|Unknown||B cell, T cell, maturation, lymphopenia, ENU|Yes| 7583.0|ENU26:008:Klotho|C57BL/6NCrlAnu-Kl/AnuApb|C57BL/6NCrlAnu-Kl/AnuApb|Recessive|klotho|Kl||alpha-kl|MGI:1101771|klotho; mutation 1, The Australian National University|Kl|MGI:5563457|5|ENSMUSG00000058488|ENSMUST00000078856|Kl-201|984|1094|G to A|ENSMUSE00000191090|2|328|Tryptophan to STOP|||||CAGAAGTCTCTTGACTTTGTGCTAGGCTGGTTTGCCAAACCCATATTTATTGATGGCGACT||||||||||||||MacropathologyThe mouse displayed moderate dehydration and respiratory distress before euthanasia. Loops of small intestine were noted in the thoracic cavity upon opening of the thoracic cavity indicating the presence of a diaphragmatic hernia. The spleen was very small and the kidneys were bronze. No masses were noted on thepaws at necropsy.HistopathologyBrain, salivary gland, liver, oesophagus, ileum, caecum, colon, pancreas, lung – unremarkable.KidneyThe kidney displays severe mineralisation of the cortex. The areas of mineralisation are multifocal to coalescingand involve the tubular tissues as well as blood vessel walls. There is golden pigment present in the medullarytubules and collecting ducts.DuodenumThe lamina propria of the duodenum is effaced by the presence of large amounts of mineralisation.HeartThe heart displays severe multifocal mineralisation of the aorta and large blood vessels. In addition, there issevere mineralisation of tracheal cartilage rings and submucosa (still attached to heart).StomachThe glandular stomach displays severe dilatation of occasional gastric glands with necrotic cellular content aswell as fragments of calcium. In addition, severe mineralisation of all small blood vessels and the entiresubmucosa of the glandular stomach is apparent. Furthermore, moderate mineralisation of the smooth muscleof the tunica muscularis is also evident.SpleenThe spleen indicates an immunocompromised phenotype with a complete absence of periarteriolar lymphoidsheaths. Minimal haemopoiesis is evident in the red pulp.PawsThere is evidence of small, focal areas of mineralisation in the dermal tissue, connective tissue as well asadjacent to the bone. The bones display moderate medullary haemorrhage and lack of trabeculae which maybe related to excessive bone destruction resulting in hypercalcaemia.DiagnosisSevere, chronic, multifocal mineralisation of glandular stomach, kidney, aorta, duodenum, trachea,dermis/connective tissue of paws.Minimal splenic haemopoiesis and absence of periarteriolar lymphoid sheaths.||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|05-Feb-2014|Cryopreserved sperm|29.0|0.0|Unknown||calcification|Yes| 5375.0|anubis|B6;CB-Cd83/AnuApb|B6;CB-Cd83/AnuApb|Recessive|CD83 antigen|Cd83|Unknown||MGI:1328316|anubis|Cd83|MGI:3819968|13|ENSMUSG00000015396|ENSMUST00000015540|Cd83-201||||||||43895078|4|||TTCTACCTGACACTCATCATTTTCACCTGCGTAAGTGTCTGGTCAAAGCACCTGTTGCTG|Yes|||||||||||||Fewer CD4 T cells in peripheral blood or in thymus. Decreased cell surface expression of MHC II and CD86 on dendritic cells and B cells. Antinuclear autoantibodies (homogeneous nuclear) although this was incompletely penetrant on B6 background and absent on CBAxB6 background and may or may not be linked to CD4 cell deficiency. ||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2010|Cryopreserved sperm|18.0|0.0|Unknown||T cell, CD4, B cell, MHC II, ENU, Wellcome Trust|Yes| 4498.0|primurus, ENU7B6:079|C57BL/6JAnu-Dock8/AnuApb|C57BL/6JAnu-Dock8/AnuApb|Recessive|dedicator of cytokinesis 8|Dock8|Unknown||MGI:1921396|primurus|Dock8|MGI:3835421|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201|5479|5601|T to C|ENSMUSE00000145941|42|1827|Serine to Proline|||||AACCCGCAATCACGAAGCTCCCGGAGATCTCACATAGACTAGAGGGATTTTATGGCCAGTG|Yes|||||||||||||Defective antibody response to immunization: failure to sustain antibody formation, undergo affinity maturation or to mount heightened recall (memory) response upon booster immunization. DOCK8-mutant B cells were unable to form marginal zone B cells or to persist in germinal centers and undergo affinity maturation. Dock8 mutations disrupted accumulation of the integrin ligand ICAM-1 in the B cell immunological synapse but did not alter other aspects of B cell antigen receptor signaling.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Feb-2009|Cryopreserved sperm|62.0|0.0|Unknown||memory, antibody, immunization, ENU, Wellcome Trust, B cell, GTP|Yes| 7674.0|ENU25:036:DDX21|C57BL/6NCrlAnu-Ddx21/AnuApb|C57BL/6NCrlAnu-Ddx21/AnuApb|Recessive|DEAD (Asp-Glu-Ala-Asp) box polypeptide 21|Ddx21|Unknown|D10Ertd645e, D10Wsu42e, RH II/Gu, RH-II/Gualpha|MGI:1860494|DEAD (Asp-Glu-Ala-Asp) box polypeptide 21; mutation 1, The Australian National University|Ddx21|MGI:5563491|10|ENSMUSG00000020075|ENSMUST00000045866|Ddx21-201|577|661|C to A|||193|Glutamic acid to STOP|||||AGCTGAAGAATGGACTCTCCCAACCTTCCGAAGAAGAGGTAGACATTCCTAAGCCCAAGAA||||||||||||||Embryonic lethal|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD measured by flow cytometry.|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||G5|Het x Het|No|08-May-2014|Cryopreserved sperm|26.0|0.0|Unknown||ENU, embryonic lethal|Yes| 2164.0|Delficio ; ENU8F:005|B6;CBA-Clcn1/AnuApb|B6;CBA-Clcn1/AnuApb|Recessive|chloride channel 1|Clcn1|Unknown|Clc-1, Clc1, nmf310, NMF355, nmf355, SMCC1|MGI:88417|chloride channel 1; mutation 1, The Australian National University|Clcn1|MGI:5563496|6|ENSMUSG00000029862|ENSMUST00000031894|Clcn1-201|99|181|C to A|ENSMUSE00000712505|1|32|Tyrosine to STOP|||||TACATGCCCTTTGAACATTGTACCAGCTACGGACTGCCCTCAGAGAATGGGGGCCTTCAGC|Yes|||||||||||||Progressive hindlimb weakness and ataxia with stiff gait. Develops sensory deficits and shows periods of increased muscular tone/tetany.||C57BL/6JSfdAnu x CBA/H|Yes|No|Yes|Yes|No|Yes|No|Poor||4|Het x Het|No|15-Oct-2007|Cryopreserved sperm|52.0|0.0|Unknown||Ataxia, weakness, hind limb, muscle, ENU|Yes| 7549.0|ENU24:048:Dennd5b|C57BL/6NCrlAnu-Dennd5b/AnuApb|C57BL/6NCrlAnu-Dennd5b/AnuApb|Recessive|DENN/MADD domain containing 5B|Dennd5b||9330160C06Rik, D030011O10Rik|MGI:2444273|DENN/MADD domain containing 5B; mutation 1, The Australian National University|Dennd5b|MGI:5563480|6|ENSMUSG00000030313|ENSMUST00000111557|Dennd5b-001|2344|2715|A to G|ENSMUSE00000898644|10|782|Cysteine to Arginine|||||TGGAAGAAAACACCTTGATCGCCAGCCTGTGTGACCTACTGGAGAGGATATGGAGCCACGG||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G5||No|19-Dec-2013|Cryopreserved sperm|46.0|0.0|Unknown||ENU|Yes| 5530.0|ENU16WT:029|C57BL/6JAnu-Inpp5d/AnuApb|C57BL/6JAnu-Inpp5d/AnuApb|Recessive|inositol polyphosphate-5-phosphatase D|Inpp5d|Unknown|s-SHIP, SHIP, SHIP-1, SHIP1, Src homology 2 domain-containing inositol-5-phosphatase|MGI:107357|inositol polyphosphate-5-phosphatase D; mutation 1, The Australian National University|Inpp5d|MGI:5563462|1|ENSMUSG00000026288|ENSMUST00000169754|Inpp5d-001|1411|1588|T to C|ENSMUSE00000157571|12|471|Serine to Proline|||||AGAAGGAGTGGCTGGAGCTACTCAGGCACTCCCTGCAAGAAGTCACCAGCATGACATTTAA||||||||||||||Animals begin to show signs of ill health between 7 and 12 weeks of age. Examination by pathologist of an affected animal gave the following report:1.Intra-alveolar acidophilic macrophage pneumonia with scattered microhaemorrhages. A superimposed recent suppurative bronchiolar pneumonia with microabscesses and early bronchitis.2.Histiocytic (B cell) Lymphoma involving mediastinal lymph nodes, lung, spleen and small intestine.3.The micromorphological changes in the lymphoid tissues were examined by three Veterinary Histopathologists and by consensus there was agreement that there was a histiocytic B cell type of lymphoma involving nodes, lung, small intestine and spleen (minimally).|Macroscopically normal. Detailed pathology not performed.|C57BL/6JAnu|No|Unknown|Yes|No|Unknown|Yes|No|Good|||Het x Het|No|06-Jul-2011|Cryopreserved sperm|31.0|0.0|No||ENU, pneumonia, macrophage|Yes| 5070.0|Warmflash|C57BL/6J-Flt3/BtlrAnuApb|C57BL/6J-Flt3/BtlrAnuApb|Recessive|FMS-like tyrosine kinase 3|Flt3|Unknown|CD135, Flk-2, Flk2, Flt-3, wmfl|MGI:95559|FMS-like tyrosine kinase 3; mutation 1, Bruce Beutler|Flt3|MGI:3628823|5|ENSMUSG00000042817|ENSMUST00000049324|Flt3-001||||||||147367088|8|||AATATCTAATTTGTAAATTTCCTTTTTACAGAAAAAGGGTTTATAAACGCTACCAGCTCG|Yes|||||||||||||Susceptible to Mouse cytomegalovirus (MCMV) at a dose of 1x10<5> PFU.Decreased dendritic cell number: conventional DCs are reduced in bone marrow and spleen.Decreased plasmacytoid dendritic cell number: both the number and percentage of pDCs are reduced in bone marrow and spleen.Decreased NK cell number: splenic NK cells are reduced in percentage and number, bone marrow NK cells are only moderately reduced.Decreased splenocyte number: spleens and lymph nodes are consistently smaller and show reduced cellularity.Small lymph nodes.Abnormal dendritic, marcophage and NK cell physiology.Decreased body weight.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Mar-2010|Cryopreserved sperm|50.0|0.0|Unknown||infection, MCMV, ENU, dendritic cell, marcophage, NK cell, ENU|Yes| 7584.0|Eeyore C57BL/6J|C57BL/6J-Muc2/AnuUqApb||Recessive|Mucin 2|Muc2|Unknown||MGI:1339364|mucin 2; eeyore|Muc2|MGI:5471473|7|ENSMUSG00000025515|ENSMUST00000026590|Muc2-201|5038|5038|T to C|ENSMUSE00000526021|32|1680|Serine to Proline|||||TAGAAGCCAAGATCTCCTACAATGGCCTTTCTTTCTCCATCCGGCTGCCCTACAAACTGTT|No|||||||||||||Intestinal inflammation. Spontaneous diarrhoea and colitis, compromised barrier function, hypersusceptible to dextran sulfate colitis, deficiency of goblet cells, goblet cell apoptosis, endoplasmic reticulum stress, misfolding of mucin-2.|Minor histological changes in the intestinal tract only, no disease phenotype|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|11|0|heterozygous x heterozygous|No|12-Feb-2014|Cryopreserved sperm|50.0|0.0|Yes|Inflammatory bowel disease|diarrhoea, inflammatory bowel disease, colitis, ENU, mucus, malabsorption|Yes| 7552.0|ENU25:011:Gdpd3:B6|C57BL/6NCrlAnu-Gdpd3/AnuApb|C57BL/6NCrlAnu-Gdpd3/AnuApb|Recessive|glycerophosphodiester phosphodiesterase domain containing 3|Gdpd3|Unknown|1110015E22Rik|MGI:1915866|glycerophosphodiester phosphodiesterase domain containing 3; mutation 1, The Australian National University|Gdpd3|MGI:5563465|7|ENSMUSG00000030703|ENSMUST00000032944|Gdpd3-201|354|411|C to A|ENSMUSE00000202169|4|118|Tyrosine to STOP|||||CCCCTCTACAAGGAAGAGTTGGAAATTTACTTCTCACCAGGCCATTTTGCCCACGGGTCAG||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Poor||G4||No|19-Dec-2013|Cryopreserved sperm|56.0|0.0|Unknown||ENU|Yes| 5151.0|BOOREANA:::B6 ; Ped11.28 ; ENU11B6:028|C57BL/6JAnu-Myb/AnuApb||Recessive|myeloblastosis oncogene|Myb|Unknown|c-myb|MGI:97249|myeloblastosis oncogene; booreana|Myb|MGI:4867909|10|ENSMUSG00000019982|ENSMUST00000020156|Myb-201|923|1189|A to G|ENSMUSE00000644654|8|308|Glutamic acid to Glycine|||||GGAGTTGCTCCTGATGTCAACAGAGAACGAGCTGAAGGGACAGCAGGCATTACCAACACAG|Yes|||||||||||||E14.5 embryo:15x increase in platelet numbers2x increase in stem cells in foetal liver.Increase in primitive RBCDecrease in definitive RBCIncrease in haemopoietic progenitor cellsPups are born and survive to adulthood. Adults display a 5x increase in platelet numbers|Normal|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|11-Jun-2010|Cryopreserved sperm|55.0|0.0|Unknown||haemopoiesis, stem cell, platelet, differentiation, transcription factor, proliferation, ENU|Yes| 5206.0|theoden ; ENU4AT:050 |STOCK H2/H2 Fas/AnuApb|STOCK H2/H2 Fas/AnuApb|Recessive|Fas (TNF receptor superfamily member 6)|Fas|Nil|APO-1, CD95, TNFR6, Tnfrsf6|MGI:95484|theoden|Fas|MGI:4455060|19|ENSMUSG00000024778|ENSMUST00000025691|Fas-201|416|422|G to A|ENSMUSE00000144910|4|139|Cysteine to Tyrosine|||||CTACTGCGATTCTCCTGGCTGTGAACACTGTGTTCGCTGCGCCTCGTGTGAACATGGAACC|Yes||||Histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Antinuclear autoantibodies, lymphadenopathy.||C57BL/6JStdAnu x C57BL/10.Cg-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Aug-2010|Cryopreserved sperm|19.0|0.0|Unknown||B cell, T cell, lymphadenopathy, ENU, Wellcome Trust|Yes| 2377.0|Pengu, ENU8B6:075|C57BL/6Apb-Gdf5/AnuApb|C57BL/6Apb-Gdf5/AnuApb|Recessive|growth differentiation factor 5|Gdf5|Unknown|bp, brp, cartilage-derived morphogenetic protein-1, CDMP-1|MGI:95688|growth differentiation factor 5; pengu|Gdf5|MGI:3847115|2|ENSMUSG00000038259|ENSMUST00000040162|Gdf5-001|2|314|T to C|ENSMUSE00000323175|1|1|Methionine to Threonine|||||ATGAGACTCCCCAAACTCCTCACTCTTTTGCTG|No|||||||||||||Limb deformity. Four shortened limbs with angular deformity, most pronounced in hindlimbs||C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Good||||No|14-Dec-2007|Cryopreserved sperm|53.0|0.0|Unknown||Limb, deformity, Brachypodism, Feet, ENU|Yes| 157.0|Lochy|C57BL/6JSfdAnu-Ptprc/AnuApb|C57BL/6JSfdAnu-Ptprc/AnuApb|Recessive|Protein tyrosine phosphatase, receptor type, C|Ptprc|Nil|B220, CD45, CD45R, Ly-5|MGI:97810|Lochy|Ptprc|MGI:3611894|1|ENSMUSG00000026395|ENSMUST00000027645|Ptprc-201||||||||139980367|20|||TCCATAAATGACTGTTCTCTTTGTGTGTTTTGATCAGGGCTTCAAGGAACCCAGGAAATA|Yes|||||||||||||Decreased expression of CD45 on CD19⁺ B cellsloc/loc mice have normal numbers of B cellsCell intrinsic defectSlightly reduced levels of IgM⁺IgD⁻, IgM⁺IgD⁺ and IgD⁺CD21⁺ cellsReduced levels of B220loCD19⁺ cells but normal levels of B220⁺CD19⁺ in bone marrow3 fold decrease in DP thymocytes10 fold decrease in CD4 SP thymocytes5 fold decrease in CD8 SP thymocytesDP thymocytes had 2.5 fold increase in expression of CD4 and CD8, cell intrinsic Co-receptor expression on SP T cells was increased 1.5 foldDramatic decrease in CD8⁺CD44lo/med cellsTCRβ is up-regulated on DP thymocytes and down regulated on mature T cells. CD5 is down-regulated on DP thymocytes and up-regulated on peripheral T cells.Decrease in DP thymocytes is not cell intrinsicDecrease in SP thymocytes is cell intrinsicThe decrease of CD69 and CD5 on thymocytes in thymus was cell intrinsicNo CD45 protein visually detected by Western blottingInhibition of DN cells progressing to DPBlock preventing DP thymocytes maturing to SP T cells attributed to defective thymic selectionDecrease in peripheral T cellsReduction in naïve CD8+ T cells and shift to activated/memory CD8⁺ T cell phenotypeLack of TCRβhi and CD69⁺ cells in thymus-implies defect in TCR signalling for positive selection||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Excellent||7||No|06-Mar-2006|Cryopreserved sperm|75.0|0.0|Unknown||CD45, T cell, B cell, CD8, lymphocyte, ENU|Yes| 82.0|Tiny, ENU4AT:013 |STOCK Lig4/AnuApb|STOCK Lig4/AnuApb|Recessive|ligase IV, DNA, ATP-dependent|Lig4|Reduced|DNA ligase IV, ligase IV|MGI:1335098|tiny|Lig4|MGI:3714783|8|ENSMUSG00000049717|ENSMUST00000095476|Lig4-201|863|1161|A to G|ENSMUSE00000610685|2|288|Tyrosine to Cysteine|||||CATGCAGATGCACAAAGATGGCGCGCTGTACCGGTACTTCTCCAGAAACGGTTACAACTAT|No|||||||||||||Animal model for human LIGIV Syndrome. Small stature. Severe combined immune deficiency. Hypogammaglobulinemia, no antibody response to immunization, very few circulating B or T cells. Hemopoiesis defect. Hypoplastic anemia, hemopoietic stem cells unable to transplant, poorly proliferative in tissue culture, unable to compete with transplanted wild-type hemopoietic stem cells even in the absence of any conditioning regime. Non-homologous end-joining DNA repair defect. Reduced DNA ligase IV protein levels and enzymatic activity. Western blot and immunofluorescent analysis of extracts from homozygous mutant mouse embryonic fibroblasts (MEFs) reveal 5-fold reduction in the protein level. Although the mutant protein complexes stably with XRCC4, in vivo adenylation activity is reduced 10-fold in mutant versus wild type MEFs.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Apr-2004|Cryopreserved sperm|18.0|0.0|Yes||T cell, CD8, severe combined immunodeficiency, DNA repair, ENU, Wellcome Trust|Yes| 2441.0|Kenny ; ENU9CAT:040|C57BL/6JAnu-Muc2/AnuApb||Recessive|mucin 2|Muc2|Unknown||MGI:1339364|kenny|Muc2|MGI:4820425|7|ENSMUSG00000025515|ENSMUST00000026590|Muc2-202|4187|4192|C to A|ENSMUSE00000519387|31|1396|Serine to STOP|||||AATGGAATACTGTACTCCTTCAACTATCTCACCTACAACTTCAACAACAACCTTGTCTACC|No|||||||||||||Diarrhoea.Multiple plaques on GIT and lymphomegaly.Other mutants homozygote for a point mutation have soft feces at weaning and develop diarrhea associated with malapsorption syndrome. Homozygous null mutants pass blood in their feces at 6 months, and 65% of null mutants have intestinal tumors at 1 year.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jan-2008|Cryopreserved sperm|11.0|0.0|Unknown||malabsorption, colon, goblet cells, diarrhoea, ENU|Yes| 8743.0|ASD696:Thunderbird|C57BL/6NCrlAnu-Ifne/AnuApb||Recessive|interferon epsilon|Ifne||Ifne1, Ifnt1|MGI:2667156|Ifne, endonuclease-mediated mutation 2, Australian National University|Ifne||4||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Jun-2019|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 4512.0|bata ;ENU8B6:058|C57BL/6JSfdAnu-Pnp/AnuApb||Recessive|purine-nucleoside phosphorylase|Pnp||Np, Np-1, Np-2, Pnp, Pnp1|MGI:97365|bata|Pnp|MGI:5468722|14|ENSMUSG00000021871|ENSMUST00000048615|Pnp-001|644|925|A to T|ENSMUSE00000617134|5|215|Aspartic acid to Valine|||||GAGTCGTCTGCTAAAGATGCTGGGGGCAGATGCTGTTGGCATGAGCACAGTCCCAGAAGTT|Yes|||||||||||||Decreased anti-IgM B cell proliferation in vitro, age-dependent increase in CD44hi ICOShi CD4 cells and decrease in marginal zone B cells.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|89.0|0.0|Unknown||B cell, T cell, ENU, Wellcome Trust|Yes| 45.0|Jasmine|C57BL/6JSfdAnu-Tap2/AnuApb|C57BL/6JSfdAnu-Tap2/AnuApb|Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Normal|ABC18, Abcb3, Ham-2, HAM2, Ham2, MTP2, PSF-2, PSF2, RING11, Tap-2, Y1|MGI:98484|jasmine|Tap2|MGI:3611893|17|ENSMUSG00000024339|ENSMUST00000025197|Tap2-001|874|1292|A to C|ENSMUSE00000141074|5|292|Threonine to Proline|||||TCTTCATGCTCCAGGTATCGCCCCGACTCACCTTCCTCTCCCTGCTGGACCTGCCCCTCAC|Yes|||||||||||||No CD8⁺ T cells.Normal CD4⁺ and B cells||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|117.0|0.0|Yes|Bare Lymphocyte syndrome type 1|Tap2, T cell, CD8, CD4, ENU, Tap1, Bare Lymphocyte syndrome type 1|Yes| 7553.0|ENU25:021:MAP4K1:B6|C57BL/6NCrlAnu-Map4k1/AnuApb|C57BL/6NCrlAnu-Map4k1/AnuApb|Recessive|mitogen-activated protein kinase kinase kinase kinase 1|Map4k1|Unknown|Hpk1|MGI:1346882|mitogen-activated protein kinase kinase kinase kinase 1; mutation 1, The Australian National University|Map4k1|MGI:5563448|7|ENSMUSG00000037337|ENSMUST00000085835|Map4k1-201|400|502|A to G|ENSMUSE00000473624|6|134|Isoleucine to Leucine|||||GACTGGCCTACCTGCATTCAGAGAAGAAGATACATCGAGACATCAAGGGAGCCAACATCCT||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|19-Dec-2013|Cryopreserved sperm|26.0|0.0|Unknown||ENU|Yes| 59.0|Nessy|C57BL/6JSfdAnu-Ncaph2/AnuApb |C57BL/6JSfdAnu-Ncaph2/AnuApb |Recessive|non-SMC condensin II complex, subunit H2|Ncaph2|Unknown|Kleisin beta|MGI:1289164|nessy|Ncaph2|MGI:3710093|15|ENSMUSG00000008690|ENSMUST00000074552|Ncaph2-001|44|144|T to A|ENSMUSE00000504356|1|15|Isoleucine to Asparagine|||||GGTGCGCTTTGCTCACCTCTTGCAGCCCATCCGGGATCTCACTAAGAACTGGGAGGTGGAC|Yes|||||||||||||The nessy mouse has a defect in T lymphocyte development that decreases circulating T cell numbers, increases their expression of the activation/memory marker CD44, and dramatically decreases the numbers of CD4(+)CD8(+) thymocytes and their immediate DN4 precursors. Thymic T cell differentiation defect at DN-DP transition, low peripheral T cell numbers, remaining cells all CD44high, Two fold more gd T cells, Defect resembles mice with exaggerated TCR signalling due to defects in c-cbl and slap proteins and defects in cbl plus cbl-b. No defect in B cells. Homozygotes grow at normal rate, size and are fertile. Intrinsic to T cells.Despite the ubiquitous expression and role of condensins, kleisin beta(nes/nes) mice were viable, fertile, and showed no defects even in the parallel pathway of B cell lymphocyte differentiation. ||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|79.0|0.0|Unknown||T cell, lymphocyte, condensin, differentiation, ENU|Yes| 4.0|San Roque|C57BL/6JSfdAnu-Rc3h1/AnuApb |C57BL/6JSfdAnu-Rc3h1/AnuApb|Recessive|RING CCCH (C3H) domains 1|Rc3h1|Unknown|Roquin|MGI:2685397|sanroque|Rc3h1|MGI:3581675|1|ENSMUSG00000040423|ENSMUST00000035911|Rc3h1-201|596|981|T to G|ENSMUSE00000536751|5|199|Methionine to Arginine|||||TAGGGGCTGCCAGTTCCTTGGACCAGCGATGCAGGAGGAAGCTCTGAAGCTGGTCTTGCTG|Yes|||||||||||||Spontaneous autoimmune disease. Systemic lupus erythematosus. Anti-nuclear autoantibodies (ANA), hypergammaglobulinemia, autoimmune nephritis, lymphadenopathy, increased numbers of CD44high activated memory T cells, increased numbers of T follicular helper cells, spontaneous germinal centres, CD28-independent activation of T cells. Increased ICOS mRNA and protein expression on T cells, defect in micro-RNA (mir) inhibition of mRNA stability.|Low penetrance in hets|C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Nov-2005|Cryopreserved sperm|155.0|20.0|Yes||Systemic lupus erythematosus (SLE), autoimmunity, T cell, ubiquitin ligase, Wellcome Trust, ENU, lymphadenopathy|Yes| 4118.0|Wobbly ; ENU9B6:046a|C57BL/6JSfdAnu-Elp6/AnuApb|C57BL/6JSfdAnu-Elp6/AnuApb|Recessive|elongator acetyltransferase complex subunit |Elp6|Unknown|2610001P13Rik, 2610002I17Rik, Tmem103|MGI:1919349|elongator acetyltransferase complex subunit ; mutation 1, The Australian National University|Elp6|MGI:5563405|11|||||||||||||||||||||||||||||Affected mice have uncoordinated movement. Video available.Fertility of affecteds is unknown.||C57BL/6JSfdAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||5||No|05-Dec-2008|Cryopreserved sperm|42.0|0.0|Unknown||Motion, Movement, Shaky, wobble, ENU, ataxia|Yes| 6.0|Face|C57BL/6JSfdAnu-Stat1/AnuApb|C57BL/6JSfdAnu-Stat1/AnuApb|Recessive|signal transducer and activator of transcription 1|Stat1|Unknown|STAT-1|MGI:103063|face|Stat1|MGI:3611892|1|ENSMUSG00000026104|ENSMUST00000070968|Stat1-201|1978|2329|T to A|ENSMUSE00000630003|22|660|Methionine to Lysine|||||TCCCAGATATTATTCGCAACTACAAAGTCATGGCTGCCGAGAACATACCAGAGAATCCCCT|Yes|||||||||||||Diminished Th1 antibody formation upon immunization with heat-killed Bordetella pertussis bacilli. Increase proportion of CD44hi activated/memory T cells in a subset of animals and increased IgE.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||16|hom x hom|No|28-Nov-2005|Cryopreserved sperm|140.0|0.0|Unknown||T cell, hypergammaglobulinaemia, B cell, ENU, Wellcome Trust|Yes| 64.0|Fragile red (redburst, fred, snow), ENU5WT:027 |STOCK H2 Steap3/AnuApb|STOCK H2 Steap3/AnuApb|Recessive|STEAP family member 3|Steap3|Nil|pHyde|MGI:1915678|fragile-red|Steap3|MGI:3758911|1|ENSMUSG00000026389|||862|1292|T to C|ENSMUSE00000158639|4|288|Tyrosine to Histidine|||||CTGCGCTTCAGCTGCGGAGGGGGACCAAGTACCAGCGCTTCCCAGACTGGCTGGACCACTG|Yes||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k2 variant|H2|MGI:3579322|17|Hypochromic microcytic anemia, erythrocyte poikilocytosis, defect in iron transport, defect in endosomal targeting to acidified endosomes.Mutation disrupts the endosomal targeting motif of the Steap3 protein.||C57BL/6JSfdAnu x B10.BR-H2|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Apr-2004|Cryopreserved sperm|28.0|0.0|Unknown||anaemia, erythrocyte, endosome, ENU, Wellcome Trust, red blood cell|Yes| 4505.0|Duane ; ENU6NIHB:019|C57BL/6JSfdAnu-Tbx21/AnuApb|C57BL/6JSfdAnu-Tbx21/AnuApb|Recessive|T-box 21|Tbx21|Reduced|T-bet, Tblym, TBT1|MGI:1888984|T-box 21; Duane|Tbx21|MGI:4367995|11|ENSMUSG00000001444|ENSMUST00000001484|Tbx21-001||||||||96962921|2|||CTGGTCGATACTTGACAATAAGGTTAACTGTCCACAGGGAACCGCTTATATGTCCACCCA|Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. Few circulating NK cells.Decreased NK cell number: the percent of NK cells in the blood, spleen, and liver is lower than in wild-type mice.Increased NK cell number:* the frequency of NK cells in the peripheral lymph nodes and bone marrow is increased compared to in wild-type mice.* NK cells accumulate in lymph nodes due to defective egression.Absent NK T cells: mice exhibit a near complete absence of invariant natural killer T cells unlike in wild-type mice.Abnormal NK cell differentiation:* NK cells exhibit an immature phenotype unlike in wild-type mice.* NK cells accumulate in lymph nodes due to defective egression.* in reconstitution experiments, derived NK cells accumulate in the peripheral lymph nodes due to defective egression.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|70.0|0.0|Unknown||antibody, B cell, NK cell, ENU, Wellcome Trust, Natural Killer cell (NK), T cell, lymphocyte|Yes| 7658.0|ENU17Ch14:KLHL6|C57BL/6JAnu-Klhl6/AnuApb|C57BL/6JAnu-Klhl6/AnuApb|Recessive|kelch-like 6|Klhl6|||MGI:2686922|kelch-like 6; mutation 1, The Australian National University|Klhl6|MGI:5563461|16|ENSMUSG00000043008|ENSMUST00000058839|Klhl6-001|799|834|C to T|ENSMUSE00000346330|3|267|Tryptophan to STOP|||||AGAATGTGCGTTTACCACTTCTGGATCCGTGGTACTTCGTGGAGATGGTTGAAGCAGACCC||||||||||||||Reduced numbers of B cells, increased numbers of immature B cells and reduced numbers of mature B cells.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||G7||No|11-Apr-2014|Cryopreserved sperm|26.0|0.0|Unknown||B cell, lymphocyte, ENU|No| 7664.0|APN 436|C57BL/6N-A Katnal2/MarpApb||Recessive|katanin p60 subunit A-like 2|Katnal2 |||MGI:1924234|katanin p60 subunit A-like 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Katnal2|MGI:4842422|18|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Apr-2014|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 123.0|CD40L -/- TCR|B10JAnu.Cg-H2 Cd40lg Tg(TcrHEL3A9)1Mmd/AnuApb|B10JAnu.Cg-H2 Cd40lg Tg(TcrHEL3A9)1Mmd/AnuApb|Recessive|CD40 ligand|Cd40lg|Nil|CD154, Cd40L, gp39, HIGM1, IMD3, Ly-62, T-BAM, Tnfsf5|MGI:88337|targeted mutation 1, Richard A Flavell|Cd40lg|MGI:2182733|X||||||||||||||||No|transgene insertion 1, Mark M Davis|TCR|||||||||||Homozygous mice display: - immune system, lymphoid development/B lymphocyte defects: - B cells failed to undergo isotype switching - failed to produce germinal centers in spleen in response to T-dependent antigens - reduced serum immunoglobulin concentrations (IgG1, IgG2a, IgG2b, IgG3), at 12 weeks of age, but not at 6 weeks of age - decreased IgM response to T-dependent antigens - failed to produce antigen-specific IgG1 after immunization - immune system, no defect detected: - no alterations in B or T lymphocyte development - T lymphocytes responded normally to mitogen stimulation - B lymphocytes had normal responses to T-independent antigens||C57BL/10J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16||No|06-Feb-2006|Cryopreserved sperm|150.0|0.0|No||B cell, T cell, immunoglobulin, germinal centre|Yes| 7621.0|EGFL6 His Siamese|C57BL/6J-Tg(CMV-Egfl6/His)||Dominant||||||||||||||||||||||||||EGF-like-domain, multiple 6|cytomegalovirus (CMV)|||||||||||Generally the EGFL6 transgenic mice appear normal and have not displayed any adverse effects due to genetic modifications. |Unknown|C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|24-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 126.0|Charles ; ML5|C57BL/6JSfdAnu-Tg(ML5sHEL)5Ccg/AnuApb|C57BL/6JSfdAnu-Tg(ML5sHEL)5Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 5, Christopher C Goodnow|metallothionein I|high||||||||||Mice express a soluble form of hen egg lysozyme, levels are higher than similar strain C57BL/6-Tg(ML4sHEL)5Ccg/J.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||22|sib x sib|No|06-Feb-2006|Cryopreserved sperm|150.0|0.0|Yes||Hen egg lysozyme (HEL), autoimmunity, T cell, B cell, tolerance|Yes| 131.0|Guildenstern ; MD2|C57BL/6JSfdAnu-Tg(IghelMD2)Ccg/AnuApb|C57BL/6JSfdAnu-Tg(IghelMD2)Ccg/AnuApb|Dominant||||||||||||||||||||||||||Heavy chain trangene for anti-HEL IgM and IgD.|normal control elements and mRNA splicing|||||||||||B cells express chimeric Ig molecule of extracellular domain of IgM and intracellular domains of IgD. Ig has affinity for Hen Egg Lysozyme||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||2|sib x sib|No|06-Feb-2006|Cryopreserved sperm|20.0|0.0|No||Hen Egg Lysozyme (HEL), immunoglobulin, lymphocyte, T cell, B cell|Yes| 117.0|Carrie ; GM2|C57BL/6JSfdAnu-Tg(IghelMG)Ccg/AnuApb|C57BL/6JSfdAnu-Tg(IghelMG)Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher C Goodnow||low||||||||||B cells express immunoglobulin specific for Hen Egg Lysozyme.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||21|Ig+ male x B6 female|No|06-Feb-2006|Cryopreserved sperm|36.0|0.0|No||Hen Egg Lysozyme, IgM, IgG, autoimmunity, tolerance, B cell|Yes| 113.0|Bcl-2 :B6:Ly5a|B6.Cg-Ptprc Tg(BCL2)22Wehi/WehiAnuApb|B6.Cg-Ptprc Tg(BCL2)22Wehi/WehiAnuApb|Recessive||||||||||||||||||||||||||transgene insertion 22, Walter and Eliza Hall Institute of Medical Research ; human Bcl-2|IgH enhancer and SV40 promoter|primarily expresses Bcl-2 in B cells (as opposed to Bcl-2-36 which is T and B and Bcl-2-25 which is T only)|protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|During an immune response, hypermutation of immunoglobulin genes in B cells proliferating within germinal centres (GCs) generates variant antibodies that react with higher affinity against either foreign or self antigens. Several experiments suggest that self-reactive B cells may be censored at this stage of the immune response, but the rarity of these cells and the dynamic nature of GC reactions have prevented direct analysis. We have developed a new approach to visualize the fate of antigen-specific B cells during GC reactions by seeding an ongoing immune response with lysozyme-specific B cells from immunoglobulin-gene transgenic animals. Administration of soluble antigen at the peak of the GC response rapidly eliminates lysozyme-specific GC B cells in two waves of apoptosis, one within the GC and a second in cells that have redistributed to lymphoid zones that are rich in T cells. Elimination of these cells is inhibited by constitutive expression of the follicular lymphoma proto-oncogene bcl-2. These findings reveal censoring steps that may normally prevent affinity maturation of autoantibodies to systemic autoantigens, and might be used by pathogenic microorganisms or in clinical strategies to interfere with antibody responses.||C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good|18||B6Ly5a x Bcl-2Tg|No|06-Feb-2006|Cryopreserved sperm|150.0|0.0|No||B cell, germinal centre, selection, Bcl-2, autoimmunity|Yes| 114.0|Bcl-6 -/-|B6.129-Bcl6/AnuApb|B6.129-Bcl6/AnuApb|Recessive|B-cell leukemia/lymphoma 6|Bcl-6|Nil|Bcl5|MGI:107187|targeted mutation 1, Louis M Staudt|Bcl6|MGI:2158439|16||||||||||||||||No|||||||||||||Homozygous null mutants develop myocarditis and pulmonary vasculitis, show impaired germinal center formation in the spleen, and display T helper 2 cell hyperimmune responsiveness. Mice frequently die before reaching maturation.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|06-Feb-2006|Cryopreserved sperm|100.0|0.0|Unknown||myocarditits, T cell, hyperimmune responsive, germinal centre|Yes| 160.0||B6.129P2-Cited1/Apb|B6.129P2-Cited1/Apb|X-linked|Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domian 1|Cited1|Nil|Msg1, ER154|MGI:108023|Cited1 targeted mutation 1, Sally L Dunwoodie|Cited1|MGI:3028946|X||||||||||||||||No|||||||||||||Results in impaired embryonic growth and survival due to defects in trophoblast and placental development.|Male hemizygotes have the same phenotype as the female homozygotes. Female heterzygotes have a variable phenotype depending on which parent the Cited1 allele is inherited from. Heterozygous females with paternally inherited Cited1 have no placental phenotype, whereas heterozygous females with maternally inherited Cited1 have the same placental phenotype as homozygotes|C57BL/6|No|No|Yes|No|No|No|No|Good|7|9|Cited1/Y x +/Cited1|No|08-Mar-2006|Cryopreserved sperm|125.0|0.0|Yes||Cited1, placenta, growth restriction, embryonic, placenta|Yes| 112.0|BALB/b-CMV1r|C.B6-Klra8 H2/AnuApb|C.B6-Klra8 H2/AnuApb|Dominant|killer cell lectin-like receptor, subfamily A, member 8|Klra8|Normal|Cmv-1, Cmv1, Ly49H, Ly49h, Ly49u<129>|MGI:102968|cytomegalovirus resistance 1, resistant|Klra8|MGI:2387148|6||||||||||||||||Yes||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|The Klra8 gene from C57BL/6 has been recombined into the genome of Balb/c mice. The H2 locus of C57BL/6 has also been recombined into this BALB/c. Mice expressing Klra8 are resistant to CMV infection compared to BALB/c H2 and BALB/c H2 controls.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|110.0|0.0|No||cytomegalovirus, lymphocyte, natural killer cell, resistance, infection|Yes| 143.0||Porthos||Dominant||||||||||||||||||||||||||Genomic IgG anti-HEL H + L||low copy||||||||||||C57BL/5 x B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|72.0|0.0|No||Hen Egg Lysozyme, autoimmunity, T cell, B cell|Yes| 166.0|Cited|B6;129S4-Cited1/Apb|B6;129S4-Cited1/Apb|X-linked|Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1|Cited1|Nil|Msg1|MGI:108023|targeted mutation 1, Finian Martin|Cited1|MGI:3623213|X||||||||||||||||Yes|||||||||||||Results in retarded mammary ductal growth at puberty.|Females have no overt phenotype|C57BL/6|No|No|No|Yes|Yes|Yes|No|Good|3|11|Cited1/Y x +/Cited1|No|15-Apr-2006|Cryopreserved sperm|135.0|0.0|Unknown||Cited1, mammary gland, Wnt inhibitor, placenta|Yes| 169.0|Adamts1 knockout|B6.129-Adamts1/Apb|B6.129-Adamts1/Apb|Recessive|a disintegrin-like and metallopeptidse (reprolysin type) with thrombospondin type 1 motif, 1|Adamts1|Nil|ADAM-TS1, ADAMTS, C3-C5, METH1|MGI:109249|targeted mutation 1, Melanie A Pritchard|B6.129-Adamts1|MGI:3574351|16||||||||||||||||No|||||||||||||perinatal lethality: the expected Mendelian ratio of null mice was present on the day preceding birth but only 55% remained on the day after birth. postnatal lethality: of those surviving after day 1, most survived to adulthood with 40% surviving at time of weaning.abnormal kidney morphology: the day following birth, pups showed a shrinkage of both layers of the kidney and an enlarged caliceal space, however kidneys were normal at E18.5.abnormal kidney cortex: saw a reduction of the width of the cortex in homozygous nulls on the days before and after birthabnormal kidney medulla morphology: saw a reduction of the width of the medulla in homozygous nulls on the days before and after birth.decreased ovulation frequency: release of oocytes from the follicles was reduced by 70% resulting in a decreased number of oocytes in the oviducts and the number of implantation sites was reduced by 43%, however females have a normal uterus and estrous cycle. Several oocytes were found to be trapped in the corpora lutea after ovulation.reduced female fertility: 38% of females give birth to pups after plug formation. The pregnancy rate was decreased during gestation at a greater rate (83% at E4.5 to 50% at E15.5) compared with wildtype (100% at E4.5 to 83% at E15.5), suggesting a loss of embryos as pregnancy progressed.decreased litter size||C57BL/6|No|No|Yes|No|No|Yes|No|Good|10||het x het OR Het male x WT female OR Het female x WT male|No|15-Apr-2006|Cryopreserved sperm|55.0|0.0|Unknown||fertility, kidney, angiogenesis, urogenital, ovulation|Yes| 167.0|Bean Knockout|C57BL/6-Bean1/Apb|C57BL/6-Bean1/Apb|Recessive|brain expressed, associated with Nedd4|Bean1|Nil||MGI:1929597|targeted mutation 1, Sharad Kumar|Bean1|MGI:5605284|8||||||||||||||||Yes|||||||||||||None detected so far|None|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Hom x Hom|Yes|15-Apr-2006|Cryopreserved sperm|40.0|0.0|Unknown||WW domain, PY motif, Nedd4, ubiquitin ligase|Yes| 164.0|C2NX1f|129/Sv-Cited2/Apb|129/Sv-Cited2/Apb|Recessive|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2|Cited2|Unknown|ER154-like, Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1, Sally L Dunwoodie|Cited2|MGI:3696061|10||||||||||||||||Yes|||||||||||||Mice homozygous for the conditional allele of Cited2 are viable and no phenotype has been observed.|No Phenotype|129S1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|0|Heterozygous mice are backcrossed into 129X1/SvJ to increase health as ES origin is not as viable|No|15-Apr-2006|Cryopreserved sperm|90.0|0.0|Yes||Cited2, heart, placenta, left-right axis|Yes| 165.0|C2B6∆|B6.129P2-Cited2/Apb|B6.129P2-Cited2/Apb|Recessive|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2|Cited2|Nil|ER154-like, Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1, Juan Pedro Martinez Barbera|Cited2|MGI:2176158|10||||||||||||||||No|||||||||||||Embryos die during gestation (~E15.5). Heart, left-right axis, neural tube, adrenal gland and placental defects.|None|C57BL/6|No|No|No|No|No|Yes|No|Good|10|4|C2B6∆ +/- (heterozygous) mated with C57BL/6|No|15-Apr-2006|Cryopreserved sperm|130.0|0.0|Yes||Cited2, heart, placenta, left-right axis|Yes| 260.0||C57BL/10ScSn-Dmd/ArcAnuApb||X-linked|dystrophin, muscular dystrophy|Dmd|Unknown|Dp427, Duchenne muscular dystrophy, mdx, pke, X-linked muscular dystrophy|MGI:94909|X linked muscular dystrophy|Dmd|MGI:1856328|X||||||||||||||||No|||||||||||||Abnormal muscle morphology.dilated sarcoplasmic reticulum.Abnormal skeletal muscle fiber morphology: * development of electron-dense bodies in the mitochondria resulting in swelling and degenerating mitochondria, and disruption of the plasmalemma basal lamina. * the normal myofibrillar architecture of bands and lines disappears and myofilaments disintegrate and become misaligned.Increased variability of skeletal muscle fiber size: variable muscle fiber size; progressive starting at 3 weeks of age.Skeletal muscle fibrosis: exhibit mild muscle fibrosis, however there is no replacement of lost muscle by fat cells.Skeletal muscle necrosis: progressive starting at 9 weeks of age.Muscle degeneration: progressive starting at 3 weeks of age.Abnormal muscle physiology: increased intracellular sodium concentration in muscle; increased severity with age.Muscular atrophy: progressive starting at 3 weeks of age.Dystrophic muscle.Myopathy: progressive degenerative myopathy; increased severity with age.Abnormal circulating enzyme level: exhibit elevated blood levels of muscle creatine kinase and pyruvate kinase.Reduced female fertility: slight reduction in fertility.||C57BL/10ScSn|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Unknown||||No|30-Apr-2006|Cryopreserved sperm|40.0|0.0|Yes||Muscular dystrophy, Duchenne Type, muscle, necrosis, degeneration|Yes| 263.0|eotaxin -/-|C.129S6-Ccl11/Apb|C.129S6-Ccl11/Apb|Recessive|chemokine (C-C motif) ligand 11|Ccl11|Nil|eotaxin, Scya11|MGI:103576|targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11|||||||||||||||||||||||||||||Abnormal immune system physiology* mutant mice have markedly fewer eosinophils in the jejunum than do wild-type controls||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Apr-2006|Cryopreserved sperm|100.0|0.0|Unknown||eosinophils, chemokine, infection, C-C, inflammation, recruitment|Yes| 267.0|B6.gA-/-|C57BL/6-Gzma/AnuApb||Recessive|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||No|||||||||||||Tumorigenesis * homozygotes control growth of syngeneic tumors (s.c. inoculation of H-2b MC57G fibrosarcoma) as efficiently as wild-type miceHematopoietic system phenotype * homozygotes are viable, fertile, and display normal hematopoiesis relative to wild-type mice* in mutant spleens, the numbers of CD4+ and CD8+ T cells, macrophages, NK cells and B cells fall within normal ranges* the frequencies of CD4+ and CD8+ T cells responding to H-2 alloantigens in primary mixed lymphocyte cultures (MLC) with proliferation are also within normal rangesImmune system phenotype* in vitro- and ex vivo-derived cytotoxic T cells and NK cells from mutant mice induce specific target cell membrane disruption, DNA fragmentation, and apoptosis as efficiently as wild-type cells * homozygotes control infections with lymphocytic choriomeningitis (LCM) virus and L. monocytogenes as efficiently as wild-type mice * homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type mice ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Apr-2006|Cryopreserved sperm|50.0|0.0|Unknown||Cytotoxic T Cell, Natural Killer Calls, Serine Proteinase|Yes| 268.0|B6.gAB-/-|B6.Cg-Gzma Gzmb/Apb|B6.Cg-Gzma Gzmb/Apb|Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||Yes|||||||||||||Increased sensitivity to induced morbidity/mortality * WNV-infected double homozygotes start to die at day 10 post-infection (p.i.); wild-type mice die between 10-13 days p.i.* 70% of WNV-infected double homozygotes versus 29% of wild-type succumb to encephalitis by day 16 p.i.Immune system phenotype * double homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type miceIncreased susceptibility to parasitic infection:* decreased clearance and survival after infection with Trypanosoma cruziIncreased susceptibility to viral infection:* double homozygotes display increased susceptibility to West Nile flavivirus (WNV) infection relative to wild-type* double mutants show a higher level of infectious virus in brain relative to wild-type or Prf1tm1Sdz mice at the same time point||C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|30-Apr-2006|Cryopreserved sperm|39.0|0.0|Unknown||T Cell, Cytotoxic, Serine Proteinase, Natural Killer Calls, Infection|Yes| 268.0|B6.gAB-/-|B6.Cg-Gzma Gzmb/Apb|B6.Cg-Gzma Gzmb/Apb|Recessive|granzyme B|Gzmb|Nil|CCP-1/C11, CCP1, Ctla-1, Ctla1|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14|||||||||||||||||||||||||||||Increased sensitivity to induced morbidity/mortality * WNV-infected double homozygotes start to die at day 10 post-infection (p.i.); wild-type mice die between 10-13 days p.i.* 70% of WNV-infected double homozygotes versus 29% of wild-type succumb to encephalitis by day 16 p.i.Immune system phenotype * double homozygotes develop a normal contact hypersensitivity (CHS) response (based on increase in ear thickness) to trinitrophenyl (TNP) relative to wild-type miceIncreased susceptibility to parasitic infection:* decreased clearance and survival after infection with Trypanosoma cruziIncreased susceptibility to viral infection:* double homozygotes display increased susceptibility to West Nile flavivirus (WNV) infection relative to wild-type* double mutants show a higher level of infectious virus in brain relative to wild-type or Prf1tm1Sdz mice at the same time point||C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|30-Apr-2006|Cryopreserved sperm|||Unknown||T Cell, Cytotoxic, Serine Proteinase, Natural Killer Calls, Infection|Yes| 2462.0||B6.CBA-Tg(hGMCSF-2CK1)1200/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|30.0|0.0|Unknown||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 270.0|gB -/-|C57BL/6-Gzmb/Apb||Recessive|granzyme B|Gzmb|Nil|CCP-1/C11, CCP1, Ctla-1, Ctla1|MGI:109267|targeted mutation 1, Timothy J Ley|Gzmb|MGI:1857156|14||||||||||||||||No|||||||||||||Homozygous mutant mice develop normally, with normal lymphopoiesis and hematopoiesis. However, CTLs from mutant mice are unable to induce rapid fragmentation of DNA and apoptosis in target cells; with long incubation, fragmentation is partially and cell lysis completely rescued (J:23560). Natural killer (NK) cells also release granzyme-bearing granules, and rapid cytoxicity by these cells is dependent on granzyme B. Granzyme B independent mechanisms of cytotoxicity exist, since CTLs from null homozygotes can lyse target cells after extended incubation, but these mechanism are not active in null mutant NK cells (J:28160).specific activity of caspase 3 executioner protease in cytoplasm of CTLs is decreaseddefective cytotoxic T cell cytolysis (J:23560)cytotoxic T lymphocytes (CTLs) defective in ability to induce rapid DNA fragmentation and apoptosis in allogeneic target cellswith long incubation, fragmentation is partially and cell lysis completely rescuednormal activation and proliferation of cytotoxic T lymphocytes (CTLs) in mixed lymphocyte cultures (MLCs)defective NK cell cytolysis (J:113213)impaired ability of NK cells to induce DNA fragmenting but normal ability to induce membrane damage||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Apr-2006|Cryopreserved sperm|90.0|0.0|Unknown||Fas, natural killer cell, cytotoxic T cell|Yes| 341.0|EphA1-/- hPLAP|B6;129-Epha1/Apb|B6;129-Epha1/Apb|Recessive|Eph receptor A1|Epha1|Nil|5730453L17Rik, Eph, Esk|MGI:107381|targeted mutation 1, Shannon L Duffy|Epha1|MGI:3822370|6||||||||||||||||Yes|internal ribosome entry site - human placental alkaline phosphatase|endogenous EphA1|Restricted to epithelial tissue||||||||||Vaginal inflammation:mice exhibit inflammation of the vaginal mucosa secondary to hydrometrocolpos.Endometrium inflammation:mice exhibit endometrium inflammation secondary to hydrometrocolpos.Dilated uterine horn:mice exhibit dilated, attenuated uterine horns secondary to hydrometrocolposEnlarged uterus:mice exhibit an enlarged uterus due to an accumulation of clear uterine fluid (hydrometrocolpos).Increased uterus weight:Vagina atresia:18% of mice exhibit a failure of vaginal openingdespite normal estrogen receptor expression, beta-estradiol treatment fails to induce precocious vaginal opening in P12 mice unlike in wild-type mice and vaginal opening can not be induced by likewise treating affected adult mice.Hydrometrocolpos:mice exhibit inflammation of the vaginal mucosa and endometrium with dilated, attenuated uterine horns secondary to hydrometrocolposFemale infertility:female mice affected by hydrometrocolpos are sterileKinked tail:up to 80% of mice exhibit a kinky tail due to incorrectly positioned caudal vertebraeDistended abdomen:in some mice due to an enlarged uterusAbnormal response/metabolism to endogenous compounds:treatment with beta-estradiol fails to induce apoptosis in the lower genital tract and precocious vaginal opening unlike in wild-type mice.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|5|Homozygous knockout crossed with homozygous knockout or C57BL/6 wildtype|No|22-Sep-2006|Cryopreserved sperm|40.0|0.0|No||Eph, Receptor Tyrosine Kinase, ephrin, epithelium, uterus, tail, hydrometrocolpos|Yes| 344.0|B7C bb|C57BL/6-Tg(SERPINC1-CD86)/Apb||Dominant||||||||||||||||||||||||||murine CD86|human anti-thrombin III (SERPINC1)+ regulatory intronic sequences of MHC class II|low on 15% of hepatocytes||||||||||Expression of CD86 on 15% of hepatocytes. Expression elsewhere has not been reported.|Expression of CD86 on 15% of hepatocytes. Expression elsewhere has not been reported.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|15|B7Cbb x B7Cbb|No|22-Sep-2006|Cryopreserved sperm|40.0|0.0|Unknown||costimulation, hepatocytes, T cells, liver, T cell activation, Hepatocellular carcinoma, Hepatitis C virus (HCV)|Yes| 345.0|Human GM-CSF|NOD.Cg-Prkdc Tg(hGM-CSF)8KHsr/Apb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc||DNAPDcs, DNA-PK, DNA-PKcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16||||||||||Unknown to Unknown||||||No|human granulocyte-macrophage colony stimulating factor |murine T Cell Receptor (TCR) enhancer and H2-K promoter|High||||||||||Unable to maintain colony in homozygous state|Normal|NOD/SCID|Yes|No|Yes|Yes|No|Yes|No|Excellent|20|0|Purchased NOD/SCID mated with transgenic mouse from colony to maintain colony|No|25-Sep-2006|Cryopreserved sperm|85.0|0.0|No||cytokine secreting, GM-CSF, immunodeficient, chronic myelomonocytic leukaemia (CMML), engraftment|Yes| 347.0|C2f|B6;129S1-Cited2/Apb|B6;129S1-Cited2/Apb|Semi-dominant|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal|Cited2|Nil|ER154-like, Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1.1, Sally L Dunwoodie|Cited2|MGI:3696062|10||||||||||Unknown to Unknown||||||Yes|||||||||||||Mice homozygous for the conditional allele of Cited2 are viable and no phenotype has been observed.|Normal|75% C57BL/6, 25% 129S1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2|2|Homozygous sib-matings to propagate the line in the homozygous state|No|25-Sep-2006|Cryopreserved sperm|106.0|0.0|Yes||Cited2, heart, placenta, left-right axis|Yes| 282.0||129/Sv-Ifngr/Apb||Recessive|interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gamma R, Ifngr, INF-g receptor, Nktar|MGI:107655|targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10||||||||||Unknown to Unknown||||||Yes|||||||||||||abnormal immunoglobulin level:levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virusincreased susceptibility to viral infection:slightly more susceptible to MCMV viral infection than controls increased susceptibility to Ectromelia virus 100% mortality by day 6-12 after primary infection infectionelevated virus titers in all organs tested after primary infection but much improved after secondary infectionssurvive secondary infections ||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-May-2006|Cryopreserved sperm|100.0|0.0|Unknown||infection, interleukin, splenocyte|Yes| 283.0||129/Sv-Irf1/Apb|129/Sv-Irf1|Recessive|interferon regulatory factor 1|Irf1|Unknown|Irf-1|MGI:96590|targeted mutation 1, Charles Weissmann|Irf1|MGI:2429553|11||||||||||||||||Yes|||||||||||||Immune systemabnormal T cell proliferation:higher background proliferation rateshyperproliferation requires higher MOGp35-55 peptide concentrations as a stimulusabnormal cytokine level:lower expression of lymphotoxin alpha and lymphotoxin beta after stimulation with anti-CD3 antibody or with MOGp35-55 peptidedecreased circulating interferon-gamma level:levels are reduced relative to controls after stimulation with anti-CD3 antibody or with MOGp35-55 peptideabnormal circulating interleukin-10 level:detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-13 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptideabnormal circulating interleukin-4 level:detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-5 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-6 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptidedecreased susceptibility to experimental autoimmune encephalomyelitis:develop an attenuated disease after injection with MOGp35-55disease onset delayed about 4 daysHematopoietic systemabnormal T cell proliferation:higher background proliferation rateshyperproliferation requires higher MOGp35-55 peptide concentrations as a stimulusHomeostasis/metabolismAbnormal cytokine level:lower expression of lymphotoxin alpha and lymphotoxin beta after stimulation with anti-CD3 antibody or with MOGp35-55 peptidedecreased circulating interferon-gamma level:levels are reduced relative to controls after stimulation with anti-CD3 antibody or with MOGp35-55 peptideabnormal circulating interleukin-10 level:detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-13 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptideabnormal circulating interleukin-4 level:detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-5 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptideincreased circulating interleukin-6 level:after stimulation with anti-CD3 antibody or with MOGp35-55 peptide||129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|02-May-2006|Cryopreserved sperm|135.0|0.0|Unknown||interferon, T cell, CD4, CD8, iNOS|Yes| 290.0||C.CBA-Tg(CD2-IL5)5C2Ldt/Apb [cc]|C.CBA-Tg(CD2-IL5)5C2Ldt/Apb [cc]|Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blotanalysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|Balb/c|No|No|Yes|No|No|Yes|No|Excellent|20||Transgenic male with wild type female|No|03-May-2006|Cryopreserved sperm|135.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 6638.0|Circling ; ENU18PiDTau_ TBx1|STOCK Tbx1 Tg(Thy1-MAPT*K369I)K3Gotz/AnuApb||Dominant|T-box 1|Tbx1|||MGI:98493|T-box 1; enu37|Tbx1|MGI:5490246|16|||||||||||||||||transgene insertion K3, Jurgen Gotz|Thy1|neuron specific||||||||||Unknown|Head tilt:• head tilting and weavingBidirectional circling|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|02-Nov-2011|Cryopreserved sperm|18.0|0.0|Yes|Frontotemporal dementia (FTD)|Pick's disease, Parkinsonism, Frontotemporal dementia (FTD)|Yes| 338.0|Activin Beta C+ FL2|C57BL/6-Tg(ACTIVIN-β{C})3Grb/Apb||Semi-dominant|||||||||Unknown||||||||||||||||No|human activin beta C|CMV|Greater than 20 copies, mRNA upregulated at least 3 fold in tissues assessed to date||||||||||Essenitally normal at gross level, male fertility decreased from 10 weeks (decreased sperm production and litter size), liver disease (mild fibrosis) from 14 weeks, prostate hyperplasia from 20 weeks.|Essenitally normal at gross level, male fertility decreased from 14 weeks (decreased sperm production and litter size), liver disease (mild fibrosis), prostate hyperplasia from 25 weeks.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||3|het x wt OR het x het|No|20-Sep-2006|Cryopreserved sperm|55.0|0.0|Unknown||activin, inhibin, prostate, testis, liver|Yes| 1494.0|B6.C1q-/-|B6;129S-C1qa/Apb|B6;129S-C1qa/Apb|Recessive|complement component 1, q subcomponent, alpha polypeptide|C1qa|Nil|C1q|MGI:88223|complement component 1, q subcomponent, alpha polypeptide; targeted mutation 1, Mark J Walport|C1qa|MGI:2158701|4||||||||||||||||No|||||||||||||Premature death: 15% die at 4 - 6 months of ageIncreased anti-nuclear antigen antibody level:* mutants develop high titers of anti-nuclear antibodiesIncreased anti-histone antibody level.Glomerulonephritis:* Background Sensitivity: severe proliferative crescentic glomerulonephritis evident in 27% mice.* Background Sensitivity: striking feature is presence of multiple apoptotic bodies in diseased glomeruli.* among mutants without glomerulonephritis, significantly greater numbers of glomerular apoptotic bodies are seen than in controls.Increased susceptibility to bacterial infection:* animals challenged with virulent pneumococci develop bacteremia and pneumonia after passive immunization with human IgG1 or human IgG2 unlike wild-type mice that are protected after immunization.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jul-2007|Cryopreserved sperm|136.0|0.0|Unknown||glomerulonephritis, autoimmunity, anti-nuclear antibodies, infection|Yes| 1502.0||C57BL/6NTac-IL15/AnuApb||Recessive|interleukin 15|Il15|Nil|IL-15|MGI:103014|targeted mutation 1, Immunex Research and Development Corporation|Il15|MGI:2136897|8||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions of this gene have normal life spans but display a variety of immune system abnormalities and maternal placental defects.These mutant mice lack NK cells and have marked reductions in memory CD8+ T cells, NK 1.1 T cells and Thy-CD8a intraepithelial lymphocytes. Mice are unable to mount a protective immune response to challenge with vaccinia virus.Abnormal immune system morphology.Abnormal dendritic cell morphology/development:* lower numbers of splenic dendritc cells after Plasmodium chabaudi infection.Abnormal lymphocyte morphology/development:* Intestinal intraepithelial lymphocytes maturing outside of the thymus greatly reduced in numbers.Abnormal CD8+ T cell morphology/development:* two fold reduction in numbers of CD8 single positive cells in spleen and lymph nodes.Abnormal NK cell morphology/development:* reduced numbers of natural killer cells in thymus liver and spleen.* absent in uterusSmall lymph nodes: peripheral lymph nodes significantly lower in weight.Abnormal immune system physiology:Defective NK cell cytolysis: significantly reduced cytolytic activityabnormal immune serum protein physiology.Decreased immunoglobulin concentration:* lower levels of malaria specific antibodies producedlower levels of total immune globulin.Decreased IgG level: decreased levels of IgG1, IgG2a, IgG2b, and IgG3 after Plasmodium infection.Decreased IgM level: after plasmodium infection.Abnormal cytokine physiology.Abnormal interferon physiology: reduced production of IFN gamma by NK cells.Abnormal interleukin physiology:* reduced Il12 production by dendritic cells after Plasmodium infection.Altered susceptibility to infection.Decreased susceptibility to bacterial infection.* Improved survival after infection with Listeria monocytogenesincreased susceptibility to parasitic infection.* parasitemia higher but only minor effect on mortalityincreased susceptibility to viral infection.* dead by day 9 after Vaccinia infection* very susceptible to HSV-2 infectionDecreased susceptibility to type IV hypersensitivity reaction: no contact hypersensitivity* T mediated effects delayed but not B cell activation or antibody production.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5||brother x sister mating|No|04-Jul-2007|Cryopreserved sperm|110.0|0.0|Unknown||T cell, infection, Natural killer cell, memory|Yes| 4838.0|Speedy|ENU7B6:044||Recessive|Unknown||Unknown||||||13|||||||||||||||||||||||||||||Circling in both directions, hyperactive in response to stimulation (cage changing, moving cage, walking past cage). Possible histological phenotype in brain as assessed by APN Histopathology and Organ Pathology.|Normal|C57BL/6 x C57BL/10|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|15.0|0.0|Unknown||circling, hyperactive, ENU|Yes| 1514.0|eNOS -/-|B6.129S4-Nos3/AnuApb|B6.129S4-Nos3/AnuApb|Recessive|nitric oxide synthase 3, endothelial cell|Nos3|Nil|2310065A03Rik, ecNOS, eNOS, Nos-3|MGI:97362|targeted mutation 1, Paul L Huang|Nos3|MGI:2150145|5||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit reduced survival, hypertension, inhibited basal vasodilation, insulin resistance, fewer mitochondria, reduced heart rate, impaired ovulation and, in some, shortened limbs. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||oocytes, limb, gonadotrophin, hypertension|Yes| 631.0|Pkr KO|B6;129-Eif2ak2/Apb|B6;129-Eif2ak2/Apb|Recessive|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|Nil|dsRNA-activated kinase, eIF-2 alpha, eIF-2 alpha, Eif2ak2, IFN- type I-induced and dsRNA-activated kinase, IFN-induced and double-stranded RNA-activated kinase, Pkr, Prkr, Tik|MGI:1353449|targeted mutation 1, Charles Weissmann|Eif2ak2|MGI:2182566|17||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions in this gene display altered susceptibility to viral infection. Enlarged lymph nodes. Altered susceptibility to viral infection.increased T cell proliferation.Proliferative responses of both CD4+ and CD8+ T-cells from sensitized mice is somewhat increasedabnormal inflammatory mediator physiology.A 2 fold increase in Il4 production by CD44+ cellsincreased susceptibility to viral infection.Susceptibility to encephalomyocarditis virus testedresponse to infection and survival were similar to control mice; however, pretreatment of mice with IFNgamma failed to improve survival as it did in controlsincreased susceptibility to type IV hypersensitivity reaction. Exaggerated response to challenge after presensitization in contact hypersensitivity testeffect can be transferred to naive mice using CD8+ cells from sensitized mice.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Excellent|||Hom x Hom|No|25-Apr-2007|Cryopreserved sperm|96.0|0.0|No||T cell, stimulation, viral infection, hypersensitivity, proliferation|Yes| 637.0|Human GM-CSF transgenic 8L|NOD.Cg-Prkdc Tg(hGM-CSF)8LHsr/Apb||Dominant|||||||||Unknown||||||||||||||||No|human granulocyte-macrophage colony stimulating factor (GM-CSF)|murine TCR enhancer and H2-K promoter|high expression||||||||||Unable to breed Hom x Hom|Normal|NOD/SCID|Yes|No|Yes|Yes|No|Yes|No|Excellent|20|0||No|25-Apr-2007|Cryopreserved sperm|35.0|0.0|No||cytokine secreting, GM-CSF, immunodeficient, chronic myelomonocytic leukaemia (CMML), engraftment|Yes| 633.0|Elvis|NOD.129-Tg(Csf2rb) Csf2rb1 Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)|Csf2rb1|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, C Glenn Begley|Csf2rb1|MGI:2181245|15||||||||||||||||Yes|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)||High||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|25-Apr-2007|Cryopreserved sperm|65.0|0.0|No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 633.0|Elvis|NOD.129-Tg(Csf2rb) Csf2rb1 Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|25-Apr-2007|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 633.0|Elvis|NOD.129-Tg(Csf2rb) Csf2rb1 Csf2rb Prkdc/Apb||Dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc||DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|25-Apr-2007|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 778.0|MPDtg|C57BL/6-Tg(Ckm-hPDGF-BB)/Apb||Dominant||||||||||||||||||||||||||human platelet derived growth factor receptor b|a mouse muscle creatine kinase 6.5-kb enhancer/promoter/first intron segment|||||||||||Transgenic mice that specifically express the PDGF receptor in skeletal muscle. In these mice, PDGF stimulated glucose transport into skeletal muscle in vitro and in vivo. The degree of glucose uptake in vivo reached ∼60% of that by insulin injection in skeletal muscle, but blood glucose levels were not decreased by PDGF in these mice. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-May-2007|Cryopreserved sperm|50.0|0.0|Unknown||platelet derived growth factor receptor (PDGFR), receptor, transgene, membrane, insulin, glucose, skeletal muscle|Yes| 1357.0|ATM-ΔSR1|B6.129T2(FVB)-Atm/Apb|B6.129T2(FVB)-Atm/Apb|Semi-dominant|ataxia telangiectasia mutated homolog (human)|Atm|Normal|C030026E19Rik|MGI:107202|targeted mutation 1, Martin F Lavin|Atm|MGI:2181756|9||||||||||||||||Yes|||||||||||||Premature death: 50% mortality by 40 weeks of ageDecreased body size: smaller size persists through adulthoodPostnatal growth retardation: 20% growth reduction in males and 18% reduction in females from birth to 45 days of age.Increased tumor incidence: mice dying after 40 weeks of age usually have tumors that are not thymic lymphomasThymic lymphoma: found in all mice dying before 40 weeks, diverse cell types involved, spongy tumors with a high proportion of cells undergoing apoptosisAbnormal immune system cell morphology: occasional increase in thymocyte size.Abnormal T lymphocyte development: lymph node T cells are primarily at early stages of development.Increased double-negative T cell count: occurs at randomAbnormal effector T cell morphology/development: randomly observed increases in single positive T cells.Decreased thymocyte number: 10% reduction in thymocytes, 30-50% reduction in thymocytes expressing alpha and beta T cell receptors or CD3.Abnormal immune system organ morphology:enlarged spleen: usually found in mice dying after 40 weeks of age.small spleen: in mice under 40 weeks of agesmall thymussmall lymph nodesAbnormal chromosome morphology: 3 fold increase in radiation induced chromosomal aberrations.Increased cellular sensitivity to ionizing radiation: increased sensitivity of thymocytes and splenocytes to ionizing radiation.Seminiferous tubule degeneration: tubules disruptedAbnormal testis development: poorly developedAbnormal gametogenesis:abnormal oogenesis: disrupted, lack of maturing follicles and oocytes.Abnormal spermatogenesis: disrupted spermatogenesis, degenerating spermatocytes, loss of spermatidsNervous system phenotype: no gross neuronal degeneration at time points between 2 and 16 months of age.Abnormal Purkinje cell morphology: survival of Purkinje cells in culture less than 60% of controls at 4 days and about 40% at 10 day, survival of cultured cells improves if cultured with cerebellar astroglial cells, develop simpler dendritic arboritization with reduced secondary branching, nitroxide free radicals improve survival and arborizationSeminiferous tubule degeneration: tubules disrupted|Increased tumor incidence: average age at onset 18.6 months, varying tumor types including dermatoid cystsadenoma: 13% of totalleukemia: 5% of totallymphoma:24% of totalovary tumor: 8% of totalsarcoma: 32% of total, half of sarcomas are in Mammary glands|C57BL/6|Yes|No|Yes|Yes|No|Yes|Yes|Unknown|6|||No|22-Jun-2007|Cryopreserved sperm|100.0|0.0|Yes||ataxia telangiectasia, lymphoma, T cell, spermatogenesis, thymocyte|Yes| 651.0|Aromatase knockout|FVB.129S6(B6)-Cyp19a1/Apb|FVB.129S6(B6)-Cyp19a1/Apb|Recessive|cytochrome P450, family 19, subfamily a, polypeptide 1|Cyp19a1|Nil|Ar, ArKO, aromatase, Cyp19, Int-5, Int5, p450arom|MGI:88587|targeted mutation 1, Evan R Simpson|Cyp19a1|MGI:2154536|9||||||||||||||||No|||||||||||||Abnormal coat color At 3 weeks of age, both males and females exhibit Dull coatAdipose tissueAbnormal fat pad Females exhibited a 50% to 80% increase in mammary fat pad weightAbnormal gonadal fat pad Males and females exhibited a 50% and 50% to 80% increase in gonadal fat pad weight, respectivelyendocrine/exocrine glandsAbnormal ovary morphology The ovaries of mice on a soy free diet exhibited seminiferous tubule-like structures throughout 80% of ovaries, hemorrhagic cysts, and age dependent increase in collagen deposition of collagen in constrast, animals fed a soy diet did not display Sertoli-like cells in follicles absent corpora lutea impaired ovarian folliculogenesis though ovaries contained numerous follicles with abundant granulosa cells, antrum formation was arrested before ovulationno corpora leuteaabnormal prostate morphology increase in combined prostate/urinary bladder weightincreased seminal gland weight increased weight of seminal vescicles, putatively due to an increased volume of secretions rather than due to structural changesabnormal seminiferous tubule morphologydecrease in the volume of epitheliumin contrast to Esr1tm1Ksk homozygotes, no decrease in luminal volumedecreased testis weight reduction in weight, 1 year of agehomeostasis/metabolismincreased circulating follicle stimulating hormone level female FSH levels were elevated 3- to 4-fold relative to wild type femalesincreased circulating luteinizing hormone level female LH levels were elevated 2- to 10-fold relative to wild type femalesLH levels were also increased in male miceincreased circulating testosterone level female testosterone level was increased to ~10 times the level in wild type femalesmale testosterone levels varied though they were in general increased relative to those of control malesreproductive systemabnormal reproductive system morphologyabnormal female reproductive anatomy abnormal ovary morphologythe ovaries of mice on a soy free diet exhibited seminiferous tubule-like structures throughout 80% of ovaries, hemorrhagic cysts, and age dependent increase in collagen deposition of collagen in constrast, animals fed a soy diet did not display Sertoli-like cells in follicles absent corpora lutea impaired ovarian folliculogenesis though ovaries contained numerous follicles with abundant granulosa cells, antrum formation was arrested before ovulationno corpora leuteaabnormal uterus development underdeveloped uterus observed at 12 to 14 weeks of age3-fold enlargement of the clitoral gland relative to that of wild typeabnormal labium morphologylabial folds do not developabnormal spermiogenesisnormal at 4.5 months of agedysfunction evident at 1 year of agespermatids did not complete elongation and spermiationdegenerating round spermatidsabnormal prostate morphology increase in combined prostate/urinary bladder weightincreased seminal gland weight increased weight of seminal vescicles, putatively due to an increased volume of secretions rather than due to structural changesabnormal seminiferous tubule morphologydecrease in the volume of epitheliumin contrast to Esr1tm1Ksk homozygotes, no decrease in luminal volumedecreased testis weight reduction in weight, 1 year of ageabnormal primary sex determinationon a soy free diet, the ovaries develop cells that possess structural and functional characteristics of testicular interstitial (Leydig) cells and of seminiferous tubule-like structures lined with Sertoli cellsthe development of testicular tissue was postponed and reduced with estrogen replacementfemale infertilitymale infertilityprogressive infertility developing between 4.5 months and 1 year of age||FVB/N|Yes|No|Yes|Yes|No|Yes|Yes|Unknown|12||Het x Het|No|25-Apr-2007|Cryopreserved sperm|90.0|0.0|Unknown||Cyp19, reproductive system, adipose, cholesterol, sperm|Yes| 696.0|PrlΔ|STOCK Prl/Apb|STOCK Prl/Apb|Recessive|prolactin|Prl|Nil|Prl, Prl1a1|MGI:97762|targeted mutation 1, Nelson D Horseman|Prl|MGI:1934021|13||||||||||||||||Yes|||||||||||||Homozygous null female mice have irregular oestrus cycles and are infertile. Defects of the pituitary gland include hyperplasia, which progresses to adenoma, and impaired secretion.Abnormal branching of the mammary ductal tree:* ductal system comprises an extended branching network but devoid of terminal and lateral lobulationDecreased prolactin level: * in the pituitaryDecreased circulating prolactin level Failure of embryo implantation Abnormal mammary gland morphology Abnormal branching of the mammary ductal tree:* ductal system comprises an extended branching network but devoid of terminal and lateral lobulationAbnormal estrous cycle: * a consistent pattern of cycling was not established.||Unknown|Yes|No|Yes|Yes|Yes|Yes|No|Unknown|||HET x HET to maintain colony, KO male x HET female to produce more KOs|No|01-May-2007|Cryopreserved sperm|95.0|0.0|Unknown||eostrous cycle (estrous), infertility, pituitary gland, hyperplasia, mammary gland, duct, lobe|Yes| 5419.0|IL21 KO NOD|NOD.129-IL21/Apb||Recessive|interleukin 21|Il21|Nil||MGI:1890474|targeted mutation 1, Lexicon Genetics|Il21|MGI:3528994|3||||||||||||||||No|||||||||||||Protected from diabetes on NOD background.Decreased germinal center B cell number:* the percentage of GC B cells that make up the total B cell population in the spleen of immunized mice is reduced by two-thirdsAbnormal CD4-positive T cell morphology:* the percentage of follicular T helper cells (defined as CXCR5+ICOS+CD4+ T cells) is reduced by a third.Abnormal spleen germinal center morphology:* the number of actively proliferating T cells found within GC is reduced 3- to 4- fold.* the percentage of follicular T helper cells (defined as CXCR5+ICOS+CD4+ T cells) is reduced by a third.Decreased spleen germinal center number:* there is a paucity of GC in the spleen of mice after immunization with sheep red blood cells (SRBC).Decreased CD4-positive T cell number:* Il-17+ CD4+ cells are absent from lamina propria and spleen in mutants.Abnormal T cell differentiation:* when naive TH cells are subjected to TH17 differentiation, a deficit in generation of Il-17-producing cells is observed with an increased number of Foxp3+ cells compared to wild-type.* one week after immunization with MOG peptide in CFA, restimulation of spleen cells with TPA or MOG peptide results in production of almost no Il-17 producing cells, showing impaired TH17 differentiation.Abnormal gamma-delta T cell morphology:*lamina propria and splenic TCRgd+ T cells show <10-fold decrease in Il-17-expressing cells compared to wild-type cells.Abnormal interleukin level:* CNS-infiltrating and splenic CD4+ T cells produce interferon gamma, in contrast to CD4+ T cells from controls which produce predominantly Il-17.|Normal|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|0|intercross hets to derive homozygous for experiments|No|04-Feb-2011|Cryopreserved sperm|60.0|0.0|Unknown||interleukin, Immunoglobulin, B cell, T cell, CD4, germinal centre, IL17|Yes| 1526.0|B6.LMP2-/-|B6.129P2-Psmb9/AnuApb||Recessive|proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)|Psmb9|Nil|Lmp-2, Lmp2|MGI:1346526|targeted mutation 1, Susumu Tonegawa|Psmb9|MGI:2152729|17||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions in this gene have a grossly normal phenotype but suffer from increased susceptibility to some viruses and have an increased risk of tumor development.Decreased CD8-positive T cell number:* by 36% in blood* by 22% in spleen* by 49% in thymusAbnormal CD8-positive, alpha-beta cytotoxic T cell morphology :* 5-6 fold lower levels of cytotoxic T lymphocyte precursors after infection with influenza A virus but not Sendai virusAbnormal immune system physiology:* splenic lymphoblasts and peritoneal exudates cells are less efficient stimulators of CD8+ T cells.Increased susceptibility to viral infection:* 5-6 fold lower levels of cytotoxic T lymphocyte precursors after infection with influenza A virus but not Sendai virus.||C57BL/6 x 129S2|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Brother x Sister|No|05-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||T cell, CD8, tumour, viral infection, cytotoxic|Yes| 1527.0||B6.129S2-Tap1/AnuApb||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham-1, Ham1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483|targeted mutation 1, Philip Ashton-Rickardt|Tap1|MGI:1857253|17||||||||||||||||No|||||||||||||Mice homozygous for targeted mutations that inactivate the gene are deficient in antigen presentation, surface class I antigens, and CD4-8+ T cells. absent CD4-8+ cells (J:3524)decreased double-negative T cell count (J:3524)exhibit a 30-40 fold reduction in CD4-CD8- T cells in spleen, blood and lymph nodes, but not thymusabnormal dendritic cell antigen presentation (J:112436)mutant bone marrow-derived dendritic cells (BM-DC) treated with ovalbumin-immune complexes (OVA-IC) do not present the MHC class I-restricted epitope after OVA-IC internalizationdecreased level of surface class I molecules (J:3524)splenocytes exhibit little or no H2-Kb or -Db surface expression, however, at lower temperatures (26C) surface expression is increaseddefective intracellular transport of class I molecules (J:3524)class I Kb and Db molecules have little heavy chain sialylation indicating an impaired delivery to trans Golgihematopoietic systemabsent CD4-8+ cells (J:3524)decreased double-negative T cell count (J:3524)exhibit a 30-40 fold reduction in CD4-CD8- T cells in spleen, blood and lymph nodes, but not thymus||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|140.0|0.0|Unknown||T cell, MHC, antigen presentation, dendritic cell, CD8, CD4|Yes| 1535.0|IL-4 -/- IL-13 -/-|BALB/c-Il4/Il13/AnuApb||Recessive|interleukin 4|Il4|Nil|Il-4|MGI:96556|targeted mutation 3, Andrew NJ McKenzie|Il4/Il13|MGI:3038244|11||||||||||||||||Yes|||||||||||||Using a pulmonary granuloma model, induced with Schistosoma mansoni eggs, eosinophil infiltration, immunoglobulin E, and IL-5 production are abolished only in the combined absence of both cytokines. Furthermore, IL-4/13-deficient animals are severely impaired in their ability to expel the gastrointestinal nematode Nippostrongylus brasiliensis. Unexpectedly, N. brasiliensis-infected IL-4/13-deficient mice developed elevated IL-5 and eosinophilia, indicating that compensatory mechanisms exist for the expression of IL-5, although serum IgE remained undetectable. IL-4/13-deficient mice default to a Th1-like phenotype characterized by the expression of interferon gamma and the production of IgG2a and IgG2b.Decreased IgE level:less antigen-specific IgE is made compared to controls during an induced airway hyperresponsiveness model.Increased IgG2a level:more antigen-specific IgG2a is made compared to controls during an induced airway hyperresponsiveness modelDecreased interferon-gamma secretion:lymphocytes from mice sensitized and challenged with OVA produce less IFN-gamma than controlsDecreased interleukin-13 secretion:lymphocytes fail to produce IL-13Abnormal interleukin-4 secretion:lymphocytes fail to produce IL-4Decreased interleukin-5 secretion:lymphocytes from mice sensitized and challenged with OVA produce less IL-5 than controlsDecreased susceptibility to autoimmune disorder:mice fail to develop airway hyperresponsiveness after first being sensitized and challenged with OVA peptidein these mice, inflammation with eosinophil infiltrates occurs in the airways but there is a conspicuous absence of mucosal production.||Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|150.0|0.0|Unknown||T cell, CD4, dendritic cell, interferon, asthma, IgE|Yes| 1535.0|IL-4 -/- IL-13 -/-|BALB/c-Il4/Il13/AnuApb||Recessive|interleukin 13|Il13|Unknown|Il-13|MGI:96541|targeted mutation 3, Andrew NJ McKenzie|Il4/Il13|MGI:3038244|11|||||||||||||||||||||||||||||Using a pulmonary granuloma model, induced with Schistosoma mansoni eggs, eosinophil infiltration, immunoglobulin E, and IL-5 production are abolished only in the combined absence of both cytokines. Furthermore, IL-4/13-deficient animals are severely impaired in their ability to expel the gastrointestinal nematode Nippostrongylus brasiliensis. Unexpectedly, N. brasiliensis-infected IL-4/13-deficient mice developed elevated IL-5 and eosinophilia, indicating that compensatory mechanisms exist for the expression of IL-5, although serum IgE remained undetectable. IL-4/13-deficient mice default to a Th1-like phenotype characterized by the expression of interferon gamma and the production of IgG2a and IgG2b.Decreased IgE level:less antigen-specific IgE is made compared to controls during an induced airway hyperresponsiveness model.Increased IgG2a level:more antigen-specific IgG2a is made compared to controls during an induced airway hyperresponsiveness modelDecreased interferon-gamma secretion:lymphocytes from mice sensitized and challenged with OVA produce less IFN-gamma than controlsDecreased interleukin-13 secretion:lymphocytes fail to produce IL-13Abnormal interleukin-4 secretion:lymphocytes fail to produce IL-4Decreased interleukin-5 secretion:lymphocytes from mice sensitized and challenged with OVA produce less IL-5 than controlsDecreased susceptibility to autoimmune disorder:mice fail to develop airway hyperresponsiveness after first being sensitized and challenged with OVA peptidein these mice, inflammation with eosinophil infiltrates occurs in the airways but there is a conspicuous absence of mucosal production.||Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2007|Cryopreserved sperm|||Unknown||T cell, CD4, dendritic cell, interferon, asthma, IgE|Yes| 4477.0||B6.129-Hcn1/AnuApb||Recessive|hyperpolarization-activated, cyclic nucleotide-gated K+ 1|Hcn1|Nil|Bcng1, HAC2|MGI:1096392|targeted mutation 2, Eric R Kandel|Hcn1|MGI:2686951|13||||||||||||||||Yes|||||||||||||Behavior/neurological phenotype* basic motor functions were all normalIncreased thigmotaxis * observed during water maze testsAbnormal eye blink conditioning behavior * a deficiency was observed in latency to peak conditioned responseAbnormal learning/ memory Abnormal motor learning* there is a learned motor skill deficit in a rotorod test* impairment apparently involves learning and memory of relatively fast coordinated movementsAbnormal spatial learning* impaired learning in a water maze test||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|120.0|0.0|Unknown||motor, Purkinje cell, cerebellar, retina, earning|Yes| 8744.0|ASD572:Shn-2 KO:AIRE KO|B6.Cg-Aire Hivep2/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10|||||||||||||||||||||||||||||unknown|unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Jul-2019|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8744.0|ASD572:Shn-2 KO:AIRE KO|B6.Cg-Aire Hivep2/AnuApb||Recessive|human immunodeficiency virus type I enhancer binding protein 2|Hivep2|Nil|Gm20114, MIBP1, Schnurri-2, Shn-2|MGI:1338076|human immunodeficiency virus type I enhancer binding protein 2; targeted mutation 1, Shunsuke Ishii|Hivep2|MGI:2182914|10|||||||||||||||||||||||||||||unknown|unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Jul-2019|Cryopreserved sperm|||Unknown|||Yes| 1929.0|Balb/C Stat6-/- N10|C.129P2-Stat6/AnuApb|C.129P2-Stat6/AnuApb|Recessive|signal transducer and activator of transcription 6|Stat6|Nil|stat6-|MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10||||||||||||||||No|||||||||||||Skin inflammation:* mice exhibit mild dermal infiltration of inflammatory cells.* few CD4+ cells infiltrate the perioral dermis and epidermis.Acanthosis: sight.Decreased B cell proliferation:* B cell proliferation in response to anti-IgM plus IL-4 is impaired.* however, B cell proliferation in response to LPS is normal.Decreased T cell proliferation:* thymocyte proliferation in response to TPA is impaired.* however, thymocyte proliferate in response to other stimuli.Decreased IgE level: IgE levels are lower than in wild-type mice following infection with N. brasiliensis.Decreased IgG1 level: IgG1 levels are 16-fold lower than in wild-type mice and following infection with N. brasiliensis they are 10-fold lower than in infected wild-type mice.Increased IgA level: IgA levels are slightly increased following infection with N. brasiliensis.Increased IgG level: IgG2 and IgG3 levels are slightly increased following infection with N. brasiliensis.Abnormal T-helper 2 physiology: mice fail to produce increased levels of Th2 cytokines in response to infection with N. brasiliensis.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Aug-2007|Cryopreserved sperm|63.0|0.0|Unknown||T cell, IL-4, signal transduction, lymphocyte, B cell|Yes| 1945.0|CBA/H. IL5 -/-|CBA/H.B6-Il5/AnuApb||Recessive|interleukin 5|Il5|Nil|Il-5|MGI:96557|targeted mutation 1, Manfred A Kopf|Il5|MGI:1861948|11||||||||||||||||Yes|||||||||||||Homozygotes for a targeted null mutation exhibit loss of normal airway hyperreactivity resulting from aeroallergen challenge, reduced numbers of CD5+ B cells in the peritoneal cavity at 2 weeks, and some altered responses to schistosomiasis infection. Mice appear normal. They have normal basal levels of eosinophils but in response to parasite infections or aeroallergen challenge, numbers do not increase. Further, resistance to some phases of helminthic infections may be impaired. Decreased airway responsiveness: airways of aeroallergen-challenged knockout mice lose hyperresponsiveness to methacholine.Increased neutrophil cell number: after aerosolized OVA challenge, knockout mice have increased levels of neutrophils in BALF compared to unchallenged animals.Increased lymphocyte cell number: after aerosolized OVA challenge, knockout mice have increased levels of lymphocytes in BALF compared to unchallenged animals but the increase is less pronounced than in wild type mice.Abnormal interferon physiology: in mesenteric lymph nodes in culture, there is a marked increase in IFNG production in knockouts compared to wild type after restimulation with mitogen or SEA.Granulomatous inflammation:* pulmonary granulomas that form in knockout mice in response to schistosome eggs are almost completely devoid of eosinophils compared to granulomas in wild type mice; the average size of granulomas in knockout mice are 40% smaller than those of wild type.* there is a 20-25% increase in numbers of macrophages associated with granulomas in knockouts compared with wild type; with acute or chronic parasite infection, the numbers of both fibroblasts and macrophages nearly double in knockout animals compared to wild type.Liver fibrosis: hepatic fibrosis is significantly reduced in knockouts with acute or chronic helminth parasite infection.Increased eosinophil cell number: knockout mice infected with parasites do not show eosinophil counts above baseline values, while 35-week old controls develop eosinophilia in the blood, bone marrow and peritoneal cavity.||CBA/H|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|20||IL5-/- male mated with IL5-/- female|No|01-Sep-2007|Cryopreserved sperm|140.0|0.0|Unknown||infection, T cell, B cell, CD5, eosinophil|Yes| 1626.0|C2X1f|129X1;129S1-Cited2/Apb|129X1;129S1-Cited2/Apb|Recessive|Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2|Cited2|Normal|ER154-like, Mrg1, Msg2, p35srj|MGI:1306784|targeted mutation 1.1, Sally L Dunwoodie|Cited2|MGI:3696062|10||||||||||||||||No|||||||||||||Normal|None|129X1/SvJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|0|Backcrossed into 129X1/SvJ to increase health as ES origin is not as viable.|No|16-Jul-2007|Cryopreserved sperm|200.0|0.0|Yes||Cited2, heart, placenta, left-right axis|Yes| 2465.0||B6.CBA-Tg(hGMCSF-2CK1)91/AnuApb||Dominant|||||||||Unknown||||||||||||||||No|human GMCSF (GM-CSF)|human GM-CSF promoter and enhancer (10.5kb)|||||||||||Express human GM-CSF. hGM-CSF detected in serum by ELISA. Murine GM-CSF used as internal control.||C57BL/6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2008|Cryopreserved sperm|30.0|0.0|No||T cell, lymphocyte, transcription, chromatin remodelling, NF-kappaB|Yes| 1635.0|Itsn1-L knockout|129/Sv-Itsn1/Apb|129/Sv-Itsn1/Apb|Recessive|intersectin 1 (SH3 domain protein 1A)|Itsn1|Reduced|Eh domain, SH3 domain regulator of endocytosis 1, EHSH1, Ese1, Intersectin-L, Sh3p17|MGI:1338069|intersectin 1 (SH3 domain protein 1A); targeted mutation 2.1, Melanie A Pritchard|Itsn1|MGI:3812035|16||||||||||||||||Yes|||||||||||||Some homozygotes are runty after birth compared to the wildtype and die before weaning age. Otherwise they can catch up with the wildtype|No overt phenotype|129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||Het x het|No|17-Jul-2007|Cryopreserved sperm|36.0|0.0|Yes|Alzheimer’s disease and Down syndrome|Alzheimer's disease, Down Syndrome, endocytosis, endosome, neuron|Yes| 1636.0|Lefty2-Cre ; L2Cre (Ninnag)|B6.Cg-Tg(Lefty2-cre)21bHmd/Apb|B6.Cg-Tg(Lefty2-cre)21bHmd/Apb|Dominant||||||||||||||||||||||||||transgene insertion 21b, Hiroshi Hamada|3.0kb upstream region of murine Lefty2 gene|High||||||||||No overt phenotype|Expresses Cre-recombinase in mesoderm of 8.5dpc embryos.The promoter specifically directed cre expression in the epiblast and its derivatives between E5.5 and E8.0.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|6||Transgenic x wildtype|No|17-Jul-2007|Cryopreserved sperm|100.0|0.0|Unknown||Mesoderm, left-right, transcription, Nodal|Yes| 1637.0|NDE-Cre|C57BL/6-Tg(Nodal-cre)16Hmd/Apb|C57BL/6-Tg(Nodal-cre)16Hmd/Apb|Dominant||||||||||||||||||||||||||transgene insertion 16, Hiroshi Hamada|Two tandem copies of the NDE enhancer element from Nodal genes upstream region (0.7kb each) ligated upstream of heat shock promoter|Weak initially in node ~LB stage. Becomes stronger as embryos age ie quiet strong at 4 somites|||||||||||Expresses Cre-recombinase in node at LB/EHF stage.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|6||Transgenic x wildtype|No|17-Jul-2007|Cryopreserved sperm|140.0|0.0|Unknown||Nodal, left-right, Heat shock Protein, Mesoderm|Yes| 1927.0|S1 SuprMam/09:S2Balb/Balb Hom::G4|B6.BALB/c-SuprMam1 SuprMam2/AnuApb||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Mice are more susceptible to mammary tumours.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|6|||No|23-Aug-2007|Cryopreserved sperm|100.0|0.0|Unknown||mammary, tumour, DMBT1, p53, modifier|Yes| 2355.0|Patel|B6.129S2-Cd28 Tg(TcrLCMV)327Sdz Tcra/AnuApb||Recessive|CD28 antigen|CD28|Nil|Tcr alpha, Tcralpha|MGI:88327|targeted mutation 1, Tak Mak|Cd28|MGI:1857150|1||||||||||||||||Yes|transgene insertion 327, Birgit Ledermann||High||||||||||Homozygous mutation of this CD28 results in impairment of some T cell responses and decreased basal immunoglobulin levels. Mutant animals have reduced T helper cell activity and impaired T cell response to lectins, but cytotoxic T cells can still be induced||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2007|Cryopreserved sperm|25.0|0.0|Unknown||T cell, immunoglobulin, receptor|Yes| 2355.0|Patel|B6.129S2-Cd28 Tg(TcrLCMV)327Sdz Tcra/AnuApb||Recessive|T-cell receptor alpha chain|Tcra|Unknown|Tcr alpha, Tcralpha|MGI:98553|targeted mutation 1, Peter Mombaerts|Tcra|MGI:1857255|14|||||||||||||||||||||||||||||Homozygous mutation of this CD28 results in impairment of some T cell responses and decreased basal immunoglobulin levels. Mutant animals have reduced T helper cell activity and impaired T cell response to lectins, but cytotoxic T cells can still be induced||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2007|Cryopreserved sperm|||Unknown||T cell, immunoglobulin, receptor|Yes| 2390.0|Light Knockout|B6.129-Tnfsf14/AnuApb||Recessive|tumor necrosis factor (ligand) superfamily, member 14|Tnfsf14|Nil|HVEM-L, LIGHT|MGI:1355317|tumor necrosis factor (ligand) superfamily, member 14; targeted mutation 1, Klaus Pfeffer|Tnfsf14|MGI:2671122|17||||||||||||||||No|||||||||||||Develop intact lymphoid organs.Abnormal immune system physiology.The knockout provides in vivo evidence for a cooperative role forLIGHT and Lymphotoxin in lymphoid organogenesis and indicates important costimulatory functions for LIGHT in T cell activation.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Unknown||||No|19-Dec-2007|Cryopreserved sperm|130.0|0.0|No||T cell, lymphotoxin, lymphocyte, CD28, activation|Yes| 8746.0|ASD873:Pear:XB3bpins|C57BL/6NCrlAnu-Xbp1/AnuApb||Recessive|X-box binding protein 1|Xbp1|Unknown|D11Ertd39e, TREB5, TREB-5, XBP-1|MGI:98970|Xbp1, endonuclease-mediated mutation 2, Australian National University|Xbp1||11||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Jul-2019|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 1952.0|BALB/c.Zeta|BALB/c-Gstz1/AnuApb||Recessive|glutathione transferase zeta 1 (maleylacetoacetate isomerase)|Gstz1|Nil|maleylacetoacetate isomerase|MGI:1341859|glutathione transferase zeta 1 (maleylacetoacetate isomerase); targeted mutation 1, Philip G Board|Gstz1|MGI:3050206|12||||||||||||||||No|||||||||||||Increased sensitivity to induced morbidity/mortality: 3% phenylalanine in the water is lethal to young homozygotes, less than 28 days old, but not to older homozygotes, greater than 66 days old.Premature death: several mutants died after 1 year of age from heart pathologies.Dystrophic cardiac calcinosis:* in some mutants over 1 year of age calcification of the myocardium in the right atrium and/or ventricle is seen* calcification is also seen in 3 of 8 young mutants that died after 3% phenylalanine exposure.Cellular necrosis:* in some mutants over 1 year of age myocyte necrosis is seen* myocyte necrosis is also seen in 2 of 8 young mutants that died after 3% phenylalanine exposure.Decreased body weight: male homozygotes weigh slightly less than wild-type or heterozygous males.Weight loss: 3% phenylalanine in the water results in greater weight loss and growth restriction in male homozygotes compared to wild-type mice.Decreased leukocyte cell number: 3% phenylalanine in the water results in decreased total white cell counts in mutants but not in wild-type mice.Decreased spleen weight: * spleen weight is significantly decreased in female homozygotes and tends to be decreased in male homozygotes compared to wild-type mice.* 3% phenylalanine in the water results in a dramatic decrease in spleen weight in homozygotes with reduction in both white and red pulp, but an increase in spleen weight in wild-type mice.Chronic inflammation: in some mutants over 1 year of age chronic inflammation is seen in the heart.Liver inflammation: at 6 weeks and 6 months of age multifocal hepatitis is seen.Abnormal hepatocyte morphology: large pleomorphic mitochondria are seen in hepatocytes from mutants.Increased liver weight: on a normal diet liver weight is greater in homozygotes compared to wild-type mice.Hepatic necrosis:* at 6 months of age 3 of 7 homozygotes show hepatocyte necrosis.* 3 out of 8 homozygotes that died after 3% phenylalanine exposure displayed hepatocyte necrosis.Hepatic steatosis: 5 out of 8 homozygotes that died after 3% phenylalanine exposure displayed macrovesicular steatosis.Increased kidney weight:* kidney weight is greater in homozygotes compared to wild-type mice.* 3% phenylalanine in the water results in an increase in kidney weight in homozygotes but not in wild-type mice.||BALB/c |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Sep-2007|Cryopreserved sperm|50.0|0.0|Yes||GST, maleylacetoacetate, maleylacetone (MA) and succinylacetone, phenylalanine and tyrosine, Keap1/Nrf2 pathway, oxidative stress, inflammation, glutathione transferase|Yes| 5427.0|203.3 ; cTnI-G203S.3|C57BL/6-Tg(Myh6-TNNI3*G203S)3Chs/Apb||Dominant||||||||||||||||||||||||||transgene insertion 3, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|58% of endogenous||||||||||Unknown|Mice develop cardiac phenotype - hypertrophic cardiomyopathy. Onset age dependent upon the amount of transgene protein expressed.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||17|Transgenic x non-transgenic sibs|No|10-Feb-2011|Cryopreserved sperm|36.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 2397.0|Zap70 knockout|B6;129X1-Zap70/AnuApb|B6;129X1-Zap70/AnuApb|Recessive|zeta-chain (TCR) associated protein kinase|Zap70|Nil|Srk, TZK, ZAP-70|MGI:99613|targeted mutation 1, Arthur Weiss|Zap70|MGI:2176252|1||||||||||||||||No|||||||||||||Abnormal T cell differentiation:* the number of dendritic epidermal T cells is reduced and those cells present lack the characteristic dendritic extensions.* few intestinal intraepithelial lymphocytes express gamma delta or alpha beta T cell receptors.Arrested T cell differentiation: arrest at the double positive stageAbnormal splenic cell ratio: spleens are composed of mostly B cells.Abnormal lymph node cell ratio:* lymph nodes contain mostly B cells and a significant percentage of CD3+ (but CD4- and CD8-) cells which are primarily gamma delta T cells.* the percentage of gamma delta T cells is increased but the absolute number of these cell is similar to wild-type.||C57BL/6 x 129X1|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|20.0|0.0|No||T cell, lymphocyte, B cell, lymph node, spleen, differentiation|Yes| 5431.0|Funky|STOCK Ndufs4/DrthApb|STOCK-Ndufs4/Drth|Recessive|NADH dehydrogenase (ubiquinone) Fe-S protein 4|Ndufs4|Reduced|C1-18k|MGI:1343135|funky|Ndufs4|MGI:4942335|13||||||||||||||||Yes|||||||||||||Homozygous mice initially present with fur loss around postnatal day 14, which regrows in the next hair cycle. They show reduced growth and several behavioural abnormalities that appear from postnatal week five, such as tilting of the head, walking in circles and twisting of the body when suspended by the tail. Due to progressively wobbly gait and general deterioration in physical condition, all homozygous mice have to be euthanased around postnatal week eight in compliance with ethical guidelines.|Appears indistinguishable from Wild-Type|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Poor|unknown||het X het|No|14-Feb-2011|Cryopreserved sperm|49.0|0.0|Yes|Mitochondrial Disease; Leigh Syndrome|Mitochondria, Oxidative Phosphorylation, Complex I|Possibly| 2398.0|Activin Beta C ++ FL2|C57BL/6-Tg(ACTIVIN-β{C})2Grb/Apb||Recessive|||||||||Unknown||||||||||||||||No|human activin betaC|CMV|High||||||||||No gross external abnormalities evident, male sub-fertile (narrow window of fertility 7-9 weeks), limited pups resulting from matings, infertile from around 9 weeks. |No gross external abnormalities evident, male sub-fertile (window of fertility 7-14 weeks), decreased litter size, infertile from around 15 weeks. |C57BL/6|Yes|Yes|Yes|Yes|No|Yes|Yes|Poor|||Het x Het or Het x WT|No|20-Dec-2007|Cryopreserved sperm|90.0|0.0|Unknown||activin, inhibin, prostate, testis, liver|Yes| 2418.0|Gz alpha knockout|C57BL/6JAnu-Gnaz/AnuApb|C57BL/6JAnu-Gnaz/AnuApb|Recessive|guanine nucleotide binding protein, alpha z subunit|Gnaz|Nil|Gz|MGI:95780|guanine nucleotide binding protein, alpha z subunit; targeted mutation 1, I A Hendry|Gnaz|MGI:3575007|10||||||||||||||||No|||||||||||||Decreased sensitivity to xenobiotic induced morbidity/mortality:* morphine treated homozygotes are able to tolerate higher morphine doses compared to wild-type mice (LD50 of 800 mg/kg compared to 700 mg/kg for wild-type).* however no significant difference in the serum levels of morphine or its metabolites is seen.Decreased chemically-elicited antinociception:* in previously unexposed female homozygotes reduced analgesia at low morphine doses is seen, a similar but not significant effect was seen in males.* with repeated morphine doses mutants develop tolerance faster than wild-type mice.* acute morphine administration induces the same degree of antinociception; however homozygotes develop tolerance to morphine more rapidly compared to wild-type mice in the hot and cold plate tests.* spinal mechanisms of morphine tolerance are normalReduced fertility: litters from homozygous parents on the C57BL/6 background had increased mortality that was not seen in litters from heterozygous or mixed strain parents.Decreased body weight:* body weight is normal at birth but homozygotes gain less weight and males and females are 22% and 27% smaller than their wild-type littermates at 2 - 3 weeks of age.* After 3 weeks of age homozygotes gain weight more rapidly and the body weight difference is gone by 2 - 3 months of age.|Abnormal chemically-elicited antinociception: with repeated morphine doses heterozygotes develop tolerance faster than wild-type mice but not as quickly as homozygous mutants.Decreased sensitivity to xenobiotic induced morbidity/mortality: morphine treated homozygotes are able to tolerate higher morphine doses compared to wild-type mice (LD50 of 750 mg/kg compared to 700 mg/kg for wild-type).|C57BL/6jAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|20|||No|09-Jan-2008|Cryopreserved sperm|109.0|0.0|Unknown||G-protein, Tolerance, Feeding Behaviour, xenobiotic, morphine|Yes| 2474.0||B6.129-Bmi1/WehiApb||Recessive|Bmi1 polycomb ring finger oncogene|Bmi1|Nil|Bmi-1, Bmi1, Pcgf4|MGI:88174|targeted mutation 1, Anton Berns|Bmi1|MGI:1857632|2||||||||||||||||Yes|||||||||||||Homozygous null mutants display decreased hematopoietic cell number, immune deficiency, neurological abnormalities, and posterior transformation, while transgenic overexpressing mice show an opposite dose-dependent anterior transformation of vertebral identity.Postnatal lethality.|Vertebral transformation||No|No|Yes|No|No|Yes|No|Poor||||No|18-Jan-2008|Cryopreserved sperm|150.0|0.0|Unknown||Proliferation, Ataxia, Sporadic seizures, posterior transformation, anteroposterior axis|Yes| 2475.0|Mel18|B6;129-Pcgf2RbrcApb||Recessive|polycomb group ring finger 2|Pcgf2|Unknown|mel-18, Mel18, Rnf110, Zfp144|MGI:99161|polycomb group ring finger 2; targeted mutation 1, Haruhiko Koseki|Pcgf2|MGI:1857633|11||||||||||||||||Yes|||||||||||||Homozygous null mutants exhibit multiple abnormalities of the axial skeleton (including homeotic transformations), grow markedly slower, and die either perinatally or between 3-6 weeks of age depending on genetic background.||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|18-Jan-2008|Cryopreserved sperm|140.0|0.0|Unknown||growth retardation, Ataxia, posterior transformation, anteroposterior axis|Yes| 2732.0|-0.9E3CreERT line 90|C57BL/6-Tg(Tal1-cre/ERT)90Jame/Apb|C57BL/6-Tg(Tal1-cre/ERT)90Jame/Apb|Semi-dominant||||||||||||||||||||||||||transgene insertion 90, J Anke M van Eekelen|-0.9E3 neural enhancer/promoter of the Stem Cell Leukemia (Scl/tal1) gene|Moderate expression of creERT in Scl expressing neurons of the CNS||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||-0.9E3CreERT line 90 x C57BL/6J|No|06-Feb-2008|Cryopreserved sperm|89.0|0.0|No||Cre/loxP, tamoxifen inducibility, neurogenesis, transcription factor , conditional gene deletion|Yes| 2733.0|-0.9E3CreERT line 145B|C57BL/6-Tg(Tal1-cre/ERT)145BJame/Apb||Semi-dominant||||||||||||||||||||||||||transgene insertion 145B, J Anke M van Eekelen|-0.9E3 neural enhancer/promoter of the Stem Cell Leukemia (Scl/tal1) gene|Moderate expression of creERT in Scl expressing neurons of the CNS||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4||-0.9E3CreERT line 145B x C57BL/6J|No|06-Feb-2008|Cryopreserved sperm|70.0|0.0|No||Cre/loxP, tamoxifen inducibility, neurogenesis, transcription factor, conditional gene deletion|Yes| 2734.0|-0.9E3CreERT line 145A|C57BL/6-Tg(Tal1-cre/ERT)145AJame/Apb|C57BL/6-Tg(Tal1-cre/ERT)145AJame/Apb|Semi-dominant||||||||||||||||||||||||||transgene insertion 145A, J Anke M van Eekelen|-0.9E3 neural enhancer/promoter of the Stem Cell Leukemia (Scl/tal1) gene|Moderate expression of creERT in Scl expressing neurons of the CNS||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||-0.9E3CreERT line 145A x C57BL/6J|No|06-Feb-2008|Cryopreserved sperm|65.0|0.0|No||Cre/loxP, conditional gene deletion, tamoxifen inducibility, neurogenesis, transcription factor|Yes| 8750.0|Gsdmd KO|C57BL/6N-Gsdmd/GneAnu||Recessive|gasdermin D|Gsdmd||1810036L03Rik, DF5L, Dfna5l, Gsdmdc1, M2-4|MGI:1916396|gasdermin D; endonuclease-mediated mutation 1, Genentech|Gsdmd|MGI:6259809|15|||||||||||||||||||||||||||||||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jul-2019||0.0|0.0|Unknown||Caspase-11, infection|Yes| 7790.0||C57BL/6NCrlAnu-Prdm1/AnuApb|C57BL/6NCrlAnu-Prdm1/AnuApb|Recessive|PR domain containing 1, with ZNF domain|Prdm1||b2b1765Clo, Blimp1, Blimp-1, PRDI-BF1|MGI:99655|Prdm1; mutation 1, Australian National University|Prdm1||10||||||A to T||||Unknown to Unknown|||||||||||||||||||Absence of B and T cells|Small reduction in %B cells and increased CD44 expression on B cells|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Nov-2014|Cryopreserved sperm|40.0|0.0|Unknown||T cell, B cell, Cd44|Yes| 2746.0|BALB/c.Flii 1.5F ; FIN|BALB/c-Flii/AnuApb|BALB/c-Flii/AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop. embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type|BALB/c|No|No|Yes|No|No|Yes|No|Good|10|11|Het male x wt female|No|10-Feb-2008|Cryopreserved sperm|150.0|0.0|Yes||cell migration, embryonic lethal, wound repair, gelsolin, gastrulation|Yes| 2763.0|BALB/c.Flii 2.1A|BALB/c-Flii/3AnuApb|BALB/c-Flii/3AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop. embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type|BALB/c|No|No|Yes|No|No|Yes|No|Good|10|11|Het male x WT female|No|14-Feb-2008|Cryopreserved sperm|150.0|0.0|No||gelsolin, embryonic lethal, wound repair, cell migration, gastrulation|Yes| 2766.0|BALB/c.Flii<+/+> FLII ; FIC|BALB/c-Tg(FLII)1Hdc/AnuApb|BALB/c-Tg(FLII)1Hdc|Dominant||||||||||||||||||||||||||transgene insertion 1, Hugh D Campbell|human flightless promoer|||||||||||Ubiquitous expression of human Flightless gene.|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||1|Hom x Hom|No|15-Feb-2008|Cryopreserved sperm|150.0|0.0|Unknown||human Flightless, wound repair, cellular proliferation, cell migration, gelsolin|Yes| 2772.0|BALB/c.Flii<+/+> FLII ; FIT|BALB/c-Tg(FLII)2Hdc/AnuApb|BALB/c-Tg(FLII)2Hdc|Dominant||||||||||||||||||||||||||Human Flightless gene|Human Flightless|||||||||||Ubiquitous expression of human Flightless protein||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het x wt BALB/c|No|16-Feb-2008|Cryopreserved sperm|80.0|0.0|Unknown||human flightless, wound repair, cellular proliferation, cell migration, gelsolin|Yes| 2776.0|Balb/c-hK14FLII 18|BALB/c-Tg(hK14-FLII)18/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|Human Flightless|Human Keratin 14|||||||||||Not bred to homozygous state|Normal|BALB/C|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het FLII transgenic x WT BALB/c|No|16-Feb-2008|Cryopreserved sperm|45.0|0.0|Unknown||human, skin, enhancer, keratin|Yes| 2779.0|C57BL/6.hK14-FLII 5|C57BL/6-Tg(hK14-FLII)5/AnuApb||Dominant|||||||||Unknown||||||||||||||||Yes|Human Flightless|Human Keratin 14|||||||||||Not bred to Homozygous state|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Het FLII transgenic x WT C57BL/6|No|16-Feb-2008|Cryopreserved sperm|60.0|0.0|Unknown||human, keratin, skin, enhancer|Yes| 2782.0|C57BL/6.Flii 1.5F|B6.C-Flii/AnuApb|B6.C-Flii/AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop. embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|10|11|Het male x WT female|No|16-Feb-2008|Cryopreserved sperm|75.0|0.0|Unknown||embryonic lethal, gelsolin, wound repair, egg cylinder, gastrulation|Yes| 3324.0|TGM2 floxed|B6;129S1-Tgm2/Apb|B6;129S1-Tgm2/Apb|Recessive|transglutaminase 2, C polypeptide|Tgm2|Normal|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 1, Robert M Graham|Tgm2|MGI:3525256|2||||||||||||||||Yes|||||||||||||Normal|Normal|129S1/Sv x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||Hom x Hom|No|15-Jun-2008|Cryopreserved sperm|138.0|0.0|Unknown||Transgluatminase, Gh, G-protein, cross-linking|Yes| 3341.0|CBA/Ca Tg(IL5)C1|CBA/Ca-Tg(CD2-Il5)5C1Ldt/Apb [cc]|CBA/Ca-Tg(CD2-Il5)5C1Ldt/Apb [cc]|Recessive||||||||||||||||||||||||||transgene insertion 5C1, Lindsay A Dent|dominant controlling region (DCR), to approx. 2.1kb, 3' of the genomic sequence of the human CD2 gene|8 copies||||||||||Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow.Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|CBA/Ca|No|No|Yes|No|No|Yes|No|Excellent|||Tg male wild type female|No|20-Jun-2008|Cryopreserved sperm|150.0|0.0|Yes||eosinophil, asthma, resistance to helminthic parasites, allergy, immune surveillance|Yes| 3342.0|CBA/Ca Tg(IL5)C2|CBA/Ca-Tg(CD2-Il5)5C2Ldt/Apb [cc]|CBA/Ca-Tg(CD2-Il5)5C2Ldt/Apb [cc]|Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|Dominant controlling region (DCR), to approx. 2.1kb, 3' of the genomic sequence of the human CD2 gene|49 copies. The DCR drives thymocyte and T cell specific expression.||||||||||Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|CBA/Ca|No|No|Yes|No|No|Yes|No|Excellent|||Tg male wild type female|No|20-Jun-2008|Cryopreserved sperm|150.0|0.0|Yes||eosinophil, asthma, resistance to helminthic parasites, allergy, immune surveillance|Yes| 8751.0|Db|B6-Lepr/AnuApb||Recessive|leptin receptor|Lepr||Leprb, LEPROT, leptin receptor gene-related protein, Modb1, obese-like, obl, Obr, OB-RGRP|MGI:104993|leptin receptor; diabetes|Lepr|MGI:1856009|4|||||||||||||||||||||||||||||ObesityDiabetes||C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|17-Jul-2019|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 3314.0|P301L tau ; pR5|C57BL/6-Tg(Thy1-MAPT)183Gotz/Apb||Recessive||||||||||||||||||||||||||transgene insertion 183, Jurgen Gotz|murine Thy1|High in the hippocampus, fornix fimbriae, amygdala, spinal cord, and cortex|||||||||||Transgene expression high in brain, low in spinalcord. No altered physical phenotype.Tangle formation|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||T6 x C57BL/6|No|09-Jun-2008|Cryopreserved sperm|20.0|0.0|Yes||memory impairment, Alzheimer’s disease, tangles, phosphorylation, amygdala, tau, microtubule-associated protein tau|Yes| 3926.0|K5-crePR1 , K5cre*PR1 ; K5S|BALB/c-Tg(KRT5-cre*/PGR)1Der/AnuApb||Dominant||||||||||||||||||||||||||Cre recombinase, mutant; Cre* fused to a deletion mutant of the human progesterone receptor (PR)|bovine keratin 5|Normal to high, restricted to keratinocytes||||||||||To activate or inactivate conditional alleles in murine stratified epithelia, a novel system has been developed. It is based on the generation of transgenic mice that express an inducible Cre recombinase under the control of a promoter specific for stratified epithelia. The inducible features of Cre were achieved by fusing Cre to a deletion mutant of the human progesterone receptor (PR), which fails to bind progesterone but can be activated by progesterone antagonists, such as RU486. This fusion protein (CrePR1) is sequestered in the cytoplasm. After activation with RU486, CrePR1 translocates to the nucleus, where it mediates the excision of DNA sequences flanked by LoxP sites. Mice generated express CrePR1 under the control of the K5 which is expressed in the basal cells of stratified epithelia ||Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|4||Backcross to balb/c|No|14-Oct-2008|Cryopreserved sperm|86.0|0.0|Unknown||RU486, codon optimised Cre, modified Cre, keratin, inducible|Yes| 3945.0|MommeD3|FVB/N-MommeD3 Tg(HBA1-Gfp)1Ew/Apb||Semi-dominant|||Unknown|||modifiers of murine metastable epiallele D3|MommeD3|MGI:3586550|11||||||||||||||||Yes|transgene insertion 3 Emma Whitelaw|human alpha-globin promoter and enhancer region|||||||||||Homozygous embryonic lethality around 10.5 dpc|Percentage of cells expressing the GFP transgene (Line3) is increased (suppressor of variegation). Heterozygotes are slightly smaller than wild-types at weaning.|FVB/NJ|No|No|Yes|No|No|Yes|No|Good|||MommeD3<+/->;Tg(Hba1-Gfp)3Ew x Tg(Hba1-Gfp)3Ew|No|17-Oct-2008|Cryopreserved sperm|60.0|0.0|Unknown||epigenetics, suppressor of variegation, modifier, ENU|Yes| 4185.0||C57BL/6-CD151/Apb||Recessive|Cd151 antigen|Cd151|Nil|PETA-3, SFA-1, Tspan24|MGI:1096360|targeted mutation 1, Leonie K Ashman|Cd151|MGI:3050539|7||||||||||||||||Yes|||||||||||||abnormal cell migration: keratinocyte migration is significantly impaired hematopoietic system: abnormal T cell proliferation, a significant increase in proliferation of activated T cells is seen. Abnormal bone marrow cell number: a slight but significant increase in the number of immature myeloid lineage cells and corresponding decrease in lymphocyte numbers is seen.homeostasis/metabolism: increased bleeding time- a small but significant increase in mean tail bleeding time and a 3 fold increase in the volume of blood lost is seen||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2008|Cryopreserved sperm|100.0|0.0|Unknown||epithelium, integrin, fibroblast, wound, migration|Yes| 4196.0||NOD.129P2/Ola-Csf2/WehiApb|NOD.129P2/Ola-Csf2/WehiApb|Recessive|colony stimulating factor 2 (granulocyte-macrophage)|Csf2|Nil|Csfgm, Gm-CSf, MGI-IGM|MGI:1339752|targeted mutation 1, Ashley R Dunn|Csf2|MGI:1930997|11||||||||||||||||Yes|||||||||||||These mice may develop diabetes beginning at around 12 weeks of age. When these mice are used for incidence curves, the longest they are kept alive is 300 days.Mice develop pulmonary pathology from 10 weeks onwards. They are more susceptible to lung infections caused by bacterial or fungal organisms.|Phenotype as for wild type NOD/Lt mice- develop type 1 diabetes starting around 12-15 weeks of age|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|16|2|sib x sib|No|20-Dec-2008|Cryopreserved sperm|135.0|0.0|Yes||Macrophage, haematopoiesis|Yes| 3392.0|C3H.PRI-Flv; C3H/Rv|C3.PRI-Oas1b/ArcApb|C3.PRI-Oas1b/ArcApb|Dominant|2'-5' oligoadenylate synthetase 1B|Oas1b|Normal|Flavivirus resistance, Flv, L1, Mmu-L1, Oias-2, Oias2, Wnv|MGI:97430|flavivirus resistance|Oas1b|MGI:1857800|5||||||||||||||||No|||||||||||||Decreased susceptibility to viral infection: viral replication was inhibited in mice from resistant strains upon innoculation with the following viruses: Yellow Fever, Dengue Fever, West Nile Fever, Japanese Encephalitis, St. Louis Encephalitis, Russian Spring Summer Encephalities. Flv Phenotpye:- resistance to infections by Flaviviruses. Tlr4 Phenotpye:- Toll 4 receptor is responsive to LPS infection. Diht Phenotpye:- an increased hypothermia response as measured by a drop in core temperature following peripheral administration of a dopamine agonist.|Flv Phenotpye:- dominant phenotype, heterozygotes are resistant to infection. Tlr4 Phenotpye:- dominant phenotype, heterzygotes show responsiveness to LPS. Diht Phenotpye:- dominant and dopamine-induced hypothermia in heterozygotes show the high responder phenotype.|C3.PRI.Oas1b|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||12|brother x sister|No|11-Jul-2008|Cryopreserved sperm|145.0|0.0|Unknown||dopamine, flavivirus resistance, apomorphine, hypothermia, lipopolysaccharide (LPS)|Yes| 3393.0|C3H.PRI-Hyp|C3.PRI-Diht/ArcApb|C3.PRI-Diht/ArcApb|Recessive|||Normal|||dopamine-induced hypothermia; C3.PRI|Diht|MGI:3586688|5||||||||||||||||No|||||||||||||High dopamine-induced hypothermia characterised in Dihrt/Diht (Diht x Diht) homozygous mice|High dopamine-induced hypothermia characterised in Dihrt/Diht (Diht x Diht) heterozygous mice|C3H/HeJARC|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||8|brother x sister|No|11-Jul-2008|Cryopreserved sperm|150.0|0.0|Unknown||dopamine, flavivirus resistance, apomorphine, hypothermia, lipopolysaccharide (LPS)|Yes| 3395.0|C3H/HeJARC|C3H/HeJArcApb|C3H/HeJArcApb|Recessive|2'-5' oligoadenylate synthetase 1B|Oas1b|Normal|Flavivirus resistance, Flv, L1, Mmu-L1, Oias-2, Oias2, Wnv|MGI:97430|2'-5' oligoadenylate synthetase 1B; flavivirus susceptibility|Oas1b|MGI:2181524|5||||||||||||||||Yes|||||||||||||Flv phenotype:- Susceptible to infections by Flaviviruses. Tlr4 Phenotype:- responsiveness of Toll 4 Receptor to LPS infection. Diht Phenotype:- a decreased hypothermia response as measured by drop in core temperature following the peripheral administration of a dopamine agonist|Flv Phenotype:- recessive phenotype, hets are resistant to infection by Flaviviruses. Tlr4 phenotype:- is dominant and heterozygous mice show responsiveness to LPS.Diht phenotype is recessive and dopamine-induced hypothermia in heterozygotes show the high responder type.|C3H/HeJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16|brother x sister|No|11-Jul-2008|Cryopreserved sperm|150.0|0.0|Unknown||dopamine, flavivirus resistance, apomorphine, hypothermia, lipopolysaccharide (LPS)|Yes| 3395.0|C3H/HeJARC|C3H/HeJArcApb|C3H/HeJArcApb|Recessive|dopamine-induced hypothermia|Diht|Unknown||MGI:3033372|C3H/HeJArc|Diht|MGI:3586687|5|||||||||||||||||||||||||||||Flv phenotype:- Susceptible to infections by Flaviviruses. Tlr4 Phenotype:- responsiveness of Toll 4 Receptor to LPS infection. Diht Phenotype:- a decreased hypothermia response as measured by drop in core temperature following the peripheral administration of a dopamine agonist|Flv Phenotype:- recessive phenotype, hets are resistant to infection by Flaviviruses. Tlr4 phenotype:- is dominant and heterozygous mice show responsiveness to LPS.Diht phenotype is recessive and dopamine-induced hypothermia in heterozygotes show the high responder type.|C3H/HeJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16|brother x sister|No|11-Jul-2008|Cryopreserved sperm|||Unknown||dopamine, flavivirus resistance, apomorphine, hypothermia, lipopolysaccharide (LPS)|Yes| 3395.0|C3H/HeJARC|C3H/HeJArcApb|C3H/HeJArcApb|Recessive|toll-like receptor 4|Tlr4||lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; wild type revertant|Tlr4|MGI:4943781|4||||||||||||||||Yes|||||||||||||Flv phenotype:- Susceptible to infections by Flaviviruses. Tlr4 Phenotype:- responsiveness of Toll 4 Receptor to LPS infection. Diht Phenotype:- a decreased hypothermia response as measured by drop in core temperature following the peripheral administration of a dopamine agonist|Flv Phenotype:- recessive phenotype, hets are resistant to infection by Flaviviruses. Tlr4 phenotype:- is dominant and heterozygous mice show responsiveness to LPS.Diht phenotype is recessive and dopamine-induced hypothermia in heterozygotes show the high responder type.|C3H/HeJArc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||16|brother x sister|No|11-Jul-2008|Cryopreserved sperm|||Unknown||dopamine, flavivirus resistance, apomorphine, hypothermia, lipopolysaccharide (LPS)|Yes| 5435.0|Funky|B6.Cg-Ndufs4/DrthApb|B6.Cg-Ndufs4/Drth|Recessive|NADH dehydrogenase (ubiquinone) Fe-S protein 4|Ndufs4|Reduced|C1-18k|MGI:1343135|funky|Ndufs4|MGI:4942335|13||||||||||||||||Yes|||||||||||||Homozygous mice initially present with fur loss around postnatal day 14, which regrows in the next hair cycle. They show reduced growth and several behavioural abnormalities that appear from postnatal week five, such as tilting of the head, walking in circles and twisting of the body when suspended by the tail. Due to progressively wobbly gait and general deterioration in physical condition, all homozygous mice have to be euthanased around postnatal week eight in compliance with ethical guidelines.|Appears indistinguishable from Wild-Type|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Poor|10||het X het|No|15-Feb-2011|Cryopreserved sperm|73.0|0.0|Yes|Mitochondrial Disease; Leigh Syndrome|Mitochondria, Oxidative Phosphorylation, Complex I|Possibly| 4184.0||C57BL/6-CD151/Apb||Recessive|CD151 antigen|Cd151|Normal|PETA-3, SFA-1, Tspan24|MGI:1096360||||7||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2008|Cryopreserved sperm|106.0|0.0|Unknown||tetraspanin, integrin, wound repair, cell migration, angiogenesis|Yes| 4197.0|NOD-Tg(IE-Igrp)44Wehi/J|NOD-Tg(H2-Ea-G6pc2)44Tkay/Apb||Dominant||||||||||||||||||||||||||glucose-6-phosphatase, catalytic, 2. The ∆G6pc2 transgene has a mutation in the dominant epitope of G6pc2 (G6pc2206-214).|1.8-kb fragment encoding nucleotides -1,903 through -39 of the 5' flanking sequence of the MHC Class II gene, H2-Ea (k allele)||||||||||||Type 1 Diabetes with same incidence as NOD/Lt control or littermate control mice. Mice do not develop T cell responses to the beta cell autoantigen G6pc2.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Transgene positive males were then backcrossed to NOD/LtJ females.|No|20-Dec-2008|Cryopreserved sperm|140.0|0.0|Yes||Tolerance, Autoimmunity, Autoantigen|Yes| 4444.0|GSTkappa -/-|BALB/c-Gstk1/AnuApb||Recessive|glutathione S-transferase kappa 1|Gstk1|Unknown||MGI:1923513|glutathione S-transferase kappa 1; targeted mutation 1, Philip G Board|Gstk1|MGI:5294676|6||||||||||||||||Yes|||||||||||||Abnormal survival:• male mice exhibit a different shaped survival curve compared with wild-type mice• over 1 year, fewer male mice die of heart pathologies compared with wild-type mice• however, female mice exhibit normal survival curvePremature death:• at 6 months, male mice exhibit increased death due to kidney or urinary tract pathologies compared with wild-type miceIncreased testis weight.Rrenal/urinary system phenotype: • kidney tubules are normalIncreased urine micro albumin level• microalbuminuria at 12 and 26 weeks of age• dexamethasone treatment does not improve albumin to creatinine levels• however, microalbuminuria is the same as in wild-type mice at 45 to 48 weeks of ageUrethritis:• urethra inflammed in mice that die of kidney or urinary tract pathologiesUrinary bladder inflammation:• in mice that die of kidney or urinary tract pathologiesPodocyte foot process effacement:• in male and female mice at 5 to 6 months of ageAbnormal renal glomerulus basement membrane morphology:• at 3 months, glomerular basement membrane changes include laminations, splits, subepithelial protrusions, and lucent areasAbnormal renal glomerulus morphology:• at 3 months, male and female mice develop glomerular nephropathy with glomerular basement membrane changes• dexamethasone treatment does not improve abnormal glomerulus morphologyGlomerulonephritis.Increased kidney weight.Distended urinary bladder:• in mice that die of kidney or urinary tract pathologiesUrinary bladder obstruction:• in mice that die of kidney or urinary tract pathologiesDecreased circulating triglyceride level:• at 25 weeks of age but not in older miceDecreased adiponectin level:• slightlyIncreased urine micro albumin level:• microalbuminuria at 12 and 26 weeks of age• dexamethasone treatment does not improve albumin to creatinine levels• however, microalbuminuria is the same as in wild-type mice at 45 to 48 weeks of age.Decreased spleen red pulp amount:• at 25 weeks of age but not in older miceUrethritis:• urethra inflammed in mice that die of kidney or urinary tract pathologiesUrinary bladder inflammation:• in mice that die of kidney or urinary tract pathologiesCellular phenotype: • mice exhibit little or no oxidative stressIncreased testis weight.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Feb-2009|Cryopreserved sperm|100.0|0.0|Unknown||Mitochondria, antioxidant, enzyme, glomerular nephropathy, kidney|No| 4449.0||C57BL/6-Gpx4/Apb||Dominant|glutathione peroxidase 4|Gpx4|Reduced|mtPHGPx, PHGPx, phospholipid hydroperoxide glutathione peroxidase, snGPx, sperm nuclei glutathione peroxidase|MGI:104767|targeted mutation 1, Tomas A Prolla|Gpx4|MGI:2651590|10||||||||||||||||No|||||||||||||Lethality/Prenatal-PerinatalEmbryonic lethality before somite formation * embryos die around E7.5Embryogenesis*Failure to gastrulate*Abnormal triploblastic development|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Good||||No|20-Feb-2009|Cryopreserved sperm|100.0|0.0|Unknown||glutathione peroxidase, oxidative stress, lipoperoides|Yes| 4454.0||C57BL/6-Tg(CD2-IL5)5C2Ldt/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blot analysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower. These mice appeared macroscopically normal apart from splenomegaly. Eosinophils were at least 65- and 265-fold higher in blood from transgenics, relative to normal littermates, and approximately two- or sevenfold more numerous relative to blood from mice infected with the helminth Mesocestoides corti. Much more modest increases in blood neutrophil, lymphocyte, and monocyte numbers were noted in transgenics, relative to normal littermates (less than threefold). Thus IL-5 in vivo is relatively specific for the eosinophil lineage. Large numbers of eosinophils were present in spleen, bone marrow, and peritoneal exudate, and were highest in the line with the greatest transgene copy number. Eosinophilia was also noted in histological sections of transgenic lungs, Peyer's patches, mesenteric lymph nodes, and gut lamina propria but not in other tissues examined. IL-5 was detected in the sera of transgenics at levels comparable to those seen in sera from parasite-infected animals.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|||Transgenic male with wild type female|No|20-Feb-2009|Cryopreserved sperm|50.0|0.0|Unknown||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 4467.0||C57BL/6-H2-K1 H2-D1/AnuApb||Recessive|histocompatibility 2, K1, K region|H2-K1|Nil|H-2K|MGI:95904|targeted mutation 1, Beatrice Perarnau|H2-K1|MGI:1931444|17||||||||||||||||Yes|||||||||||||The double knockout mice are virtually devoid of Class Ia cell surface molecules. 90% reduction in peripheral CD8<+> T cells without Vβ diversity alteration. Double knockout mice survived intracranial infection by lymphocytic choriomeningitis virus.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|2|sib x sib|No|22-Feb-2009|Cryopreserved sperm|150.0|0.0|Unknown||T cell, CD8, Presentation, Major histocompatibility complex (MHC), viral infection|Yes| 4467.0||C57BL/6-H2-K1 H2-D1/AnuApb||Recessive|histocompatibility 2, D region locus 1|H2-D1|Unknown|H-2D|MGI:95896|targeted mutation 1, Beatrice Perarnau|H2-D1|MGI:1931445|17|||||||||||||||||||||||||||||The double knockout mice are virtually devoid of Class Ia cell surface molecules. 90% reduction in peripheral CD8<+> T cells without Vβ diversity alteration. Double knockout mice survived intracranial infection by lymphocytic choriomeningitis virus.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|2|sib x sib|No|22-Feb-2009|Cryopreserved sperm|||Unknown||T cell, CD8, Presentation, Major histocompatibility complex (MHC), viral infection|Yes| 4596.0|NOD.scid H-2K homozygous|NOD-Prkdc Tg(H2K)1Rms/MarpApb||Dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16||||||||||||||||Yes|transgene insertion 1, Robyn M Slattery|MHC Class I|||||||||||Decreased T and B cells.||NOD-Prkdc|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Mar-2009|Cryopreserved sperm|100.0|0.0|Yes|Type I diabetes|MHC, autoimmunity, diabetes, T cell, autoimmune|Yes| 4469.0|FVB/n-Tg(GFAP-hGFP-S56T)|FVB/n-Tg(GFAPGFP)14Mes/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 14, Albee Messing|astrocyte specific glial fibrillary, glial fibrillary acidic protein (Gfap)|||||||||||Bright fluorescence was observed in the cell bodiesand processes of unfixed or fixed astrocytes, using both whole mount and brain slice preparations, from multiple areas of thecentral nervous system. However, in contrast to GFAP–lacZ transgenics, retinal Muller cells expressed the GFP transgene inresponse to degeneration of neighboring photoreceptors. These data indicate that the 2.2-kb hGFAP promoter contains sufficientregulatory elements to direct expression in Muller cells, and that GFP is a suitable reporter gene for use in living preparationsof the mammalian nervous system.||FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|130.0|0.0|Unknown||GFP, neuron, photoreceptor, astrocyte|Yes| 5443.0|NODGrzA|NOD.B6-Gzma/LtJApb||Dominant|granzyme A|Gzma|Nil|BLT esterase, Ctla-3, Ctla3, H factor, Hanukah factor, Hf, SE1, serine esterase 1, TSP-1, TSP1|MGI:109266|granzyme A; targeted mutation 1, Markus M Simon|Gzma|MGI:2449926|13||||||||||||||||No|||||||||||||Mice are healthy and develop normally, but develop diabetes at a slightly accelerated rate compared to NOD/Lt mice.|Mice are healthy and develop normally, but will develop diabetes similar to NOD/Lt mice.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|11|5|Sister X Brother|Yes|23-Feb-2011|Cryopreserved sperm|50.0|0.0|No||Cytotoxic T lymphocytes, Granzymes, Type 1 Diabetes, Apoptosis, Pancreatic beta cell|Possibly| 5506.0|Brca1 floxed|B6.Cg-Brca1/Apb||Recessive|breast cancer 1|Brca1|Normal||MGI:104537|breast cancer 1; targeted mutation 2, Chu-Xia Deng|Brca1|MGI:1931238|11||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||epithelium, mammary, breast|Yes| 5540.0|Circletail|B6.Cg-Scrib/MarpApb||Semi-dominant|scribbled homolog (Drosophila)|Scrib|Reduced|Circletail|MGI:2145950|scribbled homolog (Drosophila); circletail|Scrib|MGI:1889322|15|||||||||||||||||||||||||||||Mice homozygous for this spontaneous mutation develop severe neural tube defects and die at birth. In it's most severe form, the neural tube fails to initiate Closure 1 (craniorachischichisis). Heterozygotes, predominantly males, often exhibit a looping or kinked tail. This strain may used to research neural tube defects. |Heterozygotes, predominantly males, often exhibit a looping or kinked tail. |C57BL/6|No|No|Yes|No|No|Yes|No|Good|||wildtype x heterzygote|No|18-Jul-2011|Cryopreserved sperm|50.0|0.0|No||planar cell polarity, neural tube|No| 4530.0|B6.129-163C Del Neo|B6.129-Ryr1/AnuApb||Recessive|ryanodine receptor 1, skeletal muscle|Ryr1|Unknown|calcium release channel isoform 1, Ryr, skrr|MGI:99659|ryanodine receptor 1, skeletal muscle; targeted mutation 2.1, Paul D Allen|Ryr1|MGI:4887389|7||||||||||||||||Yes|||||||||||||Embryonic lethal, E17-18|Fulminant malignant hyperthermia episodes in R163C heterozygous mice after exposure to 1.25–1.75% halothane or an ambient temperature of 42°C characterized by increased rectal temperature, respiratory rate, and inspiratory effort, with significant blood biochemical changes indicating metabolic acidosis, ending in death and hyperacute rigor mortis; (3) intraperitoneal pretreatment with dantrolene provided 100% protection from the halothane-triggered fulminant malignant hyperthermia episode; (4) significantly increased sensitivity (decreased effective concentration causing 50% of the maximal response) of R163C heterozygous and homozygous myotubes to caffeine, 4-chloro-m-cresol, and K-induced depolarization; (5) R163C heterozygous and homozygous myotubes have a significantly increased resting intracellular Ca2 concentration compared with wild type; (6) R163C heterozygous sarcoplasmic reticulum membranes have a twofold higher affinity (Kd =35.4 nM) for [3H]ryanodine binding compared with wild type (Kd= 80.1 nM) and a diminished inhibitory regulation by Mg2.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|4|||No|27-Feb-2009|Cryopreserved sperm|70.0|0.0|Unknown||hyperthermia, muscle, sarcoplasmic reticulum, myotubules|Yes| 4533.0|Drasic -/-|B6.129-Asic3/Apb||Recessive|acid-sensing (proton-gated) ion channel 3|Asic3|Unknown|Accn3, DRASIC|MGI:2159339|acid-sensing (proton-gated) ion channel 3; targeted mutation 1, Michael J Welsh |Asic3|MGI:2429689|5||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit reduced latency to onset of pain responses, increased sensitivity to light touch, but decreased sensitivity to noxious pinch and responses of acid- and noxious heat-sensitive nociceptors. Hyperglasia- at site of injury (carrageenan-induced inflammation), mice showed increased sensitivity to mechanical stimuli, but not to noxious thermal stimulus. Responses to somatosensory stimuli under normal conditions were similar to wild-type littermates||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|27-Feb-2009|Cryopreserved sperm|100.0|0.0|Unknown||cation channel, visceral afferents, mechanosensation, touch sensation|No| 4595.0|REKO|C57BL/6-Ren1/Apb||Recessive|renin 1 structural|Ren1|Nil|Ren, Ren-1, Ren-A, Ren1c, Ren1d, Rn-1, Rnr|MGI:97898|targeted mutation 1, Brian J Morris|Ren1|MGI:3699140|1||||||||||||||||No|||||||||||||Abnormal renal tubule morphology; decreased renal glomerular filtration rate; decreased diastolic blood pressure; decreased mean arterial blood pressure; hypotension increased heart rate; increased circulating creatinine level; locomotor activity is 35% lower than in wild-type; chronic in vivo stimulus (low salt/enalapril) leads to blunted renin response |Not determined|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Mar-2009|Cryopreserved sperm|100.0|0.0|Unknown||enhancer, blood pressure, low sodium diet, hypotension|Yes| 4742.0|San Roque:CBA|CBA;B6-Rc3h1/AnuApb|CBA;B6-Rc3h1/AnuApb|Recessive|Ring finger and CCCH-type zinc finger domains 1|Rc3h1|Unknown|roquin|MGI:2685397|sanroque|Rc3h1|MGI:3581675|1||||||||||Unknown to Unknown||||||Yes|||||||||||||Spontaneous autoimmune disease. Systemic lupus erythematosus. Anti-nuclear autoantibodies (ANA), hypergammaglobulinemia, autoimmune nephritis, lymphadenopathy, increased numbers of CD44high activated memory T cells, increased numbers of T follicular helper cells, spontaneous germinal centres, CD28-independent activation of T cells. Increased ICOS mRNA and protein expression on T cells, defect in micro-RNA (mir) inhibition of mRNA stability.|Low penetrance of disease phenotype in Hets|CBA x C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Unknown||7||No|27-Apr-2009|Cryopreserved sperm|5.0|0.0|Yes||Systemic lupus erythematosus (SLE), autoimmunity, T cell, ubiquitin ligase, Wellcome Trust|Yes| 4785.0|Line3|FVB-Tg(HBA1-GFP)3Ew/Apb||Dominant|||Increased||||||Unknown||||||||||||||||No|transgene insertion 3, Emma Whitelaw|α-Globin (-570 to +37) (4.1kb of enhancer)|36 copies||||||||||Fluorescence in erythrocytes can be observed by FACS or fluorescent microscopy. The allele is subject to variegation.|Fluorescence in erythrocytes can be observed by FACS or fluorescent microscopy. The allele is subject to variegation|FVB|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||Hom x Hom|No|06-Sep-2009|Cryopreserved sperm|150.0|0.0|No||Metastable epiallele, Transgene silencing, Green fluorescent protein|Yes| 4862.0||C57BL/6-Tg(ICAM2-huCD59)/Apb||Dominant||||||||||||||||||||||||||human CD59 |ICAM2|endothelial cells and neutrophils||||||||||Expression of membrane bound human CD59 on endothelial cells and neutrophils.|Expression of membrane bound human CD59 on endothelial cells and neutrophils.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Sep-2009|Cryopreserved sperm|70.0|0.0|Unknown||complement, heart, endothelial, ischemia, reperfusion, xenotransplantation|Yes| 4700.0|NOD-Tg(IE-Insll)1Wehi/J (NODPI)|NOD-Tg(H2-Ea-Ins2)1Wehi/WehiApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Walter and Eliza Hall Institute|MHC Class II gene H2-Ea (k allele|spleen and thymus of transgenic NOD/LtWehi mice||||||||||The mononuclear cell infiltration of the islets (insulitis) is almost completely absent, and diabetes is prevented in these transgenic NOD mice. The mononuclear cell infiltration of the salivary glands (sialitis) and immune responses to ovalbumin (OVA) are not altered, indicating that the protective effect of the transgene is specific for islet pathology and not due to general immunosuppression. |Mice do not develop T1D when compared with NOD/Lt control or littermate control mice. Mice do not develop T cell responses to the beta cell autoantigen proinsulin.|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2009|Cryopreserved sperm|150.0|0.0|Yes||Autoimmunity, Tolerance, Insulin, Autoantigen|Yes| 4729.0|Louise2|B6;B10.BR-H2 Tg(TLK2mHEL)2Ccg/AnuApb|B6;B10.BR-H2 Tg(TLK2mHEL)2Ccg/AnuApb|Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher C Goodnow|rat thyroglobulin|expression limited to thyroid|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Express low levels of membrane bound HEL in thyroid. Low serum levels of HEL detected.||B10.Cg-H2 x C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|7|sib x sib|No|17-Apr-2009|Cryopreserved sperm|150.0|0.0|No||autoimmunity, B cell, tolerance, Hen egg lysozyme (HEL), T cell|Yes| 4756.0|NOD eGFP|STOCK Tg(CAG-EGFP)1Osb/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Research Institute for Microbial Diseases, Osaka University|chicken beta-actin promoter and CMV intermediate early enhancer|||||||||||Transgenic mice were uniformly green with the exception of hair and red blood cells. The brain, liver, kidney, adrenal gland and testis, lung, muscle, heart, intestine, and adipose tissue, thymus, spleen and testicular cells of all transgenic mouse lines were naturally green when irradiated with excitation light.||NOD x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Apr-2009|Cryopreserved sperm|135.0|0.0|Unknown||GFP, expression|Yes| 4769.0|C57BL/6J.i-K|C57BL/6-H2-K1/AnuApb||Recessive|histocompatibility 2, K1, K region|H2-K1|Unknown|H2-K1tm1Bpe|MGI:95904|targeted mutation 1, Beatrice Perarnau|H2-K1|MGI:1931444|17||||||||||||||||Yes|||||||||||||increased CD4-positive T cell number: numbers increase in parallel to decrease in CD8+ cells.decreased CD8-positive T cell number: 30-50% reduction of single positive CD8<+> peripheral T cells.Abnormal susceptibility to viral infections||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|2|Sib x sib|No|06-May-2009|Cryopreserved sperm|150.0|0.0|No||T cell, CD8, Presentation, Major histocompatibility complex (MHC)|Yes| 4786.0|Blades|C.129-IL5 Eotaxin/AnuApb||Recessive|interleukin 5|Il5|Unknown|Il-5|MGI:96557|targeted mutation 1, Manfred A Kopf|Il5|MGI:1861948|11||||||||||||||||Yes|||||||||||||Unknown||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|06-Sep-2009|Cryopreserved sperm|125.0|0.0|Unknown||eosinophil, chemokine, asthma, B cell, infection|Yes| 4786.0|Blades|C.129-IL5 Eotaxin/AnuApb||Recessive|chemokine (C-C motif) ligand 11|Ccl11|Unknown|eotaxin, Scya11|MGI:103576|targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11||||||||||Unknown to Unknown|||||||||||||||||||Unknown||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|06-Sep-2009|Cryopreserved sperm|||Unknown||eosinophil, chemokine, asthma, B cell, infection|Yes| 5451.0|HOM.NOD.407|NOD.Cg-H2-K Tg(RIP2-Bcl2)407Wehi/LtJApb||Dominant|histocompatibility 2, K region|H2-K|Unknown||MGI:3040519|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17|||||||||||||||||human B-cell leukemia/lymphoma 2|rat insulin promoter 2 (RIP)|||||||||||Homozygous NOD.407 mice get non-immune diabetes starting at weaning age. Males remain diabetic but females recover after about 100 days of age. They do not need insulin to remain healthy but should be monitored and killed if unwell|Mice develop type 1 diabetes at the same incidence as NOD/Lt mice|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|20|Sister X Brother|No|02-Mar-2011|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes|Pancreatic beta cell, Type 1 Diabetes, Apoptosis, Bcl2, cytokines|Possibly| 4878.0|B6.Rag1.KO|C57BL/6-Rag1/ArcStvApb||Recessive|recombination activating gene 1|Rag1|Nil|Rag-1|MGI:97848|targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2||||||||||||||||No|||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2009|Cryopreserved sperm|93.0|0.0|Unknown||T cell, B cell, eosinophil, inflammation, interferon|Yes| 4897.0|B6-Lym1|B6.C-Nfkb2/SviApb||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100|Nfkb2|Unknown|NF kappaB2, p52|MGI:1099800|Lym1|Lym1||19|||||||||||||||||||||||||||||Increased circulating lymphocytes.A comprehensive histopathological analysis of these mice, however, revealed an absence of peripheral LN (inguinal, brachial, axillary, cervical) and Peyer’s patches. Mesenteric LN were present, but were reduced in size and cellularity.presence of inflammatory cell infiltrates in the lung and liver.The number of mature recirculating B cells was significantly reduced.Nfkb2 bone marrow was almost completely unresponsive to RANKL with osteoclast formation <0.5% of that seen with wt.Mild osteopetrosis, with significantly increased trabecular bone volume|The ability of Nfkb2 cells to form osteoclasts in response to RANKL stimulation was significantly reduced|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|09-Oct-2009|Cryopreserved sperm|70.0|0.0|Unknown||noncanonical, p52, signal transduction, lymph node, osteopetrosis, B cell|Yes| 5454.0|Phc2|C57BL/6-Phc2/WehiApb||Recessive|polyhomeotic-like 2 (Drosophila)|Phc2|Nil|Edr2, Mph2|MGI:1860454|polyhomeotic-like 2 (Drosophila); targeted mutation 1, Haruhiko Koseki|Phc2|MGI:3586989|4|||||||||||||||||||||||||||||Minor skeletal abnormalities. Female infertilityAbnormal axial skeleton morphology: * all homozygotes have at least a few alterations to the axial skeleton characteristic of posterior transformations; however, the skull is similar to wild-type. * an ectopic bone floats between the occipital bones and the first cervical vertebra.Abnormal rib morphology.Increased rib number: ectopic ribs are associated with C7 in 67% of homozygotes.Rib fusion: C7 ectopic ribs are imperfect and fused to the middle part of the first ribs; the rest of the ribs are perfect and directly associated with the cranially shifted sternum.Abnormal sternum morphology: the sternum is shifted cranially.Asymmetric rib-sternum attachment: the 7th rib pair are detached from the sternum and the 13th rib pair are missing or floating.Fusion of atlas and odontoid process: the odontoid process is fused to the first cervical vertebra (C1).Split cervical atlas: the dorsal part of the C1 is often bifurcated.Split cervical axis: the dorsal part of C2 is often bifurcated.Vertebral transformation: the thoracolumbar and lumbosacral boundaries are shifted anteriorly.Thoracic vertebral transformation: a prominent spinous process normally associated with the second thoracic vertebra (T2) is associated with T1 in all homozygotes.Cervical vertebral transformation: in the lateral view C2 resembles C3.Decreased cell proliferation: MEFs grow more slowly and stop dividing earlier.|Normal|C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good|10||Het x WT or Het x Het or Hom male x Het or WT female|No|03-Mar-2011|Cryopreserved sperm|60.0|0.0|Unknown||Polycomb group proteins, polycomb repressive complex 1, Hox, skeleton, Cdkn2a|Yes| 5468.0|gpx1 ko|C57BL/6J-Gpx1/MarpApb||Recessive|glutathione peroxidase 1|Gpx1|Nil|cellular GPx, CGPx, Gpx, GPx-1, GSHPx-1|MGI:104887|glutathione peroxidase 1; targeted mutation 1, Ismail Kola|Gpx1|MGI:2388705|9|||||||||||||||||||||||||||||It is reported that the mice exhibit no overt behavioural, physiological, reproductive or developmental defects. However, these animals have deficient responses to oxidative stress caused by brain injury and by myocardial infarction.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|23-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||antioxidant, oxidative stress, ischemia / reperfusion|Yes| 4902.0||BALB/c-Il4/MelbApb||Recessive|interleukin 4|Il4|Unknown|IgG1, Il-4|MGI:96556|targeted mutation 2, Nancy Noben-Trauth|Il4|MGI:1857195|11||||||||||||||||No|||||||||||||decreased IgG:IgG1 response to immunization with the protein antigen OVA is severely impairedabnormal T helper 2 physiology:homozygotes display impaired pulmonary granuloma formation in response to schistosome egg immunizationeosinophil infiltration is impaired in response to schistosome egg immunization||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|150.0|0.0|Unknown||infection, inflammation, immunoglobulin, lymphocyte|Yes| 5484.0|MPSIIIA-GFP|B6.Cg-Sgsh Tg(UBC-GFP)30Scha/JApb||Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Reduced|sulphamidase|MGI:1350341|N-sulfoglucosamine sulfohydrolase (sulfamidase); mucopolysaccharidosis IIIA|Sgsh|MGI:2151181|11||||||||||||||||Yes|transgene insertion 30, Brian Schaefer|Human ubiquitin C|Increased||||||||||The phenotype of the mice has not been fully characterised but is expected to be similar to MPS IIIA mice that do not express the GFP gene (Crawley et al (2006) Brain Research 1104:1-17). Newborn MPS IIIA-GFP mice are no different to their unaffected counterparts. It is not until around 10 weeks of age that we begin to see increased aggression in MPS IIIA-GFP males.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygous x homozygous|No|15-Apr-2011|Cryopreserved sperm|50.0|0.0|Yes|Progressive neurodegenerative condition|Sanfilippo, Mucopolysaccharidosis, GFP|Possibly| 7683.0|TG2KI.B6|B6.Cg-Tgm2/Apb|MGI:5521582|Recessive|transglutaminase 2, C polypeptide|Tgm2|Normal|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 2.1, Robert M Graham|Tgm2|MGI:5521582|2||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|Maintained on C57BL/6J|N/A|Het x het matings|No|15-May-2014|Cryopreserved sperm|50.0|0.0|Unknown||transgluatminase, Gh, G-protein, cross linking, constitutively-active|Yes| 7682.0|TG2KI.129T2|129.B6(Cg)-Tgm2/Apb|MGI:5521582|Recessive|transglutaminase 2, C polypeptide|Tgm2|Normal|G[a]h, protein-glutamine gamma-glutamyltransferase, TG C, TG2, tissue transglutaminase, tTG, tTGas|MGI:98731|targeted mutation 2.1, Robert M Graham|Tgm2|MGI:5521582|2||||||||||||||||No|||||||||||||Normal|Normal|129T2|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10 generations back-crossed to 129T2/SvImsJ|N/A|Het x het matings|No|15-May-2014|Cryopreserved sperm|50.0|0.0|Unknown||transgluatminase, Gh, G-protein, cross linking, constitutively-active|Yes| 4913.0|VASP|C57BL/6-Vasp/Apb||Recessive|vasodilator-stimulated phosphoprotein|Vasp|Nil||MGI:109268|targeted mutation 1, Michael Zimmer|Vasp|MGI:1858032|7|||||||||||||||||||||||||||||Haematopoietic system phenotype:homozygotes show no differences in platelet number in total blood and platelet-rich plasma relative to wild-type littermatesIncreased megakaryocyte cell number:homozygotes display a moderate megakaryocyte hyperplasia in bone marrow and spleenAbnormal platelet activation:upon stimulation of platelet-rich plasma with 0.5 units/ml of thrombin, mutant platelets show a 2-fold increase in surface expression of P-selectin and fibrinogen binding relative to wild-type platelets, indicating enhanced agonist-induced platelet activation.unexpectedly, preincubation with the cAMP-elevating prostaglandin E1 completely abolished thrombin-induced fibrinogen binding and P-selectin expression, as well as platelet aggregation, in both wild-type and homozygous mutant platelets.||C57BL/6`|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom, Hom x Het|No|16-Oct-2009|Cryopreserved sperm|90.0|0.0|Unknown||cAMP, kinase, platelet, megakaryocytes, profilin|Yes| 4914.0|EphA1-/- hPLAP|B6;129/Sv-Epha1/Apb|B6;129/Sv-Epha1/Apb|Recessive|Eph receptor A1|Epha1|Nil|5730453L17Rik, Eph, Esk|MGI:107381|targeted mutation 1, Shannon L Duffy|Epha1|MGI:3822370|6||||||||||||||||Yes|internal ribosome entry site - human placental alkaline phosphatase|endogenous EphA1|Restricted to epithelial tissue||||||||||Vaginal inflammation:mice exhibit inflammation of the vaginal mucosa secondary to hydrometrocolpos.Endometrium inflammation:mice exhibit endometrium inflammation secondary to hydrometrocolpos.Dilated uterine horn:mice exhibit dilated, attenuated uterine horns secondary to hydrometrocolposEnlarged uterus:mice exhibit an enlarged uterus due to an accumulation of clear uterine fluid (hydrometrocolpos).Increased uterus weight:Vagina atresia:18% of mice exhibit a failure of vaginal openingdespite normal estrogen receptor expression, beta-estradiol treatment fails to induce precocious vaginal opening in P12 mice unlike in wild-type mice and vaginal opening can not be induced by likewise treating affected adult mice.Hydrometrocolpos:mice exhibit inflammation of the vaginal mucosa and endometrium with dilated, attenuated uterine horns secondary to hydrometrocolposFemale infertility:female mice affected by hydrometrocolpos are sterileKinked tail:up to 80% of mice exhibit a kinky tail due to incorrectly positioned caudal vertebraeDistended abdomen:in some mice due to an enlarged uterusAbnormal response/metabolism to endogenous compounds:treatment with beta-estradiol fails to induce apoptosis in the lower genital tract and precocious vaginal opening unlike in wild-type mice.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|5|Homozygous knockout crossed with homozygous knockout or C57BL/6 wildtype|No|16-Oct-2009|Cryopreserved sperm|300.0|0.0|No||Eph, Receptor Tyrosine Kinase, ephrin, epithelium, uterus, tail, hydrometrocolpos|Yes| 4916.0|IL-4ra -/-|BALB/c-IL4ra/AnuApb||Recessive|interleukin 4 receptor, alpha|Il4ra|Unknown|CD124, IL-4 receptor alpha chain, Il4r|MGI:105367|targeted mutation 1, Leonard Shultz|Il4ra|MGI:1861951|7|||||||||||||||||||||||||||||Abnormal microglial cell morphology:microglial cells fail to express the cell marker Ym1 (Chi3l3)Decreased IgE level:lower circulating levels of IgE in normal and bacterial infected miceDecreased IgG1 level:lower circulating levels in normal and bacterial infected miceIncreased IgG2a levelAbnormal T-helper 2 physiology:mice are unable to mount an effective Th2 response to N. brasiliensis bacteria as determined by Th2 cyotkine production by T cellsDecreased interleukin-10 secretion:decrease production by T cells from mice infected with N. brasiliensis bacteriaDecreased interleukin-4 secretion:decrease production of IL-4 by T cells from mice infected with N. brasiliensis bacteriaDecreased interleukin-5 secretion:decrease production of IL-5 by T cells from mice infected with N. brasiliensis bacteria||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Oct-2009|Cryopreserved sperm|100.0|0.0|Unknown||T cell, signal transduction, TH2, infection, IL10, parasite, CD4|Yes| 4921.0|Kinks|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)|Csf2rb1|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, C Glenn Begley|Csf2rb|MGI:2181245|15||||||||||||||||Yes|colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macrophage)||High||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|110.0|0.0|No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 4921.0|Kinks|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb|Nil|AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|targeted mutation 1, Clare L Scott|Csf2rb|MGI:3653883|15|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 4921.0|Kinks|NOD.129/Sv-Tg(Csf2rb) Csf2rb Csf2rb Prkdc/Apb||Dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc||DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||None detected|Normal|NOD/SCID|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Matings of 2 transgenic non-sibling mice|Yes|22-Oct-2009|Cryopreserved sperm|||No||murine beta chain, GM-CSF, receptor, phosphorylation, signal transduction|Yes| 4940.0|Linie 659|Swiss-Tg(tPA-LacZ)659/MarpApb||Dominant||||||||||||||||||||||||||Beta-galactosidase|9.5kb of human t-PA gene promoter|||||||||||Normal.Expression of LacZ in brain. Very high expression in hippocampus, dentate gyrus and cortex.||Swiss white|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|||Tg Het x WT Swiss white|No|04-Dec-2009|Cryopreserved sperm|40.0|0.0|No||tissue type plasminogen activator, brain, hippocampus, medial habenula, dentate gyrus|Yes| 4955.0|BALB/c. IL5 -/-; Lynagh|C.B6-Il5/AnuApb||Recessive|interleukin 5|Il5|Nil|Il-5|MGI:96557|targeted mutation 1, Manfred A Kopf|Il5|MGI:1861948|11||||||||||||||||Yes|||||||||||||Homozygotes for a targeted null mutation exhibit loss of normal airway hyperreactivity resulting from aeroallergen challenge, reduced numbers of CD5+ B cells in the peritoneal cavity at 2 weeks, and some altered responses to schistosomiasis infection. Mice appear normal. They have normal basal levels of eosinophils but in response to parasite infections or aeroallergen challenge, numbers do not increase. Further, resistance to some phases of helminthic infections may be impaired. Decreased airway responsiveness: airways of aeroallergen-challenged knockout mice lose hyperresponsiveness to methacholine.Increased neutrophil cell number: after aerosolized OVA challenge, knockout mice have increased levels of neutrophils in BALF compared to unchallenged animals.Increased lymphocyte cell number: after aerosolized OVA challenge, knockout mice have increased levels of lymphocytes in BALF compared to unchallenged animals but the increase is less pronounced than in wild type mice.Abnormal interferon physiology: in mesenteric lymph nodes in culture, there is a marked increase in IFNG production in knockouts compared to wild type after restimulation with mitogen or SEA.Granulomatous inflammation:* pulmonary granulomas that form in knockout mice in response to schistosome eggs are almost completely devoid of eosinophils compared to granulomas in wild type mice; the average size of granulomas in knockout mice are 40% smaller than those of wild type.* there is a 20-25% increase in numbers of macrophages associated with granulomas in knockouts compared with wild type; with acute or chronic parasite infection, the numbers of both fibroblasts and macrophages nearly double in knockout animals compared to wild type.Liver fibrosis: hepatic fibrosis is significantly reduced in knockouts with acute or chronic helminth parasite infection.Increased eosinophil cell number: knockout mice infected with parasites do not show eosinophil counts above baseline values, while 35-week old controls develop eosinophilia in the blood, bone marrow and peritoneal cavity.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|20||IL5-/- male mated with IL5-/- female|No|14-Dec-2009|Cryopreserved sperm|100.0|0.0|Unknown||infection, T cell, B cell, CD5, eosinophil|Yes| 5042.0|PRlacZ|B6.129S7/SvEvBrd-Pgr/Apb||Recessive|progesterone receptor|Pgr|Unknown|NR3C3, PR, PR-A, PR-B|MGI:97567|progesterone receptor; targeted mutation 1, John P Lydon|Pgr|MGI:3032652|9||||||||||||||||No|||||||||||||Abnormal sexual interaction: females did not exhibit sexual behavior.Abnormal female reproductive system morphology.Abnormal mammary gland development.Absent corpus luteum.Uterus hyperplasia.Abnormal reproductive system physiology.Abnormal ovulation: ovulation could not be stimulated with exogenous hormones.Female infertility.|Normal|129S7/SvEvBrd x C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|96.0|0.0|Unknown||Progesterone, mammary, receptor, luminal epithelial, ducts|Yes| 5127.0|Aire KO|B10.Br(Cg)-Aire/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10||||||||||||||||No|||||||||||||Targeted mutations that inactivate the gene result in immune system dysfunction characterized by multiorgan lymphocytic infiltration and circulating autoantibodies.Absent adrenal gland: absence of the adrenal glands is seen with incomplete penetrance; however, the thyroid and pancreas are normal.Abnormal T cell morphology: the TCR-Vbeta repertoire is altered in peripheral T cells.Increased T cell proliferation: immunization with hen egg lysozyme antigen results in a 4-5-fold increase in proliferating response of peripheral T cells, with mutants showing twice as many T cells in the lymph nodes than controls.Thymus atrophy: thymic atrophy is seen in 2 of 14 mutants.Increased autoantibody level: 73% of homozygous mice generated autoantibodies against at least one of the organs (liver, testis, pancreas and adrenal gland) tested and 40% of mice contain autoantibodies against two or more of the organs.Liver inflammation: 50% of mutants exhibit accumulation of lymphocytes in periportal regions.Infertility: 85% of male or female mutants fail to produce any litters.||129 x C57BL/6 x C57BL/10.Br|Yes|No|Yes|Yes|No|Yes|No|Poor||||No|19-May-2010|Cryopreserved sperm|50.0|0.0|Yes|Autoimmune polyendocrinopathy syndrome type 1|autoimmunity, clonal deletion, T cell, tolerance|Yes| 5065.0|Zic5 V504G: C3H/HeH|C3H.C-Zic5/AnuApb||Recessive|Zinc finger protein of the cerebellum 5|Zic5|Unknown|odd-paired related, Opr|MGI:1929518||||14||||||||||||||||Yes|||||||||||||Viable and fertile|Viable and fertile|C3H/HeH|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||Homozygote male paired with homozygote female|No|25-Mar-2010|Cryopreserved sperm|40.0|0.0|Unknown||zinc finger, ENU|Yes| 4959.0|K5-crePR1 , K5crePR1 ; K5C|C(Cg)-Tg(KRT5-cre/PGR)1Der/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Dennis R Roop|bovine keratin 5|||||||||||To activate or inactivate conditional alleles in murine stratified epithelia, a novel system has been developed. It is based on the generation of transgenic mice that express an inducible Cre recombinase under the control of a promoter specific for stratified epithelia. The inducible features of Cre were achieved by fusing Cre to a deletion mutant of the human progesterone receptor (PR), which fails to bind progesterone but can be activated by progesterone antagonists, such as RU486. This fusion protein (CrePR1) is sequestered in the cytoplasm. After activation with RU486, CrePR1 translocates to the nucleus, where it mediates the excision of DNA sequences flanked by LoxP sites. Mice generated express CrePR1 under the control of the K5 which is expressed in the basal cells of stratified epithelia||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|12-Jan-2010|Cryopreserved sperm|138.0|0.0|Unknown||RU486, keratin, inducible, receptor|Yes| 4961.0|B6 Stat6-/- N10|B6(Cg)-Stat6/AnuApb||Recessive|signal transducer and activator of transcription 6|Stat6|Nil|stat6-|MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10||||||||||||||||No|||||||||||||Skin inflammation:* mice exhibit mild dermal infiltration of inflammatory cells.* few CD4+ cells infiltrate the perioral dermis and epidermis.Acanthosis: sight.Decreased B cell proliferation:* B cell proliferation in response to anti-IgM plus IL-4 is impaired.* however, B cell proliferation in response to LPS is normal.Decreased T cell proliferation:* thymocyte proliferation in response to TPA is impaired.* however, thymocyte proliferate in response to other stimuli.Decreased IgE level: IgE levels are lower than in wild-type mice following infection with N. brasiliensis.Decreased IgG1 level: IgG1 levels are 16-fold lower than in wild-type mice and following infection with N. brasiliensis they are 10-fold lower than in infected wild-type mice.Increased IgA level: IgA levels are slightly increased following infection with N. brasiliensis.Increased IgG level: IgG2 and IgG3 levels are slightly increased following infection with N. brasiliensis.Abnormal T-helper 2 physiology: mice fail to produce increased levels of Th2 cytokines in response to infection with N. brasiliensis.||C57BL/6 x BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jan-2010|Cryopreserved sperm|100.0|0.0|Unknown||T cell, IL-4, signal transduction, lymphocyte, B cell|Yes| 4970.0|B6.Flii 1.5F|B6;C-Flii/AnuApb|B6;C-Flii/AnuApb|Recessive|flightless I homolog (Drosophila)|Flii|Nil|Fli1, Fliih|MGI:1342286|targeted mutation 1, Hugh D Campbell|Flii|MGI:2179825|11||||||||||||||||Yes|||||||||||||Embryonic lethality at implantation: no embryos are recovered after E5.5; embryos develop normally until cellularization, the development arrests before completion of gastrulation blastocysts initiate uterine implantation but embryos fail to develop. embryonic growth arrest: development arrests during gastrulation|Enhanced wound healing: 3 days after a 1 cm full-thickness incision was made in the dorsal skin, surface wound area measurements show smaller, more contracted wounds than in wild-type mice. Length of neoepidermis is significantly greater in mutant animals, and percentage or re-epithelialization of wounds is greater at 5 days after wounding. By day 7, healing is comparable in mutants and wild-type|C57BL/6|No|No|Yes|No|No|Yes|No|Good|4||Het male x wt female|No|15-Jan-2010|Cryopreserved sperm|40.0|0.0|Yes||cell migration, embryonic lethal, wound repair, gelsolin, gastrulation|Yes| 4966.0|pGL3(-1501bp)CYP27B1 promotor-luciferase reporter|B6;CBA-Tg(Cyp27B1-Luc)/Apb||Dominant||||||||||||||||||||||||||luciferase|1.5kb human CYP27B1|||||||||||Strain not maintained in homozygous state|Luciferase activity are observed in a variety of tissues which is driven by the human 1501 bp CYP27B1 flanking sequence. The level of luciferase activity can vary depending on age and treatment. No other phenotype is observed.|CBA x C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Het x WT|No|15-Jan-2010|Cryopreserved sperm|100.0|0.0|No||Vitamin D, 25-Hydroxyvitamin D 1-hydroylase|Yes| 5137.0|A7|C57BL/6-Tg(Tcra149.42)Cbn/JWehiApb||Dominant||||||||||||||||||||||||||transgene insertion Tcra149.42, Francis R Carbone|H-2Kb|||||||||||Homozygous mice exhibit an increased incidence of seizures so mice are maintained as heterozygous.|The majority of CD8 T cells express the trangenic Va2 T cell receptor.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||greater than 30|brother-sister|No|26-May-2010|Cryopreserved sperm|50.0|0.0|No||TCR tansgenic, cytotoxic T lymphocytes, T cell repertoire|Yes| 4987.0|BYAC|B6.SJL-Tg(YACA201F4)/Apb||Dominant||||||||||||||||||||||||||human β-globin locus|β-globin|||||||||||Transgenic human β-globin locus expression was limited to spleen and blood.To establish the pattern of expression of the transgenichuman β-globin locus during development, RNA was analyzedby primer extension. At day 8.5, the first human gene expressed was the foetal γ-globin gene. In day 10.5 yolk sac, the percentage of γ-globin mRNA decreased, while theε-globin mRNA level increased, and this trend continued on day 11.5. At day 12.5, expression of the ε-globin gene hadlargely been switched off. There is an abrupt shift to β-globingene expression that exceeds the level of γ-globin mRNA.Human β-globin expression continued to increase at day 14.5as the dominant globin mRNA. Quantitation by Phosphorlmageranalysis revealed that the ratio of adult mouse toadult human β-globin gene activity per gene copy was 1.35.Thus, the expression level of the single, integrated humanβ-globin locus was comparable to that of the endogenousmurine β-globin locus. The pattern of ε- and β-globin geneactivity followed the expression of the mouse embryonic andadult genes, respectively. However, expression ofthe humanγ-globin gene preceded ε-globin gene expression at day 8.5and persisted throughout the fetal stage. In adult transgenicanimals, low-level human fetal gene expression was occasionally detected. This may be a consequence of theextreme erythroid hyperplasia observed after treatment withphenylhydrazine.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|100.0|0.0|No||erythrocyte, red blood cell, globin, YAC, yeast artificial chromosome|Yes| 4990.0|EPO IL5tg1|C.129/Ola-Epx Tg(CD2-IL5)5C2Ldt/AnuApb||Dominant|eosinophil peroxidase|Epx|Nil|EPO|MGI:107569|eosinophil peroxidase; targeted mutation 1, Nancy A Lee|Epx|MGI:2182952|11||||||||||||||||Yes|transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. Northern blotanalysis identified 11,5 mRNA in the thymus, Peyer's patches, and subcutaneous (pooled inguinal and axillary) lymph nodes. No IL5 mRNA was detected in liver, heart, brain, or skeletal muscle tissues from transgenics, nor in any tissues from normal littermates. Do not maintain as homozygotes. While this is apparently possible, survival of homozygotes likely to be lower.|Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|BALB/c x 129|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|28-Jan-2010|Cryopreserved sperm|105.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 4991.0|Lps2|C57BL/6-Ticam1/BtlrAnuApb|C57BL/6-Ticam1/BtlrAnuApb|Recessive|toll-like receptor adaptor molecule 1|Ticam1||TICAM-1, Trif|MGI:2147032|toll-like receptor adaptor molecule 1; lipopolysaccharide 2|Ticam1|MGI:2679794|17|||||||||||||||||||||||||||||Abnormal cytokine secretion:* cytokine secretion induced by naked polyI:C is severely impaired by 5- to 10-fold.* however, secretion induced by transfected polyI:C is unaffectedDecreased susceptibility to endotoxin shock: though some mice became ill and died after intraperitoneal LPS injection, the survival rate was significantly greater than that of wild-type.Increased susceptibility to viral infection: no production of type I interferons in response to mouse cytomegalovirus (mCMV).||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Jan-2010|Cryopreserved sperm|58.0|0.0|Unknown||ENU, Toll like receptor, LPS, endotoxin, MyD88, cytokine|No| 4899.0||129-Actn3/Apb||Recessive|actinin alpha 3|Actn3|Nil||MGI:99678|targeted mutation 1, Kathryn N North|Actn3|MGI:3760255|19|||||||||||||||||||||||||||||Abnormal skeletal muscle morphology: fast muscle fibers exhibit an increase in mitochondria density compared to wild-type.Abnormal muscle physiology: fast muscle fibers exhibit more staining for two markers of aerobic metabolism (NADH-tetrazolium reductase and succinate dehydroganse) compared to wild-type mice.Fast muscle metabolism is shifted from anaerobic to aerobic as determined by pyruvate metabolism enzyme activity, however, the increase in oxidative enzyme activity does not result in the loss of fast muscle fibers.Increased aerobic running capacity: when run until exhaustion, mice run 33% further than wild-type mice when run until exhaustion.||129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|140.0|0.0|Unknown||Muscle, mitochondria, skeletal, twitch, endurance|Yes| 5157.0|LacZ1 ; Tg(ACTA1-Tnni1(USE)-(nls)lacZ)27BHrd|B6;D2-Tg(ACTA1-lacZ)27BHrd/AusbApb|Hrd|Dominant||||||||||||||||||||||||||Tg(ACTA1-lacZ)27BHrd|Human Skeletal Actin |Skeletal muscle-specific expression of nuclear localised b-galactosidase in differentiated muscle fibres driven by the human -skeletal actin promoter + the upstream enhancer of the rat troponin I slow. Predominant expression in skeletal muscle (soleus>EDL); might have expression in the heart.||||||||||Normal|Normal|C57BL/6J x DB2|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|>20||Heterozygote males crossed with C57BL/6J females|No|17-Jun-2010|Cryopreserved sperm|50.0|0.0|Unknown||LacZ reporter gene, Transgenic Mouse, Skeletal Actin, Mouse Skeletal Muscle, Mouse Muscle transplantation|No| 7786.0|Dynll-KO|C57BL/6-Dynll1/StvApb||Dominant|dynein light chain LC8-type 1|Dynll1|Nil|8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|dynein light chain LC8-type 1; germline knockout 1.2, Jorg Heierhorst|Dynll1||5||||||||||Unknown to Unknown||||||Yes|||||||||||||Embryonic Lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Excellent||||No|17-Nov-2014|Cryopreserved sperm|50.0|0.0|Unknown||Dynll-1, ASCIZ|Possibly| 5225.0|FvbN Adamts1 null|FVB/N-Adamts1/Apb|FVB/N-Adamts1/Apb|Recessive|a disintegrin-like and metallopeptidse (reprolysin type) with thrombospondin type 1 motif, 1|Adamts1|Nil|ADAM-TS1, ADAMTS, C3-C5, METH1|MGI:109249|targeted mutation 1, Melanie A Pritchard|B6.129-Adamts1|MGI:3574351|16||||||||||||||||No|||||||||||||Female sub-fertility. Reduced nubers of ovulated oocytes and reduced litter size of homozygous nulls compared to heterozygous or wildtype littermates|Unknown|FVB/N|No|No|Yes|Yes|Yes|Yes|No|Good|8|8|het x het OR Het male x WT female OR Het female x WT male|No|01-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||fertility, ovulation, angiogenesis, urogenital|Possibly| 5066.0|Zic5 V504G: C57BL/6|B6(Cg)-Zic5/AnuApb||Recessive|Zinc finger protein of the cerebellum 5|Zic5|Unknown|odd-paired related, Opr|MGI:1929518||||14||||||||||||||||Yes|||||||||||||Viable and fertile|Viable and fertile|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Homozygote male paired with homozygote female|No|25-Mar-2010|Cryopreserved sperm|50.0|0.0|Unknown||zinc finger, ENU|Yes| 5131.0|Delta 358 ; Tie2DeltaCx40.358|B6;CBA-Tg(Tie2-Gja5)/AnuApb||Dominant|gap junction protein, alpha 5|Gja5|Increased|connexin 40, Cx40, Gja-5|MGI:95716||||Unknown|||||||||||||||||dominant negative of Cx40|Tie2 endothelial specific|||||||||||Unknown|Mild Hypertension|N3 B6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2|||No|24-May-2010|Cryopreserved sperm|50.0|0.0|Yes|hypertension|connexins, hypertension, gap junctions|Possibly| 5146.0|Aire KO|B6.129-Aire/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10||||||||||||||||No|||||||||||||Targeted mutations that inactivate the gene result in immune system dysfunction characterized by multiorgan lymphocytic infiltration and circulating autoantibodies.Absent adrenal gland: absence of the adrenal glands is seen with incomplete penetrance; however, the thyroid and pancreas are normal.Abnormal T cell morphology: the TCR-Vbeta repertoire is altered in peripheral T cells.Increased T cell proliferation: immunization with hen egg lysozyme antigen results in a 4-5-fold increase in proliferating response of peripheral T cells, with mutants showing twice as many T cells in the lymph nodes than controls.Thymus atrophy: thymic atrophy is seen in 2 of 14 mutants.Increased autoantibody level: 73% of homozygous mice generated autoantibodies against at least one of the organs (liver, testis, pancreas and adrenal gland) tested and 40% of mice contain autoantibodies against two or more of the organs.Liver inflammation: 50% of mutants exhibit accumulation of lymphocytes in periportal regions.Infertility: 85% of male or female mutants fail to produce any litters.||C57BL/6|Yes|No|Yes|Yes|No|Yes|No|Poor||||No|02-Jun-2010|Cryopreserved sperm|50.0|0.0|Yes|Autoimmune polyendocrinopathy syndrome type 1|autoimmunity, clonal deletion, T cell, tolerance|Yes| 5160.0|NODCD19cre|NOD.129-Cd19/MarpApb||Dominant|CD19 antigen|Cd19|Nil||MGI:88319|CD19 antigen; targeted mutation 1, University of Cologne|Cd19|MGI:1931143|7||||||||||Unknown to Unknown|||||||||||||||||||No CD19 expression.Decreased B-1 B cell number: reduced numbers of B1 cells (Cd23-, IgM hi, IgD lo).Abnormal B cell differentiation.Absent spleen germinal center: failure of germinal center formation.Abnormal B cell physiology: impaired B cell response to T cell dependent antigens; mutants exhibit a decreased hapten-specific antibody response by an NP-chicken-gamma-globulin conjugate.Abnormal immunoglobulin level: failure of affinity maturation of serum antibodies.Decreased IgE level.Decreased IgG1 level: absence of high-affinity NP-specific IgG1 antibody following immunization with NP-chicken-gamma-globulin conjugate.Decreased IgM level: reduction in serum IgM.|Mice express Cre recombinase under the control of Cd19 promoter, B cell specific.|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|>10|||No|28-Jun-2010|Cryopreserved sperm|50.0|0.0|Unknown||Cd19, B cell, Cre recombinase|Possibly| 5217.0|Ku70 null 129/SvJ|129/SvJ-Xrcc6/AnuApb||Recessive|X-ray repair complementing defective repair in Chinese hamster cells 6|Xrcc6|Nil|G22p1, Ku p70, Ku70|MGI:95606|X-ray repair complementing defective repair in Chinese hamster cells 6; targeted mutation 1, Frederick W Alt|Xrcc6|MGI:2179954|15||||||||||||||||No|||||||||||||Smaller than littermate controls (about 50% reduction in size). Ku70 null male and females are infertile; they also have impaired T cell development with 1% developing thymic or T cell lymphomas by >9 mths.|Normal|129/SvJ|Yes|No|Yes|Yes|No|Yes|Yes|Poor|||Ku70 het to Ku70 het crossings required|No|14-Sep-2010|Cryopreserved sperm|140.0|0.0|Yes||T cell, hepatocyte, hepatocellular carcinoma (HCC), DNA-dependent protein kinase (DNA-PK), repair, T cell, immunoglobulin, V(D)J, lymphocyte|Possibly| 5219.0|Lyn|B6;129S1/Sv-Lyn/LudApb|B6;129S1/Sv-Lyn/LudApb|Dominant|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Reduced|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Margaret Hibbs|Lyn|MGI:2157016|4||||||||||||||||Yes|||||||||||||The mice carry a gene-targeted gain-of-function mutation in the Lyn tyrosine kinase. The mice display a severe diminution of mature B cells but have increased numbers of B1a B cells. Their B cells display marked down-regulation of surface IgM, Ig-beta, CD19, CD21 and CD22, and they are poorly responsive to B cell receptor cross-linking. With age, the mice develop antibody-mediated autoimmune disease. Due to the dominant nature of the gain-of-function Lyn mutation, Lyn-expressing cells from Lyn mice show hyper-phosphorylation of many signaling proteins.Increased neutrophil cell number: in the spleen and peripheral blood.Decreased spleen weight: unlike Lyn null mice, mice do not develop age-dependent splenomegaly and spleen weight are modestly lower than in wild-type mice.|Lyn<+/up> mice show a reduction in numbers of B cells and Lyn-expressing cells show hyper-phosphorylation of many signaling proteins.|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Sep-2010|Cryopreserved sperm|50.0|0.0|Yes||phophatase, signal transduction, myeloid, neutrophil, tyrosine, src family, B cell, lymphocyte|Possibly| 5557.0|T16; IL1RA T16OX|B6;CBA-Tg(Il1rn)1Dih/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, David Hirsh|IL1RA promoter|||||||||||Increased circulating interleukin-1 level: serum IL-1 levels are higher following lipopolysaccharide (LPS) endotoxin challenge.Decreased susceptibility to endotoxin shock: less susceptible to lipopolysaccharide (LPS) endotoxin challenge.Increased susceptibility to bacterial infection: more susceptible to experimental Listeria monocytogenes infection.|Abnormal angiogenesis: reduced angiogenesis observed in stromal keratitis caused by herpes simplex virus (HSV) ocular infection, reduced vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) levels.Decreased circulating interleukin-6 level: reduced IL-6 levels in response to stromal keratitis caused by herpes simplex virus (HSV) ocular infection.Abnormal circulating serum amyloid protein level: 30% decrease in serum amyloid P levels after subcutaneous turpentine administration.Decreased susceptibility to endotoxin shock: less susceptible to lipopolysaccharide (LPS) endotoxin challenge, hemizygotes exhibit an intermediate phenotype when compared to wild-type and homozygous.Decreased inflammatory response: reduced polymorphonuclear leukocyte infiltration in response to stromal keratitis caused by herpes simplex virus (HSV) ocular infection.Decreased susceptibility to viral infection: severity of stromal keratitis caused by herpes simplex virus (HSV) ocular infection is diminished.Increased susceptibility to bacterial infection: more susceptible to experimental Listeria monocytogenes infection, hemizygotes exhibit an intermediate phenotype when compared to wild-type and homozygous.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown|2 since arrival at ANU||No|12-Aug-2011|Cryopreserved sperm|95.0|0.0|Unknown||IL1, infection, interleukin, LPS, endotoxin, infection, cytokine|Possibly| 5562.0|S100-EGFP|B6;D2-Tg(S100B-EGFP)/Apb||Dominant||||||||||||||||||||||||||Enhanced Green Fluorescence Protein|-1669/+3106 sequence of the murine S100B|||||||||||NormalS100B promoter drives expression of eGFP.From embryonic day 13 onward, EGFP expression was targeted to selected neuroepithelial, glial, and neuronal cells, indicating that cell-specific expression of S100B is regulated at the transcriptional level during development. In adult mice, the highest level of EGFP expression was found in ependymocytes; astrocytes; and spinal, medullar, pontine, and deep cerebellar S100B neurons.|Normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||homozygote x homozygote|No|16-Aug-2011|Cryopreserved sperm|60.0|0.0|No||S100B promoter, EGFP reporter mice, nervous system, glial cells, brain|Possibly| 5223.0|C57.Lyn up/up|B6.129-Lyn/LudApb||Semi-dominant|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Reduced|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Margaret Hibbs|Lyn|MGI:2157016|4||||||||||||||||Yes|||||||||||||The mice carry a gene-targeted gain-of-function mutation in the Lyn tyrosine kinase. The mice display a severe diminution of mature B cells but have increased numbers of B1a B cells. Their B cells display marked down-regulation of surface IgM, Ig-beta, CD19, CD21 and CD22, and they are poorly responsive to B cell receptor cross-linking. With age, the mice develop antibody-mediated autoimmune disease. Due to the dominant nature of the gain-of-function Lyn mutation, Lyn-expressing cells from Lyn mice show hyper-phosphorylation of many signaling proteins.Increased neutrophil cell number: in the spleen and peripheral blood.Decreased spleen weight: unlike Lyn null mice, mice do not develop age-dependent splenomegaly and spleen weight are modestly lower than in wild-type mice.|Lyn<+/up> mice show a reduction in numbers of B cells and Lyn-expressing cells show hyper-phosphorylation of many signaling proteins.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10||Het female x Hom male|No|30-Sep-2010|Cryopreserved sperm|50.0|0.0|Unknown||B cell, signal transduction, phosphorylation, src family, mlymphocyte|Yes| 5577.0|∆SRI |C.129T2-Atm/QimrApb||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Reduced|C030026E19RIK|MGI:107202|ataxia telangiectasia mutated homolog (human); targeted mutation 1, Martin F Lavin|Atm|MGI:2181756|9|||||||||||||||||||||||||||||Premature death: 50% mortality by 40 weeks of age Decreased body size: smaller size persists through adulthood Postnatal growth retardation: 20% growth reduction in males and 18% reduction in females from birth to 45 days of age. Increased tumor incidence: mice dying after 40 weeks of age usually have tumors that are not thymic lymphomas Thymic lymphoma: found in all mice dying before 40 weeks, diverse cell types involved, spongy tumors with a high proportion of cells undergoing apoptosis Abnormal immune system cell morphology: occasional increase in thymocyte size. Abnormal T lymphocyte development: lymph node T cells are primarily at early stages of development. Increased double-negative T cell count: occurs at random Abnormal effector T cell morphology/development: randomly observed increases in single positive T cells. Decreased thymocyte number: 10% reduction in thymocytes, 30-50% reduction in thymocytes expressing alpha and beta T cell receptors or CD3. Abnormal immune system organ morphology: enlarged spleen: usually found in mice dying after 40 weeks of age. small spleen: in mice under 40 weeks of age small thymus small lymph nodes Abnormal chromosome morphology: 3 fold increase in radiation induced chromosomal aberrations. Increased cellular sensitivity to ionizing radiation: increased sensitivity of thymocytes and splenocytes to ionizing radiation. Seminiferous tubule degeneration: tubules disrupted Abnormal testis development: poorly developed Abnormal gametogenesis: abnormal oogenesis: disrupted, lack of maturing follicles and oocytes. Abnormal spermatogenesis: disrupted spermatogenesis, degenerating spermatocytes, loss of spermatids Nervous system phenotype: no gross neuronal degeneration at time points between 2 and 16 months of age. Abnormal Purkinje cell morphology: survival of Purkinje cells in culture less than 60% of controls at 4 days and about 40% at 10 day, survival of cultured cells improves if cultured with cerebellar astroglial cells, develop simpler dendritic arboritization with reduced secondary branching, nitroxide free radicals improve survival and arborization Seminiferous tubule degeneration: tubules disrupted|Increased tumor incidence: average age at onset 18.6 months, varying tumor types including dermatoid cysts adenoma: 13% of total leukemia: 5% of total lymphoma:24% of total ovary tumor: 8% of total sarcoma: 32% of total, half of sarcomas are in Mammary glands|BALB/c|Yes|No|Yes|Yes|No|Yes|No|Good|22|14|Hetrezygotes x Heterozygotes|Yes|05-Sep-2011|Cryopreserved sperm|47.0|0.0|Yes|A-T is characterized by immunodeficiency, neurological abnormalities and a |ataxia telangiectasia , T cell , spermatogenesis, thymocyte, lymphoma |Possibly| 6030.0|Robo2Cond|B.129-Robo2/Apb||Recessive|roundabout homolog 2 (Drosophila)|Robo2||2600013A04Rik, 9430089E08Rik, D230004I22Rik, mKIAA1568|MGI:1890110|roundabout homolog 2 (Drosophila); targeted mutation 1, Richard Maas|Robo2|MGI:3759447|16|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Sep-2011|Cryopreserved sperm|50.0|0.0|Unknown||slit|Possibly| 6635.0|Cd11c-DTR/EGFP|C.FVB-Tg(Itgax-DTR/EGFP)57Lan/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 57, Richard A Lang|mouse Itgax promoter (CD11c)|||||||||||Immune system phenotype: conventional T cell, macrophages, B cell, NK cell, and NK T cell numbers are unaffected by treatment with diphtheria toxin.Decreased dendritic cell number: 24 hours after treatment with diphtheria toxin, spleens and livers are depleted of dendritic cells.Decreased circulating interferon-gamma level: following treatment with diphtheria toxin, little IFN-gamma in alpha-GalCer-injected mice and no IFN-gamma in alpha-C-GalCer-injected mice was detected unlike in transgenic mice not treated with diphtheria toxin.Decreased circulating interleukin-12 level: following treatment with diphtheria toxin and stimulation with alpha-GalCer or alpha-C-GalCer, virtually no serum IL-12 was detected unlike in transgenic mice not treated with diphtheria toxin.Abnormal NK cell physiology: following treatment with diphtheria toxin and stimulation with alpha-GalCer, only 2% at 6 hours and 4% at 12 hours post-treatment of liver or spleen NK cells stain positive for IFN-gamma compared to 20% to 23% and 13% to 16%, respectively, of cells from transgenic mice not treated with diphtheria toxin.Decreased interferon-gamma secretion: following treatment with diphtheria toxin and stimulation with alpha-GalCer, only 2% at 6 hours and 4% at 12 hours post-treatment of liver or spleen NK cells stain positive for IFN-gamma compared to 20% to 23% and 13% to 16%, respectively, of cells from transgenic mice not treated with diphtheria toxin.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown||CD11c, dendritic cell, CD8, T cell|Yes| 5229.0|Ripk2tm1Flv|C57BL/6-Ripk2/Apb||Recessive|receptor (TNFRSF)-interacting serine-threonine kinase 2|Ripk2||CARD3, CARDIAK, CCK, D4Bwg0615e, RICK, RIP2|MGI:1891456|receptor (TNFRSF)-interacting serine-threonine kinase 2; targeted mutation 1, Richard A Flavell|Ripk2|MGI:2660793|4||||||||||||||||No|||||||||||||Abnormal macrophage physiology: * bone marrow derived macrophages produce less IL-6 and TNF when cultured in the presence of L. monocytogenes * in macrophages pre-treated with TLR ligands (i.e. "tolerized"), macrophages produce significantly less inflammatory cytokines upon incubation with L. monocytogenes than controls that were LPS pre-treatedDecreased interleukin-6 secretion: * bone marrow derived macrophages secrete half the amount of IL-6 as wild-type controls in response to culturing with L. monocytogenes * IL-6 secretion is 22% that of controls when macrophages are pre-treated with LPS prior to L. monocytogenes incubation * bone marrow derived macrophages fail to produce IL-6 when pre-treated with LPS prior to NOD2 stimulationDecreased tumor necrosis factor secretion: * bone marrow derived macrophages secrete 61% TNF as wild-type controls in response to culturing with L. monocytogenes * IL-6 secretion is about 20% that of controls when macrophages are pre-treated with LPS or LTA prior to L. monocytogenes incubation * bone marrow derived macrophages fail to produce TNF when pre-treated with LPS prior to NOD2 stimulation|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||Nod1, adaptive, signal transduction|Yes| 8004.0|Hes7|C57BL/6-Hes7/KagDunwApb||Recessive|hairy and enhancer of split 7 (Drosophila)|Hes7|Unknown|bHLHb37|MGI:2135679|hairy and enhancer of split 7 (Drosophila); targeted mutation 1, Ryoichiro Kageyama|Hes7|MGI:2652222|11|||||||||||||||||||||||||||||Complete neonatal lethality• most died within a few hours of birth, apparently from respiratory failureAbnormal somite developmentAbnormal left-right axis symmetry of the somites:• loss of left-right axis somite symmetryAbnormal dorsal-ventral polarity of the somites:• disrupted anterior-posterior polarity of the somitesAbnormal somite shape:• somites were irregular in both size and shape, and the boundaries between somites were less clearAbnormal somite size:• somites were irregular in both size and shape, and the boundaries between somites were less clearIncomplete somite formation:• abnormal segmentation|Some mice have a vertebral defect|C57BL/6J|No|Unknown|Unknown|No|Unknown|Unknown|No|Good||||No|08-Dec-2015||0.0|0.0|Unknown||Scoliosis, presomitic mesoderm, Somites|Possibly| 7686.0|DBH-GFP|B6.Cg-Tg(DBH-tauGFP)17/RbrcAnu||Dominant||||||||||||||||||||||||||Tg(DBH-tauGFP)17 |human dopamine beta hydroxylase|||||||||||These transgenic mice express a fusion gene of bovine tau protein and GFP under the control of the human DBH promoter in typical noradrenergic and adrenergic cell groups. Line 17 and 36 were generated. The expression level of Tg in each line was following order: 17 > 36 (developer's information). ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|20|||No|22-May-2014|Cryopreserved sperm|48.0|0.0|Unknown||GFP, T cell|Yes| 7696.0|Spi6 conditional KO clone 1D|C57BL/6J-SerpinB91D/PibMarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9||ovalbumin, PI-9, Spi6|MGI:106603||||13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Jun-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 6767.0|580s/TVA |STOCK Apc Tg(Gpa33-TVA)#Ern/LudApb||Dominant|adenomatosis polyposis coli|Apc|Reduced|CC1, Min|MGI:88039|adenomatosis polyposis coli; targeted mutation 1, Tetsuo Noda|Apc|MGI:1857966|18|||||||||||||||||transgenic insertion 1, Matthias Ernst|glycoprotein A33 (transmembrane)|||||||||||Liver tumours will develop in animals 18 months or older|Liver tumours will develop in animals 18 months or older|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 6873.0|A1A2f|C57BL/6-Acaca Acacb/AusbApb|C57BL/6-Acaca Acacb/Ausb|Dominant|acetyl-Coenzyme A carboxylase alpha|Acaca|Normal|A530025K05Rik, Acac, Acc1, acetyl-CoA carboxylase, LOC327983|MGI:108451|acetyl-Coenzyme A carboxylase alpha; targeted mutation 1, David E James|Acaca|MGI:5618483|11||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Apr-2012|Cryopreserved sperm|50.0|0.0|No||ACC1, ACC2, Flox, adipose|Yes| 6873.0|A1A2f|C57BL/6-Acaca Acacb/AusbApb|C57BL/6-Acaca Acacb/Ausb|Dominant|acetyl-Coenzyme A carboxylase beta|Acacb|Normal|Acc2, Accb|MGI:2140940|acetyl-Coenzyme A carboxylase beta; targeted mutation 1.1, David James| Acacb|MGI:4430244|5||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Apr-2012|Cryopreserved sperm|||No||ACC1, ACC2, Flox, adipose|Yes| 7028.0|MKB ; Met-Kb|STOCK-Aire Tg(sMt1-H2-K)/ArcApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Part Peterson|Aire|MGI:3722595|10|||||||||||||||||mouse H2-K (MHC class I)|Sheep metallothionein promoter|variable and slightly lower than wild type H2-K. Expression can be induced with Zinc||||||||||Normal|Normal|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||Yes|25-Jul-2012|Cryopreserved sperm|50.0|0.0|No||tolerance, liver, CD8 T cells, MHC class I, autoimmunity|Possibly| 7033.0|TFF-Cre/PIK3flox|STOCK Pik3ca Tg(Tff1-CreERT2/Tff2-CreERT2)/LudApb||Dominant|phosphatidylinositol 3-kinase, catalytic, alpha polypeptide|Pik3ca|Normal|6330412C24Rik, caPI3K, p110alpha|MGI:1206581|phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; targeted mutation 1.1, Wayne A Phillips|Pik3ca|MGI:5427579|3|||||||||||||||||trefoil1/2|Tff1/Tff2|||||||||||Tumour formation in the stomach after Cre activation by tamoxifen.|Unknown|Mixed|No|Unknown|Yes|No|Unknown|Yes|No|Unknown||||No|30-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7777.0|ORX/Arch ; Orexin/archaerhodopsin-3|STOCK Tg(HRCT-Arch)#Ahky||Dominant||||||||||||||||||||||||||archaerhodopsin-3|Homo sapiens prepro-orexin (HRCT, hypocretin)|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7778.0|ORX/tTA|B6.Cg-Tg(HCRT-tTA)#Ahky||Dominant||||||||||||||||||||||||||transgene insertion, Akihiro Yamanaka|Homo sapiens prepro-orexin|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Oct-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7780.0|ENU31:G3|ANU:ENU31:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|07-Nov-2014|Cryopreserved sperm|308.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 4956.0|OT2.CD45.1|B6.Cg-Ptprc Tg(TcraTcrb)425Cbn/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 425, Frank Carbone|||protein tyrosine phosphatase, receptor type, C|Ptprc||220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Homozygous mice are viable and fertile. In these mice there is a four-fold increase in the CD4 to CD8 peripheral T-cell ratio, and lymph node T-cells demonstrate a dose-dependent proliferative response to the specific ovalbumin ligand.T cells express T cell receptor specific for chicken ovalalbumin residues 323 - 339 in the context of H2-Ab1 (I-A)Transgenic mice express the mouse alpha-chain and beta-chain T-cell receptor that pairs with the CD4 coreceptor and is specific for chicken ovalbumin 323-339 in the context of I-A b. Homozygous transgenic mice are viable and fertile. In these mice there is a four-fold increase in the CD4 to CD8 peripheral T-cell ratio, and lymph node T-cells demonstrate a dose-dependent proliferative response to the specific ovalbumin ligand.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Dec-2009|Cryopreserved sperm|80.0|0.0|Unknown||receptor (TCR), CD4, ovalbumin, thymic selection, B cell receptor|Yes| 7789.0||C57BL/6JAnu-Elovl3/AnuApb|C57BL/6JAnu-Elovl3/AnuApb|Recessive|elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3|Elovl3|Unknown|Cig30, CIN-2|MGI:1195976|Elovl3; mutation 1, Australian National University|Elovl3||19|ENSMUSG00000038754|ENSMUST00000043739|Elovl3-001|545|718|T to A|ENSMUSE00000380471|4|182|Methionine to Lysine|||||GACCATGAACTTTGGCGTCCATTCTGTCATGTACACTTACTACACTATGAAGGCTGCCAAA||||||||||||||Hom mice have sparse fur and can been phenotyped at weaning||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Nov-2014|Cryopreserved sperm|51.0|0.0|Unknown|||Yes| 8363.0|ASD867|BALB/cNCrlAnu:Yellow||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2017||0.0|869.0|Unknown|||No| 7787.0|Dynll-SHH|C57BL/6-Dynll1 Shh/StvApb||Dominant|dynein light chain LC8-type 1|Dynll1|Normal|8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|dynein light chain LC8-type 1; targeted mutation 1.1, Jorg Heierhorst|Dynll1||5||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|17-Nov-2014|Cryopreserved sperm|50.0|0.0|Unknown||Dynll-1, ASCIZ, SHH|Possibly| 7787.0|Dynll-SHH|C57BL/6-Dynll1 Shh/StvApb||Dominant|sonic hedgehog|Shh||Hhg1, Hx, Hxl3, M100081|MGI:98297|sonic hedgehog; targeted mutation 1, Clifford J Tabin|Shh|MGI:3053959|5|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|17-Nov-2014|Cryopreserved sperm|||Unknown||Dynll-1, ASCIZ, SHH|Possibly| 7794.0|MPEG1 targeted KO clone 7F|C57BL/6J-Mpeg17F/PibMarpApb||Dominant|macrophage expressed gene 1|Mpeg1||Mpg-1, MPS1|MGI:1333743||||19|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|25-Nov-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8780.0|Tph2-GFP|CD1.FVB/N-Tg(Tph2-EGFP)LO210Gsat/Apb||Dominant||||||||||||||||||||||||||transgene insertion LO210, GENSAT Project at Rockefeller University|Tph2|||||||||||GFP expressed in Tph2-expressing cells. No other phenotype abnormalities. Breeding not great as Homs|GFP expressed in Tph2-expressing cells. No other phenotype abnormalities. prefer maintain line as hets for breeding.|Crl:CD1(ICR) |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Aug-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7796.0|Tiger ; Cx40Tg|B6.CBA-Tg(Tie2-Gja5/EGFP)1/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, |endothelial-specific receptor tyrosine kinase; Tie2, Tek||||||||||||Expression of Cx40 (Gja5) at endothelial gap junctions.Arteries from Cx40Tg mice were significantly more sensitiveto the vasodilator, calcitonin gene related peptide (CGRP), thanwild-type or Cx40T202STg arteries.There was no difference among the genotypes in the sensitivityto phenylephrine (PE) or the total vascular tone achievedat 70 mm Hg (Figure III in the online-only Data Supplement).However, the maximum constriction to PE was significantlygreater in Cx40Tg arteries than in Cx40T202STg and wild typearteries.|C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|8|||No|25-Nov-2014|Cryopreserved sperm|49.0|0.0|Unknown||arterial dysfunction, connexin40, endothelium, myogenic response, stiffness|Yes| 7793.0|LMN|B6.129S1(Cg)-Lmna/VccriApb||Dominant|lamin A|Lmna|Nil|Dhe, lamin A/C|MGI:96794|lamin A; targeted mutation 1, Colin L Stewart|Lmna|MGI:2177930|3|||||||||||||||||||||||||||||Lethal by 6-8weeks.Postnatal growth retardation.Muscle weakness.Small seminiferous tubules.Small testis.Azoospermia: spermatids and spermatozoa are largely absentArrest of male meiosis: * increased frequency of leptotene and zygotene spermatocytes and decreased frequency of pachytene and diplotene spermatocytes resulting from arrest and apoptosis of spermatocytes during the pachytene stage * unpaired chromosomes and/or improperly paired sex chromosomes and failure to progress through prophase I are seen * however, oogenesis in females is normal.|Viable, fertile.Abnormal nucleus morphology: in many MEFs, nuclei appear elongated but distribution of nuclear envelope proteins is normal except for increased levels of cytoplasmic emerin.|C57BL/6|No|Unknown|Yes|No|Unknown|Yes|No|Good|Backcrossed to C57BL/6 since 2009|None since 2009|LMN het male x BL6 female|No|21-Nov-2014|Cryopreserved sperm|70.0|0.0|Unknown||muscular dystrophy, membrane, interphase, spermatogenesis|Yes| 7788.0||C57BL/6JAnu-Scd1/AnuApb|C57BL/6JAnu-Scd1/AnuApb|Recessive|stearoyl-Coenzyme A desaturase 1|Scd1||SCD, Scd-1, stearoyl-CoA desaturase|MGI:98239||||19|ENSMUSG00000037071|ENSMUST00000041331|Scd1-201||||||||||||||||||||||||||Hom mice have sparse fur and can been phenotyped at weaning||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Nov-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7791.0||C57BL/6NCrlAnu-Nck/AnuApb|C57BL/6NCrlAnu-Nck/AnuApb|Recessive|non-catalytic region of tyrosine kinase adaptor protein 1|Nck1|Unknown|6330586M15Rik, D230010O13Rik, Nck|MGI:109601||||9|||||||||||||||||||||||||||||Increased IgM expression on mature B cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Nov-2014|Cryopreserved sperm|30.0|0.0|Unknown||B cell, IgM|Yes| 7795.0|CAG-KD:ER; MMTV-Cre|C57BL/6-Hprt Tg(MMTV-Cre)/Apb||X-linked|hypoxanthine guanine phosphoribosyl transferase|Hprt|Normal||MGI:96217||||X||||||||||||||||||MMTV|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|5|||No|25-Nov-2014|Cryopreserved sperm|50.0|0.0|No|||Possibly| 7797.0|Favola ; Cx40T202STg ; DeltaF|B6.CBA-Tg(Tie2-Gja5*T202S/EGFP)1/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, |endothelial-specific receptor tyrosine kinase; Tie2, Tek||||||||||||Expression of mutant form of Cx40 (Gja5) (amino acid substitution T202S at endothelial gap junctions.Body weight, blood pressure and heart rate are normal.Expression of transgene results in significant decrease in Cx37 expression.Endothelial Cx40T202S expression enhances myogenic activation and impairs endothelium-derived hyperpolarization (EDH) in mesenteric resistance arteries.Endothelial Cx40T202S expression increases stiffness of mesenteric resistance arteries. |C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|8|||No|25-Nov-2014|Cryopreserved sperm|63.0|0.0|Unknown||arterial dysfunction, connexin40, endothelium, myogenic response, stiffness|Yes| 7798.0|DeltaG ; Cx40T152ATg|C57BL/6JAnu-Tg(Tie2-Gja5*T152A/EGFP)1/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, |endothelial-specific receptor tyrosine kinase; Tie2, Tek|||||||||||||C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|8|||No|25-Nov-2014|Cryopreserved sperm|48.0|0.0|Unknown||arterial dysfunction, connexin40, endothelium, myogenic response, stiffness|Yes| 7805.0|DBC2 / DBC3 knockout|C57BL/6-Brinp2 Brinp3/PibMarpApb||Recessive|bone morphogenic protein/retinoic acid inducible neural-specific 2|Brinp2|Nil|6430517E21Rik, Fam5b, mKIAA1747|MGI:2443333|bone morphogenic protein/retinoic acid inducible neural-specific 2; targeted mutation 1.1, Phillip I Bird|Brinp2|MGI:5604615|1||||||||||||||||Yes|||||||||||||DBC2 and DBC3 mice show behavioral phenotypes similar to DBC3 knockout mice. * Reduced anxiety in the elevated plus maze* Reduction in sociability. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||From homozygous breeding|Yes|08-Dec-2014|Cryopreserved sperm|50.0|0.0|Unknown||Brinp3, Brinp2|Yes| 7805.0|DBC2 / DBC3 knockout|C57BL/6-Brinp2 Brinp3/PibMarpApb||Recessive|bone morphogenetic protein/retinoic acid inducible neural specific 3|Brinp3||B830045N13Rik, Fam5c|MGI:2443035|bone morphogenetic protein/retinoic acid inducible neural specific 3; targeted mutation 1.1, Phillip I Bird|Brinp3|MGI:5604620|1|||||||||||||||||||||||||||||DBC2 and DBC3 mice show behavioral phenotypes similar to DBC3 knockout mice. * Reduced anxiety in the elevated plus maze* Reduction in sociability. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||From homozygous breeding|Yes|08-Dec-2014|Cryopreserved sperm|||Unknown||Brinp3, Brinp2|Yes| 7806.0|DBC2 knockout|C57BL/6-Brinp2/PibMarpApb||Recessive|bone morphogenic protein/retinoic acid inducible neural-specific 2|Brinp2||6430517E21Rik, Fam5b, mKIAA1747|MGI:2443333|bone morphogenic protein/retinoic acid inducible neural-specific 2; targeted mutation 1.1, Phillip I Bird|Brinp2|MGI:5604615|1|||||||||||||||||||||||||||||Hyperactive.Mice have normal short-term memory, olfactory responses, pre-pulse inhibition, and motor learning.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||From hetrozygous breeding|No|08-Dec-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7803.0|p16f|C57BL/6-Cdkn2a/Apb||Recessive|cyclin-dependent kinase inhibitor 2A|Cdkn2a|Unknown|Arf, ARF-INK4a, Ink4a/Arf, INK4a-ARF, MTS1, p16, p16INK4a, p19ARF, p19, Pctr1|MGI:104738|cyclin-dependent kinase inhibitor 2A; targeted mutation 2.1, Norman E Sharpless|Cdkn2a|MGI:4835008|4|||||||||||||||||||||||||||||Normal|Normal|C57BL6/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Nov-2014|Cryopreserved sperm|60.0|0.0|Unknown||melanoma, melanocyte, Ras|Possibly| 7807.0|ENU28:020:Usp37|C57BL/6NCrlAnu-Usp37/AnuApb|C57BL/6NCrlAnu-Usp37/AnuApb|Recessive|ubiquitin specific peptidase 37|Usp37|Unknown|4932415L06Rik, C330008N13Rik|MGI:2442483|ubiquitin specific peptidase 37; mutation 1, The Australian National University|Usp37|MGI:5648437|1|ENSMUSG00000033364|ENSMUST00000189257|Usp37-001|187|560|G to A|ENSMUSE00000393309|5|63|Arginine to STOP|||||TAAGTCATAACATTAAAAATGTGGTACTACGACCCAGTGGAATAAAACAAAGCCGCCTAAT||||||||||||||Embryonic lethal||C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Dec-2014|Cryopreserved sperm|51.0|0.0|Unknown||ENU, embryonic lethal|Yes| 7802.0| 14CreER|B6.CD1-Tg(KRT14-cre/ERT)20Efu/MarpApb||Recessive||||||||||||||||||||||||||transgene insertion 20, Elaine Fuchs|human keratin 14 (KRT14) promoter|||||||||||skin lesions, increased skin squamous cell carcinoma incidence, hyperkerotosis, parakerotosis, reddish skin, scaly skin||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|6||No|26-Nov-2014|Cryopreserved sperm|50.0|0.0|No||Keratin 76, tight junctions, CLDN1, inflammation, skin|Possibly| 7809.0|ENU26:042:Depdc5:B6:G4|C57BL/6NCrlAnu-Depdc5/AnuApb|C57BL/6NCrlAnu-Depdc5/AnuApb|Recessive|DEP domain containing 5|Depdc5|Unknown||MGI:2141101|DEP domain containing 5; mutation 1, The Australian National University|Depdc5|MGI:5648440|5|ENSMUSG00000037426|ENSMUST00000087897|Depdc5-001|510|979|G to T|ENSMUSE00000246481|10|170|Methionine to Isoleucine|||||AGGGTGGTGTTCCGTTCTACGTCGGCTATGGTTTACATATTTATTCAGATGAGCTGTGAAA||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|3|Het x het |No|09-Dec-2014|Cryopreserved sperm|50.0|0.0|Unknown||ENU, mutagenesis, screen, random, Depdc5|Possibly| 5124.0|B6-ANU.A2G-Mx1/IFNAR-/-Mx1+/+|B6.A2G-Mx1 Ifnar1/AnuApb||Dominant|interferon (alpha and beta) receptor 1|Ifnar1|Nil|Ifar, IFN-alpha/betaR, Ifrc|MGI:107658|interferon (alpha and beta) receptor 1; targeted mutation 1, Michel Aguet|Ifnar1|MGI:1930950|16||||||||||||||||No|||||||||||||Due to the lack of a functional type I interferon receptor (IFNAR), mice don't respond to interferon (IFN) alpha/beta. Consequently they are highly susesptible to virus infections.|Normal in respect to IFN signalling, but highly resistant to influenza virus infections due to Mx1 (note that most inbred strains such as B6 and Balb don't have functional Mx genes). |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|More than 10|||No|19-May-2010|Cryopreserved sperm|60.0|0.0|Unknown||influenza, infection, resistance, Interferon|Possibly| 5124.0|B6-ANU.A2G-Mx1/IFNAR-/-Mx1+/+|B6.A2G-Mx1 Ifnar1/AnuApb||Dominant|myxovirus (influenza virus) resistance 1|Mx1|Normal|Mx, Mx-1, myxovirus (influenza) resistance 1 polypeptide|MGI:97243|myxovirus (influenza virus) resistance 1; myxovirus resistance|Mx1|MGI:3715151|16|||||||||||||||||||||||||||||Due to the lack of a functional type I interferon receptor (IFNAR), mice don't respond to interferon (IFN) alpha/beta. Consequently they are highly susesptible to virus infections.|Normal in respect to IFN signalling, but highly resistant to influenza virus infections due to Mx1 (note that most inbred strains such as B6 and Balb don't have functional Mx genes). |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|More than 10|||No|19-May-2010|Cryopreserved sperm|||Unknown||influenza, infection, resistance, Interferon|Possibly| 7256.0|APN275|C57BL/6N(Ag)-Katnb1MarpApb||Recessive|katanin p80 (WD40-containing) subunit B 1|Katnb1 ||2410003J24Rik, KAT |MGI:1921437 |katanin p80 (WD40-containing) subunit B 1; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Katnb1tm1a(EUCOMM)Hmgu|MGI:4436305|8|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Jan-2013|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 7808.0|ENU28:011:Etaa1|C57BL/6NCrlAnu-Etaa1/AnuApb|C57BL/6NCrlAnu-Etaa1/AnuApb|Recessive|Ewing tumor-associated antigen 1|Etaa1|Unknown|5730466H23Rik|MGI:1915395|Ewing tumor-associated antigen 1; mutation 1, Australian National University|Etaa1|MGI:6343404|11|ENSMUSG00000016984|ENSMUST00000076661|Etaa1-001||||||||17952576|2|||TCAAAATTCTCCAATGACAAAGCAGTTAGGTAATCTGTTGTTATTTTTATGTGGGTAGGT||||||||||||||Poor response to immunisation.Partial embryonic lethality||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|08-Dec-2014|Cryopreserved sperm|91.0|0.0|Unknown||ENU|Yes| 7814.0|SGSH Flox|C57Bl/6-Sgsh/LdruApb|ldru|Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Normal|4632406A19Rik, sulphamidase|MGI:1350341||||11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|6|brother X sister|No|15-Dec-2014|Cryopreserved sperm|50.0|0.0|Unknown||Flox, SGSH|Possibly| 7817.0|Transgenic Control|C57BL/6-Sgsh/LrduApb|ldru|Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Unknown|4632406A19Rik, sulphamidase|MGI:1350341||||11|||||||||||||||||||||||||||||Expected to be normal|Expected to be normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|6|brother X sister|No|15-Dec-2014|Cryopreserved sperm|85.0|0.0|Unknown|||Possibly| 7781.0|203.4 ; cTnI-G203S.4|C57BL/6-Tg(Myh6-TNNI3*G203S)4Chs/Apb|MGI:3690014|Dominant||||||||||||||||||||||||||transgene insertion 4, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|83% of endogenous||||||||||Unknown|Mice develop cardiac phenotype - hypertrophic cardiomyopathy by 21 weeks of age. Left ventricular hypertrophy was observed on echocardiography, it was associated with a significant 4-fold increase in RNA markers of hypertrophy, ANF and BNP. Myocyte hypertrophy, myofiber disarray and interstitial fibrosis were observed. |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||21|Transgenic x non-transgenic sibs|No|11-Nov-2014|Cryopreserved sperm|60.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 7801.0|Krt76 tm1c x K14CreER|B6(Cg)-Krt76Tg(KRT14-Cre/ER)20Efu/MarpApb||Recessive|keratin 76|Krt76|Nil|2310001L23Rik|MGI:1924305||||15|||||||||||||||||transgene insertion 20, Elaine Fuchs|human keratin 14 (KRT14) promoter|||||||||||Unkempt, dull coats and smaller body size, scaling of skin of the tail, abnormal paw pad hyperpigmentation |Abnormal sebaceous gland morphology, abnormal hair cycle, abnormal epidermis stratum basale morphology, hyperkerotosis, parakerotosis|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|6||No|26-Nov-2014|Cryopreserved sperm|50.0|0.0|No||Keratin 76, tight junctions, CLDN1, inflammation, skin|Possibly| 7819.0|Ctss KO:MHC II KO|B6NCrl;129-Ctss H2/AnuApb||Recessive|cathepsin S|Ctss|Nil|Cat S|MGI:107341|cathepsin S; targeted mutation 1, Harold A Chapman|Ctss|MGI:2182133|3||||||||||||||||Yes|||||||||||||Defective CD4 T cell response and humoral responses, but no overt immunodeficiency. Homozygous null mice are resistant to the development of experimental autoimmune myasthenia gravis and showed reduced T and B cell responses to acetylcholine receptor.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jan-2015|Cryopreserved sperm|10.0|0.0|Unknown||T cell, MHC class II, cysteine proteinase, Humoral resposne, arthritis, germinal centre|Yes| 7819.0|Ctss KO:MHC II KO|B6NCrl;129-Ctss H2/AnuApb||Recessive|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17|||||||||||||||||||||||||||||Defective CD4 T cell response and humoral responses, but no overt immunodeficiency. Homozygous null mice are resistant to the development of experimental autoimmune myasthenia gravis and showed reduced T and B cell responses to acetylcholine receptor.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jan-2015|Cryopreserved sperm|||Unknown||T cell, MHC class II, cysteine proteinase, Humoral resposne, arthritis, germinal centre|Yes| 7822.0|ENU15NIH:085:a:B6:BC8|B6(Cg)-Sppl2a/AnuApb|B6(Cg)-Sppl2a/AnuApb|Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802 |signal peptide peptidase like 2A; mutation 1, The Australian National University|Sppl2a|MGI:5432126|2|ENSMUSG00000027366|ENSMUST00000028844|2010106G01Rik-001||||||||126746052|7|||ATTCATAGGATGCCATGTGGACAGTGCACGTACGTATCTGTTAGCCTATGATGCAATTAG||||||||||||||Decreased number of B cells.Very low expression of IgD on the IgM subset of mature B cells.25-fold less serum IgM.6-fold less serum IgG1.Almost no specific antibody was made after immunization with formalin-inactivated and heat-killed Bordetella pertussis and alum-precipitated chicken gamma globulin (CGG) coupled to p-azobenzenearsonate (ABA) hapten or after immunization with the T-independent antigen 4-hydroxy-3-nitrophenylacetyl-Ficoll (NP-Ficoll.Normal numbers of pro-B, pre-B, and immature B cells, and normal cell surface IgM and normal onset of IgD expression among the IgM T1 subset.Mature IgD<+>IgM recirculating B cells were selectively decreased in the bone marrow and had very low surface IgD. In the spleen, the T1 subset of recent bone marrow emigrants (CD93<+>IgMCD23<−>) was present in normal numbers and expressed levels of surface IgM comparable with controls.Subsequent maturational stages of T2, T3, and mature CD93<−>IgM B cells were 20-fold reduced, whereas the mature marginal zone B cell subset was decreased 200-fold. Immunofluorescent staining of spleen sections showed that the residual B cells in SPPL2A-deficient mice nevertheless localized normally in primary follicles.Sppl2a<−/−> mice had fewer CD11c<+> DCs as the result of only 12% of normal numbers in the CD4<+> and the CD4<−>CD8<−> double-negative (DN) DC subsets, whereas CD8<+> and plasmacytoid DCs were present at normal and increased numbers, respectively. Less CD11c and CD8 was present on the B220<−>CD8<+> DCs in Sppl2a<−/−> animals.|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|8|||No|03-Jan-2015|Cryopreserved sperm|55.0|0.0|Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|No| 7821.0|ENU15NIH:085:Cd19-cre:Ikk2ca-Tg:G2|C57BL/6JAnu-Cd19 Gt(ROSA)26Sor Sppl2a/AnuApb||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802 |signal peptide peptidase like 2A; mutation 1, The Australian National University|Sppl2a|MGI:5432126|2|ENSMUSG00000027366|ENSMUST00000028844|2010106G01Rik-001||||||||126746052|7|||ATTCATAGGATGCCATGTGGACAGTGCACGTACGTATCTGTTAGCCTATGATGCAATTAG|||||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|03-Jan-2015|Cryopreserved sperm|10.0|0.0|Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|Possibly| 7821.0|ENU15NIH:085:Cd19-cre:Ikk2ca-Tg:G2|C57BL/6JAnu-Cd19 Gt(ROSA)26Sor Sppl2a/AnuApb||Recessive|CD19 antigen|Cd19|||MGI:88319|targeted mutation 1, University of Cologne|Cd19|MGI:1931143|7||||||||||||||||||||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|03-Jan-2015|Cryopreserved sperm|||Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|Possibly| 7821.0|ENU15NIH:085:Cd19-cre:Ikk2ca-Tg:G2|C57BL/6JAnu-Cd19 Gt(ROSA)26Sor Sppl2a/AnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 4, Klaus Rajewsky|Gt(ROSA)26Sor|MGI:3687199|6||||||||||||||||||||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|03-Jan-2015|Cryopreserved sperm|||Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|Possibly| 7830.0|MH2-403|FVB-Tg(tetO7-hCMVmin-aMHCR403Q)1Rmgr/VccriApb||Dominant||||||||||||||||||||||||||tetO7-hCMVmin-aMHCR403Q|tetO7-hCMVmin|||||||||||Unknown|Normal|FVB/n|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|more than 10|N/A|FVB/n female x hemizygous MH2-403 male|No|13-Jan-2015|Cryopreserved sperm|70.0|0.0|Unknown|||Possibly| 8785.0|Ap2a2 floxed|C57BL/6N-Ap2a2/MarpApb||Recessive|adaptor-related protein complex 2, alpha 2 subunit|Ap2a2||2410074K14Rik, Adtab, alpha-adaptin C, alpha-C adaptin, L25|MGI:101920||||7|||||||||||||||||||||||||||||Although Ap2a2 deletion had onlyminor effects on glycaemic control, it led to substantial impairment in b-adrenergic activation of lipolysis, as evidencedby a loss of cAMPresponse,PKAactivation, andglycerol/fattyacidrelease. These differenceswere related to increased cell surface localization of the b2- and b3-ARs. Lipolytic defects were accompanied by impaired WY-mediated loss of fat mass and whole-body fat oxidation.|Normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2019|Cryopreserved sperm|50.0|0.0|Unknown||Lipolysis, adipose, PPARα|Yes| 7831.0|tTA|FVB.Cg-Tg(Myh6-tTA)6Smbf/VccriApb||Dominant||||||||||||||||||||||||||transgene insertion 6, Section of Myocardial Biology - Fishman Lab|rat Myh6 promoter|||||||||||Unknown|Normal|FVB/n|Unknown|Unknown|Yes|Unknown|Unknown|Unknown|No|Excellent|more than 10|N/A|FVB/n male x hemizygous tTA female|No|13-Jan-2015|Cryopreserved sperm|50.0|0.0|Unknown||tet|Possibly| 7832.0|C57BL/6-Nabp2-KO|C57BL/6J-Nabp2/QimrApb|Already registered |Recessive|nucleic acid binding protein 2|Nabp2|Nil|Ssb1; Obfc2b, 2610036N15Rik|MGI:1917167|Nuceic Acid Binding Protein 2; targeted mutation 1.2; Kum Kum Khanna|Nabp2-tm1.2Kkha|MGI:5502335|10|||||||||||||||||||||||||||||Homozygous Nabp2-/- offspring die perinatally from respiratory distress at birth due to aberrant ossification of the ribcage. Nabp2-/- embryos also exhibit skeletal malformations of the craniofacial skeleton, limb outgrowth defects and oligodactyly of the hindlimb. |Heterozygotes are viable and fertile. |C57BL/6|No|No|Yes|No|No|Yes|No|Good|||Heterozygous X Heterzyous or Heterozygous x Wild-type|No|15-Jan-2015|Cryopreserved sperm|50.0|0.0|Unknown||SSB, DNA repair, Skeletal Development|Yes| 9053.0|R26-LSL-Adar1p110|C57BL/6-Gt(ROSA)26Sor/CwaApb ||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|C57BL/6-Gt(ROSA)26Sor/CwaApb|||6|||||||||||||||||Adenosine Deaminase RNA specific|R26 endogenous|Moderate to low||||||||||Normal - Lox-stop-lox KI of Adar1p110 into Rosa26 locus; requires Cre to express|Normal - Lox-stop-lox KI of Adar1p110 into Rosa26 locus; requires Cre to express|C57Bl/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown||Unknown|No|06-Aug-2020|Cryopreserved sperm|40.0|0.0|No||Adenosine Deaminase RNA specific, Stress, anti-apoptotic, p110|No| 7834.0|Il15 KO|B6(Cg)-IL15/AnuApb||Recessive|interleukin 15|Il15|Nil|IL-15|MGI:103014|targeted mutation 1, Immunex Research and Development Corporation|Il15|MGI:2136897|8||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions of this gene have normal life spans but display a variety of immune system abnormalities and maternal placental defects.These mutant mice lack NK cells and have marked reductions in memory CD8+ T cells, NK 1.1 T cells and Thy-CD8a intraepithelial lymphocytes. Mice are unable to mount a protective immune response to challenge with vaccinia virus.Abnormal immune system morphology.Abnormal dendritic cell morphology/development:* lower numbers of splenic dendritc cells after Plasmodium chabaudi infection.Abnormal lymphocyte morphology/development:* Intestinal intraepithelial lymphocytes maturing outside of the thymus greatly reduced in numbers.Abnormal CD8+ T cell morphology/development:* two fold reduction in numbers of CD8 single positive cells in spleen and lymph nodes.Abnormal NK cell morphology/development:* reduced numbers of natural killer cells in thymus liver and spleen.* absent in uterusSmall lymph nodes: peripheral lymph nodes significantly lower in weight.Abnormal immune system physiology:Defective NK cell cytolysis: significantly reduced cytolytic activityabnormal immune serum protein physiology.Decreased immunoglobulin concentration:* lower levels of malaria specific antibodies producedlower levels of total immune globulin.Decreased IgG level: decreased levels of IgG1, IgG2a, IgG2b, and IgG3 after Plasmodium infection.Decreased IgM level: after plasmodium infection.Abnormal cytokine physiology.Abnormal interferon physiology: reduced production of IFN gamma by NK cells.Abnormal interleukin physiology:* reduced Il12 production by dendritic cells after Plasmodium infection.Altered susceptibility to infection.Decreased susceptibility to bacterial infection.* Improved survival after infection with Listeria monocytogenesincreased susceptibility to parasitic infection.* parasitemia higher but only minor effect on mortalityincreased susceptibility to viral infection.* dead by day 9 after Vaccinia infection* very susceptible to HSV-2 infectionDecreased susceptibility to type IV hypersensitivity reaction: no contact hypersensitivity* T mediated effects delayed but not B cell activation or antibody production.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5||brother x sister mating|No|25-Jan-2015|Cryopreserved sperm|22.0|0.0|Unknown||T cell, infection, Natural killer cell, memory|Yes| 7833.0||C57BL/6-Klf5/Apb||Dominant|Kruppel-like factor 5|Klf5||4930520J07Rik, Bteb2, CKLF, IKLF|MGI:1338056||||14|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||No|23-Jan-2015|Cryopreserved sperm|80.0|0.0|No||signal transduction, proliferation|No| 7836.0|Louise:TCR:Ly5a::N12|C57BL/6JSfdAnu-Tg(TLK2mHEL)2Ccg TCR:Ly5a::N12 /AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 2, Christopher C Goodnow|rat thyroglobulin|expression limited to thyroid|Ly5a||||||||Unknown|Express low levels of membrane bound HEL in thyroid. Low serum levels of HEL detected.||C57BL/6JStdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5|sib x sib|No|25-Jan-2015|Cryopreserved sperm|22.0|0.0|Unknown||autoimmunity, B cell, tolerance, Hen egg lysozyme (HEL), T cell|Yes| 7836.0|Louise:TCR:Ly5a::N12|C57BL/6JSfdAnu-Tg(TLK2mHEL)2Ccg TCR:Ly5a::N12 /AnuApb||Dominant||||||||||||||||||||||||||tcr||||||||||||Express low levels of membrane bound HEL in thyroid. Low serum levels of HEL detected.||C57BL/6JStdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||5|sib x sib|No|25-Jan-2015|Cryopreserved sperm|||Unknown||autoimmunity, B cell, tolerance, Hen egg lysozyme (HEL), T cell|Yes| 7837.0|Vavbcl69|C57BL/6-Tg(Vav-BCL2)1Jad/WehiAnuApb||Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Jerry M Adams|mouse Vav promoter|Overexpression||||||||||Abnormal lymphocyte cell number:*The ratio of CD4 cells per B cell is 25% to 50% lower than in wild-type mice. Increased B cell number: *5-fold higher in the spleen at 18 weeks. Increased T cell number: *Mice exhibit higher splenic T cell numbers than in wild-type and Tg(BCL2)22Wehi or Tg(BCL2)36Wehi mice. Increased CD4-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells. Increased CD8-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells.Abnormal class switch recombination:*The total number of B cells that undergo class switching is 50-fold higher than in wild-type mice.Abnormal somatic hypermutation frequency:*22 of 23 clones isolated from class-switching cells harbor on average about 6 somatic mutations compared to in wild-type cells where no mutations are found.Enlarged spleenAbnormal spleen germinal center morphology:*Mice exhibit a larger pool of cycling B cells with a germinal center phenotype than in wild-type mice.*At 18 weeks, mice exhibit an increased in germinal center size and number compared to in wild-type mice.*However, expansion of germinal centers is dependent on CD4 T cell help. Increased spleen germinal center number: *At 18 weeks. Increased spleen germinal center size: *At 18 weeks.Enlarged lymph nodesGlomerulonephritis:*At 40 weeks, 15% to 25% of mice develop autoimmune glomerulonephritis.Increased tumor incidence:*12% of mice develop plasma cell tumors. Increased lymphoma incidence: *Less than 10% of mice develop lymphoblastic lymphomas. B cell derived lymphoma: *Less than 10% of mice develop large cell B lymphomas. Follicular lymphoma: *At 18 months, 37% to 50% of mice develop monoclonal follicular lymphoma. Increased histiocytic sarcoma incidence: *In less than 10% of mice. Thymic lymphoma: *In less than 10% of mice.Abnormal renal glomerular capsule:*Bowman epithelium proliferates to form crescents in the most advanced cases.Abnormal renal glomerulus morphology:*Mice develop hypercellular glomeruli that contain amorphous, eosinophilic deposits.*Most capillaries are no longer patent.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|66.0|0.0|Unknown||Bcl-2, Hematopoietic system|Yes| 7838.0||VavBcl2:CD11c-DTR:::F1||Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Jerry M Adams|mouse Vav promoter|Overexpression||||||||||Abnormal lymphocyte cell number:*The ratio of CD4 cells per B cell is 25% to 50% lower than in wild-type mice. Increased B cell number: *5-fold higher in the spleen at 18 weeks. Increased T cell number: *Mice exhibit higher splenic T cell numbers than in wild-type and Tg(BCL2)22Wehi or Tg(BCL2)36Wehi mice. Increased CD4-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells. Increased CD8-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells.Abnormal class switch recombination:*The total number of B cells that undergo class switching is 50-fold higher than in wild-type mice.Abnormal somatic hypermutation frequency:*22 of 23 clones isolated from class-switching cells harbor on average about 6 somatic mutations compared to in wild-type cells where no mutations are found.Enlarged spleenAbnormal spleen germinal center morphology:*Mice exhibit a larger pool of cycling B cells with a germinal center phenotype than in wild-type mice.*At 18 weeks, mice exhibit an increased in germinal center size and number compared to in wild-type mice.*However, expansion of germinal centers is dependent on CD4 T cell help. Increased spleen germinal center number: *At 18 weeks. Increased spleen germinal center size: *At 18 weeks.Enlarged lymph nodesGlomerulonephritis:*At 40 weeks, 15% to 25% of mice develop autoimmune glomerulonephritis.Increased tumor incidence:*12% of mice develop plasma cell tumors. Increased lymphoma incidence: *Less than 10% of mice develop lymphoblastic lymphomas. B cell derived lymphoma: *Less than 10% of mice develop large cell B lymphomas. Follicular lymphoma: *At 18 months, 37% to 50% of mice develop monoclonal follicular lymphoma. Increased histiocytic sarcoma incidence: *In less than 10% of mice. Thymic lymphoma: *In less than 10% of mice.Abnormal renal glomerular capsule:*Bowman epithelium proliferates to form crescents in the most advanced cases.Abnormal renal glomerulus morphology:*Mice develop hypercellular glomeruli that contain amorphous, eosinophilic deposits.*Most capillaries are no longer patent.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|33.0|0.0|Unknown||Bcl-2, Hematopoietic system|Yes| 7838.0||VavBcl2:CD11c-DTR:::F1||Semi-dominant||||||||||||||||||||||||||CD11c -DTR||||||||||||Abnormal lymphocyte cell number:*The ratio of CD4 cells per B cell is 25% to 50% lower than in wild-type mice. Increased B cell number: *5-fold higher in the spleen at 18 weeks. Increased T cell number: *Mice exhibit higher splenic T cell numbers than in wild-type and Tg(BCL2)22Wehi or Tg(BCL2)36Wehi mice. Increased CD4-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells. Increased CD8-positive T cell number: *The increase in CD4+ T cells is greater than the increase in CD8+ T cells.Abnormal class switch recombination:*The total number of B cells that undergo class switching is 50-fold higher than in wild-type mice.Abnormal somatic hypermutation frequency:*22 of 23 clones isolated from class-switching cells harbor on average about 6 somatic mutations compared to in wild-type cells where no mutations are found.Enlarged spleenAbnormal spleen germinal center morphology:*Mice exhibit a larger pool of cycling B cells with a germinal center phenotype than in wild-type mice.*At 18 weeks, mice exhibit an increased in germinal center size and number compared to in wild-type mice.*However, expansion of germinal centers is dependent on CD4 T cell help. Increased spleen germinal center number: *At 18 weeks. Increased spleen germinal center size: *At 18 weeks.Enlarged lymph nodesGlomerulonephritis:*At 40 weeks, 15% to 25% of mice develop autoimmune glomerulonephritis.Increased tumor incidence:*12% of mice develop plasma cell tumors. Increased lymphoma incidence: *Less than 10% of mice develop lymphoblastic lymphomas. B cell derived lymphoma: *Less than 10% of mice develop large cell B lymphomas. Follicular lymphoma: *At 18 months, 37% to 50% of mice develop monoclonal follicular lymphoma. Increased histiocytic sarcoma incidence: *In less than 10% of mice. Thymic lymphoma: *In less than 10% of mice.Abnormal renal glomerular capsule:*Bowman epithelium proliferates to form crescents in the most advanced cases.Abnormal renal glomerulus morphology:*Mice develop hypercellular glomeruli that contain amorphous, eosinophilic deposits.*Most capillaries are no longer patent.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|||Unknown||Bcl-2, Hematopoietic system|Yes| 7835.0|Foxp3-gfp:kk:TCR:N12|B6.B10.BR-H2 Foxp3 Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|targeted mutation 2, Alexander Y Rudensky|Foxp3|MGI:3574964|X||||||||||||||||No|transgene insertion 1, Mark M Davis|||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|Histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Normal. Cells expressing FoxP3 fluoresce green, predominantly T cells.T cell express T cell receptor alpha and beta (Tcra and Tcrb, respectively) chains from the hen egg lysozyme (HEL)-specific T cell hybridoma 3A9||129 x C57BL/6 x C57BL10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|23.0|0.0|Unknown||T cell, IL-2, GFP, transcription factor|Yes| 7828.0|TetO ET/TC, B6-tetO-ChR2/ETTC KI |B6.Cg-Actb ||Dominant|actin, beta|Actb||Actx, A-X actin-like protein, beta-actin, E430023M04Rik|MGI:87904||||5|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Jan-2015|Cryopreserved sperm|50.0|0.0|Unknown||Channelrhodopsin2, MCH neuron|Yes| 7842.0|Foxo1-flox|B6.129-Foxo1/AnuApb||Recessive|forkhead box O1|Foxo1|Normal|Afxh, FKHR, Fkhr1, Foxo1a|MGI:1890077|forkhead box O1; targeted mutation 1, Richard A Flavell|Foxo1|MGI:3840910|3|||||||||||||||||||||||||||||Normal||C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Feb-2015|Cryopreserved sperm|22.0|0.0|Unknown||T cell, transcription|Possibly| 7845.0|Foxp3-gfp:kk:N12|B6.B10.BR-H2 Foxp3/AnuApb||Recessive|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|targeted mutation 2, Alexander Y Rudensky|Foxp3|MGI:3574964|X||||||||||||||||No||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Normal. Cells expressing FoxP3 fluoresce green, predominantly T cells||129 x C57BL/6 x C57BL10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Feb-2015|Cryopreserved sperm|66.0|0.0|Unknown||T cell, IL-2, GFP, transcription factor|Yes| 7841.0|ENU32:G3|ANU:ENU32:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Feb-2015|Cryopreserved sperm|296.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7843.0|CD11c-DTR|B6.Cg-Tg(Itgax-DTR/EGFP)57Lan/AnuApb||Semi-dominant||||||||||||||||||||||||||transgene insertion 57, Richard A Lang|mouse Itgax promoter (CD11c)|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Feb-2015|Cryopreserved sperm|33.0|0.0|Unknown||Cytotoxic T lymphocytes (CTL) , Dentritic cells|Yes| 7844.0|gzmK ko|B6(Cg)-Gzmk Tg(CMV-Cre)/MarpApb||Recessive|Granzyme K|Gzmk|Reduced||MGI:1298232||||13|||||||||||||||||transgene insertion 1, University of Cologne||||||||||||unknown|unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Feb-2015|Cryopreserved sperm|77.0|0.0|Unknown|||Possibly| 4713.0|Rolex/C57|B6.129-Hccs/MarpApb||X-linked|holocytochrome c synthetase|Hccs|Unknown||MGI:106911|targeted mutation 1, Timothy C Cox|Hccs|MGI:3826866|X||||||||||||||||Yes|||||||||||||NormalHomozygous female or hemizygous males for a conditional allele activated in the heart exhibit fetal lethality associated with abnormal fetal cardiomyocyte morphology and physiology.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|100.0|0.0|Unknown||cardiac, midgestation, mitochondria|Yes| 4868.0|FxyC57|B6.129-Mid1/MarpApb||X-linked|midline 1|Mid1|Nil|61B3-R, DXHXS1141, Fxy, Trim18|MGI:1100537|midline 1; targeted mutation 1, Alan Ashworth|Mid1|MGI:5562687|X|||||||||||||||||||||||||||||Viable. Reduced / delayed fertility. Litter size may be slightly reduced. No other phenotype described as yet.Abnormal axon morphology:• axon length and branch number are increased in cultured cortical neurons• callosal axons grow further into the contralateral hemisphere at P4• at P14, axon distribution in the corpus callosum is disturbed with a greater number of axon terminals, with a wider distribution in both the S1 and S2 regions• broader distribution of the contralateral axon projection pattern in the corpus callosumEmbryogenesis phenotype:• no obvious midline defects, unlike in Opitz Syndrome patients|Breeder pairs often only litter down after 3 months together, if they litter down at all. Around 1 in 3 produce litters.|C57BL/6|Yes|Yes|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Sep-2009|Cryopreserved sperm|75.0|0.0|Yes|Opitz GBBB syndrome|X-linked, craniofacial, cleft lip|Yes| 7359.0|ENU23 15 NIP7|C57BL/6NCrlAnu-Nip7/AnuApb|C57BL/6NCrlAnu-Nip7/AnuApb|Recessive|nuclear import 7 homolog (S. cerevisiae)|NIP7|Unknown|1110017C15Rik, 6330509M23Rik |MGI:1913414|nuclear import 7 homolog (S. cerevisiae); mutation 1, The Australian National University|Nip7|MGI:5563445|8|ENSMUSG00000031917|ENSMUST00000034392|Nip7-201|134|192|A to G|ENSMUSE00000214640|2|45|Tyrosine to Cysteine|||||CTGTTTCCGGCTGCACAACGACCGAGTGTACTATGTGAGTGAGATGATGCTGAAGCTGGCC||||||||||||||Homozygous mutation appears lethal|Heterozygous mice appear normal and healthy|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Good|none|Generation 4|HET x HET|No|20-Jun-2013|Cryopreserved sperm|36.0|0.0|Unknown||lethal, embryo, ENU|Yes| 7851.0|ENU34:G1|ANU:ENU34:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|04-Mar-2015|Cryopreserved sperm|1963.0|41.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7852.0|ENU34:G2|ANU:ENU34:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|04-Mar-2015|Cryopreserved sperm|6300.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7856.0|ENU30:057|C57BL/6NCrlANu-Pik3ap1/AnuApb||Recessive|phosphoinositide-3-kinase adaptor protein 1|Pik3ap1|Unknown|1810044J04Rik, BCAP|MGI:1933177|mutation 1, Australian National University|Pik3ap1||19|ENSMUSG00000025017|ENSMUST00000059672|Pik3ap1-201|1094|1195|G to A|ENSMUSE00000147300|7|365|Alanine to Valine|||||GCTGCTCACCTGTCCAGGGGCTCTCCAGGCCTACAGTGTAGCCAACAAGCACGGCCACTAT||||||||||||||High IgM expression on mature B cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Mar-2015|Cryopreserved sperm|55.0|0.0|Unknown||B cell, IgM|Yes| 7853.0|Thunder|B6(Cg)-Bcl2l11 Hnrnpll/AnuApb|B6(Cg)-Bcl2l11 Hnrnpll/AnuApb|Recessive|heterogeneous nuclear ribonucleoprotein L-like|Hnrpll|Nil||MGI:1919942|heterogeneous nuclear ribonucleoprotein L-like; thunder|Hnrpll|MGI:3707008|17|ENSMUSG00000024095|ENSMUST00000061331|Hnrpll-201|407|683|T to A|ENSMUSE00000138333|2|136|Valine to Aspartic acid|||||TGTCCATGTTCGAGGGCTCTGTGAATCTGTTGTGGAAGCTGACCTTGTGGAGGCACTGGAG|Yes|||||||||||||Unknown||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|7||No|05-Mar-2015|Cryopreserved sperm|44.0|0.0|Unknown||T cell, B cell, lymphocyte, CD45, ENU, Bim|Yes| 7853.0|Thunder|B6(Cg)-Bcl2l11 Hnrnpll/AnuApb|B6(Cg)-Bcl2l11 Hnrnpll/AnuApb|Recessive|BCL2-like 11 (apoptosis facilitator)|Bcl2l11||1500006F24Rik, Bim, Bod|MGI:1197519|BCL2-like 11 (apoptosis facilitator); targeted mutation 1.1, Andreas Strasser|Bcl2l11|MGI:2156498|2|||||||||||||||||||||||||||||Unknown||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|7||No|05-Mar-2015|Cryopreserved sperm|||Unknown||T cell, B cell, lymphocyte, CD45, ENU, Bim|Yes| 8789.0||B6.Cg-Mcc/Ausb||Recessive|mutated in colorectal cancers|Mcc||D18Ertd451e|MGI:96930||||Unknown|||||||||||||||||||||||||||||Normal viability. MCC whole body knockout mice are expected to develop a DNA repair defect in the inflamed tissue after induction of chronic inflammation, such as colitis, that can lead to cancer development.|Normal viability. MCC whole body heterozygous mice may have an attenuated phenotype compared to homozygous mice.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Sep-2019|Cryopreserved sperm|50.0|0.0|Unknown||DNA damage, colorectal|Yes| 10407.0|Wheat|C57BL/6CrlAnu-5(Gbp8-Gbp4-Gbp9)em1Anu||Recessive|guanylate-binding protein 8|Gbp8|||MGI:1923324||||5|ENSMUSG00000034438||||||||||||||||||||||||||||Normal|Normal||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Mar-2024|Cryopreserved sperm|39.0|0.0|Unknown|||Possibly| 10407.0|Wheat|C57BL/6CrlAnu-5(Gbp8-Gbp4-Gbp9)em1Anu||Recessive|guanylate binding protein 4|Gbp4|||MGI:97072||||5|ENSMUSG00000079363||||||||||||||||||||||||||||Normal|Normal||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Mar-2024|Cryopreserved sperm|||Unknown|||Possibly| 10407.0|Wheat|C57BL/6CrlAnu-5(Gbp8-Gbp4-Gbp9)em1Anu||Recessive|guanylate-binding protein 9|Gbp9|||MGI:3605620||||5|ENSMUSG00000029298 ||||||||||||||||||||||||||||Normal|Normal||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|07-Mar-2024|Cryopreserved sperm|||Unknown|||Possibly| 5499.0|Twist-delBp|B6;129-Twist1/WchriApb||Semi-dominant|twist gene homolog 1 (Drosophila)|Twist1|Nil|charlie chaplin, M-Twist, pdt, Pluridigite, Skam10Jus, Ska10|MGI:98872|targeted mutation 1, Richard R Behringer|Twist1|MGI:1857265|12||||||||||||||||Yes|||||||||||||Homozygous mutant embyros have neural tube defects and die around E11.|Heterozygous mutants are viable and exhibit features of human Saethre-Chotzen syndrome, including hindlimb polydactyly, craniofacial defects, long bone abnormalities, an abnormal gait and a small size.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|1|||No|04-May-2011|Cryopreserved sperm|20.0|0.0|Yes||polydactyly, neural tube, mesenchyme, cranial, morphogenesis|Yes| 7859.0|ASD146:C57BL/6NTac:IL15 tm1imx:C57BL/6NCrl:N12|B6(Cg)-IL15/AnuApb||Recessive|interleukin 15|Il15|Nil|IL-15|MGI:103014|targeted mutation 1, Immunex Research and Development Corporation|Il15|MGI:2136897|8||||||||||||||||Yes|||||||||||||Mice homozygous for disruptions of this gene have normal life spans but display a variety of immune system abnormalities and maternal placental defects.These mutant mice lack NK cells and have marked reductions in memory CD8+ T cells, NK 1.1 T cells and Thy-CD8a intraepithelial lymphocytes. Mice are unable to mount a protective immune response to challenge with vaccinia virus.Abnormal immune system morphology.Abnormal dendritic cell morphology/development:* lower numbers of splenic dendritc cells after Plasmodium chabaudi infection.Abnormal lymphocyte morphology/development:* Intestinal intraepithelial lymphocytes maturing outside of the thymus greatly reduced in numbers.Abnormal CD8+ T cell morphology/development:* two fold reduction in numbers of CD8 single positive cells in spleen and lymph nodes.Abnormal NK cell morphology/development:* reduced numbers of natural killer cells in thymus liver and spleen.* absent in uterusSmall lymph nodes: peripheral lymph nodes significantly lower in weight.Abnormal immune system physiology:Defective NK cell cytolysis: significantly reduced cytolytic activityabnormal immune serum protein physiology.Decreased immunoglobulin concentration:* lower levels of malaria specific antibodies producedlower levels of total immune globulin.Decreased IgG level: decreased levels of IgG1, IgG2a, IgG2b, and IgG3 after Plasmodium infection.Decreased IgM level: after plasmodium infection.Abnormal cytokine physiology.Abnormal interferon physiology: reduced production of IFN gamma by NK cells.Abnormal interleukin physiology:* reduced Il12 production by dendritic cells after Plasmodium infection.Altered susceptibility to infection.Decreased susceptibility to bacterial infection.* Improved survival after infection with Listeria monocytogenesincreased susceptibility to parasitic infection.* parasitemia higher but only minor effect on mortalityincreased susceptibility to viral infection.* dead by day 9 after Vaccinia infection* very susceptible to HSV-2 infectionDecreased susceptibility to type IV hypersensitivity reaction: no contact hypersensitivity* T mediated effects delayed but not B cell activation or antibody production.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|12||brother x sister mating|No|17-Mar-2015|Cryopreserved sperm|48.0|0.0|Unknown||T cell, infection, Natural killer cell, memory|Yes| 7862.0|ENU26:034:Shroom3:B6:G3|C57BL/6NCrlAnu-Shroom3/AnuApb||Recessive|shroom family member 3|Shroom3|Unknown|D5Ertd287e, Shrm, Shrm3|MGI:1351655|Shroom3; mutation 1, Australian National University|Shroom3||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|25-Mar-2015|Cryopreserved sperm|88.0|0.0|Unknown||ENU, mutagenesis, screen, random|Yes| 7864.0|ENU18::B6|C57BL/6JAnu-Gsdmd/AnuApb||Recessive|gasdermin D|Gsdmd|Unknown|1810036L03Rik, DF5L, Dfna5l, Gsdmdc1, M2-4|MGI:1916396||||15||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|01-Apr-2015|Cryopreserved sperm|87.0|0.0|Unknown||ENU, random, mutagenesis, screen|Possibly| 7119.0|MNEI KO|B6.129S6-Serpinb1a/CbenMarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 1a|Serpinb1a|Nil|1190005M04Rik, EIA, ELANH2, LEI, MNEI, M/NEI, ovalbumin|MGI:1913472|serine (or cysteine) peptidase inhibitor, clade B, member 1a; targeted mutation 1, Charaf Benarafa|Serpinb1a|MGI:3761627|13|||||||||||||||||||||||||||||Normal.Increased susceptibility to infection with P. Aeruginosa. P. Aeruginosa infection results in abnormal neutrophil physiology, numbers in lungs.|Normal|C57B/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Oct-2012|Cryopreserved sperm|50.0|0.0|Unknown||neutrophil, infection, lung|Yes| 7393.0|B6.TLR4 0/0|B6.C3-Tlr4/Apb||Semi-dominant|||||||||||||||||||||||||||||toll-like receptor 4|Tlr4||lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; defective lipopolysaccharide response|Tlr4|MGI:1857718|4|The Lps-d allele renders the animals endotoxin-resistant. |unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Excellent|13|||Yes|06-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||LPS, endotoxin, TLR4|Yes| 1236.0|Pinky ; ENU8C:027|B6JSfdAnu;CBA(Cg)-Zbtb16/AnuApb|B6JSfdAnu;CBA(Cg)-Zbtb16/AnuApb|Recessive|zinc finger and BTB domain containing 16|Zbtb16|Unknown|Green's luxoid, PLZF, Zfp145|MGI:103222|pinky|Zbtb16|MGI:4462277|9|ENSMUSG00000066687|ENSMUST00000093852|Zbtb16-201|210|457|T to A|ENSMUSE00000584531|2|70|Tyrosine to STOP|||||ATCCTCTTCCACCGAAACAGCCAGCACTATACTCTAGACTTCCTCTCGCCAAAAACCTTCC|Yes|||||||||||||Limb deformity. Shortening and angular deformity of hindlimbs with extra digits present in some cases. Deformity affects mouse mobility. Previously described homozygous mutants exhibit abnormal anterior-posterior patterning, with skeletal abnormalities of the limb, especially the hindlimb, and homeotic transformations of anterior skeletal elements into posterior structures. Males develop infertility due to loss of germline cells with age.||C57Bl6JSfdAnu x CBA/HAnu|Yes|No|Yes|Yes|No|Yes|Yes|Good|1 to B6JSfdAnu, 1x CBH/CaJ|||No|15-Jun-2007|Cryopreserved sperm|175.0|0.0|Unknown||limb, deformity, extra digit, anterior-posterior patterning, ENU|Yes| 7867.0|tetO-ChR2(C128S), tetO-ChR2 BAC Tg, B6-tetO-ChR2/YFP Tg|B6(Cg)-Tg(tetO-ChR2*C128S/EYFP)1Kftnk||Dominant||||||||||||||||||||||||||Channelrhodopsin-2 (C128S)|E. coli Tetracycline operator, CMV minimal promotor, rabbit Beta globin intron |||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||over 20|hemizygous transgenic x non-transgenic (wild type) sibs|No|09-Apr-2015|Cryopreserved sperm|50.0|0.0|Unknown||tetO-system, light, channel|Yes| 7868.0||ENU18Flt3-ITD:G1||Recessive|FMS-like tyrosine kinase 3|Flt3||CD135, Flk2, Flk-2, Flt-3, wmfl|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5|||||||||||||||||||||||||||||Accelerated onset of AML compared to control FLT3-ITD mice.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|09-Apr-2015|Cryopreserved sperm|40.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Yes| 7868.0||ENU18Flt3-ITD:G1||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Accelerated onset of AML compared to control FLT3-ITD mice.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|09-Apr-2015|Cryopreserved sperm|||Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Yes| 8790.0|Slc1a5:Eif2ak4|C57BL/6NCrlAnu-Eif2ak4 Slc1a5/AnuApb||Recessive|eukaryotic translation initiation factor 2 alpha kinase 4|Eif2ak4|Unknown|GCN2|MGI:1353427|Eif2ak4; mutation 1, Australian National University|Eif2ak4||2||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|22.0|0.0|Unknown||ENU|Yes| 8790.0|Slc1a5:Eif2ak4|C57BL/6NCrlAnu-Eif2ak4 Slc1a5/AnuApb||Recessive|solute carrier family 1 (neutral amino acid transporter), member 5|Slc1a5|Unknown|ASCT2|MGI:105305|Slc1a5; mutation 1, Australian National University|Slc1a5||7||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|||Unknown||ENU|Yes| 7881.0|C57BL/6-Nabp-Floxed|C57BL/6J-Nabp2||Recessive|nucleic acid binding protein 2|Nabp2|Normal|2610036N15Rik, Nabp2, Obfc2b|MGI:1917167|nucleic acid binding protein 2; targeted mutation 1.1, Kum Kum Khanna|Nabp2|MGI:5502334|10|||||||||||||||||||||||||||||Viable and Fertile|Viable and Fertile|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Apr-2015|Cryopreserved sperm|50.0|0.0|Unknown||Single-stranded binding protein, DNA repair, DNA damage, Skeletogenesis|Possibly| 7882.0|C57BL/6-Nabp1-floxed|STOCK Nabp1/KkhaApb|STOCK Nabp1/KkhaApb|Recessive|nucleic acid binding protein 1|Nabp1|Normal|Nbp1, Obfc2a, Ssb2|MGI:1923258|nucleic acid binding protein 1; targeted mutation 1, Kum Kum Khanna|Nabp1|MGI:5644720|1||||||||||Unknown to Unknown|||||||||||||||||||Viable and Fertile|Viable and Fertile|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Apr-2015|Cryopreserved sperm|50.0|0.0|Unknown||Single-stranded binding protein, DNA repair, DNA damage|Possibly| 7883.0|C57BL/6-Nabp1-floxed strain 2|STOCK Nabp1/2KkhaApb||Recessive|nucleic acid binding protein 1|Nabp1|Normal|Nbp1, Obfc2a, Ssb2|MGI:1923258|targeted mutation 1, Kum Kum Khanna|Nabp||1|||||||||||||||||||||||||||||Viable and Fertile|Viable and Fertile|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Apr-2015|Cryopreserved sperm|50.0|0.0|Unknown||Single-stranded binding protein, DNA repair, DNA damage|Possibly| 7884.0|C57BL/6-Nabp1-KO strain 1|STOCK Nabp1/KkhaApb||Recessive|nucleic acid binding protein 1|Nabp1|Normal|Nbp1, Obfc2a, Ssb2|MGI:1923258|targeted mutation 1.1, Kum Kum Khanna|Nabp|MGI:5644800|1||||||||||Unknown to Unknown|||||||||||||||||||Viable and Fertile|Viable and Fertile|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozygous x homozygous|No|21-Apr-2015|Cryopreserved sperm|50.0|0.0|Unknown||Single-stranded binding protein, DNA repair, DNA damage|Possibly| 7872.0|Sppl2a KO2 conditional|B6.Cg-Sppl2a Tg(ACTFLPe)9205Dym/2MarpAnuApb||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2a|MGI:4887673|2|||||||||||||||||transgene insertion 9205, Susan Dymecki|ACTB, actin, beta, human|The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being 4X and 10X that of wildtype FLP at 37°C and 40°C, respectively||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2015|Cryopreserved sperm|33.0|0.0|Unknown||Conditional|Possibly| 7106.0|Nude|B6.B10.BR-Foxn1/WehiAnuApb||Recessive|forkhead box N1|Foxn1|Unknown|D11Bhm185e, Hfh11, whn|MGI:102949|nude|Foxn1|MGI:1856108|11||||||||||||||||Yes|||||||||||||Postnatal lethality:some mice die within 1 week of birth55% mortality within 2 weeksPremature death:100% mortality by 25 weeksDecreased body size and weight.Postnatal growth retardation.Abnormal T cell differentiation.Athymia.Abnormal cell-mediated immunity.Abnormal liver morphology:liver lobes were atrophied and covered with red scarsvariable degrees of severity, typically increasing with age at time of death.Small ovaryCoiled sperm flagellum: many sperm had coiled tailsAbnormal estrous cycle: many females exhibited continuous dioestrus and metaoestrus phasesFemale infertility: severely reduced fertilityReduced male fertility.Asthenozoospermia.Nude: sparse hair growth around 5 weeks of agein some mice, cephalo-caudal migration of an irregular band of short sparse hairThin skin:reduction in skin thickness at 3 weeks of age, corresponding to the catagen stage of normal skinAbsent vibrissae: absent at birthShort and wavy vibrissae: older mice show repeated growth and loss of short and wavy vibrissae.|Same as wild-type|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor|4|0|Male hom x female het if possible|No|16-Oct-2012|Cryopreserved sperm|36.0|0.0|Unknown||hair loss, T cell, thymus, body size / mass, growth retardation, alopecia, keratin|Yes| 5531.0|Woodrat|C57BL/6J-Mbtps1/BtlrAnuApb||Recessive|membrane-bound transcription factor peptidase, site 1|Mbtps1|Normal|0610038M03Rik; AV003995; site-1 protease, S1P; subtilisin/kexin isozyme-1, SKI-1; mKIAA0091; membrane-bound transcription factor protease, site 1|MGI:1927235|membrane-bound transcription factor peptidase, site 1; woodrat|Mbtps1|MGI:3652524|8|ENSMUSG00000031835|ENSMUST00000098362|Mbtps1-202|1487|2075|A to G|ENSMUSE00000319486|13|496|Tyrosine to Cysteine|||||TAGCTACATCGACCTGACTGAGTGTCCCTACATGTGGCCCTACTGCTCCCAGCCTATCTAC||||||||||||||The woodrat (wrt) phenotype was identified as a visible recessive variant among G3 mice homozygous for mutations induced by ENU. Homozygous woodrat mice exhibit coat hypopigmentation beginning on postnatal day 8, which progresses with time so that by 4 weeks of age wrt/wrt coats are composed of both white and black hairs, varying in pigment content along the length of each hair shaft. Adult wrt/wrt mice have a more homogeneous coat composed of hairs with a white base and a grey/brown tip|Compound heterozygosity for a null mutation (a gene trap allele) and the wrt allele (Mbtps1wrt/trap) results in embryonic lethality, while 53% and 54% of the expected numbers of Mbtps1+/trap or Mbtps1wrt/wrt mice, respectively, survive to term. Because a single copy of the gene (Mbtps1+/trap) is associated with diminished survival to term and causes no visible phenotype, while Mbtps1wrt/wrt is associated with about the same impairment of survival to term but does cause a visible phenotype, it is inferred that the wrt allele encodes a protein with ≤50% of wild type activity. In addition, it appears that the survival threshold likely falls between 25% and 50% of wild type enzyme activity levels.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|unknown|unknown||No|06-Jul-2011|Cryopreserved sperm|50.0|0.0|Unknown||ENU, colitis, endoplasmic reticulum|Possibly| 7684.0|Thunder|B6(Cg)-Hnrnpll/AnuApb|B6(Cg)-Hnrnpll/AnuApb|Recessive|heterogeneous nuclear ribonucleoprotein L-like|Hnrpll|Nil||MGI:1919942|heterogeneous nuclear ribonucleoprotein L-like; thunder|Hnrpll|MGI:3707008|17|ENSMUSG00000024095|ENSMUST00000061331|Hnrpll-201|407|683|T to A|ENSMUSE00000138333|2|136|Valine to Aspartic acid|||||TGTCCATGTTCGAGGGCTCTGTGAATCTGTTGTGGAAGCTGACCTTGTGGAGGCACTGGAG|Yes|||||||||||||Low T cell numbers which are hyperactivated. By flow cytometric staining of blood, initially detected a strain with CD4 T cells decreased to 25% of wild-type. Further analysis revealed entirely normal thymic development and single positive cells, but a marked reduction in the number of peripheral T cells especially naïve CD4 and CD8 cells, and poor survival of thunder T cells upon adoptive transfer. During this analysis, it was found that thunder thymocytes stain with the RA3-6B2 antibody that selectively recognizes the CD45RABC B220 isoform normally restricted to B cells. Staining with antibodies to CD45RA, B or C showed a 50-fold increase in staining on all thymocytes and peripheral T cells, as well as macrophages and dendritic cells, so that the staining intensity matched that on B cells. Amplification of cDNA with primers spanning CD45 exons 4-6 showed a dramatic increase in the inclusion of these exons in thymocyte CD45 mRNA, establishing that the thunder mutation interferes with the normal CD45 exon 4-6 silencing process.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|10|7||No|16-May-2014|Cryopreserved sperm|40.0|0.0|Unknown||T cell, B cell, lymphocyte, CD45, ENU, NIH|Yes| 8794.0|Tpbeta - Transgenic|C57BL/6-Tg(Tp beta)/Apb||Dominant||||||||||||||||||||||||||Tb beta||||||||||||Unknown|Unknown||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7702.0|Mot|B6.Cg-Rabl2a/MarpApb||Recessive|RAB, member of RAS oncogene family-like 2A|Rabl2a|||MGI:1915958|RAB, member of RAS oncogene family-like 2; mot|Rabl2|MGI:5469381|15|ENSMUSG00000022621|ENSMUST00000023294|Rabl2a-201|218|311|A to G|ENSMUSE00000128937|5|73|Aspartic acid to Glycine|||||CACAGTAGACGGCAAGACGATCCTTGTGGACTTCTGGGATACAGCAGGCCAGGAGCGGTTC|Yes|||||||||||||Male InfertilityDecreased testis weightOligozoospermiaShort sperm flagellumAsthenozoospermia:• low total motility and minimal progressive motility• however, ultrastructure is normal||C57BL/6|Yes|Yes|Yes|Yes|No|Yes|No|Poor|15|||No|13-Jun-2014|Cryopreserved sperm|50.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|No| 7562.0|Spi6 KO|C57BL/6J-SerpinB9/MarpApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9|Nil|ovalbumin, PI-9, Spi6|MGI:106603||||13|||||||||||||||||||||||||||||Increased apoptosis:• apoptosis is increased in LCMV- and LM-specific CTLs in mutantsAbnormal CD8-positive, alpha-beta cytotoxic T cell morphology:• upon infection with LCMV Armstrong or a strain of Listeria monocytogenes (LM), numbers of LCMV-specific CTLs are reduced 5-fold and LM-specific CTLs are reduced 9-fold compared to control B6 mice.• frequency of CTLs devoid of Gsmb granules is 3 times greater than in controls; number of Gzmb granules per CTL is 2-fold lower than in controls.Abnormal cytotoxic T cell physiology:• apoptosis is increased in LCMV- and LM-specific CTLs in mutants.Defective cytotoxic T cell cytolysis:• deficit in CTL activity is observed in ex vivo activity assay over course of LCMV infection; on day 10, activity is decrease 6-fold compared to controls.Abnormal enzyme/ coenzyme level:• caspase 3 in cytoplasm is increased.Abnormal enzyme/coenzyme activity:• GranzymeB activity is significantly increased in cytoplasm of mutants compared to controls.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|07-Jan-2014|Cryopreserved sperm|50.0|0.0|Unknown||T cell, CD8, dendritic cell, MHC I, cross-priming|Possibly| 4456.0||B6;C-Gstz1/AnuApb||Recessive|glutathione transferase zeta 1 (maleylacetoacetate isomerase)|Gstz1|Nil|maleylacetoacetate isomerase|MGI:1341859|targeted mutation 1, Philip G Board|Gstz1|MGI:3050206|12||||||||||||||||No|||||||||||||Increased sensitivity to induced Morbidity/Mortality * 3% phenylalanine in the water is lethal to young homozygotes, less than 28 days old, but not to older homozygotes, greater than 66 days oldpremature death * several mutants died after 1 year of age from heart pathologiesDystrophic cardiac calcinosis* in some mutants over 1 year of age Calcification of the myocardium in the right atrium and/or ventricle is seen* calcification is also seen in 3 of 8 young mutants that died after 3% phenylalanine exposurecellular necrosis* in some mutants over 1 year of age myocyte necrosis is seen* myocyte necrosis is also seen in 2 of 8 young mutants that died after 3% phenylalanine exposureDecreased leukocyte cell number* 3% phenylalanine in the water results in decreased total white cell counts in mutants but not in wild-type micedecreased spleen weight * spleen weight is significantly decreased in female homozygotes and tends to be decreased in male homozygotes compared to wild-type mice* 3% phenylalanine in the water results in a dramatic decrease in spleen weight in homozygotes with reduction in both white and red pulp, but an increase in spleen weight in wild-type micechronic inflammation* in some mutants over 1 year of age chronic inflammation is seen in the heartliver inflammation* at 6 weeks and 6 months of age multifocal hepatitis is seenLiver inflammation* at 6 weeks and 6 months of age multifocal hepatitis is seenAbnormal hepatocyte morphology* large pleomorphic mitochondria are seen in hepatocytes from mutantsIncreased liver weight* on a normal diet liver weight is greater in homozygotes compared to wild-type miceHepatic necrosis* at 6 months of age 3 of 7 homozygotes show hepatocyte necrosis* 3 out of 8 homozygotes that died after 3% phenylalanine exposure displayed hepatocyte necrosisHepatic steatosis * 5 out of 8 homozygotes that died after 3% phenylalanine exposure displayed macrovesicular steatosis||C57BL/6 x BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Feb-2009|Cryopreserved sperm|149.0|0.0|Unknown||GST, maleylacetoacetate, maleylacetone (MA) and succinylacetone, phenylalanine and tyrosine, Keap1/Nrf2 pathway, Oxidative stress|Yes| 10392.0|Wt/Rosa26:D3|C57Bl/6-Rosa26-delta(D3muc)/Apb||Semi-dominant|mucin 2|Muc2|||MGI:1339364 ||||7|ENSMUSG00000025515 ||||||||||||||||gene trap ROSA 26, Philippe Soriano||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Dec-2023|Cryopreserved sperm|22.0|0.0|Unknown|||No| 5450.0|WT1-GFP|C57BL/6-Wt1/MarpApb||Dominant|Wilms tumor 1 homolog|Wt1|Nil|Wt-1|MGI:98968|Wilms tumor 1 homolog; targeted mutation 1, Naoki Hosen|Wt1|MGI:3721102|11||||||||||||||||Yes|Green fluorescent protein|WT1|||||||||||Embryonic lethal. Fetuses day around E10 from heart defect.|Heterozygotes express green fluorescent protein wherever WT1 is expressed. Otherwise phenotype is normal|C57BL/6-CD45.2|No|No|Yes|No|No|Yes|No|Poor||||No|02-Mar-2011|Cryopreserved sperm|50.0|0.0|No||Wilms tumour, GFP, neural, urogenital, kidney|Yes| 7049.0|Sftpc-/- 129|129/Sv-Sftpc/MarpApb||Recessive|surfactant associated protein C|Sftpc|Nil|pro-SpC, Sftp2, Sftp-2, SP-C|MGI:109517|surfactant associated protein C; targeted mutation 1, Stephan W Glasser|Sftpc|MGI:2387813|14|||||||||||||||||||||||||||||The lungs of the SP-C (−/−) mice lack detectable mature SP-C or precursor SP-C (proSP-C). In the absence of detectable SP-C, these mice survive and grow normally with no adverse effects on health, reproduction, or pulmonary function. SP-B mRNA levels and the level of SP-A, SP-B, and SP-D proteins were unaltered in the alveolar lavage of SP-C (−/−) mice. Both SP-C and SP-B are hydrophobic peptides that dramatically enhance surface activity of surfactant phospholipids. The survival of the SP-C (−/−) mice in the absence of the mature active SP-C peptide indicates that SP-C is not required for the surface properties of the alveolar phospholipid films required for respiratory function in vivo. However, subtle abnormalities in lung mechanics and the instability of SP-C (−/−) surfactant at low bubble size support the importance of SP-C in surfactant function at low lung volumes such as that seen in respiratory distress syndrome in adults and preterm infants. The present findings in the SP-C (−/−) mice are distinct from results reported for SP-B gene-targeted mice and infants with hereditary SP-B deficiency, wherein severe respiratory failure occurs at birth (15, 19). In the SP-B (−/−) mice and human infants with hereditary SP-B deficiency, the mature form of SP-C was absent or diminished and an aberrant form of proSP-C was detected.|Normal|129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>20|||No|13-Aug-2012|Cryopreserved sperm|40.0|0.0|Yes|Interstitial Pneumonitis, Desquamative, Familial; DIP|lung, alveolar, surfactant, respiratory|Possibly| 7622.0|Shiraz KO ; SCN1B C121W|C57BL/6J-Scn1b/Apb||Dominant|sodium channel, voltage-gated, type I, beta|Scn1b|Normal||MGI:98247|sodium channel, voltage-gated, type I, beta; targeted mutation 1.1, Bionomics Limited|Scn1b|MGI:4829975|7|||||||||||||||||||||||||||||Seizures:• spontaneous and heat-inducedenvironmentally induced seizures.• when exposed to a stream of warm air, mice exhibit febrile seizures (including behavioral arrest, facial automatisms, and early epileptiform discharges localized to the hippocampus) unlike similarly treated wild-type mice• febrile seizures rapidly evolve into tonic-clonic seizures unlike in wild-type mice• mice exhibit febrile seizures at lower temperatures than wild-type miceTonic-clonic seizures:• febrile seizures rapidly evolve into tonic-clonic seizures unlike in wild-type miceAbnormal brain wave pattern.Postnatal growth retardation.Tremors: • severe|Environmentally induced seizures:• when exposed to a stream of warm air, mice exhibit febrile seizures (including behavioral arrest, facial automatisms, and early epileptiform discharges localized to the hippocampus) unlike similarly treated wild-type mice• mice exhibit febrile seizures at lower temperatures than wild-type miceAbnormal nervous system electrophysiology:• average burst duration in subicular pyramidal neurons is lengthened compared to in wild-type cells• neurons exhibit axonal hyperexcitability, increased spike gain, and increased burst firing compared with wild-type cells• however, total burst events and frequency of action potentials within bursts is normalAbnormal action potential:• the number of action potentials (APs) per bursts is increased compared to in wild-type mice• neurons begin firing APs at lower drive currents compared to in wild-type mice• the threshold for AP initiation is more negative than in wild-type cells• the amplitude of first APs is higher than in wild-type cells• the AP half-width is decreased compared to in wild-type cells• however, the frequency of action potentials within bursts is normal|C57BL/6J|Yes|No|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|24-Mar-2014|Cryopreserved sperm|50.0|0.0|Yes|Generalized Epilepsy with Febrile Seizures Plus, Type 1; GEFSP1|epilepsy, seizure, axon, sodium channel, di-sulphide|Yes| 7623.0|RQ/B6 ; GABRG2 R43Q|B6.129-Gabrg2/Apb||Dominant|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2|Gabrg2|Reduced||MGI:95623|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2; targeted mutation 1, Steven Petrou|Gabrg2|MGI:3764923|11|||||||||||||||||||||||||||||Partial perinatal lethality:• mice are rarely bornComplete postnatal lethality:• mice that are born die before P19Tremors:• mice that are born exhibit a severe tremorAbnormal gait:• mice that are born have altered gaitsAbnormal brain wave pattern:• mice lack normal brain rhythms|Mice heterozygous for the mutation demonstrated behavioral arrest associated with 6-to 7-Hz spike-and-wave discharges, which are blocked by ethosuximide, a first-line treatment for absence epilepsy in man. Seizures in the mouse showed an abrupt onset at around age 20 days corresponding to the childhood nature of this disease. Reduced cell surface expression of gamma2(R43Q) was seen in heterozygous mice in the absence of any change in alpha1 subunit surface expression|C57BL/6J|No|No|Yes|No|No|Yes|No|Unknown|8|||No|24-Mar-2014|Cryopreserved sperm|60.0|0.0|Yes|childhood absence epilepsy|Epilepsy, febrile, seizure, R43Q|Yes| 7518.0|HA-TetO (4)|C57BL/6-Tg(tetO-CYP19A1)4/MarpApb||Dominant||||||||||||||||||||||||||Human Aromatase ; human cytochrome P450, family 19, subfamily a, polypeptide 1|TetO|||||||||||None; no phenotype|None; no phenotype|C57BL/6J|No|Yes|Unknown|No|Yes|Unknown|No|Unknown||||No|29-Nov-2013|Cryopreserved sperm|50.0|0.0|Unknown||aromatase|Yes| 2783.0|C57BL/6.OCIL-KO|B6(Cg)-Clec2d/Apb|B6(Cg)-Clec2d/Apb|Recessive|C-type lectin domain family 2, member d|Clec2d|Unknown|Clr-b, Clrb, Ocil|MGI:2135589|targeted mutation 1.1, Matthew T Gillespie|Clec2d|MGI:3826396|6||||||||||||||||Yes|||||||||||||The mice show no overt phenotype. The bone phenotype (as analysed by bone histomorphometry) is mild "osteopenia" or a low bone mass due to a high bone turnover(caused by increased numbers of osteoclasts).|Not examined|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5|9|Hom x Hom|Yes|16-Feb-2008|Cryopreserved sperm|98.0|0.0|Unknown||c-type lectin, osteoclast, bone remodelling, natural killer cell|Yes| 5497.0|PAF|C57BL/6-Ptafr/Apb||Recessive|platelet-activating factor receptor|Ptafr||PAF receptor, PAFR|MGI:106066|platelet-activating factor receptor; targeted mutation 1, Takao Shimizu|Ptafr|MGI:3036770|4||||||||||||||||No|||||||||||||Normal.Increased susceptibility to type I hypersensitivity reaction: * homozygous mutants have a marked reduction in systemic anaphylactic symptoms when challenged with ovalbumin (OVA) * compared to controls, homozygous mice did not develop anaphylactic hypotension, anaphylactic tachycardia followed by bradycardia nor do they develop any anaphylaxis dependent changes in the lungs or suffer lethal affects in response to antigen challenge * homozygous mutants do respond normally to endotoxins and develop endotoixc shock at the same level as controls.Decreased inflammatory response: inflammatory response to S. venezuelensis worm infection is lower at 7 days after infection as indicated by lower numbers of eosinophils and globlet cells in tissue and diminished cytokine production, with a reduction in the production of Th2 cytokines (IL-4, IL-5, and IL-10) in the small intestine and by specific antigen-stimulated spleen or MLN cells.Increased susceptibility to parasitic infection: while the fecundity of the worm, Strongyloides venezuelensis, is decreased in mutant mice, overall elimination is delayed.||C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|04-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||anaphylaxis, sperm, endotoxin|Possibly| 7891.0|ENU19:Mapt:B6|C57BL/6JAnu-Mapt/AnuApb||Recessive|microtubule-associated protein tau|Mapt|Nil|Mtapt, Tau|MGI:97180|Mapt; mutation 1, Australian National University|Mapt||11||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6JAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|11-May-2015|Cryopreserved sperm|44.0|0.0|Unknown||Tau, neuronal|Yes| 7887.0||SJL-MRI156922||Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||none|Small red cells|SJL|No|No|Yes|No|No|Yes|No|Unknown||||No|30-Apr-2015|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 7888.0|Bim Knockout|B6.129-Bcl2l11/WehiAnuApb||Recessive|BCL2-like 11 (apoptosis facilitator)|Bcl2l11|Nil|1500006F24Rik, Bim, Bod|MGI:1197519|BCL2-like 11 (apoptosis facilitator); targeted mutation 1.1, Andreas Strasser|Bcl2l11|MGI:2156498|2||||||||||||||||Yes|||||||||||||Increased numbers of lymphoid and myeloid cells. Spleen and lymph nodes are 2-3-fold bigger than in wt. Sternum is sticking out. Bim-/- females are bad mothers and should not be used for breeding unless necessary. Bim -/-: blood - increased lymphocytes (B + T cells), granulocytes & monocytes. - decreased platelets - Increased serum Ig. Thymus - fewer pre T cells. Age 1 year - lymphadenopathy - 55% -/-, 35% +/- mice sick with kidney disease or cardiac infarction/vasculitis. Fewer -/- females born. When born, often have poorly formed reproductive organs. -/- have protruding sternum. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-May-2015|Cryopreserved sperm|92.0|0.0|Unknown||T cell, B cell, Lymphoid, Myeloid, Sternum|Yes| 7898.0|ENU22:Stat4|C57BL/6JAnu-Stat4/AnuApb||Recessive|signal transducer and activator of transcription 4|Stat4|||MGI:103062|Stat4; mutation 1, Australian National University|Stat4||1||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-May-2015|Cryopreserved sperm|54.0|0.0|Unknown||signal transduction, T cell, NK cell|Yes| 7900.0|L3mbtl1 KO|B6.129-L3mbtl1/Marp||Recessive|l(3)mbt-like (Drosophila)|L3mbtl1|Nil|L3MBTL1|MGI:2676663|l(3)mbt-like (Drosophila); targeted mutation 1.1, Hanno Hock|L3mbtl1|MGI:4840260|2|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-May-2015|Cryopreserved sperm|50.0|0.0|Unknown||methylation, brain|Yes| 7901.0|Cd19-cre|C57BL/6JAnu-Cd19/AnuApb||Recessive|CD19 antigen|Cd19|||MGI:88319|targeted mutation 1, University of Cologne|Cd19|MGI:1931143|7||||||||||||||||||||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Jun-2015|Cryopreserved sperm|44.0|0.0|Unknown||Cre recombinase, CD19|No| 7897.0|"p75-AD" mouse|129(Cg)-Ngfr Tg(APPSWE)2576Kha/Apb||Dominant|nerve growth factor receptor (TNFR superfamily, member 16)|Ngfr|Reduced|LNGFR, p75, p75 neurotrophin receptor, p75NGFR, p75NTR, Tnfrsf16|MGI:97323|nerve growth factor receptor (TNFR superfamily, member 16); targeted mutation 1, Rudolf Jaenisch|Ngfr|MGI:1857226|11|||||||||||||||||transgene insertion 2576, Karen Hsiao Ashe|Hamster Prion protein promoter|medium to high||||||||||Develop plaque in brain from 6-8 months of age. Cognitive performance is normal due to reduced p75 expression|Normal|129Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20 or more|20|p75 null homozygotes mated to APP transgenic heterozygotes|No|26-May-2015|Cryopreserved sperm|49.0|0.0|Yes|Alzheimers Disease|dementa, p75NTR, nerve growth factor|Possibly| 9381.0|ENU55:G2|ANU:ENU55:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|11-May-2022|Cryopreserved sperm|87.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7906.0|ENUProx1-GFP|ENUProx1-GFP||Recessive|||||||||||||||||||||||||||||||||||||||||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Jun-2015|Cryopreserved sperm|175.0|0.0|Unknown||Prox1-GFP, GFP, ENU|No| 7894.0|ENU32:047:Ikzf1|C57BL/6NCrlAnu-Ikzf1/AnuApb||Recessive|IKAROS family zinc finger 1|Ikzf1||5832432G11Rik, Ikaros, LyF-1, Zfpn1a1|MGI:1342540||||11|ENSMUSG00000018654|ENSMUST00000076700|Ikzf1-201|395|665|T to C|ENSMUSE00000330373|4|132|Leucine to Proline||||||Unknown|||||||||||||Low B cells in peripheral blood in HOM. |HETS may have a subtle phenotype of a small increase in CD44 MFI on CD4s|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|15-May-2015|Cryopreserved sperm|55.0|0.0|Unknown||ENU, B cell, CD44, T cell, CD4|Yes| 7908.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a normal phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|16-Jun-2015|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 7909.0||SJL/ASAM||Dominant|unknown|unknown|Reduced||||||Unknown|||||||||||||||||||||||||||||Unknown|The mice displays a normal phenotype.|SJL/J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|16-Jun-2015|Cryopreserved sperm|34.0|0.0|Unknown|||Yes| 7910.0|CAG-rtTA3|B6(Cg).129-Tg(CAG-rtTA3)#Slowe/Anu||Dominant||||||||||||||||||||||||||transgene insertion, Scott Lowe|cytomegalovirus (CMV) early enhancer element and chicken beta-actin||||||||||||Ubiquitous expression of Cre recombinase|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5|||No|18-Jun-2015|Cryopreserved sperm|54.0|0.0|Unknown||Cre recombinase|Yes| 7914.0|iCre Rictor fl|B6.129-Rictor Tg(UBC-cre/ERT2)1Ejb/Anu||Recessive|RPTOR independent companion of MTOR, complex 2|Rictor|Unknown|4921505C17Rik, 6030405M08Rik, D530039E11Rik|MGI:1926007|RPTOR independent companion of MTOR, complex 2; targeted mutation 1.1, Kun-Liang Guan|Rictor|MGI:5448837|15|||||||||||||||||transgene insertion 1, Eric J Brown|Human ubiquitin C (UBC) promoter|||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|18-Jun-2015|Cryopreserved sperm|107.0|0.0|Unknown||mTOR, inducible, Cre recombinase|Yes| 8797.0|Osteopontin null|B6.129S7-Spp1/Apb||Recessive|secreted phosphoprotein 1|Spp1||2ar, 44kDa bone phosphoprotein, Apl-1, BNSP, bone sialoprotein 1, ETA-1, minopontin, OP, Opn, Opnl, osteopontin, osteopontin-like protein, Ric, Spp-1|MGI:98389|secreted phosphoprotein 1; targeted mutation 1, Susan R Rittling|Spp1|MGI:1932084|5|||||||||||||||||||||||||||||Mortality/aging:N • homozygotes are viable, fertile and overtly normal with no significant differences in lactation, growth development, or organ and tissue histologyDecreased osteoclast cell number:• fewer osteoclasts accumulate at the site of an implanted bone disc compared to in similarly treated wild-type mice.Increased osteoclast cell number:• homozygotes exhibit a 3-fold increase in osteoclast number relative to wild-type mice; ovariectomy does not increase the number of osteoclasts significantly• in vitro, several-fold more osteoclasts are generated in co-culture systems with wild-type calvarial osteoblast cells by using spleen cells (3- to 13-fold) or bone marrow cells (~2- to 4-fold) from homozygous mutant mice compared with wild-type mice.Abnormal osteoclast physiology:• in contrast to wild-type mice, homozygotes are resistant to ovariectomy-induced bone resorption despite a comparable reduction in uterine weight (25-30%)• ovariectomized homozygotes exhibit a 12% reduction in trabecular bone volume in the absence of increased bone formation, whereas ovariectomized wild-type mice show a 58% reduction in trabecular bone volume along with a 73% increase in bone formation• bone resorption and osteoclast formation induced by PTH in cultured mouse calvariae are absent in calvariae from homozygous mutant miceDecreased interferon-gamma secretion:• following treatment with polyvinyl pyrrolidone, mice exhibit a 90% reduction in IL12 production compared with in similarly treated wild-type mice• splenocytes from L. monocytogenes infected mice produce less IFN-gamma when restimulated with heat-killed bacteria compared with similarly treated wild-type miceIncreased interleukin-10 secretion:• draining lymph node cells from HSV-1-infected mice produce increased IL10 compared with cells from similarly treated wild-type mice.Decreased interleukin-12 secretion:• following treatment with polyvinyl pyrrolidone, mice exhibit a 95% reduction in IL12 production compared with in similarly treated wild-type mice• draining lymph node cells and splenocytes from HSV-1-infected mice produce decreased IL12 compared with cells from similarly treated wild-type mice.Increased interleukin-4 secretion:• draining lymph node cells from HSV-1-infected mice produce increased IL4 compared with cells from similarly treated wild-type mice.Abnormal inflammatory response:• mice treated with polyvinyl pyrrolidone fail to exhibit a granulomatous response unlike similarly treated wild-type miceDecreased susceptibility to type IV hypersensitivity reaction:• mice infected with HSV-1 do not display a tuberculin-type delayed-type hypersensitivity when challenged with HSV-1 unlike similarly treated wild-type miceAbnormal response to infection:• clearance of Listeria monocytogenes is defective compared to in similarly treated wild-type mice• splenocytes from L. monocytogenes infected mice produce less IFN-gamma when restimulated with heat-killed bacteria compared with similarly treated wild-type miceDecreased susceptibility to viral infection:• mice infected with HSV-1 do not display a tuberculin-type delayed-type hypersensitivity when challenged with HSV-1 unlike similarly treated wild-type mice• corneal HSV-1 infection fails to trigger herpes simplex keratitis unlike in similarly treated wild-type mice|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Oct-2019|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 7913.0|iCre|B6.129-Tg(UBC-cre/ERT2)1Ejb/Anu||Dominant||||||||||||||||||||||||||transgene insertion 1, Eric J Brown|human ubiquitin C (UBC) promoter||||||||||||Mice display tamoxifen-inducible Cre activity in all tissue types. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Jun-2015|Cryopreserved sperm|55.0|0.0|Unknown||Cre recombinase, inducible, tamoxifen|Yes| 7904.0|Astn2 KO|C57BL/6-Astn2/Marp|MGI:5636645|Recessive|Astrotactin 2|Astn2|Nil|1d8, Astnl|MGI:1889277|Astrotactin 2, endonuclease mutation 1, Phillip I Bird|Astn2|MGI:5636645|4||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||||No|12-Jun-2015|Cryopreserved sperm|50.0|0.0|Unknown||Astrotactin, membrane attack complex / perforin domain, MACPF|Possibly| 7917.0|Vav-cre|C57BL/6-Tg(Vav1-Cre)1Awr/WehiAnu||Dominant||||||||||||||||||||||||||transgene insertion 1, Andrew W Roberts|Vav1|Haemopoietic||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Jun-2015|Cryopreserved sperm|75.0|0.0|Unknown||Cre recombinase|Yes| 7918.0|Mb1-cre|B6.C-Cd79a/Anu||Dominant|CD79A antigen (immunoglobulin-associated alpha)|Cd79a||Cd79a, Iga, Igalpha, Ig alpha, Ig-alpha, Ly54, Ly-54, mb-1|MGI:101774|CD79A antigen (immunoglobulin-associated alpha); targeted mutation 1, Michael Reth|Cd79a|MGI:3687451|7||||||||||||||||||||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|154.0|0.0|Unknown||B cell, Cre recombinase|Yes| 7919.0|Ubf fl|STOCK Ubtf/Anu||Recessive|upstream binding transcription factor, RNA polymerase I|Ubtf||A930005G04Rik, Tcfubf, UBF, UBF1|MGI:98512|upstream binding transcription factor, RNA polymerase I; targeted mutation 1.1, Tom Moss|Ubtf|MGI:5708602|11||||||||||Unknown to Unknown|||||||||||||||||||Normal|||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|66.0|0.0|Unknown||RNA polymerase, rRNA|Yes| 7921.0|Pad4 KO|B6.Cg-Padi4/KmowAnu||Recessive|peptidyl arginine deiminase, type IV|Padi4|Nil|Pad4, PAD type IV, Pdi4|MGI:1338898|peptidyl arginine deiminase, type IV; targeted mutation 1.1, Kerri A Mowen|Padi4|MGI:5285854|4|||||||||||||||||||||||||||||Abnormal neutrophil physiology:• neutrophils lack histone deimination unlike wild-type cellsdecreased susceptibility to viral infection• influenza-infected mice exhibit decreased weight loss compared with similarly treated wild-type mice• however, influenza-infected mice exhibit normal survival, neutrophil recruitment into the lung, lung viral titers, and pro-inflammatory cytokine levelsDecreased susceptibility to weight loss:• influenza-infected mice exhibit decreased weight loss compared with similarly treated wild-type mice||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|55.0|0.0|Unknown||Infection, neutrophil, extracellular traps|Yes| 7915.0|TiF1a fl|B6.129-Rrn3/Anuapb||Recessive|RRN3 RNA polymerase I transcription factor homolog (yeast)|Rrn3||E130302O19Rik, TIF-1A|MGI:1925255|RRN3 RNA polymerase I transcription factor homolog (yeast); targeted mutation 1.1, Ingrid Grummt|Rrn3|MGI:3584035|16|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|11|||No|18-Jun-2015|Cryopreserved sperm|105.0|0.0|Unknown||rRNA, p53, cell cycle|Yes| 7920.0|VCE ER/Stop YFP:VAV-CreER|C57BL/-Tg(Vav1-cre/ERT)1Wehi/WehiAnu||Dominant||||||||||||||||||||||||||Vav1-cre/ERT|||||||||||||Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|109.0|0.0|Unknown||Cre recombinase, inducible, tamoxifen|Yes| 7923.0|RORgt|B6.129-Rorc/WehiAnu||Dominant|RAR-related orphan receptor gamma|Rorc||RORgamma, Thor, thymus orphan receptor|MGI:104856|RAR-related orphan receptor gamma; targeted mutation 2, Dan R Littman|Rorc|MGI:3026635|3|||||||||||||||||||||||||||||Increased thymocyte apoptosis:• isolated thymocytes undergo apoptosis in culture within 2-3 hours compared to controls that survive for more than 5 hoursdecreased double-negative T cell number• numbers of intestinal alpha beta T cells including CD4-CD8- cells are significantly reducedDecreased double-positive T cell number:• fewer double-positive T cells (30-50% that of wild-type)decreased NK cell number• the percentage and absolute numbers of the Ncr(NKp46)+CD127+NK1.1- subset of intestinal natural killer cells is strongly decreased compared to controls• however, the number of NK1.1+ subset of intestinal natural killer cells is normalAbnormal CD4-positive, alpha-beta intraepithelial T cell morphology:• numbers of intestinal alpha beta T cells including CD4+ cells are significantly reducedAbnormal CD8 positive, alpha-beta intraepithelial T cell morphology:• numbers of intestinal alpha beta T cells including CD8alpha-beta+ and CD8alpha-alpha+ cells are significantly reducedAbnormal gut-associated lymphoid tissue morphology• absence of lymphoid tissue inducer (LTi) cells• intestinal cryptopatches and isolated lymphoid follicles are absentAbsent Peyer's patchesAbsent lymph nodes:• mice lack all lymph nodesAbnormal lymph organ development:• absence of lymphoid tissue inducer (LTi) cells||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|30.0|0.0|Unknown||Lymph node, Peyer's patches|Yes| 7925.0|Il22-DY|C57BL/6NTac-Tg(Il22-DY)01Stsc/Anu||Recessive|interleukin 22|Il22||IL-22, Iltif, IL-TIF|MGI:1355307||||10|||||||||||||||||||||||||||||Reporter for IL22 cytokine expression, no pathological phenotype||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|21.0|0.0|Unknown||Cytokine|Yes| 7926.0|2A10gHC|C57BL/6-Tg(IgH2A10)1Anu/Anu||Dominant||||||||||||||||||||||||||2A10||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|46.0|0.0|Unknown||Infection|Yes| 7930.0|A23.Foxp3-DTR|BALB/c(Cg)-Foxp3 Tg(TcraA23,TcrbA23)#Ird/IrdApb||Dominant|forkhead box P3|Foxp3||JM2, scurfin|MGI:1891436|forkhead box P3; targeted mutation 3, Alexander Y Rudensky|Foxp3|MGI:3698131|X|||||||||||||||||A23 T cell reeptor|T cell receptor|||||||||||Restricted T cell receptor usage due to TCR transgene. |As above|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jun-2015|Cryopreserved sperm|50.0|0.0|Unknown||autoimmune gastritis, autoimmune disease, T cell receptor, Treg cells, regulatory T cell|Possibly| 7927.0|Mdm2 S6 Mx1-Cre |B6(Cg).129(Cg)-Mdm2 Rps6 Tg(Mx1-Cre)1Cgn/JAnu||Recessive|transformed mouse 3T3 cell double minute 2|Mdm2||1700007J15Rik, Mdm-2|MGI:96952|transformed mouse 3T3 cell double minute 2; targeted mutation 1.1, Yangping Zhang|Mdm2|MGI:4836988|10|||||||||||||||||transgene insertion 1, University of Cologne|Mx1|||||||||||Unknown||C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|54.0|0.0|Unknown|||Yes| 7927.0|Mdm2 S6 Mx1-Cre |B6(Cg).129(Cg)-Mdm2 Rps6 Tg(Mx1-Cre)1Cgn/JAnu||Recessive|ribosomal protein S6|Rps6|Normal|S6R|MGI:98159|ribosomal protein S6; targeted mutation 1, George Thomas|Rps6|MGI:2387471|4|||||||||||||||||||||||||||||Unknown||C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Jun-2015|Cryopreserved sperm|||Unknown|||Yes| 7929.0|A23.IEβ|BALB/c-Tg(H2-Ea-Atp4b) Tg(TcraA23,TcrbA23)#Ird/Ird||Dominant||||||||||||||||||||||||||H⁺/K⁺ ATPase β subunit ; ATPase, H+/K+ exchanging, beta polypeptide|MHC I-E|||||||||||Restricted T cell receptor usage due to TCR transgene. Resistant to autoimmune gastritis|As above|BALB/c|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|22-Jun-2015|Cryopreserved sperm|50.0|0.0|Unknown||autoimmune gastritis, autoimmune disease, T cell receptor, Thymus|Possibly| 7929.0|A23.IEβ|BALB/c-Tg(H2-Ea-Atp4b) Tg(TcraA23,TcrbA23)#Ird/Ird||Dominant||||||||||||||||||||||||||A23 T cell reeptor|T cell receptor|||||||||||Restricted T cell receptor usage due to TCR transgene. Resistant to autoimmune gastritis|As above|BALB/c|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|22-Jun-2015|Cryopreserved sperm|||Unknown||autoimmune gastritis, autoimmune disease, T cell receptor, Thymus|Possibly| 7933.0|Solox Med |B6.CBA-Ifnar2 Tg(sIfnar2)1Pjh/Marp||Recessive|interferon (alpha and beta) receptor 2 |Ifnar2|Nil|Ifnar-2 |MGI:1098243|interferon (alpha and beta) receptor 2; targeted mutation 1, Paul J Hertzog|Ifnar2|MGI:2680693|16|||||||||||||||||soluble type I interferon (alpha and beta) receptor 2a overexpressing|Endogenous|Medium||||||||||Normal|Normal|B6/CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|24-Jun-2015|Cryopreserved sperm|50.0|0.0|Unknown||soluble, cytokine, interferon|Possibly| 7935.0|ENU26:037:Pkhd1:B6:|C57BL/6NCrlAnu-Pkhd1/AnuApb||Recessive|polycystic kidney and hepatic disease 1|Pkhd1|Unknown|FPC, tigmin|MGI:2155808|Pkhd1; mutation 1, Australian National University|Pkhd1||1|ENSMUSG00000043760|ENSMUST00000088448|Pkhd1-001|823|1059|A to T|ENSMUSE00000630693|38|275|Isoleucine to Phenylalanine|||||AAGTTGGGAGCCTTGGGGGAAGAACGGACATCATCATTACGGGAGATTTCTTTGACCCTTC||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|44.0|0.0|Unknown||ENU, mutagenesis, screen, random|Possibly| 7936.0|ENU18:Recql4::B6|C57BL/6JAnu-Recql4/AnuApb||Recessive|RecQ protein-like 4|Recql4|Unknown||MGI:1931028|Recql4; mutation 1, Australian National University|Recql4||15|ENSMUSG00000033762|ENSMUST00000036852|Recql4-201|1039|1122|G to A|ENSMUSE00000237138|5|347|Arginine to STOP|||||CAGCTTCCCTAGACAGAGGGAACTATATTCGACTCAACATGAAAAACAAACGCTTTGTACG|Unknown|||||||||||||Unknown|Unknown|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|44.0|0.0|Unknown||ENU, random, mutagenesis, screen|Possibly| 7938.0|ENU31:016 B6|C57BL/6NCrlAnu-Gfi1/AnuApb||Recessive|growth factor independent 1|Gfi1|Unknown|Gfi-1, Pal1, Pal-1|MGI:103170||||5|ENSMUSG00000029275|ENSMUST00000065478|Gfi1-201||||||||107723722|2|||GGAGACCGTGCCTGCGCCGGGCAGAGCAGGTGCGAAGCGCGCAGAGGCCGGGTAGGGCAG||||||||||||||Activated CD8 T cells in blood.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|43.0|0.0|Unknown||T cell, CD8, ENU|Yes| 7939.0|ENU31:104:Mll2:b6|C57BL/6NCrlAnu-Kmt2d/AnuApb||Recessive|lysine (K)-specific methyltransferase 2D|Kmt2d|Unknown|C430014K11Rik, Mll2, Mll4|MGI:2682319||||15|ENSMUSG00000048154|ENSMUST00000023741|Kmt2d-001|16445|16673|A to T|ENSMUSE00000268270|52|5482|Isoleucine to Asparagine|||||||||||||||||||Embryonic Lethal|Normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|55.0|0.0|Unknown||ENU, embryonic lethal|Yes| 7931.0|B6.SJL|B6.SJL-Ptprc/AnuApb||Recessive|||||||||||||||||||||||||||||protein tyrosine phosphatase receptor type C|Ptprc |||MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1|T cells express the Ptprc allele instead of Ptprc allele usually carried by Lymphocytes isolated from C57BL/6 mice.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jun-2015|Cryopreserved sperm|21.0|0.0|Unknown||Ly5a|Yes| 7941.0|Kaos|B6.Cg-Lrguk/MarpApb||Recessive|leucine-rich repeats and guanylate kinase domain containing|Lrguk|Unknown||MGI:1921604||||6|ENSMUSG00000056215|ENSMUST00000070189|Lrguk-001|1582|1591|C to T|ENSMUSE00000459708|14|528|Arginine to STOP|||||GAAGTTTGAAATATTCTTATTTTGAGCCTCGATATATCTTGGTGGTGCCTATGGACAAGGA|Yes|||||||||||||Male infertility. ||C57BL/6J|Yes|Yes|Yes|Yes|No|Yes|No|Poor|13|||No|26-Jun-2015|Cryopreserved sperm|50.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|Yes| 7934.0|ENU27:005:Cfh:B6|C57BL/6NCrlAnu-Cfh/AnuApb||Recessive|complement component factor h|Cfh|Unknown|Mud-1, Sas1, Sas-1|MGI:88385|Cfh; mutation 1, Australian National University|Cfh||1|ENSMUSG00000026365|ENSMUST00000111976|Cfh-201|3538|3673|A to G|ENSMUSE00001040918|21|1180|Tryptophan to Arginine|||||AGAAGACAATAACATGTAGAAATGGAAAGTGGTCTGAGCCACCAACATGCTTACATGCATG|Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|26-Jun-2015|Cryopreserved sperm|55.0|0.0|Unknown||ENU, random, mutagenesis, screen|Possibly| 7942.0|ENU33:G3|ANU:ENU33:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|02-Jul-2015|Cryopreserved sperm|111.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7943.0|HNT Thy1.1|BALB/c-Thy1 Tg(Tcra,Tcrb)1Mcd/Wehi||Recessive||||||||||||||||||||||||||transgene insertion 1, Hugh O McDevitt|||thymus cell antigen 1, theta|Thy1||CD90, T25, theta, Thy-1, Thy1.1, Thy 1.2, Thy-1.2, Thy1.2|MGI:98747|thymus cell antigen 1, theta; a variant|Thy1|MGI:3579311|9|HNT-TCR mice express an I-A-restricted TCR specific for the HA peptide 126–138 (HNTngvtaacshe). TCR transgenics immunocompromised by having mono-specific TCR however in a clean environment mice do not show a phenotype different to B6.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jul-2015|Cryopreserved sperm|33.0|0.0|Unknown||T cell, receptor (TCR), selection, tolerance, haemaglutanin|Yes| 4768.0|C57BL/6J.i-D|C57BL/6;129P2-H2-D1/AnuApb||Recessive|histocompatibility 2, D region locus 1|H2-D1|Nil|H2-D1|MGI:95896|targeted mutation 1, Beatrice Perarnau|H2-D1|MGI:1931445|17||||||||||||||||Yes|||||||||||||Mice lack H-2D molecule and are deficient in antigen presentation to CD8<+> T cells||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|2|sib x sib|No|06-May-2009|Cryopreserved sperm|90.0|0.0|No||T cell, CD8, presentation, Major histocompatibility complex (MHC)|Yes| 7944.0|Db -/-|B6.129P2-H2-D1/AnuApb||Recessive|histocompatibility 2, D region locus 1|H2-D1|Nil|H-2D|MGI:95896|histocompatibility 2, D region locus 1; targeted mutation 1, Beatrice Perarnau|H2-D1|MGI:1931445|17|||||||||||||||||||||||||||||||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jul-2015|Cryopreserved sperm|22.0|0.0|Unknown||H2|Yes| 7956.0|TetO ArchT, B6-tetO-ArchT/GFP Tg |C57BL/6-Tg(tetO-ArchT/EGFP)1Ahky ||Dominant||||||||||||||||||||||||||Archaerhodopsin-T (Halorubrum strain TP009) |E. coli Tetracycline operator, CMV minimal promotor, rabbit Beta globin intron |||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||over 20|hemizygous transgenic x non-transgenic (wild type) sibs|No|27-Jul-2015|Cryopreserved sperm|49.0|0.0|Unknown||tetO-system, light, Archaerhodopsin|Yes| 7946.0|ENU35:G1|ANU:ENU35:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|21-Jul-2015|Cryopreserved sperm|2367.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7948.0|ENU35:G2|ANU:ENU35:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|23-Jul-2015|Cryopreserved sperm|2996.0|30.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7949.0|ENU36:G1|ANU:ENU36:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|23-Jul-2015|Cryopreserved sperm|2646.0|22.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7950.0|ENU36:G2|ANU:ENU36:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|23-Jul-2015|Cryopreserved sperm|2550.0|42.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7776.0|TnI.2; cTnIwt.2|C57BL/6-Tg(Myh6-TNNI3*wt)2Chs||Dominant||||||||||||||||||||||||||transgene insertion wild type 1, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|50% of endogenous (hemizygous)||||||||||Unknown|Indistinguishable from non-transgenic wild type C57BL/6 mice |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||over 20|hemizygous transgenic x non-transgenic (wild type) sibs|No|29-Oct-2014|Cryopreserved sperm|50.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 7895.0|HOM.bm1.407|B6-H2-K Tg(RIP1-Bcl2)407Wehi/J|WEHI|Dominant|histocompatibility 2, K region|H2-K|Unknown||MGI:3040519|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17|||||||||||||||||human BCL2|rat insulin promoter|islet b cells||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Brother x sister and C57BL/6 x Positive|No|18-May-2015|Cryopreserved sperm|50.0|0.0|Unknown||pancreas, Bcl2, islet|No| 7782.0|203.4sv ; cTnI-G203S.4sv|129SvEv.B6-Tg(Myh6-TNNI3*G203S)4Chs/Apb||Dominant||||||||||||||||||||||||||transgene insertion 4, Christopher Semsarian|cardiac specific mouse αMHC promoter (alpha myosin heavy chain)|83% of endogenous||||||||||Unknown|Mice develop cardiac phenotype - hypertrophic cardiomyopathy by 21 weeks of age. Left ventricular hypertrophy was observed on echocardiography, it was associated with a significant 4-fold increase in RNA markers of hypertrophy, ANF and BNP. Myocyte hypertrophy, myofiber disarray and interstitial fibrosis were observed. |129SvEv|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|10|4|Transgenic x non-transgenic sibs|No|11-Nov-2014|Cryopreserved sperm|40.0|0.0|Yes|Hypertrophic cardiomyopathy (HCM) is a primary disorder of the myocardium characterized by cardiac hypertrophy. The clinical course of HCM is variable, with inter- and intra-familial variations ranging from benign asymptomatic disease to a malignant phenotype with a high risk of cardiac failure or sudden cardiac death.|Hypertrophy, Cardiomyopathy, Calcium, Troponin I gene|Yes| 7952.0|ENU30:065:Ddhd2:B6|C57BL/6NCrlAnu-Ddh2/AnuApb||Recessive|DDHD domain containing 2|Ddhd2||2010305K11Rik, SAMWD1|MGI:1919358|Ddh2; mutation 2, Australian National University|Ddh2||8|ENSMUSG00000061313|ENSMUST00000033975|Ddhd2-201|1685|1786|A to T|ENSMUSE00000637587|15|562|Leucine to STOP|||||ACACCATAAAGGCAGGAAGCGGATGCACTTAGAACTGAGAGAGGGCTTGACCAGGATGAGT||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Jul-2015|Cryopreserved sperm|44.0|0.0|Unknown||ENU|Yes| 7953.0|ENU29:030:Polr3b:B6|C57BL/6NCrlAnu-Polr3b/AnuApb||Recessive|polymerase (RNA) III (DNA directed) polypeptide B|Polr3b||2700078H01Rik, A330032P03Rik, RPC2|MGI:1917678|Polr3b; mutation 1, Australian National University|Polr3b||10|ENSMUSG00000034453|ENSMUST00000077175|Polr3b-201|3365|3395|T to A|ENSMUSE00000514755|28|1122|Isoleucine to Asparagine|||||GCTCTTCCAGGAGTTACAGTCCATGAACATCATCCCCAGGCTGAAACTGGCCAAGTACAAC||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Jul-2015|Cryopreserved sperm|48.0|0.0|Unknown||ENU|Yes| 7954.0|ENU30:078:Polr3b:B6|C57BL/6NCrlAnu-Polr3b/AnuApb||Recessive|polymerase (RNA) III (DNA directed) polypeptide B|Polr3b||2700078H01Rik, A330032P03Rik, RPC2|MGI:1917678|Polr3b; mutation 2, Australian National University|Polr3b||10|ENSMUSG00000034453|ENSMUST00000077175|Polr3b-201|283|313|A to T|ENSMUSE00000292314|5|95|Arginine to STOP|||||CTGATGTTGAAGAAAGCTTCAATGTAACTAGACCAGTGTCCCCTCATGAGTGCCGTCTGAG||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Jul-2015|Cryopreserved sperm|55.0|0.0|Unknown||ENU|Yes| 7951.0|ENU30:033:Ddhd2:B6|C57BL/6NCrlAnu-Ddh2/AnuApb||Recessive|DDHD domain containing 2|Ddhd2||2010305K11Rik, SAMWD1|MGI:1919358|Ddh2; mutation 1, Australian National University|Ddh2||8|ENSMUSG00000061313|ENSMUST00000033975|Ddhd2-201|1499|1600|A to T|ENSMUSE00000637598|8|500|Methionine to Lysine|||||CTTCTTTGCCTTTGGCTCCCCCATCGGAATGTTTCTTACTGTCCGAGGGTTGAGAAGAATT||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||G4, G5|Het x Het|No|27-Jul-2015|Cryopreserved sperm|78.0|0.0|Unknown||ENU|Yes| 7306.0|RIP-OVAhi|C57BL/6-Tg(Ins2-OVA)Wehi/WehiApb||Dominant||||||||||||||||||||||||||transgene insertion, Walter and Eliza Hall Institute of Medical Research|rat Ins2rat insulin 2|estimate 1ug/mg of pancreatic islet tissue||||||||||Normal. Mice express OVA in the pancreas beta cells. Protein can be detected by immunohistology.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||>30|brother-sister or Tg x C57BL/6|No|05-Apr-2013|Cryopreserved sperm|50.0|0.0|No||pancreas, autoimmunity, ovalbumin|Yes| 7960.0|DC-SIGN|B6-Tg(Itgax-DC-SIGN)Litt/LittAnu||Dominant||||||||||||||||||||||||||DC-SIGN|CD11c; Itgax|||||||||||Decreased Pathology and Prolonged Survival of Human DC-SIGN Transgenic Mice during Mycobacterial Infection||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Aug-2015|Cryopreserved sperm|115.0|0.0|Unknown||infection|Yes| 7675.0|ENU27:034:DZIP3:B6:G4|C57BL/6NCrlAnu-Dzip3/AnuApb|C57BL/6NCrlAnu-Dzip3/AnuApb|Recessive|DAZ interacting protein 3, zinc finger|Dzip3|Unknown|2310047C04Rik, 2A-HUB, 6430549P11Rik|MGI:1917433|DAZ interacting protein 3, zinc finger; mutation 1, The Australian National University|Dzip3|MGI:5563492|16|ENSMUSG00000064061|ENSMUST00000121869|Dzip3-001||||||||48935497|25|||ATGTTCGAAACAAGATTGCATTCCTCAGGGTAAGTTCTGAGTATACTTAATCAAAGTGGC||||||||||||||Embryonic lethal|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD measured by flow cytometry.|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||G4|Het x Het|No|09-May-2014|Cryopreserved sperm|27.0|0.0|Unknown||ENU, embryonic lethal|Yes| 7961.0|ENU33:003:B6|C57BL/6NCrlAnu-Trex1/AnuApb||Recessive|three prime repair exonuclease 1|Trex1|Unknown||MGI:1328317||||9|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Poor||||No|12-Aug-2015|Cryopreserved sperm|44.0|0.0|Unknown||ENU|Yes| 7624.0|Gabrg2KO|STOCK Gabrg2/Apb||Recessive|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2|Gabrg2|Nil|GABAA-R, Gabrg-2, gamma2|MGI:95623|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2; targeted mutation 1, Bernhard Luscher|Gabrg2|MGI:2177608|11|||||||||||||||||||||||||||||Complete postnatal lethality:• most mice died within a few days of birth, although the animals had normal birth weight and peripheral organ structure• remainder of surviving mice failed to thrive and none survived beyond P18Impaired righting response.Limb grasping.Hyperactivity:• exceessive hyperactivity in body and limb movement following birth.Abnormal gait:• described as duck walkNervous system phenotype: no obvious alterations in brain cytoarchitecture in newborn mutant mice (J:28662)||DBA|No|No|Yes|No|No|Yes|No|Unknown||||No|24-Mar-2014|Cryopreserved sperm|70.0|0.0|Unknown||Epilepsy, benzodiazepine (BZ), GABAA receptor|Yes| 5537.0|APN 75|C57BL/6N-Trim35/Marp||Recessive|tripartite motif-containing 35 |Trim35|Unknown|0710005M05Rik, A430106H13Rik, Hls5, Mair, mKIAA1098 |MGI:1914104 |tripartite motif-containing 35 ; targeted mutation 1, Velocigene|Trim35||14||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Jul-2011|Cryopreserved sperm|60.0|0.0|Unknown||ES cell|Yes| 7947.0|IL-38 KO|C57BL/6NMarp-Il1f10/Marp|Mnold|Recessive|interleukin 1 family, member 10|Il1f10|||MGI:2652548|interleukin 1 family, member 10; targeted mutation 1a, Wellcome Trust Sanger Institute|Il1f10|MGI:5008051|2|||||||||||||||||||||||||||||normal|normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Jul-2015|Cryopreserved sperm|49.0|0.0|Unknown|||Possibly| 7963.0||NOD.Cg-Prkdc Il2rg/SzJAnuApb||Recessive|interleukin 2 receptor, gamma chain|Il2rg|Nil|[g]c, CD132, common cytokine receptor gamma chain, common gamma chain, gamma C receptor, gamma(c), gc |MGI:96551 |interleukin 2 receptor, gamma chain; targeted mutation 1, Warren J Leonard |Il2rgtm1|MGI:1857455|X|||||||||||||||||||||||||||||Premature death:*Median survival time is lengthened to between 59-95 weeks (median 89 weeks) in contrast to the shorter lifespan observed homozygous Prkdc controls.*The majority of autopsies indicate no evidence of lymphomas.Decreased leukocyte cell number:*Decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc controls Decreased immature B cell number: *Flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc controls Decreased mature B cell number: *Spleens are deficient in B220+ IgK+ B cells Decreased NK cell number: *Mice are deficient in cells expressing NK cell markers in comparison to Prkdc controls *Spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity Decreased CD4-positive T cell number: *Spleens are deficient in mature T cells Decreased CD8-positive T cell number: *Spleens are deficient in mature T cellsAbnormal immune system organ morphology:*Lymph tissues are severely depleted of lymphoid cells Abnormal spleen B cell follicle morphology: *Spleens do not have detectable follicles Abnormal splenic cell ratio: *Two fold reduction in nucleated spleen cell numbers in comparison to Prkdc controls Abnormal thymus morphology: *Thymus consists mostly of stromal cells with sporadic cyst structures Small lymph nodes: *Lymph nodes in the double mutant are markedly smaller than those of homozygous Prkdc mice Lymph node hypoplasia: *Lymph nodes are hypocellularDecreased immunoglobulin level:*No detectable immunoglobulin in mice at 394-426 days of ageAbnormal response to transplant:*Mice support CD34+ human stem cell engraftment at much higher levels than Prkdc controls*Human CD45+ cells comprise almost 50% of cells in the spleen, approximately 35% in bone marrow and thymus, and 6% in blood at 10 weeks post-engraftmentDecreased mean corpuscular volume:*Slight decrease in packed cell volume at 10 weeks as compared to to Prkdc controlsDecreased leukocyte cell number:*Decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc controls Decreased immature B cell number: *Flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc controls Decreased mature B cell number: *Spleens are deficient in B220+ IgK+ B cells Decreased NK cell number: *Mice are deficient in cells expressing NK cell markers in comparison to Prkdc controls *Spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity Decreased CD4-positive T cell number: *Spleens are deficient in mature T cells Decreased CD8-positive T cell number: *Spleens are deficient in mature T cellsAbnormal spleen B cell follicle morphology:*Spleens do not have detectable folliclesAbnormal splenic cell ratio:*Two fold reduction in nucleated spleen cell numbers in comparison to Prkdc controlsAbnormal thymus morphology:*Thymus consists mostly of stromal cells with sporadic cyst structuresIncreased cellular sensitivity to X-ray irradiation:*Mice do not survive doses above or equal to 400cGyDecreased incidence of ionizing radiation-induced tumors:*Mice irradiated with doses below 400cGy do not exhibit thymic lymphomas in contrast to homozygous Prkdc controlsAbnormal glucose homeostasis:*Streptozotocin-diabetic mice are not restored to euglycemia after receiving transplants of 1000 to 3000 IEQ, while 4000 IEQ transplant was successful in two long-term survivors Hyperglycemia: *Treptozotocin effectively induced hyperglycemia essentially equally in male and female mice at doses of 120to 160 mg/kg; some mice do not become hyperglycemic at all doses of streptozotocin administered||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Aug-2015|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 7963.0||NOD.Cg-Prkdc Il2rg/SzJAnuApb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Nil|DNA-PK, DNA-PKcs, DNAPDcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779 |protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency |Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||Premature death:*Median survival time is lengthened to between 59-95 weeks (median 89 weeks) in contrast to the shorter lifespan observed homozygous Prkdc controls.*The majority of autopsies indicate no evidence of lymphomas.Decreased leukocyte cell number:*Decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc controls Decreased immature B cell number: *Flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc controls Decreased mature B cell number: *Spleens are deficient in B220+ IgK+ B cells Decreased NK cell number: *Mice are deficient in cells expressing NK cell markers in comparison to Prkdc controls *Spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity Decreased CD4-positive T cell number: *Spleens are deficient in mature T cells Decreased CD8-positive T cell number: *Spleens are deficient in mature T cellsAbnormal immune system organ morphology:*Lymph tissues are severely depleted of lymphoid cells Abnormal spleen B cell follicle morphology: *Spleens do not have detectable follicles Abnormal splenic cell ratio: *Two fold reduction in nucleated spleen cell numbers in comparison to Prkdc controls Abnormal thymus morphology: *Thymus consists mostly of stromal cells with sporadic cyst structures Small lymph nodes: *Lymph nodes in the double mutant are markedly smaller than those of homozygous Prkdc mice Lymph node hypoplasia: *Lymph nodes are hypocellularDecreased immunoglobulin level:*No detectable immunoglobulin in mice at 394-426 days of ageAbnormal response to transplant:*Mice support CD34+ human stem cell engraftment at much higher levels than Prkdc controls*Human CD45+ cells comprise almost 50% of cells in the spleen, approximately 35% in bone marrow and thymus, and 6% in blood at 10 weeks post-engraftmentDecreased mean corpuscular volume:*Slight decrease in packed cell volume at 10 weeks as compared to to Prkdc controlsDecreased leukocyte cell number:*Decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc controls Decreased immature B cell number: *Flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc controls Decreased mature B cell number: *Spleens are deficient in B220+ IgK+ B cells Decreased NK cell number: *Mice are deficient in cells expressing NK cell markers in comparison to Prkdc controls *Spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity Decreased CD4-positive T cell number: *Spleens are deficient in mature T cells Decreased CD8-positive T cell number: *Spleens are deficient in mature T cellsAbnormal spleen B cell follicle morphology:*Spleens do not have detectable folliclesAbnormal splenic cell ratio:*Two fold reduction in nucleated spleen cell numbers in comparison to Prkdc controlsAbnormal thymus morphology:*Thymus consists mostly of stromal cells with sporadic cyst structuresIncreased cellular sensitivity to X-ray irradiation:*Mice do not survive doses above or equal to 400cGyDecreased incidence of ionizing radiation-induced tumors:*Mice irradiated with doses below 400cGy do not exhibit thymic lymphomas in contrast to homozygous Prkdc controlsAbnormal glucose homeostasis:*Streptozotocin-diabetic mice are not restored to euglycemia after receiving transplants of 1000 to 3000 IEQ, while 4000 IEQ transplant was successful in two long-term survivors Hyperglycemia: *Treptozotocin effectively induced hyperglycemia essentially equally in male and female mice at doses of 120to 160 mg/kg; some mice do not become hyperglycemic at all doses of streptozotocin administered||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Aug-2015|Cryopreserved sperm|||Unknown|||Yes| 4515.0|Anaef ; ENU8B6:004|C57BL/6JSfdAnu-Rasgrp1/AnuApb|C57BL/6JSfdAnu-Rasgrp1/AnuApb|Recessive|RAS guanyl releasing protein 1|Rasgrp1|||MGI:1314635|RAS guanyl releasing protein 1; mutation 1, The Australian National University|Rasgrp1|MGI:4838027|2|ENSMUSG00000027347|ENSMUST00000102534|Rasgrp1-001|1555|1847|A to G|ENSMUSE00000295147|13|518|Arginine to Glycine|||||TGGACAAAGATAGGGAAGGCCTCATCAGCAGAGACGAGATCACGGCCTACTTCATGAGGGC||||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies.Thymocyte selection in affected mice is mostly normal in vivo, although CD44 is overexpressed on naïve thymocytes and T cells in a T-cell-autonomous manner. ||C57BL6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||9||No|26-Feb-2009|Cryopreserved sperm|56.0|0.0|Unknown||autoimmunity, Antinuclear antibodies (ANA), ENU, Wellcome Trust, T cell, signal transduction|Yes| 7964.0|ENU33:034|C57BL/6NCrlAnu-Fnip1/AnuApb||Recessive|folliculin interacting protein 1|Fnip1||A730024A03Rik, mKIAA1961|MGI:2444668|Fnip1; mutation 1, Australian National University|Fnip1||11|ENSMUSG00000035992|ENSMUST00000046835|Fnip1-001|228|326|T to A|ENSMUSE00000288119|3|76|Cysteine to STOP|||||AATGAGGACACATCAGTATCGAAGCTCTGTAATGATGCTCAAGTCAAGGTCTTTGGGAAGT||||||||||||||No B cells in peripheral blood as measured by flow cytometry.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||G4||No|02-Sep-2015|Cryopreserved sperm|46.0|0.0|Unknown||B cell|Yes| 7569.0|ENU14Yaa:032:b:-Yaa:G5|B6(SB)-Lyn/AnuApb|B6(SB)-Lyn/AnuApb|Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn||Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; mutation 1 Anu|Lyn|MGI:5563397|4|ENSMUSG00000042228|ENSMUST00000041377|Lyn-001||||||||3683632|9|||CTACATCATCACCGAGTTCATGGCTAAGGGTGAGTGGCATCACGAGTCTGTACCCCTAAA||||||||||||||Increased % immature B cells, and reduced % mature B cells (Almost no Mature B cells)||C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|17-Jan-2014|Cryopreserved sperm|10.0|0.0|Unknown||ENU, B cell, signal transduction|Possibly| 7083.0|Pinky ; ENU8C:027|B6(Cg).CBA-Zbtb16/AnuApb|B6.CBA-Zbtb16/AnuApb|Recessive|zinc finger and BTB domain containing 16|Zbtb16|Unknown|Green's luxoid, PLZF, Zfp145|MGI:103222|zinc finger and BTB domain containing 16; pinky|Zbtb16|MGI:4462277|9|ENSMUSG00000066687|ENSMUST00000093852|Zbtb16-201|210|457|T to A|ENSMUSE00000584531|2|70|Tyrosine to STOP|||||ATCCTCTTCCACCGAAACAGCCAGCACTATACTCTAGACTTCCTCTCGCCAAAAACCTTCC|Yes|||||||||||||Limb deformity. Shortening and angular deformity of hindlimbs with extra digits present in some cases. Deformity affects mouse mobility. Previously described homozygous mutants exhibit abnormal anterior-posterior patterning, with skeletal abnormalities of the limb, especially the hindlimb, and homeotic transformations of anterior skeletal elements into posterior structures. Males develop infertility due to loss of germline cells with age.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|10|8||No|14-Sep-2012|Cryopreserved sperm|26.0|0.0|Unknown||limb, deformity, extra digit, anterior-posterior patterning, ENU|Yes| 7336.0|ENU17NIH:050b|C57BL/6JAnu-Zfp318/AnuApb|C57BL/6JAnu-Zfp318/AnuApb|Recessive|zinc finger protein 318|Zfp318|Unknown|2610034E08Rik, D530032D06Rik, TZF |MGI:1889348|zinc finger protein 318; mutation 1, The Australian National University|Zfp318|MGI:5563395|17|ENSMUSG00000015597|ENSMUST00000113481|Zfp318-001|4040|4148|T to C|ENSMUSE00000695799|10|1347|Isoleucine to Threonine|||||TGAAGTTGGAAAGGCAAAGCCCATCAAAATCAAGCTTTCTGGAAAAACTGTCATTGCACAC||||||||||||||Abolished IgD expression on marginal zone B cells, decreased IgD on follicular B cells, and increased IgM, but only slightly decreased the percentage of B cells and did not decrease expression of other maturation markers CD21, CD23, or CD62L.Gene is highly expressed in testis and male mice homozygous for a null allele seem to have reduced fertility.|Normal|C57BL/6JAnu|Yes|Unknown|Yes|Yes|Yes|Yes|No|Good|3|G7|Usually het x het but have used homozygous males|No|14-May-2013|Cryopreserved sperm|37.0|0.0|Unknown||B cell development, Follicular B cells, ENU|No| 7410.0|ENU26:020:Dock8:B6|C57BL/6NCrlAnu-Dock8/AnuApb|C57BL/6NCrlAnu-Dock8/AnuApb|Recessive|dedicator of cytokinesis 8|Dock8|Unknown|1200017A24Rik, 5830472H07Rik, A130095G14Rik|MGI:1921396|dedicator of cytokinesis 8; mutation 1, The Australian National University|Dock8|MGI:5563486|19|ENSMUSG00000052085|ENSMUST00000025831|Dock8-201|5656|5778|G to T|ENSMUSE00000145933|44|1886|Glutamic acid to STOP|||||ATGAGATGAAAGACCGGGTGACCTACTTCGAGAAGAATTTCAACCTCCGGAGGTTCATGTA||||||||||||||Peripheral blood shows reduced T cell numbers, activated CD8<+>T cells (high CD44 expression) and low IgM expression on mature B cells. No Marginal Zone B cells in spleen.Parameters measured by flow cytometry using antibodies against following antigens: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4|Het x Het|No|23-Aug-2013|Cryopreserved sperm|33.0|0.0|Unknown||T cell, B cell, antibody, ENU|Yes| 7415.0|ENU25:040:MAST4:B6|C57BL/6NCrlAnu-Mast4/AnuApb|C57BL/6NCrlAnu-Mast4/AnuApb|Recessive|microtubule associated serine/threonine kinase family member 4|Mast4|Unknown|4930420O11Rik, mKIAA0303|MGI:1918885|microtubule associated serine/threonine kinase family member 4; mutation 1, The Australian National University|Mast4|MGI:5563453|13|ENSMUSG00000034751|ENSMUST00000167058|Mast4-001|2176|2444|C to A|ENSMUSE00000483603|17|726|Glutamic acid to STOP|||||GATTAATGAGCATGACCACCAATCTCTATGAAGGCCACATAGAGAAGGACGCTCGAGAGTT||||||||||||||Malocclusion.Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, C4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|23-Aug-2013|Cryopreserved sperm|45.0|0.0|Unknown||malocclusion, ENU|Yes| 7558.0|ENU27:009:RASGRP1:B6|C57BL/6NCrlAnu-Rasgrp1/AnuApb|C57BL/6NCrlAnu-Rasgrp1/AnuApb|Recessive|RAS guanyl releasing protein 1|Rasgrp1|Unknown||MGI:1314635|RAS guanyl releasing protein 1; mutation 2, The Australian National University|Rasgrp1|MGI:5563430|2|ENSMUSG00000027347|ENSMUST00000102534|Rasgrp1-001|1976|2268|T to C|ENSMUSE00000295129|16|659|Lysine to Arginine|||||CATCATGCTCCTCGGAGTGTCCTCCCAGAAAATTTCAGTTCGGCTGAAGAGGACTGTTGCC||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|19-Dec-2013|Cryopreserved sperm|46.0|0.0|Unknown||ENU|Yes| 7559.0|ENU27:048:ATP10A:B6|C57BL/6NCrlAnu-Atp10a/AnuApb|C57BL/6NCrlAnu-Atp10a/AnuApb|Recessive|ATPase, class V, type 10A|Atp10a|Unknown|Atp10c, pfatp|MGI:1330809|ATPase, class V, type 10A; mutation 1, The Australian National University|Atp10a|MGI:5563515|7|ENSMUSG00000025324|ENSMUST00000168747|Atp10a-202|2716|2969|G to T|ENSMUSE00000149782|13|906|Aspartic acid to Tyrosine|||||CTGGCCTGCAGATTTGGGTTCTCACAGGTGACAAACAGGAAACAGCCATTAACATTGCATA||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||G4||No|19-Dec-2013|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Yes| 7977.0|Kaede Tg|B6.Cg-Tg(CAG-Kaede)#Kgwa/AusbAnuApb||Recessive||||||||||||||||||||||||||transgene insertion, Osami Kanagawa|Beta actin|||||||||||These mice expressed photoconvertible Kaede in all of the cell types analyzed with no abnormality in their growth and reproduction.|These mice expressed photoconvertible Kaede in all of the cell types analyzed with no abnormality in their growth and reproduction.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Sep-2015|Cryopreserved sperm|11.0|0.0|Unknown||fluorescence|Yes| 7965.0|ENU32:045|C57BL/6NCrlAnu-Galns/AnuApb||Recessive|galactosamine (N-acetyl)-6-sulfate sulfatase|Galns||N-acetylgalactosamine-6-sulfate sulfatase|MGI:1355303||||8|ENSMUSG00000015027|ENSMUST00000015171|Galns-201|176|325|A to G|ENSMUSE00000215107|2|59|Methionine to Threonine|||||TTCCAGAGAGACCCCAAATTTAGACCGGATGGCTGCAGAAGGGATGCTTTTCCCAAGCTTC||||||||||||||Low IgM expression on mature B cells in peripheral blood as measured by flow cytometry.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Sep-2015|Cryopreserved sperm|36.0|0.0|Unknown||B cell, IgM, immunoglobulin|Yes| 7735.0|Duane ; ENU6NIHB:019|B6(Cg)-Tbx21/AnuApb|B6(Cg)-Tbx21/AnuApb|Recessive|T-box 21|Tbx21|Reduced|T-bet, Tblym, TBT1|MGI:1888984|T-box 21; Duane|Tbx21|MGI:4367995|11|ENSMUSG00000001444|ENSMUST00000001484|Tbx21-001||||||||96962921|2|||CTGGTCGATACTTGACAATAAGGTTAACTGTCCACAGGGAACCGCTTATATGTCCACCCA|Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. Few circulating NK cells.Decreased NK cell number: the percent of NK cells in the blood, spleen, and liver is lower than in wild-type mice.Increased NK cell number:* the frequency of NK cells in the peripheral lymph nodes and bone marrow is increased compared to in wild-type mice.* NK cells accumulate in lymph nodes due to defective egression.Absent NK T cells: mice exhibit a near complete absence of invariant natural killer T cells unlike in wild-type mice.Abnormal NK cell differentiation:* NK cells exhibit an immature phenotype unlike in wild-type mice.* NK cells accumulate in lymph nodes due to defective egression.* in reconstitution experiments, derived NK cells accumulate in the peripheral lymph nodes due to defective egression.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|4|G5N4|Het x Het ; Hom x Hom|No|06-Sep-2014|Cryopreserved sperm|14.0|64.0|Unknown||antibody, B cell, NK cell, ENU, Wellcome Trust, Natural Killer cell (NK), T cell, lymphocyte|Yes| 7967.0|GZMB-cre|B6.FVB-Tg(GZMB-cre)1Jcb/JWehiAnu||Dominant||||||||||||||||||||||||||transgene insertion 1, Joshy Jacob|human granzyme B|||||||||||Normal|Normal|C57L/6JWehi|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|07-Sep-2015|Cryopreserved sperm|22.0|0.0|Unknown||Cre recombinase, T cell, CD8, granzyme|Yes| 7973.0||RBC10|RBC10|Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Unknown|Microcytosis|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|24-Sep-2015|Cryopreserved sperm|30.0|0.0|Unknown||ENU|No| 7974.0|Mst1r|C57BL/6-Gt(Rosa)26Sor/AnuApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||||6||||||||||||||||No|||||||||||||Normal|Normal||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||Yes|24-Sep-2015|Cryopreserved sperm|45.0|0.0|No||Cre recombinase, Mst1r|No| 7969.0|HSPE Tg x HIP-Cre|C57BL/6-Gt(ROSA)26Sor Tg(INS-cre)2Rms/AnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||||6|||||||||||||||||transgene insertion 2, Robyn M Slattery|human insulin promoter|||||||||||Unknown||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|18-Sep-2015|Cryopreserved sperm|54.0|0.0|Unknown||heparanase, Cre recombinase|Yes| 7970.0|Srsf3-flox UBC-cre/ert|B6;129-Srsf3 Tg((UBC-cre/ERT2)1Ejb/MarpApb||Recessive|serine/arginine-rich splicing factor 3|Srsf3|Unknown|Sfrs3, X16|MGI:98285||||17|||||||||||||||||transgene insertion 1, Eric J Brow|human ubiquitin C (UBC) promoter|||||||||||No phenotype|No phenotype|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|22-Sep-2015|Cryopreserved sperm|30.0|0.0|No||LoxP|Possibly| 7980.0|Nrp2:Cre/dsRed|C57BL/6-Tg(Nrp2-cre/dsRed)||Dominant||||||||||||||||||||||||||Cre rcombinase fused to dsRed|Nrp2|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|10|Male homozygous cross female homozygous|No|09-Oct-2015|Cryopreserved sperm|49.0|0.0|No||Neuropilin 2, Nrp2, Cre recombinase|Possibly| 7982.0|F/F:STAT3-SA , BJ33|B6.129-IL6st Stat3/MarpApb||Recessive|signal transducer and activator of transcription 3|Stat3|Unknown|1110034C02Rik, Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, James E Darnell|Stat3|MGI:3028651|11||||||||||||||||No|||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|13-Oct-2015|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, JAK-STAT, cytokine, interferon, kinase, phosphorylation|Yes| 7982.0|F/F:STAT3-SA , BJ33|B6.129-IL6st Stat3/MarpApb||Recessive|interleukin 6 signal transducer|Il6st|Normal|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good||||No|13-Oct-2015|Cryopreserved sperm|||Unknown||signal transduction, JAK-STAT, cytokine, interferon, kinase, phosphorylation|Yes| 7599.0|TRAMP|B6;FVB/N-Tg(TRAMP)8247Ng/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 8247, Norman M Greenberg|rat probasin|prostate||||||||||Males develop prostate cancer from 10weeks, penetrance ~80% at 1yr of age|Males develop prostate cancer from 10weeks, penetrance ~80% at 1yr of age|C57BL/6J|Unknown|Unknown|Yes|No|No|No|Yes|Poor|||Heterozygous female crossed with wt male|No|19-Feb-2014|Cryopreserved sperm|60.0|0.0|Unknown||prostate, SV40, epithelium, androgen|Yes| 7978.0|C3 ; Fgf10 c.505_507del CRISPR|C57BL/6J-Fgf10/MarpApb||Recessive|fibroblast growth factor 10|Fgf10|Unknown|AEY17, FGF-10, Gsfaey17 |MGI:1099809||||13|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|05-Oct-2015|Cryopreserved sperm|40.0|0.0|Unknown||CRISPR|Possibly| 10424.0|CD89Tgflx|B6-Tg(flox/cd89)227Ltku||Dominant|FCAR||||||||Unknown|||||||||||||||||LoxP-mCherry-Stop codon-LoxP-human CD89-IRES-GFP|CMV|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-May-2024|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7516.0|PB-Tet|B6.FVB-Tg(Pbsn-rtTA*M2)42Xy/MarpApb|B6.FVB-Tg(Pbsn-rtTA*M2)42Xy/MarpApb|Dominant||||||||||||||||||||||||||transgene insertion 42, Xin Yuan|anterior prostate-specific rat promoter|||||||||||Prostate specific rtTA expression; no other phenotype |None/Unknown|C57BL/6J|No|Yes|Unknown|No|Yes|Unknown|No|Unknown||||No|29-Nov-2013|Cryopreserved sperm|60.0|0.0|Unknown||tetracycline, inducible|Possibly| 7983.0|Foxn1|B6(Cg)-Foxn1/JAnu||Dominant|forkhead box N1|Foxn1|Normal|D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Oct-2015|Cryopreserved sperm|21.0|0.0|Unknown||Cre recombinase|No| 7988.0|PTX3 knockout|B6.129-Ptx3||Semi-dominant|pentraxin related gene|Ptx3||pentraxin 3, TSG-14|MGI:104641|pentraxin related gene; targeted mutation 1, Alberto Mantovani|Ptx3|MGI:2675283|3|||||||||||||||||||||||||||||Reduced female fertility: • homozygotes display a severe defect in female fertilityLung inflammation:• lungs from Aspergillus fumigatus infected homozygotes display a massive inflammatory response, the presence of hyphae and numerous, mostly extracellular, conidia, relative to similarly infected wild-type controlsAbnormal T-helper 1 physiology:• upon challenge with Aspergillus fumigatus, homozygotes fail to develop an appropriate TH1-type response and display a cytokine profile skewed towards a TH2-type response, as revealed by reduced IFN-gamma and IL-12 levels and increased IL-4 levels in mutant lungsAbnormal macrophage physiology:• homozygotes exhibit defective recognition of Aspergillus fumigatus conidia by alveolar macrophagesImpaired macrophage phagocytosis:• in vitro, the ability of mutant alveolar macrophages to ingest and kill resting Aspergillus fumigatus conidia is impaired relative to wild-type macrophages|Normal.|C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Good||||No|03-Nov-2015|Cryopreserved sperm|50.0|0.0|No|||No| 10415.0|TNFAIP3 KO|C57BL6/NCrl-Tnfaip3/Anu||Recessive|tumor necrosis factor, alpha-induced protein 3|Tnfaip3||zinc finger protein A20|MGI:1196377|Tnfaip3:endonuclease-mediated mutation 3, Australian National University|Tnfaip3/||10|ENSMUSG00000019850||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|08-Apr-2024|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7993.0|Rag2|C.129S6-Rag2/UcApb|C.129S6-Rag2/UcApb|Recessive|recombination activating gene 2|Rag2|Normal|Rag-2|MGI:97849|recombination activating gene 2; targeted mutation 1, Frederick W Alt|Rag2|MGI:1858556|2|||||||||||||||||||||||||||||Homozygous mice exhibit total inability to initiate V(D)J rearrangement and fail to generate mature T or B lymphocytes.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Nov-2015|Cryopreserved sperm|50.0|0.0|Unknown||B cell, T cell, IgM|Yes| 8875.0|Mal fl|C57BL/6-Mal/PjhApb||Recessive|myelin and lymphocyte protein, T cell differentiation protein|Mal|Normal|VIP17|MGI:892970||||2|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7994.0|564Igi|B6.129S4-Igk Igh/TikAnu||Dominant|immunoglobulin kappa chain complex|Igk||kappa|MGI:96494|immunoglobulin kappa chain complex; targeted mutation 1, Thereza Imanishi-Kari|Igk|MGI:3687307|6|||||||||||||||||||||||||||||Glomerulonephritis:• mutant mice kidney changes consistent with those seen in mesangioproliferative glomerulonephropathies in humanAbnormal podocyte morphology:• mild basement membrane thickeningPodocyte foot process effacement• segmental epithelial cell foot process effacementAbnormal glomerular mesangium morphology:• expansion of the glomerular mesangium by increased mesangial cells, matrix, and numerous electron dense depositsMesangial cell hyperplasiaExpanded mesangial matrixSystemic Lupus Erythematosus; SLE||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|20|||No|19-Nov-2015|Cryopreserved sperm|32.0|0.0|Yes|Systemic Lupus Erythematosus; SLE|Immunoglobulin, autoimmunity, lupus|Yes| 7994.0|564Igi|B6.129S4-Igk Igh/TikAnu||Dominant|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Thereza Imanishi-Kari|Igh|MGI:3687305|12|||||||||||||||||||||||||||||Glomerulonephritis:• mutant mice kidney changes consistent with those seen in mesangioproliferative glomerulonephropathies in humanAbnormal podocyte morphology:• mild basement membrane thickeningPodocyte foot process effacement• segmental epithelial cell foot process effacementAbnormal glomerular mesangium morphology:• expansion of the glomerular mesangium by increased mesangial cells, matrix, and numerous electron dense depositsMesangial cell hyperplasiaExpanded mesangial matrixSystemic Lupus Erythematosus; SLE||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|20|||No|19-Nov-2015|Cryopreserved sperm|||Yes|Systemic Lupus Erythematosus; SLE|Immunoglobulin, autoimmunity, lupus|Yes| 7990.0|PEP-R619W 104|C57BL/6-Ptpn22/104MarpApb||Dominant|protein tyrosine phosphatase, non-receptor type 22 |Ptpn22|Unknown|70zpep, Ptpn8|MGI:107170||||3|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Nov-2015|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7991.0|PEP-R619W 106 |C57BL/6-Ptpn22/106Marp ||Dominant|protein tyrosine phosphatase, non-receptor type 22 (lymphoid)|Ptpn22|Unknown|70zpep, Ptpn8|MGI:107170||||3|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Nov-2015|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8001.0|Y-RFP ; Ddx3y_cl.330_RFP|129-Ddx3y/330KalpApb|Yrfp|Semi-dominant|DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked|Ddx3y|Normal||MGI:1349406||||Y|||||||||||||||||||||||||||||Normal|Most tissues express the mKate2 red fluorescent protein gene. There is some variation in expression between tissues.|129S1/Sv1mJ |Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Dec-2015|Cryopreserved sperm|50.0|0.0|No||RFP|Yes| 10417.0|Tnfaip3S381A (1)|C57BL6/NCrl-Tnfaip3/AnuApb||Recessive|tumor necrosis factor, alpha-induced protein 3|Tnfaip3||zinc finger protein A20|MGI:1196377|Tnfaip3: endonuclease-mediated mutation 2, Australian National University|Tnfaip3||10|ENSMUSG00000019850||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Apr-2024|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7996.0|SMB|B6.129P2-Smg1||Dominant|SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans)|Smg1|Unknown|SMG-1, ATX|MGI:1919742|SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans); gene trap AG0297, Wellcome Trust Sanger Institute|Smug|MGI:3876748|7|||||||||||||||||||||||||||||Early embryonic lethal|Premature death:• due to high tumor incidenceIncreased tutor incidence:• in various organsIncreased lymphoma incidence:• predominantly B cell of follicular center originIncreased B cell derived lymphoma incidence:• of follicular center originIncreased lung adenocarcinoma incidence:• papillary adenocarcinoma in the lungAbnormal basicranium angle:• the angle formed by the plane of the mandible to the plane of the cranial base is decreased compared to in wild-type micePrognathiaAbnormal tooth morphology:• over-grownAbnormal tooth development:• producing over-grown teethIncreased body sizeIncreased body weightIncreased body lengthEnlarged spleenDecreased circulating interleukin-1 beta levelIncreased circulating interleukin-6 levelChronic inflammation:• low level inflammation that progresses to chronic inflammation• mainly in the kidney and lungEnlarged liverHepatic steatosisAbnormal kidney morphologyAbnormal basicranium angle:• the angle formed by the plane of the mandible to the plane of the cranial base is decreased compared to in wild-type mice|C57BL/6N|No|No|Yes|No|No|Yes|No|Good|20||Het x WT|No|20-Nov-2015|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8005.0|Fgrf2|B6.129X1-Fgfr2/DunwApb||Recessive|fibroblast growth factor receptor 2|Fgfr2|Unknown|Bek, Fgfr-2, Fgfr7, Fgfr-7, KGFRTr, svs|MGI:95523|fibroblast growth factor receptor 2; targeted mutation 1, David M Ornitz|Fgfr2|MGI:3044679|7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||||No|08-Dec-2015|Cryopreserved sperm|49.0|0.0|Unknown|||Possibly| 8003.0|FcRn-|C.Cg-Fcgrt/DcrJApb||Dominant|Fc receptor, IgG, alpha chain transporter|Fcgrt|Nil|FcRn, neonatal Fc receptor|MGI:103017|Fc receptor, IgG, alpha chain transporter; targeted mutation 1, Derry C Roopenian|Fcgrt|MGI:3511510|7|||||||||||||||||||||||||||||Decreased circulating serum albumin, decreased circulating IgG, decreased IgG halflife, increased albumin/IgG catabolism, impaired IgG-mediated cross presentation, impaired IgG transcytosis, deminished perinatal maternal IgG transport, |Impaired|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>9||Normal|No|08-Dec-2015|Cryopreserved sperm|90.0|0.0|Unknown||IgG receptor, IgG transcytosis, antigen presentation, neonatal Fc receptor|Possibly| 8006.0|FgfR1null|B6.129-FgfR1/DunwApb||Recessive|fibroblast growth factor receptor 1|Fgfr1|Unknown|Eask, Fgfr-1, FGFR-I, Flt-2, Hspy|MGI:95522|Fgfr1; targeted mutation 1.1, Sally Dunwoodie|FgfR1|MGI:2686864|Recessive||||||||||||||||||||||||||||||||||||||homozygous lethal|normal|C35BL6/J|No|No|Yes|No|No|Yes|No|Good||||No|09-Dec-2015||0.0|0.0|Unknown|||Possibly| 8002.0|PEP-Delta 87 |C57BL/6-Ptpn22MarpApb ||Recessive|protein tyrosine phosphatase, non-receptor type 22 (lymphoid)|Ptpn22|Unknown|70zpep, Ptpn8|MGI:107170||||3||||||||||||||||Yes|||||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Dec-2015|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8013.0|Aicda fl|C57BL/6N(Cg)-Aicda/MarpAnuApb||Recessive|activation-induced cytidine deaminase|Aicda|Normal|Aid|MGI:1342279|activation-induced cytidine deaminase; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Aicda|MGI:4460367|6|||||||||||||||||||||||||||||Normal||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4||No|17-Dec-2015|Cryopreserved sperm|80.0|0.0|Unknown||EuCOMM|Yes| 10394.0|GtROSA|B6.129-Gt(ROSA)26Sor/JWehiAnu||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||R26, ROSA26|MGI:104735||||6|ENSMUSG00000086429||||||||||||||||GtROSA-Flox-Betagalactosidase||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|20-Dec-2023|Cryopreserved sperm|50.0|0.0|Unknown|||No| 8010.0|Pax8 x TetOCre|B6.Cg-Tg(Pax8rtTA2S*M2)1Koes/J Tg(tetOcre)1Jaw/J||Dominant||||||||||||||||||||||||||transgene insertion 1, Robert Koesters|Pax8|||||||||||Normal|Normal|C57B/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||double x double|Yes|14-Dec-2015|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8010.0|Pax8 x TetOCre|B6.Cg-Tg(Pax8rtTA2S*M2)1Koes/J Tg(tetOcre)1Jaw/J||Dominant||||||||||||||||||||||||||transgene insertion 1, Jeffrey A Whitsett|CMV|||||||||||Normal|Normal|C57B/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||double x double|Yes|14-Dec-2015|Cryopreserved sperm|||Unknown|||Yes| 4746.0|Rag:KK|B6.Cg-H2 Rag1/AnuApb||Recessive|recombination activating gene 1|Rag1|Unknown|Rag-1|MGI:97848|targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.||C57BL/10.BR x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||18||No|27-Apr-2009|Cryopreserved sperm|205.0|0.0|Unknown||T cell, B cell, MHC, lymphocyte|Yes| 4746.0|Rag:KK|B6.Cg-H2 Rag1/AnuApb||Recessive|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|||||||||||||||||||||||||||||Homozygotes for targeted null mutations exhibit arrested development of T and B cell maturation at the CD4-8- thymocyte or B220+/CD43+pro-B cell stage due to inability to undergo V(D)J recombination.||C57BL/10.BR x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||18||No|27-Apr-2009|Cryopreserved sperm|||Unknown||T cell, B cell, MHC, lymphocyte|Yes| 8017.0|ENU37:G1|ANU:ENU37:G1||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|07-Jan-2016|Cryopreserved sperm|1249.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8018.0|ENU37:G2|ANU:ENU37:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|07-Jan-2016|Cryopreserved sperm|1599.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8020.0|ICExiNOSxRKO/BL6|B6;129S2-Casp1 Ifngr1 Nos2/AnuApb||Recessive|caspase 1|Casp1|Nil|Caspase-1, ICE, Il1bc, interleukin 1 beta-converting enzyme|MGI:96544|caspase 1; targeted mutation 1, Tara Seshadri|Casp1|MGI:1927822|9|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown||Hom X hom|No|09-Feb-2016|Cryopreserved sperm|43.0|0.0|Unknown|||Possibly| 8020.0|ICExiNOSxRKO/BL6|B6;129S2-Casp1 Ifngr1 Nos2/AnuApb||Recessive|interferon gamma receptor 1|Ifngr1||CD119, Ifgr, IFN-gammaR, IFN-gamma R, Ifngr, Nktar|MGI:107655|interferon gamma receptor 1; targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown||Hom X hom|No|09-Feb-2016|Cryopreserved sperm|||Unknown|||Possibly| 8020.0|ICExiNOSxRKO/BL6|B6;129S2-Casp1 Ifngr1 Nos2/AnuApb||Recessive|nitric oxide synthase 2, inducible|Nos2|Nil|iNOS, Nos-2, Nos2a, NOS-II|MGI:97361|nitric oxide synthase 2, inducible; targeted mutation 1, Merck Research Laboratory|Nos2|MGI:2158791|11|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown||Hom X hom|No|09-Feb-2016|Cryopreserved sperm|||Unknown|||Possibly| 8007.0|Fgf8flox|B6.Cg-Fgf8/DunwApb||Recessive|fibroblast growth factor 8|Fgf8|Unknown|Aigf, Fgf-8|MGI:99604|fibroblast growth factor 8; targeted mutation 1, Anne M Moon|Fgf8|MGI:2686864|19|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Dec-2015|Cryopreserved sperm|50.0|0.0|Unknown||Ectoderm, Endoderm|Possibly| 8014.0|HSA-GPX1-TG21|C57BL/6-Tg(ACTA1-Gpx1)21Ttig||Dominant||||||||||||||||||||||||||glutathione peroxidase 1|human skeletal apha actin|||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|21-Dec-2015|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 8021.0|Gstz1 KO|B6.C-Gstz1/AnuApb||Recessive|glutathione transferase zeta 1 (maleylacetoacetate isomerase)|Gstz1|Nil|maleylacetoacetate isomerase|MGI:1341859|targeted mutation 1, Philip G Board|Gstz1|MGI:3050206|12||||||||||||||||No|||||||||||||Increased sensitivity to induced Morbidity/Mortality * 3% phenylalanine in the water is lethal to young homozygotes, less than 28 days old, but not to older homozygotes, greater than 66 days oldpremature death * several mutants died after 1 year of age from heart pathologiesDystrophic cardiac calcinosis* in some mutants over 1 year of age Calcification of the myocardium in the right atrium and/or ventricle is seen* calcification is also seen in 3 of 8 young mutants that died after 3% phenylalanine exposurecellular necrosis* in some mutants over 1 year of age myocyte necrosis is seen* myocyte necrosis is also seen in 2 of 8 young mutants that died after 3% phenylalanine exposureDecreased leukocyte cell number* 3% phenylalanine in the water results in decreased total white cell counts in mutants but not in wild-type micedecreased spleen weight * spleen weight is significantly decreased in female homozygotes and tends to be decreased in male homozygotes compared to wild-type mice* 3% phenylalanine in the water results in a dramatic decrease in spleen weight in homozygotes with reduction in both white and red pulp, but an increase in spleen weight in wild-type micechronic inflammation* in some mutants over 1 year of age chronic inflammation is seen in the heartliver inflammation* at 6 weeks and 6 months of age multifocal hepatitis is seenLiver inflammation* at 6 weeks and 6 months of age multifocal hepatitis is seenAbnormal hepatocyte morphology* large pleomorphic mitochondria are seen in hepatocytes from mutantsIncreased liver weight* on a normal diet liver weight is greater in homozygotes compared to wild-type miceHepatic necrosis* at 6 months of age 3 of 7 homozygotes show hepatocyte necrosis* 3 out of 8 homozygotes that died after 3% phenylalanine exposure displayed hepatocyte necrosisHepatic steatosis * 5 out of 8 homozygotes that died after 3% phenylalanine exposure displayed macrovesicular steatosis||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Feb-2016|Cryopreserved sperm|55.0|0.0|Unknown||GST, maleylacetoacetate, maleylacetone (MA) and succinylacetone, phenylalanine and tyrosine, Keap1/Nrf2 pathway, Oxidative stress|Yes| 8024.0|ENU26:Prpf40b|C57BL/6NCrlAnu-Prpf40b/Anu||Recessive|pre-mRNA processing factor 40B|Prpf40b|Unknown|2610317D23Rik|MGI:1925583|Prpf40b; mutation 1, Australian National University|Prpf40b||15|ENSMUSG00000023007|ENSMUST00000145482|Prpf40b-001|2570|2791|A to G|ENSMUSE00001300864|26|857|Glutamic acid to Glycine|||||CACGTCAGAAAGCGAGCTGAGTGAGGGGGAGCTGGAGAGGCGAAGGCGGACACTCCTACAG|||||||||||||||Normal|C57BL/6NCrlAnu|Unknown|Yes|Yes|Unknown|Yes|Yes|No|Unknown||||No|16-Feb-2016|Cryopreserved sperm|44.0|0.0|Unknown||ENU|Yes| 8026.0|Ndfip1 Gzmb-cre |B6.Cg-Ndfip1 Tg(GZMB-cre)1Jcb/AnuApb||Recessive|Nedd4 family interacting protein 1|Ndfip1|Normal|0610010M22Rik|MGI:1929601|Nedd4 family interacting protein 1; targeted mutation 1, Seong-Seng Tan|Ndfip1|MGI:5313245|18|||||||||||||||||transgene insertion 1, Joshy Jacob|human granzyme B|||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|19-Feb-2016|Cryopreserved sperm|31.0|0.0|Unknown||Nedd4, pten, ubiquitination|Yes| 7652.0|RBL-1|SJL/J-Arhgap40 Rbl1/Marp||Semi-dominant|retinoblastoma-like 1 (p107)|Rbl1|Reduced|p107|MGI:103300||||2|||||||||||||||||||||||||||||Display macrocytosis|Mild macrocytosis|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|50.0|0.0|Unknown||RBL1, Cell cycle, ENU|Possibly| 7652.0|RBL-1|SJL/J-Arhgap40 Rbl1/Marp||Semi-dominant|Rho GTPase activating protein 40|Arhgap40|Reduced||MGI:3649852||||2|||||||||||||||||||||||||||||Display macrocytosis|Mild macrocytosis|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||homozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|||Unknown||RBL1, Cell cycle, ENU|Possibly| 8027.0|alphaMHC-Rln1|C57BL/6-Tg(Myh6-Rln1)1Nros/Marp||Dominant||||||||||||||||||||||||||relaxin 1 (Mus musculus) |Myh6 (alpha myosin heavy chain)|high||||||||||Unknown|Males are normal. Females have enlarged nipples and are prone to pseudopregnancy and have fertility issues. |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|>50||use TG male and WT female|No|02-Mar-2016|Cryopreserved sperm|60.0|0.0|No|||Yes| 8028.0|ENU34:001:Zfp318|C57BL/6NCrlAnu-Zfp318/AnuApb||Recessive|zinc finger protein 318|Zfp318||2610034E08Rik, D530032D06Rik, TZF|MGI:1889348|Zfp318; mutation 2, Australian National University|Zfp318||17|ENSMUSG00000015597|ENSMUST00000113481|Zfp318-001|3301|3409|T to C|ENSMUSE00001294148|7|1101|Phenylalanine to Leucine|||||AAGACTGCAATACCACCTGTGGGACCATGTTTGACTTCTTCACCCATATGCACAATAAGAA||||||||||||||Increased expression of IgM and decreased expression of IgD on mature B cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Mar-2016|Cryopreserved sperm|44.0|0.0|Unknown||B cell, IgM, IgD|Yes| 8030.0|Hs2st1 fl|B6.129-Hs2st1/UcsdAnu||Recessive|heparan sulfate 2-O-sulfotransferase 1|Hs2st1|Normal|Hs2st, mKIAA0448|MGI:1346049|heparan sulfate 2-O-sulfotransferase 1; targeted mutation 1.1, Jeffrey D Esko|Hs2st1|MGI:4439161|3|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|24-Mar-2016|Cryopreserved sperm|33.0|0.0|Unknown||Heparan sulphate, sulfation, triglyceride|Yes| 8029.0|Ndst1 fl|B6.129-Ndst1/UcsdAnu||Recessive|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1|Ndst1|Normal|1200015G06Rik, b2b2230Clo, glucosaminyl N-deacetylase/N-sulfotransferase 1, Hsst, Ndst-1|MGI:104719|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1; targeted mutation 1, Jeffrey D Esko|Ndst1|MGI:3589211|18|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|24-Mar-2016|Cryopreserved sperm|57.0|0.0|Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 7997.0|Osterix-Cre EphrinB2 fl|B6.Cg-Efnb2 Tg((Sp7-tTA,tetO-EGFP/cre)1Amc/StVApb||Semi-dominant|ephrin B2|Efnb2|Reduced|ELF-2, Epl5, Eplg5, Htk-L, Lerk5, LERK-5, NLERK-1|MGI:105097|ephrin B2; targeted mutation 1, David J Anderson|Efnb2|MGI:2176476|8|||||||||||||||||transgene insertion 1, Andrew P McMahon|Sp7|||||||||||Mice with an osteoblast-specific knockout of ephrinB2 have altered osteoblast differentiation and delayed bone mineralisation, causing their bones to have reduced stiffness. Their response to anabolic PTH treatment was altered. This is due to ephrinB2-deficient osteoblasts becoming more apoptotic, compared to cre +ve controls. |N/A|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5|||No|27-Nov-2015|Cryopreserved sperm|50.0|0.0|Unknown||Osteoblast, Ephrin|Yes| 8032.0|CD11c-cre x Atg7|C57BL/6-Atg7 Tg(Itgax-cre)1-1Reiz/Wehi||Recessive|autophagy related 7|Atg7|Normal|1810013K23Rik, Apg7l|MGI:1921494|autophagy related 7; targeted mutation 1, Tomaki Chiba|Atg7|MGI:3587769|6|||||||||||||||||transgene insertion 1-1, Boris Reizis|mouse integrin alpha X (Cd11c)|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-Mar-2016|Cryopreserved sperm|10.0|0.0|Unknown||Dendritic cell, autophagy|Yes| 8816.0|AXDND1-571|C57BL/6-Axdnd1/MarpApb||Recessive|axonemal dynein light chain domain containing 1|Axdnd1|Unknown|9430070O13Rik, LOC381304|MGI:1924602||||1|||||||||||||||||||||||||||||Infertile|Unknown|C57/BL/6J|Yes|Unknown|Yes|Yes|No|Yes|No|Unknown||||No|21-Oct-2019|Cryopreserved sperm|50.0|0.0|Unknown||Infertility|Yes| 8031.0|Hs6st1 fl|B6.129-Hs6st1/WvcUcsdAnu||Recessive|heparan sulfate 6-O-sulfotransferase 1|Hs6st1|Normal|6)ST1|MGI:1354958|heparan sulfate 6-O-sulfotransferase 1; targeted mutation 1, Wellington V Cardoso|Hs6st1|MGI:3793786|1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|24-Mar-2016|Cryopreserved sperm|57.0|0.0|Unknown||Heparan sulphate|Yes| 8037.0|FRG1|C57BL/6J-Tg(HSA-FRG1)/MarpApb|MARP|Dominant||||||||||||||||||||||||||human Fascioscapulohumeral muscular dystrophy gene 1|HSA|High||||||||||FRG1 transgenic mice represent a mouse model of the human muscle disease Facioscapulohumeral muscular dystrophy. The phenotype of FRG1 transgenic mice has been very well characterized (Sancisi et al., 2014. Am J Physiol Regul Integr, V306(2); R127-37), (Xynos et al., 2013. J Cell Sci, V126(10); 2236-45), (Gabellini et al., 2006. Nature, V439(7079); 973-7) and (Feeney and McGrath et al., 2015. PLoS One, V10(2): e0117665). The FRG1 transgenic mice develop muscle disease from 6 weeks of age affecting predominantly hindlimb muscles (tibialis anterior, quadriceps) as well as triceps and trapezius muscles. They display hindlimb weakness and spinal kyphosis. This muscle disease does not affect mobility, food intake or survival (Gabellini et al., 2006. Nature, V439(7079); 973-7).|FRG1 transgenic mice represent a mouse model of the human muscle disease Facioscapulohumeral muscular dystrophy. The phenotype of FRG1 transgenic mice has been very well characterized (Sancisi et al., 2014. Am J Physiol Regul Integr, V306(2); R127-37), (Xynos et al., 2013. J Cell Sci, V126(10); 2236-45), (Gabellini et al., 2006. Nature, V439(7079); 973-7) and (Feeney and McGrath et al., 2015. PLoS One, V10(2): e0117665). The FRG1 transgenic mice develop muscle disease from 6 weeks of age affecting predominantly hindlimb muscles (tibialis anterior, quadriceps) as well as triceps and trapezius muscles. They display hindlimb weakness and spinal kyphosis. This muscle disease does not affect mobility, food intake or survival (Gabellini et al., 2006. Nature, V439(7079); 973-7).|C57BL6/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Wild type females crossed with FRG1-transgenic males|No|05-Apr-2016|Cryopreserved sperm|50.0|0.0|Yes|Fascioscapulohumeral muscular dystrophy. Individuals with this type of muscular dystrophy develop muscle weakness in face, arms and torso.|FSHD, muscular dustrophy, muscle disease|Yes| 8818.0|hHER2|BALB/c-Tg(Wap-ERBB2)||Dominant||||||||||||||||||||||||||human erb-b2 receptor tyrosine kinase 2|whey acidic protein (Wap)|||||||||||BALB/c hHer2 +/+ is embryonic lethal|Heterozygous +/- BALB/c-Hher2 pups are viable. No overt phenotype|BALB/c|No|No|Yes|No|No|Yes|No|Unknown||||No|23-Oct-2019|Cryopreserved sperm|44.0|0.0|Unknown||Her-2|Yes| 8040.0|C57BL/6-TLR-4|B6;129P2-Tlr4|B6;129P2-Tlr4|Recessive|toll-like receptor 4|Tlr4|Nil|lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; targeted mutation 1, Shizuo Akira|Tlr4|MGI:1860885|4||||||||||||||||Yes|||||||||||||Homozygotes for spontaneous or targeted mutations are hyporesponsive to bacterial lipopolysaccharide and more susceptible to infection by gram negative bacteria.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Apr-2016|Cryopreserved sperm|54.0|82.0|Unknown||infection, T cell, inflammation, eosinophil, hyperresponsiveness|Yes| 8036.0|Nrp2:CreERT2/EGFP|C57BL/6-Tg(Nrp2-CreERT2/EGFP)#Qsch||Dominant||||||||||||||||||||||||||CreERT2 recombinase with IRES EGFP|Nrp2|low||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|10|Male homozygous cross female homozygous|No|05-Apr-2016|Cryopreserved sperm|49.0|0.0|No||Neuropilin 2, Nrp2, CreERT2 recombinase, EGFP|Possibly| 8042.0|gp130Y757F x sgp130Fc|B6.129- Il6st Tg(Hbb-sgp130Fc)/MarpApb||Recessive|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|soluble gp130 fused to Fc portion of IgG1|beta globin|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|13-Apr-2016|Cryopreserved sperm|50.0|0.0|Yes||gp130|No| 8042.0|gp130Y757F x sgp130Fc|B6.129- Il6st Tg(Hbb-sgp130Fc)/MarpApb||Recessive|||Nil||||||1||||||||||||||||No|||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|13-Apr-2016|Cryopreserved sperm|||Yes||gp130|No| 8034.0|ENU34:001:Relb|C57BL/6NCrlAnu-Relb/AnuApb||Recessive|avian reticuloendotheliosis viral (v-rel) oncogene related B|Relb|Unknown|shep|MGI:103289||||7|ENSMUSG00000002983|ENSMUST00000094762|Relb-001|842|1038|A to T|ENSMUSE00001216935|8|281|Leucine to Glutamine|||||||||||||||||||Activated T cells and dermatitis||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Het x het|No|04-Apr-2016|Cryopreserved sperm|11.0|0.0|Unknown||ENU, T cell, dermatitis, autoimmunity|Yes| 8035.0|B6Bst2|B6.129-Bst2/Wehi||Recessive|bone marrow stromal cell antigen 2|Bst2||2310015I10Rik, Bst-2, C87040, GREG|MGI:1916800||||8|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Apr-2016|Cryopreserved sperm|30.0|0.0|Unknown|||Yes| 8038.0|NanogLacZ|C57BL/6J-Nanog/Lartf||Recessive|Nanog homeobox|Nanog|Nil|2410002E02Rik, ecat4, ENK|MGI:1919200|targeted mutation 1, Adam Hart|Nanog| |6||||||||||Unknown to Unknown||||||Yes|||||||||||||LethalHomozygous embryos fail at e5-6, due to a defect in epiblast development. Nanog is required for epiblast development.|None.Heterozygous males and females are normal and fertile and are generated in the expected medelian ratios.|C57BL/6J|No|No|Yes|No|No|Yes|No|Good|10+||backcross heterzgote males to C57BL/6 females|No|06-Apr-2016|Cryopreserved sperm|50.0|0.0|No||germline, spermatogenesis, stem cell|No| 5172.0|Mir146 -/-|C57BL/6-Mir146/BalAnuApb||Recessive|microRNA 146|Mir146|Nil|miR-146a, Mirn146, mmu-mir-146, mmu-mir-146a|MGI:2676831|microRNA 146; targeted mutation 1.1, David Baltimore|MIr146|MGI:4882045|11|||||||||||||||||||||||||||||Premature death:• mice become moribund by 18 to 22 months of ageAbnormal lymphopoiesis:• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice• however, mice exhibit normal lymphoid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blockerMyeloid hyperplasia:• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice• however, mice exhibit normal myeloid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blocker• chronic myeloproliferation and myelofibrosis in the bone marrowExtramedullary hematopoiesis:• in the spleenAnemia:Abnormal bone marrow cell morphology/development:• by 18 to 22 months, mice develop end-stage fibrosis or a hypercellular bone marrow and pale bone marrow unlike wild-type miceIncreased bone marrow cell number:• by 18 to 22 monthsDecreased erythrocyte cell number:Decreased hematocrit:Decreased hemoglobin contentThrombocytopenia:Increased regulatory T cell number:• in the periphery but not thymus• not rescued by treatment with an IFNgamma blockerDecreased leukocyte cell number:Decreased lymphocyte cell numberDecreased monocyte cell numberEnlarged spleen:• progressive starting at 5 to 6 months of age• 6 to 7 times on necropsyIncreased spleen weightAbnormal regulatory T cell physiology:• increased proliferation and suppressive function (measured by Th1 cytokine production)Increased T cell derived lymphoma incidence:• some mice develop lymphomas of B cell or mixed T and B cell lineage in the cervical lymph node, gastrointestinal tract, liver and kidneyIncreased B cell derived lymphoma incidence:• some mice develop lymphomas of B cell or mixed T and B cell lineage in the cervical lymph node, gastrointestinal tract, liver and kidney• some mice develop high-grade diffuse large B cell lymphoma with apoptotic bodies and atypical mitosisIncreased follicular lymphoma incidence:• low-grade in some miceIncreased myeloid sarcoma incidence:• in the spleen and occasionally in the liver and kidney• myeloid tumors are transplantable into immunocompromised miceIncreased spleen neoplasm incidence:• spleen tumors with myeloid sarcoma histology in many miceMyelofibrosis:• myelofibrosis in the bone marrow||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Jul-2010|Cryopreserved sperm|93.0|0.0|Unknown||T cell, lymphoma, myeloproliferation|No| 8046.0|ENU36:G3|ANU:ENU36:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||2||No|29-Apr-2016|Cryopreserved sperm|164.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8043.0|B6:Thy1.1|B6.Cg-Thy1/AnuApb||Recessive|thymus cell antigen 1, theta|Thy1||CD90, T25, theta, Thy-1, Thy1.1, Thy 1.2, Thy-1.2, Thy1.2|MGI:98747|thymus cell antigen 1, theta; a variant|Thy1|MGI:3579311|9|||||||||||||||||||||||||||||Normal||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|15-Apr-2016|Cryopreserved sperm|55.0|0.0|Unknown||Thy1.1|Yes| 8045.0|Ndufa10/C57|C57BL/6JAnu-Ndufa10/AnuUsa||Semi-dominant|NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 10|Ndufa10|Unknown|2900053E13Rik|MGI:1914523|Ndufa10: mutation 2, Australian National University|Ndufa10||1||||||||||Unknown to Unknown|||||||||||||||||||changes in blood compartment|changes in blood compartment|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|21-Apr-2016|Cryopreserved sperm|50.0|0.0|Unknown|||No| 4988.0|ATM 7271 T⇒G ; Adonis|C.B6-ATM ||Recessive|ataxia telangiectasia mutated homolog (human)|Atm|Normal|C030026E19Rik|MGI:107202|targeted mutation 1, Georgia Chenevix-Trench|ATM||9||||||||||Unknown to Unknown||||||No|||||||||||||Infertile. Increased sensitivity to ionizing radiation. Immune deficiencies. Increased susceptability to lymphoid tumours|Normal|BALB/c|Yes|No|Yes|Yes|No|Yes|Yes|Good|8|||No|28-Jan-2010|Cryopreserved sperm|163.0|0.0|Yes||ATM, cancer, Radiation, Breast|Possibly| 8052.0|Thor:Ins|Folr4:Ins||Recessive|IZUMO1 receptor, JUNO|Izumo1r||0910001L11Rik, Folbp3, Folr4, Juno|MGI:1929185||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-May-2016|Cryopreserved sperm|22.0|0.0|Unknown||CRISPR|Yes| 8050.0|Tar mice; SPTB D1781R|SJL/JAnu-Sptb/AnuApb||Dominant|spectrin beta, erythrocytic|Sptb|Reduced|brain erythroid spectrin (235E), D330027P03Rik, LOC383567, spectrin R, Spnb1, Spnb-1|MGI:98387||||12|||||||||||||||||||||||||||||Low red blood cell count and increase osmotic fragility|Low red blood cell count and increase osmotic fragility|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-May-2016|Cryopreserved sperm|54.0|0.0|Unknown||Red blood cells, osmotic fragility|Yes| 8044.0|NanogLoxP|C57BL/6J-Nanog/Lartf||Recessive|Nanog homeobox|Nanog|Normal|2410002E02Rik, ecat4, ENK|MGI:1919200|targeted mutation 2, Adam Hart|Nanog| |6||||||||||Unknown to Unknown||||||Yes|||||||||||||Homozygous Nanog (LoxP/LoxP) mice are normal and fertile.|None.Heterozygous Nanog (LoxP/+) males and females are normal and fertile and are generated in the expected medelian ratios.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10+|10+|backcross heterzgote males to C57BL/6 females, or interbreed homozygotes|No|20-Apr-2016|Cryopreserved sperm|50.0|0.0|No||germline, spermatogenesis, stem cell|No| 7450.0|Lifr fl|B6NTac;B6N-Lifr/HTacAnuApb||Dominant|leukemia inhibitory factor receptor|Lifr|Normal|A230075M04Rik, soluble differentiation-stimulating factor receptor|MGI:96788|leukemia inhibitory factor receptor; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Lifr|MGI:4841519|15|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Oct-2013|Cryopreserved sperm|75.0|0.0|Unknown||receptor, growth|Yes| 8048.0|Gadd45a KO|B6.129-Gadd45a||Recessive|growth arrest and DNA-damage-inducible 45 alpha|Gadd45a|Nil|Ddit1|MGI:107799|growth arrest and DNA-damage-inducible 45 alpha; targeted mutation 1, Albert J Fornace|Gadd45a|MGI:2182720|6|||||||||||||||||||||||||||||Premature death:• homozygous mice begin to die after 7 months of age and the median life span of females is reduced to 16 months compared to about 22 months for wild-typeAbnormal cell nucleus morphology:• splenocytes and keratinocytes have 3 or more centrosomes per cell and many keratinocytes have asymmetric distribution of centrosomes during mitosis• most MEFs with extra centrosomes also have large, partially cleaved, bilobed nucleiAbnormal chromosome morphology:• chromosomal aberrations including double minutes, centromere fusions or end associations, chromatid deletions, and incomplete triradials and quadraradialsAbnormal chromosome number:• less than 40% of homozygous MEFs are diploid at passage 4 with the rest either tetraploid or aneuploid, unlike wild-type MEFs where about 70% of cells are diploid, 30% are tetraploid and no aneuploid cells are seen• at passage 11 no homozygous MEFs are diploid and over 60% are aneuploidAneuploidy:• at passage 4 some aneuploid cells are seen and by passage 11 over 60% of cells are aneuploid• about 2% of freshly isolated splenic lymphoblasts display aneuploidy while no aneuploid cells are found in wild-type miceAbnormal cell physiology:• retroviral transfection of homozygous MEFs with an activated ras allele produces obvious transformed foci and these cells are able to form colonies in soft agar, unlike wild-type MEFs where the introduction of 2 activated oncogenes is needed for transformation• the number of colonies produced in the soft agar assay is less than in transfected homozygous Trp53 null MEFs• however, when exposed to ionizing radiation or UV apoptosis is similar to wild-type unlike Trp53 null MEFsAbnormal mitosis:• some MEFs fail to fully condense all their chromatin at mitosis• IR induces a strong G1 delay similar to wild-type cells and unlike in Cdkn1a null cellsDecreased mitotic index:• when exposed to UV the dose dependent reduction in the mitotic index is decreased compared to wild-type cells; however, when exposed to ionizing radiation (IR), the reduction in mitotic index is similar to wild-type and IR or UV-induced apoptosis is similar to wild-type unlike Trp53 null MEFsIncreased fibroblast proliferation:• from passage 5-7 homozygous MEFs progressively grow more rapidly and attain higher saturation densities compared to wild-type cells; however at earlier passages growth is similar to wild-type• low passage MEFs have a plating efficiency of about 0.025% compared to 0.005% in wild-type cells, 1.6% in Trp53 null cells, 1.2% in Cdkn1a null cells, and up to 1.4% in Gadd45a Cdkn1a double null cellsIncreased kidney cell proliferation:• diffuse global mesangial proliferation involving 40 - 100% of glomeruli is seen in older homozygotesIncreased thymus weight:• thymus weight as a percent of body weight is increased about 70% compared to wild-typeAbnormal lymphopoiesis:• lymphoid hyperplasia is seen in the lymph nodes and spleen of 9 month old homozygotesIncreased T cell number:• the proportion of total T cells is increased in the spleen and lymph nodes compared to wild-type miceIncreased thymocyte number:• thymocyte number is increased but the distribution of thymocyte subpopulations is similar to wild-typeDecreased leukocyte cell number:• at 7-9 months of age 47% of homozygous females are leukopenic compared to 7% of wild-type miceDecreased basophil cell number.Decreased eosinophil cell number.Decreased lymphocyte cell number:• at 7-9 months of age 40% of homozygous females are lymphopenic compared to 7% of wild-type miceIncreased IgG1 level:• 2-fold increase in IgG1 and high levels of IgG2b and IgG3 anti-double stranded DNA antibodies at 7 - 9 months of ageIncreased IgM level:• 2-fold increase in IgM at 7 - 9 months of ageIncreased T cell proliferation:• the sensitivity of primary T cell activation by anti-CD3 is increased with a 3- to 10-fold leftward shift in the dose-response curve and the maximal proliferative response is about 2-fold more than in wild-type cells• however, proliferation in response to cytokines and T cell receptor independent proliferation is not increased compared to controlsIncreased autoantibody level.Increased anti-double stranded DNA antibody level:• after 7 months of age in female homozygotes the occurrence and titer of antibodies against double stranded DNA is increased compared to wild-type miceIncreased anti-histone antibody level:• after 7 months of age in female homozygotes the occurrence and titer of antibodies against histones is increased compared to wild-type miceIncreased anti-single stranded DNA antibody level:• after 7 months of age in female homozygotes the occurrence and titer of antibodies against single stranded DNA is increased compared to wild-type miceIncreased inflammatory response:• lymphocytic infiltrates are seen in the lung and salivary glands at 9 months of ageGlomerulonephritis:• some glomeruli contain inflammatory cells, nuclear debris, and mesangial cell interposition, mild dilation of the proximal tubules occurs, and mild to severe dense perivascular mononuclear cell infiltrates are seen suggesting autoimmune glomerulonphritis.Exencephaly:• about 8% of pups from homozygous crosses display exencephalyParturition failure:• about 50% of females fail to deliver their first litter resulting in death of the femaleIncreased incidence of tumors by ionizing radiation induction:• following gamma irradiation tumor latency is decreased, frequency is increased, and most of the tumors are lymphomas of thymic originIncreased kidney cell proliferation:• diffuse global mesangial proliferation involving 40 - 100% of glomeruli is seen in older homozygotesIncreased urine protein level:• 150 +/- 50 mg/dl of protein is seen in the urine of homozygous females suggesting chronic nephropathyGlomerulonephritis:• some glomeruli contain inflammatory cells, nuclear debris, and mesangial cell interposition, mild dilation of the proximal tubules occurs, and mild to severe dense perivascular mononuclear cell infiltrates are seen suggesting autoimmune glomerulonphritisMesangial cell hyperplasia:• diffuse global mesangial proliferation involving 40 - 100% of glomeruli is seen in older homozygotesMesangial cell interposition:• in some glomeruliDilated proximal convoluted tubules:• mild dilation of the proximal tubulesDecreased sensitivity to skin irradiation:• in newborn and adult homozygous mice acute UVB-induced epidermal apoptosis, erythema, and induction of subcorneal pustules or epidermal erosion is reduced• after UVB irradiation homozygous primary keratinocytes show an attenuated G1 arrest and a more pronounced reduction in G2 arrest compared to wild-type cells; however UVB-induced G1 and G2 arrest in dermal fibroblasts is similar to wild-type|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-May-2016|Cryopreserved sperm|50.0|0.0|Yes|Systemic Lupus Erythematosus; SLE||Possibly| 8049.0|Slc6a19 fl|C57BL/6-Slc6a19/MarpAnu||Recessive|solute carrier family 6 (neurotransmitter transporter), member 19|Slc6a19|Normal|4632401C08Rik, B<0>AT1|MGI:1921588||||13|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-May-2016|Cryopreserved sperm|94.0|0.0|Unknown|||Yes| 8058.0|Mid1 Fxy|B6(Cg).129-Mid1/AnuApb||X-linked|midline 1|Mid1|Nil|61B3-R, DXHXS1141, Fxy, Trim18|MGI:1100537|midline 1; targeted mutation 1, Alan Ashworth|Mid1|MGI:5562687|X|||||||||||||||||||||||||||||Viable. Reduced / delayed fertility. Litter size may be slightly reduced. No other phenotype described as yet.Abnormal axon morphology:• axon length and branch number are increased in cultured cortical neurons• callosal axons grow further into the contralateral hemisphere at P4• at P14, axon distribution in the corpus callosum is disturbed with a greater number of axon terminals, with a wider distribution in both the S1 and S2 regions• broader distribution of the contralateral axon projection pattern in the corpus callosumEmbryogenesis phenotype:• no obvious midline defects, unlike in Opitz Syndrome patients|Breeder pairs often only litter down after 3 months together, if they litter down at all. Around 1 in 3 produce litters.|C57BL/6NCrlAnu|Yes|Yes|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Jun-2016|Cryopreserved sperm|55.0|0.0|Yes|Opitz GBBB syndrome|X-linked, craniofacial, cleft lip|Yes| 8063.0|ENU32:020:Ebf1|C57BL/6NCrlAnu-Ebf1/AnuApb||Dominant|early B cell factor 1|Ebf1|Unknown|O/E-1, Olf1, Olf-1|MGI:95275|Ebf1; mutation 2, Australian National University|Ebf1||11|ENSMUSG00000057098|ENSMUST00000081265|Ebf1-001||||||||44924576|10|||AAGGGACACCAGGCAGATTCATCTACACAGGTAAGCGTGCCTGCAGATGGGAACCACAGA||||||||||||||Homozygous lethal, unknown at what stage.|Abnormal and reduced numbers of B cells|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||5||No|05-Jul-2016|Cryopreserved sperm|33.0|0.0|Unknown||B cell, lymphocyte|Yes| 8062.0|ENU32:083:Bcl11b|C57BL/6NCrlAnu-Bcl11b/AnuApb||Dominant|B cell leukemia/lymphoma 11B|Bcl11b|Unknown|9130430L19Rik, B630002E05Rik, COUP-TF interacting protein 2, CTIP2, Rit1|MGI:1929913|Bcl11b; mutation 1, Australian National University|Bcl11b||12|ENSMUSG00000048251|ENSMUST00000066060|Bcl11b-001|||T to C||||Unknown to Unknown|||||||||||||||||||Homozygous lethal, unknown at what stage.|increased %CD4 T cells, decreased %CD8 T cells and high CD44 MFI on CD4 and CD8 T cells in peripheral blood.|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||5||No|05-Jul-2016|Cryopreserved sperm|44.0|0.0|Unknown||T cell, lymphocyte|Yes| 7715.0|BatInbred|C57BL/6J-Frem1/MarpApb||Dominant|Fras1 related extracellular matrix protein 1|Frem1|Unknown|crf11, eye, eyes2, heb, QBRICK|MGI:2670972|Fras1 related extracellular matrix protein 1; bat|Frem1|MGI:3526691|4|||||||||||||||||||||||||||||Cryptophthalmos, absent eyelids, abnormal eye development, syndactyly, abnormal craniofacial morphology.Abnormal conjunctiva morphology:• coloboma defects are associated with defects in formation of the conjunctivaAbnormal cornea morphology:• coloboma defects are associated with cornea fibrosisdecreased cornea thickness• coloboma defects are associated with absence of corneal epithelium leading to thinning of the cornea.Abnormal corneal epithelium morphology:• coloboma defects are associated with absence of corneal epitheliumAbnormal eye development:• defects in the adhesion of the surface ectoderm and corneal stroma.Coloboma:• several mutants exhibit eyelid coloboma similar to that seen in Manitoba-oculo-tricho-anal syndrome, affecting only one part of the eyelid• coloboma defects are associated with failure of eyelid formation, defects in formation of the conjunctiva, and absence of corneal epithelium leading to thinning of the cornea and fibrosis on the external face.Ocular hypertelorism:• greater intercanthal distanceAbsent eyelids:• have no true eyelids and the closed-eye appearance results from the presence of a pseudoblepharon that can be either unilateral or bilateral.Cryptophthalmos:• majority of mutants exhibit cryptophthalmos.Syndactyly:• seen occasionallyAbnormal kidney morphology:• exhibit renal abnormalitiesSingle kidney:• about 20% of adults show unilateral renal agenesis.Bleb:• epidermis separates from the dermis below the level of the lamina densa creating blebs/blisters during embryonic development• Background Sensitivity: blebbing phenotype is 100% penetrant on a C57BL/6J background but is only about 70% penetrant on a mixed C57BL/6J and C3H/NeJ background• from E13.5, develop blebs located predominantly around the eyes and the sides of the head.Abnormal craniofacial morphology:• upper midface is raised along the proximal aspect of the metopic suture and is wider at the level of the coronal suture• abnormalities include medial depression along the internasal suture and/or marked curvature of the nasal bones• slightly shorter philtrum-columella height.Abnormal cranial suture morphology:• most mutants exhibit abnormal maxillary-premaxillary suture morphology.Abnormal metopic suture morphology:• mutants exhibit advanced fusion of the posterior frontal suture compared to wild-type miceAsymmetric snout:• 7 of 16 mutants exhibit varying degrees of midfacial asymmetry and/or midface hypoplasia (J:177282)Short snout:• 7 of 16 mutants exhibit varying degrees of midfacial asymmetry and/or mid face hypoplasia.• reduction in snout length is inversely correlated with both cranial width and intercanthal distance.Abnormal cranial suture morphology:• most mutants exhibit abnormal maxillary-premaxillary suture morphology.Abnormal metopic suture morphology:• mutants exhibit advanced fusion of the posterior frontal suture compared to wild-type miceBroad nasal bone.Premature suture closure:• mutants exhibit anterofrontal cranial deformation similar to Metopic craniosynostosis and trigonocephaly:• mutants exhibit advanced fusion of the posterior frontal suture compared to wild-type mice, with fusion seen at postnatal day 28 compared to day 45 in controls.Rectal prolapse:• 4 of 138 mutants exhibit anal prolapse, showing protrusion of the rectal epithelia and an immune infiltrate in exposed tissue• the musculature of the anal sphincter is present in mutants with anal prolapse but is misplaced• however, anorectal musculature appears normal.Asymmetric snout:• 7 of 16 mutants exhibit varying degrees of midfacial asymmetry and/or midface hypoplasiaShort snout:• 7 of 16 mutants exhibit varying degrees of midfacial asymmetry and/or midface hypoplasia• reduction in snout length is inversely correlated with both cranial width and intercanthal distance.|Abnormal cranial suture morphology:• 42% of heterozygotes exhibit variable sutural abnormalities, including complete fusion, sutural asymmetry and advanced endocranial suture fusionAsymmetric snout:• 2 of 21 mutants exhibit varying degrees of midfacial asymmetry and/or midface hypoplasiaShort snout:• 2 of 21 mutants exhibit varying degrees of midfacial asymmetry and/or midface hypoplasiaPremature suture closure:• mutants exhibit anterofrontal cranial deformation similar to metopic craniosynostosis and trigonocephaly, although less severe than seen in homozygotes.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|10||No|02-Jul-2014|Cryopreserved sperm|50.0|0.0|Yes|Fraser Syndrome- autosomal recessive congenital disorder characterising developmental defects|Fraser Syndrome|Possibly| 8066.0|ENU36:034:Itpkb|C7BL/6NCrlAnu-Itpkb/AnuApb||Recessive|inositol 1,4,5-trisphosphate 3-kinase B|Itpkb|Unknown|1110033J02Rik, E130307H12Rik|MGI:109235|Itpkb; mutation 1, Australian National University|Itpkb||1||||||||||Unknown to Unknown|||||||||||||||||||Mice lack T cells and have abnormal B cells in blood.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||3||No|05-Jul-2016|Cryopreserved sperm|33.0|0.0|Unknown||T cell, B cell, lymphocyte|Yes| 8067.0|Slc6a19 KO|C57BL/6-Slc6a19/AnuApb||Recessive|solute carrier family 6 (neurotransmitter transporter), member 19|Slc6a19|Nil|4632401C08Rik, B<0>AT1|MGI:1921588|Slc6a19: targeted mutation 2, Australian National University|Slc6a19||13||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2016|Cryopreserved sperm|21.0|0.0|Unknown|||Yes| 8070.0|Pdgfra-cre|C57BL/6-Tg(Pdgfra-cre)1Clc/JAnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Constance L Cepko|mouse platelet derived growth factor receptor alpha|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2016|Cryopreserved sperm|49.0|0.0|Unknown||Cre recombinase|No| 8072.0|Mir124a-3 fl|STOCK Mir124a-3/Mmjax||Recessive|microRNA 124a-3|Mir124a-3|Normal|mir-124a-3, Mirn124a-3, mmu-mir-124-3, mmu-mir-124a-3|MGI:3618704|microRNA 124a-3; targeted mutation 1, Michael McManus|Mir124a-3|MGI:5314768|2||||||||||||||||||||||||||||||Normal|C57L/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2016|Cryopreserved sperm|55.0|0.0|Unknown||micro RNA|No| 8076.0|TZF KO|B6(Cg)-Zfp318/RbrcAnuApb||Recessive|zinc finger protein 318|Zfp318|Nil|2610034E08Rik, D530032D06Rik, TZF|MGI:1889348|zinc finger protein 318; targeted mutation 1, Hiromi Hagiwara|Zfp318|MGI:5578603|17|||||||||||||||||||||||||||||Hematopoietic system phenotype:N • normal level of circulating B cells and matured to the CD93-negative stageDecreased IgD level:• expression abolished in immature and mature B cellsIncreased IgM level:• threefold increase in mature B cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8||B6NCrl x Het|No|17-Jul-2016|Cryopreserved sperm|30.0|0.0|Unknown||B cell|Yes| 8078.0|SJL Jax|B6(Cg).SJL-Ptprc/JAnuApb||Recessive||||||||||||||||||||||||||||||||||||||T cells express the Ptprc allele instead of Ptprc allele usually carried by Lymphocytes isolated from C57BL/6 mice.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|1|a x a|No|25-Jul-2016|Cryopreserved sperm|55.0|0.0|Unknown||Ly5a|Yes| 8079.0|SJL NCrl|B6(Cg).SJL-Ptprc/NCrlAnuApb||Recessive|||||||||||||||||||||||||||||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|T cells express the Ptprc allele instead of Ptprc allele usually carried by Lymphocytes isolated from C57BL/6 mice.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|9|2|a x a|No|25-Jul-2016|Cryopreserved sperm|87.0|0.0|Unknown||Ly5a|Yes| 8081.0|Dicer1flox/flox x EsrCRE|B6.129-Dicer Gt(ROSA)26Sor/MarpApb||Recessive|dicer 1, ribonuclease type III|Dicer1|Normal|1110006F08Rik, D12Ertd7e, Dicer1, mKIAA0928|MGI:2177178|dicer 1, ribonuclease type III; targeted mutation 1, Brian D Harfe|Dicer1|MGI:3589208|12|||||||||||||||||CreERT |Rosa26|||||||||||Normal|Normal|C57BL/6×129 |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Aug-2016|Cryopreserved sperm|50.0|45.0|Unknown|||Yes| 8081.0|Dicer1flox/flox x EsrCRE|B6.129-Dicer Gt(ROSA)26Sor/MarpApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Jeremy Nathans|Gt(ROSA)26Sor|MGI:2669525|6|||||||||||||||||||||||||||||Normal|Normal|C57BL/6×129 |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Aug-2016|Cryopreserved sperm|||Unknown|||Yes| 8074.0|Adar1 -/- Ifih1-/-|B6.129-Adar1 Ifih1/Apb||Recessive|adenosine deaminase, RNA-specific|Adar|Nil|ADAR1, Adar1p110, Adar1p150, mZaADAR|MGI:1889575|adenosine deaminase, RNA-specific; targeted mutation 1, Peter H Seeburg|Adar|MGI:3029789|3|||||||||||||||||||||||||||||Double homozygous are lethal at or near birth|Adar1+/- Ifih1-/- are viable and normal (likely susceptible to viral infection due to Ifih1-/-)Ifih1+/- = normalAdar1+/- = normal|C57BL6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Jul-2016|Cryopreserved sperm|30.0|0.0|Unknown||RNA editing, double stranded|Yes| 8074.0|Adar1 -/- Ifih1-/-|B6.129-Adar1 Ifih1/Apb||Recessive|interferon induced with helicase C domain 1|Ifih1|Nil|9130009C22Rik, Helicard, MDA5, MDA-5|MGI:1918836|interferon induced with helicase C domain 1; targeted mutation 1.1, Marco Colonna|Ifih1|MGI:3663677|2|||||||||||||||||||||||||||||Double homozygous are lethal at or near birth|Adar1+/- Ifih1-/- are viable and normal (likely susceptible to viral infection due to Ifih1-/-)Ifih1+/- = normalAdar1+/- = normal|C57BL6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Jul-2016|Cryopreserved sperm|||Unknown||RNA editing, double stranded|Yes| 8093.0|ENU35:029:ppp3cb|C57BL/6NCrlAnu-Ppp3cb/AnuApb||Recessive|protein phosphatase 3, catalytic subunit, beta isoform|Ppp3cb|Unknown|1110063J16Rik, Calnb, Cnab, CnAbeta, PP2BA beta|MGI:107163|Ppp3cb; mutation 1, Australian National University|Ppp3cb||14|ENSMUSG00000021816|ENSMUST00000159027.7|Ppp3cb-001||||||||20520552|6|||ATGGTCTTTACCATTTGTTGGAGAAAAAGGTGCGATTTTTGTTTTTTTGGGGGGGTATTT||||||||||||||Reduced numbers of peripheral blood T cells.T cells are activated.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4||No|01-Sep-2016|Cryopreserved sperm|55.0|0.0|Unknown||ENU, T cell|Yes| 8082.0|ASD661:Pique:7|C57BL/6NCrlAnu-Zfr2/AnuApb||Recessive|zinc finger RNA binding protein 2|Zfr2|Unknown|2010013I23Rik, 9130206N08Rik|MGI:2143792||||10|||||||||||||||||||||||||||||Unknown at this stage||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|Poor||||No|11-Aug-2016|Cryopreserved sperm|11.0|0.0|Unknown||CRISPR|Possibly| 8084.0|RHBDF1_PKD_1|C57BL/6-Rhbdf1/MarpApb||Recessive|rhomboid 5 homolog 1|Rhbdf1|Unknown|Dist, Dist1, Egfr-rs|MGI:104328||||11|ENSMUSG00000020282|ENSMUST00000020524.14|Rhbdf1-006|584|740|C to T|ENSMUSE00001312827|5|195|Serine to Phenylalanine|||||TGCAGCCTCCCTCTGCTCTTTCTCCAGCTCCCGCTCAGGTTTCAACCGACTCCCTCGGCGT||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Aug-2016|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8095.0|CD11c-DTR|B6.Cg-Tg(Itgax-DTR/EGFP)57Lan/MelbApb||Semi-dominant||||||||||||||||||||||||||transgene insertion 57, Richard A Lang|mouse Itgax promoter (CD11c)||||||||||||CD11c positive dendritic cells will be deleted upon treatment of mice with diphtheria toxin.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2016|Cryopreserved sperm|20.0|0.0|Unknown||Cytotoxic T lymphocytes (CTL) , Dentritic cells|Yes| 8821.0|Npffr2 flox|B6.Cg-Npffr2/Apb||Recessive|neuropeptide FF receptor 2|Npffr2||Gpr74, NPFF2|1860130|neuropeptide FF receptor 2; targeted mutation 1, H Herzog|Npffr2|MGI:6313710|5|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Oct-2019|Cryopreserved sperm|4.0|0.0|Unknown||Adipose, thernogenesis|Yes| 8090.0|LAT3_SRNS_1|C57BL/6-Slc43a1/MarpApb||Recessive|solute carrier family 43, member 1|Slc43a1|Unknown|2610016F07Rik, Lat3, PB39, Pov1|MGI:1931352||||2|ENSMUSG00000027075|ENSMUST00000121114.7|Slc43a1-001|597|1442|G to C|ENSMUSE00001223444|7|199|Methionine to Isoleucine|||||GATGCCGGAGTCCCCTTCACTGTCATCATGTTCACATGGTCTGGCCTGGCCTGTCTCATCT||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Aug-2016|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8091.0|ENU36:080|C57BL/6NCrlAnu-Car2/AnuApb||Recessive|carbonic anhydrase 2|Car2|Unknown|CAII, CA II, Car-2, Ltw-5, Lvtw-5|MGI:88269||||3|ENSMUSG00000027562|ENSMUST00000029078.8|Car2-001|143|465|T to A| ENSMUSE00000371047 |2|47|Leucine to Glutamine|||||||||||||||||||RBC resistant to lysis||C57BL/6NCrlAnu|Unknown|Yes|Yes|Unknown|Yes|Yes|No|Unknown||3||No|29-Aug-2016|Cryopreserved sperm|22.0|0.0|Unknown||ENU|Yes| 8094.0|ENU28:008:Slc1a5|C57BL/6NCrlAnu-Slc1a5/AnuApb||Recessive|solute carrier family 1 (neutral amino acid transporter), member 5|Slc1a5|Unknown|ASCT2|MGI:105305|solute carrier family 1 (neutral amino acid transporter), member 5; mutation 1, Australian National University|Slc1a5|MGI:6446934|7||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10||No|05-Sep-2016|Cryopreserved sperm|31.0|0.0|Unknown||ENU|Yes| 8096.0|Cliff79B-A3|C57BL/6NCrlAnu-Cd79b/AnuApb||Recessive|CD79B antigen|Cd79b|Unknown|B29, Igb, Igbeta, Ig-beta|MGI:96431||||11|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Sep-2016|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 8097.0|Cliff79B-A4|C57BL/6NCrlAnu-Cd79b/AnuApb||Recessive|CD79B antigen|Cd79b|Unknown|B29, Igb, Igbeta, Ig-beta|MGI:96431||||11|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Sep-2016|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8098.0|Cliff79B-A5|C57BL/6NCrlAnu-Cd79b/AnuApb||Recessive|CD79B antigen|Cd79b|Unknown|B29, Igb, Igbeta, Ig-beta|MGI:96431||||11|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Sep-2016|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 8099.0|ENU34:047:Olfr603|C57BL/6NCrlAnu-Olfr603/AnuApb||Recessive|olfactory receptor 603|Olfr603|Unknown|GA_x6K02T2PBJ9-6092550-6092362, GA_x6K02T2PBJ9-6096387-6095449, MOR32-14_i, MOR32-2, Olfr604|MGI:3030437||||7|ENSMUSG00000059874|ENSMUST00000071844.1|Olfr603-001|386|386|C to T|ENSMUSE00001043266|1|129|Cysteine to Tyrosine|||||CATGGCAATTGACCGTTTTGTTGCCATCTGTTACCCACTTAGGTATACCTCTGTTCTCACC||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Sep-2016|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 8104.0|Cliff79B-A2|C57BL/6NCrlAnu-Cd79b/AnuApb||Recessive|CD79B antigen|Cd79b|Unknown|B29, Igb, Igbeta, Ig-beta|MGI:96431|Cd79b; endonuclease mutation 5, Australian National University|Cd79b||11||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2016|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 8105.0|Cliff79B-A1|C57BL/6NCrlAnu-Cd79b/AnuApb||Recessive|CD79B antigen|Cd79b|Unknown|B29, Igb, Igbeta, Ig-beta|MGI:96431||||11|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2016|Cryopreserved sperm|20.0|0.0|Unknown|||Yes| 8106.0|T1germTg|Germline SIRT1 transgenics||Dominant||||||||||||||||||||||||||||||||||||||Improved glucose tolerance,resistance to ageing, expected prolonged lifespan.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2016|Cryopreserved sperm|50.0|0.0|Unknown||Glucose, body weight|Possibly| 8101.0|ASD543:Weidenfeller|C57BL/6NCrlAnu-Vps51/AnuApb||Recessive|VPS51 GARP complex subunit|Vps51|Unknown|1110014N23Rik, 3110057M17Rik|MGI:1915755||||19|||||||||||||||||||||||||||||Embryonic lethal||C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|09-Sep-2016|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8112.0|Ets1Flp|C57BL/6-Ets1/Pjh||Recessive|E26 avian leukemia oncogene 1, 5' domain|Ets1|Normal|Ets-1, MGC:18571, p42Ets-1, p51Ets-1, Tpl1, vs|MGI:95455|E26 avian leukemia oncogene 1, 5' domain #198Flp#20|Ets1||9||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|10-Oct-2016|Cryopreserved sperm|50.0|0.0|Unknown||Transcription factor|Possibly| 8118.0||ASD565:Hummels:F1#12:Mertk:Timd4 #2||Recessive|c-mer proto-oncogene tyrosine kinase|Mertk|Unknown|Eyk, Mer, nmf12, Nyk, Tyro 12|MGI:96965||||2|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|26-Oct-2016|Cryopreserved sperm|12.0|0.0|Unknown|||No| 8118.0||ASD565:Hummels:F1#12:Mertk:Timd4 #2||Recessive|T cell immunoglobulin and mucin domain containing 4|Timd4||B430010N18Rik, Tim4, TIM-4|MGI:2445125||||11|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|26-Oct-2016|Cryopreserved sperm|||Unknown|||No| 7800.0|Krt76 tm1d|B6(Cg)-Krt76/MarpApb||Recessive|keratin 76|Krt76|Nil|2310001L23Rik|MGI:1924305||||15|||||||||||||||||||||||||||||Unkempt, dull coats and smaller body size, scaling of skin of the tail, abnormal paw pad hyperpigmentation |Abnormal sebaceous gland morphology, abnormal hair cycle, abnormal epidermis stratum basale morphology, hyperkerotosis, parakerotosis|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2|4||No|26-Nov-2014|Cryopreserved sperm|50.0|0.0|No||Keratin 76, tight junctions, CLDN1, inflammation, skin|Possibly| 8107.0|Vps51 tm1a|C57BL/6N-Vps51/WtsiHAnu||Recessive|VPS51 GARP complex subunit|Vps51|Normal|1110014N23Rik, 3110057M17Rik|MGI:1915755|VPS51 GARP complex subunit; targeted mutation 1a, Wellcome Trust Sanger Institute|Vps51|MGI:4458528|19|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Sep-2016|Cryopreserved sperm|42.0|0.0|Unknown|||Yes| 8108.0|gp130Y757F x Nlrp3 KO|B6.129- Il6st Nlrp3/MarpApb||Recessive|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric tumours and emphysema||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|06-Oct-2016|Cryopreserved sperm|50.0|0.0|Yes||gp130|Yes| 8108.0|gp130Y757F x Nlrp3 KO|B6.129- Il6st Nlrp3/MarpApb||Recessive|NLR family, pyrin domain containing 3|Nlrp3|Nil|Cias1, cryopyrin, Mmig1, NALP3, Pypaf1|MGI:2653833|NLR family, pyrin domain containing 3; targeted mutation 1, Richard A Flavell|Nlrp3|MGI:3686871|11||||||||||||||||No|||||||||||||Mice develop gastric tumours and emphysema||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|06-Oct-2016|Cryopreserved sperm|||Yes||gp130|Yes| 8122.0|ENU31:065|C57BL/6NCrlAnu-Eif2ak4/AnuApb||Recessive|eukaryotic translation initiation factor 2 alpha kinase 4|Eif2ak4|Unknown|GCN2|MGI:1353427|Eif2ak4: mutation 1, Australian National University|Eif2ak4||2|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Oct-2016|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 8128.0|ENU18:021:Baff|B6(Cg)-Tnfsf13b/AnuApb||Recessive|tumor necrosis factor (ligand) superfamily, member 13b|Tnfsf13b||BAFF, BLyS, D8Ertd387e, TALL-1, zTNF4|MGI:1344376|Tnfsf13b: mutation 2, Australian National University|Tnfsf13b||8|||||||||||||||||||||||||||||Block in B cell development||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|31-Oct-2016|Cryopreserved sperm|45.0|0.0|Unknown||B cell|Yes| 8132.0|WEHIG1:Fcho1:C57Crl|B6.Cg-Fcho1/Anuapb||Recessive|FCH domain only 1|Fcho1|Unknown|3322402E17Rik|MGI:1921265||||8|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Nov-2016|Cryopreserved sperm|33.0|0.0|Unknown||ENU|Yes| 8116.0|ENU18:Olfr603:B6|C57BL/6NCrlAnu-Olfr603/AnuApb||Recessive|olfactory receptor 603|Olfr603|Unknown|GA_x6K02T2PBJ9-6092550-6092362, GA_x6K02T2PBJ9-6096387-6095449, MOR32-14_i, MOR32-2, Olfr604|MGI:3030437||||7|ENSMUSG00000059874|ENSMUST00000071844.1|Olfr603-001||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Oct-2016|Cryopreserved sperm|42.0|0.0|Unknown|||Yes| 8133.0|Blimp1 fl|B6.Cg-Prdm1/WehiMarpAnu||Recessive|PR domain containing 1, with ZNF domain|Prdm1||b2b1765Clo, Blimp1, Blimp-1, PRDI-BF1|MGI:99655|PR domain containing 1, with ZNF domain; targeted mutation 2.1, Stephen L Nutt|Prdm1|MGI:4355900|10|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|14-Nov-2016|Cryopreserved sperm|66.0|0.0|Unknown||T cell|Yes| 8135.0|Sm22-rtTA|FVB/N-Tg(Tagln-rtTA)E1Jwst||Dominant||||||||||||||||||||||||||transgene insertion E1, James West|murine smooth muscle-specific SM22-alpha|||||||||||Same as wildtype|Same as wildtype|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Nov-2016|Cryopreserved sperm|50.0|0.0|Unknown||SM22, Tetracycline|Yes| 8137.0|Rosa26-FlagCep55 Tg|BALB/c-Gt(ROSA)26Sor||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Increased|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|Flag-Cep55 Floxed|||6|||||||||||||||||||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|5|||No|16-Nov-2016|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8139.0|Cd11c-cre-GFP|C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J||Dominant||||||||||||||||||||||||||transgene insertion 4097, Alexander V Chervonsky|Itgax|||||||||||Normal||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Nov-2016|Cryopreserved sperm|45.0|0.0|Unknown||GFP|No| 8140.0|Pvr KO|B6N.129S2-Pvr/JAnu||Recessive|poliovirus receptor|Pvr|Nil|3830421F03Rik, CD155, D7Ertd458e, mE4, necl-5, Taa1, Tage4|MGI:107741|poliovirus receptor; targeted mutation 1, Gunter Bernhardt|Pvr|MGI:3719436|7|||||||||||||||||||||||||||||Decreased IgA level: • following oral immunization with cholera toxin, IgA levels are decreased relative to wild-type miceDecreased IgG level: • following oral immunization with cholera toxin, IgG1, IgG2a and IgG2b levels are decreased relative to wild-type miceDecreased IgG1 level.Decreased IgG2a level. Decreased IgG2b level.Abnormal response to infection: • following oral immunization with cholera toxin, IgA, IgG1, IgG2a and IgG2b levels are decreased relative to wild-type mice||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|24-Nov-2016|Cryopreserved sperm|44.0|0.0|Unknown||receptor, CD155|No| 8141.0|Lck-icre|B6.Cg-Tg(Lck-icre)3779Nik/JAnu||Dominant||||||||||||||||||||||||||transgene insertion 3779, Nigel Killeen|distal Lck|T cells||||||||||Cre recombinase is expressed in T cells||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|12|||No|24-Nov-2016|Cryopreserved sperm|54.0|0.0|Unknown||Cre recombinase|No| 8822.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|recombination activating 1|Rag1|||MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|ENSMUSG00000061311|ENSMUST00000078494|||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Nov-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8822.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|histocompatibility 2, D region locus 1|H2-D1||H-2D|MGI:95896|H2-D1Ab1Ea2|||17|ENSMUSG00000073411 ||||||||||||||||Tg(TCR A1.2)||||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Nov-2019|Cryopreserved sperm|||Unknown|||Yes| 8822.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|insulin I|Ins1|||MGI:96572||Ins1||19|ENSMUSG00000035804 ||||||||||||||||Tg(HLA-DR4,HLA-DQ8)||||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Nov-2019|Cryopreserved sperm|||Unknown|||Yes| 8131.0|TetO7-BMPR2 R899X|FVB/N-Tg(tetO-Bmpr2*R899X)#Jwst||Dominant||||||||||||||||||||||||||transgene insertion, James West|A septad of tetracycline respons element with a minimal CMV promoter|||||||||||Same as wildtype|Same as wildtype|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Nov-2016|Cryopreserved sperm|50.0|0.0|Unknown||Familial pulmonary arterial hypertension (PAH), muscle, BMPR2|Yes| 8138.0|Vps51:35bp deletion|B6(Cg)-Vps51/AnuApb||Recessive|VPS51 GARP complex subunit|Vps51|Unknown|1110014N23Rik, 3110057M17Rik|MGI:1915755||||19|||||||||||||||||||||||||||||Embryonic lethal||C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown|4|||No|18-Nov-2016|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8159.0|NODlga|NOD-Ifnlr1 Ifngr1 Ifnar1||Recessive|Interferon lambda receptor 1|Ifnlr1|Unknown|CRF2-12, IFNLR1, Il28ra|MGI:2429859||em13Tcb||4|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Dec-2016|Cryopreserved sperm|40.0|0.0|Yes|Type 1 diabetes||Possibly| 8159.0|NODlga|NOD-Ifnlr1 Ifngr1 Ifnar1||Recessive|Interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gammaR, IFN-gamma R, Ifngr, Nktar|MGI:107655||em15Tcb||10|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Dec-2016|Cryopreserved sperm|||Yes|Type 1 diabetes||Possibly| 8159.0|NODlga|NOD-Ifnlr1 Ifngr1 Ifnar1||Recessive|Interferon alpha receptor 1|Ifnar1|Unknown|Ifar, IFN-alpha/betaR, Ifrc|MGI:107658||em16Tcb||16|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|17-Dec-2016|Cryopreserved sperm|||Yes|Type 1 diabetes||Possibly| 8148.0|Arpc1b KO, Arpc1b fl|C57BL/6N-Arpc1b/WtsiAnu||Recessive|actin related protein 2/3 complex, subunit 1B|Arpc1b|Normal|L72, p41-ARC, SOP2Hs|MGI:1343142|actin related protein 2/3 complex, subunit 1B; targeted mutation 1a, Wellcome Trust Sanger Institute|Arpc1b|MGI:4431851|5|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Dec-2016|Cryopreserved sperm|58.0|0.0|Unknown|||Yes| 8149.0|NODCrisprGzmA|NOD-Gzma||Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla3, Ctla-3, Hanukah factor, Hf, H factor, SE1, serine esterase 1, TSP1, TSP-1 |MGI:109266||||13|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|11-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8151.0|NODCrisprGzmA|NOD-Gzma||Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla3, Ctla-3, Hanukah factor, Hf, H factor, SE1, serine esterase 1, TSP1, TSP-1|MGI:109266||em3Tcb||13|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|15-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8152.0|NODSTING|NOD-Tmem173||Recessive|Transmembrane protein 173|Sting1|Unknown|2610307O08Rik, ERIS, MPYS, Sting, Tmem173|MGI:1919762|stimulator of interferon response cGAMP interactor 1; endonuclease-mediated mutation 1, Thomas Brodnicki|Sting1|MGI:7341356|18||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|15-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8154.0|NODlga|NOD-Ifnlr1||Recessive|Interferon lambda receptor 1|Ifnlr1|Unknown|CRF2-12, IFNLR1, Il28ra|MGI:2429859||em13Tcb||4|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Dec-2016|Cryopreserved sperm|70.0|0.0|Yes|Type 1 diabetes||Possibly| 8156.0|NODlga|NOD-Ifngr1||Recessive|Interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gammaR, IFN-gamma R, Ifngr, Nktar|MGI:107655||em15Tcb||10|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8157.0|NODlga|NOD-Ifnar1||Recessive|Interferon alpha receptor 1|Ifnar1|Unknown|Ifar, IFN-alpha/betaR, Ifrc|MGI:107658||em16Tcb||16|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8165.0|Prox1enhCRISPR-Shenzi|C57BL/6-Prox1||Recessive|prospero homeobox 1|Prox1|Unknown|A230003G05Rik|MGI:97772||||1|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-Jan-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8169.0|Prox1enhCRISPR-Zazu|C57BL/6-Prox1||Recessive|prospero homeobox 1|Prox1|Unknown|A230003G05Rik|MGI:97772||||1|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-Jan-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8153.0|NODSTING|NOD-Tmem173||Recessive|Transmembrane protein 173|Sting1|Unknown|2610307O08Rik, ERIS, MPYS, Sting, Tmem173|MGI:1919762|stimulator of interferon response cGAMP interactor 1; endonuclease-mediated mutation 2, Thomas Brodnicki|Sting1|MGI:7341357|18||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8160.0||ENU36:080:Car2||Recessive|carbonic anhydrase 2|Car2|Unknown|CAII, CA II, Car-2, Ltw-5, Lvtw-5|MGI:88269||||3|ENSMUSG00000027562|ENSMUST00000029078.8|Car2-001|140|465|T to A|ENSMUSE00000371047|2|47|Leucine to Glutamine|||||TGCCCAGCATGACCCTGCCCTACAGCCTCTGCTCATATCTTATGATAAAGCTGCGTCCAAG||||||||||||||Red blood cells are resistent to lysis||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Dec-2016|Cryopreserved sperm|36.0|0.0|Unknown||Red blood cell|Possibly| 8170.0|Prox1enhCRISPR-Ed|C57BL/6-Prox1||Recessive|prospero homeobox 1|Prox1|Unknown|A230003G05Rik|MGI:97772||||1|||||||||||||||||||||||||||||unknown|unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-Jan-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7681.0|ENU7PMH:130:B6 ; Krusty|B6(Cg)-Ndfip1/AnuApb|B6(Cg)-Ndfip1/AnuApb|Recessive|Nedd4 family interacting protein 1|Ndfip1||0610010M22Rik|MGI:1929601|Nedd4 family interacting protein 1; krusty|Ndfip1|MGI:5442611|18|ENSMUSG00000024425|ENSMUST00000025293|Ndfip1-201||||||||38612084|5|||TCTCTAATTAAGTGGATCCTTATTGTCAGGGTAAGTTGCATAGCAGAGAACAGATTGTGA||||||||||||||Autoimmune disease.Spontaneous mast cell-rich dermatitis with median onset age 90 d, followed by weight loss and premature mortality at a median age of 160 d||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Yes|Yes|No|Unknown||G4N5|Het x Het ; Het x Hom|No|13-May-2014|Cryopreserved sperm|26.0|0.0|Unknown||T cell, autoimmunity, CD4, ENU|Yes| 7679.0|ENU7PMH:130:B10:B6-ATkk:G9 ; Krusty:3A9:H2|B6.Cg-H2 Ndfip1 Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive|Nedd4 family interacting protein 1|Ndfip1|Unknown|0610010M22Rik|MGI:1929601|krusty|kru||18|ENSMUSG00000024425|ENSMUST00000025293|Ndfip1-201||||||||38612084|5|||TCTCTAATTAAGTGGATCCTTATTGTCAGGGTAAGTTGCATAGCAGAGAACAGATTGTGA||transgene insertion 1, Mark M Davis|TCR||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Spontaneous mast cell-rich dermatitis with median onset age 90 d, followed by weight loss and premature mortality at a median age of 160 d. This was accompanied by lymph- adenopathy, splenomegaly, increased CD86 and CD23 activation markers on B cells, expansion of the activated/memory subset of CD4<+> and CD8<+> T cells, greatly elevated serum IgE, and for- mation of a prominent population of IL-4<+> and IFN-γ<+> CD4<+>.Autonomous accumulation of CD4<+> effector cells not corrected by normal Foxp3<+> cells.Absence of Ndfip1 did not result in spontaneous activation of naïve CD4+ T cells. Naive Ndfip1 Tg(TcrHel3A9) CD4<+> transferred to congenic B10.BR CD45 mice injected with hen egg lysozyme. After 6 days continued to increase in frequency, a further 4 fold over d3 levels, whereas WT cells decreased 5 fold from d3 levels.||C57BL/6JSfdAnu x B10.BR-H2|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|13-May-2014|Cryopreserved sperm|50.0|0.0|Unknown||T cell, autoimmune, CD4, FoxP3, tolerance|Yes| 8177.0|ENU36:195:Map3k8|C57BL/6NCrlAnu-Map3k8/AnuApb||Recessive|mitogen-activated protein kinase kinase kinase 8|Map3k8|Unknown|c-COT, Cot, Cot/Tpl2, Tpl2, Tpl-2|MGI:1346878||||18|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|03-Feb-2017|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Yes| 8178.0|ENU37:055:Casp4|C57BL/6NCrlAnu-Casp4/AnuApb||Recessive|caspase 4, apoptosis-related cysteine peptidase|Casp4|Unknown|Casp11, Caspase-11, ich-3|MGI:107700||||9|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|03-Feb-2017|Cryopreserved sperm|36.0|0.0|Unknown||ENU|Yes| 8176.0|ENU35:180:Nlrp3|C57BL/6NCrlAnu-Nlrp3/Anu||Recessive|NLR family, pyrin domain containing 3|Nlrp3|Unknown|Cias1, cryopyrin, Mmig1, NALP3, Pypaf1|MGI:2653833||||11|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|03-Feb-2017|Cryopreserved sperm|22.0|0.0|Unknown||ENU|Yes| 8179.0|ENU26:003:Nlrp3|C57BL/6NCrlAnu-Nlrp3/Anu||Recessive|NLR family, pyrin domain containing 3|Nlrp3|Unknown|Cias1, cryopyrin, Mmig1, NALP3, Pypaf1|MGI:2653833||||11|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|03-Feb-2017|Cryopreserved sperm|24.0|0.0|Unknown||ENU|Yes| 7873.0|ACTFLPtg|B6.Cg-Tg(ACTFLPe)9205Dym/JAusbAnuApb||Dominant||||||||||||||||||||||||||transgene insertion 9205, Susan Dymecki|ACTB, actin, beta, human|The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being 4X and 10X that of wildtype FLP at 37°C and 40°C, respectively||||||||||The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being 4X and 10X that of wildtype FLP at 37°C and 40°C, respectively. |Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2015|Cryopreserved sperm|43.0|1228.0|Unknown||recombinase, deleter, Cre, actin|Yes| 8187.0|WEHIG1:Srgap1:C57Crl|B6.Cg-Srgap1/WehiAnuApb||Recessive|SLIT-ROBO Rho GTPase activating protein 1|Srgap1|Unknown|4930572H05Rik, Arhgap13|MGI:2152936||||10|ENSMUSG00000020121|ENSMUST00000081688.12|Srgap1-201|1994|2116|G to A|ENSMUSE00001215240|17|665|Proline to Leucine|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|10-Feb-2017|Cryopreserved sperm|48.0|0.0|Unknown||ENU|Yes| 8181.0|Tap1/Tap2 KO ET26|C57BL/6J-Tap1/Tap2/26MarpAnu||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham1, Ham-1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Feb-2017|Cryopreserved sperm|24.0|0.0|Unknown|||Yes| 8181.0|Tap1/Tap2 KO ET26|C57BL/6J-Tap1/Tap2/26MarpAnu||Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Nil|Abcb3, Ham2, Ham-2, HAM2, MTP2, PSF2, Tap-2|MGI:98484||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Feb-2017|Cryopreserved sperm|||Unknown|||Yes| 8180.0|hTAP1/hTAP2 BAC Tg ET18|C57BL/6J-Tg(hTAP1/hTAP2)/18MarpAnu||Recessive||||||||||||||||||||||||||human transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) / human transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Feb-2017|Cryopreserved sperm|72.0|0.0|Unknown|||Yes| 8185.0|Tcf3 6bp KO|C57BL/6NCrlAnu-Tcf3/Anu||Recessive|transcription factor 3|Tcf3|Unknown|A1, ALF2, bHLHb21, E12, E2A, E47, Pan1, Pan2, Tcfe2a|MGI:98510||||10|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|||No|09-Feb-2017|Cryopreserved sperm|24.0|0.0|Unknown||CRISPR, transcription factor|Yes| 8186.0|Tcf3 1bp KI|C57BL/6NCrlAnu-Tcf3/Anu||Recessive|transcription factor 3|Tcf3|Unknown|A1, ALF2, bHLHb21, E12, E2A, E47, Pan1, Pan2, Tcfe2a|MGI:98510||||10|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|||No|09-Feb-2017|Cryopreserved sperm|48.0|0.0|Unknown||CRISPR, transcription factor|Yes| 8189.0|ENU36:091:Rag2|C57BL/6NCrlAnu-Rag2/AnuApb||Recessive|recombination activating gene 2|Rag2|Unknown|Rag-2|MGI:97849||||2|ENSMUSG00000032864|ENSMUST00000044031.3|Rag2-001|173|414|A to G|ENSMUSE00000230533|3|58|Lysine to Glutamic acid|||||TGATATAAAACAAAATCATCTCAAACTGAAGCCTGCAATCTTCTCTAAAGATTCCTGCTAC||||||||||||||FACS phenotype: Low B cells numbers in peripheral blood|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Feb-2017|Cryopreserved sperm|35.0|0.0|Unknown||ENU, B cell|Yes| 8174.0|NODSOCS1/hCD4|NOD.B6-Socs1JWehi|Tkay|Semi-dominant|suppressor of cytokine signaling 1|Socs1|Nil|Cish1, Cish7, JAB, JAK2-binding protein, JAK-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|suppressor of cytokine signaling 1; targeted mutation 3.1, Walter and Eliza Hall Institute of Medical Research|Socs1|MGI:2656956|16|||||||||||||||||||||||||||||These mice die at weaning and are runted.|Normal|NOD/Lt|No|No|Yes|No|No|Yes|No|Good|10+|NA|NOD/Lt x SOCS1/hCD4 Heterozygous|No|24-Jan-2017|Cryopreserved sperm|50.0|0.0|No||Suppressor of cytokine signalling, NOD/Lt, hCD4|Possibly| 8184.0|Par2 KO|B6.129-F2rl1||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1|Nil|Gpcr11, Par2, PAR-2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1, Shaun R Coughlin|F2rl1|MGI:2179844|13|||||||||||||||||||||||||||||Decreased dendritic cell number:• mice fail to develop bone marrow-derived dendritic cells with to without soy bean trypsin inhibitor treatment unlike wild-type mice• however, stimulation with TNG-alpha or by crosslinking CD40 results in mature dendritic cell development|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Feb-2017|Cryopreserved sperm|50.0|0.0|Unknown||Thrombin|Yes| 8193.0|hPAR1-KI|C57BL/6J-F2rl2||Recessive|coagulation factor II (thrombin) receptor-like 2|F2rl2|Nil|PAR3|MGI:1298208||||13|||||||||||||||||||||||||||||Platelets fail to express human PAR1 protein and do not respond to PAR1 specific antagonists.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Feb-2017|Cryopreserved sperm|50.0|0.0|Unknown||platelet, thrombin|Yes| 8197.0|ENU36:028:Gfi1|C57BL/6NCrlAnu-Gfi1/AnuApb||Recessive|growth factor independent 1|Gfi1|Unknown|Gfi-1, Pal1, Pal-1|MGI:103170||||5|||||||||||||||||||||||||||||Reduced CD44 mean fluorescence intensity (MFI) on CD4<+> T cells and increased number of CD44 CD4<+> and CD8<+> T cells in peripheral blood as measured by flow cytometry.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Feb-2017|Cryopreserved sperm|36.0|0.0|Unknown||T cell, CD4, CD8, CD44|Yes| 8195.0|ASD552:Cahill:62bpdel|C57BL/6NCrlAnu-Ikbkb/1AnuApb||Recessive|inhibitor of kappaB kinase beta|Ikbkb|Unknown|IKK2, IKK-2, IKK[b], IKKbeta, IKK-beta|MGI:1338071||||8|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Feb-2017|Cryopreserved sperm|72.0|0.0|Unknown||CRISPR|Yes| 4865.0|C3H-Kumba|C3H/HeH.Cg-Zic2/AnuApb|C3H/HeH.Cg-Zic2/AnuApb|Recessive|zinc finger protein of the cerebellum 2|Zic2|Unknown|GENA 29, Ku, odd-paired homolog|MGI:106679|kumba|Zic2|MGI:1862004|14||||||||||||||||Yes|||||||||||||Lethal during embryogenesis|Incomplete penetrance and variable expressivity of the following: ventral spot, curled tail, distal tail kink, spina bifida (rare).|C3H/HeH|No|No|Yes|No|No|Yes|No|Good||||No|24-Sep-2009|Cryopreserved sperm|75.0|0.0|Yes|Holoprosencephaly and spina bifida|Gastrulation, Neuralation, holoprosencephaly|Yes| 8198.0|pKZ1|B6.Cg-Tg(CAG<*>-LacZ)||Dominant||||||||||||||||||||||||||E.coli lac Z|Chicken beta actin enhancer complex|||||||||||Normal physiology. In cells where a somatic intrachromosomal recombination event occurs, beta galactosidase protein is expressed which can be detected using the chromogenic substrate 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal) which appears as a small blue punctate dot.|Normal physiology. In cells where a somatic intrachromosomal recombination event occurs, beta galactosidase protein is expressed which can be detected using the chromogenic substrate 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal) which appears as a small blue punctate dot.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Feb-2017|Cryopreserved sperm|40.0|0.0|Unknown||Radiation, DNA damage, LacZ|Yes| 8194.0|ASD552:Cahill:V203I|C57BL/6NCrlAnu-Ikbkb/3AnuApb||Recessive|inhibitor of kappaB kinase beta|Ikbkb|Unknown|IKK2, IKK-2, IKK[b], IKKbeta, IKK-beta|MGI:1338071|Ikbkb:endonuclease-mediated mutation 1, Australian National University|Ikbkb||8|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Feb-2017|Cryopreserved sperm|24.0|0.0|Unknown||CRISPR|Yes| 8196.0|ASD544:Leckie:P450S|C57BL/6NCrlAnu-Stat4/AnuApb||Recessive|signal transducer and activator of transcription 4|Stat4|Unknown||MGI:103062|Stat4:endonuclease-mediated mutation 1, Australian National University|Stat4||1|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Feb-2017|Cryopreserved sperm|24.0|0.0|Unknown||signal transduction, CRISPR|Yes| 8200.0|ENU23:Etaa1|C57BL/6NCrlAnu-Etaa1/AnuApb||Recessive|Ewing tumor-associated antigen 1|Etaa1|Unknown|5730466H23Rik|MGI:1915395||||11|ENSMUSG00000016984|ENSMUST00000076661.6|Etaa1-001|498|579|A to T|ENSMUSE00000471991|4|166|Cysteine to STOP|||||GTATGGATTGGTGAAACTGCTATTCCTTGTACTCCTGGCGTAGCAAAAGAGAAGTCAAGAG||||||||||||||Absence of antigen specific T cells following immunisation.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Feb-2017|Cryopreserved sperm|82.0|0.0|Unknown||T cell, immunisation|Yes| 8201.0|Thy1-EGFP|B6.CBA-Tg(Thy1-EGFP)MJrs/J||Dominant||||||||||||||||||||||||||transgene insertion M, Joshua R Sanes|Thy1, thymus cell antigen 1, theta, mouse, laboratory|||||||||||Unknown|Mice harboring the Thy1-GFP transgene are viable and fertile with enhanced green fluorescent protein (EGFP) expression under the control of a modified Thy1 promoter region (containing the sequences required for neuronal expression but lacking the sequences required for expression in non-neural cells). Homozygous or hemizygous Thy1-GFP mice derived from founder line M (Thy1-GFP-M or Thy1-GFPM) express EGFP in sparse subsets of neurons within specific populations; providing a bright, vital Golgi-like stain. Less than 10% of all motor axons, retinal ganglion cells, lumbar dorsal root ganglion, and cortex express EGFP. These Thy1-GFPM transgenic mice may be useful in neurobiological studies for fluorescent labeling of neural tissues, especially for mossy fibers in the cerebellum and intense, yet sparse, labeling of a variety of neuronal subsets. |C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Feb-2017|Cryopreserved sperm|56.0|0.0|Unknown||GFP|Yes| 5286.0|B6.CD73.KO|C57BL/6-Nt5e||Recessive|5' nucleotidase, ecto|Nt5e|Nil|CD73, ecto-5'-nucleotidase, Nt5|MGI:99782|5' nucleotidase, ecto; targeted mutation 1, Linda F Thompson|Nt5e|MGI:3522017|9||||||||||||||||No|||||||||||||Increased aggression toward humans: under hypoxic conditions mutants are less compliant compared to wild-type littermates.Lethargy: under hypoxic conditions mutants are more lethargic compared to wild-type littermates.Increased vascular permeability: * under hypoxic conditions increased vascular leakage is seen. * under normoxic conditions increased vascular permeability is seen in the lung and colon.Altered response to myocardial infarction: * ischemic preconditioning fails to attenuate infarct size as in wild-type mice. * however, treatment of mice with adenosine or 5' nucleotidase infusion partially-restores cardioprotection offered by ischemic preconditioning.Increased infarction size: mice exhibit increased infarct size after 60 minutes of ischemia compared to in similarly-treated wild-type mice.Edema: under hypoxic conditions increased edema is seen in all organs except the brain.Abnormal response/metabolism to endogenous compounds: mice exhibit an attenuated bradycardia response to AMP.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||21||No|28-Oct-2010|Cryopreserved sperm|50.0|0.0|Yes||ischemia, infarction, myocardium, hypoxia|Yes| 8206.0|Tap1/Tap2 KO ET33|C57BL/6J-Tap1/Tap2/33MarpAnu||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham1, Ham-1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|24.0|0.0|Unknown|||Yes| 8206.0|Tap1/Tap2 KO ET33|C57BL/6J-Tap1/Tap2/33MarpAnu||Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Nil|Abcb3, Ham2, Ham-2, HAM2, MTP2, PSF2, Tap-2|MGI:98484||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|||Unknown|||Yes| 8207.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #2|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)20/2MarpAnu||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham1, Ham-1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483||||17|||||||||||||||||human transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) / human transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8207.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #2|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)20/2MarpAnu||Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Nil|Abcb3, Ham2, Ham-2, HAM2, MTP2, PSF2, Tap-2|MGI:98484||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|||Unknown|||Yes| 8205.0|hTAP1/hTAP2 BAC Tg ET20|C57BL/6J-Tg(hTAP1/hTAP2)/20MarpAnu||Recessive||||||||||||||||||||||||||human transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) / human transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8204.0|NSG.VNTR.HuINS|NOD.Cg-Prkdc H2-Ab1 Il2rg Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(INS*VNTR)/J||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNAPDcs, DNA-PK, DNA-PKcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||transgene insertion 1, Chella David||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Mar-2017|Cryopreserved sperm|50.0|0.0|Unknown||H2, Insulin|No| 8204.0|NSG.VNTR.HuINS|NOD.Cg-Prkdc H2-Ab1 Il2rg Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(INS*VNTR)/J||Recessive|histocompatibility 2, class II antigen A, beta 1|H2-Ab1|Nil|Abeta, A beta, H-2Ab, H2-Ab, Ia2, Ia-2, IAb, I-Ab, I-Abeta, Rmcs1|MGI:103070|histocompatibility 2, class II antigen A, beta 1; targeted mutation 1, Michael J Grusby|H2-Ab1|MGI:2158420|17|||||||||||||||||human insulin with microsatellite variable number tandem repeat (VNTR) region|human insulin|||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Mar-2017|Cryopreserved sperm|||Unknown||H2, Insulin|No| 8204.0|NSG.VNTR.HuINS|NOD.Cg-Prkdc H2-Ab1 Il2rg Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(INS*VNTR)/J||Recessive|interleukin 2 receptor, gamma chain|Il2rg|Nil|CD132, common cytokine receptor gamma chain, common gamma chain, gamma(c), gammaC, gamma C receptor, gc, [g]c|MGI:96551|interleukin 2 receptor, gamma chain; targeted mutation 1, Warren J Leonard|Il2rg|MGI:1857455|X|||||||||||||||||||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Mar-2017|Cryopreserved sperm|||Unknown||H2, Insulin|No| 8214.0|DEREG|C57BL/6-Tg(Foxp3-DTR/EGFP)23.2Spar/Mmjax||Dominant||||||||||||||||||||||||||transgene insertion 23.2, Tim Sparwasser|Foxp3 (forkhead box P3)|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Mar-2017|Cryopreserved sperm|110.0|0.0|Unknown||T cell, scurfy|Yes| 8215.0|R1584P KI ; Cav3.2 R1584P Knock-in|C57BL/6-Cacna1h||Dominant|calcium channel, voltage-dependent, T type, alpha 1H subunit|Cacna1h|Unknown|alpha13.2, Cav3.2, mKIAA1120, T-type Cav3.2|MGI:1928842||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good|||Brother x Sister|No|09-Mar-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8212.0|B6 – HSPA5tm1Dtau|C57BL/6N-Hspa5/MarpDtau||Recessive|heat shock protein 5|Hspa5|Unknown|78kDa, baffled, Bip, D2Wsu141e, D2Wsu17e, Grp78, Hsce70, mBiP, Sez7, XAP-1 antigen|MGI:95835|heat shock protein 5; targeted mutation 1, Velocigene|Hspa5|MGI:4399453|2|||||||||||||||||||||||||||||Lethal|Heterozygous mice expressed 50% level ofwild type HSPA5 expression. However, there was no difference in biochemical induction of the ER stress response in vivo.|C57BL/6N|No|No|Yes|No|No|Yes|No|Unknown||||No|07-Mar-2017|Cryopreserved sperm|47.0|0.0|Unknown|||Yes| 8209.0|Ngn3-GFP/RIP-DsRed|B6.Cg-Tg(Neurog3-GFP) Tg(Ins2-DsRed)#/Arc||Dominant||||||||||||||||||||||||||Green Fluorescent Protein|Neurog3|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|05-Mar-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8209.0|Ngn3-GFP/RIP-DsRed|B6.Cg-Tg(Neurog3-GFP) Tg(Ins2-DsRed)#/Arc||Dominant||||||||||||||||||||||||||DsRed|Rat insulin promoter (RIP)|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|05-Mar-2017|Cryopreserved sperm|||Unknown|||Yes| 8243.0|gp130Y757F x Asc KO|B6.129- Il6st Pycard/MarpApb||Recessive|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13||||||||||||||||Yes|||||||||||||Mice develop gastric tumours, emphysema and splenomegaly.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|05-Apr-2017|Cryopreserved sperm|50.0|0.0|Yes||gp130|Yes| 8243.0|gp130Y757F x Asc KO|B6.129- Il6st Pycard/MarpApb||Recessive|PYD and CARD domain containing|Pycard|Nil|9130417A21Rik, Asc, TMS-1|MGI:1931465|PYD and CARD domain containing; targeted mutation 1, Gabriel Nunez|Pycard|MGI:3771030|7||||||||||||||||No|||||||||||||Mice develop gastric tumours, emphysema and splenomegaly.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||heterozogous x homozygous|No|05-Apr-2017|Cryopreserved sperm|||Yes||gp130|Yes| 8218.0|Roquin fl:Lck-cre|B6.Cg-Rc3h1 Tg(Lck-cre)157Jxm/AnuApb||Recessive|RING CCCH (C3H) domains 1|Rc3h1|Unknown|5730557L09Rik, roquin|MGI:2685397|RING CCCH (C3H) domains 1; targeted mutation 1.1, Carola Vinuesa|Rc3h1|MGI:5508920|1|||||||||||||||||targeted mutation I57, Jamey Marth; transgene insertion I57, Jamey Marth|mouse proximal Lck promoter|active in thymocytes and splenocytes|||||||||||No phenotypic analysis|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||15||No|19-Mar-2017|Cryopreserved sperm|84.0|0.0|Unknown||T cell, arthritis, autoimmunity, mRNA, stress granules|Yes| 8226.0|CD4cre:AhRflox|B6.129-Ahr Tg(Cd4-cre)1Cwi/MarpAnu||Recessive|aryl-hydrocarbon receptor|Ahr|Normal|Ah, Ahh, Ahre, bHLHe76, dioxin receptor, In|MGI:105043|aryl-hydrocarbon receptor; targeted mutation 3.1, Christopher A Bradfield|Ahr|MGI:3612477|12|||||||||||||||||transgene insertion 1, Christopher B Wilson||||||||||||||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Mar-2017|Cryopreserved sperm|21.0|0.0|Unknown||Cd4, T cell|Yes| 8225.0|ASD543:Weidenfeller:R78P-CC-Ins|C57BL/6NCrlAnu-Vps51/AnuApb||Recessive|VPS51 GARP complex subunit|Vps51|Unknown|1110014N23Rik, 3110057M17Rik|MGI:1915755||||19|ENSMUSG00000024797|ENSMUST00000159832.7|ps51-001||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|27-Mar-2017|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 8249.0|ENU37:044|ENU37:044||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Apr-2017|Cryopreserved sperm|46.0|0.0|Unknown||ENU|Yes| 8222.0|ENU35:014:Fam129c|C57BL/6NCrlAnu-Fam129c/AnuApb||Recessive|family with sequence similarity 129, member C|Fam129c|Unknown|Bcnp1|MGI:3686743||||8|ENSMUSG00000043243|ENSMUST00000143662.7|Fam129c-001|184|305|A to T|ENSMUSE00001283995|2|62|Lysine to STOP|||||ACCCAGCCGGATGCCAGCTGTCCCACACCAAAAAGCTGCCTCGAGTCAGGGAGCACCAAGG||||||||||||||Increased IgM expression on mature B cells in mice homozygous for the mutation, as measured by peripheral blood flow cytometry.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Mar-2017|Cryopreserved sperm|24.0|0.0|Unknown||Immunoglobulin, B cell|Yes| 8826.0|CaMKK2 SD KI|CaMKK2 (S129D/S133D/S137D) KI||Recessive|CaMKK2|CaMKK2|||||||5|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Nov-2019|Cryopreserved sperm|47.0|30.0|Unknown|||Yes| 8827.0|ASD534:C57BL/6-Ins2Akita/JArc:::G12|C57BL/6JArc-Ins2/AnuApb||Dominant|insulin II|Ins2||Ins-2, InsII, Mody, Mody4|MGI:96573|insulin II; Akita|Ins2|MGI:1857572|7|||||||||||||||||||||||||||||Postnatal lethality.Hyperglycemia:• blood glucose levels are slightly higher at 1 day of age and much higher at 14 days of age with no gender differences seen.Abnormal pancreatic alpha cell morphology: • alpha cell density is markedly increasedAbnormal pancreatic beta cell morphology: • density of beta cells is decreased within 24 hours of birth and at 2 weeks of age• beta cell granules are fewer in number and smaller and mitochondrial swelling and an increase in endoplasmic reticulum are seen at 2 weeks of ageSmall pancreatic islets:• islet area is reducedDecreased insulin secretion:• the pancreatic ratio of insulin to glucagon is decreased to 0.21 and 0.01 at birth and 14 days of age, respectively, compared to 1.17 and 1.11 in wild-type mice.Premature death:• untreated homozygous mice rarely survive past 12 weeks of age, with death resulting from extreme hyperglycemia;|unknown|C57BL/6J|No|No|Yes|No|No|Yes|No|Unknown||||No|20-Nov-2019|Cryopreserved sperm|58.0|0.0|Unknown||Hypoglycaemia|Yes| 8237.0||NOD-Gzma Tmem173||Recessive|Transmembrane protein 173|Tmem173|Unknown|2610307O08Rik, ERIS, MPYS, Sting|MGI:1919762||||18|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|31-Mar-2017|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||No| 8237.0||NOD-Gzma Tmem173||Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla3, Ctla-3, Hanukah factor, Hf, H factor, SE1, serine esterase 1, TSP1, TSP-1|MGI:109266||em3Tcb||13|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|31-Mar-2017|Cryopreserved sperm|||Yes|Type 1 diabetes||No| 8829.0|ASD091:NOD/Scid:::EXP|NOD.CB17-Prkdc/AnuApb||Dominant|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNAPDcs, DNA-PK, DNA-PKcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||||||||||||||premature death:• average lifespan in SPF housing is 257 days for females and 269 days for males• the major cause of death is thymic lymphoma• median life span is 37 weeks; death is a result of thymic lymphomasAbnormal thymus lobule morphology: • thymic lobes are small and may contain cystsAbnormal thymus corticomedullary boundary morphology: • the cortico-medullary junction is not demarcated in tissues from a 10 week old female.Thymus cysts:• may be presentIncreased granulocyte number:• Gr1+ splenic and bone marrow granulocytes are increased in comparison to controlDecreased lymphocyte cell number:• percentages of circulating lymphocytes are significantly decreased in comparison to control, however, percentages of monocytes, neutrophils and eosinophils are increased and total peripheral leukocyte counts are similar• thymus, spleen and lymph nodes are depleted of lymphoid cells.Decreased B cell number:• B220+ splenic B cells are decreased (36.0% vs. 10.4%) in comparison to NOD control as measured by flow cytometryDecreased mature B cell number:• spleens are deficient in B220+ IgK+ B cellsDecreased pre-B cell number:• there is a significant absence of splenic B cells bearing the Ig kappa light chain (30.7% vs. 2.8%)• B220+ bone marrow pre-B cells are decreased in number (19.0% vs. 10.2%)Decreased NK cell number:• no NK1.1+ splenic NK cells were detected by flow cytometry, however some NK cell activity is detected.Decreased T cell number:• significant numbers of CD3+ splenic T cells are absent in comparison to control (44.9% vs. 0.2%)Decreased CD4-positive, alpha beta T cell number:• spleens are deficient in mature T cellsDecreased CD8-positive, alpha-beta T cell number: • spleens are deficient in mature T cellsIncreased macrophage cell number:• F4/80+ splenic macrophages are increased in comparison to controlSpleen hypoplasia:• spleen cellularity is decreased four fold in comparison to NOD control• splenic follicles are hypoplasticAbnormal spleen white pulp morphology:• splenic follicles exhibit a marked loss of lymphoid cells, however, red pulp is normal• splenic follicles are hypoplasticDecreased immunoglobulin level:• only 1/11 homozygotes can produce greater than 1 ug/ml serum Ig at up to 100 days of age• only 2/30 homozygotes can produce greater than 1 ug/ml serum Ig between 100-200 days of ageImpaired natural killer cell mediated cytotoxicity :• Background Sensitivity: NK cell activity in homozygous spleen cell suspensions is markedly decreased in comparison to homozygotes on the CB17 backgroundAbnormal lymph node morphology:• lymph nodes lack follicles and consist mostly of stromal cells• lymph nodes are hypocellularDecreased level of surface class I molecules.Impaired complement classical pathway:• complement activity is not detected in either homozygous or control sera using a 51Cr-release assayAbnormal response to transplant:• following injection of human T lymphoblastoid cells, 80% of nucleated spleen cells are of human origin by 4 weeks post injection• peripheral blood has a five fold increase of human cells by 4 weeks post injection• mice support CD34+ human stem cell engraftment, although not as well as mice homozygous for Il2rg and Prkdc• human CD45+ cells comprise 5.2% of cells in the spleen, 6.2% in bone marrow, 0.4% in thymus at 10 weeks post-engraftment.Increased length of allograft survival:• homozygotes (5-6 weeks of age) do not reject orthotopic tail skin allografts throughout a 3 month observation period||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Nov-2019|Cryopreserved sperm|60.0|0.0|Unknown||scid, T cell, B cell|Yes| 4864.0|Kumba: 129SvEv|129/SvEv.Cg-Zic2/AnuApb|129/SvEv.Cg-Zic2/AnuApb|Recessive|zinc finger protein of the cerebellum 2|Zic2|Unknown|GENA 29, Ku, odd-paired homolog|MGI:106679|kumba|Zic2|MGI:1862004|14||||||||||||||||Yes|||||||||||||Lethal during embryogenesis|Incomplete penetrance and variable expressivity of the following: ventral spot, curled tail, distal tail kink, spina bifida (rare).|129SvEv|No|No|Yes|No|No|Yes|No|Good|30||Heterozygote male paired with wild-type 129/SvEv female|No|24-Sep-2009|Cryopreserved sperm|80.0|0.0|Yes|Holoprosencephaly and spina bifida|Gastrulation, Neuralation, holoprosencephaly|Yes| 8253.0|Warpy B6|B6(Cg)-Dzip1l/AnuUqApb||Recessive|DAZ interacting protein 1-like|Dzip1l|||MGI:1919757|DAZ interacting protein 1-like; Warpy|Dzip1l|MGI:5563494|9|ENSMUSG00000037784|ENSMUST00000078367|Dzip-1l-001|1123|1326|C to T|ENSMUSE00000325142|8|375|Glutamine to STOP|||||TGTCTCAGGACCAGAAGAAAGCAGCTGCCCAGTCTCAGCGCCATATCAATGCCCTCCGTGC|Yes|||||||||||||Polydactlyly and craniofacial dismorphology in embryos at e14.5.Extra digits on each limb some have 6 some have 7) and there is a craniofacial dismorphology (the front of the head protrudes, the eye position is changed and there is a mandible malformation.|Normal|C57BL/6JUq|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|10|||No|08-May-2017|Cryopreserved sperm|40.0|0.0|Unknown||polydactyly, ENU|No| 8255.0|Vil1-cre|B6.Cg-Tg(Vil1-cre)1000Gum/J||Dominant||||||||||||||||||||||||||transgene insertion 1000, Deborah L Gumucio|Vilin1|||||||||||Normal||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-May-2017|Cryopreserved sperm|59.0|0.0|Unknown||Cre recombinase|Yes| 8252.0|Warpy CD1|CD1-Dzip1l/AnuUqApb||Recessive|DAZ interacting protein 1-like|Dzip1l|||MGI:1919757|DAZ interacting protein 1-like; Warpy|Dzip1l|MGI:5563494|9|ENSMUSG00000037784|ENSMUST00000078367|Dzip-1l-001|1123|1326|C to T|ENSMUSE00000325142|8|375|Glutamine to STOP|||||TGTCTCAGGACCAGAAGAAAGCAGCTGCCCAGTCTCAGCGCCATATCAATGCCCTCCGTGC|Yes|||||||||||||Polydactlyly and craniofacial dismorphology in embryos at e14.5.Extra digits on each limb some have 6 some have 7) and there is a craniofacial dismorphology (the front of the head protrudes, the eye position is changed and there is a mandible malformation.|Normal|CD1|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|10|||No|08-May-2017|Cryopreserved sperm|50.0|0.0|Unknown||polydactyly, ENU|No| 8250.0|Ywhaz-EUCE0076e02|129(Cg)-Ywhaz||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Unknown|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap EUCE0076e02, Helmholtz Zentrum Muenchen GmbH|Ywhaz|MGI:4393774|15|||||||||||||||||||||||||||||Unknown, we have not been able to generate homozygous mutants for this line.|In Heterozygous state the mice are smaller than WT, some have hind limb paralysis, and do not socialise with littermates.|129Sv|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-May-2017|Cryopreserved sperm|60.0|0.0|Unknown||signal transduction|Yes| 8254.0||ASD733:Forge:::F0||Recessive|RING CCCH (C3H) domains 1|Rc3h1||5730557L09Rik, roquin|MGI:2685397||||1|||||||||||||||||||||||||||||Unknown|TBA|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-May-2017|Cryopreserved sperm|11.0|0.0|Unknown|||No| 8245.0|ENU32:096:Pank4|C57BL/6NCrlAnu-Pank4/AnuApb||Recessive|pantothenate kinase 4|Pank4|Unknown|D030031I12Rik|MGI:2387466||||4|ENSMUSG00000029056|ENSMUST00000030931.10|Pank4-001|625|648|T to C|ENSMUSE00000231970|5|209|Phenylalanine to Leucine|||||CCATCGTGAAGGTGGAGACAGAGGACCGGTTTGAGTGGATTGGTGGAAGCTCCATTGGAGG||||||||||||||Normal|Normal|C57BL/6NCrIAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Apr-2017|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8831.0|ASD902:Durian:SO54|C57BL/6NCrlAnu-Socs1/AnuApb||Recessive|suppressor of cytokine signaling 1|Socs1|Unknown|Cish1, Cish7, JAB, JAK2-binding protein, JAK-binding protein, SOCS-1, SSI-1, STAT-induced STAT inhibitor 1|MGI:1354910|Socs1; endonuclease-mediated mutation 1, Australian National University|Socs1||16||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Nov-2019|Cryopreserved sperm|58.0|70.0|Unknown|||Yes| 8832.0|Csf2rb fl/fl|C57BL/6N-Csf2rb||Recessive|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)|Csf2rb||AIC2B, Bc, beta c, CDw131, common beta chain, Csf2rb1, Il3r, Il3rb1, Il5rb|MGI:1339759|colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage); targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Csf2rb|MGI:5792881|15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2019|Cryopreserved sperm|50.0|0.0|Unknown||GM-CSF|Yes| 8259.0|PbT-II|C57BL/6-Tg(Tcra,TcrbPbA)1Cbn||Dominant||||||||||||||||||||||||||T cell receptor alpha, T cell receptor beta||||||||||||Expression of a TCR specific for the malaria parasite Plasmodium||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-May-2017|Cryopreserved sperm|14.0|0.0|Unknown|||Yes| 8262.0|Nlrc4 KO|B6(Cg)-Nlrc4/VmdUqAnu||Recessive|NLR family, CARD domain containing 4|Nlrc4|Nil|9530011P19Rik, Card12, Ipaf|MGI:3036243|NLR family, CARD domain containing 4; targeted mutation 1, Vishva M Dixit|Nlrc4|MGI:3046934|17|||||||||||||||||||||||||||||Abnormal cell death:• caspase dependent cell death resulting from infection with Salmonella typhimurium reduced to minor levelsDecreased interleukin-1 beta secretion:• negligible amounts of Il-1beta produced when infected with Salmonella typhimurium||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2017|Cryopreserved sperm|23.0|0.0|Unknown||Apaf-1, Caspase, Toll|Yes| 8263.0|Asc KO|B6.129-Pycard/VmdUqAnu||Recessive|PYD and CARD domain containing|Pycard|Nil|9130417A21Rik, Asc, TMS-1|MGI:1931465|PYD and CARD domain containing; targeted mutation 1, Vishva M Dixit|Pycard|MGI:3046932|7|||||||||||||||||||||||||||||Abnormal macrophage physiology:• improved bone marrow derived macrophage viability following infection with F. tularensisDecreased circulating interleukin-1 beta level:• in response to LPS challenge in a model of acute septic shockDecreased circulating interleukin-18 level:• in response to LPS challenge in a model of acute septic shockIncreased interferon-beta secretion:• in bone marrow derived macrophages stimulated by poly(dA:dT) or pcDNA3Decreased interleukin-1 beta secretion:• in LPS-primed bone marrow derived macrophages stimulated by S. typhimurium or dsDNA• bone marrow derived macrophages do not secrete IL1B in response to F. tularensis• from LPS-primed bone marrow-derived macrophages stimulated with E. coli, C. rodentium, C. cholera and CTBIncreased tumor necrosis factor secretion:• in bone marrow derived macrophages stimulated by poly(dA:dT) or pcDNA3Decreased susceptibility to endotoxin shock:• mice treated with LPS challenge in a model of acute septic shock exhibit reduced serum levels of IL1b and IL18 compared with controls• however, mice do not survive beyond 20 hours and serum levels of IL1a are increased||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2017|Cryopreserved sperm|10.0|0.0|Unknown||Toll, caspase, interleukin, inflammasome|Yes| 5150.0|McBride|C;B6-Myd88/AnuApb||Recessive|myeloid differentiation primary response gene 88|Myd88|Nil||MGI:108005|myeloid differentiation primary response gene 88; targeted mutation 1, Shizuo Akira|Myd88|MGI:2385681|9||||||||||||||||Yes|||||||||||||Increased apoptosis:* 5 days after lung injury, mutants show significantly increased numbers of apoptotic lung epithelial and inflammatory cells.Increased physiological sensitivity to xenobiotics:* knockout mice are more susceptible to bleomycin-induced lung injury.Abnormal dendritic cell differentiation:* dendritic cell maturation fails to occur in vivo upon exposure to TLR9 agonists.Increased dendritic cell number:* increased numbers of dendritic cells in brains of mice infected with Plasmodium.Abnormal immune system physiology:* response to LPS and CpG is completely abrogatedAbnormal dendritic cell physiology:* cytokine secretion elicited by zymosan or LPS is impaired.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40, IL-6 and interferon-gamma relative to wild-type mice.Abnormal macrophage physiology:* TNF production is impaired in thioglycollate-elicited macrophages treated with intact zymosan.* cytokine production by macrophages cultured with P. carinii cysts is reduced compared to wild-type.Abnormal NK cell physiology:* NK cells fail to make IFN-gamma in response to injections of TLR9 agonists.Abnormal T cell physiology:* induction of the antigen-specific CD8+ T-cell response by immunizing with soluble ovalbumin and TLR9 agonists, but not TLR2 and TLR6 agonists, was severely impaired.Abnormal cytokine secretion:* LPS-induced cytokine production by BMDCs is almost abolished compared to controls and Myd88-sufficient mutantsAbnormal chemokine secretion:* hyaluronan fragment-induced expression of chemokines by peritoneal macrophages is completely abolished in double knockout mice.Decreased interferon-alpha secretion:* CpG-A or RNA polyuridylic acid induced production of interferon-alpha was abolished in plasmacytoid dendritic cells.Decreased interferon-gamma secretion:* less up regulation of INF-gamma in Plasmodium infection.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less interferon-gamma.Decreased interleukin-12 secretion:* after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals.Decreased interleukin-12b secretion:* less upregulation of IL-12b in Plasmodium infection>* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice.Decreased interleukin-6 secretion:* following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, IL-6 secretion is reduced.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-6 relative to wild-type mice.Decreased tumor necrosis factor secretion:* less upregulation of TNF-alpha in Plasmodium infection.* following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced.* after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals.Decreased inflammatory response:* in a model of induced pneumococcal meningitis-associated labyrinthitis, homozygotes exhibit a significantly lower granulocytic infiltration of the labyrinth and increased bacterial density in the cochlea at 24 hrs post-infection relative to wild-type control mice.Abnormal response to infection:* following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a decreased immune response in terms of TNF and IL-6 secretion and response to CpG.Decreased susceptibility to parasitic infection:* resistant to cerebral malaria but eventually die of extremely high parasitemia.Increased susceptibility to viral infection:* increased susceptibility to encephalomyocarditis virus (EMCV) infection compared to wildtype.||BALB/c x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jun-2010|Cryopreserved sperm|40.0|0.0|Unknown||T cell, Natural Killer, IL-18, IL-1 receptor, interferon, eosinophil, dendritic cell, cytokine, infection|Yes| 8257.0|ENU35:042:Ifih1|C57BL/6NCrlAnu-Ifih1/AnuApb||Recessive|interferon induced with helicase C domain 1|Ifih1|Unknown|9130009C22Rik, Helicard, MDA5, MDA-5|MGI:1918836||||2|||||||||||||||||||||||||||||Mice exhibit activated lymphocytes in peripheral blood and require ethical culling around 6 months of age due to poor health||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|19-May-2017|Cryopreserved sperm|95.0|0.0|Unknown||Lymphocyte|Yes| 8258.0||ASD696:Thunderbird:1del::F2||Recessive||||||||||||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-May-2017|Cryopreserved sperm|24.0|0.0|Unknown||CRISPR|Yes| 8261.0||NOD-Ins1/Tkay||Recessive|insulin I|Ins1|||MGI:96572|INS knockin|||19|||||||||||||||||||||||||||||Normal|Normal|NOD/Lt|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-May-2017|Cryopreserved sperm|48.0|113.0|Unknown||insulin|Yes| 4796.0|NODLt|NOD/Lt||Dominant||||||||||||||||||||||||||||||||||||||Predisposed to diabetes||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Sep-2009|Cryopreserved sperm|150.0|0.0|Unknown||NOD|No| 8087.0|RHBDF1_PKD_2|C57BL/6-Rhbdf12/MarpApb||Recessive|rhomboid 5 homolog 1|Rhbdf1|Unknown|Dist, Dist1, Egfr-rs|MGI:104328||||11|ENSMUSG00000020282|ENSMUST00000020524.14|Rhbdf1-006|584|740|C to T|ENSMUSE00001312827|5|195|Serine to Phenylalanine|||||TGCAGCCTCCCTCTGCTCTTTCTCCAGCTCCCGCTCAGGTTTCAACCGACTCCCTCGGCGT||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Aug-2016|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8172.0|Prox1enhCRISPR-Rafiki|C57BL/6-Prox1||Recessive|prospero homeobox 1|Prox1|Unknown|A230003G05Rik|MGI:97772||||1|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-Jan-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 4466.0|B10.PD1|C57BL/10-Tg(PD1)/AnuApb||Dominant||||||||||||||||||||||||||porcine class I major histocompatibility complex (SLA) gene||||||||||||This transgenic mouse expressed SLA antigen on its cell surfaces and transmitted the gene to offspring, in which the gene is also expressed. Skin grafts of such transgenic mice were rejected by normal C57BL/10 mice, suggesting that the foreign SLA antigen expressed in the transgenic mice is recognized as a functional transplantation antigen.||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2009|Cryopreserved sperm|150.0|0.0|Unknown||xenotransplant, transplantation, class I, porcine, major histocompatibility class (MHC)|Yes| 8182.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #1|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)18/1MarpAnu||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham1, Ham-1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483||||17|||||||||||||||||human transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) / human transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Feb-2017|Cryopreserved sperm|9.0|0.0|Unknown|||Yes| 8182.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #1|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)18/1MarpAnu||Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Nil|Abcb3, Ham2, Ham-2, HAM2, MTP2, PSF2, Tap-2|MGI:98484||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Feb-2017|Cryopreserved sperm|||Unknown|||Yes| 8202.0|Ryr2 Y2932H ; ASD589:Mystique|C57BL/6-Ryr2/AnuApb||Recessive|ryanodine receptor 2, cardiac|Ryr2|Unknown|9330127I20Rik|MGI:99685||||13|||||||||||||||||||||||||||||Unkown|Unkown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Feb-2017|Cryopreserved sperm|34.0|0.0|Unknown||CRISPR|Yes| 4083.0||ENU7PMH:118, Metabolic_Lean_1||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Low percentage of body fat when fed on a high fat diet.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||3||No|04-Dec-2008|Cryopreserved sperm|20.0|0.0|Yes||ENU, obesity, diet, fat, adipose|No| 4084.0||ENU7PMH:133, Metabolic Lean 2||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Low percentage of body fat when fed on a high fat diet.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Dec-2008|Cryopreserved sperm|30.0|0.0|Yes||ENU, Obesity, Diet, Fat, Adipose|No| 6803.0|APN 183|C57BL/6N-Csf3r/Marp||Recessive|colony stimulating factor 3 receptor (granulocyte) |Csf3r |Unknown||MGI:1339755 |colony stimulating factor 3 receptor (granulocyte); targeted mutation 1, Velocigene |Csf3rtm1(KOMP)Vlcg|MGI:4452883|4||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6906.0|APN 297|C57BL/6N-Hhex/Marp||Recessive|hematopoietically expressed homeobox|Hhex |Unknown|Hex, Hhex-rs2, Prhx |MGI:96086 |gene trap IST11279G10, Texas A&M Institute for Genomic Medicine |Gt(IST11279G10)Tigm|MGI:3996083|19||||||||||Unknown to Unknown||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Jun-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell, Gene Trap|Possibly| 8269.0|Lifr fl:LysMcre|B6.129P2-Lifr Lyz2/JAusbAnu||Recessive|lysozyme 2|Lyz2|Normal|Lys, Lysm, Lyzs, Lzm, Lzm-s1, Lzp|MGI:96897|lysozyme 2; targeted mutation 1, Irmgard Forster|Lyz2|MGI:1934631|10|||||||||||||||||||||||||||||Unknown|Enlarged spleen:*Rare|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|16-Jun-2017|Cryopreserved sperm|12.0|0.0|Unknown||Macrophage, Granulocyte, Conditional mutagenesis|Yes| 8269.0|Lifr fl:LysMcre|B6.129P2-Lifr Lyz2/JAusbAnu||Recessive|leukemia inhibitory factor receptor|Lifr||A230075M04Rik, soluble differentiation-stimulating factor receptor|MGI:96788|leukemia inhibitory factor receptor; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Lifr|MGI:4841519|15|||||||||||||||||||||||||||||Unknown|Enlarged spleen:*Rare|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|16-Jun-2017|Cryopreserved sperm|||Unknown||Macrophage, Granulocyte, Conditional mutagenesis|Yes| 8130.0|Stat6 -/-|B6.129P2-Stat6/Wehi||Recessive|signal transducer and activator of transcription 6|Stat6|Nil||MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10|||||||||||||||||||||||||||||Unable to transduce IL-4/13 intracellular signalling.Decreased T-helper 2 cell number. Decreased B cell proliferation:• B cell proliferation in response to anti-IgM plus IL-4 is impaired• however, B cell proliferation in response to LPS is normalIncreased IgA level:• IgA levels are slightly increased following infection with N. brasiliensisDecreased IgE level:• IgE levels are lower than in wild-type mice following infection with N. brasiliensisDecreased IgG1 level:• IgG1 levels are 16-fold lower than in wild-type mice and following infection with N. brasiliensis they are 10-fold lower than in infected wild-type miceIncreased IgG level: • IgG2 and IgG3 levels are slightly increased following infection with N. brasiliensisAbnormal T-helper 2 physiology: • mice fail to produce increased levels of Th2 cytokines in response to infection with N. brasiliensisDecreased T cell proliferation: • thymocyte proliferation in response to TPA is impaired• however, thymocyte proliferate in response to other stimuliSkin inflammation: • mice exhibit mild dermal infiltration of inflammatory cells• few CD4+ cells infiltrate the perioral dermis and epidermis|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Nov-2016|Cryopreserved sperm|50.0|0.0|Unknown||T cell, signal transduction, phosphorylation|Yes| 8266.0||ENU37:009||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Homozygous mice have increased immature B cells in the blood and absence of marginal zone B cells in the spleen.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Jun-2017|Cryopreserved sperm|24.0|0.0|Unknown||B cell, marginal zone|Yes| 8268.0|CXCR5KO:P14 TCR:Ly5a|B6.Cg-Cxcr5 Ptprc Tg(TcrLCMV)#Sdz/MarpAnu||Recessive|chemokine (C-X-C motif) receptor 5|Cxcr5||Blr1, CXCR-5, Gpcr6|MGI:103567|chemokine (C-X-C motif) receptor 5; targeted mutation 1, Martin Lipp|Cxcr5|MGI:2158677|9|||||||||||||||||transgene insertion, Birgit Ledermann|||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Cxcr5 KO mice:Abnormal leukocyte migration:• homozygotes exhibit a severely impaired lymphocyte migration to the Peyer's pathces and the B cell follicles of the spleen, resulting in morphologically abnormal primary lymphoid follicles• activated B cells fail to migrate from the T cell-rich zone into B cell follicles of the spleenIncreased B cell number:• homozygotes display a 2- to 4-fold increase in spleen or peripheral blood cells co-expressing B220 and high amounts fo IgMAbnormal spleen primary B follicle morphology:• at 8 wks of age, homozygotes display defective formation of primary splenic follicles, including: the T cell zone is located centrally but not polarized in the follicle; the T cell zone is completely surrounded by a small rim of B cell-expressing IgD but not IgM (i.e. IgM+IgD+ subset is absent); a prominent marginal zone surrounds the follicle completelyAbnormal spleen secondary B follicle morphology.Absent spleen germinal centre:• despite high numbers of germinal center founder cells, no functional germinal centers develop in mutant spleen after immunization with the T cell-dependent antigen DNP-KHLAbsent follicular dendritic cells:• absence of primary follicular dendritic cellsAbnormal Peyer's patch morphology:• ~30% (26 of 76) of homozygotes exhibit 1-4 small and rudimentary structures resembling Peyer's patches• ~16% (12 of 76) of homozygotes exhibit normally sized Peyer's patches with multiple B and T cell-rich zones instead of the large follicles present in wild-type miceAbsent Peyer's patches:• 55% (42 of 76) of homozygotes show complete absence of Peyer's patchesAbsent axillary lymph nodes Absent brachial lymph nodes Absent cervical lymph nodes Absent inguinal lymph nodes:• homozygotes lack inguinal lymph nodesAbsent lymph nodes:• absence of inguinal, iliac/periaortic, axillary, branchial, deep cervical, sacral/caudal, and parathymic lymph nodesTransgenic mice carry a T-cell receptor (Tcra-V2, Tcra-J TA31 / Tcrb-V8.1, Tcrb-D, Tcrb-J 2.4) specific for LCMV (lymphocytic choriomeningitis virus), H2-Db||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2017|Cryopreserved sperm|34.0|0.0|Unknown||T cell, CMV|Yes| 8270.0||C57BL/6J-Serpinb9a||Recessive|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9|Unknown|ovalbumin, PI-9, Spi6|MGI:106603|serine (or cysteine) peptidase inhibitor, clade B, member 9; targeted mutation 2, Phillip I Bird|Serpinb9a||13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|21-Jun-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8276.0|Ccr6 KO: P14|B6.129-Ccr6 Tg(TcrLCMV)#Sdz/MarpAnu||Recessive|chemokine (C-C motif) receptor 6|Ccr6|Nil|Cmkbr6|MGI:1333797|chemokine (C-C motif) receptor 6; targeted mutation 1, Deltagen|Ccr6|MGI:3604541|17|||||||||||||||||transgene insertion, Birgit Ledermann||||||||||||Unknown||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Aug-2017|Cryopreserved sperm|24.0|0.0|Unknown||T cell, CD8|Yes| 1.0|Plastic|C57BL/6JSfdAnu-Ikzf1/AnuApb|C57BL/6JSfdAnu-Ikzf1/AnuApb|Recessive|IKAROS family zinc finger protein 1|Ikzf1|Nil|Ikaros, hlk-1, LyF-1, Zfpn1a1|MGI:1342540|IKAROS family zinc finger 1; plastic|Ikzf1|MGI:2669987|11|ENSMUSG00000018654|ENSMUST00000076700|Ikzf1-201|572|842|A to G|ENSMUSE00000655504|5|191|Histidine to Arginine|||||CTGCCGCCGGAGGGACGCCCTCACCGGCCACCTGAGGACGCACTCCGTTGGTAAGCCTCAC|Yes|||||||||||||Embryonic lethal E15.5-17.5AnemiaFailure of normal erythroblast growth and differentiation in fetal liverExpansion of myeloid cells including: CD34⁺CD45⁺FcγR⁺ and Mac-1hi and Gr-1lo cell populationsNo detectable Gr-1hi cellsEarly lymphocyte development arrestAccumulation of precursor B cells in thymus at expense of T cell developmentPremature down regulation of c-kit expressionCell intrinsic defectFetal liver cells fail to engraft|T cell Lymphoma, arrested at DN (pro-T3) stage orLymphoblastic lymphoma/leukaemia (pre-T-LBL)|C57BL/6JSfdAnu|No|No|Yes|No|No|Yes|Yes|Good||7||No|25-Nov-2005|Cryopreserved sperm|152.0|0.0|Unknown||haemopoiesis, T cell, B cell, transcription factor, ENU|Yes| 8203.0|A2b923flox,A2b923/Germ-line Cre |B6.Cg-Adora2b||Recessive|adenosine A2b receptor|Adora2b|Nil|A2b, A2BAR, A2BR, A2b, Rs, AA2BR|MGI:99403|adenosine A2b receptor; targeted mutation 1.1, Michail Sitkovsky|Adora2b|MGI:4941886|11|||||||||||||||||||||||||||||No overt difference in phenotype is apparent under normal circumstances. No special monitoring or care is required.|No overt difference in phenotype is apparent under normal circumstances. No special monitoring or care is required.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Feb-2017|Cryopreserved sperm|50.0|0.0|Unknown||receptor, Macrophage|Yes| 8288.0|AMPK a1(S496A) KI|C57BL/6-Prkaa1||Recessive|protein kinase, AMP-activated, alpha 1 catalytic subunit|Prkaa1||AMPKalpha1, C130083N04Rik|MGI:2145955||||15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Aug-2017|Cryopreserved sperm|18.0|0.0|Unknown|||Yes| 8289.0|AMPK a1(T481/S487A) KI|C57BL/6-Prkaa1/Ausb||Recessive|protein kinase, AMP-activated, alpha 1 catalytic subunit|Prkaa1|Unknown|AMPKalpha1, C130083N04Rik|MGI:2145955||||15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|22-Aug-2017|Cryopreserved sperm|70.0|0.0|Unknown|||Yes| 8316.0|GLUT12FloxMCKCre|C57BL/6-Slc2a12 Tg(Ckm-cre)28Arte/Apb||Semi-dominant|solute carrier family 2 (facilitated glucose transporter), member 12|Slc2a12||Glut12, GLUT-12|MGI:3052471||||10|||||||||||||||||transgene insertion 28, TaconicArtemis||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|02-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8295.0|HeparanaseKO|B6.129-Hpse/AnuApb||Recessive|heparanase|Hpse|Nil|Hpa|MGI:1343124|heparanase; targeted mutation 1, Jin-Ping Li|Hpse|MGI:3844469|5|||||||||||||||||||||||||||||Heparanase KO mice are fertile with no immunological phenotype observed.|Normal.|C57BL/6JAnu|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|29-Aug-2017|Cryopreserved sperm|58.0|0.0|Unknown||Heparan sulphate, MMP2|Yes| 8302.0|IGFBP-3-null |B6J.129S-Igfbp3||Recessive|insulin-like growth factor binding protein 3|Igfbp3|Nil|IGFBP-3|MGI:96438|insulin-like growth factor binding protein 3; targeted mutation 1, John E Pintar|Igfbp3|MGI:3663361|11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Sep-2017|Cryopreserved sperm|30.0|0.0|Unknown||Growth, metabolism|Yes| 8299.0|IRF4:T95R|C57BL/6NCrlAnu-Irf4/Anu||Recessive|interferon regulatory factor 4|Irf4|Unknown|IRF-4, Spip|MGI:1096873|Irf4, endonuclease-mediated mutation 2, Australian National University|Irf4||13|ENSMUSG00000021356.11|ENSMUST00000110307.3|Irf4-202|284|386|C to G|ENSMUSE00000117279|3||Threonine to Arginine|||||CGACAAGCCAGATCCTCCTACTTGGAAGACAAGATTACGATGTGCTCTGAACAAGAGCAAT||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|07-Sep-2017|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 8301.0|IRF4:47bp deletion|C57BL/6NCrlAnu-Irf4/Anu||Recessive|interferon regulatory factor 4|Irf4|Unknown|IRF-4, Spip|MGI:1096873|Irf4, endonuclease-mediated mutation 5, Australian National University|Irf4||13||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|07-Sep-2017|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8297.0|ASD547:Tle2|C57BL/6NCrlANu-Tle2/Anu||Recessive|transducin-like enhancer of split 2|Tle2|Unknown|Grg2|MGI:104635|Tle2, endonuclease-mediated mutation 1, Australian National University|Tle2||10||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|05-Sep-2017|Cryopreserved sperm|36.0|0.0|Unknown||CRISPR|Yes| 8296.0|ASD737:Zic2|C57BL/6NCrlAnu-Zic2/AnuApb||Recessive|zinc finger protein of the cerebellum 2|Zic2|Unknown|GENA 29, Ku, odd-paired homolog|MGI:106679|Zic2, endonuclease-mediated mutation 1, Australian National University|Zic2||14||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Sep-2017|Cryopreserved sperm|12.0|0.0|Unknown||CRISPR, Zic2|Yes| 8293.0|AMPK a1(S487A) KI|C57BL/6-Prkaa1/Ausb||Recessive|protein kinase, AMP-activated, alpha 1 catalytic subunit|Prkaa1||AMPKalpha1, C130083N04Rik|MGI:2145955||||15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Aug-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8307.0|Slp2 KO|B6.129P2-Sytl2/RbrcAnuApb||Recessive|synaptotagmin-like 2|Sytl2|Nil|Slp2, Slp2-a, Slp2-b, Slp2-c, Slp2-d|MGI:1933366|synaptotagmin-like 2; targeted mutation 1, Mitsunori Fukuda|Sytl2|MGI:3693881|7|||||||||||||||||||||||||||||Abnormal gastric surface mucous cell morphology:• the number of mucus granules is decreased, 2.8-fold fewer granules are docked with the apical membrane, mucus granule size is increased, and irregular apical membranes are frequently observed• however, no clear abnormalities are seen in the thickness of the epithelia or the numbers of parietal, neck, or chief cellsDecreased digestive secretion:• reduced basal mucin secretion by gastric epithelial cells; however when stimulated with A23187 mucus secretion is similar to wild-type cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Sep-2017|Cryopreserved sperm|33.0|0.0|Unknown||Rab27, mucus granules|Yes| 8308.0|Helios floxed:Lck-cre|B6.Cg-Ikzf2 Tg(Lck-Cre)/Anu||Recessive|IKAROS family zinc finger 2|Ikzf2||A730095J18Rik, Helios, Zfpn1a2|MGI:1342541|IKAROS family zinc finger 2; targeted mutation 1.1, Ethan M Shevach|Ikzf2|MGI:4456473|1|||||||||||||||||targeted mutation I57, Jamey Marth; transgene insertion I57, Jamey Marth|mouse proximal Lck promoter|active in thymocytes and splenocytes||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Sep-2017|Cryopreserved sperm|55.0|0.0|Unknown||CD4, T cell, Treg|Yes| 8309.0|CD19-cre.Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3 Cd19/AnuApb||Recessive|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296|early growth response 2; targeted mutation 3, Patrick Charnay|Egr2|MGI:2183227|10|||||||||||||||||||||||||||||Egr2 f/f.Egr3-/-.CD4-cre+ mice develop autoimmune disease at around three months of age or older. Egr2 f/f.CD4-cre+ mice develop milder autoimmune disease and at a slower rate. Egr3-/- exhibit some neurological defects.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|22-Sep-2017|Cryopreserved sperm|44.0|0.0|Unknown||B cell|Yes| 8309.0|CD19-cre.Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3 Cd19/AnuApb||Recessive|early growth response 3|Egr3|Nil|Pilot|MGI:1306780|early growth response 3; targeted mutation 1, Jeffrey Milbrandt|Egr3|MGI:2180063|14|||||||||||||||||||||||||||||Egr2 f/f.Egr3-/-.CD4-cre+ mice develop autoimmune disease at around three months of age or older. Egr2 f/f.CD4-cre+ mice develop milder autoimmune disease and at a slower rate. Egr3-/- exhibit some neurological defects.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|22-Sep-2017|Cryopreserved sperm|||Unknown||B cell|Yes| 8309.0|CD19-cre.Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3 Cd19/AnuApb||Recessive|CD19 antigen|Cd19|||MGI:88319|CD19 antigen; targeted mutation 1, University of Cologne|Cd19|MGI:1931143|7|||||||||||||||||||||||||||||Egr2 f/f.Egr3-/-.CD4-cre+ mice develop autoimmune disease at around three months of age or older. Egr2 f/f.CD4-cre+ mice develop milder autoimmune disease and at a slower rate. Egr3-/- exhibit some neurological defects.||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|22-Sep-2017|Cryopreserved sperm|||Unknown||B cell|Yes| 8310.0||Kif1bp KO||Recessive|kinesin family member 1 binding protein|Kif1bp|Nil|0710007C18Rik, 2510003E04Rik, mKIAA1279|MGI:1919570|Kif1bp; KBP |||10|||||||||||||||||||||||||||||Neonatal lethal. Die at birth due to breathing difficulties. Mice display broad peripheral neuropathies, as well as small olfactory bulbs and reduced white mater tracts (anterior commissure). |"Normal"|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Sep-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8314.0|ENU37:037:Casp4|C57BL/6NCrlAnu-Casp4/AnuApb||Recessive|caspase 4, apoptosis-related cysteine peptidase|Casp4|Unknown|Casp11, Caspase-11, ich-3|MGI:107700|Casp4, mutation 2, Australian National University|Casp4||9||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Sep-2017|Cryopreserved sperm|44.0|0.0|Unknown||ENU|Yes| 8319.0|SKAM gene trapped|B6.129P2-Fgfr1op2/MarpApb||Recessive|FGFR1 oncogene partner 2|Fgfr1op2||1500031J01Rik|MGI:1914779|FGFR1 oncogene partner 2; gene trap CA0175, Wellcome Trust Sanger Institute|Fgfr1op2|MGI:3858415|6|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|03-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9408.0|Lcp12|C57BL/6NCrlAnu-Lcp1/Apb||Semi-dominant|lymphocyte cytosolic protein 1|Lcp1|||MGI:104808|Lcp1: endonuclease-mediated mutation 1, Australian National University|Lcp1||14|||||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Jul-2022|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 8315.0|GLUT12 KO|C57BL/6-Slc2a12||Recessive|solute carrier family 2 (facilitated glucose transporter), member 12|Slc2a12||Glut12, GLUT-12|MGI:3052471||Slc2a12||10|ENSMUSG00000037490||||||||||||||||||||||||||||Glucose intolerantInsulin intolerantInsulin Resistance|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Oct-2017|Cryopreserved sperm|100.0|0.0|Unknown||Glucose|Yes| 8326.0||C57BL/6NCcb||Dominant|N/A|||||N/A|||Unknown|||||||||||||||||||||||||||||Wild type|Wild type|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Oct-2017|Cryopreserved sperm|80.0|0.0|Unknown||Control|Yes| 8325.0|Dsg2floxed-Cdh5-iCreER-T2 |C57BL/6N-Dsg2 Tg(Cdh5-creERT2)1Rha/CcbApb||Recessive|desmoglein 2|Dsg2||D18Ertd293e|MGI:1196466||||18|||||||||||||||||transgene insertion 1, Ralf H Adams|VE-cadherin (Cdh5)|||||||||||Phenotypically healthy under normal conditions. Unknown state when induced with tamoxifen, but predicted to exhibit depleted Dsg2 in vascular endothelial cells only, suggested to cause vascular complications.|Predicted to be the same, but less pronounced, than the homozygous mice.|C57BL/6N|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|05-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||Angiogenesis, endothelium|Yes| 8311.0|Surge|C57BL/6NCrlAnu-Foxb1/AnuApb||Recessive|forkhead box B1|Foxb1|Unknown|C43, Fkh5, Foxb1a, Foxb1b, Hfh-e5.1, Mf3, TWH|MGI:1927549|Foxb1, endonuclease-mediated mutation 1, Australian National University|Foxb1||9||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Sep-2017|Cryopreserved sperm|7.0|0.0|Unknown|||Yes| 8324.0|Dsg2fl/fl|C57BL/6N-Dsg2/CcbApb||Recessive|desmoglein 2|Dsg2||D18Ertd293e|MGI:1196466||||18|||||||||||||||||||||||||||||Normal|Normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||Angiogenesis|Yes| 8328.0|empire ; hSPHK1-Tie2 Tg|C57BL/6-Tg(Tie2-SPHK1)/CcbApb||Dominant||||||||||||||||||||||||||human Sphingosine Kinase 1 (SPHK1)|Tie-2|||||||||||Homozygous mice are viable, fertile, normal in size and to not display any gross physical or behavioural abnormalities. Enhanced SPHK1 expression and activity in the blood vasculature, particularly highly vascularised organs, due to the tie-2 promoter. Some differences seen in blood vessel development and arthritis development compared to wild type. |Normal |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4|||No|05-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||angiogenesis|Yes| 8331.0|ASD756:RC3H1:1bpins:4:N3|C57BL/6NCrlAnu-Rc3h14/AnuApb||Recessive|RING CCCH (C3H) domains 1|Rc3h1|Unknown|5730557L09Rik, roquin|MGI:2685397|Rc3h1, endonuclease-mediated mutation 1, Australian National University|Rc3h1||1||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|12-Oct-2017|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 8320.0|SK1 KO|B6.129S6-Sphk1/Apb||Recessive|sphingosine kinase 1|Sphk1|Nil|1110006G24Rik, SK1|MGI:1316649|sphingosine kinase 1; targeted mutation 1, Richard L Proia|Sphk1|MGI:3526071|11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||kinase|Yes| 8321.0|DSG2tma1|C57BL/6N-Dsg2/MarpCcbApb||Recessive|desmoglein 2|Dsg2|Reduced|D18Ertd293e|MGI:1196466|DSG2, ARVC10, ARVD10, CDHF5, CMD1BB, HDGC|||18|||||||||||||||||||||||||||||Homozygous mice are viable, fertile, normal in size and Mendelian ratio. They do not display any gross physical or behavioural abnormalities under homeostatic conditions. Notably, when challenged their significant reduction in Dsg2 gene expression translates into noticeable differences in blood vessel development, morphology and function, diabetes susceptibility and cancer progression. A pathology of cardiac fibrosis, which mimics the human condition, has been observed after humane killing but no observable effects related to this have been observed prior. Gene and protein expression experiments confirm that a low level of DSG2 is maintained in these mice; hence Dsg2 lo/lo.|Normal|C57BL/6N|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|05-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown||Angiogenesis, endothelium|Yes| 8336.0|ptpn14flox/flox|B6(Cg)-Ptpn14/MarpCcb||Recessive|protein tyrosine phosphatase, non-receptor type 14|Ptpn14||C130080N23Rik, OTTMUSG00000022087, PTP36|MGI:102467||||1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Oct-2017|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 1781.0|Cathepsin L Knockout|C57BL/6-Cstl/WehiAnuApb||Recessive|cathepsin L|Ctsl|Unknown|1190035F06Rik, Cat L, major excreted protein, MEP|MGI:88564|cathepsin L; targeted mutation 1, Christoph Peters|Ctsl|MGI:2136432|13||||||||||||||||Yes|||||||||||||Homozygotes for mutant alleles may exhibit partial or complete hair-loss, skin defects, impaired T cell maturation, dilated cardiomyopathy, and high postnatal mortality. Mutant males for some alleles show both normal and atrophic seminiferous tubules and reduced sperm production.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Aug-2007|Cryopreserved sperm|60.0|0.0|Unknown||Coat, T cell, CD4, Hair Loss, seminiferous tubules, alopecia|Yes| 8339.0|Egr2f/f|B6.129-Egr2/AnuApb||Recessive|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296|early growth response 2; targeted mutation 3, Patrick Charnay|Egr2|MGI:2183227|10|||||||||||||||||||||||||||||Unknown||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|27-Oct-2017|Cryopreserved sperm|22.0|0.0|Unknown||B cell|Yes| 8339.0|Egr2f/f|B6.129-Egr2/AnuApb||Recessive|early growth response 3|Egr3|Nil|Pilot|MGI:1306780|early growth response 3; targeted mutation 1, Jeffrey Milbrandt|Egr3|MGI:2180063|14|||||||||||||||||||||||||||||Unknown||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|27-Oct-2017|Cryopreserved sperm|||Unknown||B cell|Yes| 8334.0|R26 WT-Hoxa1 ki|B6JArc.Cg-Gt(ROSA)26Sor||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3237, TaconicArtemis|Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6JArc|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Excellent|10|||No|23-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8337.0|ptpn14flox/flox/CMVCre|B6(Cg)-Ptpn14/MarpCcb||Recessive|protein tyrosine phosphatase, non-receptor type 14|Ptpn14|Unknown|C130080N23Rik, OTTMUSG00000022087, PTP36|MGI:102467||Ptpn14||1|||||||||||||||||||||||||||||Periorbital oedema, lower limb oedema|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Oct-2017|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 8338.0|Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3/AnuApb||Recessive|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296|early growth response 2; targeted mutation 3, Patrick Charnay|Egr2|MGI:2183227|10|||||||||||||||||||||||||||||Unknown||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|27-Oct-2017|Cryopreserved sperm|24.0|0.0|Unknown||B cell|Yes| 8338.0|Egr2f/f.Egr3-/-|B6.129-Egr2 Egr3/AnuApb||Recessive|early growth response 3|Egr3|Nil|Pilot|MGI:1306780|early growth response 3; targeted mutation 1, Jeffrey Milbrandt|Egr3|MGI:2180063|14|||||||||||||||||||||||||||||Unknown||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|>10|||No|27-Oct-2017|Cryopreserved sperm|||Unknown||B cell|Yes| 8341.0|SKAM1A Trangsgenic|C57BL/6-Tg(CAG-FGFR1OP2)/TasqCcb||Dominant|||||||||Unknown|||||||||||||||||human Fibroblast Growth Factor Receptor1 Oncongne partner 2|Chicken Beta actin|All cells||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|31-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8346.0|AMPK b1 KO|C57BL/6-Prkab1||Recessive|protein kinase, AMP-activated, beta 1 non-catalytic subunit|Prkab1|Nil|1300015D22Rik|MGI:1336167|protein kinase, AMP-activated, beta 1 non-catalytic subunit; targeted mutation 1, Bruce E Kemp|Prkab1|MGI:4439277|5|||||||||||||||||||||||||||||Homeostasis/metabolism phenotype:N• when fed a high-fat diet, mice exhibit resistance to diet induced hyperinsulinemia and insulin resistance.• mice exhibit normal response to renal ischemia-reperfusion injury.Decreased susceptibility to diet-induced obesity:• when fed a high-fat dietDecreased circulating insulin level:• in fasted mice fed a high-fat dietDecreased circulating leptin level:• whether fed chow or a high-fat dietDecreased circulating interleukin-6 level:• whether fed chow or a high-fat dietIncreased insulin sensitivity:• whether fed chow or a high-fat diet, mice exhibit increased insulin sensitivity compared with similarly treated wild-type mice• when fed a high-fat diet, mice exhibit increased glucose infusion rate suggesting improved skeletal muscle insulin sensitivity compared with similarly treated wild-type mice• whether fed chow or a high-fat diet, mice exhibit reduced hepatic glucose output and greater insulin-induced suppression of hepatic glucose production indicating increased hepatic insulin sensitivity compared with similarly treated wild-type miceAbnormal lipid level:• when fed a high-fat diet, mice exhibit decreased hepatic levels of triglyceride, diglyceride, and ceramide compared with wild-type miceDecreased liver triglyceride level:• when fed a high-fat dietDecreased susceptibility to hepatic steatosis:• when fed a high-fat diet, mice exhibit decreased hepatic levels of triglyceride, diglyceride, and ceramide compared with wild-type miceAbnormal hepatocyte physiology:• hepatocytes exhibit increased fatty acid synthesis and reduced fatty acid oxidation compared with wild-type cells• however, insulin sensitivity of hepatocytes is normal.Decreased epididymal fat pad weight:• whether fed chow or a high-fat diet|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Nov-2017|Cryopreserved sperm|49.0|0.0|Unknown||AMP-activated protein kinase (AMPK)|Yes| 8347.0|AMPK Beta 2 KO|C57BL/6-Prkab2||Recessive|protein kinase, AMP-activated, beta 2 non-catalytic subunit|Prkab2||5730553K21Rik|MGI:1336185|protein kinase, AMP-activated, beta 2 non-catalytic subunit; targeted mutation 1, Gregory R Steinberg|Prkab2|MGI:5293372|3|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Nov-2017|Cryopreserved sperm|50.0|0.0|Unknown||AMP-activated protein kinase (AMPK) β subunits (β1 and β2)|Yes| 8335.0|ptpn14LacZ/+|B6(Cg)-Ptpn14/MarpCcb||Recessive|protein tyrosine phosphatase, non-receptor type 14|Ptpn14|Unknown|C130080N23Rik, OTTMUSG00000022087, PTP36|MGI:102467|protein tyrosine phosphatase, non-receptor type 14; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Ptpn14|MGI:5318763|1|||||||||||||||||||||||||||||Periorbital oedema, lower limb oedema.|Normal|C57/BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Oct-2017|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 8333.0|ASD670:Nacho:::F2|C57BL/6NCrlAnu-Amigo3/AnuApb||Recessive|adhesion molecule with Ig like domain 3|Amigo3|Unknown|E430002N15Rik|MGI:2444854|Amigo3, endonuclease-mediated mutation 1, Australian National University|Amigo3||9||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|19-Oct-2017|Cryopreserved sperm|24.0|0.0|Unknown|||Yes| 8352.0|GABRG2 R43Q|DBA-Gabrg2||Semi-dominant|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 |Gabrg2||GABAA-R, Gabrg-2, gamma2|MGI:95623||||11|||||||||||||||||||||||||||||Partial perinatal lethality:• mice are rarely bornComplete postnatal lethality:• mice that are born die before P19Tremors:• mice that are born exhibit a severe tremorAbnormal gait:• mice that are born have altered gaitsAbnormal brain wave pattern:• mice lack normal brain rhythms|Mice heterozygous for the mutation demonstrated behavioral arrest associated with 6-to 7-Hz spike-and-wave discharges, which are blocked by ethosuximide, a first-line treatment for absence epilepsy in man. Seizures in the mouse showed an abrupt onset at around age 20 days corresponding to the childhood nature of this disease. Reduced cell surface expression of gamma2(R43Q) was seen in heterozygous mice in the absence of any change in alpha1 subunit surface expression|DBA|No|No|Yes|No|No|Yes|No|Unknown||||No|23-Nov-2017|Cryopreserved sperm|47.0|54.0|Unknown||epilepsy, seizures|Yes| 8350.0|ASD726:Taco:3::N1F1|C57BL/6NCrlAnu-Tax1bp1/AnuApb||Recessive|Tax1 (human T cell leukemia virus type I) binding protein 1|Tax1bp1|Unknown|1200003J11Rik, 1700069J21Rik, D6Ertd404e, D6Ertd772e, T6BP, TXBP151|MGI:1289308|Tax1bp1|Tax1bp1, endonuclease-mediated mutation 2, Australian National University||6||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Nov-2017|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8348.0|A1(T183A) KI|C57BL/6-Prkaa1||Recessive|protein kinase, AMP-activated, alpha 1 catalytic subunit|Prkaa1|Unknown|AMPKalpha1, C130083N04Rik|MGI:2145955||||15|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|14-Nov-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8358.0|ASD869:Sumo|C57BL/6NCrlANU-Irak2/AnuApb||Recessive|interleukin-1 receptor-associated kinase 2|Irak2||6330415L08Rik, IRAK-2, Irak2a, Irak2b, Irak2c, Irak2d|MGI:2429603|Irak2, endonuclease-mediated mutation 1, Australian National University|Irak2||6|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|29-Nov-2017|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 8362.0|ASD867|BALB/cNCrlAnu:Orange||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2017||0.0|615.0|Unknown|||No| 8364.0|ASD867|BALB/cNCrlAnu:Green||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2017||0.0|164.0|Unknown|||No| 8366.0|ASD726:Taco2:11bp del|C57BL/6NCrlANu-Tax1bp1/AnuApb||Recessive|Tax1 (human T cell leukemia virus type I) binding protein 1|Tax1bp1|Unknown|1200003J11Rik, 1700069J21Rik, D6Ertd404e, D6Ertd772e, T6BP, TXBP151|MGI:1289308|Tax1bp1, endonuclease-mediated mutation 1, Australian National University|Tax1bp1||6||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|2018|||No|08-Dec-2017|Cryopreserved sperm|33.0|0.0|Unknown||CRISPR|Yes| 8368.0|Aire:Cbl-b:Rag1 KO|C57BL/6JSfdAnu-Aire Cblb Rag1/AnuApb||Recessive|Casitas B-lineage lymphoma b|Cblb||Cbl-b|MGI:2146430|Casitas B-lineage lymphoma b; targeted mutation 1, Josef M Penninger|Cblb|MGI:2180570|16|||||||||||||||||||||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|08-Dec-2017|Cryopreserved sperm|22.0|0.0|No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell, selection|Yes| 8368.0|Aire:Cbl-b:Rag1 KO|C57BL/6JSfdAnu-Aire Cblb Rag1/AnuApb||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||||||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|08-Dec-2017|Cryopreserved sperm|||No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell, selection|Yes| 8368.0|Aire:Cbl-b:Rag1 KO|C57BL/6JSfdAnu-Aire Cblb Rag1/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10|||||||||||||||||||||||||||||||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||sib x sib|No|08-Dec-2017|Cryopreserved sperm|||No||Hen egg Lysozyme, tolerance, immunity, T cell, B cell, selection|Yes| 8367.0|Cblb KO|B6(Cg)-Cblb/AnuApb|B6(Cg)-Cblb/AnuApb|Recessive|Casitas B-lineage lymphoma b|Cblb|Nil|Cbl-b|MGI:2146430|targeted mutation 1, Josef M Penninger|Cblb|MGI:2180570|16||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit elevated IL2 production by T cells, develop spontaneous autoimmunity, and are highly susceptible to experimental autoimmune encephalomyelitis.||C57BL/NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|2|||No|08-Dec-2017|Cryopreserved sperm|33.0|0.0|No||IL-2, T cell, encephalomyelitis, autoimmune, signal transduction|Yes| 8374.0|NOD.Nkrp1b.CD3z|NOD-Cd247 Klrb1b Nkt1/Bax||Recessive|||||||||||||||||||||||||||||CD247 antigen|Cd247||4930549J05Rik, CD3-eta, Cd3h, Cd3z, CD3zeta, CD3 zeta, CD3-zeta, CD3-zeta/eta, T3z, TCRk, Tcrz|MGI:88334||||1|Mice that are homozygous for this allele are viable, fertile and normal in size. Can be difficult breeders.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for CD3z region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8374.0|NOD.Nkrp1b.CD3z|NOD-Cd247 Klrb1b Nkt1/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size. Can be difficult breeders.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for CD3z region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8374.0|NOD.Nkrp1b.CD3z|NOD-Cd247 Klrb1b Nkt1/Bax||Recessive|||||||||||||||||||||||||||||natural killer T cell numbers 1|Nktcn1||Nkt1|MGI:2681136|natural killer T cell numbers 1; C57BL/6J|Nktcn1|MGI:2681149|1|Mice that are homozygous for this allele are viable, fertile and normal in size. Can be difficult breeders.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for CD3z region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8372.0|NOD.H2b.SCID-/-|NOD.Cg-H2 Prkdc/BaxApb||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Nil|DNA-PK, DNA-PKcs, DNAPDcs, slip, XRCC7|MGI:104779|severe combined immunodeficiency|Prkdc|MGI:1857113|16||||||||||||||||Yes||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|SCID mutation prevents TCR and BCR rearrangements. This prevents maturation of B and T cells at very early stages of development. These mice, therefore lack, T and B cells in periphery. Please refer to MGI allele page for further information using the link above.Mice that are homozygous for the SCID mutation are viable, fertile, normal in size. This strain is immunocomprimised. Mice homozygous for the severe combined immune deficiency spontaneous mutation (Prkdcscid, commonly referred to as scid) are characterized by an absence of functional T cells and B cells, lymphopenia, hypogammaglobulinemia, and a normal hematopoietic microenvironment. Normal antigen-presenting cell, myeloid, and NK cell functions are strain dependent. scid mice carry a DNA repair defect and a defect in the rearrangement of genes that code for antigen-specific receptors on lymphocytes. Most homozygotes have no detectable IgM, IgG1, IgG2a, IgG2b, IgG3, or IgA. Thymus, lymph nodes, and splenic follicles are virtually devoid of lymphocytes. scid mice accept allogeneic and xenogeneic grafts making them an ideal model for cell transfer experiments. Some scid mice will spontaneously develop partial immune reactivity. scid mice that have serum Ig levels greater than 1 ug/ml are considered "leaky." scid leakiness is highly strain dependent, increases with age, and is higher in mice housed under non-SPF conditions. In general, scid leakiness is high on the C57BL/6J and BALB/cBy genetic backgrounds, low on the C3H/HeJ background, and even lower on the NOD/ShiLtSz background. NOD/ShiLtSz-Prkdcscid mice are both insulitis- and diabetes-free throughout life and serve as a diabetes-free control for comparison to NOD/ShiLtJ mice. Thymic lymphomas occur with high frequency, however, and life span typically is limited to only 8.5 months under specific pathogen-free conditions.Also contains congenic markers MHC haplotype H2ᵇThe NOD.H2ᵇstrain does not develop insulitis, cyclophosphamide-induced diabetes, or spontaneous diabetes, but does develop extensive lymphocytic infiltrates in the pancreas and the submandibular glands.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||19||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Yes||SCID, severe combined immunodeficiency, transplant, T cell, B cell|Yes| 8373.0|NOD.Nkrp1b.Nkt1|NOD-Klrb1b Nkt1/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8373.0|NOD.Nkrp1b.Nkt1|NOD-Klrb1b Nkt1/Bax||Recessive|||||||||||||||||||||||||||||natural killer T cell numbers 1|Nktcn1||Nkt1|MGI:2681136|natural killer T cell numbers 1; C57BL/6J|Nktcn1|MGI:2681149|1|Mice that are homozygous for this allele are viable, fertile, normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8376.0|NOD.Nkrp1b.Slam1c|NOD-Klrb1b Nkt1 Slam1c/Bax||Recessive||||||||||||||||||||||||||||||||||||||Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1c region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8851.0|mHEL3x|B6.Cg-Gt(ROSA)26Sor/Anu||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1.1, Robert Brink|Gt(ROSA)26Sor||6||||||||||||||||||||||||||||||Ubiquitous expression of HEL3x|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Feb-2020|Cryopreserved sperm|52.0|39.0|Unknown||HEL, selection|Yes| 8381.0|TCR7|C57BL/6-Tg(TcraBO4H9.1,TcrbBO4H9.1)7Aog||Dominant||||||||||||||||||||||||||transgene insertion 7 Anne O'Garra||||||||||||T cells express anti-hen egg lysozyme (HEL) TCR Valpha11 and Vbeta3 chains||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Dec-2017|Cryopreserved sperm|1.0|127.0|Unknown||T cell, TCR, HEL, CD4|Yes| 8383.0|Integrin beta3 Knockout|C.129S2-Itgb3||Recessive|integrin beta 3|Itgb3|Nil|CD61, platelet glycoprotein IIIa (GP3A)|MGI:96612|integrin beta 3; targeted mutation 1, Richard Hynes|Itgb3|MGI:2175913|11|||||||||||||||||||||||||||||Mice look normal, are fertile and breed normally. They have a mild bone phenotype due to dysfunctional osteoclasts. Mice a prone to excesasive bleeding after injury due to defective platelets lacking alphaIIbBeta3 integrin. Females may have placental defects that can lead to fetal mortality. For this reason, only heterozygote females are used for breeding.|Normal, as WT mice|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Dec-2017|Cryopreserved sperm|30.0|0.0|Unknown||Glanzmann thrombasthenia, thrombosis|Yes| 8371.0|NOD.H2b.Nkrp1b|NOD-H2 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8371.0|NOD.H2b.Nkrp1b|NOD-H2 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8379.0|NOD.Nkrp1b.Nkt2a|NOD-Klrb1b Nktcn2a/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.|Differences in susceptibility to autoimmunity.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8379.0|NOD.Nkrp1b.Nkt2a|NOD-Klrb1b Nktcn2a/Bax||Recessive|||||||||||||||||||||||||||||natural killer T cell numbers 2|Nktcn2||Nkt2a|MGI:2681137|natural killer T cell numbers 2; C57BL/6J|Nktcn2|MGI:2681151|2|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.|Differences in susceptibility to autoimmunity.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8392.0|NOD.Idd13|NOD-Idd13/Bax||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 13|Idd13|||MGI:99415|insulin dependent diabetes susceptibility 13; C57BL/6|Idd13|MGI:3044074|2|Mice that are homozygous for this allele are viable, fertile, normal in size.Difference in autoimmunity susceptibility compared to NOD.This strain is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||NK cell, autoimmunity|Yes| 8390.0|Fat4 flox|B6.129-Fat4/HmcApb||Recessive|FAT atypical cadherin 4|Fat4||6030410K14Rik|MGI:3045256|FAT atypical cadherin 4; targeted mutation 1.1, Helen McNeill|Fat4|MGI:3846573|3|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||cystic kidney disease|Yes| 8389.0|Conditional SMAD1 f/f|C.129-Smad1||Recessive|SMAD family member 1|Smad1||Madh1, Madr1, Smad 1|MGI:109452|SMAD family member 1; targeted mutation 2, Elizabeth J Robertson|Smad1|MGI:2155484|8|||||||||||||||||||||||||||||Normal|Normal|BALB/c |Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|10|||No|18-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||TGF, BMP|Yes| 8391.0|Gata2 flox|B6.129-Gata2||Recessive|GATA binding protein 2|Gata2||Gata-2|MGI:95662|GATA binding protein 2; targeted mutation 1, Marjo Salminen|Gata2|MGI:4818492|6|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||transcription factor|Yes| 8395.0|NOD.Nkrplb.Slam1D.CD-1|NOD-CD1 Klrb1b Slamf1D/Bax||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Animals homozygous for CD1 KO mutation lack an NK-like cell subset (HSA<-/low>, NK1.1+, TCRint, CD44high, CD122+) of thymocytes. TCR cross-linking and anti-CD3 stimulation fails to induce IL-4 production."Mice can have trouble breeding. Keep a close eye on progress and increase breeders as required to maintain line. If a case of breeding ceasing, may need to cross back onto a parental line. Ideally NOD.Nkrplb.Nktl.SlamlD to reduce genotyping.Nkrplb:Congenic Nk Cell Marker. Nktl:Congenic Marker for NKT1 region. Increased Nkt cell numbers.CD-1:Knockout lacking the CD1 antigen complex gene. Lack an NK-like cell subset.SlamlD:Congenic Marker for Slam1D region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8395.0|NOD.Nkrplb.Slam1D.CD-1|NOD-CD1 Klrb1b Slamf1D/Bax||Recessive|||||||||||||||||||||||||||||signaling lymphocytic activation molecule family member 1|Slamf1||CD150, CDw150, ESTM51, IPO-3, Slam|MGI:1351314||||1|Animals homozygous for CD1 KO mutation lack an NK-like cell subset (HSA<-/low>, NK1.1+, TCRint, CD44high, CD122+) of thymocytes. TCR cross-linking and anti-CD3 stimulation fails to induce IL-4 production."Mice can have trouble breeding. Keep a close eye on progress and increase breeders as required to maintain line. If a case of breeding ceasing, may need to cross back onto a parental line. Ideally NOD.Nkrplb.Nktl.SlamlD to reduce genotyping.Nkrplb:Congenic Nk Cell Marker. Nktl:Congenic Marker for NKT1 region. Increased Nkt cell numbers.CD-1:Knockout lacking the CD1 antigen complex gene. Lack an NK-like cell subset.SlamlD:Congenic Marker for Slam1D region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8394.0|NOD.Idd13.Nkrp1b.Cd-1-/-|NOD-CD1 Idd13 Klrb1b/Bax||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Animals homozygous for CD1 KO mutation lack an NK-like cell subset (HSA<-/low>, NK1.1+, TCRint, CD44high, CD122+) of thymocytes. TCR cross-linking and anti-CD3 stimulation fails to induce IL-4 production.Idd13:Idd13 is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.H2b:Congenic markers MHC haplotype H2ᵇ. Nkrplb:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2ᵇ"||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|30.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8394.0|NOD.Idd13.Nkrp1b.Cd-1-/-|NOD-CD1 Idd13 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 13|Idd13|||MGI:99415|insulin dependent diabetes susceptibility 13; C57BL/6|Idd13|MGI:3044074|2|Animals homozygous for CD1 KO mutation lack an NK-like cell subset (HSA<-/low>, NK1.1+, TCRint, CD44high, CD122+) of thymocytes. TCR cross-linking and anti-CD3 stimulation fails to induce IL-4 production.Idd13:Idd13 is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.H2b:Congenic markers MHC haplotype H2ᵇ. Nkrplb:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2ᵇ"||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8396.0|NOD.Nkrp1b.Nkt2b.CD-1|NOD-Cd1 Klrb1b Nktcn2b/Bax||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Difficult breeders. Have had to restart the breeding, multiple times due to the difficulty in getting them homozygous. Seems homozygous mice do not breed. Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.Knockout lacking the CD1 antigen complex gene||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8396.0|NOD.Nkrp1b.Nkt2b.CD-1|NOD-Cd1 Klrb1b Nktcn2b/Bax||Recessive|||||||||||||||||||||||||||||natural killer T cell numbers 2|Nktcn2||Nkt2b|MGI:2681137||||2|Difficult breeders. Have had to restart the breeding, multiple times due to the difficulty in getting them homozygous. Seems homozygous mice do not breed. Congenic Nk Cell Marker. Congenic Marker for NKT2 region. Increased Nkt cell numbers.Knockout lacking the CD1 antigen complex gene||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8397.0|NOD.Faslm1|NOD-Fasl/Bax||Recessive|Fas ligand (TNF superfamily, member 6)|Fasl|Unknown|APT1LG1, CD178, CD95L, Fasl, Fas-L, Tnfsf6|MGI:99255||Fasl||1|||||||||||||||||||||||||||||Mice that are homozygous for these alleles are viable, fertile, normal in size. Mice have affected severity of autoimmunity compared to controls.Spontaneous Mutation of Ligand||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity|Yes| 8398.0|NOD.Faslm2|NOD-Fasl/Bax||Recessive|Fas ligand (TNF superfamily, member 6)|Fasl|Unknown|APT1LG1, CD178, CD95L, Fasl, Fas-L, Tnfsf6|MGI:99255||Fasl||1|||||||||||||||||||||||||||||Mice that are homozygous for these alleles are viable, fertile, normal in size. Affects severity of autoimmunity compared to controlsSpontaneous Mutation of LigandFaslm2bSpontaneous Mutation of Ligand from C57Bl6 Identical to NOD.Faslm2||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity|Yes| 8399.0|NOD.Faslm2b|NOD-Fasl/Bax||Recessive|Fas ligand (TNF superfamily, member 6)|Fasl|Unknown|APT1LG1, CD178, CD95L, Fasl, Fas-L, Tnfsf6|MGI:99255||Fasl||1|||||||||||||||||||||||||||||Mice that are homozygous for these alleles are viable, fertile, normal in size. Affects severity of autoimmunity compared to controlsSpontaneous Mutation of LigandFaslm2bSpontaneous Mutation of Ligand from C57Bl6 Identical to NOD.Faslm2||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|149.0|0.0|Unknown||autoimmunity|Yes| 8400.0|NOD.Trail|NOD.129-Tnfsf10/MjsBax||Recessive|tumor necrosis factor (ligand) superfamily, member 10|Tnfsf10|Nil|A330042I21Rik, APO-2L, Trail|MGI:107414|tumor necrosis factor (ligand) superfamily, member 10; targeted mutation 1, Mark J Smyth|Tnfsf10|MGI:2179709|3||||||||||||||||||||||||||||| Thymus hyperplasia, abnormal negative T cell selection, increased susceptibility to autoimmune diseases and to tumor initiation and metastasis, and resistance to induced hepatitis.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||TNF, metastasis|Yes| 8401.0|BALB.4220-3855|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|80.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8403.0|BALB.8755-3855|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8404.0|BALB.931-189B|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8405.0|BALB.931-203.344-3855|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8406.0|BALB.931-203.64-3855|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8409.0|NOD.Idd5r|NOD-Idd5r/Bax||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 5r|Idd5r|||||||2|Mice that are homozygous for this allele are viable, fertile, normal in size.This strain is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd5r||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||insulin|Yes| 8410.0|NOD.H2d.Nkrp1b|NOD-H2 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; d variant|H2|MGI:3579320|17|Mice that are homozygous for this allele are viable, fertile, normal in size.Nkrplb:Congenic Nk Cell Marker.H2d:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2d. ||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8410.0|NOD.H2d.Nkrp1b|NOD-H2 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.Nkrplb:Congenic Nk Cell Marker.H2d:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2d. ||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8414.0|Cd25 KO;OT-I|B6.Cg-Il2ra Tg(TcraTcrb)1100Mjb/WehiAnu||Recessive|interleukin 2 receptor, alpha chain|Il2ra||CD25, Il2r, IL-2R alpha chain, Ly-43|MGI:96549|interleukin 2 receptor, alpha chain; targeted mutation 1, Dennis M Willerford|Il2ra|MGI:1857192|2|||||||||||||||||transgene insertion 1100, Michael J Bevan|MGI:3054907|||||||||||Mice homozygous for the CD25 (IL2Ra) targeted mutation are characterized by a lymphoproliferative disorder, hemolytic anemia and an inflammatory bowel disease beginning at approximately 9 weeks of age. Homozygous females may not be healthy enough to breed. ||C57BL/6J|Yes|Unknown|No|Yes|Unknown|No|No|Unknown||||No|10-Jan-2018|Cryopreserved sperm|21.0|0.0|Unknown||T cell|Yes| 8419.0|Tcf7 fl|B6(Cg)-Tcf7/WehiAnuApb||Recessive|transcription factor 7, T cell specific|Tcf7||T cell factor-1, T-cell factor 1, Tcf1, TCF-1|MGI:98507|transcription factor 7, T cell specific; targeted mutation 1c, Wellcome Trust Sanger Institute|Tcf7|MGI:5816259|11||||||||||Unknown to Unknown|||||||||||||||||||Normal||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Jan-2018|Cryopreserved sperm|21.0|0.0|Unknown|||Yes| 8407.0|NOD.H2d|NOD-H2/Bax||Recessive|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; d variant|H2|MGI:3579320|17|Mice that are homozygous for this allele are viable, fertile, normal in size.Congenic markers MHC haplotype H2||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|49.0|0.0|Unknown||MHC|Yes| 8408.0|NOD.Idd27|NOD-Idd27/Bax||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 27|Idd27|||MGI:3608893||||7|Mice that are homozygous for this allele are viable, fertile, normal in size.This strain is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd27||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||insulin|Yes| 8416.0|Pad4 fl|B6.Cg-Padi4/KmowAnu||Recessive|peptidyl arginine deiminase, type IV|Padi4|Nil|Pad4, PAD type IV, Pdi4|MGI:1338898|peptidyl arginine deiminase, type IV; targeted mutation 1.2, Kerri A Mowen|Padi4|MGI:5695766|4|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2018|Cryopreserved sperm|44.0|0.0|Unknown||Infection, neutrophil, extracellular traps|Yes| 8412.0|ELF5-rRTA-TetO-Cre-Neu|FVB/N.Cg-Tg(Elf5-rtTA,tetO-cre)||Dominant||||||||||||||||||||||||||ELF5-rRTA, TetO-Cre, Neu|ELF5, TetO, MMTV|||||||||||Normal|Normal|FVB/N X BL6/129|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Dec-2017|Cryopreserved sperm|30.0|0.0|Unknown|||No| 8426.0|RBC19|SJL-Tpi||Semi-dominant|triosephosphate isomerase 1|Tpi1|Unknown|Tpi-1|MGI:98797|Tpi^F57S/F57S|||6|||||||||||||||||||||||||||||Macrocytosis and haemolytic anaemia, high MCV, low RBC, splenomegaly, viable and fertile.|Macrocytosis, high MCV.|SJL|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Jan-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8428.0|Wnt11-myrTagRFP-IRES-CE|B6.Cg-Tg(Wnt11-TagRFP/cre/ERT2)28Amc||Dominant||||||||||||||||||||||||||transgene insertion 28, Andrew McMahon|Wnt11, wingless-type MMTV integration site family, member 11, mouse, laboratory|||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Jan-2018|Cryopreserved sperm|49.0|0.0|Unknown||Wnt11, RFP|Yes| 8422.0|uPAR KO|B6.129-Plaur||Recessive|plasminogen activator, urokinase receptor|Plaur||Cd87, uPAR, u-PAR, urokinase-type plasminogen activator receptor|MGI:97612|plasminogen activator, urokinase receptor; targeted mutation 1, Jay L Degen|Plaur|MGI:1857290|7|||||||||||||||||||||||||||||Liver inflammationTrachea inflammation|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||brother x sister|Yes|18-Jan-2018|Cryopreserved sperm|50.0|0.0|No||Haemostasis|Possibly| 8423.0|Kif1bp KO #2|C57BL/6-Kif1bp/Hmy||Recessive|KIF1 binding protein|Kif1bp||0710007C18Rik, 2510003E04Rik, mKIAA1279|MGI:1919570|kinesin family binding protein; endonuclease-mediated mutation 1, Heather Young|Kif1bp|MGI:6150321|10||||||||||Unknown to Unknown|||||||||||||||||||Neonatal lethal. Die at birth due to breathing difficulties. Mice display broad peripheral neuropathies, as well as small olfactory bulbs and reduced white mater tracts (anterior commissure).|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|19-Jan-2018|Cryopreserved sperm|50.0|0.0|Yes|Goldberg-Shprintzen syndrome|Nerve, olfactory, commissures|Yes| 8427.0|tPA-/-|B6.129-Plat/Mlg||Recessive|plasminogen activator, tissue|Plat|Nil|D8Ertd2e, MGC:18508, tPA, t-PA|MGI:97610|plasminogen activator, tissue; targeted mutation 1, Richard C Mulligan|Plat|MGI:1857288|8|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|25-Jan-2018|Cryopreserved sperm|50.0|0.0|Unknown||fibrin, clot|Yes| 8425.0|RBC21|B6.Cg-Tfrc||Semi-dominant|transferrin receptor|Tfrc|Unknown|2610028K12Rik, CD71, E430033M20Rik, Mtvr1, Mtvr-1, p90, TfR1, Trfr|MGI:98822|Tfrc^R654H|||16|||||||||||||||||||||||||||||Homozygous lethal E16.5-18.5 due to profound anaemia.|Mild anaemia, low MCV, high RBC, low Hb.|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Jan-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8430.0|RBC16|BALB/c-Cpox/WehiMarpApb||Dominant|coproporphyrinogen oxidase|Cpox|Nil|cac, clone 560, Cpo, nct|MGI:104841|Cpox|||16|||||||||||||||||||||||||||||Lethal (e9.5) |Microcytosis (low MCV), low Hb|BALB/c|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Feb-2018||0.0|0.0|Unknown||Haem, porphyrins, Hereditary coproporphyria, Anaemia|Yes| 8434.0|14-3-3zeta(Gt(OST062)Lex ; Armada|C.129S5-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST432062, Lexicon Genetics|Ywhaz|MGI:4315078|15|||||||||||||||||||||||||||||Homozygous KO mice are smaller than their littermate and have behavioural abnormalities, including hyperactivity and congnitive defects. 20% of KO mice die prior to weaning.|Normal|BALB/c|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Feb-2018|Cryopreserved sperm|50.0|0.0|Unknown||Dopamine, schizophrenia|Yes| 8432.0|14-3-3zetaGt(OST062)Lex ; Savvy|129(Cg)-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST432062, Lexicon Genetics|Ywhaz|MGI:4315078|15|||||||||||||||||||||||||||||Mice have behavioural abnormalities, including hyperactivity and reduced cognitive abilities. KO mice are smaller than their littermates and around 20% die prior to weaning. |Normal|129/Sv|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Feb-2018|Cryopreserved sperm|50.0|0.0|Unknown||Dopamine, schizophrenia|Yes| 8435.0|14-3-3zeta(Gt(OST062)Lex ; Jaxx|B6.129S5-Ywhaz/Apb||Recessive|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz|Nil|1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap OST432062, Lexicon Genetics|Ywhaz|MGI:4315078|15|||||||||||||||||||||||||||||Homozygous animals are smaller than their littermate and have mild hyperactivity and cognitive defects. 20% of KO mice die prior to weaning.|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|08-Feb-2018|Cryopreserved sperm|40.0|0.0|Unknown||Dopamine, schizophrenia|Yes| 8424.0|ASD735:Cannonball:F0|C57BL/6NCrlAnu-Camk2d/Anu||Recessive|calcium/calmodulin-dependent protein kinase II, delta|Camk2d|Unknown|2810011D23Rik, 8030469K03Rik, CaMK II, MGC:60852|MGI:1341265|Camk2d, endonuclease-mediated mutation 1, Australian National University|Camk2d||3||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Jan-2018|Cryopreserved sperm|56.0|0.0|Unknown|||Yes| 8431.0|Dmp1Cre.SOCS3f/f|B6-Socs3 Tg(Dmp1-cre)1Jqfe/StVApb||Recessive|suppressor of cytokine signaling 3|Socs3||CIS3, Cish3, cytokine-inducible SH2 protein 3, E2a-Pbx1 target gene in fibroblasts 10, EF-10, SOCS-3, SSI-3, STAT-induced STAT inhibitor 3|MGI:1201791|suppressor of cytokine signaling 3; targeted mutation 2, Warren S Alexander|Socs3|MGI:2663917|11|||||||||||||||||transgene insertion 1, Jian Q Feng|Dmp1|odontoblast-specific expression||||||||||Sex-specific delay in bone corticalization. |Normal|C75BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Feb-2018|Cryopreserved sperm|50.0|0.0|Unknown||corticalization, IL6, androgen|Yes| 8436.0||Actc1-TRE||Dominant||||||||||||||||||||||||||||||||||||||Unknown|||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|09-Feb-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8445.0|CTR flox|B6(Cg).129-Calcr/AnuApb||Dominant|calcitonin receptor|Calcr||Clr|MGI:101950|calcitonin receptor; targeted mutation 1, Rachel A Davey|Calcr|MGI:4352932|6|||||||||||||||||||||||||||||Normal.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|>20|||No|14-Mar-2018|Cryopreserved sperm|60.0|0.0|Unknown||hypercalcemia|Yes| 8439.0|Tlt2|C57BL/6-Treml2/Apb||Recessive|triggering receptor expressed on myeloid cells-like 2|Treml2||LOC328833|MGI:2147038||||17|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Feb-2018|Cryopreserved sperm|40.0|0.0|Unknown||CRISPR|Yes| 8440.0|TREML4/TLT2 DKO|C57BL/6-Treml4 Treml2/Apb||Recessive|triggering receptor expressed on myeloid cells-like 2|Treml2|Unknown|LOC328833|MGI:2147038||||17|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|16-Feb-2018|Cryopreserved sperm|30.0|0.0|Unknown||CRISPR|Yes| 8440.0|TREML4/TLT2 DKO|C57BL/6-Treml4 Treml2/Apb||Recessive|triggering receptor expressed on myeloid cells-like 4|Treml4||5031403H21Rik|MGI:1923239||||17|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|16-Feb-2018|Cryopreserved sperm|||Unknown||CRISPR|Yes| 8442.0|Mdm2|B6(Cg).129(Cg)-Mdm2/JAnu||Recessive|transformed mouse 3T3 cell double minute 2|Mdm2||1700007J15Rik, Mdm-2|MGI:96952|transformed mouse 3T3 cell double minute 2; targeted mutation 1.1, Yangping Zhang|Mdm2|MGI:4836988|10|||||||||||||||||||||||||||||Unknown||C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|05-Mar-2018|Cryopreserved sperm|123.0|0.0|Unknown|||Yes| 8437.0|TREML4 KO ; FUMR|C57BL/6-Treml4/Apb||Recessive|triggering receptor expressed on myeloid cells-like 4|Treml4|Unknown|5031403H21Rik|MGI:1923239||||17|||||||||||||||||||||||||||||Mice are immune to polymicrobial sepsis i.e. peritonitis and subsequent pneumonia.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Feb-2018|Cryopreserved sperm|20.0|0.0|Unknown||CRISPR, Sepsis, peritonitis|Yes| 8441.0|Lx12|B6.129-Abca12/MarpApb|3528440|Dominant|ATP-binding cassette, sub-family A (ABC1), member 12|Abca12||4832428G11Rik, 4833417A11Rik|MGI:2676312|ATP-binding cassette, sub-family A (ABC1), member 12; targeted mutation 1, Lexicon Genetics|Abca12|MGI:3528440|1|||||||||||||||||||||||||||||Neonatal lethality, epidermal hyperkeratosis, fail to develop epidermal permability barrier, disrupted interstitial lamellar lipid structure, |Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Good|11||heterozygote to wildtype|No|05-Mar-2018|Cryopreserved sperm|50.0|0.0|Yes|harlequin ichthyosis||No| 8450.0|BALB.931-343|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Mar-2018|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8444.0|ASD541:Lifr flox:Flpe:Cre-ERT2|B6(Cg)-Lifr/AnuApb||Recessive|leukemia inhibitory factor receptor|Lifr||A230075M04Rik, soluble differentiation-stimulating factor receptor|MGI:96788|LIF receptor alpha; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Lifr|MGI:5692896|15||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|09-Mar-2018|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8449.0|35bp del|C57BL/6NCrlAnu-Arpc1b/Anu||Recessive|actin related protein 2/3 complex, subunit 1B|Arpc1b|Normal|L72, p41-ARC, SOP2Hs|MGI:1343142|actin related protein 2/3 complex, subunit 1B; endonuclease-mediated mutation 2, Australian National University|Arpc1b||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2018|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8464.0|Heparanase KO:OT-I|B6.129-Hpse Tg(TcraTcrb)1100Mjb/AnuApb||Recessive|heparanase|Hpse|Nil|Hpa|MGI:1343124|heparanase; targeted mutation 1, Jin-Ping Li|Hpse|MGI:3844469|5|||||||||||||||||transgene insertion 1100, Michael J Bevan||||||||||||Heparanase KO mice are fertile with no immunological phenotype observed.|Normal.|C57BL/6JAnu|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2018|Cryopreserved sperm|55.0|0.0|Unknown||Heparan sulphate, MMP2, T cell|Yes| 8465.0|Heparanase KO:OT-II|B6.129-Hpse Tg(TcraTcrb)425Cbn/AnuApb||Recessive|heparanase|Hpse|Nil|Hpa|MGI:1343124|heparanase; targeted mutation 1, Jin-Ping Li|Hpse|MGI:3844469|5|||||||||||||||||transgene insertion 425, Frank Carbone||||||||||||Heparanase KO mice are fertile with no immunological phenotype observed.|Normal.|C57BL/6JAnu|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2018|Cryopreserved sperm|55.0|0.0|Unknown||Heparan sulphate, MMP2, T cell|Yes| 8466.0|Heparanase KO:RIP-OVA|B6.129-Hpse Tg(Ins2-OVA)59Wehi/AnuApb||Recessive|heparanase|Hpse|Nil|Hpa|MGI:1343124|heparanase; targeted mutation 1, Jin-Ping Li|Hpse|MGI:3844469|5|||||||||||||||||transgene insertion 59, Walter and Eliza Hall Institute of Medical Research|rat insulin 2|High - 49 Copies||||||||||Heparanase KO mice are fertile with no immunological phenotype observed.Mice bearing RIP-OVA transgene express a secreted form of ovalbumin from the full-length chicken ovalbumin cDNA under control of the rat insulin 2 promoter.|Normal.|C57BL/6JAnu|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2018|Cryopreserved sperm|55.0|0.0|Unknown||Heparan sulphate, MMP2, T cell, ovalbumin|Yes| 8452.0|Hrg KO|B6.129-Hrg/WjaAnuApb||Recessive|histidine-rich glycoprotein|Hrg|Nil|D16JH2, D18020|MGI:2146636|histidine-rich glycoprotein; targeted mutation 1, Willi Jahnen-Dechent|Hrg|MGI:3789962|16|||||||||||||||||||||||||||||Homeostasis/metabolism phenotype:Normal • despite abnormalities in coagulation and fibrinolysis no significant differences are detected in skin wound healingAbnormal circulating fibrinogen level:• 35% increase in plasma fibrinogen levels in females compared to wild-type controlsAbnormal blood coagulation:• significant reduction in prothrombin time compared to wild-type controlsAbnormal thrombolysis:• faster spontaneous clot lysisDecreased bleeding time:• in a tail bleed assayIncreased monocyte cell number:• mild||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Mar-2018|Cryopreserved sperm|55.0|0.0|Unknown||cystatin, haemostasis , innate, thrombin|Yes| 8457.0|ASD867:F2|BALB/cNCrlAnu:Pink:F2||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|403.0|Unknown|||No| 8458.0|ASD867:F2|BALB/cNCrlAnu:Orange:F2||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|70.0|Unknown|||No| 8459.0|ASD867:F2|BALB/cNCrlAnu:Yellow:F2||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|288.0|Unknown|||No| 8460.0|ASD867:F2|BALB/cNCrlAnu:Green:F2||Dominant|||||||||||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|557.0|Unknown|||No| 8461.0|ASD872:F2|B6.SJL-Ptprc/CrlAnu:Line A:F2||Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||||C57BL/6NCrl|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|255.0|Unknown||T cell|No| 8462.0|ASD872:F2|B6.SJL-Ptprc/CrlAnu:Line B:F2||Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||||C57BL/6NCrl|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||2||No|06-Apr-2018||0.0|481.0|Unknown||T cell|No| 8473.0|Gpx1 KO|B6.129-Gpx1/KolaAnu||Recessive|glutathione peroxidase 1|Gpx1|Nil|cellular GPx, CGPx, Gpx, GPx-1, GSHPx-1|MGI:104887|glutathione peroxidase 1; targeted mutation 1, Ismail Kola|Gpx1|MGI:2388705|9|||||||||||||||||||||||||||||Immune system phenotype:Normal: • upon infection with P. berghei ANKA or P. berghei K173, homozygotes show no significant differences in malaria parasite burdens relative to wild-type mice, suggesting normal intraerythrocytic parasite progression and malarial immunityIncreased inflammatory response:• at 24 hrs after cold-induced brain injury, homozygotes exhibit an accelerated neuroinflammatory response, with a significant increase in Mac-1+ cells which rapidly declines by 96 hrs and reappears at 10 days post-injury, suggesting changes in response/activation/recruitment of macrophages and microglia to this type of injuryIncreased neuron apoptosis:• at 24 hrs after ischemia/reperfusion damage in the mid cerebral artery (MCA), homozygotes exhibit increased neuronal apoptosis, as shown by accelerated caspase-3 activation and increased TUNEL staining in post-ischemic mutant brains • at 24 and 96 hrs after cold-induced brain injury, homozygotes display significantly increased neuronal cell death in regions immediately proximal to the infarct core (penumbra)Increased susceptibility to ischemic brain injury :• upon MCA stroke surgery, homozygotes display increased susceptibility to ischemia/reperfusion injury relative to wild-type miceincreased cerebral infarction size ( J:71798 )• in response to ischemia/reperfusion damage in the MCA, homozygotes exhibit a a significantly increased infarct size (area in mm2) relative to wild-type miceCNS ischemia:• in response to ischemia/reperfusion damage in the MCA, homozygotes show an increased neurological deficit score (1.97 vs 0.9) and higher mortality rates (19% vs 7%) relative to wild-type mice, with most mutants dying from severe stroke rather than surgical complications||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2018||0.0|0.0|Unknown||H2O2, oxidative stressors, neurodegenerative disorders|Yes| 7755.0|Flt3-ITD|B6.129-Flt3/AnuApb||Dominant|FMS-like tyrosine kinase 3|Flt3|Increased|CD135, Flk-2, Flk2, Flt-3|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5||||||||||||||||Yes|||||||||||||these mice bearing a knocked in FLT3-ITD allele develop only a mild myeloproliferative disease (MPD) at 3 to 6 months. FLT3-ITD has been shown to cooperate with known oncogenes to induce overt AML. Onset of Acute Myeloid leukaemia.Abnormal hematopoiesis: * bone marrow cells exhibit a two-fold increase in the Lin-Sca1+cKit+ (LSK) compartment compared to in wild-type and heterozygous mice. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice. * the relative percentage of immunophenotypic granulocyte-monocyte progenitors is expanded while the percent of megakaryocyte-erythroid progenitors is decreased. * the proportion of LSK cells in S/G2/M phase is increased while the proportion in G0/G1 is increased compared to in wild-type mice. * fewer LSK cells undergo apoptosis compared to in wild-type and heterozygous mice. * however, the total number of myeloid progenitor cells is the same as in wild-type mice.Abnormal common myeloid progenitor cell morphology: * when cultured on methylcellulose, bone marrow cells produce more colonies than wild-type cells with a greater number of monocytes and fewer erythroid burst forming units and granulocyte-erythroid burst forming units compared to wild-type and heterozygous mice. * however, re-plated colonies do not exhibit increased self-renewal properties.Decreased B cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Decreased mature B cell number: the number of mature B cells in the bone marrow and spleen is decreased compared to in wild-type mice.Decreased T cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Increased leukocyte cell number: mice exhibit leukocytosis and monocytosis with a reversal in the neutrophil to lymphocyte ratio compared to in wild-type mice.Increased granulocyte number: granulocyte populations are increased in peripheral blood compared to in wild-type mice.Increased monocyte cell number: * monocyte populations are increased in peripheral blood. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice.Abnormal B cell differentiation: B cell maturation is blocked at the pre-B stage.Increased spleen red pulp amount: expanded red pulp is comprised of mainly mature myeloid and ad-mixed erythroid elements.Enlarged spleen: mice develop a variable and progressive splenomegaly that is more severe than in heterozygous miceIncreased spleen white pulp amount: expanded white pulp is comprised of cells resembling maturing monocytes.|Onset of Acute Myeloid leukaemia.Abnormal hematopoiesis: * bone marrow cells exhibit a two-fold increase in the Lin-Sca1+cKit+ (LSK) compartment compared to in wild-type and heterozygous mice. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice. * the relative percentage of immunophenotypic granulocyte-monocyte progenitors is expanded while the percent of megakaryocyte-erythroid progenitors is decreased. * the proportion of LSK cells in S/G2/M phase is increased while the proportion in G0/G1 is increased compared to in wild-type mice. * fewer LSK cells undergo apoptosis compared to in wild-type and heterozygous mice. * however, the total number of myeloid progenitor cells is the same as in wild-type mice.Abnormal common myeloid progenitor cell morphology: * when cultured on methylcellulose, bone marrow cells produce more colonies than wild-type cells with a greater number of monocytes and fewer erythroid burst forming units and granulocyte-erythroid burst forming units compared to wild-type and heterozygous mice. * however, re-plated colonies do not exhibit increased self-renewal properties.Decreased B cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Decreased mature B cell number: the number of mature B cells in the bone marrow and spleen is decreased compared to in wild-type mice.Decreased T cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Increased leukocyte cell number: mice exhibit leukocytosis and monocytosis with a reversal in the neutrophil to lymphocyte ratio compared to in wild-type mice.Increased granulocyte number: granulocyte populations are increased in peripheral blood compared to in wild-type mice.Increased monocyte cell number: * monocyte populations are increased in peripheral blood. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice.Abnormal B cell differentiation: B cell maturation is blocked at the pre-B stage.Increased spleen red pulp amount: expanded red pulp is comprised of mainly mature myeloid and ad-mixed erythroid elements.Enlarged spleen: mice develop a variable and progressive splenomegaly that is more severe than in heterozygous miceIncreased spleen white pulp amount: expanded white pulp is comprised of cells resembling maturing monocytes.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|08-Oct-2014|Cryopreserved sperm|55.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML|Yes| 8472.0|MxCreS1P1floxed|B6.Cg-S1pr1 Tg(Mx1-cre)1Cgn/UsaApb||Recessive|sphingosine-1-phosphate receptor 1|S1pr1||Edg1, S1P, S1P1|MGI:1096355|sphingosine-1-phosphate receptor 1; targeted mutation 2, Richard L Proia|S1pr1|MGI:2681911|3|||||||||||||||||transgene insertion 1, University of Cologne|inducible Mx1|||||||||||No phenotype unless the Cre is activated.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Apr-2018|Cryopreserved sperm|40.0|0.0|Unknown||Stem cell, bone marrow egress, Cxcr4|Yes| 8476.0|Tg(Dmp1-cre)1Jqfe. Pthlhtm1Ack|B6.129-Pthlh Tg(Dmp1-cre)1Jqfe/SviApb||Recessive|parathyroid hormone-like peptide|Pthlh|Normal|parathyroid hormone-like hormone, parathyroid hormone-related peptide, parathyroid hormone-related protein, PTH-like, PTH-related peptide, Pthrp|MGI:97800|parathyroid hormone-like peptide; targeted mutation 1, Andrew C Karaplis|Pthlh|MGI:2387462|6|||||||||||||||||transgene insertion 1, Jian Q Feng||||||||||||Adult mice had lower trabecular bone mass and lower bone formation. There was no difference in body weight or bone length compared to controls.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Apr-2018|Cryopreserved sperm|50.0|0.0|Unknown||Osteocyte, Osteoblast, cortical|Yes| 8853.0|IL13 KO|Balb/C:B6129-IL13/AnuApb||Recessive|interleukin 13|Il13|Unknown|Il13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11||||||||||||||||No|||||||||||||abnormal T helper 2 physiology: homozygotes display impaired pulmonary granuloma formation in response to schistosome egg immunizationeosinophil infiltration is impaired in response to schistosome egg immunizationincreased susceptibility to parasitic infection:the expulsion of parasitic worms from the gut is delayedA neomycin cassette was inserted into exon 3.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Feb-2020|Cryopreserved sperm|60.0|0.0|Unknown||IL4, IL5, T cell, infection|Yes| 8855.0|Naip1-6 KO|B6.Cg-Del(13Naip1-Naip5)1Vnce Naip2/JAnu||Recessive||||||deletion, Chr 13, Russell Vance 1|Del(13Naip1-Naip5)1Vnce|MGI:6246513|13|||||||||||||||||||||||||||||Homozygous Naip1-6Δ mice fail to respond to cytosolic flagellin, consistent with previous biochemical data implicating Naip6 in flagellin detection. They also fail to respond to type III secretion system needle or inner rod protein.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Feb-2020||0.0|30.0|Unknown||flagellin|Yes| 8855.0|Naip1-6 KO|B6.Cg-Del(13Naip1-Naip5)1Vnce Naip2/JAnu||Recessive|NLR family, apoptosis inhibitory protein 2|Naip2||Birc1b, Naip2, Naip-rs6|MGI:1298226|NLR family, apoptosis inhibitory protein 2; endonuclease-mediated mutation 2, Russell Vance|Naip2|MGI:6246533|13|||||||||||||||||||||||||||||Homozygous Naip1-6Δ mice fail to respond to cytosolic flagellin, consistent with previous biochemical data implicating Naip6 in flagellin detection. They also fail to respond to type III secretion system needle or inner rod protein.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Feb-2020||||Unknown||flagellin|Yes| 7823.0|ENU15NIH:085:a:HamletxCharles:G7|B6.129-Sppl2a Tg(IghelMD4)4Ccg Tg(MLsHEL)Ccg/AnuApb||Recessive|signal peptide peptidase like 2A|Sppl2a|Nil|cbl-b|MGI:1913802 |signal peptide peptidase like 2A; mutation 1, The Australian National University|Sppl2a|MGI:5432126|2|ENSMUSG00000027366|ENSMUST00000028844|2010106G01Rik-001|||||||||7||||Yes|transgene insertion 4, Christopher C Goodnow||||||||||||Defect in T cell signalling||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||10||No|03-Jan-2015|Cryopreserved sperm|20.0|0.0|No||T cell, Hen Egg Lysozyme (HEL), signal transduction, ENU|Yes| 7823.0|ENU15NIH:085:a:HamletxCharles:G7|B6.129-Sppl2a Tg(IghelMD4)4Ccg Tg(MLsHEL)Ccg/AnuApb||Recessive||||||||||||||||||||||||||immunoglobulin kappa chain complex, immunoglobulin heavy chain complex. (IgM and IgD). Genomic clones of H+L genes with normal control elements. soluble HEL (hen egg lysozyme)|H-2K|||||||||||Defect in T cell signalling||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||10||No|03-Jan-2015|Cryopreserved sperm|||No||T cell, Hen Egg Lysozyme (HEL), signal transduction, ENU|Yes| 8881.0|Nampt knockout|C57BL/6J-Nampt/DunwApb||Recessive|nicotinamide phosphoribosyltransferase|Nampt|Unknown|1110035O14Rik, Pbef1, Visfatin|MGI:1929865|Nampt; endonuclease-mediated mutation 1, Sally L Dunwoodie|Nampt||12||||||||||Unknown to Unknown|||||||||||||||||||Homozygous loss of Nampt is embryonic lethal|Nampt heterozygous mice reported to have hydroencephaly, abnormal skin morphology and enlarged heart. No reported lethality|C57BL/6J|No|No|Yes|No|No|Yes|No|Unknown||||No|11-Mar-2020|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8873.0|Prss57 KO|B6;129S5-Prss57/MmucdMarpApb||Recessive|protease, serine 57|Prss57|Nil|2900092M14Rik, GLGL782, Prssl1, UNQ782|MGI:1920356|protease, serine 57; targeted mutation 1, Lexicon Pharmaceuticals|Prss57|MGI:5007300|10|||||||||||||||||||||||||||||||B6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Mar-2020||0.0|0.0|Unknown|||Yes| 8893.0|ENU32:002|C57BL/6NCrlAnu-Pcgf5/AnuApb||Recessive|polycomb group ring finger 5|Pcgf5|Unknown||MGI:1923505|Pcgf5;mutation 1, Australian National University|Pcgf5||19||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8|||No|17-Mar-2020|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8451.0|Todr1KO|C57BL/6N-2610318N02Rik/Wtsi||Recessive|RIKEN cDNA 2610318N02 gene|2610318N02Rik|||MGI:1917708|RIKEN cDNA 2610318N02 gene; targeted mutation 1a, Wellcome Trust Sanger Institute|2610318N02Rik|MGI:4451963|16|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Mar-2018|Cryopreserved sperm|20.0|0.0|Unknown||Dendritic cell, RNA, myelopoiesis|Yes| 8863.0|Foz:NOD|NOD.B10-Alms1/AnuTchApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Mice are hyperphagic leading to obesity and diabetes. Males are sterile. High fat feeding accelerates obesity and diabetes development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis.Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.|Normal|NOD.B10|Yes|Yes|Yes|Yes|No|Yes|Yes|Excellent|>10||heterozygote mating|No|20-Feb-2020|Cryopreserved sperm|44.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 10426.0|Tet-IGRP#11|NOD-Tg(TetO-IGRP) Tg(IEa-tTA)/Apb||Dominant|glucose-6-phosphatase, catalytic, 2|G6pc2|Increased|IGRP, islet specific glucose-6-phosphatase|MGI:1277193||||2|ENSMUSG00000005232|ENSMUST00000005364|||||||||||||||IGRP|CMV-tetracycline response element|||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-May-2024|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10426.0|Tet-IGRP#11|NOD-Tg(TetO-IGRP) Tg(IEa-tTA)/Apb||Dominant||||||||||||||||||||||||||tet-transactivator|MHC class II IEa|||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-May-2024|Cryopreserved sperm|||Unknown|||Possibly| 8874.0|Ets2 fl|C57BL/6-Ets2/PjhApb||Recessive|E26 avian leukemia oncogene 2, 3' domain|Ets2|Normal|Ets-2|MGI:95456||||16|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Mar-2020|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 8868.0|Snx5 KO-3064| B6(Cg)-Snx5/Apb||Recessive|sorting nexin 5|Snx5||0910001N05Rik, 1810032P22Rik, D2Ertd52e|MGI:1916428|sorting nexin 5; targeted mutation 1a, Wellcome Trust Sanger Institute|Snx5|MGI:4362512|2|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Feb-2020|Cryopreserved sperm|50.0|0.0|Unknown||Macrophage, ruffling, macropinocytosis|Yes| 8871.0|Tip2#78|NOD-Tg(TetO-Ins2) Tg(IEa-tTA)/Apb||Dominant||||||||||||||||||||||||||Insulin II|TetO|||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8871.0|Tip2#78|NOD-Tg(TetO-Ins2) Tg(IEa-tTA)/Apb||Dominant||||||||||||||||||||||||||tetracycline transactivator|IEa|||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Mar-2020|Cryopreserved sperm|||Unknown|||Yes| 8876.0|NOD.B6Idd11F|NOD-Idd11F/Apb||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 11|Idd11|||MGI:96402|nsulin dependent diabetes susceptibility 11; C57BL/6|Idd11|MGI:3036811|4|Mice exhibit decreased diabetes incidence compared to NOD/Lt wildtype mice|Unknown|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Mar-2020|Cryopreserved sperm|30.0|0.0|Yes|Type 1 Diabetes|T1D|Yes| 8887.0|ASD755:Tcf7 fl|B6(Cg)-Tcf7/WehiAnuApb||Recessive|transcription factor 7, T cell specific|Tcf7||T cell factor-1, T-cell factor 1, Tcf1, TCF-1|MGI:98507|transcription factor 7, T cell specific; targeted mutation 1c, Wellcome Trust Sanger Institute|Tcf7|MGI:5816259|11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Mar-2020|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 8468.0|Tcf7-GFP|C57BL/6-Tcf7/HhxAnu||Recessive|transcription factor 7, T cell specific|Tcf7||T cell factor-1, T-cell factor 1, Tcf1, TCF-1|MGI:98507|transcription factor 7, T cell specific; targeted mutation 1, Hai-Hui Xue|Tcf7|MGI:5805838|11|||||||||||||||||||||||||||||Using newly-generated Tcf7GFP reporter mice, we identified novel early innate lymphoid progenitors that express high levels of TCF-1 but lack surface markers of adaptive and innate lymphocyte lineages. These early innate lymphoid progenitors closely resemble bone marrow lymphoid progenitors at the transcriptome level, but lack efficient T and B lymphocyte potential. Instead, they efficiently gave rise to various ILC lineages, including conventional NK cells as well as cytokine-producing helper ILC at the clonal level, indicating that they are the earliest identifiable ILC progenitors. ||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Apr-2018|Cryopreserved sperm|19.0|0.0|Unknown||T cell, ILC, Tcf-1|Yes| 8474.0|ASD598:Albiol:Aire:HIVEP2Indel|B6.129-Aire Hivep2/Apb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|Aire, endonuclease-mediated mutation 1, Australian National University|Aire||10|||||||||||||||||||||||||||||Unknown|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2018|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 8474.0|ASD598:Albiol:Aire:HIVEP2Indel|B6.129-Aire Hivep2/Apb||Recessive|human immunodeficiency virus type I enhancer binding protein 2|Hivep2||Gm20114, MIBP1, Schnurri-2, Shn-2|MGI:1338076|Hivep2, endonuclease-mediated mutation 1, Australian National University|Hivep2||10|||||||||||||||||||||||||||||Unknown|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2018|Cryopreserved sperm|||Unknown|||Yes| 8836.0||NOL3-KO||Recessive|Nol3-Ko||||||||Unknown|||||||||||||||||||||||||||||Homozygous|Homozygous|C57Bl6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|09-Jan-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8846.0||SJL/JAnu||Dominant||||||||||||||||||||||||||||||||||||||Normal|Normal|SJL/J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-Jan-2020|Cryopreserved sperm|55.0|0.0|Unknown|||No| 8869.0|Furinflox/flox |B6.129-Furin/Apb||Recessive|furin (paired basic amino acid cleaving enzyme)|Furin|Normal|9130404I01Rik, Fur, PACE, Pcsk3, SPC1|MGI:97513|Furin, Paired Basic Amino Acid Cleaving Enzyme|furin (paired basic amino acid cleaving enzyme); targeted mutation 1, John W M Creemers|Furin|7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Mar-2020|Cryopreserved sperm|20.0|0.0|Unknown||Liver|Yes| 10440.0|Dnase1L3/Dnase1 (6)|C57BL6NCrl-Dnase1L3Dnase1/ANU||Recessive|deoxyribonuclease 1-like 3|Dnase1l3||DNasegamma|MGI:1314633|Dnase1L3:endonuclease-mediated mutation 5, Australian National University|Dnase1L3||14|ENSMUSG00000025279||||||||||||||||||||||||||||The DNase double knockout mice do not express two deoxyribonucleases (DNases), DNase1and DNase1-like 3, which are responsible for the degradation of neutrophil extracellular traps (NETs) in circulation during sterile neutrophilia and septicemia. Inthe absence of both DNases, intravascular NETs formed clots that obstructed blood vesselsand caused organ damage. These mice do not express two DNase enzyme|Unknown|C57BL6/NCrl/Anu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Jul-2024|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 10440.0|Dnase1L3/Dnase1 (6)|C57BL6NCrl-Dnase1L3Dnase1/ANU||Recessive|deoxyribonuclease I|Dnase1|||MGI:103157|Dnase1:endonuclease-mediated mutation 5, Australian National University|Dnase1||16|ENSMUSG00000005980 ||||||||||||||||||||||||||||The DNase double knockout mice do not express two deoxyribonucleases (DNases), DNase1and DNase1-like 3, which are responsible for the degradation of neutrophil extracellular traps (NETs) in circulation during sterile neutrophilia and septicemia. Inthe absence of both DNases, intravascular NETs formed clots that obstructed blood vesselsand caused organ damage. These mice do not express two DNase enzyme|Unknown|C57BL6/NCrl/Anu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Jul-2024|Cryopreserved sperm|||Unknown|||Possibly| 8705.0|gBT-I.1|C57BL/6-Tg(TcraHsv2.3,TcrbHsv2.3)L118-1Cbn/CbnAnuapb||Dominant||||||||||||||||||||||||||transgene insertion L118-1, Francis R Carbone |a 2 kb fragment of the H-2Kb and a 700 bp fragment including the Igh enhancer.|||||||||||TCR transgenics are immunocompromised by having a mono-specific T cell receptor however, in a clean envirnoment, mice show no difference in phenotype from wild-type B6 mice.T cells express Va2<+>Vb8<+> TCR derived from the K,B> restricted HSV-1 glycoprotein B (gB498-505)-specific CTL clone HSV2.3.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-May-2019|Cryopreserved sperm|42.0|0.0|Unknown||T cell, CD4 , CD8, T cell receptor (TCR), herpes Simplex Virus (HSV), selection, thymus|Yes| 7992.0|2D2tg|C57BL/6-Tg(Tcra2D2,Tcra2D2)1Kuch/AusbAnuApb||Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Vijay Kuchroo ||||||||||||Homozygous lethal|Expanded T cells population.Spontaneus cases of paralysis might occur.Altered inmunoregulation in brain.Spontaneus optic neuritis.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|||+/+ sibling x Hemizygote (Female x Male) |No|11-Nov-2015|Cryopreserved sperm|32.0|0.0|Unknown||T cells, Experimental autoimmune encephalomyelitis, CNS, Optic Nerve, multiple sclerosis |Yes| 10416.0|Kimba|B6-Tg(mRho- tr029VEGF)/Kimba. ||Recessive|human vascular endothelial growth factor|hVEGF|||||||Unknown|||||||||||||||||transgene insertion 029, Elizabeth Piroska Rakoczy|Rodopsin|||||||||||a transgenic mouse model expressing low VEGF levels which would lead to a slow progression of retinal neovascularisation akin to vascular changes observed in Diabetic retinopathy|a transgenic mouse model expressing low VEGF levels which would lead to a slow progression of retinal neovascularisation akin to vascular changes observed in Diabetic retinopathy,||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Apr-2024|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10416.0|Kimba|B6-Tg(mRho- tr029VEGF)/Kimba. ||Recessive|rhodopsin|Rho||LWS opsin|MGI:97914||||6|ENSMUSG00000030324 |ENSMUST00000032471|||||||||||||||||||||||||||a transgenic mouse model expressing low VEGF levels which would lead to a slow progression of retinal neovascularisation akin to vascular changes observed in Diabetic retinopathy|a transgenic mouse model expressing low VEGF levels which would lead to a slow progression of retinal neovascularisation akin to vascular changes observed in Diabetic retinopathy,||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Apr-2024|Cryopreserved sperm|||Unknown|||Possibly| 8902.0||DBA/2J-Tg(fos-tau/LacZ)/Apb||Dominant||||||||||||||||||||||||||Fos-tau/LacZ||||||||||||NORMAL|NORMAL|DBA/2J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2020||0.0|0.0|Unknown||Fear, memory|Yes| 8904.0||B6.D2-CHR12-STR1-Tg(fos-tau/LacZ)/Apb||Dominant||||||||||||||||||||||||||FOS-TAU-LACZ|||Stress response QTL||||||||12|Decreased activity in open field activity test. Increased stress responsiveness.Decreased fear memory.|Decreased activity in open field activity test. Increased stress responsiveness.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown||Fear, memory|Yes| 8905.0||B6.D2-CHR12-STR2-Tg(fos-tau/LacZ)/Apb||Dominant||||||||||||||||||||||||||Fos-tau/LacZ|||Stress response QTL||||||||12|Decreased activity in open field activity test. Increased stress responsiveness.Increased fear memory|Decreased activity in open field activity test. Increased stress responsiveness.|C57BL6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown||Fear, Memory, Stress|Yes| 8919.0|Dicer fl:CMV-cre|B6.129-Dicer1 Tg(CMV-cre)/WehiAnuApb||Recessive|dicer 1, ribonuclease type III|Dicer1|||MGI:2177178|dicer 1, ribonuclease type III; targeted mutation 1, Brian D Harfe|||12|||||||||||||||||Cre recombinase|CMV|||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Mar-2020|Cryopreserved sperm|57.0|0.0|Unknown||microRNA, Cre|Yes| 8918.0|ASD085:C57BL/6:MyD88-/-|B6.Cg-Myd88/AnuApb||Recessive|myeloid differentiation primary response gene 88|Myd88|Nil||MGI:108005|targeted mutation 1, Shizuo Akira|Myd88|MGI:2385681|9|||||||||||||||||||||||||||||Increased apoptosis:* 5 days after lung injury, mutants show significantly increased numbers of apoptotic lung epithelial and inflammatory cells.Increased physiological sensitivity to xenobiotics:* knockout mice are more susceptible to bleomycin-induced lung injury.Abnormal dendritic cell differentiation:* dendritic cell maturation fails to occur in vivo upon exposure to TLR9 agonists.Increased dendritic cell number:* increased numbers of dendritic cells in brains of mice infected with Plasmodium.Abnormal immune system physiology:* response to LPS and CpG is completely abrogatedAbnormal dendritic cell physiology:* cytokine secretion elicited by zymosan or LPS is impaired.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40, IL-6 and interferon-gamma relative to wild-type mice.Abnormal macrophage physiology:* TNF production is impaired in thioglycollate-elicited macrophages treated with intact zymosan.* cytokine production by macrophages cultured with P. carinii cysts is reduced compared to wild-type.Abnormal NK cell physiology:* NK cells fail to make IFN-gamma in response to injections of TLR9 agonists.Abnormal T cell physiology:* induction of the antigen-specific CD8+ T-cell response by immunizing with soluble ovalbumin and TLR9 agonists, but not TLR2 and TLR6 agonists, was severely impaired.Abnormal cytokine secretion:* LPS-induced cytokine production by BMDCs is almost abolished compared to controls and Myd88-sufficient mutantsAbnormal chemokine secretion:* hyaluronan fragment-induced expression of chemokines by peritoneal macrophages is completely abolished in double knockout mice.Decreased interferon-alpha secretion:* CpG-A or RNA polyuridylic acid induced production of interferon-alpha was abolished in plasmacytoid dendritic cells.Decreased interferon-gamma secretion:* less up regulation of INF-gamma in Plasmodium infection.* following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less interferon-gamma.Decreased interleukin-12 secretion:* after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals.Decreased interleukin-12b secretion:* less upregulation of IL-12b in Plasmodium infection * following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-12p40 relative to wild-type mice. Decreased interleukin-6 secretion: * following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, IL-6 secretion is reduced. * following infection with attenuated yellow fever vaccine 17D (YF-17D), dendritic cells produce less IL-6 relative to wild-type mice. Decreased tumor necrosis factor secretion: * less upregulation of TNF-alpha in Plasmodium infection. * following treatment with PbA(Plasmodium bergbei ANKA)-parasitized erythrocytes or LPS-stimulation, TNF secretion is reduced. * after stimulation with zymosan, TNF production is significantly reduced in Myd88-deficient animals. Decreased inflammatory response: * in a model of induced pneumococcal meningitis-associated labyrinthitis, homozygotes exhibit a significantly lower granulocytic infiltration of the labyrinth and increased bacterial density in the cochlea at 24 hrs post-infection relative to wild-type control mice. Abnormal response to infection: * following treatment with PbA (Plasmodium bergbei ANKA)-parasitized erythrocytes, mice have a decreased immune response in terms of TNF and IL-6 secretion and response to CpG. Decreased susceptibility to parasitic infection:* resistant to cerebral malaria but eventually die of extremely high parasitemia. Increased susceptibility to viral infection: * increased susceptibility to encephalomyocarditis virus (EMCV) infection compared to wildtype. ||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Mar-2020|Cryopreserved sperm|6.0|0.0|Unknown||IL1 receptor, T cell, IL18 receptor|Yes| 8913.0|Arjuna:B10.BR:Rag1(tm1Mom)|B6.B10-H2 Rag1 Tg(ILK3mHEL)3Ccg/AnuApb||Recessive|recombination activating 1|Rag1||Rag-1|MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter||histocompatibility-2, MHC|H2|||MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|Rag1 KO mice lack mature T and B cells. Hen egg lysozyme expressed on the pancreatic islet beta cells.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Mar-2020|Cryopreserved sperm|24.0|0.0|Unknown||Hen Egg Lysozyme (HEL), T cell, B cell, autoimmune|Yes| 8914.0|Arjuna:Rag1(tm1Mom)::B6|B6(Cg)-Rag1 Tg(ILK3mHEL)3Ccg/AnuApb||Recessive|recombination activating 1|Rag1||Rag-1|MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Rag1 KO mnice are deficient of mature T and B cells. Hen egg lysozyme expressed on surface og pancreatic islet beta cells.H2b background||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Mar-2020|Cryopreserved sperm|36.0|0.0|Unknown||T cell, B cell, autoimmunity, Hen Egg Lysozyme (HEL)|Yes| 8103.0|Kca3.1|B6.129-Kcnn4/Apb||Recessive|potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4|Kcnn4|Unknown|IK1, IKCa1, KCa3.1, mIKCa1, SK4|MGI:1277957|potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; targeted mutation 1, James E Melvin|Kcnn4|MGI:3521668|7|||||||||||||||||||||||||||||Increased parotid gland size:• in homozygous males the weight of the parotid gland is significantly increased, however no change in salivary flow or composition is seenAbnormal hematopoietic system physiology:• A23187-stimulated, clotrimazole sensitive uptake of 86Rb into red blood cells is nearly eliminated in homozygous mutants and A23187 has no effect on the tonicity at which 50% of mutant red cells lyseAbnormal T cell physiology:• shrinkage of T lymphocytes induced by the Ca2+ ionophore, ionomycin, is greatly reduced||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Sep-2016|Cryopreserved sperm|45.0|0.0|Unknown||Potassium channel|Yes| 8340.0|Spi6 fl; SerpinB9 conditional|C57BL/6J-SerpinB9/PibMarpAnuApb||Dominant|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9||ovalbumin, PI-9, Spi6|MGI:106603||||13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|30-Oct-2017|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8946.0|ENU47:G2|ANU:ENU47:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|29-Mar-2020|Cryopreserved sperm|289.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8937.0|Heatr3:Flpe|C57BL/6NTac-Heatr3 Tg(ACTFLPe)9205Dym/AnuApb||Recessive|HEAT repeat containing 3|Heatr3|Normal|C030036P15Rik|MGI:2444491|HEAT repeat containing 3; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Heatr3||8||||||||||Unknown to Unknown|||||||transgene insertion 9205, Susan Dymecki|ACTB, actin, beta, human|The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being 4X and 10X that of wildtype FLP at 37°C and 40°C, respectively||||||||||Unknown|Normal|C57BL/6NCrlAnu|Unknown|Yes|Yes|Unknown|Yes|Yes|No|Unknown||||No|27-Mar-2020|Cryopreserved sperm|112.0|0.0|Unknown||EUCOMM|Yes| 8947.0|ENU48:G2|ANU:ENU48:G2||Recessive||||||||||||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|29-Mar-2020|Cryopreserved sperm|170.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 8934.0|Ighg1-cre Igk KO:Ly5a|B6.129P2(Cg)-Ighg1 Igk Ptprc/AnuApb||Recessive|immunoglobulin kappa chain complex|Igk|Nil|kappa|MGI:96494|immunoglobulin kappa chain complex; targeted mutation 1, Dennis Huszar|Igk|MGI:2429510|6|||||||||||||||||||||||||||||Homozygous mice are viable, fertile, normal in size, and do not display any gross physical or behavioural abnormalities. They do exhibit a reduction in IgG1+ memory B cells and in IgG1 serum antibody titers.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Mar-2020|Cryopreserved sperm|24.0|0.0|Unknown||B cell, Germinal Centre, Immunoglobulin|Yes| 8934.0|Ighg1-cre Igk KO:Ly5a|B6.129P2(Cg)-Ighg1 Igk Ptprc/AnuApb||Recessive|immunoglobulin heavy constant gamma 1 (G1m marker)|Ighg1||IgG1, Igh-4|MGI:96446|immunoglobulin heavy constant gamma 1 (G1m marker); targeted mutation 1, University of Cologne|Ighg1|MGI:3652526|12|||||||||||||||||||||||||||||Homozygous mice are viable, fertile, normal in size, and do not display any gross physical or behavioural abnormalities. They do exhibit a reduction in IgG1+ memory B cells and in IgG1 serum antibody titers.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Mar-2020|Cryopreserved sperm|||Unknown||B cell, Germinal Centre, Immunoglobulin|Yes| 8934.0|Ighg1-cre Igk KO:Ly5a|B6.129P2(Cg)-Ighg1 Igk Ptprc/AnuApb||Recessive|protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||Homozygous mice are viable, fertile, normal in size, and do not display any gross physical or behavioural abnormalities. They do exhibit a reduction in IgG1+ memory B cells and in IgG1 serum antibody titers.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Mar-2020|Cryopreserved sperm|||Unknown||B cell, Germinal Centre, Immunoglobulin|Yes| 8945.0|ENU46:G2|ANU:ENU46:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|29-Mar-2020|Cryopreserved sperm|11.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 10445.0|ASD1138:Tlr4 D298G:19|C57BL/6NcrlAnu-Tlr4/19Anu||Dominant|toll-like receptor 4|Tlr4||Lps, Rasl2-8|MGI:96824|Tlr4; endonuclease-mediated mutation 1, Australian National University|Tlr4||4|ENSMUSG00000039005 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-Aug-2024|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 8208.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #3|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)18/3MarpAnu||Recessive|transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)|Tap1|Nil|Abcb2, Ham1, Ham-1, MTP1, PSF-1, RING4, TAP, Tap-1|MGI:98483||||17|||||||||||||||||human transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) / human transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8208.0|Tap1/Tap2 KO x Tg(hTAP1/hTAP2) BAC #3|C57BL/6J-Tap1/Tap2 Tg(hTAP1/hTAP2)18/3MarpAnu||Recessive|transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)|Tap2|Nil|Abcb3, Ham2, Ham-2, HAM2, MTP2, PSF2, Tap-2|MGI:98484||||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Mar-2017|Cryopreserved sperm|||Unknown|||Yes| 4514.0|Thebes ; ENU7B6:039 (CD4)|B6JAnu;CBA-Cd4/AnuApb|B6JAnu;CBA-Cd4/AnuApb|Recessive|CD4 antigen|Cd4|Unknown|L3T4, Ly-4|MGI:88335|CD4 antigen; thebes|Cd4|MGI:5007797|6|ENSMUSG00000023274|ENSMUST00000024044|Cd4-001|339|508|G to T|ENSMUSE00000246632|4|112|Glutamic acid to Aspartic acid|||||ATGGAAGACTCTCAGACTTATATCTGTGAGCTGGAGAACAGGAAAGAGGAGGTGGAGTTGT|Yes|||||||||||||Reduced CD4 expression||B6 x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|142.0|0.0|Unknown||autoimmunity, antinuclear antibodies (ANA), ENU, Wellcome Trust, CD4|Yes| 8903.0||B6.D2-Cfq# Tg(Fos-tau/LacZ)/Apb||Dominant||||||||||||||||||||||||||Fos-tau/LacZ|||conditioned fear QTL|Cfq|||||||1|Decreased activity in open field activity test. Increased stress responsiveness.Increased fear memory.|Decreased activity in open field activity test. Increased stress responsiveness.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2020||0.0|0.0|Unknown||c-fos, fear, memory|Yes| 8970.0|Vav-cre|B6.Cg-Tg(Vav1-Cre)1Awr/WehiAnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Andrew W Roberts|Vav1|Haemopoietic||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|2|||No|09-Apr-2020|Cryopreserved sperm|60.0|0.0|Unknown||Cre recombinase|Yes| 8972.0|Ubtf|B6(Cg)-Ubtf/AnuApb||Recessive|upstream binding transcription factor, RNA polymerase I|Ubtf||A930005G04Rik, Tcfubf, UBF, UBF1|MGI:98512|pstream binding transcription factor, RNA polymerase I; targeted mutation 1, Mark LeDoux|Ubtf|MGI:6695077|11|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|||No|09-Apr-2020|Cryopreserved sperm|59.0|0.0|Unknown|||Yes| 8971.0|Ubf fl|B6(Cg)-Ubtf/AnuApb||Recessive|upstream binding transcription factor, RNA polymerase I|Ubtf||A930005G04Rik, Tcfubf, UBF, UBF1|MGI:98512||||11|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|1|||No|09-Apr-2020||0.0|0.0|Unknown||RNA polymerase, rRNA|Yes| 8967.0|ENU7B6:039 (CD8)|B6(Cg)-Senp2/AnuApb|B6(Cg)-Senp2/AnuApb|Recessive|SUMO/sentrin specific peptidase 2|Senp2|Unknown||MGI:1923076|SUMO/sentrin specific peptidase 2; mutation 1, The Australian National University|Senp2|MGI:5563407|16|ENSMUSG00000022855|ENSMUST00000023561| Senp2-201|939|1097|A to G|ENSMUSE00000131327|11|313|Glycine to Glycine|||||CTCCGATTTGAAAAGGAAGGTACAAGAGGACACCAAATGGAGCCTGATCTGTCAGAAGAAG|Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.Low CD8 protein expression and reduced T cell numbers.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|8 onto B6JAnu and then 3 onto C57BL/6NCrlAnu|||No|05-Apr-2020|Cryopreserved sperm|44.0|0.0|Unknown||autoimmunity, antinuclear antibodies (ANA), ENU, Wellcome Trust, T cell, CD8|Yes| 8879.0|Nadsyn1 null|C57BL/6-Nadsyn1/DunwApb||Recessive|NAD synthetase 1|Nadsyn1|Nil|9130012B15Rik|MGI:1926164|Nadsyn1; endonuclease-mediated mutation 1, Sally L Dunwoodie|Nadsyn1||7||||||||||Unknown to Unknown|||||||||||||||||||No overt phenotypes|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8969.0|ENU15NIH:036a|C57BL/6JAnu-Itgal/AnuApb||Recessive|integrin alpha L|Itgal|Unknown|Cd11a, LFA-1, Ly-15, Ly-21|MGI:96606||||7|||||||||||||||||||||||||||||||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Apr-2020|Cryopreserved sperm|71.0|0.0|Unknown||CD8, LFA-1, hepatic|Yes| 8968.0||B6.Cg-Tg(TcraBO4H9.1,TcrbBO4H9.1)7Aog/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 7 Anne O'Garra|||||||||||||Mice carry a TCR transgene specific for Hen egg lysozyme peptide|C57BL/6NCrlAnu|Unknown|Yes|Yes|Yes|Yes|Yes|No|Unknown|4|||No|08-Apr-2020|Cryopreserved sperm|33.0|0.0|Unknown||T cell, CD4, CTLA-4|Yes| 8284.0|Spi6 KO ; Spi6|C57BL/6-Serpinb9/Marp||Recessive|serine (or cysteine) peptidase inhibitor, clade B, member 9|Serpinb9|Unknown|ovalbumin, PI-9, Spi6|MGI:106603|serine (or cysteine) peptidase inhibitor, clade B, member 9; targeted mutation 1.1, Phillip I Bird|Serpinb9|MGI:5140012|13|||||||||||||||||||||||||||||immune system phenotype ( J:252016 )N • mice exhibit normal thymus and spleen cellularity and numbers of dendritic cells, splenic CD4 T cells, CD8 T cells, NK cells and CD103+CD8+ dendritic cellsabnormal immune system morphology ( J:252016 ) • authors state that the base phenotype resembles that of Serpinb9tm1Arpabnormal immune system physiology ( J:252016 ) • authors state that the base phenotype resembles that of Serpinb9tm1Arpdecreased cytotoxic T cell apoptosis ( J:252016 ) • in mice immunized with apoptotic cells displaying ovalbumin due to a dendritic cell dependent priming deficitabnormal dendritic cell antigen presentation ( J:252016 ) • impaired cross-presentation• however, dendritic cells exhibit normal antigen uptake, survival after antigenic challenge and antigen degradation machinery||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Aug-2017|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8877.0|NOD.B6Idd14R6|NOD/Lt-Idd31/Apb||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 31|Idd31|||MGI:5509150||||13|Mice exhibit decreased diabetes incidence compared to NOD/Lt wildtype mice|Unknown|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Mar-2020|Cryopreserved sperm|50.0|0.0|Yes|Type 1 Diabetes|Pulmonary mycoplasmosis, Mycoplasma pulmonis|Yes| 8878.0|NOD.B6Idd14R8|NOD/Lt-Idd14/Apb||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 14|Idd14/Listr2|||MGI:99416||||13|Mice exhibit increased diabetes incidence compared to NOD/Lt wildtype mice|Unknown|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Mar-2020|Cryopreserved sperm|40.0|0.0|Yes|Type 1 Diabetes|Mycoplasma pulmonis, Pulmonary mycoplasmosis|Yes| 8896.0|DmdS3059A|C57BL/6-Dmd/Apb||Recessive|Dystrophin, muscular dystrophy|Dmd||Dp427, Dp71, Duchenne muscular dystrophy, dys, mdx, pke, X-linked muscular dystrophy|MGI:94909||||X|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Mar-2020|Cryopreserved sperm|60.0|0.0|Yes|Muscular dystrophy||Yes| 8586.0|Mx1Cre.Sphk1floxed.Spk2KO|B6.129-Sphk1 Sphk2 Tg(Mx1-cre)1Cgn/UsaApb||Recessive|sphingosine kinase 1|Sphk1|Unknown|1110006G24Rik, SK1|MGI:1316649|sphingosine kinase 1; targeted mutation 2, Shaun R Coughlin|Sphk1|MGI:3707997|11|||||||||||||||||transgene insertion 1, University of Cologne|Mx dynamin-like GTPase 1 (Mx1)|||||||||||Whilst the Cre is inactivated these mice are normal|Whilst the Cre is inactivated these mice are normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2018|Cryopreserved sperm|40.0|0.0|Unknown||Endothelial, Lymphocytes|Yes| 8586.0|Mx1Cre.Sphk1floxed.Spk2KO|B6.129-Sphk1 Sphk2 Tg(Mx1-cre)1Cgn/UsaApb||Recessive|sphingosine kinase 2|Sphk2|Nil||MGI:1861380|sphingosine kinase 2; targeted mutation 1, Richard L Proia|Sphk2|MGI:3611080|7|||||||||||||||||||||||||||||Whilst the Cre is inactivated these mice are normal|Whilst the Cre is inactivated these mice are normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Oct-2018|Cryopreserved sperm|||Unknown||Endothelial, Lymphocytes|Yes| 8974.0|ASD940:Lef1 fl Tcf7 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor/HhxAnuApb||Recessive|lymphoid enhancer binding factor 1|Lef1||Lef-1, lymphoid enhancer factor 1|MGI:96770|lymphoid enhancer binding factor 1; targeted mutation 1, Hai-Hui Xue|Lef1|MGI:5447957|3|||||||||||||||||||||||||||||normal|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Apr-2020|Cryopreserved sperm|22.0|0.0|Unknown||T cell, autoimmunity, CD8|Yes| 8974.0|ASD940:Lef1 fl Tcf7 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor/HhxAnuApb||Recessive|transcription factor 7, T cell specific|Tcf7||T cell factor-1, T-cell factor 1, Tcf1, TCF-1|MGI:98507|transcription factor 7, T cell specific; targeted mutation 1c, Wellcome Trust Sanger Institute|Tcf7|MGI:5816259|11|||||||||||||||||||||||||||||normal|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Apr-2020|Cryopreserved sperm|||Unknown||T cell, autoimmunity, CD8|Yes| 8974.0|ASD940:Lef1 fl Tcf7 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor/HhxAnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Stuart Orkin|Gt(ROSA)26Sor|MGI:2136519|6|||||||||||||||||||||||||||||normal|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Apr-2020|Cryopreserved sperm|||Unknown||T cell, autoimmunity, CD8|Yes| 8420.0|Lef1 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor Tg(CD2-cre)1Lov/HhxAnuApb||Recessive|lymphoid enhancer binding factor 1|Lef1||Lef-1, lymphoid enhancer factor 1|MGI:96770|lymphoid enhancer binding factor 1; targeted mutation 1, Hai-Hui Xue|Lef1|MGI:5447957|3|||||||||||||||||transgene insertion 1, Paul Love|human CD2|||||||||||Mice do not have T cell–development defects or aberrant activation of mature T cells.On day 8 after infection with vaccinia virus the frequency and number of SLAMCxcr5<+> TFH cells were diminished.Mice exhibited a significantly lower frequency and number of GL7+Fas+ GC B cells than that of control mice|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Jan-2018|Cryopreserved sperm|29.0|0.0|Unknown||T cell, autoimmunity, CD8|Yes| 8420.0|Lef1 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor Tg(CD2-cre)1Lov/HhxAnuApb||Recessive|transcription factor 7, T cell specific|Tcf7||T cell factor-1, T-cell factor 1, Tcf1, TCF-1|MGI:98507|transcription factor 7, T cell specific; targeted mutation 1c, Wellcome Trust Sanger Institute|Tcf7|MGI:5816259|11|||||||||||||||||||||||||||||Mice do not have T cell–development defects or aberrant activation of mature T cells.On day 8 after infection with vaccinia virus the frequency and number of SLAMCxcr5<+> TFH cells were diminished.Mice exhibited a significantly lower frequency and number of GL7+Fas+ GC B cells than that of control mice|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Jan-2018|Cryopreserved sperm|||Unknown||T cell, autoimmunity, CD8|Yes| 8420.0|Lef1 fl|B6(Cg)-Lef1 Tcf7 Gt(ROSA)26Sor Tg(CD2-cre)1Lov/HhxAnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Stuart Orkin|Gt(ROSA)26Sor|MGI:2136519|6|||||||||||||||||||||||||||||Mice do not have T cell–development defects or aberrant activation of mature T cells.On day 8 after infection with vaccinia virus the frequency and number of SLAMCxcr5<+> TFH cells were diminished.Mice exhibited a significantly lower frequency and number of GL7+Fas+ GC B cells than that of control mice|normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Jan-2018|Cryopreserved sperm|||Unknown||T cell, autoimmunity, CD8|Yes| 8882.0|Pbx1 R184P|C57BL/6J-Pbx1R184P/DunwApb||Recessive|pre B cell leukemia homeobox 1|Pbx1|Unknown|2310056B04Rik, D230003C07Rik, Pbx-1, Pbx1a, Pbx1b|MGI:97495|Pbx1R184P;endonuclease-mediated mutation 1, Sally L Dunwoodie|Pbx1R184P||1||||||||||Unknown to Unknown|||||||||||||||||||Multiple embryonic defects- congenital heart defects (persistent truncus arteriosus, ventricular septal defect), hypoplastic lungs, aplastic adrenal glands, hypoplastic/ectopic kidneys, palate defects, aplastic spleen, hypoplastic/ectopic thymi, defects in sex determination/ gonad development, subcutaneous edema, umbilical hernia, embryonic death.|A proportion of heterozygotes display heart defects (ventricular septal defect, cardiac edema), lung defects (hypoplastic), kidney defects (hypoplastic, pelvic), and subcutaneous edema. |C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|12-Mar-2020|Cryopreserved sperm|30.0|0.0|Yes|CAKUTHED syndrome|transcription faactor, pulmonary valve, congenital|Yes| 8979.0|NOD.B6 Idd11D|NOD/Lt-C57BL/6<(D4Mit72-D4Mit339)>/TcbApb||Recessive|Insulin dependent diabetes locus 11|Idd11|Unknown|||Idd11|Idd11|96402|4||||||||||||||||||||Insulin dependent diabetes locus 11|Idd11|||96402|insulin dependent diabetes susceptibility 11; C57BL/6|Idd11||4|These homozygous congenic mice exhibit a decreased diabetes incidence compared to NOD/Lt wildtype mice.|Unknown|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Unknown|No|Good|10|||No|12-Apr-2020|Cryopreserved sperm|50.0|0.0|Yes|type 1 diabetes||Possibly| 8749.0|Arjuna:TCR:B10:kk|B6.B10-H2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter||histocompatibility-2, MHC|H2|||MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jul-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8749.0|Arjuna:TCR:B10:kk|B6.B10-H2 Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis|||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Jul-2019|Cryopreserved sperm|||Unknown|||Yes| 8915.0|SwHel:RAG1KO:Hc.Lc:Ly5a|B6(Cg)-Ptprc Rag1 Igh Tg(IgkHyHEL10)1Rbr/AnuApb||Recessive|recombination activating 1|Rag1||Rag-1|MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||transgene insertion 1, Robert Brink|||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Rag1 KO mice lack mature T and B cells. Homozygous for SwHEL Heavy chain (Hc/Hc) Heterozygous for SwHEL Light chain (Lc/WT), B cell specific for Hen egg lysozyme.|All B cells are specific for Hen egg lysozyme|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Mar-2020|Cryopreserved sperm|24.0|0.0|Unknown||B cell, Hen Egg Lysozyme (HEL)|Yes| 8915.0|SwHel:RAG1KO:Hc.Lc:Ly5a|B6(Cg)-Ptprc Rag1 Igh Tg(IgkHyHEL10)1Rbr/AnuApb||Recessive|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Robert Brink|Igh|MGI:3800383|12|||||||||||||||||||||||||||||Rag1 KO mice lack mature T and B cells. Homozygous for SwHEL Heavy chain (Hc/Hc) Heterozygous for SwHEL Light chain (Lc/WT), B cell specific for Hen egg lysozyme.|All B cells are specific for Hen egg lysozyme|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Mar-2020|Cryopreserved sperm|||Unknown||B cell, Hen Egg Lysozyme (HEL)|Yes| 8247.0|Srsf3-flox|B6;129-Srsf3/MarpApb||Recessive|serine/arginine-rich splicing factor 3|Srsf3|Unknown|Sfrs3, X16|MGI:98285||||17|||||||||||||||||||||||||||||No phenotype|No phenotype|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|20-Apr-2017|Cryopreserved sperm|20.0|0.0|No||LoxP|Possibly| 8960.0||C;129SV4-Csf2/Il3 Il2rg Rag2/J AnuApb||Recessive|colony stimulating factor 2 (granulocyte-macrophage)|Csf2||Csfgm, Gm-CSf, GMCSF, MGI-IGM|MGI:1339752|colony stimulating factor 2 (granulocyte-macrophage); targeted mutation 1.1, Richard A Flavell|Csf2/Il3|MGI:4887879|11|||||||||||||||||||||||||||||Abnormal response to transplant:• mice exhibit improved engraftment with CD34+ hematopoietic cells with improved human myeloid cell reconstitution in the lung compared with wild-type mice||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Apr-2020|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 8960.0||C;129SV4-Csf2/Il3 Il2rg Rag2/J AnuApb||Recessive|interleukin 2 receptor, gamma chain|Il2rg||CD132, common cytokine receptor gamma chain, common gamma chain, gamma(c), gammaC, gamma C receptor, gc, [g]c|MGI:96551|interleukin 2 receptor, gamma chain; targeted mutation 1.1, Richard A Flavell|Il2rg|MGI:4887837|X|||||||||||||||||||||||||||||Abnormal response to transplant:• mice exhibit improved engraftment with CD34+ hematopoietic cells with improved human myeloid cell reconstitution in the lung compared with wild-type mice||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Apr-2020|Cryopreserved sperm|||Unknown|||Yes| 8960.0||C;129SV4-Csf2/Il3 Il2rg Rag2/J AnuApb||Recessive|recombination activating gene 2|Rag2|||MGI:97849|recombination activating gene 2; targeted mutation 1.1, Richard A Flavell|Rag2|MGI:4887836|2|||||||||||||||||||||||||||||Abnormal response to transplant:• mice exhibit improved engraftment with CD34+ hematopoietic cells with improved human myeloid cell reconstitution in the lung compared with wild-type mice||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Apr-2020|Cryopreserved sperm|||Unknown|||Yes| 8978.0|NOD.B6Idd11G|NOD/Lt-C57BL/6<(D4Mit72 -rs27507071)>/TcbApb||Recessive|insulin dependent diabetes susceptibility 11|Idd11|Unknown||MGI:96402|insulin dependent diabetes susceptibility 11; C57BL/6 |Idd11||4||||||||||||||||||||insulin dependent diabetes susceptibility 11; C57BL/6 |Idd11|||96402|Idd11|||4|These homozygous congenic mice exhibit a decreased diabetes incidence compared to NOD/Lt wildtype mice.|Unknown|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|||No|12-Apr-2020|Cryopreserved sperm|50.0|0.0|Yes|type 1 diabetes|autoimmune disease|No| 8900.0|Tip2#65|NOD/Lt-Tg(TetO-Ins2) Tg(H2-IEa-tTA)/Apb||Dominant||||||||||||||||||||||||||transgene insertion||||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown||proinsulin|Yes| 8900.0|Tip2#65|NOD/Lt-Tg(TetO-Ins2) Tg(H2-IEa-tTA)/Apb||Dominant||||||||||||||||||||||||||transgene insertion||||||||||||Normal|Normal|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Mar-2020|Cryopreserved sperm|||Unknown||proinsulin|Yes| 8778.0|NODk|NOD.Cg-H2/AnuApb||Recessive|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|||||||||||||||||||||||||||||NODk mice are resistant to diabetes.||NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Aug-2019|Cryopreserved sperm|44.0|517.0|Unknown||Haplotype|Yes| 8248.0|Srsf3-flox UBC-cre/ert tetO-OSKM|B6;129-Srsf3 Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn Tg((UBC-cre/ERT2)1Ejb/MarpApb||Recessive|serine/arginine-rich splicing factor 3|Srsf3|Unknown|Sfrs3, X16|MGI:98285||||17|||||||||||||||||transgene insertion 1, Eric J Brow|human ubiquitin C (UBC) promoter|||||||||||Unknown|Normal|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Apr-2017|Cryopreserved sperm|40.0|0.0|No||LoxP|Possibly| 8248.0|Srsf3-flox UBC-cre/ert tetO-OSKM|B6;129-Srsf3 Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn Tg((UBC-cre/ERT2)1Ejb/MarpApb||Recessive||||||||||||||||||||||||||transgene insertion 1, Manuel Serrano||||||||||||Unknown|Normal|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|28-Apr-2017|Cryopreserved sperm|||No||LoxP|Possibly| 8490.0|C57BL/6.Scmh1-196|C57BL/6N-Scmh1196/BaxApb||Recessive|sex comb on midleg homolog 1|Scmh1||Scml3|MGI:1352762|sex comb on midleg homolog 1; targeted mutation 1a, Wellcome Trust Sanger Institute|Scmh1|MGI:4441791|4|||||||||||||||||||||||||||||Mice homozygous for a knock-out allele exhibit abnormal hematopoiesis but normal fertility and skeleton.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9227.0|ASD816:TCF-Lef:H2B-GFP|B6.129-Tg(TCF/Lef1-HIST1H2BB/EGFP)61Hadj/Apb||Dominant|TCF/Lef:H2B/GFP||||||||Unknown|||||||||||||||||transgene insertion 61, Anna-Katerina Hadjantonakis|Hspa1b, heat shock protein 1B, mouse, laboratory|||||||||||No externally observable phenotype. GFP expression in cells with active canonical WNT signalling. GFP expression is evident in cells of the extraembryonic visceral endoderm, the primitive streak, the mature node, presomitic mesoderm and newly formed somites, posterior neural plate, cranial neural crest, face, and branchial arches. By E12.5 fluorescence is also seen in the kidney, gonads, and some neuronal subsets in the brain.|No externally observable phenotype. GFP expression in cells with active canonical WNT signalling. GFP expression is evident in cells of the extraembryonic visceral endoderm, the primitive streak, the mature node, presomitic mesoderm and newly formed somites, posterior neural plate, cranial neural crest, face, and branchial arches. By E12.5 fluorescence is also seen in the kidney, gonads, and some neuronal subsets in the brain.|C57BL.6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Jul-2021|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 8498.0|NOD.Nkrplb.SlamB.CD-1|NOD-Cd1 Klrb1b Tg(Slamf1)1/BaxApb||Recessive|CD1 antigen complex|Cd1|Nil||MGI:102561|CD1 antigen complex; targeted mutation 1, Michael Grusby|Cd1|MGI:1857482|3|||||||||||||||||signaling lymphocytic activation molecule family member 1|||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size. Can be difficult breedersNk Cell Marker Transgenic over expression of Slam. Knockout lacking the CD1 antigen complex gene. Increased Nkt cell numbers. Lack an NK-like cell subset.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|31-May-2018|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8495.0|NOD.Hc|NOD-Hc/BaxApb||Recessive|||||||||||||||||||||||||||||hemolytic complement|Hc||C5, C5a, He, Hfib2|MGI:96031||||2|Mice that are homozygous for this allele are viable, fertile, normal in size.Congenic markers C5 Locus|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8989.0|ENU15NIH:036a:uGFP|C57BL/6JAnu-Itgal Tg(UBC-GFP)30Scha/AnuApb||Recessive|integrin alpha L|Itgal|Unknown|Cd11a, LFA-1, Ly-15, Ly-21|MGI:96606||||7|||||||||||||||||transgene insertion 30, Brian Schaefer|human ubiquitin C promoter|||||||||||||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-May-2020|Cryopreserved sperm|33.0|0.0|Unknown||CD8, LFA-1, hepatic|Yes| 8500.0|ASD797:Persimmon:10|C57BL/6NCrlAnu-Ifit3b/AnuApb||Recessive|interferon-induced protein with tetratricopeptide repeats 3B|Ifit3b|Unknown|I830012O16Rik|MGI:3698419|Ifit3b, endonuclease-mediated mutation 1, Australian National University|Ifit3b||19||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2018|Cryopreserved sperm|68.0|0.0|Unknown|||Yes| 8502.0|ASD798:Sapote:4|C57BL/6NCrlAnu-Ifit3 Ifit3b/AnuApb||Recessive|interferon-induced protein with tetratricopeptide repeats 3B|Ifit3b|Unknown|I830012O16Rik|MGI:3698419|Ifit3b, endonuclease-mediated mutation 3, Australian National University |Ifit3b||19||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2018|Cryopreserved sperm|95.0|0.0|Unknown|||Yes| 8502.0|ASD798:Sapote:4|C57BL/6NCrlAnu-Ifit3 Ifit3b/AnuApb||Recessive|interferon-induced protein with tetratricopeptide repeats 3|Ifit3|Unknown|Ifi49|MGI:1101055|Ifit3, endonuclease-mediated mutation, Australian National University|Ifit3||19||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2018|Cryopreserved sperm|||Unknown|||Yes| 8503.0|ASD798:Sapote:8|C57BL/6NCrlAnu-Ifit3/AnuApb||Recessive|interferon-induced protein with tetratricopeptide repeats 3|Ifit3|Unknown|Ifi49|MGI:1101055|Ifit3, endonuclease-mediated mutation 2, Australian National University |Ifit3||19||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2018|Cryopreserved sperm|59.0|0.0|Unknown|||Yes| 8504.0|ASD888:Banana|C57BL/6NCrlAnu-Prdm1/AnuApb||Recessive|PR domain containing 1, with ZNF domain|Prdm1|Unknown||MGI:99655|Prdm1, endonuclease-mediated mutation 2, Australian National University|Prdm1||10||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jun-2018|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8524.0||C57BL/6N-Abca12/MarpApb||Recessive|ATP-binding cassette, sub-family A (ABC1), member 12|Abca12|Unknown|4832428G11Rik, 4833417A11Rik|MGI:2676312|ATP-binding cassette, sub-family A (ABC1), member 12; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Abca12|MGI:4941545|1|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Jun-2018|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 8987.0|Ubf fl Vav-cre|STOCK Ubtf Tg(Vav1-Cre)1Awr/AnuApb||Recessive|upstream binding transcription factor, RNA polymerase I|Ubtf||A930005G04Rik, Tcfubf, UBF, UBF1|MGI:98512||||11|||||||||||||||||transgene insertion 1, Andrew W Roberts|Vav1|Haemopoietic||||||||||Normal||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-May-2020|Cryopreserved sperm|60.0|0.0|Unknown||RNA polymerase, rRNA|Yes| 1601.0|GAD67-GFP|C57BL/6-Gad1/AnuApb||Dominant|glutamic acid decarboxylase 1|Gad1|Normal|EP10, Gad-1, GAD67, Z49976|MGI:95632|glutamate decarboxylase 1; targeted mutation 1.1, Nobuaki Tamamaki|Gad1|MGI:3590301|2||||||||||||||||Yes|||||||||||||Abnormal involuntary movement:*at E14, the frequency of mouth opening and tongue withdrawal are reduced compared to wild type littermates.Abnormal nervous system electrophysiology:* at E14 the frequency of neural discharges from the hypoglossal nerve and C4 ventral root that stimulate muscle activity in the neck and tongue is reduced however the amplitude of these discharges is similar to wild type.||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|11-Jul-2007|Cryopreserved sperm|80.0|0.0|Unknown||cerebral cortex, green fluorescence protein, GFP, cleft palate, apnea|Yes| 8993.0|48L|B6(Cg)-Et(tTA/TRE-mCit/Wre)48L/AnuApb||Recessive||||||||||||||||||||||||||Et(tTA/TRE/mCit/Wre)48L||||||||||||Unknown|A subset of neurons in the brain express a construct containing a minimal heat shock promoter, tetracycline response transactivator (tTA), tet response element (TRE), mCitrine (mCit), and the woodchuck hepatitis post-transcriptional regulatory element flanked by long terminal repeats.|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-May-2020|Cryopreserved sperm|55.0|0.0|Unknown||semilunar (SL) cells, anterior piriform cortex (aPC)|Yes| 8527.0|ASD778:Lrrfip1|C57BL/6NCrlAnu-Lrrfip1/AnuApb||Recessive|leucine rich repeat (in FLII) interacting protein 1|Lrrfip1|Unknown|FLAP (FLI LRR associated protein), Fliiap1|MGI:1342770|Lrrfip1, endonuclease-mediated mutation 1, Australian National University |Lrrfip1||1||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Jun-2018|Cryopreserved sperm|10.0|0.0|Unknown|||Yes| 8251.0|Warpy mix|B6;C3H-Dzip1l/AnuUqApb||Recessive|DAZ interacting protein 1-like|Dzip1l|||MGI:1919757|DAZ interacting protein 1-like; Warpy|Dzip1l|MGI:5563494|9|ENSMUSG00000037784|ENSMUST00000078367|Dzip-1l-001|1123|1326|C to T|ENSMUSE00000325142|8|375|Glutamine to STOP|||||TGTCTCAGGACCAGAAGAAAGCAGCTGCCCAGTCTCAGCGCCATATCAATGCCCTCCGTGC|Yes|||||||||||||Polydactlyly and craniofacial dismorphology in embryos at e14.5.Extra digits on each limb some have 6 some have 7) and there is a craniofacial dismorphology (the front of the head protrudes, the eye position is changed and there is a mandible malformation.|Normal|B6 x C3H|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||1||No|08-May-2017|Cryopreserved sperm|40.0|0.0|Unknown||polydactyly, ENU|No| 8996.0|HobitBlimpLck|B6.Cg-Prdm1 Zfp683 Tg(Lck-cre)1Cwi/Apb||Recessive|PR domain containing 1, with ZNF domain|Prdm1||b2b1765Clo, Blimp1, Blimp-1, PRDI-BF1|MGI:99655|PR domain containing 1, with ZNF domain; targeted mutation 2.1, Stephen L Nutt|Prdm1|MGI:4355900|10|||||||||||||||||transgene insertion 1, Christopher B Wilson||||||||||||Mice have defects in tissue resident memory T cells, but are otherwise relatively normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-May-2020|Cryopreserved sperm|40.0|0.0|Unknown||Trm, tissue resident lymphocyte|Yes| 8996.0|HobitBlimpLck|B6.Cg-Prdm1 Zfp683 Tg(Lck-cre)1Cwi/Apb||Recessive|zinc finger protein 683|Zfp683||Hobit|MGI:3650254|zinc finger protein 683; gene trap OST314703, Lexicon Genetics|Zfp683|MGI:4276801|4|||||||||||||||||||||||||||||Mice have defects in tissue resident memory T cells, but are otherwise relatively normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-May-2020|Cryopreserved sperm|||Unknown||Trm, tissue resident lymphocyte|Yes| 8999.0||B6.129-Rarg Tg(Cdh5(PAC)Cre/ERT2)1Rha Gt(ROSA)26Sor/StVApb||Recessive|Retinoic acid receptor, gamma|Rarg|Nil|MGC:11555, MGC:18523, RARgamma2, RAR gamma 2|MGI:97858|retinoic acid receptor, gamma; targeted mutation 3, Pierre Chambon|Rarg|MGI:2386111|15|||||||||||||||||transgene insertion 1, Ralf H Adams|VE-cadherin|||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8999.0||B6.129-Rarg Tg(Cdh5(PAC)Cre/ERT2)1Rha Gt(ROSA)26Sor/StVApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 4, Liqun Luo|Gt(ROSA)26Sor|MGI:3716464|6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2020|Cryopreserved sperm|||Unknown|||Yes| 8529.0|ASD669:Alba|C57BL/6NCrlAnu-Prdm1/AnuApb||Recessive|PR domain containing 1, with ZNF domain|Prdm1||b2b1765Clo, Blimp1, Blimp-1, PRDI-BF1|MGI:99655|Prdm1, endonuclease-mediated mutation 1, Australian National University|Prdm1||10||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jul-2018|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 8531.0|Srsf2 P95H/+|C57BL/6NTac-Srsf2/Apb||Recessive|serine/arginine-rich splicing factor 2|Srsf2||D11Wsu175e, MRF-1, SC35, Sfrs10, Sfrs2|MGI:98284|serine and arginine-rich splicing factor 2; targeted mutation 2874.1, TaconicArtemis|rsf2|MGI:7408195|11|||||||||||||||||||||||||||||Lethal|Develops myelodysplastic/myeloproliferative syndrome|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|03-Jul-2018|Cryopreserved sperm|40.0|0.0|Unknown||myelodysplastic (MDS) and myelodysplastic/myeloproliferative (MDS/MPN) syndromes, myeloid bias, monocytosis, dysplasia|Yes| 9004.0|Hs6st1 fl x FoxN1 cre|B6.129-Hs6st1 Foxn1/AnuApb||Recessive|heparan sulfate 6-O-sulfotransferase 1|Hs6st1|Normal|6)ST1|MGI:1354958|heparan sulfate 6-O-sulfotransferase 1; targeted mutation 1, Wellington V Cardoso|Hs6st1|MGI:3793786|1||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|11.0|0.0|Unknown||Heparan sulphate|Yes| 9004.0|Hs6st1 fl x FoxN1 cre|B6.129-Hs6st1 Foxn1/AnuApb||Recessive|forkhead box N1|Foxn1||D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|||Unknown||Heparan sulphate|Yes| 9005.0|Ndst1 fl x FoxN1 cre|B6.129-Ndst1 Foxn1/AnuApb||Recessive|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1|Ndst1|Normal|1200015G06Rik, b2b2230Clo, glucosaminyl N-deacetylase/N-sulfotransferase 1, Hsst, Ndst-1|MGI:104719|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1; targeted mutation 1, Jeffrey D Esko|Ndst1|MGI:3589211|18||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|11.0|0.0|Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 9005.0|Ndst1 fl x FoxN1 cre|B6.129-Ndst1 Foxn1/AnuApb||Recessive|forkhead box N1|Foxn1||D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|||Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 9001.0|Cd11c-cre-GFP:Hs2st1 fl|B6.129-Hs2st1 Tg(Itgax-cre,-EGFP)4097Ach/AnuApb||Recessive|heparan sulfate 2-O-sulfotransferase 1|Hs2st1|Normal|Hs2st, mKIAA0448|MGI:1346049|heparan sulfate 2-O-sulfotransferase 1; targeted mutation 1.1, Jeffrey D Esko|Hs2st1|MGI:4439161|3|||||||||||||||||transgene insertion 4097, Alexander V Chervonsky|Itgax||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|55.0|0.0|Unknown||Heparan sulphate, sulfation, triglyceride|Yes| 9002.0|Cd11c-cre-GFP:Hs6st1 fl|B6.129-Hs6st1 Tg(Itgax-cre,-EGFP)4097Ach/AnuApb||Recessive|heparan sulfate 6-O-sulfotransferase 1|Hs6st1|Normal|6)ST1|MGI:1354958|heparan sulfate 6-O-sulfotransferase 1; targeted mutation 1, Wellington V Cardoso|Hs6st1|MGI:3793786|1|||||||||||||||||transgene insertion 4097, Alexander V Chervonsky|Itgax||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|33.0|0.0|Unknown||Heparan sulphate|Yes| 9003.0|Cd11c-cre-GFP:Ndst1 fl|B6.129-Ndst1 Tg(Itgax-cre,-EGFP)4097Ach/AnuApb||Recessive|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1|Ndst1|Normal|1200015G06Rik, b2b2230Clo, glucosaminyl N-deacetylase/N-sulfotransferase 1, Hsst, Ndst-1|MGI:104719|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1; targeted mutation 1, Jeffrey D Esko|Ndst1|MGI:3589211|18|||||||||||||||||transgene insertion 4097, Alexander V Chervonsky|Itgax||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|42.0|0.0|Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 9006.0|Ndst1 fl x FoxN1 cre:TCRb-transgenic|B6.129-Ndst1 Foxn1 Tg(CD2-Tcrb)/AnuApb||Recessive|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1|Ndst1|Normal|1200015G06Rik, b2b2230Clo, glucosaminyl N-deacetylase/N-sulfotransferase 1, Hsst, Ndst-1|MGI:104719|N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1; targeted mutation 1, Jeffrey D Esko|Ndst1|MGI:3589211|18|||||||||||||||||CD2-mTcrb|||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|33.0|0.0|Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 9006.0|Ndst1 fl x FoxN1 cre:TCRb-transgenic|B6.129-Ndst1 Foxn1 Tg(CD2-Tcrb)/AnuApb||Recessive|forkhead box N1|Foxn1||D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020|Cryopreserved sperm|||Unknown||heparan sulphate, endothelial, chemokine, neutrophil|Yes| 9007.0|Hs6st1 fl x FoxN1 cre:TCRb-transgenic|B6.129-Hs6st1 Foxn1 Tg(CD2-mTcrb)/AnuApb||Recessive|heparan sulfate 6-O-sulfotransferase 1|Hs6st1|Normal|6)ST1|MGI:1354958|heparan sulfate 6-O-sulfotransferase 1; targeted mutation 1, Wellington V Cardoso|Hs6st1|MGI:3793786|1|||||||||||||||||CD2-mTcrb|||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020||0.0|0.0|Unknown||Heparan sulphate|Yes| 9007.0|Hs6st1 fl x FoxN1 cre:TCRb-transgenic|B6.129-Hs6st1 Foxn1 Tg(CD2-mTcrb)/AnuApb||Recessive|forkhead box N1|Foxn1||D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11||||||||||||||||||||||||||||||Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|>10|||No|12-Jun-2020||||Unknown||Heparan sulphate|Yes| 8275.0|Ccr6 KO: OT-I|B6.129-Ccr6 Tg(TcraTcrb)1100Mjb/MarpAnu||Recessive|chemokine (C-C motif) receptor 6|Ccr6|Nil|Cmkbr6|MGI:1333797|chemokine (C-C motif) receptor 6; targeted mutation 1, Deltagen|Ccr6|MGI:3604541|17|||||||||||||||||transgene insertion 1100, Michael J Bevan||||||||||||Unknown||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Aug-2017|Cryopreserved sperm|42.0|0.0|Unknown||T cell, Ccl20|Yes| 8536.0|C66 ; Hobit|C57BL/6JMarp-Zfp683/MgmpApb||Recessive|zinc finger protein 683|Zfp683|Unknown|Hobit|3650254 ||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Jul-2018|Cryopreserved sperm|30.0|0.0|Unknown||CRISPR|No| 9008.0|Rag2 KO|BALB/c-Rag2/AnuApb||Recessive|ecombination activating gene 2|Rag2||Rag-2|MGI:97849||||2|||||||||||||||||||||||||||||||BALB/c|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|12-Jun-2020|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 9009.0|Mpl(hlb219)|C.B6-Mpl/JAnuApb||Recessive|myeloproliferative leukemia virus oncogene|Mpl||CD110, c-mpl, c-mpl-I, c-mpl-II, hlb219, thrombopoietin receptor, TPO-R|MGI:97076|myeloproliferative leukemia virus oncogene; heart, lung and blood, 219|Mpl|MGI:2680465|4|||||||||||||||||||||||||||||abnormal definitive hematopoiesis ( J:146577 ) • mutant bone marrow cells gave rise to significantly smaller CFU-granulocyte-macrophage (CFU-GM) and CFU-granulocyte (CFU-G) than controlsdecreased common myeloid progenitor cell number ( J:146577 ) • mutant bone marrow cells gave rise to significantly smaller CFU-granulocyte-erythrocyte-monocytemacrophage (CFU-GEMM) than controlsanemia ( J:146577 ) decreased megakaryocyte cell number ( J:146577 ) • mutant mice exhibit a decreased number of megakaryocytes in the bone marrowabnormal megakaryocyte progenitor cell morphology ( J:146577 ) • mutant bone marrow cells gave rise to significantly smaller CFU-Mk populations than controlsdecreased erythrocyte cell number ( J:146577 ) • significantly fewer red blood cells compared to controlsdecreased hematocrit ( J:146577 ) decreased hemoglobin content ( J:146577 ) thrombocytopenia ( J:82961 , J:146577 ) • mice had a platelet count of 106 X 103 cells/ul at 6 weeks of age (J:82961)• the platelet level is reduced by approximately 80% in comparison to controls (J:146577)• platelet morphology is normal and there is no sign of platelet aggregation in blood smears stained with Wright-Giemsa (J:146577)decreased leukocyte cell number ( J:146577 ) • lower white blood cells counts than controlsenlarged spleen ( J:146577 ) • two of three mice showed minor splenomegaly upon necroscopy||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Jun-2020|Cryopreserved sperm|55.0|0.0|Unknown||Platelet, Megakaryocyte|Yes| 9017.0|Kingsleys #7|C57BL/6NCrlAnu-Rab13/AnuApb||Recessive|RAB13, member RAS oncogene family|Rab13|Unknown|610007N03Rik, B230212B15Rik|MGI:1927232|Rab13; endonuclease-mediated mutation 2, The Australian National University|Rab13||3||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jun-2020|Cryopreserved sperm|59.0|0.0|Unknown|||Yes| 8229.0|hAHRKI|B6.129P2-Ahr/MarpAnu||Recessive|aryl-hydrocarbon receptor|Ahr||Ah, Ahh, Ahre, bHLHe76, dioxin receptor, In|MGI:105043|aryl-hydrocarbon receptor; targeted mutation 1, Masayuki Yamamoto|Ahr|MGI:3776466|12|||||||||||||||||||||||||||||Unknown||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Mar-2017|Cryopreserved sperm|73.0|0.0|Unknown||dioxin, toxin|Yes| 9018.0|San Roque|B6N(Cg)-Rc3h1/AnuApb |B6N(Cg)-Rc3h1/AnuApb|Recessive|RING CCCH (C3H) domains 1|Rc3h1|Unknown|Roquin|MGI:2685397|sanroque|Rc3h1|MGI:3581675|1|ENSMUSG00000040423|ENSMUST00000035911|Rc3h1-201|596|981|T to G|ENSMUSE00000536751|5|199|Methionine to Arginine|||||TAGGGGCTGCCAGTTCCTTGGACCAGCGATGCAGGAGGAAGCTCTGAAGCTGGTCTTGCTG|Yes|||||||||||||Spontaneous autoimmune disease. Systemic lupus erythematosus. Anti-nuclear autoantibodies (ANA), hypergammaglobulinemia, autoimmune nephritis, lymphadenopathy, increased numbers of CD44high activated memory T cells, increased numbers of T follicular helper cells, spontaneous germinal centres, CD28-independent activation of T cells. Increased ICOS mRNA and protein expression on T cells, defect in micro-RNA (mir) inhibition of mRNA stability.|Low penetrance in hets|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|7|||No|22-Jun-2020|Cryopreserved sperm|55.0|0.0|Yes||Systemic lupus erythematosus (SLE), autoimmunity, T cell, ubiquitin ligase, Wellcome Trust, ENU, lymphadenopathy|Yes| 8228.0|CXCR5KO:OT1:Ly5a|B6.Cg-Cxcr5 Ptprc Tg(TcraTcrb)1100Mjb/MarpAnu||Recessive|chemokine (C-X-C motif) receptor 5|Cxcr5||Blr1, CXCR-5, Gpcr6|MGI:103567|chemokine (C-X-C motif) receptor 5; targeted mutation 1, Martin Lipp|Cxcr5|MGI:2158677|9|||||||||||||||||transgene insertion 1100, Michael J Bevan||||||||||||Cxcr5 KO mice:Abnormal leukocyte migration:• homozygotes exhibit a severely impaired lymphocyte migration to the Peyer's pathces and the B cell follicles of the spleen, resulting in morphologically abnormal primary lymphoid follicles• activated B cells fail to migrate from the T cell-rich zone into B cell follicles of the spleenIncreased B cell number:• homozygotes display a 2- to 4-fold increase in spleen or peripheral blood cells co-expressing B220 and high amounts fo IgMAbnormal spleen primary B follicle morphology:• at 8 wks of age, homozygotes display defective formation of primary splenic follicles, including: the T cell zone is located centrally but not polarized in the follicle; the T cell zone is completely surrounded by a small rim of B cell-expressing IgD but not IgM (i.e. IgM+IgD+ subset is absent); a prominent marginal zone surrounds the follicle completelyAbnormal spleen secondary B follicle morphology.Absent spleen germinal centre:• despite high numbers of germinal center founder cells, no functional germinal centers develop in mutant spleen after immunization with the T cell-dependent antigen DNP-KHLAbsent follicular dendritic cells:• absence of primary follicular dendritic cellsAbnormal Peyer's patch morphology:• ~30% (26 of 76) of homozygotes exhibit 1-4 small and rudimentary structures resembling Peyer's patches• ~16% (12 of 76) of homozygotes exhibit normally sized Peyer's patches with multiple B and T cell-rich zones instead of the large follicles present in wild-type miceAbsent Peyer's patches:• 55% (42 of 76) of homozygotes show complete absence of Peyer's patchesAbsent axillary lymph nodes Absent brachial lymph nodes Absent cervical lymph nodes Absent inguinal lymph nodes:• homozygotes lack inguinal lymph nodesAbsent lymph nodes:• absence of inguinal, iliac/periaortic, axillary, branchial, deep cervical, sacral/caudal, and parathymic lymph nodes||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Mar-2017|Cryopreserved sperm|64.0|0.0|Unknown||T cell|Yes| 8482.0|IL10 KO|B6.129-Il10/LudAnuApb||Recessive|interleukin 10|Il10||cytokine synthesis inhibitory factor, IL-10|MGI:96537|interleukin 10; targeted mutation 1, University of Cologne|Il10|MGI:1857199|1|||||||||||||||||||||||||||||Large intestinal inflammation: • mutants develop severe inflammation in the colon leading to inflammatory bowel disease Abnormal regulatory T cell physiology: • CD25-positive CD4 T cells from these mice fail to protect against the wasting disease induced by transferring nave CD4 T cells into immunodeficient hosts|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-May-2018|Cryopreserved sperm|55.0|0.0|Unknown||il10, colitis, T cell|Possibly| 9045.0|Irf7-|B6;129P2-Irf7/TtgRbrc||Recessive|interferon regulatory factor 7|Irf7|||MGI:3577089||||7|ENSMUSG00000025498|ENSMUST00000106023.7|||||||||||||||||||||||||||Homozygous mutant mice are vulnerable to viral infection with a decreased serum interferon level.|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown||Homozygote x Homozygote, Homozygous x B6, Het x het|Yes|21-Jul-2020||0.0|50.0|Unknown||Irf7, Knockout|Possibly| 9046.0|IRF3|B6.Cg-Irf3||Recessive|interferon regulatory factor 3|Irf3|Unknown||MGI:6353293||||7|ENSMUSG00000003184|ENSMUST00000003284.15|Irf3-201|||||||||||||||||Irf3||||||||7|Homozygous mutant mice are vulnerable to viral infection with a decreased serum interferon level.|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown||Homozygote x Homozygote, Homozygous x B6, Het x het|Yes|21-Jul-2020||0.0|42.0|Unknown||Irf3, Knockout, Infection, Viral|Possibly| 9042.0|Dynll1 Cd23 Bim|Dynll1Tg(Fcer2a-cre)<5Mbu>Bcl2l11||Recessive|Dynein light chain LC8-type 1|Dynll1|Reduced|8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|Dynein light chain LC8-type 1|Dynll1|MGI:5755433|5|||||||||||||||||Tg(Fcer2a-cre)5Mbu|Cd23|Unknown||||||||||Moderately reduced Ig class-switchingreduced T cell-indendent (TI-1) immune response in vivo and reduced activation by LPS and IL1 in vitro|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|14-Jul-2020|Cryopreserved sperm|50.0|0.0|Unknown||Proapoptotic, B Cells, BIM, CRE|No| 9042.0|Dynll1 Cd23 Bim|Dynll1Tg(Fcer2a-cre)<5Mbu>Bcl2l11||Recessive|||||||||Unknown|||||||||||||||||||||||||||||Moderately reduced Ig class-switchingreduced T cell-indendent (TI-1) immune response in vivo and reduced activation by LPS and IL1 in vitro|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|14-Jul-2020|Cryopreserved sperm|||Unknown||Proapoptotic, B Cells, BIM, CRE|No| 9042.0|Dynll1 Cd23 Bim|Dynll1Tg(Fcer2a-cre)<5Mbu>Bcl2l11||Recessive|BCL2-like 11 (apoptosis facilitator)|Bcl2l11 |Reduced|1500006F24Rik, Bim, Bod|MGI:1197519 |BCL2-like 11 (apoptosis facilitator); targeted mutation 6.1, Philippe Bouillet|Bcl2l11|MGI:5562690|2|||||||||||||||||||||||||||||Moderately reduced Ig class-switchingreduced T cell-indendent (TI-1) immune response in vivo and reduced activation by LPS and IL1 in vitro|Normal|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|14-Jul-2020|Cryopreserved sperm|||Unknown||Proapoptotic, B Cells, BIM, CRE|No| 8550.0|ASD935:Navel:9|C57BL/6NCrlAnu-Tlr3/AnuApb||Recessive|toll-like receptor 3|Tlr3|Unknown||MGI:2156367|Tlr3, endonuclease-mediated mutation 1, Australian National University|Tlr3||8||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Aug-2018|Cryopreserved sperm|11.0|0.0|Unknown||CRISPR|Yes| 9066.0|ENU48:125:St3gal5|C57BL/6NCrl/ApbAnu||Recessive|ST3 beta-galactoside alpha-2,3-sialyltransferase 5|St3gal5||GM3-specific sialytransferase, GM3 synthase, mST3Gal V, Siat9, ST3Gal V|MGI:1339963||||6|ENSMUSG00000056091|ENSMUST00000069994|||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Aug-2020|Cryopreserved sperm|40.0|0.0|Unknown||ENU, Random, Mutagenesis, Screen|Yes| 9060.0|MDM2 C305F|B6(Cg).129(Cg)-Mdm2 /AnuNCrl||Recessive|Transformed mouse 3T3 cell double minute 2|MDM2|Normal|1700007J15Rik, Mdm-2 |MGI:96952|Transformed mouse 3T3 cell double minute 2; targeted mutation 1.1, Yangping Zhang|Mdm2|MGI:4836988|10|||||||||||||||||||||||||||||Homozygote animals smaller in size but otherwise normal|Heterozygote animals smaller in size (less pronounced than homozygotes) but otherwise normal.|C57.BL6 AnuNCrl|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Aug-2020|Cryopreserved sperm|55.0|0.0|Unknown||Mdm2, Ribosomal biogenesis, Cancer, p53|Possibly| 7902.0|K14-Cre|B6.FVB-Tg(KRT14-cre)8Brn/MarpApb||Dominant||||||||||||||||||||||||||transgene insertion 8, Anton Bern|Keratin 14|||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|unknown|unknown||No|10-Jun-2015|Cryopreserved sperm|47.0|0.0|No||Skin, dermis, Cre recombinase|Yes| 8539.0|ASD550:Juanfran:::F6|C57BL/6NCrlAnu-Samsn1/AnuApb||Recessive|SAM domain, SH3 domain and nuclear localization signals, 1|Samsn1|Unknown|4930571B16Rik, Hacs1|MGI:1914992|Samsn1, endonuclease-mediated mutation 1, Australian National University|Samsn1||16||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Jul-2018|Cryopreserved sperm|60.0|0.0|Unknown|||Yes| 8538.0|ERT-Cre-SB-Neu|STOCK Tg(Elf5-rtTA/TetO-cre) Tg(MMTVneu) TgTn(sb-T2/Onc2)Njen/OnjcriApb||Recessive||||||||||||||||||||||||||Elf5-rtTA/TetO-cre|E74-like factor 5|||||||||||Normal|Normal|C57BL/6:Balb/c:FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jul-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8538.0|ERT-Cre-SB-Neu|STOCK Tg(Elf5-rtTA/TetO-cre) Tg(MMTVneu) TgTn(sb-T2/Onc2)Njen/OnjcriApb||Recessive||||||||||||||||||||||||||Tg(MMTVneu)|MMTV|Mammary gland||||||||||Normal|Normal|C57BL/6:Balb/c:FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jul-2018|Cryopreserved sperm|||Unknown|||Yes| 8538.0|ERT-Cre-SB-Neu|STOCK Tg(Elf5-rtTA/TetO-cre) Tg(MMTVneu) TgTn(sb-T2/Onc2)Njen/OnjcriApb||Recessive||||||||||||||||||||||||||transgenic transposon concatemer, Nancy A Jenkins||||||||||||Normal|Normal|C57BL/6:Balb/c:FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jul-2018|Cryopreserved sperm|||Unknown|||Yes| 9034.0|CD4-cre|B6.Cg-Tg(Cd4-Cre)1Cwi/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Christopher B Wilson|Cd4|||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jun-2020|Cryopreserved sperm|55.0|0.0|Unknown||Cre recombinase|Yes| 9031.0|TRAIL-R.flox|B6.129-Tnfrs10b/Apb||Recessive|tumor necrosis factor receptor superfamily, member 10b|Tnfrsf10b||DR5, KILLER, Killer/Dr5, Ly98, TRAILR2, TRAIL-R2, Trail Receptor, TRICK2A, TRICK2B, TRICKB|MGI:1341090|Trail-r.flox|tumor necrosis factor receptor superfamily, member 10b; targeted mutation 1, Christopher J Kemp|Tnfrsf10b|14|||||||||||||||||||||||||||||Normal - requires crossing to relevant cre strain to delete TRAIL-R|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jun-2020|Cryopreserved sperm|50.0|0.0|Unknown||Metastasis|Yes| 8227.0|CD28KO:H2G7|B6.NOD-Cd28 H2/MarpAnu||Recessive|CD28 antigen|Cd28|||MGI:88327|CD28 antigen; targeted mutation 1, Tak Mak|Cd28|MGI:1857150|1||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; g7 variant|H2|MGI:3579321|17|CD28 KO mice:Increased T cell apoptosis:• after 96 hours in culture, only 68% of T cells are alive compared to 83% of controls• more mutant T cells are apoptotic after radiation dosage than in controlsAbnormal NK cell physiology:• alpha-galactosylceramide-induced cytotoxic activity of splenic and hepatic mononuclear cells was reduced compared to wild-type• alpha-galactosylceramide-induced anti-metastatic effect was substantially reduced compared to wild-type, indicating that natural killer cells are not able to fight off cancer cellsDecreased T cell proliferation:• T cells have markedly impaired proliferation in response to T cell co-stimulation (anti-CD3 + anti-CD28)Decreased circulating interferon-gamma level:• alpha-galactosylceramide-induced serum IFN-gamma levels were reduced compared to wild-typeDecreased circulating interleukin-4 level:• alpha-galactosylceramide-induced (an antigen that activates invariant natural killer T cells) serum IL-4 levels were reduced compared to wild-typeIncreased susceptibility to type I hypersensitivity reaction:• mice have reduced airway hyperresponsiveness after sensitization and challenge with OVADecreased interleukin-2 secretion:• T cells secrete less IL-2 when activated compared to controlsDecreased susceptibility to experimental autoimmune encephalomyelitis:• mice fail to develop EAE after immunization with MOG and even lack inflammatory infiltrates into the spinal cord|H2G7 mice are resistant to type 1 diabetes|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Mar-2017|Cryopreserved sperm|34.0|0.0|Unknown||T cell|Yes| 7366.0|BCL6-flox |B6.129-Bcl6/AnuApb||Recessive|B cell leukemia/lymphoma 6|Bcl6|Normal|Bcl5|MGI:107187|B cell leukemia/lymphoma 6; targeted mutation 1.1, Alexander Dent|Bcl6|MGI:5518542|16|||||||||||||||||||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jul-2013|Cryopreserved sperm|77.0|0.0|Unknown||T cell, transcription, follicular|Yes| 8998.0|C57BL/6N RIP3 Knockout|B6.129-Ripk3/VmdApb||Recessive|receptor-interacting serine-threonine kinase 3|Ripk3|Nil|2610528K09Rik, Rip3|MGI:2154952|receptor-interacting serine-threonine kinase 3; targeted mutation 1, Vishva M Dixit|Ripk3|MGI:3028853|14|||||||||||||||||||||||||||||Decreased inflammatory response:• do not develop severe hypothermia or die after treatment with TNF unlike wild-type mice• however, intestinal damage 3 and 6 hours after TNF treatment is similar to wild-type mice• onset of mortality following cecal ligation and puncture is delayed and fewer mice die compared to wild-type mice||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2020|Cryopreserved sperm|50.0|0.0|Unknown||NF-kappa B|Yes| 2428.0|H2KK|B6.AK-H2/FlaEgJAnuApb|B6.AK-H2/FlaEgJAnuApb|Recessive|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|||||||||||||||||||||||||||||The H2 complex contains 3 major classes of highly polymorphic gene sets: class I (H2-K, H2-D, Q, H2-T18 genes), class II (H2-I genes), and class III (H2-S genes). These genes are involved in many processes, including graft rejection, immune response, antigen presentation and complement component.||C57BL/6JFlaEg|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Jan-2008|Cryopreserved sperm|25.0|0.0|No||MHC, T cell, antigen presentation, H2|Yes| 7481.0|cpg15 fl|C57BL/6-Nrn1/AnuApb||Dominant|neuritin 1|Nrn1|Normal|0710008J23Rik, cpg15|MGI:1915654|neuritin 1; targeted mutation 1.1, Elly Nedivi|Nrn1|MGI:5307917|13|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Nov-2013|Cryopreserved sperm|61.0|0.0|Unknown||synapse|Yes| 9029.0||B10.BR.(Cg)-Rag1 Tg(CAG-DsRed*MST)1Nagy Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive|recombination activating |Rag1||Rag-1|MGI:97848||||2|||||||||||||||||transgene insertion 1, Andras Nagy|chicken beta actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer|||||||||||Tg mice in which all CD8 T cells express a transgenic TCR recognizing H-2Kb + self peptide and a ubiquitous strong red fluorescence in all cells . Mice have been bred onto a RAG-1 -/- background and have no B cells, no CD4 T cells and no NKT cells). Endogenous alpha and beta TCR chain recombination is also excluded so that all CD8 T cells are naive and express the Tg TCR. DsRed mice (Actb-DsRed.T3 transgenic mice express the red fluorescent protein variant DsRed.MST under the control of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer and may be useful for widespread fluorescent protein expression) were originally on a B6 background and have been backrossed with Des-RAG-/- for more than 10 generations. Mice homozygous for this Actb-DsRed.T3 transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express the red fluorescent protein variant DsRed.MST under the control of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer. All tissues of homozygotes fluoresce red. Mice hemizygous for the transgene express red fluorescent protein less intensely than homozygotes. Expression is observed throughout all embryonic and adult stages and very high expression is found in pancreas, skeletal muscle, heart and seminal vesicle. |Same phenotype as homozygous mice|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jun-2020|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 9029.0||B10.BR.(Cg)-Rag1 Tg(CAG-DsRed*MST)1Nagy Tg(TcraKB5.C20,TcrbKB5.C20)10395Arnd/Apb||Recessive||||||||||||||||||||||||||transgene insertion 10395, Bernd Arnold||||||||||||Tg mice in which all CD8 T cells express a transgenic TCR recognizing H-2Kb + self peptide and a ubiquitous strong red fluorescence in all cells . Mice have been bred onto a RAG-1 -/- background and have no B cells, no CD4 T cells and no NKT cells). Endogenous alpha and beta TCR chain recombination is also excluded so that all CD8 T cells are naive and express the Tg TCR. DsRed mice (Actb-DsRed.T3 transgenic mice express the red fluorescent protein variant DsRed.MST under the control of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer and may be useful for widespread fluorescent protein expression) were originally on a B6 background and have been backrossed with Des-RAG-/- for more than 10 generations. Mice homozygous for this Actb-DsRed.T3 transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express the red fluorescent protein variant DsRed.MST under the control of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer. All tissues of homozygotes fluoresce red. Mice hemizygous for the transgene express red fluorescent protein less intensely than homozygotes. Expression is observed throughout all embryonic and adult stages and very high expression is found in pancreas, skeletal muscle, heart and seminal vesicle. |Same phenotype as homozygous mice|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jun-2020|Cryopreserved sperm|||Unknown|||Yes| 9038.0||c-mpl(tm1Wsa) KO||Recessive|Thrombopoietin receptor |c-mpl|Nil||2660811||||4|ENSMUSG00000022847||||||||||||||||||||||||||||Platelet deficient mice|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Jul-2020|Cryopreserved sperm|55.0|0.0|Unknown||c-Mpl, Thrombopoietin, TPO, Hematopoiesis, Hematopoietic stem cells|No| 8256.0||ASD565:Hummels:F1#14||Recessive|c-mer proto-oncogene tyrosine kinase|Mertk|Unknown|Eyk, Mer, nmf12, Nyk, Tyro 12|MGI:96965||||2|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-May-2017|Cryopreserved sperm|36.0|0.0|Unknown||ENU, CRISPR|Yes| 9037.0|Winnie|B6N;B6JAnu-Muc2/AnuApb||Recessive|mucin 2|Muc2|Nil||MGI:1339364|Winnie|Muc2|MGI:3614806|7|ENSMUSG00000025515|ENSMUST00000026590|Muc2-202|2963|2968|G to A|ENSMUSE00000467940|25|988|Cysteine to Tyrosine|||||GCTGGACCCCTCTTACAAGGGCACTGTATGTGGTCTGTGTGGGAACTTTGATGACCAGACC|Yes|||||||||||||Diarrhoea, soft feces at weaning, some develop rectal prolapse. GIT does not appear inflamed, goblet cell hyperplasia and developmental or functional deficiency - malabsorption syndrome||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|1|1||No|02-Jul-2020|Cryopreserved sperm|101.0|0.0|Unknown||diarrhoea, malabsorption, goblet cell, ENU|Yes| 8553.0|bhlhe40, C65|C57BL/6-Bhlhe40/MarpApb||Recessive|basic helix-loop-helix family, member e40|Bhlhe40|Unknown|Bhlhb2, C130042M06Rik, Clast5, CR8, cytokine response gene 8, DEC1, eip1 (E47 interaction protein 1), Sharp2, Stra13, Stra14|MGI:1097714|Conditional KO|||6|||||||||||||||||||||||||||||unknown|normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Aug-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9047.0|ASD528:B1-8 High Affinity +/-:(Rosa)td Tomato -/- KI|C57BL/6NCrl-Igh:Gt(ROSA)26Sor/APB||Recessive|Immunoglobulin heavy chain complex| Igh |Normal||MGI:96442|Immunoglobulin heavy chain complex; targeted mutation 1, Michel C Nussenzweig|Igh|MGI:3712224|12|||||||||||||||||tdTomato|Gt(ROSA)26Sor|Normal||||||||||These mice carry a tdTomato red fluorescent protein reporter in the Rosa26 locus and thus, ubiquitously express tdTomato throughout their bodies and are visibly red compared to WT littermates. These mice were then crossed to B1-8hi mice, that carry a Trp to Leu point mutation at codon 33 of the heavy chain variable region. When combined to a lambda light chain, the resulting B cell receptor has a 40-fold increase in antigen binding affinity to the hapten NP (4-hydroxy-3-nitrophenylacetyl). Homozygous mice for B1-8hi have around 12% of NP-binding B cells from total splenic B cells.|Heterozygous and homozygous mice have a similar phenotype, although tdTomato cells are less bright in the heterozygous mice.|ASD866:C57BL/6NCrl|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|27-Jul-2020|Cryopreserved sperm|33.0|0.0|Unknown||B Cells, TI-2 responses, (4-hydroxy-3-nitrophenyl)-acetyl , Heavy chain|No| 301.0|MRL-Fas|B6.MRL-Fas/AnuApb||Recessive|Fas (TNF receptor superfamily member)|Fas|Unknown|APO-1, APT1, CD95, Fas, TNFR6, Tnfrsf6|MGI:95484|lymphoproliferation|Fas|MGI:1856334|19||||||||||||||||No|||||||||||||Premature death:median survival is 284 days, compared to 795 days for controls.50% mortality is observed at 13.5 months with 90% mortality at 16 months, significantly reduced from wild-type.64% survival at 24 weeks.Increased double-negative T cell number.Enlarged spleen.Abnormal lymph node morphology:larger lymph nodes often show extensive hemorrhage and necrosis.Enlarged lymph nodes:by 4 months of age, lymph nodes are increased 10- to 20-fold.nodes are 13 times normal size.generalized lymphadenopathy.Increased immunoglobulin level:IgG and IgM levels are increased in serum at 6 monthsDecreased interleukin-2 secretion:defect in Il2 activity begins during early life and worsens with age; spleen cells show no stimulated Il2 production upon stimulation with concanavalin A.Increased autoantibody level:increase in thymocytotoxic autoantibodies at 6 months is seen.mice have elevated levels of anti-chromatin antibodies compared to double mutants.Increased anti-nuclear antigen antibody level:anti-nuclear antibodies are present at 6 months of age.mice have significantly increased levels of anti-ssDNA antibodies.mice have elevated levels of anti-chromatin (anti-nucleosome) antibodies compared to double mutants.Increased anti-double stranded DNA antibody level:antibodies are increased relative to controlsIncreased immature B cell number:plasmablast numbers in spleen are increased relative to wild-type.Increased transitional stage B cell number:higher numbers of T2 B cells in spleen relative to wild-typeIncreased follicular B cell number:higher in spleen relative to wild-type.Increased marginal zone B cell number:higher in spleen relative to wild-type, Fas homozygotes, and Bcl2l11-deficient mice.Abnormal splenic cell ratio:T1:follicular B cell ratio is higher than wild-type or Bcl2l11-deficient mice.Increased splenocyte number:total number of CD19+ splenocytes is higher than wild-typetotal number of splenocytes is increased relative to wild-type.Glomerulonephritis:Immune complex glomerulonephritis develops by 1 year of age but is much milder than in MRL homozygotes.interstitial lymphoid infiltration is observed at 6 months; glomerular IgG deposits that are exclusively mesangial are observed.Abnormal renal glomerulus morphology:nephritic changes consist of focal increase in mesangial substance and mild mesangial proliferation||C57BL/6 x MRL|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-May-2006|Cryopreserved sperm|102.0|0.0|Unknown||B cell, Immunoglobulin, lymphadenopathy, T cell, autoimmunity, glomerulonephritis|Yes| 8300.0|IRF4:1 bp deletion|C57BL/6NCrlAnu-Irf4/Anu||Recessive|interferon regulatory factor 4|Irf4|Unknown|IRF-4, Spip|MGI:1096873|Irf4, endonuclease-mediated mutation 2.1, Australian National University|Irf4||13|ENSMUSG00000021356 |||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|07-Sep-2017|Cryopreserved sperm|45.0|0.0|Unknown|||Yes| 8317.0|CIB1 Transgenic |C57BL/6-Tg(CAG-CIB1)/CcbApb||Dominant||||||||||||||||||||||||||human Calcium and Integrin Binding Protein 1|Chicken Beta actin|||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|03-Oct-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9048.0|BCMA-/-|B6;129S-Tnfrsf17/Apb||Recessive|Tumor necrosis factor receptor superfamily, member 17|TNFrsf17|Nil|CM, BCMA, Tnfrsf13, Tnfrsf13a |MGI:1343050|Tumor necrosis factor receptor superfamily, member 17; targeted mutation 1, Martin L Scott|Tnfrsf17|MGI:2387427|16|||||||||||||||||||||||||||||BCMA-/- mice have a deficiency in long lived plasma cells due to ablated expression of the receptor B cell maturation antigen (BCMA). |BCMA+/- mice are normal|C57BL/6 |Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Jul-2020||0.0|0.0|Unknown||B cell development, B cell survival, lymphoid organs|Possibly| 8291.0|NSG.DQ8.HuPI|NOD.Cg-Prkdc H2-Ab1 Il2rg Ins1 Tg(HLA-DQA1,HLA-DQB1)1Dv ||Recessive|protein kinase, DNA activated, catalytic polypeptide|Prkdc|Unknown|DNAPDcs, DNA-PK, DNA-PKcs, DOXNPH, dxnph, slip, XRCC7|MGI:104779|protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency|Prkdc|MGI:1857113|16|||||||||||||||||transgene insertion 1, Chella David||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Aug-2017|Cryopreserved sperm|50.0|0.0|Unknown||H2, Insulin|No| 8291.0|NSG.DQ8.HuPI|NOD.Cg-Prkdc H2-Ab1 Il2rg Ins1 Tg(HLA-DQA1,HLA-DQB1)1Dv ||Recessive|histocompatibility 2, class II antigen A, beta 1|H2-Ab1|Nil|Abeta, A beta, H-2Ab, H2-Ab, Ia2, Ia-2, IAb, I-Ab, I-Abeta, Rmcs1|MGI:103070|histocompatibility 2, class II antigen A, beta 1; targeted mutation 1, Michael J Grusby|H2-Ab1|MGI:2158420|17|||||||||||||||||||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Aug-2017|Cryopreserved sperm|||Unknown||H2, Insulin|No| 8291.0|NSG.DQ8.HuPI|NOD.Cg-Prkdc H2-Ab1 Il2rg Ins1 Tg(HLA-DQA1,HLA-DQB1)1Dv ||Recessive|interleukin 2 receptor, gamma chain|Il2rg|Nil|CD132, common cytokine receptor gamma chain, common gamma chain, gamma(c), gammaC, gamma C receptor, gc, [g]c|MGI:96551|interleukin 2 receptor, gamma chain; targeted mutation 1, Warren J Leonard|Il2rg|MGI:1857455|X|||||||||||||||||||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Aug-2017|Cryopreserved sperm|||Unknown||H2, Insulin|No| 8291.0|NSG.DQ8.HuPI|NOD.Cg-Prkdc H2-Ab1 Il2rg Ins1 Tg(HLA-DQA1,HLA-DQB1)1Dv ||Recessive|insulin I|Ins1|Nil||MGI:96572||||19|||||||||||||||||||||||||||||Immunocompromised.Expresses HLA-DQ8 and human insulin.|Immunocompromised.Expresses HLA-DQ8 and human insulin.|NOD (NSG)|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Aug-2017|Cryopreserved sperm|||Unknown||H2, Insulin|No| 9061.0|GBPchrom3|B6.Gbp||Recessive|Guanylate binding protein 2|Gbp2 |Reduced||MGI:102772||||3|||||||||||||||||||||||||||||Mice lacking Gbpchr3 were highly susceptible to T. gondii infection, resulting in increased parasite burden in immune organs. Furthermore,Gbpchr3-deleted macrophages were defective in IFN-g-mediated suppression of T. gondii intracellular growth and recruitment of IFN-g-inducible p47GTPase Irgb6 to the parasitophorous vacuole. Gbpchr3 play a pivotal role in anti-T.gondii host defense by controlling IFN-g-mediated Irgb6-dependent cellular innate immunity.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygote x Homozygote|No|18-Aug-2020|Cryopreserved sperm|72.0|0.0|Unknown||Gbp2, Gbp5, IFN-γ, guanylate binding protein , Gbp|No| 9061.0|GBPchrom3|B6.Gbp||Recessive|Guanylate binding protein 2b |Gbp2b|Reduced||||||3|ENSMUSG00000040264|ENSMUST00000029936.4|||||||||||||||||||||||||||Mice lacking Gbpchr3 were highly susceptible to T. gondii infection, resulting in increased parasite burden in immune organs. Furthermore,Gbpchr3-deleted macrophages were defective in IFN-g-mediated suppression of T. gondii intracellular growth and recruitment of IFN-g-inducible p47GTPase Irgb6 to the parasitophorous vacuole. Gbpchr3 play a pivotal role in anti-T.gondii host defense by controlling IFN-g-mediated Irgb6-dependent cellular innate immunity.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygote x Homozygote|No|18-Aug-2020|Cryopreserved sperm|||Unknown||Gbp2, Gbp5, IFN-γ, guanylate binding protein , Gbp|No| 9061.0|GBPchrom3|B6.Gbp||Recessive|Guanylate binding protein 3|Gbp3|Reduced||MGI:1926263||||3|ENSMUSG00000028268|ENSMUST00000106221.7|Gbp3-202||||||||||||||||||||||||||Mice lacking Gbpchr3 were highly susceptible to T. gondii infection, resulting in increased parasite burden in immune organs. Furthermore,Gbpchr3-deleted macrophages were defective in IFN-g-mediated suppression of T. gondii intracellular growth and recruitment of IFN-g-inducible p47GTPase Irgb6 to the parasitophorous vacuole. Gbpchr3 play a pivotal role in anti-T.gondii host defense by controlling IFN-g-mediated Irgb6-dependent cellular innate immunity.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygote x Homozygote|No|18-Aug-2020|Cryopreserved sperm|||Unknown||Gbp2, Gbp5, IFN-γ, guanylate binding protein , Gbp|No| 9061.0|GBPchrom3|B6.Gbp||Recessive|Guanylate binding protein 7|Gbp7|Reduced||MGI:2444421||||3|ENSMUSG00000040253|ENSMUST00000045097.10|Gbp7-201||||||||||||||||||||||||||Mice lacking Gbpchr3 were highly susceptible to T. gondii infection, resulting in increased parasite burden in immune organs. Furthermore,Gbpchr3-deleted macrophages were defective in IFN-g-mediated suppression of T. gondii intracellular growth and recruitment of IFN-g-inducible p47GTPase Irgb6 to the parasitophorous vacuole. Gbpchr3 play a pivotal role in anti-T.gondii host defense by controlling IFN-g-mediated Irgb6-dependent cellular innate immunity.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygote x Homozygote|No|18-Aug-2020|Cryopreserved sperm|||Unknown||Gbp2, Gbp5, IFN-γ, guanylate binding protein , Gbp|No| 9061.0|GBPchrom3|B6.Gbp||Recessive|Guanylate binding protein 5|Gbp5|Reduced||MGI:2429943||||3|ENSMUSG00000105504|ENSMUST00000090127.6|Gbp5-201||||||||||||||||||||||||||Mice lacking Gbpchr3 were highly susceptible to T. gondii infection, resulting in increased parasite burden in immune organs. Furthermore,Gbpchr3-deleted macrophages were defective in IFN-g-mediated suppression of T. gondii intracellular growth and recruitment of IFN-g-inducible p47GTPase Irgb6 to the parasitophorous vacuole. Gbpchr3 play a pivotal role in anti-T.gondii host defense by controlling IFN-g-mediated Irgb6-dependent cellular innate immunity.|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Homozygote x Homozygote|No|18-Aug-2020|Cryopreserved sperm|||Unknown||Gbp2, Gbp5, IFN-γ, guanylate binding protein , Gbp|No| 4452.0|BALB/c.B6 TLR-4tm1 ; Billy Whiz|BALB/c-Tlr4/AnuApb||Recessive|toll-like receptor 4|Tlr4|Nil|lipopolysaccharide response, Lps, Rasl2-8|MGI:96824|toll-like receptor 4; targeted mutation 1, Shizuo Akira|Tlr4|MGI:1860885|4||||||||||||||||Yes|||||||||||||Homozygotes for spontaneous or targeted mutations are hyporesponsive to bacterial lipopolysaccharide and more susceptible to infection by gram negative bacteria.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|20-Feb-2009|Cryopreserved sperm|115.0|0.0|Unknown||infection, lipopolysaccharide (LPS), bacterial infection, hyoresponse, macrophage|Yes| 9041.0|Asciz Mb-1 Dynll1|Atmin Cd79 Dynll1||Recessive|ATM interactor|Atmin |Reduced|Asciz, gpg6, MGC:79206, mKIAA0431 |MGI:2682328|ATM interactor; targeted mutation 1.2, Jorg Heierhorst|Atmin|MGI:5463937|8|||||||||||||||||CD79A antigen (immunoglobulin-associated alpha); targeted mutation 1, Michael Reth|Cd79a|Unknown||||||||||Severe reduction of B cell numbers (in Asciz f/f Mb1-Cre Ki/+ Dynll1 f/f conditional cKO mice)|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Jul-2020|Cryopreserved sperm|50.0|0.0|Unknown||B cell development, Adaptive and innate B cells, Lymphoid cells|Possibly| 9041.0|Asciz Mb-1 Dynll1|Atmin Cd79 Dynll1||Recessive|Dynein light chain LC8-type 1|Dynll1 ||8kDa LC, DLC8, Dnclc1, Pin|MGI:1861457|Dynein light chain LC8-type 1; targeted mutation 1.1, Jorg Heierhorst|Dynll1|MGI:5755433|5|||||||||||||||||||||||||||||Severe reduction of B cell numbers (in Asciz f/f Mb1-Cre Ki/+ Dynll1 f/f conditional cKO mice)|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Jul-2020|Cryopreserved sperm|||Unknown||B cell development, Adaptive and innate B cells, Lymphoid cells|Possibly| 9064.0|Galanin receptor-3 knockout|C57BL/6J-Galr3/Apb||Recessive|Galanin receptor 3|Galnr3|Reduced||MGI:1329003 |galanin receptor 3; targeted mutation 1, Lexicon Genetics|Galr3|MGI:3528737|15|||||||||||||||||||||||||||||Increased anxiety-like behaviour and preference for alcohol over water.|Normal.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Aug-2020|Cryopreserved sperm|50.0|0.0|Unknown||Depression , Anxiety disorders, Neuropeptides, Stress-related diseases, Mood disorders|No| 9065.0|ENU49:B3galt4|ANU:ENU49:084:B3galt4||Recessive|Unknown||||||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Aug-2020|Cryopreserved sperm|55.0|0.0|Unknown||ENU, Random, Mutagenesis, Screen|Yes| 7015.0|ENU21:035:a:B6:G3|ANU:ENU21:035:a:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|06-Jul-2012|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 7940.0|ENU30:045:B6|C57BL/6NCrlAnu-Rasgrp1/AnuApb||Recessive|RAS guanyl releasing protein 1|rasgrp1|Unknown||MGI:1314635|Rasgrp1; mutation 2, Australian National University|Rasgrp1||2|ENSMUSG00000027347|ENSMUST00000102534|Rasgrp1-001|1473|1785|T to C|ENSMUSE00000295156|12|498|Isoleucine to Valine|||||||||||||||||||Increased CD44 expression on CD4 T cells|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|39.0|0.0|Unknown||T cell, ENU|Yes| 8583.0|ASD546:Cazorla|C57BL/6NCrlAnu-Blk/AnuApb||Recessive|B lymphoid kinase|Blk|Unknown||MGI:88169|Blk, endonuclease-mediated mutation 1, Australian National University |Blk||14||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Oct-2018|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 9070.0|Myostatin KO|BALB/c-Mstn/APB||Recessive|Myostatin|Mstn|Reduced|Gdf8|MGI:95691|myostatin; targeted mutation 1, Se-Jin Lee|Mstntm1Sjl|MGI:2148177|1|NCBI Gene: 17700||||||||||||||||||||||||||||Increased muscle mass|Increased muscle mass|BALB/c|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Sep-2020|Cryopreserved sperm|50.0|0.0|Unknown|||No| 9071.0|FXYD1 KO|B6;129S-Fxyd1/APB||Recessive|FXYD domain-containing ion transport regulator 1|Fxyd1 |Reduced|0610012C17Rik, 1110006M24Rik, phospholemman, PLM, PML |MGI:1889273 |FXYD domain-containing ion transport regulator 1; targeted mutation 1, Amy L Tucker|Fxyd1|MGI:3576231|7||||||||||||||||||||FXYD domain-containing ion transport regulator 1|Fxyd1 ||0610012C17Rik, 1110006M24Rik, phospholemman, PLM, PML |MGI:1889273|FXYD domain-containing ion transport regulator 1; targeted mutation 1, Amy L Tucker|Fxyd1|MGI:3576231|7|Hypertrophy, increased ejection fraction, and reduced Na-K-ATPase activity|unknown|C57BL/6N|Yes|Yes|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Sep-2020|Cryopreserved sperm|50.0|0.0|Unknown||Hypertrophy, Ejection fraction, Phospholemman, Ion channel, Na-K-ATPase|Possibly| 8582.0|ASD874:Whopper:F0|C57BL/6NCrlAnu-Irf7/AnuApb||Recessive|interferon regulatory factor 7|Irf7|Unknown||MGI:1859212|Irf7, endonuclease-mediated mutation 1, Australian National University |Irf7||7||||||||||Unknown to Unknown|||||||||||||||||||Normal |Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Oct-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8558.0|ASD891:Sorghum|C57BL/6NCrlAnu-Nlrp9a/AnuApb||Recessive|NLR family, pyrin domain containing 9A|Nlrp9a|Unknown|D7Ertd565e, Nalp9a, Nalp-theta|MGI:2675292|Nlrp9a, endonuclease-mediated mutation 1, Australian National University |Nlrp9a||7||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Sep-2018|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 4508.0|ENU7B6:071|C57BL/6JAnu-Ltb/AnuApb||Recessive|lymphotoxin B|Ltb||LTbeta, lymphotoxin beta, p33, Tnfc, Tnfsf3|MGI:104796||Ltb||17|ENSMUSG00000024399|ENSMUST00000025262|Ltb-001|623|706|G to A|ENSMUSE00000930622|3|208|Arginine to Lysine|||||CTATTACCTCTACTGCCACGTCGGGTACAGGGGCAGGACGCCCCCTGCCGGCCGAAGCCGT|Yes|||||||||||||Defective antibody response to immunization: failure to mount a normal Th1 polarized IgG2c antibody response to heat killed B pertussis bacteria. |||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|26-Feb-2009|Cryopreserved sperm|83.0|0.0|Unknown||B cell, antibody, immunization, ENU, Wellcome Trust|Yes| 8223.0|Enu32:025:Tmem2|C57BL/6NCrlAnu-Cemip2/AnuApb||Recessive|cell migration inducing hyaluronidase 2|Cemip2|Unknown|3110012M15Rik, mKIAA1412, Tmem2|MGI:1890373|mutation 1, Australian National University|Cemip2||19|ENSMUSG00000024754|ENSMUST00000096194.8|Tmem2-202||||||||21811978|9|||TCACCGTGCACGGGACCAGTGGCTTGCTAGTAAGTAGCCTCACCTTGTGTTGACATGCAG||||||||||||||Embryonic lethal. Embryos die before E14.|Unknown|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|21-Mar-2017|Cryopreserved sperm|33.0|0.0|Unknown||embryonic lethal|Yes| 7855.0|ENU31:049|C57BL/6NCrlANu-Blnk/AnuApb||Recessive|B cell linker|Blnk|Unknown|BASH, Bca, BCA, BLNK, Ly57, Ly-57, SLP-65|MGI:96878|mutation 1, Australian National University|Blnk||19|ENSMUSG00000061132|ENSMUST00000054769|Blnk-001|1197|1674|A to G|ENSMUSE00000519585|16|399|Valine to Alanine|||||||||||||||||||High IgM expression on mature B cells||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Mar-2015|Cryopreserved sperm|55.0|0.0|Unknown||B cell, IgM|Yes| 7371.0|ENU26:044:G6pc:B6:G2|C57BL/6NCrlAnu-G6pc/AnuApb||Recessive|glucose-6-phosphatase, catalytic|G6pc|Unknown|G6Pase, G6pt, Glc-6-Pase, Glc-6-Pase-alpha|MGI:95607|mutation 1, The Australian National University|G6pc||11|ENSMUSG00000078650|ENSMUST00000019469|G6pc-001|248|484|G to T|ENSMUSE00000113003|2|83|Arginine to Leucine|||||CGTCTTCAAGTGGATTCTGTTTGGACAACGCCCGTATTGGTGGGTCCTGGACACCGACTAC||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jul-2013|Cryopreserved sperm|55.0|0.0|Unknown||ENU|Yes| 7734.0|ENU24:043 - CD4|C57BL/6NCrlAnu-Cd4/AnuApb||Recessive|CD4 antigen|Cd4||L3T4, Ly-4|MGI:88335|mutation 1, Australian National University|Cd4||6|||||||||||||||||||||||||||||defective upregulation of CD4 expression during T cell development||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Sep-2014|Cryopreserved sperm|52.0|0.0|Unknown|||Yes| 7854.0|ENU27:041:Card11|C57BL/6NCrlAnu-Card11/AnuApb||Recessive|caspase recruitment domain family, member 1|Card11|Unknown|0610008L17Rik, 2410011D02Rik, BIMP3, CARMA1|MGI:1916978|mutation 1, Australian National University|Card11||5|ENSMUSG00000036526|ENSMUST00000085786|Card11-201|1093|1414|A to T|ENSMUSE00000431469|8|365|Methionine to Lysine|||||GGAAGGACTGTGAAATGTACAAGCACCGCATGAACACAGTTATGCTGCAGCTGGAGGAGGT||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Mar-2015|Cryopreserved sperm|33.0|0.0|Unknown||ENU|Possibly| 8681.0|Dicer del|B6.129-Dicer1/WehiAnuApb||Recessive|dicer 1, ribonuclease type III|Dicer1|||MGI:2177178|dicer 1, ribonuclease type III; targeted mutation 1.1, Brian D Harfe|Dicer1|MGI:3589209|12|||||||||||||||||||||||||||||Embryonic growth arrest:• homozygous embryos arrest at E7.5||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Mar-2019|Cryopreserved sperm|53.0|0.0|Unknown||microRNA|Yes| 8717.0|Pfn1 KO|BALB/c-Pfr1/SdzApb||Recessive|perforin 1 (pore forming protein)|Prf1|Nil|perforin, Pfn, Pfp, Prf-1|MGI:97551|perforin 1 (pore forming protein); targeted mutation 1, Sandoz Pharmaceuticals|Prf1|MGI:1857235|10|||||||||||||||||||||||||||||These mice breed and develop normally. Loss of this gene has no significant effect on the immune function of these mice.There is a high susceptibility to ectromelia virus. Aged mice are susceptible to tumour growth.|Normal|BALB/c (H-2Kd)|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-May-2019|Cryopreserved sperm|50.0|0.0|Unknown||T cell, CD8|Yes| 142.0|Plexin B2|STOCK Plxnb2/AnuApb||Recessive|plexin B2|Plxnb2|Unknown|Debt|MGI:2154239|plexin B2; targeted mutation 1, Marc Tessier-Lavigne|Plxnb2|MGI:3620317|15||||||||||||||||Yes|||||||||||||Homozygotes for a targeted mutation of this gene die perinatally of exencephaly or survive and seem normal despite severe abnormalities in cerebellar layering and foliation; the external granule cell layer is disorganized due to continued proliferation and migration of differentiated granule cells. Survivors among mutant mice of a mixed, partly (outbred) CD-1 background behave normally and even breed, although their cerebellar architecture is severly disrupted.||CD1|Yes|No|Yes|Yes|No|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|105.0|0.0|No||Cerebellar granule cells, Pukinje, transmembrane receptor, differentiation, progenitor|Yes| 8706.0|Pedro:PR36 SJ|C57BL/6-Prdm1/AnuApb||Recessive|PR domain containing 1, with ZNF domain|Prdm1|Unknown|b2b1765Clo, Blimp1, Blimp-1, PRDI-BF1|MGI:99655|Prdm1, endonuclease-mediated mutation 3, Australian National University|Prdm1||10||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-May-2019|Cryopreserved sperm|36.0|0.0|Unknown|||Yes| 8566.0|ASD949:PKR big del:EIF2AK2|C57BL/6NCrlAnu-Eif2ak2/AnuApb||Recessive|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|Unknown|2310047A08Rik, 4732414G15Rik, dsRNA-activated kinase, eIF-2 alpha, eIF-2 alpha, IFN-induced and double-stranded RNA-activated kinase, IFN- type I-induced and dsRNA-activated kinase, Pkr, Prkr, Tik|MGI:1353449|Eif2ak2, endonuclease-mediated mutation 2, Australian National University |Eif2ak2||17||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Sep-2018|Cryopreserved sperm|53.0|0.0|Unknown|||Yes| 8579.0|Tweak KO/C57BL/6 |C57BL/6-Tnfsf12/Apb||Recessive|tumor necrosis factor (ligand) superfamily, member 12|Tnfsf12||APO3L, DR3L, Tweak|MGI:1196259||||11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Oct-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7945.0|Elane KO|B6.129X1-Elane/J||Recessive|elastase, neutrophil expressed|Elane||Ela2, F430011M15Rik, NE, neutrophil elastase|MGI:2679229|elastase, neutrophil expressed; targeted mutation 1, Steven D Shapiro|Elane|MGI:2182771|10|||||||||||||||||||||||||||||Abnormal neutrophil physiology:• despite normal neutrophil recruitment, recognition and binding, neutrophils fail to degrade phagocytosed Klebsiella pneumoniae or Escherichia coli unlike in wild-type micedecreased susceptibility to bacterial infection induced Morbidity/mortality• mice are less susceptible to death induced by Gram positive Staphylococcus aureus infection compared to wild-type miceIncreased susceptibility to bacterial infection:• mice appear clinically worse than wild-type mice following infection with Gram negative Klebsiella pneumoniae or Escherichia coli• when infected with Klebsiella pneumoniae, mice exhibit signs of severe infection including ruffled fur, hunched posture, impaired ambulation and diarrhea unlike wild-type mice• despite normal neutrophil recruitment, recognition and binding, bacterial burden is greater than in wild-type mice following infection with Klebsiella pneumoniaeIncreased susceptibility to bacterial infection induced morbidity/mortality:• at 16 hours following infection with Gram negative Klebsiella pneumoniae, 50% of mice are dead unlike wild-type mice that do not display mortality due to infection at 16 hours• at 48 hours following infection with Klebsiella pneumoniae, all mice are dead unlike wild-type mice that display 50% mortalityDecreased physiological sensitivity to xenobiotic:• mice exhibit 59% protection from emphysema induced by a 6 month cigarette smoke exposure• following a 6 month exposure to cigarette smoke, mice exhibit fewer neutrophils and 60% less macrophages in bronchoalveolar lavage samples compared to wild-type mice||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Jul-2015|Cryopreserved sperm|78.0|0.0|Unknown||Infection, Proteinase, Neutrophil|Yes| 8134.0|ROSA-Cas9|B6J.129(B6N)-Gt(ROSA)26Sor/J||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Normal|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1.1, Feng Zhang|Gt(ROSA)26Sor|MGI:5583838|6|||||||||||||||||||||||||||||Normal||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Nov-2016|Cryopreserved sperm|59.0|0.0|Unknown||CRISPR, Cas9|Yes| 8735.0|ASD976:Gomez:2:N1|C57BL/6NCrlAnu-Ryr2/AnuApb||Recessive|ryanodine receptor 2, cardiac|Ryr2|Unknown|9330127I20Rik|MGI:99685|Ryr2, endonuclease-mediated mutation 3, Australian National University|Ryr2||13||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|19-Jun-2019|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 9052.0|cCblA/+|C57BL/6 x 129SvJ-Cbl/APB||Recessive|Casitas B-lineage lymphoma|Cbl |Normal|4732447J05Rik, Cbl-2, c-Cbl|MGI:88279|Casitas B-lineage lymphoma; targeted mutation 2, Wallace Y Langdon|Cbl|MGI:3610727|9|||||||||||||||||||||||||||||A point mutation resulted in a cysteine to alanine substitution at position 379 (C379A). Western blot showed that protein levels in thymocytes were not affected by the mutation.Homozygous rarely viable|Heterozygous animals develop myeloproliferative disease (exacerbated by cross to null allele)|C57Bl/6 x 129SvJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Aug-2020|Cryopreserved sperm|40.0|0.0|Unknown||T-cell receptor, c-Cbl, Thymus, p85, PI 3-kinase|No| 9087.0|GABRB3.D120N|C57BL/6J-Gabrb3/Nathan Absalom||Semi-dominant|gamma-aminobutyric acid (GABA) A receptor, subunit beta 3|GABRB3|Unknown|A230092K12Rik, beta3, Gabrb-3|MGI:95621|endonuclease mediated targeting 1; Nathan Absalom|Gabrb3||7||||||||||Unknown to Unknown|||||||||||||||||||Unknown, likely lethal.|Febrile seizures, behavioural abnormalities expected|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|23-Sep-2020||0.0|0.0|Unknown|||Possibly| 9091.0||C57Bl/6N-ENU48:196:Tlr4||Semi-dominant|Tlr4||||||||Unknown|||||||||||||||||||||||||||||||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Nov-2020|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 9088.0|C1ra null|C57Bl/6J-C1ra/Apb||Recessive|Complement 1 receptor a|Cr1a|||MGI:1355313| C57BL/6J (C1ra)|||6|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Oct-2020|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 8605.0|Cldn10 KO|C57BL/6-Cldn10/MarpApb||Recessive|claudin 10|Cldn10||6720456I16Rik, Cldn10a, Cldn10b, D14Ertd728e|MGI:1913101||||14|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|14-Nov-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8594.0|Katnal2 Y86C|C57BL/6-Katnal2/MarpApb||Recessive|katanin p60 subunit A-like 2|Katnal2||3110023G01Rik, 4933439B08Rik|MGI:1924234||Katnal2||18||||||||||Unknown to Unknown|||||||||||||||||||Male infertility |Normal|C57BL/6J|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|30-Oct-2018|Cryopreserved sperm|50.0|0.0|Unknown||infertility, sperm|Yes| 8613.0|ASD661:Pique:10|C57BL/6NCrlAnu-Zfr2/AnuApb||Recessive|zinc finger RNA binding protein 2|Zfr2|Unknown|2010013I23Rik, 9130206N08Rik|MGI:2143792|Zfr2, endonuclease-mediated mutation 1, Australian National University|Zfr2||10||||||||||Unknown to Unknown|||||||||||||||||||Unknown at this stage||C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|Poor||||No|21-Nov-2018|Cryopreserved sperm|12.0|0.0|Unknown||CRISPR|Yes| 9092.0|Met-K|B10.BR-Met-H2-K/APB||Dominant|Major histocompatibility-2, MHC; b variant|H-2Kb|||MGI:3579319|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17||||||||||Unknown to Unknown|||||||Major histocompatibility-2, MHC; b variant|sheep metallothionein promoter|||||||||||These transgenic mice have a normal phenotype but express a transgenic H-2Kb MHC I molecule in hepatocytes under the control of the sheep metallothionein promoter. These transgenic mice were originally bred onto a B10.BR background and have been bred for more than 10 generations onto an H-2Kbm1 background. |Same as homozygous mice |H-2Kbm1|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Nov-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8618.0|ASD696:Thunderbird:19del|C57BL/6NCrlAnu-Ifne/AnuApb||Recessive|interferon epsilon|Ifne|Unknown|Ifne1, Ifnt1|MGI:2667156|Ifne, endonuclease-mediated mutation 1, Australian National University|Ifne||4||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Dec-2018|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8617.0|ASD869:IRAK2:S47Y|C57BL/6NCrlAnu-Irak2/AnuApb||Recessive|interleukin-1 receptor-associated kinase 2|Irak2|Unknown|6330415L08Rik, IRAK-2, Irak2a, Irak2b, Irak2c, Irak2d|MGI:2429603|Irak2, endonuclease-mediated mutation 1, Australian National University|Irak2||6||||||C to A||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|05-Dec-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 9054.0|R26-LSL-Adar1p150|C57BL/6-Gt(ROSA)26Sor/CwaApb ||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Increased|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||Gt(ROSA)26Sor||6|||||||||||||||||Adar1p150-ires-GFP|R26 endogenous|Moderate to low||||||||||normal - lox-stop-lox Adar1p150 only expressed after Cre|normal - lox-stop-lox Adar1p150 only expressed after Cre|C57Bl/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown||Unknown|No|06-Aug-2020|Cryopreserved sperm|40.0|0.0|Unknown||Adenosine Deaminase RNA specific, RNA , Dyschromatosis symmetrica hereditaria|No| 8630.0|LIMK2|C57BL/6-Link2||Recessive|LIM motif-containing protein kinase 2|Limk2|Reduced|A930024P04Rik, Limk2a, Limk2b, LIM kinase 2, whe|MGI:1197517||||11|||||||||||||||||||||||||||||Normal|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Dec-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8612.0|ENU41:076:Gsdmd|C57BL/6NCrlAnu-Gsdmd/AnuApb||Recessive|gasdermin D|Gsdmd|Unknown|1810036L03Rik, DF5L, Dfna5l, Gsdmdc1, M2-4|MGI:1916396|Gsdmd; mutation 2, Australian National University|Gsdmd||15||||||||||Unknown to Unknown||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||1||No|21-Nov-2018|Cryopreserved sperm|60.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 9103.0|ENU29:Areg|C57BL/6NCrlAnu-Areg/AnuApb||Recessive|Amphiregulin|Areg|Unknown|AR, Mcub, Sdgf |MGI:88068|Areg; mutation 2, Australian National University|Areg||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||1||No|03-Dec-2020||0.0|0.0|Unknown||ENU, Mutagenesis, Mammary Glad|Yes| 9102.0|C57Bl/6-Mstn-/-|B6N.129-Mstn||Recessive|Myostatin|Mstn|Reduced|Gdf8|MGI:95691|Mstn||MGI:3790519|1||||||||||||||||||||Myostatin|Mstn ||Gdf8 |95691||||1|Hyperplasia and hypertrophy of muscle tissues.|Mild hyperplasia and hypertrophy of muscle tissues.|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Nov-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9098.0|CD8 Cre|Tg(ECD-CACG-Cre)||Semi-dominant|CD8 Cre||||||||Unknown|||||||||||||||||CD8 Cre|CAGG|Unknown||||||||||Normal|Normal|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Nov-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8642.0|WHIP.Ly5.1|C57BL/6-Tg(TcraHsv,TcrabHsv)/Cbn||Dominant||||||||||||||||||||||||||transgene insertion||||||||||||Normal; Majority of CD4 T cells are specific for gD peptide 290-302 from HSV-1.|Normal |C57BL/6 |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown||T cell, HSV|Yes| 8645.0|p60 KO|C57BL/6N-Katna1/MarpApb||Recessive|katanin p60 (ATPase-containing) subunit A1|Katna1|Nil|http://www.informatics.jax.org/marker/MGI:1344353|MGI:1344353|katanin p60 subunit A-like 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Katna1|MGI:4458514|10|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6N|No|No|Yes|No|No|Yes|No|Unknown||||No|24-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8644.0|p60 flox|C57BL/6N-Katna1/MarpApb||Recessive|katanin p60 (ATPase-containing) subunit A1|Katna1|Nil||MGI:1344353|katanin p60 (ATPase-containing) subunit A1; targeted mutation 1c, Wellcome Trust Sanger Institute|Katna1||10||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6N|No|No|Yes|No|No|Yes|No|Unknown||||No|24-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown||Spermatogenesis|Yes| 8652.0|PKHD1 KO|C57BL/6-Pkhd1/SmyMarp||Recessive|polycystic kidney and hepatic disease 1|Pkhd1||FPC, tigmin|MGI:2155808||||1|||||||||||||||||||||||||||||unknown|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8023.0|LysMcre|B6.129P2-Lyz2/JAusbAnu||Dominant|lysozyme 2|Lyz2|Normal|Lys, Lysm, Lyzs, Lzm, Lzm-s1, Lzp|MGI:96897|lysozyme 2; targeted mutation 1, Irmgard Forster|Lyz2|MGI:1934631|10|||||||||||||||||||||||||||||Unknown|Enlarged spleen:*Rare|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|16-Feb-2016|Cryopreserved sperm|44.0|0.0|Unknown||Macrophage, Granulocyte, Conditional mutagenesis|Yes| 8656.0|LMR|B6.Cg-Msh2 Rag1 Tg(IgkHyHEL10)1Rbr/Cjo||Recessive|mutS homolog 2|Msh2|||MGI:101816||||17|||||||||||||||||transgene insertion 1, Robert Brink||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8656.0|LMR|B6.Cg-Msh2 Rag1 Tg(IgkHyHEL10)1Rbr/Cjo||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, David Baltimore|Rag1|MGI:2448994|2|||||||||||||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 8658.0|S25HR|B6(Cg)-Igh Rag1 Samhd1/Cjo||Recessive|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Robert Brink|Igh|MGI:3800383|12|||||||||||||||||||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8658.0|S25HR|B6(Cg)-Igh Rag1 Samhd1/Cjo||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 8658.0|S25HR|B6(Cg)-Igh Rag1 Samhd1/Cjo||Recessive|SAM domain and HD domain, 1|Samhd1||E330031J07Rik|MGI:1927468||||2|||||||||||||||||||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 8659.0|S41LR|B6(Cg)-Rag1 Samhd1 Tg(IgkHyHEL10)1Rbr/Cjo||Recessive|recombination activating gene 1|Rag1||Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||transgene insertion 1, Robert Brink||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8659.0|S41LR|B6(Cg)-Rag1 Samhd1 Tg(IgkHyHEL10)1Rbr/Cjo||Recessive|SAM domain and HD domain, 1|Samhd1||E330031J07Rik|MGI:1927468||||2|||||||||||||||||||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|||Unknown|||Yes| 9116.0|Myl9 fl/fl|C57Bl/6-Myl9/AnuApb||Semi-dominant|myosin, light polypeptide 9, regulatory|Myl9|||MGI:2138915|myosin, light polypeptide 9, regulatory; targeted mutation 1c, Wellcome Trust Sanger Institute|Myl9||2||||||||||Unknown to Unknown|||||||||||||||||||Wildtype|Wildtype|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Jan-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9117.0|Coro2a|C57BL/6-Coro2a||Semi-dominant|coronin, actin binding protein 2A|Coro2a||9030208C03Rik, coronin 4, IR10 |MGI:1345966|coronin, actin binding protein 2A; targeted mutation 1, Wellcome Trust Sanger Institute|Coro2a|MGI:4364905|4||||||||||Unknown to Unknown|||||||||||||||||||Minor alterations in T cell development, but essentially wildtype|Wildtype|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Jan-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8633.0|Katnal2 Flox|C57BL/6N-Katnal2/MarpApb||Recessive|katanin p60 subunit A-like 2|Katnal2||3110023G01Rik, 4933439B08Rik|MGI:1924234|katanin p60 subunit A-like 2; targeted mutation 1c, Wellcome Trust Sanger Institute|Katnal2|MGI:6164199|18|||||||||||||||||||||||||||||Normal|Normal|C57/BL6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Jan-2019|Cryopreserved sperm|50.0|0.0|Unknown||spermatogenesis|Yes| 8657.0|P18.B6|C57BL/6JAusb-Ipo4/Cjo||Recessive|importin 4|Ipo4||8430408O15Rik|MGI:1923001||||14|||||||||||||||||||||||||||||Unknown||C57BL/6JAusb|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8653.0|HRGKO|C57BL/6-Hrg||Recessive|histidine-rich glycoprotein|Hrg|Nil|D16JH2, D18020|MGI:2146636|HRG|||16|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9119.0|ASD1069:Rudolph:AD94|C57BL/6NCrlAnu-Adal/AnuApb||Semi-dominant|adenosine deaminase-like|Adal|||MGI:1923144|Adal; endonuclease-mediated mutation 1, Australian National University|AdalAnu||2|ENSMUSG00000027259 |||||||||Unknown to Unknown|||||||||||||||||||Undetermined|Undetermined|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jan-2021|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 8667.0|Haao knockout|C57BL/6J-Haao/Dunw||Recessive|3-hydroxyanthranilate 3,4-dioxygenase|Haao||0610007K21Rik, 0610012J07Rik, 3HAO, 3-HAO, 3-HAOxase|MGI:1349444||||17|||||||||||||||||||||||||||||Mice homozygous for a knock-out allele exhibit reduced LPS-induced depressive behaviors and altered kynurenine metabolism.|Normal|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9137.0|MG37_Satb2_chr1_TWAR_5|C57BL/6-MG37-Satb2(chr1-TWAR-5)/Apb||Recessive|special AT-rich sequence binding protein 2|Satb2|||MGI:2679336||||1||||||||||Unknown to Unknown|||||||transgenic lacZ|minimal promoter hsp68, chr1_TWAR_6 (thylacine)|||||||||||Normal|Normal|C57BL6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Jan-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9138.0|G10flox|C57BL/6J-G10flox/Apb||Semi-dominant|Grb10||||||||Unknown|||||||||||||||||||||||||||||normal|normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Feb-2021||0.0|0.0|Unknown|||Possibly| 8661.0|Nmnat2 knockout|C57BL/6J-Nmnat2/Dunw||Recessive|nicotinamide nucleotide adenylyltransferase 2|Nmnat2||D030041I09Rik, mKIAA0479, PNAT1|MGI:2444155||||1|||||||||||||||||||||||||||||Perinatal lethality, neuromuscular malformations,lack of functional organ and muscle innervation, distended bladder|Normal|C57BL/6J|No|No|Yes|No|No|Yes|No|Unknown||||No|25-Feb-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8662.0|CCDC112KO|C57BL/6J-Ccdc112/MkobMarp||Recessive|coiled-coil domain containing 112|Ccdc112||8430438M01Rik|MGI:1918800||||18|||||||||||||||||||||||||||||Males are infertile, females are normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|26-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown||spermatogenesis|Yes| 8675.0|Fcho2|C57BL/6NCrlAnu-Fcho2/AnuApb||Recessive|FCH domain only 2|Fcho2|Unknown|5832424M12Rik|MGI:3505790|Fcho2, endonuclease-mediated mutation 1, Australian National University|Fcho2||13||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|12-Mar-2019|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 6417.0|GRB7Δ|B6.CBA-Grb7/Ausb||Recessive|growth factor receptor bound protein 7|Grb7|Unknown||MGI:102683||||11|||||||||||||||||||||||||||||Cell metastasis||C57BL/6 x CBA|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-Sep-2011|Embryo|0.0|0.0|Unknown|||Possibly| 6416.0|G14Δ|B6.129SV-Grb14/Ausb||Dominant|growth factor receptor bound protein 14|Grb14|Normal||MGI:1355324|growth factor receptor bound protein 14; targeted mutation 1, Roger J Daly|Grb14|MGI:3029164|2|||||||||||||||||||||||||||||Improved glucose tolerance:*Males exhibit increased glucose tolerance between 16 and 24 weeks of age.*Circulating level of insulin is lower in males in response to the same glucose load.*Males exhibit an increase in glucose incorporation into tissue glycogen.Increased insulin sensitivity:*Decrease in blood glucose than wild-type males.*Fasting plasma insulin levels in males are lower at 28-30 and 54-56 weeks of age.*Male skeletal muscle and liver exhibits enhanced insulin-induced glucose uptake.Increased heart weight:*28 week old males exhibit an 18% increase in heart weight.Decreased body weight:*Small but significant decrease in body weight for both males (5-10%) and females (5%).Decreased spleen weight:*28 week old males exhibit a disproportionate decrease (29%) in spleen weight.Decreased liver weight:*28 week old males exhibit a disproportionate decrease (16%) in liver weight.||B6/129SV|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Sep-2011||0.0|0.0|Unknown||Growth factor receptor-bound (Grb)14, Insulin receptor (IR), Tyrosine phosphorylation|Yes| 7697.0|IFNe 202 flp<#65>(FF)|C57BL/6-Ifne/MarpApb||Recessive|Interferon epsilon|Ifne|Normal|Ifne1, Ifnt1 |MGI:2667156|interferon epsilon; targeted mutation 1.1, Paul J Hertzog|Ifne|MGI:5503221|4|||||||||||||||||||||||||||||Normal wild-type|Normal wild-type|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-Jun-2014|Cryopreserved sperm|48.0|0.0|Unknown||interferon, receptor, infection|No| 9150.0|Dmd null|BALB/c.mdx62||Semi-dominant|dystrophin, muscular dystrophy|Dmd||Duchenne muscular dystrophy, dys, mdx, pke, X-linked muscular dystrophy|MGI:94909|dystrophin, muscular dystrophy; endonuclease-mediated mutation 1, Walter and Eliza Hall Institute of Medical Research|Dmd|MGI:7865766|X|ENSMUSG00000045103|ENSMUST00000114000||||||||Unknown to Unknown|||||||||||||||||||Progressive skeletal muscle wasting characterised by degeneration/regeneration of skeletal musculature. Lifespan not characterised but at least 12 months.|Unknown.||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Feb-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6414.0|G10Δ|B6.CBA-Grb10/Ausb||Recessive|growth factor receptor bound protein 10|Grb10|Nil|5730571D09Rik, maternally expressed gene 1, Meg1, mKIAA0207|MGI:103232|growth factor receptor bound protein 10; gene trap 1, Andrew Ward|Grb10|MGI:2668436|11|||||||||||||||||||||||||||||Enlarged placenta:*The size of the placenta was also increased ~30% relative to wild-type.Increased birth body size:*Neonates are ~30% larger than wild-type.Increased fetal size:*Embryonic overgrowth resulting in neonates that are ~30% larger than wild-type.Enlarged liver:*Disproportionate overgrowth of the liver.|Partial perinatal lethality:*Approximately 12% of mice with a maternally inherited allele die shortly after birth.Paternal imprinting:*Only heterozygotes inheriting the allele from the mother display a phenotype.Enlarged placenta:*The size of the placenta is increased ~30% relative to wild-type.Increased birth body size:*Neonates are ~30% larger than wild-type.Increased fetal size:*Embryonic overgrowth resulting in neonates that are ~30% larger than wild-type.Enlarged liver:Disproportionate overgrowth of the liver.Increased glycogen level:*Hepatocytes have a very high glycogen content.Abnormal pulmonary alveolus morphology:*Mice that die shortly after birth exhibit blood-filled alveoli.Abnormal trachea morphology:*Mice that die shortly after birth exhibit a blood-filled trachea.|CBA/B6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Sep-2011||0.0|0.0|Unknown||Grb10 adapter protein, Gene trap|Yes| 819.0|Grb10 KO x Grb14 KO|C57BL/6-Grb10 Grb14||Recessive|growth factor receptor bound protein 10|Grb10|Nil|5730571D09Rik, maternally expressed gene 1, Meg1, mKIAA0207|MGI:103232|gene trap 1, Andrew Ward|Grb10|MGI:2668436|11||||||||||||||||Yes|||||||||||||Double KOs do not show increased insulin signalling over single KOs.Compound KOs exhibit an increase in lean mass.Compound KOs are protected from impaired glucose tolerance that results from high-fat diet whereas sible KOs are not protected.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-May-2007||0.0|0.0|Unknown||insulin, receptor, phosphorylation, kinase|Yes| 819.0|Grb10 KO x Grb14 KO|C57BL/6-Grb10 Grb14||Recessive|growth factor receptor bound protein 14|Grb14|Nil||MGI:1355324|targeted mutation 1, Roger J Daly|Grb14|MGI:3029164|2|||||||||||||||||||||||||||||Double KOs do not show increased insulin signalling over single KOs.Compound KOs exhibit an increase in lean mass.Compound KOs are protected from impaired glucose tolerance that results from high-fat diet whereas sible KOs are not protected.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-May-2007||||Unknown||insulin, receptor, phosphorylation, kinase|Yes| 9157.0|Jax WT Stock|ASD517:C57BL.6J.JAX/Anu:::G33||Dominant|N/A|N/A|||||||Unknown|||||||||||||||||N/A||||||||||||normal-wildtype|normal-wildtype|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good|||inbred|No|10-Mar-2021|Cryopreserved sperm|56.0|0.0|Unknown|||No| 9151.0|ASD656:F4|C57BL/6NcrlAnu-Aicda-flox:CD23cre:Ly5a||Semi-dominant|activation-induced cytidine deaminase|Aicda |||MGI:1342279||||6|||||||||||||||||||||||||||||Lack of Aid expression in mature B cells|Normal|B6/Ncrl ptprca back crossed 4 times|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Feb-2021|Cryopreserved sperm|12.0|0.0|Unknown|||Possibly| 9151.0|ASD656:F4|C57BL/6NcrlAnu-Aicda-flox:CD23cre:Ly5a||Semi-dominant|Fc receptor, IgE, low affinity II, alpha polypeptide|Fcer2a ||CD23, Fce2,|MGI:95497||||8|||||||||||||||||||||||||||||Lack of Aid expression in mature B cells|Normal|B6/Ncrl ptprca back crossed 4 times|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Feb-2021|Cryopreserved sperm|||Unknown|||Possibly| 9151.0|ASD656:F4|C57BL/6NcrlAnu-Aicda-flox:CD23cre:Ly5a||Semi-dominant|protein tyrosine phosphatase receptor type C|Ptprc|||MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||Lack of Aid expression in mature B cells|Normal|B6/Ncrl ptprca back crossed 4 times|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Feb-2021|Cryopreserved sperm|||Unknown|||Possibly| 9153.0|Vangl1(KO)|C57BL/6N-Vangl1/MmucdAnu||Semi-dominant|VANGL planar cell polarity 1|Vangl1||Lpp2, mStbm, stbm|MGI:2159344|VANGL planar cell polarity 1; targeted mutation 1e, Wellcome Trust Sanger Institute|Vangl1|MGI:4365105|3|ENSMUSG00000027860 |ENSMUST00000029453|||||||||||||||||||||||||||unknown|unknown|B6Ncrl |Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Mar-2021|Cryopreserved sperm|31.0|9.0|Unknown|||Possibly| 8701.0|Cep76KO|C57BL/6J-Cep76/MkobMarp||Recessive|centrosomal protein 76|Cep76||6230425F05Rik|MGI:1923401||||18|||||||||||||||||||||||||||||Sub-fertile male|Normal|C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8669.0|CBE1-5|C57BL/6-Cbe1/MarpMob||Recessive|collagen and calcium binding EGF domains 1|Ccbe1|Unknown|Cbe1, Smrp1|MGI:2445053||||13||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Mar-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8699.0|INHBB|C57BL/6-Inhbb/Marp||Recessive|inhibin beta-B|Inhbb||activin beta-B|MGI:96571||||1|||||||||||||||||||||||||||||Sub-fertile|Normal|C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8683.0||C57BL/6NCrlAnu-Ikbkb/1AnuApb||Recessive|inhibitor of kappaB kinase beta|Ikbkb||IKK2, IKK-2, IKK[b], IKKbeta, IKK-beta|MGI:1338071|Ikbkb, endonuclease-mediated mutation 2, Australian National University|Ikbkb||8||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Apr-2019|Cryopreserved sperm|58.0|0.0|Unknown|||Yes| 8710.0|Fut7 KO (line 2) |C57BL/6-Fut7/Apb||Recessive|fucosyltransferase 7|Fut7|Unknown|FTVII, Fuc-TVII, FucT-VII|MGI:107692||||2|||||||||||||||||||||||||||||Unknown. These mice have a defect in immune cell migration, which may make them more susceptible to infections. Regular monitoring is important to establish phenotype of these CRISPR mice. |Unknown. These mice have a defect in immune cell migration, which may make them more susceptible to infections. Regular monitoring is important to establish phenotype of these CRISPR mice. |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8700.0|SCRN1KO|C57BL/6J-Scrn1/MkobMarp||Recessive|secernin 1|Scrn1||2810019K23Rik, 6330535A03Rik, mKIAA0193, SES1|MGI:1917188||||6|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9167.0|ASD1105:Bsn|C57BL/6NCrlAnu-Bsn8/AnuApb||Semi-dominant|bassoon|Bsn|||MGI:1277955||||9|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|30-Mar-2021|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8698.0|Katbn1 flox|C57BL/6N-Katnb1/Marp||Recessive|katanin p80 (WD40-containing) subunit B 1|Katnb1||2410003J24Rik, KAT|MGI:1921437|katanin p80 (WD40-containing) subunit B 1; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Katnb1||8|||||||||||||||||||||||||||||Normal|Normal|C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8697.0|Katnb1KO|C57BL/6N-Katnb1/Marp||Recessive|katanin p80 (WD40-containing) subunit B 1|Katnb1||2410003J24Rik, KAT|MGI:1921437|katanin p80 (WD40-containing) subunit B 1; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Katnb1|MGI:4436305|8|||||||||||||||||||||||||||||Embryonic lethal|Normal|C57BL/6N|No|No|Yes|No|No|Yes|No|Unknown||||No|15-Apr-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8707.0|Katnal2 KO|C57BL/6N-Katnal2/MarpApb||Recessive|katanin p60 subunit A-like 2|Katnal2|Nil|3110023G01Rik, 4933439B08Rik|MGI:1924234|katanin p60 subunit A-like 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Katnal2|MGI:4842422|18|||||||||||||||||||||||||||||Male homozygous mice are infertile|Normal|C57BL/6N|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|50.0|0.0|Unknown||Spermatogenesis|Yes| 4951.0|Ifne|C57BL/6-Ifne||Recessive|interferon epsilon|Ifne||Ifne1, Ifnt1|MGI:2667156||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|10-Dec-2009||0.0|0.0|No||interferon, reproductive tract|Yes| 9175.0|Vcp fl/fl|C57BL/6J-Vcp/APF||Semi-dominant|valosin containing protein|Vcp ||AAA ATPase p97, CDC48, p97, p97/VCP |MGI:99919|valosin containing protein|Vcp ||4|||||||||||||||||||||||||||||Knockout muscle demonstrated a necrotic myopathy with increased macroautophagic/autophagic proteins and damaged lysosomes|Unknown|C57BL/6N APB|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|23-Apr-2021||0.0|0.0|Unknown||Autophagy, Lysosome, Myopathy, Skeletal muscle, TFEB, VCP|Possibly| 8716.0|Wbp11|C57BL/6-Wbp11/DunwApb||Recessive|WW domain binding protein 11|Wbp11||2510026P17Rik, D6Wsu113e, Npwbp, SIPP1|MGI:1891823|Wbp11; endonuclease-mediated mutation 1, Sally L Dunwoodi|Wbp11||6||||||||||Unknown to Unknown|||||||||||||||||||Embryonic lethal|Multiple congenital defectsPartial lethality|FVB x C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|14-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8726.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|recombination activating 1|Rag1|||MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1 |MGI:1857241|2|ENSMUSG00000061311|ENSMUST00000078494||||||||Unknown to Unknown|||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-Jun-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8726.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|histocompatibility 2, D region locus 1|H2-D1||H-2D|MGI:95896||H2-D1Ab1Ea2||17|ENSMUSG00000073411 |||||||||Unknown to Unknown|||||||Tg(TCR A1.2)||||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-Jun-2019|Cryopreserved sperm|||Unknown|||Yes| 8726.0||NOD.129S7B6-Rag1 H2d1Ab1Ea2 Ins1 Tg(hCD4) Tg(HLA-DR4,HLA-DQ8) Tg(TCR A1.2)||Recessive|insulin I|Ins1|||MGI:96572||Ins1||19||||||||||Unknown to Unknown|||||||Tg(HLA-DR4,HLA-DQ8)||||||||||||Unknown|Unknown|NOD|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-Jun-2019|Cryopreserved sperm|||Unknown|||Yes| 8712.0|Tube1 Flox|C57BL/6J-Tube1/MarpApb||Recessive|epsilon-tubulin 1|Tube1|Unknown|2310061K05Rik|MGI:1919174||Tube1||10||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8722.0|ASD783:Man2a1:1bp ins|C57BL/6NCrlAnu-Man2a1/AnuApb||Recessive|mannosidase 2, alpha 1|Man2a1||Mana2, Mana-2, Map-2|MGI:104669|Man2a1, endonuclease-mediated mutation 1, Australian National University|Man2a1||17||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|31-May-2019|Cryopreserved sperm|48.0|0.0|Unknown|||Yes| 9187.0||B6(Cg).129-Rps6 Tg<(Mx1-Cre)1Cgn/NCrl>/Apb||Semi-dominant|ribosomal protein S6|Rps6||S6R|98159|ribosomal protein S6; targeted mutation 1, George Thomas|Rps6|MGI:2387471|4|||||||||||||||||transgene insertion 1, University of Cologne|Mx1|||||||||||Normal until Cre induction with interferon gamma|Normal until Cre induction with interferon gamma|C57BLN6/NCrl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-May-2021|Cryopreserved sperm|59.0|0.0|Unknown|||Possibly| 9185.0|ENU52:G2|ANU:ENU52:G2||Recessive|Not known yet||||||||Unknown||||||||||||||||||||||||||||| | |C57BL/6NcrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|13-May-2021|Cryopreserved sperm|1321.0|0.0|Unknown|||Possibly| 5455.0|ENU13NIH:069b|C57BL/6JAnu-Pax5/AnuApb|C57BL/6JAnu-Pax5/AnuApb|Recessive|paired box gene 5|Pax5|Reduced|EBB-1, Pax-5|MGI:97489|paired box gene 5; mutation 1, The Australian National University|Pax5|MGI:5563444|4|ENSMUSG00000014030|ENSMUST00000014174|Pax5-001|1053|1307|T to A|ENSMUSE00000660796|9|351|Tyrosine to STOP|||||TCTGGAAGTCCCTACAGCCACCCTCAGTATTCTTCCTACAATGATTCTTGGAGGTTCCCCA|Yes|||||||||||||No B cells.Small and sick looking.||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Mar-2011|Cryopreserved sperm|79.0|0.0|Unknown||B cell, lymphocyte, ENU|Possibly| 9177.0|ASD541:CD4cre/AhRflox:Flpe:CD4-Cre |C57Bl/6N-CD4cre/AhRflox:Flpe:CD4-Cre/Apb||Recessive|||||||||||||||||||||||||||||||||||||||||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-May-2021||0.0|0.0|Unknown|||Possibly| 8745.0|ASD873:Pear:XB151|C57BL/6NCrlAnu-Xbp1/AnuApb||Recessive|X-box binding protein 1|Xbp1||D11Ertd39e, TREB5, TREB-5, XBP-1|MGI:98970|Xbp1, endonuclease-mediated mutation 1, Australian National University|Xbp1||11||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Jul-2019|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 8747.0|ASD960:Orange:XB131|C57BL/6NCrlAnu-Xbp1/AnuApb||Recessive|X-box binding protein 1|Xbp1|Unknown|D11Ertd39e, TREB5, TREB-5, XBP-1|MGI:98970|Xbp1, endonuclease-mediated mutation 3, Australian National University|Xbp1||11||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Jul-2019|Cryopreserved sperm|66.0|0.0|Unknown|||Yes| 8708.0|Katnal2 KO x Katna1 Flox|C57BL/6N-Katna1 Katnal2/MarpApb||Recessive|katanin p60 (ATPase-containing) subunit A1|Katna1|||MGI:1344353|katanin p60 (ATPase-containing) subunit A1; targeted mutation 1c, Wellcome Trust Sanger Institute|Katna1||10||||||||||Unknown to Unknown|||||||||||||||||||Male infertile|Normal|C57BL/6N|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8708.0|Katnal2 KO x Katna1 Flox|C57BL/6N-Katna1 Katnal2/MarpApb||Recessive|katanin p60 subunit A-like 2|Katnal2||3110023G01Rik, 4933439B08Rik|MGI:1924234|katanin p60 subunit A-like 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Katnal2|MGI:4842422|18|||||||||||||||||||||||||||||Male infertile|Normal|C57BL/6N|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|06-May-2019|Cryopreserved sperm|||Unknown|||Yes| 8739.0|LAMA5 HS PM|C57BL/6-Lama5/MarpApb||Recessive|Laminin, alpha 5|Lama5|Unknown|mKIAA0533|MGI:105382||||2|||||||||||||||||||||||||||||Lethal|unknown|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|26-Jun-2019|Cryopreserved sperm|50.0|0.0|Unknown||Embryonic lethal|Yes| 9076.0|R26-YAP5SA|C57BL/6-Gt(ROSA)26Sor<(CAGGS-Yap5SA,LacZ)Mao>/Apb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||||6|||||||||||||||||||||||||||||Overexpression of activated YAP (NLS-YAP-5SA) with Keratin-5 (K5-CreERt) is sufficient to induce rapid formation of both SCC and spSCC in mice. spSCC tumours arise at sites of epithelial scratch wounding, where tumour-initiating epithelial cells undergo EMT to generate spSCC. Expression of the EMT transcription factor ZEB1 arises upon wounding and is a defining characteristic of spSCC in mice and humans. Thus, the wound healing response synergises with YAP to drive metaplastic transformation of SCC to spSCC.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-Sep-2020|Cryopreserved sperm|50.0|0.0|Unknown||Hippo, epithelium, Squamous cell carcinoma (SCC) |Yes| 8740.0|ASD977:Zambrero:6|C57BL/6NCrlAnu-Ryr2/AnuApb||Recessive|ryanodine receptor 2, cardiac|Ryr2|Unknown|9330127I20Rik|MGI:99685|Ryr2, endonuclease-mediated mutation 2, Australian National University|Ryr2||13||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Jun-2019|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 6641.0|NOD.HinsATriple427|NOD.Cg-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(Ins2-INS1)/Apb||Dominant|histocompatibility-2, MHC|H2|Nil|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; targeted deletion, H2 complex|H2|MGI:2658725|17||||||||||||||||No|human leukocyte antigen class II||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Nov-2011|Cryopreserved sperm|45.0|83.0|Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 6641.0|NOD.HinsATriple427|NOD.Cg-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(Ins2-INS1)/Apb||Dominant||||||||||||||||||||||||||transgene insertion 2362, Dan R Littman|murine Cd4 and human CD4|equivalent to human CD4+ cells||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Nov-2011|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 6641.0|NOD.HinsATriple427|NOD.Cg-H2 Tg(Cd4-CD4)2362Litt Tg(HLA DR4-DQ8)427 Tg(Ins2-INS1)/Apb||Dominant||||||||||||||||||||||||||human insulin|rat insulin promoter (RIP) (Ins2)|||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Nov-2011|Cryopreserved sperm|||Unknown||MHC, B cell, selection, autoimmunity, celiac disease|Yes| 7957.0|Castella|C.Cg-Rag2 Tg(CD2-IL5)5C2Ldt/AnuApb||Recessive|recombination activating gene 2|Rag2||Rag-2|MGI:97849|recombination activating gene 2; targeted mutation 1, Frederick W Alt|Rag2|MGI:1858556|2|||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||Constitutive expression of the IL5 gene is sufficient to induce lifelong high-level eosinophilia. |Appear normal with peripheral blood eosinophilia and increased numbers of eosinophils in the spleen (with splenomegaly), bone marrow. Heterozygous BALB/c and C57BL/6 IL-5 Tg2 mice are resistant to methylcholanthrene-induced carcinogenesis - see Simson, L, et al., 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol., 178:4222-4229.|BALB/c|No|No|Yes|No|No|Yes|No|Excellent|20||Transgenic male with wild type female|No|28-Jul-2015|Cryopreserved sperm|22.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 9032.0|Youngs|C.Cg-Tg(CD2-IL5)5C2Ldt/AnuApb||Recessive||||||||||||||||||||||||||transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High - 49 Copies||||||||||||BALB/c|No|No|Yes|No|No|Yes|No|Excellent|20||Transgenic male with wild type female|No|26-Jun-2020|Cryopreserved sperm|55.0|0.0|Yes||eosinophil, immune surveillance, resistance to helminthic parasites, asthma, allergy|Yes| 8125.0|Er81 fl:PV-Cre|B6.129-Etv1 Pvalb/Anu||Recessive|ets variant 1|Etv1|Unknown|ER81, Etsrp81|MGI:99254|ets variant 1; targeted mutation 1, William D Snider|Etv1|MGI:2663693|12|||||||||||||||||||||||||||||Unknown||C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Oct-2016|Cryopreserved sperm|24.0|0.0|Unknown|||Yes| 8125.0|Er81 fl:PV-Cre|B6.129-Etv1 Pvalb/Anu||Recessive|parvalbumin|Pvalb||Parv, PV, Pva|MGI:97821|parvalbumin; targeted mutation 1, Silvia Arber|Pvalb|MGI:3590684|15|||||||||||||||||||||||||||||Unknown||C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Oct-2016|Cryopreserved sperm|||Unknown|||Yes| 8614.0|Ubtf|C57BL/6J-Ubtf/AnuApb||Recessive|upstream binding transcription factor, RNA polymerase I|Ubtf||A930005G04Rik, Tcfubf, UBF, UBF1|MGI:98512|pstream binding transcription factor, RNA polymerase I; targeted mutation 1, Mark LeDoux|Ubtf|MGI:6695077|11|||||||||||||||||||||||||||||Unknown||C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Nov-2018|Cryopreserved sperm|10.0|0.0|Unknown|||Yes| 8757.0|R26-LSL-Adar1 E861A|C57BL/6-Gt(ROSA)26Sor/CwaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Normal (requires Cre to induce expression of editing deficient Adar1 - both p110 and p150 isoforms)|Normal (requires Cre to induce expression of editing deficient Adar1 - both p110 and p150 isoforms)|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Yes|No|Unknown||||No|31-Jul-2019|Cryopreserved sperm|70.0|0.0|Unknown|||Yes| 9205.0||C57Bl/6-C-Tg(CMV-cre)1Cgn/J/Apb||Semi-dominant|||||||||Unknown|||||||||||||||||transgene insertion 1, University of Cologne|CMV, cytomegalovirus, human|||||||||||Normal|Normal|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Jun-2021|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9204.0|Tek-cre|B6.Cg-Tg<(Tek-cre)1Ywa>/J||Dominant|||||||||Unknown|||||||||||||||||transgene insertion 1, Masashi Yanagisawa|mouse Tek promoter and enhancer|Unknown|sortilin-related VPS10 domain containing receptor 2|Sorcs2 ||mKIAA1329, VPS10 domain receptor protein|MGI:1932289||||5|Normal|Normal|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Jun-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8758.0|ASD783:Man2a1:GtoC|C57BL/6NCrlAnu-Man2a1/AnuApb||Recessive|mannosidase 2, alpha 1|Man2a1||Mana2, Mana-2, Map-2|MGI:104669|Man2a1, endonuclease-mediated mutation 2, Australian National University|Man2a1||17|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|31-Jul-2019|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 9207.0|ASD521:cpg15 fl:FoxP3-Cre|C57BL/6-Nrn1Fox3(cre)/Apb||Dominant|neuritin 1|Nrn1|||MGI:1915654||||13|||||||||||||||||||||||||||||||C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|18-Jun-2021||0.0|0.0|Unknown|||Possibly| 8752.0|LAMA5 HS|C57BL/6-Lama5/MarpApb||Recessive|Laminin, alpha 5|Lama5|Unknown|mKIAA0533|MGI:105382||Lama5||2||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Jul-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8738.0|CRISP4 KO|C57BL/6J-Crisp4/MarpApb||Recessive|cysteine-rich secretory protein 4|Crisp4|Nil|9230112K08Rik|MGI:1925331|cysteine-rich secretory protein 4; targeted mutation 1a, Wellcome Trust Sanger Institute|Crisp4|MGI:4363007|1|||||||||||||||||||||||||||||Sub-fertile|Nomrmal|C57Bl/6J|Yes|Yes|Yes|Yes|No|Yes|No|Unknown||||No|24-Jun-2019|Cryopreserved sperm|50.0|0.0|Unknown||Sperm, epididymis, Capacitation|Yes| 9218.0||C57Bl6/N-Sntb1 /Apb||Semi-dominant|syntrophin, basic 1|Sntb1||59-1 DAP, beta1-Syntrophin|MGI:101781||||15|ENSMUSG00000060429|ENSMUST00000039769||||||||Unknown to Unknown|||||||||||||||||||unknown|unknown|C57Bl/6NCrl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Jul-2021|Cryopreserved sperm|11.0|0.0|Unknown|||Possibly| 9214.0|Lcp1 KO (founder 17)|C57Bl/6N-Lcp1/Apb||Recessive|lymphocyte cytosolic protein 1|Lcp1|||MGI:104808|Lcp; endonuclease-mediated mutation 5, Australian National University|Lcp1||14|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6NCrl|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|07-Jul-2021|Cryopreserved sperm|64.0|0.0|Unknown|||Possibly| 8760.0|ASD873:XBP1:indel|C57BL/6NCrlAnu-Xbp1/AnuApb||Recessive|X-box binding protein 1|Xbp1|Unknown|D11Ertd39e, TREB5, TREB-5, XBP-1|MGI:98970|Xbp1, endonuclease-mediated mutation 4, Australian National University|Xbp1||11||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|02-Aug-2019|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 9212.0|Bsn KO - ASD1106:Bsn:70|C57Bl/6N-Bsn70/Apb||Semi-dominant|bassoon|Bsn||presynaptic cytomatrix protein|MGI:1277955|Bsn:endonuclease-mediated mutation 2, Australian National University|Bsn||9|ENSMUSG00000032589 |ENSMUST00000035208|||||||||||||||||||||||||||unknown|unknown|C57BL/6NCrl|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Jul-2021|Cryopreserved sperm|11.0|0.0|Unknown|||Possibly| 9225.0|ASD917::Zud1 |C57BL/6N-Zic2/Apb||Semi-dominant|zinc finger protein of the cerebellum 2|Zic2||GENA 29, Ku, odd-paired homolog|MGI:106679|Zic2; endonuclease-mediated mutation 1, Ruth Arkel|Zic2Ark||14|ENSMUSG00000061524 |ENSMUST00000075888|||||||||||||||||||||||||||Homozygous animals are viable in to adulthood and display belly spots (with incomplete penetrance). |No observable phenotype in the heterozygous state.|C57BL.6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|14-Jul-2021|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 9224.0|B10.BR(B6)-Ptprca/J|B10.BR(B6)-Ptprca/J||Semi-dominant|protein tyrosine phosphatase receptor type C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1||||||||||Unknown to Unknown|||||||||||||||||||B10.BR mice express CD45.1 in all leucocytes instead of CD45.2 |same as above except that hets would express both CD45.1 and CD45.2. |B10.BR|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Jul-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9247.0|Ntsr1-cre|FVB/N-Tg(Ntsr1-cre)||Semi-dominant|neurotensin receptor 1|Ntsr1||NT-1R, NTR1, NTR-1, Ntsr1|Ntsr1|ransgene insertion GN209, GENSAT Project at Rockefeller University|Tg(Ntsr1-cre)GN209Gsat|MGI:4367043|Unknown|||||||||||||||||cre recombinase|Ntsr1|||||||||||Undetermined|Undetermined|FVB/N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||N1F2| hemizygous state|No|09-Aug-2021||0.0|0.0|Unknown|||Possibly| 8415.0|Mdm2 S6|B6(Cg).129(Cg)-WT/JAnu||Recessive||||||||||||||||||||||||||||||||||||||Normal||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Jan-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8776.0|ENU35:042:B6|B6(Cg)-Ifih1/AnuApb||Recessive|interferon induced with helicase C domain 1|Ifih1||9130009C22Rik, Helicard, MDA5, MDA-5|MGI:1918836|Ifih1, mutation 1, Australian National University|Ifih1||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Aug-2019|Cryopreserved sperm|65.0|0.0|Unknown|||Yes| 8782.0|R26-Adar1|C57BL/6-Gt(ROSA)26Sor/CwaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|||MGI:104735|Gt(ROSA)26Sor|||6|||||||||||||||||||||||||||||Normal (Rosa26 Lox-Stop-Lox Adar1 cDNA); needs Cre exposure to activate Adar1 expression|Normal (Rosa26 Lox-Stop-Lox Adar1 cDNA); needs Cre exposure to activate Adar1 expression|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Sep-2019|Cryopreserved sperm|60.0|0.0|Unknown|||Yes| 9223.0|Alb-Kb B10.BR| Tg(Alb-H2-Kb)/Apb or Alb-Kb||Semi-dominant|H-2Kb (histocompatibility 2, K region; b haplotype)|h2-k1|Normal||||||Unknown|||||||||||||||||H-2Kb (histocompatibility 2, K region; b haplotype)|mouse albumin promoter|||||||||||This transgenic mouse line expresses a mouse MHC Class I molecule H-2Kb under the control of the mouse albumin promoter, allowing restricted expression of H-2Kb in hepatocytes in addition to endogenous H-2K molecules expression in all cells (Including hepatocytes). The original mouse line was originally generated in the DBA2 background (H-2 d haplotype). To generate Alb-Kb on the B10.BR background (k background), the original line was backcrossed for >10 generations with B10BR mice. Mice have a normal phenotype and no liver anomaly.|Same as above.|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10||Homozygous mice are intercrossed|No|08-Jul-2021|Cryopreserved sperm|50.0|0.0|No||tolerance, liver, CD8 T cells, MHC class I, autoimmunity|Possibly| 7870.0|MHC II KO|B6NCrl.Cg-H2-Aa/AnuApb||Recessive|histocompatibility 2, class II antigen A, alpha|H2-Aa||Aalpha, A alpha, H-2Aa, Ia1, Ia-1, I-Aalpha|MGI:95895|histocompatibility 2, class II antigen A, alpha; targeted mutation 1, Horst Bluethmann|H2-Aa|MGI:2157977|17|||||||||||||||||||||||||||||enlarged thymus ( J:16372 )• slightly enlargedthymus hyperplasia ( J:16372 )• slightly increased cell numberabnormal T cell morphology ( J:16372 )decreased CD4-positive, alpha beta T cell number ( J:16372 )• very few or no CD4+ T-cells in thymus• about 4% CD4+ peripheral T-cells as opposed to 60% normallyincreased CD8-positive, alpha-beta T cell number ( J:16372 )• about 90% of lymph node T-cells are CD8+abnormal MHC II cell surface expression on macrophages ( J:67924 )• Class II expression is absent on bone-marrow derived macrophagesabnormal splenocyte physiology ( J:16372 )• no splenocyte response to staphylococcal enterotoxin B• response to T-cell independent antigens is normalenlarged lymph nodes ( J:16372 )• slightly enlarged||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2015|Cryopreserved sperm|43.0|0.0|Unknown||T cell, MHC class II|Yes| 8779.0|Maggott:13|NOD/Lt-Slc6a19/13AnuApb||Recessive|solute carrier family 6 (neurotransmitter transporter), member 19|Slc6a19||4632401C08Rik, B<0>AT1|MGI:1921588|Slc6a19, endonuclease-mediated mutation 1, Australian National University|Slc6a19||13||||||||||Unknown to Unknown|||||||||||||||||||||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|15-Aug-2019|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8781.0|ENU23:039:Pola1|C57BL/6NCrlAnu-Pola1 Pola1/AnuApb||Recessive|polymerase (DNA directed), alpha 1|Pola1||Pola|MGI:99660|Pola1, mutation 1, Australian National University|Pola1||X|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|30-Aug-2019|Cryopreserved sperm|33.0|0.0|Unknown|||Yes| 8781.0|ENU23:039:Pola1|C57BL/6NCrlAnu-Pola1 Pola1/AnuApb||Recessive|polymerase (DNA directed), alpha 1|Pola1||Pola1|MGI:99660|Pola1, mutation 2, Australian National University|||X|ENSMUSG00000006678|ENSMUST00000006856|||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|30-Aug-2019|Cryopreserved sperm|||Unknown|||Yes| 5015.0|MHC II KO|B6.129-H2-Aa/AnuApb||Recessive|histocompatibility 2, class II antigen A, alpha|H2-Aa|Nil|Aalpha, A alpha, H-2Aa, Ia1, Ia-1, I-Aalpha|MGI:95895|histocompatibility 2, class II antigen A, alpha; targeted mutation 1, Horst Bluethmann|H2-Aa|MGI:2157977|17|||||||||||||||||||||||||||||enlarged thymus ( J:16372 )• slightly enlargedthymus hyperplasia ( J:16372 )• slightly increased cell numberabnormal T cell morphology ( J:16372 )decreased CD4-positive, alpha beta T cell number ( J:16372 )• very few or no CD4+ T-cells in thymus• about 4% CD4+ peripheral T-cells as opposed to 60% normallyincreased CD8-positive, alpha-beta T cell number ( J:16372 )• about 90% of lymph node T-cells are CD8+abnormal MHC II cell surface expression on macrophages ( J:67924 )• Class II expression is absent on bone-marrow derived macrophagesabnormal splenocyte physiology ( J:16372 )• no splenocyte response to staphylococcal enterotoxin B• response to T-cell independent antigens is normalenlarged lymph nodes ( J:16372 )• slightly enlarged||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|77.0|65.0|Unknown||T cell, MHC II|No| 9228.0|Ocn-Cre|B6.FVB-Tg1/Clem/J||Semi-dominant||||||||||||||||||||||||||transgene insertion 1, Thomas L Clemens|human bone gamma carboxyglutamate protein (BGLAP)|Unknown||||||||||Transgenic |unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jul-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8791.0|ASD739:ELK KO|C57BL/6NCrlAnu-Elk1/AnuApb||Recessive|ELK1, member of ETS oncogene family|Elk1||Elk-1|MGI:101833|Elk1, endonuclease-mediated mutation 1, Australian National University|Elk1||X||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|58.0|0.0|Unknown|||Yes| 9266.0||B6.129-Rrn3Tg(Vav1-cre/ERT)1Wehi/AnuApb||Recessive|RRN3 RNA polymerase I transcription factor homolog (yeast)|Rrn3|||MGI:1925255|RRN3 RNA polymerase I transcription factor homolog (yeast); targeted mutation 1.1, Ingrid Grummt|Rrn3|MGI:3584035|16||||||||||Unknown to Unknown|||||||CreERT2|Vav1|||||||||||normal|normal|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Aug-2021|Cryopreserved sperm|60.0|0.0|Unknown|||Possibly| 8792.0|ASD739:ELK KO:37bp-Del|C57BL/6NCrlAnu-Elk1/AnuApb||Recessive|ELK1, member of ETS oncogene family|Elk1||Elk-1|MGI:101833|Elk1, endonuclease-mediated mutation 2, Australian National University|Elk1||X||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|56.0|0.0|Unknown|||Yes| 8755.0||FVB(Cg)-Ccnd1 Tg(CAG-cre/Esr1*)5Amc Tg(MMTV-rtTA) Tg(tetO-HER2)||Recessive|cyclin D1|Ccnd1|Unknown|bcl-1, cD1, CycD1, Cyl-1, PRAD1 |MGI:88313 |cyclin D1; targeted mutation 5.1, Piotr Sicinski|Ccnd1|MGI:5468336|7|||||||||||||||||transgene insertion 5, Andrew P McMahon||||||||||||||>87.5% FVB|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Jul-2019|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 8755.0||FVB(Cg)-Ccnd1 Tg(CAG-cre/Esr1*)5Amc Tg(MMTV-rtTA) Tg(tetO-HER2)||Recessive||||||||||||||||||||||||||transgene insertion 1, Lewis A Chodosh||||||||||||||>87.5% FVB|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Jul-2019|Cryopreserved sperm|||Unknown|||Yes| 8755.0||FVB(Cg)-Ccnd1 Tg(CAG-cre/Esr1*)5Amc Tg(MMTV-rtTA) Tg(tetO-HER2)||Recessive||||||||||||||||||||||||||transgene insertion, Jean J Zhao||||||||||||||>87.5% FVB|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Jul-2019|Cryopreserved sperm|||Unknown|||Yes| 8793.0|Ubl3|C57BL/6-Ubl3/Apb||Recessive|ubiquitin-like 3|Ubl3|||MGI:1344373||||5|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|17-Sep-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9271.0||C57BL/6J-Tg<(mAce2-hACE2)49MGMP>/Apb ||Semi-dominant|angiotensin 1 converting enzyme 2||||||||Unknown|||||||||||||||||pAMP-mAce2 promoter-hACE2 cDNA-pA |mouse Ace2 promoter|||||||||||Unknown|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Sep-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8802.0|ASD1034:Blackcurrant:1:N1|C57BL/6NCrlAnu-Slc7a9/AnuApb||Recessive|solute carrier family 7 (cationic amino acid transporter, y+ system), member 9|Slc7a9|Unknown|b, + amino acid transporter, b, +AT, CSNU3|MGI:1353656|Slc7a9; endonuclease-mediated mutation 1, Australian National University|Slc7a9||7||||||||||Unknown to Unknown|||||||||||||||||||Mice may develop lupus-like symptoms|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|10-Oct-2019|Cryopreserved sperm|12.0|0.0|Unknown||Lupus|Yes| 8803.0|ASD899:Lychee:Ct4bpdel|C57BL/6NCrlAnu-Ctbp1/AnuApb||Recessive|C-terminal binding protein 1|Ctbp1|Unknown|BARS, CtBP1-L, CtBP1-S, CtBP3/BARS, D4S115h, D5H4S115|MGI:1201685|Ctbp1; endonuclease-mediated mutation 1, Australian National University|Ctbp1||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|11-Oct-2019|Cryopreserved sperm|29.0|0.0|Unknown|||Yes| 8805.0|ASD900:Dragonfruit:PH196|C57BL/6NCrlAnu-Phrf1/AnuApb||Recessive|PHD and ring finger domains 1|Phrf1|||MGI:2141847|Phrf1; endonuclease-mediated mutation 1, Australian National University|Phrf1||7||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|21-Oct-2019|Cryopreserved sperm|44.0|0.0|Unknown|||Yes| 8817.0|ASD950:Rambutan:::F1|C57BL/6NCrlAnu-Tet2/Anuapb||Recessive|tet methylcytosine dioxygenase 2|Tet2|Unknown|Ayu17-449, E130014J05Rik, mKIAA1546|MGI:2443298|Tet2; endonuclease-mediated mutation 1, Australian National University|Tet2||3||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Oct-2019|Cryopreserved sperm|57.0|50.0|Unknown|||Yes| 9280.0|Tg(mAce2-hACE2)|C57BL/6J /AnuApb||Recessive|||||||||Unknown|||||||||||||||||pAMP-mAce2 promoter-hACE2 cDNA-pA |mouse Ace2 promoter|Unknown||||||||||Unknown|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Oct-2021|Cryopreserved sperm|60.0|0.0|Unknown||Coronovirus, Covid19|Possibly| 9277.0|LSA|B6;Balb-Gt(ROSA)26Sor/AnuApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1 |MGI:104735 |gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Unknown|Unknown|Balb/c, C57BL/6J|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown||||No|30-Sep-2021||0.0|0.0|Unknown||Gt(ROSA)26Sor , Beta-actin, Large BiT|Yes| 9279.0|Pthrpflox, PTHrPL2|B6;129-Pthlh/AnuApb|MGI:2387462|Recessive|parathyroid hormone-like peptide|Pthlh|Normal|parathyroid hormone-like hormone, parathyroid hormone-related peptide, parathyroid hormone-related protein, PTH-like, PTH-related peptide, Pthrp |MGI:97800 |parathyroid hormone-like peptide; targeted mutation 1, Andrew C Karaplis|Pthlh|MGI:2387462|6|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6;129|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good||||No|05-Oct-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9273.0||B6-Gt(ROSA)26SorApb||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|||MGI:104735||||6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2021||0.0|0.0|Unknown|||Yes| 9275.0|Irf4 em11.2^47bp|C57BL/6NCrlAnu-Ifr4/AnuApb||Semi-dominant|interferon regulatory factor 4|Irf4||IRF-4, Spip|MGI:1096873|Irf4; endonuclease mediated mutation 11.2, Australian National University|Ifr4||13|ENSMUSG00000021356 |||||||||Unknown to Unknown|||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Sep-2021|Cryopreserved sperm|11.0|0.0|Unknown|||Possibly| 8820.0|ASD924:Longan:PA1bpdel|C57BL/6NCrlAnu-Pacsin1/AnuApb||Recessive|protein kinase C and casein kinase substrate in neurons 1|Pacsin1|Unknown|A830061D09Rik, mKIAA1379, Syndapin I|MGI:1345181|Pacsin1; endonuclease-mediated mutation 2, Australian National University|Pacsin1||17||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Oct-2019|Cryopreserved sperm|65.0|41.0|Unknown|||Yes| 8810.0|ASD951:Mangosteen:RA203|C57BL/6NCrlAnu-Rasal1/AnuApb||Recessive|RAS protein activator like 1 (GAP1 like)|Rasal1|Unknown|MRASAL|MGI:1330842|Rasal1; endonuclease-mediated mutation 1, Australian National University|Rasal1||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|21-Oct-2019|Cryopreserved sperm|46.0|42.0|Unknown|||Yes| 9272.0| ASD1068:Apricot| C57Bl/6N-Ctla4/Apb||Semi-dominant|cytotoxic T-lymphocyte-associated protein 4|Ctla4||Ctla-4, Ly-56|MGI:88556|Ctla4; endonuclease-mediated mutation 4, Australian National University|Ctla4||1|ENSMUSG00000026011 ||||||||||||||||||||||||||||Develops autoimmunity when homozygous|normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2021|Cryopreserved sperm|55.0|0.0|Unknown|||Possibly| 9282.0|Tg(DCLK1-CreERT2)Ernst;Dclk1tm1(EUCOMM)|C57Bl/6N-Tg<(DCLK1-CreERT2)Ernst>;Dclk1/AnuApb||Recessive|doublecortin-like kinase 1|DCKL1||1700113D08Rik, 2810480F11Rik, Click-I, CPG16, Dcamkl1, Dcl, DCLK, mKIAA0369 |MGI:1330861|doublecortin-like kinase 1; targeted mutation 1a, Wellcome Trust Sanger Institute|Dclk1|MGI:5543459|3|||||||||||||||||cre recombinase fused to the human estrogen receptor ligand binding domain|DCLK1|||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Oct-2021||0.0|0.0|Unknown|||Possibly| 9288.0|ASD929:Gala:623del:Ly5a:N4 |C57BL/6NCrlAnu-Gm14718 Ptprc/Anu||Dominant|predicted gene 14718|Gm14718|Unknown|lncRNA gene|MGI:3705113 |endonuclease mediated targeting 1|lncRNA <623del>||X|||||||||||||||||||||||||||||A slight decrease in CD40L expression in CD4 T cells when activated in vitro||C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Oct-2021|Cryopreserved sperm|46.0|0.0|Unknown|||Possibly| 8823.0|ASD951:Mangosteen:RA1bpdel|C57BL/6NCrlAnu-Rasal1/AnuApb||Recessive|RAS protein activator like 1 (GAP1 like)|Rasal1|Unknown|MRASAL|MGI:1330842|Rasal1; endonuclease-mediated mutation 2, Australian National University|Rasal1||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|07-Nov-2019|Cryopreserved sperm|65.0|35.0|Unknown|||Yes| 9283.0||C57Bl/6J-PANX1/Apb||Semi-dominant|Panx1|pannexin 1|||MGI:1860055||||9|ENSMUSG00000031934 |||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Oct-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9285.0|PANX1TCTStop|C57Bl/6-PANX1/Apb||Semi-dominant|pannexin 1|Panx1|||MGI:1860055||||9|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Oct-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9281.0||C57Bl/6N-Tg(DCLK1-CreERT2)Ernst-Dclk1/Apb||Semi-dominant|doublecortin-like kinase 1|Dclk1||1700113D08Rik, 2810480F11Rik, Click-I, CPG16, Dcamkl1, Dcl, DCLK, mKIAA0369|MGI:1330861|doublecortin-like kinase 1; targeted mutation 1a, Wellcome Trust Sanger Institute|Dclk1|MGI:5543459|3|||||||||||||||||Tg(DCLK1-CreERT2)Ernst||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Oct-2021||0.0|0.0|Unknown|||Possibly| 8828.0|ASD950:Rambutan:TE1806|C57BL/6NCrlAnu-Tet2/Anuapb||Recessive|tet methylcytosine dioxygenase 2|Tet2|Unknown|Ayu17-449, E130014J05Rik, mKIAA1546|MGI:2443298|Tet2; endonuclease-mediated mutation 2, Australian National University|Tet2||3||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Nov-2019|Cryopreserved sperm|73.0|25.0|Unknown|||Yes| 9289.0|FoxP3ko:TCR7:Rag1(Tm1Mom)::F4|B6(Cg)-Foxp3 Rag1 Tg(TcraBO4H9.1,TcrbBO4H9.1)7Aog/Anu||Dominant|forkhead box P3|Foxp3|||MGI:1891436|Foxp3:targeted mutation 1.1, Alexander Y Rudensky|Foxp3 |MGI:2654936|X|||||||||||||||||transgene insertion 7, Anne O'Garra||||||||||||Mice are Foxp3 KO and carry the HEL-specific TCR transgene "TCR7". These mice are on a Rag1 ko background, so they do not have the scurfy phenotype.|Normal|B6/121-Rag1(tm1Mom/ANU) x C57Bl/6N |Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Oct-2021|Cryopreserved sperm|60.0|0.0|Unknown|||Yes| 9289.0|FoxP3ko:TCR7:Rag1(Tm1Mom)::F4|B6(Cg)-Foxp3 Rag1 Tg(TcraBO4H9.1,TcrbBO4H9.1)7Aog/Anu||Dominant|recombination activating 1|Rag1|||MGI:97848|Rag1:targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|||||||||||||||||||||||||||||Mice are Foxp3 KO and carry the HEL-specific TCR transgene "TCR7". These mice are on a Rag1 ko background, so they do not have the scurfy phenotype.|Normal|B6/121-Rag1(tm1Mom/ANU) x C57Bl/6N |Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Oct-2021|Cryopreserved sperm|||Unknown|||Yes| 9148.0|Stra8-iCre|C57BL6/J-Tg(Stra8-iCre)1Reb/LguJ||Semi-dominant|stimulated by retinoic acid gene 8|Stra8|||MGI:107917||||6|ENSMUSG00000029848 |||||||||Unknown to Unknown|||||||transgene insertion 1, Robert E Braun|Stra8|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Feb-2021|Cryopreserved sperm|50.0|0.0|Unknown||Spermatogonia, Male Germ Cells, Primordial germ cells|Possibly| 9274.0|Hoxb7-EGFP|C57BL/6J-Tg<(Hoxb7-EGFP)33Cos>/AnuApb||Semi-dominant||||||||||||||||||||||||||transgene insertion 33, Franklin Costantini|homeobox B7 promoter/enhancer sequences|||||||||||not viable|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|23-Sep-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8199.0|B/c.BlGpA; B/c.TgN(HUFUT1-HUGTA-MUSMICAM2)|C.B6-Tg(Icam2-FUT1, GTA)||Dominant||||||||||||||||||||||||||human H-transferase and human A-transferase|ICAM2|||||||||||These mice are transgenic for two human genes encoding enzymes responsible for the synthesis of the blood group A antigen, which mice do not normally express. They express human blood group A on the surface of blood vessels throughout the body, and on erythrocytes and neutrophils. They develop and behave normally, and do not require special monitoring or care.|These mice are transgenic for two human genes encoding enzymes responsible for the synthesis of the blood group A antigen, which mice do not normally express. They express human blood group A on the surface of blood vessels throughout the body, and on erythrocytes and neutrophils. They develop and behave normally, and do not require special monitoring or care.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|11|||No|24-Feb-2017|Cryopreserved sperm|50.0|0.0|Unknown||transferase|Yes| 8830.0|ASD899:Lychee:Ct96|C57BL/6NCrlAnu-Ctbp1/AnuApb||Recessive|C-terminal binding protein 1|Ctbp1|Unknown|BARS, CtBP1-L, CtBP1-S, CtBP3/BARS, D4S115h, D5H4S115|MGI:1201685|Ctbp1; endonuclease-mediated mutation 2, Australian National University|Ctbp1||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Nov-2019|Cryopreserved sperm|19.0|0.0|Unknown|||Yes| 9267.0|ENU54:G2|ANU:ENU54:G2||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|23-Aug-2021|Cryopreserved sperm|6702.0|41.0|Unknown||ENU, random, mutagenesis, screen|Yes| 9306.0|Gabrd L260V|C57Bl/6J-Gabrd/Apb ||Semi-dominant|gamma-aminobutyric acid (GABA) A receptor, subunit delta|GABRD|||MGI:95622||||4|||||||||||||||||||||||||||||Unknown|No overt phenotype, seizures possible|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Nov-2021|Cryopreserved sperm|38.0|0.0|Unknown|||Possibly| 9172.0|ENU53:G2|ANU:ENU53:G2||Recessive|Not known yet||||||||Unknown||||||||||||||||||||||||||||| | |C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Apr-2021|Cryopreserved sperm|10829.0|37.0|Unknown||ENU, Random, mutagenesis, screen|Possibly| 9278.0|ENU53:G3|ANU:ENU53:G3||Recessive|Unknown||||||||Unknown||||||||||||||||Unknown|||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|03-Oct-2021|Cryopreserved sperm|80.0|0.0|Unknown||ENU, random, mutagenesis, screen|Yes| 9069.0|ASD891:Sorghum|C57BL/6N-NLRP9a/Apb||Recessive|NLR family, pyrin domain containing 9A|Nlrp9a ||D7Ertd565e, Nalp9a, Nalp-theta|MGI:2675292|NLR family, pyrin domain containing 9A |Nlrp9a||7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|01-Sep-2020|Cryopreserved sperm|48.0|0.0|Unknown||Nlrp9a, ATP binding, Inflammatory response, Innate immune response|Possibly| 9300.0|PRαMCM|C57Bl/6J-Pdgfra/Apb||Dominant|platelet derived growth factor receptor, alpha polypeptide|Pdgfra|Unknown||MGI:97530|platelet derived growth factor receptor, alpha polypeptide; targeted mutation 1, Shin-Ichi Nishikawa|Pdgfra|MGI:5475226|5|||||||||||||||||||||||||||||This strain is reported to be lethal in a homozygous state|Normal|C57Bl/6J|No|No|Yes|No|No|Yes|No|Unknown||||No|09-Nov-2021||0.0|0.0|Unknown|||Possibly| 9299.0|Wnt11 KO|129:B6-Wnt11||Semi-dominant|wingless-type MMTV integration site family, member 11|Wnt11|||MGI:101948 |wingless-type MMTV integration site family, targeted mutation 1; Andrew McMahon|Wnt11 |MGI:2665014|7|||||||||||||||||||||||||||||These mice display incomplete embryonic and perinatal lethality in a homozygous state with defects in kidney development|Normal, with slightly smaller kidneys|129S1/B6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-Nov-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9270.0|Tg(mAce2-hACE2)|C57BL/6J/AnuApb||Recessive|||||||||Unknown|||||||||||||||||pAMP-mAce2 promoter-hACE2 cDNA-pA |mouse Ace2 promoter|Unknown||||||||||Unknown|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Sep-2021|Cryopreserved sperm|50.0|0.0|Unknown||Coronovirus, Covid19|Possibly| 5257.0|CathepsinK.gp130fl/fl|C57BL/6-Il6st Ctsk||Recessive|interleukin 6 signal transducer|Il6st|Normal|CD130, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Werner Mueller|Il6st|MGI:1931239|13||||||||||||||||Yes|||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Oct-2010|Cryopreserved sperm|169.0|0.0|Unknown||osteoclast, signal transduction|Possibly| 5257.0|CathepsinK.gp130fl/fl|C57BL/6-Il6st Ctsk||Recessive|cathepsin K|Ctsk||catK, Cat K|MGI:107823|cathepsin K; targeted mutation 1, Shigeaki Kato|Ctsk|MGI:3764465|3|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Oct-2010|Cryopreserved sperm|||Unknown||osteoclast, signal transduction|Possibly| 9303.0|Ntsr1-cre|C57BL/6J-Tg<(Ntsr1-cre)GN209Gsat>/AnuApb||Semi-dominant|neurotensin receptor 1|Ntsr1||NT-1R, NTR1, NTR-1, Ntsr1|MGI:97386||||2|||||||||||||||||transgene insertion GN209, GENSAT Project at Rockefeller University|neurotensin receptor 1 gene|||||||||||Unknown|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|16-Nov-2021|Cryopreserved sperm, Live|55.0|0.0|Unknown||Nervous system, Brain|Possibly| 9302.0||C57Bl/6-Il6st/Apb||Semi-dominant|interleukin 6 signal transducer|IL6st||5133400A03Rik, CD130, D13Ertd699e, gp130 |MGI:96560 |interleukin 6 signal transducer; targeted mutation 1b, Mouse Biology Program, UC Davis|Il6sttm1b(KOMP)Mbp|MGI:5474976|13|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Nov-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9310.0|mettl3 flox/flox|C57BL/6J-Mettl3/AnuApb||Semi-dominant|methyltransferase like 3|Mettl3 ||2310024F18Rik, M6A, Spo8|MGI:1927165|methyltransferase like 3; targeted mutation 1, Jacob Hanna|Mettl3|MGI:5911703|14|||||||||||||||||||||||||||||||C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Dec-2021||0.0|0.0|Unknown|||Possibly| 9308.0|Adar1 em2Crwy|C57Bl/6J-Adar1/Apb||Dominant|adenosine deaminase, RNA-specific|Adar||Adar1p110, Adar1p150|MGI:1889575|adenosine deaminase, RNA-specific; endonuclease-mediated mutation 3, Carl R Walkley|Adar||3|ENSMUSG00000027951||||||||||||||||||||||||||||Would be expected to be embryonic lethal (not tested prior to cryopreservation)|Normal, fertile and health. No discernable phenotype|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Nov-2021|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 9313.0||C57Bl/6-Tcf3 KO/Apb||Semi-dominant|Tcf3||||||||Unknown|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Dec-2021|Cryopreserved sperm|11.0|0.0|Unknown|||Possibly| 7966.0|Heatr3 KO|C57BL/6NTac-Heatr3/IcsOrlAnu|C57BL/6NTac-Heatr3/IcsOrlAnu|Recessive|HEAT repeat containing 3|Heatr3|Normal|C030036P15Rik|MGI:2444491|HEAT repeat containing 3; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Heatr3|MGI:4435825|8|||||||||||||||||||||||||||||Normal|Normal|C57BL/6NTac|Unknown|Yes|Yes|Unknown|Yes|Yes|No|Unknown||||No|04-Sep-2015|Cryopreserved sperm|31.0|0.0|Unknown||EUCOMM|Yes| 8224.0|R26 MUT-Hoxa1 ki|B6JArc.Cg-Gt(ROSA)26Sor||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3237, TaconicArtemis|Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6JArc|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Excellent|>6|||No|27-Mar-2017|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9328.0|Myl9tm1a(KOMP)Wtsi|C57BL/6J-Myl9/Apb||Semi-dominant|myosin, light polypeptide 9, regulatory|Myl9||MLC20, Mylc2c, RLC-C |MGI:2138915 |myosin, light polypeptide 9, regulatory; targeted mutation 1a, Wellcome Trust Sanger Institute|Myl9|MGI:5299665|2|||||||||||||||||||||||||||||Perinatal lethal around Day 1 after birth due to loss of muscularis propria function in the bladder and small intestine|Normal. Expresses LacZ under control of the Mtl9 promoter.|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Jan-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9333.0|B10.BR:Foxp3 KO:TCR/Apb |B6.B10-H2 Foxp3 Tg(TcrHEL3A9)1Mmd/Anu||Semi-dominant|histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||mice harbour the TCR3A9 transgene, which recognizes HELThey are also knockout for Foxp3 and Rag1||B10BR N6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|04-Feb-2022|Cryopreserved sperm|18.0|0.0|Unknown|||Possibly| 9333.0|B10.BR:Foxp3 KO:TCR/Apb |B6.B10-H2 Foxp3 Tg(TcrHEL3A9)1Mmd/Anu||Semi-dominant|forkhead box P3|Foxp3|||MGI:1891436|forkhead box P3; targeted mutation 1.1, Alexander Y Rudensky|Foxp3|MGI:2654936|X|ENSMUSG00000039521 ||||||||||||||||||||||||||||mice harbour the TCR3A9 transgene, which recognizes HELThey are also knockout for Foxp3 and Rag1||B10BR N6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|04-Feb-2022|Cryopreserved sperm|||Unknown|||Possibly| 9339.0|Matk cKO|C57BL/6J-Matk/HaqueWehi||Semi-dominant|megakaryocyte-associated tyrosine kinase|Matk||CHK, Csk homologous kinase, HYL, Ntk |MGI:99259 |Matk|Matk cKO||10|NCBI Gene: 17179|||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2022|Cryopreserved sperm|50.0|0.0|Unknown||Heamatopoietic system, Megakaryocyte, Kinases|Possibly| 8267.0|ENU36:006:Acss1|C57BL/6NCrlAnu-Acss1/AnuApb||Recessive|acyl-CoA synthetase short-chain family member 1|Acss1||1110032O15Rik, Acas2, Acas2l, AceCS2|MGI:1915988||||2|ENSMUSG00000027452|ENSMUST00000028944.3|Acss1-201|908|969|C to T|ENSMUSE00001270508|5|303|Glycine to Aspartic acid|||||ACCCAAGGGACTCGTTCATACACAGGCAGGCTATCTACTGTATGCCGCCATGACGCACAAG||||||||||||||Homozygous mice have increased CD44 MFI on T cells in the blood||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Jun-2017|Cryopreserved sperm|48.0|0.0|Unknown||T cell, CD44|Yes| 9341.0||C57BL/6-Myo1f/HaqueWehi||Dominant|myosin IF|Myo1f|||MGI:107711||||17||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9340.0|Asap1 fl/fl|C57BL/6-Asap1/Wehi||Semi-dominant|ArfGAP with SH3 domain, ankyrin repeat and PH domain1|Asap1||Ddef1, mKIAA1249 |MGI:1342335 ||Asap1||15||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8929.0|CD23cre|B6.Cg-Tg(Fcer2a-cre)5Mbu/JMarpAnuApb||Dominant||||||||||||||||||||||||||transgene insertion 5, Meinrad Busslinger|Fcer2a|||||||||||These Cd23-cre transgenic mice express cre under the control of the Fcer2a promoter. Cre recombinase expression is detected in immature, transitional and late B cells in the bone marrow and spleen. Mice that are hemizygous for the transgene are viable and fertile.|These Cd23-cre transgenic mice express cre under the control of the Fcer2a promoter. Cre recombinase expression is detected in immature, transitional and late B cells in the bone marrow and spleen. Mice that are hemizygous for the transgene are viable and fertile.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Mar-2020|Cryopreserved sperm|17.0|18.0|Unknown||Cre recombinase, CD23, B cell|Yes| 4078.0|Frink ; ENU6PH:052 |C;B6JAnu-Irf4/AnuApb||Recessive|interferon regulatory factor 4|Irf4||IRF-4, Spip|MGI:1096873|rf4: mutation 1, The Australian National University|Irf4||13|ENSMUSG00000021356|ENSMUST00000021784|Irf4-001|332|434|T to A|ENSMUSE00000117279|3|111|Valine to Aspartic acid|||||GAACAAGAGCAATGACTTTGAGGAATTGGTCGAGAGGAGCCAGCTGGATATCTCTGACCCA|Yes|||||||||||||Hypo IgE response following allergic challenge.Panhypogamma.||C57BL/6 x BALB/b|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Dec-2008|Cryopreserved sperm|195.0|0.0|Unknown||allergic challenge, ENU, Immunoglobulin, IgE, autoimmune disease, arthritis|No| 9351.0||C57BL/6J-Prr13/HaqueWehi||Semi-dominant|proline rich 13|Prr13||1110020C13Rik, 2010324E22Rik|MGI:1913401||Prr13||15||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9349.0|Mef2C-LacZ; Nedd4fl/fl|C57;129S1/Sv;CD1-Tg(Mef2c-lacZ)-Nedd4/Apb||Semi-dominant|neural precursor cell expressed, developmentally down-regulated 4|Nedd4 ||E430025J12Rik, mKIAA0093, Nedd4, Nedd4-1, Nedd4a |MGI:97297||||9|||||||||||||||||LacZ|Mef2C|||||||||||Mice are fully viable|Mice are fully viable|C57Bl/6; 129S1/Sv; CD1|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9350.0||C57BL/6J-Prr13/HaqueWehi||Semi-dominant|proline rich 13|Prr13|||MGI:1913401||Prr13||15||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8188.0|ENU33:009:Clk1|C57BL/6NCrlAnu-Clk1/AnuApb||Recessive|CDC-like kinase 1|Clk1|Unknown|Clk1, STY|MGI:107403||||1|ENSMUSG00000026034|ENSMUST00000034868.13|Clk1-001|971|1118|T to C|ENSMUSE00001227858|9|324|Aspartic acid to Glycine|||||TATAGTAAATCCAGATATTAAAGTGGTGGACTTTGGAAGTGCAACATATGATGATGAACAC||||||||||||||FACS phenotype: Increase IgM and decreased IgD on mature B cells.|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Feb-2017|Cryopreserved sperm|48.0|0.0|Unknown||ENU, B cell, IgD|Yes| 9347.0|SwHel:RAG1KO:B10BR N3|B6N(Cg)-Igh Tg(IgkHyHEL10)1Rbr H2 Rag<1tm1Mom>/Anu||Dominant|recombination activating 1|Rag1|||MGI:97848|recombination activating 1; targeted mutation 1, Peter Mombaerts|Rag1|MGI:1857241|2|ENSMUSG00000061311||||||||||||||||transgene insertion 1, Robert Brink||||||||||||Mice carry BCR knocked in alleles that recognise HEL protein so that ~10% of B cells recognise HELMice are also deficient for Rag1 (lacking mature B and T cells)||B10BR Rag1KO|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|27.0|0.0|Unknown|||No| 9347.0|SwHel:RAG1KO:B10BR N3|B6N(Cg)-Igh Tg(IgkHyHEL10)1Rbr H2 Rag<1tm1Mom>/Anu||Dominant|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Robert Brink|Igh|MGI:3800383|12|||||||||||||||||||||||||||||Mice carry BCR knocked in alleles that recognise HEL protein so that ~10% of B cells recognise HELMice are also deficient for Rag1 (lacking mature B and T cells)||B10BR Rag1KO|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|||Unknown|||No| 9347.0|SwHel:RAG1KO:B10BR N3|B6N(Cg)-Igh Tg(IgkHyHEL10)1Rbr H2 Rag<1tm1Mom>/Anu||Dominant|histocompatibility-2, MHC|H2|||MGI:95894|histocompatibility 2, K region|H2||17|||||||||||||||||||||||||||||Mice carry BCR knocked in alleles that recognise HEL protein so that ~10% of B cells recognise HELMice are also deficient for Rag1 (lacking mature B and T cells)||B10BR Rag1KO|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|||Unknown|||No| 9348.0|cpg15 fl:FoxP3-Cre:TCR.B10BR|B6.B10-Nrn1 Foxp3 Tg(TcrHEL3A9)1Mmd/Apb||Dominant|neuritin 1|Nrn1||cpg15|MGI:1915654|neuritin 1; targeted mutation 1.1, Elly Nedivi|Nrn1 |MGI:5307917|13|ENSMUSG00000039114 ||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carry the TCR3a9 transgene together with floxed Cpg15 and cre under the Foxp3 promotor|-|B10BR N3|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|35.0|0.0|Unknown|||No| 9348.0|cpg15 fl:FoxP3-Cre:TCR.B10BR|B6.B10-Nrn1 Foxp3 Tg(TcrHEL3A9)1Mmd/Apb||Dominant|forkhead box P3|Foxp3||scurfin|MGI:1891436|forkhead box P3; targeted mutation 4, Alexander Y Rudensky|Foxp3|MGI:3790499|X|ENSMUSG00000039521||||||||||||||||||||||||||||Mice carry the TCR3a9 transgene together with floxed Cpg15 and cre under the Foxp3 promotor|-|B10BR N3|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|||Unknown|||No| 10453.0|B6.A2G-Mx1 Wildtype|B6.A2G-Mx1/AnuApb||Dominant|myxovirus (influenza virus) resistance 1|Mx1|Normal|Mx, Mx-1, myxovirus (influenza) resistance 1 polypeptide|MGI:97243|myxovirus (influenza virus) resistance 1; myxovirus resistance|Mx1|MGI:3715151|16|||||||||||||||||||||||||||||Normal, i.e. highly influenza resistant.|Normal.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Sep-2024||0.0|0.0|Unknown||Infection, resistance, Interferon|Yes| 9297.0|Robo2 KO|C57Bl/6J-Robo2/AnuApb||Semi-dominant|Roundabout guidance receptor 2|Robo2|Unknown|2600013A04Rik, 9430089E08Rik, D230004I22Rik, mKIAA1568|MGI:1890110|Roundabout guidance receptor 2|Robo2||16|||||||||||||||||||||||||||||Homozygous mice have duplex kidneys during development. Adult phenotype unknown for this line.|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Nov-2021|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9368.0||C57BL/6N-Myb<(em1)41Δ2bp>/Apb||Semi-dominant|myeloblastosis oncogene|Myb||c-myb|MGI:97249||||10|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|06-Apr-2022|Cryopreserved sperm|10.0|0.0|Unknown|||Possibly| 9367.0||C57Bl/6NCrlAnu-Fads2Anu/Apb||Semi-dominant|fatty acid desaturase 2|Fads2|||MGI:1930079|Fads2; endonuclease-mediated mutation 1, Australian National University|Fads2Anu||19||||||||||Unknown to Unknown|||||||||||||||||||Defective in fatty acid desaturase. Mice are mostly normal. Male mice are defective in reproduction (e.g. low sperm numbers) unless supplied with a high DHA diet.|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Apr-2022|Cryopreserved sperm|102.0|0.0|Unknown|||Possibly| 9366.0|Aicda fl:Ly5a|B6(Cg)-Aicda Ptprc/AnuApb||Recessive|activation-induced cytidine deaminase|Aicda|||MGI:1342279|activation-induced cytidine deaminase; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Aicda|MGI:6478196|6|ENSMUSG00000040627||||||||||||||||||||||||||||Normal|Normal|Founder strain C57Bl/6N (Agouti) JM8A3.N1. Current mice: 7 backcrosses (N7) to C57Bl/6N Ly5a|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Mar-2022|Cryopreserved sperm|31.0|0.0|Unknown|||Yes| 9366.0|Aicda fl:Ly5a|B6(Cg)-Aicda Ptprc/AnuApb||Recessive|protein tyrosine phosphatase receptor type C|Ptprc||Ly-5, Lyt-4, T200||protein tyrosine phosphatase receptor type C; a variant|Ptprca|MGI:4819849|1||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|Founder strain C57Bl/6N (Agouti) JM8A3.N1. Current mice: 7 backcrosses (N7) to C57Bl/6N Ly5a|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Mar-2022|Cryopreserved sperm|||Unknown|||Yes| 9365.0||B6.129P-Mgea5/NIDDK||Semi-dominant|O-GlcNAcase (OGA / Mgea5)|Oga||Hy5, Mgea5,|MGI:1932139|O-GlcNAcase; targeted mutation 2, John A Hanover|Oga||19||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9353.0|Asap1 Floxed|C57BL/6-Asap1/Wehi||Semi-dominant|ArfGAP with SH3 domain, ankyrin repeat and PH domain1|Asap1|Unknown|Ddef1, mKIAA124|MGI:1342335 |endonuclease mediated targeting 2; Ashraful Haque|Asap1||15|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9192.0|Wdr1rd/rd|C57BL/6- Wdr1/ApbAnu||Semi-dominant|WD repeat domain 1|Wdr1||Aip1, D5Wsu185e, rede |MGI:1337100|Wdr1|Wdr1 rd/rd||5|||||||||||||||||||||||||||||Homozygous mice begin to develop inflamed ears after ~100 days of age. The inflammation at the ears emerge in ‘pockets’ at the tip of the ears and as the mice age, the ears will have redness and oedema with immune infiltration. The inflammation at the tail would also emerge in pockets throughout the tail, though most prominently at the tip of the tail. As the mice age, the tail will become hardened and inflamed.|unknown|C57BL/6 “The rd mutation was induced on an inbred C57BL/6 background, isolated on a mixed C57BL/6J: 129S6/SvEv:C3HeB/FeJ background,38 and back-crossed 10 generations to C57BL/6.” (Kile et al., 2007, Blood, PMID: 17515402)|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Jun-2021|Cryopreserved sperm|50.0|0.0|Unknown||platelets, neutrophils, Megakaryocyte|Possibly| 9352.0|Myo1f flox|C57BL/6-Myo1f/HaqueWehi||Recessive|myosin IF|Myo1f||C330006B10Rik|MGI:107711|Myo1f|Myo1 flox||17|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9376.0|SwHel:Hc.Lc:Ly5a:Ptprca/NCrl|SwHel:Hc.Lc:Ly5a:Ptprca/NCrl||Dominant|immunoglobulin heavy chain complex ||||||||Unknown|||||||||||||||||The HyHEL10 hybridoma produces an antibody that binds hen egg lysozyme peptide (HEL) with high affinity. The rearranged variable heavy gene segment from the HyHEL10 hybridoma replaced the endogenous J gene segments of the IgH locus. A floxed neomycin cassette was placed upstream for targeting purposes. About 0.4% of B cells produce antibody that bind HEL with high affinity. The strain also express congenic mark Ly5a||||||||||||B cells express Immunoglobulin specific for hen egg lysozyme and are capable of undergoing class switch.|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Apr-2022|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 9176.0|Zic5R (Kiska; Ki)|C57BL/6J Zic5R /ApbAnu||Recessive|zinc finger protein of the cerebellum 5|Zic5||1700049L20Rik, odd-paired related, Opr |MGI:1929518|Zic5|K363R (Kiska; Ki)||14|||||||||||||||||||||||||||||This hypomorphic allele of Zic5 leads to hypoplasia of the neural crest. This leads to a small proportion of homozygous animals will develop hydrocephaly post birth (5%). Homozygous animals also are more likely to have a ventral spot/colour change on their coat or line of white hair (13%) compared with heterozygous animals (3%). |A small proportion of heterozygous animals have a ventral spot/colour change on their coat or line of white hair (3%). |C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|27-Apr-2021|Cryopreserved sperm|57.0|0.0|Unknown|||Possibly| 10454.0|B6.A2G-Mx1 (Cg/Cg)|B6.A2G-Mx1/AnuApb||Dominant|myxovirus (influenza virus) resistance 1|Mx1|Normal|Mx, Mx-1, myxovirus (influenza) resistance 1 polypeptide|MGI:97243|myxovirus (influenza virus) resistance 1; myxovirus resistance|Mx1|MGI:3715151|16|||||||||||||||||||||||||||||Sensitive to influenza infection|Normal, i.e. highly influenza resistant.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Sep-2024||0.0|0.0|Unknown||Infection, resistance, Interferon|Yes| 9390.0||C57Bl/6J-Mdfic<(em)H133fs* 8 bp>/Apb||Dominant|MyoD family inhibitor domain containing|Mdfic|Normal||MGI:104611||||6|||||||||||||||||||||||||||||Chylothorax develops between 8-45 days after birth resulting in death within 24 hours.|Normal|C57Bl/6J|No|Unknown|Yes|No|Unknown|Yes|No|Excellent|||Het x Het|No|19-May-2022|Cryopreserved sperm|40.0|0.0|No|||No| 9388.0|Prox1enh-LacZ(Simba)|C57Bl/6J-Prox1(enh-LacZ)(Simba)/Apb||Dominant|prospero homeobox 1|Prox1|Normal||MGI:97772| -11kb enhancer|||1|||||||||||||||||LacZ|Hsp68|||||||||||Presence of the transgene drives LacZ expression, chiefly in lymphatic vessels and valves.|Presence of the transgene drives LacZ expression, chiefly in lymphatic vessels and valves.|C57Bl/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|19-May-2022|Cryopreserved sperm|40.0|0.0|No|||No| 9392.0|BSN stop|C57Bl/6N-BsnAnu/Apb||Semi-dominant| bassoon|Bsn|||MGI:1277955|Bsn, mutation 1, Australian National University|Bsn||9||||||||||Unknown to Unknown|||||||||||||||||||May develop epilepsy|normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-May-2022|Cryopreserved sperm|17.0|0.0|Unknown|||Possibly| 9389.0|MDFIC-CRISPR(Dory)|C57Bl/6j-Mdfic/AnuApb||Dominant|MyoD family inhibitor domain containing|Mdfic|Normal||MGI:104611||||6|||||||||||||||||||||||||||||Chylothorax develops between 8-45 days after birth resulting in death within 24 hours.|Normal|C57Bl/6J|No|Unknown|Yes|No|Unknown|Yes|No|Excellent|||Het x Het|No|19-May-2022|Cryopreserved sperm|40.0|0.0|No|||No| 9397.0|ROCK1nc|C57BL/6-Rock1/Apb||Semi-dominant|Rho-associated coiled-coil containing protein kinase 1|Rock1 |||MGI:107927|Rho-associated coiled-coil containing protein kinase 1; targeted mutation 1.1, Cancer Research UK Beatson Institute|Rock1tm1.1Bicrq|MGI:6696418|18|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|15-Jun-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9399.0|Nod1fl/fl x A33 cre|C57Bl/6J-Nod1 Gpa33/Apb||Dominant|nucleotide-binding oligomerization domain containing 1|Nod1||Nlrc1, Card4|MGI:1341839|Nucleotide-binding oligomerisation domain-containing protein 1, targeted mutation 1|Nod1||6|ENSMUSG00000038058 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Jun-2022|Cryopreserved sperm|50.0|0.0|Unknown|||No| 9399.0|Nod1fl/fl x A33 cre|C57Bl/6J-Nod1 Gpa33/Apb||Dominant|glycoprotein A33 transmembrane|Gpa33||A33 antigen|MGI:1891703|glycoprotein A33 transmembrane; targeted mutation 2, Matthias Ernst|Gpa33|MGI:6806128|1|ENSMUSG00000000544 ||||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Jun-2022|Cryopreserved sperm|||Unknown|||No| 8718.0|FANCM KO|FVB-Fancm/StVApb||Recessive|Fanconi anemia, complementation group M|Fancm|Nil|C730036B14Rik, D12Ertd364e|MGI:2442306||||11|||||||||||||||||||||||||||||Reduced fertility: smaller testis and epidydmis. Reduced sperm count and sperm motility.May have decreased lifespan.May have increased cancer susceptibility.|May have increased cancer susceptibility.|FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|23-May-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 1858.0|Eu-myc/mOVA|C57BL/6-Tg(IghMyc)22Bri Tg(act-mOVA)||Dominant||||||||||||||||||||||||||transgene insertion 22, Ralph L Brinster|Lymphoid-specific immunoglobulin heavy chain enhancer (Eμ)|B cell lineage|||||||||||Phenotype expected to be similar to parental Emu-myc line. These mice will develop high incidence pre-B and B lymphoma. More than 90% of Emu-myc mice die between 6 and 18 weeks of age (median 11 weeeks). Enlargement of all lymph nodes, spleen, infiltration of thymus (thymoma), bone marrow, liver, lung, weight loss. Further more, these mice will express ubiquitously the membrane bound chicken ovalbumin under the chicken beta - actin promoter. MICE WILL BE MONITORED BY PALPATION OF LYMPH NODES AND SPLEEN 3X/WEEK. act-mOVa are on a C57BL/6 background. Homozygous breeding considerably less productive than heterozygous B6 myc: excess pre - B cells in bone marrow.||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Mate - transgenic males with wild type B6 females|No|10-Aug-2007||0.0|0.0|Unknown||Lymphoma, ovalbumin, B cell|Yes| 1858.0|Eu-myc/mOVA|C57BL/6-Tg(IghMyc)22Bri Tg(act-mOVA)||Dominant||||||||||||||||||||||||||membrane bound ovalbumin|actin||||||||||||Phenotype expected to be similar to parental Emu-myc line. These mice will develop high incidence pre-B and B lymphoma. More than 90% of Emu-myc mice die between 6 and 18 weeks of age (median 11 weeeks). Enlargement of all lymph nodes, spleen, infiltration of thymus (thymoma), bone marrow, liver, lung, weight loss. Further more, these mice will express ubiquitously the membrane bound chicken ovalbumin under the chicken beta - actin promoter. MICE WILL BE MONITORED BY PALPATION OF LYMPH NODES AND SPLEEN 3X/WEEK. act-mOVa are on a C57BL/6 background. Homozygous breeding considerably less productive than heterozygous B6 myc: excess pre - B cells in bone marrow.||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Mate - transgenic males with wild type B6 females|No|10-Aug-2007||||Unknown||Lymphoma, ovalbumin, B cell|Yes| 1860.0|Mcl-1flox/Bak/Bax knockout|Un-Mcl1 Bak1 Bax/Wehi||Recessive|myeloid cell leukemia sequence 1|Mcl1|Normal|Mcl-1|MGI:101769|targeted mutation 3, Stanley J Korsmeyer|Mcl1|MGI:2684151|3||||||||||||||||Yes|||||||||||||Mcl-1 - No -/- offsrping as -/- blastocysts die at E4 prior to implanation. Therefore only +/+ and +/- which are completely normal. Mice lacking bax display limited phenotypic abnormalities. Bak(-/-) mice were found to be developmentally normal and reproductively fit and failed to develop any age-related disorders. However, when Bak-deficient mice were mated to Bax-deficient mice to create mice lacking both genes, the majority of bax(-/-)bak(-/-) animals died perinatally with fewer than 10% surviving into adulthood. bax(-/-)bak(-/-) mice displayed multiple developmental defects, including persistence of interdigital webs, an imperforate vaginal canal, and accumulation of excess cells within both the central nervous and hematopoietic systems. Thus, Bax and Bak have overlapping roles in the regulation of apoptosis during mammalian development and tissue homeostasis. Those that survive are runted and grey.|||No|No|Yes|No|No|Yes|No|Unknown||||No|10-Aug-2007||0.0|0.0|No||Bcl2, BH3 only, Lymphocyte, B cell, T cell|Yes| 1860.0|Mcl-1flox/Bak/Bax knockout|Un-Mcl1 Bak1 Bax/Wehi||Recessive|BCL2-antagonist/killer 1|Bak1|Nil|Bak, N-Bak|MGI:1097161|BCL2-antagonist/killer 1; targeted mutation 1, Craig B Thompson|Bak1|MGI:2159364|17|||||||||||||||||||||||||||||Mcl-1 - No -/- offsrping as -/- blastocysts die at E4 prior to implanation. Therefore only +/+ and +/- which are completely normal. Mice lacking bax display limited phenotypic abnormalities. Bak(-/-) mice were found to be developmentally normal and reproductively fit and failed to develop any age-related disorders. However, when Bak-deficient mice were mated to Bax-deficient mice to create mice lacking both genes, the majority of bax(-/-)bak(-/-) animals died perinatally with fewer than 10% surviving into adulthood. bax(-/-)bak(-/-) mice displayed multiple developmental defects, including persistence of interdigital webs, an imperforate vaginal canal, and accumulation of excess cells within both the central nervous and hematopoietic systems. Thus, Bax and Bak have overlapping roles in the regulation of apoptosis during mammalian development and tissue homeostasis. Those that survive are runted and grey.|||No|No|Yes|No|No|Yes|No|Unknown||||No|10-Aug-2007||||No||Bcl2, BH3 only, Lymphocyte, B cell, T cell|Yes| 1860.0|Mcl-1flox/Bak/Bax knockout|Un-Mcl1 Bak1 Bax/Wehi||Recessive|Bcl2-associated X protein|Bax|Nil||MGI:99702|BCL2-associated X protein; targeted mutation 1, Stanley J Korsmeyer|Bax|MGI:1857429|7|||||||||||||||||||||||||||||Mcl-1 - No -/- offsrping as -/- blastocysts die at E4 prior to implanation. Therefore only +/+ and +/- which are completely normal. Mice lacking bax display limited phenotypic abnormalities. Bak(-/-) mice were found to be developmentally normal and reproductively fit and failed to develop any age-related disorders. However, when Bak-deficient mice were mated to Bax-deficient mice to create mice lacking both genes, the majority of bax(-/-)bak(-/-) animals died perinatally with fewer than 10% surviving into adulthood. bax(-/-)bak(-/-) mice displayed multiple developmental defects, including persistence of interdigital webs, an imperforate vaginal canal, and accumulation of excess cells within both the central nervous and hematopoietic systems. Thus, Bax and Bak have overlapping roles in the regulation of apoptosis during mammalian development and tissue homeostasis. Those that survive are runted and grey.|||No|No|Yes|No|No|Yes|No|Unknown||||No|10-Aug-2007||||No||Bcl2, BH3 only, Lymphocyte, B cell, T cell|Yes| 1825.0|PUT/Mxcre|C57BL/6-Sfpi1 Tg(Mx1-cre)1Cgn||Recessive|SFFV proviral integration 1|Sfpi1|Unknown|Dis-1, PU.1, Sfpi-1, Spi-1, Tcfpu1, Tfpu.1|MGI:98282|targeted mutation 1.2, Stephen L Nutt|Sfpi1|MGI:3578011|2||||||||||||||||Yes|transgene insertion 1, University of Cologne|Inducible MX1|||||||||||Prior to PolyIC treatment the phenotype is the same as wild type phenotype of the same genetic background. After polyIC treatment (ie after the deletion of PU.1 gene) mice exhibit transient weight loss, which sometimes can be sever (more than 10%) and splenomegaly. Myeloid leukaemia development in average 6 months after polyIC treatment.Absent erythrocytes: bone marrow lacked the nucleated erythroid cells that represent 17% of the control bone marrow.Decreased B cell number: B lymphocyte numbers were reduced variably in the bone marrow, with most cells having a preB cell phenotype.Increased granulocyte number: expansion of granulocyte precursors in the bone marrow and spleen.Abnormal granulocyte differentiation: granulocytes maintained c-kit expression and displayed some, but not complete, maturation.Extramedullary hematopoiesis: spleen cells generated vastly increased numbers of granulocytic colonies, excessive numbers of megakaryocytic colonies and IL-3 responsive macrophage-containing colonies.Abnormal bone marrow cell morphology/development: the bone marrow contained normal total cellularity but exhibited an increased proportion of blast cells, and immature cells of the granulocyte lineage (promyelocytes and myelocytes).Absent common myeloid progenitor cells:* bone marrow lacked eosinophil colony-forming cells that were responsive to granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3 or IL-5, but had greatly elevated numbers of granulocytic colonies developed when stimulated by G-CSF, IL-3 or stem cell factor but not with IL-6.* few or no megakaryoctye colonies developed in cultures of bone marrow cells under optimal culture for megakaryoctye formation.* loss of any readily identifiable lymphoid and myeloid progenitor or stem cell populations.Abnormal spleen morphology: in severe cases, spleen showed homogeneous infiltration by immature granulocytic forms and loss of splenic architecture.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Aug-2007||0.0|0.0|Unknown||B cell, lymphocyte, Myeloid Leukaemia, granulocyte, erythrocyte|Yes| 9417.0|Solox H x AR2 -/-|C57BL/6J-Solox H x AR2 -/-/Apb||Semi-dominant|Ifnar2 -/- x Soluble Ifnar2 ||||||||Unknown|||||||||||||||||||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Aug-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9414.0|IFNAR2 KO|C57Bl/6J-Ifnar2/AnuApb||Semi-dominant|interferon (alpha and beta) receptor 2|Ifnar2|||MGI:1098243 ||||16|||||||||||||||||||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Aug-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9413.0|IFNAR1 KO|C57Bl/6J-Ifnar1/AnuApb||Semi-dominant|interferon (alpha and beta) receptor 1|Ifnar1|||MGI:107658||||16|||||||||||||||||||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Aug-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9416.0|Solox High|C57Bl/6J- Ifnar2/Apb||Recessive|interferon (alpha and beta) receptor 2 |Ifnar2 |||MGI:1098243||||16|ENSMUSG00000022971 |||||||||Unknown to Unknown|||||||||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Aug-2022|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9415.0|Ifne KO|C57Bl/6-Ifne KO/AnuApb||Semi-dominant|Interferon epsilon|Ifne|||MGI:2667156||||4|ENSMUSG00000045364 |||||||||Unknown to Unknown|||||||||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Aug-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9429.0||C57BL/6NCrlAnu-Lyn8/AnuApb||Semi-dominant|LYN proto-oncogene, Src family tyrosine kinase|Lyn|||MGI:96892|Lyn: endonuclease mutation 1, Australian National University|Lyn||4|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Sep-2022|Cryopreserved sperm|10.0|0.0|Unknown|||Possibly| 9433.0||C57Bl/6J-Tg<(Ace2-ACE2)4Pqt>/Apb||Semi-dominant|angiotensin converting enzyme 2|Ace2 |||MGI:1917258|mAce2-hACE2|||X||||||||||Unknown to Unknown|||||||transgene insertion 4, Paul Q Thomas|mAce2|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2022|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9431.0||C57Bl/6J-Tg<(Ace2-ACE2)2Pqt>/Apb||Semi-dominant|angiotensin converting enzyme 2|Ace2 |||MGI:1917258|MAce2-hACE2|||X||||||||||Unknown to Unknown|||||||transgene insertion 2, Paul Q Thomas|mAce2|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9443.0|Kenobi:Nfkb2|B6(Cg)-Cd79a Nfkb2/Anu||Recessive|CD79A antigen (immunoglobulin-associated alpha)|Cd79a||Igalpha, Ly-54, Ly54, mb-1|MGI:101774|Cd79a; mutation 1, Australian National University|Cd79a||7|ENSMUSG00000003379 |||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Nov-2022|Cryopreserved sperm|43.0|0.0|Unknown|||Possibly| 9443.0|Kenobi:Nfkb2|B6(Cg)-Cd79a Nfkb2/Anu||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B cells 2|Nfkb2 |||MGI:1099800|Nfkb2:endonuclease-mediated mutation 1, Australian National University|Nfkb2||19|||||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Nov-2022|Cryopreserved sperm|||Unknown|||Possibly| 9432.0||C57BL/6J-Tg<(Ace2-ACE2)3Pqt>/Apb||Semi-dominant|angiotensin converting enzyme 2|Ace2 ||Ace3 |MGI:1917258|mAce2-hACE2|||X||||||||||Unknown to Unknown|||||||transgene insertion 3, Paul Q Thomas|mAce2|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Sep-2022|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 9437.0|GAD67-GFP|C57BL/6J-Tg(Gad1-EGFP)/Apb||Semi-dominant|GAD67-GFP|||||GAD67-GFP|||Unknown|||||||||||||||||||||||||||||Transgenic knock In |Heterozygous|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Sep-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9436.0|Brca2 KO|Balb/c-Brca2/Anu||Dominant|breast cancer 2, early onset|BRCA2|||MGI:109337|Brca2: endonuclease mutation 2, Australian National University|Brca2||5||||||||||Unknown to Unknown|||||||||||||||||||embryonic lethal|normal|Balb/cJ|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Sep-2022|Cryopreserved sperm|49.0|0.0|Unknown|||Yes| 10455.0|B6.A2G-Mx1 (Cg/Cg)|B6.A2G-Mx1/AnuApb||Dominant|myxovirus (influenza virus) resistance 1|Mx1|Normal|Mx, Mx-1, myxovirus (influenza) resistance 1 polypeptide|MGI:97243|myxovirus (influenza virus) resistance 1; myxovirus resistance|Mx1|MGI:3715151|16|||||||||||||||||||||||||||||Sensitive to influenza infection|Normal, i.e. highly influenza resistant.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Sep-2024||0.0|0.0|Unknown||Infection, resistance, Interferon|Yes| 9448.0|OsxCherry.Col1a1GFP|C57Bl/6J-Tg(Sp7/mCherry)2Pmay Tg(Col1a1*2.3-GFP)1Rowe/Apb||Dominant| Tg(Sp7/mCherry)2Pmay. Tg(Col1a1*2.3-GFP)1Rowe .||||||||Unknown|||||||||||||||||transgene insertion 2, Peter Maye|Transgene 1: 2.3 kb (from the upstream promoter sequence to 22300 bp) rat procollagen, type 1, alpha 1( Col1a1) promoter. Transgene 2: 39 kb BAC (#RP24-362M3) containing the entire mouse Sp7 gene. |||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Nov-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9448.0|OsxCherry.Col1a1GFP|C57Bl/6J-Tg(Sp7/mCherry)2Pmay Tg(Col1a1*2.3-GFP)1Rowe/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, David Rowe||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Nov-2022|Cryopreserved sperm|||Unknown|||Yes| 9450.0|Olig2Cre; 14-3-3zeta fl/fl|C57:129-Olig2(Cre)Ywhaz/Apb||Semi-dominant|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide|Ywhaz||1110013I11Rik, 14-3-3 zeta|MGI:109484|tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; gene trap EUCE0076e02, Helmholtz Zentrum Muenchen GmbH|Ywhaz|MGI:4393774|15|||||||||||||||||||||||||||||Normal with mild behavioural anomolies|Normal|129S1/Sv, C57Bl/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Nov-2022|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 9455.0||C57Bl/6-eIF2αk2/Apb||Semi-dominant|eukaryotic translation initiation factor 2-alpha kinase 2|Eif2ak2|||MGI:1353449||||17|ENSMUSG00000024079 |ENSMUST00000024884||||||||Unknown to Unknown|||||||mutagenic casette subsequently removed by CRE-mediated excision||||||||||||normal|normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|29-Nov-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9454.0||C57Bl/6-Eif2αk2TgN(OT-I)|B6.129-Rag1 Tg(TcraTcrb)1100Mjb||Recessive|recombination activating gene 1|Rag1|Unknown|Rag-1|MGI:97848|recombination activating gene 1; targeted mutation 1, David Baltimore|Rag1|MGI:2448994|2||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-May-2006||0.0|0.0|Unknown||T cell, Ovalbumin, CD8, H2|Yes| 106.0|4-1BBL -/-|B6.129Apb-Tnfsf9/Apb||Recessive|tumor necrosis factor (ligand) superfamily, member 9|Tnfsf9|Nil|4-1BB ligand, 4-1BB-L, 4-1BBL, Cd137l, Ly63l|MGI:1101058|targeted mutation 1, Tania H Watts|Tnfsf9|MGI:2179297|17||||||||||Unknown to Unknown||||||Yes|||||||||||||Mice homozygous for a null allele exhibit increased susceptibility to viral infection and defective memory T cell activation.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|06-Feb-2006|Cryopreserved sperm|119.0|0.0|Unknown||TNF, T cell, viral infection, CD28, memory|Yes| 294.0|eotaxin Tg(IL5)|C;B6-Ccl11 Tg(CD2-Il5)5C2Ldt||Dominant|small chemokine (C-C motif) ligand 11|Ccl11|Nil|eotaxin, Scya11|MGI:103576|chemokine (C-C motif) ligand 11; targeted mutation 1, Marc E Rothenberg|Ccl11|MGI:2384435|11||||||||||||||||Yes|transgene insertion 5C2, Lindsay A Dent|the dominant control region (DCR) of the gene encoding human CD2|High||||||||||Eosinophil-deficient. Tumor incidence was greatly increased.Eotaxin(-/-) mice with or without the IL-5 transgene, were no more susceptible than WT or IL-5 Tg mice to protracted primary infections with Heligmosomoides bakeri, a parasitic nematode that is restricted to the gut. ||BALB/c x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||10||No|03-May-2006||0.0|0.0|Unknown||interleukin, eosinophil, tumour, immune surveillance, infection|Yes| 340.0|TgAPP751 (Tg72-3 line)|B6.SJL-Tg(APP751)72-3Aust ||Dominant||||||||||||||||||||||||||amyloid beta (A4) precursor protein|moPrP, hamster prion protein promotor|||||||||||Transgene primarily expressed in brain.No overt phenotype, normal growth and breeding.|No overt phenotype, normal growth and breeding.|C57BL/6 x SJL|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Strain is homozygous for transgene. Positive male breeds with female.|Yes|22-Sep-2006|Cryopreserved sperm|90.0|0.0|Yes||Amyloid precursor protein, amyloid Aβ, Alzheimer's disease, early onset Australian FAD mutation|No| 649.0|HAP KO|Un.129-Hap1||Recessive|huntingtin-associated protein 1|Hap1|Nil|HAP-1|MGI:1261831|huntingtin-associated protein 1; targeted mutation 1, Xiao-Jiang Li|Hap1|MGI:2670598|11||||||||||||||||Yes|||||||||||||Postnatal lethality:* most homozygotes die at 3 to 4 days after birth.* a few survive beyond 9 days of age, in the absence of skin, bone, or organ abnormalities* no homozygotes survive beyond 15 days of age.Absent gastric milk in neonates: mutant pups contain very little gastric milk, suggesting a feeding defect that may retard postnatal growth.Abnormal hypothalamus morphology:* at P1, TUNEL-positive cells are observed in the paraventricular nuclei (PVN) and the lateral hypothalamus (LH) of mutant but not wild-type mice; very few or no TUNEL-positive cells are noted in the arcuate nucleus (ARC) of mutant mice.* by P3, TUNEL-labeled cells are more widely spread in various regions of the hypothalamus which control eating, food intake, and energy metabolism, including the ventromedial hypothalamic nucleus (VMN).Neurodegeneration:* as early as P1, homozygotes display degeneration in specific regions of the hypothalamus that control feeding behavior, as determined by TUNEL staining.* in contrast, other brain regions (e.g. cortex, striatum, cerebellum, and hippocampus) display significantly fewer TUNEL-positive cells or show no difference relative to wild-type mice.|||No|No|Yes|No|No|Yes|No|Unknown||||No|25-Apr-2007||0.0|0.0|Yes|Huntington's disease|nerve, degeneration, hypothalamus, huntingtin, EGFR|Yes| 650.0|Fat Aussie|NOD-Alms1||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Nil||MGI:1934606|fat aussie|Alms1|MGI:3621984|6||||||||||||||||No|||||||||||||Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behaviour: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.||NOD|Yes|No|Yes|Yes|No|Yes|No|Poor||||No|25-Apr-2007||0.0|0.0|Yes||obesity, diabetes, diet|Yes| 8491.0|C57BL/6.Scmh1-197|C57BL/6N-Scmh1197/BaxApb||Recessive|sex comb on midleg homolog 1|Scmh1||Scml3|MGI:1352762|sex comb on midleg homolog 1; targeted mutation 1a, Wellcome Trust Sanger Institute|Scmh1|MGI:4441791|4|||||||||||||||||||||||||||||Mice homozygous for a knock-out allele exhibit abnormal hematopoiesis but normal fertility and skeleton.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-May-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8053.0|JNK1 -/-, JNK1 KO|B6.129S1-Mapk8/JApb||Recessive|mitogen-activated protein kinase 8|Mapk8 |Nil|c-Jun N-terminal kinase, JNK1, Prkm8 |MGI:1346861|mitogen-activated protein kinase 8; targeted mutation 1, Richard Flavell|Mapk8|MGI:2176239|14|||||||||||||||||||||||||||||Mice that are homozygous for the targeted mutation are viable, normal in size, do not display any gross physical or behavioral abnormalities and are fertile but poor breeders. No gene product, protein or mRNA, is detected. Lymphocyte development, T cell to B cell ratio and CD4 to CD8 ratio are normal. Naive Th cells activated in vitro preferentially differentiate into Th2 cells. Mutant mice are susceptible to infection when challenged with the intracellular pathogen, Leishmania major. Primary murine embryonic fibroblasts prepared from mutant embryos are partially protected from UV-induced apoptosis. This mutant mouse strain represents a model that may be useful in studies related to signal transduction.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|5||Heterozygote x Heterozygote|No|23-May-2016|Cryopreserved sperm|55.0|0.0|Unknown|||No| 638.0|HtrA3-KO (MP10 Cre65)|C57BL/6-Htra3||Dominant|HtrA serine peptidase 3|Htra3|Nil|2210021K23Rik, 9530081K03Rik|MGI:1925808||||5||||||||||||||||Yes|||||||||||||Mice are fertile and do not show any clear signs of immunodeficiency.|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|25-Apr-2007|Cryopreserved sperm|55.0|0.0|Unknown||HtrA3, placentation, pregnancy, serine protease, placental insufficiency|No| 37.0|Dwarf|C57BL/6JSfdAnu-Wars/Apb||Recessive|tryptophanyl-tRNA synthetase|Wars|Unknown|dwarf|MGI:104630|tukkuburko|Wars|MGI:4819385|12|ENSMUSG00000021266|ENSMUST00000078788|Wars-201|89|220|T to C|ENSMUSE00000116158|2|30|Leucine to Proline|||||AGCTACTCAAGGGGAGCTCGTGAGGTCCCTCAAAGCTGGAAATGCACCAAAAGATGAGATT|Yes|||||||||||||Dwarfism; small at weaning/adult 60% of wt sib.Small to non-existant pituitary gland.Low IGF levels in serum.Phenotype unique to this chromosome location|||Yes|Unknown|Yes|Yes|Unknown|Yes|Yes|Good||6|het x het|No|06-Feb-2006|Cryopreserved sperm|126.0|0.0|Unknown||Dwarfism, pituitary, Small, ENU, runted|Yes| 8402.0|BALB.5702-3855|BALB/c-Gasa/Bax||Recessive|||||||||||||||||||||||||||||Unknown||||||||Unknown|Altered response to induced neonatal thymectomy induced gastritis compared to BALB/c mcie.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Hom x Hom|No|19-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||autoimmunity, gastritis|Yes| 8393.0|NOD.Idd13.H2b.Nkrp1b|NOD-H2 Idd13 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|Mice that are homozygous for this allele are viable, fertile, normal in size.Idd13:Idd13 is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.H2b:Congenic markers MHC haplotype H2ᵇ. Nkrplb:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2ᵇ"||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|49.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8393.0|NOD.Idd13.H2b.Nkrp1b|NOD-H2 Idd13 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile, normal in size.Idd13:Idd13 is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.H2b:Congenic markers MHC haplotype H2ᵇ. Nkrplb:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2ᵇ"||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8393.0|NOD.Idd13.H2b.Nkrp1b|NOD-H2 Idd13 Klrb1b/Bax||Recessive|||||||||||||||||||||||||||||insulin dependent diabetes susceptibility 13|Idd13|||MGI:99415|insulin dependent diabetes susceptibility 13; C57BL/6|Idd13|MGI:3044074|2|Mice that are homozygous for this allele are viable, fertile, normal in size.Idd13:Idd13 is congenic for a 32 cM segment of Chr 2 extending from D2Mit274 through D2Mit343 that includes the insulin dependent diabetes susceptibility locus Idd13.H2b:Congenic markers MHC haplotype H2ᵇ. Nkrplb:Congenic Nk Cell Marker. Congenic markers MHC haplotype H2ᵇ"||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|19-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8377.0|NOD.Nkrp1b.Slam1D|NOD-Klrb1b Nkt1 Slam1D/Bax||Recessive|||||||||||||||||||||||||||||killer cell lectin-like receptor subfamily B member 1B|Klrb1b||Klrb1d, Ly55b, Ly55d, Nkrp1-b, NKR-P1B, Nkrp1d, NKR-P1D|MGI:107539||||6|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|50.0|0.0|Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8377.0|NOD.Nkrp1b.Slam1D|NOD-Klrb1b Nkt1 Slam1D/Bax||Recessive|||||||||||||||||||||||||||||natural killer T cell numbers 1|Nktcn1||Nkt1|MGI:2681136|natural killer T cell numbers 1; C57BL/6J|Nktcn1|MGI:2681149|1|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8377.0|NOD.Nkrp1b.Slam1D|NOD-Klrb1b Nkt1 Slam1D/Bax||Recessive|||||||||||||||||||||||||||||signaling lymphocytic activation molecule family member 1|Slamf1|||MGI:1351314||||1|Mice that are homozygous for this allele are viable, fertile and normal in size.Congenic Nk Cell Marker. Congenic Marker for NKT1 region. Congenic Marker for Slam1d region. Increased Nkt cell numbers.||NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|11-Dec-2017|Cryopreserved sperm|||Unknown||Nk1.1, TCR, NK cell, autoimmunity|Yes| 8109.0||B10.BR-H2/JAnuApb||Dominant|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||Congenic black: Congenic partner C57BL/10ScSn.|MGI:95894|histocompatibility-2, MHC; k variant|H2|MGI:3579322|17|General Information: See C57BL/10ScSn. Moderate breeders, 0.8 young/female/wk., average litter 6. Fecundity lower than C57BL/10ScSn but can have large litters.|||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Oct-2016|Cryopreserved sperm|164.0|292.0|No|||Yes| 1551.0||BALB/c-IL13 Tg(iFABPp-IL9)||Recessive|interleukin 13|Il13|Unknown|Il-13|MGI:96541|targeted mutation 2, Andrew NJ McKenzie|Il13|MGI:1931804|11||||||||||||||||Yes|interleukin 9|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences).|High||||||||||Restricted expression of IL9 transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|100.0|0.0|Unknown||T cell, infection, IL-4, IL-5, allergy, mast cell|Yes| 1552.0||BALB/c-IL4R Tg(iFABPp-IL9)||Recessive|interleukin 4 receptor, alpha|Il4ra|Unknown|CD124, IL-4 receptor alpha chain, Il4r|MGI:105367||||7||||||||||||||||Yes|Interleukin 9|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences). |High||||||||||Restricted expression of IL9 transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|130.0|0.0|Unknown||T cell, lymphocyte, immunoglobulin, interleukin|Yes| 1554.0||BALB/c-Stat6 Tg(iFABPp-IL9) ||Recessive|signal transducer and activator of transcription 6|Stat6|Unknown||MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10||||||||||||||||No|interleukin 9|rat intestinal fatty acid binding protein (nucleotides -1178 - +28) - iFABP , i-FABP linked to nucleotides 3–2,150 of the human growth hormone (hGH) gene (except for its 5' regulatory sequences). |High||||||||||Restricted expression of IL9 transgene to intestine - duodenum and proximal jejunum.||BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Jul-2007|Cryopreserved sperm|95.0|0.0|Unknown||IL-4, T cell, B cell, immunoglobulin, infection, mast cell, allergy, anaphylaxis|Yes| 2354.0|Azharrudin|B6.129S2-Cd28 Tg(TcraTcrb)1100Mjb||Recessive|CD28 antigen|CD28|Nil|OT-1, OT-I, OT-I(OVA)TCR, OT-ITCR, OT1, OTI, OVA-tcr-I, OVA-Tg, TCR-OT-I, Tg(OT-I), Tg(TcrOva)1100Mjb|MGI:88327|targeted mutation 1, Tak Mak|Cd28|MGI:1857150|1||||||||||||||||Yes|transgene insertion 1100, Michael J Bevan||||||||||||The OT-1 strain carries a transgenic T cell receptor that recognizes ovalbumin residues 257-264 (SIINFEKL) in the context of H2K||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2007|Cryopreserved sperm|150.0|0.0|Unknown||T cell, immunoglobulin, ovalbumin, lymphocyte|Yes| 2354.0|Azharrudin|B6.129S2-Cd28 Tg(TcraTcrb)1100Mjb||Recessive|||Unknown||||Tg(TcraTcrb)1100Mjb|MGI:3054907|Unknown|||||||||||||||||||||||||||||The OT-1 strain carries a transgenic T cell receptor that recognizes ovalbumin residues 257-264 (SIINFEKL) in the context of H2K||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Dec-2007|Cryopreserved sperm|||Unknown||T cell, immunoglobulin, ovalbumin, lymphocyte|Yes| 2395.0||C57BL/6-Tnf Tnfrsf1a Tnfrsf1b||Recessive|tumor necrosis factor|Tnf|Normal|DIF, TNF alpha, TNF-alpha, Tnfa, TNFalpha, Tnfsf1a, tumor necrosis factor-alpha|MGI:104798|targeted mutation 2, Jonathon D Sedgwick|Tnf|MGI:3578747|17||||||||||||||||Yes|||||||||||||||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|100.0|301.0|Unknown||lymphocyte, inflammation, lipopolysaccharide, neutrophil, innate immunity|Yes| 2395.0||C57BL/6-Tnf Tnfrsf1a Tnfrsf1b||Recessive|tumor necrosis factor receptor superfamily, member 1a|Tnfrsf1a|Nil|CD120a, p55, p55-R, TNF receptor alpha chain, TNF-alpha-R1, TNF-alphaR1, TNF-R-I, TNF-R1, TNF-R55, TNFalpha-R1, TNFAR, Tnfr-2, Tnfr1, TNFR60, TNFRI, TNFRp55|MGI:1314884|targeted mutation 1, Immunex Research and Development Corporation|Tnfrsf1a|MGI:1857468|6|||||||||||||||||||||||||||||||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|||Unknown||lymphocyte, inflammation, lipopolysaccharide, neutrophil, innate immunity|Yes| 2395.0||C57BL/6-Tnf Tnfrsf1a Tnfrsf1b||Recessive|tumor necrosis factor receptor superfamily, member 1b|Tnfrsf1b|Nil|CD120b, p75, p75 TNFR, TNF-alphaR2, TNF-R-II, TNF-R2, TNF-R75, TNFalpha-R2, TNFBR, Tnfr-1, Tnfr2, TNFR80, TNFRII|MGI:1314883|targeted mutation 1, Immunex Research and Development Corporation|Tnfrsf1b|MGI:1860087|4|||||||||||||||||||||||||||||||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|||Unknown||lymphocyte, inflammation, lipopolysaccharide, neutrophil, innate immunity|Yes| 3389.0|EphA1 conditional full knockout (EA1C KO)|B6.129-Epha1||Recessive|Eph receptor A1|Epha1|Normal|5730453L17Rik, Eph, Esk|MGI:107381|targeted mutation 2, Shannon L Duffy|Epha1||6||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3|5|Hom x Hom|No|11-Jul-2008|Cryopreserved sperm|255.0|0.0|Unknown||Receptor Tyrosine Kinase, ephrin, epithelium, uterus, tail, embryonic|Yes| 4513.0|ENU10B6a:007|C57BL/6JAnu-Tnfrsf1a/AnuApb||Dominant|tumor necrosis factor receptor superfamily, member 1a|Tnfrsf1a||CD120a, p55, p55-R, TNF receptor alpha chain, TNF-alpha-R1, TNF-alphaR1, TNF-R-I, TNF-R1, TNF-R55, TNFalpha-R1, TNFAR, Tnfr-2, Tnfr1, TNFR60, TNFRI, TNFRp55|MGI:1314884||||6|ENSMUSG00000030341|ENSMUST00000032491|Tnfrsf1a-001|152|453|A to G|ENSMUSE00000242873|2|50|Histidine to Arginine|||||TAGCTTGTGTCCCCAAGGAAAGTATGTCCATTCTAAGAACAATTCCATCTGCTGCACCAAG|Yes|||||||||||||Increased susceptibility to tuberculosis. Failure to limit multiplication of Mycobacterium tuberculosis in lung after inhalation. ||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Sib x Sib|No|26-Feb-2009|Cryopreserved sperm|29.0|0.0|Unknown||tuberculosis, infection, lung, ENU, Wellcome Trust|Yes| 4888.0||129-Ctsg/H||Dominant|cathepsin G|Ctsg|Nil||MGI:88563|targeted mutation 1.1, Jurgen Roes|Ctsgtm1.1Roes|MGI:2182170|14|||||||||||||||||||||||||||||Decreased susceptibility to bacterial infection: median survival time is increased to 560 +/- 47 min compared to 435 +/- 8 min in wild-type miceIncreased susceptibility to fungal infection: after infection with 500,000 A. fumigatus spores median survival time was only 13 +/- 4 days compared to wild-type mice which all survive6 days after infection kidney fungal load (457 mean CFU) is higher than in wild-type (16 mean CFU) but lower than in Ctsg and Ela double homozygotes (1009 mean CFU)||129/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|28-Sep-2009|Cryopreserved sperm|89.0|0.0|Unknown||Neutrophil, serine protease, reactive oxygen intermediates, endotoxin, LPS, TNF alpha, elastase|Yes| 4950.0|Light -/- IFNgR -/-|C57BL/6-Tnfsf14 Ifngr1||Recessive|tumor necrosis factor (ligand) superfamily, member 14|Tnfsf14|Nil|HVEM-L, LIGHT|MGI:1355317|tumor necrosis factor (ligand) superfamily, member 14; targeted mutation 1, Klaus Pfeffer|Tnfsf14|MGI:2671122|17|||||||||||||||||||||||||||||In the experimental model of Active EAE we found no significant difference between the LIGHT-/-IFN GAMMA R-/-BL6 strain and the IFN GAMMA R -/-BL6 strain in both the EAE disease development and daily clinical score. At the time of termination of experimentation the mice from both the experimental groups were of a similar severe level of EAE disease in comparison with the significantly lower level of EAE in the C57/BL6/Wt control mice. There was also no histopathological difference in the brain and spinal cord samples of the two experimental groups at the completion of the EAE experiment.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|100.0|0.0|Unknown||TNF, T cell, IL2, costimulation, lymphotoxin beta receptor|Yes| 4950.0|Light -/- IFNgR -/-|C57BL/6-Tnfsf14 Ifngr1||Recessive|interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|interferon gamma receptor 1; targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|Unknown|||||||||||||||||||||||||||||In the experimental model of Active EAE we found no significant difference between the LIGHT-/-IFN GAMMA R-/-BL6 strain and the IFN GAMMA R -/-BL6 strain in both the EAE disease development and daily clinical score. At the time of termination of experimentation the mice from both the experimental groups were of a similar severe level of EAE disease in comparison with the significantly lower level of EAE in the C57/BL6/Wt control mice. There was also no histopathological difference in the brain and spinal cord samples of the two experimental groups at the completion of the EAE experiment.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2009|Cryopreserved sperm|||Unknown||TNF, T cell, IL2, costimulation, lymphotoxin beta receptor|Yes| 4968.0|IL-15NΔ|NOD.B6-Il15||Recessive|interleukin 15|Il15|Unknown||MGI:103014||||8||||||||||||||||No|||||||||||||Unknown|Unknow|NOD|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|14|||No|15-Jan-2010|Cryopreserved sperm|100.0|0.0|Unknown||IL-15, diabetes, cytokine|Yes| 2375.0|Eddie ; ENU6WTNIH:028|CBA;B6JSfdAnu-Kcnn2/AnuApb||Recessive|potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2|Kcnn2||SK2, small conductance calcium-activated potassium channel 2|MGI:2153182|eddie|||18|ENSMUSG00000054477|ENSMUST00000066890|Kcnn2-201|||||||||||||No|||||||||||||Generalised shaking, mild hypermetria, jerky movements, non progressive. First noted at weaning.||C57BL/6 x CBA|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|14-Dec-2007|Cryopreserved sperm|95.0|0.0|Unknown||shaking, ataxia, ENU|No| 2454.0||ENU6PH:043||Recessive|interferon regulatory factor 4|Irf4|Unknown|IRF-4, Spip|MGI:1096873||||13||||||||||||||||No|||||||||||||Hypo IgE response following allergic challenge.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jan-2008|Cryopreserved sperm|60.0|0.0|Unknown||T cell, B cell, lymphocyte, allergy, autoimmune, immunoglobulin, IgE|No| 3936.0|APN1|B6.129-Rbbp7/MIMR||Recessive|retinoblastoma binding protein 7|Rbbp7|Nil|mRbAp46|MGI:1194910|retinoblastoma binding protein 7; gene trap AD0754, Wellcome Trust Sanger Institute|Rbbp7|MGI:3856325|X||||||||||||||||Yes|||||||||||||Not bred to homozygocity|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|16-Oct-2008|Cryopreserved sperm|135.0|0.0|Unknown||retinoblastoma, Gene trap, chromatin remodelling|Yes| 3937.0|APN2|B6.129-Stx16/MIMR||Recessive|syntaxin 16|Stx16|Unknown|SYN16|MGI:1923396|syntaxin 16; gene trap CD0253, Wellcome Trust Sanger Institute|Stx16|MGI:3864547|2||||||||||||||||Yes|||||||||||||Unknown at this time|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|||No|16-Oct-2008|Cryopreserved sperm|45.0|0.0|Unknown||ES cell genetrap, APN|Yes| 4076.0||ENU6PH:016||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Hypo IgG1 and IgE response following allergic challenge.||B6 B10 Balb/b|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||3||No|04-Dec-2008|Cryopreserved sperm|15.0|0.0|Unknown||allergic challenge, ENU, Immunoglobulin, IgE|No| 4180.0|mNET|C3H.FVB-Tg(Foxa2enhancer.β-globin-LacZ) ||Dominant||||||||||||||||||||||||||lacZ (Beta-galactosidase)|mouse notochord Foxa2 enhancer element, β-globin minimal promoter|||||||||||Normal. LacZ expressed in the 8.0 dpc notochord|Normal. LacZ expressed in the 8.0 dpc notochord|C3H/HeH|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Dec-2008|Cryopreserved sperm|50.0|0.0|Unknown||Notochord, transcription factor, enhancer|Yes| 3383.0|K14-Grhl3|B6-Tg(K14-Grhl3) ||Dominant||||||||||||||||||||||||||grainyhead-like 3 (Drosophila) (Grhl3)|keratin 14 (K14)|||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||transgenic x transgenic|No|09-Jul-2008|Cryopreserved sperm|150.0|0.0|Unknown||Transcription Factor, epidermis, keratin|Yes| 3938.0|HtrA3-KO (MP10 Cre55)|C57BL/6-Htra355||Recessive|HtrA serine peptidase 3|Htra3|Nil||MGI:1925808||||5||||||||||||||||No|||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Oct-2008|Cryopreserved sperm|100.0|0.0|Unknown||placenta, pregnancy, serine protease, placental insufficiency|Yes| 4080.0||ENU6PH:078||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Hypo IgE response following allergic challenge.||C57BL/6 x C57BL/10 x Balb/b|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Dec-2008|Cryopreserved sperm|60.0|0.0|Unknown||Allergic challenge, ENU, Immunoglobulin, IgE|No| 4081.0||ENU6PH:094||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Hypo IgE response following allergic challenge.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Dec-2008|Cryopreserved sperm|60.0|0.0|Unknown||Allergic challenge, ENU, Immunoglobulin, IgE|No| 4082.0||ENU7PMH:036||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Hypo IgE response following allergic challenge.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|04-Dec-2008|Cryopreserved sperm|45.0|0.0|Unknown||Allergic challenge, ENU, Immunoglobulin, IgE|No| 4176.0|APN3|B6;129-Uba2/MIMR||Recessive|ubiquitin-like modifier activating enzyme 2|Uba2|Unknown|anthracycline-associated resistance, Arx, SAE2, Sumo-1 activating enzyme subunit 2, UBA2, Uble1b|MGI:1858313|ubiquitin-like modifier activating enzyme 2; gene trap RRO015, BayGenomics|Uba2|MGI:4329423|7||||||||||||||||No|||||||||||||Unknown|Normal|C57BL/6 x NODk|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||1|chimera x C57BL/6|No|18-Dec-2008|Cryopreserved sperm|40.0|0.0|Unknown||ES cell genetrap, APN|Yes| 4178.0|APN4|B6;129-Rbbp4/MIMR||Recessive|retinoblastoma binding protein 4|Rbbp4|Unknown|CAF-1 p48 subunit, mRbAp48|MGI:1194912|retinoblastoma binding protein 4; gene trap AD0773, Wellcome Trust Sanger Institute|Rbbp4|MGI:3863854|4||||||||||||||||Yes|||||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1||Chimera x C57BL/6|No|18-Dec-2008|Cryopreserved sperm|45.0|0.0|Unknown||Gene trap, retinoblastoma, Rb, APN, ES cell|Yes| 4179.0|APN7|B6;29-Ifrd1/MIMR||Recessive|interferon-related developmental regulator 1|Ifrd1|Unknown|Ifnl, PC4, Tis7|MGI:1316717|interferon-related developmental regulator 1; gene trap AZ0065, Wellcome Trust Sanger Institute|Ifrd1|MGI:3857584|12||||||||||||||||Yes|||||||||||||Unknown. Note: Homozygous null mice display impaired muscle regeneration and myogenic differentiation and decreased body weight in older mice.|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1||Chimera x C57BL/6|No|18-Dec-2008|Cryopreserved sperm|30.0|0.0|Unknown||Gene trap, APN, ES cell|Yes| 4603.0|mIMPα2FL|C57BL/6-Tg(EGFP-Kpna2 full length) ||Recessive|karyopherin (importin) alpha 2|Kpna2|Unknown|Importin alpha, m-importin, m-importin-alpha-P1, pendulin, Rch1|MGI:103561||||11||||||||||||||||Yes|EGFP fused to full length Kpna2|Protamine 1|||||||||||Unknown|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Mar-2009|Cryopreserved sperm|40.0|0.0|Unknown||nuclear transport, importin, testis|No| 4719.0|TgAPP751 (Tg80.1 line)|B6.SJL-Tg(APP751)80.1Aust ||Dominant|amyloid beta (A4) precursor protein|APP|Unknown|Abeta, Adap, appican, betaAPP, Cvap, E030013M08Rik, protease nexin II, A4, AD1|MGI:88059||||16||||||||||||||||Yes|amyloid beta (A4) precursor protein|? moPrP, hamster prion protein promotor|||||||||||? Transgene primarily expressed in brain. No overt phenotype, normal growth and breeding.||? C57BL/6 x SJL|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Apr-2009|Cryopreserved sperm|70.0|0.0|Yes||Amyloid precursor protein, amyloid Aβ, Alzheimer's disease, early onset Australian FAD mutation|No| 8306.0|AMPK a2(T485A/S491A) KI|C57BL/6-Prkaa2||Recessive|protein kinase, AMP-activated, alpha 2 catalytic subunit|Prkaa2|Unknown|2310008I11Rik, AMPKalpha2|MGI:1336173||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|19-Sep-2017|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8899.0|DmdS3059E|C57BL/6-Dmd/Apb||Recessive|Dystrophin, muscular dystrophy|Dmd|Unknown|Dp427, Dp71, Duchenne muscular dystrophy, dys, mdx, pke, X-linked muscular dystrophy|MGI:94909||||X|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Mar-2020|Cryopreserved sperm|40.0|0.0|Yes|Muscular dystrophy||Yes| 8463.0|ASD598:Albiol:AireKO|B6.129-Aire Hivep2/AnuApb||Recessive|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)|Aire|Nil||MGI:1338803|autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy); targeted mutation 1, Leena Peltonen|Aire|MGI:2182940|10|||||||||||||||||||||||||||||Unknown|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Apr-2018|Cryopreserved sperm|24.0|0.0|Unknown||T cell|Yes| 8463.0|ASD598:Albiol:AireKO|B6.129-Aire Hivep2/AnuApb||Recessive|human immunodeficiency virus type I enhancer binding protein 2|Hivep2||Gm20114, MIBP1, Schnurri-2, Shn-2|MGI:1338076|Hivep2, endonuclease-mediated mutation 1, Australian National University|Hivep2||10||||||||||Unknown to Unknown|||||||||||||||||||Unknown|Unknown|B10.BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Apr-2018|Cryopreserved sperm|||Unknown||T cell|Yes| 4436.0||C57BL/6-Tg(PDHA2-eGFP-MAP2cN)||Recessive||||||||||||||||||||||||||Enhanced green fluorescent protein (GFP) fused to microtubule-associated protein 2 (human) (EGFP-MAP2cN)|pyruvate dehydrogenase E1 alpha 2 (PDHA2)|||||||||||Appears to be infertile|||Yes|Yes|Yes|No|No|No|No|Poor||||No|17-Feb-2009|Cryopreserved sperm|18.0|0.0|Unknown||infertility, testis|Yes| 4448.0|APN16|B6;129-Dusp4/MIMR||Recessive|Dual specificity phosphatase 4|Dusp4|Unknown|MKP2|MGI:2442191|dual specificity phosphatase 4; gene trap XG164, BayGenomics|Dusp4|MGI:4127030|8||||||||||||||||Yes|||||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|0||No|20-Feb-2009|Cryopreserved sperm|70.0|0.0|Unknown||somite, clock, signal transduction, ES cell genetrap, APN|Yes| 4490.0|EphA1 conditional transgenic|B6.129-Tg(Ubc-Epha1)1Sld||Dominant||||||||||||||||||||||||||Eph receptor A1|Ubiquitin C|2.5x wildtype in tissue tested by QPCR||||||||||||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||hemizygote x wildtype|No|24-Feb-2009|Cryopreserved sperm|100.0|0.0|Unknown||receptor tyrosine kinase, migration, adhesion, embryonic|Yes| 4604.0|mIMPα2delta|C57BL/6-Tg(EGFP-Kpna2 dominant negative) ||Dominant|karyopherin (importin) alpha 2|Kpna2|Unknown|Importin alpha, m-importin, m-importin-alpha-P1, pendulin, Rch1|MGI:103561||||11||||||||||||||||Yes|EGFP fused to dominant negative Kpna2|Protamine 1|||||||||||Fertility maybe affected||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|13-Mar-2009|Cryopreserved sperm|30.0|0.0|Unknown||importin, testis, protamine 1, fertility, nuclear transport|No| 4733.0||B6;B10Br;129-Cblb Tg(MLsHEL)Ccg ||Recessive|Casitas B-lineage lymphoma b|Cblb|Nil|Cbl-b|MGI:2146430|targeted mutation 1, Josef M Penninger|Cblb|MGI:2180570|16||||||||||||||||Yes|soluble Hen Egg Lysozyme (HEL)|H-2K|high||||||||||Defect in T cell signalling||C57BL/6 x C57BL/10.Br x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|1|2||No|19-Apr-2009|Cryopreserved sperm|30.0|0.0|No||T cell, Hen Egg Lysozyme, signal transduction|Yes| 8382.0|Ighg1-cre Igk KO|B6.129P2(Cg)-Ighg1 Igk/UbAnu||Recessive|immunoglobulin kappa chain complex|Igk|Nil|kappa|MGI:96494|immunoglobulin kappa chain complex; targeted mutation 1, Dennis Huszar|Igk|MGI:2429510|6|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Dec-2017|Cryopreserved sperm|11.0|0.0|Unknown||B cell, Germinal Centre, Immunoglobulin|Yes| 8382.0|Ighg1-cre Igk KO|B6.129P2(Cg)-Ighg1 Igk/UbAnu||Recessive|immunoglobulin heavy constant gamma 1 (G1m marker)|Ighg1||IgG1, Igh-4|MGI:96446|immunoglobulin heavy constant gamma 1 (G1m marker); targeted mutation 1, University of Cologne|Ighg1|MGI:3652526|12|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Dec-2017|Cryopreserved sperm|||Unknown||B cell, Germinal Centre, Immunoglobulin|Yes| 8356.0|ASD666:Ramos:TtoC|C57BL/6NCrlAnu-Tlr7/AnuApb||X-linked|toll-like receptor 7|Tlr7|||MGI:2176882|Tlr7, endonuclease-mediated mutation 2, Australian National University|Tlr7/Anu||X||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Nov-2017|Cryopreserved sperm|33.0|108.0|Unknown|||Yes| 8552.0|Fut7 KO (line 1) |C57BL/6-Fut7/Apb||Recessive|fucosyltransferase 7|Fut7|Unknown|FTVII, Fuc-TVII, FucT-VII|MGI:107692||||2|||||||||||||||||||||||||||||Unknown. These mice have a defect in immune cell migration, which may make them more susceptible to infections. Regular monitoring is important to establish phenotype of these CRISPR mice. |Unknown. These mice have a defect in immune cell migration, which may make them more susceptible to infections. Regular monitoring is important to establish phenotype of these CRISPR mice. |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|28-Aug-2018|Cryopreserved sperm|20.0|0.0|Unknown|||Yes| 4438.0|APN14|B6.129-Kdm1a/MIMR||Recessive|lysine (K)-specific demethylase 1A|Kdm1a|Unknown|Aof2, Kdm1, LSD1, mKIAA0601|MGI:1196256|lysine (K)-specific demethylase 1A; gene trap XP0207, Wellcome Trust Sanger Institute|Kdm1a|MGI:3858605|4||||||||||||||||No|||||||||||||Unknown for genetrap. Germline deletion of Aof2 causes early embryonic lethality (E7.5) probably due to defects in pituitary development and hormone production.||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown|1|||No|17-Feb-2009|Cryopreserved sperm|40.0|0.0|Unknown||ES cell genetrap, APN, pituitary, embryonic lethal|Yes| 4952.0|APN 15|B6.129-Slc2a3/MIMR||Recessive|solute carrier family 2 (facilitated glucose transporter), member 3|Slc2a3|Reduced|Glut-3, Glut3|MGI:95757|solute carrier family 2 (facilitated glucose transporter), member 3; gene trap XG611, BayGenomics|Slc2a3|MGI:3822325|6||||||||||||||||||||||||||||||Nervous system phenotype:* no paroxysmal EEG activity* no epileptic seizuresAbnormal brain wave pattern: absolute EEG power densities show a slight but significant elevation.Decreased prepulse inhibition:* significant reduction in inhibition by a low intensity prepulse* inhibition due to a high intensity prepulse is normalBehavior/neurological phenotype:* performance normal in rotarod, open field, and shuttle box tests.* normal performance in a Morris water maze.* generally normal responses in anxiety related tests although some trends are noted.Increased anxiety-related response:* preference for closed compartment in elevated maze.* increased tendency to stay in illuminated areas in light/dark avoidance tests.Increased startle reflex: increased startle response.|C57BL/6 x 129|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|14-Dec-2009|Cryopreserved sperm|81.0|0.0|Unknown||GLUT3, behaviour, anxiety|No| 4974.0|C151 CD9 DKO|C57BL/6-CD151 CD9||Recessive|Cd151 antigen|Cd151|Nil|PETA-3, SFA-1, Tspan24|MGI:1096360|targeted mutation 1, Leonie K Ashman|Cd151|MGI:3050539|7||||||||||||||||Yes|||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|60.0|0.0|Unknown||epithelium, integrin, fibroblast, wound, migration|Yes| 4974.0|C151 CD9 DKO|C57BL/6-CD151 CD9||Recessive|CD19 antigen|Cd9|Nil|Tspan29|MGI:88348|targeted mutation 1, Claude Boucheix|Cd9|MGI:2180795|6||||||||||Unknown to Unknown|||||||||||||||||||||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|||Unknown||epithelium, integrin, fibroblast, wound, migration|Yes| 8528.0|17NF|B6.Cg-Tg(Cyp17a1-NGF)2456Oje/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 2456, Sergio R Ojeda|17alpha-hydroxylase promoter|thecal-interstitial cells||||||||||Polycystic ovary disease|||Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|29-Jun-2018|Cryopreserved sperm|44.0|0.0|Yes|polycystic ovarian syndrome (PCOS)|ovarian nerve growth factor (NGF), ovulation|Yes| 8279.0|Tet2fl/fl|B6.129-Tet2/J||Recessive|tet methylcytosine dioxygenase 2|Tet2||Ayu17-449, E130014J05Rik, mKIAA1546|MGI:2443298|tet methylcytosine dioxygenase 2; targeted mutation 1.1, Iannis Aifantis|Tet2|MGI:5141120|3|||||||||||||||||||||||||||||Normal (conditional line)|Normal (conditional line)|C57Bl/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|09-Aug-2017|Cryopreserved sperm|40.0|0.0|Unknown||Myeloid, stem cell|Yes| 4905.0|Stiliom; ENU4AT:032|C57BL/6JSfdAnu-Tomm40/AnuApb||Semi-dominant|translocase of outer mitochondrial membrane 40 homolog (yeast)|Tomm40|Nil|Tom40|MGI:1858259|Stiliom|Stil||7|ENSMUSG00000002984|ENSMUST00000093552|Tomm40-202|977|1048|C to T|ENSMUSE00000582554|10|326|Alanine to Valine|||||CTCTGTGAACAGTAACTGGATCGTGGGCGCCACGCTGGAGAAGAAGCTTCCGCCCTTGCCC|Yes|||||||||||||Lethal lung haemorrhage at 4 – 6 weeks, blood vessel fragility may be caused by suspected transdifferentiation of smooth muscle cells into skeletal muscle (a physiological process in the oesophagus) occurring throughout the body.TOM complex is absent in Blue-native PAGE analysis|Blue-native PAGE shows reduced levels of TOM complex in mitochondria in HETs; Monomeric Tomm40 is detected, but the mutant version of the protein migrates faster on SDS-PAGE than the wild-type protein (data from Diana Stojanovski and Mike Ryan at Latrobe.|C57BL/6SfdAnu x B10.BR x CBA|Yes|No|Yes|Yes|No|Yes|No|Unknown||||No|09-Oct-2009|Cryopreserved sperm|32.0|0.0|Unknown||lung, haemorrhage, smooth muscle, mitochondrial myopathy, skeletal muscle, differentiation, blood vessel, transdifferentiation, JDRF, ENU|Yes| 5045.0|APN27|B6;129P2/OlaHsd-Rbm5/MAS||Recessive|RNA binding motif protein 5|Rbm5|Unknown||MGI:1933204|RNA binding motif protein 5; gene trap PST20293, Mammalian Functional Genomics Centre|Rbm5|MGI:3902497|9||||||||||||||||No|||||||||||||Unknown|Unknown|C57BL/6 x 129P2/OlaHsd|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|25-Feb-2010|Cryopreserved sperm|54.0|0.0|Unknown||RNA, ES cell|Yes| 5047.0|NOD.pIgR-/- R2 N13|NOD.B6(pIgR-D1Mit348)N13-Pigr||Recessive|polymeric immunoglobulin receptor|Pigr|Unknown||MGI:103080|polymeric immunoglobulin receptor; targeted mutation 1, Richard A Strugnell|Pigrtm1|MGI:2651659|1||||||||||||||||No|||||||||||||Like B6.pIgR-/- mice (described in Uren et al., 2003), this mouse strain does not produce functional pIgR, and therefore lacks IgA in secretions and has increased levels of IgA in serum. The incidence of diabetes in female mice is about 40% after 43-weeks, which is significantly lower than the incidence of diabetes in NOD/Lt mice in host facility (~60% at 43-weeks of age).|Like B6.pIgR+/- mice, heterozygotes of this mouse strain produce functional pIgR, and have normal levels of IgA in secretions, however the levels of IgA in serum are intermediate between NOD/Lt and NOD.pIgR-/-. The incidence of diabetes has not been tested in heterozygotes of this mouse strain.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|13|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5048.0|NOD.pIgR-/- R0 N10|NOD.B6(D1Mit48-D1Mit348)N10-Pigr||Recessive|polymeric immunoglobulin receptor|Pigr|Unknown||MGI:103080|||MGI:2651659|1||||||||||||||||No|||||||||||||Like B6.pIgR-/- mice (described in Uren et al., 2003), this mouse strain does not produce functional pIgR, and therefore lacks IgA in secretions and has increased levels of IgA in serum. The incidence of diabetes in female mice is 75-85% after 43-weeks, which is significantly higher than the incidence of diabetes in female NOD/Lt mice in our facility (50-60% at 43-weeks of age). The incidence of diabetes in male mice is 25-50% after 43 weeks of age, which is significantly higher than the incidence of diabetes in male NOD/Lt mice in our facility (5-10% at 43-weeks of age).|Like B6.pIgR+/- mice, heterozygotes of this mouse strain produce functional pIgR, and have normal levels of IgA in secretions, however the levels of IgA in serum are intermediate between NOD/Lt and NOD.pIgR-/-. The incidence of diabetes in heterozygous females is 70%, and heterozygous males is 30%. |NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5049.0|NOD.pIgR-/- R1 N10|NOD.B6(D1Mit495-D1Mit348)N10-Pigr||Recessive|polymeric immunoglobulin receptor|Pigr|Unknown||MGI:103080|||MGI:2651659|1||||||||||||||||No|||||||||||||Like B6.pIgR-/- mice (described in Uren et al., 2003), this mouse strain does not produce functional pIgR, and therefore lacks IgA in secretions and has increased levels of IgA in serum. The incidence of diabetes in female mice is 60-65% after 43-weeks, which is consistently, but not significantly higher than the incidence of diabetes in NOD/Lt mice in host facility (50-60% at 43-weeks of age). The incidence of diabetes in mice of this strain is not significantly different from NOD/Lt males in our facility.|Like B6.pIgR+/- mice, heterozygotes of this mouse strain produce functional pIgR, and have normal levels of IgA in secretions, however the levels of IgA in serum are intermediate between NOD/Lt and NOD.pIgR-/-. The incidence of diabetes of heterozygote females is 63% at 40-weeks of age.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5050.0|NOD.pIgR-/- R1 N14|NOD.B6(D1Mit495-D1Mit348)N14-Pigr||Recessive|polymeric immunoglobulin receptor|Pigr|Unknown||MGI:103080|||MGI:2651659|1||||||||||||||||No|||||||||||||Like B6.pIgR-/- mice (described in Uren et al., 2003), this mouse strain does not produce functional pIgR, and therefore lacks IgA in secretions and has increased levels of IgA in serum. The incidence of diabetes has not been tested for this strain but it is expected that it would be the same as the NOD.pIgR-/- R1 N10 strain (female mice is 60-65% after 43-weeks, the incidence of diabetes in NOD/Lt mice in host facility is 50-60% at 43-weeks of age). |Like B6.pIgR+/- mice, heterozygotes of this mouse strain produce functional pIgR, and have normal levels of IgA in secretions, however the levels of IgA in serum are intermediate between NOD/Lt and NOD.pIgR-/-. |NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|14|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5054.0|NOD.B6 R11 N12|NOD.B6(D1Mit495-D1Mit286)N12||Recessive||||||||||||||||||||||||||||||||||||||The incidence of diabetes has not been tested in this mouse strain as yet but may prove useful in the dissection of the Idd5.4 susceptibility locus.|The incidence of diabetes has not been tested in heterozygotes of this mouse strain.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|12|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5079.0|Fzd5|C57BL/6-Fzd5||Recessive|frizzled homolog 5 (Drosophila)|Fzd5|Normal|Fz5|MGI:108571|frizzled homolog 5 (Drosophila); targeted mutation 1, Hans Clevers|Fzd5|MGI:3583769|1||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|20||Maintained as heterozygous by crossing to C57BL/6|No|25-Mar-2010|Cryopreserved sperm|50.0|0.0|Unknown||Wnt pathway, Cre recombinase|Yes| 8417.0|Egr2-GFP|B6.Cg-Egr2/Anu||Recessive|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296||||10||||||||||||||||||||||||||||||||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Jan-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8305.0|APPPS1|B6.C3-Tg(APPswe,PSEN1dE9)85Dbo/JAusbAnu|B6.C3-Tg(APPswe,PSEN1dE9)85Dbo/JAusbAnu|Dominant||||||||||||||||||||||||||transgene insertion 85, David R Borchelt|mouse prion protein |Predominantly to CNS neurons||||||||||Unknown|Mice develop beta amyloid deposits in brain by 6 or 7 months of age. The humanized Mo/HuAPP695swe transgene allows the mice to secrete a human A-beta peptide.A slight alteration in the tail can occur due to mixed background.|C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|1|1|Maintained as a hemizygote by crossing transgenic mice to B6C3F1/J mice|No|14-Sep-2017|Cryopreserved sperm|15.0|187.0|Yes|Alzheimers|CNS neurons, hippocampus, amyloid beta peptide , astrocytosis|Yes| 5051.0|NOD.pIgR-/- R2 N15|NOD.B6(pIgR-D1Mit348)N15-Pigr||Recessive|polymeric immunoglobulin receptor|Pigr|Unknown||MGI:103080|||MGI:2651659|1||||||||||||||||No|||||||||||||Like B6.pIgR-/- mice (described in Uren et al., 2003), this mouse strain does not produce functional pIgR, and therefore lacks IgA in secretions and has increased levels of IgA in serum. The incidence of diabetes in female mice is about 40% after 43-weeks, which is significantly lower than the incidence of diabetes in NOD/Lt mice in our facility (~60% at 43-weeks of age).|Like B6.pIgR+/- mice, heterozygotes of this mouse strain produce functional pIgR, and have normal levels of IgA in secretions, however the levels of IgA in serum are intermediate between NOD/Lt and NOD.pIgR-/-. The incidence of diabetes has not been tested in heterozygotes of this mouse strain.|NOD/Lt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|15|8|Hom x Hom|No|26-Feb-2010|Cryopreserved sperm|45.0|0.0|Yes|Type 1 Diabetes|IgA, IgM, Idd5.4, B cell|Yes| 5064.0|Zic5 K363R:C3H/HeH|C3H/HeH-Zic5||Recessive|Zinc finger protein of the cerebellum 5|Zic5|Unknown|odd-paired related, Opr|MGI:1929518||||14||||||||||||||||Yes|||||||||||||Viable and fertile|Viable and fertile|C3H/HeH|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10||Homozygote male paired with homozygote female|No|25-Mar-2010|Cryopreserved sperm|30.0|0.0|Unknown||zinc finger, ENU|Yes| 5114.0|ENU7B6:039 (CD8)|C57BL/6JSfdAnu-Senp2/AnuApb|C57BL/6JSfdAnu-Senp2/AnuApb|Recessive|SUMO/sentrin specific peptidase 2|Senp2|Unknown||MGI:1923076|SUMO/sentrin specific peptidase 2; mutation 1, The Australian National University|Senp2|MGI:5563407|16|ENSMUSG00000022855|ENSMUST00000023561| Senp2-201|939|1097|A to G|ENSMUSE00000131327|11|313|Glycine to Glycine|||||CTCCGATTTGAAAAGGAAGGTACAAGAGGACACCAAATGGAGCCTGATCTGTCAGAAGAAG|Yes|||||||||||||Subclinical autoimmune susceptibility. Antinuclear autoantibodies: homogeneous nuclear.Low CD8 protein expression and reduced T cell numbers.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-May-2010|Cryopreserved sperm|60.0|0.0|Unknown||autoimmunity, antinuclear antibodies (ANA), ENU, Wellcome Trust, T cell, CD8|Yes| 5097.0|Hic1lox|C57BL/6-Hic1/MarpApb||Dominant|Hypermethylated in Cancer-1|Hic1|Normal||1338010|Hic1lox|Hic1||11|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|3||homozygote to homozygote|No|27-Apr-2010|Cryopreserved sperm|43.0|0.0|Unknown||Hic1, epigenetics, development, cancer|Possibly| 5105.0|APN23, RRR232|B6;129-Tbc1d15/Marp||Recessive|TBC1 domain family, member 15|Tbc1d15|Unknown|Ly6dl|MGI:1913937|TBC1 domain family, member 15; gene trap RRR232, BayGenomics|Tbc1d15|MGI:4397430|10||||||||||||||||No|||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|30-Apr-2010|Cryopreserved sperm|50.0|0.0|Unknown||Genetrap, ES cell|Yes| 5198.0|tghFS315(mFS WT)|Transgenic Human Follistatin 315 on mouse wildtype follistatin background||Dominant||||||||||||||||||||||||||Human follistatin-315 splice variant|endogenous human promoter|unknown||||||||||Unknown|Hemizygous: normal Note: An abnormal phenotype is not observed until these mice are bred onto a mouse follistatin knockout background|129 x C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|04-Aug-2010|Cryopreserved sperm|50.0|0.0|No||FST315, FST288, angiogenesis, ovary|Possibly| 5220.0|Lyn|C57BL/6-Lyn||Semi-dominant|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Normal|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 2, Margaret Hibbs|Lyn||4||||||||||||||||Yes|||||||||||||The mice carry a mutation in the ATP-binding site of Lyn kinase (K275M) which renders the kinase catalytically inactive. Lyn mice have reduced numbers of recirculating B cells, their B cells have an activated phenotype and they are hyper-responsive to B cell antigen receptor cross-linking. Lyn mice develop titres of circulating autoantibodies with age but they are reduced compared to age-matched Lyn<-/-> mice. The findings to date demonstrate considerable phenotypic similarity between this Lyn kinase-dead strain and Lyn<-/-> mice. |Similar to homozygous state but with reduced severity.|C67BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Sep-2010|Cryopreserved sperm|100.0|0.0|Unknown||signal transduction, phosphatase, tyrosine, myeloid, neutrophil, B cell, src family, lymphocyte|Yes| 5224.0|BALB.Lyn up/up STAT6 knockout mice; BALB.Lyn-Y508FSTAT6 -/-|BALB/c-Lyn Stat6/Apb||Recessive|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Reduced|Hck-2|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Margaret Hibbs|Lyn|MGI:2157016|4|||||||||||||||||||||||||||||Not well defined|Not defined|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Oct-2010|Cryopreserved sperm|50.0|0.0|Unknown||src family, signal transduction, inflammation, lung, tyrosine kinase, phosphorylation|Yes| 5224.0|BALB.Lyn up/up STAT6 knockout mice; BALB.Lyn-Y508FSTAT6 -/-|BALB/c-Lyn Stat6/Apb||Recessive|signal transducer and activator of transcription 6|Stat6|Nil||MGI:103034|signal transducer and activator of transcription 6; targeted mutation 1, Shizuo Akira|Stat6|MGI:2386746|10||||||||||||||||No|||||||||||||Not well defined|Not defined|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Oct-2010|Cryopreserved sperm|||Unknown||src family, signal transduction, inflammation, lung, tyrosine kinase, phosphorylation|Yes| 5314.0|BALB.Lyn up/up |BALB/c-Lyn/Apb||Semi-dominant|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog|Lyn|Reduced|Lyn, Lyn|MGI:96892|Yamaguchi sarcoma viral (v-yes-1) oncogene homolog; targeted mutation 1, Margaret Hibbs|Lyn|MGI:2157016|4||||||||||||||||Yes|||||||||||||The mice carry a gene-targeted gain-of-function mutation in the Lyn tyrosine kinase (Y508F). The mice display a severe diminution of mature B cells but have increased numbers of B1a B cells. Their B cells display marked down-regulation of surface IgM, Ig-beta, CD19, CD21 and CD22, and they are poorly responsive to B cell receptor cross-linking. Unlike mixed genetic background Lyn mice, BALB/c background mice are not autoimmune-prone. Due to the dominant nature of the gain-of-function Lyn mutation, Lyn-expressing cells from Lyn mice show hyper-phosphorylation of many signaling proteins.On the BALB/c genetic background, the mice develop a severe inflammatory lung disease that resembles bullous emphysema. The disease is obvious in 12 wk old mice.|Lyn<+/up> mice show a reduction in numbers of B cells and Lyn-expressing cells show hyper-phosphorylation of many signaling proteins.|Balb/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|09-Nov-2010|Cryopreserved sperm|50.0|0.0|Unknown||kinase, phosphorylation, signal transduction, ITIM, tyrosine|Yes| 5317.0|Kamu ; ENU14WT:020|C57BL/6JAnu-Pde2a/AnuApb|C57BL/6JAnu-Pde2a/AnuApb|Recessive|phosphodiesterase 2A, cGMP-stimulated|Pde2a|||MGI:2446107|phosphodiesterase 2A, cGMP-stimulated; mutation 1, The Australian National University|Pde2a|MGI:5563440|7|ENSMUSG00000030653|ENSMUST00000084894|Pde2a-202|2198|2425|T to C|ENSMUSE00000633282|26|733|Leucine to Proline|||||GCACCACTTTGCTCAAGCCATTGCTATCCTCAACACCCACGGCTGCAATATCTTTGACCAC|Yes|||||||||||||Pale embryos at E14.5 with hematopoetic development defect manifesting in a tiny/absent fetal liver and increase in primitive red blood cells|Unknown|C57BL/6JAnu|No|No|Yes|No|No|Yes|No|Good||||No|12-Nov-2010|Cryopreserved sperm|10.0|0.0|Unknown||ENU, haemopoiesis, stem cell|Yes| 5496.0|A33:Lgp130YFKQ ; TgNA33L-gp130YFKQ (line 10) (ME-216)|CB;129-Tg(Gpa33-Il6st*)10Ern/Lud||Dominant||||||||||||||||||||||||||transgene insertion 10, Matthias Ernst|glycoprotein A33 (transmembrane)|||||||||||Unknown|Unknown|CBA x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||stat, epithelium, colon|Yes| 5333.0|ENU16FOX:020 B6.129-Tg(FoxP3-GFP)|B6.129-Zap70 Foxp3/AnuApb||Recessive|zeta-chain (TCR) associated protein kinase|Zap70||Srk, TZK, ZAP-70|MGI:99613||||1|ENSMUSG00000026117|ENSMUST00000027291|Zap70‐201|728|830|C to T|ENSMUSE00000155943|5|243|Alanine to Valine|||||GCAGCTGGTGGAGTACCTGAAGCTGAAGGCGGATGGACTAATTTACCGCTTGAAGGAGGTC|Unknown|||||||||||||Elevated regulatory T cell population. Phenotype detected by peripheral blood FACS.Cells from the Foxp3-gfp background strain that express FoxP3 fluoresce green, predominantly T cells|Normal |129 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Affected x affected|Yes|26-Nov-2010|Cryopreserved sperm|45.0|0.0|Unknown||regulatory T cells, immunology|Possibly| 5333.0|ENU16FOX:020 B6.129-Tg(FoxP3-GFP)|B6.129-Zap70 Foxp3/AnuApb||Recessive|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|forkhead box P3; targeted mutation 2, Alexander Y Rudensky|Foxp3|MGI:3574964|X|||||||||||||||||||||||||||||Elevated regulatory T cell population. Phenotype detected by peripheral blood FACS.Cells from the Foxp3-gfp background strain that express FoxP3 fluoresce green, predominantly T cells|Normal |129 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Affected x affected|Yes|26-Nov-2010|Cryopreserved sperm|||Unknown||regulatory T cells, immunology|Possibly| 5470.0|APN 82|C57BL/6N-Gkn2/Marp||Recessive|gastrokine 2|Gkn2|Unknown||MGI:1913534|gastrokine 2; targeted mutation 1, Velocigene|Gkn2|MGI:4399717|6||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 5472.0|APN 87 ; Golga4|B6;129/Ola-Golga4/Marp||Recessive|golgi autoantigen, golgin subfamily a, 4|Golga4|Nil|golgin-245, Olp-1 |MGI:1859646 |golgi autoantigen, golgin subfamily a, 4; gene trap XG298, BayGenomics|Golga4|MGI:4125759|9||||||||||||||||Yes|||||||||||||Not bred to homozygocity|Normal|C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|25-Mar-2011|Cryopreserved sperm|50.0|0.0|Unknown||Gene trap, ES cell|Yes| 5475.0|ENU1WT:049|C57BL/6JAnu-Knyn/Anu||Recessive|||Unknown|||kanyon|knyn|MGI:5510719|7||||||||||||||||Yes|||||||||||||Skeletal defect, exencephaly at embryonic day 13.5.Facial clefts.|Normal|C57BL/6JAnu|No|No|Yes|No|No|Yes|Yes|Unknown|||het x het|No|06-Apr-2011|Cryopreserved sperm|50.0|0.0|Yes|frontonasal dysplasias (OMIM 136760)|exencephaly, skeletal, bone, development, embryonic, ENU|Possibly| 5486.0|ENU20FLT3-ITD:G1(#37)|ENU20FLT3-ITD:G1||Dominant|FMS-like tyrosine kinase 3|Flt3|Increased|CD135, Flk-2, Flk2, Flt-3|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5||||||||||||||||Yes|||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G1||No|19-Apr-2011|Cryopreserved sperm|10.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 5486.0|ENU20FLT3-ITD:G1(#37)|ENU20FLT3-ITD:G1||Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G1||No|19-Apr-2011|Cryopreserved sperm|||Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 5485.0|ENU18FLT3-ITD:G2 #58|ENU18FLT3-ITD:G2||Dominant|FMS-like tyrosine kinase 3|Flt3|Increased|CD135, Flk-2, Flk2, Flt-3|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5||||||||||||||||Yes|||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G2||No|19-Apr-2011|Cryopreserved sperm|20.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 5485.0|ENU18FLT3-ITD:G2 #58|ENU18FLT3-ITD:G2||Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G2||No|19-Apr-2011|Cryopreserved sperm|||Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 4085.0||ENU7PMH:139, Metabolic Lean 3||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||Low percentage of body fat when fed on a high fat diet.||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||3||No|04-Dec-2008|Cryopreserved sperm|40.0|0.0|No||ENU, Obesity, Diet, Fat, Adipose|No| 4087.0||ENU8PH:139, Metabolic Obese 1||Recessive|||||||||Unknown||||||||||||||||Yes|||||||||||||High percentage of body fat on a low fat diet||C57BL/6 x C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||3||No|04-Dec-2008|Cryopreserved sperm|30.0|0.0|Unknown||ENU, Obesity, Diet, Fat, Adipose|Possibly| 4772.0|4AT31|ENU4AT:031||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|50.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4772.0|4AT31|ENU4AT:031||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 5442.0|81.BR ; (ADAR2—/—/AGluR-B)|B6;129-Adarb1 Gria2||Recessive|adenosine deaminase, RNA-specific, B1|Adarb1|Reduced|ADAR2, D10Bwg0447e, RED1|MGI:891999|adenosine deaminase, RNA-specific, B1; targeted mutation 1, Peter H Seeburg|Adarb1|MGI:2178079|10||||||||||||||||No|||||||||||||No abnormal phenotype detected: double homozygous null mice appear normal at all ages, as judged by food intake, weight increase, postnatal development, breeding and general behavior (full rescue)|Adarb1/Adarb1Gria2/Gria2<+>Postnatal lethality: compound mutant mice survive up to P35 (partial rescue; extended postnatal survival).|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|Unknown|||No|17-Feb-2011|Cryopreserved sperm|49.0|0.0|Unknown||AMPA receptor, ion channel, motor neuron, RNA, deamination|Yes| 5442.0|81.BR ; (ADAR2—/—/AGluR-B)|B6;129-Adarb1 Gria2||Recessive|glutamate receptor, ionotropic, AMPA2 (alpha 2)|Gria2||Glur-2, GluR-B, GluR2, Glur2|MGI:95809|glutamate receptor, ionotropic, AMPA2 (alpha 2); targeted mutation 1.1, Peter H Seeburg|Gria2|MGI:2178125|3||||||||||||||||Yes|||||||||||||No abnormal phenotype detected: double homozygous null mice appear normal at all ages, as judged by food intake, weight increase, postnatal development, breeding and general behavior (full rescue)|Adarb1/Adarb1Gria2/Gria2<+>Postnatal lethality: compound mutant mice survive up to P35 (partial rescue; extended postnatal survival).|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown|Unknown|||No|17-Feb-2011|Cryopreserved sperm|||Unknown||AMPA receptor, ion channel, motor neuron, RNA, deamination|Yes| 5542.0|Wonggan (Wong); ENU14nih 002|ENU14NIH:002||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Embryos @14.5 appear smaller than normal, have increased KLS cell in fetal liver, increased primitive RBCs and decreased definitive RBCs.|normal|C57BL/6JAnu x C57BL/10|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|19-Jul-2011|Cryopreserved sperm|18.0|0.0|Unknown||red blood cell|Possibly| 5546.0|ENU15China:072a|C57BL/6JAnu-Ptpn6/AnuApb|C57BL/6JAnu-Ptpn6/AnuApb|Dominant|protein tyrosine phosphatase, non-receptor type 6|Ptpn6 |Reduced|hcp, Hcph, Ptp1C, SHP-1, Spin|MGI:96055|protein tyrosine phosphatase, non-receptor type 6; mutation 1, The Australian National University|Ptpn6|MGI:5563436|6|ENSMUSG00000004266|ENSMUST00000004377|Ptpn6-003|1385|1498|C to T|ENSMUSE00000195628|12|462|Threonine to Methionine|||||TGTGCATTGCAGCGCTGGCATCGGCCGCACGGGCACCATCATCGTCATTGATATGCTTATG||||||||||||||Homozygous mice are unhealthy at weaning and are usually euthanised.Mice that survive to 8 weeks have a reduced percent of B cells and few mature B cells. Phenotype measured by flow cytometry using antibodies against the following antigens: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD|Reduced IgM expression on mature B cells as measured by flow cytometry.Phenotype measured by flow cytometry using antibodies against the following antigens: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD|C57BL/6JAnu|Yes|No|Yes|Yes|No|Yes|No|Good|4-6|4|Affected x B6|No|01-Aug-2011|Cryopreserved sperm|58.0|0.0|Unknown||B cell, IgM|Possibly| 5566.0|ENU20Bcl2.05 VavP-BCL2-69; C57BL/6-Tg(Vav-BCL2)1Jad/Wehi|B6(Cg)-Nin Tg(Vav-BCL2)1Jad/WehiAnuApb||Dominant|ninein|Nin||3110068G20Rik, mKIAA1565|MGI:105108||||12|ENSMUSG00000021068|ENSMUST00000085314|Nin-001|1240|1240|A to G|ENSMUSE00000114325|9|414|Asparagine to Glycine|||||TGGACGATCACCACGCGGCCATTGAGCGGAGGAATGAATACAACCTCAGGAAACTGGATGA||transgene insertion 1, Jerry M Adams|mouse Vav promoter|High, haemopoietic cells||||||||||Increased numbers of Monocytes and Granulocytes in peripheral blood|Abnormal lymphocyte cell number:* the ratio of CD4 cells per B cell is 25% to 50% lower than in wild-type mice.Increased B cell number: 5-fold higher in the spleen at 18 weeksIncreased T cell number:* mice exhibit higher splenic T cell numbers than in wild-type and Tg(BCL2)22Wehi or Tg(BCL2)36Wehi mice.Increased CD4-positive T cell number:* the increase in CD4+ T cells is greater than the increase in CD8+ T cells.Increased CD8-positive T cell number:* the increase in CD4+ T cells is greater than the increase in CD8+ T cells.Abnormal class switch recombination:* the total number of B cells that undergo class switching is 50-fold higher than in wild-type mice.Abnormal somatic hypermutation frequency:* 22 of 23 clones isolated from class-switching cells harbor on average about 6 somatic mutations compared to in wild-type cells where no mutations are found.Enlarged spleen:Abnormal spleen germinal center morphology:* mice exhibit a larger pool of cycling B cells with a germinal center phenotype than in wild-type mice.* at 18 weeks, mice exhibit an increased in germinal center size and number compared to in wild-type mice.* however, expansion of germinal centers is dependent on CD4 T cell help.Increased spleen germinal center number: at 18 weeks.Increased spleen germinal center size: at 18 weeks.Enlarged lymph nodes.Glomerulonephritis:* at 40 weeks, 15% to 25% of mice develop autoimmune glomerulonephritis.Increased tumor incidence:* 12% of mice develop plasma cell tumorsLymphoma: less than 10% of mice develop lymphoblastic lymphomas.B cell derived lymphoma:* less than 10% of mice develop large cell B lymphomasFollicular lymphoma:* at 18 months, 37% to 50% of mice develop monoclonal follicular lymphoma.Thymic lymphoma: in less than 10% of miceHistiocytic sarcoma: in less than 10% of mice.|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Aug-2011|Cryopreserved sperm|12.0|0.0|Unknown||B cell, bcl-2, vav, Progenitor, lymphoma, germinal centre, granulocyte|Yes| 4773.0|4AT62|ENU4AT:062||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|90.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4773.0|4AT62|ENU4AT:062||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4775.0|5AT142|ENU5AT:142||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|50.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4775.0|5AT142|ENU5AT:142||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background (see figure). Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4810.0|Burnum|ENU8BAT:061||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|30.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4810.0|Burnum|ENU8BAT:061||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4814.0|Alba|ENU8BAT:079||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|45.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4814.0|Alba|ENU8BAT:079||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 6904.0|APN125|C57Bl/6N-Ptcra/Marp||Recessive|pre T cell antigen receptor alpha|Ptcra|Unknown|pT-alpha, pT[a], pTalpha|MGI:104857|pre T cell antigen receptor alpha; targeted mutation 2a, Helmholtz Zentrum Muenchen GmbH|Ptcratm2a(EUCOMM)Hmgu|MGI:4434686|17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|31-May-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 4804.0|Mallee|ENU8BAT:018||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|40.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4804.0|Mallee|ENU8BAT:018||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4805.0|Akama|ENU8BAT:022||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|45.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4805.0|Akama|ENU8BAT:022||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4806.0|Koora|ENU8BAT:032||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|25.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4806.0|Koora|ENU8BAT:032||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4807.0|Jayne|ENU8BAT:023||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Male infertility. Mutant found in HEL:TCR ENU library.HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|45.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|Possibly| 4807.0|Jayne|ENU8BAT:023||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Male infertility. Mutant found in HEL:TCR ENU library.HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|||Yes|Male Infertility|ENU, fertility, sperm|Possibly| 4907.0|ENUstrain:005|High Five||Recessive||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background. Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Oct-2009|Cryopreserved sperm|100.0|0.0|Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 4907.0|ENUstrain:005|High Five||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Heightened susceptibility to autoimmune diabetes on the transgenically sensitized TCR x insHEL background. Phenotype Screen: Urine glucose|Normal|C57BL/6 x B10BR x CBA|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Oct-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, JDRF, T cell, autoimmunity|Possibly| 7578.0|Inpp5efl|C57BL/6-Inpp5e/Marp||Dominant|inositol polyphosphate-5-phosphatase E|Inpp5e|Normal|1200002L24Rik, 72kDa, mKIAA0123|MGI:1927753|inositol polyphosphate-5-phosphatase E; targeted mutation 1, Christina A Mitchell|Inpp5e|MGI:5823279|2||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jan-2014|Cryopreserved sperm|50.0|0.0|Unknown||cilia|Possibly| 4809.0|Cooee|ENU8BAT:044||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|75.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose, JDRF|Possibly| 4809.0|Cooee|ENU8BAT:044||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose, JDRF|Possibly| 4812.0|ENU8BAT:070:Wash|C57BL/6JSfdAnu-Henmt1/AnuApb||Recessive|HEN1 methyltransferase homolog 1 (Arabidopsis)|Henmt1|Unknown|4921515J06Rik, Hen1|MGI:1913965||||3|ENSMUSG00000045662|ENSMUST00000106586|4921515J06Rik-204||||||||108745775|3|||ATTTAGTGGATCGCCATGAACCCAAGAAGGTAATTATTATTATTATTATTGTTATTATTA|Yes|||||||||||||Male infertility. Mutant found in HEL:TCR ENU library.HEL:TCR transgenes not required for mutant phenotype||C57BL/6 x CBA x C57BL/10BR|Yes|Yes|Yes|Yes|No|Yes|No|Poor||||No|24-Sep-2009|Cryopreserved sperm|125.0|0.0|Yes|Male Infertility|ENU, fertility, sperm|Possibly| 4983.0|6AT:HELxTCR:14:non-lactation:G5|ENU6AT:14:non-lactation||Recessive|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Mothers fail to lactate|Normal|C57BL/6 x CBA|Yes|No|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|25.0|0.0|Unknown||ENU, lactation, fertility, milk|Yes| 5082.0|Slc2a6 (Glut6) KO|C57BL/6-Slc2a6||Recessive|solute carrier family 2 (facilitated glucose transporter), member 6|Slc2a6|Normal|Glut6, Glut9|MGI:2443286||||2||||||||||||||||Yes|||||||||||||Unknown|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|25-Mar-2010|Cryopreserved sperm|30.0|0.0|Unknown||transporter, glucose, channel|Possibly| 5089.0|Mulberry ; Mulkirri|B10;B6JAnu-Pde2a/AnuApb||Recessive|phosphodiesterase 2A, cGMP-stimulated|Pde2a|||MGI:2446107||||7|ENSMUSG00000030653|ENSMUST00000084894|Pde2a-202|1964|2191|A to T|ENSMUSE00000633285|23|655|Histidine to Leucine|||||CCGGGATCCACCCTACCACAACTGGATGCACGCCTTCTCTGTCTCTCATTTTTGCTACCTG|Yes|||||||||||||Reduced fetal liver size in embryos at E14.5.Increase % of primitive RBCs and HSCs.|Normal|C57BL/6 x C57BL/10|No|No|Yes|No|No|Yes|No|Good||||No|12-Apr-2010|Cryopreserved sperm|19.0|0.0|Unknown||ENU, haemopoietic stem cell, RBC|Possibly| 5090.0|ALZ17|C57BL/6-Tg(Thy1-MAPT)ALZ17Godt||Dominant||||||||||||||||||||||||||transgene insertion ALZ17, Michel Goedert|murine Thy1||||||||||||Neuron-specific expression of the longest human brain isoform 17 of MAPT.Transgenic mice aged 3 weeks to 25 months overexpressed human tau protein in nerve cells of brain and spinal cord. Numerous abnormal, tau-immunoreactive nerve cell bodies and dendrites were seen. In addition, large numbers of pathologically enlarged axons containing neurofilament- and tau-immunoreactive spheroids were present, especially in spinal cord. Signs of Wallerian degeneration and neurogenic muscle atrophy were observed. When motor function was tested, transgenic mice showed signs of muscle weakness. Taken together, these findings demonstrate that overexpression of human four-repeat tau leads to a central and peripheral axonopathy that results in nerve cell dysfunction and amyotrophy. |C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Apr-2010|Cryopreserved sperm|40.0|0.0|Yes|Frontotemporal dementia and parkinsonism|frontotemporal dementia, parkinson disease, axonopathy, amyotrophy, nerve, tau|Possibly| 4815.0|Hanya|ENU8BAT:083||Recessive|||||||||Unknown|||||||||||||||||transgene insertion 3, Christopher C Goodnow|Rat insulin promoter|Expression of the inserted sequence specifically to pancreatic islet beta cells||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|15.0|0.0|Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 4815.0|Hanya|ENU8BAT:083||Recessive||||||||||||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice carrying the ins-HEL gene have a subclinical predisposition to diabetes due to islet cell failure. Mice carrying the insHEL and TCR transgenes have asubclinical predisposition to autoimmune destruction of the beta cell. Screening mice by urine glucose test. High glucose levels indicate diabetes and thus autoimmunity. "Early onset diabetes" definition changed during screen from approx 80 days to 40 days.||C57BL/6 x C57BL/10BR|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Breed diabetic Double transgenic with a non transgenic sib for next generation|No|24-Sep-2009|Cryopreserved sperm|||Yes|Type I Diabetes|ENU, Singapore, autoimmunity, T cell, B cell, glucose|Possibly| 8448.0|W140S|C57BL/6NCrlAnu-Arpc1b/Anu||Recessive|actin related protein 2/3 complex, subunit 1B|Arpc1b|Normal|L72, p41-ARC, SOP2Hs|MGI:1343142|actin related protein 2/3 complex, subunit 1B; endonuclease-mediated mutation 1, Australian National University|Arpc1b||5||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2018|Cryopreserved sperm|12.0|0.0|Unknown|||Yes| 8616.0|Aicda fl:Flpe|C57BL/6N(Cg)-Aicda/MarpAnuApb||Recessive|activation-induced cytidine deaminase|Aicda|Normal|Aid|MGI:1342279|activation-induced cytidine deaminase; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH|Aicda|MGI:4460367|6|||||||||||||||||||||||||||||Normal||C57BL/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||4||No|29-Nov-2018|Cryopreserved sperm|66.0|0.0|Unknown||EuCOMM|Yes| 8560.0|ASD542:Busquets:C57Bl/6crlAnu|C57BL/6NCrlAnu-Bank1/AnuApb||Recessive|B cell scaffold protein with ankyrin repeats 1|Bank1|Unknown|A530094C12Rik|MGI:2442120|Bank1, endonuclease-mediated mutation 1, Australian National University |Bank1||3||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Sep-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8477.0|Traj18 KO|BALB/c-Traj18/Apb||Recessive|T cell receptor alpha joining 18|Traj18|Nil|Gm17009|MGI:4440521||||14|||||||||||||||||||||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Apr-2018|Cryopreserved sperm|30.0|0.0|Unknown|||Yes| 8748.0|S1ECN*Smad1-ERT-cre-neu|STOCK Smad1 Tg(Elf5-rtTa-TetO) Tg(MMTVneu)202Mul/Apb||Recessive|SMAD family member 1|Smad1||Madh1, Madr1, Smad 1|MGI:109452|SMAD family member 1; targeted mutation 2, Elizabeth J Robertson|Smad1|MGI:2155484|8|||||||||||||||||Elf5-rtTa-TetO||||||||||||These mice are normal and breed well, and develop normally. Adult mice older than 6 month may develop multiple tumours in mammary glands.Younger mice seem to be more active than wild type mice. At the moment the phenotype of smad1 CRE/ERT mediated deletion is unknown.Doxycycline is required from a young age for effective knockout of Smad1.|ERT/CRE and NEU modifications are active in heterozygous setting, so the above phenotype is the same. Smad1 flox is required in the homozygous state for effective knockout.|mixed-mainly BALBc and FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Jul-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8748.0|S1ECN*Smad1-ERT-cre-neu|STOCK Smad1 Tg(Elf5-rtTa-TetO) Tg(MMTVneu)202Mul/Apb||Recessive||||||||||||||||||||||||||transgene insertion 202, William Muller|MMTV|||||||||||These mice are normal and breed well, and develop normally. Adult mice older than 6 month may develop multiple tumours in mammary glands.Younger mice seem to be more active than wild type mice. At the moment the phenotype of smad1 CRE/ERT mediated deletion is unknown.Doxycycline is required from a young age for effective knockout of Smad1.|ERT/CRE and NEU modifications are active in heterozygous setting, so the above phenotype is the same. Smad1 flox is required in the homozygous state for effective knockout.|mixed-mainly BALBc and FVB/N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|04-Jul-2019|Cryopreserved sperm|||Unknown|||Yes| 8447.0|Arpc1b fl|C57BL/6N-Arpc1b Tg(ACTFLPe)9205Dym/Anu||Recessive|actin related protein 2/3 complex, subunit 1B|Arpc1b|Normal|L72, p41-ARC, SOP2Hs|MGI:1343142|actin related protein 2/3 complex, subunit 1B; targeted mutation 1c, Wellcome Trust Sanger Institute|Arpc1b||5|||||||||||||||||transgene insertion 9205, Susan Dymecki||||||||||||Normal||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|19-Mar-2018|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8330.0|Chat-cre|B6;129S6-Chat/JAnu||Dominant|choline acetyltransferase|Chat||B230380D24Rik|MGI:88392|choline acetyltransferase; targeted mutation 2, Bradford B Lowell|Chat|MGI:5475195|14|||||||||||||||||||||||||||||Normal||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|11-Oct-2017|Cryopreserved sperm|12.0|0.0|Unknown||Glucose|Yes| 4976.0|ENU14:G1 ; Chokerre|ENU14China:014||Recessive|||||||||Unknown|||||||||||||||||||||||||||||Embryonic lethal.E14 embryos are alive but look sick.Increase in primitive RBCDecrease in definitive RBC|Possible embryonic blood defect|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|22-Jan-2010|Cryopreserved sperm|10.0|0.0|Unknown||Haemopoietic stem cell, red blood cell, differentiation, proliferation, ENU, embryonic lethal|Yes| 5011.0|Ova BCR|B6.129-Ova BCR Tg1||Dominant||||||||||||||||||||||||||||||||||||||||10|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|150.0|0.0|Unknown|||Possibly| 5121.0|GDNF+/-|C57BL/6-Gdnf||Recessive|glial cell line derived neurotrophic factor|Gdnf|Unknown|glial cell line-derived neurotrophic factor|MGI:107430|glial cell line derived neurotrophic factor; targeted mutation 1, Laboratory of Mammalian Genes and Development, Heiner Westphal|Gdnf|MGI:2136846|15||||||||||||||||No|||||||||||||Neonatal lethality: die 12-24 hours after birthAbnormal kidney development: * severe renal dysgenesis or renal agenesis * metanephric development is halted between E11 and E14.5Abnormal ureteric bud morphology: ureteric bud is absent in most mice.Absent kidney.Abnormal ureter development: delayed or total absence of ureteric branching in cultured urogenital blocks.Abnormal enteric cholinergic neuron morphology: devoid of enteric parasympathetic cholinergic ganglion cells.Absent enteric neurons: neurons of the myenteric plexus are absent from the intestine.Hypoperistalsis: presence of milk in the oesophagus and reduced progression of food into the gastrointestinal tract.|On 129 background:Abnormal kidney morphology: 35% possess a wide range of renal defects between 3 to 5 months of age.Abnormal kidney development: 12% have severe bilateral kidney dysgenesis.Abnormal ureteric bud morphology: ureteric bud defects.Abnormal ureteric bud branching morphogenesis: reduced ureteric branching in cultured urogenital blocks.Small kidney: 23% have unilateral small kidneys with abnormal shape and/or cortical cysts or rough surface.Single kidney: unilateral kidney agenesis.On 129 x C57BL/6 backgroundPostnatal lethality: * Background Sensitivity: 17.1% preweaning lethality on the C57BL/6 background and 8.4% preweaning lethality on the CD-1 background which increased to 16.7% after interbreeding of offspring on the CD-1 background. * low, but highly significant, preweaning lethalitySingle kidney: 10% exhibit unilateral kidney agenesisAbnormal enteric ganglia morphology * hypoganglionisis, as indicated by reduced numbers and mesh density of ganglionic cells in both the myenteric and the submucosal plexus formations of the gastrointestinal tract. * 64% reduction of ganglionic cells in the ileocecum and colon and 50% reduction in the stomach and small intestine. * exhibit aganglionic regions interspersed along the hypoganglionic regions of the intestine.Megacolon: 84% have varying degrees of colon dilationAbnormal stomach morphology: 38.5% exhibit stomach distention.Chronic constipation: 74% exhibit fecal retention, a sign of chronic constipation.Hypoperistalsis: delayed gastric emptying of milk in newborns, indicating impaired intestinal motility.|C57BL/6|No|No|Yes|No|No|Yes|No|Poor||||No|12-May-2010|Cryopreserved sperm|40.0|0.0|Yes|Hirschsprung Disease, Susceptibility to, 1; HSCR1 OMIM ID: 142623|neuron, migration, enteric, colon, lethal|Yes| 5128.0|152|B6-Tg(Thy1-APPSwe,Prnp-PSEN2*N141I)152HLaoz||Dominant||||||||||||||||||||||||||transgene insertion 152H, Laurence Ozmen|Thy1 promoter driving expression of the human APP ; Prnp promoter driving the expression of human PSEN2||||||||||||Abnormal spatial learning: * in a Morris water maze, mice exhibit increased swim speed during cued acquisition at 2 and 4 months compared with wild-type mice. * in a Morris water maze, mice exhibit exhibited decreased spatial learning at 4 and 12 months compared with wild-type mice.Impaired coordination: on at rotarod at 4 months.Amyloid beta deposits: * from 4 to 16 months, mice exhibit amyloid beta deposits unlike wild-type mice. * amyloid beta deposits worsen with age.Increased body weight: at 4 to 12 months|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-May-2010|Cryopreserved sperm|30.0|0.0|Yes|Alzheimer's disease (AD)|amyloid, Abeta plaques, tau, neuron|Yes| 5129.0|H2g7apf|KRN:241:H2g7apf:B10||Recessive|histocompatibility-2, MHC|H2|Unknown|H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; g7 variant|H2|MGI:3579321|17||||||||||||||||Yes|||||||||||||Normal.Spontaneous recombinant incorporating a short length of the C57BL/10 derived H2 into the congenic H2g7. Alters the H2 expressed resulting in change to presentation that was using the g7 allele.|Normal|C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|2||het x het|No|21-May-2010|Cryopreserved sperm|50.0|0.0|Unknown||Histocompatability, H2, presentation, T cell|Possibly| 5142.0|16FOX 009 B6.129-Tg(FoxP3-GFP)|ENU16FOX:009 Foxp3||Recessive|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|||MGI:3574964|X||||||||||||||||No|||||||||||||Grey coloured coat.Cells from the background strain that express FoxP3 fluoresce green, predominantly T cells|Normal |129 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Affected x affected|No|27-May-2010|Cryopreserved sperm|20.0|0.0|Unknown||grey, coat, colour, melanocyte|Yes| 5142.0|16FOX 009 B6.129-Tg(FoxP3-GFP)|ENU16FOX:009 Foxp3||Recessive|Unknown|Unknown|||||||Unknown|||||||||||||||||||||||||||||Grey coloured coat.Cells from the background strain that express FoxP3 fluoresce green, predominantly T cells|Normal |129 x C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Affected x affected|No|27-May-2010|Cryopreserved sperm|||Unknown||grey, coat, colour, melanocyte|Yes| 5144.0|ENU15CHINA:002|C57BL/6JAnu-Gmds/AnuApb|C57BL/6JAnu-Gmds/AnuApb|Recessive|GDP-mannose 4, 6-dehydratase|Gmds|||MGI:1891112|GDP-mannose 4, 6-dehydratase; mutation 1, The Australian National University|Gdpd3|MGI:5563465|13|ENSMUSG00000038372|ENSMUST00000041859|Gmds-001|561|692|T to A|ENSMUSE00000282995|6|187|Tyrosine to STOP|||||CCCTATGGAGCAGCCAAACTCTATGCCTATTGGATTGTGGTGAATTTCCGTGAAGCTTATA|Yes|||||||||||||Highly activated T cells, expansion of myeloid cells.High CD44<+> B and T cells, Low T cells, Low NK cells.|Unknown|C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Poor||2||No|28-May-2010|Cryopreserved sperm|53.0|0.0|Unknown||T cell, ENU|Possibly| 5538.0|APN 112|C57BL/6N-Ptpn22/Marp||Recessive|protein tyrosine phosphatase, non-receptor type 22 (lymphoid) |Ptpn22|Unknown|70zpep, Ptpn8 |MGI:107170 |protein tyrosine phosphatase, non-receptor type 22 (lymphoid); targeted mutation 1a, Wellcome Trust Sanger Institute |Ptpn22tm1a(EUCOMM)Wtsi|MGI:4434268|3||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Jul-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6828.0|APN 241|C57Bl/6N-Rnpc3/Marp||Recessive|RNA-binding region (RNP1, RRM) containing 3|Rnpc3|Unknown|2810441O16Rik, AI447568, C030014B17Rik|1914475|RNA-binding region (RNP1, RRM) containing 3; targeted mutation 1a, Wellcome Trust Sanger Institute |Rnpc3 |MGI:4433222|3|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 5547.0|Snoopy ; ENU12WT009:B6G2|C57BL/6JAnu-Crkl/AnuMarpApb||Recessive|v-crk sarcoma virus CT10 oncogene homolog (avian)-like|Crkl|Unknown|1110025F07Rik, Crkol|MGI:104686||Snoopy|MGI:5510713|16||||||||||Unknown to Unknown|||||||||||||||||||Abnormal eye development:• poorly developed at E13.5Cyclopia:• in some miceOcular hypotelorism:• at E13.5Absent mandible:• hypoplasia/aplasia at E13.5Mandible hypoplasia:• hypoplasia/aplasia at E13.5Holoprosencephaly:• some mice exhibit complete failure of forebrain vesicle separationAbnormal forebrain morphology:• at E13.5|Normal|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|03-Aug-2011|Cryopreserved sperm|10.0|0.0|Unknown||ENU, mandible, holoprosencephaly|Possibly| 5550.0|ENU16China:071a|C57BL/6JAnu-Pax5/AnuApb|C57BL/6JAnu-Pax5/AnuApb|Recessive|paired box gene 5|Pax5 |Reduced|EBB-1, Pax-5 |MGI:97489 |paired box gene 5; mutation 2, The Australian National University|Pax5|MGI:5563442|4|ENSMUSG00000014030|ENSMUST00000014174|Pax5-001|233|1271|T to A|ENSMUSE00000527453|3|78|Isoleucine to Asparagine|||||TCTTGGCAGGTATTATGAGACAGGAAGCATCAAGCCGGGGGTGATTGGAGGATCCAAACCA||||||||||||||Mice have severely reduced numbers of B cells|Some Het mice seem to have increased immature B cells|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4-6|5|Sib x sib|No|09-Aug-2011|Cryopreserved sperm|55.0|0.0|Unknown||B cell, lymphocyte, ENU|Yes| 5571.0|Zic5 V504G: C57BL/6|B6.C(C3H)-Zic5/HAnu|B6.C(C3H)-Zic5/HAnu|Recessive|Zinc finger protein of the cerebellum 5|Zic5|Unknown|odd-paired related, Opr|MGI:1929518||||14||||||||||||||||Yes|||||||||||||Viable and fertile|Viable and fertile|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|0|Heterozygote animal paired with C57BL/6 animal|No|31-Aug-2011|Cryopreserved sperm|50.0|0.0|Unknown||zinc finger, ENU|Yes| 6616.0|APN 113|CPT1a||Recessive|carnitine palmitoyltransferase 1a, liver |Cpt1a||Cpt1, CPTI, L-CPT I |MGI:1098296 ||||19|Cpt1a|ENSMUST00000025835|Cpt1a-201||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|No|Unknown|Unknown|Unknown|No|Excellent||||No|13-Oct-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6649.0|APN 116|C57BL/6N-Cish/Marp||Recessive|cytokine inducible SH2-containing protein |Cish ||Cis, CIS1, cytokine-inducible SH2 protein, F23 |MGI:103159 |cytokine inducible SH2-containing protein; targeted mutation 1e, Wellcome Trust Sanger Institute |Cishtm1e(KOMP)Wtsi|MGI:4363203|9|||||||||||||||||||||||||||||Unknow - Not bred to homozygocity|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Nov-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6653.0|VavP-BCL2-69; C57BL/6-Tg(Vav-BCL2)1Jad/Wehi|ENU22Bcl2.006||Dominant|Unknown||||||||Unknown|||||||||||||||||transgene insertion 1, Jerry M Adams|mouse Vav promoter|High, haemopoietic cells|||||||||||Abnormal lymphocyte cell number:* the ratio of CD4 cells per B cell is 25% to 50% lower than in wild-type mice.Increased B cell number: 5-fold higher in the spleen at 18 weeksIncreased T cell number:* mice exhibit higher splenic T cell numbers than in wild-type and Tg(BCL2)22Wehi or Tg(BCL2)36Wehi mice.Increased CD4-positive T cell number:* the increase in CD4+ T cells is greater than the increase in CD8+ T cells.Increased CD8-positive T cell number:* the increase in CD4+ T cells is greater than the increase in CD8+ T cells.Abnormal class switch recombination:* the total number of B cells that undergo class switching is 50-fold higher than in wild-type mice.Abnormal somatic hypermutation frequency:* 22 of 23 clones isolated from class-switching cells harbor on average about 6 somatic mutations compared to in wild-type cells where no mutations are found.Enlarged spleen:Abnormal spleen germinal center morphology:* mice exhibit a larger pool of cycling B cells with a germinal center phenotype than in wild-type mice.* at 18 weeks, mice exhibit an increased in germinal center size and number compared to in wild-type mice.* however, expansion of germinal centers is dependent on CD4 T cell help.Increased spleen germinal center number: at 18 weeks.Increased spleen germinal center size: at 18 weeks.Enlarged lymph nodes.Glomerulonephritis:* at 40 weeks, 15% to 25% of mice develop autoimmune glomerulonephritis.Increased tumor incidence:* 12% of mice develop plasma cell tumorsLymphoma: less than 10% of mice develop lymphoblastic lymphomas.B cell derived lymphoma:* less than 10% of mice develop large cell B lymphomasFollicular lymphoma:* at 18 months, 37% to 50% of mice develop monoclonal follicular lymphoma.Thymic lymphoma: in less than 10% of miceHistiocytic sarcoma: in less than 10% of mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|01-Dec-2011|Cryopreserved sperm|10.0|0.0|Unknown||B cell, bcl-2, vav, Progenitor, lymphoma, germinal centre|Yes| 6763.0|APN 150|C57BL/6N-Acss1/Marp||Recessive|acyl-CoA synthetase short-chain family member 1 |Acss1|Unknown|1110032O15Rik, Acas2, Acas2l, AceCS2 |MGI:1915988 |acyl-CoA synthetase short-chain family member 1; targeted mutation 1a, Wellcome Trust Sanger Institute |Acss1tm1a(EUCOMM)Wtsi|MGI:4441709|2||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|15-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6617.0|ENU23 MDX:::B6:F1|ANU:ENU23MDX:F1||X-linked|dystrophin, muscular dystrophy|Dmd|Unknown|Dp427, Duchenne muscular dystrophy, mdx, pke, X-linked muscular dystrophy|MGI:94909|X linked muscular dystrophy|Dmd|MGI:1856328|X||||||||||||||||No|||||||||||||Abnormal muscle morphology.dilated sarcoplasmic reticulum.Abnormal skeletal muscle fiber morphology: * development of electron-dense bodies in the mitochondria resulting in swelling and degenerating mitochondria, and disruption of the plasmalemma basal lamina. * the normal myofibrillar architecture of bands and lines disappears and myofilaments disintegrate and become misaligned.Increased variability of skeletal muscle fiber size: variable muscle fiber size; progressive starting at 3 weeks of age.Skeletal muscle fibrosis: exhibit mild muscle fibrosis, however there is no replacement of lost muscle by fat cells.Skeletal muscle necrosis: progressive starting at 9 weeks of age.Muscle degeneration: progressive starting at 3 weeks of age.Abnormal muscle physiology: increased intracellular sodium concentration in muscle; increased severity with age.Muscular atrophy: progressive starting at 3 weeks of age.Dystrophic muscle.Myopathy: progressive degenerative myopathy; increased severity with age.Abnormal circulating enzyme level: exhibit elevated blood levels of muscle creatine kinase and pyruvate kinase.Reduced female fertility: slight reduction in fertility.||C57BL/6 x C57BL/10|Unknown|Unknown|Yes|Unknown|Unknown|Yes|Yes|Unknown||||No|14-Oct-2011|Cryopreserved sperm|220.0|0.0|Yes||Muscular dystrophy, Duchenne Type, muscle, necrosis, degeneration|Possibly| 6617.0|ENU23 MDX:::B6:F1|ANU:ENU23MDX:F1||X-linked|Unknown||||||||Unknown|||||||||||||||||||||||||||||Abnormal muscle morphology.dilated sarcoplasmic reticulum.Abnormal skeletal muscle fiber morphology: * development of electron-dense bodies in the mitochondria resulting in swelling and degenerating mitochondria, and disruption of the plasmalemma basal lamina. * the normal myofibrillar architecture of bands and lines disappears and myofilaments disintegrate and become misaligned.Increased variability of skeletal muscle fiber size: variable muscle fiber size; progressive starting at 3 weeks of age.Skeletal muscle fibrosis: exhibit mild muscle fibrosis, however there is no replacement of lost muscle by fat cells.Skeletal muscle necrosis: progressive starting at 9 weeks of age.Muscle degeneration: progressive starting at 3 weeks of age.Abnormal muscle physiology: increased intracellular sodium concentration in muscle; increased severity with age.Muscular atrophy: progressive starting at 3 weeks of age.Dystrophic muscle.Myopathy: progressive degenerative myopathy; increased severity with age.Abnormal circulating enzyme level: exhibit elevated blood levels of muscle creatine kinase and pyruvate kinase.Reduced female fertility: slight reduction in fertility.||C57BL/6 x C57BL/10|Unknown|Unknown|Yes|Unknown|Unknown|Yes|Yes|Unknown||||No|14-Oct-2011|Cryopreserved sperm|||Yes||Muscular dystrophy, Duchenne Type, muscle, necrosis, degeneration|Possibly| 6643.0|IPO5 FL/FL|C57BL/6-Ipo5||Dominant|importin 5|Ipo5|Normal|1110011C18Rik, 5730478E03Rik, IMB3, Kpnb3, Ranbp5|MGI:1917822||||14|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||FL/FL x FL/FL|No|07-Nov-2011|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 6650.0|APN 119|C57BL/6N-PYY/Marp||Recessive|peptide YY |Pyy ||MGC:19143 |MGI:99924 |peptide YY; targeted mutation 1, Wellcome Trust Sanger Institute |Pyytm1(KOMP)Wtsi|MGI:4363090|11|||||||||||||||||||||||||||||Unknown - Not bred to homozygocity|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|22-Nov-2011|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6761.0|ENU17FOX:008|C57BL/6JAnu-Il17f Foxp3/AnuApb||Recessive|interleukin 17F|Il17f|||MGI:2676631||||1|ENSMUSG00000041872|ENSMUST00000039046|Il17f-201|158|229|C to A|ENSMUSE00000308433|2|53|Valine to Leucine|||||GAACTGTCCTCCCCTGGAGGATAACACTGTGAGAGTTGACATTCGAATCTTCAACCAAAAC||||||||||||||N/A|Hyper IgE, high numbers of monocytes and low numbers of B cells in peripheral blood.|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||B cell, lymphocyte|Possibly| 6761.0|ENU17FOX:008|C57BL/6JAnu-Il17f Foxp3/AnuApb||Recessive|forkhead box P3|Foxp3|Normal|JM2, scurfin|MGI:1891436|forkhead box P3; targeted mutation 2, Alexander Y Rudensky|Foxp3|MGI:3574964|X|||||||||||||||||||||||||||||N/A|Hyper IgE, high numbers of monocytes and low numbers of B cells in peripheral blood.|C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Dec-2011|Cryopreserved sperm|||Unknown||B cell, lymphocyte|Possibly| 6769.0|APN 154|C57BL/6N-Hspa5/Marp||Recessive|heat shock protein 5 |Hspa5|Unknown|78kDa, Bip, D2Wsu141e, D2Wsu17e, Grp78, Hsce70, mBiP, Sez7, XAP-1 antigen 98 |MGI:95835 |heat shock protein 5; targeted mutation 1, Velocigene |Hspa5tm1(KOMP)Vlcg|MGI:4399453|2||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|20-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Possibly| 6783.0|APN 103|C57BL/6N-F2rl1/Marp||Recessive|coagulation factor II (thrombin) receptor-like 1 |F2rl1 |Unknown|Gpcr11, PAR-2, Par2, Protease-activated receptor-2, proteinase-activated receptor-2 |MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1a, Wellcome Trust Sanger Institute |F2rl1tm1a(EUCOMM)Wtsi|MGI:4460480|13||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6785.0|APN 122|C57BL/6N-Plin5/Marp||Recessive|perilipin 5 |Plin5 |Unknown|2310076L09Rik, Lsdp5, MLDP |MGI:1914218|perilipin 5; targeted mutation 2a, Wellcome Trust Sanger Institute |Plin5tm2a(KOMP)Wtsi|MGI:4455577|17||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 8446.0|Choir|C57BL/6NCrlAnu-Fcho1/AnuApb||Recessive|FCH domain only 1|Fcho1|Unknown|3322402E17Rik|MGI:1921265|Fcho1, endonuclease-mediated mutation 1, Australian National University|Fcho1||8||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Mar-2018|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8501.0|ASD798:Sapote:2|C57BL/6NCrlAnu-Ifit3b/AnuApb||Recessive|interferon-induced protein with tetratricopeptide repeats 3B|Ifit3b|Unknown|I830012O16Rik|MGI:3698419|Ifit3b, endonuclease-mediated mutation 2, Australian National University|Ifit3b||19||||||||||Unknown to Unknown|||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2018|Cryopreserved sperm|46.0|0.0|Unknown|||Yes| 6786.0|APN 149|C57BL/6N-Acss1/Marp||Recessive|acyl-CoA synthetase short-chain family member 1 |Acss1|Unknown|1110032O15Rik, Acas2, Acas2l, AceCS2 |MGI:1915988 |acyl-CoA synthetase short-chain family member 1; targeted mutation 1a, Wellcome Trust Sanger Institute |Acss1tm1a(EUCOMM)Wtsi|MGI:4441709|2||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|60.0|0.0|Unknown||ES cell|Yes| 6787.0|APN 94|C57BL/6N-Inpp4a /Marp||Recessive|inositol polyphosphate-4-phosphatase, type I |Inpp4a |Unknown|107kDa |MGI:1931123 |inositol polyphosphate-4-phosphatase, type I; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Inpp4atm1a(EUCOMM)Hmgu|MGI:4434756|1||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Yes| 6792.0|A33CreERt2/LacZ13 (ME-223)|STOCK Tg(Gpa33-cre/ERT2) Tg(Pgk1-lacZ)13Vmel/LudApb||Dominant||||||||||||||||||||||||||cre recombinase|glycoprotein A33 (transmembrane)|||||||||||Unknown|Unknown|Mixed|No|Unknown|Yes|No|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|45.0|0.0|Unknown||LacZ, cre recombinase|Yes| 6792.0|A33CreERt2/LacZ13 (ME-223)|STOCK Tg(Gpa33-cre/ERT2) Tg(Pgk1-lacZ)13Vmel/LudApb||Dominant||||||||||||||||||||||||||transgenic insertion 13, Harald von Melchner|mouse Pgk1 promoter|||||||||||Unknown|Unknown|Mixed|No|Unknown|Yes|No|Unknown|Yes|No|Unknown||||No|18-Jan-2012|Cryopreserved sperm|||Unknown||LacZ, cre recombinase|Yes| 6832.0|APN 185|C57Bl/6N-Plin5/MarpApb||Recessive|perilipin 5|Plin5|Unknown|2310076L09Rik, Lsdp5, MLDP|MGI:1914218|perilipin 5; targeted mutation 1a, Wellcome Trust Sanger Institute|Plin5 |MGI:4364899|17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6833.0|APN 207|C57Bl/6NTac-Gpr183/MarpApb||Recessive|G protein-coupled receptor 183 |Gpr183 |Unknown|Ebi2 |MGI:2442034 |G protein-coupled receptor 183; targeted mutation 1, Velocigene |Gpr183tm1(KOMP)Vlcg |MGI:3808449|14|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6834.0|APN 267|C57Bl/6J-Gkn3/Marp||Recessive|gastrokine 3 |Gkn3|Unknown|1190003M12Rik |MGI:1916138 |gastrokine 3; targeted mutation 1a, Wellcome Trust Sanger Institute |Gkn3tm1a(EUCOMM)Wtsi |MGI:4433233|6|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|01-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6870.0|APN126|C57Bl/6N-Ptcra/MarpApb||Recessive|pre T cell antigen receptor alpha|Ptcra|Unknown|pT-alpha, pT[a], pTalpha|MGI:104857|pre T cell antigen receptor alpha; targeted mutation 2a, Helmholtz Zentrum Muenchen GmbH|Ptcratm2a(EUCOMM)Hmgu|MGI:4434686|17|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Good||||No|05-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6874.0|DBC1 Clone 5C8B|C57BL/6-Dbc1/Marp||Recessive|deleted in bladder cancer 1 (human)|Dbc1||Dbccr1, Fam5a|MGI:1928478||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6899.0|B6.BlGpA ; B6.TgN(HUFUT1-HUGTA-MUSMICAM2)|C57BL/6-Tg(Icam2-FUT1, GTA)/StV||Dominant||||||||||||||||||||||||||human H-transferase and human A-transferase|ICAM2|||||||||||Expression of human blood group A on vascular endothelium and on a subset of polymorphonuclear cells|Expression of human blood group A on vascular endothelium and on a subset of polymorphonuclear cells|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|20|||No|24-May-2012|Cryopreserved sperm|50.0|0.0|No||Blood group A, Transgenic|Possibly| 6877.0|Abca1fl/fl Abcg1fl/fl|C57BL/6-Abca1Abcg1/Marp ||Semi-dominant|ATP-binding cassette, sub-family A (ABC1), member 1|Abca1|Unknown|Abca1|MGI:99607||||4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|24-Apr-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 6877.0|Abca1fl/fl Abcg1fl/fl|C57BL/6-Abca1Abcg1/Marp ||Semi-dominant|ATP-binding cassette, sub-family G (WHITE), member 1|Abcg1||Abc8, White|MGI:107704||||17|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|24-Apr-2012|Cryopreserved sperm|||Unknown|||Possibly| 6905.0|APN 259|C57BL/6N-Ift140/Marp||Recessive|intraflagellar transport 140 homolog (Chlamydomonas)|Ift140 |Unknown|mKIAA0590, Tce5, Wdtc2 |MGI:2146906 | intraflagellar transport 140 homolog (Chlamydomonas); targeted mutation 1a, Wellcome Trust Sanger Institute |Ift140tm1a(KOMP)Wtsi|MGI:4363217|17||||||||||||||||Yes|||||||||||||Unknown - Not bred to homozygocity |Normal |C57BL/6N |Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|01-Jun-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell|Possibly| 8542.0|Rab32.3|C57BL/6-Rab32/Apb||Recessive|RAB32, member RAS oncogene family|Rab32||2810011A17Rik|MGI:1915094||||10|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|30-Jul-2018|Cryopreserved sperm|50.0|0.0|Unknown||Ras, CRISPR/Cas9|Yes| 8520.0|OGT-flox|B6.129-Ogt/J||Recessive|O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)|Ogt|Unknown|1110038P24Rik, 4831420N21Rik, OGT, Ogtl|MGI:1339639|O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase); targeted mutation 1, Gerald W Hart|Ogt|MGI:2387867|X|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jun-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 6907.0|ENU15NIH49a|C57BL/6JAnu-Satb1/AnuApb|C57BL/6JAnu-Satb1/AnuApb|Dominant|special AT-rich sequence binding protein 1|Satb1|Unknown|2610306G12Rik |MGI:105084|special AT-rich sequence binding protein 1; mutation 1, The Australian National University|Satb1|MGI:5563413|17|ENSMUSG00000023927|ENSMUST00000144331|Satb1-001|1179|1416|T to A|ENSMUSE00000322390|7|393|Phenylalanine to Leucine|||||AAACGAGCCGGAATCTCACAGGCAGTATTTGCACGCGTGGCTTTTAACCGAACTCAGGGAT||||||||||||||Reduced expression of CD44 on CD4<+> and CD8<+> T cells|Intermediate phenotype of reduced expression of CD44 on CD4<+> and CD8<+> T cells|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||7||No|08-Jun-2012|Cryopreserved sperm|50.0|0.0|Unknown||lymphocyte, T cell, CD44, CD4, CD8, ENU|Possibly| 6908.0|BAC(A33:M2rtTA)|B6;129-Tg(Gpa33-rtTAS*M2)1||Dominant|||||||||||||||||||||||||||glycoprotein A33 (transmembrane), Gpa33|Mosaic activity in intestinal epithelium||||||||||Not described|The M2rtTA tet transactivator is expressed in the epithelium of the intestine and colon under the control of the intestine-specific A33 promoter. The expression/activety of the transactivator is mosaic, most likely due to stochastic transgene silencing. Approximately 1 to 5 crypts in the proximal small intestine express the transgene, fewer in the distral intestine and colon.|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|14-Jun-2012|Cryopreserved sperm|50.0|0.0|No||intestine, epithelium, tetracycline|Possibly| 6910.0|MPS IIIA/MIP KO|B6.Cg-Ccl3 Sgsh/J||Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Reduced|sulphamidase|MGI:1350341|N-sulfoglucosamine sulfohydrolase (sulfamidase); mucopolysaccharidosis IIIA|Sgsh|MGI:2151181|11|||||||||||||||||||||||||||||The phenotype of the MPSIIIA/MIPKO mice has not been fully characterized but is anticipated to be similar to that of the MPSIIIA Mice (Crawley et al (2006) Brain res 1104:1-17). |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Generation 14 (MPSIIIA strain)||Brother x Sister (MPSIIIA strain and MIP KO strain), Non-brother X Sister for MPS/MIP crosses|No|20-Jun-2012|Cryopreserved sperm|50.0|0.0|Yes|MPSIIIA is a progressive neurodegenerative disorder|Lysosomal storage disorder, Mucopolysaccharidosis, Neuroinflammation, Macrophage Inflammatory Protein|Yes| 6910.0|MPS IIIA/MIP KO|B6.Cg-Ccl3 Sgsh/J||Recessive|chemokine (C-C motif) ligand 3|Ccl3|Nil|CCL3, G0S19-1, LD78alpha, macrophage inflammatory protein-1alpha, Mip1a, MIP1-(a), MIP-1alpha, MIP-1 alpha, MIP1-alpha, Scya3|MGI:98260|chemokine (C-C motif) ligand 3; targeted mutation 1, University of North Carolina|Ccl3|MGI:1857243|11|||||||||||||||||||||||||||||The phenotype of the MPSIIIA/MIPKO mice has not been fully characterized but is anticipated to be similar to that of the MPSIIIA Mice (Crawley et al (2006) Brain res 1104:1-17). |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Generation 14 (MPSIIIA strain)||Brother x Sister (MPSIIIA strain and MIP KO strain), Non-brother X Sister for MPS/MIP crosses|No|20-Jun-2012|Cryopreserved sperm|||Yes|MPSIIIA is a progressive neurodegenerative disorder|Lysosomal storage disorder, Mucopolysaccharidosis, Neuroinflammation, Macrophage Inflammatory Protein|Yes| 7022.0|APN152|C57BL/6N-A Ptafr/Marp||Recessive|platelet-activating factor receptor|Ptafr|Unknown|PAFR, PAF receptor|MGI:106066|platelet-activating factor receptor; targeted mutation 1a, Wellcome Trust Sanger Institute |Ptafr |MGI:4460278|4|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jul-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 7034.0||ENU22 Bcl2:015||Dominant|unknown|unknown|||||||Unknown|||||||||||||||||||||||||||||High Platelet phenotype. Phenotyping technique by Advia. Not: Even though sperm freezing shows medium to low concentration and motility these mice breed extremely well.|Normal.Not: Even though sperm freezing shows medium to low concentration and motility these mice breed extremely well.|C57BL/6NCrl|Unknown|Unknown|Unknown|Unknown|Yes|Yes|No|Excellent|Mice will be frozen at G4||Affected by B6|No|31-Jul-2012|Cryopreserved sperm|45.0|0.0|Unknown||ENU|Possibly| 7076.0|APN159|C57BL/6N-A-Recql4/Marp|MGI:5050948|Recessive|RecQ protein-like 4|Recql4|Unknown||MGI:1931028|RecQ protein-like 4; targeted mutation 3, Wellcome Trust Sanger Institute |Recql4/Marp |MGI:5050948|15|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Sep-2012|Cryopreserved sperm|50.0|0.0|Unknown||ES cell clone|Possibly| 7213.0|NOD-SBmut12|NOD/ShiLt-Slc16a10/Svi||Recessive|solute carrier family 16 (monocarboxylic acid transporters), member 10|Slc16a10|Unknown|2610103N14Rik, Mct10, PRO0813, TAT1|MGI:1919722|solute carrier family 16 (monocarboxylic acid transporters), member 10; transgenic transposon insertion 12, Thomas Brodnicki|Tn(sb-lacZ,GFP)12Tcb||10|||||||||||||||||||||||||||||Unknown|Unknown|NOD/ShiLt|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|NA|||No|15-Nov-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7214.0|ENU15WT007b|C57BL/6JAnu-Tec/Apb|C57BL/6JAnu-Tec/Apb|Recessive|tec protein tyrosine kinase|Tec|Unknown||MGI:98662||||5|ENSMUSG00000029217|ENSMUST00000071944|Tec-001|1309|1503|A to G|ENSMUSE00001280689|15|437|Isoleucine to Threonine|||||TCTATGGTGTATGCACCCAGCAGAAGCCCATCTACATCGTTACCGAGTTCATGGAACGGGG||||||||||||||Increased susceptibility to infection with TB|Unknown|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|None|10|Het x Het and Hom x Hom|No|16-Nov-2012|Cryopreserved sperm|20.0|0.0|Unknown||ENU, infection|Possibly| 7229.0|APN310|C57Bl/6NTac-Ptcd1/Marp||Recessive|pentatricopeptide repeat domain 1|Ptcd1|Unknown|1110069M14Rik|MGI:1919049|pentatricopeptide repeat domain 1; targeted mutation 1, Velocigene/Marp|Ptcd<1tm1(KOMP)Vlcg/Marp>|MGI:4951221|5|||||||||||||||||||||||||||||Unknown|Normal|C57Bl6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Good||||No|22-Nov-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7249.0|APN319|C57Bl/6N-A Sppl2a||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2atm1a(EUCOMM)Hmgu|MGI:4887673|2|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|12-Dec-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7250.0|ENU18China:68b|C57BL/6JAnu-Ptpn6/AnuApb|C57BL/6JAnu-Ptpn6/AnuApb|Dominant|protein tyrosine phosphatase, non-receptor type 6|Ptpn6 |Reduced|hcp, Hcph, Ptp1C, SHP-1, Spin|MGI:96055|protein tyrosine phosphatase, non-receptor type 6; mutation 2, The Australian National University|Ptpn6|MGI:5563434|6|ENSMUSG00000004266|ENSMUST00000112484|Ptpn6-002|4|205|C to T|ENSMUSE00000691827|1|2|Valine to Methionine|||||ATGGTGAGGTGGTTTCACCGGGACCTCAGCGGGCC||||||||||||||Reduced IgM expression on mature B cells. Reduced percentage of mature B cells. Adult homozygous mice are healthy.|Mild reduction in the percent of mature B cells and mild reduction of IgM on mature B cells|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||7|homozygous x homozygous|No|13-Dec-2012|Cryopreserved sperm|47.0|0.0|Unknown||B cell, IgM, signaling, ENU|Possibly| 7261.0|APN246|C57BL/6N(Ag)-Casp9MarpApb||Recessive|caspase 9|Casp9 ||Caspase-9, ICE-LAP6, Mch6 |MGI:1277950 |caspase 9; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Casp9tm1a(EUCOMM)Hmgu|MGI:4950193|4|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Jan-2013|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7274.0|Primurus:swHEL:HcLc:Ly5a x EGFP|C57BL/6-Dock8 Igh Ptprc Tg(IgkHyHEL10)1Rbr Tg(nZeg EGFP)||Dominant|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Robert Brink|Igh|MGI:3800383|12||||||||||||||||Yes|transgene insertion 1, Robert Brink||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Feb-2013|Cryopreserved sperm|70.0|0.0|Unknown||Immunoglobulin, Hen Egg lysozyme (HEL), self-tolerance, autoimmunity, B cell, ENU, memory|Yes| 7274.0|Primurus:swHEL:HcLc:Ly5a x EGFP|C57BL/6-Dock8 Igh Ptprc Tg(IgkHyHEL10)1Rbr Tg(nZeg EGFP)||Dominant|dedicator of cytokinesis 8|Dock8||1200017A24Rik, 5830472H07Rik, A130095G14Rik|MGI:1921396|primurus|Dock8|MGI:3835421|19|||||||||||||||||nZEG EGFP||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Feb-2013|Cryopreserved sperm|||Unknown||Immunoglobulin, Hen Egg lysozyme (HEL), self-tolerance, autoimmunity, B cell, ENU, memory|Yes| 7274.0|Primurus:swHEL:HcLc:Ly5a x EGFP|C57BL/6-Dock8 Igh Ptprc Tg(IgkHyHEL10)1Rbr Tg(nZeg EGFP)||Dominant|protein tyrosine phosphatase, receptor type, C|Ptprc|Unknown|B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||Unknown||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|13-Feb-2013|Cryopreserved sperm|||Unknown||Immunoglobulin, Hen Egg lysozyme (HEL), self-tolerance, autoimmunity, B cell, ENU, memory|Yes| 7275.0|B6.SJL.RIIa Tg|B6.SJL Fcgr 2a Tg|HOGA|Semi-dominant|Human Fcgamma r2a|FcgR2a|Normal||||||Unknown|||||||||||||||||human FcyR2a|human FcyR2a|normal|FcyR2a|FcyR2a||FcyRIIa, CD32a||FcyR2a high responder|FcyR2a HR||Unknown|spontaneous development of autoimmune disease including distructive arthritis in 40% of animals|not known|inbred|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||Yes|15-Feb-2013|Cryopreserved sperm|50.0|0.0|Yes|Rheumatoid arthritis, inflamation of joints|Fc receptor, antibody, immune complex, inflammation, arthritis|Possibly| 7277.0|SJL.RIIa Tg|SJL.Fcgr2a Tg|HOGA|Semi-dominant|Fcgamma r2a|FcgR2a|Normal||||||Unknown|||||||||||||||||human FcyR2a|human FcyR2a|normal||||||||||spontaneous arthritis|not known|SJL|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Good|12|||Yes|15-Feb-2013|Cryopreserved sperm|45.0|0.0|Yes|immune complex disease|Fc receptor, antibody, immune complex, inflammation, arthritis, thrombocytopenia|Possibly| 7354.0|Lck-Cre:Foxo1-flox|B6.129-Foxo1 Tg(Lck-cre)157Jxm/Anu||Recessive|forkhead box O1|Foxo1|Normal|Afxh, FKHR, Fkhr1, Foxo1a|MGI:1890077|forkhead box O1; targeted mutation 1, Richard A Flavell|Foxo1|MGI:3840910|3|||||||||||||||||targeted mutation I57, Jamey Marth; transgene insertion I57, Jamey Marth|mouse proximal Lck promoter|active in thymocytes and splenocytes||||||||||||C57BL/6JAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jun-2013|Cryopreserved sperm|30.0|0.0|Unknown||T cell, transcription|Possibly| 7420.0|Ankyrin1 ; ENU20_44b|C57BL/6NCrlAnu-Ank1/Apb||Recessive|Ankyrin 1|Ank1|Unknown|Ank-1, pale|MGI:88024||||8|||||||||||||||||||||||||||||Increased levels of reticulocytes - high, Low RBC number, low hematocrit, low haemoglobin, low MCV|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|Poor||4|het x het|No|26-Aug-2013|Cryopreserved sperm|20.0|0.0|Unknown||Reticulocyte, Anaemia|Possibly| 7461.0|Hes7|B6.Cg-Hes7||Recessive|hairy and enhancer of split 7 (Drosophila)|Hes7|Nil|bHLHb37|MGI:2135679|hairy and enhancer of split 7 (Drosophila); targeted mutation 1, Ryoichiro Kageyama|Hes7|MGI:2652222|11||||||||||||||||No|||||||||||||Null pups die perinatally with vertebal segmentation defects.|Some heterozygous mice have tail kinks|C57BL/6|No|No|Yes|No|No|Yes|No|Good|10|0|Hes7 +/- (heterozygous) mated with C57BL/6|No|22-Oct-2013|Cryopreserved sperm|80.0|0.0|Unknown|Spondylocostal dysostosis|Hes7, Somitogenesis, Notch signalling|Possibly| 8761.0|TBXAS- B6129P2|B6.129P2-Tg(TbxAS)||Dominant||||||||||||||||||||||||||TbxAS||||||||||||Unknown||C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|05-Aug-2019|Cryopreserved sperm|30.0|0.0|Unknown|||Yes| 8664.0|C169 (Gabrg2 PM)|C57BL/6J-Gabrg2/Mgmp||Recessive|gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2|Gabrg2||GABAA-R, Gabrg-2, gamma2|MGI:95623||||11|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|26-Feb-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 2.0|Unmodulated|C57BL/6JSfdAnu-Card11/AnuApb|C57BL/6JSfdAnu-Card11/AnuApb|Recessive|caspase recruitment domain family, member 11|Card11|Normal|CARMA1, BIMP3|MGI:1916978|caspase recruitment domain family, member 11; unmodulated|Card11|MGI:3045963|5|ENSMUSG00000036526|ENSMUST00000085786|Card11-201|914|1235|T to A|ENSMUSE00000431473|7|305|Leucine to Glutamine|||||TGACTCAGACAAGGCCATCTTGGACATCCTGGAACATGACCGGAAGGAGGCGCTAGAGGAC|Yes|||||||||||||Diminished antibody formation upon T cell-independent type 2 and T cell-dependent immunization. Diminished B cell NFκB activation and proliferation to antigen receptor engagement, but normal proliferation to TLR4 stimulation. Failure to form normal IgMlow IgDhi follicular B cells, and failure to form peritoneal B1 B cells. Diminished T cell NFκB activation and proliferation to TCR+CD28 stimulation. Spontaneous dermatitis accompanied by dermal mastocytosis and hyper-IgE syndrome.||C57BL/6JSfdAnu|Yes|Yes|Yes|Yes|Yes|Yes|Yes|Poor||||No|25-Nov-2005|Cryopreserved sperm|125.0|0.0|Unknown||B cell, T cell, dermititis, ENU, Wellcome Trust|Yes| 173.0||C57BL/6-Tau-GFP||Dominant|microtubule-associated protein tau|Mapt ||Tau|MGI:97180||||11|ENSMUSG00000018411|ENSMUST00000106989|||||||||||||||transgene insertion |CMV intermediate early enhancer coupled to the chicken beta actin promoter|||||||||||Every cell expresses a tau-GFP fusion protein, enabling visualization of microtubules and long cell processes (including axons). Mice homozygous for the transgene do not survive. ||C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|17-Apr-2006||0.0|0.0|No||GFP, microtubules, tau, axon|Yes| 10461.0|OT-II_B6N|B6.Cg-Tg(TcraTcrb)425Cbn/Anu||Recessive|transgene insertion 425, Frank Carbone|Tg:Tg(TcraTcrb)425Cbn||OT2, OT-II|MGI:3046083|Tg(TcraTcrb)425Cbn|Tg:OT2||Unknown|||||||||||||||||transgene insertion 425, Frank Carbone||||||||||||OVA-specif Cd4 T cells ||C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Nov-2024|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 8907.0|Flk2CremTmG|B6-Tg(Flt3-Cre)#Ccb Gt(ROSA)26Sor/Apb||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 4, Liqun Luo|Gt(ROSA)26Sor|MGI:3716464|6|||||||||||||||||transgene insertion, Conrad C Bleul|Flt3|||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|20-Mar-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7430.0|APN 369|C57BL/6N-A Katna1MarpApb||Recessive|katanin p60 (ATPase-containing) subunit A1|Katna1 |||MGI:1344353 |katanin p60 (ATPase-containing) subunit A1; targeted mutation 1a, Wellcome Trust Sanger Institute |Katna1tm1a(KOMP)Wtsi|MGI:4458514|10|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Yes|No|Unknown||||No|05-Sep-2013|Cryopreserved sperm|20.0|0.0|Unknown|||Possibly| 7479.0|dll1|C57BL/6J-Dll1|C57BL/6J-Dll1|Recessive|delta-like 1 (Drosophila)|Dll1|Nil|Delta1|MGI:104659|delta-like 1 (Drosophila); targeted mutation 1, Michael J Owen|Dll1|MGI:3044907|17||||||||||||||||No|||||||||||||None|None|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|10|0|D1flox homozygous intercross|No|13-Nov-2013|Cryopreserved sperm|80.0|0.0|No||Dll1, Notch, receptor, B cell, marginal zone|Possibly| 7534.0|ENU20Flt3ITD:37|ENU20FLT3-ITD:037||Dominant|FMS-like tyrosine kinase 3|Flt3|Increased|CD135, Flk-2, Flk2, Flt-3|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5||||||||||||||||Yes|||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G2||No|10-Dec-2013|Cryopreserved sperm|74.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 7534.0|ENU20Flt3ITD:37|ENU20FLT3-ITD:037||Dominant|Unknown||Unknown||||||Unknown|||||||||||||||||||||||||||||Accelerated onset of Acute Myeloid leukaemia.|Accelerated onset of Acute Myeloid leukaemia.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||G2||No|10-Dec-2013|Cryopreserved sperm|||Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML, ENU|Possibly| 7557.0|ENU27:002:PIK3IP1:B6|C57BL/6NCrlAnu-Pik3ip1/AnuApb|C57BL/6NCrlAnu-Pik3ip1/AnuApb|Recessive|phosphoinositide-3-kinase interacting protein 1|Pik3ip1|Unknown|1500004A08Rik, 5830455E04Rik|MGI:1917016|phosphoinositide-3-kinase interacting protein 1; mutation 1, The Australian National University|Pik3ip1|MGI:5563439|11|ENSMUSG00000034614|ENSMUST00000045153|Pik3ip1-001|313|847|A to G|ENSMUSE00000314294|4|105|Serine to Alanine|||||CCTGCGAGGACGTGAGTTGCCCAGAGACCACTTCCCAAGCACCACCGCCATCCTCTGCCAT||||||||||||||Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|Normal blood lymphocyte populations as measured by expression of following proteins: B220, CD3, CD4, CD44, KLRG1, NK1.1, IgM, IgD by flow cytometry.|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|19-Dec-2013|Cryopreserved sperm|30.0|0.0|Unknown||ENU|Yes| 7565.0|ENU27:020:Katnal2:B6|C57BL/6NCrlAnu-Katnal2/AnuApb||Recessive|Katanin p60 subunit A-like 2|Katnal2|Unknown|3110023G01Rik, 4933439B08Rik|MGI:1924234|katanin p60 subunit A-like 2; mutation 1, Australian National University|Katnal2|MGI:6164198|18|ENSMUSG00000025420|ENSMUST00000026486|Katnal2-005|257|329|T to C|ENSMUSE00001268471|3|86|Tyrosine to Cysteine|||||GAGCTATTATTTTGTAAAGTTCCAGAAGTACCCCAAAGTGGTTAAGAAGGCCCCGGACCCA||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|No|Yes|Yes|Unknown||||No|14-Jan-2014|Cryopreserved sperm|52.0|0.0|Unknown||ENU, missense, mutation, MMP|Possibly| 7600.0|APN 366|C57BL/6N-A Prrt2MarpApb||Recessive|proline-rich transmembrane protein 2|Prrt2 |||MGI:1916267 |proline-rich transmembrane protein 2; targeted mutation 1a, Wellcome Trust Sanger Institute|Prrt2tm1a(KOMP)Wtsi|MGI:4362325|7|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Feb-2014|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 7600.0|APN 366|C57BL/6N-A Prrt2MarpApb||Recessive|nonagouti|a||agouti, agouti signal protein, As, ASP|MGI:87853|nonagouti; targeted mutation 1, Allan Bradley|A|MGI:3842513|2|||||||||||||||||||||||||||||Unknown|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Feb-2014|Cryopreserved sperm|||Unknown|||Possibly| 7651.0|RBC10|C;B6-Slc12a4/WehiMarpApb||Dominant|solute carrier family 12, member 4|slc12a4|Unknown|KCC1, K-Cl Co-transporter-1|MGI:1309465|solute carrier family 12, member 4; red blood cell mutant 10|Slc12a4|MGI:5703920|8||||||||||Unknown to Unknown|||||||||||||||||||Homozygotes are viable and fertile. They display microcytic anaemia.|Intermediate between homozygotes and wild types.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||heterozygous intercrosses or homozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|60.0|0.0|Unknown||KCC1, Gain of function, ENU|Possibly| 7661.0|ENU26:014:Setx|C57BL/6NCrlAnu-Setx/AnuApb|C57BL/6NCrlAnu-Setx/AnuApb|Recessive|senataxin|Setx||A930037J23Rik, Als4|MGI:2443480|senataxin; mutation 1, The Australian National University|Setx|MGI:5563422|2|ENSMUSG00000043535|ENSMUST00000061578|Setx-001|140|823|A to G|ENSMUSE00001221495|3|47|Tyrosine to Cysteine|||||CTGCTACTGCTTAGAGTGTGTGGCTGAGTACCACCGAGCCAGAGATGAGGTGCCGTTCTTG||||||||||||||Increased numbers of IgM IgD expressing B cells.|Normal|C57BL/6NCrlAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|11-Apr-2014|Cryopreserved sperm|33.0|0.0|Unknown||ENU, B cell, lymphocyte|Possibly| 7668.0|ASCIZ CD23 Bcl6|B6.Cg-Atmin Ighm Tg(Fcer2a-cre)5Mbu/SviApb||Dominant|ATM interactor|Atmin|||MGI:2682328|ATM interactor; targeted mutation 1.2, Jorg Heierhorst|Atmin|MGI:5463937|8|||||||||||||||||transgene insertion 5, Meinrad Busslinger|Fcer2a |||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|more than 10|||No|30-Apr-2014|Cryopreserved sperm|50.0|0.0|No|||Possibly| 7668.0|ASCIZ CD23 Bcl6|B6.Cg-Atmin Ighm Tg(Fcer2a-cre)5Mbu/SviApb||Dominant|immunoglobulin heavy constant mu|Ighm||BCR, Igh6, Igh-M, IgM, Ig mu, muH, muMT|MGI:96448|immunoglobulin heavy constant mu; targeted mutation 1, Riccardo Dalla-Favera|Ighm|MGI:3581517|12|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|more than 10|||No|30-Apr-2014|Cryopreserved sperm|||No|||Possibly| 7672.0||C57BL/6NCrlAnu-Pikfyve/AnuApb||Recessive|phosphoinositide kinase, FYVE finger containing|Pikfyve|Unknown|5230400C17Rik, Pip5k3, PipkIII|MGI:1335106||||1|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-May-2014|Cryopreserved sperm|11.0|0.0|Unknown||ENU|Yes| 7698.0|R26 WT-Hoxa1 ki|C57BL/6-Gt(ROSA)26Sor||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Unknown|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 3237, TaconicArtemis|Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent||||No|12-Jun-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 8581.0|Fn14 KO/C57BL/6 |C57BL/6-Tnfrsf12a/Apb||Recessive|tumor necrosis factor receptor superfamily, member 12a|Tnfrsf12a|Unknown|Fn14, TweakR, TWEAK-R|MGI:1351484||||17|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|02-Oct-2018|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8833.0|AMPK A2(S345A) KI|C57BL/6 Prkaa2(S345A)||Recessive|protein kinase, AMP-activated, alpha 2 catalytic subunit|Prkaa2||AMPKalpha2|MGI:1336173||||4|ENSMUSG00000028518|ENSMUST00000030243|||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|10-Dec-2019|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 7617.0|Helios floxed|B6.Cg-Ikzf2 Tg(CD4-Cre)/Anu||Recessive|IKAROS family zinc finger 2|Ikzf2||A730095J18Rik, Helios, Zfpn1a2|MGI:1342541|IKAROS family zinc finger 2; targeted mutation 1.1, Ethan M Shevach|Ikzf2|MGI:4456473|1|||||||||||||||||transgene insertion 1, Christopher B Wilson|CD4|||||||||||Abnormal regulatory T cell physiology:• regulatory T cells fail to respond to TCR stimulation or IL2 unlike wild-type cells• however, regulatory T cells respond normally to anti-CD3 and IL2 and are as suppressive as wild-type regulatory T cells||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|07-Mar-2014|Cryopreserved sperm|9.0|0.0|Unknown||CD4, T cell, Treg, FoxP3|Possibly| 7625.0|Srsf7-KO|B6NTac;B6N-A Srsf7/WtsiMarp||Dominant|serine/arginine-rich splicing factor 7|Srsf7||9430065L19Rik, 9G8, NX-96, Sfrs7|MGI:1926232|serine/arginine-rich splicing factor 7; targeted mutation 1a, Wellcome Trust Sanger Institute|Srsf7|MGI:4433826|17|||||||||||||||||||||||||||||Embryonic lethal|Uncharacterised|C57BL/6NTacMarp|No|No|Yes|No|No|Yes|No|Good|na|na||No|24-Mar-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7654.0|Hbbtm2(HBG1,HBB*)Tow|C57BL/6-Hba Hbb Hbb/MarpApb||Dominant|hemoglobin alpha chain complex|Hba|Nil||MGI:96014|hemoglobin alpha chain complex; targeted mutation 1, Timothy Townes|Hba|MGI:3790755|11|||||||||||||||||||||||||||||Display sickle cell disease. Mice develop anemia from 3 weeks of age. Lethality occurs at variable rates (after 3 months). |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||heterozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|60.0|0.0|Unknown||Sickle cell disease, haematology|Yes| 7654.0|Hbbtm2(HBG1,HBB*)Tow|C57BL/6-Hba Hbb Hbb/MarpApb||Dominant|hemoglobin beta chain complex|Hbb|Nil||MGI:96020|hemoglobin beta chain complex; targeted mutation 2, Timothy Townes|Hbb|MGI:3790753|7|||||||||||||||||||||||||||||Display sickle cell disease. Mice develop anemia from 3 weeks of age. Lethality occurs at variable rates (after 3 months). |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||heterozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|||Unknown||Sickle cell disease, haematology|Yes| 7654.0|Hbbtm2(HBG1,HBB*)Tow|C57BL/6-Hba Hbb Hbb/MarpApb||Dominant|hemoglobin beta chain complex|Hbb|||MGI:96020|hemoglobin beta chain complex; targeted mutation 3, Timothy Townes|Hbb|MGI:3790756|7|||||||||||||||||||||||||||||Display sickle cell disease. Mice develop anemia from 3 weeks of age. Lethality occurs at variable rates (after 3 months). |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||heterozygous intercrosses|No|08-Apr-2014|Cryopreserved sperm|||Unknown||Sickle cell disease, haematology|Yes| 7677.0|Egr2-GFP|C57BL/6-Egr2/JhmiAnu||Dominant|early growth response 2|Egr2||Egr-2, Krox20, Krox-20, NGF1-B, Zfp-25|MGI:95296||||10|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|09-May-2014|Cryopreserved sperm|11.0|0.0|Unknown|||Yes| 7714.0|UK dep|C57BL/6-Zdhhc21/MarpApb||Recessive|zinc finger, DHHC domain containing 21| Zdhhc21|Unknown|9130404H11Rik, D130004H04Rik, dep|MGI:1915518|zinc finger, DHHC domain containing 21; depilated|Zdhhc21|MGI:1856841|4|||||||||||||||||||||||||||||Abnormal coat appearance:• identifiable at about 1 week of age when first coat appearsabnormal hair shaft melanin granule morphology• clumps of pigment appear to be the remains of degenerating follicles• excessive accumulation and clumping of pigment in the hairAbnormal hair growth.Premature hair loss:• some mice are nearly hairless at 3 weeks of age; others may have a nearly normal coat.Short hair.Sparse hair.Matted coat.Greasy coat.Abnormal hair medullary septa cells:• 20% of coat hairs show an irregular arrangement of septa or complete interruption of septa.Abnormal hair follicle morphology.Abnormal hair follicle orientation.Abnormal hair cycle.Abnormal epidermal layer morphology:• dermal-epidermal recombination grafts of embryonic skin shows this allele acts in the epidermis.Enlarged sebaceous gland:• enlarged sebaceous glands with an excess of sebumSebaceous gland hyperplasia:• mild sebaceous gland hyperplasia at P5Abnormal sebaceous gland physiology:• increase in the percentage of BrdU positive, proliferating cells that are observed in sebaceous glandsAbnormal sebaceous lipid secretion:• excess of sebum|Wildtype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||11||No|02-Jul-2014|Cryopreserved sperm|40.0|0.0|Unknown||palmitoylation, hair follicles|Possibly| 7815.0|MPS IIIA Knock out|C57BL/6-Sgsh/LdruApb|ldru|Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Unknown|4632406A19Rik, sulphamidase|MGI:1350341||||11|||||||||||||||||||||||||||||We anticipate that the phenotype of MPS IIIA knock-out mice will be similar to our well-characterised present mouse model of MPS IIIA that expresses ~3% residual sulphamidase activity. This includes storage of heparan sulphate in tissues and fluids and behavioural changes such as altered locomotor activity and anxiety-related behaviours, memory and learning defects and changes in the walking pattern (gait) of the mice.|Expected to be normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|8|brother X sister|No|15-Dec-2014|Cryopreserved sperm|50.0|0.0|Yes|Sanfilippo syndrome (Mucopolysaccharidosis IIIA)||Possibly| 7716.0|Fras1|B6.Cg-Fras1/MarpApb||Dominant|Fraser syndrome 1 homolog (human)|Fras1|Unknown|bl, E130113P14Rik, mKIAA1500|MGI:2385368|Fraser syndrome 1 homolog (human); blebbed|Fras1|MGI:1856691|5|||||||||||||||||||||||||||||Embryonic lethal.• most homozygotes die before birth• however, a few reach adulthood with no signs of skin blisteringSyndactyly:• adult homozygotes exhibit distal limb defects, such as syndactyly of the hind limbs.Clubfoot:• homozygotes may exhibit clubbed feet or hands.Abnormal kidney development:• at E11.5-E15.5, homozygotes show a range of defects in metanephric kidney development, followed by degeneration of early metanephric rudiments• however, 20% of homozygous mutant embryos display a relatively normal metanephric development, including formation of glomeruli by E15.5Abnormal metanephric mesenchyme morphology:• by E13.5-E14.5, the metanephric mesenchyme is poorly differentiated with many cells containing pyknotic nuclei suggestive of apoptosis.Increased metanephric mesenchyme apoptosis:• by E13.5-E14.5, many cells contain pyknotic nuclei suggesting apoptosis.Abnormal metanephros morphology:• at E11.5-E15.5, some homozygotes display small and pooorly differentiated metanephroi, followed by degeneration of early metanephric rudiments.Delayed kidney development:• by E13.5-E14.5, mutant kidneys appear developmentally delayed and are much smaller than those of wild-type mice.Small kidney:• at E13.5-E14.5Absent kidney:• homozygotes may lack one or both kidneys.Kidney cysts:• 2 of 146 live-born survivors display grossly cystic kidneysSingle kidney:• homozygotes may exhibit only one kidney.• 20 of 146 live-born survivors display complete unilateral renal agenesis.Abnormal ureteric bud morphology:• at E11.5-E12.5, homozygous mutant embryos exhibit a dilated uteric bud.Impaired branching involved in ureteric bud morphogenesis:• at E11.5-E12.5, homozygous mutant embryos display reduced ureteric bud branching relative to wild-type embryos.Microphthalmia:• homozygotes display reduced eyesCryptophthalmos:• adult homozygotes display cryptophthalmosAbnormal hair growth:• homozygotes often display abnormal hair development between the eyesBleb:• blebs are still visible at birthFetal bleb:• at E14.5, homozygotes display prominent blebs over the rump and smaller blebs over the head and forelimb• however, homozygotes that survive and are live-born show no signs of skin blistering.|wildtype|C57BL/6|No|No|Yes|No|No|Yes|No|Good|7|4||No|02-Jul-2014|Cryopreserved sperm|80.0|0.0|Yes|Fraser Syndrome|Fraser Syndrome|Possibly| 7732.0|A/J - Joey-RSA|A/J.B6-Rbm5/MarpApb||Recessive|RNA binding motif protein 5|Rbm5|Unknown||MGI:1933204|RNA binding motif protein 5; spermatid differentiation arrest|Rbm5|MGI:5563424|9|ENSMUSG00000032580|ENSMUST00000035199|Rbm5-201|788|940|G to C|ENSMUSE00000251397|10|63|Arginine to Proline|||||CTATGCTTCCTTAGCTGTCAATAACATTCGCCTCATAAAAGACAAACAGACACAACAGAAC|Yes|||||||||||||Embryonic lethal|Round spermatid arrest.|A/JMarp|No|No|Yes|No|No|Yes|No|Unknown|8|||No|05-Sep-2014|Cryopreserved sperm|50.0|0.0|Unknown||infertility, sperm, arrest, ENU|Yes| 7739.0|Pax5-Exon 8|C57BL/6NJAnu-Pax5/AnuApb||Recessive|paired box 5|Pax5||EBB-1, Pax-5|MGI:97489||||4|||||||||||||||||||||||||||||B cell||C57BL/6JAnu|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|12-Sep-2014|Cryopreserved sperm|22.0|0.0|Unknown|||Yes| 7799.0|Krt76 tm1a|B6(Cg)-Krt76/MarpApb||Dominant|keratin 76|Krt76|Reduced|2310001L23Rik|MGI:1924305|keratin 76; targeted mutation 1a, Wellcome Trust Sanger Institute|Krt76|MGI:4363117|15|||||||||||||||||||||||||||||Unkempt, dull coats and smaller body size, scaling of skin of the tail, abnormal paw pad hyperpigmentation |Abnormal sebaceous gland morphology, abnormal hair cycle, abnormal epidermis stratum basale morphology, hyperkerotosis, parakerotosis|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|2|6||No|26-Nov-2014|Cryopreserved sperm|50.0|0.0|No||Keratin 76, tight junctions, CLDN1, inflammation, skin|Possibly| 8155.0|NODlga|NOD-Ifngr1||Recessive|Interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gammaR, IFN-gamma R, Ifngr, Nktar|MGI:107655||em10Tcb||10|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|16-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 7816.0|Heterozygote MPS IIIA KO / Transgenic control|C57BL/6-Sgsh Sgsh/Apb|ldru|Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Unknown|4632406A19Rik, sulphamidase|MGI:1350341||||11||||||||||Unknown to Unknown|||||||||||||||||||We anticipate that the phenotype of MPS IIIA knock-out mice will be similar to our well-characterised present mouse model of MPS IIIA that expresses ~3% residual sulphamidase activity. This includes storage of heparan sulphate in tissues and fluids and behavioural changes such as altered locomotor activity and anxiety-related behaviours, memory and learning defects and changes in the walking pattern (gait) of the mice.|Expected to be normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|4|brother X sister|No|15-Dec-2014|Cryopreserved sperm|49.0|0.0|Yes|Sanfilippo syndrome (Mucopolysaccharidosis IIIA)|MPS IIIA , Sanfilippo syndrome, Knockout|Possibly| 7816.0|Heterozygote MPS IIIA KO / Transgenic control|C57BL/6-Sgsh Sgsh/Apb|ldru|Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh||4632406A19Rik, sulphamidase|MGI:1350341||||11|||||||||||||||||||||||||||||We anticipate that the phenotype of MPS IIIA knock-out mice will be similar to our well-characterised present mouse model of MPS IIIA that expresses ~3% residual sulphamidase activity. This includes storage of heparan sulphate in tissues and fluids and behavioural changes such as altered locomotor activity and anxiety-related behaviours, memory and learning defects and changes in the walking pattern (gait) of the mice.|Expected to be normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|0|4|brother X sister|No|15-Dec-2014|Cryopreserved sperm|||Yes|Sanfilippo syndrome (Mucopolysaccharidosis IIIA)|MPS IIIA , Sanfilippo syndrome, Knockout|Possibly| 7857.0|Sppl2a:Ctss KO|C57BL/6JAnu-Sppl2a Ctss/AnuApb|C57BL/6JAnu-Sppl2a Ctss/AnuApb|Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802 |signal peptide peptidase like 2A; mutation 1, The Australian National University|Sppl2a|MGI:5432126|2|ENSMUSG00000027366|ENSMUST00000028844|2010106G01Rik-001||||||||126746052|7|||ATTCATAGGATGCCATGTGGACAGTGCACGTACGTATCTGTTAGCCTATGATGCAATTAG||||||||||||||Unknown|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|10-Mar-2015|Cryopreserved sperm|33.0|0.0|Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|Yes| 7857.0|Sppl2a:Ctss KO|C57BL/6JAnu-Sppl2a Ctss/AnuApb|C57BL/6JAnu-Sppl2a Ctss/AnuApb|Recessive|cathepsin S|Ctss|Nil|Cat S|MGI:107341|cathepsin S; targeted mutation 1, Harold A Chapman|Ctss|MGI:2182133|3|||||||||||||||||||||||||||||Unknown|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|10-Mar-2015|Cryopreserved sperm|||Unknown||lymphocyte, B cell, IgD, ENU, immunoglobulin|Yes| 7860.0|Rosa26-Cryab floxed knockin|B6;C-Gt(ROSA)26Sor/KkhaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|Increased|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|Rosa26-Cryab-KI|Cryab-FLAG||6|||||||||||||||||||||||||||||Floxed mice are viable and fertile|floxed mice are viable and fertile|C57BL/6 and Balb/C mixed background|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|18-Mar-2015|Cryopreserved sperm|50.0|0.0|Unknown||crystallin|Possibly| 7871.0|Sppl2a KO1 conditional|B6.Cg-Sppl2a Tg(ACTFLPe)9205Dym/1MarpAnuApb||Recessive|signal peptide peptidase like 2A|Sppl2a|Unknown|2010106G01Rik, C130089K23Rik|MGI:1913802|signal peptide peptidase like 2A; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH|Sppl2a|MGI:4887673|2|||||||||||||||||transgene insertion 9205, Susan Dymecki|ACTB, actin, beta, human|The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being 4X and 10X that of wildtype FLP at 37°C and 40°C, respectively||||||||||Normal|Normal|C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Apr-2015|Cryopreserved sperm|66.0|0.0|Unknown||Conditional|Possibly| 7893.0|ENU31:014:Itgb2|C57BL/6NCrlAnu-Itgb2/AnuApb||Recessive|integrin beta 2|Itgb2||2E6, Cd18, Mac-1 beta|MGI:96611||||10|ENSMUSG00000000290|ENSMUST00000000299|Itgb2-001|857|1068|G to T|ENSMUSE00001306558|7|286|Cysteine to Phenylalanine|||||TGCCATCCTGACCCCCAATGATGGCCGCTGCCACCTGGAGGATAACATGTACAAGAGGAGC|Unknown|||||||||||||Activated T cells in blood|Normal|C57BL/6NCrlAnu|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||1||No|15-May-2015|Cryopreserved sperm|44.0|0.0|Unknown||ENU, random, mutagenesis, screen, T cell|Yes| 7903.0|APN 405; Immp2l|C57BL/6NTac-Immp2l/MarpApb||Recessive|IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae)|Immp2l|Unknown|IMP2|MGI:2135611|IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae); gene trap IST11147G7, Texas A&M Institute for Genomic Medicine|Immp2l|MGI:3992884|12|||||||||||||||||||||||||||||Tourette like hyperactive and repetitive behaviour|Tourette like hyperactive and repetitive behaviour|C57BL/6NTacMarp|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|||Bro x sis; het x het and hom x het|No|10-Jun-2015|Cryopreserved sperm|100.0|0.0|Unknown|||Possibly| 7937.0|ENU29:005:Tmem30a|C57BL/6NCrlAnu-Tmem30a/AnuApb||Recessive|transmembrane protein 30A|Tmem30a|Unknown|2010200I23Rik, Cdc50a, D9Wsu20e|MGI:106402||Tmem30a||9|ENSMUSG00000032328|ENSMUST00000034878|Tmem30a-001||||||||79775100|6|||AAAAGAGAGCCTCGAAGAAAAGTTTAAAGGTAAAATATGATCAATATCCCTTCTTGTCTA||||||||||||||Embryonic Lethal|Normal|C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|26-Jun-2015|Cryopreserved sperm|54.0|0.0|Unknown||Embryonic lethal, ENU|Yes| 8033.0|Foxn1-cre x Atg5 loxp|B6.129-Atg5 Foxn1/Wehi||Recessive|autophagy related 5|Atg5|Normal|2010107M05Rik, 3110067M24Rik, Apg5l, Paddy|MGI:1277186|autophagy related 5; targeted mutation 1, Minesuke Yokoyama|Atg5|MGI:3663625|10|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Apr-2016|Cryopreserved sperm|10.0|0.0|Unknown||Autophagy, dendritic cell|Yes| 8033.0|Foxn1-cre x Atg5 loxp|B6.129-Atg5 Foxn1/Wehi||Recessive|forkhead box N1|Foxn1|Normal|D11Bhm185e, Hfh11, whn|MGI:102949|forkhead box N1; targeted mutation 3, Nancy R Manley|Foxn1|MGI:3760775|11|||||||||||||||||||||||||||||Normal||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Apr-2016|Cryopreserved sperm|||Unknown||Autophagy, dendritic cell|Yes| 8009.0|Dll1null|B6-DII1/DunwApb||Recessive|delta-like 1 (Drosophila)|Dll1|||MGI:104659|delta like canonical Notch ligand 1; targeted mutation 1.1, Michael J Owen|DII1|MGI:5431502|17||||||||||Unknown to Unknown|||||||||||||||||||Dll1 homozygous embryos die during gestation|Normal|C57BL/6J|No|No|No|No|No|No|Yes|Poor||||No|10-Dec-2015|Cryopreserved sperm|50.0|0.0|Unknown||Embryonic lethal|Possibly| 8077.0|Fcho1|B6(Cg)-Fcho1/AnuApb||Recessive|FCH domain only 1|Fcho1|Unknown|3322402E17Rik|MGI:1921265||||8|||||||||||||||||||||||||||||Unknown||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Jul-2016|Cryopreserved sperm|10.0|0.0|Unknown|||Yes| 8089.0|RHBDF1 KO|C57BL/6-Rhbdf1/MarpApb||Recessive|rhomboid 5 homolog 1|Rhbdf1||Dist, Dist1, Egfr-rs|MGI:104328||||11|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|24-Aug-2016|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8092.0|HoxB7-Cre|C57BL/6-Tg(Hoxb7-cre)13AmcMarpApb||Dominant||||||||||||||||||||||||||transgene insertion 13, Andrew P McMahon|Hoxb7, homeobox B7, mouse, laboratory|||||||||||Not viable|Mice hemizygous for the transgenic insert are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. |C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|31-Aug-2016|Cryopreserved sperm|50.0|0.0|Unknown||Cre recombinase|Yes| 8100.0|ASD601:Mertesacker|C57BL/6NCrlAnu-Vps51/AnuApb||Recessive|VPS51 GARP complex subunit|Vps51|Unknown|1110014N23Rik, 3110057M17Rik|MGI:1915755||||19|ENSMUSG00000024797|ENSMUST00000159832.7|Vps51-001|233|659|G to C|ENSMUSE00001277360|3|78|Arginine to Proline|||||CGACCCGGAAGTTTATCTTGACAAGCTGCGTAGAGAATGTCCTCTGGCCCAGCTGATGGAC||||||||||||||Embryonic lethal||C57BL/6NCrlAnu|No|No|Yes|No|No|Yes|No|Unknown||||No|09-Sep-2016|Cryopreserved sperm|55.0|0.0|Unknown|||Yes| 8121.0|Foxb1|B6.129X1-Foxb1/Anu||Dominant|forkhead box B1|Foxb1||C43, Fkh5, Foxb1a, Foxb1b, Hfh-e5.1, Mf3, TWH|MGI:1927549|forkhead box B1; targeted mutation 1, Gonzalo Alvarez-Bolado|Foxb1|MGI:3772366|9|||||||||||||||||||||||||||||No phenotypic analysis||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|27-Oct-2016|Cryopreserved sperm|43.0|0.0|Unknown||Cre recombinase|Yes| 8150.0|NODCrisprGzmA|NOD-Gzma||Recessive|granzyme A|Gzma|Unknown|BLT esterase, Ctla3, Ctla-3, Hanukah factor, Hf, H factor, SE1, serine esterase 1, TSP1, TSP-1|MGI:109266||em2Tcb||13|||||||||||||||||||||||||||||Unknown|Unknown|NOD/LtJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|15-Dec-2016|Cryopreserved sperm|50.0|0.0|Yes|Type 1 diabetes||Possibly| 8622.0|Zeb1 fl K5-creERt R26-YAP5SA|STOCK Zeb1 Gt(ROSA)26Sor<(CAGGS-Yap5SA,LacZ)Mao> Tg(KRT5-cre/ERT2)2Ipc||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||||6|||||||||||||||||transgene insertion 2, I Pierre Chambon||||||||||||Overexpression of activated YAP (NLS-YAP-5SA) with Keratin-5 (K5-CreERt) is sufficient to induce rapid formation of both SCC and spSCC in mice. spSCC tumours arise at sites of epithelial scratch wounding, where tumour-initiating epithelial cells undergo EMT to generate spSCC. Expression of the EMT transcription factor ZEB1 arises upon wounding and is a defining characteristic of spSCC in mice and humans. Thus, the wound healing response synergises with YAP to drive metaplastic transformation of SCC to spSCC.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Dec-2018|Cryopreserved sperm|55.0|106.0|Unknown||Hippo, epithelium, Squamous cell carcinoma (SCC) , epithelial-mesenchymal transition (EMT)|Yes| 8622.0|Zeb1 fl K5-creERt R26-YAP5SA|STOCK Zeb1 Gt(ROSA)26Sor<(CAGGS-Yap5SA,LacZ)Mao> Tg(KRT5-cre/ERT2)2Ipc||Recessive|zinc finger E-box binding homeobox 1|Zeb1|Unknown|3110032K11Rik, AREB6, [delta]EF1, MEB1, Nil2, Tcf18, Tcf8, Tw, ZEB, Zfhep, Zfhx1a, Zfx1a |MGI:1344313|zinc finger E-box binding homeobox 1; targeted mutation 1.1, Marc Stemmler|Zeb1|MGI:5901939|18|||||||||||||||||||||||||||||Overexpression of activated YAP (NLS-YAP-5SA) with Keratin-5 (K5-CreERt) is sufficient to induce rapid formation of both SCC and spSCC in mice. spSCC tumours arise at sites of epithelial scratch wounding, where tumour-initiating epithelial cells undergo EMT to generate spSCC. Expression of the EMT transcription factor ZEB1 arises upon wounding and is a defining characteristic of spSCC in mice and humans. Thus, the wound healing response synergises with YAP to drive metaplastic transformation of SCC to spSCC.||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|18-Dec-2018|Cryopreserved sperm|||Unknown||Hippo, epithelium, Squamous cell carcinoma (SCC) , epithelial-mesenchymal transition (EMT)|Yes| 9019.0|Lang-GFP|B6.129S2-Cd207/JApb||Dominant|CD207 antigen|Cd207||Langerin|MGI:2180021|CD207|CD207 antigen; targeted mutation 1, Bernard Malissen|Cd207|6|||||||||||||||||||||||||||||Lang-EGFP mutant mice contain an internal ribosome entry site (IRES) and an enhanced green fluorescent protein (EGFP) downstream of the internal stop codon of the CD207 antigen (Cd207 or Langerin) gene. Homozygotes are viable, fertile, and normal in size. Langerin is a transmembrane receptor produced by specialized antigen-presenting cells located in the skin called Langerhans cells (LCs), and other dendritic cells including dermal DCs and splenic CD8+ DCs. Langerin is specifically localized in the Birbeck granules, where it is necessary for their formation. In these mice, EGFP expression is evident in the cytosol of immature Langerin-derived DCs and CD8+ DCs and is decreased upon LC maturation. These mice may be useful for visualizing Langerhans cells and monitoring their movement during inflammation.|same phenotype as homozygous|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Jun-2020|Cryopreserved sperm|50.0|0.0|Unknown||Langerhans cells|Yes| 9112.0|Leptin Receptor fl/fl LysMCre|B6.129P2-LeprLyz2/JAusbAnuApb ||Semi-dominant|Leptin receptor; targeted mutation 1.1 Streamson C Chua, Jr|Lepr|Reduced|Leprb, LEPROT, leptin receptor gene-related protein, Modb1, obese-like, obl, Obr, OB-RGRP |MGI:104993 |Leptin receptor; targeted mutation 1.1 Streamson C Chua, Jr|Lepr|MGI:3511284|4|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Dec-2020|Cryopreserved sperm|50.0|0.0|Unknown||Immune response, leptin receptor, Signalling|Possibly| 9112.0|Leptin Receptor fl/fl LysMCre|B6.129P2-LeprLyz2/JAusbAnuApb ||Semi-dominant|Lysozyme 2|Lyz2 ||Lys, Lysm, Lyzs, Lzm, Lzm-s1, Lzp |MGI:96897|Lysozyme 2; targeted mutation 1, Irmgard Forster|Lyz2|MGI:1934631|10|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|11-Dec-2020|Cryopreserved sperm|||Unknown||Immune response, leptin receptor, Signalling|Possibly| 9201.0|ASD896:Eureka|C57Bl/6N-Setd5/Apb||Semi-dominant|SET domain containing 5|Setd5|||MGI:1920145|Setd5; endonuclease-mediated mutation 2, Australian National University|Setd5||6|||||||||||||||||||||||||||||may develop symptoms of autoimmune disease |may develop symptoms of autoimmune disease |Bcl6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|07-Jun-2021|Cryopreserved sperm|24.0|0.0|Unknown|||Possibly| 9099.0|B10.BR|B10.BR-H2 H2-T18/SgSnJ||Semi-dominant|||||||||||||||||||||||||||||histocompatibility-2, MHC|H2||H2|MGI:95894|Histocompatibility-2, MHC; k2 variant|H2|MGI:4936842|17||||Yes|Yes|Unknown|Yes|Unknown|Yes|No|Unknown||||No|25-Nov-2020||0.0|216.0|Unknown||T cells, leukocyte cellularity, CD4, CD8|Possibly| 9099.0|B10.BR|B10.BR-H2 H2-T18/SgSnJ||Semi-dominant|||||||||||||||||||||||||||||histocompatibility 2, T region locus 18|H2-T18|||MGI:95950|Histocompatibility 2, T region locus 18; a variant|H2-T18|MGI:4820507|17||||Yes|Yes|Unknown|Yes|Unknown|Yes|No|Unknown||||No|25-Nov-2020||||Unknown||T cells, leukocyte cellularity, CD4, CD8|Possibly| 8234.0|Il21r KO_Smarta_Ly5a|B6.Cg-Il21r Ptprc Tg(TcrLCMV)Aox/MarpAnu||Semi-dominant|interleukin 21 receptor|Il21r|Nil|NILR|MGI:1890475|interleukin 21 receptor; targeted mutation 1, Warren J Leonard|Il21r|MGI:2446509|7|||||||||||||||||transgene insertion, Annette Oxenius|||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Lack of Il21 receptor expression.Il21r KO mice have:Abnormal immunoglobulin level.Increased IgE level:• serum levels of IgE in nave mice are higher than in controls• ovalbumin immunized mice have variable total IgE levels with some mice having levels similar to wild-type and some mice having 3- to 6- fold higher amounts• total IgE production is increased about 50-fold after KLH immunization with similar increases with antigen specific antibody• IgE levels are 20- to 25- fold greater than controls 100 days after infection with toxoplasma gondiiDecreased IgG1 level:• serum levels of IgG1 in nave mice are lower than in controls• after immunization with ovalbumin, the normal increase in IgG1 seen in wild-type mice is markedly impaired in these mice• in immunized mice, total serum IgG1 is 4 to 5% of wild-type and levels of antigen-specific antibody is 0.1% of that in wild-type• an impaired IgG1 response is also observed after keyhole limpet hemocyanin (KLH) immunization, with antigen specific antibodies being 1/10 of that found in wild-type• IgG1 levels are third of controls 100 days after infection with toxoplasma gondiiDecreased IgG2a level:• IgG2a levels are lower than controls 100 days after infection with toxoplasma gondiiDecreased IgG2b level:• serum levels of IgG2b in nave mice are lower than in controls• after ovalbumin immunization, levels of antigen specific IgGb2 antibody are significantly lower• an impaired IgG2b response is also observed after KLH immunization, with antigen specific antibodies being 1/10 of that found in wild-type• IgG2b levels are lower than controls 100 days after infection with toxoplasma gondiiDecreased IgG3 level:• after ovalbumin immunization, levels of antigen specific IgG3 antibody are significantly lower• an impaired IgG3 response is also observed after KLH immunization, with antigen specific antibodies being 1/10 of that found in wild-type• IgG3 levels are lower than controls 100 days after infection with toxoplasma gondiiAbnormal CD8-positive, alpha-beta T cell physiology:• CD8+ T cell proliferation in vitro is not enhanced in the presence of IL-15 in the same manner as wild-type CD8+ T cells• the percentage of antigen-specific CD8+ T cells found in the spleen is a third lower than controls after vaccination• the percentage of CD8+ T cells making IFN-gamma one week after vaccination is about half that of wild-type controlsDecreased cytotoxic T cell cytolysis:• the cytotoxic activity of CD8+ T cells is significantly lower than wild-type cellsDecreased interleukin-17 secretion:• IL-17 production by CD4 T cells is much lower than controls when activated with IL-6 and TGF-beta in vitro• there is no IL-17 production from T cells when activated in vitro with IL-21 and TGF-beta compared to the robust production of controlsExpresses TCR specific for LCMV GP-derived epitpoe P13||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|28-Mar-2017|Cryopreserved sperm|20.0|0.0|Unknown||LCMV, TCR, IL21 receptor, immunoglobulin|Yes| 9364.0|C3TAC (CX3CR1-CreERT2 x Ai9 x CSF1Ffl/fl)|B6.129P2(C)-Cx3cr1/J, Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, Csf1r/J|MGI:3813511, MGI:5568569, MGI:5780867|Semi-dominant|colony stimulating factor 1 receptor|Csf1r|||MGI:1339758|colony stimulating factor 1 receptor; targeted mutation 1.2, Jeffrey W Pollard|Csf1r|MGI:5780867|18|||||||||||||||||||||||||||||Mice in which tamoxifen treatment induces Cre expression in all CX3CR1+ cells, leading them to express Tomato and disrupt CSF1R expression in all CX3CR1+ cells. This mouse line results from the cross of 3 mouse lines imported from Jackson labs:Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J): a Tamoxifen inducible CreERT2 reporter tool strain designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. This strain is congenic on the C57BL/6J genetic background. CX3CR1-CreERT2 (B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)Jung/J) : Cx3cr1CreER knock-in/knock-out mice express tamoxifen-inducible Cre recombinase under the direction of the Cx3cr1 promoter in the mononuclear phagocyte system making them useful for fate-mapping studies of the monocyte and macrophage compartment, as well as microglia.CSF1R fl/fl (B6.Cg-Csf1rtm1.2Jwp/J): a floxed mutant mice possess loxP sites flanking exon 5 of the colony stimulating factor 1 receptor (Csf1r) gene and may be useful in studying the role of CSF1R in development.Mice homozygous for the 3 mutations are CX3CR-1 deficient. While in untreated mice, all cells do not express Tomato and are CSF1R sufficient, Tamoxifen treatment induces Tomato exppression and CSF1R deficiency in all CX3CR1+ cells |Mice heterozygous for the 3 mutations are hemizygous for CX3CR1 Untreated mice have a normal phenotype with no Tomato expression and CSF1R deficiency. Tamoxifen treatment induces Tomato expression and disruption of one CSF1 gene. Their phenotype looks normal otherwise. |C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|21-Mar-2022|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 9364.0|C3TAC (CX3CR1-CreERT2 x Ai9 x CSF1Ffl/fl)|B6.129P2(C)-Cx3cr1/J, Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, Csf1r/J|MGI:3813511, MGI:5568569, MGI:5780867|Semi-dominant|chemokine (C-X3-C motif) receptor 1|Cx3cr1||| MGI:1333815|C-X3-C motif chemokine receptor 1; targeted mutation 2.1, Steffen Jung|Cx3cr1|MGI:5467985|9|||||||||||||||||||||||||||||Mice in which tamoxifen treatment induces Cre expression in all CX3CR1+ cells, leading them to express Tomato and disrupt CSF1R expression in all CX3CR1+ cells. This mouse line results from the cross of 3 mouse lines imported from Jackson labs:Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J): a Tamoxifen inducible CreERT2 reporter tool strain designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. This strain is congenic on the C57BL/6J genetic background. CX3CR1-CreERT2 (B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)Jung/J) : Cx3cr1CreER knock-in/knock-out mice express tamoxifen-inducible Cre recombinase under the direction of the Cx3cr1 promoter in the mononuclear phagocyte system making them useful for fate-mapping studies of the monocyte and macrophage compartment, as well as microglia.CSF1R fl/fl (B6.Cg-Csf1rtm1.2Jwp/J): a floxed mutant mice possess loxP sites flanking exon 5 of the colony stimulating factor 1 receptor (Csf1r) gene and may be useful in studying the role of CSF1R in development.Mice homozygous for the 3 mutations are CX3CR-1 deficient. While in untreated mice, all cells do not express Tomato and are CSF1R sufficient, Tamoxifen treatment induces Tomato exppression and CSF1R deficiency in all CX3CR1+ cells |Mice heterozygous for the 3 mutations are hemizygous for CX3CR1 Untreated mice have a normal phenotype with no Tomato expression and CSF1R deficiency. Tamoxifen treatment induces Tomato expression and disruption of one CSF1 gene. Their phenotype looks normal otherwise. |C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|21-Mar-2022|Cryopreserved sperm|||Unknown|||Possibly| 9364.0|C3TAC (CX3CR1-CreERT2 x Ai9 x CSF1Ffl/fl)|B6.129P2(C)-Cx3cr1/J, Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, Csf1r/J|MGI:3813511, MGI:5568569, MGI:5780867|Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|||MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 9, Hongkui Zeng|Gt(ROSA)26Sor|MGI:3809523|6|||||||||||||||||||||||||||||Mice in which tamoxifen treatment induces Cre expression in all CX3CR1+ cells, leading them to express Tomato and disrupt CSF1R expression in all CX3CR1+ cells. This mouse line results from the cross of 3 mouse lines imported from Jackson labs:Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J): a Tamoxifen inducible CreERT2 reporter tool strain designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. This strain is congenic on the C57BL/6J genetic background. CX3CR1-CreERT2 (B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)Jung/J) : Cx3cr1CreER knock-in/knock-out mice express tamoxifen-inducible Cre recombinase under the direction of the Cx3cr1 promoter in the mononuclear phagocyte system making them useful for fate-mapping studies of the monocyte and macrophage compartment, as well as microglia.CSF1R fl/fl (B6.Cg-Csf1rtm1.2Jwp/J): a floxed mutant mice possess loxP sites flanking exon 5 of the colony stimulating factor 1 receptor (Csf1r) gene and may be useful in studying the role of CSF1R in development.Mice homozygous for the 3 mutations are CX3CR-1 deficient. While in untreated mice, all cells do not express Tomato and are CSF1R sufficient, Tamoxifen treatment induces Tomato exppression and CSF1R deficiency in all CX3CR1+ cells |Mice heterozygous for the 3 mutations are hemizygous for CX3CR1 Untreated mice have a normal phenotype with no Tomato expression and CSF1R deficiency. Tamoxifen treatment induces Tomato expression and disruption of one CSF1 gene. Their phenotype looks normal otherwise. |C57Bl/6N|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 10|||No|21-Mar-2022|Cryopreserved sperm|||Unknown|||Possibly| 10466.0|NODk_TCH|NOD.Cg-H2/Anu||Dominant|histocompatibility-2, MHC|H2||MHC-II|MGI:95894|Histocompatibility H2k variant|H2k||17|||||||||||||||||||||||||||||This strain is prone to develop diabetes with western diet feeding|Not applicable|NOD|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Poor|N5F10RF14|||No|20-Jan-2025||0.0|225.0|Unknown|||Possibly| 10468.0|Foz:NOD.B10:R97/16|NOD(Cg)-H2 Alms1/Anu||Dominant|ALMS1, centrosome and basal body associated|Alms1||Alstrom syndrome 1|MGI:1934606|Alms1:Fat Aussie|Alms1:Foz||6|ENSMUSG00000063810||||||||||||||||||||||||||||NOD.B10 mice homozygous for foz/foz mutation develop obesity and with high fat feeding fatty liver disease and diabetes.|Normal|NOD.B10 Hybrid|Unknown|Unknown|Unknown|Unknown|No|Unknown|No|Unknown||||No|20-Jan-2025||0.0|369.0|Unknown|||No| 10464.0|nor-1 Nr4a3|B6;129-Nr4a3/J||Dominant|nuclear receptor subfamily 4, group A, member 3|Nr4a3||MINOR, Nor1, NOR-1, TEC|MGI:1352457|nuclear receptor subfamily 4, group A, member 3; targeted mutation 1, Orla M Conneely|Nr4a3|MGI:3037444|4|ENSMUSG00000028341|ENSMUST00000153369|||||||||||||||||||||||||||Normal|Normal|C57Bl/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|03-Dec-2024||0.0|30.0|Unknown|||No| 9307.0||C57Bl/6-Adar/Apb||Semi-dominant|adenosine deaminase, RNA-specific|Adar||ADAR1, Adar1p110, Adar1p150, mZaADAR|MGI:1889575|adenosine deaminase, RNA-specific; endonuclease-mediated mutation 1, Carl R Walkley|Adar|MGI:7514376|3|||||||||||||||||||||||||||||Homozygous L196C/L196C is embryonic lethal at E11.5-E12.5. This mutation leads to the loss of the p150 isoform of ADAR1 specifically; p110 is expressed still. Phenotype similar to the full ADAR1 null mouse|Heterozygous animals are viable, fertile and normal|C57Bl/6N|No|Unknown|Unknown|No|Unknown|Unknown|No|Unknown||||No|26-Nov-2021|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 10347.0||B6.129-Nox4/Apb||Dominant|NADPH Oxidase 4 |Nox4|||MGI:1354184|NADPH oxidase 4; targeted mutation 1, Karl-Heinz Krause|Nox4|MGI:5502326|7|ENSMUSG00000030562 | ENSMUST00000068829|||||||||||||||||||||||||||Phenotype information includes data collected from the published literature. Nox4 deficiency reduced oxidative stress and apoptosis in alveolar epithelial cells stimulated with TGFb1. Bleomycin-treated mice demonstrate decreased bleomycin-induced weight loss, lung fibrosis, myofibroblasts accumulation and alveolar epithelial cell death compared to wild-type mice, however, bleomycin-induced inflammation is normal. Homozygous mice are viable and fertile. |Normal|C57Bl/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5x||homozygote x homozygote|No|30-Jun-2023|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10439.0|Lcp1 I232F (10)|C57Bl/6N-Lcp1/Apb||Recessive|lymphocyte cytosolic protein 1 |Lcp1||D14Ertd310e, L-fimbrin, L-plastin, Pls2|MGI:104808|Lcp1:endonuclease-mediated mutation 3, Australian National University|Lcp1||14|ENSMUSG00000021998||||||||||||||||||||||||||||Leukopenic in the bloodT cell proliferation defect, cytokinesis arrest leading to polyploidy cells|Leukopenic in the bloodT cell proliferation defect, cytokinesis arrest leading to polyploidy cells|C57Bl/6N|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||||No|28-Jun-2024|Cryopreserved sperm|54.0|0.0|Unknown|||No| 10473.0|Ubf1 KO bp12|C57BL/6NCrlAnu-Ubtf/ANU||Recessive|Upstream binding transcription factor, RNA polymerase I|Ubtf||Tcfubf, UBF, UBF1|MGI:98512|Ubtf|Ubf1 KO||11|ENSMUSG00000020923|ENSMUST00000174302|||||||||||||||||||||||||||Embryonic lethal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Jan-2025|Cryopreserved sperm|59.0|0.0|Unknown|||No| 9324.0|Agxt/Apb||Semi-dominant|alanine-glyoxylate aminotransferase|Agxt|||MGI:1329033|Agxt: endonuclease-mediated mutation 1, Australian National University|Agxt||1|||||||||||||||||||||||||||||unknown|unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Dec-2021|Cryopreserved sperm|10.0|0.0|Unknown|||Possibly| 10402.0|mPfCSPrev-mCherry|C57BL/6J-Gt(ROSA)26Sor/Anu||Recessive|Plasmodium falciparum circumsporozoite protein|PfCSPrev-mCherry|||Plasmodium falciparum circumsporozoite protein||||Unknown|||||||||||||||||mCherry red fluorescent protein||||||||||||Presence of gene trap indicated by mCherry expression|Presence of gene trap indicated by mCherry expression|C57Bl/6J|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|backcrossed to C57BL / 6NCrlAnu|||No|31-Jan-2024|Cryopreserved sperm|41.0|0.0|Unknown|||No| 5352.0|B6.SOD1.SOD3.Gpx1.Tg|C57BL/6-Tg(H2-K-GPX1,-SOD1,-SOD3/CD55)CCpj/Apb||Dominant||||||||||||||||||||||||||human CuZn superoxide dismutase (SOD1) tagged with a hemagglutinin epitope tag|H2-K|medium||||||||||Expression of all three enzymes was the only combination protective against hypoxia/reoxygenation. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|20-Dec-2010|Cryopreserved sperm|45.0|0.0|Unknown||reactive oxygen species (ROS), transplantation, islet, antioxidant, graft|No| 5352.0|B6.SOD1.SOD3.Gpx1.Tg|C57BL/6-Tg(H2-K-GPX1,-SOD1,-SOD3/CD55)CCpj/Apb||Dominant||||||||||||||||||||||||||human extracellular superoxide dismutase (SOD3) modified to include a glycosyl phosphatidylinositol (GPI) membrane linkage signal & tagged with a FLAG epitope tag|H2-K|||||||||||Expression of all three enzymes was the only combination protective against hypoxia/reoxygenation. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|20-Dec-2010|Cryopreserved sperm|||Unknown||reactive oxygen species (ROS), transplantation, islet, antioxidant, graft|No| 5352.0|B6.SOD1.SOD3.Gpx1.Tg|C57BL/6-Tg(H2-K-GPX1,-SOD1,-SOD3/CD55)CCpj/Apb||Dominant||||||||||||||||||||||||||human cellular glutathione peroxidase (Gpx-1) tagged with a histidine (6xHis) tag|H2-K|||||||||||Expression of all three enzymes was the only combination protective against hypoxia/reoxygenation. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type. In contrast to single- and double-transgenic grafts, triple-transgenic grafts significantly improved control of blood glucose compared with wild type.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|20-Dec-2010|Cryopreserved sperm|||Unknown||reactive oxygen species (ROS), transplantation, islet, antioxidant, graft|No| 10487.0|CK1D1 ROSA26 KI|B6.-Gt(ROSA)26Sor||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|||MGI:104735|casein kinase 1 delta transcript variant 1 knock in|Gt(ROSA)26Sor||6||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Feb-2025|Cryopreserved sperm|50.0|0.0|Unknown|||No| 10474.0|Ubf1 KO bp3|C57BL/6NCrlAnu-Ubtf/ANU||Recessive|Upstream binding transcription factor, RNA polymerase I|Ubtf||Tcfubf, UBF, UBF1|MGI:98512|Ubtf|Ubf1 KO||11|ENSMUSG00000020923|ENSMUST00000174302|||||||||||||||||||||||||||Embryonic lethal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|21-Jan-2025|Cryopreserved sperm|54.0|0.0|Unknown|||No| 9435.0|Brca2 KO|Balb/c-Brca2/Apb||Dominant|breast cancer 2, early onset|BRCA2|||MGI:109337|Brca2: endonuclease mutation 1, Australian National University|Brca2||5|||||||||||||||||||||||||||||Heterozygous - normalHomozygous - embryonic lethal|Normal|Balb/cJ|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Sep-2022|Cryopreserved sperm|54.0|0.0|Unknown|||Possibly| 4939.0|B6.Asciz|C57BL/6-Atmin/Apb||Recessive|ATM interactor ; ATM substrate Chk2-interacting Zinc-finger protein|Atmin ; ASCIZ|Nil|Asciz, MGC:79206, mKIAA0431|MGI:2682328|ATM interactor; targeted mutation 1.1, Jorg Heierhorst|Atmin|MGI:4881337|8||||||||||||||||Yes|||||||||||||Embryonic lethal. late embryonic lethality (~E16.5) with complete absence of lungs and severe tracheal atresia (100% penetrance);Frequent exencephaly (~25% penetrance); Increased cellular DNA base damage sensitivity, including oxidative DNA damage and damage-dependent premature senescence; Highly reduced Dynll1 gene expression (>10-fold) in all tissues and cell types investigated.|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Excellent|2|||No|03-Dec-2009|Cryopreserved sperm|100.0|0.0|Unknown||Base excision repair, embryonic lethal, zinc finger, ATM kinase|Yes| 5030.0|Hulett 5B|C57BL/6J-Hpse/AnuApb||Recessive|heparanase|Hpse||Hpa|MGI:1343124|Hpse; targeted mutation 1, Australian National University|Hpse ||5||||||||||Unknown to Unknown|||||||||||||||||||Mice are anatomically normal and fertile.The trafficking of dendritic cells from the skin to the draining lymph nodes was markedly reduced in Hpse<−/−> mice. Impaired ability to generate an allergic inflammatory response in the airways.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|22-Feb-2010|Cryopreserved sperm|90.0|0.0|Unknown||migration, dendritic cell, trafficking|Possibly| 5270.0|Crouzon|STOCK Fgfr2/Apb|MGI:3053095|Dominant|fibroblast growth factor receptor 2|Fgfr2|Normal|Bek, Fgfr-2, Fgfr-7, Fgfr7, KGFRTr, svs|MGI:95523|fibroblast growth factor receptor 2; targeted mutation 4, Peter Lonai|Fgfr2|MGI:3053095|7||||||||||||||||No|||||||||||||Homozygous mutants display multiple joint fusions,cleft palate, and trachea and lung defects, and die shortly afterbirth.|Fgfr2cC342Y/+ heterozygote miceare viable and fertile with shortened face, protruding eyes, prematurefusion of cranial sutures, and enhanced Spp1 expression inthe calvaria. Prone to malocclusion.|C57BL/6 (not congenic)|No|No|Yes|No|No|Yes|No|Good||||No|25-Oct-2010|Cryopreserved sperm|50.0|0.0|Yes|Crouzon craniosynostosis|Craniosynostosis, fibroblast growth factor receptor, bone, suture, gain of function|Yes| 5323.0|NfiB Conditional|B6.129-Nfib/Apb||Dominant|nuclear factor I/B|NFib|Reduced||MGI:103188|nuclear factor I/B; targeted mutation 2, Richard M Gronostajski|Nfib|MGI:5052268|4|||||||||||||||||||||||||||||Apparently normal. Viable as homozygous mice when not crossed to a Cre expressing line.|Apparently normal. Viable as heterozygous mice when not crossed to a Cre expressing line.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Nov-2010|Cryopreserved sperm|44.0|0.0|Unknown||lung, epithelium|Possibly| 10489.0|CK1D2 KO |B6-Csnk1dHO||Recessive|casein kinase 1, delta|Csnk1d|||MGI:1355272|casein kinase 1 delta Knock out|CSNK1D||11|ENSMUSG00000025162 | ENSMUST00000239115|||||||||||||||||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|25-Feb-2025|Cryopreserved sperm|50.0|0.0|Unknown|||No| 10475.0|GLR|Tg(TcraHsv2.3,TcrbHsv2.3)L118-1Cbn B6.SJL-Ptprca Pepcb/BoyJ, B6.129S7-Rag1tm1Mom/J||Recessive|Tcra, Tcrb, RAG-1, ptprca|||||Tcra, Tcrb, RAG-1, ptprca|TCR, RAG-1 and Ly5.1||Unknown|||||||||||||||||TCR|2 kb fragment of the H-2Kb and a 700 bp fragment including the Igh enhancer.|||||||||||Tg mouse line in which all T cells express the rearranged Tcra and Tcrb derived from HSV-1 glycoprotein B specific CTL clone HSV2.3, under the control of a 2 kb fragment of the H-2Kb and a 700 bp fragment including the Igh enhancer. T C57BL/6 congenic strain carries the differential Ptprca pan leukocyte marker commonly known as CD45.1 or Ly5.1. This mouse line was backcrossed onto wildtype C57BL/6 inbred mice expressing the Ptprcb (CD45.2 or Ly5.2) allele and are also deficient for RAG-1 as mice are deficient for RAG, they lack B cells and all their T cells express the same transgenic TCR|Normal ||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Jan-2025|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 5386.0|Fat Aussie|NOD.B10-Alms1/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Mice are hyperphagic leading to obesity and diabetes. Males are sterile. High fat feeding accelerates obesity and diabetes development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis.Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.|Normal|NOD.B10|Yes|Yes|Yes|Yes|No|Yes|Yes|Excellent|>10||heterozygote mating|No|17-Jan-2011|Cryopreserved sperm|50.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 5387.0|Fat Aussie|C57BL/6-Alms1/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Mice are hyperphagic leading to obesity. Males are sterile. High fat feeding accelerates obesity development, and leads to nonalcoholic steatohepatitis which progresses to liver fibrosis. Steatohepatitis also develops in chow-fed animals.Hyperglycemia: female mice are diabetic by 200 days of age.Increased circulating insulin level: female mice develop insulinemia (20ng/mL insulin vs. 2-5ng/mL in wild-type).Insulin resistance: female mice develop insulin resistance by 200 days of age.Increased eating behavior: mutants eat more than wild-type.Abnormal hepatocyte morphology: mutant livers show many hepatocytes with ballooning degeneration and extensive lobular inflammation with polymorphs and mononuclear cells.Enlarged liver: mice fed high-fat diet show hepatomegaly compared to wild-type (8.9g vs. 2g).Increased liver weight: liver weights in mutant are twice that of wild-type (3.4g vs. 1.6g).Liver fibrosis: mutant livers show pericellular and pericentral fibrosis.Hepatic steatosis: chow-fed mutants develop steatosis; mutants fed the high-fat diet develop severe steatohepatitis.|Normal|C57BL/6|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|17-Jan-2011|Cryopreserved sperm|32.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 5391.0|MPS IIIA Congenic Strain|B6.Cg-Sgsh/Apb||Recessive|N-sulfoglucosamine sulfohydrolase (sulfamidase)|Sgsh|Reduced|sulphamidase|MGI:1350341|N-sulfoglucosamine sulfohydrolase (sulfamidase); mucopolysaccharidosis IIIA|Sgsh|MGI:2151181|11|||||||||||||||||||||||||||||General health and vigour is generally good, at least until 30 weeks of age. Newborn MPS IIIA mice are no different to their unaffected counterparts. It is not until around 10 weeks of age that we begin to see differences. From 10 weeks onwards, MPS IIIA males can be aggressive towards each other. If we test the mice in an open-field test of activity, they are less active. They are heavier (presumably due to slightly enlarged liver and spleen), plus urinary retention in some (but not all) mice. Affected females and males are both fertile. From around 18-20 weeks mice are less able to perform a test of learning and memory (Morris water maze) and can best be described as a little ‘duller’ than unaffected mice. Their fur is ruffled and rough looking. We do not often retain mice past around 30 weeks of age, however we might expect that some (but not all) will die younger than unaffected mice. The reason for this is not known, but may relate to liver dysfunction.We have primarily sought to characterise the brain disease in the MPS IIIA mice as this is the area of the body most affected in the mice/patients with this condition. Mice exhibit reduced anxiety, reduced activity, reduced cognition (memory and learning). Other deficits, which may have both a central nervous system and somatic organ/tissue involvement include mildly impaired gait, reduced grip strength. None of these observations are likely to have a major welfare impact. Fighting in affected male mice has been observed, and monitoring for this followed by separation is required. This has significant welfare implications. Early death is seen (40+ weeks). Monitoring more often after 30 weeks of age is recommended, so humane euthanasia can occur. |Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|13||Brother Sister|No|20-Jan-2011|Cryopreserved sperm|50.0|0.0|Yes|Neurodegenerative lysosomal storage disorder characterised by mental decline, sleep disturbance and hyperactivity.|Lysosomal storage disorder, Mucopolysaccharidosis, Neurodegenerative|Yes| 5392.0|Adam22|B6;CBA-Adam22/Apb||Recessive|a disintegrin and metallopeptidase domain 22|Adam22|Nil|MDC2|MGI:1340046|a disintegrin and metallopeptidase domain 22; targeted mutation 1, Koji Sagane|Adam22|MGI:3584137|5||||||||||||||||Yes|||||||||||||Complete postnatal lethality: start to die after P10 and all die before P20.Ataxia: * all display severe ataxia after P10 * unable to support themselves on hindlimbs at P18Convulsive seizures: occasionally observe convulsive seizures.Decreased body size.Decreased body weight: average body weight is approximately half that of controls at P10.Abnormal Schwann cell morphology: higher density of pro-myelinating Schwann cells in the sciatic nerve and delay in differentiation of Schwann cells.Abnormal myelination: lack of myelin or thin myelin in the sciatic nerves and trigeminal nerves, however myelin formation in spinal cord and brain is normal.Abnormal glial cell morphology: enteric sections exhibit fewer glial cells than in wild-type mice.Abnormal neuron morphology: cultured primary neurons cannot be myelinated by Rat Schwann cells unlike similarly treated neurons from heterozygous mice.Demyelination: * in the sciatic nerve at P12 that is less severe than in Lgi4 homozygotes * of peripheral nerves|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|20.0|0.0|Unknown||myelin, neuron, ataxia, integrin, adhesion|Yes| 5393.0|a33 b-neo/b-neo|C57BL/6-Gpa33/Apb||Dominant|glycoprotein A33 (transmembrane)|Gpa33||A33 antigen|MGI:1891703|glycoprotein A33 (transmembrane) targeted mutation 2, Matthias Ernst|Gpa33||1||||||||||||||||Yes|||||||||||||Unknown|Unknown|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|50.0|0.0|Unknown||A33, epithelium, b-catenin|Yes| 8483.0|Scn2a R851X|C57BL/6-Scn2a/Apb||Recessive|sodium channel, voltage-gated, type II, alpha|Scn2a||A230052E19Rik, Nav1.2, Scn2a1|MGI:98248||Scn2a||2|||||||||||||||||||||||||||||Lethal before P5|Life expectancy is similar to wild type. No obvious abnormal phenotype.|C57BL/6|No|No|Yes|No|No|Yes|No|Unknown||||No|11-May-2018|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 5388.0|Fat Aussie|BALB/c-Alms1/AnuApb||Recessive|Alstrom syndrome 1 homolog (human)|Alms1|Unknown||MGI:1934606|Alstrom syndrome 1 homolog (human); fat aussie|Alms1|MGI:3621984|6||||||||||||||||Yes|||||||||||||Mice are hyperphagic leading to obesity . Males are sterile. High fat feeding accelerates obesity development. Compared to foz/foz mice on NOD.B10 background, BALB/c foz/foz mice do not develop diabetes and liver disease is less severe.|normal|BALB/c|Yes|Unknown|Yes|Yes|No|Yes|Yes|Good|>10||heterozygote mating|No|17-Jan-2011|Cryopreserved sperm|39.0|0.0|Yes|Alstrom syndrome is a disorder of childhood obesity, diabetes development and infertility.|obesity, diabetes, nonalcoholic fatty liver disease, alstrom syndrome, cilia|Yes| 5394.0|A33/B-cat del/580's|Stock Gpa33 Ctnnb1 Apc/LudApb||Dominant|glycoprotein A33 (transmembrane)|Gpa33|||MGI:1891703|glycoprotein A33 (transmembrane) targeted mutation 2, Matthias Ernst|Gpa33||1|||||||||||||||||||||||||||||Unknown|Unknown||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|40.0|0.0|Unknown||Wnt, polyposis|Yes| 5394.0|A33/B-cat del/580's|Stock Gpa33 Ctnnb1 Apc/LudApb||Dominant|catenin (cadherin associated protein), beta 1|Ctnnb1||beta catenin, beta-catenin, Bfc, Catnb|MGI:88276|catenin (cadherin associated protein), beta 1; targeted mutation 4, Walter Birchmeier|Ctnnb1|MGI:2148594|9||||||||||||||||No|||||||||||||Unknown|Unknown||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|||Unknown||Wnt, polyposis|Yes| 5394.0|A33/B-cat del/580's|Stock Gpa33 Ctnnb1 Apc/LudApb||Dominant|adenomatosis polyposis coli|Apc|Reduced|CC1, Min|MGI:88039|adenomatosis polyposis coli; targeted mutation 1, Tetsuo Noda|Apc|MGI:1857966|18||||||||||||||||Yes|||||||||||||Unknown|Unknown||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|24-Jan-2011|Cryopreserved sperm|||Unknown||Wnt, polyposis|Yes| 5551.0|Krüppel-like Factor 8 (Klf8) Knockout |FVB/N.129P2-Klf8/Apb||X-linked|Kruppel-like factor 8|Klf8|Nil||MGI:2442430|Kruppel-like factor 8; gene trap AD0101, Wellcome Trust Sanger Institute|Klf8|MGI:4331301|X||||||||||||||||Yes|||||||||||||Largely normal.Some mice by 6 months of age.Mice exhibit normal full blood counts indicating normal erythroid parameters and platelet numbers and normal response to phenylhydrazine treatment |Normal.Premature death: • some mice by 6 months|FVB/N|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Aug-2011|Cryopreserved sperm|49.0|0.0|Unknown||Kruppel-like Factor 8, KLF, Apoptosis, cell cycle|No| 6764.0|gp130/Stat3 (BJ-13)|STOCK Il6st Stat3/LudApb||Recessive|interleukin 6 signal transducer|Il6st|Normal|5133400A03Rik, CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Matthias Ernst|Il6st|MGI:2388478|13|||||||||||||||||||||||||||||Homozygous Stat3 mice are not viable. They are embryonic lethal.The Gp130 mutation will result in gastric polyp development, although this is significantly delayed in comparison to BJ-12 (Stat3 wt). Check for hunching and general disintrest.|Normal||No|No|Unknown|No|No|Unknown|No|Unknown||||No|16-Dec-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction|Yes| 6764.0|gp130/Stat3 (BJ-13)|STOCK Il6st Stat3/LudApb||Recessive|signal transducer and activator of transcription 3|Stat3|Nil|1110034C02Rik, Aprf|MGI:103038|signal transducer and activator of transcription 3; targeted mutation 1, Shizuo Akira|Stat3|MGI:1926814|11|||||||||||||||||||||||||||||Homozygous Stat3 mice are not viable. They are embryonic lethal.The Gp130 mutation will result in gastric polyp development, although this is significantly delayed in comparison to BJ-12 (Stat3 wt). Check for hunching and general disintrest.|Normal||No|No|Unknown|No|No|Unknown|No|Unknown||||No|16-Dec-2011|Cryopreserved sperm|||Unknown||signal transduction|Yes| 5490.0|Hck(129sv/ter) ;Hck up mutant.129sv/ter|129T1/Sv-Hck/LudApb||Dominant|hemopoietic cell kinase|Hck|Reduced|Bmk, Hck-1|MGI:96052|hemopoietic cell kinase; targeted mutation 1, Matthias Ernst|Hck|MGI:3663799|2||||||||||||||||Yes|||||||||||||Abnormal alveolar macrophage morphology: * there are large macrophages in mutant lungs despite specific pathogen-free (SPF) housing. * alveolar macrophages are frequently vacuolated with eosinophilic cytoplasm.Lung inflammation: * lungs have areas of infiltration into the interstitium and alveoli at 3-4 months of age and older * lungs are characterized by areas of accumulation of mononuclear inflammatory cells around airways and blood vessels * areas of pulmonary consolidations become evident around 5-6 weeks of age and progress from that pointPulmonary hyperplasia: lungs are consistently characterized by increased cellularity within the parenchymaAbnormal pulmonary alveolus morphology: alveolar spaces contain eosinophilic matter accompanied by degranulated eosinophilic proteinOverexpanded pulmonary alveoli: lungs show some areas of enlarged airspaces at 3-4 months of age and older.Thick pulmonary interalveolar septum: excessive fibrotic deposits of extracellular matrix in the alveolar septa.Emphysema: lungs show areas of emphysema, with loss of orderly appearance of acinus.Pulmonary fibrosis: lungs display signs of fibrosis characterized by depostion of extracellular matrix material in the alveolar septa.Abnormal respiratory epithelium morphology: epithelial cells lining the conducting airways exhibit extensive mucus cell metaplasia resulting in mucus aggregates in the airway lumen.Respiratory epithelium hypertrophy: epithelium lining conducting airways is frequently hypertrophic and many epithelial cells are enlarged due to excessive production/accumulation of mucus material.Decreased lung elastance: mutants show decreased tissue elastance of the lung tissue at baseline compared with wild-type.Respiratory distress: aging mice show signs of respiratory distress, evident by use of accessory muscles.Atelectasis: in 3-4 month-old and older mutants, lungs show areas of atelectasis.Increased eosinophil cell number: eosinophils are most prominent cell type in infiltrates in lungs (30% of total bronchoalveolar lavage fluid (BALF) from mutants compared to 2% in wild-type.||129T1/Sv|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Apr-2011|Cryopreserved sperm|80.0|0.0|Unknown||kinase, macrophage, hyperplasia, pulmonary, eosinophil, SRC|Yes| 5503.0|Gp130stat|Stock Il6st/LudApb||Dominant|interleukin 6 signal transducer|Il6st|Unknown|CD130, D13Ertd699e, gp130|MGI:96560|interleukin 6 signal transducer; targeted mutation 1, Ashley R Dunn|Il6st|MGI:2388476|13||||||||||||||||Yes|||||||||||||Postnatal lethality: * numbers deficient at weaning * ratio of homozygotes normal at E18.Premature death (J:79555): * 6 month life span for males * 8 month life span for femalesDecreased body length: 20-30% shorter trunk length at birth.Decreased body weight: 20-30% lower body weight at birth.Abnormal uterine environment: failure of implantation, blastocysts will develop to term in wild-type recipient femalesFemale infertility: females show no external signs of pregnancy regardless of male genotype.Gastrointestinal haemorrhage: faecal blood at 4 months of age.Abnormal digestive system morphology.Rectal prolapse.Gastrointestinal ulcer: * caecal ulcers * ulceration of the anorectal regionGgastric ulcer: ulceration of the gastric pylorus at 4 months of age.Large intestinal inflammation: caecal inflammation.Increased susceptibility to induced colitis: * severe erosion of the intestinal epithelium from exposure to 3.5% dextran sodium sulfate. * remain moribund when exposure is ended.Abnormal leukocyte cell number: white blood cell count significantly higher than in controls.Decreased immunoglobulin level.Decreased IgA level: * basal IgA levels are reduced * impaired ability to mount an intestinal IgA response after challenge * basal IgM is normalDecreased IgG level: impaired ability to mount an intestinal IgG response after challenge.Conjunctivitis.Increased susceptibility to parasitic infection: tend to carry higher parasitic loads.Abnormal common myeloid progenitor cell morphology: * colony forming cells elevated in the spleen but not in bone marrow * elevated "CFU-S" hematopoietic progenitor cells * hematopoietic progenitors elevated in the liver at E14 relative to controls.Abnormal megakaryocyte morphology.Abnormal thrombopoiesis: * impaired maturation of megakaryocytes to produce platelets * 40% reduction in the number of platelets produced per megakaryocyte.Decreased platelet cell number: platelet count reduced 30%.Decreased megakaryocyte cell number: by 23% in bone marrow.Increased megakaryocyte cell number: numbers in spleen increased 2 fold relative to controls.Skeleton phenotype: trabecular bone volume is normal.Abnormal femur morphology.Decreased diameter of femur: significantly reduced femoral width.Short femur.Abnormal joint morphology.Abnormal joint capsule morphology: * cartilaginous nodules in joint capsules that replace menisci and support cartilage in knee joints * erosion of articular surfaces in older mice.Joint swelling: * of weight bearing joints in 60% of adults * observed by 7 days of age * more severe in males than femalesAbnormal joint mobility: * flexion abnormalities of hindlimbs * reluctance to stand * restricted flexion and extension of ankles and wrists * stiffness of one or more limbsIncreased cell proliferation: proliferative response of fibroblasts in culture to Il6 is increased.Gastrointestinal hemorrhage: fecal blood at 4 months of age.|Unknown||Yes|No|Yes|Yes|Yes|Yes|No|Unknown|||Mate homozygous males with heterozygote females|No|09-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||signal transduction, kinase, STAT, IL6, gp130, joint|Yes| 5570.0|MCC floxed|B6.Cg-Mcc/AusbApb|Maija|Recessive|mutated in colorectal cancers|Mcc|||MGI:96930|mutated in colorectal cancers; targeted mutation 1, Maija Kohonen-Corish|Mcc|MGI:6810152|18||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|29-Aug-2011|Cryopreserved sperm|50.0|0.0|Unknown||tumour suppressor, phosphorylation, nuclear localization, signal transduction|Possibly| 6640.0|NOD.HinsA|NOD-Tg(Tcra/Tcrb) Tg(Ins2-INS1)1/StvApb||Dominant||||||||||||||||||||||||||T-cell receptor alpha chain /T-cell receptor beta chain||||||||||||Unknown|Normal|NOD/Lt|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Intercrossing|No|03-Nov-2011|Cryopreserved sperm|45.0|0.0|Yes|NOD/Lt mice develop type 1 diabetes. These transgenic mice were made to study this disease.|Diabetes, Tolerance, Autoantigen, Autoimmunity, insulin|Yes| 6640.0|NOD.HinsA|NOD-Tg(Tcra/Tcrb) Tg(Ins2-INS1)1/StvApb||Dominant||||||||||||||||||||||||||human insulin|rat insulin promoter (RIP) (Ins2)|||||||||||Unknown|Normal|NOD/Lt|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Intercrossing|No|03-Nov-2011|Cryopreserved sperm|||Yes|NOD/Lt mice develop type 1 diabetes. These transgenic mice were made to study this disease.|Diabetes, Tolerance, Autoantigen, Autoimmunity, insulin|Yes| 6849.0|BomKI ; Grhl2 knockin|B6.129-Grhl3/MarpApb||Recessive|grainyhead-like 3 (Drosophila)|Grhl3||ct, Get1, nmf231, Som|MGI:2655333|grainyhead-like 3 (Drosophila); targeted mutation 2.1, Stephen M Jane|Grhl3|MGI:4836382|4|||||||||||||||||||||||||||||All homozygous mice have neural tube defects including spina bifida (in the lumbo-sacral region in almost all embryos) and curly tail.Complete lethality during fetal growth through weaning:• die between E18.5 and weaning|Normal, small percentage displays neural tube defects such as curlytail and spina-bifida.|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||KI/+ x +/+|No|14-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown||spine, embryonic lethal, closure|Possibly| 6850.0|Grhl1KO|C57BL/6-Grhl1/MarpApb||Recessive|grainyhead-like 1 (Drosophila)|Grhl1|Nil|LBP-32, p61 MGR, p70 MGR, Tcfcp2l2|MGI:2182540|grainyhead-like 1 (Drosophila); targeted mutation 1, Stephen M Jane|Grhl1|MGI:3778923|2|||||||||||||||||||||||||||||Homozygous mice are small and have a variable hair phenotype leading to hair loss.Postnatal growth retardation: similar in size at birth and at 2 months of age but significantly smaller than littermate controls at weaning.Cardiovascular system phenotype: unlike human patients with striate palmoplantar keratoderma disorder, no evidence of cardiomyopathy is detected.Alopecia: * over 30% of mice lack hair at weaning with the remainder having sparse coats * extensive regional hair loss is seen when mice are housed with other mice with regrowth when mice are housed alone * despite the thinner coat, in a tape-stripping test more hairs are removed compared to wild-type controls.Delayed hair appearance: delay in coat growth that may be the result of maternal grooming.Sparse hair: * over 30% of mice lack hair at weaning with the remainder having sparse coats * coat remains sparse throughout lifeAbnormal hair follicle morphology: * sections of skin from hypotrichotic regions contain empty cysts in telogen follicles * cleft between the inner and outer root sheath * depilated hairs have a naked anagen bulb lacking the inner and outer root sheathAbnormal epidermal layer morphology: fewer desmosomes are identified in the interfolicular epidermis and unlike in wild-type mice, this number is further reduced after EGTA treatment.Hyperkeratosis: marked thickening of the stratum corneum on the palmoplantar surfaces of the paws.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||+/- x +/-|No|14-Mar-2012|Cryopreserved sperm|50.0|0.0|Yes|Keratosis Palmoplantaris Striata I; PPKS1 ; Loose Anagen Hair Syndrome|Hair, Coat, follicle|Possibly| 6851.0|Grhl2KO|B6.129S1-Grhl2/MarpApb||Recessive|grainyhead-like 2 (Drosophila)|Grhl2|Nil|0610015A08Rik, BOM, Tcfcp2l3|MGI:2182543|grainyhead-like 2 (Drosophila); targeted mutation 1.1, Stephen M Jane|Grhl2|MGI:4836381|15|||||||||||||||||||||||||||||Homozygous mice are embryonic lethal, dying around E12.5.Complete embryonic lethality during organogenesis: die at approximately E11.5.Abnormal neural tube closure: the posterior neuropore remains open at E10.5.Cranioschisis.Facial cleft: fully penetrant split face malformation.Abnormal neural fold elevation formation: * the dorso-lateral hinge points fail to form in the cephalic region by the 15 - 25 somite stage * however, in areas of the spinal cord above the neural tube defect dorso-lateral hinge formation is seen.|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||+/- x +/+|No|14-Mar-2012|Cryopreserved sperm|50.0|0.0|Unknown||neural fold, split-face malformation, exencephaly, neuro-epithelial folding, neural tube|Possibly| 7754.0|GFP|BALB/c-Tg(CAG-GFP)/MarpApb||Dominant||||||||||||||||||||||||||Green fluorescent protein|B-actin (CAG)|||||||||||Wildtype are normal.These mice express the GFP reporter gene under the beta-actin promoter. All cells are fluorescent green under UV light. GPF expressed in all cells where beta-actin in transcribed.|These mice express the GFP reporter gene under the beta-actin promoter. All cells are fluorescent green under UV light. GPF expressed in all cells where beta-actin in transcribed.|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|not applicable|Over 5 years|Heterozygote with wildtype (either sex)|No|07-Oct-2014|Cryopreserved sperm|40.0|0.0|No||stem cells|Yes| 7989.0|Muc13 knockout|B6.129-Muc13||Dominant|mucin 13, epithelial transmembrane|Muc13|Nil|114/A10, Ly64|MGI:103190||||16|||||||||||||||||||||||||||||No unchallenged phenotype and more severe intestinal inflammation and epithelial apoptosis under stress.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|12||This strain can be maintained by het x het or hom x hom.|No|04-Nov-2015|Cryopreserved sperm|48.0|0.0|No||mucin, Muc13, colonic cancer, epithelial transmembrane, inflammation, colitis|Yes| 7999.0|Y-GFPd2 ; Ddx3y_cl.115_GFP|129-Ddx3y/KalpApb|Ygfpd2|Semi-dominant|DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked|Ddx3y|Normal|8030469F12Rik, D1Pas1-rs1, Dby|MGI:1349406||||Y|||||||||||||||||||||||||||||Normal|Most tissues express the green fluorescent protein gene. There is variation in expression between tissues.|12951/Sv1mJ |Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Dec-2015|Cryopreserved sperm|60.0|0.0|No||GFP, reporter|Yes| 6852.0|Grhl3KO|B6.129S1-Grhl3/MarpApb||Recessive|grainyhead-like 3 (Drosophila)|Grhl3|Nil|ct, Get1, nmf231, Som|MGI:2655333|grainyhead-like 3 (Drosophila); targeted mutation 1, Stephen M Jane|Grhl3|MGI:2684328|4|||||||||||||||||||||||||||||Homozygous mice die at birth from severe spina bifida.Complete preweaning lethality: mutant embryos were represented in Mendelian ratios up to E18.5; no mice survived to weaning.Decreased embryo size: embryos show growth retardationSpina bifida: * all embryos had thoracolumbosacral spina bifida and curled tails * the neural plate appeared to furrow normally, but neural foled elevation did not occur * the incidence of spina bifida could not be reduced with folate treatment.Kinked tail.Kyphosis.Abnormal vertebrae morphology: full body skeletal preparations showed abnormalities in the vertebral column.Abnormal vertebral spinous process morphology: splayed spinal processes.Absent vertebral arch: lack of vertebral arch formation.Exencephaly: 2% of mutants had coincident exencephaly|Normal|C57BL/6|No|No|Yes|No|No|Yes|No|Good|||+/- x +/+|No|14-Mar-2012|Cryopreserved sperm|50.0|0.0|Yes|Spina Bifida|transcription factor, epidermis, lipid, neural tube, spina bifida|Possibly| 7979.0|Nrp1:Cre/EGFP|C57BL/6-Tg(Nrp1-cre/Egfp)||Dominant||||||||||||||||||||||||||Cre recombinase/EGFP|Nrp1|low||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|09-Oct-2015|Cryopreserved sperm|50.0|0.0|No||Neuropilin 1, Nrp1, Cre recombinase|Possibly| 8000.0|Y-RFP ;Ddx3y_cl.106_RFP|129-Ddx3y/106KalpApb|Yrfp|Semi-dominant|DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked|Ddx3y|Normal||MGI:1349406||||Y|||||||||||||||||||||||||||||Normal|Most tissues express the mKate2 red fluorescent protein gene. There is some variation in expression between tissues.|12951/Sv1mJ |Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|04-Dec-2015|Cryopreserved sperm|50.0|0.0|No||RFP|Yes| 6909.0|BAC(A33:M2rtTA)|B6;129-Tg(Gpa33-rtTAS*M2)2/LudApb||Dominant|||||||||||||||||||||||||||glycoprotein A33 (transmembrane), Gpa33|Mosaic activity in intestinal epithelium||||||||||Not described|The M2rtTA tet transactivator is expressed in the epithelium of the intestine and colon under the control of the intestine-specific A33 promoter. The expression/activety of the transactivator is mosaic, most likely due to stochastic transgene silencing. Approximately 1 to 5 crypts in the proximal small intestine express the transgene, fewer in the distral intestine and colon.|C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|20-Jun-2012|Cryopreserved sperm|50.0|0.0|No||intestine, epithelium, tetracycline|Possibly| 7792.0|LacIR|B6.FVB/N-Tg(ACTB-lacI*)1Scrb/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 1, Heidi Scrable|Human beta-actin rabbit beta-globin fusion promoter|ubiquitous||||||||||Normal|Normal|C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent| more than 8|3|Standard|No|20-Nov-2014|Cryopreserved sperm|84.0|0.0|Unknown|||Possibly| 7053.0|A33 hfneo|B6;129/Sv-Gpa33/LudApb||Recessive|glycoprotein A33 (transmembrane)|Gpa33|Unknown|2010310L10Rik, 2210401D16Rik, A33 antigen|MGI:1891703||||1|||||||||||||||||||||||||||||This strain shows no phenotypic signs different from wildtype|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|21-Aug-2012|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7236.0|K5rTA-TetOmOVA 0413|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetOmOVA)13Cbn/Apb||Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter for mOVA expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57Bl/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|28-Nov-2012|Cryopreserved sperm|45.0|0.0|No||autoimmunity, ovalbumin, doxycyline inducible|Yes| 7236.0|K5rTA-TetOmOVA 0413|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetOmOVA)13Cbn/Apb||Dominant||||||||||||||||||||||||||transferrin receptor membrane domain and ovalbumin residues 139-385)|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter for mOVA expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57Bl/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good||||No|28-Nov-2012|Cryopreserved sperm|||No||autoimmunity, ovalbumin, doxycyline inducible|Yes| 7237.0|K5rTA-TSLP 0419|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-TSLP)19Cbn/Apb||Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving TSLP expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57Bl/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Tg/+ +/+ x +/+ Tg/+|No|28-Nov-2012|Cryopreserved sperm|50.0|0.0|Yes||thymic stromal lymphopoietin, dermatitis, doxycyline inducible|Possibly| 7237.0|K5rTA-TSLP 0419|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-TSLP)19Cbn/Apb||Dominant||||||||||||||||||||||||||thymic stromal lymphopoietin|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving TSLP expression in the skin.In the absence of doxycyline treatment the mice are normal for lifespan and breeding.|As for homozygous mice.|C57Bl/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|||Tg/+ +/+ x +/+ Tg/+|No|28-Nov-2012|Cryopreserved sperm|||Yes||thymic stromal lymphopoietin, dermatitis, doxycyline inducible|Possibly| 7039.0|Osx-Cre p53.1224 pRbfl/fl|C57BL/6-Rb1 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc Tg(tetO-GFP/RNAi:Trp53)Slowe/CrwApb||Dominant|retinoblastoma 1|Rb1|Nil|pRb, Rb, Rb-1|MGI:97874|retinoblastoma 1; targeted mutation 3, Tyler Jacks|Rb1|MGI:2450162|14|||||||||||||||||transgene insertion 1, Andrew P McMahon|Osterix (Sp7)|medium||||||||||Mice generate osteosarcoma (bone cancer) which is the osteoblastic subtype (Cre:lox line generated a fibroblastic OS).|Mice are slightly smaller, susceptible to malocclusion. long latency, highly metastatic OS. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Cre+ve males to Cre-ve females, homozygous pRb and p53.1224 +ve|No|06-Aug-2012|Cryopreserved sperm|54.0|0.0|Yes|Osteosarcoma|osteosarcoma, Osx-Cre, TRE-p53.1224, pRbfl/fl, shRNA|Yes| 7039.0|Osx-Cre p53.1224 pRbfl/fl|C57BL/6-Rb1 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc Tg(tetO-GFP/RNAi:Trp53)Slowe/CrwApb||Dominant||||||||||||||||||||||||||TRE-p53.1224|tet-responsive TRE-CMV promoter|good||||||||||Mice generate osteosarcoma (bone cancer) which is the osteoblastic subtype (Cre:lox line generated a fibroblastic OS).|Mice are slightly smaller, susceptible to malocclusion. long latency, highly metastatic OS. |C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Cre+ve males to Cre-ve females, homozygous pRb and p53.1224 +ve|No|06-Aug-2012|Cryopreserved sperm|||Yes|Osteosarcoma|osteosarcoma, Osx-Cre, TRE-p53.1224, pRbfl/fl, shRNA|Yes| 7304.0|PbT-II-129|C57BL/6-Tg(H-2K-TcraD78TcrbD78)129Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 129, Francis Carbone|H-2Kb|||||||||||Majority of CD4 T cells express the transgenic T cell recepter Va2Vb12 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||4|brother-sister or Tg positive to C57BL/6|No|05-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD4 TCR transgenic|Yes| 7309.0|K5rTA-Rae1-29|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)29Cbn/Apb||Dominant||||||||||||||||||||||||||tetracycline-regulated transcriptional transactivator|bovine keratin-5|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 7309.0|K5rTA-Rae1-29|C57BL/6-Tg(K5-rTA)04Cbn Tg(TetO-RaeT1e)29Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 29, Frank Carbone|CMV minimal promoter and 7 TetO sequences|||||||||||In these mice following oral doxycyline treatment, rTA expresssion induced in the skin activates the TetO promoter driving RaeT1e expression in the skin.|As for homozygous mice.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||5|Tg Tg x Tg Tg|No|09-Apr-2013|Cryopreserved sperm|||Yes||etinoic acid early transcript 1E, doxycyline inducible|Yes| 7467.0|Bm1.OT-1|B6.C-H2 Tg(TcraTcrb)1100Mjb/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1100, Michael J Bevan|H-2K promoter||histocompatibility 2, K region|H2-K|||MGI:3040519|histocompatibility 2, K region; b haplotype mutation 1|H2-K|MGI:3618114|17|Transgenic mice on a C57BL/6 background are somewhat immunodeficient, and may be used to study the role of peptides in positive selection and the response of CD8+ T cells to antigen.Carry OVA-specific, H-2K-restricted T cell receptor|Normal|B6.C-H2/ByJ|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|10|||No|29-Oct-2013|Cryopreserved sperm|50.0|0.0|No||T cell, receptor, ovalbumin, CD8|Yes| 7589.0||C57BL/6-Grb10-global||Dominant|growth factor receptor bound protein 10|Grb10|Reduced|5730571D09Rik, maternally expressed gene 1, Meg1, mKIAA0207|MGI:103232||Grb10Δ||11|||||||||||||||||||||||||||||Homozygotes are rare. If produced, they have the phenotype of being very large at birth|Paternal heterozygotes - normalMaternal heterozygotes - large during embryogenesis and large at birth|C57BL/6|Unknown|No|Yes|Unknown|Unknown|Yes|No|Good|||paternal heterozygotes x WT to be used for breeding|No|14-Feb-2014|Cryopreserved sperm|50.0|0.0|Unknown||imprinting, development, muscle, growth|Yes| 7240.0|ADAR1 E861A|C57BL/6-Adar/SviApb||Dominant|adenosine deaminase, RNA-specific|Adar |Unknown|ADAR1, mZaADAR|MGI:1889575 |adenosine deaminase, RNA-specific; targeted mutation 2184, TaconicArtemis|Adar1|MGI:5805648|3|||||||||||||||||||||||||||||Homozygous lethal at ~E12.5|heterozygous animals are normal and fertile with no apparent abnormalities|C57BL/6|No|Yes|Yes|No|Yes|Yes|No|Good|on pure C57BL/6 - was derived on C57 ES line||ki/+ crossed to ki/+|No|03-Dec-2012|Cryopreserved sperm|36.0|0.0|Yes|Aicardi-Goutières syndrome||Possibly| 7291.0|floxed AR Neo-|B6.129-Ar/Apb||X-linked|androgen Receptor|Ar|Normal||MGI:88064|androgen receptor; targeted mutation 1, Jeffrey D Zajac|Ar|MGI:3717246|X|||||||||||||||||||||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Unknown|Unknown|Yes|No|Excellent|>20|||No|19-Mar-2013|Cryopreserved sperm|50.0|0.0|Unknown||androgen, fertility|Possibly| 7303.0|PbT-II-157|C57BL/6-Tg(TcraD78TcrbD78)157Cbn/Apb||Dominant||||||||||||||||||||||||||transgene insertion 157, Francis Carbone|H-2Kb|||||||||||Majority of CD4 T cells express the transgenic T cell recepter Va2Vb12 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||4|brother-sister or Tg positive to C57BL/6|No|05-Apr-2013|Cryopreserved sperm|45.0|0.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD4 TCR transgenic|Yes| 7331.0|ADAR1 +/-|B6.129-Adar/TacStvApb||Dominant|adenosine deaminase, RNA-specific|Adar|Nil|ADAR1, mZaADAR|MGI:1889575|adenosine deaminase, RNA-specific; targeted mutation 1, Peter H Seeburg |Adar|MGI:3029789|3|||||||||||||||||||||||||||||Homozygous animals die at E11.5.|Heterozygous animals normal and healthy|C57BL/6|No|Yes|Yes|No|Yes|Yes|No|Excellent|more than 6|unknown/not collected|+/- to +/-|No|09-May-2013|Cryopreserved sperm|30.0|0.0|Yes|Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012 Sep 23. doi: 10.1038/ng.2414|ADAR1, RNA editing|Yes| 7480.0|PbT-I-25/Ly5.1 ; C57BL/6-Tg(TCRaB4-46TcrbB4-46)25Cbn|C57BL/6-Ptprc Tg(H2-K-Tcra,-Tcrb)25Cbn/AnuApb||Dominant||||||||||||||||||||||||||transgene insertion 25, Francis Carbone|H-2Kb||protein tyrosine phosphatase, receptor type, C|Ptprc||B220, CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase, receptor type, C; a variant|Ptprc|MGI:4819849|1|Majority of CD8 T cells express the transgenic T cell recepter Va8Vb10 specific for Plasmodium berghei (Pb) parasites.|As for homozygous|C57BL/6|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Excellent||4|brother-sister|No|14-Nov-2013|Cryopreserved sperm|20.0|107.0|Yes|Used to model cerebral/severe malaria|malaria, Plasmodium berghei, CD8 TCR transgenic|Yes| 7263.0|R26-CreERT2 Recql4fl/fl|B6.129-Gt(ROSA)26Sor Recql4/SviApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor |Unknown|Gt(ROSA)26Sor, R26, Rosa26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Tyler Jacks|Gt(ROSA)26Sor|MGI:3699244|6|||||||||||||||||||||||||||||Non tamoxifen treated animals are viable, fertile and are slightly smaller than wild-type controls|No apparent phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on C57 (Recql4fl/fl); 129S4/SvJae-derived J1 embryonic stem (ES) cells and backcrossed 8 times to C57BL/6 by the donating laboratory|1|R26-CreERT2 ki/ki Recql4fl/+ male crossed to Recql4fl/+ female|No|18-Jan-2013|Cryopreserved sperm|50.0|0.0|Yes|Rothmund-Thomson Syndrome|Recql4, R26-CreERT2|Possibly| 7263.0|R26-CreERT2 Recql4fl/fl|B6.129-Gt(ROSA)26Sor Recql4/SviApb||Dominant|RecQ protein-like 4|Recql4|Nil|RECQ4|MGI:1931028|RecQ protein-like 4; targeted mutation 1.1, TaconicArtemis|Recql4|MGI:5645319|15|||||||||||||||||||||||||||||Non tamoxifen treated animals are viable, fertile and are slightly smaller than wild-type controls|No apparent phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on C57 (Recql4fl/fl); 129S4/SvJae-derived J1 embryonic stem (ES) cells and backcrossed 8 times to C57BL/6 by the donating laboratory|1|R26-CreERT2 ki/ki Recql4fl/+ male crossed to Recql4fl/+ female|No|18-Jan-2013|Cryopreserved sperm|||Yes|Rothmund-Thomson Syndrome|Recql4, R26-CreERT2|Possibly| 7590.0|R26-CreER p53fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Rb1 Trp53/StvApb||Dominant|transformation related protein 53|Trp53|Nil|p53|MGI:98834|transformation related protein 53; targeted mutation 1, Anton Berns|Trp53|MGI:1931011|11|||||||||||||||||||||||||||||Normal in absence of tamoxifnen treatment.|no phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous pRb and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|50.0|0.0|Yes|Osteosarcoma|R26-CreER, p53fl/fl, pRbfl/fl|Yes| 7590.0|R26-CreER p53fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Rb1 Trp53/StvApb||Dominant|retinoblastoma 1|Rb1|Nil|pRb, Rb, Rb-1|MGI:97874|retinoblastoma 1; targeted mutation 3, Tyler Jacks|Rb1|MGI:2450162|14|||||||||||||||||||||||||||||Normal in absence of tamoxifnen treatment.|no phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous pRb and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|||Yes|Osteosarcoma|R26-CreER, p53fl/fl, pRbfl/fl|Yes| 7590.0|R26-CreER p53fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Rb1 Trp53/StvApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor |Normal|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Tyler Jacks|Gt(ROSA)26Sor|MGI:3699244|6|||||||||||||||||||||||||||||Normal in absence of tamoxifnen treatment.|no phenotype|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous pRb and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|||Yes|Osteosarcoma|R26-CreER, p53fl/fl, pRbfl/fl|Yes| 7591.0|R26-CreER Recql4fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Recql4 Trp53/StvApb||Dominant|transformation related protein 53|Trp53|Nil|p53|MGI:98834|transformation related protein 53; targeted mutation 1, Anton Berns|Trp53|MGI:1931011|11|||||||||||||||||||||||||||||Normal in absence of tamoxifen treatment.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous Recql4 and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|20.0|0.0|Yes|Rothmund-Thomson syndrome|R26-CreER, p53fl/fl, Recql4fl/fl|Possibly| 7591.0|R26-CreER Recql4fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Recql4 Trp53/StvApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor |Normal|beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Tyler Jacks|Gt(ROSA)26Sor|MGI:3699244|6|||||||||||||||||||||||||||||Normal in absence of tamoxifen treatment.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous Recql4 and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|||Yes|Rothmund-Thomson syndrome|R26-CreER, p53fl/fl, Recql4fl/fl|Possibly| 7591.0|R26-CreER Recql4fl/fl pRbfl/fl|C57BL/6-Gt(ROSA)26Sor Recql4 Trp53/StvApb||Dominant|RecQ protein-like 4|Recql4|Reduced|RECQ4 |MGI:1931028 |Recql4|Recql4fl/fl||15|||||||||||||||||||||||||||||Normal in absence of tamoxifen treatment.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|generated on a C57bl6 background||R26-CreERki/+ homozygous Recql4 and p53 intercrosses|No|14-Feb-2014|Cryopreserved sperm|||Yes|Rothmund-Thomson syndrome|R26-CreER, p53fl/fl, Recql4fl/fl|Possibly| 5230.0|Mincle F / MNB|C57BL/6J-Clec4e/Apb||Semi-dominant|C-type lectin domain family 4, member e|Clec4e|Nil|Clecsf9, Mincle|MGI:1861232|C-type lectin domain family 4, member e; targeted mutation 1, Peter Sobieszczuk|Clec4e|MGI:3618604|6||||||||||||||||Yes|||||||||||||Approx 20% decrease in white blood cell count, though still within normal range. Heart valves with increased amounts of extracellular matrix.|Unknown|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|not known|4 years||No|06-Oct-2010|Cryopreserved sperm|40.0|0.0|Yes|oral and vaginal candidiasis (thrush)|C-type lectin, Pattern recognition receptor, Innate immunity, Macrophage, Tuberculosis, Yeast infection|Yes| 5382.0|Clone 4|BALB/c-Tg(TcraCl4,TcrbCl4)1Shrm/Apb||Dominant||||||||||||||||||||||||||transgene insertion 1, Linda Sherman|Tcra, Tcrb|||||||||||Normal|Normal|BALB/c|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor|||Clone 4 males with clone 4 females or BALB/c females|No|07-Jan-2011|Cryopreserved sperm|10.0|0.0|Unknown||TCR transgenic, CD8, influenza A virus|Possibly| 7536.0|Tpcn1∆|B6.129S5-Tpcn1/Ausb||Dominant|two pore channel 1|Tpcn1|Unknown||MGI:2182472|two pore channel 1; gene trap OST359423, Lexicon Genetics|Tpcn1|MGI:3529820|5||||||||||||||||No|||||||||||||Unknown|Unknown|C57Bl/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|12-Dec-2013|Cryopreserved sperm|40.0|0.0|Unknown||channel, Pore|Possibly| 5416.0|APC (580s) ; MF-01|STOCK Apc/Apb||Dominant|adenomatosis polyposis coli|Apc|Reduced|CC1, Min|MGI:88039|adenomatosis polyposis coli; targeted mutation 1, Tetsuo Noda|Apc|MGI:1857966|18||||||||||||||||Yes|||||||||||||Normal until:Hepatocellular carcinoma: * all mutant mice (n=15) develop hepatocellular carcinomas by 450 days of age * hepatic tumor volumes in homozygous mice are larger than in heterozygous mice * no intestinal polyps (>18 month, n=24)|Normal||Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Feb-2011|Cryopreserved sperm|50.0|0.0|Yes|Familial adenomatous polyposis coli (FAP)|Familial adenomatous polyposis coli (FAP), colorectal adenomas, epithelium|Yes| 9073.0|Scl-Cre-ERT|C57BL/6J-Tg/Jrg||Dominant|||||||||Unknown|||||||||||||||||ERT Inducible Cre|Tal enhancer|Unknown||||||||||Normal|Normal|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|Unknown|||No|04-Sep-2020|Cryopreserved sperm, Live|67.0|0.0|No||CRE, SCL, TAL1, Tamoxifen-inducible, Hematopoietic stem cells|Yes| 10496.0|APP/PS1/IFNAR1-/-|APP/PS1/IFNAR1-/-||Dominant|APP - amyloid precursor protein||||||||Unknown|||||||||||||||||||||||||||||This mouse develops amyloid plaques and lacks the type-I interferon receptor.|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|20-Mar-2025|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 128.0|Deirdre ; IgMdE|C57BL/6JSfdAnu-Tg(IgMdEHEL)Ccg/AnuApb|C57BL/6JSfdAnu-Tg(IgMδEHEL)Ccg/AnuApb|Dominant||||||||||||||||||||||||||chimeric anti-Hen Egg Lysozyme Ig molecule, the extracellular spacer of IgM was substituted for IgD.||H and L genes are cointegrated||||||||||B cells express chimeric IgM/D molecule with affinity for Hen Egg Lysozyme||C57BL/6JAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||10|sib x sib|No|06-Feb-2006|Cryopreserved sperm|20.0|0.0|No||B cell, Hen Egg Lysozyme (HEL), Immunoglobulin, tolerance, glycosylation|Yes| 5523.0|NOD-SBmut8|NOD/Lt-Tg(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)8TCB/Apb||Recessive||||||||||||||||||||||||||TgTn(sb-pTrans-SA-IRESLacZ-CAG-GFP-SD:Neo)2TCB||||||||||||Unknown|Unknown|NOD/Lt|Unknown|Unknown|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|10-Jun-2011|Cryopreserved sperm|50.0|0.0|Unknown|||No| 8724.0|Adar1E861A/E861A Ifih1-/- Adar2-/- Gria2R/R|B6.129-Adar Adarb1 Gria2 Ifih1/StVApb||Recessive|adenosine deaminase, RNA-specific|Adar||ADAR1, Adar1p110, Adar1p150, mZaADAR|MGI:1889575|adenosine deaminase, RNA-specific; targeted mutation 1.1, Taconic Biosciences|Adar|MGI:5805648|3|||||||||||||||||||||||||||||Compound homozygous animals are normal|Compound heterozygous animals are normal. Note all Adar2-/-Gria2R/+ and Adar2-/-Gria2+/+ die shortly after birth independent of the Adar1/Ifih1 genotypes|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Jun-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 8724.0|Adar1E861A/E861A Ifih1-/- Adar2-/- Gria2R/R|B6.129-Adar Adarb1 Gria2 Ifih1/StVApb||Recessive|adenosine deaminase, RNA-specific, B1|Adarb1||1700057H01Rik, ADAR2, D10Bwg0447e, RED1|MGI:891999|adenosine deaminase, RNA-specific, B1; targeted mutation 1, Peter H Seeburg|Adarb1|MGI:2178079|10|||||||||||||||||||||||||||||Compound homozygous animals are normal|Compound heterozygous animals are normal. Note all Adar2-/-Gria2R/+ and Adar2-/-Gria2+/+ die shortly after birth independent of the Adar1/Ifih1 genotypes|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Jun-2019|Cryopreserved sperm|||Unknown|||Yes| 8724.0|Adar1E861A/E861A Ifih1-/- Adar2-/- Gria2R/R|B6.129-Adar Adarb1 Gria2 Ifih1/StVApb||Recessive|glutamate receptor, ionotropic, AMPA2 (alpha 2)|Gria2|Reduced|GluA2, Glur2, Glur-2, GluR2, GluR-B|MGI:95809|glutamate receptor, ionotropic, AMPA2 (alpha 2); targeted mutation 1, Peter H Seeburg|Gria2|MGI:2178124|3|||||||||||||||||||||||||||||Compound homozygous animals are normal|Compound heterozygous animals are normal. Note all Adar2-/-Gria2R/+ and Adar2-/-Gria2+/+ die shortly after birth independent of the Adar1/Ifih1 genotypes|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Jun-2019|Cryopreserved sperm|||Unknown|||Yes| 8724.0|Adar1E861A/E861A Ifih1-/- Adar2-/- Gria2R/R|B6.129-Adar Adarb1 Gria2 Ifih1/StVApb||Recessive|interferon induced with helicase C domain 1|Ifih1||9130009C22Rik, Helicard, MDA5, MDA-5|MGI:1918836|interferon induced with helicase C domain 1; targeted mutation 1.1, Marco Colonna|Ifih1|MGI:3663677|2|||||||||||||||||||||||||||||Compound homozygous animals are normal|Compound heterozygous animals are normal. Note all Adar2-/-Gria2R/+ and Adar2-/-Gria2+/+ die shortly after birth independent of the Adar1/Ifih1 genotypes|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|04-Jun-2019|Cryopreserved sperm|||Unknown|||Yes| 7804.0|R26CreER RARaRARg R26eYFP|B6.Cg-Gt(ROSA)26Sor RARa RARg Gt(ROSA)26Sor/Apb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor ||Gtrosa26, R26|MGI:104735||Gt(ROSA)26Sor|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Tyler Jacks|6|ENSMUSG00000086429 ||||||||||||||||||||||||||||In absence of tamoxifen cells are wildtype, when treated with tamoxifen loss of the vitamin A receptors, RARa and RARg occur, causing different phenotypes in distinct cell types.|Unknown|C57BL/6|Yes|Unknown|Unknown|Yes|Unknown|Unknown|No|Excellent|At least 10|||No|03-Dec-2014|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 7804.0|R26CreER RARaRARg R26eYFP|B6.Cg-Gt(ROSA)26Sor RARa RARg Gt(ROSA)26Sor/Apb||Recessive|retinoic acid receptor, alpha|Rara|||MGI:97856|retinoic acid receptor, alpha; targeted mutation 1, Pierre Chambon|Rara|MGI:1857622|11|ENSMUSG00000037992 ||||||||||||||||||||||||||||In absence of tamoxifen cells are wildtype, when treated with tamoxifen loss of the vitamin A receptors, RARa and RARg occur, causing different phenotypes in distinct cell types.|Unknown|C57BL/6|Yes|Unknown|Unknown|Yes|Unknown|Unknown|No|Excellent|At least 10|||No|03-Dec-2014|Cryopreserved sperm|||Unknown|||Possibly| 7804.0|R26CreER RARaRARg R26eYFP|B6.Cg-Gt(ROSA)26Sor RARa RARg Gt(ROSA)26Sor/Apb||Recessive|retinoic acid receptor, gamma|Rarg||RARgamma2|MGI:97858|retinoic acid receptor, gamma; targeted mutation 1, Pierre Chambon|Rarg|MGI:1931079|15|||||||||||||||||||||||||||||In absence of tamoxifen cells are wildtype, when treated with tamoxifen loss of the vitamin A receptors, RARa and RARg occur, causing different phenotypes in distinct cell types.|Unknown|C57BL/6|Yes|Unknown|Unknown|Yes|Unknown|Unknown|No|Excellent|At least 10|||No|03-Dec-2014|Cryopreserved sperm|||Unknown|||Possibly| 7804.0|R26CreER RARaRARg R26eYFP|B6.Cg-Gt(ROSA)26Sor RARa RARg Gt(ROSA)26Sor/Apb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor ||Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Frank Costantini|Gt(ROSA)26Sor|MGI:2449038|6|ENSMUSG00000086429||||||||||||||||||||||||||||In absence of tamoxifen cells are wildtype, when treated with tamoxifen loss of the vitamin A receptors, RARa and RARg occur, causing different phenotypes in distinct cell types.|Unknown|C57BL/6|Yes|Unknown|Unknown|Yes|Unknown|Unknown|No|Excellent|At least 10|||No|03-Dec-2014|Cryopreserved sperm|||Unknown|||Possibly| 8075.0|Adar1E861A/E861A Ifih1-/-|B6.129-Adar1 Ifih1/Apb||Recessive|adenosine deaminase, RNA-specific|Adar||ADAR1, Adar1p110, Adar1p150, mZaADAR|MGI:1889575|Adar1E861A/E861A Ifih1-/-|||3|||||||||||||||||||||||||||||Adar1E861A/E861A Ifih1-/- and viable, fertile, and largely normal. They are smaller at birth and weaning but recover by 12 weeks.|Heterozygous animals are normal and fertile for both alleles individually and as compound mutants.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jul-2016|Cryopreserved sperm|50.0|0.0|Unknown||RNA editing, erythropoiesis|Yes| 8075.0|Adar1E861A/E861A Ifih1-/-|B6.129-Adar1 Ifih1/Apb||Recessive|interferon induced with helicase C domain 1|Ifih1|Nil|9130009C22Rik, Helicard, MDA5, MDA-5|MGI:1918836|interferon induced with helicase C domain 1; targeted mutation 1.1, Marco Colonna|Ifih1|MGI:3663677|2|||||||||||||||||||||||||||||Adar1E861A/E861A Ifih1-/- and viable, fertile, and largely normal. They are smaller at birth and weaning but recover by 12 weeks.|Heterozygous animals are normal and fertile for both alleles individually and as compound mutants.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|14-Jul-2016|Cryopreserved sperm|||Unknown||RNA editing, erythropoiesis|Yes| 7839.0|C-alphaKO:Ly5aa:B6-JAX::G9|C57BL/6J-Ptprc Tcra ||Recessive| T cell receptor alpha chain|Tcra|||MGI:98553|T cell receptor alpha chain; targeted mutation 1, Peter Mombaerts|Tcra |MGI:1857255|14|||||||||||||||||||||||||||||TCR Calpha knockout mice on B6 background were obtained from Jackson labs in 1996. They have been maintained as B10.BR Ly5a with TCR transgene. Absence of Calpha gene prevents endogenous TCR alpha chain rearrangments. T cell development is blocked at the DP thymocyte stage and no T cell can be found in the periphery of homozygote mice. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|33.0|0.0|Unknown||T cell, receptor, rearrangement|Yes| 7839.0|C-alphaKO:Ly5aa:B6-JAX::G9|C57BL/6J-Ptprc Tcra ||Recessive|protein tyrosine phosphatase receptor type C|Ptprc|||MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1|||||||||||||||||||||||||||||TCR Calpha knockout mice on B6 background were obtained from Jackson labs in 1996. They have been maintained as B10.BR Ly5a with TCR transgene. Absence of Calpha gene prevents endogenous TCR alpha chain rearrangments. T cell development is blocked at the DP thymocyte stage and no T cell can be found in the periphery of homozygote mice. ||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|25-Jan-2015|Cryopreserved sperm|||Unknown||T cell, receptor, rearrangement|Yes| 7865.0|TRAMP|C57BL/6-Tg(TRAMP)8247Ng/Apb||Recessive||||||||||||||||||||||||||transgene insertion 8247, Norman M Greenberg|rat Probasin promoter|||||||||||Transgenic mice on a C57BL6 background develop progressive forms of prostate cancer with distant site metastasis. Forms of disease range from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. Tumors are detected in the prostate as early as 10 weeks of age. The tumors have elevated levels of nuclear TRP53 and decreased androgen receptor expression.|Transgenic mice on a C57BL6 background develop progressive forms of prostate cancer with distant site metastasis. Forms of disease range from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. Tumors are detected in the prostate as early as 10 weeks of age. The tumors have elevated levels of nuclear TRP53 and decreased androgen receptor expression.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||Yes|08-Apr-2015|Cryopreserved sperm|50.0|0.0|Yes|Prostate Adenocarcinoma|TRAMP, Prostate cancer, preclinical trials|Yes| 10456.0|B6N GSTO1 ko mice|C57B6;129/Sv-Gsto1/TacAnu||Recessive|glutathione S-transferase omega 1|Gsto1||GSTX, p28|MGI:1342273|glutathione S-transferase omega 1; targeted mutation 1, TaconicArtemis|Gsto1|MGI:6258601|19|||||||||||||||||||||||||||||Normal|Normal|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Oct-2024|Cryopreserved sperm|50.0|0.0|Unknown|||No| 7105.0|ADAR1 fl/fl|B6.129-Adar/StvApb||Dominant|adenosine deaminase, RNA-specific|Adar|Nil|ADAR1, mZaADAR|MGI:1889575|adenosine deaminase, RNA-specific; targeted mutation 1.1, Peter H Seeburg|Adar|MGI:3828307|3|||||||||||||||||||||||||||||Homozygous animals normal and healthy, breed normally in the absence of Cre|Heterozygous animals normal and healthy, breed normally in the absence of Cre|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|more than 6|unknown/not collected|fl/fl to fl/fl|No|12-Oct-2012|Cryopreserved sperm|44.0|0.0|Yes|Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012 Sep 23. doi: 10.1038/ng.2414|ADAR1, RNA editing|Yes| 7840.0|SCN2A Ki/Ki|C57BL/6-Scn2a1/Apb||Dominant|sodium channel, voltage-gated, type II, alpha 1|Scn2a1||A230052E19Rik, Nav1.2|MGI:98248||||2|||||||||||||||||||||||||||||significant increases in action potential firing in NaV1.2 neurons and in seizure susceptibility of NaV1.2 mice, supporting our hypothesis. At postnatal day 15 (P15), when 17% of the WT NaV1.2 is 'neonatal', the firing properties of NaV1.2 and WT neurons converged. However, inhibitory postsynaptic currents in NaV1.2 neurons were larger and the expression level of Scn2a mRNA was 24% lower compared with the WT. The enhanced seizure susceptibility of the NaV1.2 mice persisted into adult age. The adult NaV1.2 mice also exhibited greater risk-taking behaviour. |unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|27-Jan-2015|Cryopreserved sperm|60.0|0.0|Unknown||sodium channel, neuron, seizure|Possibly| 9345.0|Arjuna:TCR:B10.BR |B10.BR-Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/Anu||Dominant|TCR3A9,InsHEL transgenes||||||||Unknown|||||||||||||||||transgene insertion 1, Mark M Davis||||||||||||Mice express the TCR3A9 transgene, which recognizes HEL petide in the context of H2K(K)and the noe-self antigen HEL under the insulin promotor|mice are hemizygous only|B10BR|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|17.0|0.0|Unknown|||Possibly| 9345.0|Arjuna:TCR:B10.BR |B10.BR-Tg(ILK3mHEL)3Ccg Tg(TcrHEL3A9)1Mmd/Anu||Dominant||||||||||||||||||||||||||transgene insertion 3, Christopher C Goodnow||||||||||||Mice express the TCR3A9 transgene, which recognizes HEL petide in the context of H2K(K)and the noe-self antigen HEL under the insulin promotor|mice are hemizygous only|B10BR|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Feb-2022|Cryopreserved sperm|||Unknown|||Possibly| 4600.0|Epo-R-Cre pRbfl/fl|B6.129-Epor Rb1/Apb||Dominant|retinoblastoma 1|Rb1|Unknown|pRb, Rb, Rb-1|MGI:97874|targeted mutation 3, Tyler Jacks|Rb1|MGI:2450162|14||||||||||||||||Yes|||||||||||||Compound mutant: Mild anaemia. Single Epo-R-Cre – lethal as homozygous, heterozygous maintained only. Single pRbfl/fl – no phenotype until Cre exposed||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|5||Epor -ve Rb1 female x Epor +ve Rb1 het male|No|13-Mar-2009|Cryopreserved sperm|39.0|0.0|Unknown||anaemia, MDS, mitochondria, erythroid differentiation|Yes| 4600.0|Epo-R-Cre pRbfl/fl|B6.129-Epor Rb1/Apb||Dominant|erythropoietin receptor|Epor|Unknown||MGI:95408|erythropoietin receptor; targeted mutation 1, Ursula Klingmuller|Epor|MGI:3052727|9|||||||||||||||||||||||||||||Compound mutant: Mild anaemia. Single Epo-R-Cre – lethal as homozygous, heterozygous maintained only. Single pRbfl/fl – no phenotype until Cre exposed||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|5||Epor -ve Rb1 female x Epor +ve Rb1 het male|No|13-Mar-2009|Cryopreserved sperm|||Unknown||anaemia, MDS, mitochondria, erythroid differentiation|Yes| 10503.0|Rdh5 KO B6J|C57BL/6JAnu-Rdh5/7Anu||Recessive|retinol dehydrogenase 5|Rdh5|||MGI:1201412|Rdh5:endonuclease-mediated mutation 4, Australian National University|Rdh5||10|ENSMUSG00000025350 ||||||||||||||||||||||||||||Possible retinal degenerative phenotype|unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|28-Mar-2025||0.0|0.0|Unknown|||Possibly| 7100.0|Osx-Cre Rb|B6(Cg)-Rb1 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/StvApb||Dominant|retinoblastoma 1|Rb1|Normal|pRb, Rb, Rb-1|MGI:97874|retinoblastoma 1; targeted mutation 3, Tyler Jacks|Rb1|MGI:2450162|14|||||||||||||||||transgene insertion 1, Andrew P McMahon|Osterix (Sp7)|good in osteoblast precursors||||||||||No obvious phenotype. No effect on lifespan, breeding or skeleton|None observed. Osx-Cre mice have phenotypes due to teh Osx-Cre - malocclusion, slightly smaller than a truw wild-type. No other effect of loss of Rb|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5|unknown/not collected|Osx-Cre+ve pRBfl/+ male to Osx-Cre-ve pRBfl/+ female|No|04-Oct-2012|Cryopreserved sperm|40.0|0.0|Yes|hereditary retinoblastoma - bone specifc model|Rb, Osx-Cre, osteosarcoma|Yes| 9188.0|Drosha|B6.129P2-Drosha/AnuApb||Recessive|drosha, ribonuclease type III|Drosha|Nil|1110013A17Rik, Etohi2, Rnasen|MGI:1261425|drosha, ribonuclease type III; targeted mutation 1, Dan R Littman|Drosha|MGI:3801076|15|||||||||||||||||||||||||||||When bred to mice with a cre recombinase gene under the control of a promoter of interest, exon 9 is excised in the tissue of interest. Full knockouts of this gene are embryonic lethal before embryonic day 10.5 (E10.5).|These mice possess loxP sites on either side of exon 9 of the ribonuclease III, nuclear gene. Mice that are homozygous for this allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. |C57BL/6J |No|Yes|Yes|No|Yes|Yes|No|Unknown|Unknown|||Yes|14-May-2021|Live|0.0|30.0|Unknown||miRNA biogenesis, T reg cells, Drosha, Dicer, Foxp3|Yes| 2396.0|B6.TnfRI-/-RII-/-|B6.129S-Tnfrsf1a Tnfrsf1b/J||Recessive|tumor necrosis factor receptor superfamily, member 1a|Tnfrsf1a|Nil|CD120a, p55, p55-R, TNF receptor alpha chain, TNF-R-I, TNF-R1, TNF-R55, TNFAR, Tnfr-2, Tnfr1, TNFR60, TNFRI, TNFRp55|MGI:1314884|targeted mutation 1, Immunex Research and Development Corporation|Tnfrsf1a|MGI:1857468|6||||||||||||||||No|||||||||||||Increased circulating tumor necrosis factor level: two hours post lipopolysaccharide (LPS) challenge serum levels are 15-20 fold higher than controls, however, TNF kinetics and activity are not altered.Decreased susceptibility to endotoxin shock: exhibits resistance to a lethal LPS dose plus hepatoxin D-gal (increases sensitivity to LPS).Decreased inflammatory response: M. faeni- induced neutrophil accumulation in the lung is decreased as compared to control, however monocyte and lymphocyte levels are comparable to control.Osteomyelitis:* osteolytic lesions of molars are significantly larger in these mice 2 weeks after bacterial inoculation of the dental pulp* the osteolytic lesions continue to be larger for at least 38 days after innoculation.Increased susceptibility to bacterial infection: mice have 3 log greater bacterial penetration of the dental pulp eight days after experimental bacterial infection.Necrosis:* mice have significantly higher necrosis scores of the dental pulp seven days after bacterial inoculation.* complete necrosis of the dental pulp is observed by 21 days after inoculation compared to control mice that still have intact dental pulp at 38 days post-innoculation.Increased bone resorption:* there is significantly more osteoclastogenesis that occurs in molars between 7 and 21 days after bacterial infection of the dental pulp.* osteoclast activity of the molars is almost 2-fold higher than in wild-types 7 days after bacterial inoculation.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|70.0|0.0|Unknown||inflammation, lipopolysaccharide (LPS), neutrophil, lymphocyte, innate immunity|Yes| 2396.0|B6.TnfRI-/-RII-/-|B6.129S-Tnfrsf1a Tnfrsf1b/J||Recessive|tumor necrosis factor receptor superfamily, member 1b|Tnfrsf1b|Nil|CD120b, p75, p75 TNFR, TNF-R-II, TNF-R2, TNF-R75, TNFBR, Tnfr-1, Tnfr2, TNFR80, TNFRII|MGI:1314883|targeted mutation 1, Immunex Research and Development Corporation|Tnfrsf1b|MGI:1860087|4|||||||||||||||||||||||||||||Increased circulating tumor necrosis factor level: two hours post lipopolysaccharide (LPS) challenge serum levels are 15-20 fold higher than controls, however, TNF kinetics and activity are not altered.Decreased susceptibility to endotoxin shock: exhibits resistance to a lethal LPS dose plus hepatoxin D-gal (increases sensitivity to LPS).Decreased inflammatory response: M. faeni- induced neutrophil accumulation in the lung is decreased as compared to control, however monocyte and lymphocyte levels are comparable to control.Osteomyelitis:* osteolytic lesions of molars are significantly larger in these mice 2 weeks after bacterial inoculation of the dental pulp* the osteolytic lesions continue to be larger for at least 38 days after innoculation.Increased susceptibility to bacterial infection: mice have 3 log greater bacterial penetration of the dental pulp eight days after experimental bacterial infection.Necrosis:* mice have significantly higher necrosis scores of the dental pulp seven days after bacterial inoculation.* complete necrosis of the dental pulp is observed by 21 days after inoculation compared to control mice that still have intact dental pulp at 38 days post-innoculation.Increased bone resorption:* there is significantly more osteoclastogenesis that occurs in molars between 7 and 21 days after bacterial infection of the dental pulp.* osteoclast activity of the molars is almost 2-fold higher than in wild-types 7 days after bacterial inoculation.||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|20-Dec-2007|Cryopreserved sperm|||Unknown||inflammation, lipopolysaccharide (LPS), neutrophil, lymphocyte, innate immunity|Yes| 5083.0|Bn|B6;BNT/LeJ-Zic3/AnuApb||X-linked|zinc finger protein of the cerebellum 3|Zic3|||MGI:106676 |zinc finger protein of the cerebellum 3; bent tail|Zic3|MGI:1856679|X||||||||||||||||Yes|||||||||||||Hemizygous males and homozygous females have a shortened as well as a bent tail.|Heterozygous females have a variable bent tail ranging from an almost imperceptible bend, to extreme cases where the tail is curled up and pressed against the body.|C57BL/6 (backcross N1 - N3)|No|No|Yes|No|No|Yes|Yes|Poor|1 to 3||Hemizygous male to C57BL/6 female. Heterozygous female to C57BL/6 male.|No|08-Apr-2010|Cryopreserved sperm|100.0|0.0|Yes|Neural tube defects, exencephaly, laterality defects, embryonic lethality|Neural tube defect, situs defects, exencephaly, embryonic lethality, gastrulation|Yes| 7586.0|ADAR3+/-|C57BL/6-Adarb2/StvApb||Dominant|adenosine deaminase, RNA-specific, B2|Adarb2 |Nil|Adar3, RED2 |MGI:2151118|Adar3|Adar3+/-||13|||||||||||||||||||||||||||||Normal as far as investigator / depositor of strain can tell.|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|4||+/- to +/- (can breed -/- to -/- happily also)|No|14-Feb-2014|Cryopreserved sperm|30.0|0.0|No||ADAR3, Adarb2|Yes| 7818.0|CD74 KO|B6.129-Cd74/JAnuApb||Recessive|CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)|Cd74|Nil|CLIP, Ii|MGI:96534|CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); targeted mutation 1, Elizabeth Bikoff|Cd74|MGI:1927530|18|||||||||||||||||||||||||||||Decreased B cell number:• in the spleen and lymph nodeDecreased CD4-positive, alpha beta T cell number:• significant reduction in numbers of mature CD4+CD8- thymocytes in thymus and periphery is seen compared to wild-typeDecreased T cell proliferation:• lymph node cells show significantly lower proliferative responses to immunization with keyhole limpet cyanin (KLH) compared to wild-typeAbnormal T-helper 1 physiology:• in vivo, Th1 response to MOG is absent unlike in wild-type mice• in vitro, lymph node cells from mice receiving wild-type MOG T cells exhibit reduced Th1 recall response compared with similarly treated wild-type mice• in vivo, Th1 response to PLP is reduced compared to in wild-type mice• in vitro, the frequency of Th1 recall response is greater than in H2-Dma homozygotesDecreased susceptibility to type IV hypersensitivity reaction:• dramatically compared to in wild-type mice when wild-type MOG T cells are transferredAbnormal antigen presentation:• antigen presenting cells cannot process and present recombinant MOG protein unlike wild-type cellsAbnormal antigen presentation via MHC class II:• class II molecules are relatively ineffective for presentation of native protein antigensAbnormal level of surface class II molecules:• mutants expressed greatly reduced amounts of class II on spleen cells compared to wild-typeDefective assembly of class II molecules:• in spleen cells, immature alpha and beta chains exhibiting no evidence of having been exported past the cis-Golgi are observed, whereas compact alpha/beta dimers efficiently transported past the cis-Golgi are produced by Cd74-deficient cells; floppy conformers are seen, compared to compact dimers in wild-typeDecreased susceptibility to experimental autoimmune encephalomyelitis:• whether MOG-primed or adoptively transferred with MOG-specific T blasts, mice fail to develop symptoms of experimental autoimmune encephalomyelitis (EAE) unlike wild-type mice• PLP-treated mice fail to develop EAE unlike similarly treated wild-type mice||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|03-Jan-2015|Cryopreserved sperm|31.0|0.0|Unknown||MHC II, T cell, B cell, CD4|No| 7968.0|iNOSΔ|B6.129P2-Nos2/JAusbAnuApb||Recessive|nitric oxide synthase 2, inducible|Nos2|Nil|iNOS, Nos-2, NOS-II, Nos2a|MGI:97361|nitric oxide synthase 2, inducible; targeted mutation 1, Victor E Laubach|Nos2|MGI:1857228|11|||||||||||||||||||||||||||||Abnormal surfactant physiology:*Following infection with mycoplasma, the numbers of large surfactant aggregates is decreased and higher protein to lipid ratios are present in the bronchoalveolare lavage fluid compared to similarly infected wild-type mice.*Following infection with mycoplasma, the minimal surface area on the pulsating bubble is increased and the levels of surfactant protein are decreased compared to similarly infected wild-type mice.Abnormal circadian rhythm:*Mice display a more pronounced diurnal variation of sleep-wake activity.Abnormal sleep pattern:*Mice spend more time in REM sleep during the light phase as a result of an increased number of REM episodes and shortened duration of the inter REM intervals.*Mice display a more pronounced diurnal variation of sleep-wake activity.*Mice spend less time in non-REM sleep during the dark phase.*During the light phase mice spend the same amount of time in non-REM sleep but have a higher number of non-REM episodes of shorter average duration.Abnormal brain wave pattern:*During non-REM sleep the absolute value of slow wave activity is increased.Abnormal inflammatory response:*Unlike in wild-type mice, LPS injection fails to reduce nighttime body temperature relative to saline injected controls. Decreased inflammatory response: *Fever in response to LPS injection is partially reduced compared to wild-type controls. *The fever response to LPS is initiated but not sustained. *However, fever in response to turpentine injection is not different from controls.||unknown|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|17-Sep-2015|Cryopreserved sperm, Embryo|45.0|0.0|Unknown||iNOS, Inflammatory disorders|Yes| 6784.0|APPPS1B6C3|B6.C3-Tg(APPswe,PSEN1dE9)85Dbo/JAusb|B6.C3-Tg(APPswe,PSEN1dE9)85Dbo/JAusb|Dominant||||||||||||||||||||||||||transgene insertion 85, David R Borchelt|mouse prion protein |Predominantly to CNS neurons||||||||||Unknown|Mice develop beta amyloid deposits in brain by 6 or 7 months of age. The humanized Mo/HuAPP695swe transgene allows the mice to secrete a human A-beta peptide.A slight alteration in the tail can occur due to mixed background.|B6/C3|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown|||Maintained as a hemizygote by crossing transgenic mice to B6C3F1/J mice|No|18-Jan-2012|Cryopreserved sperm|2.0|0.0|Yes|Alzheimers|CNS neurons, hippocampus, amyloid beta peptide , astrocytosis|Yes| 8143.0|Alcam KO|B6.129(FVB)-Alcam/JAnu||Recessive|activated leukocyte cell adhesion molecule|Alcam|Nil|BEN, CD166, DM-GRASP, MGC:27910, MuSC, SC1|MGI:1313266|activated leukocyte cell adhesion molecule; targeted mutation 1, Joshua A Weiner|Alcam|MGI:3056579|16|||||||||||||||||||||||||||||Abnormal retina morphology: • in 75% of mutant eyes retinal dysplasia is seen with finger like projections of photoreceptor cells protruding into the outer nuclear layer and/or invagination of the retina without disrupting the cell layers• dysplasia can be detected on P1Abnormal photoreceptor outer segment morphology: • photoreceptor outer segments appear elongated and disorganizedAbnormal retinal ganglion layer morphology: • axons are loosely bundled and occasionally have aberrant trajectories however all exit the optic disc normallyAbnormal motor neuron innervation pattern: • motor neurons are loosely bundled with some axons exiting the bundles at a right angle to the adjacent nerve and ending blindly or forming bridges to neighboring bundles||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-Nov-2016|Cryopreserved sperm|44.0|0.0|Unknown||BEN, retina, motor, axon|No| 8981.0|progesterone receptor; Isoform A (PRAKO)|B6;129S7-Pgr/J||Recessive|progesterone receptor|Pgr||9930019P03Rik, ENSMUSG00000074510, NR3C3, PR, PR-A, PR-B|MGI:97567|progesterone receptor; targeted mutation 1, Orla M Conneely|Pgr|MGI:2183208|9|||||||||||||||||||||||||||||Uterus hyperplasia:• treatment of female homozygotes with estrogen plus progesterone results in a progesterone-dependent increase in uterine epithelial proliferation over that observed with estrogen alone.Abnormal ovulation:• following treatment with pregnant mare serum gonadotropin and human chorionic gonadotropin, female homozygotes produce a reduced number of oocytes relative to superovulated wild-type females.Abnormal uterine environment:• defective uterine implantation is associated with loss of progesterone-regulated expression of a subset of uterine epithelial target genes associated with receptivity.Abnormal decidualization:• uteri of superovulated female homozygotes fail to exhibit decidualization of stromal cells in response to traumal stimulation.Female infertility:• female homozygotes appear normal but are infertile• matings between superovulated female homozygotes and wild-type males fail to result in successful pregnancies although a small number of oocytes is released in mutant femalesEndocrine/exocrine gland phenotype:N • following estrogen and progesterone treatment, ovariectomized female homozygotes display normal thoracic mammary gland development with extensive hormone-dependent ductal branching and multiple alveolar lobules, as well as normal proliferation and differentiation of the mammary epithelium in response to progesterone• also, estrogen- and progesterone-treated ovariectomized female homozygotes exhibit normal thymic involution relative to similarly-treated wild-type females||C57BL/6|Yes|No|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Apr-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 9230.0|ASD712:Cx3cr1-cre:Dicer fl/fl:RFP fl/fl|B6.129P2(Cg)-Cx3cr1 Dicer1 Gt(ROSA)26Sor/JAnuApb||Semi-dominant|dicer 1, ribonuclease type III|Dicer1||1110006F08Rik, D12Ertd7e, Dicer1, mKIAA0928|MGI:2177178|dicer 1, ribonuclease type III; targeted mutation 1, Brian D Harfe|Dicer1|MGI:3589208|12|||||||||||||||||LoxP Cre recombinase|Cx3cr1|||||||||||Newly developed stain, phenotype unknown. Expected phenotype; Dicer deficient, YFP microglia, RFP with tamoxifen administration.|As above.|C57BL6J (ANU)|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jul-2021|Cryopreserved sperm|22.0|0.0|Unknown|||Possibly| 9230.0|ASD712:Cx3cr1-cre:Dicer fl/fl:RFP fl/fl|B6.129P2(Cg)-Cx3cr1 Dicer1 Gt(ROSA)26Sor/JAnuApb||Semi-dominant|C-X3-C motif chemokine receptor 1|Cx3cr1|||MGI:1333815|Cx3cr1:targeted mutation 2.1, Dan R Littman|Cx3cr1|MGI:5450813|9|ENSMUSG00000052336 ||||||||||||||||||||||||||||Newly developed stain, phenotype unknown. Expected phenotype; Dicer deficient, YFP microglia, RFP with tamoxifen administration.|As above.|C57BL6J (ANU)|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jul-2021|Cryopreserved sperm|||Unknown|||Possibly| 9230.0|ASD712:Cx3cr1-cre:Dicer fl/fl:RFP fl/fl|B6.129P2(Cg)-Cx3cr1 Dicer1 Gt(ROSA)26Sor/JAnuApb||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrosa26, R26, ROSA26,|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 14, Hongkui Zeng|Gt(ROSA)26Sor|MGI:3809524|6|||||||||||||||||||||||||||||Newly developed stain, phenotype unknown. Expected phenotype; Dicer deficient, YFP microglia, RFP with tamoxifen administration.|As above.|C57BL6J (ANU)|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|19-Jul-2021|Cryopreserved sperm|||Unknown|||Possibly| 281.0|B6.IfngTm1 Ts|B6.129-Ifng/Apb||Recessive|interferon gamma|Ifng|Nil|Ifg, IFN-gamma|MGI:107656|targeted mutation 1, Timothy Stewart|Ifng|MGI:1857184|10||||||||||||||||Yes|||||||||||||Immune systemincreased splenocyte proliferation:splenocytes from BCG infected mice exhibit increased proliferation in response to Con Aabnormal macrophage physiology:macrophages from BCG infected mice fail to produce nitric oxide in response to LPS challengemacrophages from BCG infected mice exhibit reduced production of superoxide anion in response to PMA challengeabnormal MHC II cell surface expression on macrophages:macrophages from BCG infected mice exhibit reduced class II expressionabnormal NK cell physiology:significantly lower resting splenic NK cell activityincreased susceptibility to bacterial infection:increased mortality following a sublethal dose of Mycobacterium bovis (BCG )tumorigenesisincreased resistance to tumor development:tumor-bearing mice treated with Th-17-polarized cells from Tg(Tcra,Tcrb)9Rest cells show increased tumor rejection compared to controlshematopoietic systemincreased splenocyte proliferation:splenocytes from BCG infected mice exhibit increased proliferation in response to Con A||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|02-May-2006|Cryopreserved sperm|114.0|0.0|Unknown||macrophage, MHC, Mycobacterium bovis, T cell, cytotoxic|Yes| 8136.0|Ai32; ChR2(H134R)-EYFP|B6.129S6-Gt(ROSA)26Sor/JAusb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 32, Hongkui Zeng|Gt(ROSA)26Sor|MGI:5013789|6|||||||||||||||||||||||||||||No analysis performed||C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|16-Nov-2016|Cryopreserved sperm|88.0|0.0|Unknown|||Yes| 8265.0|Edn3 KO|B6.129-Edn3/J||Recessive|endothelin 3|Edn3|Nil|114CH19, 114-CH19, tmgc48|MGI:95285|endothelin 3; targeted mutation 1, Masashi Yanagisawa|Edn3|MGI:1857160|2|||||||||||||||||||||||||||||This mutation is alleleic with the lethal spotting spontaneous mutation in the endothelin 3 gene (Edn3; ET-3). Homozygous mice are viable at birth. In original 129-Edn3/J mice most die within about a month. However, these have been backcrossed onto C57BL/6 and once backcrossed, aganglionosis is right up to small intestine resulting in early postnatal lethality. They show a disruption in neural crest lineage development. They die from peritonitis subsequent to aganglionic megacolon. They may serve as a model for human Hirschsprung's disease.|Hets have no phenotype|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|06-Jun-2017|Cryopreserved sperm|50.0|0.0|Yes|Hirschprung's Disease ; Waardenburg syndrome type 4B|enteric neuron, epidermal melanocyte|Yes| 8756.0|R26-LSL-Adar1 p110|C57BL/6-Gt(ROSA)26Sor/CwaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Normal (requires Cre to induce expression of Adar1 p110 isoform ectopically)|Normal (requires Cre to induce expression of Adar1 p110 isoform ectopically)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|31-Jul-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 842.0|Sap KO|B6;129-Sh2d1a/Apb|B6;129-Sh2d1a/Apb|X-linked|SH2 domain protein 1A|Sh2d1a|Nil|Duncan disease homolog, SAP|MGI:1328352|targeted mutation 1, Pamela L Schwartzberg|Sh2d1a|MGI:2388241|X||||||||||||||||No|||||||||||||Decreased IgE level: * after immunization with ovalbumin, severe deficit in IgE is observed with little or no Ig E detected.Abnormal lymphocyte cell number:* although lymphocyte numbers were generally normal, occasional animals had increased T cell and NK cell numbers together with decreased B cell numbers in the spleen.Increased T cell proliferation:* tendency for T-cell proliferation to be increased even in the absence of infection.Abnormal T-helper 1 cell morphology:* biased toward the production of the Th1 cytokines Il-2 and IFN-gamma.Abnormal T-helper 2 cell morphology:* biased toward decreased production of the Th2 cytokine Il-4Decreased IgE level:* although levels of IgM, IgG, and IgA were normal, IgE levels were reduced.Increased susceptibility to infection.Increased susceptibility to parasitic infection:* elevated T-cell response to Toxoplasma gondii infectionlower titers of Ig isotypes directed against Toxoplasma antigensIncreased susceptibility to viral infection:* increased T-cell response to infection with lymphocyte choriomeningitis virus (LCMV).* Elevated activity of CD8+ cytotoxic T lymphocytes in spleenCD4+ cells also increased 2-3X.* decrease in antibody secreting cells in spleen and bone marrow.* more virulent strains led to increased morbidity.||C57BL/6 x MLB|Yes|Yes|Yes|Yes|Yes|Yes|No|Good||||No|23-May-2007|Cryopreserved sperm|200.0|0.0|Yes||T cell, lymphoproliferative disease, X-linked, lymphocyte, B cell|Yes| 8982.0|Progesterone receptor; Isoform B (PRBKO)|B6;129S7-Pgr/J||Recessive|progesterone receptor|Pgr|Nil|9930019P03Rik, ENSMUSG00000074510, NR3C3, PR, PR-A, PR-B|MGI:97567|progesterone receptor; targeted mutation 2, Orla M Conneely|Pgr|MGI:2674932|9|||||||||||||||||||||||||||||Abnormal mammary gland growth during pregnancy: • reduction in both ductal sidebranching and development of alveolar lobules during pregnancy, seen as early as 7.5 days of pregnancy.Abnormal mammary gland epithelium morphology: • mammary glands supplemented for 21 days with pregnancy levels of estrogen and progesterone exhibit a 30% decrease in proliferation of the ductal epithelium• mammary glands supplemented for 21 days with pregnancy levels of estrogen and progesterone exhibit an increase in apoptosis in the alveolar epithelium.Abnormal branching of the mammary ductal tree:• reduction in the ductal sidebranching during pregnancy• mammary glands from ovariectomized mutants supplemented for 21 days with pregnancy levels of estrogen and progesterone display a decrease in ductal sidebranching.Abnormal mammary gland alveolus morphology:• reduction in the development of alveolar lobules during pregnancy• at day 1 of lactation, glands show lower density of alveolar lobules than wild-type glands, however they do not appear underdeveloped• mammary glands from ovariectomized mutants supplemented for 21 days with pregnancy levels of estrogen and progesterone display a decrease in lobuloalveolar development.Abnormal lactation:• even though females are able to lactate, offspring of homozygous mothers are growth retarded independent of their genotype, indicating lactational defectsReproductive system phenotype:N • in contrast to female mice lacking isoform A, female mice ovulate normally and are fertile.Abnormal mammary gland growth during pregnancy:• reduction in both ductal sidebranching and development of alveolar lobules during pregnancy, seen as early as 7.5 days of pregnancy||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|23-Apr-2020|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 10414.0|Nox 2 KO|B6.129S6-Cybb/J||X-linked|cytochrome b-245, beta polypeptide|Cybb||Cgd, gp91phox, gp91phox, Nox2|MGI:88574|cytochrome b-245, beta polypeptide; targeted mutation 1, Mary C Dinauer|Cybb|MGI:1857284|X|ENSMUSG00000015340 ||||||||||||||||||||||||||||Nox2 KO mice have a compromised immune system|Heterozygous female mice are normal. Hemizygous male mice are KO or WT as the Nox2 gene is X-linked, and as a KO male it has a compromised immune system.|C57Bl/6J|Unknown|Unknown|Yes|Unknown|Unknown|Unknown|No|Unknown||||No|14-Mar-2024|Cryopreserved sperm|50.0|0.0|Unknown|||No| 8786.0|R26-LSL-Adar1 p150|C57BL/6-Gt(ROSA)26Sor/CwaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor|||MGI:104735||Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||Normal (requires Cre treatment to activate expression of Adar1 p150 isoform)|Normal (requires Cre treatment to activate expression of Adar1 p150 isoform)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|06-Sep-2019|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 2420.0|Nos1 -/-|B6;129S4-Nos1/AnuApb|B6;129S4-Nos1|Recessive|nitric oxide synthase 1, neuronal|Nos1|Nil|bNOS, nNOS, NO, Nos-1|MGI:97360|targeted mutation 1, Paul L Huang|Nos1|MGI:1857227|5||||||||||||||||Yes|||||||||||||The neurons normally expressing NOS appear intact, and the mutant NOS mice are viable, fertile, and without evident histopathological abnormalities in the central nervous system. The most evident effect of disrupting the neuronal NOS gene is the development of grossly enlarged stomachs, with hypertrophy of the pyloric sphincter and the circular muscle layer. This phenotype resembles the human disorder infantile pyloric stenosis, in which gastric outlet obstruction is associated with the lack of NDP neurons in the pylorus.||C57BL/6 x 129|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|10-Jan-2008|Cryopreserved sperm|90.0|0.0|Yes||Pyloric Stenosis, hypertrophy, stomach, neurogenesis|Yes| 5072.0|Flt3-ITD|B6.129-Flt3/Apb||Dominant|FMS-like tyrosine kinase 3|Flt3||CD135, Flk2, Flk-2, Flt-3, wmfl|MGI:95559|FMS-like tyrosine kinase 3; targeted mutation 1, D Gilliland|Flt3|MGI:3763385|5|||||||||||||||||||||||||||||Onset of Acute Myeloid leukaemia.Abnormal hematopoiesis: * bone marrow cells exhibit a two-fold increase in the Lin-Sca1+cKit+ (LSK) compartment compared to in wild-type and heterozygous mice. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice. * the relative percentage of immunophenotypic granulocyte-monocyte progenitors is expanded while the percent of megakaryocyte-erythroid progenitors is decreased. * the proportion of LSK cells in S/G2/M phase is increased while the proportion in G0/G1 is increased compared to in wild-type mice. * fewer LSK cells undergo apoptosis compared to in wild-type and heterozygous mice. * however, the total number of myeloid progenitor cells is the same as in wild-type mice.Abnormal common myeloid progenitor cell morphology: * when cultured on methylcellulose, bone marrow cells produce more colonies than wild-type cells with a greater number of monocytes and fewer erythroid burst forming units and granulocyte-erythroid burst forming units compared to wild-type and heterozygous mice. * however, re-plated colonies do not exhibit increased self-renewal properties.Decreased B cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Decreased mature B cell number: the number of mature B cells in the bone marrow and spleen is decreased compared to in wild-type mice.Decreased T cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Increased leukocyte cell number: mice exhibit leukocytosis and monocytosis with a reversal in the neutrophil to lymphocyte ratio compared to in wild-type mice.Increased granulocyte number: granulocyte populations are increased in peripheral blood compared to in wild-type mice.Increased monocyte cell number: * monocyte populations are increased in peripheral blood. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice.Abnormal B cell differentiation: B cell maturation is blocked at the pre-B stage.Increased spleen red pulp amount: expanded red pulp is comprised of mainly mature myeloid and ad-mixed erythroid elements.Enlarged spleen: mice develop a variable and progressive splenomegaly that is more severe than in heterozygous miceIncreased spleen white pulp amount: expanded white pulp is comprised of cells resembling maturing monocytes.|Onset of Acute Myeloid leukaemia.Abnormal hematopoiesis: * bone marrow cells exhibit a two-fold increase in the Lin-Sca1+cKit+ (LSK) compartment compared to in wild-type mice * fewer LSK cells undergo apoptosis compared to in wild-type. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice.Decreased B cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Decreased mature B cell number: the number of mature B cells in the bone marrow and spleen is decreased compared to in wild-type mice.Decreased T cell number: the rise in monocytes in the bone marrow and spleen is accompanied by a decrease in the percentage of T and B lymphoid cells.Increased leukocyte cell number: mice exhibit leukocytosis and monocytosis with a reversal in the neutrophil to lymphocyte ratio compared to in wild-type mice.Increased granulocyte number: granulocyte populations are increased in peripheral blood compared to in wild-type mice.Increased monocyte cell number: * monocyte populations are increased in peripheral blood. * monocytes are present in the bone marrow and liver in a background of increased number of maturing myeloid cells is increased compared to in wild-type mice.Abnormal B cell differentiation: B cell maturation is blocked at the pre-B stage.Increased spleen red pulp amount: expanded red pulp is comprised of mainly mature myeloid and ad-mixed erythroid elements.Enlarged spleen: mice develop a variable and progressive splenomegaly that is not as severe as in homozygous mice.Increased spleen white pulp amount: expanded white pulp is comprised of cells resembling maturing monocytes.|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Poor||||No|25-Mar-2010|Cryopreserved sperm|75.0|0.0|Yes|Myelomonocytic Leukaemia|AML, myeloid, lymphocyte, CML|Yes| 8784.0|R26-LSL-Adar1 Za|C57BL/6-Gt(ROSA)26Sor/CwaApb||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26, Thumpd3as1|MGI:104735||Gt(ROSA)26Sor||6|||||||||||||||||||||||||||||normal (requires Cre to express Adar1 cDNA)|Normal (requires Cre to express Adar1 cDNA)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Sep-2019|Cryopreserved sperm|60.0|0.0|Unknown|||Yes| 7986.0|Recql4 R347*|C57BL/6JAnu-Recql4/AnuCrwApb||Recessive|RecQ protein-like 4|Recql4|Unknown||MGI:1931028|Recql4; mutation 2, Australian National University|Recql4||15|ENSMUSG00000033762|ENSMUST00000036852|Recql4-201|1039|1122|G to A|ENSMUSE00000237138|5|347|Arginine to STOP|||||CAGCTTCCCTAGACAGAGGGAACTATATTCGACTCAACATGAAAAACAAACGCTTTGTACG|Unknown|||||||||||||Unknown as none recovered at time of submission|Appear normal and fertile|C57BL/6JAnu|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Good|2 to C57BL/6|1|PM/+ to either PM/+ or WT|No|27-Oct-2015|Cryopreserved sperm|40.0|0.0|Yes|Rothmund-Thomson Syndrome|ENU, Recql4|Possibly| 10329.0||C57BL/6-Osxp53(fl/fl>pRbR26/Apb||Semi-dominant|Osx-Cre p53fl/fl pRbfl/fl R26-Adar1|||||Osx-Cre p53fl/fl pRbfl/fl R26-Adar1|||Unknown|||||||||||||||||Osx-Cre|Sp7|||||||||||Homozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|Heterozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-May-2023|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 10331.0||C57Bl/6-Osx(Cre p53fl/fl) pRb< R26-Adar1p110/Apb||Semi-dominant|Osx-Cre p53fl/fl pRbfl/fl R26-Adar1p110|||||Osx-Cre p53fl/fl pRbfl/fl R26-Adar1p110|||Unknown|||||||||||||||||Osx-Cre|Sp7|||||||||||Homozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma.|Heterozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma.|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-May-2023|Cryopreserved sperm|40.0|0.0|Unknown|||Possibly| 3385.0|Histamine receptor type 2 -/- |B6.129P2-Hrh2|B6.129P2-Hrh2|Recessive|histamine receptor H2|Hrh2|Nil||MGI:108482|histamine receptor H2; targeted mutation 1, Takeshi Watanabe|Hrh2|MGI:2182949|13||||||||||||||||No|||||||||||||Homozygotes for a targeted null mutation exhibit enlarged folds in gastric mucosa, elevated serum gastrin levels, increased numbers of parietal and enterochromaffin-like cells, and lack of secretion of gastric acid in response to histamine or gastrin.Abnormal gastric mucosa morphology:* enterochromaffin-like (ECL) cells are increased in number and are found not only in the basal region, but also in the neck region and isthmus.* increase in H+, K+-ATPase negative cells in the isthmus and neck region.* histamine content in the gastric mucosa is elevated.* young mice (4 weeks old) in which hypertrophy of the oxyntic mucosa is not yet seen, exhibit a significant increase in cell proliferation in the mucosa.Abnormal gastric parietal cell morphology: parietal cells are increased in number, are smaller and contain enlarged secretory canaliculi with a lower density of microvilli and few typical tubulovesicles in the narrow cytoplasm.Increased thickness of gastric mucosa:* thickness of the oxyntic mucosa in the glandular region is increased in 16-week old mutants resulting in the formation of enlarged gastric folds.* change in mucosal thickness is most prominent in the isthmus and neck region.Decreased digestive secretion: induction of gastric acid secretion by histamine or gastrin is completely abolished, however carbachol still induced secretion.Abnormal stomach pH: basal gastric pH is normal, however elevation of gastric pH by administration of an Hrh2 antagonist, famotidine, is not observed.Increased circulating gastrin level: 12- to 18-week old mutants exhibit elevated serum gastrin levels (hypergastrinemia).||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|||Brother x sister|No|09-Jul-2008|Cryopreserved sperm|150.0|0.0|Unknown||UV immunosuppression, resistance, mucosa, gastric, histamine, stomach, pH|Yes| 10513.0|Hck S431F|C57BL/6J-Hck/Anu||Recessive|hemopoietic cell kinase|Hck||Bmk, Hck-1|MGI:96052|hemopoietic cell kinase; endonuclease-mediated mutation 1,Monash Genome Modification Platform|Hck||2|ENSMUSG00000003283 ||||||||||||||||||||||||||||Unknown|Unknown||Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Jun-2025||0.0|0.0|Unknown|||No| 2421.0|B10.H2g7|B10.NOD-H2/AnuApb|B10.NOD-H2/AnuApb|Recessive|histocompatibility-2, MHC|H2|Normal|H-2, MHC-II|MGI:95894|g7 variant|H2|MGI:3579321|17||||||||||||||||Yes|||||||||||||The H2 complex contains 3 major classes of highly polymorphic gene sets: class I (H2-K, H2-D, Q, H2-T18 genes), class II (H2-I genes), and class III (H2-S genes). These genes are involved in many processes, including graft rejection, immune response, antigen presentation and complement component. The g7 variant is found in NOD strain||C57BL/10|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|10-Jan-2008|Cryopreserved sperm|129.0|0.0|No||MHC, diabetes, autoimmune disease, insulitis|Yes| 10330.0||C57Bl/6N-Osxp53pRbR26/Apb||Semi-dominant|Osx-Cre p53fl/fl pRbfl/fl R26-Adar1E861A|||||Osx-Cre p53fl/fl pRbfl/fl R26-Adar1E861A|||Unknown|||||||||||||||||Osx-Cre|Sp7|||||||||||Homozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|Heterozygous viable and fertile; stock maintained as Cre negative line with all other alleles homozygous. When crossed to Osx-Cre will develop osteosarcoma|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-May-2023|Cryopreserved sperm|30.0|0.0|Unknown|||Possibly| 10514.0|Hck KO|C57BL/6J-Hck/Anu||Recessive|hemopoietic cell kinase|Hck||Bmk, Hck-1|MGI:96052|hemopoietic cell kinase; endonuclease-mediated mutation 2, Monash Genome Modification Platform|Hck||2|ENSMUSG00000003283 ||||||||||||||||||||||||||||Abnormal neutrophil physiology - neutrophil degranulation following adhesion is decreased compared to wild type mice.|Unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|26-Jun-2025||0.0|82.0|Unknown|||No| 4576.0||B6.129S7-Ifngr1/AnuApb||Recessive|interferon gamma receptor 1|Ifngr1|Unknown|CD119, Ifgr, IFN-gamma R, IFN-gammaR, Ifngr, Nktar|MGI:107655|targeted mutation 1, Michel Aguet|Ifngr1|MGI:1857286|10||||||||||||||||Yes|||||||||||||abnormal immune cell physiology (J:99347)splenocytes proliferate against the antigen and a mitogen more vigorously than those from wild-typeincreased interferon-gamma secretion (J:99347)stimulation of splenocytes with an antigen or a mitogen induces a higher production of IFN-gamma than in wild-typeincreased interleukin-6 secretion (J:99347)stimulation of splenocytes with an antigen induces a higher production of IL-4, IL-6, IL-13 and IFN-gamma than in wild-typestimulation of splenocytes with a mitogen induces a higher production of IL-13increased susceptibility to experimental autoimmune uveoretinitis (J:99347)exhibit increased incidence and severity of induced experimental autoimmune uveoretinitis compared to wild-type (59.3% vs. 40% of wild-type)upon uveoretinitis induction, see a significant infiltration of eosinophils into the eyes compared to wild-typeliver/biliary systemliver/biliary system phenotype (J:120559)mice show no liver injury on treatment with HBsAg-specific Th1 cells and HBsAgtumorigenesisaltered tumor susceptibility (J:138466)tumor growth in tumor-bearing mice treated with Th-17-polarized cells from Tg(Tcra,Tcrb)9Rest cells is minimally delayed, and develop progressive disease||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10|||No|08-Mar-2009|Cryopreserved sperm|58.0|0.0|Unknown||cytokine, interleukin, infection, immunoglobulin, macrophage|Yes| 7228.0|Mx-Cre pRb TNFa-/-|C57BL/6-Rb1 Tnf Tg(Mx1-cre)1Cgn/SviApb||Dominant|tumor necrosis factor|Tnf|Nil|DIF, Tnfa, TNFalpha, TNF alpha, TNF-alpha, Tnfsf1a, tumor necrosis factor-alpha|MGI:104798|tumor necrosis factor; targeted mutation 1, George Kollias|Tnf|MGI:2149024|17|||||||||||||||||transgene insertion 1, University of Cologne|Mx1|high after interferon stimulation||||||||||Normal if not treated with pIpC|Normal if not treated with pIpC|C57Bl/6|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Good|all were C57BL/6 when inbred, no further backcrossing done||Cre+ male to Cre-ve female (all Rbfl/fl TNFa-/-)|No|22-Nov-2012|Cryopreserved sperm|60.0|0.0|Unknown||Mx-Cre, Rb, TNFa|Yes| 7228.0|Mx-Cre pRb TNFa-/-|C57BL/6-Rb1 Tnf Tg(Mx1-cre)1Cgn/SviApb||Dominant|retinoblastoma 1|Rb1 |Nil|pRb, Rb, Rb-1 |MGI:97874|retinoblastoma 1; targeted mutation 3, Tyler Jacks |Rb1|MGI:2450162|14|||||||||||||||||||||||||||||Normal if not treated with pIpC|Normal if not treated with pIpC|C57Bl/6|Yes|Yes|Yes|Unknown|Unknown|Unknown|No|Good|all were C57BL/6 when inbred, no further backcrossing done||Cre+ male to Cre-ve female (all Rbfl/fl TNFa-/-)|No|22-Nov-2012|Cryopreserved sperm|||Unknown||Mx-Cre, Rb, TNFa|Yes| 6922.0|Recql4+/-|C57BL/6-Recql4/Apb||Dominant|RecQ protein-like 4|Recql4|Nil||MGI:1931028|Recql4 germ-line knockout|||15|||||||||||||||||||||||||||||homozygous lethal at or before E10.5|apparently normal - viable, fertile|C57BL/6|No|No|Yes|No|No|Yes|No|Excellent|generated on pure C57Bl/6 so not backcrossed. Only maintained on C57||+/- to +/-|No|27-Jun-2012|Cryopreserved sperm|64.0|0.0|Yes|Rothmund-Thomson Syndrome||Possibly| 6921.0|Recql4 fl/fl|C57BL/6-Recql4/Apb||Dominant|RecQ protein-like 4|Recql4|Nil||MGI:1931028|Recql4 fl/fl|||15|||||||||||||||||||||||||||||homozygous fl/fl mice are normal, viable and fertile||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent|generated on pure C57BL/6 so not backcrossed. Only maintained on C57||fl/+ to fl/+|No|27-Jun-2012|Cryopreserved sperm|97.0|0.0|Yes|Rothmund-Thomson Syndrome||Possibly| 7984.0|Recql4 K525A|C57BL/6-Recql4||Dominant|RecQ protein-like 4|Recql4|Nil||MGI:1931028|Recql4|Recql4 K525A||15|||||||||||||||||||||||||||||As young mice no phenotype is yet apparent (8-12 week old) homozygous PM. Fertility unknown at this point|Hets appear normal and fertile|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Excellent|generated on pure C57BL/6 so not backcrossed. Only maintained on C57|NA|PM/+ to either PM/+ or WT|No|27-Oct-2015|Cryopreserved sperm|30.0|0.0|Yes|Rothmund-Thomson Syndrome|Recql4|Possibly| 7392.0|B6.Nramp|B6.129-Slc11a1/Apb||Dominant|solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1|Slc11a1|Normal|Bcg, host resistance locus Bcg/Ity/Lsh, ity, Ity, Lsh, Nramp, Nramp1|MGI:1345275|solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1; host resistance (Bcg/Ity/Lsh)|Slc11a1|MGI:1857756|1|||||||||||||||||||||||||||||Decreased susceptibility to bacterial infection:the mutation results in Gly at position 105 substitution within predicted transmembrane domain 2 of Nramp.This results in resistance to infection with Mycobacteria, Salmonella and Leishmania|Similar to hom state but resistance is intermediate.|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Excellent|13|||Yes|06-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||infection, resistance, bacteria|Yes| 7044.0|Activin BA knockout ; Inhba-/-|B6;129S7-Inhba/MarpApb||Dominant|inhibin beta-A|Inhba||activin|MGI:96570|inhibin beta-A; targeted mutation 1, Martin M Matzuk|Inhba|MGI:1861957|13|||||||||||||||||||||||||||||Mice die at birth due to abnormal palate development, precluding feeding.|Delayed onset of fertility, no impact on general viability|C57BL/6 x 129S|No|No|Yes|No|No|Yes|Yes|Good|Unknown||Heterozygous matings|No|06-Aug-2012|Cryopreserved sperm|50.0|0.0|No||activin|Possibly| 10518.0|OT-I:CD45.1|B6.Cg-Ptprc Tg(TcraTcrb)1100Mjb/Anu||Dominant|protein tyrosine phosphatase receptor type C|Ptprc ||CD45, Ly-5, Lyt-4, T200|MGI:97810|protein tyrosine phosphatase receptor type C; a variant|Ptprc|MGI:4819849|1|ENSMUSG00000026395||||||||||||||||transgene insertion 1100, Michael J Bevan||||||||||||Normal|Normal|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|09-Jul-2025||0.0|204.0|Unknown|||Yes| 7394.0|B6.ICE-/-|B6.129S2-Casp1/Apb||Recessive|caspase 1|Casp1|Nil|Caspase-1, ICE, Il1bc, interleukin 1 beta-converting enzyme|MGI:96544|caspase 1; targeted mutation 1, Richard Flavell|Casp1|MGI:2158744|9|||||||||||||||||||||||||||||mice lack expression of interleukin-1 converting enzyme (or caspase-1) and therefore cannot proteolytically cleave interleukin 1β and interleukin 18 into active mature peptides. |unknown|C57BL/6|Yes|Yes|Unknown|Yes|Yes|Unknown|No|Excellent|13|||Yes|06-Aug-2013|Cryopreserved sperm|50.0|0.0|Unknown||caspase-1, IL-1b, IL-18|Yes| 7568.0|Mt3KO:ANU|B6.129-Mt3/Apb||Recessive|metallothionein 3|Mt3|Nil|MT-3|MGI:97173|metallothionein 3; targeted mutation 1, Richard D Palmiter|Mt3|MGI:2389488|8|||||||||||||||||||||||||||||Mice homozygous for a knock-out allele exhibit a zinc deficiency in several brain regions, abnormal astrocyte morphology, increased susceptibility to kainic acid induced seizures, and altered zinc accumulation and neuronal death in certain brain areas following seizure-induced or acute brain injury.|Unknown|C57BL/6|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Excellent||||No|17-Jan-2014|Cryopreserved sperm|50.0|0.0|Unknown||zinc, metals, seizures|Possibly| 8213.0|Ifnar KO|B6.129-Ifnar1/AnuApb||Recessive|interferon (alpha and beta) receptor 1|Ifnar1|Unknown|CD118, Ifar, Ifrc, INF-a receptor, Infar|MGI:107658|targeted mutation 1, Michel Aguet|Ifnar1|MGI:1930950|16||||||||||||||||Yes|||||||||||||Homozygotes for targeted null mutations exhibit increased susceptibility to viral infection, elevated levels of myeloid lineage cells in the peripheral blood and bone marrow, and reduced immune response to immunostimulatory DNA.||C57BL/6NCrlAnu|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|08-Mar-2017|Cryopreserved sperm|48.0|0.0|Unknown||interferon, infection, immunity, T cell|Yes| 7531.0|R-DTA|B6.129-Gt(ROSA)26Sor/MelbAnuApb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Richard M Locksley|Gt(ROSA)26Sor|MGI:3829362|6|||||||||||||||||||||||||||||Mice heterozygous or homozygous for the ROSA26 retroviral insertion display no distinguishing phenotype. lacZ is expressed in all tissues of the developing embryo and in most tissues of the adult mouse.Removal of flexed stuffer sequence by Cre recombinase results in diphtheria expression and cell death.Abnormal cell death:• T cells infected with a retroviral cre exhibit cell death without inducing cell death in uninfected cells||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|04-Dec-2013|Cryopreserved sperm|36.0|0.0|Unknown||diphtheria toxin|Yes| 8015.0|CD122 KO|B6.129-Il2rb/AusbAnuApb||Recessive|interleukin 2 receptor, beta chain|Il2rb|Nil|CD122, IL15Rbeta, IL-15Rbeta, IL-15 receptor beta chain, IL-2/15Rbeta, Il-2Rbeta|MGI:96550|interleukin 2 receptor, beta chain; targeted mutation 1, Tak Mak|Il2rb|MGI:1857193|15|||||||||||||||||||||||||||||Increased susceptibility to autoimmune hemolytic anemia:• by 26 days of age• can be prevented with adoptive transfer at birth of 1 x 10<5> CD25-positive CD4 T cells from wild-type miceAbnormal lymphocyte morphology.Decreased regulatory T cell number:• there is a 2 to 5 fold reduction in the percentage of CD25-postive CD4 T cells in both the thymus and lymph nodes• transgeneic expression of Il2rb in the thymus rescues number of regulatory T cells.Enlarged spleen:• in mice by 26 days of age• can be prevented with adoptive transfer at birth of 1 x 10<5> CD25-positive CD4 T cells from wild-type miceabnormal spleen periarteriolar lymphoid sheath morphology ( J:113547 )• increased in size at 26 days of age• can be prevented with adoptive transfer at birth of 1 x 105 CD25-positive CD4 T cells from wild-type miceAbnormal T cell activation:• percentage of CD4 and CD8 T cells that express high levels of activation markers is increased• T cells are hyporesponsive to inflammatory cytokines as measured by in vitro proliferation assays• expression of activation markers is normalized upon transfer of 1 x 10<5> CD25-positive CD4 T cells from wild-type miceDecreased T cell proliferation:• in mice by 26 days of age• can be prevented with adoptive transfer at birth of 1 x 10<5> CD25-positive CD4 T cells from wild-type miceEnlarged lymph nodes:• in mice by 26 days of age• can be prevented with adoptive transfer at birth of 1 x 10<5> CD25-positive CD4 T cells from wild-type miceIncreased anti-double stranded DNA antibody level:• can be prevented with adoptive transfer at birth of 1 x 10<5> CD25-positive CD4 T cells from wild-type mice• in mice by 26 days of ageAbnormal response to transplant:• adoptively transfered regulatory T cell expand at least 15 to 20 times until they make up 3-5% of the total cells in the lymph nodes and spleen• regulatory T cells were unable to engraft in wild-type mice.||C57BL/6|Unknown|Yes|Yes|Unknown|Yes|Yes|No|Unknown||||No|21-Dec-2015|Cryopreserved sperm|22.0|0.0|Unknown||T cell, Lymphocyte|Yes| 7981.0|Nrp1Sema|B6.129P2-Nrp1/DdgApb||Recessive|neuropilin 1|Nrp1|Normal|Neuropilin-1, NP-1, Npn1, NPN-1|MGI:106206|neuropilin 1; targeted mutation 1, David D Ginty|Nrp1|MGI:3512099|8|||||||||||||||||||||||||||||Mutant embryos from het X het matings have axonal guidance defects in a range of central and peripheral neurons. Adults mutants are smaller than littermates and also have axonal defasciculation. Postnatal lethality:• 40% die by P7Dilated heart atrium:• exhibited bilateral atrial enlargement, however no vascular branching defects were observedPostnatal growth retardation:• 70% of P7 survivors are growth retardedAbnormal axon guidance:• guidance of ophthalmic nerve axons and cutaneous sensory neurons was abnormal so that projections extended beyond their normal zonesAbnormal corpus callosum morphology:• callosal axons displayed varying degrees of defasciculation with agenesis of corpus callosum resulting in the formation of Probst bundles in extreme cases.Abnormal hippocampus morphology:• entorhinohippocampal axons were no longer restricted in the stratum lacunosum-moleculare of the ipsilateral hippocampus with many fibers innervating ectopic layers.Abnormal cranial nerve morphology:Abnormal trigeminal nerve morphology:• defasciculated and abnormally extended ophthalmic branch of the trigeminal nerve, however defects were less severe than in Nrp1.Abnormal vestibulocochlear nerve morphology:• E12.5 mutants have additional smaller fiber bundles that extend beyond their normal termination zones within the sensory end organs with projection defects persisting at E14.5 and E15.5Abnormal dorsal root ganglion morphology:• many cutaneous afferent axons entered the gray matter a E14.5 with some projections extending into the most ventral regions of the spinal cord.• at P2, some axons were outside their normal termination zones, along the midline and in the medial-ventral spinal cord.Abnormal spinal nerve morphology:• disorganized peripheral projections of spinal nerves in E11.5 mutants.Abnormal T cell physiology:• defective T-cell priming by antigenAbnormal dendritic cell physiology:• impaired dendritic cell migration|Normal|C57BL/6J|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Good||||No|12-Oct-2015|Cryopreserved sperm|60.0|0.0|Unknown||Neuropilin, Nrp1, Npn1, Semaphorins, vascular endothelial growth factor|Possibly| 8469.0|Sphingosine kinase 2 Knockout |B6.129S6-Sphk2/RlpUsaApb||Recessive|sphingosine kinase 2|Sphk2|||MGI:1861380|sphingosine kinase 2; targeted mutation 1, Richard L Proia|Sphk2|MGI:3611080|7|||||||||||||||||||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|12-Apr-2018|Cryopreserved sperm|50.0|0.0|Unknown||Vascular development, Angiogenesis|Yes| 9000.0||B6.129-F2rl1 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/Apb||Recessive|coagulation factor II (thrombin) receptor-like 1|F2rl1||Gpcr11, Par2, PAR-2, Protease-activated receptor-2, proteinase-activated receptor-2|MGI:101910|coagulation factor II (thrombin) receptor-like 1; targeted mutation 1c, Wellcome Trust Sanger Institute|F2rl1|MGI:6151132|13|||||||||||||||||transgene insertion 1, Andrew P McMahon|SP7|||||||||||Homozygous B6.129-F2rl1tm1c(EUCOMM)Wtsi mice that are positive for the transgene Sp7-tTA,tetO-EGFP/cre are viable and fertile. Like B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J mice, slow longitudinal bone growth is noticeable. This appears to last up to 13 weeks of age.|Like homozygous.|C57BL/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|05-Jun-2020|Cryopreserved sperm|40.0|0.0|Unknown|||Yes| 9190.0|Ago2|B6.129P2(129S4)-Ago2/AnuApb||Recessive|argonaute RISC catalytic subunit 2|Ago2|Nil|1110029L17Rik, 2310051F07Rik, argonaute 2, Eif2c2, mKIAA1567|MGI:2446632|argonaute RISC catalytic subunit 2; targeted mutation 1.1, Alexander Tarakhovsky|Ago2|MGI:4839762|15|||||||||||||||||||||||||||||These mice possess loxP sites on either side of exons 9-11 in the Eif2c2 (eukaryotic translation initiation factor 2C, 2) gene, also known as Ago2. Mice that are homozygous for this floxed allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. When crossed with a Cre recombinase-expressing strain, the Mid domain is deleted and Ago2 expression is lost, causing functional inactivation of the gene.|Unknown|C57BL/6J |Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Unknown|||Yes|21-May-2021|Live|0.0|0.0|Unknown||miRNA biogenesis, T reg cells, Ago2, Argonaute|Yes| 7985.0|Recql4 G522EfsX43|C57BL/6-Recql4||Dominant|RecQ protein-like 4|Recql4|Nil||MGI:1931028|Recql4|Recql4 G522EfsX43||15|||||||||||||||||||||||||||||unknown - we havent recovered any homozygous point mutants at time of submission to APN|Hets appear normal and fertile|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Excellent|generated on pure C57BL/6 so not backcrossed. Only maintained on C57||PM/+ to either PM/+ or WT|No|27-Oct-2015|Cryopreserved sperm|40.0|0.0|Yes|Rothmund-Thomson Syndrome|Recql4|Possibly| 10517.0|cNLRC4 (50)|C57BL/6NCrlAnu-Nlrc4/AnuApb||Dominant|NLR family, CARD domain containing 4|Nlrc4||Card12, Ipaf|MGI:3036243|Nlrc4:endonuclease-mediated mutation 2, Australian National University|Nlrc4||17|ENSMUSG00000039193||||||||||||||||||||||||||||Normal|Normal||Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|||hom x hom|No|08-Jul-2025|Cryopreserved sperm|21.0|0.0|Unknown|||No| 10521.0|cNLRC4 (50)|C57BL/6NCrlAnu-Nlrc4/AnuApb||Dominant|NLR family, CARD domain containing 4|Nlrc4||Card12, Ipaf|MGI:3036243|Nlrc4:endonuclease-mediated mutation 2, Australian National University|Nlrc4||17|ENSMUSG00000039193||||||||||||||||||||||||||||Normal|Normal||Yes|Yes|Unknown|Yes|Yes|Unknown|No|Good|||hom x hom|No|18-Aug-2025|Cryopreserved sperm|55.0|0.0|Unknown|||No| 7582.0|B1-8 High Affinity +/-, (ROSA)td Tomato -/- KI|B6.129-IgH Gt(ROSA)26Sor/JMnzAnu||Recessive|immunoglobulin heavy chain complex|Igh|||MGI:96442|immunoglobulin heavy chain complex; targeted mutation 1, Michel C Nussenzweig|Igh|MGI:3712224|12|||||||||||||||||||||||||||||All cells express red colour from Tomato||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Tomato - 8x to B6; B1-8 high >15x to B6|||No|05-Feb-2014|Cryopreserved sperm|32.0|0.0|Unknown||T cell, Germinal centre, B cell|Possibly| 7582.0|B1-8 High Affinity +/-, (ROSA)td Tomato -/- KI|B6.129-IgH Gt(ROSA)26Sor/JMnzAnu||Recessive|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||beta geo, Gtrgeo26, Gtrosa26, R26, ROSA26 |MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 9, Hongkui Zeng|Gt(ROSA)26Sor|MGI:3809523|6|||||||||||||||||||||||||||||All cells express red colour from Tomato||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|Tomato - 8x to B6; B1-8 high >15x to B6|||No|05-Feb-2014|Cryopreserved sperm|||Unknown||T cell, Germinal centre, B cell|Possibly| 10486.0|Wnt4GCE-nTnG|B6.Cg-Wnt4-Gt(ROSA)26Sor/Apb||Dominant|wingless-type MMTV integration site family, member 4|Wnt4|||MGI:98957|wingless-type MMTV integration site family, member 4; targeted mutation 2, Andrew P McMahon|Wnt4|MGI:3845544|4|ENSMUSG00000036856||||||||||||||||||||||||||||Homozygous mice die in utero or in early postnatal life due to a lack of kidney function and other abnormalities arising from the loss of Wnt4 function.|Heterozygous mice are viable and fertile|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Feb-2025|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10486.0|Wnt4GCE-nTnG|B6.Cg-Wnt4-Gt(ROSA)26Sor/Apb||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrosa26, R26|MGI:104735|gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Edward E Schmidt|Gt(ROSA)26Sor|MGI:5504463|6|ENSMUSG00000086429 ||||||||||||||||||||||||||||Homozygous mice die in utero or in early postnatal life due to a lack of kidney function and other abnormalities arising from the loss of Wnt4 function.|Heterozygous mice are viable and fertile|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|05-Feb-2025|Cryopreserved sperm|||Unknown|||Possibly| 5512.0|c-myc fl/fl|B6.129S6-Myc/Apb||Semi-dominant|myelocytomatosis oncogene|Myc|Normal|c-myc, Myc2, Niard, Nird|MGI:97250|myelocytomatosis oncogene; targeted mutation 2, Frederick W Alt|Myc|MGI:2178233|15||||||||||||||||No|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Excellent||||No|24-May-2011|Cryopreserved sperm|50.0|0.0|Unknown||myc|Possibly| 7035.0|Osx-Cre p53fl/fl pRbfl/fl|STOCK Rb1 Trp53 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/StvApb||Dominant|transformation related protein 53|Trp53|Nil|p53|MGI:98834|transformation related protein 53; targeted mutation 1, Anton Berns|Trp53|MGI:1931011|11|||||||||||||||||Osx-Cre:GFP - transgene insertion 1, Andrew P McMahon|Osterix (Sp7)|medium||||||||||Generate osteosarcoma (bone cancer)Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.|Slightly smaller, susceptible to malocclusion. Generate osteosarcoma if p53fl/+ but at long latency (1yr)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Cre+ve males to Cre-ve females, homozygous pRb and p53|No|03-Aug-2012|Cryopreserved sperm|26.0|0.0|Yes|Osteosarcoma|osteosarcoma, Osx-Cre, p53fl/fl, pRbfl/fl|Yes| 7035.0|Osx-Cre p53fl/fl pRbfl/fl|STOCK Rb1 Trp53 Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/StvApb||Dominant|retinoblastoma 1|Rb1|Nil|pRb, Rb, Rb-1|MGI:97874|retinoblastoma 1; targeted mutation 3, Tyler Jacks|Rb1|MGI:2450162|14|||||||||||||||||||||||||||||Generate osteosarcoma (bone cancer)Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.|Slightly smaller, susceptible to malocclusion. Generate osteosarcoma if p53fl/+ but at long latency (1yr)|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|5||Cre+ve males to Cre-ve females, homozygous pRb and p53|No|03-Aug-2012|Cryopreserved sperm|||Yes|Osteosarcoma|osteosarcoma, Osx-Cre, p53fl/fl, pRbfl/fl|Yes| 10536.0|Tacstd2 KI|C57BL/6J-Tacstd2/Apb||Dominant|tumor-associated calcium signal transducer 2|Tacstd2||Ly97, TROP2|MGI:1861606||Tacstd2||6|ENSMUSG00000051397 ||||||||||||||||||||||||||||unknown|unknown|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|02-Dec-2025|Cryopreserved sperm|30.0|0.0|Unknown|||No| 10537.0|BALB.B - JAX# 001952|C.B10-H2/LilMcdJ ||Dominant|||||||||17||||||||||||||||||||histocompatibility-2, MHC|H2||H-2, MHC-II|MGI:95894|histocompatibility-2, MHC; b variant|H2|MGI:3579319|17|Normal|Normal|C57BL/10 |Yes|Yes|Unknown|Yes|Yes|Unknown|No|Unknown|BALB/c was crossed with C57BL/10 and after 13 consecutive backcrosses with selection for C57BL/10-derived H2b at each generation, this congenic was inbred by continuous sibling intercross (Freedman and Lilly, 1975).||homozygous mice may be bred together.|No|12-Dec-2025||0.0|0.0|Unknown|||No| 10539.0|BALB.B HuTAP|Balb/b-Tap1/Tap2em1Anu Tg(hTAP1/hTAP2)/MarpAnu||Dominant|Tap1/Tap2:endonuclease-mediated mutation 1, Australian National University|||||Tap1/Tap2:endonuclease-mediated mutation 1, Australian National University|Tap1/Tap2:KO||Unknown|||||||||||||||||||||||||||||Normal|Normal|Balb/b|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|18-Dec-2025||0.0|117.0|Unknown|||No| 7911.0|B6.p53|B6.129-Trp53/AnuApb||Dominant|transformation related protein 53|Trp53|Nil|p44, p53|MGI:98834|transformation related protein 53; targeted mutation 1, Tyler Jacks|Trp53|MGI:1857263|11|||||||||||||||||||||||||||||Premature death:* 90% had succumbed to tumors and died by 7 months of age.*average life span 160 days.Increased tumor incidence.Adenoma.Lymphoma.Thymic lymphoma: 75% of observed tumors were thymic lymphomasCarcinoma.Sarcoma.Abnormal apoptosis.Chromosome breakage: aneuploidyIncreased cellular sensitivity to ionizing radiation:* at P10, pattern and extent of oocyte loss in ovaries of mutants after exposure to 0.45 Gy radiation on P5 is similar to wild-type and much more sever than Trp63 mutants|Increased tumor incidence: age of onset 9 monthsLymphoma.Sarcoma|C57BL/6|Yes|Unknown|Yes|Yes|Unknown|Yes|No|Unknown||||No|18-Jun-2015|Cryopreserved sperm|120.0|53.0|Unknown|||Yes| 10538.0|Rps19-D:R26 M2-rtTA|C57BL/6NCrlAnu-Col1a1 Gt(ROSA)26Sor/Anu||Dominant|collagen, type I, alpha 1|Col1a1||Cola1, Mov-13| MGI:88467|Col1a1:targeted mutation 1, Stefan Karlsson|Col1a1|MGI:5304754|11|ENSMUSG00000001506||||||||||||||||||||||||||||Normal without doxycycline treatment.Premature death:• most mice die within 2 months following doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatment.Thrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased neutrophil cell number:• seven weeks after doxycycline treatment.Thrombocytopenia:• seven weeks after doxycycline treatment.Decreased lymphocyte cell number:• two and seven weeks after doxycycline treatment.Reticulocytopenia:• two weeks after doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment|Normal without doxycycline treatment.mortality/agingN • unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatmentAbnormal bone marrow cell morphology/development:• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment.Decreased bone marrow cell number:• by 10 days after doxycycline treatment• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment.Decreased megakaryocyte cell number:• seven weeks after doxycycline treatment.Abnormal proerythroblast morphology:• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatmentThrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased lymphocyte cell number:• two and seven weeks after doxycycline treatmentReticulocytopenia:• two weeks after doxycycline treatmentAbnormal bone marrow cell physiology:• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment• less pronounced than in homozygous mice|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Dec-2025|Cryopreserved sperm|87.0|0.0|Unknown|||No| 10538.0|Rps19-D:R26 M2-rtTA|C57BL/6NCrlAnu-Col1a1 Gt(ROSA)26Sor/Anu||Dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||Gtrosa26, R26, ROSA26|MGI:104735|Gt(ROSA)26Sor:targeted mutation 1, Rudolf Jaenisch|Gt(ROSA)26Sor||6|ENSMUSG00000086429 ||||||||||||||||||||||||||||Normal without doxycycline treatment.Premature death:• most mice die within 2 months following doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatment.Thrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased neutrophil cell number:• seven weeks after doxycycline treatment.Thrombocytopenia:• seven weeks after doxycycline treatment.Decreased lymphocyte cell number:• two and seven weeks after doxycycline treatment.Reticulocytopenia:• two weeks after doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment|Normal without doxycycline treatment.mortality/agingN • unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatmentAbnormal bone marrow cell morphology/development:• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment.Decreased bone marrow cell number:• by 10 days after doxycycline treatment• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment.Decreased megakaryocyte cell number:• seven weeks after doxycycline treatment.Abnormal proerythroblast morphology:• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment.Macrocytosis:• seven weeks after doxycycline treatmentThrombocytosis:• two weeks after doxycycline treatmentDecreased hematopoietic cell number.Decreased erythrocyte cell number:• two and seven weeks after doxycycline treatmentDecreased lymphocyte cell number:• two and seven weeks after doxycycline treatmentReticulocytopenia:• two weeks after doxycycline treatmentAbnormal bone marrow cell physiology:• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatmentPostnatal growth retardation:• following doxycycline treatment• less pronounced than in homozygous mice|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|12-Dec-2025|Cryopreserved sperm|||Unknown|||No| 10545.0|Balbc|Balb/cBy||Dominant|None||||||||Unknown|||||||||||||||||||||||||||||Normal|Normal|Balb/cJ|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|17-Mar-2026|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 8294.0|Sparc KO|B6.129S-Sparc/Apb||Recessive|secreted acidic cysteine rich glycoprotein|Sparc|Nil|BM-40, osteonectin|MGI:98373|secreted acidic cysteine rich glycoprotein; targeted mutation 1, Chin Chen Howe|Sparc|MGI:1888383|11|||||||||||||||||||||||||||||Early onset of cataract formation. Otherwise normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|29-Aug-2017|Cryopreserved sperm|50.0|0.0|Unknown||cortex, eye, cataracts|Yes| 8260.0|Ck6/ECFP|B6.129-Tg(CAG-ECFP)CK6Nagy||Dominant||||||||||||||||||||||||||transgene insertion CK6, Andras Nagy|cytomegalovirus (CMV) immediate early enhancer coupled to the chicken beta actin promoter|||||||||||Expression of enhanced cyan fluorescent protein||C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown||||No|24-May-2017|Cryopreserved sperm|24.0|0.0|Unknown||ECFP|Yes| 10285.0|ASK-1 KO|B6J.B6N-Map3k5/Apb||Recessive|mitogen-activated protein kinase kinase kinase 5|Map3k5||ASK1|MGI:1346876|mitogen-activated protein kinase kinase kinase 5; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Map3k5|MGI:4434801|10||||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|N6+|||No|01-Feb-2023|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10286.0|ASK-1 flox|B6J.B6N-Map3k5/Apb||Recessive|mitogen-activated protein kinase kinase kinase 5|Map3k5||ASK1|MGI:1346876|mitogen-activated protein kinase kinase kinase 5; targeted mutation 1a, Helmholtz Zentrum Muenchen GmbH |Map3k5||10|ENSMUSG00000071369|||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Yes|Yes|Yes|Yes|Yes|Yes|No|Good|N6+|||No|01-Feb-2023|Cryopreserved sperm|50.0|0.0|Unknown|||No| 4971.0|Fzd7|C57BL/6-Fzd7||Recessive|frizzled homolog 7 (Drosophila)|Fzd7|Normal|Fz7|MGI:108570||||1||||||||||||||||Yes|||||||||||||Normal|Normal|C57BL/6|Yes|Yes|Yes|Yes|Yes|Yes|No|Unknown|10||Het x C57BL/6|No|21-Jan-2010|Cryopreserved sperm|96.0|0.0|Unknown||Frizzled -7, Wnt pathway, conditional gene deletion, LoxP, Cre recombinase|Possibly| 8146.0|LAT3_KO|C57BL/6JMarp-Slc43a1/Marp||Recessive|solute carrier family 43, member 1|Slc43a1||2610016F07Rik, Lat3, PB39, Pov1|MGI:1931352||||Unknown|||||||||||||||||||||||||||||Unknown|Unknown|C57BL/6|Unknown|Unknown|Yes|Unknown|Unknown|Yes|No|Unknown||||No|29-Nov-2016|Cryopreserved sperm|50.0|0.0|Unknown|||Yes| 10280.0|iDMPcre.Ai9|B6.Cg-Tg(Dmp1-cre/ERT2)D77Pdp Gt(ROSA)26Sor/Apb||Semi-dominant|gene trap ROSA 26, Philippe Soriano|Gt(ROSA)26Sor||R26, ROSA26, Thumpd3as1|MGI:104735||||6|||||||||||||||||transgene insertion D77, Paola Divieti Pajevic|Dmp1-cre/ERT2|||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|16-Jan-2023|Cryopreserved sperm|50.0|0.0|Unknown|||Possibly| 10287.0|Adidas:indel07, S866fs|C57BL/6NCrlAnu-Nfkb2/Anu||Recessive|nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100|Nfkb2|||MGI:1099800 |Nfkb2: endonuclease-mediated mutation 2, Australian National University|Nfkb2||19|||||||||||||||||||||||||||||Unknown|Unknown|C57Bl/6N|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|08-Feb-2023|Cryopreserved sperm|22.0|0.0|Unknown|||Possibly| 10296.0||C57Bl/6-TFF3(CreGFP)-Rosa26-Td(tomato)/Apb||Semi-dominant|trefoil factor 3, intestinal|Tff3||ITF, mITF|MGI:104638||||17|ENSMUSG00000024029|||||||||Unknown to Unknown|||||||||||||||||||Normal|Normal|C57Bl/6J|Unknown|Unknown|Unknown|Unknown|Unknown|Unknown|No|Unknown||||No|22-Feb-2023|Cryopreserved sperm|44.0|0.0|Unknown|||Possibly|